Report_Name Item Master Report Report_ID IR Release 5 Institution_Name YALE UNIVERSITY Institution_ID Silverchair:1325 Metric_Types Report_Filters Report_Attributes Exceptions Reporting_Period Begin_Date=2021-01-01; End_Date=2021-12-31 Created 2022-02-12T10:20:02Z Created_By Silverchair Item Publisher Publisher_ID Platform DOI Proprietary_ID ISBN Print_ISSN Online_ISSN URI Metric_Type Reporting_Period_Total Jan-21 Feb-21 Mar-21 Apr-21 May-21 Jun-21 Jul-21 Aug-21 Sep-21 Oct-21 Nov-21 Dec-21 “Cup-like” blasts in acute myeloid leukemia with FLT3 and NPM1 mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-603381 Silverchair:34078 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 “Cup-like” blasts in acute myeloid leukemia with FLT3 and NPM1 mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-603381 Silverchair:34078 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 “Cup-like” blasts in acute myeloid leukemia with FLT3 and NPM1 mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-603381 Silverchair:34078 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 “Cup-like” blasts in acute myeloid leukemia with FLT3 and NPM1 mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-603381 Silverchair:34078 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 “How I treat”: a new style of clinical review article The American Society of Hematology American Society of Hematology 10.1182/blood.V96.4.1205 Silverchair:258411 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 “How I treat”: a new style of clinical review article The American Society of Hematology American Society of Hematology 10.1182/blood.V96.4.1205 Silverchair:258411 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 “How I treat”: a new style of clinical review article The American Society of Hematology American Society of Hematology 10.1182/blood.V96.4.1205 Silverchair:258411 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 “How I treat”: a new style of clinical review article The American Society of Hematology American Society of Hematology 10.1182/blood.V96.4.1205 Silverchair:258411 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 “Myelodysplasia” from copper deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-884981 Silverchair:260587 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 “Myelodysplasia” from copper deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-884981 Silverchair:260587 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 “Myelodysplasia” from copper deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-884981 Silverchair:260587 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 “Myelodysplasia” from copper deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-884981 Silverchair:260587 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 “TEG talk”: expanding clinical roles for thromboelastography and rotational thromboelastometry The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000090 Silverchair:474316 Total_Item_Investigations 8 1 3 1 0 0 3 0 0 0 0 0 0 “TEG talk”: expanding clinical roles for thromboelastography and rotational thromboelastometry The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000090 Silverchair:474316 Total_Item_Requests 8 1 3 1 0 0 3 0 0 0 0 0 0 “TEG talk”: expanding clinical roles for thromboelastography and rotational thromboelastometry The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000090 Silverchair:474316 Unique_Item_Investigations 6 1 2 1 0 0 2 0 0 0 0 0 0 “TEG talk”: expanding clinical roles for thromboelastography and rotational thromboelastometry The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000090 Silverchair:474316 Unique_Item_Requests 6 1 2 1 0 0 2 0 0 0 0 0 0 ACTN1-related thrombocytopenia: identification of novel families for phenotypic characterization The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-594531 Silverchair:34092 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 ACTN1-related thrombocytopenia: identification of novel families for phenotypic characterization The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-594531 Silverchair:34092 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 ACTN1-related thrombocytopenia: identification of novel families for phenotypic characterization The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-594531 Silverchair:34092 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 ACTN1-related thrombocytopenia: identification of novel families for phenotypic characterization The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-594531 Silverchair:34092 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 ATG4A is a Novel Regulator of Mitophagy during Human Erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130567 Silverchair:428161 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 ATG4A is a Novel Regulator of Mitophagy during Human Erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130567 Silverchair:428161 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 ATG4A is a Novel Regulator of Mitophagy during Human Erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130567 Silverchair:428161 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 ATG4A is a Novel Regulator of Mitophagy during Human Erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130567 Silverchair:428161 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 BCL6 breaks occur at different AID sequence motifs in Ig–BCL6 and non-Ig–BCL6 rearrangements The American Society of Hematology American Society of Hematology 10.1182/blood-2012-10-464958 Silverchair:31352 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 BCL6 breaks occur at different AID sequence motifs in Ig–BCL6 and non-Ig–BCL6 rearrangements The American Society of Hematology American Society of Hematology 10.1182/blood-2012-10-464958 Silverchair:31352 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 BCL6 breaks occur at different AID sequence motifs in Ig–BCL6 and non-Ig–BCL6 rearrangements The American Society of Hematology American Society of Hematology 10.1182/blood-2012-10-464958 Silverchair:31352 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 BCL6 breaks occur at different AID sequence motifs in Ig–BCL6 and non-Ig–BCL6 rearrangements The American Society of Hematology American Society of Hematology 10.1182/blood-2012-10-464958 Silverchair:31352 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-393041 Silverchair:30086 Total_Item_Investigations 4 0 0 4 0 0 0 0 0 0 0 0 0 BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-393041 Silverchair:30086 Total_Item_Requests 4 0 0 4 0 0 0 0 0 0 0 0 0 BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-393041 Silverchair:30086 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-393041 Silverchair:30086 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-11-467787 Silverchair:31497 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-11-467787 Silverchair:31497 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-11-467787 Silverchair:31497 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-11-467787 Silverchair:31497 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 C4BPB/C4BPA is a new susceptibility locus for venous thrombosis with unknown protein S–independent mechanism: results from genome-wide association and gene expression analyses followed by case-control studies The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-263038 Silverchair:27727 Total_Item_Investigations 5 5 0 0 0 0 0 0 0 0 0 0 0 C4BPB/C4BPA is a new susceptibility locus for venous thrombosis with unknown protein S–independent mechanism: results from genome-wide association and gene expression analyses followed by case-control studies The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-263038 Silverchair:27727 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 C4BPB/C4BPA is a new susceptibility locus for venous thrombosis with unknown protein S–independent mechanism: results from genome-wide association and gene expression analyses followed by case-control studies The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-263038 Silverchair:27727 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 C4BPB/C4BPA is a new susceptibility locus for venous thrombosis with unknown protein S–independent mechanism: results from genome-wide association and gene expression analyses followed by case-control studies The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-263038 Silverchair:27727 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 CALR-mutated essential thrombocythemia evolving to chronic myeloid leukemia with coexistent CALR mutation and BCR-ABL translocation The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-616847 Silverchair:33849 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 CALR-mutated essential thrombocythemia evolving to chronic myeloid leukemia with coexistent CALR mutation and BCR-ABL translocation The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-616847 Silverchair:33849 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 CALR-mutated essential thrombocythemia evolving to chronic myeloid leukemia with coexistent CALR mutation and BCR-ABL translocation The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-616847 Silverchair:33849 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 CALR-mutated essential thrombocythemia evolving to chronic myeloid leukemia with coexistent CALR mutation and BCR-ABL translocation The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-616847 Silverchair:33849 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1 The American Society of Hematology American Society of Hematology 10.1182/blood.2020006528 Silverchair:474916 No_License 1 0 0 0 1 0 0 0 0 0 0 0 0 CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1 The American Society of Hematology American Society of Hematology 10.1182/blood.2020006528 Silverchair:474916 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1 The American Society of Hematology American Society of Hematology 10.1182/blood.2020006528 Silverchair:474916 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 "CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-292433 Silverchair:21386 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 "CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-292433 Silverchair:21386 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-292433 Silverchair:21386 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-292433 Silverchair:21386 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 CEBPA bZip mutations: just a single shot The American Society of Hematology American Society of Hematology 10.1182/blood.2021011263 Silverchair:477005 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 CEBPA bZip mutations: just a single shot The American Society of Hematology American Society of Hematology 10.1182/blood.2021011263 Silverchair:477005 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 CEBPA bZip mutations: just a single shot The American Society of Hematology American Society of Hematology 10.1182/blood.2021011263 Silverchair:477005 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 CEBPA bZip mutations: just a single shot The American Society of Hematology American Society of Hematology 10.1182/blood.2021011263 Silverchair:477005 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "Crebbp haploinsufficiency in mice alters the bone marrow microenvironment, leading to loss of stem cells and excessive myelopoiesis" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-307942 Silverchair:28440 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 "Crebbp haploinsufficiency in mice alters the bone marrow microenvironment, leading to loss of stem cells and excessive myelopoiesis" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-307942 Silverchair:28440 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 "Crebbp haploinsufficiency in mice alters the bone marrow microenvironment, leading to loss of stem cells and excessive myelopoiesis" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-307942 Silverchair:28440 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Crebbp haploinsufficiency in mice alters the bone marrow microenvironment, leading to loss of stem cells and excessive myelopoiesis" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-307942 Silverchair:28440 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-733469 Silverchair:36159 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-733469 Silverchair:36159 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-733469 Silverchair:36159 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-733469 Silverchair:36159 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Dnmt3a Mutation Confers a Selective Advantage Specifically to Cells within the Long-Term Hematopoietic Stem Cell (LT-HSC) Compartment The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124540 Silverchair:426451 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Dnmt3a Mutation Confers a Selective Advantage Specifically to Cells within the Long-Term Hematopoietic Stem Cell (LT-HSC) Compartment The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124540 Silverchair:426451 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Dnmt3a Mutation Confers a Selective Advantage Specifically to Cells within the Long-Term Hematopoietic Stem Cell (LT-HSC) Compartment The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124540 Silverchair:426451 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Dnmt3a Mutation Confers a Selective Advantage Specifically to Cells within the Long-Term Hematopoietic Stem Cell (LT-HSC) Compartment The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124540 Silverchair:426451 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 EZH2 mutations are frequent and represent an early event in follicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-496893 Silverchair:31818 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 EZH2 mutations are frequent and represent an early event in follicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-496893 Silverchair:31818 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 EZH2 mutations are frequent and represent an early event in follicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-496893 Silverchair:31818 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 EZH2 mutations are frequent and represent an early event in follicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-496893 Silverchair:31818 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia The American Society of Hematology American Society of Hematology 10.1182/blood-2004-03-0787 Silverchair:18726 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia The American Society of Hematology American Society of Hematology 10.1182/blood-2004-03-0787 Silverchair:18726 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia The American Society of Hematology American Society of Hematology 10.1182/blood-2004-03-0787 Silverchair:18726 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia The American Society of Hematology American Society of Hematology 10.1182/blood-2004-03-0787 Silverchair:18726 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Frascati , a Mitochondrial Solute Transporter, and Its Role in Vertebrate Erythropoiesis." The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.49.49 Silverchair:55876 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Frascati , a Mitochondrial Solute Transporter, and Its Role in Vertebrate Erythropoiesis." The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.49.49 Silverchair:55876 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Frascati , a Mitochondrial Solute Transporter, and Its Role in Vertebrate Erythropoiesis." The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.49.49 Silverchair:55876 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Frascati , a Mitochondrial Solute Transporter, and Its Role in Vertebrate Erythropoiesis." The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.49.49 Silverchair:55876 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-515148 Silverchair:31945 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-515148 Silverchair:31945 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-515148 Silverchair:31945 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-515148 Silverchair:31945 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 GNE variants causing autosomal recessive macrothrombocytopenia without associated muscle wasting The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-845545 Silverchair:39491 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 GNE variants causing autosomal recessive macrothrombocytopenia without associated muscle wasting The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-845545 Silverchair:39491 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 GNE variants causing autosomal recessive macrothrombocytopenia without associated muscle wasting The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-845545 Silverchair:39491 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 GNE variants causing autosomal recessive macrothrombocytopenia without associated muscle wasting The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-845545 Silverchair:39491 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL) The American Society of Hematology American Society of Hematology 10.1182/blood-2004-10-3900 Silverchair:103180 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL) The American Society of Hematology American Society of Hematology 10.1182/blood-2004-10-3900 Silverchair:103180 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL) The American Society of Hematology American Society of Hematology 10.1182/blood-2004-10-3900 Silverchair:103180 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL) The American Society of Hematology American Society of Hematology 10.1182/blood-2004-10-3900 Silverchair:103180 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 IDH1 mutation contributes to myeloid dysplasia in mice by disturbing heme biosynthesis and erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.2020007075 Silverchair:474374 No_License 1 0 0 1 0 0 0 0 0 0 0 0 0 IDH1 mutation contributes to myeloid dysplasia in mice by disturbing heme biosynthesis and erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.2020007075 Silverchair:474374 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 IDH1 mutation contributes to myeloid dysplasia in mice by disturbing heme biosynthesis and erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.2020007075 Silverchair:474374 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127615 Silverchair:423100 Total_Item_Investigations 7 5 1 1 0 0 0 0 0 0 0 0 0 "Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127615 Silverchair:423100 Total_Item_Requests 6 4 1 1 0 0 0 0 0 0 0 0 0 "Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127615 Silverchair:423100 Unique_Item_Investigations 3 1 1 1 0 0 0 0 0 0 0 0 0 "Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127615 Silverchair:423100 Unique_Item_Requests 3 1 1 1 0 0 0 0 0 0 0 0 0 IKZF1 (Ikaros) Deletions Are a Hallmark of BCR-ABL1 Positive Acute Lymphoblastic Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.721.721 Silverchair:118293 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 IKZF1 (Ikaros) Deletions Are a Hallmark of BCR-ABL1 Positive Acute Lymphoblastic Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.721.721 Silverchair:118293 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 IKZF1 (Ikaros) Deletions Are a Hallmark of BCR-ABL1 Positive Acute Lymphoblastic Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.721.721 Silverchair:118293 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 IKZF1 (Ikaros) Deletions Are a Hallmark of BCR-ABL1 Positive Acute Lymphoblastic Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.721.721 Silverchair:118293 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 In Vivo reconstruction of Human Erythropoiesis with Circulating Mature Human RBCs in Humanized Liver Mistrg Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130701 Silverchair:426253 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 In Vivo reconstruction of Human Erythropoiesis with Circulating Mature Human RBCs in Humanized Liver Mistrg Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130701 Silverchair:426253 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 In Vivo reconstruction of Human Erythropoiesis with Circulating Mature Human RBCs in Humanized Liver Mistrg Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130701 Silverchair:426253 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 In Vivo reconstruction of Human Erythropoiesis with Circulating Mature Human RBCs in Humanized Liver Mistrg Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130701 Silverchair:426253 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-12-689216 Silverchair:35788 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-12-689216 Silverchair:35788 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-12-689216 Silverchair:35788 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-12-689216 Silverchair:35788 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 "JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome–negative CML, and megakaryocytic leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2005-05-1800 Silverchair:20926 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome–negative CML, and megakaryocytic leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2005-05-1800 Silverchair:20926 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome–negative CML, and megakaryocytic leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2005-05-1800 Silverchair:20926 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome–negative CML, and megakaryocytic leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2005-05-1800 Silverchair:20926 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-539098 Silverchair:32351 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-539098 Silverchair:32351 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-539098 Silverchair:32351 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-539098 Silverchair:32351 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-014712 Silverchair:22607 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-014712 Silverchair:22607 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-014712 Silverchair:22607 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-014712 Silverchair:22607 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 JAK2-V617F and interferon-a induce megakaryocyte-biased stem cells characterized by decreased long-term functionality The American Society of Hematology American Society of Hematology 10.1182/blood.2020005563 Silverchair:475343 Total_Item_Investigations 4 0 0 2 1 1 0 0 0 0 0 0 0 JAK2-V617F and interferon-a induce megakaryocyte-biased stem cells characterized by decreased long-term functionality The American Society of Hematology American Society of Hematology 10.1182/blood.2020005563 Silverchair:475343 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 JAK2-V617F and interferon-a induce megakaryocyte-biased stem cells characterized by decreased long-term functionality The American Society of Hematology American Society of Hematology 10.1182/blood.2020005563 Silverchair:475343 Unique_Item_Investigations 3 0 0 1 1 1 0 0 0 0 0 0 0 JAK2-V617F and interferon-a induce megakaryocyte-biased stem cells characterized by decreased long-term functionality The American Society of Hematology American Society of Hematology 10.1182/blood.2020005563 Silverchair:475343 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 "KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group" The American Society of Hematology American Society of Hematology 10.1182/blood-2005-08-3408 Silverchair:133401 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group" The American Society of Hematology American Society of Hematology 10.1182/blood-2005-08-3408 Silverchair:133401 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group" The American Society of Hematology American Society of Hematology 10.1182/blood-2005-08-3408 Silverchair:133401 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group" The American Society of Hematology American Society of Hematology 10.1182/blood-2005-08-3408 Silverchair:133401 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 KZF-L162R Mutation Affects Splenic Mature B Cell Development and Alters Expression of Aiolos Target Genes The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115483 Silverchair:266232 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 KZF-L162R Mutation Affects Splenic Mature B Cell Development and Alters Expression of Aiolos Target Genes The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115483 Silverchair:266232 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 KZF-L162R Mutation Affects Splenic Mature B Cell Development and Alters Expression of Aiolos Target Genes The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115483 Silverchair:266232 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 KZF-L162R Mutation Affects Splenic Mature B Cell Development and Alters Expression of Aiolos Target Genes The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115483 Silverchair:266232 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 miR-125b promotes MLL-AF9–driven murine acute myeloid leukemia involving a VEGFA-mediated non–cell-intrinsic mechanism The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-721027 Silverchair:35946 Total_Item_Investigations 4 2 0 2 0 0 0 0 0 0 0 0 0 miR-125b promotes MLL-AF9–driven murine acute myeloid leukemia involving a VEGFA-mediated non–cell-intrinsic mechanism The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-721027 Silverchair:35946 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 miR-125b promotes MLL-AF9–driven murine acute myeloid leukemia involving a VEGFA-mediated non–cell-intrinsic mechanism The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-721027 Silverchair:35946 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 miR-125b promotes MLL-AF9–driven murine acute myeloid leukemia involving a VEGFA-mediated non–cell-intrinsic mechanism The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-721027 Silverchair:35946 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 mpeg1 promoter transgenes direct macrophage-lineage expression in zebrafish The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-314120 Silverchair:28611 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 mpeg1 promoter transgenes direct macrophage-lineage expression in zebrafish The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-314120 Silverchair:28611 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 mpeg1 promoter transgenes direct macrophage-lineage expression in zebrafish The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-314120 Silverchair:28611 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 mpeg1 promoter transgenes direct macrophage-lineage expression in zebrafish The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-314120 Silverchair:28611 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 NCOA4 is regulated by HIF and mediates mobilization of murine hepatic iron stores after blood loss The American Society of Hematology American Society of Hematology 10.1182/blood.2020006321 Silverchair:461325 Total_Item_Investigations 5 4 0 0 0 0 0 0 1 0 0 0 0 NCOA4 is regulated by HIF and mediates mobilization of murine hepatic iron stores after blood loss The American Society of Hematology American Society of Hematology 10.1182/blood.2020006321 Silverchair:461325 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 NCOA4 is regulated by HIF and mediates mobilization of murine hepatic iron stores after blood loss The American Society of Hematology American Society of Hematology 10.1182/blood.2020006321 Silverchair:461325 Unique_Item_Investigations 3 2 0 0 0 0 0 0 1 0 0 0 0 NCOA4 is regulated by HIF and mediates mobilization of murine hepatic iron stores after blood loss The American Society of Hematology American Society of Hematology 10.1182/blood.2020006321 Silverchair:461325 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 NPM1-mutated acute myeloid leukemia: from bench to bedside The American Society of Hematology American Society of Hematology 10.1182/blood.2019004226 Silverchair:461241 No_License 5 0 3 2 0 0 0 0 0 0 0 0 0 NPM1-mutated acute myeloid leukemia: from bench to bedside The American Society of Hematology American Society of Hematology 10.1182/blood.2019004226 Silverchair:461241 Total_Item_Investigations 12 1 6 4 0 1 0 0 0 0 0 0 0 NPM1-mutated acute myeloid leukemia: from bench to bedside The American Society of Hematology American Society of Hematology 10.1182/blood.2019004226 Silverchair:461241 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 NPM1-mutated acute myeloid leukemia: from bench to bedside The American Society of Hematology American Society of Hematology 10.1182/blood.2019004226 Silverchair:461241 Unique_Item_Investigations 4 1 1 1 0 1 0 0 0 0 0 0 0 NPM1-mutated acute myeloid leukemia: from bench to bedside The American Society of Hematology American Society of Hematology 10.1182/blood.2019004226 Silverchair:461241 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-020362 Silverchair:23399 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-020362 Silverchair:23399 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-020362 Silverchair:23399 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-020362 Silverchair:23399 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Ph+ ALL: drawing strength from a benign past The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-632174 Silverchair:34242 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Ph+ ALL: drawing strength from a benign past The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-632174 Silverchair:34242 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Ph+ ALL: drawing strength from a benign past The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-632174 Silverchair:34242 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Ph+ ALL: drawing strength from a benign past The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-632174 Silverchair:34242 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Plasmodium falciparum uses a key functional site in complement receptor type-1 for invasion of human erythrocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-341305 Silverchair:29731 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Plasmodium falciparum uses a key functional site in complement receptor type-1 for invasion of human erythrocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-341305 Silverchair:29731 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Plasmodium falciparum uses a key functional site in complement receptor type-1 for invasion of human erythrocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-341305 Silverchair:29731 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Plasmodium falciparum uses a key functional site in complement receptor type-1 for invasion of human erythrocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-341305 Silverchair:29731 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 PTG-300 Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137285 Silverchair:470195 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 PTG-300 Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137285 Silverchair:470195 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 PTG-300 Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137285 Silverchair:470195 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 PTG-300 Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137285 Silverchair:470195 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Runx1 Deficiency and MDS-Associated U2af1 Mutation Cooperate for Leukemia Development in a New Mouse Model The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.964.964 Silverchair:98908 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Runx1 Deficiency and MDS-Associated U2af1 Mutation Cooperate for Leukemia Development in a New Mouse Model The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.964.964 Silverchair:98908 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Runx1 Deficiency and MDS-Associated U2af1 Mutation Cooperate for Leukemia Development in a New Mouse Model The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.964.964 Silverchair:98908 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Runx1 Deficiency and MDS-Associated U2af1 Mutation Cooperate for Leukemia Development in a New Mouse Model The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.964.964 Silverchair:98908 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 "RUNX1 Mutations in MDS, s-AML and De Novo AML: Differences in Accompanying Cytogenetic and Molecular Genetic Alterations, Clonal Architecture and Outcome" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2683.2683 Silverchair:80019 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 "RUNX1 Mutations in MDS, s-AML and De Novo AML: Differences in Accompanying Cytogenetic and Molecular Genetic Alterations, Clonal Architecture and Outcome" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2683.2683 Silverchair:80019 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 "RUNX1 Mutations in MDS, s-AML and De Novo AML: Differences in Accompanying Cytogenetic and Molecular Genetic Alterations, Clonal Architecture and Outcome" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2683.2683 Silverchair:80019 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 "RUNX1 Mutations in MDS, s-AML and De Novo AML: Differences in Accompanying Cytogenetic and Molecular Genetic Alterations, Clonal Architecture and Outcome" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2683.2683 Silverchair:80019 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 SALL4 is a robust stimulator for the expansion of hematopoietic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-333641 Silverchair:28952 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 SALL4 is a robust stimulator for the expansion of hematopoietic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-333641 Silverchair:28952 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 SALL4 is a robust stimulator for the expansion of hematopoietic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-333641 Silverchair:28952 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 SALL4 is a robust stimulator for the expansion of hematopoietic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-333641 Silverchair:28952 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-633537 Silverchair:34510 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-633537 Silverchair:34510 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-633537 Silverchair:34510 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-633537 Silverchair:34510 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS The American Society of Hematology American Society of Hematology 10.1182/blood.2020004850 Silverchair:454668 Total_Item_Investigations 4 0 1 2 0 0 0 1 0 0 0 0 0 SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS The American Society of Hematology American Society of Hematology 10.1182/blood.2020004850 Silverchair:454668 Total_Item_Requests 4 0 1 2 0 0 0 1 0 0 0 0 0 SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS The American Society of Hematology American Society of Hematology 10.1182/blood.2020004850 Silverchair:454668 Unique_Item_Investigations 4 0 1 2 0 0 0 1 0 0 0 0 0 SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS The American Society of Hematology American Society of Hematology 10.1182/blood.2020004850 Silverchair:454668 Unique_Item_Requests 4 0 1 2 0 0 0 1 0 0 0 0 0 SLFN11 promotes stalled fork degradation that underlies the phenotype in Fanconi anemia cells The American Society of Hematology American Society of Hematology 10.1182/blood.2019003782 Silverchair:461664 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 SLFN11 promotes stalled fork degradation that underlies the phenotype in Fanconi anemia cells The American Society of Hematology American Society of Hematology 10.1182/blood.2019003782 Silverchair:461664 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 SLFN11 promotes stalled fork degradation that underlies the phenotype in Fanconi anemia cells The American Society of Hematology American Society of Hematology 10.1182/blood.2019003782 Silverchair:461664 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 SLFN11 promotes stalled fork degradation that underlies the phenotype in Fanconi anemia cells The American Society of Hematology American Society of Hematology 10.1182/blood.2019003782 Silverchair:461664 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "SOD2-deficiency anemia: protein oxidation and altered protein expression reveal targets of damage, stress response, and antioxidant responsiveness" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-11-3858 Silverchair:19075 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 "SOD2-deficiency anemia: protein oxidation and altered protein expression reveal targets of damage, stress response, and antioxidant responsiveness" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-11-3858 Silverchair:19075 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 "SOD2-deficiency anemia: protein oxidation and altered protein expression reveal targets of damage, stress response, and antioxidant responsiveness" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-11-3858 Silverchair:19075 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "SOD2-deficiency anemia: protein oxidation and altered protein expression reveal targets of damage, stress response, and antioxidant responsiveness" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-11-3858 Silverchair:19075 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 SRP54 mutations induce congenital neutropenia via dominant-negative effects on XBP1 splicing The American Society of Hematology American Society of Hematology 10.1182/blood.2020008115 Silverchair:474249 No_License 1 0 0 1 0 0 0 0 0 0 0 0 0 SRP54 mutations induce congenital neutropenia via dominant-negative effects on XBP1 splicing The American Society of Hematology American Society of Hematology 10.1182/blood.2020008115 Silverchair:474249 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 SRP54 mutations induce congenital neutropenia via dominant-negative effects on XBP1 splicing The American Society of Hematology American Society of Hematology 10.1182/blood.2020008115 Silverchair:474249 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Srsf2P95H initiates myeloid bias and myelodysplastic/myeloproliferative syndrome from hemopoietic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-845602 Silverchair:39449 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Srsf2P95H initiates myeloid bias and myelodysplastic/myeloproliferative syndrome from hemopoietic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-845602 Silverchair:39449 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Srsf2P95H initiates myeloid bias and myelodysplastic/myeloproliferative syndrome from hemopoietic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-845602 Silverchair:39449 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Srsf2P95H initiates myeloid bias and myelodysplastic/myeloproliferative syndrome from hemopoietic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-845602 Silverchair:39449 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics The American Society of Hematology American Society of Hematology 10.1182/blood-2011-02-339747 Silverchair:28728 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics The American Society of Hematology American Society of Hematology 10.1182/blood-2011-02-339747 Silverchair:28728 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics The American Society of Hematology American Society of Hematology 10.1182/blood-2011-02-339747 Silverchair:28728 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics The American Society of Hematology American Society of Hematology 10.1182/blood-2011-02-339747 Silverchair:28728 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002512 Silverchair:467894 Total_Item_Investigations 6 2 0 2 0 0 0 0 0 0 2 0 0 TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002512 Silverchair:467894 Total_Item_Requests 6 2 0 2 0 0 0 0 0 0 2 0 0 TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002512 Silverchair:467894 Unique_Item_Investigations 4 2 0 1 0 0 0 0 0 0 1 0 0 TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002512 Silverchair:467894 Unique_Item_Requests 4 2 0 1 0 0 0 0 0 0 1 0 0 "TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-375758 Silverchair:30233 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 "TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-375758 Silverchair:30233 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 "TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-375758 Silverchair:30233 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-375758 Silverchair:30233 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 TP53 and CD19-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2021-145158 Silverchair:479529 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 TP53 and CD19-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2021-145158 Silverchair:479529 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 TP53 and CD19-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2021-145158 Silverchair:479529 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 TP53 and CD19-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2021-145158 Silverchair:479529 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-779736 Silverchair:36514 Total_Item_Investigations 4 2 0 0 1 0 0 1 0 0 0 0 0 TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-779736 Silverchair:36514 Total_Item_Requests 4 2 0 0 1 0 0 1 0 0 0 0 0 TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-779736 Silverchair:36514 Unique_Item_Investigations 4 2 0 0 1 0 0 1 0 0 0 0 0 TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-779736 Silverchair:36514 Unique_Item_Requests 4 2 0 0 1 0 0 1 0 0 0 0 0 TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype The American Society of Hematology American Society of Hematology 10.1182/blood.2020006158 Silverchair:461624 Total_Item_Investigations 17 4 4 0 0 5 0 0 0 3 0 1 0 TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype The American Society of Hematology American Society of Hematology 10.1182/blood.2020006158 Silverchair:461624 Total_Item_Requests 5 4 0 0 0 0 0 0 0 0 0 1 0 TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype The American Society of Hematology American Society of Hematology 10.1182/blood.2020006158 Silverchair:461624 Unique_Item_Investigations 10 3 4 0 0 1 0 0 0 1 0 1 0 TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype The American Society of Hematology American Society of Hematology 10.1182/blood.2020006158 Silverchair:461624 Unique_Item_Requests 4 3 0 0 0 0 0 0 0 0 0 1 0 TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype The American Society of Hematology American Society of Hematology 10.1182/blood.2020006158 Silverchair:461624 No_License 2 0 2 0 0 0 0 0 0 0 0 0 0 U2AF1 Mutations in S34 and Q157 Create Distinct Molecular and Clinical Contexts The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3155.3155 Silverchair:98129 Total_Item_Investigations 25 0 0 2 10 3 4 2 2 2 0 0 0 U2AF1 Mutations in S34 and Q157 Create Distinct Molecular and Clinical Contexts The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3155.3155 Silverchair:98129 Total_Item_Requests 25 0 0 2 10 3 4 2 2 2 0 0 0 U2AF1 Mutations in S34 and Q157 Create Distinct Molecular and Clinical Contexts The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3155.3155 Silverchair:98129 Unique_Item_Investigations 15 0 0 2 4 3 2 1 2 1 0 0 0 U2AF1 Mutations in S34 and Q157 Create Distinct Molecular and Clinical Contexts The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3155.3155 Silverchair:98129 Unique_Item_Requests 15 0 0 2 4 3 2 1 2 1 0 0 0 VAV1 mutations contribute to development of T-cell neoplasms in mice The American Society of Hematology American Society of Hematology 10.1182/blood.2020006513 Silverchair:463990 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 VAV1 mutations contribute to development of T-cell neoplasms in mice The American Society of Hematology American Society of Hematology 10.1182/blood.2020006513 Silverchair:463990 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 VAV1 mutations contribute to development of T-cell neoplasms in mice The American Society of Hematology American Society of Hematology 10.1182/blood.2020006513 Silverchair:463990 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 VAV1 mutations contribute to development of T-cell neoplasms in mice The American Society of Hematology American Society of Hematology 10.1182/blood.2020006513 Silverchair:463990 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 100 Already? American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004107 Silverchair:474887 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 100 Already? American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004107 Silverchair:474887 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 100 Already? American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004107 Silverchair:474887 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 100 Already? American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004107 Silverchair:474887 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020010510 Silverchair:475778 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 3 0 0 0 14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020010510 Silverchair:475778 Unique_Item_Investigations 2 0 0 0 0 0 0 0 0 2 0 0 0 "1α,25-dihydroxyvitamin D3 is a potent suppressor of interferon γ–mediated macrophage activation" The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-1029 Silverchair:133290 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "1α,25-dihydroxyvitamin D3 is a potent suppressor of interferon γ–mediated macrophage activation" The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-1029 Silverchair:133290 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "1α,25-dihydroxyvitamin D3 is a potent suppressor of interferon γ–mediated macrophage activation" The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-1029 Silverchair:133290 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "1α,25-dihydroxyvitamin D3 is a potent suppressor of interferon γ–mediated macrophage activation" The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-1029 Silverchair:133290 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document The American Society of Hematology American Society of Hematology 10.1182/blood.2021013626 Silverchair:477736 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 0 2 2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document The American Society of Hematology American Society of Hematology 10.1182/blood.2021013626 Silverchair:477736 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document The American Society of Hematology American Society of Hematology 10.1182/blood.2021013626 Silverchair:477736 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document The American Society of Hematology American Society of Hematology 10.1182/blood.2021013626 Silverchair:477736 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 25-Hydroxyvitamin D3-1α-hydroxylase– and multiple cytokine–producing diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-832568 Silverchair:6538 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 25-Hydroxyvitamin D3-1α-hydroxylase– and multiple cytokine–producing diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-832568 Silverchair:6538 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 25-Hydroxyvitamin D3-1α-hydroxylase– and multiple cytokine–producing diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-832568 Silverchair:6538 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 25-Hydroxyvitamin D3-1α-hydroxylase– and multiple cytokine–producing diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-832568 Silverchair:6538 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 27-Hydroxycholesterol Induces Hematopoietic Stem Cell Mobilization and Extramedullary Hematopoiesis Mediated By Estrogen Receptor Alpha The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.636.636 Silverchair:83377 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 27-Hydroxycholesterol Induces Hematopoietic Stem Cell Mobilization and Extramedullary Hematopoiesis Mediated By Estrogen Receptor Alpha The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.636.636 Silverchair:83377 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 27-Hydroxycholesterol Induces Hematopoietic Stem Cell Mobilization and Extramedullary Hematopoiesis Mediated By Estrogen Receptor Alpha The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.636.636 Silverchair:83377 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 27-Hydroxycholesterol Induces Hematopoietic Stem Cell Mobilization and Extramedullary Hematopoiesis Mediated By Estrogen Receptor Alpha The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.636.636 Silverchair:83377 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 28 days later: eosinophils stop viruses The American Society of Hematology American Society of Hematology 10.1182/blood-2013-12-543389 Silverchair:32808 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 28 days later: eosinophils stop viruses The American Society of Hematology American Society of Hematology 10.1182/blood-2013-12-543389 Silverchair:32808 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 28 days later: eosinophils stop viruses The American Society of Hematology American Society of Hematology 10.1182/blood-2013-12-543389 Silverchair:32808 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 28 days later: eosinophils stop viruses The American Society of Hematology American Society of Hematology 10.1182/blood-2013-12-543389 Silverchair:32808 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 40 Is the New 50: Reducing the Need for Platelet Transfusions Prior to Lumbar Puncture in Patients with Hematologic Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114264 Silverchair:262316 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 40 Is the New 50: Reducing the Need for Platelet Transfusions Prior to Lumbar Puncture in Patients with Hematologic Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114264 Silverchair:262316 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 40 Is the New 50: Reducing the Need for Platelet Transfusions Prior to Lumbar Puncture in Patients with Hematologic Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114264 Silverchair:262316 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 40 Is the New 50: Reducing the Need for Platelet Transfusions Prior to Lumbar Puncture in Patients with Hematologic Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114264 Silverchair:262316 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 5-Azacytidine Depletes Hematopoietic Stem Cells and Synergizes with an Anti-CD117 Antibody to Augment Engraftment of Donor Stem Cells in Immunocompetent Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139058 Silverchair:471258 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 5-Azacytidine Depletes Hematopoietic Stem Cells and Synergizes with an Anti-CD117 Antibody to Augment Engraftment of Donor Stem Cells in Immunocompetent Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139058 Silverchair:471258 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 5-Azacytidine Depletes Hematopoietic Stem Cells and Synergizes with an Anti-CD117 Antibody to Augment Engraftment of Donor Stem Cells in Immunocompetent Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139058 Silverchair:471258 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 5-Azacytidine Depletes Hematopoietic Stem Cells and Synergizes with an Anti-CD117 Antibody to Augment Engraftment of Donor Stem Cells in Immunocompetent Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139058 Silverchair:471258 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "5q Deletions in MDS and MPN: The Accompanying Molecular Mutations Determine the Phenotype but TP53 Is Frequently Mutated in All Entities: MPN, MDS and MPN/MDS Overlap" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1926.1926 Silverchair:90126 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "5q Deletions in MDS and MPN: The Accompanying Molecular Mutations Determine the Phenotype but TP53 Is Frequently Mutated in All Entities: MPN, MDS and MPN/MDS Overlap" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1926.1926 Silverchair:90126 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "5q Deletions in MDS and MPN: The Accompanying Molecular Mutations Determine the Phenotype but TP53 Is Frequently Mutated in All Entities: MPN, MDS and MPN/MDS Overlap" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1926.1926 Silverchair:90126 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "5q Deletions in MDS and MPN: The Accompanying Molecular Mutations Determine the Phenotype but TP53 Is Frequently Mutated in All Entities: MPN, MDS and MPN/MDS Overlap" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1926.1926 Silverchair:90126 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model The American Society of Hematology American Society of Hematology 10.1182/blood.V97.3.616 Silverchair:52791 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model The American Society of Hematology American Society of Hematology 10.1182/blood.V97.3.616 Silverchair:52791 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model The American Society of Hematology American Society of Hematology 10.1182/blood.V97.3.616 Silverchair:52791 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model The American Society of Hematology American Society of Hematology 10.1182/blood.V97.3.616 Silverchair:52791 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-330530 Silverchair:29009 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-330530 Silverchair:29009 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-330530 Silverchair:29009 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-330530 Silverchair:29009 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A bispecific approach to improving CAR T cells in AML The American Society of Hematology American Society of Hematology 10.1182/blood.2020004791 Silverchair:452592 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 A bispecific approach to improving CAR T cells in AML The American Society of Hematology American Society of Hematology 10.1182/blood.2020004791 Silverchair:452592 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 A bispecific approach to improving CAR T cells in AML The American Society of Hematology American Society of Hematology 10.1182/blood.2020004791 Silverchair:452592 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 A bispecific approach to improving CAR T cells in AML The American Society of Hematology American Society of Hematology 10.1182/blood.2020004791 Silverchair:452592 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 A case of benign Pelger-Huët anomaly The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-640474 Silverchair:126436 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 0 3 0 0 A case of benign Pelger-Huët anomaly The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-640474 Silverchair:126436 Total_Item_Requests 3 0 0 0 0 0 0 0 0 0 3 0 0 A case of benign Pelger-Huët anomaly The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-640474 Silverchair:126436 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 A case of benign Pelger-Huët anomaly The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-640474 Silverchair:126436 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004904 Silverchair:476134 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004904 Silverchair:476134 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004904 Silverchair:476134 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004904 Silverchair:476134 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 "A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018017517 Silverchair:15908 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 "A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018017517 Silverchair:15908 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 "A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018017517 Silverchair:15908 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018017517 Silverchair:15908 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A CD99-related antigen on endothelial cells mediates neutrophil but not lymphocyte extravasation in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-043109 Silverchair:23067 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 A CD99-related antigen on endothelial cells mediates neutrophil but not lymphocyte extravasation in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-043109 Silverchair:23067 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 A CD99-related antigen on endothelial cells mediates neutrophil but not lymphocyte extravasation in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-043109 Silverchair:23067 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A CD99-related antigen on endothelial cells mediates neutrophil but not lymphocyte extravasation in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-043109 Silverchair:23067 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-843763 Silverchair:39623 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-843763 Silverchair:39623 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-843763 Silverchair:39623 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-843763 Silverchair:39623 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP) The American Society of Hematology American Society of Hematology 10.1182/blood-2006-03-004481 Silverchair:23032 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP) The American Society of Hematology American Society of Hematology 10.1182/blood-2006-03-004481 Silverchair:23032 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP) The American Society of Hematology American Society of Hematology 10.1182/blood-2006-03-004481 Silverchair:23032 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP) The American Society of Hematology American Society of Hematology 10.1182/blood-2006-03-004481 Silverchair:23032 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 A Compendium of Transcriptional and Mutational Data to Improve the Stratification of Peripheral T-Cell Lymphoma Subtypes The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3997.3997 Silverchair:72004 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A Compendium of Transcriptional and Mutational Data to Improve the Stratification of Peripheral T-Cell Lymphoma Subtypes The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3997.3997 Silverchair:72004 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A Compendium of Transcriptional and Mutational Data to Improve the Stratification of Peripheral T-Cell Lymphoma Subtypes The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3997.3997 Silverchair:72004 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A Compendium of Transcriptional and Mutational Data to Improve the Stratification of Peripheral T-Cell Lymphoma Subtypes The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3997.3997 Silverchair:72004 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-166801 Silverchair:24378 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-166801 Silverchair:24378 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-166801 Silverchair:24378 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-166801 Silverchair:24378 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A comprehensive transcriptome signature of murine hematopoietic stem cell aging The American Society of Hematology American Society of Hematology 10.1182/blood.2020009729 Silverchair:475784 Total_Item_Investigations 5 0 0 0 0 0 0 2 2 1 0 0 0 A comprehensive transcriptome signature of murine hematopoietic stem cell aging The American Society of Hematology American Society of Hematology 10.1182/blood.2020009729 Silverchair:475784 Unique_Item_Investigations 3 0 0 0 0 0 0 1 1 1 0 0 0 A conceptual framework for managing iTTP The American Society of Hematology American Society of Hematology 10.1182/blood.2021011007 Silverchair:475659 Total_Item_Investigations 13 0 0 0 9 4 0 0 0 0 0 0 0 A conceptual framework for managing iTTP The American Society of Hematology American Society of Hematology 10.1182/blood.2021011007 Silverchair:475659 Total_Item_Requests 10 0 0 0 8 2 0 0 0 0 0 0 0 A conceptual framework for managing iTTP The American Society of Hematology American Society of Hematology 10.1182/blood.2021011007 Silverchair:475659 Unique_Item_Investigations 3 0 0 0 2 1 0 0 0 0 0 0 0 A conceptual framework for managing iTTP The American Society of Hematology American Society of Hematology 10.1182/blood.2021011007 Silverchair:475659 Unique_Item_Requests 3 0 0 0 2 1 0 0 0 0 0 0 0 A CRISPR RNA-binding protein screen reveals regulators of RUNX1 isoform generation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002090 Silverchair:475380 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 A CRISPR RNA-binding protein screen reveals regulators of RUNX1 isoform generation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002090 Silverchair:475380 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 A CRISPR RNA-binding protein screen reveals regulators of RUNX1 isoform generation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002090 Silverchair:475380 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 A CRISPR RNA-binding protein screen reveals regulators of RUNX1 isoform generation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002090 Silverchair:475380 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 A critical function for B-Raf at multiple stages of myelopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2004-11-4458 Silverchair:21868 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 3 0 0 0 A critical function for B-Raf at multiple stages of myelopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2004-11-4458 Silverchair:21868 Total_Item_Requests 3 0 0 0 0 0 0 0 0 3 0 0 0 A critical function for B-Raf at multiple stages of myelopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2004-11-4458 Silverchair:21868 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 A critical function for B-Raf at multiple stages of myelopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2004-11-4458 Silverchair:21868 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 A day (or 5) in a neutrophil's life The American Society of Hematology American Society of Hematology 10.1182/blood-2010-05-283184 Silverchair:27471 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 A day (or 5) in a neutrophil's life The American Society of Hematology American Society of Hematology 10.1182/blood-2010-05-283184 Silverchair:27471 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 A day (or 5) in a neutrophil's life The American Society of Hematology American Society of Hematology 10.1182/blood-2010-05-283184 Silverchair:27471 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A day (or 5) in a neutrophil's life The American Society of Hematology American Society of Hematology 10.1182/blood-2010-05-283184 Silverchair:27471 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome The American Society of Hematology American Society of Hematology 10.1182/blood-2004-01-0338 Silverchair:18338 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome The American Society of Hematology American Society of Hematology 10.1182/blood-2004-01-0338 Silverchair:18338 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome The American Society of Hematology American Society of Hematology 10.1182/blood-2004-01-0338 Silverchair:18338 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome The American Society of Hematology American Society of Hematology 10.1182/blood-2004-01-0338 Silverchair:18338 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A Descriptive Study on Healthcare Utilization and Costs in Secondary Acute Myeloid Leukemia Patients Treated with CPX-351 Versus Those Treated with 7+3 The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127075 Silverchair:422818 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 A Descriptive Study on Healthcare Utilization and Costs in Secondary Acute Myeloid Leukemia Patients Treated with CPX-351 Versus Those Treated with 7+3 The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127075 Silverchair:422818 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 A Descriptive Study on Healthcare Utilization and Costs in Secondary Acute Myeloid Leukemia Patients Treated with CPX-351 Versus Those Treated with 7+3 The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127075 Silverchair:422818 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 A Descriptive Study on Healthcare Utilization and Costs in Secondary Acute Myeloid Leukemia Patients Treated with CPX-351 Versus Those Treated with 7+3 The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127075 Silverchair:422818 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 A Diagnostic Approach to Patients with an IgM Monoclonal Protein American Society of Hematology American Society of Hematology 10.1182/hem.V11.5.3186 Silverchair:462673 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A Diagnostic Approach to Patients with an IgM Monoclonal Protein American Society of Hematology American Society of Hematology 10.1182/hem.V11.5.3186 Silverchair:462673 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A Diagnostic Approach to Patients with an IgM Monoclonal Protein American Society of Hematology American Society of Hematology 10.1182/hem.V11.5.3186 Silverchair:462673 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A Diagnostic Approach to Patients with an IgM Monoclonal Protein American Society of Hematology American Society of Hematology 10.1182/hem.V11.5.3186 Silverchair:462673 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A disease risk index for patients undergoing allogeneic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-418202 Silverchair:105623 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A disease risk index for patients undergoing allogeneic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-418202 Silverchair:105623 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A disease risk index for patients undergoing allogeneic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-418202 Silverchair:105623 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A disease risk index for patients undergoing allogeneic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-418202 Silverchair:105623 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A Dose and Schedule Finding Study of Maintenance Therapy with Low-Dose 5-Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for High-Risk AML or MDS. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3012.3012 Silverchair:74372 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A Dose and Schedule Finding Study of Maintenance Therapy with Low-Dose 5-Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for High-Risk AML or MDS. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3012.3012 Silverchair:74372 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A Dose and Schedule Finding Study of Maintenance Therapy with Low-Dose 5-Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for High-Risk AML or MDS. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3012.3012 Silverchair:74372 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A Dose and Schedule Finding Study of Maintenance Therapy with Low-Dose 5-Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for High-Risk AML or MDS. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3012.3012 Silverchair:74372 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A dynamic intron retention program in the mammalian megakaryocyte and erythrocyte lineages The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-692764 Silverchair:34966 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A dynamic intron retention program in the mammalian megakaryocyte and erythrocyte lineages The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-692764 Silverchair:34966 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A dynamic intron retention program in the mammalian megakaryocyte and erythrocyte lineages The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-692764 Silverchair:34966 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A dynamic intron retention program in the mammalian megakaryocyte and erythrocyte lineages The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-692764 Silverchair:34966 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) The American Society of Hematology American Society of Hematology 10.1182/blood-2009-09-245837 Silverchair:27216 Total_Item_Investigations 5 3 0 2 0 0 0 0 0 0 0 0 0 A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) The American Society of Hematology American Society of Hematology 10.1182/blood-2009-09-245837 Silverchair:27216 Total_Item_Requests 5 3 0 2 0 0 0 0 0 0 0 0 0 A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) The American Society of Hematology American Society of Hematology 10.1182/blood-2009-09-245837 Silverchair:27216 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) The American Society of Hematology American Society of Hematology 10.1182/blood-2009-09-245837 Silverchair:27216 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 A Favorable BCL-2 Family Expression Profile May Explain the Increased Susceptibility of the t(11;14) Multiple Myeloma Subgroup to Single Agent Venetoclax The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5613.5613 Silverchair:94838 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 A Favorable BCL-2 Family Expression Profile May Explain the Increased Susceptibility of the t(11;14) Multiple Myeloma Subgroup to Single Agent Venetoclax The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5613.5613 Silverchair:94838 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 A Favorable BCL-2 Family Expression Profile May Explain the Increased Susceptibility of the t(11;14) Multiple Myeloma Subgroup to Single Agent Venetoclax The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5613.5613 Silverchair:94838 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A Favorable BCL-2 Family Expression Profile May Explain the Increased Susceptibility of the t(11;14) Multiple Myeloma Subgroup to Single Agent Venetoclax The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5613.5613 Silverchair:94838 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "A First in Human Study Planned to Evaluate Hdp-101, an Anti-BCMA Amanitin Antibody-Drug Conjugate with a New Payload and a New Mode of Action, in Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142285 Silverchair:472856 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 "A First in Human Study Planned to Evaluate Hdp-101, an Anti-BCMA Amanitin Antibody-Drug Conjugate with a New Payload and a New Mode of Action, in Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142285 Silverchair:472856 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 "A First in Human Study Planned to Evaluate Hdp-101, an Anti-BCMA Amanitin Antibody-Drug Conjugate with a New Payload and a New Mode of Action, in Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142285 Silverchair:472856 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 "A First in Human Study Planned to Evaluate Hdp-101, an Anti-BCMA Amanitin Antibody-Drug Conjugate with a New Payload and a New Mode of Action, in Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142285 Silverchair:472856 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 A Five Year Experience of Acute Intrahepatic Cholestasis in Patients with Sickle Cell Disease at a Large Teaching Hospital in London The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3416.3416 Silverchair:90960 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 A Five Year Experience of Acute Intrahepatic Cholestasis in Patients with Sickle Cell Disease at a Large Teaching Hospital in London The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3416.3416 Silverchair:90960 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 A Five Year Experience of Acute Intrahepatic Cholestasis in Patients with Sickle Cell Disease at a Large Teaching Hospital in London The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3416.3416 Silverchair:90960 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 A Five Year Experience of Acute Intrahepatic Cholestasis in Patients with Sickle Cell Disease at a Large Teaching Hospital in London The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3416.3416 Silverchair:90960 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 "A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008164 Silverchair:474122 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 "A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008164 Silverchair:474122 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008164 Silverchair:474122 No_License 1 0 0 1 0 0 0 0 0 0 0 0 0 A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo The American Society of Hematology American Society of Hematology 10.1182/blood.V99.11.3885 Silverchair:106822 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo The American Society of Hematology American Society of Hematology 10.1182/blood.V99.11.3885 Silverchair:106822 Total_Item_Requests 4 0 4 0 0 0 0 0 0 0 0 0 0 A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo The American Society of Hematology American Society of Hematology 10.1182/blood.V99.11.3885 Silverchair:106822 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo The American Society of Hematology American Society of Hematology 10.1182/blood.V99.11.3885 Silverchair:106822 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4239.4239 Silverchair:136004 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4239.4239 Silverchair:136004 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4239.4239 Silverchair:136004 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4239.4239 Silverchair:136004 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A Functional Characterization of BCL2-Family Members Identifies BH3 Mimetics As Potential Therapeutics in T-Cell Lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.292.292 Silverchair:114103 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A Functional Characterization of BCL2-Family Members Identifies BH3 Mimetics As Potential Therapeutics in T-Cell Lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.292.292 Silverchair:114103 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A Functional Characterization of BCL2-Family Members Identifies BH3 Mimetics As Potential Therapeutics in T-Cell Lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.292.292 Silverchair:114103 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A Functional Characterization of BCL2-Family Members Identifies BH3 Mimetics As Potential Therapeutics in T-Cell Lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.292.292 Silverchair:114103 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A Geno-Clinical Decision Model for the Diagnosis of Myelodysplastic Syndromes American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004755 Silverchair:477106 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 A Geno-Clinical Decision Model for the Diagnosis of Myelodysplastic Syndromes American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004755 Silverchair:477106 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 A HaemAtlas: characterizing gene expression in differentiated human blood cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-06-162958 Silverchair:25963 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 A HaemAtlas: characterizing gene expression in differentiated human blood cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-06-162958 Silverchair:25963 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 A HaemAtlas: characterizing gene expression in differentiated human blood cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-06-162958 Silverchair:25963 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A HaemAtlas: characterizing gene expression in differentiated human blood cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-06-162958 Silverchair:25963 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A Heparin-Based Inhibitor of Heparanase Blocks Myeloma Growth In Vivo by Targeting the Tumor Microenvironment. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.1502.1502 Silverchair:56991 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A Heparin-Based Inhibitor of Heparanase Blocks Myeloma Growth In Vivo by Targeting the Tumor Microenvironment. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.1502.1502 Silverchair:56991 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A Heparin-Based Inhibitor of Heparanase Blocks Myeloma Growth In Vivo by Targeting the Tumor Microenvironment. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.1502.1502 Silverchair:56991 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A Heparin-Based Inhibitor of Heparanase Blocks Myeloma Growth In Vivo by Targeting the Tumor Microenvironment. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.1502.1502 Silverchair:56991 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A High Incidence of Disseminated Intravascular Coagulation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Its Management The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2500.2500 Silverchair:113046 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A High Incidence of Disseminated Intravascular Coagulation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Its Management The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2500.2500 Silverchair:113046 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A High Incidence of Disseminated Intravascular Coagulation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Its Management The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2500.2500 Silverchair:113046 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A High Incidence of Disseminated Intravascular Coagulation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Its Management The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2500.2500 Silverchair:113046 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "A High Incidence of Patients with MTHFR (methylenetetrahydrofolate reductase) Gene Mutations Noted in An Appalachian Population Seen for Thrombophilia at the West Virginia University Outpatient Hematology Clinic, 2006–2008" The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.4500.4500 Silverchair:62232 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "A High Incidence of Patients with MTHFR (methylenetetrahydrofolate reductase) Gene Mutations Noted in An Appalachian Population Seen for Thrombophilia at the West Virginia University Outpatient Hematology Clinic, 2006–2008" The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.4500.4500 Silverchair:62232 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "A High Incidence of Patients with MTHFR (methylenetetrahydrofolate reductase) Gene Mutations Noted in An Appalachian Population Seen for Thrombophilia at the West Virginia University Outpatient Hematology Clinic, 2006–2008" The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.4500.4500 Silverchair:62232 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "A High Incidence of Patients with MTHFR (methylenetetrahydrofolate reductase) Gene Mutations Noted in An Appalachian Population Seen for Thrombophilia at the West Virginia University Outpatient Hematology Clinic, 2006–2008" The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.4500.4500 Silverchair:62232 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-339879 Silverchair:29193 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 "A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-339879 Silverchair:29193 Total_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 "A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-339879 Silverchair:29193 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 "A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-339879 Silverchair:29193 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 A human SIRPA knock-in xenograft mouse model to study human hematopoietic and cancer stem cells The American Society of Hematology American Society of Hematology 10.1182/blood.2019002194 Silverchair:452764 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A human SIRPA knock-in xenograft mouse model to study human hematopoietic and cancer stem cells The American Society of Hematology American Society of Hematology 10.1182/blood.2019002194 Silverchair:452764 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML The American Society of Hematology American Society of Hematology 10.1182/blood.2020009023 Silverchair:475475 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML The American Society of Hematology American Society of Hematology 10.1182/blood.2020009023 Silverchair:475475 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML The American Society of Hematology American Society of Hematology 10.1182/blood.2020009023 Silverchair:475475 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML The American Society of Hematology American Society of Hematology 10.1182/blood.2020009023 Silverchair:475475 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "A Longitudinal Population Level Analysis of Healthcare Resource Utilization, Comorbidity, and Survival in Idiopathic Multicentric Castleman Disease Patients" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140449 Silverchair:471796 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 "A Longitudinal Population Level Analysis of Healthcare Resource Utilization, Comorbidity, and Survival in Idiopathic Multicentric Castleman Disease Patients" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140449 Silverchair:471796 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 "A Longitudinal Population Level Analysis of Healthcare Resource Utilization, Comorbidity, and Survival in Idiopathic Multicentric Castleman Disease Patients" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140449 Silverchair:471796 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 "A Longitudinal Population Level Analysis of Healthcare Resource Utilization, Comorbidity, and Survival in Idiopathic Multicentric Castleman Disease Patients" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140449 Silverchair:471796 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 A Long-Term (5-Year) Sustained Efficacy of Tocilizumab for Multicentric Castleman’s Disease and the Effect on Pulmonary Complications. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.646.646 Silverchair:118397 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A Long-Term (5-Year) Sustained Efficacy of Tocilizumab for Multicentric Castleman’s Disease and the Effect on Pulmonary Complications. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.646.646 Silverchair:118397 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A Long-Term (5-Year) Sustained Efficacy of Tocilizumab for Multicentric Castleman’s Disease and the Effect on Pulmonary Complications. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.646.646 Silverchair:118397 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A Long-Term (5-Year) Sustained Efficacy of Tocilizumab for Multicentric Castleman’s Disease and the Effect on Pulmonary Complications. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.646.646 Silverchair:118397 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A macrophage colony-stimulating factor receptor–green fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse The American Society of Hematology American Society of Hematology 10.1182/blood-2002-02-0569 Silverchair:88823 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 A macrophage colony-stimulating factor receptor–green fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse The American Society of Hematology American Society of Hematology 10.1182/blood-2002-02-0569 Silverchair:88823 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A macrophage colony-stimulating factor receptor–green fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse The American Society of Hematology American Society of Hematology 10.1182/blood-2002-02-0569 Silverchair:88823 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A macrophage colony-stimulating factor receptor–green fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse The American Society of Hematology American Society of Hematology 10.1182/blood-2002-02-0569 Silverchair:88823 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-860270 Silverchair:272753 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-860270 Silverchair:272753 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-860270 Silverchair:272753 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-860270 Silverchair:272753 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A Mendelian randomization of γ′ and total fibrinogen levels in relation to venous thromboembolism and ischemic stroke The American Society of Hematology American Society of Hematology 10.1182/blood.2019004781 Silverchair:461598 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 A Mendelian randomization of γ′ and total fibrinogen levels in relation to venous thromboembolism and ischemic stroke The American Society of Hematology American Society of Hematology 10.1182/blood.2019004781 Silverchair:461598 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 A Mendelian randomization of γ′ and total fibrinogen levels in relation to venous thromboembolism and ischemic stroke The American Society of Hematology American Society of Hematology 10.1182/blood.2019004781 Silverchair:461598 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A Mendelian randomization of γ′ and total fibrinogen levels in relation to venous thromboembolism and ischemic stroke The American Society of Hematology American Society of Hematology 10.1182/blood.2019004781 Silverchair:461598 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000491 Silverchair:430086 Total_Item_Investigations 3 1 0 2 0 0 0 0 0 0 0 0 0 A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000491 Silverchair:430086 Total_Item_Requests 3 1 0 2 0 0 0 0 0 0 0 0 0 A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000491 Silverchair:430086 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000491 Silverchair:430086 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 A method for noninvasive prenatal diagnosis of monogenic autosomal recessive disorders The American Society of Hematology American Society of Hematology 10.1182/blood.2019002099 Silverchair:374893 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 A method for noninvasive prenatal diagnosis of monogenic autosomal recessive disorders The American Society of Hematology American Society of Hematology 10.1182/blood.2019002099 Silverchair:374893 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 A method for noninvasive prenatal diagnosis of monogenic autosomal recessive disorders The American Society of Hematology American Society of Hematology 10.1182/blood.2019002099 Silverchair:374893 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A method for noninvasive prenatal diagnosis of monogenic autosomal recessive disorders The American Society of Hematology American Society of Hematology 10.1182/blood.2019002099 Silverchair:374893 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A mouse model of HIES reveals pro- and anti-inflammatory functions of STAT3 The American Society of Hematology American Society of Hematology 10.1182/blood-2013-09-523167 Silverchair:32665 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 A mouse model of HIES reveals pro- and anti-inflammatory functions of STAT3 The American Society of Hematology American Society of Hematology 10.1182/blood-2013-09-523167 Silverchair:32665 Total_Item_Requests 4 0 4 0 0 0 0 0 0 0 0 0 0 A mouse model of HIES reveals pro- and anti-inflammatory functions of STAT3 The American Society of Hematology American Society of Hematology 10.1182/blood-2013-09-523167 Silverchair:32665 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 A mouse model of HIES reveals pro- and anti-inflammatory functions of STAT3 The American Society of Hematology American Society of Hematology 10.1182/blood-2013-09-523167 Silverchair:32665 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102 The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136828 Silverchair:470533 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102 The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136828 Silverchair:470533 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102 The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136828 Silverchair:470533 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102 The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136828 Silverchair:470533 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-581868 Silverchair:33789 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-581868 Silverchair:33789 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-581868 Silverchair:33789 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-581868 Silverchair:33789 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors" The American Society of Hematology American Society of Hematology 10.1182/blood.2019001869 Silverchair:375128 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 0 3 0 0 "A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors" The American Society of Hematology American Society of Hematology 10.1182/blood.2019001869 Silverchair:375128 Total_Item_Requests 3 0 0 0 0 0 0 0 0 0 3 0 0 "A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors" The American Society of Hematology American Society of Hematology 10.1182/blood.2019001869 Silverchair:375128 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors" The American Society of Hematology American Society of Hematology 10.1182/blood.2019001869 Silverchair:375128 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 A Multicentre Randomised Trial of First Line Treatment Pathways for Newly Diagnosed Immune Thrombocytopenia: Standard Steroid Treatment Versus Combined Steroid and Mycophenolate. the Flight Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143563 Silverchair:474192 Total_Item_Investigations 12 3 9 0 0 0 0 0 0 0 0 0 0 A Multicentre Randomised Trial of First Line Treatment Pathways for Newly Diagnosed Immune Thrombocytopenia: Standard Steroid Treatment Versus Combined Steroid and Mycophenolate. the Flight Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143563 Silverchair:474192 Total_Item_Requests 12 3 9 0 0 0 0 0 0 0 0 0 0 A Multicentre Randomised Trial of First Line Treatment Pathways for Newly Diagnosed Immune Thrombocytopenia: Standard Steroid Treatment Versus Combined Steroid and Mycophenolate. the Flight Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143563 Silverchair:474192 Unique_Item_Investigations 7 1 6 0 0 0 0 0 0 0 0 0 0 A Multicentre Randomised Trial of First Line Treatment Pathways for Newly Diagnosed Immune Thrombocytopenia: Standard Steroid Treatment Versus Combined Steroid and Mycophenolate. the Flight Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143563 Silverchair:474192 Unique_Item_Requests 7 1 6 0 0 0 0 0 0 0 0 0 0 A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-475111 Silverchair:32417 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 2 0 0 0 A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-475111 Silverchair:32417 Total_Item_Requests 2 0 0 0 0 0 0 0 0 2 0 0 0 A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-475111 Silverchair:32417 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-475111 Silverchair:32417 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 A mutation in the Gardos channel is associated with hereditary xerocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-642496 Silverchair:34389 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A mutation in the Gardos channel is associated with hereditary xerocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-642496 Silverchair:34389 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A mutation in the Gardos channel is associated with hereditary xerocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-642496 Silverchair:34389 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A mutation in the Gardos channel is associated with hereditary xerocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-642496 Silverchair:34389 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A natural DNMT1 mutation elevates the fetal hemoglobin level via epigenetic derepression of the γ-globin gene in β-thalassemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020006425 Silverchair:474248 Total_Item_Investigations 3 0 2 1 0 0 0 0 0 0 0 0 0 A natural DNMT1 mutation elevates the fetal hemoglobin level via epigenetic derepression of the γ-globin gene in β-thalassemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020006425 Silverchair:474248 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A natural DNMT1 mutation elevates the fetal hemoglobin level via epigenetic derepression of the γ-globin gene in β-thalassemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020006425 Silverchair:474248 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 A natural DNMT1 mutation elevates the fetal hemoglobin level via epigenetic derepression of the γ-globin gene in β-thalassemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020006425 Silverchair:474248 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A NET-thrombosis axis in COVID-19 The American Society of Hematology American Society of Hematology 10.1182/blood.2020007951 Silverchair:463532 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 A NET-thrombosis axis in COVID-19 The American Society of Hematology American Society of Hematology 10.1182/blood.2020007951 Silverchair:463532 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 A NET-thrombosis axis in COVID-19 The American Society of Hematology American Society of Hematology 10.1182/blood.2020007951 Silverchair:463532 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A NET-thrombosis axis in COVID-19 The American Society of Hematology American Society of Hematology 10.1182/blood.2020007951 Silverchair:463532 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A neutrophil activation signature predicts critical illness and mortality in COVID-19 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003568 Silverchair:475293 Total_Item_Investigations 129 0 20 83 5 3 3 5 1 2 5 2 0 A neutrophil activation signature predicts critical illness and mortality in COVID-19 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003568 Silverchair:475293 Total_Item_Requests 125 0 20 79 5 3 3 5 1 2 5 2 0 A neutrophil activation signature predicts critical illness and mortality in COVID-19 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003568 Silverchair:475293 Unique_Item_Investigations 79 0 12 51 2 2 2 4 1 1 3 1 0 A neutrophil activation signature predicts critical illness and mortality in COVID-19 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003568 Silverchair:475293 Unique_Item_Requests 79 0 12 51 2 2 2 4 1 1 3 1 0 A New CAR-T Option for Mantle Cell Lymphoma American Society of Hematology American Society of Hematology Silverchair:474712 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A New CAR-T Option for Mantle Cell Lymphoma American Society of Hematology American Society of Hematology Silverchair:474712 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A New CAR-T Option for Mantle Cell Lymphoma American Society of Hematology American Society of Hematology Silverchair:474712 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A New CAR-T Option for Mantle Cell Lymphoma American Society of Hematology American Society of Hematology Silverchair:474712 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A new era for hemophilia B treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2016-02-694869 Silverchair:34738 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 A new era for hemophilia B treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2016-02-694869 Silverchair:34738 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 A new era for hemophilia B treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2016-02-694869 Silverchair:34738 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 A new era for hemophilia B treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2016-02-694869 Silverchair:34738 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM) The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1826.1826 Silverchair:88611 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM) The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1826.1826 Silverchair:88611 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM) The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1826.1826 Silverchair:88611 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM) The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1826.1826 Silverchair:88611 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A New Path to Remission for Older Patients With AML American Society of Hematology American Society of Hematology Silverchair:464080 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 A New Path to Remission for Older Patients With AML American Society of Hematology American Society of Hematology Silverchair:464080 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 A New Path to Remission for Older Patients With AML American Society of Hematology American Society of Hematology Silverchair:464080 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 A New Path to Remission for Older Patients With AML American Society of Hematology American Society of Hematology Silverchair:464080 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2007-06-095331 Silverchair:103675 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2007-06-095331 Silverchair:103675 Total_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2007-06-095331 Silverchair:103675 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2007-06-095331 Silverchair:103675 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 A New Rapid Test for the Detection of PF4:Heparin Antibodies. The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.3708.3708 Silverchair:67426 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A New Rapid Test for the Detection of PF4:Heparin Antibodies. The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.3708.3708 Silverchair:67426 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A New Rapid Test for the Detection of PF4:Heparin Antibodies. The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.3708.3708 Silverchair:67426 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A New Rapid Test for the Detection of PF4:Heparin Antibodies. The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.3708.3708 Silverchair:67426 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "A New Staging System for AL Amyloidosis Incorporating Serum Free Light Chains, cardiac Troponin-T and NT-ProBNP." The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.2796.2796 Silverchair:132246 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "A New Staging System for AL Amyloidosis Incorporating Serum Free Light Chains, cardiac Troponin-T and NT-ProBNP." The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.2796.2796 Silverchair:132246 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "A New Staging System for AL Amyloidosis Incorporating Serum Free Light Chains, cardiac Troponin-T and NT-ProBNP." The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.2796.2796 Silverchair:132246 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "A New Staging System for AL Amyloidosis Incorporating Serum Free Light Chains, cardiac Troponin-T and NT-ProBNP." The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.2796.2796 Silverchair:132246 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A novel “vascular” thrombophilia The American Society of Hematology American Society of Hematology 10.1182/blood.2020010321 Silverchair:475761 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 A novel “vascular” thrombophilia The American Society of Hematology American Society of Hematology 10.1182/blood.2020010321 Silverchair:475761 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 A novel “vascular” thrombophilia The American Society of Hematology American Society of Hematology 10.1182/blood.2020010321 Silverchair:475761 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 A novel “vascular” thrombophilia The American Society of Hematology American Society of Hematology 10.1182/blood.2020010321 Silverchair:475761 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-291633 Silverchair:28367 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-291633 Silverchair:28367 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-291633 Silverchair:28367 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-291633 Silverchair:28367 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020008955 Silverchair:475782 Total_Item_Investigations 2 0 0 0 0 0 0 2 0 0 0 0 0 A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020008955 Silverchair:475782 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 A Novel and Successful Patient or Donor-Derived CD7-Targeted CAR T-Cell Therapy for Relapsed or Refractory T-Cell Lymphoblastic Lymphoma (R/R T-LBL) The American Society of Hematology American Society of Hematology 10.1182/blood-2021-147754 Silverchair:479962 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 A Novel and Successful Patient or Donor-Derived CD7-Targeted CAR T-Cell Therapy for Relapsed or Refractory T-Cell Lymphoblastic Lymphoma (R/R T-LBL) The American Society of Hematology American Society of Hematology 10.1182/blood-2021-147754 Silverchair:479962 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 A Novel and Successful Patient or Donor-Derived CD7-Targeted CAR T-Cell Therapy for Relapsed or Refractory T-Cell Lymphoblastic Lymphoma (R/R T-LBL) The American Society of Hematology American Society of Hematology 10.1182/blood-2021-147754 Silverchair:479962 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 A Novel and Successful Patient or Donor-Derived CD7-Targeted CAR T-Cell Therapy for Relapsed or Refractory T-Cell Lymphoblastic Lymphoma (R/R T-LBL) The American Society of Hematology American Society of Hematology 10.1182/blood-2021-147754 Silverchair:479962 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 A Novel Assay of Neutrophil Extracellular Traps (NETs) Formation Independently Predicts DIC and Identifies the Rationale for Anti-IL-8 Therapies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128493 Silverchair:426365 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 A Novel Assay of Neutrophil Extracellular Traps (NETs) Formation Independently Predicts DIC and Identifies the Rationale for Anti-IL-8 Therapies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128493 Silverchair:426365 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 A Novel Assay of Neutrophil Extracellular Traps (NETs) Formation Independently Predicts DIC and Identifies the Rationale for Anti-IL-8 Therapies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128493 Silverchair:426365 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 A Novel Assay of Neutrophil Extracellular Traps (NETs) Formation Independently Predicts DIC and Identifies the Rationale for Anti-IL-8 Therapies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128493 Silverchair:426365 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001188 Silverchair:452643 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001188 Silverchair:452643 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001188 Silverchair:452643 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001188 Silverchair:452643 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A Novel Device Suitable for Home Monitoring of White Blood Cell and Neutrophil Counts The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112647 Silverchair:262667 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A Novel Device Suitable for Home Monitoring of White Blood Cell and Neutrophil Counts The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112647 Silverchair:262667 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A Novel Device Suitable for Home Monitoring of White Blood Cell and Neutrophil Counts The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112647 Silverchair:262667 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A Novel Device Suitable for Home Monitoring of White Blood Cell and Neutrophil Counts The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112647 Silverchair:262667 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A novel disease-causing synonymous exonic mutation in GATA2 affecting RNA splicing The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-837336 Silverchair:39369 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 0 3 0 0 A novel disease-causing synonymous exonic mutation in GATA2 affecting RNA splicing The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-837336 Silverchair:39369 Total_Item_Requests 3 0 0 0 0 0 0 0 0 0 3 0 0 A novel disease-causing synonymous exonic mutation in GATA2 affecting RNA splicing The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-837336 Silverchair:39369 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 A novel disease-causing synonymous exonic mutation in GATA2 affecting RNA splicing The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-837336 Silverchair:39369 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 A Novel Homozygous CTC1 Germline Mutation Associated with Bone Marrow Failure The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1508.1508 Silverchair:91318 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A Novel Homozygous CTC1 Germline Mutation Associated with Bone Marrow Failure The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1508.1508 Silverchair:91318 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A Novel Homozygous CTC1 Germline Mutation Associated with Bone Marrow Failure The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1508.1508 Silverchair:91318 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A Novel Homozygous CTC1 Germline Mutation Associated with Bone Marrow Failure The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1508.1508 Silverchair:91318 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A novel homozygous variant of the thrombomodulin gene causes a hereditary bleeding disorder American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003814 Silverchair:476764 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 A novel homozygous variant of the thrombomodulin gene causes a hereditary bleeding disorder American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003814 Silverchair:476764 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 A novel homozygous variant of the thrombomodulin gene causes a hereditary bleeding disorder American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003814 Silverchair:476764 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 A novel homozygous variant of the thrombomodulin gene causes a hereditary bleeding disorder American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003814 Silverchair:476764 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "A novel humanized mouse model with significant improvement of class-switched, antigen-specific antibody production" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-709584 Silverchair:36357 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 "A novel humanized mouse model with significant improvement of class-switched, antigen-specific antibody production" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-709584 Silverchair:36357 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 "A novel humanized mouse model with significant improvement of class-switched, antigen-specific antibody production" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-709584 Silverchair:36357 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 "A novel humanized mouse model with significant improvement of class-switched, antigen-specific antibody production" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-709584 Silverchair:36357 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 A novel method to generate T-cell receptor–deficient chimeric antigen receptor T cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017012823 Silverchair:15798 Total_Item_Investigations 7 4 3 0 0 0 0 0 0 0 0 0 0 A novel method to generate T-cell receptor–deficient chimeric antigen receptor T cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017012823 Silverchair:15798 Total_Item_Requests 7 4 3 0 0 0 0 0 0 0 0 0 0 A novel method to generate T-cell receptor–deficient chimeric antigen receptor T cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017012823 Silverchair:15798 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 A novel method to generate T-cell receptor–deficient chimeric antigen receptor T cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017012823 Silverchair:15798 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 "A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4)" The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-631937 Silverchair:34518 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 3 0 0 0 "A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4)" The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-631937 Silverchair:34518 Total_Item_Requests 3 0 0 0 0 0 0 0 0 3 0 0 0 "A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4)" The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-631937 Silverchair:34518 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 "A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4)" The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-631937 Silverchair:34518 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403 The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-881961 Silverchair:260519 Total_Item_Investigations 9 9 0 0 0 0 0 0 0 0 0 0 0 A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403 The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-881961 Silverchair:260519 Total_Item_Requests 9 9 0 0 0 0 0 0 0 0 0 0 0 A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403 The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-881961 Silverchair:260519 Unique_Item_Investigations 5 5 0 0 0 0 0 0 0 0 0 0 0 A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403 The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-881961 Silverchair:260519 Unique_Item_Requests 5 5 0 0 0 0 0 0 0 0 0 0 0 A Perfect Storm: Chromosomal Alterations Cooperate With Clonal Hematopoiesis to Generate Therapy-Related Myeloid Neoplasia American Society of Hematology American Society of Hematology Silverchair:475641 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 A Perfect Storm: Chromosomal Alterations Cooperate With Clonal Hematopoiesis to Generate Therapy-Related Myeloid Neoplasia American Society of Hematology American Society of Hematology Silverchair:475641 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 A Perfect Storm: Chromosomal Alterations Cooperate With Clonal Hematopoiesis to Generate Therapy-Related Myeloid Neoplasia American Society of Hematology American Society of Hematology Silverchair:475641 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 A Perfect Storm: Chromosomal Alterations Cooperate With Clonal Hematopoiesis to Generate Therapy-Related Myeloid Neoplasia American Society of Hematology American Society of Hematology Silverchair:475641 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020005524 Silverchair:463599 No_License 1 0 1 0 0 0 0 0 0 0 0 0 0 A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020005524 Silverchair:463599 Total_Item_Investigations 7 1 4 0 0 2 0 0 0 0 0 0 0 A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020005524 Silverchair:463599 Total_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020005524 Silverchair:463599 Unique_Item_Investigations 5 1 3 0 0 1 0 0 0 0 0 0 0 A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020005524 Silverchair:463599 Unique_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 "A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-109762 Silverchair:264250 Total_Item_Investigations 7 0 7 0 0 0 0 0 0 0 0 0 0 "A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-109762 Silverchair:264250 Total_Item_Requests 7 0 7 0 0 0 0 0 0 0 0 0 0 "A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-109762 Silverchair:264250 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-109762 Silverchair:264250 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125966 Silverchair:423108 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 "A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125966 Silverchair:423108 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 "A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125966 Silverchair:423108 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125966 Silverchair:423108 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137685 Silverchair:469911 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137685 Silverchair:469911 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137685 Silverchair:469911 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137685 Silverchair:469911 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study) The American Society of Hematology American Society of Hematology 10.1182/blood.2020007848 Silverchair:469618 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study) The American Society of Hematology American Society of Hematology 10.1182/blood.2020007848 Silverchair:469618 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study) The American Society of Hematology American Society of Hematology 10.1182/blood.2020007848 Silverchair:469618 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study) The American Society of Hematology American Society of Hematology 10.1182/blood.2020007848 Silverchair:469618 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 "A Phase 1 Study of LY3410738, a First-in-Class Covalent Inhibitor of Mutant IDH in Advanced Myeloid Malignancies (Trial in Progress)" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134307 Silverchair:472509 Total_Item_Investigations 2 0 1 0 0 0 0 0 0 0 1 0 0 "A Phase 1 Study of LY3410738, a First-in-Class Covalent Inhibitor of Mutant IDH in Advanced Myeloid Malignancies (Trial in Progress)" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134307 Silverchair:472509 Total_Item_Requests 2 0 1 0 0 0 0 0 0 0 1 0 0 "A Phase 1 Study of LY3410738, a First-in-Class Covalent Inhibitor of Mutant IDH in Advanced Myeloid Malignancies (Trial in Progress)" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134307 Silverchair:472509 Unique_Item_Investigations 2 0 1 0 0 0 0 0 0 0 1 0 0 "A Phase 1 Study of LY3410738, a First-in-Class Covalent Inhibitor of Mutant IDH in Advanced Myeloid Malignancies (Trial in Progress)" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134307 Silverchair:472509 Unique_Item_Requests 2 0 1 0 0 0 0 0 0 0 1 0 0 A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-806737 Silverchair:38526 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-806737 Silverchair:38526 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-806737 Silverchair:38526 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-806737 Silverchair:38526 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Healthy Adults" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123695 Silverchair:424252 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Healthy Adults" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123695 Silverchair:424252 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Healthy Adults" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123695 Silverchair:424252 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Healthy Adults" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123695 Silverchair:424252 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.254.254 Silverchair:112989 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.254.254 Silverchair:112989 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.254.254 Silverchair:112989 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.254.254 Silverchair:112989 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "A Phase 1 Study to Assess the Absolute Bioavailability and Safety of An Oral Solution of Decitabine In Subjects with Myelodysplastic Syndromes (MDS)," The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.3801.3801 Silverchair:69136 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 "A Phase 1 Study to Assess the Absolute Bioavailability and Safety of An Oral Solution of Decitabine In Subjects with Myelodysplastic Syndromes (MDS)," The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.3801.3801 Silverchair:69136 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 "A Phase 1 Study to Assess the Absolute Bioavailability and Safety of An Oral Solution of Decitabine In Subjects with Myelodysplastic Syndromes (MDS)," The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.3801.3801 Silverchair:69136 Unique_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 "A Phase 1 Study to Assess the Absolute Bioavailability and Safety of An Oral Solution of Decitabine In Subjects with Myelodysplastic Syndromes (MDS)," The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.3801.3801 Silverchair:69136 Unique_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-422683 Silverchair:30870 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-422683 Silverchair:30870 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-422683 Silverchair:30870 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-422683 Silverchair:30870 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124994 Silverchair:426344 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124994 Silverchair:426344 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124994 Silverchair:426344 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124994 Silverchair:426344 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124437 Silverchair:426368 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124437 Silverchair:426368 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124437 Silverchair:426368 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124437 Silverchair:426368 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128773 Silverchair:427323 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128773 Silverchair:427323 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128773 Silverchair:427323 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128773 Silverchair:427323 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-273151 Silverchair:27645 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-273151 Silverchair:27645 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-273151 Silverchair:27645 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-273151 Silverchair:27645 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122546 Silverchair:426593 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122546 Silverchair:426593 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122546 Silverchair:426593 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122546 Silverchair:426593 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A Phase 2 Study Of Single-Agent Brentuximab Vedotin For Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above: Interim Results The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4389.4389 Silverchair:13918 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A Phase 2 Study Of Single-Agent Brentuximab Vedotin For Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above: Interim Results The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4389.4389 Silverchair:13918 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A Phase 2 Study Of Single-Agent Brentuximab Vedotin For Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above: Interim Results The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4389.4389 Silverchair:13918 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A Phase 2 Study Of Single-Agent Brentuximab Vedotin For Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above: Interim Results The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4389.4389 Silverchair:13918 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123986 Silverchair:426357 Total_Item_Investigations 5 0 0 0 0 0 0 0 0 0 3 0 2 A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123986 Silverchair:426357 Total_Item_Requests 3 0 0 0 0 0 0 0 0 0 2 0 1 A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123986 Silverchair:426357 Unique_Item_Investigations 2 0 0 0 0 0 0 0 0 0 1 0 1 A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123986 Silverchair:426357 Unique_Item_Requests 2 0 0 0 0 0 0 0 0 0 1 0 1 A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-341131 Silverchair:29718 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-341131 Silverchair:29718 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-341131 Silverchair:29718 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-341131 Silverchair:29718 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-517276 Silverchair:32378 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-517276 Silverchair:32378 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-517276 Silverchair:32378 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-517276 Silverchair:32378 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-015560 Silverchair:22818 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-015560 Silverchair:22818 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-015560 Silverchair:22818 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-015560 Silverchair:22818 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.312.312 Silverchair:112224 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.312.312 Silverchair:112224 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.312.312 Silverchair:112224 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.312.312 Silverchair:112224 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Intensive Chemotherapy (IC)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125924 Silverchair:423350 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Intensive Chemotherapy (IC)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125924 Silverchair:423350 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Intensive Chemotherapy (IC)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125924 Silverchair:423350 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Intensive Chemotherapy (IC)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125924 Silverchair:423350 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002544 Silverchair:474117 Total_Item_Investigations 15 6 4 1 4 0 0 0 0 0 0 0 0 A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002544 Silverchair:474117 Total_Item_Requests 15 6 4 1 4 0 0 0 0 0 0 0 0 A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002544 Silverchair:474117 Unique_Item_Investigations 6 2 2 1 1 0 0 0 0 0 0 0 0 A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002544 Silverchair:474117 Unique_Item_Requests 6 2 2 1 1 0 0 0 0 0 0 0 0 A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136465 Silverchair:470996 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136465 Silverchair:470996 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136465 Silverchair:470996 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136465 Silverchair:470996 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125363 Silverchair:427299 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125363 Silverchair:427299 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125363 Silverchair:427299 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125363 Silverchair:427299 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117089 Silverchair:272950 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117089 Silverchair:272950 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117089 Silverchair:272950 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117089 Silverchair:272950 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130337 Silverchair:423365 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130337 Silverchair:423365 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130337 Silverchair:423365 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130337 Silverchair:423365 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127390 Silverchair:426095 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127390 Silverchair:426095 Total_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127390 Silverchair:426095 Unique_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127390 Silverchair:426095 Unique_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 "A Phase I/IIa Study of Lemzoparlimab, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Initial Phase I Results" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134391 Silverchair:473356 Total_Item_Investigations 4 0 1 2 0 0 1 0 0 0 0 0 0 "A Phase I/IIa Study of Lemzoparlimab, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Initial Phase I Results" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134391 Silverchair:473356 Total_Item_Requests 4 0 1 2 0 0 1 0 0 0 0 0 0 "A Phase I/IIa Study of Lemzoparlimab, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Initial Phase I Results" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134391 Silverchair:473356 Unique_Item_Investigations 4 0 1 2 0 0 1 0 0 0 0 0 0 "A Phase I/IIa Study of Lemzoparlimab, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Initial Phase I Results" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134391 Silverchair:473356 Unique_Item_Requests 4 0 1 2 0 0 1 0 0 0 0 0 0 "A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126192 Silverchair:427169 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 "A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126192 Silverchair:427169 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 "A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126192 Silverchair:427169 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126192 Silverchair:427169 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "A Phase II Open-Label Study Evaluating Hemostatic Activity, Pharmacokinetics and Safety of Recombinant Porcine Factor VIII (OBI-1) in Hemophilia A Patients with Alloantibody Inhibitors Directed Against Human FVIII." The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.783.783 Silverchair:118517 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 "A Phase II Open-Label Study Evaluating Hemostatic Activity, Pharmacokinetics and Safety of Recombinant Porcine Factor VIII (OBI-1) in Hemophilia A Patients with Alloantibody Inhibitors Directed Against Human FVIII." The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.783.783 Silverchair:118517 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 "A Phase II Open-Label Study Evaluating Hemostatic Activity, Pharmacokinetics and Safety of Recombinant Porcine Factor VIII (OBI-1) in Hemophilia A Patients with Alloantibody Inhibitors Directed Against Human FVIII." The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.783.783 Silverchair:118517 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 "A Phase II Open-Label Study Evaluating Hemostatic Activity, Pharmacokinetics and Safety of Recombinant Porcine Factor VIII (OBI-1) in Hemophilia A Patients with Alloantibody Inhibitors Directed Against Human FVIII." The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.783.783 Silverchair:118517 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143180 Silverchair:470487 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143180 Silverchair:470487 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143180 Silverchair:470487 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143180 Silverchair:470487 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "A Phase II, Single-Center, Open-Label Study Of Oral Panobinostat In Combination With Lenalidomide and Weekly Dexamethasone In Patients With Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.5392.5392 Silverchair:13672 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 "A Phase II, Single-Center, Open-Label Study Of Oral Panobinostat In Combination With Lenalidomide and Weekly Dexamethasone In Patients With Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.5392.5392 Silverchair:13672 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 "A Phase II, Single-Center, Open-Label Study Of Oral Panobinostat In Combination With Lenalidomide and Weekly Dexamethasone In Patients With Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.5392.5392 Silverchair:13672 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 "A Phase II, Single-Center, Open-Label Study Of Oral Panobinostat In Combination With Lenalidomide and Weekly Dexamethasone In Patients With Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.5392.5392 Silverchair:13672 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 A potent tetravalent T-cell–engaging bispecific antibody against CD33 in acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017014373 Silverchair:16077 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A potent tetravalent T-cell–engaging bispecific antibody against CD33 in acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017014373 Silverchair:16077 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A potent tetravalent T-cell–engaging bispecific antibody against CD33 in acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017014373 Silverchair:16077 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A potent tetravalent T-cell–engaging bispecific antibody against CD33 in acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017014373 Silverchair:16077 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A practical approach to evaluating postoperative thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001414 Silverchair:452553 Total_Item_Investigations 4 0 0 1 0 1 0 0 0 2 0 0 0 A practical approach to evaluating postoperative thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001414 Silverchair:452553 Total_Item_Requests 4 0 0 1 0 1 0 0 0 2 0 0 0 A practical approach to evaluating postoperative thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001414 Silverchair:452553 Unique_Item_Investigations 3 0 0 1 0 1 0 0 0 1 0 0 0 A practical approach to evaluating postoperative thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001414 Silverchair:452553 Unique_Item_Requests 3 0 0 1 0 1 0 0 0 1 0 0 0 A prognostic model (BATAP) with external validation for patients with transplant-associated thrombotic microangiopathy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004530 Silverchair:476860 Total_Item_Investigations 4 0 0 0 0 0 0 0 0 3 1 0 0 A prognostic model (BATAP) with external validation for patients with transplant-associated thrombotic microangiopathy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004530 Silverchair:476860 Total_Item_Requests 2 0 0 0 0 0 0 0 0 1 1 0 0 A prognostic model (BATAP) with external validation for patients with transplant-associated thrombotic microangiopathy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004530 Silverchair:476860 Unique_Item_Investigations 2 0 0 0 0 0 0 0 0 1 1 0 0 A prognostic model (BATAP) with external validation for patients with transplant-associated thrombotic microangiopathy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004530 Silverchair:476860 Unique_Item_Requests 2 0 0 0 0 0 0 0 0 1 1 0 0 A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003600 Silverchair:475551 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003600 Silverchair:475551 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003600 Silverchair:475551 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003600 Silverchair:475551 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 A Prospective Evaluation of Neurocognitive Function and Neurologic Symptoms in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Undergoing Anti-CD22 Chimeric Antigen Receptor Therapy The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1625.1625 Silverchair:113439 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A Prospective Evaluation of Neurocognitive Function and Neurologic Symptoms in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Undergoing Anti-CD22 Chimeric Antigen Receptor Therapy The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1625.1625 Silverchair:113439 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A Prospective Evaluation of Neurocognitive Function and Neurologic Symptoms in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Undergoing Anti-CD22 Chimeric Antigen Receptor Therapy The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1625.1625 Silverchair:113439 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A Prospective Evaluation of Neurocognitive Function and Neurologic Symptoms in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Undergoing Anti-CD22 Chimeric Antigen Receptor Therapy The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1625.1625 Silverchair:113439 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481 The American Society of Hematology American Society of Hematology 10.1182/blood-2005-06-2448 Silverchair:129256 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481 The American Society of Hematology American Society of Hematology 10.1182/blood-2005-06-2448 Silverchair:129256 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481 The American Society of Hematology American Society of Hematology 10.1182/blood-2005-06-2448 Silverchair:129256 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481 The American Society of Hematology American Society of Hematology 10.1182/blood-2005-06-2448 Silverchair:129256 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "A prospective, blinded study of a PF4-dependent assay for HIT diagnosis" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008195 Silverchair:463714 No_License 1 0 0 0 0 0 0 0 0 1 0 0 0 "A prospective, blinded study of a PF4-dependent assay for HIT diagnosis" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008195 Silverchair:463714 Total_Item_Investigations 11 0 2 5 0 0 0 0 0 2 2 0 0 "A prospective, blinded study of a PF4-dependent assay for HIT diagnosis" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008195 Silverchair:463714 Total_Item_Requests 9 0 2 5 0 0 0 0 0 0 2 0 0 "A prospective, blinded study of a PF4-dependent assay for HIT diagnosis" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008195 Silverchair:463714 Unique_Item_Investigations 5 0 1 2 0 0 0 0 0 1 1 0 0 "A prospective, blinded study of a PF4-dependent assay for HIT diagnosis" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008195 Silverchair:463714 Unique_Item_Requests 4 0 1 2 0 0 0 0 0 0 1 0 0 A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-270082 Silverchair:27350 Total_Item_Investigations 3 0 0 0 0 0 0 3 0 0 0 0 0 A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-270082 Silverchair:27350 Total_Item_Requests 3 0 0 0 0 0 0 3 0 0 0 0 0 A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-270082 Silverchair:27350 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-270082 Silverchair:27350 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML The American Society of Hematology American Society of Hematology 10.1182/blood-2016-07-730648 Silverchair:36558 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML The American Society of Hematology American Society of Hematology 10.1182/blood-2016-07-730648 Silverchair:36558 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML The American Society of Hematology American Society of Hematology 10.1182/blood-2016-07-730648 Silverchair:36558 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML The American Society of Hematology American Society of Hematology 10.1182/blood-2016-07-730648 Silverchair:36558 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-295279 Silverchair:28412 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-295279 Silverchair:28412 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-295279 Silverchair:28412 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-295279 Silverchair:28412 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019004596 Silverchair:454293 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019004596 Silverchair:454293 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019004596 Silverchair:454293 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019004596 Silverchair:454293 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood.2020006892 Silverchair:463981 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood.2020006892 Silverchair:463981 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood.2020006892 Silverchair:463981 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood.2020006892 Silverchair:463981 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-330126 Silverchair:28713 Total_Item_Investigations 4 0 2 0 0 2 0 0 0 0 0 0 0 A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-330126 Silverchair:28713 Total_Item_Requests 4 0 2 0 0 2 0 0 0 0 0 0 0 A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-330126 Silverchair:28713 Unique_Item_Investigations 2 0 1 0 0 1 0 0 0 0 0 0 0 A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-330126 Silverchair:28713 Unique_Item_Requests 2 0 1 0 0 1 0 0 0 0 0 0 0 A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331 The American Society of Hematology American Society of Hematology 10.1182/blood-2019-132435 Silverchair:428839 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331 The American Society of Hematology American Society of Hematology 10.1182/blood-2019-132435 Silverchair:428839 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331 The American Society of Hematology American Society of Hematology 10.1182/blood-2019-132435 Silverchair:428839 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331 The American Society of Hematology American Society of Hematology 10.1182/blood-2019-132435 Silverchair:428839 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study The American Society of Hematology American Society of Hematology 10.1182/blood.2020006844 Silverchair:461625 Total_Item_Investigations 8 2 2 0 0 0 0 4 0 0 0 0 0 A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study The American Society of Hematology American Society of Hematology 10.1182/blood.2020006844 Silverchair:461625 Total_Item_Requests 8 2 2 0 0 0 0 4 0 0 0 0 0 A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study The American Society of Hematology American Society of Hematology 10.1182/blood.2020006844 Silverchair:461625 Unique_Item_Investigations 4 1 1 0 0 0 0 2 0 0 0 0 0 A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study The American Society of Hematology American Society of Hematology 10.1182/blood.2020006844 Silverchair:461625 Unique_Item_Requests 4 1 1 0 0 0 0 2 0 0 0 0 0 A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.226.226 Silverchair:98470 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.226.226 Silverchair:98470 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.226.226 Silverchair:98470 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.226.226 Silverchair:98470 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-120779 Silverchair:375111 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-120779 Silverchair:375111 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-120779 Silverchair:375111 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-120779 Silverchair:375111 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-514398 Silverchair:32870 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 "A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-514398 Silverchair:32870 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 "A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-514398 Silverchair:32870 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 "A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-514398 Silverchair:32870 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 "A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008021 Silverchair:474080 Total_Item_Investigations 23 0 7 3 0 6 0 0 0 0 4 0 3 "A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008021 Silverchair:474080 Total_Item_Requests 20 0 7 0 0 6 0 0 0 0 4 0 3 "A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008021 Silverchair:474080 Unique_Item_Investigations 6 0 2 1 0 1 0 0 0 0 1 0 1 "A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008021 Silverchair:474080 Unique_Item_Requests 5 0 2 0 0 1 0 0 0 0 1 0 1 "A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008021 Silverchair:474080 No_License 1 0 0 1 0 0 0 0 0 0 0 0 0 A remarkABL new fusion oncogene in T-cell ALL The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-1302 Silverchair:19667 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A remarkABL new fusion oncogene in T-cell ALL The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-1302 Silverchair:19667 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A remarkABL new fusion oncogene in T-cell ALL The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-1302 Silverchair:19667 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A remarkABL new fusion oncogene in T-cell ALL The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-1302 Silverchair:19667 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A report of clustered COVID-19 in a hematology ward American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001982 Silverchair:461023 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A report of clustered COVID-19 in a hematology ward American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001982 Silverchair:461023 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A report of clustered COVID-19 in a hematology ward American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001982 Silverchair:461023 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A report of clustered COVID-19 in a hematology ward American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001982 Silverchair:461023 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A robust approach for the generation of functional hematopoietic progenitor cell lines to model leukemic transformation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003022 Silverchair:474811 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A robust approach for the generation of functional hematopoietic progenitor cell lines to model leukemic transformation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003022 Silverchair:474811 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A robust approach for the generation of functional hematopoietic progenitor cell lines to model leukemic transformation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003022 Silverchair:474811 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A robust approach for the generation of functional hematopoietic progenitor cell lines to model leukemic transformation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003022 Silverchair:474811 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A role for BLyS in the activation of innate immune cells The American Society of Hematology American Society of Hematology 10.1182/blood-2005-12-017319 Silverchair:22632 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 A role for BLyS in the activation of innate immune cells The American Society of Hematology American Society of Hematology 10.1182/blood-2005-12-017319 Silverchair:22632 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A role for BLyS in the activation of innate immune cells The American Society of Hematology American Society of Hematology 10.1182/blood-2005-12-017319 Silverchair:22632 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A role for BLyS in the activation of innate immune cells The American Society of Hematology American Society of Hematology 10.1182/blood-2005-12-017319 Silverchair:22632 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A second CD19 CAR T-cell infusion: yes or no? The American Society of Hematology American Society of Hematology 10.1182/blood.2020009206 Silverchair:474945 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 A second CD19 CAR T-cell infusion: yes or no? The American Society of Hematology American Society of Hematology 10.1182/blood.2020009206 Silverchair:474945 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 A second CD19 CAR T-cell infusion: yes or no? The American Society of Hematology American Society of Hematology 10.1182/blood.2020009206 Silverchair:474945 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A second CD19 CAR T-cell infusion: yes or no? The American Society of Hematology American Society of Hematology 10.1182/blood.2020009206 Silverchair:474945 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A second-generation TKI should always be used as initial therapy for CML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018018655 Silverchair:15979 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 A second-generation TKI should always be used as initial therapy for CML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018018655 Silverchair:15979 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 A second-generation TKI should always be used as initial therapy for CML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018018655 Silverchair:15979 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A second-generation TKI should always be used as initial therapy for CML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018018655 Silverchair:15979 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A simple Rx for congenital erythropoietic porphyria The American Society of Hematology American Society of Hematology 10.1182/blood.2020007968 Silverchair:474154 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 A simple Rx for congenital erythropoietic porphyria The American Society of Hematology American Society of Hematology 10.1182/blood.2020007968 Silverchair:474154 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 A simple Rx for congenital erythropoietic porphyria The American Society of Hematology American Society of Hematology 10.1182/blood.2020007968 Silverchair:474154 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 A simple Rx for congenital erythropoietic porphyria The American Society of Hematology American Society of Hematology 10.1182/blood.2020007968 Silverchair:474154 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 A single-cell hematopoietic landscape resolves 8 lineage trajectories and defects in Kit mutant mice The American Society of Hematology American Society of Hematology 10.1182/blood-2017-12-821413 Silverchair:37145 Total_Item_Investigations 6 0 5 1 0 0 0 0 0 0 0 0 0 A single-cell hematopoietic landscape resolves 8 lineage trajectories and defects in Kit mutant mice The American Society of Hematology American Society of Hematology 10.1182/blood-2017-12-821413 Silverchair:37145 Total_Item_Requests 5 0 4 1 0 0 0 0 0 0 0 0 0 A single-cell hematopoietic landscape resolves 8 lineage trajectories and defects in Kit mutant mice The American Society of Hematology American Society of Hematology 10.1182/blood-2017-12-821413 Silverchair:37145 Unique_Item_Investigations 3 0 2 1 0 0 0 0 0 0 0 0 0 A single-cell hematopoietic landscape resolves 8 lineage trajectories and defects in Kit mutant mice The American Society of Hematology American Society of Hematology 10.1182/blood-2017-12-821413 Silverchair:37145 Unique_Item_Requests 3 0 2 1 0 0 0 0 0 0 0 0 0 A single-cell resolution map of mouse hematopoietic stem and progenitor cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-716480 Silverchair:35749 Total_Item_Investigations 17 2 15 0 0 0 0 0 0 0 0 0 0 A single-cell resolution map of mouse hematopoietic stem and progenitor cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-716480 Silverchair:35749 Total_Item_Requests 17 2 15 0 0 0 0 0 0 0 0 0 0 A single-cell resolution map of mouse hematopoietic stem and progenitor cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-716480 Silverchair:35749 Unique_Item_Investigations 5 2 3 0 0 0 0 0 0 0 0 0 0 A single-cell resolution map of mouse hematopoietic stem and progenitor cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-716480 Silverchair:35749 Unique_Item_Requests 5 2 3 0 0 0 0 0 0 0 0 0 0 A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow The American Society of Hematology American Society of Hematology 10.1182/blood-2004-02-0526 Silverchair:19369 Total_Item_Investigations 5 5 0 0 0 0 0 0 0 0 0 0 0 A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow The American Society of Hematology American Society of Hematology 10.1182/blood-2004-02-0526 Silverchair:19369 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow The American Society of Hematology American Society of Hematology 10.1182/blood-2004-02-0526 Silverchair:19369 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow The American Society of Hematology American Society of Hematology 10.1182/blood-2004-02-0526 Silverchair:19369 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A step closer to GVL without GVHD The American Society of Hematology American Society of Hematology 10.1182/blood.2020010132 Silverchair:475918 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 A step closer to GVL without GVHD The American Society of Hematology American Society of Hematology 10.1182/blood.2020010132 Silverchair:475918 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 A step closer to GVL without GVHD The American Society of Hematology American Society of Hematology 10.1182/blood.2020010132 Silverchair:475918 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 A step closer to GVL without GVHD The American Society of Hematology American Society of Hematology 10.1182/blood.2020010132 Silverchair:475918 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 A subset of high-titer anti–factor VIII A2 domain antibodies is responsive to treatment with factor VIII The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-670034 Silverchair:34861 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 3 0 0 0 A subset of high-titer anti–factor VIII A2 domain antibodies is responsive to treatment with factor VIII The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-670034 Silverchair:34861 Total_Item_Requests 3 0 0 0 0 0 0 0 0 3 0 0 0 A subset of high-titer anti–factor VIII A2 domain antibodies is responsive to treatment with factor VIII The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-670034 Silverchair:34861 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 A subset of high-titer anti–factor VIII A2 domain antibodies is responsive to treatment with factor VIII The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-670034 Silverchair:34861 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 A systematic analysis of global anemia burden from 1990 to 2010 The American Society of Hematology American Society of Hematology 10.1182/blood-2013-06-508325 Silverchair:32839 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 A systematic analysis of global anemia burden from 1990 to 2010 The American Society of Hematology American Society of Hematology 10.1182/blood-2013-06-508325 Silverchair:32839 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 A systematic analysis of global anemia burden from 1990 to 2010 The American Society of Hematology American Society of Hematology 10.1182/blood-2013-06-508325 Silverchair:32839 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 A systematic analysis of global anemia burden from 1990 to 2010 The American Society of Hematology American Society of Hematology 10.1182/blood-2013-06-508325 Silverchair:32839 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories The American Society of Hematology American Society of Hematology 10.1182/blood-2004-01-0002 Silverchair:18289 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories The American Society of Hematology American Society of Hematology 10.1182/blood-2004-01-0002 Silverchair:18289 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories The American Society of Hematology American Society of Hematology 10.1182/blood-2004-01-0002 Silverchair:18289 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories The American Society of Hematology American Society of Hematology 10.1182/blood-2004-01-0002 Silverchair:18289 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003628 Silverchair:474821 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003628 Silverchair:474821 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003628 Silverchair:474821 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003628 Silverchair:474821 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A systematic review of the association between anti-β-2 glycoprotein I antibodies and APS manifestations American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005205 Silverchair:476986 Total_Item_Investigations 6 0 0 0 0 0 0 0 0 0 6 0 0 A systematic review of the association between anti-β-2 glycoprotein I antibodies and APS manifestations American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005205 Silverchair:476986 Total_Item_Requests 6 0 0 0 0 0 0 0 0 0 6 0 0 A systematic review of the association between anti-β-2 glycoprotein I antibodies and APS manifestations American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005205 Silverchair:476986 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 A systematic review of the association between anti-β-2 glycoprotein I antibodies and APS manifestations American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005205 Silverchair:476986 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 A Systematic Review on the Use of Intrathecal Rituximab in CNS Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.4987.4987 Silverchair:81974 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 A Systematic Review on the Use of Intrathecal Rituximab in CNS Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.4987.4987 Silverchair:81974 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 A Systematic Review on the Use of Intrathecal Rituximab in CNS Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.4987.4987 Silverchair:81974 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 A Systematic Review on the Use of Intrathecal Rituximab in CNS Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.4987.4987 Silverchair:81974 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 A tale of two mantle cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2018-05-853077 Silverchair:103898 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A tale of two mantle cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2018-05-853077 Silverchair:103898 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A tale of two mantle cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2018-05-853077 Silverchair:103898 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 A tale of two mantle cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2018-05-853077 Silverchair:103898 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A targeted proteomics investigation of the obesity paradox in venous thromboembolism American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003800 Silverchair:476424 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 A targeted proteomics investigation of the obesity paradox in venous thromboembolism American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003800 Silverchair:476424 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 A targeted proteomics investigation of the obesity paradox in venous thromboembolism American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003800 Silverchair:476424 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 A targeted proteomics investigation of the obesity paradox in venous thromboembolism American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003800 Silverchair:476424 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-549022 Silverchair:32784 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-549022 Silverchair:32784 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-549022 Silverchair:32784 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-549022 Silverchair:32784 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells The American Society of Hematology American Society of Hematology 10.1182/blood-2015-10-674465 Silverchair:35347 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells The American Society of Hematology American Society of Hematology 10.1182/blood-2015-10-674465 Silverchair:35347 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells The American Society of Hematology American Society of Hematology 10.1182/blood-2015-10-674465 Silverchair:35347 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells The American Society of Hematology American Society of Hematology 10.1182/blood-2015-10-674465 Silverchair:35347 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A toolkit for the collection of thrombosis-related data elements in COVID-19 clinical studies American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003269 Silverchair:474702 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 A toolkit for the collection of thrombosis-related data elements in COVID-19 clinical studies American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003269 Silverchair:474702 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 A toolkit for the collection of thrombosis-related data elements in COVID-19 clinical studies American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003269 Silverchair:474702 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 A toolkit for the collection of thrombosis-related data elements in COVID-19 clinical studies American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003269 Silverchair:474702 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 A tour through the transcriptional landscape of platelets The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-512756 Silverchair:33357 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 A tour through the transcriptional landscape of platelets The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-512756 Silverchair:33357 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 A tour through the transcriptional landscape of platelets The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-512756 Silverchair:33357 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A tour through the transcriptional landscape of platelets The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-512756 Silverchair:33357 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "A TREM family member, TLT-1, is found exclusively in the α-granules of megakaryocytes and platelets" The American Society of Hematology American Society of Hematology 10.1182/blood-2004-01-0315 Silverchair:18435 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "A TREM family member, TLT-1, is found exclusively in the α-granules of megakaryocytes and platelets" The American Society of Hematology American Society of Hematology 10.1182/blood-2004-01-0315 Silverchair:18435 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "A TREM family member, TLT-1, is found exclusively in the α-granules of megakaryocytes and platelets" The American Society of Hematology American Society of Hematology 10.1182/blood-2004-01-0315 Silverchair:18435 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "A TREM family member, TLT-1, is found exclusively in the α-granules of megakaryocytes and platelets" The American Society of Hematology American Society of Hematology 10.1182/blood-2004-01-0315 Silverchair:18435 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 A Unique Case of CSF3R-Mutated Chronic Neutrophilic Leukemia with Thrombocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142047 Silverchair:473645 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A Unique Case of CSF3R-Mutated Chronic Neutrophilic Leukemia with Thrombocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142047 Silverchair:473645 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A Unique Case of CSF3R-Mutated Chronic Neutrophilic Leukemia with Thrombocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142047 Silverchair:473645 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A Unique Case of CSF3R-Mutated Chronic Neutrophilic Leukemia with Thrombocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142047 Silverchair:473645 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference The American Society of Hematology American Society of Hematology 10.1182/blood-2018-05-848986 Silverchair:39417 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference The American Society of Hematology American Society of Hematology 10.1182/blood-2018-05-848986 Silverchair:39417 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference The American Society of Hematology American Society of Hematology 10.1182/blood-2018-05-848986 Silverchair:39417 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference The American Society of Hematology American Society of Hematology 10.1182/blood-2018-05-848986 Silverchair:39417 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.2020009342 Silverchair:474200 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.2020009342 Silverchair:474200 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.2020009342 Silverchair:474200 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.2020009342 Silverchair:474200 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 A wave of bipotent T/ILC-restricted progenitors shapes the embryonic thymus microenvironment in a time-dependent manner The American Society of Hematology American Society of Hematology 10.1182/blood.2020006779 Silverchair:464127 No_License 1 0 0 1 0 0 0 0 0 0 0 0 0 A wave of bipotent T/ILC-restricted progenitors shapes the embryonic thymus microenvironment in a time-dependent manner The American Society of Hematology American Society of Hematology 10.1182/blood.2020006779 Silverchair:464127 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 A wave of bipotent T/ILC-restricted progenitors shapes the embryonic thymus microenvironment in a time-dependent manner The American Society of Hematology American Society of Hematology 10.1182/blood.2020006779 Silverchair:464127 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup The American Society of Hematology American Society of Hematology 10.1182/blood.V99.10.3517 Silverchair:106963 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup The American Society of Hematology American Society of Hematology 10.1182/blood.V99.10.3517 Silverchair:106963 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup The American Society of Hematology American Society of Hematology 10.1182/blood.V99.10.3517 Silverchair:106963 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup The American Society of Hematology American Society of Hematology 10.1182/blood.V99.10.3517 Silverchair:106963 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "A zinc transporter, transmembrane protein 163 (TMEM163), is critical for the biogenesis of platelet dense granules" The American Society of Hematology American Society of Hematology 10.1182/blood.2020007389 Silverchair:475088 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "A zinc transporter, transmembrane protein 163 (TMEM163), is critical for the biogenesis of platelet dense granules" The American Society of Hematology American Society of Hematology 10.1182/blood.2020007389 Silverchair:475088 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002236 Silverchair:463325 Total_Item_Investigations 3 1 0 2 0 0 0 0 0 0 0 0 0 Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002236 Silverchair:463325 Total_Item_Requests 3 1 0 2 0 0 0 0 0 0 0 0 0 Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002236 Silverchair:463325 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002236 Silverchair:463325 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-05-285999 Silverchair:28265 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-05-285999 Silverchair:28265 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-05-285999 Silverchair:28265 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-05-285999 Silverchair:28265 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2005-05-2125 Silverchair:131481 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2005-05-2125 Silverchair:131481 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2005-05-2125 Silverchair:131481 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2005-05-2125 Silverchair:131481 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Abnormalities in IgA and IgM are associated with treatment-resistant ITP The American Society of Hematology American Society of Hematology 10.1182/blood-2011-09-381020 Silverchair:29953 Total_Item_Investigations 2 0 1 0 0 0 0 0 0 1 0 0 0 Abnormalities in IgA and IgM are associated with treatment-resistant ITP The American Society of Hematology American Society of Hematology 10.1182/blood-2011-09-381020 Silverchair:29953 Total_Item_Requests 2 0 1 0 0 0 0 0 0 1 0 0 0 Abnormalities in IgA and IgM are associated with treatment-resistant ITP The American Society of Hematology American Society of Hematology 10.1182/blood-2011-09-381020 Silverchair:29953 Unique_Item_Investigations 2 0 1 0 0 0 0 0 0 1 0 0 0 Abnormalities in IgA and IgM are associated with treatment-resistant ITP The American Society of Hematology American Society of Hematology 10.1182/blood-2011-09-381020 Silverchair:29953 Unique_Item_Requests 2 0 1 0 0 0 0 0 0 1 0 0 0 ABO blood group glycans modulate sialic acid recognition on erythrocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2009-06-227041 Silverchair:26467 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 ABO blood group glycans modulate sialic acid recognition on erythrocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2009-06-227041 Silverchair:26467 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 ABO blood group glycans modulate sialic acid recognition on erythrocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2009-06-227041 Silverchair:26467 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 ABO blood group glycans modulate sialic acid recognition on erythrocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2009-06-227041 Silverchair:26467 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 ABO Blood Type and Outcomes in a Diverse COVID-19 Infected Population The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142943 Silverchair:473941 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 ABO Blood Type and Outcomes in a Diverse COVID-19 Infected Population The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142943 Silverchair:473941 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 ABO Blood Type and Outcomes in a Diverse COVID-19 Infected Population The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142943 Silverchair:473941 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 ABO Blood Type and Outcomes in a Diverse COVID-19 Infected Population The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142943 Silverchair:473941 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Absence of a common founder mutation in patients with cooccurring myelodysplastic syndrome and plasma cell disorder The American Society of Hematology American Society of Hematology 10.1182/blood.2020007555 Silverchair:469792 Total_Item_Investigations 3 2 0 0 0 1 0 0 0 0 0 0 0 Absence of a common founder mutation in patients with cooccurring myelodysplastic syndrome and plasma cell disorder The American Society of Hematology American Society of Hematology 10.1182/blood.2020007555 Silverchair:469792 Unique_Item_Investigations 2 1 0 0 0 1 0 0 0 0 0 0 0 Absence of a common founder mutation in patients with cooccurring myelodysplastic syndrome and plasma cell disorder The American Society of Hematology American Society of Hematology 10.1182/blood.2020007555 Silverchair:469792 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Absence of a common founder mutation in patients with cooccurring myelodysplastic syndrome and plasma cell disorder The American Society of Hematology American Society of Hematology 10.1182/blood.2020007555 Silverchair:469792 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Absolute proteome quantification of highly purified populations of circulating reticulocytes and mature erythrocytes American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018023515 Silverchair:16121 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Absolute proteome quantification of highly purified populations of circulating reticulocytes and mature erythrocytes American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018023515 Silverchair:16121 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Absolute proteome quantification of highly purified populations of circulating reticulocytes and mature erythrocytes American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018023515 Silverchair:16121 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Absolute proteome quantification of highly purified populations of circulating reticulocytes and mature erythrocytes American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018023515 Silverchair:16121 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136317 Silverchair:471066 Total_Item_Investigations 3 0 2 1 0 0 0 0 0 0 0 0 0 Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136317 Silverchair:471066 Total_Item_Requests 3 0 2 1 0 0 0 0 0 0 0 0 0 Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136317 Silverchair:471066 Unique_Item_Investigations 3 0 2 1 0 0 0 0 0 0 0 0 0 Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136317 Silverchair:471066 Unique_Item_Requests 3 0 2 1 0 0 0 0 0 0 0 0 0 Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018030007 Silverchair:246792 Total_Item_Investigations 2 0 0 0 0 0 0 2 0 0 0 0 0 Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018030007 Silverchair:246792 Total_Item_Requests 2 0 0 0 0 0 0 2 0 0 0 0 0 Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018030007 Silverchair:246792 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018030007 Silverchair:246792 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Acalabrutinib Monotherapy in Patients with Ibrutinib Intolerance: Results from the Phase 1/2 ACE-CL-001 Clinical Study The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.638.638 Silverchair:95446 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Acalabrutinib Monotherapy in Patients with Ibrutinib Intolerance: Results from the Phase 1/2 ACE-CL-001 Clinical Study The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.638.638 Silverchair:95446 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Acalabrutinib Monotherapy in Patients with Ibrutinib Intolerance: Results from the Phase 1/2 ACE-CL-001 Clinical Study The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.638.638 Silverchair:95446 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Acalabrutinib Monotherapy in Patients with Ibrutinib Intolerance: Results from the Phase 1/2 ACE-CL-001 Clinical Study The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.638.638 Silverchair:95446 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B–associated thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-493312 Silverchair:31796 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B–associated thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-493312 Silverchair:31796 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B–associated thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-493312 Silverchair:31796 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B–associated thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-493312 Silverchair:31796 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-779579 Silverchair:36807 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-779579 Silverchair:36807 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-779579 Silverchair:36807 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-779579 Silverchair:36807 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Acid sphingomyelinase plays a critical role in LPS- and cytokine-induced tissue factor procoagulant activity The American Society of Hematology American Society of Hematology 10.1182/blood.2019001400 Silverchair:260728 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Acid sphingomyelinase plays a critical role in LPS- and cytokine-induced tissue factor procoagulant activity The American Society of Hematology American Society of Hematology 10.1182/blood.2019001400 Silverchair:260728 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Acid sphingomyelinase plays a critical role in LPS- and cytokine-induced tissue factor procoagulant activity The American Society of Hematology American Society of Hematology 10.1182/blood.2019001400 Silverchair:260728 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Acid sphingomyelinase plays a critical role in LPS- and cytokine-induced tissue factor procoagulant activity The American Society of Hematology American Society of Hematology 10.1182/blood.2019001400 Silverchair:260728 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Acquired bleeding disorders in the elderly The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.231 Silverchair:20643 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Acquired bleeding disorders in the elderly The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.231 Silverchair:20643 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Acquired bleeding disorders in the elderly The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.231 Silverchair:20643 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Acquired bleeding disorders in the elderly The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.231 Silverchair:20643 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Acquired Disorders of Platelet Function The American Society of Hematology American Society of Hematology 10.1182/asheducation-2011.1.391 Silverchair:96432 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Acquired Disorders of Platelet Function The American Society of Hematology American Society of Hematology 10.1182/asheducation-2011.1.391 Silverchair:96432 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Acquired Disorders of Platelet Function The American Society of Hematology American Society of Hematology 10.1182/asheducation-2011.1.391 Silverchair:96432 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Acquired Disorders of Platelet Function The American Society of Hematology American Society of Hematology 10.1182/asheducation-2011.1.391 Silverchair:96432 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Acquired Factor VIII Inhibitors: Pathophysiology and Treatment The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.432 Silverchair:19703 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Acquired Factor VIII Inhibitors: Pathophysiology and Treatment The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.432 Silverchair:19703 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Acquired Factor VIII Inhibitors: Pathophysiology and Treatment The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.432 Silverchair:19703 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Acquired Factor VIII Inhibitors: Pathophysiology and Treatment The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.432 Silverchair:19703 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy" The American Society of Hematology American Society of Hematology 10.1182/blood.V97.6.1885 Silverchair:107298 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy" The American Society of Hematology American Society of Hematology 10.1182/blood.V97.6.1885 Silverchair:107298 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy" The American Society of Hematology American Society of Hematology 10.1182/blood.V97.6.1885 Silverchair:107298 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy" The American Society of Hematology American Society of Hematology 10.1182/blood.V97.6.1885 Silverchair:107298 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Acquired marrow failure syndromes: aplastic anemia, paroxysmal nocturnal hemoglobinuria, and myelodysplastic syndromes" American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter19 Silverchair:77020 No_License 7 2 0 0 0 0 0 0 1 0 3 1 0 "Acquired marrow failure syndromes: aplastic anemia, paroxysmal nocturnal hemoglobinuria, and myelodysplastic syndromes" American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter19 Silverchair:77020 Total_Item_Investigations 7 2 0 0 0 0 0 0 1 0 3 1 0 "Acquired marrow failure syndromes: aplastic anemia, paroxysmal nocturnal hemoglobinuria, and myelodysplastic syndromes" American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter19 Silverchair:77020 Unique_Item_Investigations 5 1 0 0 0 0 0 0 1 0 2 1 0 Acquired underproduction anemias American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter06 Silverchair:74060 No_License 2 0 0 0 0 0 0 0 1 0 0 1 0 Acquired underproduction anemias American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter06 Silverchair:74060 Total_Item_Investigations 9 0 0 0 3 1 0 2 2 0 0 1 0 Acquired underproduction anemias American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter06 Silverchair:74060 Unique_Item_Investigations 7 0 0 0 2 1 0 2 1 0 0 1 0 Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2005-11-009605 Silverchair:22427 Total_Item_Investigations 5 5 0 0 0 0 0 0 0 0 0 0 0 Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2005-11-009605 Silverchair:22427 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2005-11-009605 Silverchair:22427 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2005-11-009605 Silverchair:22427 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Actin/microtubule crosstalk during platelet biogenesis in mice is critically regulated by Twinfilin1 and Cofilin1 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001303 Silverchair:455313 Total_Item_Investigations 5 0 0 5 0 0 0 0 0 0 0 0 0 Actin/microtubule crosstalk during platelet biogenesis in mice is critically regulated by Twinfilin1 and Cofilin1 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001303 Silverchair:455313 Total_Item_Requests 5 0 0 5 0 0 0 0 0 0 0 0 0 Actin/microtubule crosstalk during platelet biogenesis in mice is critically regulated by Twinfilin1 and Cofilin1 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001303 Silverchair:455313 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Actin/microtubule crosstalk during platelet biogenesis in mice is critically regulated by Twinfilin1 and Cofilin1 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001303 Silverchair:455313 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003291 Silverchair:475792 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003291 Silverchair:475792 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003291 Silverchair:475792 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003291 Silverchair:475792 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-536888 Silverchair:116633 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-536888 Silverchair:116633 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-536888 Silverchair:116633 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-536888 Silverchair:116633 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Activated platelets can deliver mRNA regulatory Ago2•microRNA complexes to endothelial cells via microparticles The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-492801 Silverchair:31670 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Activated platelets can deliver mRNA regulatory Ago2•microRNA complexes to endothelial cells via microparticles The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-492801 Silverchair:31670 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Activated platelets can deliver mRNA regulatory Ago2•microRNA complexes to endothelial cells via microparticles The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-492801 Silverchair:31670 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Activated platelets can deliver mRNA regulatory Ago2•microRNA complexes to endothelial cells via microparticles The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-492801 Silverchair:31670 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V88.7.2699.bloodjournal8872699 Silverchair:125222 Total_Item_Investigations 3 0 0 0 0 0 0 3 0 0 0 0 0 Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V88.7.2699.bloodjournal8872699 Silverchair:125222 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V88.7.2699.bloodjournal8872699 Silverchair:125222 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V88.7.2699.bloodjournal8872699 Silverchair:125222 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 "Activation of CD8 T cells induces expression of CD4, which functions as a chemotactic receptor" The American Society of Hematology American Society of Hematology 10.1182/blood.V99.1.207 Silverchair:107276 Total_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 "Activation of CD8 T cells induces expression of CD4, which functions as a chemotactic receptor" The American Society of Hematology American Society of Hematology 10.1182/blood.V99.1.207 Silverchair:107276 Total_Item_Requests 3 2 0 1 0 0 0 0 0 0 0 0 0 "Activation of CD8 T cells induces expression of CD4, which functions as a chemotactic receptor" The American Society of Hematology American Society of Hematology 10.1182/blood.V99.1.207 Silverchair:107276 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 "Activation of CD8 T cells induces expression of CD4, which functions as a chemotactic receptor" The American Society of Hematology American Society of Hematology 10.1182/blood.V99.1.207 Silverchair:107276 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Activation of Regulatory T Cells with IL-2 and TNF-α to Promote Homing to the Gut and to Improve Acute GvHD Prevention The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123202 Silverchair:424829 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Activation of Regulatory T Cells with IL-2 and TNF-α to Promote Homing to the Gut and to Improve Acute GvHD Prevention The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123202 Silverchair:424829 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Activation of Regulatory T Cells with IL-2 and TNF-α to Promote Homing to the Gut and to Improve Acute GvHD Prevention The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123202 Silverchair:424829 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Activation of Regulatory T Cells with IL-2 and TNF-α to Promote Homing to the Gut and to Improve Acute GvHD Prevention The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123202 Silverchair:424829 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Activation of the Hedgehog signaling pathway in T-lineage cells inhibits TCR repertoire selection in the thymus and peripheral T-cell activation The American Society of Hematology American Society of Hematology 10.1182/blood-2006-07-037655 Silverchair:23608 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Activation of the Hedgehog signaling pathway in T-lineage cells inhibits TCR repertoire selection in the thymus and peripheral T-cell activation The American Society of Hematology American Society of Hematology 10.1182/blood-2006-07-037655 Silverchair:23608 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Activation of the Hedgehog signaling pathway in T-lineage cells inhibits TCR repertoire selection in the thymus and peripheral T-cell activation The American Society of Hematology American Society of Hematology 10.1182/blood-2006-07-037655 Silverchair:23608 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Activation of the Hedgehog signaling pathway in T-lineage cells inhibits TCR repertoire selection in the thymus and peripheral T-cell activation The American Society of Hematology American Society of Hematology 10.1182/blood-2006-07-037655 Silverchair:23608 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities" The American Society of Hematology American Society of Hematology 10.1182/blood-2006-11-056168 Silverchair:133614 Total_Item_Investigations 2 0 1 0 1 0 0 0 0 0 0 0 0 "Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities" The American Society of Hematology American Society of Hematology 10.1182/blood-2006-11-056168 Silverchair:133614 Total_Item_Requests 2 0 1 0 1 0 0 0 0 0 0 0 0 "Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities" The American Society of Hematology American Society of Hematology 10.1182/blood-2006-11-056168 Silverchair:133614 Unique_Item_Investigations 2 0 1 0 1 0 0 0 0 0 0 0 0 "Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities" The American Society of Hematology American Society of Hematology 10.1182/blood-2006-11-056168 Silverchair:133614 Unique_Item_Requests 2 0 1 0 1 0 0 0 0 0 0 0 0 Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1 The American Society of Hematology American Society of Hematology 10.1182/blood.2020005734 Silverchair:469830 No_License 3 0 3 0 0 0 0 0 0 0 0 0 0 Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1 The American Society of Hematology American Society of Hematology 10.1182/blood.2020005734 Silverchair:469830 Total_Item_Investigations 6 0 6 0 0 0 0 0 0 0 0 0 0 Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1 The American Society of Hematology American Society of Hematology 10.1182/blood.2020005734 Silverchair:469830 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Active MAC-1 (CD11b/CD18) on DCs inhibits full T-cell activation The American Society of Hematology American Society of Hematology 10.1182/blood-2005-12-023044 Silverchair:23527 Total_Item_Investigations 6 0 6 0 0 0 0 0 0 0 0 0 0 Active MAC-1 (CD11b/CD18) on DCs inhibits full T-cell activation The American Society of Hematology American Society of Hematology 10.1182/blood-2005-12-023044 Silverchair:23527 Total_Item_Requests 6 0 6 0 0 0 0 0 0 0 0 0 0 Active MAC-1 (CD11b/CD18) on DCs inhibits full T-cell activation The American Society of Hematology American Society of Hematology 10.1182/blood-2005-12-023044 Silverchair:23527 Unique_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 Active MAC-1 (CD11b/CD18) on DCs inhibits full T-cell activation The American Society of Hematology American Society of Hematology 10.1182/blood-2005-12-023044 Silverchair:23527 Unique_Item_Requests 4 0 4 0 0 0 0 0 0 0 0 0 0 Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study The American Society of Hematology American Society of Hematology 10.1182/blood-2006-09-046409 Silverchair:23302 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study The American Society of Hematology American Society of Hematology 10.1182/blood-2006-09-046409 Silverchair:23302 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study The American Society of Hematology American Society of Hematology 10.1182/blood-2006-09-046409 Silverchair:23302 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study The American Society of Hematology American Society of Hematology 10.1182/blood-2006-09-046409 Silverchair:23302 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-446120 Silverchair:31483 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-446120 Silverchair:31483 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-446120 Silverchair:31483 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-446120 Silverchair:31483 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Activity of Rituximab-Bendamustine (RB) Combination in Nodular Lymphocyte Predominant Hodgkins Lymphoma (NLPHL) The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4894.4894 Silverchair:87017 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Activity of Rituximab-Bendamustine (RB) Combination in Nodular Lymphocyte Predominant Hodgkins Lymphoma (NLPHL) The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4894.4894 Silverchair:87017 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Activity of Rituximab-Bendamustine (RB) Combination in Nodular Lymphocyte Predominant Hodgkins Lymphoma (NLPHL) The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4894.4894 Silverchair:87017 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Activity of Rituximab-Bendamustine (RB) Combination in Nodular Lymphocyte Predominant Hodgkins Lymphoma (NLPHL) The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4894.4894 Silverchair:87017 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL–positive leukemic cells" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-03-211466 Silverchair:27478 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL–positive leukemic cells" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-03-211466 Silverchair:27478 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL–positive leukemic cells" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-03-211466 Silverchair:27478 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL–positive leukemic cells" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-03-211466 Silverchair:27478 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2017-08-802470 Silverchair:104427 Total_Item_Investigations 7 3 3 1 0 0 0 0 0 0 0 0 0 "Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2017-08-802470 Silverchair:104427 Total_Item_Requests 7 3 3 1 0 0 0 0 0 0 0 0 0 "Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2017-08-802470 Silverchair:104427 Unique_Item_Investigations 5 3 1 1 0 0 0 0 0 0 0 0 0 "Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2017-08-802470 Silverchair:104427 Unique_Item_Requests 5 3 1 1 0 0 0 0 0 0 0 0 0 Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126005 Silverchair:427792 Total_Item_Investigations 3 0 1 2 0 0 0 0 0 0 0 0 0 Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126005 Silverchair:427792 Total_Item_Requests 3 0 1 2 0 0 0 0 0 0 0 0 0 Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126005 Silverchair:427792 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126005 Silverchair:427792 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Acute lymphoblastic leukemia and lymphoblastic lymphoma American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter21 Silverchair:77301 No_License 3 0 2 0 0 0 0 0 1 0 0 0 0 Acute lymphoblastic leukemia and lymphoblastic lymphoma American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter21 Silverchair:77301 Total_Item_Investigations 4 0 2 0 0 0 0 1 1 0 0 0 0 Acute lymphoblastic leukemia and lymphoblastic lymphoma American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter21 Silverchair:77301 Unique_Item_Investigations 3 0 1 0 0 0 0 1 1 0 0 0 0 Acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter20 Silverchair:77231 No_License 4 0 2 0 0 0 0 0 1 0 0 1 0 Acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter20 Silverchair:77231 Total_Item_Investigations 9 0 2 0 1 0 0 3 2 0 0 1 0 Acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter20 Silverchair:77231 Unique_Item_Investigations 8 0 1 0 1 0 0 3 2 0 0 1 0 Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498 [see comments] The American Society of Hematology American Society of Hematology 10.1182/blood.V80.9.2210.2210 Silverchair:169572 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498 [see comments] The American Society of Hematology American Society of Hematology 10.1182/blood.V80.9.2210.2210 Silverchair:169572 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Acute Myeloid Leukemia and Cirrhosis: Trends in Utilization of Induction Chemotherapy, Rate of Hospitalizations and Mortality" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126177 Silverchair:424235 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Acute Myeloid Leukemia and Cirrhosis: Trends in Utilization of Induction Chemotherapy, Rate of Hospitalizations and Mortality" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126177 Silverchair:424235 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Acute Myeloid Leukemia and Cirrhosis: Trends in Utilization of Induction Chemotherapy, Rate of Hospitalizations and Mortality" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126177 Silverchair:424235 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Acute Myeloid Leukemia and Cirrhosis: Trends in Utilization of Induction Chemotherapy, Rate of Hospitalizations and Mortality" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126177 Silverchair:424235 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow The American Society of Hematology American Society of Hematology 10.1182/blood.2020006219 Silverchair:464167 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow The American Society of Hematology American Society of Hematology 10.1182/blood.2020006219 Silverchair:464167 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow The American Society of Hematology American Society of Hematology 10.1182/blood.2020006219 Silverchair:464167 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow The American Society of Hematology American Society of Hematology 10.1182/blood.2020006219 Silverchair:464167 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Acute promyelocytic leukemia: from highly fatal to highly curable The American Society of Hematology American Society of Hematology 10.1182/blood-2007-07-102798 Silverchair:109933 Total_Item_Investigations 4 1 2 1 0 0 0 0 0 0 0 0 0 Acute promyelocytic leukemia: from highly fatal to highly curable The American Society of Hematology American Society of Hematology 10.1182/blood-2007-07-102798 Silverchair:109933 Total_Item_Requests 4 1 2 1 0 0 0 0 0 0 0 0 0 Acute promyelocytic leukemia: from highly fatal to highly curable The American Society of Hematology American Society of Hematology 10.1182/blood-2007-07-102798 Silverchair:109933 Unique_Item_Investigations 3 1 1 1 0 0 0 0 0 0 0 0 0 Acute promyelocytic leukemia: from highly fatal to highly curable The American Society of Hematology American Society of Hematology 10.1182/blood-2007-07-102798 Silverchair:109933 Unique_Item_Requests 3 1 1 1 0 0 0 0 0 0 0 0 0 Acute sickle cell hepatopathy represents a potential contraindication for percutaneous liver biopsy The American Society of Hematology American Society of Hematology 10.1182/blood-2002-06-1823 Silverchair:88937 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Acute sickle cell hepatopathy represents a potential contraindication for percutaneous liver biopsy The American Society of Hematology American Society of Hematology 10.1182/blood-2002-06-1823 Silverchair:88937 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Acute sickle cell hepatopathy represents a potential contraindication for percutaneous liver biopsy The American Society of Hematology American Society of Hematology 10.1182/blood-2002-06-1823 Silverchair:88937 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Acute sickle cell hepatopathy represents a potential contraindication for percutaneous liver biopsy The American Society of Hematology American Society of Hematology 10.1182/blood-2002-06-1823 Silverchair:88937 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Acute treatment of venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood.2019001881 Silverchair:430068 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Acute treatment of venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood.2019001881 Silverchair:430068 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Acute treatment of venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood.2019001881 Silverchair:430068 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Acute treatment of venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood.2019001881 Silverchair:430068 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 ADAMTS13 activity in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients The American Society of Hematology American Society of Hematology 10.1182/blood-2003-01-0193 Silverchair:16796 Total_Item_Investigations 7 0 2 0 0 0 0 0 0 0 3 0 2 ADAMTS13 activity in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients The American Society of Hematology American Society of Hematology 10.1182/blood-2003-01-0193 Silverchair:16796 Total_Item_Requests 5 0 1 0 0 0 0 0 0 0 2 0 2 ADAMTS13 activity in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients The American Society of Hematology American Society of Hematology 10.1182/blood-2003-01-0193 Silverchair:16796 Unique_Item_Investigations 3 0 1 0 0 0 0 0 0 0 1 0 1 ADAMTS13 activity in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients The American Society of Hematology American Society of Hematology 10.1182/blood-2003-01-0193 Silverchair:16796 Unique_Item_Requests 3 0 1 0 0 0 0 0 0 0 1 0 1 ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001987 Silverchair:461269 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001987 Silverchair:461269 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001987 Silverchair:461269 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001987 Silverchair:461269 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003855 Silverchair:475243 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003855 Silverchair:475243 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003855 Silverchair:475243 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003855 Silverchair:475243 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-348367 Silverchair:29350 Total_Item_Investigations 6 0 0 0 0 2 4 0 0 0 0 0 0 Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-348367 Silverchair:29350 Total_Item_Requests 4 0 0 0 0 1 3 0 0 0 0 0 0 Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-348367 Silverchair:29350 Unique_Item_Investigations 3 0 0 0 0 1 2 0 0 0 0 0 0 Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-348367 Silverchair:29350 Unique_Item_Requests 3 0 0 0 0 1 2 0 0 0 0 0 0 "Addition of the PARP Inhibitor, Talazoparib, to Gemtuzumab Ozogamicin Significantly Enhances Anti-Leukemic Activity in Human CD33+ Acute Myeloid Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130427 Silverchair:427213 Total_Item_Investigations 4 2 2 0 0 0 0 0 0 0 0 0 0 "Addition of the PARP Inhibitor, Talazoparib, to Gemtuzumab Ozogamicin Significantly Enhances Anti-Leukemic Activity in Human CD33+ Acute Myeloid Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130427 Silverchair:427213 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 "Addition of the PARP Inhibitor, Talazoparib, to Gemtuzumab Ozogamicin Significantly Enhances Anti-Leukemic Activity in Human CD33+ Acute Myeloid Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130427 Silverchair:427213 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 "Addition of the PARP Inhibitor, Talazoparib, to Gemtuzumab Ozogamicin Significantly Enhances Anti-Leukemic Activity in Human CD33+ Acute Myeloid Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130427 Silverchair:427213 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Additional Prognostic Impact of Specific Sites of Extramedullary Leukemia in Pediatric AML with MLL-Rearrangements but Not in Core-Binding Factor (CBF) AML. The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.2621.2621 Silverchair:112849 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Additional Prognostic Impact of Specific Sites of Extramedullary Leukemia in Pediatric AML with MLL-Rearrangements but Not in Core-Binding Factor (CBF) AML. The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.2621.2621 Silverchair:112849 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Additional Prognostic Impact of Specific Sites of Extramedullary Leukemia in Pediatric AML with MLL-Rearrangements but Not in Core-Binding Factor (CBF) AML. The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.2621.2621 Silverchair:112849 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Additional Prognostic Impact of Specific Sites of Extramedullary Leukemia in Pediatric AML with MLL-Rearrangements but Not in Core-Binding Factor (CBF) AML. The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.2621.2621 Silverchair:112849 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Adenylate kinase 2 expression and addiction in T-ALL American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002700 Silverchair:475048 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Adenylate kinase 2 expression and addiction in T-ALL American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002700 Silverchair:475048 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Adenylate kinase 2 expression and addiction in T-ALL American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002700 Silverchair:475048 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Adenylate kinase 2 expression and addiction in T-ALL American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002700 Silverchair:475048 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Adherence to Treatment in Myelofibrosis Patients: Preliminary Results from Italian Romei Observational Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124730 Silverchair:425740 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Adherence to Treatment in Myelofibrosis Patients: Preliminary Results from Italian Romei Observational Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124730 Silverchair:425740 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Adherence to Treatment in Myelofibrosis Patients: Preliminary Results from Italian Romei Observational Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124730 Silverchair:425740 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Adherence to Treatment in Myelofibrosis Patients: Preliminary Results from Italian Romei Observational Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124730 Silverchair:425740 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Adjuvant low-dose rituximab and plasma exchange for acquired TTP The American Society of Hematology American Society of Hematology 10.1182/blood.2019000795 Silverchair:374917 Total_Item_Investigations 4 0 1 0 0 0 0 0 0 0 3 0 0 Adjuvant low-dose rituximab and plasma exchange for acquired TTP The American Society of Hematology American Society of Hematology 10.1182/blood.2019000795 Silverchair:374917 Total_Item_Requests 4 0 1 0 0 0 0 0 0 0 3 0 0 Adjuvant low-dose rituximab and plasma exchange for acquired TTP The American Society of Hematology American Society of Hematology 10.1182/blood.2019000795 Silverchair:374917 Unique_Item_Investigations 2 0 1 0 0 0 0 0 0 0 1 0 0 Adjuvant low-dose rituximab and plasma exchange for acquired TTP The American Society of Hematology American Society of Hematology 10.1182/blood.2019000795 Silverchair:374917 Unique_Item_Requests 2 0 1 0 0 0 0 0 0 0 1 0 0 Adjuvant rituximab to prevent TTP relapse The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-710475 Silverchair:35427 Total_Item_Investigations 4 2 0 0 2 0 0 0 0 0 0 0 0 Adjuvant rituximab to prevent TTP relapse The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-710475 Silverchair:35427 Total_Item_Requests 4 2 0 0 2 0 0 0 0 0 0 0 0 Adjuvant rituximab to prevent TTP relapse The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-710475 Silverchair:35427 Unique_Item_Investigations 2 1 0 0 1 0 0 0 0 0 0 0 0 Adjuvant rituximab to prevent TTP relapse The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-710475 Silverchair:35427 Unique_Item_Requests 2 1 0 0 1 0 0 0 0 0 0 0 0 "Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143349 Silverchair:470342 Total_Item_Investigations 4 1 3 0 0 0 0 0 0 0 0 0 0 "Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143349 Silverchair:470342 Total_Item_Requests 4 1 3 0 0 0 0 0 0 0 0 0 0 "Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143349 Silverchair:470342 Unique_Item_Investigations 4 1 3 0 0 0 0 0 0 0 0 0 0 "Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143349 Silverchair:470342 Unique_Item_Requests 4 1 3 0 0 0 0 0 0 0 0 0 0 Adoptive Transfer of CMV- and EBV- Specific Peptide-Stimulated T Cells after Allogeneic Stem Cell Transplantation: First Results of a Phase I/IIa Clinical Trial [Multivir-01] The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2179.2179 Silverchair:100400 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Adoptive Transfer of CMV- and EBV- Specific Peptide-Stimulated T Cells after Allogeneic Stem Cell Transplantation: First Results of a Phase I/IIa Clinical Trial [Multivir-01] The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2179.2179 Silverchair:100400 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Adoptive Transfer of CMV- and EBV- Specific Peptide-Stimulated T Cells after Allogeneic Stem Cell Transplantation: First Results of a Phase I/IIa Clinical Trial [Multivir-01] The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2179.2179 Silverchair:100400 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Adoptive Transfer of CMV- and EBV- Specific Peptide-Stimulated T Cells after Allogeneic Stem Cell Transplantation: First Results of a Phase I/IIa Clinical Trial [Multivir-01] The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2179.2179 Silverchair:100400 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-262089 Silverchair:28159 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-262089 Silverchair:28159 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-262089 Silverchair:28159 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-262089 Silverchair:28159 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Adult blood stem cell localization reflects the abundance of reported bone marrow niche cell types and their combinations The American Society of Hematology American Society of Hematology 10.1182/blood.2020006574 Silverchair:461765 Total_Item_Investigations 5 0 5 0 0 0 0 0 0 0 0 0 0 Adult blood stem cell localization reflects the abundance of reported bone marrow niche cell types and their combinations The American Society of Hematology American Society of Hematology 10.1182/blood.2020006574 Silverchair:461765 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Adult blood stem cell localization reflects the abundance of reported bone marrow niche cell types and their combinations The American Society of Hematology American Society of Hematology 10.1182/blood.2020006574 Silverchair:461765 No_License 3 0 3 0 0 0 0 0 0 0 0 0 0 Adult bone marrow-derived pluripotent hematopoietic stem cells are engraftable when transferred in utero into moderately anemic fetal recipients The American Society of Hematology American Society of Hematology 10.1182/blood.V85.3.833.bloodjournal853833 Silverchair:125783 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Adult bone marrow-derived pluripotent hematopoietic stem cells are engraftable when transferred in utero into moderately anemic fetal recipients The American Society of Hematology American Society of Hematology 10.1182/blood.V85.3.833.bloodjournal853833 Silverchair:125783 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Adult Burkitt leukemia and lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2004-02-0405 Silverchair:18728 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Adult Burkitt leukemia and lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2004-02-0405 Silverchair:18728 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Adult Burkitt leukemia and lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2004-02-0405 Silverchair:18728 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Adult Burkitt leukemia and lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2004-02-0405 Silverchair:18728 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Adult Donor-Derived Human CD34+ Cell Engraftment and Hemato-Lymphoid System Development in 3rd Generation Humanized Mice The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4378.4378 Silverchair:92036 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Adult Donor-Derived Human CD34+ Cell Engraftment and Hemato-Lymphoid System Development in 3rd Generation Humanized Mice The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4378.4378 Silverchair:92036 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Adult Donor-Derived Human CD34+ Cell Engraftment and Hemato-Lymphoid System Development in 3rd Generation Humanized Mice The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4378.4378 Silverchair:92036 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Adult Donor-Derived Human CD34+ Cell Engraftment and Hemato-Lymphoid System Development in 3rd Generation Humanized Mice The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4378.4378 Silverchair:92036 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Adult human megakaryocyte-erythroid progenitors are in the CD34+CD38mid fraction The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-693705 Silverchair:35871 Total_Item_Investigations 5 3 2 0 0 0 0 0 0 0 0 0 0 Adult human megakaryocyte-erythroid progenitors are in the CD34+CD38mid fraction The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-693705 Silverchair:35871 Total_Item_Requests 5 3 2 0 0 0 0 0 0 0 0 0 0 Adult human megakaryocyte-erythroid progenitors are in the CD34+CD38mid fraction The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-693705 Silverchair:35871 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Adult human megakaryocyte-erythroid progenitors are in the CD34+CD38mid fraction The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-693705 Silverchair:35871 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1–infected T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-692574 Silverchair:36572 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1–infected T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-692574 Silverchair:36572 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1–infected T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-692574 Silverchair:36572 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1–infected T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-692574 Silverchair:36572 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Advancing Diversity, Equity, and Inclusion in ASH's Publishing Activities: No Audition Required" American Society of Hematology American Society of Hematology Silverchair:475876 Total_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 "Advancing Diversity, Equity, and Inclusion in ASH's Publishing Activities: No Audition Required" American Society of Hematology American Society of Hematology Silverchair:475876 Total_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 "Advancing Diversity, Equity, and Inclusion in ASH's Publishing Activities: No Audition Required" American Society of Hematology American Society of Hematology Silverchair:475876 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 "Advancing Diversity, Equity, and Inclusion in ASH's Publishing Activities: No Audition Required" American Society of Hematology American Society of Hematology Silverchair:475876 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Adverse effects of intrathecal methotrexate in children with acute leukemia in remission The American Society of Hematology American Society of Hematology 10.1182/blood.V45.2.189.189 Silverchair:160144 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Adverse effects of intrathecal methotrexate in children with acute leukemia in remission The American Society of Hematology American Society of Hematology 10.1182/blood.V45.2.189.189 Silverchair:160144 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Adverse effects of intrathecal methotrexate in children with acute leukemia in remission The American Society of Hematology American Society of Hematology 10.1182/blood.V45.2.189.189 Silverchair:160144 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Adverse effects of intrathecal methotrexate in children with acute leukemia in remission The American Society of Hematology American Society of Hematology 10.1182/blood.V45.2.189.189 Silverchair:160144 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic Purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131064 Silverchair:426869 Total_Item_Investigations 4 0 0 0 3 1 0 0 0 0 0 0 0 African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic Purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131064 Silverchair:426869 Total_Item_Requests 4 0 0 0 3 1 0 0 0 0 0 0 0 African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic Purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131064 Silverchair:426869 Unique_Item_Investigations 3 0 0 0 2 1 0 0 0 0 0 0 0 African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic Purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131064 Silverchair:426869 Unique_Item_Requests 3 0 0 0 2 1 0 0 0 0 0 0 0 Age-related Diseases of Inflammation in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2021014418 Silverchair:482919 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Age-related Diseases of Inflammation in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2021014418 Silverchair:482919 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-810739 Silverchair:39442 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-810739 Silverchair:39442 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-810739 Silverchair:39442 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-810739 Silverchair:39442 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Aggressive genomic features in clinically indolent primary HHV8-negative effusion-based lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-12-822171 Silverchair:272771 Total_Item_Investigations 7 0 7 0 0 0 0 0 0 0 0 0 0 Aggressive genomic features in clinically indolent primary HHV8-negative effusion-based lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-12-822171 Silverchair:272771 Total_Item_Requests 6 0 6 0 0 0 0 0 0 0 0 0 0 Aggressive genomic features in clinically indolent primary HHV8-negative effusion-based lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-12-822171 Silverchair:272771 Unique_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Aggressive genomic features in clinically indolent primary HHV8-negative effusion-based lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-12-822171 Silverchair:272771 Unique_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 "AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation" The American Society of Hematology American Society of Hematology 10.1182/blood-2021-147805 Silverchair:479500 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 "AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation" The American Society of Hematology American Society of Hematology 10.1182/blood-2021-147805 Silverchair:479500 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 "AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation" The American Society of Hematology American Society of Hematology 10.1182/blood-2021-147805 Silverchair:479500 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 "AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation" The American Society of Hematology American Society of Hematology 10.1182/blood-2021-147805 Silverchair:479500 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 "AGS62P1, a Novel Anti-FLT3 Antibody Drug Conjugate, Employing Site Specific Conjugation, Demonstrates Preclinical Anti-Tumor Efficacy in AML Tumor and Patient Derived Xenografts" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3806.3806 Silverchair:92951 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "AGS62P1, a Novel Anti-FLT3 Antibody Drug Conjugate, Employing Site Specific Conjugation, Demonstrates Preclinical Anti-Tumor Efficacy in AML Tumor and Patient Derived Xenografts" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3806.3806 Silverchair:92951 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "AGS62P1, a Novel Anti-FLT3 Antibody Drug Conjugate, Employing Site Specific Conjugation, Demonstrates Preclinical Anti-Tumor Efficacy in AML Tumor and Patient Derived Xenografts" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3806.3806 Silverchair:92951 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "AGS62P1, a Novel Anti-FLT3 Antibody Drug Conjugate, Employing Site Specific Conjugation, Demonstrates Preclinical Anti-Tumor Efficacy in AML Tumor and Patient Derived Xenografts" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3806.3806 Silverchair:92951 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 AIDS-related lymphoproliferative disease The American Society of Hematology American Society of Hematology 10.1182/blood-2004-11-4278 Silverchair:21725 Total_Item_Investigations 3 1 0 0 0 1 0 0 1 0 0 0 0 AIDS-related lymphoproliferative disease The American Society of Hematology American Society of Hematology 10.1182/blood-2004-11-4278 Silverchair:21725 Total_Item_Requests 3 1 0 0 0 1 0 0 1 0 0 0 0 AIDS-related lymphoproliferative disease The American Society of Hematology American Society of Hematology 10.1182/blood-2004-11-4278 Silverchair:21725 Unique_Item_Investigations 3 1 0 0 0 1 0 0 1 0 0 0 0 AIDS-related lymphoproliferative disease The American Society of Hematology American Society of Hematology 10.1182/blood-2004-11-4278 Silverchair:21725 Unique_Item_Requests 3 1 0 0 0 1 0 0 1 0 0 0 0 AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome The American Society of Hematology American Society of Hematology 10.1182/blood-2008-02-138156 Silverchair:24549 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome The American Society of Hematology American Society of Hematology 10.1182/blood-2008-02-138156 Silverchair:24549 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome The American Society of Hematology American Society of Hematology 10.1182/blood-2008-02-138156 Silverchair:24549 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome The American Society of Hematology American Society of Hematology 10.1182/blood-2008-02-138156 Silverchair:24549 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Alemtuzumab as First Line Treatment in Children with Familial Lymphohistiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124477 Silverchair:424432 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Alemtuzumab as First Line Treatment in Children with Familial Lymphohistiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124477 Silverchair:424432 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Alemtuzumab as First Line Treatment in Children with Familial Lymphohistiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124477 Silverchair:424432 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Alemtuzumab as First Line Treatment in Children with Familial Lymphohistiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124477 Silverchair:424432 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-12-327536 Silverchair:29453 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-12-327536 Silverchair:29453 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-12-327536 Silverchair:29453 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-12-327536 Silverchair:29453 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 ALK1 as an emerging target for antiangiogenic therapy of cancer The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-330142 Silverchair:104444 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 ALK1 as an emerging target for antiangiogenic therapy of cancer The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-330142 Silverchair:104444 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 ALK1 as an emerging target for antiangiogenic therapy of cancer The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-330142 Silverchair:104444 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 ALK1 as an emerging target for antiangiogenic therapy of cancer The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-330142 Silverchair:104444 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2 The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-107359 Silverchair:103722 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2 The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-107359 Silverchair:103722 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2 The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-107359 Silverchair:103722 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2 The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-107359 Silverchair:103722 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001581 Silverchair:475044 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001581 Silverchair:475044 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001581 Silverchair:475044 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001581 Silverchair:475044 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocolPresented in part at the 39th meeting of the American Society of Hematology, New Orleans, LA, December 1999." The American Society of Hematology American Society of Hematology 10.1182/blood-2002-02-0632 Silverchair:106096 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocolPresented in part at the 39th meeting of the American Society of Hematology, New Orleans, LA, December 1999." The American Society of Hematology American Society of Hematology 10.1182/blood-2002-02-0632 Silverchair:106096 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocolPresented in part at the 39th meeting of the American Society of Hematology, New Orleans, LA, December 1999." The American Society of Hematology American Society of Hematology 10.1182/blood-2002-02-0632 Silverchair:106096 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocolPresented in part at the 39th meeting of the American Society of Hematology, New Orleans, LA, December 1999." The American Society of Hematology American Society of Hematology 10.1182/blood-2002-02-0632 Silverchair:106096 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-02-410746 Silverchair:30826 Total_Item_Investigations 11 8 2 1 0 0 0 0 0 0 0 0 0 "All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-02-410746 Silverchair:30826 Total_Item_Requests 11 8 2 1 0 0 0 0 0 0 0 0 0 "All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-02-410746 Silverchair:30826 Unique_Item_Investigations 6 4 1 1 0 0 0 0 0 0 0 0 0 "All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-02-410746 Silverchair:30826 Unique_Item_Requests 6 4 1 1 0 0 0 0 0 0 0 0 0 Allele-specific DNA methylation reinforces PEAR1 enhancer activity The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-682153 Silverchair:35864 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Allele-specific DNA methylation reinforces PEAR1 enhancer activity The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-682153 Silverchair:35864 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Allele-specific DNA methylation reinforces PEAR1 enhancer activity The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-682153 Silverchair:35864 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Allele-specific DNA methylation reinforces PEAR1 enhancer activity The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-682153 Silverchair:35864 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127102 Silverchair:427751 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127102 Silverchair:427751 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127102 Silverchair:427751 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127102 Silverchair:427751 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2004-06-2275 Silverchair:89046 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2004-06-2275 Silverchair:89046 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2004-06-2275 Silverchair:89046 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2004-06-2275 Silverchair:89046 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-399048 Silverchair:30759 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-399048 Silverchair:30759 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-399048 Silverchair:30759 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-399048 Silverchair:30759 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-724500 Silverchair:35813 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-724500 Silverchair:35813 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-724500 Silverchair:35813 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-724500 Silverchair:35813 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-380162 Silverchair:30313 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-380162 Silverchair:30313 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-380162 Silverchair:30313 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-380162 Silverchair:30313 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Allogeneic Transplant Improves AML Outcomes Compared to Maintenance Venetoclax and Azacitidine Following Response to Initial Venetoclax and Azacitidine Therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138821 Silverchair:470502 Total_Item_Investigations 4 0 0 3 0 0 0 0 1 0 0 0 0 Allogeneic Transplant Improves AML Outcomes Compared to Maintenance Venetoclax and Azacitidine Following Response to Initial Venetoclax and Azacitidine Therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138821 Silverchair:470502 Total_Item_Requests 4 0 0 3 0 0 0 0 1 0 0 0 0 Allogeneic Transplant Improves AML Outcomes Compared to Maintenance Venetoclax and Azacitidine Following Response to Initial Venetoclax and Azacitidine Therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138821 Silverchair:470502 Unique_Item_Investigations 2 0 0 1 0 0 0 0 1 0 0 0 0 Allogeneic Transplant Improves AML Outcomes Compared to Maintenance Venetoclax and Azacitidine Following Response to Initial Venetoclax and Azacitidine Therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138821 Silverchair:470502 Unique_Item_Requests 2 0 0 1 0 0 0 0 1 0 0 0 0 ALPS or not? The American Society of Hematology American Society of Hematology 10.1182/blood.2020007418 Silverchair:469359 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 ALPS or not? The American Society of Hematology American Society of Hematology 10.1182/blood.2020007418 Silverchair:469359 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 ALPS or not? The American Society of Hematology American Society of Hematology 10.1182/blood.2020007418 Silverchair:469359 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 ALPS or not? The American Society of Hematology American Society of Hematology 10.1182/blood.2020007418 Silverchair:469359 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Altered epigenetics at the center of NK-LGL leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2021011875 Silverchair:476618 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Altered epigenetics at the center of NK-LGL leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2021011875 Silverchair:476618 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Altered epigenetics at the center of NK-LGL leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2021011875 Silverchair:476618 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Altered epigenetics at the center of NK-LGL leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2021011875 Silverchair:476618 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Altered erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2001-12-0329 Silverchair:16889 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Altered erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2001-12-0329 Silverchair:16889 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Altered erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2001-12-0329 Silverchair:16889 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Altered erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2001-12-0329 Silverchair:16889 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Altered expression of platelet proteins and calpain activity mediate hypoxia-induced prothrombotic phenotype The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-501924 Silverchair:32857 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 Altered expression of platelet proteins and calpain activity mediate hypoxia-induced prothrombotic phenotype The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-501924 Silverchair:32857 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Altered expression of platelet proteins and calpain activity mediate hypoxia-induced prothrombotic phenotype The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-501924 Silverchair:32857 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Altered expression of platelet proteins and calpain activity mediate hypoxia-induced prothrombotic phenotype The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-501924 Silverchair:32857 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Alternate Day Oral Iron Dosing in Iron Deficiency Anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112341 Silverchair:262437 Total_Item_Investigations 2 1 0 0 1 0 0 0 0 0 0 0 0 Alternate Day Oral Iron Dosing in Iron Deficiency Anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112341 Silverchair:262437 Total_Item_Requests 2 1 0 0 1 0 0 0 0 0 0 0 0 Alternate Day Oral Iron Dosing in Iron Deficiency Anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112341 Silverchair:262437 Unique_Item_Investigations 2 1 0 0 1 0 0 0 0 0 0 0 0 Alternate Day Oral Iron Dosing in Iron Deficiency Anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112341 Silverchair:262437 Unique_Item_Requests 2 1 0 0 1 0 0 0 0 0 0 0 0 Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003654 Silverchair:475197 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003654 Silverchair:475197 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003654 Silverchair:475197 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003654 Silverchair:475197 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Alternative Splice Variants of IRAK4 That Activate Innate Immune Signaling Are Associated with U2AF1 Mutations in Myelodysplastic Syndrome and Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1531.1531 Silverchair:91538 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Alternative Splice Variants of IRAK4 That Activate Innate Immune Signaling Are Associated with U2AF1 Mutations in Myelodysplastic Syndrome and Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1531.1531 Silverchair:91538 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Alternative Splice Variants of IRAK4 That Activate Innate Immune Signaling Are Associated with U2AF1 Mutations in Myelodysplastic Syndrome and Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1531.1531 Silverchair:91538 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Alternative Splice Variants of IRAK4 That Activate Innate Immune Signaling Are Associated with U2AF1 Mutations in Myelodysplastic Syndrome and Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1531.1531 Silverchair:91538 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018024828 Silverchair:16134 Total_Item_Investigations 4 2 0 2 0 0 0 0 0 0 0 0 0 American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018024828 Silverchair:16134 Total_Item_Requests 4 2 0 2 0 0 0 0 0 0 0 0 0 American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018024828 Silverchair:16134 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018024828 Silverchair:16134 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018024489 Silverchair:16129 Total_Item_Investigations 9 6 0 3 0 0 0 0 0 0 0 0 0 American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018024489 Silverchair:16129 Total_Item_Requests 8 5 0 3 0 0 0 0 0 0 0 0 0 American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018024489 Silverchair:16129 Unique_Item_Investigations 5 3 0 2 0 0 0 0 0 0 0 0 0 American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018024489 Silverchair:16129 Unique_Item_Requests 5 3 0 2 0 0 0 0 0 0 0 0 0 American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018024893 Silverchair:16107 Total_Item_Investigations 12 3 5 2 0 0 0 0 0 0 0 2 0 American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018024893 Silverchair:16107 Total_Item_Requests 12 3 5 2 0 0 0 0 0 0 0 2 0 American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018024893 Silverchair:16107 Unique_Item_Investigations 8 1 4 2 0 0 0 0 0 0 0 1 0 American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018024893 Silverchair:16107 Unique_Item_Requests 8 1 4 2 0 0 0 0 0 0 0 1 0 American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018022954 Silverchair:16115 Total_Item_Investigations 15 4 8 3 0 0 0 0 0 0 0 0 0 American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018022954 Silverchair:16115 Total_Item_Requests 15 4 8 3 0 0 0 0 0 0 0 0 0 American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018022954 Silverchair:16115 Unique_Item_Investigations 9 3 4 2 0 0 0 0 0 0 0 0 0 American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018022954 Silverchair:16115 Unique_Item_Requests 9 3 4 2 0 0 0 0 0 0 0 0 0 American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018024786 Silverchair:16093 Total_Item_Investigations 6 0 3 1 0 0 0 0 0 0 0 0 2 American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018024786 Silverchair:16093 Total_Item_Requests 6 0 3 1 0 0 0 0 0 0 0 0 2 American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018024786 Silverchair:16093 Unique_Item_Investigations 5 0 3 1 0 0 0 0 0 0 0 0 1 American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018024786 Silverchair:16093 Unique_Item_Requests 5 0 3 1 0 0 0 0 0 0 0 0 1 American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018024802 Silverchair:16094 Total_Item_Investigations 22 2 6 8 0 0 2 0 2 2 0 0 0 American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018024802 Silverchair:16094 Total_Item_Requests 22 2 6 8 0 0 2 0 2 2 0 0 0 American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018024802 Silverchair:16094 Unique_Item_Investigations 14 1 4 5 0 0 1 0 2 1 0 0 0 American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018024802 Silverchair:16094 Unique_Item_Requests 14 1 4 5 0 0 1 0 2 1 0 0 0 American Society of Hematology 2019 guidelines for immune thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000966 Silverchair:429213 Total_Item_Investigations 27 5 6 7 0 5 1 0 0 0 1 0 2 American Society of Hematology 2019 guidelines for immune thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000966 Silverchair:429213 Total_Item_Requests 27 5 6 7 0 5 1 0 0 0 1 0 2 American Society of Hematology 2019 guidelines for immune thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000966 Silverchair:429213 Unique_Item_Investigations 15 4 4 2 0 2 1 0 0 0 1 0 1 American Society of Hematology 2019 guidelines for immune thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000966 Silverchair:429213 Unique_Item_Requests 15 4 4 2 0 2 1 0 0 0 1 0 1 American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000975 Silverchair:429211 Total_Item_Investigations 17 2 4 5 0 0 2 0 0 2 2 0 0 American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000975 Silverchair:429211 Total_Item_Requests 17 2 4 5 0 0 2 0 0 2 2 0 0 American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000975 Silverchair:429211 Unique_Item_Investigations 13 2 3 4 0 0 2 0 0 1 1 0 0 American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000975 Silverchair:429211 Unique_Item_Requests 13 2 3 4 0 0 2 0 0 1 1 0 0 American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000916 Silverchair:429210 Total_Item_Investigations 3 1 0 2 0 0 0 0 0 0 0 0 0 American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000916 Silverchair:429210 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000916 Silverchair:429210 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000916 Silverchair:429210 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001830 Silverchair:463998 Total_Item_Investigations 53 14 16 19 1 0 0 0 1 0 0 2 0 American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001830 Silverchair:463998 Total_Item_Requests 53 14 16 19 1 0 0 0 1 0 0 2 0 American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001830 Silverchair:463998 Unique_Item_Investigations 37 9 9 16 1 0 0 0 1 0 0 1 0 American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001830 Silverchair:463998 Unique_Item_Requests 37 9 9 16 1 0 0 0 1 0 0 1 0 American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001851 Silverchair:460974 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001851 Silverchair:460974 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001851 Silverchair:460974 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001851 Silverchair:460974 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001142 Silverchair:454384 Total_Item_Investigations 4 0 2 1 1 0 0 0 0 0 0 0 0 "American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001142 Silverchair:454384 Total_Item_Requests 4 0 2 1 1 0 0 0 0 0 0 0 0 "American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001142 Silverchair:454384 Unique_Item_Investigations 3 0 1 1 1 0 0 0 0 0 0 0 0 "American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001142 Silverchair:454384 Unique_Item_Requests 3 0 1 1 1 0 0 0 0 0 0 0 0 American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001143 Silverchair:440607 Total_Item_Investigations 7 3 0 3 0 0 0 0 1 0 0 0 0 American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001143 Silverchair:440607 Total_Item_Requests 7 3 0 3 0 0 0 0 1 0 0 0 0 American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001143 Silverchair:440607 Unique_Item_Investigations 5 2 0 2 0 0 0 0 1 0 0 0 0 American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001143 Silverchair:440607 Unique_Item_Requests 5 2 0 2 0 0 0 0 1 0 0 0 0 American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003442 Silverchair:475194 Total_Item_Investigations 24 0 9 6 1 0 0 0 2 5 0 0 1 American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003442 Silverchair:475194 Total_Item_Requests 24 0 9 6 1 0 0 0 2 5 0 0 1 American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003442 Silverchair:475194 Unique_Item_Investigations 18 0 6 5 1 0 0 0 2 3 0 0 1 American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003442 Silverchair:475194 Unique_Item_Requests 18 0 6 5 1 0 0 0 2 3 0 0 1 American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003763 Silverchair:475154 Total_Item_Investigations 14 0 11 2 0 0 0 0 0 0 0 0 1 American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003763 Silverchair:475154 Total_Item_Requests 14 0 11 2 0 0 0 0 0 0 0 0 1 American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003763 Silverchair:475154 Unique_Item_Investigations 12 0 9 2 0 0 0 0 0 0 0 0 1 American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003763 Silverchair:475154 Unique_Item_Requests 12 0 9 2 0 0 0 0 0 0 0 0 1 American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on post-discharge thromboprophylaxis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005945 Silverchair:477753 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on post-discharge thromboprophylaxis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005945 Silverchair:477753 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on post-discharge thromboprophylaxis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005945 Silverchair:477753 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on post-discharge thromboprophylaxis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005945 Silverchair:477753 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005493 Silverchair:476770 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 1 0 1 American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005493 Silverchair:476770 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 1 0 1 American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005493 Silverchair:476770 Unique_Item_Investigations 2 0 0 0 0 0 0 0 0 0 1 0 1 American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005493 Silverchair:476770 Unique_Item_Requests 2 0 0 0 0 0 0 0 0 0 1 0 1 American Society of Hematology Self-Assessment Program Seventh Edition American Society of Hematology American Society of Hematology Silverchair:6 978-0-9789212-3-1 Total_Item_Investigations 59 0 0 0 20 6 9 8 6 10 0 0 0 American Society of Hematology Self-Assessment Program Seventh Edition American Society of Hematology American Society of Hematology Silverchair:6 978-0-9789212-3-1 Unique_Item_Investigations 36 0 0 0 10 5 4 6 4 7 0 0 0 American Society of Hematology Self-Assessment Program Seventh Edition American Society of Hematology American Society of Hematology Silverchair:6 978-0-9789212-4-8 Total_Item_Investigations 63 11 25 16 0 0 0 0 0 0 6 4 1 American Society of Hematology Self-Assessment Program Seventh Edition American Society of Hematology American Society of Hematology Silverchair:6 978-0-9789212-4-8 Unique_Item_Investigations 36 7 16 8 0 0 0 0 0 0 2 2 1 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-300541 Silverchair:28114 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-300541 Silverchair:28114 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-300541 Silverchair:28114 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-300541 Silverchair:28114 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 AMIS and antigen modulation: of mice and men The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-743914 Silverchair:116527 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 AMIS and antigen modulation: of mice and men The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-743914 Silverchair:116527 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 AMIS and antigen modulation: of mice and men The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-743914 Silverchair:116527 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 AMIS and antigen modulation: of mice and men The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-743914 Silverchair:116527 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 AML Survival and In Vivo Progression Is Dependent On β-Catenin Signaling. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.2398.2398 Silverchair:63965 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 AML Survival and In Vivo Progression Is Dependent On β-Catenin Signaling. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.2398.2398 Silverchair:63965 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 AML Survival and In Vivo Progression Is Dependent On β-Catenin Signaling. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.2398.2398 Silverchair:63965 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 AML Survival and In Vivo Progression Is Dependent On β-Catenin Signaling. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.2398.2398 Silverchair:63965 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-02-0434 Silverchair:17953 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-02-0434 Silverchair:17953 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-02-0434 Silverchair:17953 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-02-0434 Silverchair:17953 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 AML-specific cytotoxic antibodies in patients with durable graft-versus-leukemia responses The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-768762 Silverchair:107701 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 AML-specific cytotoxic antibodies in patients with durable graft-versus-leukemia responses The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-768762 Silverchair:107701 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 AML-specific cytotoxic antibodies in patients with durable graft-versus-leukemia responses The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-768762 Silverchair:107701 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 AML-specific cytotoxic antibodies in patients with durable graft-versus-leukemia responses The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-768762 Silverchair:107701 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Amoeboid shape change and contact guidance: T-lymphocyte crawling through fibrillar collagen is independent of matrix remodeling by MMPs and other proteases The American Society of Hematology American Society of Hematology 10.1182/blood-2002-12-3791 Silverchair:17799 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 Amoeboid shape change and contact guidance: T-lymphocyte crawling through fibrillar collagen is independent of matrix remodeling by MMPs and other proteases The American Society of Hematology American Society of Hematology 10.1182/blood-2002-12-3791 Silverchair:17799 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Amoeboid shape change and contact guidance: T-lymphocyte crawling through fibrillar collagen is independent of matrix remodeling by MMPs and other proteases The American Society of Hematology American Society of Hematology 10.1182/blood-2002-12-3791 Silverchair:17799 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Amoeboid shape change and contact guidance: T-lymphocyte crawling through fibrillar collagen is independent of matrix remodeling by MMPs and other proteases The American Society of Hematology American Society of Hematology 10.1182/blood-2002-12-3791 Silverchair:17799 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 AMP-activated protein kinase links acetyl-CoA homeostasis to BRD4 recruitment in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019001076 Silverchair:375147 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 AMP-activated protein kinase links acetyl-CoA homeostasis to BRD4 recruitment in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019001076 Silverchair:375147 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 AMP-activated protein kinase links acetyl-CoA homeostasis to BRD4 recruitment in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019001076 Silverchair:375147 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 AMP-activated protein kinase links acetyl-CoA homeostasis to BRD4 recruitment in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019001076 Silverchair:375147 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 AMPK-ACC signaling modulates platelet phospholipids and potentiates thrombus formation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-831503 Silverchair:39393 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 AMPK-ACC signaling modulates platelet phospholipids and potentiates thrombus formation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-831503 Silverchair:39393 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 AMPK-ACC signaling modulates platelet phospholipids and potentiates thrombus formation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-831503 Silverchair:39393 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 AMPK-ACC signaling modulates platelet phospholipids and potentiates thrombus formation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-831503 Silverchair:39393 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "AMV564, a Bivalent Bispecific (2×2) CD33/CD3 T-Cell Engager, Is Active and Improves Survival in a Mouse Model of Acute Myeloid Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118573 Silverchair:264306 Total_Item_Investigations 8 0 8 0 0 0 0 0 0 0 0 0 0 "AMV564, a Bivalent Bispecific (2×2) CD33/CD3 T-Cell Engager, Is Active and Improves Survival in a Mouse Model of Acute Myeloid Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118573 Silverchair:264306 Total_Item_Requests 8 0 8 0 0 0 0 0 0 0 0 0 0 "AMV564, a Bivalent Bispecific (2×2) CD33/CD3 T-Cell Engager, Is Active and Improves Survival in a Mouse Model of Acute Myeloid Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118573 Silverchair:264306 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "AMV564, a Bivalent Bispecific (2×2) CD33/CD3 T-Cell Engager, Is Active and Improves Survival in a Mouse Model of Acute Myeloid Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118573 Silverchair:264306 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Amyloidosis and Waldenström’s Macroglobulinemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2004.1.257 Silverchair:18696 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Amyloidosis and Waldenström’s Macroglobulinemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2004.1.257 Silverchair:18696 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Amyloidosis and Waldenström’s Macroglobulinemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2004.1.257 Silverchair:18696 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Amyloidosis and Waldenström’s Macroglobulinemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2004.1.257 Silverchair:18696 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.145.145 Silverchair:79622 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 "An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.145.145 Silverchair:79622 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 "An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.145.145 Silverchair:79622 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 "An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.145.145 Silverchair:79622 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 An Analysis of Racial and Ethnic Backgrounds within the Casire International Cohort of Sickle Cell Disease Patients: Implications for Disease Phenotype and Clinical Research The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127613 Silverchair:422834 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 An Analysis of Racial and Ethnic Backgrounds within the Casire International Cohort of Sickle Cell Disease Patients: Implications for Disease Phenotype and Clinical Research The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127613 Silverchair:422834 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 An Analysis of Racial and Ethnic Backgrounds within the Casire International Cohort of Sickle Cell Disease Patients: Implications for Disease Phenotype and Clinical Research The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127613 Silverchair:422834 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 An Analysis of Racial and Ethnic Backgrounds within the Casire International Cohort of Sickle Cell Disease Patients: Implications for Disease Phenotype and Clinical Research The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127613 Silverchair:422834 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 An Anti-Bcma CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138734 Silverchair:469918 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 An Anti-Bcma CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138734 Silverchair:469918 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 An Anti-Bcma CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138734 Silverchair:469918 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 An Anti-Bcma CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138734 Silverchair:469918 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-735365 Silverchair:36176 Total_Item_Investigations 5 0 5 0 0 0 0 0 0 0 0 0 0 An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-735365 Silverchair:36176 Total_Item_Requests 5 0 5 0 0 0 0 0 0 0 0 0 0 An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-735365 Silverchair:36176 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-735365 Silverchair:36176 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 An Artificial Intelligence (AI) Approach for Automated Flow Cytometric Diagnosis of B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113797 Silverchair:263692 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 An Artificial Intelligence (AI) Approach for Automated Flow Cytometric Diagnosis of B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113797 Silverchair:263692 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 An Artificial Intelligence (AI) Approach for Automated Flow Cytometric Diagnosis of B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113797 Silverchair:263692 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 An Artificial Intelligence (AI) Approach for Automated Flow Cytometric Diagnosis of B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113797 Silverchair:263692 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 An Artificial Neural Network Providing Highly Reliable Decision Support in a Routine Setting for Classification of B-Cell Neoplasms Based on Flow Cytometric Raw Data The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130374 Silverchair:427070 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 An Artificial Neural Network Providing Highly Reliable Decision Support in a Routine Setting for Classification of B-Cell Neoplasms Based on Flow Cytometric Raw Data The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130374 Silverchair:427070 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 An Artificial Neural Network Providing Highly Reliable Decision Support in a Routine Setting for Classification of B-Cell Neoplasms Based on Flow Cytometric Raw Data The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130374 Silverchair:427070 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 An Artificial Neural Network Providing Highly Reliable Decision Support in a Routine Setting for Classification of B-Cell Neoplasms Based on Flow Cytometric Raw Data The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130374 Silverchair:427070 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129461 Silverchair:426354 Total_Item_Investigations 10 10 0 0 0 0 0 0 0 0 0 0 0 An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129461 Silverchair:426354 Total_Item_Requests 8 8 0 0 0 0 0 0 0 0 0 0 0 An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129461 Silverchair:426354 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129461 Silverchair:426354 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 An Epigenetic Screen Identifies PRMT5 As a Target for Inhibition of FLT3-ITD AML Cell Growth in Combination with Tyrosine Kinase Inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125178 Silverchair:423197 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 An Epigenetic Screen Identifies PRMT5 As a Target for Inhibition of FLT3-ITD AML Cell Growth in Combination with Tyrosine Kinase Inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125178 Silverchair:423197 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 An Epigenetic Screen Identifies PRMT5 As a Target for Inhibition of FLT3-ITD AML Cell Growth in Combination with Tyrosine Kinase Inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125178 Silverchair:423197 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 An Epigenetic Screen Identifies PRMT5 As a Target for Inhibition of FLT3-ITD AML Cell Growth in Combination with Tyrosine Kinase Inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125178 Silverchair:423197 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 An epitope-based approach of HLA-matched platelets for transfusion: a noninferiority crossover randomized trial The American Society of Hematology American Society of Hematology 10.1182/blood.2020007199 Silverchair:469617 Total_Item_Investigations 5 2 2 1 0 0 0 0 0 0 0 0 0 An epitope-based approach of HLA-matched platelets for transfusion: a noninferiority crossover randomized trial The American Society of Hematology American Society of Hematology 10.1182/blood.2020007199 Silverchair:469617 Total_Item_Requests 5 2 2 1 0 0 0 0 0 0 0 0 0 An epitope-based approach of HLA-matched platelets for transfusion: a noninferiority crossover randomized trial The American Society of Hematology American Society of Hematology 10.1182/blood.2020007199 Silverchair:469617 Unique_Item_Investigations 5 2 2 1 0 0 0 0 0 0 0 0 0 An epitope-based approach of HLA-matched platelets for transfusion: a noninferiority crossover randomized trial The American Society of Hematology American Society of Hematology 10.1182/blood.2020007199 Silverchair:469617 Unique_Item_Requests 5 2 2 1 0 0 0 0 0 0 0 0 0 An Essential Role for NF-κB in Human CD34+ Bone Marrow Cell Survival The American Society of Hematology American Society of Hematology 10.1182/blood.V93.10.3302.410a38_3302_3308 Silverchair:137916 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 An Essential Role for NF-κB in Human CD34+ Bone Marrow Cell Survival The American Society of Hematology American Society of Hematology 10.1182/blood.V93.10.3302.410a38_3302_3308 Silverchair:137916 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 An Essential Role for NF-κB in Human CD34+ Bone Marrow Cell Survival The American Society of Hematology American Society of Hematology 10.1182/blood.V93.10.3302.410a38_3302_3308 Silverchair:137916 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 An Essential Role for NF-κB in Human CD34+ Bone Marrow Cell Survival The American Society of Hematology American Society of Hematology 10.1182/blood.V93.10.3302.410a38_3302_3308 Silverchair:137916 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 An Immune Risk Score Predicts Survival of Patients with Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137349 Silverchair:473673 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 An Immune Risk Score Predicts Survival of Patients with Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137349 Silverchair:473673 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 An Immune Risk Score Predicts Survival of Patients with Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137349 Silverchair:473673 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 An Immune Risk Score Predicts Survival of Patients with Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137349 Silverchair:473673 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 An intact gut microbiome protects genetically predisposed mice against leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019004381 Silverchair:463729 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 An intact gut microbiome protects genetically predisposed mice against leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019004381 Silverchair:463729 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 An intact gut microbiome protects genetically predisposed mice against leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019004381 Silverchair:463729 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 An intact gut microbiome protects genetically predisposed mice against leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019004381 Silverchair:463729 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-607341 Silverchair:33697 Total_Item_Investigations 4 0 0 0 2 0 2 0 0 0 0 0 0 An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-607341 Silverchair:33697 Total_Item_Requests 3 0 0 0 2 0 1 0 0 0 0 0 0 An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-607341 Silverchair:33697 Unique_Item_Investigations 2 0 0 0 1 0 1 0 0 0 0 0 0 An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-607341 Silverchair:33697 Unique_Item_Requests 2 0 0 0 1 0 1 0 0 0 0 0 0 An International Multicentre Study of Consecutively Diagnosed Patients with ALCL: Outcomes Following First-Line Therapy in Routine Clinical Practice The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122083 Silverchair:423483 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 An International Multicentre Study of Consecutively Diagnosed Patients with ALCL: Outcomes Following First-Line Therapy in Routine Clinical Practice The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122083 Silverchair:423483 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 An International Multicentre Study of Consecutively Diagnosed Patients with ALCL: Outcomes Following First-Line Therapy in Routine Clinical Practice The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122083 Silverchair:423483 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 An International Multicentre Study of Consecutively Diagnosed Patients with ALCL: Outcomes Following First-Line Therapy in Routine Clinical Practice The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122083 Silverchair:423483 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 An Off-the-Shelf™ Fratricide-Resistant CAR-T for the Treatment of T Cell Hematologic Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.844.844 Silverchair:83342 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 An Off-the-Shelf™ Fratricide-Resistant CAR-T for the Treatment of T Cell Hematologic Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.844.844 Silverchair:83342 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 An Off-the-Shelf™ Fratricide-Resistant CAR-T for the Treatment of T Cell Hematologic Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.844.844 Silverchair:83342 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 An Off-the-Shelf™ Fratricide-Resistant CAR-T for the Treatment of T Cell Hematologic Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.844.844 Silverchair:83342 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-414359 Silverchair:30289 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-414359 Silverchair:30289 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-414359 Silverchair:30289 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-414359 Silverchair:30289 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases The American Society of Hematology American Society of Hematology 10.1182/blood.V95.9.2913.009k32_2913_2921 Silverchair:125520 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases The American Society of Hematology American Society of Hematology 10.1182/blood.V95.9.2913.009k32_2913_2921 Silverchair:125520 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases The American Society of Hematology American Society of Hematology 10.1182/blood.V95.9.2913.009k32_2913_2921 Silverchair:125520 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases The American Society of Hematology American Society of Hematology 10.1182/blood.V95.9.2913.009k32_2913_2921 Silverchair:125520 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000745 Silverchair:422670 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000745 Silverchair:422670 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000745 Silverchair:422670 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000745 Silverchair:422670 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Analysis of Warfarin Therapy in Pediatric Patients: A Prospective Cohort Study of 319 Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V94.9.3007 Silverchair:252568 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Analysis of Warfarin Therapy in Pediatric Patients: A Prospective Cohort Study of 319 Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V94.9.3007 Silverchair:252568 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Analysis of Warfarin Therapy in Pediatric Patients: A Prospective Cohort Study of 319 Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V94.9.3007 Silverchair:252568 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Analysis of Warfarin Therapy in Pediatric Patients: A Prospective Cohort Study of 319 Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V94.9.3007 Silverchair:252568 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Analytical Review: The Pathogenesis of Spherocytes and Leptocytes (Target Cells) The American Society of Hematology American Society of Hematology 10.1182/blood.V7.2.261.261 Silverchair:43962 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Analytical Review: The Pathogenesis of Spherocytes and Leptocytes (Target Cells) The American Society of Hematology American Society of Hematology 10.1182/blood.V7.2.261.261 Silverchair:43962 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127072 Silverchair:426868 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127072 Silverchair:426868 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127072 Silverchair:426868 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127072 Silverchair:426868 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti–tumor necrosis factor-α antibody therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2002-01-0136 Silverchair:89118 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti–tumor necrosis factor-α antibody therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2002-01-0136 Silverchair:89118 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti–tumor necrosis factor-α antibody therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2002-01-0136 Silverchair:89118 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti–tumor necrosis factor-α antibody therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2002-01-0136 Silverchair:89118 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Anemia of inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-856500 Silverchair:6617 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Anemia of inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-856500 Silverchair:6617 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Anemia of inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-856500 Silverchair:6617 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Anemia of inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-856500 Silverchair:6617 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation The American Society of Hematology American Society of Hematology 10.1182/blood-2004-08-3382 Silverchair:19701 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation The American Society of Hematology American Society of Hematology 10.1182/blood-2004-08-3382 Silverchair:19701 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation The American Society of Hematology American Society of Hematology 10.1182/blood-2004-08-3382 Silverchair:19701 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation The American Society of Hematology American Society of Hematology 10.1182/blood-2004-08-3382 Silverchair:19701 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 ANGPTL4 modulates vascular junction integrity by integrin signaling and disruption of intercellular VE-cadherin and claudin-5 clusters The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-328716 Silverchair:28752 Total_Item_Investigations 6 3 3 0 0 0 0 0 0 0 0 0 0 ANGPTL4 modulates vascular junction integrity by integrin signaling and disruption of intercellular VE-cadherin and claudin-5 clusters The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-328716 Silverchair:28752 Total_Item_Requests 4 2 2 0 0 0 0 0 0 0 0 0 0 ANGPTL4 modulates vascular junction integrity by integrin signaling and disruption of intercellular VE-cadherin and claudin-5 clusters The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-328716 Silverchair:28752 Unique_Item_Investigations 4 2 2 0 0 0 0 0 0 0 0 0 0 ANGPTL4 modulates vascular junction integrity by integrin signaling and disruption of intercellular VE-cadherin and claudin-5 clusters The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-328716 Silverchair:28752 Unique_Item_Requests 4 2 2 0 0 0 0 0 0 0 0 0 0 Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood.2020009801 Silverchair:475390 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood.2020009801 Silverchair:475390 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-739656 Silverchair:35953 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-739656 Silverchair:35953 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-739656 Silverchair:35953 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-739656 Silverchair:35953 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Anti-Apoptotic Effects of Platelet Factor 4 on Human T-Lymphocytes The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1418.1418 Silverchair:87976 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Anti-Apoptotic Effects of Platelet Factor 4 on Human T-Lymphocytes The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1418.1418 Silverchair:87976 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Anti-Apoptotic Effects of Platelet Factor 4 on Human T-Lymphocytes The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1418.1418 Silverchair:87976 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Anti-Apoptotic Effects of Platelet Factor 4 on Human T-Lymphocytes The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1418.1418 Silverchair:87976 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2007-01-066704 Silverchair:22995 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2007-01-066704 Silverchair:22995 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2007-01-066704 Silverchair:22995 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2007-01-066704 Silverchair:22995 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Antibody-induced procoagulant platelets in severe COVID-19 infection The American Society of Hematology American Society of Hematology 10.1182/blood.2020008762 Silverchair:474776 Total_Item_Investigations 19 7 9 0 0 3 0 0 0 0 0 0 0 Antibody-induced procoagulant platelets in severe COVID-19 infection The American Society of Hematology American Society of Hematology 10.1182/blood.2020008762 Silverchair:474776 Total_Item_Requests 11 2 6 0 0 3 0 0 0 0 0 0 0 Antibody-induced procoagulant platelets in severe COVID-19 infection The American Society of Hematology American Society of Hematology 10.1182/blood.2020008762 Silverchair:474776 Unique_Item_Investigations 11 4 5 0 0 2 0 0 0 0 0 0 0 Antibody-induced procoagulant platelets in severe COVID-19 infection The American Society of Hematology American Society of Hematology 10.1182/blood.2020008762 Silverchair:474776 Unique_Item_Requests 7 1 4 0 0 2 0 0 0 0 0 0 0 Antibody-mediated immune suppression by antigen modulation is antigen-specific American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018018408 Silverchair:16218 Total_Item_Investigations 6 0 3 0 0 0 0 0 0 0 3 0 0 Antibody-mediated immune suppression by antigen modulation is antigen-specific American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018018408 Silverchair:16218 Total_Item_Requests 6 0 3 0 0 0 0 0 0 0 3 0 0 Antibody-mediated immune suppression by antigen modulation is antigen-specific American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018018408 Silverchair:16218 Unique_Item_Investigations 2 0 1 0 0 0 0 0 0 0 1 0 0 Antibody-mediated immune suppression by antigen modulation is antigen-specific American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018018408 Silverchair:16218 Unique_Item_Requests 2 0 1 0 0 0 0 0 0 0 1 0 0 Anti-CCR9 CAR-T Cells for T Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2021-146565 Silverchair:482638 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 Anti-CCR9 CAR-T Cells for T Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2021-146565 Silverchair:482638 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 Anti-CCR9 CAR-T Cells for T Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2021-146565 Silverchair:482638 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Anti-CCR9 CAR-T Cells for T Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2021-146565 Silverchair:482638 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Anti-CD117 CAR T Cells Incorporating a Safety Switch Eradicate Acute Myeloid Leukemia and Deplete Human Hematopoietic Stem Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2021-145195 Silverchair:482369 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Anti-CD117 CAR T Cells Incorporating a Safety Switch Eradicate Acute Myeloid Leukemia and Deplete Human Hematopoietic Stem Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2021-145195 Silverchair:482369 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Anti-CD117 CAR T Cells Incorporating a Safety Switch Eradicate Acute Myeloid Leukemia and Deplete Human Hematopoietic Stem Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2021-145195 Silverchair:482369 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Anti-CD117 CAR T Cells Incorporating a Safety Switch Eradicate Acute Myeloid Leukemia and Deplete Human Hematopoietic Stem Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2021-145195 Silverchair:482369 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Anti-CD123 Targeted Therapy with Talacotuzumab in Advanced MDS and AML after Failing Hypomethylating Agents - Final Results of the Samba Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113112 Silverchair:265010 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Anti-CD123 Targeted Therapy with Talacotuzumab in Advanced MDS and AML after Failing Hypomethylating Agents - Final Results of the Samba Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113112 Silverchair:265010 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Anti-CD123 Targeted Therapy with Talacotuzumab in Advanced MDS and AML after Failing Hypomethylating Agents - Final Results of the Samba Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113112 Silverchair:265010 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Anti-CD123 Targeted Therapy with Talacotuzumab in Advanced MDS and AML after Failing Hypomethylating Agents - Final Results of the Samba Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113112 Silverchair:265010 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Anti-CD1a CAR T cells to selectively target T-ALL The American Society of Hematology American Society of Hematology 10.1182/blood-2019-03-900910 Silverchair:272734 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Anti-CD1a CAR T cells to selectively target T-ALL The American Society of Hematology American Society of Hematology 10.1182/blood-2019-03-900910 Silverchair:272734 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Anti-CD1a CAR T cells to selectively target T-ALL The American Society of Hematology American Society of Hematology 10.1182/blood-2019-03-900910 Silverchair:272734 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Anti-CD1a CAR T cells to selectively target T-ALL The American Society of Hematology American Society of Hematology 10.1182/blood-2019-03-900910 Silverchair:272734 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-020057 Silverchair:22546 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-020057 Silverchair:22546 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-020057 Silverchair:22546 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-020057 Silverchair:22546 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Anti-CD21 Chimeric Antigen Receptor (CAR)-T Cells for T Cell Acute Lymphoblastic Leukaemia (T-ALL) The American Society of Hematology American Society of Hematology 10.1182/blood-2021-145725 Silverchair:482659 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 Anti-CD21 Chimeric Antigen Receptor (CAR)-T Cells for T Cell Acute Lymphoblastic Leukaemia (T-ALL) The American Society of Hematology American Society of Hematology 10.1182/blood-2021-145725 Silverchair:482659 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 Anti-CD21 Chimeric Antigen Receptor (CAR)-T Cells for T Cell Acute Lymphoblastic Leukaemia (T-ALL) The American Society of Hematology American Society of Hematology 10.1182/blood-2021-145725 Silverchair:482659 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Anti-CD21 Chimeric Antigen Receptor (CAR)-T Cells for T Cell Acute Lymphoblastic Leukaemia (T-ALL) The American Society of Hematology American Society of Hematology 10.1182/blood-2021-145725 Silverchair:482659 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-06-438002 Silverchair:31529 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-06-438002 Silverchair:31529 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-06-438002 Silverchair:31529 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-06-438002 Silverchair:31529 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Anticoagulant and Antiplatelet Use Not Associated with Improvement in Severe Outcomes in COVID-19 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134254 Silverchair:470187 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Anticoagulant and Antiplatelet Use Not Associated with Improvement in Severe Outcomes in COVID-19 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134254 Silverchair:470187 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Anticoagulant and Antiplatelet Use Not Associated with Improvement in Severe Outcomes in COVID-19 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134254 Silverchair:470187 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Anticoagulant and Antiplatelet Use Not Associated with Improvement in Severe Outcomes in COVID-19 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134254 Silverchair:470187 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis The American Society of Hematology American Society of Hematology 10.1182/blood.2020006827 Silverchair:463730 Total_Item_Investigations 16 2 0 11 1 1 0 0 0 0 1 0 0 Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis The American Society of Hematology American Society of Hematology 10.1182/blood.2020006827 Silverchair:463730 Unique_Item_Investigations 11 2 0 6 1 1 0 0 0 0 1 0 0 Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis The American Society of Hematology American Society of Hematology 10.1182/blood.2020006827 Silverchair:463730 No_License 3 0 0 3 0 0 0 0 0 0 0 0 0 Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis The American Society of Hematology American Society of Hematology 10.1182/blood.2020006827 Silverchair:463730 Total_Item_Requests 4 0 0 3 0 0 0 0 0 0 1 0 0 Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis The American Society of Hematology American Society of Hematology 10.1182/blood.2020006827 Silverchair:463730 Unique_Item_Requests 3 0 0 2 0 0 0 0 0 0 1 0 0 Anticoagulation and in vitro fertilization and ovarian stimulation The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.379 Silverchair:20251 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Anticoagulation and in vitro fertilization and ovarian stimulation The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.379 Silverchair:20251 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Anticoagulation and in vitro fertilization and ovarian stimulation The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.379 Silverchair:20251 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Anticoagulation and in vitro fertilization and ovarian stimulation The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.379 Silverchair:20251 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multi-center cohort study" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005966 Silverchair:477385 Total_Item_Investigations 4 0 0 0 0 0 0 0 0 0 2 2 0 "Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multi-center cohort study" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005966 Silverchair:477385 Total_Item_Requests 3 0 0 0 0 0 0 0 0 0 1 2 0 "Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multi-center cohort study" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005966 Silverchair:477385 Unique_Item_Investigations 2 0 0 0 0 0 0 0 0 0 1 1 0 "Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multi-center cohort study" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005966 Silverchair:477385 Unique_Item_Requests 2 0 0 0 0 0 0 0 0 0 1 1 0 Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-107292 Silverchair:25219 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-107292 Silverchair:25219 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-107292 Silverchair:25219 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-107292 Silverchair:25219 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy. Prospective Observational Study from the Acute Leukemia French Association (ALFA) Group The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3696.3696 Silverchair:97149 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy. Prospective Observational Study from the Acute Leukemia French Association (ALFA) Group The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3696.3696 Silverchair:97149 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy. Prospective Observational Study from the Acute Leukemia French Association (ALFA) Group The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3696.3696 Silverchair:97149 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy. Prospective Observational Study from the Acute Leukemia French Association (ALFA) Group The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3696.3696 Silverchair:97149 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Antigen density dictates RBC clearance, but not antigen modulation, following incompatible RBC transfusion in mice" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002695 Silverchair:474969 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 "Antigen density dictates RBC clearance, but not antigen modulation, following incompatible RBC transfusion in mice" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002695 Silverchair:474969 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 "Antigen density dictates RBC clearance, but not antigen modulation, following incompatible RBC transfusion in mice" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002695 Silverchair:474969 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "Antigen density dictates RBC clearance, but not antigen modulation, following incompatible RBC transfusion in mice" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002695 Silverchair:474969 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Antigen modulation as a potential mechanism of anti-KEL immunoprophylaxis in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-724732 Silverchair:116560 Total_Item_Investigations 4 3 1 0 0 0 0 0 0 0 0 0 0 Antigen modulation as a potential mechanism of anti-KEL immunoprophylaxis in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-724732 Silverchair:116560 Total_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 Antigen modulation as a potential mechanism of anti-KEL immunoprophylaxis in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-724732 Silverchair:116560 Unique_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 Antigen modulation as a potential mechanism of anti-KEL immunoprophylaxis in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-724732 Silverchair:116560 Unique_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 Antigen receptor–mediated changes in glucose metabolism in B lymphocytes: role of phosphatidylinositol 3-kinase signaling in the glycolytic control of growth The American Society of Hematology American Society of Hematology 10.1182/blood-2005-12-4788 Silverchair:21994 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Antigen receptor–mediated changes in glucose metabolism in B lymphocytes: role of phosphatidylinositol 3-kinase signaling in the glycolytic control of growth The American Society of Hematology American Society of Hematology 10.1182/blood-2005-12-4788 Silverchair:21994 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Antigen receptor–mediated changes in glucose metabolism in B lymphocytes: role of phosphatidylinositol 3-kinase signaling in the glycolytic control of growth The American Society of Hematology American Society of Hematology 10.1182/blood-2005-12-4788 Silverchair:21994 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Antigen receptor–mediated changes in glucose metabolism in B lymphocytes: role of phosphatidylinositol 3-kinase signaling in the glycolytic control of growth The American Society of Hematology American Society of Hematology 10.1182/blood-2005-12-4788 Silverchair:21994 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-588376 Silverchair:33709 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-588376 Silverchair:33709 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-588376 Silverchair:33709 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-588376 Silverchair:33709 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-263533 Silverchair:27097 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-263533 Silverchair:27097 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-263533 Silverchair:27097 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-263533 Silverchair:27097 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Anti-Human CD117 CAR T-Cells Efficiently Eliminate Hematopoietic Stem and CD117-Positive AML Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118230 Silverchair:265219 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Anti-Human CD117 CAR T-Cells Efficiently Eliminate Hematopoietic Stem and CD117-Positive AML Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118230 Silverchair:265219 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Anti-Human CD117 CAR T-Cells Efficiently Eliminate Hematopoietic Stem and CD117-Positive AML Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118230 Silverchair:265219 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Anti-Human CD117 CAR T-Cells Efficiently Eliminate Hematopoietic Stem and CD117-Positive AML Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118230 Silverchair:265219 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Anti-IL-12/23 p40 Antibody Attenuates Chronic Graft Versus Host Disease Via Suppression of IFN-γ/IL-17-Producing Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1095.1095 Silverchair:87847 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Anti-IL-12/23 p40 Antibody Attenuates Chronic Graft Versus Host Disease Via Suppression of IFN-γ/IL-17-Producing Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1095.1095 Silverchair:87847 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Anti-IL-12/23 p40 Antibody Attenuates Chronic Graft Versus Host Disease Via Suppression of IFN-γ/IL-17-Producing Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1095.1095 Silverchair:87847 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Anti-IL-12/23 p40 Antibody Attenuates Chronic Graft Versus Host Disease Via Suppression of IFN-γ/IL-17-Producing Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1095.1095 Silverchair:87847 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Anti-inflammatory treatment in MPN: Targeting TNFα-receptor 1 (TNFR1) and TNFR2 in JAK2-V617F induced disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004438 Silverchair:477104 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Anti-inflammatory treatment in MPN: Targeting TNFα-receptor 1 (TNFR1) and TNFR2 in JAK2-V617F induced disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004438 Silverchair:477104 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003429 Silverchair:475059 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003429 Silverchair:475059 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003429 Silverchair:475059 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003429 Silverchair:475059 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-805689 Silverchair:36908 Total_Item_Investigations 4 2 0 2 0 0 0 0 0 0 0 0 0 Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-805689 Silverchair:36908 Total_Item_Requests 3 1 0 2 0 0 0 0 0 0 0 0 0 Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-805689 Silverchair:36908 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-805689 Silverchair:36908 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-496257 Silverchair:32066 Total_Item_Investigations 5 0 0 1 0 0 0 0 0 2 2 0 0 Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-496257 Silverchair:32066 Total_Item_Requests 5 0 0 1 0 0 0 0 0 2 2 0 0 Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-496257 Silverchair:32066 Unique_Item_Investigations 3 0 0 1 0 0 0 0 0 1 1 0 0 Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-496257 Silverchair:32066 Unique_Item_Requests 3 0 0 1 0 0 0 0 0 1 1 0 0 "Anti-Tumor Activity of ASTX029, a Dual Mechanism Inhibitor of ERK1/2, in Preclinical AML Models" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139175 Silverchair:470845 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Anti-Tumor Activity of ASTX029, a Dual Mechanism Inhibitor of ERK1/2, in Preclinical AML Models" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139175 Silverchair:470845 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Anti-Tumor Activity of ASTX029, a Dual Mechanism Inhibitor of ERK1/2, in Preclinical AML Models" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139175 Silverchair:470845 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Anti-Tumor Activity of ASTX029, a Dual Mechanism Inhibitor of ERK1/2, in Preclinical AML Models" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139175 Silverchair:470845 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Apixaban Is Safe and Effective in Morbidly Obese Patients: A Retrospective Analysis of 390 Patients with BMI =40 The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1105.1105 Silverchair:116251 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Apixaban Is Safe and Effective in Morbidly Obese Patients: A Retrospective Analysis of 390 Patients with BMI =40 The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1105.1105 Silverchair:116251 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Apixaban Is Safe and Effective in Morbidly Obese Patients: A Retrospective Analysis of 390 Patients with BMI =40 The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1105.1105 Silverchair:116251 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Apixaban Is Safe and Effective in Morbidly Obese Patients: A Retrospective Analysis of 390 Patients with BMI =40 The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1105.1105 Silverchair:116251 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Aplastic Anemia in Pregnancy - a Single Centre, North American Case Series" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3909.3909 Silverchair:97233 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Aplastic Anemia in Pregnancy - a Single Centre, North American Case Series" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3909.3909 Silverchair:97233 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Aplastic Anemia in Pregnancy - a Single Centre, North American Case Series" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3909.3909 Silverchair:97233 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Aplastic Anemia in Pregnancy - a Single Centre, North American Case Series" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3909.3909 Silverchair:97233 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Apoptosis in megakaryocytes and platelets: the life and death of a lineage The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-742684 Silverchair:39214 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Apoptosis in megakaryocytes and platelets: the life and death of a lineage The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-742684 Silverchair:39214 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Apoptosis in megakaryocytes and platelets: the life and death of a lineage The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-742684 Silverchair:39214 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Apoptosis in megakaryocytes and platelets: the life and death of a lineage The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-742684 Silverchair:39214 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Approach to the diagnosis of aplastic anemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004345 Silverchair:476221 Total_Item_Investigations 4 0 0 0 0 0 2 2 0 0 0 0 0 Approach to the diagnosis of aplastic anemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004345 Silverchair:476221 Total_Item_Requests 4 0 0 0 0 0 2 2 0 0 0 0 0 Approach to the diagnosis of aplastic anemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004345 Silverchair:476221 Unique_Item_Investigations 2 0 0 0 0 0 1 1 0 0 0 0 0 Approach to the diagnosis of aplastic anemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004345 Silverchair:476221 Unique_Item_Requests 2 0 0 0 0 0 1 1 0 0 0 0 0 Approaching the crisis in medical research funding: an important role for nonprofit organizations and medical societies American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018017947 Silverchair:15894 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Approaching the crisis in medical research funding: an important role for nonprofit organizations and medical societies American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018017947 Silverchair:15894 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Approaching the crisis in medical research funding: an important role for nonprofit organizations and medical societies American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018017947 Silverchair:15894 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Approaching the crisis in medical research funding: an important role for nonprofit organizations and medical societies American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018017947 Silverchair:15894 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125579 Silverchair:426582 Total_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125579 Silverchair:426582 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125579 Silverchair:426582 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125579 Silverchair:426582 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 APRIL-TACI Interactions Mediate Non-Hodgkin Lymphoma B Cell Proliferation through Akt Regulated Cyclin D1 and P21. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3585.3585 Silverchair:58437 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 APRIL-TACI Interactions Mediate Non-Hodgkin Lymphoma B Cell Proliferation through Akt Regulated Cyclin D1 and P21. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3585.3585 Silverchair:58437 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 APRIL-TACI Interactions Mediate Non-Hodgkin Lymphoma B Cell Proliferation through Akt Regulated Cyclin D1 and P21. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3585.3585 Silverchair:58437 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 APRIL-TACI Interactions Mediate Non-Hodgkin Lymphoma B Cell Proliferation through Akt Regulated Cyclin D1 and P21. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3585.3585 Silverchair:58437 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Are CAR T cells better than antibody or HCT therapy in B-ALL? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.16 Silverchair:277627 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Are CAR T cells better than antibody or HCT therapy in B-ALL? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.16 Silverchair:277627 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Are CAR T cells better than antibody or HCT therapy in B-ALL? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.16 Silverchair:277627 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Are CAR T cells better than antibody or HCT therapy in B-ALL? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.16 Silverchair:277627 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Arf6 controls platelet spreading and clot retraction via integrin αIIbβ3 trafficking The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-648550 Silverchair:34992 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Arf6 controls platelet spreading and clot retraction via integrin αIIbβ3 trafficking The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-648550 Silverchair:34992 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Arf6 controls platelet spreading and clot retraction via integrin αIIbβ3 trafficking The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-648550 Silverchair:34992 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Arf6 controls platelet spreading and clot retraction via integrin αIIbβ3 trafficking The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-648550 Silverchair:34992 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Argatroban Inhibits Human Factor Xa at Therapeutic Drug Levels: An Explanation for Its Prolongation of the INR. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.1845.1845 Silverchair:90526 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Argatroban Inhibits Human Factor Xa at Therapeutic Drug Levels: An Explanation for Its Prolongation of the INR. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.1845.1845 Silverchair:90526 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Argatroban Inhibits Human Factor Xa at Therapeutic Drug Levels: An Explanation for Its Prolongation of the INR. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.1845.1845 Silverchair:90526 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Argatroban Inhibits Human Factor Xa at Therapeutic Drug Levels: An Explanation for Its Prolongation of the INR. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.1845.1845 Silverchair:90526 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug–induced thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.2019003749 Silverchair:454179 No_License 2 0 2 0 0 0 0 0 0 0 0 0 0 Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug–induced thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.2019003749 Silverchair:454179 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug–induced thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.2019003749 Silverchair:454179 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139677 Silverchair:470409 Total_Item_Investigations 2 1 0 0 0 1 0 0 0 0 0 0 0 "Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139677 Silverchair:470409 Total_Item_Requests 2 1 0 0 0 1 0 0 0 0 0 0 0 "Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139677 Silverchair:470409 Unique_Item_Investigations 2 1 0 0 0 1 0 0 0 0 0 0 0 "Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139677 Silverchair:470409 Unique_Item_Requests 2 1 0 0 0 1 0 0 0 0 0 0 0 "Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113609 Silverchair:266146 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113609 Silverchair:266146 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113609 Silverchair:266146 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113609 Silverchair:266146 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003265 Silverchair:474888 Total_Item_Investigations 36 21 4 4 0 1 0 2 2 1 0 0 1 ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003265 Silverchair:474888 Total_Item_Requests 36 21 4 4 0 1 0 2 2 1 0 0 1 ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003265 Silverchair:474888 Unique_Item_Investigations 24 13 2 3 0 1 0 1 2 1 0 0 1 ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003265 Silverchair:474888 Unique_Item_Requests 24 13 2 3 0 1 0 1 2 1 0 0 1 ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003264 Silverchair:474884 Total_Item_Investigations 30 17 7 5 0 0 0 1 0 0 0 0 0 ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003264 Silverchair:474884 Total_Item_Requests 30 17 7 5 0 0 0 1 0 0 0 0 0 ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003264 Silverchair:474884 Unique_Item_Investigations 18 10 5 2 0 0 0 1 0 0 0 0 0 ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003264 Silverchair:474884 Unique_Item_Requests 18 10 5 2 0 0 0 1 0 0 0 0 0 ASH Medical Educators Institute: A View From the Classroom American Society of Hematology American Society of Hematology 10.1182/hem.V15.2.8300 Silverchair:463043 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 ASH Medical Educators Institute: A View From the Classroom American Society of Hematology American Society of Hematology 10.1182/hem.V15.2.8300 Silverchair:463043 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 ASH Medical Educators Institute: A View From the Classroom American Society of Hematology American Society of Hematology 10.1182/hem.V15.2.8300 Silverchair:463043 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 ASH Medical Educators Institute: A View From the Classroom American Society of Hematology American Society of Hematology 10.1182/hem.V15.2.8300 Silverchair:463043 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 ASH Research Collaborative: A Real-World Data Infrastructure to Support Real-World Evidence Development and Learning Healthcare Systems in Hematology American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005902 Silverchair:477421 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 0 0 3 0 ASH Research Collaborative: A Real-World Data Infrastructure to Support Real-World Evidence Development and Learning Healthcare Systems in Hematology American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005902 Silverchair:477421 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 ASH Research Collaborative: A Real-World Data Infrastructure to Support Real-World Evidence Development and Learning Healthcare Systems in Hematology American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005902 Silverchair:477421 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 ASH Research Collaborative: A Real-World Data Infrastructure to Support Real-World Evidence Development and Learning Healthcare Systems in Hematology American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005902 Silverchair:477421 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Ask the Hematologists: Von Willebrand Disease and Pregnancy American Society of Hematology American Society of Hematology 10.1182/hem.V14.3.7296 Silverchair:462882 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Ask the Hematologists: Von Willebrand Disease and Pregnancy American Society of Hematology American Society of Hematology 10.1182/hem.V14.3.7296 Silverchair:462882 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Ask the Hematologists: Von Willebrand Disease and Pregnancy American Society of Hematology American Society of Hematology 10.1182/hem.V14.3.7296 Silverchair:462882 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Ask the Hematologists: Von Willebrand Disease and Pregnancy American Society of Hematology American Society of Hematology 10.1182/hem.V14.3.7296 Silverchair:462882 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Aspirin in ET: will twice a day keep thrombosis away? The American Society of Hematology American Society of Hematology 10.1182/blood.2020005970 Silverchair:461246 Total_Item_Investigations 2 1 0 0 0 0 0 1 0 0 0 0 0 Aspirin in ET: will twice a day keep thrombosis away? The American Society of Hematology American Society of Hematology 10.1182/blood.2020005970 Silverchair:461246 Total_Item_Requests 2 1 0 0 0 0 0 1 0 0 0 0 0 Aspirin in ET: will twice a day keep thrombosis away? The American Society of Hematology American Society of Hematology 10.1182/blood.2020005970 Silverchair:461246 Unique_Item_Investigations 2 1 0 0 0 0 0 1 0 0 0 0 0 Aspirin in ET: will twice a day keep thrombosis away? The American Society of Hematology American Society of Hematology 10.1182/blood.2020005970 Silverchair:461246 Unique_Item_Requests 2 1 0 0 0 0 0 1 0 0 0 0 0 Asrij/OCIAD1 suppresses CSN5-mediated p53 degradation and maintains mouse hematopoietic stem cell quiescence The American Society of Hematology American Society of Hematology 10.1182/blood.2019000530 Silverchair:273888 Total_Item_Investigations 8 7 0 1 0 0 0 0 0 0 0 0 0 Asrij/OCIAD1 suppresses CSN5-mediated p53 degradation and maintains mouse hematopoietic stem cell quiescence The American Society of Hematology American Society of Hematology 10.1182/blood.2019000530 Silverchair:273888 Total_Item_Requests 8 7 0 1 0 0 0 0 0 0 0 0 0 Asrij/OCIAD1 suppresses CSN5-mediated p53 degradation and maintains mouse hematopoietic stem cell quiescence The American Society of Hematology American Society of Hematology 10.1182/blood.2019000530 Silverchair:273888 Unique_Item_Investigations 5 4 0 1 0 0 0 0 0 0 0 0 0 Asrij/OCIAD1 suppresses CSN5-mediated p53 degradation and maintains mouse hematopoietic stem cell quiescence The American Society of Hematology American Society of Hematology 10.1182/blood.2019000530 Silverchair:273888 Unique_Item_Requests 5 4 0 1 0 0 0 0 0 0 0 0 0 Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab The American Society of Hematology American Society of Hematology 10.1182/blood-2014-03-560540 Silverchair:34068 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab The American Society of Hematology American Society of Hematology 10.1182/blood-2014-03-560540 Silverchair:34068 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab The American Society of Hematology American Society of Hematology 10.1182/blood-2014-03-560540 Silverchair:34068 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab The American Society of Hematology American Society of Hematology 10.1182/blood-2014-03-560540 Silverchair:34068 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Assessing the Validity of the Brief Pain Inventory for Use Among Adults with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5579.5579 Silverchair:115759 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Assessing the Validity of the Brief Pain Inventory for Use Among Adults with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5579.5579 Silverchair:115759 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Assessing the Validity of the Brief Pain Inventory for Use Among Adults with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5579.5579 Silverchair:115759 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Assessing the Validity of the Brief Pain Inventory for Use Among Adults with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5579.5579 Silverchair:115759 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Assessment of Provider Practices Regarding Management of VTE in Pediatric Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127428 Silverchair:423916 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Assessment of Provider Practices Regarding Management of VTE in Pediatric Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127428 Silverchair:423916 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Assessment of Provider Practices Regarding Management of VTE in Pediatric Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127428 Silverchair:423916 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Assessment of Provider Practices Regarding Management of VTE in Pediatric Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127428 Silverchair:423916 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Association between ENPP1 K173Q and stroke in a newborn cohort of 395 Brazilian children with sickle cell anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-645176 Silverchair:73104 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Association between ENPP1 K173Q and stroke in a newborn cohort of 395 Brazilian children with sickle cell anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-645176 Silverchair:73104 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Association between ENPP1 K173Q and stroke in a newborn cohort of 395 Brazilian children with sickle cell anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-645176 Silverchair:73104 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Association between ENPP1 K173Q and stroke in a newborn cohort of 395 Brazilian children with sickle cell anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-645176 Silverchair:73104 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Association between Cancer and Anatomical Site of Venous Thromboembolic Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141463 Silverchair:473234 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Association between Cancer and Anatomical Site of Venous Thromboembolic Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141463 Silverchair:473234 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Association between Cancer and Anatomical Site of Venous Thromboembolic Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141463 Silverchair:473234 Unique_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Association between Cancer and Anatomical Site of Venous Thromboembolic Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141463 Silverchair:473234 Unique_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Association of Acquired Von Willebrand Syndrome with Primary (AL) Amyloidosis. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.4078.4078 Silverchair:122735 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Association of Acquired Von Willebrand Syndrome with Primary (AL) Amyloidosis. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.4078.4078 Silverchair:122735 Total_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 Association of Acquired Von Willebrand Syndrome with Primary (AL) Amyloidosis. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.4078.4078 Silverchair:122735 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Association of Acquired Von Willebrand Syndrome with Primary (AL) Amyloidosis. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.4078.4078 Silverchair:122735 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Association of Blood Type on Clinical Outcomes in Black/African Americans Hospitalized for COVID-19 Infection The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137556 Silverchair:473107 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Association of Blood Type on Clinical Outcomes in Black/African Americans Hospitalized for COVID-19 Infection The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137556 Silverchair:473107 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Association of Blood Type on Clinical Outcomes in Black/African Americans Hospitalized for COVID-19 Infection The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137556 Silverchair:473107 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Association of Blood Type on Clinical Outcomes in Black/African Americans Hospitalized for COVID-19 Infection The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137556 Silverchair:473107 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Association of BW with Thromboembolic and Bleeding Outcomes in Phase III Randomized Controlled Trials of Direct Oral Anticoagulants: Systematic Review and Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.88.88 Silverchair:99341 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Association of BW with Thromboembolic and Bleeding Outcomes in Phase III Randomized Controlled Trials of Direct Oral Anticoagulants: Systematic Review and Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.88.88 Silverchair:99341 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Association of BW with Thromboembolic and Bleeding Outcomes in Phase III Randomized Controlled Trials of Direct Oral Anticoagulants: Systematic Review and Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.88.88 Silverchair:99341 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Association of BW with Thromboembolic and Bleeding Outcomes in Phase III Randomized Controlled Trials of Direct Oral Anticoagulants: Systematic Review and Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.88.88 Silverchair:99341 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-814608 Silverchair:36947 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-814608 Silverchair:36947 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-814608 Silverchair:36947 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-814608 Silverchair:36947 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Association of Unbalanced Translocation der(1;7) with Germline GATA2 Mutations The American Society of Hematology American Society of Hematology 10.1182/blood.2021012781 Silverchair:476750 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Association of Unbalanced Translocation der(1;7) with Germline GATA2 Mutations The American Society of Hematology American Society of Hematology 10.1182/blood.2021012781 Silverchair:476750 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Association of Unbalanced Translocation der(1;7) with Germline GATA2 Mutations The American Society of Hematology American Society of Hematology 10.1182/blood.2021012781 Silverchair:476750 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Association of Unbalanced Translocation der(1;7) with Germline GATA2 Mutations The American Society of Hematology American Society of Hematology 10.1182/blood.2021012781 Silverchair:476750 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Associations between hematology/oncology fellows’ training and mentorship experiences and hematology-only career plans American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000569 Silverchair:422668 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Associations between hematology/oncology fellows’ training and mentorship experiences and hematology-only career plans American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000569 Silverchair:422668 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Associations between hematology/oncology fellows’ training and mentorship experiences and hematology-only career plans American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000569 Silverchair:422668 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Associations between hematology/oncology fellows’ training and mentorship experiences and hematology-only career plans American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000569 Silverchair:422668 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Associations between Persistent Inflammation and Oxidative Stress with Neurocognitive Impairment in Long-Term Hodgkin Lymphoma Survivors and Community Controls The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126041 Silverchair:428322 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Associations between Persistent Inflammation and Oxidative Stress with Neurocognitive Impairment in Long-Term Hodgkin Lymphoma Survivors and Community Controls The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126041 Silverchair:428322 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Associations between Persistent Inflammation and Oxidative Stress with Neurocognitive Impairment in Long-Term Hodgkin Lymphoma Survivors and Community Controls The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126041 Silverchair:428322 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Associations between Persistent Inflammation and Oxidative Stress with Neurocognitive Impairment in Long-Term Hodgkin Lymphoma Survivors and Community Controls The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126041 Silverchair:428322 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 ASXL1 impairs osteoclast formation by epigenetic regulation of NFATc1 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018018309 Silverchair:16081 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 ASXL1 impairs osteoclast formation by epigenetic regulation of NFATc1 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018018309 Silverchair:16081 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 ASXL1 impairs osteoclast formation by epigenetic regulation of NFATc1 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018018309 Silverchair:16081 Unique_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 ASXL1 impairs osteoclast formation by epigenetic regulation of NFATc1 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018018309 Silverchair:16081 Unique_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 "ATG5 promotes eosinopoiesis, but inhibits eosinophil effector functions" The American Society of Hematology American Society of Hematology 10.1182/blood.2020010208 Silverchair:475248 Total_Item_Investigations 7 0 7 0 0 0 0 0 0 0 0 0 0 "ATG5 promotes eosinopoiesis, but inhibits eosinophil effector functions" The American Society of Hematology American Society of Hematology 10.1182/blood.2020010208 Silverchair:475248 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000499 Silverchair:429969 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000499 Silverchair:429969 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000499 Silverchair:429969 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000499 Silverchair:429969 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-644872 Silverchair:35105 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-644872 Silverchair:35105 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-644872 Silverchair:35105 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-644872 Silverchair:35105 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Atypical CML with mutated SRSF2, ASXL1, CSF3R, and MPL" The American Society of Hematology American Society of Hematology 10.1182/blood.2021013480 Silverchair:483202 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 "Atypical CML with mutated SRSF2, ASXL1, CSF3R, and MPL" The American Society of Hematology American Society of Hematology 10.1182/blood.2021013480 Silverchair:483202 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 "Atypical CML with mutated SRSF2, ASXL1, CSF3R, and MPL" The American Society of Hematology American Society of Hematology 10.1182/blood.2021013480 Silverchair:483202 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 "Atypical CML with mutated SRSF2, ASXL1, CSF3R, and MPL" The American Society of Hematology American Society of Hematology 10.1182/blood.2021013480 Silverchair:483202 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Atypical Lymphoproliferative Diseases The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2000.1.133.133 Silverchair:256731 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Atypical Lymphoproliferative Diseases The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2000.1.133.133 Silverchair:256731 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Atypical Lymphoproliferative Diseases The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2000.1.133.133 Silverchair:256731 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Atypical Lymphoproliferative Diseases The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2000.1.133.133 Silverchair:256731 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Autism-Associated Chromatin Remodeler CHD8 Governs the Survival and Differentiation of Hematopoietic Stem/Progenitor Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127313 Silverchair:426616 Total_Item_Investigations 7 5 0 2 0 0 0 0 0 0 0 0 0 Autism-Associated Chromatin Remodeler CHD8 Governs the Survival and Differentiation of Hematopoietic Stem/Progenitor Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127313 Silverchair:426616 Total_Item_Requests 7 5 0 2 0 0 0 0 0 0 0 0 0 Autism-Associated Chromatin Remodeler CHD8 Governs the Survival and Differentiation of Hematopoietic Stem/Progenitor Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127313 Silverchair:426616 Unique_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 Autism-Associated Chromatin Remodeler CHD8 Governs the Survival and Differentiation of Hematopoietic Stem/Progenitor Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127313 Silverchair:426616 Unique_Item_Requests 3 2 0 1 0 0 0 0 0 0 0 0 0 Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004957 Silverchair:476324 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004957 Silverchair:476324 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004957 Silverchair:476324 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004957 Silverchair:476324 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Autoimmune Disorders and the Development of Myeloid Disease: Should We Always Blame the Therapy? American Society of Hematology American Society of Hematology 10.1182/hem.V16.4.9711 Silverchair:463213 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Autoimmune Disorders and the Development of Myeloid Disease: Should We Always Blame the Therapy? American Society of Hematology American Society of Hematology 10.1182/hem.V16.4.9711 Silverchair:463213 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Autoimmune Disorders and the Development of Myeloid Disease: Should We Always Blame the Therapy? American Society of Hematology American Society of Hematology 10.1182/hem.V16.4.9711 Silverchair:463213 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Autoimmune Disorders and the Development of Myeloid Disease: Should We Always Blame the Therapy? American Society of Hematology American Society of Hematology 10.1182/hem.V16.4.9711 Silverchair:463213 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Autoimmune Haemolytic Anaemia after Allogeneic Haematopoietic Stem Cell Transplantation; Single Centre Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131951 Silverchair:425539 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 Autoimmune Haemolytic Anaemia after Allogeneic Haematopoietic Stem Cell Transplantation; Single Centre Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131951 Silverchair:425539 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 Autoimmune Haemolytic Anaemia after Allogeneic Haematopoietic Stem Cell Transplantation; Single Centre Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131951 Silverchair:425539 Unique_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Autoimmune Haemolytic Anaemia after Allogeneic Haematopoietic Stem Cell Transplantation; Single Centre Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131951 Silverchair:425539 Unique_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Autoimmune hemolytic anemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.382 Silverchair:277583 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Autoimmune hemolytic anemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.382 Silverchair:277583 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Autoimmune hemolytic anemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.382 Silverchair:277583 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Autoimmune hemolytic anemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.382 Silverchair:277583 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Autoimmune panmyelosis with myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019002479 Silverchair:374449 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Autoimmune panmyelosis with myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019002479 Silverchair:374449 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Autoimmune panmyelosis with myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019002479 Silverchair:374449 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Autoimmune panmyelosis with myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019002479 Silverchair:374449 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Autoimmunity associated with immunotherapy of cancer The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-325266 Silverchair:28926 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Autoimmunity associated with immunotherapy of cancer The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-325266 Silverchair:28926 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Autoimmunity associated with immunotherapy of cancer The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-325266 Silverchair:28926 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Autoimmunity associated with immunotherapy of cancer The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-325266 Silverchair:28926 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Autologous peripheral blood stem cell transplantation for acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-370247 Silverchair:29104 Total_Item_Investigations 5 0 3 2 0 0 0 0 0 0 0 0 0 Autologous peripheral blood stem cell transplantation for acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-370247 Silverchair:29104 Total_Item_Requests 4 0 3 1 0 0 0 0 0 0 0 0 0 Autologous peripheral blood stem cell transplantation for acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-370247 Silverchair:29104 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Autologous peripheral blood stem cell transplantation for acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-370247 Silverchair:29104 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 "Autologous Stem Cell Transplantation with Benda-BEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) in Aggressive Non Hodgkin and Hodgkin´s Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3982.3982 Silverchair:115432 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Autologous Stem Cell Transplantation with Benda-BEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) in Aggressive Non Hodgkin and Hodgkin´s Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3982.3982 Silverchair:115432 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Autologous Stem Cell Transplantation with Benda-BEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) in Aggressive Non Hodgkin and Hodgkin´s Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3982.3982 Silverchair:115432 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Autologous Stem Cell Transplantation with Benda-BEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) in Aggressive Non Hodgkin and Hodgkin´s Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3982.3982 Silverchair:115432 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Autophagy is dispensable for the maintenance of hematopoietic stem cells in neonates American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002410 Silverchair:475470 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Autophagy is dispensable for the maintenance of hematopoietic stem cells in neonates American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002410 Silverchair:475470 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Autophagy is dispensable for the maintenance of hematopoietic stem cells in neonates American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002410 Silverchair:475470 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Autophagy is dispensable for the maintenance of hematopoietic stem cells in neonates American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002410 Silverchair:475470 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier" The American Society of Hematology American Society of Hematology 10.1182/blood.2019002395 Silverchair:440487 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier" The American Society of Hematology American Society of Hematology 10.1182/blood.2019002395 Silverchair:440487 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier" The American Society of Hematology American Society of Hematology 10.1182/blood.2019002395 Silverchair:440487 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier" The American Society of Hematology American Society of Hematology 10.1182/blood.2019002395 Silverchair:440487 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Availability of FLT3 inhibitors: how do we use them? The American Society of Hematology American Society of Hematology 10.1182/blood.2019876821 Silverchair:260761 Total_Item_Investigations 3 0 0 0 3 0 0 0 0 0 0 0 0 Availability of FLT3 inhibitors: how do we use them? The American Society of Hematology American Society of Hematology 10.1182/blood.2019876821 Silverchair:260761 Total_Item_Requests 3 0 0 0 3 0 0 0 0 0 0 0 0 Availability of FLT3 inhibitors: how do we use them? The American Society of Hematology American Society of Hematology 10.1182/blood.2019876821 Silverchair:260761 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Availability of FLT3 inhibitors: how do we use them? The American Society of Hematology American Society of Hematology 10.1182/blood.2019876821 Silverchair:260761 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 "AVE5026: A Novel, Extractive Heparinoid with Enriched Anti-Xa Activity and Enhanced Antithrombotic Activity." The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.1881.1881 Silverchair:56464 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "AVE5026: A Novel, Extractive Heparinoid with Enriched Anti-Xa Activity and Enhanced Antithrombotic Activity." The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.1881.1881 Silverchair:56464 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "AVE5026: A Novel, Extractive Heparinoid with Enriched Anti-Xa Activity and Enhanced Antithrombotic Activity." The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.1881.1881 Silverchair:56464 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "AVE5026: A Novel, Extractive Heparinoid with Enriched Anti-Xa Activity and Enhanced Antithrombotic Activity." The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.1881.1881 Silverchair:56464 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "AVL-292, a Bruton's Tyrosine Kinase Inhibitor Impacts Bone Resorption by Abrogating Osteoclast Sealing Zone Formation in Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.1822.1822 Silverchair:102776 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 "AVL-292, a Bruton's Tyrosine Kinase Inhibitor Impacts Bone Resorption by Abrogating Osteoclast Sealing Zone Formation in Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.1822.1822 Silverchair:102776 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 "AVL-292, a Bruton's Tyrosine Kinase Inhibitor Impacts Bone Resorption by Abrogating Osteoclast Sealing Zone Formation in Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.1822.1822 Silverchair:102776 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 "AVL-292, a Bruton's Tyrosine Kinase Inhibitor Impacts Bone Resorption by Abrogating Osteoclast Sealing Zone Formation in Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.1822.1822 Silverchair:102776 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.817.817 Silverchair:118404 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.817.817 Silverchair:118404 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.817.817 Silverchair:118404 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.817.817 Silverchair:118404 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Azacitidine As Post-Allograft Maintenance Helps Reduce Relapse Risk in High-Risk MDS and AML The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5872.5872 Silverchair:94961 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Azacitidine As Post-Allograft Maintenance Helps Reduce Relapse Risk in High-Risk MDS and AML The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5872.5872 Silverchair:94961 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Azacitidine As Post-Allograft Maintenance Helps Reduce Relapse Risk in High-Risk MDS and AML The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5872.5872 Silverchair:94961 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Azacitidine As Post-Allograft Maintenance Helps Reduce Relapse Risk in High-Risk MDS and AML The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5872.5872 Silverchair:94961 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Azacitidine for Post-Remission Therapy in Elderly Patients with Acute Myeloid Leukemia : Final Results of the Qoless AZA-Amle Randomized Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125562 Silverchair:426201 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Azacitidine for Post-Remission Therapy in Elderly Patients with Acute Myeloid Leukemia : Final Results of the Qoless AZA-Amle Randomized Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125562 Silverchair:426201 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Azacitidine for Post-Remission Therapy in Elderly Patients with Acute Myeloid Leukemia : Final Results of the Qoless AZA-Amle Randomized Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125562 Silverchair:426201 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Azacitidine for Post-Remission Therapy in Elderly Patients with Acute Myeloid Leukemia : Final Results of the Qoless AZA-Amle Randomized Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125562 Silverchair:426201 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003839 Silverchair:475545 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003839 Silverchair:475545 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003839 Silverchair:475545 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003839 Silverchair:475545 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Azacitidine Maintenance after Allogeneic Stem Cell Transplantation Is Feasible in Patients with Acute Myeloid Leukemia and Myelodysplasia The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5884.5884 Silverchair:101232 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Azacitidine Maintenance after Allogeneic Stem Cell Transplantation Is Feasible in Patients with Acute Myeloid Leukemia and Myelodysplasia The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5884.5884 Silverchair:101232 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Azacitidine Maintenance after Allogeneic Stem Cell Transplantation Is Feasible in Patients with Acute Myeloid Leukemia and Myelodysplasia The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5884.5884 Silverchair:101232 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Azacitidine Maintenance after Allogeneic Stem Cell Transplantation Is Feasible in Patients with Acute Myeloid Leukemia and Myelodysplasia The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5884.5884 Silverchair:101232 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-879866 Silverchair:261475 Total_Item_Investigations 7 4 0 0 0 0 0 0 3 0 0 0 0 Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-879866 Silverchair:261475 Total_Item_Requests 7 4 0 0 0 0 0 0 3 0 0 0 0 Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-879866 Silverchair:261475 Unique_Item_Investigations 3 2 0 0 0 0 0 0 1 0 0 0 0 Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-879866 Silverchair:261475 Unique_Item_Requests 3 2 0 0 0 0 0 0 1 0 0 0 0 Azacitidine Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Systematic Review The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138616 Silverchair:470551 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Azacitidine Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Systematic Review The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138616 Silverchair:470551 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Azacitidine Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Systematic Review The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138616 Silverchair:470551 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Azacitidine Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Systematic Review The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138616 Silverchair:470551 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141213 Silverchair:470415 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141213 Silverchair:470415 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141213 Silverchair:470415 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141213 Silverchair:470415 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Azacytidine Inhibits Megakaryopoiesis Via the Induction of Immunogenic RNA Species and Activation of Type-I Interferon Signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131461 Silverchair:426606 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Azacytidine Inhibits Megakaryopoiesis Via the Induction of Immunogenic RNA Species and Activation of Type-I Interferon Signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131461 Silverchair:426606 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Azacytidine Inhibits Megakaryopoiesis Via the Induction of Immunogenic RNA Species and Activation of Type-I Interferon Signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131461 Silverchair:426606 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Azacytidine Inhibits Megakaryopoiesis Via the Induction of Immunogenic RNA Species and Activation of Type-I Interferon Signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131461 Silverchair:426606 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124684 Silverchair:424148 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124684 Silverchair:424148 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124684 Silverchair:424148 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124684 Silverchair:424148 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-495366 Silverchair:32601 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 "AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-495366 Silverchair:32601 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-495366 Silverchair:32601 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-495366 Silverchair:32601 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 B acute lymphoblastic leukemia arising during maintenance therapy for multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2020009141 Silverchair:474273 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 B acute lymphoblastic leukemia arising during maintenance therapy for multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2020009141 Silverchair:474273 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 B acute lymphoblastic leukemia arising during maintenance therapy for multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2020009141 Silverchair:474273 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 B acute lymphoblastic leukemia arising during maintenance therapy for multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2020009141 Silverchair:474273 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 B lymphocytes: how they develop and function The American Society of Hematology American Society of Hematology 10.1182/blood-2008-02-078071 Silverchair:25424 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 B lymphocytes: how they develop and function The American Society of Hematology American Society of Hematology 10.1182/blood-2008-02-078071 Silverchair:25424 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 B lymphocytes: how they develop and function The American Society of Hematology American Society of Hematology 10.1182/blood-2008-02-078071 Silverchair:25424 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 B lymphocytes: how they develop and function The American Society of Hematology American Society of Hematology 10.1182/blood-2008-02-078071 Silverchair:25424 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 B2M Gene Expression Reflects an Immunologically Active Tumor Microenvironment in DLBCL The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126537 Silverchair:423352 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 B2M Gene Expression Reflects an Immunologically Active Tumor Microenvironment in DLBCL The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126537 Silverchair:423352 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 B2M Gene Expression Reflects an Immunologically Active Tumor Microenvironment in DLBCL The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126537 Silverchair:423352 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 B2M Gene Expression Reflects an Immunologically Active Tumor Microenvironment in DLBCL The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126537 Silverchair:423352 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells The American Society of Hematology American Society of Hematology 10.1182/blood-2007-11-123141 Silverchair:25238 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells The American Society of Hematology American Society of Hematology 10.1182/blood-2007-11-123141 Silverchair:25238 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells The American Society of Hematology American Society of Hematology 10.1182/blood-2007-11-123141 Silverchair:25238 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells The American Society of Hematology American Society of Hematology 10.1182/blood-2007-11-123141 Silverchair:25238 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-265975 Silverchair:27906 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-265975 Silverchair:27906 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-265975 Silverchair:27906 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-265975 Silverchair:27906 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Bacteria and HIT: a close connection? The American Society of Hematology American Society of Hematology 10.1182/blood-2010-11-317941 Silverchair:28552 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Bacteria and HIT: a close connection? The American Society of Hematology American Society of Hematology 10.1182/blood-2010-11-317941 Silverchair:28552 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Bacteria and HIT: a close connection? The American Society of Hematology American Society of Hematology 10.1182/blood-2010-11-317941 Silverchair:28552 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Bacteria and HIT: a close connection? The American Society of Hematology American Society of Hematology 10.1182/blood-2010-11-317941 Silverchair:28552 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Balancing bleeding in brain metastases The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-648089 Silverchair:34523 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Balancing bleeding in brain metastases The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-648089 Silverchair:34523 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Balancing bleeding in brain metastases The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-648089 Silverchair:34523 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Balancing bleeding in brain metastases The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-648089 Silverchair:34523 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Baseline FDG-PET/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001579 Silverchair:454562 Total_Item_Investigations 2 0 0 0 0 0 0 0 2 0 0 0 0 Baseline FDG-PET/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001579 Silverchair:454562 Total_Item_Requests 2 0 0 0 0 0 0 0 2 0 0 0 0 Baseline FDG-PET/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001579 Silverchair:454562 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Baseline FDG-PET/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001579 Silverchair:454562 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 "Basophil tryptase mMCP-11 plays a crucial role in IgE-mediated, delayed-onset allergic inflammation in mice" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-07-729392 Silverchair:35702 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Basophil tryptase mMCP-11 plays a crucial role in IgE-mediated, delayed-onset allergic inflammation in mice" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-07-729392 Silverchair:35702 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "Basophil tryptase mMCP-11 plays a crucial role in IgE-mediated, delayed-onset allergic inflammation in mice" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-07-729392 Silverchair:35702 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Basophil tryptase mMCP-11 plays a crucial role in IgE-mediated, delayed-onset allergic inflammation in mice" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-07-729392 Silverchair:35702 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 BAX 335 hemophilia B gene therapy clinical trial results - potential impact of CpG sequences on gene expression The American Society of Hematology American Society of Hematology 10.1182/blood.2019004625 Silverchair:469614 No_License 5 0 5 0 0 0 0 0 0 0 0 0 0 BAX 335 hemophilia B gene therapy clinical trial results - potential impact of CpG sequences on gene expression The American Society of Hematology American Society of Hematology 10.1182/blood.2019004625 Silverchair:469614 Total_Item_Investigations 18 0 18 0 0 0 0 0 0 0 0 0 0 BAX 335 hemophilia B gene therapy clinical trial results - potential impact of CpG sequences on gene expression The American Society of Hematology American Society of Hematology 10.1182/blood.2019004625 Silverchair:469614 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Baz RC, Martin TG III, Lin H-Y, et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016;127(21):2561-2568." The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-721886 Silverchair:35576 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Baz RC, Martin TG III, Lin H-Y, et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016;127(21):2561-2568." The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-721886 Silverchair:35576 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Baz RC, Martin TG III, Lin H-Y, et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016;127(21):2561-2568." The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-721886 Silverchair:35576 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Baz RC, Martin TG III, Lin H-Y, et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016;127(21):2561-2568." The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-721886 Silverchair:35576 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation The American Society of Hematology American Society of Hematology 10.1182/blood.2020008276 Silverchair:475837 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation The American Society of Hematology American Society of Hematology 10.1182/blood.2020008276 Silverchair:475837 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation The American Society of Hematology American Society of Hematology 10.1182/blood.2020008276 Silverchair:475837 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation The American Society of Hematology American Society of Hematology 10.1182/blood.2020008276 Silverchair:475837 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 B-cell targeting in chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-784017 Silverchair:36612 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 B-cell targeting in chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-784017 Silverchair:36612 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 B-cell targeting in chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-784017 Silverchair:36612 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 B-cell targeting in chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-784017 Silverchair:36612 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 B-cell–specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-684183 Silverchair:35161 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 B-cell–specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-684183 Silverchair:35161 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 B-cell–specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-684183 Silverchair:35161 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 B-cell–specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-684183 Silverchair:35161 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 BCL-2 inhibition in AML: an unexpected bonus? The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-828269 Silverchair:39300 Total_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 BCL-2 inhibition in AML: an unexpected bonus? The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-828269 Silverchair:39300 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 BCL-2 inhibition in AML: an unexpected bonus? The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-828269 Silverchair:39300 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 BCL-2 inhibition in AML: an unexpected bonus? The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-828269 Silverchair:39300 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Bcl6 as a Novel Therapeutic Target in Multiple Myeloma (MM). The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.295.295 Silverchair:132546 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Bcl6 as a Novel Therapeutic Target in Multiple Myeloma (MM). The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.295.295 Silverchair:132546 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Bcl6 as a Novel Therapeutic Target in Multiple Myeloma (MM). The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.295.295 Silverchair:132546 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Bcl6 as a Novel Therapeutic Target in Multiple Myeloma (MM). The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.295.295 Silverchair:132546 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells The American Society of Hematology American Society of Hematology 10.1182/blood.2019001745 Silverchair:463728 No_License 2 0 0 2 0 0 0 0 0 0 0 0 0 BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells The American Society of Hematology American Society of Hematology 10.1182/blood.2019001745 Silverchair:463728 Total_Item_Investigations 5 0 0 5 0 0 0 0 0 0 0 0 0 BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells The American Society of Hematology American Society of Hematology 10.1182/blood.2019001745 Silverchair:463728 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.648.648 Silverchair:65113 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.648.648 Silverchair:65113 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.648.648 Silverchair:65113 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.648.648 Silverchair:65113 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet The American Society of Hematology American Society of Hematology 10.1182/blood-2010-12-326405 Silverchair:28964 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet The American Society of Hematology American Society of Hematology 10.1182/blood-2010-12-326405 Silverchair:28964 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet The American Society of Hematology American Society of Hematology 10.1182/blood-2010-12-326405 Silverchair:28964 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet The American Society of Hematology American Society of Hematology 10.1182/blood-2010-12-326405 Silverchair:28964 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 "Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-03-066936 Silverchair:103629 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 "Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-03-066936 Silverchair:103629 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 "Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-03-066936 Silverchair:103629 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 "Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-03-066936 Silverchair:103629 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib The American Society of Hematology American Society of Hematology 10.1182/blood-2008-10-183665 Silverchair:27963 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib The American Society of Hematology American Society of Hematology 10.1182/blood-2008-10-183665 Silverchair:27963 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib The American Society of Hematology American Society of Hematology 10.1182/blood-2008-10-183665 Silverchair:27963 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib The American Society of Hematology American Society of Hematology 10.1182/blood-2008-10-183665 Silverchair:27963 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002068 Silverchair:461601 Total_Item_Investigations 3 2 0 0 0 0 0 1 0 0 0 0 0 Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002068 Silverchair:461601 Total_Item_Requests 3 2 0 0 0 0 0 1 0 0 0 0 0 Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002068 Silverchair:461601 Unique_Item_Investigations 3 2 0 0 0 0 0 1 0 0 0 0 0 Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002068 Silverchair:461601 Unique_Item_Requests 3 2 0 0 0 0 0 1 0 0 0 0 0 Beneficial effects of endurance exercise training on skeletal muscle microvasculature in sickle cell disease patients The American Society of Hematology American Society of Hematology 10.1182/blood.2019001055 Silverchair:428812 Total_Item_Investigations 5 0 5 0 0 0 0 0 0 0 0 0 0 Beneficial effects of endurance exercise training on skeletal muscle microvasculature in sickle cell disease patients The American Society of Hematology American Society of Hematology 10.1182/blood.2019001055 Silverchair:428812 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Beneficial effects of endurance exercise training on skeletal muscle microvasculature in sickle cell disease patients The American Society of Hematology American Society of Hematology 10.1182/blood.2019001055 Silverchair:428812 Total_Item_Requests 5 0 5 0 0 0 0 0 0 0 0 0 0 Beneficial effects of endurance exercise training on skeletal muscle microvasculature in sickle cell disease patients The American Society of Hematology American Society of Hematology 10.1182/blood.2019001055 Silverchair:428812 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Benefit of Anti-Infectious Prophylaxis in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Receiving Frontline “Targeted Therapy”. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.2858.2858 Silverchair:74530 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Benefit of Anti-Infectious Prophylaxis in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Receiving Frontline “Targeted Therapy”. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.2858.2858 Silverchair:74530 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Benefit of Anti-Infectious Prophylaxis in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Receiving Frontline “Targeted Therapy”. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.2858.2858 Silverchair:74530 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Benefit of Anti-Infectious Prophylaxis in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Receiving Frontline “Targeted Therapy”. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.2858.2858 Silverchair:74530 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002231 Silverchair:461575 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002231 Silverchair:461575 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002231 Silverchair:461575 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002231 Silverchair:461575 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000048 Silverchair:422579 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000048 Silverchair:422579 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000048 Silverchair:422579 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000048 Silverchair:422579 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Beyond the first glance: anthracyclines in AML The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-639419 Silverchair:34290 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Beyond the first glance: anthracyclines in AML The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-639419 Silverchair:34290 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Beyond the first glance: anthracyclines in AML The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-639419 Silverchair:34290 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Beyond the first glance: anthracyclines in AML The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-639419 Silverchair:34290 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020007303 Silverchair:475244 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020007303 Silverchair:475244 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020007303 Silverchair:475244 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020007303 Silverchair:475244 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-05-849802 Silverchair:40033 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-05-849802 Silverchair:40033 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-05-849802 Silverchair:40033 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-05-849802 Silverchair:40033 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Bifurcated BACH2 control coordinates mantle cell lymphoma survival and dispersal during hypoxia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-767293 Silverchair:36805 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 Bifurcated BACH2 control coordinates mantle cell lymphoma survival and dispersal during hypoxia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-767293 Silverchair:36805 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 Bifurcated BACH2 control coordinates mantle cell lymphoma survival and dispersal during hypoxia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-767293 Silverchair:36805 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Bifurcated BACH2 control coordinates mantle cell lymphoma survival and dispersal during hypoxia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-767293 Silverchair:36805 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Big Questions in 2020: Single-cell Sequencing in Myeloid Malignancies Brings Us Closer to Answers American Society of Hematology American Society of Hematology Silverchair:474708 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Big Questions in 2020: Single-cell Sequencing in Myeloid Malignancies Brings Us Closer to Answers American Society of Hematology American Society of Hematology Silverchair:474708 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Big Questions in 2020: Single-cell Sequencing in Myeloid Malignancies Brings Us Closer to Answers American Society of Hematology American Society of Hematology Silverchair:474708 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Big Questions in 2020: Single-cell Sequencing in Myeloid Malignancies Brings Us Closer to Answers American Society of Hematology American Society of Hematology Silverchair:474708 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Binding of membrane-anchored macrophage colony-stimulating factor (M- CSF) to its receptor mediates specific adhesion between stromal cells and M-CSF receptor-bearing hematopoietic cells The American Society of Hematology American Society of Hematology 10.1182/blood.V82.9.2634.2634 Silverchair:170750 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Binding of membrane-anchored macrophage colony-stimulating factor (M- CSF) to its receptor mediates specific adhesion between stromal cells and M-CSF receptor-bearing hematopoietic cells The American Society of Hematology American Society of Hematology 10.1182/blood.V82.9.2634.2634 Silverchair:170750 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Binding of membrane-anchored macrophage colony-stimulating factor (M- CSF) to its receptor mediates specific adhesion between stromal cells and M-CSF receptor-bearing hematopoietic cells The American Society of Hematology American Society of Hematology 10.1182/blood.V82.9.2634.2634 Silverchair:170750 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Binding of membrane-anchored macrophage colony-stimulating factor (M- CSF) to its receptor mediates specific adhesion between stromal cells and M-CSF receptor-bearing hematopoietic cells The American Society of Hematology American Society of Hematology 10.1182/blood.V82.9.2634.2634 Silverchair:170750 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study The American Society of Hematology American Society of Hematology 10.1182/blood-2003-06-2072 Silverchair:18371 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study The American Society of Hematology American Society of Hematology 10.1182/blood-2003-06-2072 Silverchair:18371 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study The American Society of Hematology American Society of Hematology 10.1182/blood-2003-06-2072 Silverchair:18371 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study The American Society of Hematology American Society of Hematology 10.1182/blood-2003-06-2072 Silverchair:18371 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Biology and clinical relevance of human natural killer cells The American Society of Hematology American Society of Hematology 10.1182/blood.V76.12.2421.2421 Silverchair:167845 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Biology and clinical relevance of human natural killer cells The American Society of Hematology American Society of Hematology 10.1182/blood.V76.12.2421.2421 Silverchair:167845 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Biomarkers of Cytokine Release Syndrome and Neurotoxicity after CD19 CAR-T Cells and Mitigation of Toxicity By Cell Dose The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1852.1852 Silverchair:100431 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Biomarkers of Cytokine Release Syndrome and Neurotoxicity after CD19 CAR-T Cells and Mitigation of Toxicity By Cell Dose The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1852.1852 Silverchair:100431 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Biomarkers of Cytokine Release Syndrome and Neurotoxicity after CD19 CAR-T Cells and Mitigation of Toxicity By Cell Dose The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1852.1852 Silverchair:100431 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Biomarkers of Cytokine Release Syndrome and Neurotoxicity after CD19 CAR-T Cells and Mitigation of Toxicity By Cell Dose The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1852.1852 Silverchair:100431 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2862.2862 Silverchair:135411 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2862.2862 Silverchair:135411 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2862.2862 Silverchair:135411 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2862.2862 Silverchair:135411 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019002779 Silverchair:431045 No_License 3 0 3 0 0 0 0 0 0 0 0 0 0 Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019002779 Silverchair:431045 Total_Item_Investigations 9 0 8 1 0 0 0 0 0 0 0 0 0 Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019002779 Silverchair:431045 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019002779 Silverchair:431045 Unique_Item_Investigations 3 0 2 1 0 0 0 0 0 0 0 0 0 Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019002779 Silverchair:431045 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 "Bispecifics, trispecifics, and other novel immune treatments in myeloma" The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000110 Silverchair:474344 Total_Item_Investigations 8 4 0 3 0 0 0 0 0 1 0 0 0 "Bispecifics, trispecifics, and other novel immune treatments in myeloma" The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000110 Silverchair:474344 Total_Item_Requests 8 4 0 3 0 0 0 0 0 1 0 0 0 "Bispecifics, trispecifics, and other novel immune treatments in myeloma" The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000110 Silverchair:474344 Unique_Item_Investigations 5 2 0 2 0 0 0 0 0 1 0 0 0 "Bispecifics, trispecifics, and other novel immune treatments in myeloma" The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000110 Silverchair:474344 Unique_Item_Requests 5 2 0 2 0 0 0 0 0 1 0 0 0 BiTEs better than CAR T cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001792 Silverchair:475005 Total_Item_Investigations 3 1 0 0 1 0 0 0 0 1 0 0 0 BiTEs better than CAR T cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001792 Silverchair:475005 Total_Item_Requests 3 1 0 0 1 0 0 0 0 1 0 0 0 BiTEs better than CAR T cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001792 Silverchair:475005 Unique_Item_Investigations 3 1 0 0 1 0 0 0 0 1 0 0 0 BiTEs better than CAR T cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001792 Silverchair:475005 Unique_Item_Requests 3 1 0 0 1 0 0 0 0 1 0 0 0 "Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139668 Silverchair:471635 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 "Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139668 Silverchair:471635 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 "Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139668 Silverchair:471635 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139668 Silverchair:471635 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139752 Silverchair:472526 Total_Item_Investigations 2 0 1 0 1 0 0 0 0 0 0 0 0 "Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139752 Silverchair:472526 Total_Item_Requests 2 0 1 0 1 0 0 0 0 0 0 0 0 "Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139752 Silverchair:472526 Unique_Item_Investigations 2 0 1 0 1 0 0 0 0 0 0 0 0 "Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139752 Silverchair:472526 Unique_Item_Requests 2 0 1 0 1 0 0 0 0 0 0 0 0 Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137734 Silverchair:471900 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137734 Silverchair:471900 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137734 Silverchair:471900 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137734 Silverchair:471900 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Blastic plasmacytoid dendritic cell neoplasm associated with chronic myelomonocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-723536 Silverchair:73139 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Blastic plasmacytoid dendritic cell neoplasm associated with chronic myelomonocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-723536 Silverchair:73139 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Blastic plasmacytoid dendritic cell neoplasm associated with chronic myelomonocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-723536 Silverchair:73139 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Blastic plasmacytoid dendritic cell neoplasm associated with chronic myelomonocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-723536 Silverchair:73139 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Blastic transformation of mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-396408 Silverchair:30553 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Blastic transformation of mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-396408 Silverchair:30553 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Blastic transformation of mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-396408 Silverchair:30553 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Blastic transformation of mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-396408 Silverchair:30553 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge! The American Society of Hematology American Society of Hematology 10.1182/blood-2017-08-737502 Silverchair:39681 Total_Item_Investigations 2 0 0 0 0 0 0 2 0 0 0 0 0 Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge! The American Society of Hematology American Society of Hematology 10.1182/blood-2017-08-737502 Silverchair:39681 Total_Item_Requests 2 0 0 0 0 0 0 2 0 0 0 0 0 Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge! The American Society of Hematology American Society of Hematology 10.1182/blood-2017-08-737502 Silverchair:39681 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge! The American Society of Hematology American Society of Hematology 10.1182/blood-2017-08-737502 Silverchair:39681 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Blastoid plasma cell leukemia mimicking acute leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020006666 Silverchair:463249 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Blastoid plasma cell leukemia mimicking acute leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020006666 Silverchair:463249 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Blastoid plasma cell leukemia mimicking acute leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020006666 Silverchair:463249 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Blastoid plasma cell leukemia mimicking acute leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020006666 Silverchair:463249 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001081 Silverchair:440752 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 0 2 Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001081 Silverchair:440752 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 0 2 Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001081 Silverchair:440752 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001081 Silverchair:440752 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study The American Society of Hematology American Society of Hematology 10.1182/blood.2019003639 Silverchair:454302 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study The American Society of Hematology American Society of Hematology 10.1182/blood.2019003639 Silverchair:454302 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study The American Society of Hematology American Society of Hematology 10.1182/blood.2019003639 Silverchair:454302 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study The American Society of Hematology American Society of Hematology 10.1182/blood.2019003639 Silverchair:454302 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Bleeding complications in immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.237 Silverchair:20660 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Bleeding complications in immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.237 Silverchair:20660 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Bleeding complications in immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.237 Silverchair:20660 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Bleeding complications in immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.237 Silverchair:20660 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Bleeding disorders American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter10 Silverchair:75019 No_License 9 0 7 1 0 0 0 0 1 0 0 0 0 Bleeding disorders American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter10 Silverchair:75019 Total_Item_Investigations 18 0 7 1 6 0 0 0 1 3 0 0 0 Bleeding disorders American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter10 Silverchair:75019 Unique_Item_Investigations 11 0 2 1 4 0 0 0 1 3 0 0 0 Bleeding in patients with sickle cell disease: a population-based study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000940 Silverchair:452564 Total_Item_Investigations 2 1 0 0 0 0 0 0 1 0 0 0 0 Bleeding in patients with sickle cell disease: a population-based study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000940 Silverchair:452564 Total_Item_Requests 2 1 0 0 0 0 0 0 1 0 0 0 0 Bleeding in patients with sickle cell disease: a population-based study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000940 Silverchair:452564 Unique_Item_Investigations 2 1 0 0 0 0 0 0 1 0 0 0 0 Bleeding in patients with sickle cell disease: a population-based study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000940 Silverchair:452564 Unique_Item_Requests 2 1 0 0 0 0 0 0 1 0 0 0 0 Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS) The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-466375 Silverchair:31351 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 0 2 Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS) The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-466375 Silverchair:31351 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 0 2 Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS) The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-466375 Silverchair:31351 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS) The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-466375 Silverchair:31351 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Bleeding Risk in Patients with Essential Thrombocythemia and a Platelet Count of More Than 1.5 Million/μl: A Challenge of the Dogma of Mandatory Initiation of Cytoreductive Therapy. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4660.4660 Silverchair:117753 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Bleeding Risk in Patients with Essential Thrombocythemia and a Platelet Count of More Than 1.5 Million/μl: A Challenge of the Dogma of Mandatory Initiation of Cytoreductive Therapy. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4660.4660 Silverchair:117753 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Bleeding Risk in Patients with Essential Thrombocythemia and a Platelet Count of More Than 1.5 Million/μl: A Challenge of the Dogma of Mandatory Initiation of Cytoreductive Therapy. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4660.4660 Silverchair:117753 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Bleeding Risk in Patients with Essential Thrombocythemia and a Platelet Count of More Than 1.5 Million/μl: A Challenge of the Dogma of Mandatory Initiation of Cytoreductive Therapy. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4660.4660 Silverchair:117753 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 BLNK suppresses pre–B-cell leukemogenesis through inhibition of JAK3 The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-166355 Silverchair:25988 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 BLNK suppresses pre–B-cell leukemogenesis through inhibition of JAK3 The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-166355 Silverchair:25988 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 BLNK suppresses pre–B-cell leukemogenesis through inhibition of JAK3 The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-166355 Silverchair:25988 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 BLNK suppresses pre–B-cell leukemogenesis through inhibition of JAK3 The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-166355 Silverchair:25988 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Blood and lymphatic endothelial cell-specific differentiation programs are stringently controlled by the tissue environment The American Society of Hematology American Society of Hematology 10.1182/blood-2006-10-053280 Silverchair:23156 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Blood and lymphatic endothelial cell-specific differentiation programs are stringently controlled by the tissue environment The American Society of Hematology American Society of Hematology 10.1182/blood-2006-10-053280 Silverchair:23156 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Blood and lymphatic endothelial cell-specific differentiation programs are stringently controlled by the tissue environment The American Society of Hematology American Society of Hematology 10.1182/blood-2006-10-053280 Silverchair:23156 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Blood and lymphatic endothelial cell-specific differentiation programs are stringently controlled by the tissue environment The American Society of Hematology American Society of Hematology 10.1182/blood-2006-10-053280 Silverchair:23156 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Blood group genotyping The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-833954 Silverchair:275900 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Blood group genotyping The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-833954 Silverchair:275900 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Blood group genotyping The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-833954 Silverchair:275900 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Blood group genotyping The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-833954 Silverchair:275900 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients The American Society of Hematology American Society of Hematology 10.1182/blood.V98.1.23 Silverchair:88892 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients The American Society of Hematology American Society of Hematology 10.1182/blood.V98.1.23 Silverchair:88892 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients The American Society of Hematology American Society of Hematology 10.1182/blood.V98.1.23 Silverchair:88892 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients The American Society of Hematology American Society of Hematology 10.1182/blood.V98.1.23 Silverchair:88892 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Blood stem cells SELect quiescence The American Society of Hematology American Society of Hematology 10.1182/blood.2020009554 Silverchair:474736 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Blood stem cells SELect quiescence The American Society of Hematology American Society of Hematology 10.1182/blood.2020009554 Silverchair:474736 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Blood stem cells SELect quiescence The American Society of Hematology American Society of Hematology 10.1182/blood.2020009554 Silverchair:474736 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Blood stem cells SELect quiescence The American Society of Hematology American Society of Hematology 10.1182/blood.2020009554 Silverchair:474736 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004604 Silverchair:476052 Total_Item_Investigations 5 0 0 0 0 0 0 2 3 0 0 0 0 Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004604 Silverchair:476052 Total_Item_Requests 5 0 0 0 0 0 0 2 3 0 0 0 0 Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004604 Silverchair:476052 Unique_Item_Investigations 4 0 0 0 0 0 0 2 2 0 0 0 0 Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004604 Silverchair:476052 Unique_Item_Requests 4 0 0 0 0 0 0 2 2 0 0 0 0 BLVRB redox mutation defines heme degradation in a metabolic pathway of enhanced thrombopoiesis in humans The American Society of Hematology American Society of Hematology 10.1182/blood-2016-02-696997 Silverchair:35539 Total_Item_Investigations 5 0 3 2 0 0 0 0 0 0 0 0 0 BLVRB redox mutation defines heme degradation in a metabolic pathway of enhanced thrombopoiesis in humans The American Society of Hematology American Society of Hematology 10.1182/blood-2016-02-696997 Silverchair:35539 Total_Item_Requests 4 0 3 1 0 0 0 0 0 0 0 0 0 BLVRB redox mutation defines heme degradation in a metabolic pathway of enhanced thrombopoiesis in humans The American Society of Hematology American Society of Hematology 10.1182/blood-2016-02-696997 Silverchair:35539 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 BLVRB redox mutation defines heme degradation in a metabolic pathway of enhanced thrombopoiesis in humans The American Society of Hematology American Society of Hematology 10.1182/blood-2016-02-696997 Silverchair:35539 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 "BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis" The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.664.664 Silverchair:71030 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis" The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.664.664 Silverchair:71030 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis" The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.664.664 Silverchair:71030 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis" The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.664.664 Silverchair:71030 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD+ AML The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124322 Silverchair:424876 Total_Item_Investigations 3 1 0 2 0 0 0 0 0 0 0 0 0 BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD+ AML The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124322 Silverchair:424876 Total_Item_Requests 3 1 0 2 0 0 0 0 0 0 0 0 0 BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD+ AML The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124322 Silverchair:424876 Unique_Item_Investigations 3 1 0 2 0 0 0 0 0 0 0 0 0 BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD+ AML The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124322 Silverchair:424876 Unique_Item_Requests 3 1 0 2 0 0 0 0 0 0 0 0 0 Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3 The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123689 Silverchair:426392 Total_Item_Investigations 3 0 0 1 0 0 0 0 0 0 0 0 2 Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3 The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123689 Silverchair:426392 Total_Item_Requests 3 0 0 1 0 0 0 0 0 0 0 0 2 Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3 The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123689 Silverchair:426392 Unique_Item_Investigations 3 0 0 1 0 0 0 0 0 0 0 0 2 Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3 The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123689 Silverchair:426392 Unique_Item_Requests 3 0 0 1 0 0 0 0 0 0 0 0 2 Bone marrow dysfunction in mice lacking the cytokine receptor gp130 in endothelial cells The American Society of Hematology American Society of Hematology 10.1182/blood-2005-02-0671 Silverchair:133270 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Bone marrow dysfunction in mice lacking the cytokine receptor gp130 in endothelial cells The American Society of Hematology American Society of Hematology 10.1182/blood-2005-02-0671 Silverchair:133270 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Bone marrow dysfunction in mice lacking the cytokine receptor gp130 in endothelial cells The American Society of Hematology American Society of Hematology 10.1182/blood-2005-02-0671 Silverchair:133270 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Bone marrow dysfunction in mice lacking the cytokine receptor gp130 in endothelial cells The American Society of Hematology American Society of Hematology 10.1182/blood-2005-02-0671 Silverchair:133270 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Bone Marrow Harvest Volume and CD34+ Cell Count in Pediatric Sibling Donors: A Single Centre Retrospective Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127655 Silverchair:428127 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Bone Marrow Harvest Volume and CD34+ Cell Count in Pediatric Sibling Donors: A Single Centre Retrospective Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127655 Silverchair:428127 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Bone Marrow Harvest Volume and CD34+ Cell Count in Pediatric Sibling Donors: A Single Centre Retrospective Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127655 Silverchair:428127 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Bone Marrow Harvest Volume and CD34+ Cell Count in Pediatric Sibling Donors: A Single Centre Retrospective Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127655 Silverchair:428127 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-253534 Silverchair:28352 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-253534 Silverchair:28352 Total_Item_Requests 4 0 4 0 0 0 0 0 0 0 0 0 0 Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-253534 Silverchair:28352 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-253534 Silverchair:28352 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Bone marrow microenvironment–derived signals induce Mcl-1 dependence in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-745059 Silverchair:35866 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Bone marrow microenvironment–derived signals induce Mcl-1 dependence in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-745059 Silverchair:35866 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Bone marrow microenvironment–derived signals induce Mcl-1 dependence in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-745059 Silverchair:35866 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Bone marrow microenvironment–derived signals induce Mcl-1 dependence in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-745059 Silverchair:35866 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Bone marrow regeneration requires mitochondrial transfer from donor Cx43-expressing hematopoietic progenitors to stroma The American Society of Hematology American Society of Hematology 10.1182/blood.2020005399 Silverchair:463756 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Bone marrow regeneration requires mitochondrial transfer from donor Cx43-expressing hematopoietic progenitors to stroma The American Society of Hematology American Society of Hematology 10.1182/blood.2020005399 Silverchair:463756 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Bone marrow transplantation prevents right ventricle disease in the caveolin-1–deficient mouse model of pulmonary hypertension American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2016002691 Silverchair:15607 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Bone marrow transplantation prevents right ventricle disease in the caveolin-1–deficient mouse model of pulmonary hypertension American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2016002691 Silverchair:15607 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Bone marrow transplantation prevents right ventricle disease in the caveolin-1–deficient mouse model of pulmonary hypertension American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2016002691 Silverchair:15607 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Bone marrow transplantation prevents right ventricle disease in the caveolin-1–deficient mouse model of pulmonary hypertension American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2016002691 Silverchair:15607 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140356 Silverchair:470410 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140356 Silverchair:470410 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140356 Silverchair:470410 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140356 Silverchair:470410 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.27.27 Silverchair:113330 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.27.27 Silverchair:113330 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.27.27 Silverchair:113330 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.27.27 Silverchair:113330 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "Bortezomib, Lenalidomide and Low-Dose Dexamethasone (VRD) Versus Lenalidomide and Low-Dose Dexamethasone (Ld) for Newly-Diagnosed Multiple Myeloma- a Randomized Phase III Study" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.906.906 Silverchair:83569 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Bortezomib, Lenalidomide and Low-Dose Dexamethasone (VRD) Versus Lenalidomide and Low-Dose Dexamethasone (Ld) for Newly-Diagnosed Multiple Myeloma- a Randomized Phase III Study" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.906.906 Silverchair:83569 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Bortezomib, Lenalidomide and Low-Dose Dexamethasone (VRD) Versus Lenalidomide and Low-Dose Dexamethasone (Ld) for Newly-Diagnosed Multiple Myeloma- a Randomized Phase III Study" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.906.906 Silverchair:83569 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Bortezomib, Lenalidomide and Low-Dose Dexamethasone (VRD) Versus Lenalidomide and Low-Dose Dexamethasone (Ld) for Newly-Diagnosed Multiple Myeloma- a Randomized Phase III Study" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.906.906 Silverchair:83569 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature The American Society of Hematology American Society of Hematology 10.1182/blood-2008-04-149385 Silverchair:25469 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature The American Society of Hematology American Society of Hematology 10.1182/blood-2008-04-149385 Silverchair:25469 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature The American Society of Hematology American Society of Hematology 10.1182/blood-2008-04-149385 Silverchair:25469 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature The American Society of Hematology American Society of Hematology 10.1182/blood-2008-04-149385 Silverchair:25469 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "BOSTON Trial: Selinexor, Are We There Yet?" American Society of Hematology American Society of Hematology Silverchair:475643 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 "BOSTON Trial: Selinexor, Are We There Yet?" American Society of Hematology American Society of Hematology Silverchair:475643 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 "BOSTON Trial: Selinexor, Are We There Yet?" American Society of Hematology American Society of Hematology Silverchair:475643 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 "BOSTON Trial: Selinexor, Are We There Yet?" American Society of Hematology American Society of Hematology Silverchair:475643 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110798 Silverchair:273027 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110798 Silverchair:273027 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110798 Silverchair:273027 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110798 Silverchair:273027 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Both TMEM16F-dependent and TMEM16F-independent pathways contribute to phosphatidylserine exposure in platelet apoptosis and platelet activation The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-454314 Silverchair:31221 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Both TMEM16F-dependent and TMEM16F-independent pathways contribute to phosphatidylserine exposure in platelet apoptosis and platelet activation The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-454314 Silverchair:31221 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Both TMEM16F-dependent and TMEM16F-independent pathways contribute to phosphatidylserine exposure in platelet apoptosis and platelet activation The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-454314 Silverchair:31221 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Both TMEM16F-dependent and TMEM16F-independent pathways contribute to phosphatidylserine exposure in platelet apoptosis and platelet activation The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-454314 Silverchair:31221 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Boudreau LH, Duchez A-C, Cloutier N, et al. Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation. Blood. 2014;124(14):2173-2183." The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-615419 Silverchair:34074 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Boudreau LH, Duchez A-C, Cloutier N, et al. Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation. Blood. 2014;124(14):2173-2183." The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-615419 Silverchair:34074 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "Boudreau LH, Duchez A-C, Cloutier N, et al. Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation. Blood. 2014;124(14):2173-2183." The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-615419 Silverchair:34074 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Boudreau LH, Duchez A-C, Cloutier N, et al. Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation. Blood. 2014;124(14):2173-2183." The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-615419 Silverchair:34074 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 BRAF inhibition in hairy cell leukemia with low-dose vemurafenib The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-680074 Silverchair:35272 Total_Item_Investigations 2 0 0 0 0 0 2 0 0 0 0 0 0 BRAF inhibition in hairy cell leukemia with low-dose vemurafenib The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-680074 Silverchair:35272 Total_Item_Requests 2 0 0 0 0 0 2 0 0 0 0 0 0 BRAF inhibition in hairy cell leukemia with low-dose vemurafenib The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-680074 Silverchair:35272 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 BRAF inhibition in hairy cell leukemia with low-dose vemurafenib The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-680074 Silverchair:35272 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 BRAF inhibitor: targeted therapy in hairy cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-03-704262 Silverchair:35270 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 BRAF inhibitor: targeted therapy in hairy cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-03-704262 Silverchair:35270 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 BRAF inhibitor: targeted therapy in hairy cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-03-704262 Silverchair:35270 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 BRAF inhibitor: targeted therapy in hairy cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-03-704262 Silverchair:35270 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Brain iron in sickle cell disease? The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-867010 Silverchair:39321 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Brain iron in sickle cell disease? The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-867010 Silverchair:39321 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Brain iron in sickle cell disease? The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-867010 Silverchair:39321 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Brain iron in sickle cell disease? The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-867010 Silverchair:39321 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Braking platelet activation: deactivating the receptors The American Society of Hematology American Society of Hematology 10.1182/blood-2007-09-113365 Silverchair:107989 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Braking platelet activation: deactivating the receptors The American Society of Hematology American Society of Hematology 10.1182/blood-2007-09-113365 Silverchair:107989 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Braking platelet activation: deactivating the receptors The American Society of Hematology American Society of Hematology 10.1182/blood-2007-09-113365 Silverchair:107989 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Braking platelet activation: deactivating the receptors The American Society of Hematology American Society of Hematology 10.1182/blood-2007-09-113365 Silverchair:107989 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Branched evolution and genomic intratumor heterogeneity in the pathogenesis of cutaneous T-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001441 Silverchair:460675 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Branched evolution and genomic intratumor heterogeneity in the pathogenesis of cutaneous T-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001441 Silverchair:460675 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Branched evolution and genomic intratumor heterogeneity in the pathogenesis of cutaneous T-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001441 Silverchair:460675 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Branched evolution and genomic intratumor heterogeneity in the pathogenesis of cutaneous T-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001441 Silverchair:460675 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Breaking barriers: Quebec platelet disorder The American Society of Hematology American Society of Hematology 10.1182/blood.2020008213 Silverchair:474270 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Breaking barriers: Quebec platelet disorder The American Society of Hematology American Society of Hematology 10.1182/blood.2020008213 Silverchair:474270 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Breaking barriers: Quebec platelet disorder The American Society of Hematology American Society of Hematology 10.1182/blood.2020008213 Silverchair:474270 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Breaking barriers: Quebec platelet disorder The American Society of Hematology American Society of Hematology 10.1182/blood.2020008213 Silverchair:474270 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122576 Silverchair:426172 Total_Item_Investigations 2 1 0 0 0 0 0 0 0 0 0 1 0 Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122576 Silverchair:426172 Total_Item_Requests 2 1 0 0 0 0 0 0 0 0 0 1 0 Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122576 Silverchair:426172 Unique_Item_Investigations 2 1 0 0 0 0 0 0 0 0 0 1 0 Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122576 Silverchair:426172 Unique_Item_Requests 2 1 0 0 0 0 0 0 0 0 0 1 0 Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results The American Society of Hematology American Society of Hematology 10.1182/blood.2020009178 Silverchair:475691 Total_Item_Investigations 2 0 0 0 0 0 0 1 1 0 0 0 0 Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results The American Society of Hematology American Society of Hematology 10.1182/blood.2020009178 Silverchair:475691 Unique_Item_Investigations 2 0 0 0 0 0 0 1 1 0 0 0 0 Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122968 Silverchair:423516 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122968 Silverchair:423516 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122968 Silverchair:423516 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122968 Silverchair:423516 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-815183 Silverchair:39282 Total_Item_Investigations 4 0 3 1 0 0 0 0 0 0 0 0 0 Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-815183 Silverchair:39282 Total_Item_Requests 4 0 3 1 0 0 0 0 0 0 0 0 0 Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-815183 Silverchair:39282 Unique_Item_Investigations 3 0 2 1 0 0 0 0 0 0 0 0 0 Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-815183 Silverchair:39282 Unique_Item_Requests 3 0 2 1 0 0 0 0 0 0 0 0 0 Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3982.3982 Silverchair:93064 Total_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3982.3982 Silverchair:93064 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3982.3982 Silverchair:93064 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3982.3982 Silverchair:93064 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137677 Silverchair:470166 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137677 Silverchair:470166 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137677 Silverchair:470166 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137677 Silverchair:470166 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001837 Silverchair:461123 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001837 Silverchair:461123 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001837 Silverchair:461123 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001837 Silverchair:461123 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Bruton tyrosine kinase degradation as a therapeutic strategy for cancer The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-862953 Silverchair:260651 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Bruton tyrosine kinase degradation as a therapeutic strategy for cancer The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-862953 Silverchair:260651 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Bruton tyrosine kinase degradation as a therapeutic strategy for cancer The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-862953 Silverchair:260651 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Bruton tyrosine kinase degradation as a therapeutic strategy for cancer The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-862953 Silverchair:260651 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "Buccal epithelial cells display somatic, bone marrow–derived CALR mutation" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017012229 Silverchair:15769 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 "Buccal epithelial cells display somatic, bone marrow–derived CALR mutation" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017012229 Silverchair:15769 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 "Buccal epithelial cells display somatic, bone marrow–derived CALR mutation" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017012229 Silverchair:15769 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 "Buccal epithelial cells display somatic, bone marrow–derived CALR mutation" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017012229 Silverchair:15769 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Budget Impact Analysis of CPX-351 in the Treatment of Patients with Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC) from a US Payer Perspective The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5615.5615 Silverchair:115704 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Budget Impact Analysis of CPX-351 in the Treatment of Patients with Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC) from a US Payer Perspective The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5615.5615 Silverchair:115704 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Budget Impact Analysis of CPX-351 in the Treatment of Patients with Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC) from a US Payer Perspective The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5615.5615 Silverchair:115704 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Budget Impact Analysis of CPX-351 in the Treatment of Patients with Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC) from a US Payer Perspective The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5615.5615 Silverchair:115704 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Building a Model of Myelodysplastic Syndromes From the Ground Up American Society of Hematology American Society of Hematology Silverchair:475189 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Building a Model of Myelodysplastic Syndromes From the Ground Up American Society of Hematology American Society of Hematology Silverchair:475189 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Building a Model of Myelodysplastic Syndromes From the Ground Up American Society of Hematology American Society of Hematology Silverchair:475189 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Building a Model of Myelodysplastic Syndromes From the Ground Up American Society of Hematology American Society of Hematology Silverchair:475189 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 "Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001743 Silverchair:461777 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001743 Silverchair:461777 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001743 Silverchair:461777 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001743 Silverchair:461777 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Burkitt Leukemia Involving Only the Bone Marrow Has a Better Prognosis Than Widespread Burkitt Lymphoma Involving the Bone Marrow in Adults The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4446.4446 Silverchair:91860 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Burkitt Leukemia Involving Only the Bone Marrow Has a Better Prognosis Than Widespread Burkitt Lymphoma Involving the Bone Marrow in Adults The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4446.4446 Silverchair:91860 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Burkitt Leukemia Involving Only the Bone Marrow Has a Better Prognosis Than Widespread Burkitt Lymphoma Involving the Bone Marrow in Adults The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4446.4446 Silverchair:91860 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Burkitt Leukemia Involving Only the Bone Marrow Has a Better Prognosis Than Widespread Burkitt Lymphoma Involving the Bone Marrow in Adults The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4446.4446 Silverchair:91860 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers The American Society of Hematology American Society of Hematology 10.1182/blood.2020006926 Silverchair:461327 Total_Item_Investigations 8 3 1 4 0 0 0 0 0 0 0 0 0 Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers The American Society of Hematology American Society of Hematology 10.1182/blood.2020006926 Silverchair:461327 Total_Item_Requests 4 3 1 0 0 0 0 0 0 0 0 0 0 Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers The American Society of Hematology American Society of Hematology 10.1182/blood.2020006926 Silverchair:461327 Unique_Item_Investigations 5 3 1 1 0 0 0 0 0 0 0 0 0 Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers The American Society of Hematology American Society of Hematology 10.1182/blood.2020006926 Silverchair:461327 Unique_Item_Requests 4 3 1 0 0 0 0 0 0 0 0 0 0 Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers The American Society of Hematology American Society of Hematology 10.1182/blood.2020006926 Silverchair:461327 No_License 2 0 0 2 0 0 0 0 0 0 0 0 0 "Busulfan, Cyclophosphamide and Melphalan As Conditioning Regimen for Pediatric Patients with AML in 1st or 2nd CR: A Retrospective Analysis from the AIEOP HSCT Registry" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111805 Silverchair:261851 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Busulfan, Cyclophosphamide and Melphalan As Conditioning Regimen for Pediatric Patients with AML in 1st or 2nd CR: A Retrospective Analysis from the AIEOP HSCT Registry" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111805 Silverchair:261851 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Busulfan, Cyclophosphamide and Melphalan As Conditioning Regimen for Pediatric Patients with AML in 1st or 2nd CR: A Retrospective Analysis from the AIEOP HSCT Registry" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111805 Silverchair:261851 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Busulfan, Cyclophosphamide and Melphalan As Conditioning Regimen for Pediatric Patients with AML in 1st or 2nd CR: A Retrospective Analysis from the AIEOP HSCT Registry" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111805 Silverchair:261851 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003391 Silverchair:474239 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003391 Silverchair:474239 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003391 Silverchair:474239 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003391 Silverchair:474239 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 C3a and C5a Stimulate Chemotaxis of Human Mast Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V89.8.2863 Silverchair:139210 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 C3a and C5a Stimulate Chemotaxis of Human Mast Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V89.8.2863 Silverchair:139210 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 C3a and C5a Stimulate Chemotaxis of Human Mast Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V89.8.2863 Silverchair:139210 Unique_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 C3a and C5a Stimulate Chemotaxis of Human Mast Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V89.8.2863 Silverchair:139210 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Cael-101 Is Well-Tolerated in AL Amyloidosis Patients Receiving Concomitant Cyclophosphamide-Bortezomib-Dexamethasone (CyborD): A Phase 2 Dose-Finding Study (NCT04304144) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139323 Silverchair:471980 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Cael-101 Is Well-Tolerated in AL Amyloidosis Patients Receiving Concomitant Cyclophosphamide-Bortezomib-Dexamethasone (CyborD): A Phase 2 Dose-Finding Study (NCT04304144) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139323 Silverchair:471980 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Cael-101 Is Well-Tolerated in AL Amyloidosis Patients Receiving Concomitant Cyclophosphamide-Bortezomib-Dexamethasone (CyborD): A Phase 2 Dose-Finding Study (NCT04304144) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139323 Silverchair:471980 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Cael-101 Is Well-Tolerated in AL Amyloidosis Patients Receiving Concomitant Cyclophosphamide-Bortezomib-Dexamethasone (CyborD): A Phase 2 Dose-Finding Study (NCT04304144) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139323 Silverchair:471980 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-275305 Silverchair:28152 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 "CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-275305 Silverchair:28152 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 "CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-275305 Silverchair:28152 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-275305 Silverchair:28152 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Calcineurin Inhibitors Replacement By Ruxolitinib As Graft Versus Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125803 Silverchair:425530 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Calcineurin Inhibitors Replacement By Ruxolitinib As Graft Versus Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125803 Silverchair:425530 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Calcineurin Inhibitors Replacement By Ruxolitinib As Graft Versus Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125803 Silverchair:425530 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Calcineurin Inhibitors Replacement By Ruxolitinib As Graft Versus Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125803 Silverchair:425530 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-827246 Silverchair:39308 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-827246 Silverchair:39308 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-827246 Silverchair:39308 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-827246 Silverchair:39308 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Can HIT testing lose its radioactivity? The American Society of Hematology American Society of Hematology 10.1182/blood.2020008908 Silverchair:475263 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Can HIT testing lose its radioactivity? The American Society of Hematology American Society of Hematology 10.1182/blood.2020008908 Silverchair:475263 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Can HIT testing lose its radioactivity? The American Society of Hematology American Society of Hematology 10.1182/blood.2020008908 Silverchair:475263 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Can HIT testing lose its radioactivity? The American Society of Hematology American Society of Hematology 10.1182/blood.2020008908 Silverchair:475263 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Can Iron Every (Other) Day Keep the Doctor Away? American Society of Hematology American Society of Hematology 10.1182/hem.V15.2.8265 Silverchair:463037 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Can Iron Every (Other) Day Keep the Doctor Away? American Society of Hematology American Society of Hematology 10.1182/hem.V15.2.8265 Silverchair:463037 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Can Iron Every (Other) Day Keep the Doctor Away? American Society of Hematology American Society of Hematology 10.1182/hem.V15.2.8265 Silverchair:463037 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Can Iron Every (Other) Day Keep the Doctor Away? American Society of Hematology American Society of Hematology 10.1182/hem.V15.2.8265 Silverchair:463037 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-512442 Silverchair:31729 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-512442 Silverchair:31729 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-512442 Silverchair:31729 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-512442 Silverchair:31729 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Can we use epigenetics to prime chemoresistant lymphomas? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000092 Silverchair:474339 Total_Item_Investigations 3 0 0 1 2 0 0 0 0 0 0 0 0 Can we use epigenetics to prime chemoresistant lymphomas? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000092 Silverchair:474339 Total_Item_Requests 3 0 0 1 2 0 0 0 0 0 0 0 0 Can we use epigenetics to prime chemoresistant lymphomas? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000092 Silverchair:474339 Unique_Item_Investigations 2 0 0 1 1 0 0 0 0 0 0 0 0 Can we use epigenetics to prime chemoresistant lymphomas? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000092 Silverchair:474339 Unique_Item_Requests 2 0 0 1 1 0 0 0 0 0 0 0 0 Capizzi-Style Methotrexate with Pegasparagase (C-MTX) Is Superior to High-Dose Methotrexate (HDMTX) in T-Lineage Acute Lymphoblastic Leukemia (T-ALL): Results from Children's Oncology Group (COG) AALL0434 The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.794.794 Silverchair:136508 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Capizzi-Style Methotrexate with Pegasparagase (C-MTX) Is Superior to High-Dose Methotrexate (HDMTX) in T-Lineage Acute Lymphoblastic Leukemia (T-ALL): Results from Children's Oncology Group (COG) AALL0434 The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.794.794 Silverchair:136508 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Capizzi-Style Methotrexate with Pegasparagase (C-MTX) Is Superior to High-Dose Methotrexate (HDMTX) in T-Lineage Acute Lymphoblastic Leukemia (T-ALL): Results from Children's Oncology Group (COG) AALL0434 The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.794.794 Silverchair:136508 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Capizzi-Style Methotrexate with Pegasparagase (C-MTX) Is Superior to High-Dose Methotrexate (HDMTX) in T-Lineage Acute Lymphoblastic Leukemia (T-ALL): Results from Children's Oncology Group (COG) AALL0434 The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.794.794 Silverchair:136508 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001834 Silverchair:475768 Total_Item_Investigations 7 0 0 0 3 0 0 0 0 0 2 0 2 Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001834 Silverchair:475768 Total_Item_Requests 7 0 0 0 3 0 0 0 0 0 2 0 2 Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001834 Silverchair:475768 Unique_Item_Investigations 5 0 0 0 3 0 0 0 0 0 1 0 1 Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001834 Silverchair:475768 Unique_Item_Requests 5 0 0 0 3 0 0 0 0 0 1 0 1 "Cappuccino, a mouse model of Hermansky-Pudlak syndrome, encodes a novel protein that is part of the pallidin-muted complex (BLOC-1)" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-01-0020 Silverchair:16947 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 "Cappuccino, a mouse model of Hermansky-Pudlak syndrome, encodes a novel protein that is part of the pallidin-muted complex (BLOC-1)" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-01-0020 Silverchair:16947 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 "Cappuccino, a mouse model of Hermansky-Pudlak syndrome, encodes a novel protein that is part of the pallidin-muted complex (BLOC-1)" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-01-0020 Silverchair:16947 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Cappuccino, a mouse model of Hermansky-Pudlak syndrome, encodes a novel protein that is part of the pallidin-muted complex (BLOC-1)" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-01-0020 Silverchair:16947 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 CAR Density Influences Antitumoral Efficacy of BCMA CAR-T Cells and Correlates with Clinical Outcome The American Society of Hematology American Society of Hematology 10.1182/blood-2021-148578 Silverchair:479983 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 CAR Density Influences Antitumoral Efficacy of BCMA CAR-T Cells and Correlates with Clinical Outcome The American Society of Hematology American Society of Hematology 10.1182/blood-2021-148578 Silverchair:479983 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 CAR Density Influences Antitumoral Efficacy of BCMA CAR-T Cells and Correlates with Clinical Outcome The American Society of Hematology American Society of Hematology 10.1182/blood-2021-148578 Silverchair:479983 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 CAR Density Influences Antitumoral Efficacy of BCMA CAR-T Cells and Correlates with Clinical Outcome The American Society of Hematology American Society of Hematology 10.1182/blood-2021-148578 Silverchair:479983 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 CAR T cells better than BiTEs American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003554 Silverchair:475006 Total_Item_Investigations 4 3 0 0 0 0 0 0 0 1 0 0 0 CAR T cells better than BiTEs American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003554 Silverchair:475006 Total_Item_Requests 4 3 0 0 0 0 0 0 0 1 0 0 0 CAR T cells better than BiTEs American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003554 Silverchair:475006 Unique_Item_Investigations 2 1 0 0 0 0 0 0 0 1 0 0 0 CAR T cells better than BiTEs American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003554 Silverchair:475006 Unique_Item_Requests 2 1 0 0 0 0 0 0 0 1 0 0 0 "Cardiotoxicity Risk with Bortezomib Versus Lenalidomide for Treatment of Multiple Myeloma: A Propensity-Matched Study of 1,128 Patients" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3046.3046 Silverchair:135563 Total_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 "Cardiotoxicity Risk with Bortezomib Versus Lenalidomide for Treatment of Multiple Myeloma: A Propensity-Matched Study of 1,128 Patients" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3046.3046 Silverchair:135563 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 "Cardiotoxicity Risk with Bortezomib Versus Lenalidomide for Treatment of Multiple Myeloma: A Propensity-Matched Study of 1,128 Patients" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3046.3046 Silverchair:135563 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 "Cardiotoxicity Risk with Bortezomib Versus Lenalidomide for Treatment of Multiple Myeloma: A Propensity-Matched Study of 1,128 Patients" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3046.3046 Silverchair:135563 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.110 Silverchair:21105 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.110 Silverchair:21105 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.110 Silverchair:21105 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.110 Silverchair:21105 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Cardiovascular complications in patients with sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.423 Silverchair:21106 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Cardiovascular complications in patients with sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.423 Silverchair:21106 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Cardiovascular complications in patients with sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.423 Silverchair:21106 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Cardiovascular complications in patients with sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.423 Silverchair:21106 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Cardiovascular Disease is a Leading Cause of Mortality among TTP Survivors in Clinical Remission American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004169 Silverchair:476716 Total_Item_Investigations 6 0 0 0 0 0 0 0 1 2 0 0 3 Cardiovascular Disease is a Leading Cause of Mortality among TTP Survivors in Clinical Remission American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004169 Silverchair:476716 Total_Item_Requests 2 0 0 0 0 0 0 0 0 1 0 0 1 Cardiovascular Disease is a Leading Cause of Mortality among TTP Survivors in Clinical Remission American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004169 Silverchair:476716 Unique_Item_Investigations 3 0 0 0 0 0 0 0 1 1 0 0 1 Cardiovascular Disease is a Leading Cause of Mortality among TTP Survivors in Clinical Remission American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004169 Silverchair:476716 Unique_Item_Requests 2 0 0 0 0 0 0 0 0 1 0 0 1 "Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.835.835 Silverchair:83712 Total_Item_Investigations 2 0 0 1 0 0 0 0 0 1 0 0 0 "Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.835.835 Silverchair:83712 Total_Item_Requests 2 0 0 1 0 0 0 0 0 1 0 0 0 "Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.835.835 Silverchair:83712 Unique_Item_Investigations 2 0 0 1 0 0 0 0 0 1 0 0 0 "Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.835.835 Silverchair:83712 Unique_Item_Requests 2 0 0 1 0 0 0 0 0 1 0 0 0 "Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study" The American Society of Hematology American Society of Hematology 10.1182/blood-2014-03-563759 Silverchair:33119 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 "Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study" The American Society of Hematology American Society of Hematology 10.1182/blood-2014-03-563759 Silverchair:33119 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 "Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study" The American Society of Hematology American Society of Hematology 10.1182/blood-2014-03-563759 Silverchair:33119 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 "Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study" The American Society of Hematology American Society of Hematology 10.1182/blood-2014-03-563759 Silverchair:33119 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 "Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood.2020007522 Silverchair:461668 Total_Item_Investigations 3 1 2 0 0 0 0 0 0 0 0 0 0 "Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood.2020007522 Silverchair:461668 Total_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 "Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood.2020007522 Silverchair:461668 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 "Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood.2020007522 Silverchair:461668 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 "Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide. the EMN011 Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114029 Silverchair:266248 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 "Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide. the EMN011 Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114029 Silverchair:266248 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 "Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide. the EMN011 Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114029 Silverchair:266248 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 "Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide. the EMN011 Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114029 Silverchair:266248 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 "Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-643320 Silverchair:103856 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 "Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-643320 Silverchair:103856 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 "Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-643320 Silverchair:103856 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-643320 Silverchair:103856 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020010543 Silverchair:476241 Total_Item_Investigations 2 0 0 0 0 0 0 2 0 0 0 0 0 CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020010543 Silverchair:476241 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood.2020006619 Silverchair:461265 No_License 1 0 0 1 0 0 0 0 0 0 0 0 0 CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood.2020006619 Silverchair:461265 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood.2020006619 Silverchair:461265 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 CAR-T–cell neurotoxicity: hope is on the horizon The American Society of Hematology American Society of Hematology 10.1182/blood-2019-03-900985 Silverchair:273852 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 CAR-T–cell neurotoxicity: hope is on the horizon The American Society of Hematology American Society of Hematology 10.1182/blood-2019-03-900985 Silverchair:273852 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 CAR-T–cell neurotoxicity: hope is on the horizon The American Society of Hematology American Society of Hematology 10.1182/blood-2019-03-900985 Silverchair:273852 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 CAR-T–cell neurotoxicity: hope is on the horizon The American Society of Hematology American Society of Hematology 10.1182/blood-2019-03-900985 Silverchair:273852 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136307 Silverchair:469895 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136307 Silverchair:469895 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136307 Silverchair:469895 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136307 Silverchair:469895 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Caspase-12: a developmental link between G-protein–coupled receptors and integrin aIIbß3 activation The American Society of Hematology American Society of Hematology 10.1182/blood-2003-10-3633 Silverchair:18898 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 3 0 0 0 Caspase-12: a developmental link between G-protein–coupled receptors and integrin aIIbß3 activation The American Society of Hematology American Society of Hematology 10.1182/blood-2003-10-3633 Silverchair:18898 Total_Item_Requests 3 0 0 0 0 0 0 0 0 3 0 0 0 Caspase-12: a developmental link between G-protein–coupled receptors and integrin aIIbß3 activation The American Society of Hematology American Society of Hematology 10.1182/blood-2003-10-3633 Silverchair:18898 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Caspase-12: a developmental link between G-protein–coupled receptors and integrin aIIbß3 activation The American Society of Hematology American Society of Hematology 10.1182/blood-2003-10-3633 Silverchair:18898 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.990.990 Silverchair:102000 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.990.990 Silverchair:102000 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.990.990 Silverchair:102000 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.990.990 Silverchair:102000 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138498 Silverchair:470608 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138498 Silverchair:470608 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138498 Silverchair:470608 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138498 Silverchair:470608 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140837 Silverchair:470423 Total_Item_Investigations 3 2 0 0 0 0 0 0 1 0 0 0 0 CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140837 Silverchair:470423 Total_Item_Requests 3 2 0 0 0 0 0 0 1 0 0 0 0 CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140837 Silverchair:470423 Unique_Item_Investigations 2 1 0 0 0 0 0 0 1 0 0 0 0 CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140837 Silverchair:470423 Unique_Item_Requests 2 1 0 0 0 0 0 0 1 0 0 0 0 CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137562 Silverchair:470414 Total_Item_Investigations 7 1 4 0 0 1 1 0 0 0 0 0 0 CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137562 Silverchair:470414 Total_Item_Requests 7 1 4 0 0 1 1 0 0 0 0 0 0 CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137562 Silverchair:470414 Unique_Item_Investigations 6 1 3 0 0 1 1 0 0 0 0 0 0 CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137562 Silverchair:470414 Unique_Item_Requests 6 1 3 0 0 1 1 0 0 0 0 0 0 "CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008676 Silverchair:474181 No_License 11 0 7 4 0 0 0 0 0 0 0 0 0 "CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008676 Silverchair:474181 Total_Item_Investigations 29 0 21 8 0 0 0 0 0 0 0 0 0 "CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008676 Silverchair:474181 Unique_Item_Investigations 7 0 4 3 0 0 0 0 0 0 0 0 0 CCL16 activates an angiogenic program in vascular endothelial cells The American Society of Hematology American Society of Hematology 10.1182/blood-2003-05-1387 Silverchair:17594 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 CCL16 activates an angiogenic program in vascular endothelial cells The American Society of Hematology American Society of Hematology 10.1182/blood-2003-05-1387 Silverchair:17594 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 CCL16 activates an angiogenic program in vascular endothelial cells The American Society of Hematology American Society of Hematology 10.1182/blood-2003-05-1387 Silverchair:17594 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 CCL16 activates an angiogenic program in vascular endothelial cells The American Society of Hematology American Society of Hematology 10.1182/blood-2003-05-1387 Silverchair:17594 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 CCL5 derived from platelets increases megakaryocyte proplatelet formation The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-644583 Silverchair:35235 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 CCL5 derived from platelets increases megakaryocyte proplatelet formation The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-644583 Silverchair:35235 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 CCL5 derived from platelets increases megakaryocyte proplatelet formation The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-644583 Silverchair:35235 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 CCL5 derived from platelets increases megakaryocyte proplatelet formation The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-644583 Silverchair:35235 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 CCR2 recruits an inflammatory macrophage subpopulation critical for angiogenesis in tissue repair The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-403386 Silverchair:30460 Total_Item_Investigations 5 4 1 0 0 0 0 0 0 0 0 0 0 CCR2 recruits an inflammatory macrophage subpopulation critical for angiogenesis in tissue repair The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-403386 Silverchair:30460 Total_Item_Requests 5 4 1 0 0 0 0 0 0 0 0 0 0 CCR2 recruits an inflammatory macrophage subpopulation critical for angiogenesis in tissue repair The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-403386 Silverchair:30460 Unique_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 CCR2 recruits an inflammatory macrophage subpopulation critical for angiogenesis in tissue repair The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-403386 Silverchair:30460 Unique_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 CCR6 expression defines regulatory effector/memory-like cells within the CD25+CD4+ T-cell subset The American Society of Hematology American Society of Hematology 10.1182/blood-2004-07-2505 Silverchair:20218 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 CCR6 expression defines regulatory effector/memory-like cells within the CD25+CD4+ T-cell subset The American Society of Hematology American Society of Hematology 10.1182/blood-2004-07-2505 Silverchair:20218 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 CCR6 expression defines regulatory effector/memory-like cells within the CD25+CD4+ T-cell subset The American Society of Hematology American Society of Hematology 10.1182/blood-2004-07-2505 Silverchair:20218 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 CCR6 expression defines regulatory effector/memory-like cells within the CD25+CD4+ T-cell subset The American Society of Hematology American Society of Hematology 10.1182/blood-2004-07-2505 Silverchair:20218 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-192591 Silverchair:26838 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-192591 Silverchair:26838 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-192591 Silverchair:26838 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-192591 Silverchair:26838 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 CD169 mediates the capture of exosomes in spleen and lymph node The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-489732 Silverchair:32426 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 CD169 mediates the capture of exosomes in spleen and lymph node The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-489732 Silverchair:32426 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 CD169 mediates the capture of exosomes in spleen and lymph node The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-489732 Silverchair:32426 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 CD169 mediates the capture of exosomes in spleen and lymph node The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-489732 Silverchair:32426 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "CD16-IL15-CLEC12A Trispecific Killer Engager (TriKE) Drives NK Cell Expansion, Activation, and Antigen Specific Killing of Cancer Stem Cells in Acute Myeloid Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117150 Silverchair:272874 Total_Item_Investigations 9 0 9 0 0 0 0 0 0 0 0 0 0 "CD16-IL15-CLEC12A Trispecific Killer Engager (TriKE) Drives NK Cell Expansion, Activation, and Antigen Specific Killing of Cancer Stem Cells in Acute Myeloid Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117150 Silverchair:272874 Total_Item_Requests 9 0 9 0 0 0 0 0 0 0 0 0 0 "CD16-IL15-CLEC12A Trispecific Killer Engager (TriKE) Drives NK Cell Expansion, Activation, and Antigen Specific Killing of Cancer Stem Cells in Acute Myeloid Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117150 Silverchair:272874 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "CD16-IL15-CLEC12A Trispecific Killer Engager (TriKE) Drives NK Cell Expansion, Activation, and Antigen Specific Killing of Cancer Stem Cells in Acute Myeloid Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117150 Silverchair:272874 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-533398 Silverchair:32670 Total_Item_Investigations 5 0 4 1 0 0 0 0 0 0 0 0 0 CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-533398 Silverchair:32670 Total_Item_Requests 5 0 4 1 0 0 0 0 0 0 0 0 0 CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-533398 Silverchair:32670 Unique_Item_Investigations 3 0 2 1 0 0 0 0 0 0 0 0 0 CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-533398 Silverchair:32670 Unique_Item_Requests 3 0 2 1 0 0 0 0 0 0 0 0 0 CD19/BAFF-R Dual-Targeted CAR T Cells for the Treatment of Mixed Antigen-Negative Variants of Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2021-151293 Silverchair:482375 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 CD19/BAFF-R Dual-Targeted CAR T Cells for the Treatment of Mixed Antigen-Negative Variants of Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2021-151293 Silverchair:482375 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 CD19/BAFF-R Dual-Targeted CAR T Cells for the Treatment of Mixed Antigen-Negative Variants of Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2021-151293 Silverchair:482375 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 CD19/BAFF-R Dual-Targeted CAR T Cells for the Treatment of Mixed Antigen-Negative Variants of Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2021-151293 Silverchair:482375 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004106 Silverchair:476800 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004106 Silverchair:476800 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004106 Silverchair:476800 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004106 Silverchair:476800 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 CD229 CAR T Cell Therapy for the Treatment of Relapsed B Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2021-154503 Silverchair:482373 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 CD229 CAR T Cell Therapy for the Treatment of Relapsed B Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2021-154503 Silverchair:482373 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 CD229 CAR T Cell Therapy for the Treatment of Relapsed B Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2021-154503 Silverchair:482373 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 CD229 CAR T Cell Therapy for the Treatment of Relapsed B Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2021-154503 Silverchair:482373 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020009432 Silverchair:474751 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020009432 Silverchair:474751 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020009432 Silverchair:474751 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020009432 Silverchair:474751 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 CD22-Directed CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of CD19-Directed CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139087 Silverchair:470466 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 CD22-Directed CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of CD19-Directed CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139087 Silverchair:470466 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 CD22-Directed CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of CD19-Directed CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139087 Silverchair:470466 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 CD22-Directed CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of CD19-Directed CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139087 Silverchair:470466 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.1434.1434 Silverchair:134681 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.1434.1434 Silverchair:134681 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.1434.1434 Silverchair:134681 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.1434.1434 Silverchair:134681 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4088.4088 Silverchair:114209 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4088.4088 Silverchair:114209 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4088.4088 Silverchair:114209 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4088.4088 Silverchair:114209 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-02-414425 Silverchair:30236 Total_Item_Investigations 9 2 7 0 0 0 0 0 0 0 0 0 0 "CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-02-414425 Silverchair:30236 Total_Item_Requests 9 2 7 0 0 0 0 0 0 0 0 0 0 "CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-02-414425 Silverchair:30236 Unique_Item_Investigations 4 1 3 0 0 0 0 0 0 0 0 0 0 "CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-02-414425 Silverchair:30236 Unique_Item_Requests 4 1 3 0 0 0 0 0 0 0 0 0 0 CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117553 Silverchair:265978 Total_Item_Investigations 11 0 0 1 0 1 0 4 1 3 0 1 0 CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117553 Silverchair:265978 Total_Item_Requests 11 0 0 1 0 1 0 4 1 3 0 1 0 CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117553 Silverchair:265978 Unique_Item_Investigations 9 0 0 1 0 1 0 4 1 1 0 1 0 CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117553 Silverchair:265978 Unique_Item_Requests 9 0 0 1 0 1 0 4 1 1 0 1 0 CD28 provides T-cell costimulation and enhances PI3K activity at the immune synapse independently of its capacity to interact with the p85/p110 heterodimer The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-108050 Silverchair:25487 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 CD28 provides T-cell costimulation and enhances PI3K activity at the immune synapse independently of its capacity to interact with the p85/p110 heterodimer The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-108050 Silverchair:25487 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 CD28 provides T-cell costimulation and enhances PI3K activity at the immune synapse independently of its capacity to interact with the p85/p110 heterodimer The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-108050 Silverchair:25487 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 CD28 provides T-cell costimulation and enhances PI3K activity at the immune synapse independently of its capacity to interact with the p85/p110 heterodimer The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-108050 Silverchair:25487 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects The American Society of Hematology American Society of Hematology 10.1182/blood-2002-12-3936 Silverchair:17795 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects The American Society of Hematology American Society of Hematology 10.1182/blood-2002-12-3936 Silverchair:17795 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects The American Society of Hematology American Society of Hematology 10.1182/blood-2002-12-3936 Silverchair:17795 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects The American Society of Hematology American Society of Hematology 10.1182/blood-2002-12-3936 Silverchair:17795 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2021-148102 Silverchair:480022 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2021-148102 Silverchair:480022 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2021-148102 Silverchair:480022 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2021-148102 Silverchair:480022 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330 The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-523548 Silverchair:32300 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330 The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-523548 Silverchair:32300 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330 The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-523548 Silverchair:32300 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330 The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-523548 Silverchair:32300 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 CD4 engagement by CD1d potentiates activation of CD4+ invariant NKT cells The American Society of Hematology American Society of Hematology 10.1182/blood-2007-01-066217 Silverchair:133622 Total_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 CD4 engagement by CD1d potentiates activation of CD4+ invariant NKT cells The American Society of Hematology American Society of Hematology 10.1182/blood-2007-01-066217 Silverchair:133622 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 CD4 engagement by CD1d potentiates activation of CD4+ invariant NKT cells The American Society of Hematology American Society of Hematology 10.1182/blood-2007-01-066217 Silverchair:133622 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 CD4 engagement by CD1d potentiates activation of CD4+ invariant NKT cells The American Society of Hematology American Society of Hematology 10.1182/blood-2007-01-066217 Silverchair:133622 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 CD41 expression marks myeloid-biased adult hematopoietic stem cells and increases with age The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-457929 Silverchair:31368 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 CD41 expression marks myeloid-biased adult hematopoietic stem cells and increases with age The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-457929 Silverchair:31368 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 CD41 expression marks myeloid-biased adult hematopoietic stem cells and increases with age The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-457929 Silverchair:31368 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 CD41 expression marks myeloid-biased adult hematopoietic stem cells and increases with age The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-457929 Silverchair:31368 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 CD45RA on human CD8 T cells is sensitive to the time elapsed since the last antigenic stimulation The American Society of Hematology American Society of Hematology 10.1182/blood-2005-11-007237 Silverchair:22522 Total_Item_Investigations 4 1 2 1 0 0 0 0 0 0 0 0 0 CD45RA on human CD8 T cells is sensitive to the time elapsed since the last antigenic stimulation The American Society of Hematology American Society of Hematology 10.1182/blood-2005-11-007237 Silverchair:22522 Total_Item_Requests 4 1 2 1 0 0 0 0 0 0 0 0 0 CD45RA on human CD8 T cells is sensitive to the time elapsed since the last antigenic stimulation The American Society of Hematology American Society of Hematology 10.1182/blood-2005-11-007237 Silverchair:22522 Unique_Item_Investigations 4 1 2 1 0 0 0 0 0 0 0 0 0 CD45RA on human CD8 T cells is sensitive to the time elapsed since the last antigenic stimulation The American Society of Hematology American Society of Hematology 10.1182/blood-2005-11-007237 Silverchair:22522 Unique_Item_Requests 4 1 2 1 0 0 0 0 0 0 0 0 0 CD47 functions as a molecular switch for erythrocyte phagocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2011-10-386805 Silverchair:30357 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 CD47 functions as a molecular switch for erythrocyte phagocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2011-10-386805 Silverchair:30357 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 CD47 functions as a molecular switch for erythrocyte phagocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2011-10-386805 Silverchair:30357 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 CD47 functions as a molecular switch for erythrocyte phagocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2011-10-386805 Silverchair:30357 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 CD5 and CD23 Positive Mantle Cell Lymphoma Detected by Flow Cytometry and Confirmed by FISH Study t(11;14). The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.4814.4814 Silverchair:55889 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 CD5 and CD23 Positive Mantle Cell Lymphoma Detected by Flow Cytometry and Confirmed by FISH Study t(11;14). The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.4814.4814 Silverchair:55889 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 CD5 and CD23 Positive Mantle Cell Lymphoma Detected by Flow Cytometry and Confirmed by FISH Study t(11;14). The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.4814.4814 Silverchair:55889 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 CD5 and CD23 Positive Mantle Cell Lymphoma Detected by Flow Cytometry and Confirmed by FISH Study t(11;14). The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.4814.4814 Silverchair:55889 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-253286 Silverchair:27930 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-253286 Silverchair:27930 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-253286 Silverchair:27930 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-253286 Silverchair:27930 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "CD64 Expression Is An Independent Adverse Prognostic Factor in Pediatric Acute Myeloid Leukemia Treated with Allogeneic Stem Cell Transplantation," The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.3525.3525 Silverchair:69517 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "CD64 Expression Is An Independent Adverse Prognostic Factor in Pediatric Acute Myeloid Leukemia Treated with Allogeneic Stem Cell Transplantation," The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.3525.3525 Silverchair:69517 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "CD64 Expression Is An Independent Adverse Prognostic Factor in Pediatric Acute Myeloid Leukemia Treated with Allogeneic Stem Cell Transplantation," The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.3525.3525 Silverchair:69517 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "CD64 Expression Is An Independent Adverse Prognostic Factor in Pediatric Acute Myeloid Leukemia Treated with Allogeneic Stem Cell Transplantation," The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.3525.3525 Silverchair:69517 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 CD70-specific CAR T-cells have potent activity against Acute Myeloid Leukemia (AML) without HSC toxicity The American Society of Hematology American Society of Hematology 10.1182/blood.2020008221 Silverchair:475523 Total_Item_Investigations 6 0 0 6 0 0 0 0 0 0 0 0 0 CD70-specific CAR T-cells have potent activity against Acute Myeloid Leukemia (AML) without HSC toxicity The American Society of Hematology American Society of Hematology 10.1182/blood.2020008221 Silverchair:475523 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-761320 Silverchair:36917 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-761320 Silverchair:36917 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-761320 Silverchair:36917 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-761320 Silverchair:36917 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 CD8+ Anti-BCMA mRNA CAR T-Cells Effectively Kill Human Multiple Myeloma Cells In Vitro and In Vivo The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3067.3067 Silverchair:80476 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 CD8+ Anti-BCMA mRNA CAR T-Cells Effectively Kill Human Multiple Myeloma Cells In Vitro and In Vivo The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3067.3067 Silverchair:80476 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 CD8+ Anti-BCMA mRNA CAR T-Cells Effectively Kill Human Multiple Myeloma Cells In Vitro and In Vivo The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3067.3067 Silverchair:80476 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 CD8+ Anti-BCMA mRNA CAR T-Cells Effectively Kill Human Multiple Myeloma Cells In Vitro and In Vivo The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3067.3067 Silverchair:80476 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-635417 Silverchair:34511 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-635417 Silverchair:34511 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-635417 Silverchair:34511 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-635417 Silverchair:34511 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-02-555292 Silverchair:33474 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-02-555292 Silverchair:33474 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-02-555292 Silverchair:33474 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-02-555292 Silverchair:33474 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Cell interactions in the bone marrow microenvironment affecting myeloid malignancies American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002127 Silverchair:461770 Total_Item_Investigations 5 1 3 1 0 0 0 0 0 0 0 0 0 Cell interactions in the bone marrow microenvironment affecting myeloid malignancies American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002127 Silverchair:461770 Total_Item_Requests 5 1 3 1 0 0 0 0 0 0 0 0 0 Cell interactions in the bone marrow microenvironment affecting myeloid malignancies American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002127 Silverchair:461770 Unique_Item_Investigations 4 1 2 1 0 0 0 0 0 0 0 0 0 Cell interactions in the bone marrow microenvironment affecting myeloid malignancies American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002127 Silverchair:461770 Unique_Item_Requests 4 1 2 1 0 0 0 0 0 0 0 0 0 Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131841 Silverchair:423518 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131841 Silverchair:423518 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131841 Silverchair:423518 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131841 Silverchair:423518 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival The American Society of Hematology American Society of Hematology 10.1182/blood-2005-11-4334 Silverchair:129311 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival The American Society of Hematology American Society of Hematology 10.1182/blood-2005-11-4334 Silverchair:129311 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival The American Society of Hematology American Society of Hematology 10.1182/blood-2005-11-4334 Silverchair:129311 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival The American Society of Hematology American Society of Hematology 10.1182/blood-2005-11-4334 Silverchair:129311 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Cellular basis of hematopoiesis and stem cell transplantation American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter14 Silverchair:75976 No_License 5 0 0 4 0 0 0 0 1 0 0 0 0 Cellular basis of hematopoiesis and stem cell transplantation American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter14 Silverchair:75976 Total_Item_Investigations 6 0 0 5 0 0 0 0 1 0 0 0 0 Cellular basis of hematopoiesis and stem cell transplantation American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter14 Silverchair:75976 Unique_Item_Investigations 4 0 0 3 0 0 0 0 1 0 0 0 0 "Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-09-527044 Silverchair:32292 Total_Item_Investigations 3 1 2 0 0 0 0 0 0 0 0 0 0 "Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-09-527044 Silverchair:32292 Total_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 "Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-09-527044 Silverchair:32292 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 "Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-09-527044 Silverchair:32292 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Cellular immune therapy for chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2007-01-068932 Silverchair:23937 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Cellular immune therapy for chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2007-01-068932 Silverchair:23937 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Cellular immune therapy for chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2007-01-068932 Silverchair:23937 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Cellular immune therapy for chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2007-01-068932 Silverchair:23937 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Central nervous system complications and management in sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-618579 Silverchair:35223 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Central nervous system complications and management in sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-618579 Silverchair:35223 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Central nervous system complications and management in sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-618579 Silverchair:35223 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Central nervous system complications and management in sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-618579 Silverchair:35223 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Central Nervous System Involvement By Chronic Lymphocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2919.2919 Silverchair:135601 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Central Nervous System Involvement By Chronic Lymphocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2919.2919 Silverchair:135601 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Central Nervous System Involvement By Chronic Lymphocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2919.2919 Silverchair:135601 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Central Nervous System Involvement By Chronic Lymphocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2919.2919 Silverchair:135601 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3941.3941 Silverchair:115507 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3941.3941 Silverchair:115507 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3941.3941 Silverchair:115507 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3941.3941 Silverchair:115507 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Central Nervous System Involvement in Blastic Plasmacytoid Dendritic Cell Neoplasm The American Society of Hematology American Society of Hematology 10.1182/blood.2021011817 Silverchair:476102 No_License 2 0 0 0 0 0 1 1 0 0 0 0 0 Central Nervous System Involvement in Blastic Plasmacytoid Dendritic Cell Neoplasm The American Society of Hematology American Society of Hematology 10.1182/blood.2021011817 Silverchair:476102 Total_Item_Investigations 4 0 0 0 0 0 2 2 0 0 0 0 0 Central Nervous System Involvement in Blastic Plasmacytoid Dendritic Cell Neoplasm The American Society of Hematology American Society of Hematology 10.1182/blood.2021011817 Silverchair:476102 Unique_Item_Investigations 2 0 0 0 0 0 1 1 0 0 0 0 0 Central Nervous System Involvement in Peripheral T-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131965 Silverchair:425156 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Central Nervous System Involvement in Peripheral T-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131965 Silverchair:425156 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Central Nervous System Involvement in Peripheral T-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131965 Silverchair:425156 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Central Nervous System Involvement in Peripheral T-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131965 Silverchair:425156 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131435 Silverchair:427595 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131435 Silverchair:427595 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131435 Silverchair:427595 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131435 Silverchair:427595 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-616961 Silverchair:34361 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-616961 Silverchair:34361 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-616961 Silverchair:34361 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-616961 Silverchair:34361 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Central T Cell Tolerance and Peripheral B Cell Tolerance for An RBC Autoantigen Are Incomplete in Healthy Mice; Implications for AIHA Pathogenesis The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.693.693 Silverchair:83090 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Central T Cell Tolerance and Peripheral B Cell Tolerance for An RBC Autoantigen Are Incomplete in Healthy Mice; Implications for AIHA Pathogenesis The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.693.693 Silverchair:83090 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Central T Cell Tolerance and Peripheral B Cell Tolerance for An RBC Autoantigen Are Incomplete in Healthy Mice; Implications for AIHA Pathogenesis The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.693.693 Silverchair:83090 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Central T Cell Tolerance and Peripheral B Cell Tolerance for An RBC Autoantigen Are Incomplete in Healthy Mice; Implications for AIHA Pathogenesis The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.693.693 Silverchair:83090 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Central venous catheter–related thrombosis The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.306 Silverchair:20536 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Central venous catheter–related thrombosis The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.306 Silverchair:20536 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Central venous catheter–related thrombosis The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.306 Silverchair:20536 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Central venous catheter–related thrombosis The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.306 Silverchair:20536 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 CGD: less is more The American Society of Hematology American Society of Hematology 10.1182/blood.2020005062 Silverchair:452688 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 CGD: less is more The American Society of Hematology American Society of Hematology 10.1182/blood.2020005062 Silverchair:452688 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 CGD: less is more The American Society of Hematology American Society of Hematology 10.1182/blood.2020005062 Silverchair:452688 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 CGD: less is more The American Society of Hematology American Society of Hematology 10.1182/blood.2020005062 Silverchair:452688 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Chagas disease initially diagnosed in a lymph node The American Society of Hematology American Society of Hematology 10.1182/blood.2020008815 Silverchair:474161 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Chagas disease initially diagnosed in a lymph node The American Society of Hematology American Society of Hematology 10.1182/blood.2020008815 Silverchair:474161 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Chagas disease initially diagnosed in a lymph node The American Society of Hematology American Society of Hematology 10.1182/blood.2020008815 Silverchair:474161 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Chagas disease initially diagnosed in a lymph node The American Society of Hematology American Society of Hematology 10.1182/blood.2020008815 Silverchair:474161 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Challenges in treatment of patients with acute leukemia and COVID-19: a series of 12 patients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002543 Silverchair:474380 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Challenges in treatment of patients with acute leukemia and COVID-19: a series of 12 patients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002543 Silverchair:474380 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Challenges in treatment of patients with acute leukemia and COVID-19: a series of 12 patients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002543 Silverchair:474380 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Challenges in treatment of patients with acute leukemia and COVID-19: a series of 12 patients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002543 Silverchair:474380 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017012732 Silverchair:15770 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017012732 Silverchair:15770 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017012732 Silverchair:15770 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017012732 Silverchair:15770 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Changes in Imaging Surveillance of Diffuse Large B-Cell Lymphoma Survivors after Publication of the American Society of Hematology Choosing Wisely® Recommendations The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119179 Silverchair:266197 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Changes in Imaging Surveillance of Diffuse Large B-Cell Lymphoma Survivors after Publication of the American Society of Hematology Choosing Wisely® Recommendations The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119179 Silverchair:266197 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Changes in Imaging Surveillance of Diffuse Large B-Cell Lymphoma Survivors after Publication of the American Society of Hematology Choosing Wisely® Recommendations The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119179 Silverchair:266197 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Changes in Imaging Surveillance of Diffuse Large B-Cell Lymphoma Survivors after Publication of the American Society of Hematology Choosing Wisely® Recommendations The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119179 Silverchair:266197 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Changes in N-Glycosylation Induced By Somatic Hypermutation Modulate the Antigen Reactivity of the Immunoglobulin Receptors in CLL Stereotyped Subset #201 The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127852 Silverchair:427530 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Changes in N-Glycosylation Induced By Somatic Hypermutation Modulate the Antigen Reactivity of the Immunoglobulin Receptors in CLL Stereotyped Subset #201 The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127852 Silverchair:427530 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Changes in N-Glycosylation Induced By Somatic Hypermutation Modulate the Antigen Reactivity of the Immunoglobulin Receptors in CLL Stereotyped Subset #201 The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127852 Silverchair:427530 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Changes in N-Glycosylation Induced By Somatic Hypermutation Modulate the Antigen Reactivity of the Immunoglobulin Receptors in CLL Stereotyped Subset #201 The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127852 Silverchair:427530 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129624 Silverchair:426243 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129624 Silverchair:426243 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129624 Silverchair:426243 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129624 Silverchair:426243 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004789 Silverchair:476378 Total_Item_Investigations 2 0 0 0 0 0 0 0 2 0 0 0 0 Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004789 Silverchair:476378 Total_Item_Requests 2 0 0 0 0 0 0 0 2 0 0 0 0 Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004789 Silverchair:476378 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004789 Silverchair:476378 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 "Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134211 Silverchair:469951 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134211 Silverchair:469951 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134211 Silverchair:469951 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134211 Silverchair:469951 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Characteristics, complications, and sites of bleeding among infants and toddlers less than 2 years of age with VWD" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004141 Silverchair:475731 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 "Characteristics, complications, and sites of bleeding among infants and toddlers less than 2 years of age with VWD" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004141 Silverchair:475731 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 "Characteristics, complications, and sites of bleeding among infants and toddlers less than 2 years of age with VWD" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004141 Silverchair:475731 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 "Characteristics, complications, and sites of bleeding among infants and toddlers less than 2 years of age with VWD" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004141 Silverchair:475731 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Characterization and treatment of congenital thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-884700 Silverchair:273301 Total_Item_Investigations 3 0 0 0 0 3 0 0 0 0 0 0 0 Characterization and treatment of congenital thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-884700 Silverchair:273301 Total_Item_Requests 3 0 0 0 0 3 0 0 0 0 0 0 0 Characterization and treatment of congenital thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-884700 Silverchair:273301 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Characterization and treatment of congenital thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-884700 Silverchair:273301 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 "Characterization of Fever, Infection, and Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2530.2530 Silverchair:113389 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Characterization of Fever, Infection, and Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2530.2530 Silverchair:113389 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Characterization of Fever, Infection, and Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2530.2530 Silverchair:113389 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Characterization of Fever, Infection, and Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2530.2530 Silverchair:113389 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Characterization of Hematopoietic and Non-Hematopoietic Stem/Progenitor Cells in Freshly Isolated Adult Human Bone Marrow Using an 8-Color Flow Cytometric Assay. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4045.4045 Silverchair:84245 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Characterization of Hematopoietic and Non-Hematopoietic Stem/Progenitor Cells in Freshly Isolated Adult Human Bone Marrow Using an 8-Color Flow Cytometric Assay. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4045.4045 Silverchair:84245 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Characterization of Hematopoietic and Non-Hematopoietic Stem/Progenitor Cells in Freshly Isolated Adult Human Bone Marrow Using an 8-Color Flow Cytometric Assay. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4045.4045 Silverchair:84245 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Characterization of Hematopoietic and Non-Hematopoietic Stem/Progenitor Cells in Freshly Isolated Adult Human Bone Marrow Using an 8-Color Flow Cytometric Assay. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4045.4045 Silverchair:84245 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Characterization of Leukemias with ETV6-ABL1 Fusion The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.84.84 Silverchair:136590 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Characterization of Leukemias with ETV6-ABL1 Fusion The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.84.84 Silverchair:136590 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Characterization of Leukemias with ETV6-ABL1 Fusion The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.84.84 Silverchair:136590 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Characterization of Leukemias with ETV6-ABL1 Fusion The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.84.84 Silverchair:136590 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Characterization of Mast Cell Activation Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3683.3683 Silverchair:97034 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Characterization of Mast Cell Activation Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3683.3683 Silverchair:97034 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Characterization of Mast Cell Activation Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3683.3683 Silverchair:97034 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Characterization of Mast Cell Activation Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3683.3683 Silverchair:97034 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Characterization of optimal T Cell/Dendritic Cell (DC) Co-Culture Conditions for Ex Vivo Expansion of Antigen-Specific Human T Cells. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.3654.3654 Silverchair:127354 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Characterization of optimal T Cell/Dendritic Cell (DC) Co-Culture Conditions for Ex Vivo Expansion of Antigen-Specific Human T Cells. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.3654.3654 Silverchair:127354 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Characterization of optimal T Cell/Dendritic Cell (DC) Co-Culture Conditions for Ex Vivo Expansion of Antigen-Specific Human T Cells. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.3654.3654 Silverchair:127354 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Characterization of optimal T Cell/Dendritic Cell (DC) Co-Culture Conditions for Ex Vivo Expansion of Antigen-Specific Human T Cells. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.3654.3654 Silverchair:127354 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Characterization of the Rate, Predictors, and Thrombotic Complications of Thrombocytosis in Iron Deficiency Anemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122359 Silverchair:427145 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Characterization of the Rate, Predictors, and Thrombotic Complications of Thrombocytosis in Iron Deficiency Anemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122359 Silverchair:427145 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Characterization of the Rate, Predictors, and Thrombotic Complications of Thrombocytosis in Iron Deficiency Anemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122359 Silverchair:427145 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Characterization of the Rate, Predictors, and Thrombotic Complications of Thrombocytosis in Iron Deficiency Anemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122359 Silverchair:427145 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Characterization of Transforming NTRK2 and NTRK3 Mutations Identified in Leukemia Patient Samples The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1566.1566 Silverchair:91450 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Characterization of Transforming NTRK2 and NTRK3 Mutations Identified in Leukemia Patient Samples The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1566.1566 Silverchair:91450 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Characterization of Transforming NTRK2 and NTRK3 Mutations Identified in Leukemia Patient Samples The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1566.1566 Silverchair:91450 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Characterization of Transforming NTRK2 and NTRK3 Mutations Identified in Leukemia Patient Samples The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1566.1566 Silverchair:91450 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Characterization of WU-CART-007, an Allogeneic CD7-Targeted CAR-T Cell Therapy for T-Cell Malignancies" The American Society of Hematology American Society of Hematology 10.1182/blood-2021-153150 Silverchair:482367 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 "Characterization of WU-CART-007, an Allogeneic CD7-Targeted CAR-T Cell Therapy for T-Cell Malignancies" The American Society of Hematology American Society of Hematology 10.1182/blood-2021-153150 Silverchair:482367 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 "Characterization of WU-CART-007, an Allogeneic CD7-Targeted CAR-T Cell Therapy for T-Cell Malignancies" The American Society of Hematology American Society of Hematology 10.1182/blood-2021-153150 Silverchair:482367 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 "Characterization of WU-CART-007, an Allogeneic CD7-Targeted CAR-T Cell Therapy for T-Cell Malignancies" The American Society of Hematology American Society of Hematology 10.1182/blood-2021-153150 Silverchair:482367 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells The American Society of Hematology American Society of Hematology 10.1182/blood.2020005611 Silverchair:463464 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells The American Society of Hematology American Society of Hematology 10.1182/blood.2020005611 Silverchair:463464 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells The American Society of Hematology American Society of Hematology 10.1182/blood.2020005611 Silverchair:463464 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells The American Society of Hematology American Society of Hematology 10.1182/blood.2020005611 Silverchair:463464 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002355 Silverchair:463649 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002355 Silverchair:463649 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002355 Silverchair:463649 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002355 Silverchair:463649 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001336 Silverchair:454149 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001336 Silverchair:454149 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001336 Silverchair:454149 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001336 Silverchair:454149 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-07-102061 Silverchair:23555 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-07-102061 Silverchair:23555 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-07-102061 Silverchair:23555 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-07-102061 Silverchair:23555 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Chemokine up-regulation in SARS-coronavirus–infected, monocyte-derived human dendritic cells" The American Society of Hematology American Society of Hematology 10.1182/blood-2004-10-4166 Silverchair:21660 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 "Chemokine up-regulation in SARS-coronavirus–infected, monocyte-derived human dendritic cells" The American Society of Hematology American Society of Hematology 10.1182/blood-2004-10-4166 Silverchair:21660 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 "Chemokine up-regulation in SARS-coronavirus–infected, monocyte-derived human dendritic cells" The American Society of Hematology American Society of Hematology 10.1182/blood-2004-10-4166 Silverchair:21660 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Chemokine up-regulation in SARS-coronavirus–infected, monocyte-derived human dendritic cells" The American Society of Hematology American Society of Hematology 10.1182/blood-2004-10-4166 Silverchair:21660 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Chemokines CCL19 and CCL21 promote activation-induced cell death of antigen-responding T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-018101 Silverchair:23551 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Chemokines CCL19 and CCL21 promote activation-induced cell death of antigen-responding T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-018101 Silverchair:23551 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Chemokines CCL19 and CCL21 promote activation-induced cell death of antigen-responding T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-018101 Silverchair:23551 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Chemokines CCL19 and CCL21 promote activation-induced cell death of antigen-responding T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-018101 Silverchair:23551 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Chemosensitization of Drug and Rituximab-Resistant Daudi B-NHL Clones to Drug-Induced Apoptosis by the Proteasome Inhibitor NPI-0052. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.1521.1521 Silverchair:118938 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Chemosensitization of Drug and Rituximab-Resistant Daudi B-NHL Clones to Drug-Induced Apoptosis by the Proteasome Inhibitor NPI-0052. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.1521.1521 Silverchair:118938 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Chemosensitization of Drug and Rituximab-Resistant Daudi B-NHL Clones to Drug-Induced Apoptosis by the Proteasome Inhibitor NPI-0052. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.1521.1521 Silverchair:118938 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Chemosensitization of Drug and Rituximab-Resistant Daudi B-NHL Clones to Drug-Induced Apoptosis by the Proteasome Inhibitor NPI-0052. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.1521.1521 Silverchair:118938 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Chemotherapy Relative Dose Intensity, Overall Survival, and Hematologic Toxicity in Solid-Tumor Cancer Patients: A Literature Review and Meta-Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139279 Silverchair:473977 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Chemotherapy Relative Dose Intensity, Overall Survival, and Hematologic Toxicity in Solid-Tumor Cancer Patients: A Literature Review and Meta-Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139279 Silverchair:473977 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Chemotherapy Relative Dose Intensity, Overall Survival, and Hematologic Toxicity in Solid-Tumor Cancer Patients: A Literature Review and Meta-Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139279 Silverchair:473977 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Chemotherapy Relative Dose Intensity, Overall Survival, and Hematologic Toxicity in Solid-Tumor Cancer Patients: A Literature Review and Meta-Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139279 Silverchair:473977 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Chemotherapy-free frontline therapy for CLL: is it worth it? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000085 Silverchair:474279 Total_Item_Investigations 2 1 0 0 0 1 0 0 0 0 0 0 0 Chemotherapy-free frontline therapy for CLL: is it worth it? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000085 Silverchair:474279 Total_Item_Requests 2 1 0 0 0 1 0 0 0 0 0 0 0 Chemotherapy-free frontline therapy for CLL: is it worth it? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000085 Silverchair:474279 Unique_Item_Investigations 2 1 0 0 0 1 0 0 0 0 0 0 0 Chemotherapy-free frontline therapy for CLL: is it worth it? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000085 Silverchair:474279 Unique_Item_Requests 2 1 0 0 0 1 0 0 0 0 0 0 0 Chimeric Antigen Receptor Modified Memory-like (CAR-ML) NK Cells Exhibit Potent Responses to NK-Resistant Tumors The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127546 Silverchair:427189 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Chimeric Antigen Receptor Modified Memory-like (CAR-ML) NK Cells Exhibit Potent Responses to NK-Resistant Tumors The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127546 Silverchair:427189 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Chimeric Antigen Receptor Modified Memory-like (CAR-ML) NK Cells Exhibit Potent Responses to NK-Resistant Tumors The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127546 Silverchair:427189 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Chimeric Antigen Receptor Modified Memory-like (CAR-ML) NK Cells Exhibit Potent Responses to NK-Resistant Tumors The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127546 Silverchair:427189 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000133 Silverchair:474280 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000133 Silverchair:474280 Total_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000133 Silverchair:474280 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000133 Silverchair:474280 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004017 Silverchair:475240 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004017 Silverchair:475240 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004017 Silverchair:475240 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004017 Silverchair:475240 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Chimeric antigen receptor–T cells with cytokine neutralizing capacity American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001287 Silverchair:454299 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Chimeric antigen receptor–T cells with cytokine neutralizing capacity American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001287 Silverchair:454299 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Chimeric antigen receptor–T cells with cytokine neutralizing capacity American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001287 Silverchair:454299 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Chimeric antigen receptor–T cells with cytokine neutralizing capacity American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001287 Silverchair:454299 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 CHIP & HIPs: Clonal Hematopoiesis is Common in Hip Arthroplasty Patients and Associates with Autoimmune Disease The American Society of Hematology American Society of Hematology 10.1182/blood.2020010163 Silverchair:476225 Total_Item_Investigations 2 0 0 0 0 0 2 0 0 0 0 0 0 CHIP & HIPs: Clonal Hematopoiesis is Common in Hip Arthroplasty Patients and Associates with Autoimmune Disease The American Society of Hematology American Society of Hematology 10.1182/blood.2020010163 Silverchair:476225 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.529 Silverchair:20683 Total_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.529 Silverchair:20683 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.529 Silverchair:20683 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.529 Silverchair:20683 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Chromatin dynamics during the differentiation of long-term hematopoietic stem cells to multipotent progenitors American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2016003384 Silverchair:16184 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Chromatin dynamics during the differentiation of long-term hematopoietic stem cells to multipotent progenitors American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2016003384 Silverchair:16184 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Chromatin dynamics during the differentiation of long-term hematopoietic stem cells to multipotent progenitors American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2016003384 Silverchair:16184 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Chromatin dynamics during the differentiation of long-term hematopoietic stem cells to multipotent progenitors American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2016003384 Silverchair:16184 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Chromatin occupancy analysis reveals genome-wide GATA factor switching during hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2011-09-380634 Silverchair:29913 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Chromatin occupancy analysis reveals genome-wide GATA factor switching during hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2011-09-380634 Silverchair:29913 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Chromatin occupancy analysis reveals genome-wide GATA factor switching during hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2011-09-380634 Silverchair:29913 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Chromatin occupancy analysis reveals genome-wide GATA factor switching during hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2011-09-380634 Silverchair:29913 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Chromatin occupancy and epigenetic analysis reveal new insights into the function of the GATA1 N terminus in erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.2019001234 Silverchair:374957 Total_Item_Investigations 3 0 1 2 0 0 0 0 0 0 0 0 0 Chromatin occupancy and epigenetic analysis reveal new insights into the function of the GATA1 N terminus in erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.2019001234 Silverchair:374957 Total_Item_Requests 3 0 1 2 0 0 0 0 0 0 0 0 0 Chromatin occupancy and epigenetic analysis reveal new insights into the function of the GATA1 N terminus in erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.2019001234 Silverchair:374957 Unique_Item_Investigations 3 0 1 2 0 0 0 0 0 0 0 0 0 Chromatin occupancy and epigenetic analysis reveal new insights into the function of the GATA1 N terminus in erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.2019001234 Silverchair:374957 Unique_Item_Requests 3 0 1 2 0 0 0 0 0 0 0 0 0 Chromatin Organization By SATB1 Regulates HSP70 Induction in Early Erythropoiesis and Lost in Diamond Blackfan Anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119729 Silverchair:264252 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Chromatin Organization By SATB1 Regulates HSP70 Induction in Early Erythropoiesis and Lost in Diamond Blackfan Anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119729 Silverchair:264252 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Chromatin Organization By SATB1 Regulates HSP70 Induction in Early Erythropoiesis and Lost in Diamond Blackfan Anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119729 Silverchair:264252 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Chromatin Organization By SATB1 Regulates HSP70 Induction in Early Erythropoiesis and Lost in Diamond Blackfan Anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119729 Silverchair:264252 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Chromosomal Rearrangements Affecting ABL1 in T-Cell Acute Lymphoblastic Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.2894.2894 Silverchair:55371 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Chromosomal Rearrangements Affecting ABL1 in T-Cell Acute Lymphoblastic Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.2894.2894 Silverchair:55371 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Chromosomal Rearrangements Affecting ABL1 in T-Cell Acute Lymphoblastic Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.2894.2894 Silverchair:55371 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Chromosomal Rearrangements Affecting ABL1 in T-Cell Acute Lymphoblastic Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.2894.2894 Silverchair:55371 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001425 Silverchair:456034 Total_Item_Investigations 10 0 0 6 0 0 1 0 0 1 0 2 0 Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001425 Silverchair:456034 Total_Item_Requests 10 0 0 6 0 0 1 0 0 1 0 2 0 Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001425 Silverchair:456034 Unique_Item_Investigations 5 0 0 2 0 0 1 0 0 1 0 1 0 Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001425 Silverchair:456034 Unique_Item_Requests 5 0 0 2 0 0 1 0 0 1 0 1 0 "Chromosome Banding Analysis, FISH and RT-PCR Performed in Parallel in Hypereosinophilic Syndrome Establishes the Diagnosis of Chronic Eosinophilic Leukemia in 22% of Cases: A Study on 40 Patients." The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.2444.2444 Silverchair:54748 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Chromosome Banding Analysis, FISH and RT-PCR Performed in Parallel in Hypereosinophilic Syndrome Establishes the Diagnosis of Chronic Eosinophilic Leukemia in 22% of Cases: A Study on 40 Patients." The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.2444.2444 Silverchair:54748 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Chromosome Banding Analysis, FISH and RT-PCR Performed in Parallel in Hypereosinophilic Syndrome Establishes the Diagnosis of Chronic Eosinophilic Leukemia in 22% of Cases: A Study on 40 Patients." The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.2444.2444 Silverchair:54748 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Chromosome Banding Analysis, FISH and RT-PCR Performed in Parallel in Hypereosinophilic Syndrome Establishes the Diagnosis of Chronic Eosinophilic Leukemia in 22% of Cases: A Study on 40 Patients." The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.2444.2444 Silverchair:54748 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Chronic graft-versus-host disease: biological insights from preclinical and clinical studies The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-686618 Silverchair:35804 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Chronic graft-versus-host disease: biological insights from preclinical and clinical studies The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-686618 Silverchair:35804 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Chronic graft-versus-host disease: biological insights from preclinical and clinical studies The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-686618 Silverchair:35804 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Chronic graft-versus-host disease: biological insights from preclinical and clinical studies The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-686618 Silverchair:35804 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti–T-cell globulin ATG-Fresenius The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-329821 Silverchair:22322 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti–T-cell globulin ATG-Fresenius The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-329821 Silverchair:22322 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti–T-cell globulin ATG-Fresenius The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-329821 Silverchair:22322 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti–T-cell globulin ATG-Fresenius The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-329821 Silverchair:22322 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Chronic lymphocytic leukemia increases the pool of peripheral blood hematopoietic stem cells and skews differentiation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002863 Silverchair:474717 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Chronic lymphocytic leukemia increases the pool of peripheral blood hematopoietic stem cells and skews differentiation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002863 Silverchair:474717 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Chronic lymphocytic leukemia increases the pool of peripheral blood hematopoietic stem cells and skews differentiation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002863 Silverchair:474717 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Chronic lymphocytic leukemia increases the pool of peripheral blood hematopoietic stem cells and skews differentiation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002863 Silverchair:474717 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Chronic lymphocytic leukemia/small lymphocytic lymphoma American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter24 Silverchair:78057 No_License 2 0 1 0 0 0 0 0 1 0 0 0 0 Chronic lymphocytic leukemia/small lymphocytic lymphoma American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter24 Silverchair:78057 Total_Item_Investigations 2 0 1 0 0 0 0 0 1 0 0 0 0 Chronic lymphocytic leukemia/small lymphocytic lymphoma American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter24 Silverchair:78057 Unique_Item_Investigations 2 0 1 0 0 0 0 0 1 0 0 0 0 Chronic myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter17 Silverchair:76639 No_License 3 0 0 0 0 0 0 0 1 0 0 2 0 Chronic myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter17 Silverchair:76639 Total_Item_Investigations 6 0 0 0 0 0 0 1 1 2 0 2 0 Chronic myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter17 Silverchair:76639 Unique_Item_Investigations 5 0 0 0 0 0 0 1 1 2 0 1 0 Chronic myeloid leukemia: sequencing of TKI therapies The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.164 Silverchair:21062 Total_Item_Investigations 3 0 0 0 3 0 0 0 0 0 0 0 0 Chronic myeloid leukemia: sequencing of TKI therapies The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.164 Silverchair:21062 Total_Item_Requests 3 0 0 0 3 0 0 0 0 0 0 0 0 Chronic myeloid leukemia: sequencing of TKI therapies The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.164 Silverchair:21062 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Chronic myeloid leukemia: sequencing of TKI therapies The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.164 Silverchair:21062 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 "Chronic Myelomonocytic Leukemia in Qatar, Single Institute Experience" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134871 Silverchair:473519 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Chronic Myelomonocytic Leukemia in Qatar, Single Institute Experience" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134871 Silverchair:473519 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Chronic Myelomonocytic Leukemia in Qatar, Single Institute Experience" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134871 Silverchair:473519 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Chronic Myelomonocytic Leukemia in Qatar, Single Institute Experience" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134871 Silverchair:473519 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Chronic Myelomonocytic Leukemia With Preexisting Myelodysplastic Syndrome Or Myeloproliferative Neoplasm: Two Stages Of One Disease With Poor Prognosis The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.1342.1342 Silverchair:103303 Total_Item_Investigations 5 0 5 0 0 0 0 0 0 0 0 0 0 Chronic Myelomonocytic Leukemia With Preexisting Myelodysplastic Syndrome Or Myeloproliferative Neoplasm: Two Stages Of One Disease With Poor Prognosis The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.1342.1342 Silverchair:103303 Total_Item_Requests 4 0 4 0 0 0 0 0 0 0 0 0 0 Chronic Myelomonocytic Leukemia With Preexisting Myelodysplastic Syndrome Or Myeloproliferative Neoplasm: Two Stages Of One Disease With Poor Prognosis The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.1342.1342 Silverchair:103303 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Chronic Myelomonocytic Leukemia With Preexisting Myelodysplastic Syndrome Or Myeloproliferative Neoplasm: Two Stages Of One Disease With Poor Prognosis The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.1342.1342 Silverchair:103303 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Chronic thromboembolic pulmonary hypertension: anticoagulation and beyond The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000282 Silverchair:482970 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 0 2 Chronic thromboembolic pulmonary hypertension: anticoagulation and beyond The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000282 Silverchair:482970 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 0 2 Chronic thromboembolic pulmonary hypertension: anticoagulation and beyond The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000282 Silverchair:482970 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Chronic thromboembolic pulmonary hypertension: anticoagulation and beyond The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000282 Silverchair:482970 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 "Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants" The American Society of Hematology American Society of Hematology 10.1182/blood.2020007116 Silverchair:474177 Total_Item_Investigations 16 0 16 0 0 0 0 0 0 0 0 0 0 "Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants" The American Society of Hematology American Society of Hematology 10.1182/blood.2020007116 Silverchair:474177 Unique_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 "Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants" The American Society of Hematology American Society of Hematology 10.1182/blood.2020007116 Silverchair:474177 No_License 6 0 6 0 0 0 0 0 0 0 0 0 0 Ciraparantag: the next anticoagulant airbag? The American Society of Hematology American Society of Hematology 10.1182/blood.2020008801 Silverchair:474797 Total_Item_Investigations 5 0 5 0 0 0 0 0 0 0 0 0 0 Ciraparantag: the next anticoagulant airbag? The American Society of Hematology American Society of Hematology 10.1182/blood.2020008801 Silverchair:474797 Total_Item_Requests 5 0 5 0 0 0 0 0 0 0 0 0 0 Ciraparantag: the next anticoagulant airbag? The American Society of Hematology American Society of Hematology 10.1182/blood.2020008801 Silverchair:474797 Unique_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 Ciraparantag: the next anticoagulant airbag? The American Society of Hematology American Society of Hematology 10.1182/blood.2020008801 Silverchair:474797 Unique_Item_Requests 4 0 4 0 0 0 0 0 0 0 0 0 0 Circulating angioimmunoblastic T-cell lymphoma cells The American Society of Hematology American Society of Hematology 10.1182/blood.2020004944 Silverchair:454454 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Circulating angioimmunoblastic T-cell lymphoma cells The American Society of Hematology American Society of Hematology 10.1182/blood.2020004944 Silverchair:454454 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Circulating angioimmunoblastic T-cell lymphoma cells The American Society of Hematology American Society of Hematology 10.1182/blood.2020004944 Silverchair:454454 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Circulating angioimmunoblastic T-cell lymphoma cells The American Society of Hematology American Society of Hematology 10.1182/blood.2020004944 Silverchair:454454 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Circulating mitochondrial DNA is a pro-inflammatory DAMP in sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood.2020009063 Silverchair:475342 Total_Item_Investigations 5 0 0 5 0 0 0 0 0 0 0 0 0 Circulating mitochondrial DNA is a pro-inflammatory DAMP in sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood.2020009063 Silverchair:475342 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Circulating Plasminogen Activator Inhibitor-1 (PAI-1) Is Reduced By In Vivo Thrombin Generation and Subsequent Formation of Activated Protein C (APC) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124731 Silverchair:423057 Total_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Circulating Plasminogen Activator Inhibitor-1 (PAI-1) Is Reduced By In Vivo Thrombin Generation and Subsequent Formation of Activated Protein C (APC) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124731 Silverchair:423057 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Circulating Plasminogen Activator Inhibitor-1 (PAI-1) Is Reduced By In Vivo Thrombin Generation and Subsequent Formation of Activated Protein C (APC) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124731 Silverchair:423057 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Circulating Plasminogen Activator Inhibitor-1 (PAI-1) Is Reduced By In Vivo Thrombin Generation and Subsequent Formation of Activated Protein C (APC) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124731 Silverchair:423057 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 "Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141075 Silverchair:472579 Total_Item_Investigations 2 0 0 0 1 0 1 0 0 0 0 0 0 "Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141075 Silverchair:472579 Total_Item_Requests 2 0 0 0 1 0 1 0 0 0 0 0 0 "Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141075 Silverchair:472579 Unique_Item_Investigations 2 0 0 0 1 0 1 0 0 0 0 0 0 "Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141075 Silverchair:472579 Unique_Item_Requests 2 0 0 0 1 0 1 0 0 0 0 0 0 Classification and risk assessment in AML: integrating cytogenetics and molecular profiling The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.37 Silverchair:21134 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Classification and risk assessment in AML: integrating cytogenetics and molecular profiling The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.37 Silverchair:21134 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Classification and risk assessment in AML: integrating cytogenetics and molecular profiling The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.37 Silverchair:21134 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Classification and risk assessment in AML: integrating cytogenetics and molecular profiling The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.37 Silverchair:21134 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Clathrin-Mediated Endocytosis of Neutrophil Elastase and Cathepsin G by Lung Tumor Epithelial Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.3269.3269 Silverchair:84780 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Clathrin-Mediated Endocytosis of Neutrophil Elastase and Cathepsin G by Lung Tumor Epithelial Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.3269.3269 Silverchair:84780 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Clathrin-Mediated Endocytosis of Neutrophil Elastase and Cathepsin G by Lung Tumor Epithelial Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.3269.3269 Silverchair:84780 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Clathrin-Mediated Endocytosis of Neutrophil Elastase and Cathepsin G by Lung Tumor Epithelial Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.3269.3269 Silverchair:84780 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Clearance and Genetic Variability of Von Willebrand Factor Are Major Determinants of the Pharmacokinetic Behavior of Factor VIII Concentrates in the Treatment of Pediatric Hemophilia A The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.473.473 Silverchair:93895 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Clearance and Genetic Variability of Von Willebrand Factor Are Major Determinants of the Pharmacokinetic Behavior of Factor VIII Concentrates in the Treatment of Pediatric Hemophilia A The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.473.473 Silverchair:93895 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Clearance and Genetic Variability of Von Willebrand Factor Are Major Determinants of the Pharmacokinetic Behavior of Factor VIII Concentrates in the Treatment of Pediatric Hemophilia A The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.473.473 Silverchair:93895 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Clearance and Genetic Variability of Von Willebrand Factor Are Major Determinants of the Pharmacokinetic Behavior of Factor VIII Concentrates in the Treatment of Pediatric Hemophilia A The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.473.473 Silverchair:93895 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.2020006921 Silverchair:469716 No_License 1 0 0 1 0 0 0 0 0 0 0 0 0 CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.2020006921 Silverchair:469716 Total_Item_Investigations 8 0 2 4 0 2 0 0 0 0 0 0 0 CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.2020006921 Silverchair:469716 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.2020006921 Silverchair:469716 Unique_Item_Investigations 4 0 1 2 0 1 0 0 0 0 0 0 0 CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.2020006921 Silverchair:469716 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000644 Silverchair:381153 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000644 Silverchair:381153 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000644 Silverchair:381153 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000644 Silverchair:381153 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type The American Society of Hematology American Society of Hematology 10.1182/blood-2002-11-3496 Silverchair:17725 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type The American Society of Hematology American Society of Hematology 10.1182/blood-2002-11-3496 Silverchair:17725 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type The American Society of Hematology American Society of Hematology 10.1182/blood-2002-11-3496 Silverchair:17725 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type The American Society of Hematology American Society of Hematology 10.1182/blood-2002-11-3496 Silverchair:17725 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical and biological implications of driver mutations in myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-518886 Silverchair:32001 Total_Item_Investigations 6 0 0 0 6 0 0 0 0 0 0 0 0 Clinical and biological implications of driver mutations in myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-518886 Silverchair:32001 Total_Item_Requests 6 0 0 0 6 0 0 0 0 0 0 0 0 Clinical and biological implications of driver mutations in myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-518886 Silverchair:32001 Unique_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Clinical and biological implications of driver mutations in myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-518886 Silverchair:32001 Unique_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 "Clinical and Correlative Pilot Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRd – R) In High Risk Smoldering Multiple Myeloma Patients" The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.1939.1939 Silverchair:14845 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Clinical and Correlative Pilot Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRd – R) In High Risk Smoldering Multiple Myeloma Patients" The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.1939.1939 Silverchair:14845 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Clinical and Correlative Pilot Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRd – R) In High Risk Smoldering Multiple Myeloma Patients" The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.1939.1939 Silverchair:14845 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Clinical and Correlative Pilot Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRd – R) In High Risk Smoldering Multiple Myeloma Patients" The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.1939.1939 Silverchair:14845 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical and laboratory diagnosis of TTP: an integrated approach The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.530 Silverchair:277619 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Clinical and laboratory diagnosis of TTP: an integrated approach The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.530 Silverchair:277619 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Clinical and laboratory diagnosis of TTP: an integrated approach The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.530 Silverchair:277619 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Clinical and laboratory diagnosis of TTP: an integrated approach The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.530 Silverchair:277619 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003734 Silverchair:475453 Total_Item_Investigations 3 0 0 1 0 0 0 1 1 0 0 0 0 Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003734 Silverchair:475453 Total_Item_Requests 3 0 0 1 0 0 0 1 1 0 0 0 0 Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003734 Silverchair:475453 Unique_Item_Investigations 3 0 0 1 0 0 0 1 1 0 0 0 0 Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003734 Silverchair:475453 Unique_Item_Requests 3 0 0 1 0 0 0 1 1 0 0 0 0 Clinical and molecular response to interferon-a therapy in essential thrombocythemia patients with CALR mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-659060 Silverchair:34707 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Clinical and molecular response to interferon-a therapy in essential thrombocythemia patients with CALR mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-659060 Silverchair:34707 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Clinical and molecular response to interferon-a therapy in essential thrombocythemia patients with CALR mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-659060 Silverchair:34707 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Clinical and molecular response to interferon-a therapy in essential thrombocythemia patients with CALR mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-659060 Silverchair:34707 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002228 Silverchair:463336 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002228 Silverchair:463336 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002228 Silverchair:463336 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002228 Silverchair:463336 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125769 Silverchair:426973 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125769 Silverchair:426973 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125769 Silverchair:426973 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125769 Silverchair:426973 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-4149 Silverchair:109861 Total_Item_Investigations 15 3 2 3 1 3 0 0 0 0 2 0 1 Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-4149 Silverchair:109861 Total_Item_Requests 15 3 2 3 1 3 0 0 0 0 2 0 1 Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-4149 Silverchair:109861 Unique_Item_Investigations 7 1 1 1 1 1 0 0 0 0 1 0 1 Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-4149 Silverchair:109861 Unique_Item_Requests 7 1 1 1 1 1 0 0 0 0 1 0 1 "Clinical Benefit of Crenolanib, with or without Salvage Chemotherapy, in Multiply Relapsed, FLT3 Mutant AML Patients after Prior Treatment with Gilteritinib" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139898 Silverchair:470851 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Clinical Benefit of Crenolanib, with or without Salvage Chemotherapy, in Multiply Relapsed, FLT3 Mutant AML Patients after Prior Treatment with Gilteritinib" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139898 Silverchair:470851 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Clinical Benefit of Crenolanib, with or without Salvage Chemotherapy, in Multiply Relapsed, FLT3 Mutant AML Patients after Prior Treatment with Gilteritinib" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139898 Silverchair:470851 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Clinical Benefit of Crenolanib, with or without Salvage Chemotherapy, in Multiply Relapsed, FLT3 Mutant AML Patients after Prior Treatment with Gilteritinib" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139898 Silverchair:470851 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era The American Society of Hematology American Society of Hematology 10.1182/blood.2020005112 Silverchair:461623 Total_Item_Investigations 11 0 11 0 0 0 0 0 0 0 0 0 0 Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era The American Society of Hematology American Society of Hematology 10.1182/blood.2020005112 Silverchair:461623 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era The American Society of Hematology American Society of Hematology 10.1182/blood.2020005112 Silverchair:461623 No_License 5 0 5 0 0 0 0 0 0 0 0 0 0 "Clinical Characteristics and Outcomes of Splenic Infarction in Cancer Patients - a Retrospective, Single Center Report of 206 Cases" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136646 Silverchair:473270 Total_Item_Investigations 2 1 0 0 0 0 0 0 1 0 0 0 0 "Clinical Characteristics and Outcomes of Splenic Infarction in Cancer Patients - a Retrospective, Single Center Report of 206 Cases" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136646 Silverchair:473270 Total_Item_Requests 2 1 0 0 0 0 0 0 1 0 0 0 0 "Clinical Characteristics and Outcomes of Splenic Infarction in Cancer Patients - a Retrospective, Single Center Report of 206 Cases" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136646 Silverchair:473270 Unique_Item_Investigations 2 1 0 0 0 0 0 0 1 0 0 0 0 "Clinical Characteristics and Outcomes of Splenic Infarction in Cancer Patients - a Retrospective, Single Center Report of 206 Cases" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136646 Silverchair:473270 Unique_Item_Requests 2 1 0 0 0 0 0 0 1 0 0 0 0 "Clinical characteristics, management, and outcome of incidental pulmonary embolism in cancer patients" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001501 Silverchair:454413 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 "Clinical characteristics, management, and outcome of incidental pulmonary embolism in cancer patients" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001501 Silverchair:454413 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 "Clinical characteristics, management, and outcome of incidental pulmonary embolism in cancer patients" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001501 Silverchair:454413 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 "Clinical characteristics, management, and outcome of incidental pulmonary embolism in cancer patients" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001501 Silverchair:454413 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Clinical consequences of clonal hematopoiesis of indeterminate potential American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018020222 Silverchair:16124 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Clinical consequences of clonal hematopoiesis of indeterminate potential American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018020222 Silverchair:16124 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Clinical consequences of clonal hematopoiesis of indeterminate potential American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018020222 Silverchair:16124 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Clinical consequences of clonal hematopoiesis of indeterminate potential American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018020222 Silverchair:16124 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant The American Society of Hematology American Society of Hematology 10.1182/blood.2020009471 Silverchair:474389 Total_Item_Investigations 6 2 0 0 0 4 0 0 0 0 0 0 0 Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant The American Society of Hematology American Society of Hematology 10.1182/blood.2020009471 Silverchair:474389 Unique_Item_Investigations 3 1 0 0 0 2 0 0 0 0 0 0 0 Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002328 Silverchair:461283 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002328 Silverchair:461283 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002328 Silverchair:461283 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002328 Silverchair:461283 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.807.807 Silverchair:83400 Total_Item_Investigations 4 0 0 4 0 0 0 0 0 0 0 0 0 Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.807.807 Silverchair:83400 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.807.807 Silverchair:83400 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.807.807 Silverchair:83400 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Clinical efficacy of fecal occult blood test and colonoscopy for dasatinib-induced hemorrhagic colitis in CML patients The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-734947 Silverchair:35837 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical efficacy of fecal occult blood test and colonoscopy for dasatinib-induced hemorrhagic colitis in CML patients The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-734947 Silverchair:35837 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical efficacy of fecal occult blood test and colonoscopy for dasatinib-induced hemorrhagic colitis in CML patients The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-734947 Silverchair:35837 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical efficacy of fecal occult blood test and colonoscopy for dasatinib-induced hemorrhagic colitis in CML patients The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-734947 Silverchair:35837 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set The American Society of Hematology American Society of Hematology 10.1182/blood.2020008150 Silverchair:474113 Total_Item_Investigations 5 1 2 1 0 0 0 0 0 0 1 0 0 Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set The American Society of Hematology American Society of Hematology 10.1182/blood.2020008150 Silverchair:474113 Total_Item_Requests 5 1 2 1 0 0 0 0 0 0 1 0 0 Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set The American Society of Hematology American Society of Hematology 10.1182/blood.2020008150 Silverchair:474113 Unique_Item_Investigations 4 1 1 1 0 0 0 0 0 0 1 0 0 Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set The American Society of Hematology American Society of Hematology 10.1182/blood.2020008150 Silverchair:474113 Unique_Item_Requests 4 1 1 1 0 0 0 0 0 0 1 0 0 "Clinical Features, Treatment, and Survival of Secondary Central Nervous System Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5389.5389 Silverchair:92252 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Clinical Features, Treatment, and Survival of Secondary Central Nervous System Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5389.5389 Silverchair:92252 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Clinical Features, Treatment, and Survival of Secondary Central Nervous System Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5389.5389 Silverchair:92252 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Clinical Features, Treatment, and Survival of Secondary Central Nervous System Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5389.5389 Silverchair:92252 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical hematopoietic cell transplantation and adoptive cell therapy American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter15 Silverchair:76107 No_License 10 0 1 8 0 0 0 0 1 0 0 0 0 Clinical hematopoietic cell transplantation and adoptive cell therapy American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter15 Silverchair:76107 Total_Item_Investigations 11 0 1 9 0 0 0 0 1 0 0 0 0 Clinical hematopoietic cell transplantation and adoptive cell therapy American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter15 Silverchair:76107 Unique_Item_Investigations 7 0 1 5 0 0 0 0 1 0 0 0 0 Clinical Impact of Iron Overload on Morbidity in Patients with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4787.4787 Silverchair:72168 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Clinical Impact of Iron Overload on Morbidity in Patients with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4787.4787 Silverchair:72168 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Clinical Impact of Iron Overload on Morbidity in Patients with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4787.4787 Silverchair:72168 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Clinical Impact of Iron Overload on Morbidity in Patients with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4787.4787 Silverchair:72168 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005455 Silverchair:477023 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005455 Silverchair:477023 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005455 Silverchair:477023 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005455 Silverchair:477023 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-724161 Silverchair:35581 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 0 2 Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-724161 Silverchair:35581 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 0 2 Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-724161 Silverchair:35581 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-724161 Silverchair:35581 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Clinical insights into the origins of thrombosis in myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.2020008043 Silverchair:474275 No_License 3 0 0 2 0 0 0 0 0 1 0 0 0 Clinical insights into the origins of thrombosis in myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.2020008043 Silverchair:474275 Total_Item_Investigations 7 0 0 4 0 0 0 0 0 3 0 0 0 Clinical insights into the origins of thrombosis in myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.2020008043 Silverchair:474275 Unique_Item_Investigations 2 0 0 1 0 0 0 0 0 1 0 0 0 Clinical Next Generation Sequencing to Identify Novel Platelet Disorders The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.SCI-38.SCI-38 Silverchair:99136 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Clinical Next Generation Sequencing to Identify Novel Platelet Disorders The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.SCI-38.SCI-38 Silverchair:99136 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Clinical Next Generation Sequencing to Identify Novel Platelet Disorders The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.SCI-38.SCI-38 Silverchair:99136 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Clinical Next Generation Sequencing to Identify Novel Platelet Disorders The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.SCI-38.SCI-38 Silverchair:99136 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136395 Silverchair:469986 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136395 Silverchair:469986 Total_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136395 Silverchair:469986 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136395 Silverchair:469986 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001779 Silverchair:456022 Total_Item_Investigations 8 2 2 1 0 0 1 0 0 0 0 2 0 Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001779 Silverchair:456022 Total_Item_Requests 7 1 2 1 0 0 1 0 0 0 0 2 0 Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001779 Silverchair:456022 Unique_Item_Investigations 5 1 1 1 0 0 1 0 0 0 0 1 0 Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001779 Silverchair:456022 Unique_Item_Requests 5 1 1 1 0 0 1 0 0 0 0 1 0 Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127162 Silverchair:424839 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127162 Silverchair:424839 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127162 Silverchair:424839 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127162 Silverchair:424839 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003456 Silverchair:474881 Total_Item_Investigations 4 2 1 1 0 0 0 0 0 0 0 0 0 Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003456 Silverchair:474881 Total_Item_Requests 4 2 1 1 0 0 0 0 0 0 0 0 0 Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003456 Silverchair:474881 Unique_Item_Investigations 3 1 1 1 0 0 0 0 0 0 0 0 0 Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003456 Silverchair:474881 Unique_Item_Requests 3 1 1 1 0 0 0 0 0 0 0 0 0 "Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-12-893396 Silverchair:273855 Total_Item_Investigations 7 7 0 0 0 0 0 0 0 0 0 0 0 "Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-12-893396 Silverchair:273855 Total_Item_Requests 7 7 0 0 0 0 0 0 0 0 0 0 0 "Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-12-893396 Silverchair:273855 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-12-893396 Silverchair:273855 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia The American Society of Hematology American Society of Hematology 10.1182/blood-2006-12-064287 Silverchair:131983 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia The American Society of Hematology American Society of Hematology 10.1182/blood-2006-12-064287 Silverchair:131983 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia The American Society of Hematology American Society of Hematology 10.1182/blood-2006-12-064287 Silverchair:131983 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia The American Society of Hematology American Society of Hematology 10.1182/blood-2006-12-064287 Silverchair:131983 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2012-06-435503 Silverchair:30988 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2012-06-435503 Silverchair:30988 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2012-06-435503 Silverchair:30988 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2012-06-435503 Silverchair:30988 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 "Clinical Relevance of Clonal Hematopoiesis in the Oldest-Old Population: Analysis of the ""Health and Anemia"" Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114717 Silverchair:266180 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Clinical Relevance of Clonal Hematopoiesis in the Oldest-Old Population: Analysis of the ""Health and Anemia"" Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114717 Silverchair:266180 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Clinical Relevance of Clonal Hematopoiesis in the Oldest-Old Population: Analysis of the ""Health and Anemia"" Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114717 Silverchair:266180 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Clinical Relevance of Clonal Hematopoiesis in the Oldest-Old Population: Analysis of the ""Health and Anemia"" Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114717 Silverchair:266180 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency) The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-298372 Silverchair:28326 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency) The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-298372 Silverchair:28326 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency) The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-298372 Silverchair:28326 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency) The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-298372 Silverchair:28326 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase–deficient children receiving dapsone The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-416032 Silverchair:30568 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase–deficient children receiving dapsone The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-416032 Silverchair:30568 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase–deficient children receiving dapsone The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-416032 Silverchair:30568 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase–deficient children receiving dapsone The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-416032 Silverchair:30568 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-810796 Silverchair:6537 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-810796 Silverchair:6537 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-810796 Silverchair:6537 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-810796 Silverchair:6537 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Clinical updates in adult immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-754119 Silverchair:36293 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Clinical updates in adult immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-754119 Silverchair:36293 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Clinical updates in adult immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-754119 Silverchair:36293 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Clinical updates in adult immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-754119 Silverchair:36293 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-515239 Silverchair:32158 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 "Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-515239 Silverchair:32158 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 "Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-515239 Silverchair:32158 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-515239 Silverchair:32158 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-291328 Silverchair:28116 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-291328 Silverchair:28116 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-291328 Silverchair:28116 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-291328 Silverchair:28116 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000090 Silverchair:246784 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000090 Silverchair:246784 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000090 Silverchair:246784 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000090 Silverchair:246784 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 CLL dedifferentiation to clonally related myeloid cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002726 Silverchair:474599 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 CLL dedifferentiation to clonally related myeloid cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002726 Silverchair:474599 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 CLL dedifferentiation to clonally related myeloid cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002726 Silverchair:474599 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 CLL dedifferentiation to clonally related myeloid cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002726 Silverchair:474599 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 CLL-IPI in MBL and CLL The American Society of Hematology American Society of Hematology 10.1182/blood.2021012825 Silverchair:476357 Total_Item_Investigations 2 0 0 0 0 0 0 0 2 0 0 0 0 CLL-IPI in MBL and CLL The American Society of Hematology American Society of Hematology 10.1182/blood.2021012825 Silverchair:476357 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 CLL-IPI in MBL and CLL The American Society of Hematology American Society of Hematology 10.1182/blood.2021012825 Silverchair:476357 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 CLL-IPI in MBL and CLL The American Society of Hematology American Society of Hematology 10.1182/blood.2021012825 Silverchair:476357 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Clonal competition with alternating dominance in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-405985 Silverchair:30261 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Clonal competition with alternating dominance in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-405985 Silverchair:30261 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Clonal competition with alternating dominance in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-405985 Silverchair:30261 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Clonal competition with alternating dominance in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-405985 Silverchair:30261 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126978 Silverchair:425725 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126978 Silverchair:425725 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126978 Silverchair:425725 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126978 Silverchair:425725 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-537167 Silverchair:32472 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-537167 Silverchair:32472 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-537167 Silverchair:32472 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-537167 Silverchair:32472 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin The American Society of Hematology American Society of Hematology 10.1182/blood.2020007626 Silverchair:475246 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin The American Society of Hematology American Society of Hematology 10.1182/blood.2020007626 Silverchair:475246 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Clonal Hematopoiesis and Genetic Mutations in Individual Patients with Acquired Bone Marrow Failure Diseases The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125357 Silverchair:426954 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Clonal Hematopoiesis and Genetic Mutations in Individual Patients with Acquired Bone Marrow Failure Diseases The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125357 Silverchair:426954 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Clonal Hematopoiesis and Genetic Mutations in Individual Patients with Acquired Bone Marrow Failure Diseases The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125357 Silverchair:426954 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Clonal Hematopoiesis and Genetic Mutations in Individual Patients with Acquired Bone Marrow Failure Diseases The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125357 Silverchair:426954 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Clonal hematopoiesis and nonhematologic disorders The American Society of Hematology American Society of Hematology 10.1182/blood.2019000989 Silverchair:461661 No_License 2 0 0 2 0 0 0 0 0 0 0 0 0 Clonal hematopoiesis and nonhematologic disorders The American Society of Hematology American Society of Hematology 10.1182/blood.2019000989 Silverchair:461661 Total_Item_Investigations 10 5 0 5 0 0 0 0 0 0 0 0 0 Clonal hematopoiesis and nonhematologic disorders The American Society of Hematology American Society of Hematology 10.1182/blood.2019000989 Silverchair:461661 Total_Item_Requests 5 5 0 0 0 0 0 0 0 0 0 0 0 Clonal hematopoiesis and nonhematologic disorders The American Society of Hematology American Society of Hematology 10.1182/blood.2019000989 Silverchair:461661 Unique_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 Clonal hematopoiesis and nonhematologic disorders The American Society of Hematology American Society of Hematology 10.1182/blood.2019000989 Silverchair:461661 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-631747 Silverchair:34336 Total_Item_Investigations 7 4 0 2 0 0 0 0 0 0 0 1 0 Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-631747 Silverchair:34336 Total_Item_Requests 5 2 0 2 0 0 0 0 0 0 0 1 0 Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-631747 Silverchair:34336 Unique_Item_Investigations 4 2 0 1 0 0 0 0 0 0 0 1 0 Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-631747 Silverchair:34336 Unique_Item_Requests 4 2 0 1 0 0 0 0 0 0 0 1 0 Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post–autologous stem cell transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001157 Silverchair:452640 Total_Item_Investigations 3 2 0 0 1 0 0 0 0 0 0 0 0 Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post–autologous stem cell transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001157 Silverchair:452640 Total_Item_Requests 3 2 0 0 1 0 0 0 0 0 0 0 0 Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post–autologous stem cell transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001157 Silverchair:452640 Unique_Item_Investigations 2 1 0 0 1 0 0 0 0 0 0 0 0 Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post–autologous stem cell transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001157 Silverchair:452640 Unique_Item_Requests 2 1 0 0 1 0 0 0 0 0 0 0 0 "Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly" The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-769869 Silverchair:36791 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly" The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-769869 Silverchair:36791 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly" The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-769869 Silverchair:36791 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly" The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-769869 Silverchair:36791 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Clonal hematopoiesis: a “CHIP” off the old block The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-644690 Silverchair:34333 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Clonal hematopoiesis: a “CHIP” off the old block The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-644690 Silverchair:34333 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Clonal hematopoiesis: a “CHIP” off the old block The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-644690 Silverchair:34333 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Clonal hematopoiesis: a “CHIP” off the old block The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-644690 Silverchair:34333 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Clonal heterogeneity in mycosis fungoides and its relationship to clinical course The American Society of Hematology American Society of Hematology 10.1182/blood.V100.9.3369 Silverchair:16369 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Clonal heterogeneity in mycosis fungoides and its relationship to clinical course The American Society of Hematology American Society of Hematology 10.1182/blood.V100.9.3369 Silverchair:16369 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Clonal heterogeneity in mycosis fungoides and its relationship to clinical course The American Society of Hematology American Society of Hematology 10.1182/blood.V100.9.3369 Silverchair:16369 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Clonal heterogeneity in mycosis fungoides and its relationship to clinical course The American Society of Hematology American Society of Hematology 10.1182/blood.V100.9.3369 Silverchair:16369 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Clonal Selection of Mutant HSC in MPN: “What Do I Know?” American Society of Hematology American Society of Hematology Silverchair:474720 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Clonal Selection of Mutant HSC in MPN: “What Do I Know?” American Society of Hematology American Society of Hematology Silverchair:474720 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Clonal Selection of Mutant HSC in MPN: “What Do I Know?” American Society of Hematology American Society of Hematology Silverchair:474720 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Clonal Selection of Mutant HSC in MPN: “What Do I Know?” American Society of Hematology American Society of Hematology Silverchair:474720 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15 The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-552174 Silverchair:32994 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15 The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-552174 Silverchair:32994 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15 The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-552174 Silverchair:32994 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15 The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-552174 Silverchair:32994 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 CML Patients with Primary Resistance or Suboptimal Response to TKI Therapy Have Variants in Genes Affecting Drug Absorption and Metabolism The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3071.3071 Silverchair:113716 Total_Item_Investigations 6 0 0 0 0 0 6 0 0 0 0 0 0 CML Patients with Primary Resistance or Suboptimal Response to TKI Therapy Have Variants in Genes Affecting Drug Absorption and Metabolism The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3071.3071 Silverchair:113716 Total_Item_Requests 6 0 0 0 0 0 6 0 0 0 0 0 0 CML Patients with Primary Resistance or Suboptimal Response to TKI Therapy Have Variants in Genes Affecting Drug Absorption and Metabolism The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3071.3071 Silverchair:113716 Unique_Item_Investigations 2 0 0 0 0 0 2 0 0 0 0 0 0 CML Patients with Primary Resistance or Suboptimal Response to TKI Therapy Have Variants in Genes Affecting Drug Absorption and Metabolism The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3071.3071 Silverchair:113716 Unique_Item_Requests 2 0 0 0 0 0 2 0 0 0 0 0 0 CML Shows Characteristic Pattern by Flow Cytometry Analysis of Peripheral Blood The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4430.4430 Silverchair:86743 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 CML Shows Characteristic Pattern by Flow Cytometry Analysis of Peripheral Blood The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4430.4430 Silverchair:86743 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 CML Shows Characteristic Pattern by Flow Cytometry Analysis of Peripheral Blood The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4430.4430 Silverchair:86743 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 CML Shows Characteristic Pattern by Flow Cytometry Analysis of Peripheral Blood The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4430.4430 Silverchair:86743 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 CML-T1: a cell line derived from T-lymphocyte acute phase of chronic myelogenous leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V74.4.1381.1381 Silverchair:166803 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 CML-T1: a cell line derived from T-lymphocyte acute phase of chronic myelogenous leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V74.4.1381.1381 Silverchair:166803 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 CMV exposure drives long-term CD57+ CD4 memory T cell inflation following allogeneic stem cell transplant The American Society of Hematology American Society of Hematology 10.1182/blood.2020009492 Silverchair:476063 Total_Item_Investigations 2 0 0 0 0 0 0 2 0 0 0 0 0 CMV exposure drives long-term CD57+ CD4 memory T cell inflation following allogeneic stem cell transplant The American Society of Hematology American Society of Hematology 10.1182/blood.2020009492 Silverchair:476063 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 c-Myc is a target of RNA-binding motif protein 15 in the regulation of adult hematopoietic stem cell and megakaryocyte development The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-197921 Silverchair:25774 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 c-Myc is a target of RNA-binding motif protein 15 in the regulation of adult hematopoietic stem cell and megakaryocyte development The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-197921 Silverchair:25774 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 c-Myc is a target of RNA-binding motif protein 15 in the regulation of adult hematopoietic stem cell and megakaryocyte development The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-197921 Silverchair:25774 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 c-Myc is a target of RNA-binding motif protein 15 in the regulation of adult hematopoietic stem cell and megakaryocyte development The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-197921 Silverchair:25774 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) The American Society of Hematology American Society of Hematology 10.1182/blood-2008-10-182253 Silverchair:25572 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) The American Society of Hematology American Society of Hematology 10.1182/blood-2008-10-182253 Silverchair:25572 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) The American Society of Hematology American Society of Hematology 10.1182/blood-2008-10-182253 Silverchair:25572 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) The American Society of Hematology American Society of Hematology 10.1182/blood-2008-10-182253 Silverchair:25572 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-294108 Silverchair:19529 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-294108 Silverchair:19529 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-294108 Silverchair:19529 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-294108 Silverchair:19529 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134798 Silverchair:470236 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134798 Silverchair:470236 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134798 Silverchair:470236 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134798 Silverchair:470236 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 CNS Prophylaxis in Diffuse Large B-Cell Lymphoma & Its Outcomes- an Institutional Review The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131483 Silverchair:425105 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 CNS Prophylaxis in Diffuse Large B-Cell Lymphoma & Its Outcomes- an Institutional Review The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131483 Silverchair:425105 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 CNS Prophylaxis in Diffuse Large B-Cell Lymphoma & Its Outcomes- an Institutional Review The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131483 Silverchair:425105 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 CNS Prophylaxis in Diffuse Large B-Cell Lymphoma & Its Outcomes- an Institutional Review The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131483 Silverchair:425105 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Coactivation of NF-κB and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion The American Society of Hematology American Society of Hematology 10.1182/blood.2019001438 Silverchair:381161 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Coactivation of NF-κB and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion The American Society of Hematology American Society of Hematology 10.1182/blood.2019001438 Silverchair:381161 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Coactivation of NF-κB and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion The American Society of Hematology American Society of Hematology 10.1182/blood.2019001438 Silverchair:381161 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Coactivation of NF-κB and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion The American Society of Hematology American Society of Hematology 10.1182/blood.2019001438 Silverchair:381161 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Coagulation Factor VIII Is Synthesized In Endothelial Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.26.26 Silverchair:83242 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Coagulation Factor VIII Is Synthesized In Endothelial Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.26.26 Silverchair:83242 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Coagulation Factor VIII Is Synthesized In Endothelial Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.26.26 Silverchair:83242 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Coagulation Factor VIII Is Synthesized In Endothelial Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.26.26 Silverchair:83242 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Coagulation factor XII in thrombosis and inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-569111 Silverchair:36747 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Coagulation factor XII in thrombosis and inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-569111 Silverchair:36747 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Coagulation factor XII in thrombosis and inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-569111 Silverchair:36747 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Coagulation factor XII in thrombosis and inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-569111 Silverchair:36747 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-301523 Silverchair:20489 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-301523 Silverchair:20489 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-301523 Silverchair:20489 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-301523 Silverchair:20489 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Coagulation-Related Effect of Bortezomib Treatment in Patients with Relapsed or Refractory Multiple Myeloma. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.2733.2733 Silverchair:74544 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Coagulation-Related Effect of Bortezomib Treatment in Patients with Relapsed or Refractory Multiple Myeloma. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.2733.2733 Silverchair:74544 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Coagulation-Related Effect of Bortezomib Treatment in Patients with Relapsed or Refractory Multiple Myeloma. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.2733.2733 Silverchair:74544 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Coagulation-Related Effect of Bortezomib Treatment in Patients with Relapsed or Refractory Multiple Myeloma. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.2733.2733 Silverchair:74544 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Coagulopathy in liver disease: a balancing act The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.243 Silverchair:20682 Total_Item_Investigations 7 3 0 3 0 0 0 0 1 0 0 0 0 Coagulopathy in liver disease: a balancing act The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.243 Silverchair:20682 Total_Item_Requests 7 3 0 3 0 0 0 0 1 0 0 0 0 Coagulopathy in liver disease: a balancing act The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.243 Silverchair:20682 Unique_Item_Investigations 5 2 0 2 0 0 0 0 1 0 0 0 0 Coagulopathy in liver disease: a balancing act The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.243 Silverchair:20682 Unique_Item_Requests 5 2 0 2 0 0 0 0 1 0 0 0 0 Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing The American Society of Hematology American Society of Hematology 10.1182/blood.2019002385 Silverchair:452635 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing The American Society of Hematology American Society of Hematology 10.1182/blood.2019002385 Silverchair:452635 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing The American Society of Hematology American Society of Hematology 10.1182/blood.2019002385 Silverchair:452635 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing The American Society of Hematology American Society of Hematology 10.1182/blood.2019002385 Silverchair:452635 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Coexistent BCR-ABL1 and JAK2 V617F: converting CML dwarves to ET staghorns with imatinib therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-585141 Silverchair:33434 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Coexistent BCR-ABL1 and JAK2 V617F: converting CML dwarves to ET staghorns with imatinib therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-585141 Silverchair:33434 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Coexistent BCR-ABL1 and JAK2 V617F: converting CML dwarves to ET staghorns with imatinib therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-585141 Silverchair:33434 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Coexistent BCR-ABL1 and JAK2 V617F: converting CML dwarves to ET staghorns with imatinib therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-585141 Silverchair:33434 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Coinheritance of Gilbert Syndrome Increases the Risk for Developing Gallstones in Patients With Hereditary SpherocytosisPresented in part at the 40th Annual Meeting of the American Society of Hematology, Miami Beach, FL, December 4-8, 1998 and published in Blood 92:470a, 1998 (abstr, suppl 1) ." The American Society of Hematology American Society of Hematology 10.1182/blood.V94.7.2259.419k42_2259_2262 Silverchair:125485 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 "Coinheritance of Gilbert Syndrome Increases the Risk for Developing Gallstones in Patients With Hereditary SpherocytosisPresented in part at the 40th Annual Meeting of the American Society of Hematology, Miami Beach, FL, December 4-8, 1998 and published in Blood 92:470a, 1998 (abstr, suppl 1) ." The American Society of Hematology American Society of Hematology 10.1182/blood.V94.7.2259.419k42_2259_2262 Silverchair:125485 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Coinheritance of Gilbert Syndrome Increases the Risk for Developing Gallstones in Patients With Hereditary SpherocytosisPresented in part at the 40th Annual Meeting of the American Society of Hematology, Miami Beach, FL, December 4-8, 1998 and published in Blood 92:470a, 1998 (abstr, suppl 1) ." The American Society of Hematology American Society of Hematology 10.1182/blood.V94.7.2259.419k42_2259_2262 Silverchair:125485 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Coinheritance of Gilbert Syndrome Increases the Risk for Developing Gallstones in Patients With Hereditary SpherocytosisPresented in part at the 40th Annual Meeting of the American Society of Hematology, Miami Beach, FL, December 4-8, 1998 and published in Blood 92:470a, 1998 (abstr, suppl 1) ." The American Society of Hematology American Society of Hematology 10.1182/blood.V94.7.2259.419k42_2259_2262 Silverchair:125485 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001435 Silverchair:461055 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 "Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001435 Silverchair:461055 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 "Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001435 Silverchair:461055 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001435 Silverchair:461055 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Co-Inhibition of IL-2, IL-9 and IL-15 By the Novel Immunomodulator, Bnz-1, Provides Clinical Efficacy in Patients with Refractory Cutaneous T Cell Lymphoma in a Phase 1/2 Clinical Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143135 Silverchair:470121 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Co-Inhibition of IL-2, IL-9 and IL-15 By the Novel Immunomodulator, Bnz-1, Provides Clinical Efficacy in Patients with Refractory Cutaneous T Cell Lymphoma in a Phase 1/2 Clinical Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143135 Silverchair:470121 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Co-Inhibition of IL-2, IL-9 and IL-15 By the Novel Immunomodulator, Bnz-1, Provides Clinical Efficacy in Patients with Refractory Cutaneous T Cell Lymphoma in a Phase 1/2 Clinical Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143135 Silverchair:470121 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Co-Inhibition of IL-2, IL-9 and IL-15 By the Novel Immunomodulator, Bnz-1, Provides Clinical Efficacy in Patients with Refractory Cutaneous T Cell Lymphoma in a Phase 1/2 Clinical Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143135 Silverchair:470121 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Cold agglutinin disease The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-474437 Silverchair:32390 Total_Item_Investigations 3 1 0 1 0 0 1 0 0 0 0 0 0 Cold agglutinin disease The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-474437 Silverchair:32390 Total_Item_Requests 3 1 0 1 0 0 1 0 0 0 0 0 0 Cold agglutinin disease The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-474437 Silverchair:32390 Unique_Item_Investigations 3 1 0 1 0 0 1 0 0 0 0 0 0 Cold agglutinin disease The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-474437 Silverchair:32390 Unique_Item_Requests 3 1 0 1 0 0 1 0 0 0 0 0 0 Colesevelam Hydrochloride for the Treatment of Lenalidomide Induced Diarrhea The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5779.5779 Silverchair:101143 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Colesevelam Hydrochloride for the Treatment of Lenalidomide Induced Diarrhea The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5779.5779 Silverchair:101143 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Colesevelam Hydrochloride for the Treatment of Lenalidomide Induced Diarrhea The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5779.5779 Silverchair:101143 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Colesevelam Hydrochloride for the Treatment of Lenalidomide Induced Diarrhea The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5779.5779 Silverchair:101143 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Collection and Processing of Bone Marrow at 3% Oxygen Significantly Alters the Manifestation of Aged Mouse Hematopoietic Stem Cell Phenotype The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128642 Silverchair:426714 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Collection and Processing of Bone Marrow at 3% Oxygen Significantly Alters the Manifestation of Aged Mouse Hematopoietic Stem Cell Phenotype The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128642 Silverchair:426714 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Collection and Processing of Bone Marrow at 3% Oxygen Significantly Alters the Manifestation of Aged Mouse Hematopoietic Stem Cell Phenotype The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128642 Silverchair:426714 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Collection and Processing of Bone Marrow at 3% Oxygen Significantly Alters the Manifestation of Aged Mouse Hematopoietic Stem Cell Phenotype The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128642 Silverchair:426714 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131515 Silverchair:427640 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131515 Silverchair:427640 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131515 Silverchair:427640 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131515 Silverchair:427640 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Combination of a Cyclophosphamide-Total Body Irradiation Conditioning Regimen and Tacrolimus Plus Mycophenolate Mofetil for Gvhd Prophylaxis Is Associated with Higher HHV-6 Encephalitis Incidence after Cord Blood Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125209 Silverchair:428004 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Combination of a Cyclophosphamide-Total Body Irradiation Conditioning Regimen and Tacrolimus Plus Mycophenolate Mofetil for Gvhd Prophylaxis Is Associated with Higher HHV-6 Encephalitis Incidence after Cord Blood Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125209 Silverchair:428004 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Combination of a Cyclophosphamide-Total Body Irradiation Conditioning Regimen and Tacrolimus Plus Mycophenolate Mofetil for Gvhd Prophylaxis Is Associated with Higher HHV-6 Encephalitis Incidence after Cord Blood Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125209 Silverchair:428004 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Combination of a Cyclophosphamide-Total Body Irradiation Conditioning Regimen and Tacrolimus Plus Mycophenolate Mofetil for Gvhd Prophylaxis Is Associated with Higher HHV-6 Encephalitis Incidence after Cord Blood Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125209 Silverchair:428004 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Combination of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor T Cells for Relapsed and Refractory Diffuse Larger B Cell Lymphoma: An Open-Label, Single-Arm, Phase Ⅰ/Ⅱ Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127640 Silverchair:427301 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "Combination of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor T Cells for Relapsed and Refractory Diffuse Larger B Cell Lymphoma: An Open-Label, Single-Arm, Phase Ⅰ/Ⅱ Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127640 Silverchair:427301 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "Combination of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor T Cells for Relapsed and Refractory Diffuse Larger B Cell Lymphoma: An Open-Label, Single-Arm, Phase Ⅰ/Ⅱ Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127640 Silverchair:427301 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Combination of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor T Cells for Relapsed and Refractory Diffuse Larger B Cell Lymphoma: An Open-Label, Single-Arm, Phase Ⅰ/Ⅱ Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127640 Silverchair:427301 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Combination of Camidanlumab Tesirine, a CD25-Targeted ADC, with Gemcitabine Elicits Synergistic Anti-Tumor Activity in Preclinical Tumor Models" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137004 Silverchair:470946 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Combination of Camidanlumab Tesirine, a CD25-Targeted ADC, with Gemcitabine Elicits Synergistic Anti-Tumor Activity in Preclinical Tumor Models" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137004 Silverchair:470946 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Combination of Camidanlumab Tesirine, a CD25-Targeted ADC, with Gemcitabine Elicits Synergistic Anti-Tumor Activity in Preclinical Tumor Models" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137004 Silverchair:470946 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Combination of Camidanlumab Tesirine, a CD25-Targeted ADC, with Gemcitabine Elicits Synergistic Anti-Tumor Activity in Preclinical Tumor Models" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137004 Silverchair:470946 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Combination of the MEK Inhibitor Trametinib and Pyrvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123418 Silverchair:423184 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Combination of the MEK Inhibitor Trametinib and Pyrvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123418 Silverchair:423184 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Combination of the MEK Inhibitor Trametinib and Pyrvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123418 Silverchair:423184 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Combination of the MEK Inhibitor Trametinib and Pyrvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123418 Silverchair:423184 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-120170 Silverchair:264326 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-120170 Silverchair:264326 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-120170 Silverchair:264326 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-120170 Silverchair:264326 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Combined effects of plasma von Willebrand factor and platelet measures on the risk of incident venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood.2021011494 Silverchair:476238 Total_Item_Investigations 2 0 0 0 0 0 1 0 0 0 0 0 1 Combined effects of plasma von Willebrand factor and platelet measures on the risk of incident venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood.2021011494 Silverchair:476238 Unique_Item_Investigations 2 0 0 0 0 0 1 0 0 0 0 0 1 Combined effects of plasma von Willebrand factor and platelet measures on the risk of incident venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood.2021011494 Silverchair:476238 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Combined effects of plasma von Willebrand factor and platelet measures on the risk of incident venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood.2021011494 Silverchair:476238 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Combined Modality Low-Dose Radiation Therapy (2 Gy x 2) and Single-Agent Rituximab Immunotherapy in the Treatment of Indolent Non-Hodgkin Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131246 Silverchair:425157 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Combined Modality Low-Dose Radiation Therapy (2 Gy x 2) and Single-Agent Rituximab Immunotherapy in the Treatment of Indolent Non-Hodgkin Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131246 Silverchair:425157 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Combined Modality Low-Dose Radiation Therapy (2 Gy x 2) and Single-Agent Rituximab Immunotherapy in the Treatment of Indolent Non-Hodgkin Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131246 Silverchair:425157 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Combined Modality Low-Dose Radiation Therapy (2 Gy x 2) and Single-Agent Rituximab Immunotherapy in the Treatment of Indolent Non-Hodgkin Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131246 Silverchair:425157 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study The American Society of Hematology American Society of Hematology 10.1182/blood.2020009004 Silverchair:474133 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study The American Society of Hematology American Society of Hematology 10.1182/blood.2020009004 Silverchair:474133 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-415661 Silverchair:30619 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-415661 Silverchair:30619 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-415661 Silverchair:30619 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-415661 Silverchair:30619 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127274 Silverchair:427117 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127274 Silverchair:427117 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127274 Silverchair:427117 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127274 Silverchair:427117 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Combining antiplatelet and anticoagulant therapy in cardiovascular disease The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000151 Silverchair:474351 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Combining antiplatelet and anticoagulant therapy in cardiovascular disease The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000151 Silverchair:474351 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Combining antiplatelet and anticoagulant therapy in cardiovascular disease The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000151 Silverchair:474351 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Combining antiplatelet and anticoagulant therapy in cardiovascular disease The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000151 Silverchair:474351 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Combining CAR Engineering and CIS Checkpoint Deletion in NK Cells for the Treatment of B Cell Hematologic Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126739 Silverchair:428147 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Combining CAR Engineering and CIS Checkpoint Deletion in NK Cells for the Treatment of B Cell Hematologic Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126739 Silverchair:428147 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Combining CAR Engineering and CIS Checkpoint Deletion in NK Cells for the Treatment of B Cell Hematologic Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126739 Silverchair:428147 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Combining CAR Engineering and CIS Checkpoint Deletion in NK Cells for the Treatment of B Cell Hematologic Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126739 Silverchair:428147 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-419747 Silverchair:30765 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-419747 Silverchair:30765 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-419747 Silverchair:30765 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-419747 Silverchair:30765 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-249102 Silverchair:27151 Total_Item_Investigations 2 0 0 0 0 0 0 2 0 0 0 0 0 Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-249102 Silverchair:27151 Total_Item_Requests 2 0 0 0 0 0 0 2 0 0 0 0 0 Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-249102 Silverchair:27151 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-249102 Silverchair:27151 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003381 Silverchair:475376 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003381 Silverchair:475376 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003381 Silverchair:475376 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003381 Silverchair:475376 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-826693 Silverchair:37136 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-826693 Silverchair:37136 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-826693 Silverchair:37136 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-826693 Silverchair:37136 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Comparative analysis of human ex vivo–generated platelets vs megakaryocyte-generated platelets in mice: a cautionary tale The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-593053 Silverchair:34153 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Comparative analysis of human ex vivo–generated platelets vs megakaryocyte-generated platelets in mice: a cautionary tale The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-593053 Silverchair:34153 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Comparative analysis of human ex vivo–generated platelets vs megakaryocyte-generated platelets in mice: a cautionary tale The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-593053 Silverchair:34153 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Comparative analysis of human ex vivo–generated platelets vs megakaryocyte-generated platelets in mice: a cautionary tale The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-593053 Silverchair:34153 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129600 Silverchair:425075 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129600 Silverchair:425075 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129600 Silverchair:425075 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129600 Silverchair:425075 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Comparative Cost Analysis of Therapy in Sickle Cell Anemia: Supportive Care Vs. Bone Marrow Transplant The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4466.4466 Silverchair:93616 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Comparative Cost Analysis of Therapy in Sickle Cell Anemia: Supportive Care Vs. Bone Marrow Transplant The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4466.4466 Silverchair:93616 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Comparative Cost Analysis of Therapy in Sickle Cell Anemia: Supportive Care Vs. Bone Marrow Transplant The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4466.4466 Silverchair:93616 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Comparative Cost Analysis of Therapy in Sickle Cell Anemia: Supportive Care Vs. Bone Marrow Transplant The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4466.4466 Silverchair:93616 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Compared to Normal-Weight Pregnant Women, Overweight Pregnant Women Fail to Upregulate Iron Absorption in the Third Trimester Despite Iron Deficiency and Their Infants Are Born with Lower Body Iron Stores" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139453 Silverchair:472219 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 "Compared to Normal-Weight Pregnant Women, Overweight Pregnant Women Fail to Upregulate Iron Absorption in the Third Trimester Despite Iron Deficiency and Their Infants Are Born with Lower Body Iron Stores" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139453 Silverchair:472219 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 "Compared to Normal-Weight Pregnant Women, Overweight Pregnant Women Fail to Upregulate Iron Absorption in the Third Trimester Despite Iron Deficiency and Their Infants Are Born with Lower Body Iron Stores" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139453 Silverchair:472219 Unique_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 "Compared to Normal-Weight Pregnant Women, Overweight Pregnant Women Fail to Upregulate Iron Absorption in the Third Trimester Despite Iron Deficiency and Their Infants Are Born with Lower Body Iron Stores" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139453 Silverchair:472219 Unique_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003848 Silverchair:476779 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 1 0 1 Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003848 Silverchair:476779 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 1 0 1 Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003848 Silverchair:476779 Unique_Item_Investigations 2 0 0 0 0 0 0 0 0 0 1 0 1 Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003848 Silverchair:476779 Unique_Item_Requests 2 0 0 0 0 0 0 0 0 0 1 0 1 Comparison of Bleeding Risk between Rivaroxaban and Apixaban: a Pilot Feasibility Study The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1108.1108 Silverchair:116294 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Comparison of Bleeding Risk between Rivaroxaban and Apixaban: a Pilot Feasibility Study The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1108.1108 Silverchair:116294 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Comparison of Bleeding Risk between Rivaroxaban and Apixaban: a Pilot Feasibility Study The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1108.1108 Silverchair:116294 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Comparison of Bleeding Risk between Rivaroxaban and Apixaban: a Pilot Feasibility Study The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1108.1108 Silverchair:116294 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002439 Silverchair:474966 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002439 Silverchair:474966 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002439 Silverchair:474966 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002439 Silverchair:474966 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Comparison of Emapalumab with Conventional Treatment in Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH): Consistent Results Obtained in an Unadjusted and an Adjusted Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140298 Silverchair:473970 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Comparison of Emapalumab with Conventional Treatment in Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH): Consistent Results Obtained in an Unadjusted and an Adjusted Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140298 Silverchair:473970 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Comparison of Emapalumab with Conventional Treatment in Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH): Consistent Results Obtained in an Unadjusted and an Adjusted Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140298 Silverchair:473970 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Comparison of Emapalumab with Conventional Treatment in Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH): Consistent Results Obtained in an Unadjusted and an Adjusted Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140298 Silverchair:473970 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Comparison of Fluorescence in Situ Hybridization and Flow Cytometry (Flow-FISH) with Monochrome Multiplex Quantitative Polymerase Chain Reaction (MM-qPCR) for Telomere Length Screening in Adult Patients with Suspected Cryptic Dyskeratosis Congenita (DKC) The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117330 Silverchair:265421 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Comparison of Fluorescence in Situ Hybridization and Flow Cytometry (Flow-FISH) with Monochrome Multiplex Quantitative Polymerase Chain Reaction (MM-qPCR) for Telomere Length Screening in Adult Patients with Suspected Cryptic Dyskeratosis Congenita (DKC) The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117330 Silverchair:265421 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Comparison of Fluorescence in Situ Hybridization and Flow Cytometry (Flow-FISH) with Monochrome Multiplex Quantitative Polymerase Chain Reaction (MM-qPCR) for Telomere Length Screening in Adult Patients with Suspected Cryptic Dyskeratosis Congenita (DKC) The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117330 Silverchair:265421 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Comparison of Fluorescence in Situ Hybridization and Flow Cytometry (Flow-FISH) with Monochrome Multiplex Quantitative Polymerase Chain Reaction (MM-qPCR) for Telomere Length Screening in Adult Patients with Suspected Cryptic Dyskeratosis Congenita (DKC) The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117330 Silverchair:265421 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Comparison of human cord blood engraftment between immunocompromised mouse strains The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-271841 Silverchair:27152 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Comparison of human cord blood engraftment between immunocompromised mouse strains The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-271841 Silverchair:27152 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Comparison of human cord blood engraftment between immunocompromised mouse strains The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-271841 Silverchair:27152 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Comparison of human cord blood engraftment between immunocompromised mouse strains The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-271841 Silverchair:27152 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Comparison of Immunophenotypic Abnormalities in B-Lymphoblastic Leukemia (B-ALL) Minimal Residual Disease (MRD) of Adults and Children Utilizing the Children's Oncology Group (COG)-Validated Multiparameter Flow Cytometry (MFC)- MRD Approach: An Institutional Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112317 Silverchair:264055 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Comparison of Immunophenotypic Abnormalities in B-Lymphoblastic Leukemia (B-ALL) Minimal Residual Disease (MRD) of Adults and Children Utilizing the Children's Oncology Group (COG)-Validated Multiparameter Flow Cytometry (MFC)- MRD Approach: An Institutional Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112317 Silverchair:264055 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Comparison of Immunophenotypic Abnormalities in B-Lymphoblastic Leukemia (B-ALL) Minimal Residual Disease (MRD) of Adults and Children Utilizing the Children's Oncology Group (COG)-Validated Multiparameter Flow Cytometry (MFC)- MRD Approach: An Institutional Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112317 Silverchair:264055 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Comparison of Immunophenotypic Abnormalities in B-Lymphoblastic Leukemia (B-ALL) Minimal Residual Disease (MRD) of Adults and Children Utilizing the Children's Oncology Group (COG)-Validated Multiparameter Flow Cytometry (MFC)- MRD Approach: An Institutional Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112317 Silverchair:264055 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124586 Silverchair:427278 Total_Item_Investigations 3 0 2 1 0 0 0 0 0 0 0 0 0 Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124586 Silverchair:427278 Total_Item_Requests 3 0 2 1 0 0 0 0 0 0 0 0 0 Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124586 Silverchair:427278 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124586 Silverchair:427278 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Comparison of primary human cytotoxic T-cell and natural killer cell responses reveal similar molecular requirements for lytic granule exocytosis but differences in cytokine production The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-442558 Silverchair:138860 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Comparison of primary human cytotoxic T-cell and natural killer cell responses reveal similar molecular requirements for lytic granule exocytosis but differences in cytokine production The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-442558 Silverchair:138860 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Comparison of primary human cytotoxic T-cell and natural killer cell responses reveal similar molecular requirements for lytic granule exocytosis but differences in cytokine production The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-442558 Silverchair:138860 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Comparison of primary human cytotoxic T-cell and natural killer cell responses reveal similar molecular requirements for lytic granule exocytosis but differences in cytokine production The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-442558 Silverchair:138860 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study The American Society of Hematology American Society of Hematology 10.1182/blood.V69.5.1441.1441 Silverchair:165002 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study The American Society of Hematology American Society of Hematology 10.1182/blood.V69.5.1441.1441 Silverchair:165002 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study The American Society of Hematology American Society of Hematology 10.1182/blood.V69.5.1441.1441 Silverchair:165002 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study The American Society of Hematology American Society of Hematology 10.1182/blood.V69.5.1441.1441 Silverchair:165002 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS The American Society of Hematology American Society of Hematology 10.1182/blood.2019003863 Silverchair:429215 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS The American Society of Hematology American Society of Hematology 10.1182/blood.2019003863 Silverchair:429215 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS The American Society of Hematology American Society of Hematology 10.1182/blood.2019003863 Silverchair:429215 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS The American Society of Hematology American Society of Hematology 10.1182/blood.2019003863 Silverchair:429215 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Complement and Thrombosis: What Is, and What Might Be" American Society of Hematology American Society of Hematology Silverchair:474713 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Complement and Thrombosis: What Is, and What Might Be" American Society of Hematology American Society of Hematology Silverchair:474713 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Complement and Thrombosis: What Is, and What Might Be" American Society of Hematology American Society of Hematology Silverchair:474713 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Complement and Thrombosis: What Is, and What Might Be" American Society of Hematology American Society of Hematology Silverchair:474713 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab The American Society of Hematology American Society of Hematology 10.1182/blood.2019004218 Silverchair:430258 No_License 3 0 3 0 0 0 0 0 0 0 0 0 0 Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab The American Society of Hematology American Society of Hematology 10.1182/blood.2019004218 Silverchair:430258 Total_Item_Investigations 6 0 6 0 0 0 0 0 0 0 0 0 0 Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab The American Society of Hematology American Society of Hematology 10.1182/blood.2019004218 Silverchair:430258 Unique_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity The American Society of Hematology American Society of Hematology 10.1182/blood.2020005959 Silverchair:474570 Total_Item_Investigations 6 0 6 0 0 0 0 0 0 0 0 0 0 Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity The American Society of Hematology American Society of Hematology 10.1182/blood.2020005959 Silverchair:474570 Total_Item_Requests 6 0 6 0 0 0 0 0 0 0 0 0 0 Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity The American Society of Hematology American Society of Hematology 10.1182/blood.2020005959 Silverchair:474570 Unique_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity The American Society of Hematology American Society of Hematology 10.1182/blood.2020005959 Silverchair:474570 Unique_Item_Requests 4 0 4 0 0 0 0 0 0 0 0 0 0 Complement Inhibition Using Eculizumab Overcomes Platelet Transfusion Refractoriness in Allo-Immunized Patients Receiving HLA Mismatched Platelets The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3840.3840 Silverchair:97439 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Complement Inhibition Using Eculizumab Overcomes Platelet Transfusion Refractoriness in Allo-Immunized Patients Receiving HLA Mismatched Platelets The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3840.3840 Silverchair:97439 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Complement Inhibition Using Eculizumab Overcomes Platelet Transfusion Refractoriness in Allo-Immunized Patients Receiving HLA Mismatched Platelets The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3840.3840 Silverchair:97439 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Complement Inhibition Using Eculizumab Overcomes Platelet Transfusion Refractoriness in Allo-Immunized Patients Receiving HLA Mismatched Platelets The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3840.3840 Silverchair:97439 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Complement receptor 2/CD21− human naive B cells contain mostly autoreactive unresponsive clones The American Society of Hematology American Society of Hematology 10.1182/blood-2009-09-243071 Silverchair:27217 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Complement receptor 2/CD21− human naive B cells contain mostly autoreactive unresponsive clones The American Society of Hematology American Society of Hematology 10.1182/blood-2009-09-243071 Silverchair:27217 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Complement receptor 2/CD21− human naive B cells contain mostly autoreactive unresponsive clones The American Society of Hematology American Society of Hematology 10.1182/blood-2009-09-243071 Silverchair:27217 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Complement receptor 2/CD21− human naive B cells contain mostly autoreactive unresponsive clones The American Society of Hematology American Society of Hematology 10.1182/blood-2009-09-243071 Silverchair:27217 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Complementary JAK/STAT Signalling Is Required for the Pro-Inflammatory Effects of CD40 Ligation: Differential Effects in Human Myeloid and B Cells. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.2413.2413 Silverchair:57222 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Complementary JAK/STAT Signalling Is Required for the Pro-Inflammatory Effects of CD40 Ligation: Differential Effects in Human Myeloid and B Cells. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.2413.2413 Silverchair:57222 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Complementary JAK/STAT Signalling Is Required for the Pro-Inflammatory Effects of CD40 Ligation: Differential Effects in Human Myeloid and B Cells. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.2413.2413 Silverchair:57222 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Complementary JAK/STAT Signalling Is Required for the Pro-Inflammatory Effects of CD40 Ligation: Differential Effects in Human Myeloid and B Cells. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.2413.2413 Silverchair:57222 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Complement-mediated thrombotic microangiopathy associated with lupus nephritis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018019596 Silverchair:15916 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Complement-mediated thrombotic microangiopathy associated with lupus nephritis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018019596 Silverchair:15916 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Complement-mediated thrombotic microangiopathy associated with lupus nephritis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018019596 Silverchair:15916 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Complement-mediated thrombotic microangiopathy associated with lupus nephritis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018019596 Silverchair:15916 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-307645 Silverchair:19560 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-307645 Silverchair:19560 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-307645 Silverchair:19560 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-307645 Silverchair:19560 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134746 Silverchair:470184 Total_Item_Investigations 6 0 0 4 1 0 0 0 0 0 1 0 0 "Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134746 Silverchair:470184 Total_Item_Requests 6 0 0 4 1 0 0 0 0 0 1 0 0 "Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134746 Silverchair:470184 Unique_Item_Investigations 5 0 0 3 1 0 0 0 0 0 1 0 0 "Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134746 Silverchair:470184 Unique_Item_Requests 5 0 0 3 1 0 0 0 0 0 1 0 0 "Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119786 Silverchair:266313 Total_Item_Investigations 10 0 10 0 0 0 0 0 0 0 0 0 0 "Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119786 Silverchair:266313 Total_Item_Requests 10 0 10 0 0 0 0 0 0 0 0 0 0 "Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119786 Silverchair:266313 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119786 Silverchair:266313 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Analyses The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122703 Silverchair:426518 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Analyses The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122703 Silverchair:426518 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Analyses The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122703 Silverchair:426518 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Analyses The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122703 Silverchair:426518 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-516385 Silverchair:31979 Total_Item_Investigations 8 6 2 0 0 0 0 0 0 0 0 0 0 Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-516385 Silverchair:31979 Total_Item_Requests 4 3 1 0 0 0 0 0 0 0 0 0 0 Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-516385 Silverchair:31979 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-516385 Silverchair:31979 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Complexity within the plasma cell compartment of mice deficient in both E- and P-selectin: implications for plasma cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2003-03-0947 Silverchair:16750 Total_Item_Investigations 2 0 1 0 0 0 1 0 0 0 0 0 0 Complexity within the plasma cell compartment of mice deficient in both E- and P-selectin: implications for plasma cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2003-03-0947 Silverchair:16750 Total_Item_Requests 2 0 1 0 0 0 1 0 0 0 0 0 0 Complexity within the plasma cell compartment of mice deficient in both E- and P-selectin: implications for plasma cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2003-03-0947 Silverchair:16750 Unique_Item_Investigations 2 0 1 0 0 0 1 0 0 0 0 0 0 Complexity within the plasma cell compartment of mice deficient in both E- and P-selectin: implications for plasma cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2003-03-0947 Silverchair:16750 Unique_Item_Requests 2 0 1 0 0 0 1 0 0 0 0 0 0 Complications and Early Mortality in Patients with Acute Promyelocytic Leukemia Treated in California The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3430.3430 Silverchair:114750 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Complications and Early Mortality in Patients with Acute Promyelocytic Leukemia Treated in California The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3430.3430 Silverchair:114750 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Complications and Early Mortality in Patients with Acute Promyelocytic Leukemia Treated in California The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3430.3430 Silverchair:114750 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Complications and Early Mortality in Patients with Acute Promyelocytic Leukemia Treated in California The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3430.3430 Silverchair:114750 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Complications in pregnant women with sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000039 Silverchair:422591 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Complications in pregnant women with sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000039 Silverchair:422591 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Complications in pregnant women with sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000039 Silverchair:422591 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Complications in pregnant women with sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000039 Silverchair:422591 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Composite mantle cell lymphoma and small lymphocytic lymphoma in a lymph node The American Society of Hematology American Society of Hematology 10.1182/blood.2020009288 Silverchair:474897 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Composite mantle cell lymphoma and small lymphocytic lymphoma in a lymph node The American Society of Hematology American Society of Hematology 10.1182/blood.2020009288 Silverchair:474897 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Composite mantle cell lymphoma and small lymphocytic lymphoma in a lymph node The American Society of Hematology American Society of Hematology 10.1182/blood.2020009288 Silverchair:474897 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Composite mantle cell lymphoma and small lymphocytic lymphoma in a lymph node The American Society of Hematology American Society of Hematology 10.1182/blood.2020009288 Silverchair:474897 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Comprehensive analyses of B-cell compartments across the human body reveal novel subsets and a gut-resident memory phenotype The American Society of Hematology American Society of Hematology 10.1182/blood.2019002782 Silverchair:461697 Total_Item_Investigations 25 2 23 0 0 0 0 0 0 0 0 0 0 Comprehensive analyses of B-cell compartments across the human body reveal novel subsets and a gut-resident memory phenotype The American Society of Hematology American Society of Hematology 10.1182/blood.2019002782 Silverchair:461697 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Comprehensive analyses of B-cell compartments across the human body reveal novel subsets and a gut-resident memory phenotype The American Society of Hematology American Society of Hematology 10.1182/blood.2019002782 Silverchair:461697 Unique_Item_Investigations 3 1 2 0 0 0 0 0 0 0 0 0 0 Comprehensive analyses of B-cell compartments across the human body reveal novel subsets and a gut-resident memory phenotype The American Society of Hematology American Society of Hematology 10.1182/blood.2019002782 Silverchair:461697 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Comprehensive analyses of B-cell compartments across the human body reveal novel subsets and a gut-resident memory phenotype The American Society of Hematology American Society of Hematology 10.1182/blood.2019002782 Silverchair:461697 No_License 11 0 11 0 0 0 0 0 0 0 0 0 0 "Concentrations of Thrombopoietin in Bone Marrow in Normal Subjects and in Patients With Idiopathic Thrombocytopenic Purpura, Aplastic Anemia, and Essential Thrombocythemia Correlate With Its mRNA Expression of Bone Marrow Stromal Cells" The American Society of Hematology American Society of Hematology 10.1182/blood.V92.1.46.413k44_46_52 Silverchair:107585 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 "Concentrations of Thrombopoietin in Bone Marrow in Normal Subjects and in Patients With Idiopathic Thrombocytopenic Purpura, Aplastic Anemia, and Essential Thrombocythemia Correlate With Its mRNA Expression of Bone Marrow Stromal Cells" The American Society of Hematology American Society of Hematology 10.1182/blood.V92.1.46.413k44_46_52 Silverchair:107585 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 "Concentrations of Thrombopoietin in Bone Marrow in Normal Subjects and in Patients With Idiopathic Thrombocytopenic Purpura, Aplastic Anemia, and Essential Thrombocythemia Correlate With Its mRNA Expression of Bone Marrow Stromal Cells" The American Society of Hematology American Society of Hematology 10.1182/blood.V92.1.46.413k44_46_52 Silverchair:107585 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Concentrations of Thrombopoietin in Bone Marrow in Normal Subjects and in Patients With Idiopathic Thrombocytopenic Purpura, Aplastic Anemia, and Essential Thrombocythemia Correlate With Its mRNA Expression of Bone Marrow Stromal Cells" The American Society of Hematology American Society of Hematology 10.1182/blood.V92.1.46.413k44_46_52 Silverchair:107585 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Concept of lymphoid versus myeloid dendritic cell lineages revisited: both CD8α− and CD8α+dendritic cells are generated from CD4lowlymphoid-committed precursors The American Society of Hematology American Society of Hematology 10.1182/blood.V96.7.2511 Silverchair:181061 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Concept of lymphoid versus myeloid dendritic cell lineages revisited: both CD8α− and CD8α+dendritic cells are generated from CD4lowlymphoid-committed precursors The American Society of Hematology American Society of Hematology 10.1182/blood.V96.7.2511 Silverchair:181061 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Concept of lymphoid versus myeloid dendritic cell lineages revisited: both CD8α− and CD8α+dendritic cells are generated from CD4lowlymphoid-committed precursors The American Society of Hematology American Society of Hematology 10.1182/blood.V96.7.2511 Silverchair:181061 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Concept of lymphoid versus myeloid dendritic cell lineages revisited: both CD8α− and CD8α+dendritic cells are generated from CD4lowlymphoid-committed precursors The American Society of Hematology American Society of Hematology 10.1182/blood.V96.7.2511 Silverchair:181061 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Concizumab: a novel anti-TFPI therapeutic for hemophilia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001140 Silverchair:474883 Total_Item_Investigations 5 4 0 1 0 0 0 0 0 0 0 0 0 Concizumab: a novel anti-TFPI therapeutic for hemophilia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001140 Silverchair:474883 Total_Item_Requests 5 4 0 1 0 0 0 0 0 0 0 0 0 Concizumab: a novel anti-TFPI therapeutic for hemophilia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001140 Silverchair:474883 Unique_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 Concizumab: a novel anti-TFPI therapeutic for hemophilia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001140 Silverchair:474883 Unique_Item_Requests 3 2 0 1 0 0 0 0 0 0 0 0 0 Concomitant occurrence of BCR-ABL and JAK2V617F mutation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-365007 Silverchair:28797 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Concomitant occurrence of BCR-ABL and JAK2V617F mutation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-365007 Silverchair:28797 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Concomitant occurrence of BCR-ABL and JAK2V617F mutation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-365007 Silverchair:28797 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Concomitant occurrence of BCR-ABL and JAK2V617F mutation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-365007 Silverchair:28797 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL The American Society of Hematology American Society of Hematology 10.1182/blood.2020005655 Silverchair:463713 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL The American Society of Hematology American Society of Hematology 10.1182/blood.2020005655 Silverchair:463713 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL The American Society of Hematology American Society of Hematology 10.1182/blood.2020005655 Silverchair:463713 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL The American Society of Hematology American Society of Hematology 10.1182/blood.2020005655 Silverchair:463713 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Concomitant Use of Midostaurin with Strong CYP3A4 Inhibitors: An Analysis from the Ratify Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3814.3814 Silverchair:71849 Total_Item_Investigations 11 0 11 0 0 0 0 0 0 0 0 0 0 Concomitant Use of Midostaurin with Strong CYP3A4 Inhibitors: An Analysis from the Ratify Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3814.3814 Silverchair:71849 Total_Item_Requests 11 0 11 0 0 0 0 0 0 0 0 0 0 Concomitant Use of Midostaurin with Strong CYP3A4 Inhibitors: An Analysis from the Ratify Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3814.3814 Silverchair:71849 Unique_Item_Investigations 8 0 8 0 0 0 0 0 0 0 0 0 0 Concomitant Use of Midostaurin with Strong CYP3A4 Inhibitors: An Analysis from the Ratify Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3814.3814 Silverchair:71849 Unique_Item_Requests 8 0 8 0 0 0 0 0 0 0 0 0 0 Conditional ablation of LYVE-1+ cells unveils defensive roles of lymphatic vessels in intestine and lymph nodes The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-478941 Silverchair:31723 Total_Item_Investigations 5 0 5 0 0 0 0 0 0 0 0 0 0 Conditional ablation of LYVE-1+ cells unveils defensive roles of lymphatic vessels in intestine and lymph nodes The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-478941 Silverchair:31723 Total_Item_Requests 5 0 5 0 0 0 0 0 0 0 0 0 0 Conditional ablation of LYVE-1+ cells unveils defensive roles of lymphatic vessels in intestine and lymph nodes The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-478941 Silverchair:31723 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Conditional ablation of LYVE-1+ cells unveils defensive roles of lymphatic vessels in intestine and lymph nodes The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-478941 Silverchair:31723 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray The American Society of Hematology American Society of Hematology 10.1182/blood-2003-05-1545 Silverchair:17580 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray The American Society of Hematology American Society of Hematology 10.1182/blood-2003-05-1545 Silverchair:17580 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray The American Society of Hematology American Society of Hematology 10.1182/blood-2003-05-1545 Silverchair:17580 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray The American Society of Hematology American Society of Hematology 10.1182/blood-2003-05-1545 Silverchair:17580 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Congenital and acquired bleeding disorders in pregnancy The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.232 Silverchair:21033 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Congenital and acquired bleeding disorders in pregnancy The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.232 Silverchair:21033 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Congenital and acquired bleeding disorders in pregnancy The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.232 Silverchair:21033 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Congenital and acquired bleeding disorders in pregnancy The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.232 Silverchair:21033 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Congenital dyserythropoietic anemias The American Society of Hematology American Society of Hematology 10.1182/blood.2019000948 Silverchair:461553 No_License 3 0 2 1 0 0 0 0 0 0 0 0 0 Congenital dyserythropoietic anemias The American Society of Hematology American Society of Hematology 10.1182/blood.2019000948 Silverchair:461553 Total_Item_Investigations 8 2 4 2 0 0 0 0 0 0 0 0 0 Congenital dyserythropoietic anemias The American Society of Hematology American Society of Hematology 10.1182/blood.2019000948 Silverchair:461553 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Congenital dyserythropoietic anemias The American Society of Hematology American Society of Hematology 10.1182/blood.2019000948 Silverchair:461553 Unique_Item_Investigations 5 2 2 1 0 0 0 0 0 0 0 0 0 Congenital dyserythropoietic anemias The American Society of Hematology American Society of Hematology 10.1182/blood.2019000948 Silverchair:461553 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Congenital Methemoglobinemia Under Diagnosed Condition with Variiable Therapeurtic Options The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4746.4746 Silverchair:72173 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Congenital Methemoglobinemia Under Diagnosed Condition with Variiable Therapeurtic Options The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4746.4746 Silverchair:72173 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Congenital Methemoglobinemia Under Diagnosed Condition with Variiable Therapeurtic Options The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4746.4746 Silverchair:72173 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Congenital Methemoglobinemia Under Diagnosed Condition with Variiable Therapeurtic Options The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4746.4746 Silverchair:72173 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Congenital sideroblastic anemia due to mutations in the mitochondrial HSP70 homologue HSPA9 The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-659854 Silverchair:34910 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Congenital sideroblastic anemia due to mutations in the mitochondrial HSP70 homologue HSPA9 The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-659854 Silverchair:34910 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Congenital sideroblastic anemia due to mutations in the mitochondrial HSP70 homologue HSPA9 The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-659854 Silverchair:34910 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Congenital sideroblastic anemia due to mutations in the mitochondrial HSP70 homologue HSPA9 The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-659854 Silverchair:34910 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood.2019000402 Silverchair:374897 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood.2019000402 Silverchair:374897 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood.2019000402 Silverchair:374897 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood.2019000402 Silverchair:374897 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-689422 Silverchair:36153 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-689422 Silverchair:36153 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-689422 Silverchair:36153 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-689422 Silverchair:36153 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3 The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-299529 Silverchair:21362 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3 The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-299529 Silverchair:21362 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3 The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-299529 Silverchair:21362 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3 The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-299529 Silverchair:21362 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-839753 Silverchair:39185 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-839753 Silverchair:39185 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-839753 Silverchair:39185 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-839753 Silverchair:39185 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Constitutive activation of NF-κB during early bone marrow development results in loss of B cells at the pro-B-cell stage American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002932 Silverchair:475086 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Constitutive activation of NF-κB during early bone marrow development results in loss of B cells at the pro-B-cell stage American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002932 Silverchair:475086 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Constitutive activation of NF-κB during early bone marrow development results in loss of B cells at the pro-B-cell stage American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002932 Silverchair:475086 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Constitutive activation of NF-κB during early bone marrow development results in loss of B cells at the pro-B-cell stage American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002932 Silverchair:475086 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-02-139725 Silverchair:25037 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-02-139725 Silverchair:25037 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-02-139725 Silverchair:25037 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-02-139725 Silverchair:25037 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Consultative hematology I: hospital-based and selected outpatient topics American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter02 Silverchair:73281 No_License 10 0 0 3 0 0 0 0 1 1 0 0 5 Consultative hematology I: hospital-based and selected outpatient topics American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter02 Silverchair:73281 Total_Item_Investigations 25 0 0 3 4 0 4 2 5 2 0 0 5 Consultative hematology I: hospital-based and selected outpatient topics American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter02 Silverchair:73281 Unique_Item_Investigations 18 0 0 3 3 0 3 2 1 1 0 0 5 Consultative hematology II: women’s health issues American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter03 Silverchair:73498 No_License 6 0 2 1 0 0 0 0 1 0 0 2 0 Consultative hematology II: women’s health issues American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter03 Silverchair:73498 Total_Item_Investigations 11 0 2 1 0 0 1 3 2 0 0 2 0 Consultative hematology II: women’s health issues American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter03 Silverchair:73498 Unique_Item_Investigations 9 0 2 1 0 0 1 2 1 0 0 2 0 "Contact Between Human Bone Marrow Stromal Cells and B Lymphocytes Enhances Very Late Antigen-4/Vascular Cell Adhesion Molecule-1–Independent Tyrosine Phosphorylation of Focal Adhesion Kinase, Paxillin, and ERK2 in Stromal Cells" The American Society of Hematology American Society of Hematology 10.1182/blood.V90.4.1626 Silverchair:238124 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "Contact Between Human Bone Marrow Stromal Cells and B Lymphocytes Enhances Very Late Antigen-4/Vascular Cell Adhesion Molecule-1–Independent Tyrosine Phosphorylation of Focal Adhesion Kinase, Paxillin, and ERK2 in Stromal Cells" The American Society of Hematology American Society of Hematology 10.1182/blood.V90.4.1626 Silverchair:238124 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Contact Between Human Bone Marrow Stromal Cells and B Lymphocytes Enhances Very Late Antigen-4/Vascular Cell Adhesion Molecule-1–Independent Tyrosine Phosphorylation of Focal Adhesion Kinase, Paxillin, and ERK2 in Stromal Cells" The American Society of Hematology American Society of Hematology 10.1182/blood.V90.4.1626 Silverchair:238124 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Contact Between Human Bone Marrow Stromal Cells and B Lymphocytes Enhances Very Late Antigen-4/Vascular Cell Adhesion Molecule-1–Independent Tyrosine Phosphorylation of Focal Adhesion Kinase, Paxillin, and ERK2 in Stromal Cells" The American Society of Hematology American Society of Hematology 10.1182/blood.V90.4.1626 Silverchair:238124 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Contact ignition by single-chain XIIa The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-763532 Silverchair:35937 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Contact ignition by single-chain XIIa The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-763532 Silverchair:35937 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Contact ignition by single-chain XIIa The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-763532 Silverchair:35937 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Contact ignition by single-chain XIIa The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-763532 Silverchair:35937 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Contemporary Practice Patterns of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139531 Silverchair:473093 Total_Item_Investigations 4 1 3 0 0 0 0 0 0 0 0 0 0 Contemporary Practice Patterns of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139531 Silverchair:473093 Total_Item_Requests 4 1 3 0 0 0 0 0 0 0 0 0 0 Contemporary Practice Patterns of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139531 Silverchair:473093 Unique_Item_Investigations 4 1 3 0 0 0 0 0 0 0 0 0 0 Contemporary Practice Patterns of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139531 Silverchair:473093 Unique_Item_Requests 4 1 3 0 0 0 0 0 0 0 0 0 0 "Content, Utilization and Impact of a Hematology e-Consultation Service" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.42.42 Silverchair:136044 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Content, Utilization and Impact of a Hematology e-Consultation Service" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.42.42 Silverchair:136044 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Content, Utilization and Impact of a Hematology e-Consultation Service" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.42.42 Silverchair:136044 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Content, Utilization and Impact of a Hematology e-Consultation Service" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.42.42 Silverchair:136044 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Contraceptive in Women with Sickle Cell Disease: A Survey Study The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3263.3263 Silverchair:91187 Total_Item_Investigations 5 5 0 0 0 0 0 0 0 0 0 0 0 Contraceptive in Women with Sickle Cell Disease: A Survey Study The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3263.3263 Silverchair:91187 Total_Item_Requests 5 5 0 0 0 0 0 0 0 0 0 0 0 Contraceptive in Women with Sickle Cell Disease: A Survey Study The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3263.3263 Silverchair:91187 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Contraceptive in Women with Sickle Cell Disease: A Survey Study The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3263.3263 Silverchair:91187 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2020008206 Silverchair:463846 Total_Item_Investigations 6 5 0 0 0 0 0 0 0 0 0 1 0 Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2020008206 Silverchair:463846 Total_Item_Requests 5 4 0 0 0 0 0 0 0 0 0 1 0 Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2020008206 Silverchair:463846 Unique_Item_Investigations 4 3 0 0 0 0 0 0 0 0 0 1 0 Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2020008206 Silverchair:463846 Unique_Item_Requests 4 3 0 0 0 0 0 0 0 0 0 1 0 Convergent BCL6 and lncRNA promoters demarcate the major breakpoint region for BCL6 translocations The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-657999 Silverchair:34432 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Convergent BCL6 and lncRNA promoters demarcate the major breakpoint region for BCL6 translocations The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-657999 Silverchair:34432 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Convergent BCL6 and lncRNA promoters demarcate the major breakpoint region for BCL6 translocations The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-657999 Silverchair:34432 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Convergent BCL6 and lncRNA promoters demarcate the major breakpoint region for BCL6 translocations The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-657999 Silverchair:34432 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000251 Silverchair:246628 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000251 Silverchair:246628 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000251 Silverchair:246628 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000251 Silverchair:246628 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017009019 Silverchair:15693 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017009019 Silverchair:15693 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017009019 Silverchair:15693 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017009019 Silverchair:15693 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Cooperation between SYK and ZAP70 Kinases As a Driver of Oncogenic BCR-Signaling in B-Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116954 Silverchair:265109 Total_Item_Investigations 4 2 1 1 0 0 0 0 0 0 0 0 0 Cooperation between SYK and ZAP70 Kinases As a Driver of Oncogenic BCR-Signaling in B-Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116954 Silverchair:265109 Total_Item_Requests 3 1 1 1 0 0 0 0 0 0 0 0 0 Cooperation between SYK and ZAP70 Kinases As a Driver of Oncogenic BCR-Signaling in B-Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116954 Silverchair:265109 Unique_Item_Investigations 3 1 1 1 0 0 0 0 0 0 0 0 0 Cooperation between SYK and ZAP70 Kinases As a Driver of Oncogenic BCR-Signaling in B-Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116954 Silverchair:265109 Unique_Item_Requests 3 1 1 1 0 0 0 0 0 0 0 0 0 Cooperative transcriptional repression by BCL6 and BACH2 in germinal center B-cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-518605 Silverchair:105694 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Cooperative transcriptional repression by BCL6 and BACH2 in germinal center B-cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-518605 Silverchair:105694 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Cooperative transcriptional repression by BCL6 and BACH2 in germinal center B-cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-518605 Silverchair:105694 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Cooperative transcriptional repression by BCL6 and BACH2 in germinal center B-cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-518605 Silverchair:105694 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Copper Deficiency and Cytopenia: A Systematic Review The American Society of Hematology American Society of Hematology 10.1182/blood-2019-132265 Silverchair:424830 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Copper Deficiency and Cytopenia: A Systematic Review The American Society of Hematology American Society of Hematology 10.1182/blood-2019-132265 Silverchair:424830 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Copper Deficiency and Cytopenia: A Systematic Review The American Society of Hematology American Society of Hematology 10.1182/blood-2019-132265 Silverchair:424830 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Copper Deficiency and Cytopenia: A Systematic Review The American Society of Hematology American Society of Hematology 10.1182/blood-2019-132265 Silverchair:424830 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Copper Deficiency: A Forgotten Disorder? The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.5275.5275 Silverchair:81791 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Copper Deficiency: A Forgotten Disorder? The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.5275.5275 Silverchair:81791 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Copper Deficiency: A Forgotten Disorder? The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.5275.5275 Silverchair:81791 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Copper Deficiency: A Forgotten Disorder? The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.5275.5275 Silverchair:81791 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologists American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004568 Silverchair:476802 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologists American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004568 Silverchair:476802 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologists American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004568 Silverchair:476802 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologists American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004568 Silverchair:476802 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-615948 Silverchair:34124 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-615948 Silverchair:34124 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-615948 Silverchair:34124 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-615948 Silverchair:34124 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001996 Silverchair:475292 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001996 Silverchair:475292 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001996 Silverchair:475292 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001996 Silverchair:475292 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-398370 Silverchair:29920 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-398370 Silverchair:29920 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-398370 Silverchair:29920 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-398370 Silverchair:29920 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Correlation of Immunohistochemistry, FISH and Clinical Outcomes in Primary Mediastinal (Thymic) Large B-Cell Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5145.5145 Silverchair:81054 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Correlation of Immunohistochemistry, FISH and Clinical Outcomes in Primary Mediastinal (Thymic) Large B-Cell Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5145.5145 Silverchair:81054 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Correlation of Immunohistochemistry, FISH and Clinical Outcomes in Primary Mediastinal (Thymic) Large B-Cell Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5145.5145 Silverchair:81054 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Correlation of Immunohistochemistry, FISH and Clinical Outcomes in Primary Mediastinal (Thymic) Large B-Cell Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5145.5145 Silverchair:81054 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Correlation of Thrombosis With Increased Platelet Turnover in Thrombocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.V91.4.1288 Silverchair:139585 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Correlation of Thrombosis With Increased Platelet Turnover in Thrombocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.V91.4.1288 Silverchair:139585 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Correlation of Thrombosis With Increased Platelet Turnover in Thrombocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.V91.4.1288 Silverchair:139585 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Correlation of Thrombosis With Increased Platelet Turnover in Thrombocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.V91.4.1288 Silverchair:139585 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood.2020006052 Silverchair:474384 Total_Item_Investigations 84 8 46 1 1 10 6 2 3 1 4 1 1 Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood.2020006052 Silverchair:474384 Total_Item_Requests 60 1 30 1 1 9 6 2 3 1 4 1 1 Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood.2020006052 Silverchair:474384 Unique_Item_Investigations 28 4 10 1 1 2 2 1 2 1 2 1 1 Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood.2020006052 Silverchair:474384 Unique_Item_Requests 23 1 8 1 1 2 2 1 2 1 2 1 1 Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138515 Silverchair:470114 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138515 Silverchair:470114 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138515 Silverchair:470114 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138515 Silverchair:470114 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000827 Silverchair:441049 Total_Item_Investigations 25 0 3 3 0 5 6 0 0 2 4 2 0 Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000827 Silverchair:441049 Total_Item_Requests 25 0 3 3 0 5 6 0 0 2 4 2 0 Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000827 Silverchair:441049 Unique_Item_Investigations 9 0 2 1 0 1 2 0 0 1 1 1 0 Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000827 Silverchair:441049 Unique_Item_Requests 9 0 2 1 0 1 2 0 0 1 1 1 0 Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive (FLT3mut+) Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123811 Silverchair:424870 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive (FLT3mut+) Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123811 Silverchair:424870 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive (FLT3mut+) Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123811 Silverchair:424870 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive (FLT3mut+) Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123811 Silverchair:424870 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3-Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123819 Silverchair:424202 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3-Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123819 Silverchair:424202 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3-Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123819 Silverchair:424202 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3-Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123819 Silverchair:424202 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005472 Silverchair:476911 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 1 0 1 0 Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005472 Silverchair:476911 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005472 Silverchair:476911 Unique_Item_Investigations 2 0 0 0 0 0 0 0 0 1 0 1 0 Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005472 Silverchair:476911 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123706 Silverchair:428655 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123706 Silverchair:428655 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123706 Silverchair:428655 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123706 Silverchair:428655 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003902 Silverchair:475200 Total_Item_Investigations 32 0 16 10 0 1 0 1 2 0 0 1 1 Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003902 Silverchair:475200 Total_Item_Requests 31 0 16 9 0 1 0 1 2 0 0 1 1 Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003902 Silverchair:475200 Unique_Item_Investigations 18 0 9 4 0 1 0 1 1 0 0 1 1 Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003902 Silverchair:475200 Unique_Item_Requests 18 0 9 4 0 1 0 1 1 0 0 1 1 Cost-Effectiveness of CPX-351 Versus 7+3 Regimen in the Treatment of Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4674.4674 Silverchair:72337 Total_Item_Investigations 8 1 0 0 0 0 0 2 0 0 3 1 1 Cost-Effectiveness of CPX-351 Versus 7+3 Regimen in the Treatment of Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4674.4674 Silverchair:72337 Total_Item_Requests 8 1 0 0 0 0 0 2 0 0 3 1 1 Cost-Effectiveness of CPX-351 Versus 7+3 Regimen in the Treatment of Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4674.4674 Silverchair:72337 Unique_Item_Investigations 5 1 0 0 0 0 0 1 0 0 1 1 1 Cost-Effectiveness of CPX-351 Versus 7+3 Regimen in the Treatment of Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4674.4674 Silverchair:72337 Unique_Item_Requests 5 1 0 0 0 0 0 1 0 0 1 1 1 Cost-Effectiveness of Defibrotide for the Treatment of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) with Multi-Organ Dysfunction (MOD) Post-Hematopoietic Stem Cell Transplantation (HSCT) in Canada The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111396 Silverchair:262322 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Cost-Effectiveness of Defibrotide for the Treatment of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) with Multi-Organ Dysfunction (MOD) Post-Hematopoietic Stem Cell Transplantation (HSCT) in Canada The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111396 Silverchair:262322 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Cost-Effectiveness of Defibrotide for the Treatment of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) with Multi-Organ Dysfunction (MOD) Post-Hematopoietic Stem Cell Transplantation (HSCT) in Canada The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111396 Silverchair:262322 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Cost-Effectiveness of Defibrotide for the Treatment of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) with Multi-Organ Dysfunction (MOD) Post-Hematopoietic Stem Cell Transplantation (HSCT) in Canada The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111396 Silverchair:262322 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020004922 Silverchair:460741 Total_Item_Investigations 28 2 2 2 0 4 3 3 2 7 3 0 0 Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020004922 Silverchair:460741 Total_Item_Requests 7 2 2 0 0 0 0 0 0 0 3 0 0 Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020004922 Silverchair:460741 Unique_Item_Investigations 12 2 1 1 0 2 2 1 1 1 1 0 0 Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020004922 Silverchair:460741 Unique_Item_Requests 4 2 1 0 0 0 0 0 0 0 1 0 0 Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020004922 Silverchair:460741 No_License 2 0 0 1 0 0 0 1 0 0 0 0 0 Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017015461 Silverchair:15960 Total_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017015461 Silverchair:15960 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017015461 Silverchair:15960 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017015461 Silverchair:15960 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Cost-Effectiveness of Liposomal Cytarabine-Daunorubicin (CPX-351) Compared to Conventional Cytarabine-Daunorubicin Chemotherapy in Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2021-144992 Silverchair:478055 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Cost-Effectiveness of Liposomal Cytarabine-Daunorubicin (CPX-351) Compared to Conventional Cytarabine-Daunorubicin Chemotherapy in Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2021-144992 Silverchair:478055 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Cost-Effectiveness of Liposomal Cytarabine-Daunorubicin (CPX-351) Compared to Conventional Cytarabine-Daunorubicin Chemotherapy in Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2021-144992 Silverchair:478055 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Cost-Effectiveness of Liposomal Cytarabine-Daunorubicin (CPX-351) Compared to Conventional Cytarabine-Daunorubicin Chemotherapy in Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2021-144992 Silverchair:478055 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Cost-Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4703.4703 Silverchair:72185 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Cost-Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4703.4703 Silverchair:72185 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Cost-Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4703.4703 Silverchair:72185 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Cost-Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4703.4703 Silverchair:72185 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 "Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141972 Silverchair:471362 Total_Item_Investigations 5 0 0 0 0 0 0 2 0 0 2 0 1 "Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141972 Silverchair:471362 Total_Item_Requests 5 0 0 0 0 0 0 2 0 0 2 0 1 "Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141972 Silverchair:471362 Unique_Item_Investigations 3 0 0 0 0 0 0 1 0 0 1 0 1 "Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141972 Silverchair:471362 Unique_Item_Requests 3 0 0 0 0 0 0 1 0 0 1 0 1 Cost-Effectiveness of Venetoclax and Rituximab Combination Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in Argentina The American Society of Hematology American Society of Hematology 10.1182/blood-2019-121490 Silverchair:428047 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Cost-Effectiveness of Venetoclax and Rituximab Combination Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in Argentina The American Society of Hematology American Society of Hematology 10.1182/blood-2019-121490 Silverchair:428047 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Cost-Effectiveness of Venetoclax and Rituximab Combination Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in Argentina The American Society of Hematology American Society of Hematology 10.1182/blood-2019-121490 Silverchair:428047 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Cost-Effectiveness of Venetoclax and Rituximab Combination Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in Argentina The American Society of Hematology American Society of Hematology 10.1182/blood-2019-121490 Silverchair:428047 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Costimulation of  T cells by B7-H2, a B7-like molecule that binds ICOS" The American Society of Hematology American Society of Hematology 10.1182/blood.V96.8.2808 Silverchair:181139 Total_Item_Investigations 3 1 0 2 0 0 0 0 0 0 0 0 0 "Costimulation of  T cells by B7-H2, a B7-like molecule that binds ICOS" The American Society of Hematology American Society of Hematology 10.1182/blood.V96.8.2808 Silverchair:181139 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 "Costimulation of  T cells by B7-H2, a B7-like molecule that binds ICOS" The American Society of Hematology American Society of Hematology 10.1182/blood.V96.8.2808 Silverchair:181139 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 "Costimulation of  T cells by B7-H2, a B7-like molecule that binds ICOS" The American Society of Hematology American Society of Hematology 10.1182/blood.V96.8.2808 Silverchair:181139 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Could Transfusion be Restricted for Acute Promyelocytic Leukemia in the Era of Diffetentiating Agents? The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5021.5021 Silverchair:81072 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Could Transfusion be Restricted for Acute Promyelocytic Leukemia in the Era of Diffetentiating Agents? The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5021.5021 Silverchair:81072 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Could Transfusion be Restricted for Acute Promyelocytic Leukemia in the Era of Diffetentiating Agents? The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5021.5021 Silverchair:81072 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Could Transfusion be Restricted for Acute Promyelocytic Leukemia in the Era of Diffetentiating Agents? The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5021.5021 Silverchair:81072 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Counting the cost of caplacizumab The American Society of Hematology American Society of Hematology 10.1182/blood.2020009250 Silverchair:475218 Total_Item_Investigations 9 0 5 0 0 2 2 0 0 0 0 0 0 Counting the cost of caplacizumab The American Society of Hematology American Society of Hematology 10.1182/blood.2020009250 Silverchair:475218 Total_Item_Requests 7 0 5 0 0 1 1 0 0 0 0 0 0 Counting the cost of caplacizumab The American Society of Hematology American Society of Hematology 10.1182/blood.2020009250 Silverchair:475218 Unique_Item_Investigations 4 0 2 0 0 1 1 0 0 0 0 0 0 Counting the cost of caplacizumab The American Society of Hematology American Society of Hematology 10.1182/blood.2020009250 Silverchair:475218 Unique_Item_Requests 4 0 2 0 0 1 1 0 0 0 0 0 0 COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection The American Society of Hematology American Society of Hematology 10.1182/blood.2020006520 Silverchair:460672 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection The American Society of Hematology American Society of Hematology 10.1182/blood.2020006520 Silverchair:460672 Total_Item_Requests 4 0 4 0 0 0 0 0 0 0 0 0 0 COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection The American Society of Hematology American Society of Hematology 10.1182/blood.2020006520 Silverchair:460672 Unique_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection The American Society of Hematology American Society of Hematology 10.1182/blood.2020006520 Silverchair:460672 Unique_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 COVID-19 and its implications for thrombosis and anticoagulation The American Society of Hematology American Society of Hematology 10.1182/blood.2020006000 Silverchair:454646 Total_Item_Investigations 11 1 6 0 0 1 0 0 0 3 0 0 0 COVID-19 and its implications for thrombosis and anticoagulation The American Society of Hematology American Society of Hematology 10.1182/blood.2020006000 Silverchair:454646 Total_Item_Requests 10 1 5 0 0 1 0 0 0 3 0 0 0 COVID-19 and its implications for thrombosis and anticoagulation The American Society of Hematology American Society of Hematology 10.1182/blood.2020006000 Silverchair:454646 Unique_Item_Investigations 6 1 3 0 0 1 0 0 0 1 0 0 0 COVID-19 and its implications for thrombosis and anticoagulation The American Society of Hematology American Society of Hematology 10.1182/blood.2020006000 Silverchair:454646 Unique_Item_Requests 6 1 3 0 0 1 0 0 0 1 0 0 0 COVID-19 and the Coombs test The American Society of Hematology American Society of Hematology 10.1182/blood.2020007483 Silverchair:461638 Total_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 COVID-19 and the Coombs test The American Society of Hematology American Society of Hematology 10.1182/blood.2020007483 Silverchair:461638 Total_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 COVID-19 and the Coombs test The American Society of Hematology American Society of Hematology 10.1182/blood.2020007483 Silverchair:461638 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 COVID-19 and the Coombs test The American Society of Hematology American Society of Hematology 10.1182/blood.2020007483 Silverchair:461638 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 COVID-19 concerns aggregate around platelets The American Society of Hematology American Society of Hematology 10.1182/blood.2020007805 Silverchair:463625 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 COVID-19 concerns aggregate around platelets The American Society of Hematology American Society of Hematology 10.1182/blood.2020007805 Silverchair:463625 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 COVID-19 concerns aggregate around platelets The American Society of Hematology American Society of Hematology 10.1182/blood.2020007805 Silverchair:463625 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 COVID-19 concerns aggregate around platelets The American Society of Hematology American Society of Hematology 10.1182/blood.2020007805 Silverchair:463625 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003741 Silverchair:475624 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003741 Silverchair:475624 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003741 Silverchair:475624 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003741 Silverchair:475624 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140161 Silverchair:470398 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140161 Silverchair:470398 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140161 Silverchair:470398 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140161 Silverchair:470398 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 COVID-19 in Relation to Hematological Events (Thrombosis/Bleeding) and Mortality in Inpatient Setting The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142614 Silverchair:473143 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 COVID-19 in Relation to Hematological Events (Thrombosis/Bleeding) and Mortality in Inpatient Setting The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142614 Silverchair:473143 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 COVID-19 in Relation to Hematological Events (Thrombosis/Bleeding) and Mortality in Inpatient Setting The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142614 Silverchair:473143 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 COVID-19 in Relation to Hematological Events (Thrombosis/Bleeding) and Mortality in Inpatient Setting The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142614 Silverchair:473143 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 COVID-19 Prognostic Score Utilizing Hematological and Inflammatory Markers to Determine Outcomes of Hospitalized Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142971 Silverchair:473886 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 COVID-19 Prognostic Score Utilizing Hematological and Inflammatory Markers to Determine Outcomes of Hospitalized Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142971 Silverchair:473886 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 COVID-19 Prognostic Score Utilizing Hematological and Inflammatory Markers to Determine Outcomes of Hospitalized Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142971 Silverchair:473886 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 COVID-19 Prognostic Score Utilizing Hematological and Inflammatory Markers to Determine Outcomes of Hospitalized Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142971 Silverchair:473886 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria The American Society of Hematology American Society of Hematology 10.1182/blood.2021011548 Silverchair:475905 Total_Item_Investigations 3 0 0 0 0 2 0 0 0 0 0 1 0 COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria The American Society of Hematology American Society of Hematology 10.1182/blood.2021011548 Silverchair:475905 Total_Item_Requests 2 0 0 0 0 1 0 0 0 0 0 1 0 COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria The American Society of Hematology American Society of Hematology 10.1182/blood.2021011548 Silverchair:475905 Unique_Item_Investigations 2 0 0 0 0 1 0 0 0 0 0 1 0 COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria The American Society of Hematology American Society of Hematology 10.1182/blood.2021011548 Silverchair:475905 Unique_Item_Requests 2 0 0 0 0 1 0 0 0 0 0 1 0 COVID-19: B-Cell Depletion and Sepsis Related Changes in Bone Marrow and Spleen The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136199 Silverchair:471464 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 COVID-19: B-Cell Depletion and Sepsis Related Changes in Bone Marrow and Spleen The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136199 Silverchair:471464 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 COVID-19: B-Cell Depletion and Sepsis Related Changes in Bone Marrow and Spleen The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136199 Silverchair:471464 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 COVID-19: B-Cell Depletion and Sepsis Related Changes in Bone Marrow and Spleen The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136199 Silverchair:471464 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 CPX-351 Enables Administration of Consolidation Treatment in the Outpatient Setting and Increases the Time Spent out of the Hospital after Completion of AML Treatment Compared with 7+3 The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4507.4507 Silverchair:93618 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 2 0 0 0 CPX-351 Enables Administration of Consolidation Treatment in the Outpatient Setting and Increases the Time Spent out of the Hospital after Completion of AML Treatment Compared with 7+3 The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4507.4507 Silverchair:93618 Total_Item_Requests 2 0 0 0 0 0 0 0 0 2 0 0 0 CPX-351 Enables Administration of Consolidation Treatment in the Outpatient Setting and Increases the Time Spent out of the Hospital after Completion of AML Treatment Compared with 7+3 The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4507.4507 Silverchair:93618 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 CPX-351 Enables Administration of Consolidation Treatment in the Outpatient Setting and Increases the Time Spent out of the Hospital after Completion of AML Treatment Compared with 7+3 The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4507.4507 Silverchair:93618 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 CPX-351 for the Treatment of High-Risk Patients with Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4047.4047 Silverchair:114253 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 CPX-351 for the Treatment of High-Risk Patients with Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4047.4047 Silverchair:114253 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 CPX-351 for the Treatment of High-Risk Patients with Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4047.4047 Silverchair:114253 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 CPX-351 for the Treatment of High-Risk Patients with Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4047.4047 Silverchair:114253 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142990 Silverchair:471780 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142990 Silverchair:471780 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142990 Silverchair:471780 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142990 Silverchair:471780 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 "CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations (TP53, ASXL1, RUNX1 and EVI1) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125623 Silverchair:427327 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations (TP53, ASXL1, RUNX1 and EVI1) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125623 Silverchair:427327 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations (TP53, ASXL1, RUNX1 and EVI1) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125623 Silverchair:427327 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations (TP53, ASXL1, RUNX1 and EVI1) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125623 Silverchair:427327 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231 The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134730 Silverchair:470038 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231 The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134730 Silverchair:470038 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231 The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134730 Silverchair:470038 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231 The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134730 Silverchair:470038 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-529313 Silverchair:32155 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-529313 Silverchair:32155 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-529313 Silverchair:32155 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-529313 Silverchair:32155 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy The American Society of Hematology American Society of Hematology 10.1182/blood.2019004108 Silverchair:474390 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy The American Society of Hematology American Society of Hematology 10.1182/blood.2019004108 Silverchair:474390 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-787598 Silverchair:38326 Total_Item_Investigations 4 0 2 0 0 0 0 0 2 0 0 0 0 CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-787598 Silverchair:38326 Total_Item_Requests 4 0 2 0 0 0 0 0 2 0 0 0 0 CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-787598 Silverchair:38326 Unique_Item_Investigations 2 0 1 0 0 0 0 0 1 0 0 0 0 CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-787598 Silverchair:38326 Unique_Item_Requests 2 0 1 0 0 0 0 0 1 0 0 0 0 Critical influences on the pathogenesis of follicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-764365 Silverchair:37112 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Critical influences on the pathogenesis of follicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-764365 Silverchair:37112 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Critical influences on the pathogenesis of follicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-764365 Silverchair:37112 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Critical influences on the pathogenesis of follicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-764365 Silverchair:37112 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Critical requirement of VEGF-C in transition to fetal erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-12-687970 Silverchair:35554 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Critical requirement of VEGF-C in transition to fetal erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-12-687970 Silverchair:35554 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Critical requirement of VEGF-C in transition to fetal erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-12-687970 Silverchair:35554 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Critical requirement of VEGF-C in transition to fetal erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-12-687970 Silverchair:35554 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Cross Talk between Ikaros and RUNX1 in Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3789.3789 Silverchair:71992 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Cross Talk between Ikaros and RUNX1 in Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3789.3789 Silverchair:71992 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Cross Talk between Ikaros and RUNX1 in Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3789.3789 Silverchair:71992 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Cross Talk between Ikaros and RUNX1 in Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3789.3789 Silverchair:71992 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack" The American Society of Hematology American Society of Hematology 10.1182/blood.V99.10.3707 Silverchair:106989 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack" The American Society of Hematology American Society of Hematology 10.1182/blood.V99.10.3707 Silverchair:106989 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack" The American Society of Hematology American Society of Hematology 10.1182/blood.V99.10.3707 Silverchair:106989 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack" The American Society of Hematology American Society of Hematology 10.1182/blood.V99.10.3707 Silverchair:106989 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Cryptogenic oozers and bruisers The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000236 Silverchair:482936 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 0 2 Cryptogenic oozers and bruisers The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000236 Silverchair:482936 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 0 2 Cryptogenic oozers and bruisers The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000236 Silverchair:482936 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Cryptogenic oozers and bruisers The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000236 Silverchair:482936 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Crystal structure and functional interpretation of the erythrocyte spectrin tetramerization domain complex The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-261396 Silverchair:27813 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Crystal structure and functional interpretation of the erythrocyte spectrin tetramerization domain complex The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-261396 Silverchair:27813 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Crystal structure and functional interpretation of the erythrocyte spectrin tetramerization domain complex The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-261396 Silverchair:27813 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Crystal structure and functional interpretation of the erythrocyte spectrin tetramerization domain complex The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-261396 Silverchair:27813 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-838946 Silverchair:260569 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-838946 Silverchair:260569 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-838946 Silverchair:260569 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-838946 Silverchair:260569 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 CTLA-4: a moving target in immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-741033 Silverchair:107717 Total_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 CTLA-4: a moving target in immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-741033 Silverchair:107717 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 CTLA-4: a moving target in immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-741033 Silverchair:107717 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 CTLA-4: a moving target in immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-741033 Silverchair:107717 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.228 Silverchair:277593 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.228 Silverchair:277593 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.228 Silverchair:277593 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.228 Silverchair:277593 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Current concepts in the diagnosis and management of cytokine release syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-552729 Silverchair:32896 Total_Item_Investigations 4 0 1 3 0 0 0 0 0 0 0 0 0 Current concepts in the diagnosis and management of cytokine release syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-552729 Silverchair:32896 Total_Item_Requests 4 0 1 3 0 0 0 0 0 0 0 0 0 Current concepts in the diagnosis and management of cytokine release syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-552729 Silverchair:32896 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Current concepts in the diagnosis and management of cytokine release syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-552729 Silverchair:32896 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Current concepts in the pathophysiology and treatment of aplastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2006-03-010777 Silverchair:22551 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Current concepts in the pathophysiology and treatment of aplastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2006-03-010777 Silverchair:22551 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Current concepts in the pathophysiology and treatment of aplastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2006-03-010777 Silverchair:22551 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Current concepts in the pathophysiology and treatment of aplastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2006-03-010777 Silverchair:22551 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Current concepts on the pathogenesis of the antiphospholipid syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-001206 Silverchair:23518 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Current concepts on the pathogenesis of the antiphospholipid syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-001206 Silverchair:23518 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Current concepts on the pathogenesis of the antiphospholipid syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-001206 Silverchair:23518 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Current concepts on the pathogenesis of the antiphospholipid syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-001206 Silverchair:23518 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Current Controversies in the Formation and Treatment of Alloantibodies to Factor VIII in Congenital Hemophilia A The American Society of Hematology American Society of Hematology 10.1182/asheducation-2011.1.407 Silverchair:96477 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Current Controversies in the Formation and Treatment of Alloantibodies to Factor VIII in Congenital Hemophilia A The American Society of Hematology American Society of Hematology 10.1182/asheducation-2011.1.407 Silverchair:96477 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Current Controversies in the Formation and Treatment of Alloantibodies to Factor VIII in Congenital Hemophilia A The American Society of Hematology American Society of Hematology 10.1182/asheducation-2011.1.407 Silverchair:96477 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Current Controversies in the Formation and Treatment of Alloantibodies to Factor VIII in Congenital Hemophilia A The American Society of Hematology American Society of Hematology 10.1182/asheducation-2011.1.407 Silverchair:96477 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Current management of immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2013.1.276 Silverchair:20826 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Current management of immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2013.1.276 Silverchair:20826 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Current management of immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2013.1.276 Silverchair:20826 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Current management of immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2013.1.276 Silverchair:20826 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Cutaneous extranodal NK/T-cell lymphoma: a clinicopathologic study of 5 patients with array-based comparative genomic hybridization The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-252957 Silverchair:27150 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Cutaneous extranodal NK/T-cell lymphoma: a clinicopathologic study of 5 patients with array-based comparative genomic hybridization The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-252957 Silverchair:27150 Total_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 Cutaneous extranodal NK/T-cell lymphoma: a clinicopathologic study of 5 patients with array-based comparative genomic hybridization The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-252957 Silverchair:27150 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Cutaneous extranodal NK/T-cell lymphoma: a clinicopathologic study of 5 patients with array-based comparative genomic hybridization The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-252957 Silverchair:27150 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Cutting not the key to TMPRSS6 activity? The American Society of Hematology American Society of Hematology 10.1182/blood.2020006608 Silverchair:463241 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Cutting not the key to TMPRSS6 activity? The American Society of Hematology American Society of Hematology 10.1182/blood.2020006608 Silverchair:463241 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Cutting not the key to TMPRSS6 activity? The American Society of Hematology American Society of Hematology 10.1182/blood.2020006608 Silverchair:463241 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Cutting not the key to TMPRSS6 activity? The American Society of Hematology American Society of Hematology 10.1182/blood.2020006608 Silverchair:463241 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 CX3CL1/fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis The American Society of Hematology American Society of Hematology 10.1182/blood-2008-06-162404 Silverchair:24980 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 CX3CL1/fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis The American Society of Hematology American Society of Hematology 10.1182/blood-2008-06-162404 Silverchair:24980 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 CX3CL1/fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis The American Society of Hematology American Society of Hematology 10.1182/blood-2008-06-162404 Silverchair:24980 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 CX3CL1/fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis The American Society of Hematology American Society of Hematology 10.1182/blood-2008-06-162404 Silverchair:24980 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 CX3CR1 reduces Ly6Chigh-monocyte motility within and release from the bone marrow after chemotherapy in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-480749 Silverchair:32085 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 CX3CR1 reduces Ly6Chigh-monocyte motility within and release from the bone marrow after chemotherapy in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-480749 Silverchair:32085 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 CX3CR1 reduces Ly6Chigh-monocyte motility within and release from the bone marrow after chemotherapy in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-480749 Silverchair:32085 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 CX3CR1 reduces Ly6Chigh-monocyte motility within and release from the bone marrow after chemotherapy in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-480749 Silverchair:32085 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 CXCR3-mediated chemotaxis of human T cells is regulated by a Gi- and phospholipase C–dependent pathway and not via activation of MEK/p44/p42 MAPK nor Akt/PI-3 kinase The American Society of Hematology American Society of Hematology 10.1182/blood-2002-12-3945 Silverchair:17166 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 CXCR3-mediated chemotaxis of human T cells is regulated by a Gi- and phospholipase C–dependent pathway and not via activation of MEK/p44/p42 MAPK nor Akt/PI-3 kinase The American Society of Hematology American Society of Hematology 10.1182/blood-2002-12-3945 Silverchair:17166 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 CXCR3-mediated chemotaxis of human T cells is regulated by a Gi- and phospholipase C–dependent pathway and not via activation of MEK/p44/p42 MAPK nor Akt/PI-3 kinase The American Society of Hematology American Society of Hematology 10.1182/blood-2002-12-3945 Silverchair:17166 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 CXCR3-mediated chemotaxis of human T cells is regulated by a Gi- and phospholipase C–dependent pathway and not via activation of MEK/p44/p42 MAPK nor Akt/PI-3 kinase The American Society of Hematology American Society of Hematology 10.1182/blood-2002-12-3945 Silverchair:17166 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 CXCR4 signaling controls dendritic cell location and activation at steady state and in inflammation The American Society of Hematology American Society of Hematology 10.1182/blood.2020006675 Silverchair:475040 Total_Item_Investigations 4 0 2 0 0 1 1 0 0 0 0 0 0 CXCR4 signaling controls dendritic cell location and activation at steady state and in inflammation The American Society of Hematology American Society of Hematology 10.1182/blood.2020006675 Silverchair:475040 Unique_Item_Investigations 3 0 1 0 0 1 1 0 0 0 0 0 0 CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2005-08-3182 Silverchair:133400 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2005-08-3182 Silverchair:133400 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2005-08-3182 Silverchair:133400 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2005-08-3182 Silverchair:133400 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 CXCR4-Expressing Anti-CD25 CAR T-Cells Effectively Eliminate Human AML Cells In Vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142228 Silverchair:472102 Total_Item_Investigations 5 0 0 0 0 2 1 2 0 0 0 0 0 CXCR4-Expressing Anti-CD25 CAR T-Cells Effectively Eliminate Human AML Cells In Vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142228 Silverchair:472102 Total_Item_Requests 5 0 0 0 0 2 1 2 0 0 0 0 0 CXCR4-Expressing Anti-CD25 CAR T-Cells Effectively Eliminate Human AML Cells In Vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142228 Silverchair:472102 Unique_Item_Investigations 4 0 0 0 0 1 1 2 0 0 0 0 0 CXCR4-Expressing Anti-CD25 CAR T-Cells Effectively Eliminate Human AML Cells In Vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142228 Silverchair:472102 Unique_Item_Requests 4 0 0 0 0 1 1 2 0 0 0 0 0 Cyclin D1-negative mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-475954 Silverchair:138789 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Cyclin D1-negative mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-475954 Silverchair:138789 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Cyclin D1-negative mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-475954 Silverchair:138789 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Cyclin D1-negative mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-475954 Silverchair:138789 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Cyclin D1–negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling The American Society of Hematology American Society of Hematology 10.1182/blood-2005-04-1753 Silverchair:133229 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Cyclin D1–negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling The American Society of Hematology American Society of Hematology 10.1182/blood-2005-04-1753 Silverchair:133229 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Cyclin D1–negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling The American Society of Hematology American Society of Hematology 10.1182/blood-2005-04-1753 Silverchair:133229 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Cyclin D1–negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling The American Society of Hematology American Society of Hematology 10.1182/blood-2005-04-1753 Silverchair:133229 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood.V84.3.941.941 Silverchair:172068 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood.V84.3.941.941 Silverchair:172068 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood.V84.3.941.941 Silverchair:172068 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood.V84.3.941.941 Silverchair:172068 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-251231 Silverchair:27380 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-251231 Silverchair:27380 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-251231 Silverchair:27380 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-251231 Silverchair:27380 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111835 Silverchair:264848 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111835 Silverchair:264848 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111835 Silverchair:264848 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111835 Silverchair:264848 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Cytarabine and Etoposide (CYVE) as First-Line Therapy for Primary Central Nervous System Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.4895.4895 Silverchair:66671 Total_Item_Investigations 2 1 0 0 0 0 0 1 0 0 0 0 0 Cytarabine and Etoposide (CYVE) as First-Line Therapy for Primary Central Nervous System Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.4895.4895 Silverchair:66671 Total_Item_Requests 2 1 0 0 0 0 0 1 0 0 0 0 0 Cytarabine and Etoposide (CYVE) as First-Line Therapy for Primary Central Nervous System Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.4895.4895 Silverchair:66671 Unique_Item_Investigations 2 1 0 0 0 0 0 1 0 0 0 0 0 Cytarabine and Etoposide (CYVE) as First-Line Therapy for Primary Central Nervous System Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.4895.4895 Silverchair:66671 Unique_Item_Requests 2 1 0 0 0 0 0 1 0 0 0 0 0 Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Français de Cytogénétique Hématologique (GFCH) The American Society of Hematology American Society of Hematology 10.1182/blood-2001-12-0241 Silverchair:89123 Total_Item_Investigations 5 0 0 5 0 0 0 0 0 0 0 0 0 Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Français de Cytogénétique Hématologique (GFCH) The American Society of Hematology American Society of Hematology 10.1182/blood-2001-12-0241 Silverchair:89123 Total_Item_Requests 5 0 0 5 0 0 0 0 0 0 0 0 0 Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Français de Cytogénétique Hématologique (GFCH) The American Society of Hematology American Society of Hematology 10.1182/blood-2001-12-0241 Silverchair:89123 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Français de Cytogénétique Hématologique (GFCH) The American Society of Hematology American Society of Hematology 10.1182/blood-2001-12-0241 Silverchair:89123 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Cytokine activation induces human memory-like NK cells The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-419283 Silverchair:31009 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Cytokine activation induces human memory-like NK cells The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-419283 Silverchair:31009 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Cytokine activation induces human memory-like NK cells The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-419283 Silverchair:31009 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Cytokine activation induces human memory-like NK cells The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-419283 Silverchair:31009 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Cytokine combinations for human blood stem cell expansion induce cell type- and cytokine-specific signaling dynamics The American Society of Hematology American Society of Hematology 10.1182/blood.2020008386 Silverchair:475970 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Cytokine combinations for human blood stem cell expansion induce cell type- and cytokine-specific signaling dynamics The American Society of Hematology American Society of Hematology 10.1182/blood.2020008386 Silverchair:475970 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-485623 Silverchair:31547 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-485623 Silverchair:31547 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-485623 Silverchair:31547 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-485623 Silverchair:31547 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.2020009396 Silverchair:475413 Total_Item_Investigations 4 0 0 0 0 0 0 4 0 0 0 0 0 Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.2020009396 Silverchair:475413 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 "Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122497 Silverchair:427126 Total_Item_Investigations 5 0 0 5 0 0 0 0 0 0 0 0 0 "Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122497 Silverchair:427126 Total_Item_Requests 5 0 0 5 0 0 0 0 0 0 0 0 0 "Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122497 Silverchair:427126 Unique_Item_Investigations 5 0 0 5 0 0 0 0 0 0 0 0 0 "Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122497 Silverchair:427126 Unique_Item_Requests 5 0 0 5 0 0 0 0 0 0 0 0 0 Daratumumab for immune thrombotic thrombocytopenic purpura American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005124 Silverchair:476991 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Daratumumab for immune thrombotic thrombocytopenic purpura American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005124 Silverchair:476991 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Daratumumab for immune thrombotic thrombocytopenic purpura American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005124 Silverchair:476991 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Daratumumab for immune thrombotic thrombocytopenic purpura American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005124 Silverchair:476991 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130134 Silverchair:425424 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130134 Silverchair:425424 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130134 Silverchair:425424 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130134 Silverchair:425424 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2019000722 Silverchair:273899 Total_Item_Investigations 4 1 0 0 0 0 0 0 3 0 0 0 0 Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2019000722 Silverchair:273899 Total_Item_Requests 4 1 0 0 0 0 0 0 3 0 0 0 0 Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2019000722 Silverchair:273899 Unique_Item_Investigations 2 1 0 0 0 0 0 0 1 0 0 0 0 Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2019000722 Silverchair:273899 Unique_Item_Requests 2 1 0 0 0 0 0 0 1 0 0 0 0 Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA The American Society of Hematology American Society of Hematology 10.1182/blood.2019004460 Silverchair:454281 Total_Item_Investigations 26 4 9 1 0 1 0 3 2 4 2 0 0 Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA The American Society of Hematology American Society of Hematology 10.1182/blood.2019004460 Silverchair:454281 Unique_Item_Investigations 18 2 7 1 0 1 0 3 2 1 1 0 0 Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA The American Society of Hematology American Society of Hematology 10.1182/blood.2019004460 Silverchair:454281 Total_Item_Requests 24 4 9 1 0 1 0 3 2 2 2 0 0 Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA The American Society of Hematology American Society of Hematology 10.1182/blood.2019004460 Silverchair:454281 Unique_Item_Requests 18 2 7 1 0 1 0 3 2 1 1 0 0 Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-785246 Silverchair:36976 Total_Item_Investigations 10 8 0 0 0 0 0 0 0 0 2 0 0 Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-785246 Silverchair:36976 Total_Item_Requests 10 8 0 0 0 0 0 0 0 0 2 0 0 Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-785246 Silverchair:36976 Unique_Item_Investigations 5 4 0 0 0 0 0 0 0 0 1 0 0 Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-785246 Silverchair:36976 Unique_Item_Requests 5 4 0 0 0 0 0 0 0 0 1 0 0 Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003642 Silverchair:475239 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003642 Silverchair:475239 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003642 Silverchair:475239 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003642 Silverchair:475239 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123170 Silverchair:427102 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123170 Silverchair:427102 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123170 Silverchair:427102 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123170 Silverchair:427102 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial" The American Society of Hematology American Society of Hematology 10.1182/blood.2020005288 Silverchair:454474 Total_Item_Investigations 33 15 4 6 0 0 2 2 2 0 2 0 0 "Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial" The American Society of Hematology American Society of Hematology 10.1182/blood.2020005288 Silverchair:454474 Total_Item_Requests 33 15 4 6 0 0 2 2 2 0 2 0 0 "Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial" The American Society of Hematology American Society of Hematology 10.1182/blood.2020005288 Silverchair:454474 Unique_Item_Investigations 23 12 3 4 0 0 1 1 1 0 1 0 0 "Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial" The American Society of Hematology American Society of Hematology 10.1182/blood.2020005288 Silverchair:454474 Unique_Item_Requests 23 12 3 4 0 0 1 1 1 0 1 0 0 Darbepoetin Efficacy in Myelodysplastic Syndrome. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.4704.4704 Silverchair:55670 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Darbepoetin Efficacy in Myelodysplastic Syndrome. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.4704.4704 Silverchair:55670 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Darbepoetin Efficacy in Myelodysplastic Syndrome. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.4704.4704 Silverchair:55670 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Darbepoetin Efficacy in Myelodysplastic Syndrome. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.4704.4704 Silverchair:55670 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 DARTs point the way forward in AML The American Society of Hematology American Society of Hematology 10.1182/blood.2020009020 Silverchair:475171 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 DARTs point the way forward in AML The American Society of Hematology American Society of Hematology 10.1182/blood.2020009020 Silverchair:475171 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 DARTs point the way forward in AML The American Society of Hematology American Society of Hematology 10.1182/blood.2020009020 Silverchair:475171 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 DARTs point the way forward in AML The American Society of Hematology American Society of Hematology 10.1182/blood.2020009020 Silverchair:475171 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 DARTs take aim at BiTEs The American Society of Hematology American Society of Hematology 10.1182/blood-2011-02-337691 Silverchair:20840 Total_Item_Investigations 4 1 3 0 0 0 0 0 0 0 0 0 0 DARTs take aim at BiTEs The American Society of Hematology American Society of Hematology 10.1182/blood-2011-02-337691 Silverchair:20840 Total_Item_Requests 4 1 3 0 0 0 0 0 0 0 0 0 0 DARTs take aim at BiTEs The American Society of Hematology American Society of Hematology 10.1182/blood-2011-02-337691 Silverchair:20840 Unique_Item_Investigations 3 1 2 0 0 0 0 0 0 0 0 0 0 DARTs take aim at BiTEs The American Society of Hematology American Society of Hematology 10.1182/blood-2011-02-337691 Silverchair:20840 Unique_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-351403 Silverchair:29236 Total_Item_Investigations 4 1 1 0 0 0 0 2 0 0 0 0 0 Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-351403 Silverchair:29236 Total_Item_Requests 4 1 1 0 0 0 0 2 0 0 0 0 0 Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-351403 Silverchair:29236 Unique_Item_Investigations 3 1 1 0 0 0 0 1 0 0 0 0 0 Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-351403 Silverchair:29236 Unique_Item_Requests 3 1 1 0 0 0 0 1 0 0 0 0 0 Dasatinib Increases MHCII Surface Levels and Can Synergize with Anti-PD1 Therapy to Increase the Anti-Tumor Effect in a Pre-Clinical Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Model The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141654 Silverchair:472501 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Dasatinib Increases MHCII Surface Levels and Can Synergize with Anti-PD1 Therapy to Increase the Anti-Tumor Effect in a Pre-Clinical Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Model The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141654 Silverchair:472501 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Dasatinib Increases MHCII Surface Levels and Can Synergize with Anti-PD1 Therapy to Increase the Anti-Tumor Effect in a Pre-Clinical Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Model The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141654 Silverchair:472501 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Dasatinib Increases MHCII Surface Levels and Can Synergize with Anti-PD1 Therapy to Increase the Anti-Tumor Effect in a Pre-Clinical Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Model The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141654 Silverchair:472501 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-376087 Silverchair:29777 Total_Item_Investigations 8 0 0 0 0 0 8 0 0 0 0 0 0 Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-376087 Silverchair:29777 Total_Item_Requests 8 0 0 0 0 0 8 0 0 0 0 0 0 Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-376087 Silverchair:29777 Unique_Item_Investigations 3 0 0 0 0 0 3 0 0 0 0 0 0 Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-376087 Silverchair:29777 Unique_Item_Requests 3 0 0 0 0 0 3 0 0 0 0 0 0 Data quality in the study of the mechanisms of extracorporeal photochemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-306662 Silverchair:28729 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Data quality in the study of the mechanisms of extracorporeal photochemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-306662 Silverchair:28729 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Data quality in the study of the mechanisms of extracorporeal photochemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-306662 Silverchair:28729 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Data quality in the study of the mechanisms of extracorporeal photochemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-306662 Silverchair:28729 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "DCEP (Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin) Followed by High-Dose G-CSF Is a Highly Efficient and Safe Regimen for Stem Cell Mobilization for Multiple Myeloma." The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3284.3284 Silverchair:75491 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 "DCEP (Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin) Followed by High-Dose G-CSF Is a Highly Efficient and Safe Regimen for Stem Cell Mobilization for Multiple Myeloma." The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3284.3284 Silverchair:75491 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 "DCEP (Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin) Followed by High-Dose G-CSF Is a Highly Efficient and Safe Regimen for Stem Cell Mobilization for Multiple Myeloma." The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3284.3284 Silverchair:75491 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 "DCEP (Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin) Followed by High-Dose G-CSF Is a Highly Efficient and Safe Regimen for Stem Cell Mobilization for Multiple Myeloma." The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3284.3284 Silverchair:75491 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-548065 Silverchair:32915 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-548065 Silverchair:32915 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-548065 Silverchair:32915 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-548065 Silverchair:32915 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "D-Dimer, P-Selectin, and Microparticles: Novel Markers To Predict Deep Venous Thrombosis." The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.2607.2607 Silverchair:55122 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "D-Dimer, P-Selectin, and Microparticles: Novel Markers To Predict Deep Venous Thrombosis." The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.2607.2607 Silverchair:55122 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "D-Dimer, P-Selectin, and Microparticles: Novel Markers To Predict Deep Venous Thrombosis." The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.2607.2607 Silverchair:55122 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "D-Dimer, P-Selectin, and Microparticles: Novel Markers To Predict Deep Venous Thrombosis." The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.2607.2607 Silverchair:55122 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "De Novo Anemia and Relationship with Vitamin C Deficiency and Zinc Deficiency in a Southern Delaware Population, a Retrospective Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4547.4547 Silverchair:93596 Total_Item_Investigations 5 0 5 0 0 0 0 0 0 0 0 0 0 "De Novo Anemia and Relationship with Vitamin C Deficiency and Zinc Deficiency in a Southern Delaware Population, a Retrospective Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4547.4547 Silverchair:93596 Total_Item_Requests 5 0 5 0 0 0 0 0 0 0 0 0 0 "De Novo Anemia and Relationship with Vitamin C Deficiency and Zinc Deficiency in a Southern Delaware Population, a Retrospective Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4547.4547 Silverchair:93596 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "De Novo Anemia and Relationship with Vitamin C Deficiency and Zinc Deficiency in a Southern Delaware Population, a Retrospective Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4547.4547 Silverchair:93596 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 De novo generation of HSCs from somatic and pluripotent stem cell sources The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-570234 Silverchair:34098 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 De novo generation of HSCs from somatic and pluripotent stem cell sources The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-570234 Silverchair:34098 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 De novo generation of HSCs from somatic and pluripotent stem cell sources The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-570234 Silverchair:34098 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 De novo generation of HSCs from somatic and pluripotent stem cell sources The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-570234 Silverchair:34098 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Decay-Accelerating Factor (CD55) and Membrane Inhibitor of Reactive Lysis (CD59) Are Released Within Exosomes During In Vitro Maturation of Reticulocytes The American Society of Hematology American Society of Hematology 10.1182/blood.V91.7.2573 Silverchair:261124 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Decay-Accelerating Factor (CD55) and Membrane Inhibitor of Reactive Lysis (CD59) Are Released Within Exosomes During In Vitro Maturation of Reticulocytes The American Society of Hematology American Society of Hematology 10.1182/blood.V91.7.2573 Silverchair:261124 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Decay-Accelerating Factor (CD55) and Membrane Inhibitor of Reactive Lysis (CD59) Are Released Within Exosomes During In Vitro Maturation of Reticulocytes The American Society of Hematology American Society of Hematology 10.1182/blood.V91.7.2573 Silverchair:261124 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Decay-Accelerating Factor (CD55) and Membrane Inhibitor of Reactive Lysis (CD59) Are Released Within Exosomes During In Vitro Maturation of Reticulocytes The American Society of Hematology American Society of Hematology 10.1182/blood.V91.7.2573 Silverchair:261124 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138680 Silverchair:470421 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138680 Silverchair:470421 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138680 Silverchair:470421 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138680 Silverchair:470421 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Deconstructing the Threat of the Fava Bean American Society of Hematology American Society of Hematology 10.1182/hem.V15.2.8304 Silverchair:463044 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Deconstructing the Threat of the Fava Bean American Society of Hematology American Society of Hematology 10.1182/hem.V15.2.8304 Silverchair:463044 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Deconstructing the Threat of the Fava Bean American Society of Hematology American Society of Hematology 10.1182/hem.V15.2.8304 Silverchair:463044 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Deconstructing the Threat of the Fava Bean American Society of Hematology American Society of Hematology 10.1182/hem.V15.2.8304 Silverchair:463044 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Decreased Expression of KLF2 and KLF4 Induced by Antiphospholipid Antibodies Promotes NF-Kb-Mediated Endothelial Cell Activation and Is Modulated by CBP/p300 The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.4315.4315 Silverchair:67964 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Decreased Expression of KLF2 and KLF4 Induced by Antiphospholipid Antibodies Promotes NF-Kb-Mediated Endothelial Cell Activation and Is Modulated by CBP/p300 The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.4315.4315 Silverchair:67964 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Decreased Expression of KLF2 and KLF4 Induced by Antiphospholipid Antibodies Promotes NF-Kb-Mediated Endothelial Cell Activation and Is Modulated by CBP/p300 The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.4315.4315 Silverchair:67964 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Decreased Expression of KLF2 and KLF4 Induced by Antiphospholipid Antibodies Promotes NF-Kb-Mediated Endothelial Cell Activation and Is Modulated by CBP/p300 The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.4315.4315 Silverchair:67964 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2020006731 Silverchair:461433 No_License 7 0 7 0 0 0 0 0 0 0 0 0 0 Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2020006731 Silverchair:461433 Total_Item_Investigations 14 0 14 0 0 0 0 0 0 0 0 0 0 Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2020006731 Silverchair:461433 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Defective cytotoxic lymphocyte degranulation in syntaxin-11–deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-074468 Silverchair:24169 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Defective cytotoxic lymphocyte degranulation in syntaxin-11–deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-074468 Silverchair:24169 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Defective cytotoxic lymphocyte degranulation in syntaxin-11–deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-074468 Silverchair:24169 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Defective cytotoxic lymphocyte degranulation in syntaxin-11–deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-074468 Silverchair:24169 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Defective palmitoylation of transferrin receptor triggers iron overload in Friedreich ataxia fibroblasts The American Society of Hematology American Society of Hematology 10.1182/blood.2020006987 Silverchair:475139 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Defective palmitoylation of transferrin receptor triggers iron overload in Friedreich ataxia fibroblasts The American Society of Hematology American Society of Hematology 10.1182/blood.2020006987 Silverchair:475139 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Defective release of α granule and lysosome contents from platelets in mouse Hermansky-Pudlak syndrome models The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-586727 Silverchair:33799 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Defective release of α granule and lysosome contents from platelets in mouse Hermansky-Pudlak syndrome models The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-586727 Silverchair:33799 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Defective release of α granule and lysosome contents from platelets in mouse Hermansky-Pudlak syndrome models The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-586727 Silverchair:33799 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Defective release of α granule and lysosome contents from platelets in mouse Hermansky-Pudlak syndrome models The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-586727 Silverchair:33799 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Defective ribosome assembly in Shwachman-Diamond syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-353938 Silverchair:28856 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Defective ribosome assembly in Shwachman-Diamond syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-353938 Silverchair:28856 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Defective ribosome assembly in Shwachman-Diamond syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-353938 Silverchair:28856 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Defective ribosome assembly in Shwachman-Diamond syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-353938 Silverchair:28856 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Defective tubulin organization and proplatelet formation in murine megakaryocytes lacking Rac1 and Cdc42 The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-487942 Silverchair:31840 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Defective tubulin organization and proplatelet formation in murine megakaryocytes lacking Rac1 and Cdc42 The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-487942 Silverchair:31840 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Defective tubulin organization and proplatelet formation in murine megakaryocytes lacking Rac1 and Cdc42 The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-487942 Silverchair:31840 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Defective tubulin organization and proplatelet formation in murine megakaryocytes lacking Rac1 and Cdc42 The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-487942 Silverchair:31840 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Defective WNT Signaling and Genetic Profile Of Endothelial Cells In Patients With Low Risk Myelodysplastic Syndromes Suggest a Contribution Of Vascular Niches To Myelodysplasia The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.860.860 Silverchair:70943 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Defective WNT Signaling and Genetic Profile Of Endothelial Cells In Patients With Low Risk Myelodysplastic Syndromes Suggest a Contribution Of Vascular Niches To Myelodysplasia The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.860.860 Silverchair:70943 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Defective WNT Signaling and Genetic Profile Of Endothelial Cells In Patients With Low Risk Myelodysplastic Syndromes Suggest a Contribution Of Vascular Niches To Myelodysplasia The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.860.860 Silverchair:70943 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Defective WNT Signaling and Genetic Profile Of Endothelial Cells In Patients With Low Risk Myelodysplastic Syndromes Suggest a Contribution Of Vascular Niches To Myelodysplasia The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.860.860 Silverchair:70943 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141872 Silverchair:473242 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141872 Silverchair:473242 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141872 Silverchair:473242 Unique_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141872 Silverchair:473242 Unique_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding The American Society of Hematology American Society of Hematology 10.1182/blood.V81.9.2357.2357 Silverchair:170107 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding The American Society of Hematology American Society of Hematology 10.1182/blood.V81.9.2357.2357 Silverchair:170107 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Defining ultrahigh-risk AL amyloidosis with VWF The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-717488 Silverchair:35530 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Defining ultrahigh-risk AL amyloidosis with VWF The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-717488 Silverchair:35530 Total_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 Defining ultrahigh-risk AL amyloidosis with VWF The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-717488 Silverchair:35530 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Defining ultrahigh-risk AL amyloidosis with VWF The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-717488 Silverchair:35530 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2020008346 Silverchair:469702 Total_Item_Investigations 5 3 0 2 0 0 0 0 0 0 0 0 0 del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2020008346 Silverchair:469702 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2020008346 Silverchair:469702 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2020008346 Silverchair:469702 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2010-12-325241 Silverchair:29053 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2010-12-325241 Silverchair:29053 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2010-12-325241 Silverchair:29053 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2010-12-325241 Silverchair:29053 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002876 Silverchair:475830 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002876 Silverchair:475830 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002876 Silverchair:475830 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002876 Silverchair:475830 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Deletions of the Transcription Factor Ikaros in Myeloproliferative Neoplasms at Transformation to Acute Myeloid Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.435.435 Silverchair:76901 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Deletions of the Transcription Factor Ikaros in Myeloproliferative Neoplasms at Transformation to Acute Myeloid Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.435.435 Silverchair:76901 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Deletions of the Transcription Factor Ikaros in Myeloproliferative Neoplasms at Transformation to Acute Myeloid Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.435.435 Silverchair:76901 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Deletions of the Transcription Factor Ikaros in Myeloproliferative Neoplasms at Transformation to Acute Myeloid Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.435.435 Silverchair:76901 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Delineation of antigen-specific and antigen-nonspecific CD8+ memory T-cell responses after cytokine-based cancer immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-369736 Silverchair:29620 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Delineation of antigen-specific and antigen-nonspecific CD8+ memory T-cell responses after cytokine-based cancer immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-369736 Silverchair:29620 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Delineation of antigen-specific and antigen-nonspecific CD8+ memory T-cell responses after cytokine-based cancer immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-369736 Silverchair:29620 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Delineation of antigen-specific and antigen-nonspecific CD8+ memory T-cell responses after cytokine-based cancer immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-369736 Silverchair:29620 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002378 Silverchair:475058 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002378 Silverchair:475058 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002378 Silverchair:475058 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002378 Silverchair:475058 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Density enhanced phosphatase-1 down-regulates urokinase receptor surface expression in confluent endothelial cells The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-307694 Silverchair:20694 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Density enhanced phosphatase-1 down-regulates urokinase receptor surface expression in confluent endothelial cells The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-307694 Silverchair:20694 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Density enhanced phosphatase-1 down-regulates urokinase receptor surface expression in confluent endothelial cells The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-307694 Silverchair:20694 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Density enhanced phosphatase-1 down-regulates urokinase receptor surface expression in confluent endothelial cells The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-307694 Silverchair:20694 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-631606 Silverchair:34398 Total_Item_Investigations 7 0 0 7 0 0 0 0 0 0 0 0 0 Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-631606 Silverchair:34398 Total_Item_Requests 7 0 0 7 0 0 0 0 0 0 0 0 0 Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-631606 Silverchair:34398 Unique_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-631606 Silverchair:34398 Unique_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 "Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-03-208397 Silverchair:26369 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-03-208397 Silverchair:26369 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-03-208397 Silverchair:26369 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-03-208397 Silverchair:26369 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Deregulation of the PI3K/Akt Signal Transduction Pathway Is Associated with the Development of Chemotherapy Resistance and Can be Effectively Targeted to Improve Chemoresponsiveness in Burkitt Lymphoma Pre-Clinical Models The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1769.1769 Silverchair:88449 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Deregulation of the PI3K/Akt Signal Transduction Pathway Is Associated with the Development of Chemotherapy Resistance and Can be Effectively Targeted to Improve Chemoresponsiveness in Burkitt Lymphoma Pre-Clinical Models The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1769.1769 Silverchair:88449 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Deregulation of the PI3K/Akt Signal Transduction Pathway Is Associated with the Development of Chemotherapy Resistance and Can be Effectively Targeted to Improve Chemoresponsiveness in Burkitt Lymphoma Pre-Clinical Models The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1769.1769 Silverchair:88449 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Deregulation of the PI3K/Akt Signal Transduction Pathway Is Associated with the Development of Chemotherapy Resistance and Can be Effectively Targeted to Improve Chemoresponsiveness in Burkitt Lymphoma Pre-Clinical Models The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1769.1769 Silverchair:88449 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Describing the Point Prevalence and Characteristics of Venous Thromboembolism in Patients with Thrombotic Thrombocytopenic Purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123081 Silverchair:422977 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Describing the Point Prevalence and Characteristics of Venous Thromboembolism in Patients with Thrombotic Thrombocytopenic Purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123081 Silverchair:422977 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Describing the Point Prevalence and Characteristics of Venous Thromboembolism in Patients with Thrombotic Thrombocytopenic Purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123081 Silverchair:422977 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Describing the Point Prevalence and Characteristics of Venous Thromboembolism in Patients with Thrombotic Thrombocytopenic Purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123081 Silverchair:422977 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood.2019001163 Silverchair:381159 Total_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood.2019001163 Silverchair:381159 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood.2019001163 Silverchair:381159 Total_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood.2019001163 Silverchair:381159 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Design and characterization of an APC-specific serpin for the treatment of hemophilia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-718635 Silverchair:35834 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Design and characterization of an APC-specific serpin for the treatment of hemophilia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-718635 Silverchair:35834 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Design and characterization of an APC-specific serpin for the treatment of hemophilia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-718635 Silverchair:35834 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Design and characterization of an APC-specific serpin for the treatment of hemophilia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-718635 Silverchair:35834 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials The American Society of Hematology American Society of Hematology 10.1182/blood-2008-04-150680 Silverchair:114975 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials The American Society of Hematology American Society of Hematology 10.1182/blood-2008-04-150680 Silverchair:114975 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials The American Society of Hematology American Society of Hematology 10.1182/blood-2008-04-150680 Silverchair:114975 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials The American Society of Hematology American Society of Hematology 10.1182/blood-2008-04-150680 Silverchair:114975 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Desmopressin (DDAVP) in the Treatment of Bleeding Disorders: The First 20 Years The American Society of Hematology American Society of Hematology 10.1182/blood.V90.7.2515 Silverchair:238641 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Desmopressin (DDAVP) in the Treatment of Bleeding Disorders: The First 20 Years The American Society of Hematology American Society of Hematology 10.1182/blood.V90.7.2515 Silverchair:238641 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Desmopressin (DDAVP) in the Treatment of Bleeding Disorders: The First 20 Years The American Society of Hematology American Society of Hematology 10.1182/blood.V90.7.2515 Silverchair:238641 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Desmopressin (DDAVP) in the Treatment of Bleeding Disorders: The First 20 Years The American Society of Hematology American Society of Hematology 10.1182/blood.V90.7.2515 Silverchair:238641 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Detection of Anaplastic Lymphoma Kinase (ALK) and Nucleolar Protein Nucleophosmin (NPM)-ALK Proteins in Normal and Neoplastic Cells With the Monoclonal Antibody ALK1 The American Society of Hematology American Society of Hematology 10.1182/blood.V89.4.1394 Silverchair:139101 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Detection of Anaplastic Lymphoma Kinase (ALK) and Nucleolar Protein Nucleophosmin (NPM)-ALK Proteins in Normal and Neoplastic Cells With the Monoclonal Antibody ALK1 The American Society of Hematology American Society of Hematology 10.1182/blood.V89.4.1394 Silverchair:139101 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Detection of Anaplastic Lymphoma Kinase (ALK) and Nucleolar Protein Nucleophosmin (NPM)-ALK Proteins in Normal and Neoplastic Cells With the Monoclonal Antibody ALK1 The American Society of Hematology American Society of Hematology 10.1182/blood.V89.4.1394 Silverchair:139101 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Detection of Anaplastic Lymphoma Kinase (ALK) and Nucleolar Protein Nucleophosmin (NPM)-ALK Proteins in Normal and Neoplastic Cells With the Monoclonal Antibody ALK1 The American Society of Hematology American Society of Hematology 10.1182/blood.V89.4.1394 Silverchair:139101 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Detection of c-Kit Mutation in Peripheral Blood vs. Bone Marrow Aspirates in Patients with Systemic Mastocytosis: Comparison Study of Pathological and Clinical Laboratory Findings in Patients with and without Detectable c-Kit Mutation in the Peripheral Blood. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.3596.3596 Silverchair:127110 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Detection of c-Kit Mutation in Peripheral Blood vs. Bone Marrow Aspirates in Patients with Systemic Mastocytosis: Comparison Study of Pathological and Clinical Laboratory Findings in Patients with and without Detectable c-Kit Mutation in the Peripheral Blood. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.3596.3596 Silverchair:127110 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Detection of c-Kit Mutation in Peripheral Blood vs. Bone Marrow Aspirates in Patients with Systemic Mastocytosis: Comparison Study of Pathological and Clinical Laboratory Findings in Patients with and without Detectable c-Kit Mutation in the Peripheral Blood. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.3596.3596 Silverchair:127110 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Detection of c-Kit Mutation in Peripheral Blood vs. Bone Marrow Aspirates in Patients with Systemic Mastocytosis: Comparison Study of Pathological and Clinical Laboratory Findings in Patients with and without Detectable c-Kit Mutation in the Peripheral Blood. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.3596.3596 Silverchair:127110 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals The American Society of Hematology American Society of Hematology 10.1182/blood.V86.8.3118.3118 Silverchair:174119 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals The American Society of Hematology American Society of Hematology 10.1182/blood.V86.8.3118.3118 Silverchair:174119 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals The American Society of Hematology American Society of Hematology 10.1182/blood.V86.8.3118.3118 Silverchair:174119 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals The American Society of Hematology American Society of Hematology 10.1182/blood.V86.8.3118.3118 Silverchair:174119 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Detection of the BCR-ABL Gene By the Real-Time PCR Method in Patients with Chronic Myeloid Leukemia in Rio Grande Do Norte, Brazil" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118853 Silverchair:265499 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Detection of the BCR-ABL Gene By the Real-Time PCR Method in Patients with Chronic Myeloid Leukemia in Rio Grande Do Norte, Brazil" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118853 Silverchair:265499 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Detection of the BCR-ABL Gene By the Real-Time PCR Method in Patients with Chronic Myeloid Leukemia in Rio Grande Do Norte, Brazil" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118853 Silverchair:265499 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Detection of the BCR-ABL Gene By the Real-Time PCR Method in Patients with Chronic Myeloid Leukemia in Rio Grande Do Norte, Brazil" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118853 Silverchair:265499 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.V98.8.2580 Silverchair:53315 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.V98.8.2580 Silverchair:53315 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.V98.8.2580 Silverchair:53315 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.V98.8.2580 Silverchair:53315 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Determinants of PF4/heparin immunogenicity The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-105098 Silverchair:103211 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Determinants of PF4/heparin immunogenicity The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-105098 Silverchair:103211 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Determinants of PF4/heparin immunogenicity The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-105098 Silverchair:103211 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Determinants of PF4/heparin immunogenicity The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-105098 Silverchair:103211 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Developing a Safer Anti-CD44v6 Chimeric Antigen Receptor T Cell Against Hematological Cancers By Mitigating on-Target Off-Tumor Toxicity The American Society of Hematology American Society of Hematology 10.1182/blood-2021-153927 Silverchair:482370 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Developing a Safer Anti-CD44v6 Chimeric Antigen Receptor T Cell Against Hematological Cancers By Mitigating on-Target Off-Tumor Toxicity The American Society of Hematology American Society of Hematology 10.1182/blood-2021-153927 Silverchair:482370 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Developing a Safer Anti-CD44v6 Chimeric Antigen Receptor T Cell Against Hematological Cancers By Mitigating on-Target Off-Tumor Toxicity The American Society of Hematology American Society of Hematology 10.1182/blood-2021-153927 Silverchair:482370 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Developing a Safer Anti-CD44v6 Chimeric Antigen Receptor T Cell Against Hematological Cancers By Mitigating on-Target Off-Tumor Toxicity The American Society of Hematology American Society of Hematology 10.1182/blood-2021-153927 Silverchair:482370 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-330852 Silverchair:24329 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-330852 Silverchair:24329 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-330852 Silverchair:24329 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-330852 Silverchair:24329 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Development and validation of a predictive model for chemotherapy-associated thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2007-10-116327 Silverchair:24209 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Development and validation of a predictive model for chemotherapy-associated thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2007-10-116327 Silverchair:24209 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Development and validation of a predictive model for chemotherapy-associated thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2007-10-116327 Silverchair:24209 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Development and validation of a predictive model for chemotherapy-associated thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2007-10-116327 Silverchair:24209 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-08-452938 Silverchair:31363 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-08-452938 Silverchair:31363 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-08-452938 Silverchair:31363 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-08-452938 Silverchair:31363 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis) The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-444067 Silverchair:30914 Total_Item_Investigations 2 0 0 0 0 0 2 0 0 0 0 0 0 Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis) The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-444067 Silverchair:30914 Total_Item_Requests 2 0 0 0 0 0 2 0 0 0 0 0 0 Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis) The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-444067 Silverchair:30914 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis) The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-444067 Silverchair:30914 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Development of a CD123xCD3 Bispecific Antibody (JNJ-63709178) for the Treatment of Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2824.2824 Silverchair:113777 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Development of a CD123xCD3 Bispecific Antibody (JNJ-63709178) for the Treatment of Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2824.2824 Silverchair:113777 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Development of a CD123xCD3 Bispecific Antibody (JNJ-63709178) for the Treatment of Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2824.2824 Silverchair:113777 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Development of a CD123xCD3 Bispecific Antibody (JNJ-63709178) for the Treatment of Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2824.2824 Silverchair:113777 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Development of a Genetically-Engineered Allogeneic Anti-CD38 T Cell Therapy Utilizing a Novel Antigen Receptor Structure The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131586 Silverchair:424788 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Development of a Genetically-Engineered Allogeneic Anti-CD38 T Cell Therapy Utilizing a Novel Antigen Receptor Structure The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131586 Silverchair:424788 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Development of a Genetically-Engineered Allogeneic Anti-CD38 T Cell Therapy Utilizing a Novel Antigen Receptor Structure The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131586 Silverchair:424788 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Development of a Genetically-Engineered Allogeneic Anti-CD38 T Cell Therapy Utilizing a Novel Antigen Receptor Structure The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131586 Silverchair:424788 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery The American Society of Hematology American Society of Hematology 10.1182/blood-2006-03-012534 Silverchair:22628 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery The American Society of Hematology American Society of Hematology 10.1182/blood-2006-03-012534 Silverchair:22628 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery The American Society of Hematology American Society of Hematology 10.1182/blood-2006-03-012534 Silverchair:22628 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery The American Society of Hematology American Society of Hematology 10.1182/blood-2006-03-012534 Silverchair:22628 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Development of a Pathway-Directed Drug Screen Platform for Cutaneous T Cell Lymphoma Using Patient-Derived Xenograft Models The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122589 Silverchair:427455 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Development of a Pathway-Directed Drug Screen Platform for Cutaneous T Cell Lymphoma Using Patient-Derived Xenograft Models The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122589 Silverchair:427455 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Development of a Pathway-Directed Drug Screen Platform for Cutaneous T Cell Lymphoma Using Patient-Derived Xenograft Models The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122589 Silverchair:427455 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Development of a Pathway-Directed Drug Screen Platform for Cutaneous T Cell Lymphoma Using Patient-Derived Xenograft Models The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122589 Silverchair:427455 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Development of a virtual benign hematology consultation service: results of a pilot project involving 5 medical centers The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-887349 Silverchair:260625 Total_Item_Investigations 4 2 2 0 0 0 0 0 0 0 0 0 0 Development of a virtual benign hematology consultation service: results of a pilot project involving 5 medical centers The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-887349 Silverchair:260625 Total_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 Development of a virtual benign hematology consultation service: results of a pilot project involving 5 medical centers The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-887349 Silverchair:260625 Unique_Item_Investigations 3 1 2 0 0 0 0 0 0 0 0 0 0 Development of a virtual benign hematology consultation service: results of a pilot project involving 5 medical centers The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-887349 Silverchair:260625 Unique_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 Development of an Allogeneic Anti-Bcma T Cell Therapy Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131892 Silverchair:427875 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Development of an Allogeneic Anti-Bcma T Cell Therapy Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131892 Silverchair:427875 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Development of an Allogeneic Anti-Bcma T Cell Therapy Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131892 Silverchair:427875 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Development of an Allogeneic Anti-Bcma T Cell Therapy Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131892 Silverchair:427875 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Development of an Oral Dosage Form of Azacitidine: Overcoming Challenges in Chemistry, Formulation, and Bioavailability." The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.4850.4850 Silverchair:129604 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Development of an Oral Dosage Form of Azacitidine: Overcoming Challenges in Chemistry, Formulation, and Bioavailability." The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.4850.4850 Silverchair:129604 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Development of an Oral Dosage Form of Azacitidine: Overcoming Challenges in Chemistry, Formulation, and Bioavailability." The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.4850.4850 Silverchair:129604 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Development of an Oral Dosage Form of Azacitidine: Overcoming Challenges in Chemistry, Formulation, and Bioavailability." The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.4850.4850 Silverchair:129604 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V99.3.1085 Silverchair:53520 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 0 3 0 0 Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V99.3.1085 Silverchair:53520 Total_Item_Requests 3 0 0 0 0 0 0 0 0 0 3 0 0 Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V99.3.1085 Silverchair:53520 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V99.3.1085 Silverchair:53520 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice The American Society of Hematology American Society of Hematology 10.1182/blood-2005-02-0516 Silverchair:21502 Total_Item_Investigations 4 0 2 2 0 0 0 0 0 0 0 0 0 Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice The American Society of Hematology American Society of Hematology 10.1182/blood-2005-02-0516 Silverchair:21502 Total_Item_Requests 4 0 2 2 0 0 0 0 0 0 0 0 0 Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice The American Society of Hematology American Society of Hematology 10.1182/blood-2005-02-0516 Silverchair:21502 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice The American Society of Hematology American Society of Hematology 10.1182/blood-2005-02-0516 Silverchair:21502 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Development of luspatercept to treat ineffective erythropoiesis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002177 Silverchair:475445 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Development of luspatercept to treat ineffective erythropoiesis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002177 Silverchair:475445 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Development of luspatercept to treat ineffective erythropoiesis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002177 Silverchair:475445 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Development of luspatercept to treat ineffective erythropoiesis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002177 Silverchair:475445 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-366542 Silverchair:29754 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-366542 Silverchair:29754 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-366542 Silverchair:29754 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-366542 Silverchair:29754 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Developmental trajectory of prehematopoietic stem cell formation from endothelium The American Society of Hematology American Society of Hematology 10.1182/blood.2020004801 Silverchair:455111 No_License 3 0 2 1 0 0 0 0 0 0 0 0 0 Developmental trajectory of prehematopoietic stem cell formation from endothelium The American Society of Hematology American Society of Hematology 10.1182/blood.2020004801 Silverchair:455111 Total_Item_Investigations 9 3 4 2 0 0 0 0 0 0 0 0 0 Developmental trajectory of prehematopoietic stem cell formation from endothelium The American Society of Hematology American Society of Hematology 10.1182/blood.2020004801 Silverchair:455111 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Developmental trajectory of prehematopoietic stem cell formation from endothelium The American Society of Hematology American Society of Hematology 10.1182/blood.2020004801 Silverchair:455111 Unique_Item_Investigations 5 3 1 1 0 0 0 0 0 0 0 0 0 Developmental trajectory of prehematopoietic stem cell formation from endothelium The American Society of Hematology American Society of Hematology 10.1182/blood.2020004801 Silverchair:455111 Unique_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors The American Society of Hematology American Society of Hematology 10.1182/blood-2007-11-124156 Silverchair:25237 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors The American Society of Hematology American Society of Hematology 10.1182/blood-2007-11-124156 Silverchair:25237 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors The American Society of Hematology American Society of Hematology 10.1182/blood-2007-11-124156 Silverchair:25237 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors The American Society of Hematology American Society of Hematology 10.1182/blood-2007-11-124156 Silverchair:25237 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-235358 Silverchair:27145 Total_Item_Investigations 3 1 1 0 0 0 0 0 0 1 0 0 0 "Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-235358 Silverchair:27145 Total_Item_Requests 3 1 1 0 0 0 0 0 0 1 0 0 0 "Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-235358 Silverchair:27145 Unique_Item_Investigations 3 1 1 0 0 0 0 0 0 1 0 0 0 "Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-235358 Silverchair:27145 Unique_Item_Requests 3 1 1 0 0 0 0 0 0 1 0 0 0 Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-362608 Silverchair:30761 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-362608 Silverchair:30761 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-362608 Silverchair:30761 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-362608 Silverchair:30761 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-733196 Silverchair:36196 Total_Item_Investigations 23 6 3 0 0 1 0 3 2 4 3 0 1 Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-733196 Silverchair:36196 Total_Item_Requests 22 5 3 0 0 1 0 3 2 4 3 0 1 Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-733196 Silverchair:36196 Unique_Item_Investigations 15 4 2 0 0 1 0 2 1 2 2 0 1 Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-733196 Silverchair:36196 Unique_Item_Requests 15 4 2 0 0 1 0 2 1 2 2 0 1 Diagnosis and Management of Aplastic Anemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2011.1.76 Silverchair:96993 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Diagnosis and Management of Aplastic Anemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2011.1.76 Silverchair:96993 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Diagnosis and Management of Aplastic Anemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2011.1.76 Silverchair:96993 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Diagnosis and Management of Aplastic Anemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2011.1.76 Silverchair:96993 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Diagnosis and management of iron deficiency in chronic inflammatory conditions (CIC): is too little iron making your patient sick? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000132 Silverchair:474369 Total_Item_Investigations 16 2 6 2 0 0 2 0 0 0 4 0 0 Diagnosis and management of iron deficiency in chronic inflammatory conditions (CIC): is too little iron making your patient sick? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000132 Silverchair:474369 Total_Item_Requests 16 2 6 2 0 0 2 0 0 0 4 0 0 Diagnosis and management of iron deficiency in chronic inflammatory conditions (CIC): is too little iron making your patient sick? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000132 Silverchair:474369 Unique_Item_Investigations 8 1 3 1 0 0 1 0 0 0 2 0 0 Diagnosis and management of iron deficiency in chronic inflammatory conditions (CIC): is too little iron making your patient sick? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000132 Silverchair:474369 Unique_Item_Requests 8 1 3 1 0 0 1 0 0 0 2 0 0 Diagnosis and management of postpartum ovarian vein thrombosis The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.168 Silverchair:21112 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Diagnosis and management of postpartum ovarian vein thrombosis The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.168 Silverchair:21112 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Diagnosis and management of postpartum ovarian vein thrombosis The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.168 Silverchair:21112 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Diagnosis and management of postpartum ovarian vein thrombosis The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.168 Silverchair:21112 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Diagnosis and management of rare congenital nonimmune hemolytic disease The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.392 Silverchair:20542 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Diagnosis and management of rare congenital nonimmune hemolytic disease The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.392 Silverchair:20542 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Diagnosis and management of rare congenital nonimmune hemolytic disease The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.392 Silverchair:20542 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Diagnosis and management of rare congenital nonimmune hemolytic disease The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.392 Silverchair:20542 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.19 Silverchair:20712 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 0 0 0 3 Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.19 Silverchair:20712 Total_Item_Requests 3 0 0 0 0 0 0 0 0 0 0 0 3 Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.19 Silverchair:20712 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.19 Silverchair:20712 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 "Diagnosis of ‘double hit’ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC" The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.90 Silverchair:20557 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "Diagnosis of ‘double hit’ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC" The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.90 Silverchair:20557 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Diagnosis of ‘double hit’ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC" The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.90 Silverchair:20557 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Diagnosis of ‘double hit’ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC" The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.90 Silverchair:20557 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Diagnosis of bacteremia on a blood smear The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-623678 Silverchair:33979 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Diagnosis of bacteremia on a blood smear The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-623678 Silverchair:33979 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Diagnosis of bacteremia on a blood smear The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-623678 Silverchair:33979 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Diagnosis of bacteremia on a blood smear The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-623678 Silverchair:33979 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Diagnosis of deep vein thrombosis of the upper extremity: a systematic review and meta-analysis of test accuracy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001409 Silverchair:460681 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Diagnosis of deep vein thrombosis of the upper extremity: a systematic review and meta-analysis of test accuracy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001409 Silverchair:460681 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Diagnosis of deep vein thrombosis of the upper extremity: a systematic review and meta-analysis of test accuracy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001409 Silverchair:460681 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Diagnosis of deep vein thrombosis of the upper extremity: a systematic review and meta-analysis of test accuracy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001409 Silverchair:460681 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Diagnostic approach to von Willebrand disease The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-528398 Silverchair:33953 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Diagnostic approach to von Willebrand disease The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-528398 Silverchair:33953 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Diagnostic approach to von Willebrand disease The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-528398 Silverchair:33953 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Diagnostic approach to von Willebrand disease The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-528398 Silverchair:33953 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Diagnostic Assessment of Patients with Inherited Mucocutaneous Hemorrhages (IMCH): Opening a Pandora Box?. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.4009.4009 Silverchair:78015 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Diagnostic Assessment of Patients with Inherited Mucocutaneous Hemorrhages (IMCH): Opening a Pandora Box?. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.4009.4009 Silverchair:78015 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Diagnostic Assessment of Patients with Inherited Mucocutaneous Hemorrhages (IMCH): Opening a Pandora Box?. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.4009.4009 Silverchair:78015 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Diagnostic Assessment of Patients with Inherited Mucocutaneous Hemorrhages (IMCH): Opening a Pandora Box?. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.4009.4009 Silverchair:78015 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 "Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders" The American Society of Hematology American Society of Hematology 10.1182/blood.2018891192 Silverchair:374932 Total_Item_Investigations 14 0 8 0 0 0 0 0 5 0 0 1 0 "Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders" The American Society of Hematology American Society of Hematology 10.1182/blood.2018891192 Silverchair:374932 Total_Item_Requests 13 0 7 0 0 0 0 0 5 0 0 1 0 "Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders" The American Society of Hematology American Society of Hematology 10.1182/blood.2018891192 Silverchair:374932 Unique_Item_Investigations 4 0 2 0 0 0 0 0 1 0 0 1 0 "Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders" The American Society of Hematology American Society of Hematology 10.1182/blood.2018891192 Silverchair:374932 Unique_Item_Requests 4 0 2 0 0 0 0 0 1 0 0 1 0 Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V98.4.979 Silverchair:107104 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V98.4.979 Silverchair:107104 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V98.4.979 Silverchair:107104 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V98.4.979 Silverchair:107104 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Diagnostic workflow for hereditary erythrocytosis and thrombocytosis The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000047 Silverchair:422567 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Diagnostic workflow for hereditary erythrocytosis and thrombocytosis The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000047 Silverchair:422567 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Diagnostic workflow for hereditary erythrocytosis and thrombocytosis The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000047 Silverchair:422567 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Diagnostic workflow for hereditary erythrocytosis and thrombocytosis The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000047 Silverchair:422567 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Diamond-Blackfan anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019000947 Silverchair:461552 Total_Item_Investigations 6 0 6 0 0 0 0 0 0 0 0 0 0 Diamond-Blackfan anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019000947 Silverchair:461552 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Diamond-Blackfan anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019000947 Silverchair:461552 No_License 3 0 3 0 0 0 0 0 0 0 0 0 0 DIC and Its Association with Acute Leukemia in Pre-Treatment and Post Remission Induction Phase The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4665.4665 Silverchair:93424 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 DIC and Its Association with Acute Leukemia in Pre-Treatment and Post Remission Induction Phase The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4665.4665 Silverchair:93424 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 DIC and Its Association with Acute Leukemia in Pre-Treatment and Post Remission Induction Phase The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4665.4665 Silverchair:93424 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 DIC and Its Association with Acute Leukemia in Pre-Treatment and Post Remission Induction Phase The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4665.4665 Silverchair:93424 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Dicer1-mediated miRNA processing shapes the mRNA profile and function of murine platelets The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-661371 Silverchair:34743 Total_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 Dicer1-mediated miRNA processing shapes the mRNA profile and function of murine platelets The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-661371 Silverchair:34743 Total_Item_Requests 3 2 0 1 0 0 0 0 0 0 0 0 0 Dicer1-mediated miRNA processing shapes the mRNA profile and function of murine platelets The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-661371 Silverchair:34743 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Dicer1-mediated miRNA processing shapes the mRNA profile and function of murine platelets The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-661371 Silverchair:34743 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Dietary iron restriction improves markers of disease severity in murine sickle cell anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020006919 Silverchair:474426 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Dietary iron restriction improves markers of disease severity in murine sickle cell anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020006919 Silverchair:474426 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Diferric transferrin regulates transferrin receptor 2 protein stability The American Society of Hematology American Society of Hematology 10.1182/blood-2004-06-2477 Silverchair:19004 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Diferric transferrin regulates transferrin receptor 2 protein stability The American Society of Hematology American Society of Hematology 10.1182/blood-2004-06-2477 Silverchair:19004 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Diferric transferrin regulates transferrin receptor 2 protein stability The American Society of Hematology American Society of Hematology 10.1182/blood-2004-06-2477 Silverchair:19004 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Diferric transferrin regulates transferrin receptor 2 protein stability The American Society of Hematology American Society of Hematology 10.1182/blood-2004-06-2477 Silverchair:19004 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Difference of Clinical Parameters between GCB and Non-GCB Subtype DLBCL The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5231.5231 Silverchair:81084 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Difference of Clinical Parameters between GCB and Non-GCB Subtype DLBCL The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5231.5231 Silverchair:81084 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Difference of Clinical Parameters between GCB and Non-GCB Subtype DLBCL The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5231.5231 Silverchair:81084 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Difference of Clinical Parameters between GCB and Non-GCB Subtype DLBCL The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5231.5231 Silverchair:81084 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114273 Silverchair:273185 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114273 Silverchair:273185 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114273 Silverchair:273185 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114273 Silverchair:273185 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Differences in Histone Acetylation Levels in CD34+ Cells between Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Correlation between Higher Levels of Histone 2B Acetylation and Survival in AML. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.2769.2769 Silverchair:121620 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Differences in Histone Acetylation Levels in CD34+ Cells between Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Correlation between Higher Levels of Histone 2B Acetylation and Survival in AML. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.2769.2769 Silverchair:121620 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Differences in Histone Acetylation Levels in CD34+ Cells between Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Correlation between Higher Levels of Histone 2B Acetylation and Survival in AML. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.2769.2769 Silverchair:121620 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Differences in Histone Acetylation Levels in CD34+ Cells between Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Correlation between Higher Levels of Histone 2B Acetylation and Survival in AML. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.2769.2769 Silverchair:121620 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Different expression of CD41 on human lymphoid and myeloid progenitors from adults and neonates The American Society of Hematology American Society of Hematology 10.1182/blood.V97.7.2023 Silverchair:53393 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Different expression of CD41 on human lymphoid and myeloid progenitors from adults and neonates The American Society of Hematology American Society of Hematology 10.1182/blood.V97.7.2023 Silverchair:53393 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Different expression of CD41 on human lymphoid and myeloid progenitors from adults and neonates The American Society of Hematology American Society of Hematology 10.1182/blood.V97.7.2023 Silverchair:53393 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Different expression of CD41 on human lymphoid and myeloid progenitors from adults and neonates The American Society of Hematology American Society of Hematology 10.1182/blood.V97.7.2023 Silverchair:53393 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Different strokes for older folks (with TTP) The American Society of Hematology American Society of Hematology 10.1182/blood.2019003430 Silverchair:429574 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Different strokes for older folks (with TTP) The American Society of Hematology American Society of Hematology 10.1182/blood.2019003430 Silverchair:429574 Total_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 Different strokes for older folks (with TTP) The American Society of Hematology American Society of Hematology 10.1182/blood.2019003430 Silverchair:429574 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Different strokes for older folks (with TTP) The American Society of Hematology American Society of Hematology 10.1182/blood.2019003430 Silverchair:429574 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129383 Silverchair:424431 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129383 Silverchair:424431 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129383 Silverchair:424431 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129383 Silverchair:424431 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Differential expression of CD21 identifies developmentally and functionally distinct subsets of human transitional B cells The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-234799 Silverchair:27130 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Differential expression of CD21 identifies developmentally and functionally distinct subsets of human transitional B cells The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-234799 Silverchair:27130 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Differential expression of CD21 identifies developmentally and functionally distinct subsets of human transitional B cells The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-234799 Silverchair:27130 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Differential expression of CD21 identifies developmentally and functionally distinct subsets of human transitional B cells The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-234799 Silverchair:27130 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-03-0859 Silverchair:19417 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-03-0859 Silverchair:19417 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-03-0859 Silverchair:19417 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-03-0859 Silverchair:19417 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Differential expression of MMP-2 and MMP-9 activity in megakaryocytes and platelets The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-366195 Silverchair:29219 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Differential expression of MMP-2 and MMP-9 activity in megakaryocytes and platelets The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-366195 Silverchair:29219 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Differential expression of MMP-2 and MMP-9 activity in megakaryocytes and platelets The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-366195 Silverchair:29219 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Differential expression of MMP-2 and MMP-9 activity in megakaryocytes and platelets The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-366195 Silverchair:29219 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-168617 Silverchair:24999 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-168617 Silverchair:24999 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-168617 Silverchair:24999 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-168617 Silverchair:24999 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Diffuse Large B Cell Lymphoma (DLBCL) infiltrating T Cells Display an Activated and Exhausted Status and Are Inhibited By Ligands of Cosignaling Receptors Including PD-L1, PD-L2 and CD80 Expressed By Most DLBCL in Situ" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1665.1665 Silverchair:88806 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 "Diffuse Large B Cell Lymphoma (DLBCL) infiltrating T Cells Display an Activated and Exhausted Status and Are Inhibited By Ligands of Cosignaling Receptors Including PD-L1, PD-L2 and CD80 Expressed By Most DLBCL in Situ" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1665.1665 Silverchair:88806 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 "Diffuse Large B Cell Lymphoma (DLBCL) infiltrating T Cells Display an Activated and Exhausted Status and Are Inhibited By Ligands of Cosignaling Receptors Including PD-L1, PD-L2 and CD80 Expressed By Most DLBCL in Situ" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1665.1665 Silverchair:88806 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Diffuse Large B Cell Lymphoma (DLBCL) infiltrating T Cells Display an Activated and Exhausted Status and Are Inhibited By Ligands of Cosignaling Receptors Including PD-L1, PD-L2 and CD80 Expressed By Most DLBCL in Situ" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1665.1665 Silverchair:88806 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Dipeptidyl Peptidase 4 (DPP4) Is Altered By, and Modulates Sensitivity to, Extra-Physiologic Oxygen Shock Stress (EPHOSS): Implications for Hematopoietic Stem Cell Transplantation" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2361.2361 Silverchair:113332 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Dipeptidyl Peptidase 4 (DPP4) Is Altered By, and Modulates Sensitivity to, Extra-Physiologic Oxygen Shock Stress (EPHOSS): Implications for Hematopoietic Stem Cell Transplantation" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2361.2361 Silverchair:113332 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Dipeptidyl Peptidase 4 (DPP4) Is Altered By, and Modulates Sensitivity to, Extra-Physiologic Oxygen Shock Stress (EPHOSS): Implications for Hematopoietic Stem Cell Transplantation" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2361.2361 Silverchair:113332 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Dipeptidyl Peptidase 4 (DPP4) Is Altered By, and Modulates Sensitivity to, Extra-Physiologic Oxygen Shock Stress (EPHOSS): Implications for Hematopoietic Stem Cell Transplantation" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2361.2361 Silverchair:113332 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition The American Society of Hematology American Society of Hematology 10.1182/blood.2020008248 Silverchair:463611 Total_Item_Investigations 7 0 3 0 0 2 2 0 0 0 0 0 0 Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition The American Society of Hematology American Society of Hematology 10.1182/blood.2020008248 Silverchair:463611 Unique_Item_Investigations 4 0 2 0 0 1 1 0 0 0 0 0 0 Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition The American Society of Hematology American Society of Hematology 10.1182/blood.2020008248 Silverchair:463611 Total_Item_Requests 7 0 3 0 0 2 2 0 0 0 0 0 0 Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition The American Society of Hematology American Society of Hematology 10.1182/blood.2020008248 Silverchair:463611 Unique_Item_Requests 4 0 2 0 0 1 1 0 0 0 0 0 0 Direct interaction between Kit and the interleukin-7 receptor The American Society of Hematology American Society of Hematology 10.1182/blood-2005-12-028019 Silverchair:24141 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Direct interaction between Kit and the interleukin-7 receptor The American Society of Hematology American Society of Hematology 10.1182/blood-2005-12-028019 Silverchair:24141 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Direct interaction between Kit and the interleukin-7 receptor The American Society of Hematology American Society of Hematology 10.1182/blood-2005-12-028019 Silverchair:24141 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Direct interaction between Kit and the interleukin-7 receptor The American Society of Hematology American Society of Hematology 10.1182/blood-2005-12-028019 Silverchair:24141 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Direct oral anticoagulant (DOAC) interference in hemostasis assays The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000241 Silverchair:482974 Total_Item_Investigations 4 0 0 0 0 0 0 0 0 0 0 0 4 Direct oral anticoagulant (DOAC) interference in hemostasis assays The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000241 Silverchair:482974 Total_Item_Requests 4 0 0 0 0 0 0 0 0 0 0 0 4 Direct oral anticoagulant (DOAC) interference in hemostasis assays The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000241 Silverchair:482974 Unique_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 0 2 Direct oral anticoagulant (DOAC) interference in hemostasis assays The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000241 Silverchair:482974 Unique_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 0 2 "Direct oral anticoagulants and cancer-associated VTE: good for all, or just some?" The American Society of Hematology American Society of Hematology 10.1182/blood.2019004177 Silverchair:461114 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Direct oral anticoagulants and cancer-associated VTE: good for all, or just some?" The American Society of Hematology American Society of Hematology 10.1182/blood.2019004177 Silverchair:461114 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Direct oral anticoagulants and cancer-associated VTE: good for all, or just some?" The American Society of Hematology American Society of Hematology 10.1182/blood.2019004177 Silverchair:461114 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Direct oral anticoagulants and cancer-associated VTE: good for all, or just some?" The American Society of Hematology American Society of Hematology 10.1182/blood.2019004177 Silverchair:461114 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-571232 Silverchair:33035 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-571232 Silverchair:33035 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-571232 Silverchair:33035 Unique_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-571232 Silverchair:33035 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis The American Society of Hematology American Society of Hematology 10.1182/blood.2020005819 Silverchair:455308 Total_Item_Investigations 22 3 15 4 0 0 0 0 0 0 0 0 0 Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis The American Society of Hematology American Society of Hematology 10.1182/blood.2020005819 Silverchair:455308 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis The American Society of Hematology American Society of Hematology 10.1182/blood.2020005819 Silverchair:455308 Unique_Item_Investigations 8 1 5 2 0 0 0 0 0 0 0 0 0 Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis The American Society of Hematology American Society of Hematology 10.1182/blood.2020005819 Silverchair:455308 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis The American Society of Hematology American Society of Hematology 10.1182/blood.2020005819 Silverchair:455308 No_License 8 0 6 2 0 0 0 0 0 0 0 0 0 Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-778993 Silverchair:36991 Total_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-778993 Silverchair:36991 Total_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-778993 Silverchair:36991 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-778993 Silverchair:36991 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Direct Oral Anticoagulants in Anti-Phospholipid Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2145.2145 Silverchair:71518 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Direct Oral Anticoagulants in Anti-Phospholipid Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2145.2145 Silverchair:71518 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Direct Oral Anticoagulants in Anti-Phospholipid Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2145.2145 Silverchair:71518 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Direct Oral Anticoagulants in Anti-Phospholipid Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2145.2145 Silverchair:71518 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Direct Oral Anticoagulants in Patients with Myeloproliferative Neoplasms: A Single Institution Retrospective Study The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114234 Silverchair:265834 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Direct Oral Anticoagulants in Patients with Myeloproliferative Neoplasms: A Single Institution Retrospective Study The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114234 Silverchair:265834 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Direct Oral Anticoagulants in Patients with Myeloproliferative Neoplasms: A Single Institution Retrospective Study The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114234 Silverchair:265834 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Direct Oral Anticoagulants in Patients with Myeloproliferative Neoplasms: A Single Institution Retrospective Study The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114234 Silverchair:265834 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Direct-Acting Small Molecule Activators of PP2A (SMAPs) in Myeloid Malignancies: Understanding Mechanisms of Cytotoxicity to Inform Rational Combinatorial Therapeutic Strategies The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2517.2517 Silverchair:80010 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Direct-Acting Small Molecule Activators of PP2A (SMAPs) in Myeloid Malignancies: Understanding Mechanisms of Cytotoxicity to Inform Rational Combinatorial Therapeutic Strategies The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2517.2517 Silverchair:80010 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Direct-Acting Small Molecule Activators of PP2A (SMAPs) in Myeloid Malignancies: Understanding Mechanisms of Cytotoxicity to Inform Rational Combinatorial Therapeutic Strategies The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2517.2517 Silverchair:80010 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Direct-Acting Small Molecule Activators of PP2A (SMAPs) in Myeloid Malignancies: Understanding Mechanisms of Cytotoxicity to Inform Rational Combinatorial Therapeutic Strategies The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2517.2517 Silverchair:80010 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "DISC-0974, a Novel, First-in-Class, Anti-Hemojuvelin Monoclonal Antibody Is Predicted to be Efficacious at Low Doses in Humans As Determined By Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling in Non-Clinical Studies" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138547 Silverchair:473239 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 "DISC-0974, a Novel, First-in-Class, Anti-Hemojuvelin Monoclonal Antibody Is Predicted to be Efficacious at Low Doses in Humans As Determined By Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling in Non-Clinical Studies" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138547 Silverchair:473239 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 "DISC-0974, a Novel, First-in-Class, Anti-Hemojuvelin Monoclonal Antibody Is Predicted to be Efficacious at Low Doses in Humans As Determined By Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling in Non-Clinical Studies" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138547 Silverchair:473239 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 "DISC-0974, a Novel, First-in-Class, Anti-Hemojuvelin Monoclonal Antibody Is Predicted to be Efficacious at Low Doses in Humans As Determined By Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling in Non-Clinical Studies" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138547 Silverchair:473239 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 "DISC-a, the First in a Novel Class of Potent and Selective Matriptase-2 Inhibitors for the Treatment of Hematologic Disorders Characterized By Low Hepcidin" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138509 Silverchair:471391 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "DISC-a, the First in a Novel Class of Potent and Selective Matriptase-2 Inhibitors for the Treatment of Hematologic Disorders Characterized By Low Hepcidin" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138509 Silverchair:471391 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "DISC-a, the First in a Novel Class of Potent and Selective Matriptase-2 Inhibitors for the Treatment of Hematologic Disorders Characterized By Low Hepcidin" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138509 Silverchair:471391 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "DISC-a, the First in a Novel Class of Potent and Selective Matriptase-2 Inhibitors for the Treatment of Hematologic Disorders Characterized By Low Hepcidin" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138509 Silverchair:471391 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Discovery and Development of MEDI7247, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate Targeting ASCT2, for Treating Hematological Cancers" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119836 Silverchair:265305 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Discovery and Development of MEDI7247, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate Targeting ASCT2, for Treating Hematological Cancers" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119836 Silverchair:265305 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Discovery and Development of MEDI7247, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate Targeting ASCT2, for Treating Hematological Cancers" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119836 Silverchair:265305 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Discovery and Development of MEDI7247, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate Targeting ASCT2, for Treating Hematological Cancers" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119836 Silverchair:265305 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Discovery of novel mechanosensitive genes in vivo using mouse carotid artery endothelium exposed to disturbed flow The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-278192 Silverchair:27737 Total_Item_Investigations 6 6 0 0 0 0 0 0 0 0 0 0 0 Discovery of novel mechanosensitive genes in vivo using mouse carotid artery endothelium exposed to disturbed flow The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-278192 Silverchair:27737 Total_Item_Requests 6 6 0 0 0 0 0 0 0 0 0 0 0 Discovery of novel mechanosensitive genes in vivo using mouse carotid artery endothelium exposed to disturbed flow The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-278192 Silverchair:27737 Unique_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 Discovery of novel mechanosensitive genes in vivo using mouse carotid artery endothelium exposed to disturbed flow The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-278192 Silverchair:27737 Unique_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-474577 Silverchair:31378 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-474577 Silverchair:31378 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-474577 Silverchair:31378 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-474577 Silverchair:31378 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Disease evolution and outcomes in familial AML with germline CEBPA mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-647172 Silverchair:73133 Total_Item_Investigations 4 0 1 3 0 0 0 0 0 0 0 0 0 Disease evolution and outcomes in familial AML with germline CEBPA mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-647172 Silverchair:73133 Total_Item_Requests 3 0 1 2 0 0 0 0 0 0 0 0 0 Disease evolution and outcomes in familial AML with germline CEBPA mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-647172 Silverchair:73133 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Disease evolution and outcomes in familial AML with germline CEBPA mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-647172 Silverchair:73133 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Disorders of platelet number and function American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter11 Silverchair:75288 No_License 14 5 7 0 0 0 0 0 1 0 0 0 1 Disorders of platelet number and function American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter11 Silverchair:75288 Total_Item_Investigations 21 5 7 0 1 0 0 3 2 2 0 0 1 Disorders of platelet number and function American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter11 Silverchair:75288 Unique_Item_Investigations 16 3 6 0 1 0 0 1 2 2 0 0 1 Disruption of the Ikaros-Mediated Gene Expression Program in Multiple Myeloma with Immunomodulatory Agents The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.420.420 Silverchair:92079 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Disruption of the Ikaros-Mediated Gene Expression Program in Multiple Myeloma with Immunomodulatory Agents The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.420.420 Silverchair:92079 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Disruption of the Ikaros-Mediated Gene Expression Program in Multiple Myeloma with Immunomodulatory Agents The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.420.420 Silverchair:92079 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Disruption of the Ikaros-Mediated Gene Expression Program in Multiple Myeloma with Immunomodulatory Agents The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.420.420 Silverchair:92079 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-749879 Silverchair:35922 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-749879 Silverchair:35922 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-749879 Silverchair:35922 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-749879 Silverchair:35922 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Distinct regulatory networks control the development of macrophages of different origins in zebrafish The American Society of Hematology American Society of Hematology 10.1182/blood-2016-07-727651 Silverchair:36186 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Distinct regulatory networks control the development of macrophages of different origins in zebrafish The American Society of Hematology American Society of Hematology 10.1182/blood-2016-07-727651 Silverchair:36186 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Distinct regulatory networks control the development of macrophages of different origins in zebrafish The American Society of Hematology American Society of Hematology 10.1182/blood-2016-07-727651 Silverchair:36186 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Distinct regulatory networks control the development of macrophages of different origins in zebrafish The American Society of Hematology American Society of Hematology 10.1182/blood-2016-07-727651 Silverchair:36186 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1–expressing myeloma cells The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-327197 Silverchair:28977 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1–expressing myeloma cells The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-327197 Silverchair:28977 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1–expressing myeloma cells The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-327197 Silverchair:28977 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1–expressing myeloma cells The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-327197 Silverchair:28977 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Divergent Evolutionary Trajectories of Erk- and Stat5-Activating Lesions in Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115536 Silverchair:263198 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Divergent Evolutionary Trajectories of Erk- and Stat5-Activating Lesions in Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115536 Silverchair:263198 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Divergent Evolutionary Trajectories of Erk- and Stat5-Activating Lesions in Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115536 Silverchair:263198 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Divergent Evolutionary Trajectories of Erk- and Stat5-Activating Lesions in Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115536 Silverchair:263198 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Diversity of peripheral blood human NK cells identified by single-cell RNA sequencing American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000699 Silverchair:454300 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Diversity of peripheral blood human NK cells identified by single-cell RNA sequencing American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000699 Silverchair:454300 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Diversity of peripheral blood human NK cells identified by single-cell RNA sequencing American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000699 Silverchair:454300 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Diversity of peripheral blood human NK cells identified by single-cell RNA sequencing American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000699 Silverchair:454300 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001972 Silverchair:461238 Total_Item_Investigations 4 3 0 1 0 0 0 0 0 0 0 0 0 DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001972 Silverchair:461238 Total_Item_Requests 4 3 0 1 0 0 0 0 0 0 0 0 0 DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001972 Silverchair:461238 Unique_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001972 Silverchair:461238 Unique_Item_Requests 3 2 0 1 0 0 0 0 0 0 0 0 0 DLL1-mediated Notch activation regulates endothelial identity in mouse fetal arteries The American Society of Hematology American Society of Hematology 10.1182/blood-2008-08-174508 Silverchair:107805 Total_Item_Investigations 5 5 0 0 0 0 0 0 0 0 0 0 0 DLL1-mediated Notch activation regulates endothelial identity in mouse fetal arteries The American Society of Hematology American Society of Hematology 10.1182/blood-2008-08-174508 Silverchair:107805 Total_Item_Requests 5 5 0 0 0 0 0 0 0 0 0 0 0 DLL1-mediated Notch activation regulates endothelial identity in mouse fetal arteries The American Society of Hematology American Society of Hematology 10.1182/blood-2008-08-174508 Silverchair:107805 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 DLL1-mediated Notch activation regulates endothelial identity in mouse fetal arteries The American Society of Hematology American Society of Hematology 10.1182/blood-2008-08-174508 Silverchair:107805 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 DMT1: Tissue Specific Expression and Alternative Splicing. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.3210.3210 Silverchair:77819 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 DMT1: Tissue Specific Expression and Alternative Splicing. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.3210.3210 Silverchair:77819 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 DMT1: Tissue Specific Expression and Alternative Splicing. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.3210.3210 Silverchair:77819 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 DMT1: Tissue Specific Expression and Alternative Splicing. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.3210.3210 Silverchair:77819 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Do CD8 effector cells need IL-7R expression to become resting memory cells? The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-016857 Silverchair:22644 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Do CD8 effector cells need IL-7R expression to become resting memory cells? The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-016857 Silverchair:22644 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Do CD8 effector cells need IL-7R expression to become resting memory cells? The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-016857 Silverchair:22644 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Do CD8 effector cells need IL-7R expression to become resting memory cells? The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-016857 Silverchair:22644 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Do Sequential Compression Devices Prevent Venous Thromboembolism in Hospital Inpatients? The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2084.2084 Silverchair:71270 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Do Sequential Compression Devices Prevent Venous Thromboembolism in Hospital Inpatients? The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2084.2084 Silverchair:71270 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Do Sequential Compression Devices Prevent Venous Thromboembolism in Hospital Inpatients? The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2084.2084 Silverchair:71270 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Do Sequential Compression Devices Prevent Venous Thromboembolism in Hospital Inpatients? The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2084.2084 Silverchair:71270 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Do temperature and time matter in cold agglutinin disease? The American Society of Hematology American Society of Hematology 10.1182/blood.2020006566 Silverchair:461400 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Do temperature and time matter in cold agglutinin disease? The American Society of Hematology American Society of Hematology 10.1182/blood.2020006566 Silverchair:461400 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Do temperature and time matter in cold agglutinin disease? The American Society of Hematology American Society of Hematology 10.1182/blood.2020006566 Silverchair:461400 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Do temperature and time matter in cold agglutinin disease? The American Society of Hematology American Society of Hematology 10.1182/blood.2020006566 Silverchair:461400 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000840 Silverchair:454364 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000840 Silverchair:454364 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000840 Silverchair:454364 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000840 Silverchair:454364 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Does ABO and RhD matching matter for platelet transfusion? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000135 Silverchair:474292 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Does ABO and RhD matching matter for platelet transfusion? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000135 Silverchair:474292 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Does ABO and RhD matching matter for platelet transfusion? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000135 Silverchair:474292 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Does ABO and RhD matching matter for platelet transfusion? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000135 Silverchair:474292 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Does aspirin prevent venous thromboembolism? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000150 Silverchair:474338 Total_Item_Investigations 5 0 0 1 0 0 0 0 0 2 2 0 0 Does aspirin prevent venous thromboembolism? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000150 Silverchair:474338 Total_Item_Requests 5 0 0 1 0 0 0 0 0 2 2 0 0 Does aspirin prevent venous thromboembolism? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000150 Silverchair:474338 Unique_Item_Investigations 3 0 0 1 0 0 0 0 0 1 1 0 0 Does aspirin prevent venous thromboembolism? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000150 Silverchair:474338 Unique_Item_Requests 3 0 0 1 0 0 0 0 0 1 1 0 0 "Does Cell Size Matter?: Utilizing Mean Cell Volume in Hospitalized Patients As a Screen to Determine Common Causes of Anemia Including Iron Deficiency Anemia, Vitamin B12 and Folate Deficiency" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2338.2338 Silverchair:98858 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Does Cell Size Matter?: Utilizing Mean Cell Volume in Hospitalized Patients As a Screen to Determine Common Causes of Anemia Including Iron Deficiency Anemia, Vitamin B12 and Folate Deficiency" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2338.2338 Silverchair:98858 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Does Cell Size Matter?: Utilizing Mean Cell Volume in Hospitalized Patients As a Screen to Determine Common Causes of Anemia Including Iron Deficiency Anemia, Vitamin B12 and Folate Deficiency" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2338.2338 Silverchair:98858 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Does Cell Size Matter?: Utilizing Mean Cell Volume in Hospitalized Patients As a Screen to Determine Common Causes of Anemia Including Iron Deficiency Anemia, Vitamin B12 and Folate Deficiency" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2338.2338 Silverchair:98858 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Does Neutrophil to Lymphocyte Ratio (NLR) Predict the Prognosis of Diffuse Large B-Cell Lymphoma? The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117823 Silverchair:265642 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Does Neutrophil to Lymphocyte Ratio (NLR) Predict the Prognosis of Diffuse Large B-Cell Lymphoma? The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117823 Silverchair:265642 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Does Neutrophil to Lymphocyte Ratio (NLR) Predict the Prognosis of Diffuse Large B-Cell Lymphoma? The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117823 Silverchair:265642 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Does Neutrophil to Lymphocyte Ratio (NLR) Predict the Prognosis of Diffuse Large B-Cell Lymphoma? The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117823 Silverchair:265642 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000087 Silverchair:474294 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000087 Silverchair:474294 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000087 Silverchair:474294 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000087 Silverchair:474294 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Does Thrombocytopenia Truly Correlate with COVID-19 Severity? The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142440 Silverchair:473268 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Does Thrombocytopenia Truly Correlate with COVID-19 Severity? The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142440 Silverchair:473268 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Does Thrombocytopenia Truly Correlate with COVID-19 Severity? The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142440 Silverchair:473268 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Does Thrombocytopenia Truly Correlate with COVID-19 Severity? The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142440 Silverchair:473268 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain The American Society of Hematology American Society of Hematology 10.1182/blood-2003-10-3530 Silverchair:114457 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain The American Society of Hematology American Society of Hematology 10.1182/blood-2003-10-3530 Silverchair:114457 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain The American Society of Hematology American Society of Hematology 10.1182/blood-2003-10-3530 Silverchair:114457 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain The American Society of Hematology American Society of Hematology 10.1182/blood-2003-10-3530 Silverchair:114457 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-530212 Silverchair:32498 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-530212 Silverchair:32498 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-530212 Silverchair:32498 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-530212 Silverchair:32498 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125894 Silverchair:426083 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125894 Silverchair:426083 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125894 Silverchair:426083 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125894 Silverchair:426083 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Donor-derived myeloid neoplasm post allogeneic hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-747550 Silverchair:36578 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Donor-derived myeloid neoplasm post allogeneic hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-747550 Silverchair:36578 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Donor-derived myeloid neoplasm post allogeneic hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-747550 Silverchair:36578 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Donor-derived myeloid neoplasm post allogeneic hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-747550 Silverchair:36578 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Donor-Derived Second Generation of CD19 CAR-T Cell Therapy for Relapsed B-Cell Acute Lymphoblastic Leukemia after Allogenic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114950 Silverchair:261694 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Donor-Derived Second Generation of CD19 CAR-T Cell Therapy for Relapsed B-Cell Acute Lymphoblastic Leukemia after Allogenic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114950 Silverchair:261694 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Donor-Derived Second Generation of CD19 CAR-T Cell Therapy for Relapsed B-Cell Acute Lymphoblastic Leukemia after Allogenic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114950 Silverchair:261694 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Donor-Derived Second Generation of CD19 CAR-T Cell Therapy for Relapsed B-Cell Acute Lymphoblastic Leukemia after Allogenic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114950 Silverchair:261694 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Dose/Schedule-Adjusted Rd-R vs Continuous Rd for elderly, intermediate-fit, newly diagnosed multiple myeloma patients" The American Society of Hematology American Society of Hematology 10.1182/blood.2020009507 Silverchair:475576 Total_Item_Investigations 9 0 0 9 0 0 0 0 0 0 0 0 0 "Dose/Schedule-Adjusted Rd-R vs Continuous Rd for elderly, intermediate-fit, newly diagnosed multiple myeloma patients" The American Society of Hematology American Society of Hematology 10.1182/blood.2020009507 Silverchair:475576 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 "Dose/Schedule-Adjusted Rd-R vs Continuous Rd for elderly, intermediate-fit, newly diagnosed multiple myeloma patients" The American Society of Hematology American Society of Hematology 10.1182/blood.2020009507 Silverchair:475576 Unique_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 "Dose/Schedule-Adjusted Rd-R vs Continuous Rd for elderly, intermediate-fit, newly diagnosed multiple myeloma patients" The American Society of Hematology American Society of Hematology 10.1182/blood.2020009507 Silverchair:475576 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001804 Silverchair:456033 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001804 Silverchair:456033 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001804 Silverchair:456033 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001804 Silverchair:456033 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy The American Society of Hematology American Society of Hematology 10.1182/blood.V99.8.2685 Silverchair:89633 Total_Item_Investigations 14 1 6 6 0 0 0 1 0 0 0 0 0 Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy The American Society of Hematology American Society of Hematology 10.1182/blood.V99.8.2685 Silverchair:89633 Total_Item_Requests 14 1 6 6 0 0 0 1 0 0 0 0 0 Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy The American Society of Hematology American Society of Hematology 10.1182/blood.V99.8.2685 Silverchair:89633 Unique_Item_Investigations 12 1 4 6 0 0 0 1 0 0 0 0 0 Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy The American Society of Hematology American Society of Hematology 10.1182/blood.V99.8.2685 Silverchair:89633 Unique_Item_Requests 12 1 4 6 0 0 0 1 0 0 0 0 0 Dose-Adjusted EPOCH Chemotherapy for Untreated Peripheral T-Cell Lymphomas: Multicenter Phase II Trial of West-Jhog PTCL0707 The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5349.5349 Silverchair:100207 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Dose-Adjusted EPOCH Chemotherapy for Untreated Peripheral T-Cell Lymphomas: Multicenter Phase II Trial of West-Jhog PTCL0707 The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5349.5349 Silverchair:100207 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Dose-Adjusted EPOCH Chemotherapy for Untreated Peripheral T-Cell Lymphomas: Multicenter Phase II Trial of West-Jhog PTCL0707 The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5349.5349 Silverchair:100207 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Dose-Adjusted EPOCH Chemotherapy for Untreated Peripheral T-Cell Lymphomas: Multicenter Phase II Trial of West-Jhog PTCL0707 The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5349.5349 Silverchair:100207 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Dose-dependent regulation of primitive erythroid maturation and identity by the transcription factor Eklf The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-281196 Silverchair:28058 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Dose-dependent regulation of primitive erythroid maturation and identity by the transcription factor Eklf The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-281196 Silverchair:28058 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Dose-dependent regulation of primitive erythroid maturation and identity by the transcription factor Eklf The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-281196 Silverchair:28058 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Dose-dependent regulation of primitive erythroid maturation and identity by the transcription factor Eklf The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-281196 Silverchair:28058 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Double Induction Containing Two Courses Versus One Course of High- Dose AraC/ Mitoxantrone (HAM) and Autologous Stem Cell Transplantation Versus Prolonged Maintenance for Acute Myeloid Leukemia (AML). The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.272.272 Silverchair:122222 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Double Induction Containing Two Courses Versus One Course of High- Dose AraC/ Mitoxantrone (HAM) and Autologous Stem Cell Transplantation Versus Prolonged Maintenance for Acute Myeloid Leukemia (AML). The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.272.272 Silverchair:122222 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Double Induction Containing Two Courses Versus One Course of High- Dose AraC/ Mitoxantrone (HAM) and Autologous Stem Cell Transplantation Versus Prolonged Maintenance for Acute Myeloid Leukemia (AML). The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.272.272 Silverchair:122222 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Double Induction Containing Two Courses Versus One Course of High- Dose AraC/ Mitoxantrone (HAM) and Autologous Stem Cell Transplantation Versus Prolonged Maintenance for Acute Myeloid Leukemia (AML). The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.272.272 Silverchair:122222 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial The American Society of Hematology American Society of Hematology 10.1182/blood.2020007535 Silverchair:463595 Total_Item_Investigations 13 0 11 2 0 0 0 0 0 0 0 0 0 Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial The American Society of Hematology American Society of Hematology 10.1182/blood.2020007535 Silverchair:463595 Unique_Item_Investigations 4 0 3 1 0 0 0 0 0 0 0 0 0 Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial The American Society of Hematology American Society of Hematology 10.1182/blood.2020007535 Silverchair:463595 No_License 5 0 4 1 0 0 0 0 0 0 0 0 0 Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112899 Silverchair:262704 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112899 Silverchair:262704 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112899 Silverchair:262704 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112899 Silverchair:262704 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Double-hit B-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-297879 Silverchair:28413 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Double-hit B-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-297879 Silverchair:28413 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Double-hit B-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-297879 Silverchair:28413 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Double-hit B-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-297879 Silverchair:28413 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Down-regulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-224808 Silverchair:27347 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Down-regulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-224808 Silverchair:27347 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Down-regulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-224808 Silverchair:27347 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Down-regulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-224808 Silverchair:27347 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Down-regulation of hepcidin resulting from long-term treatment with an anti–IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-271791 Silverchair:27940 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Down-regulation of hepcidin resulting from long-term treatment with an anti–IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-271791 Silverchair:27940 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Down-regulation of hepcidin resulting from long-term treatment with an anti–IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-271791 Silverchair:27940 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Down-regulation of hepcidin resulting from long-term treatment with an anti–IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-271791 Silverchair:27940 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 "Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124176 Silverchair:423027 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124176 Silverchair:423027 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124176 Silverchair:423027 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124176 Silverchair:423027 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Driver Mutation Acquisition in Utero and Childhood Followed By Lifelong Clonal Evolution Underlie Myeloproliferative Neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143813 Silverchair:474188 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Driver Mutation Acquisition in Utero and Childhood Followed By Lifelong Clonal Evolution Underlie Myeloproliferative Neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143813 Silverchair:474188 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Driver Mutation Acquisition in Utero and Childhood Followed By Lifelong Clonal Evolution Underlie Myeloproliferative Neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143813 Silverchair:474188 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Driver Mutation Acquisition in Utero and Childhood Followed By Lifelong Clonal Evolution Underlie Myeloproliferative Neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143813 Silverchair:474188 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-294330 Silverchair:28454 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-294330 Silverchair:28454 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-294330 Silverchair:28454 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-294330 Silverchair:28454 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Drug-associated thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.576 Silverchair:277620 Total_Item_Investigations 12 1 0 5 1 0 4 0 0 1 0 0 0 Drug-associated thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.576 Silverchair:277620 Total_Item_Requests 12 1 0 5 1 0 4 0 0 1 0 0 0 Drug-associated thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.576 Silverchair:277620 Unique_Item_Investigations 9 1 0 3 1 0 3 0 0 1 0 0 0 Drug-associated thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.576 Silverchair:277620 Unique_Item_Requests 9 1 0 3 1 0 3 0 0 1 0 0 0 Drug-induced thrombotic microangiopathy: a systematic review of published reports The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-611335 Silverchair:33855 Total_Item_Investigations 5 0 3 0 0 0 0 0 0 0 0 0 2 Drug-induced thrombotic microangiopathy: a systematic review of published reports The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-611335 Silverchair:33855 Total_Item_Requests 5 0 3 0 0 0 0 0 0 0 0 0 2 Drug-induced thrombotic microangiopathy: a systematic review of published reports The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-611335 Silverchair:33855 Unique_Item_Investigations 3 0 2 0 0 0 0 0 0 0 0 0 1 Drug-induced thrombotic microangiopathy: a systematic review of published reports The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-611335 Silverchair:33855 Unique_Item_Requests 3 0 2 0 0 0 0 0 0 0 0 0 1 "DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125820 Silverchair:426215 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125820 Silverchair:426215 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125820 Silverchair:426215 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125820 Silverchair:426215 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-792267 Silverchair:36676 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-792267 Silverchair:36676 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-792267 Silverchair:36676 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-792267 Silverchair:36676 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Dual role of EZH2 on megakaryocyte differentiation The American Society of Hematology American Society of Hematology 10.1182/blood.2019004638 Silverchair:476135 Total_Item_Investigations 2 0 0 0 0 0 0 2 0 0 0 0 0 Dual role of EZH2 on megakaryocyte differentiation The American Society of Hematology American Society of Hematology 10.1182/blood.2019004638 Silverchair:476135 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Duffy Antigen Phenotyping Is a Useful and Clinically Available Test for Benign Ethnic Neutropenia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117178 Silverchair:264262 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Duffy Antigen Phenotyping Is a Useful and Clinically Available Test for Benign Ethnic Neutropenia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117178 Silverchair:264262 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Duffy Antigen Phenotyping Is a Useful and Clinically Available Test for Benign Ethnic Neutropenia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117178 Silverchair:264262 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Duffy Antigen Phenotyping Is a Useful and Clinically Available Test for Benign Ethnic Neutropenia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117178 Silverchair:264262 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.740.740 Silverchair:83633 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.740.740 Silverchair:83633 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.740.740 Silverchair:83633 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.740.740 Silverchair:83633 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism The American Society of Hematology American Society of Hematology 10.1182/blood-2013-12-512681 Silverchair:32733 Total_Item_Investigations 10 1 5 2 0 0 1 0 1 0 0 0 0 Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism The American Society of Hematology American Society of Hematology 10.1182/blood-2013-12-512681 Silverchair:32733 Total_Item_Requests 9 1 4 2 0 0 1 0 1 0 0 0 0 Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism The American Society of Hematology American Society of Hematology 10.1182/blood-2013-12-512681 Silverchair:32733 Unique_Item_Investigations 8 1 3 2 0 0 1 0 1 0 0 0 0 Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism The American Society of Hematology American Society of Hematology 10.1182/blood-2013-12-512681 Silverchair:32733 Unique_Item_Requests 8 1 3 2 0 0 1 0 1 0 0 0 0 Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Dose Optimization Efficacy Update and Expansion Phase Initial Results The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140412 Silverchair:470138 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Dose Optimization Efficacy Update and Expansion Phase Initial Results The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140412 Silverchair:470138 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Dose Optimization Efficacy Update and Expansion Phase Initial Results The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140412 Silverchair:470138 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Dose Optimization Efficacy Update and Expansion Phase Initial Results The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140412 Silverchair:470138 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003736 Silverchair:475052 Total_Item_Investigations 9 0 6 0 2 1 0 0 0 0 0 0 0 Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003736 Silverchair:475052 Total_Item_Requests 6 0 4 0 1 1 0 0 0 0 0 0 0 Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003736 Silverchair:475052 Unique_Item_Investigations 5 0 3 0 1 1 0 0 0 0 0 0 0 Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003736 Silverchair:475052 Unique_Item_Requests 5 0 3 0 1 1 0 0 0 0 0 0 0 Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131270 Silverchair:426212 Total_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131270 Silverchair:426212 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131270 Silverchair:426212 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131270 Silverchair:426212 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Dynamic changes in murine erythropoiesis from birth to adulthood: implications for the study of murine models of anemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003632 Silverchair:474781 Total_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 Dynamic changes in murine erythropoiesis from birth to adulthood: implications for the study of murine models of anemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003632 Silverchair:474781 Total_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 Dynamic changes in murine erythropoiesis from birth to adulthood: implications for the study of murine models of anemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003632 Silverchair:474781 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Dynamic changes in murine erythropoiesis from birth to adulthood: implications for the study of murine models of anemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003632 Silverchair:474781 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Dynamic CTCF binding directly mediates interactions among cis-regulatory elements essential for hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.2020005780 Silverchair:474571 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 Dynamic CTCF binding directly mediates interactions among cis-regulatory elements essential for hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.2020005780 Silverchair:474571 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Dynamic molecular modeling of pathogenic mutations in the spectrin self-association domain The American Society of Hematology American Society of Hematology 10.1182/blood.V98.6.1645 Silverchair:134114 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Dynamic molecular modeling of pathogenic mutations in the spectrin self-association domain The American Society of Hematology American Society of Hematology 10.1182/blood.V98.6.1645 Silverchair:134114 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Dynamic molecular modeling of pathogenic mutations in the spectrin self-association domain The American Society of Hematology American Society of Hematology 10.1182/blood.V98.6.1645 Silverchair:134114 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Dynamic molecular modeling of pathogenic mutations in the spectrin self-association domain The American Society of Hematology American Society of Hematology 10.1182/blood.V98.6.1645 Silverchair:134114 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Dysregulation of Frizzled 6 is a critical component of B-cell leukemogenesis in a mouse model of chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2008-06-163303 Silverchair:24756 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Dysregulation of Frizzled 6 is a critical component of B-cell leukemogenesis in a mouse model of chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2008-06-163303 Silverchair:24756 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Dysregulation of Frizzled 6 is a critical component of B-cell leukemogenesis in a mouse model of chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2008-06-163303 Silverchair:24756 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Dysregulation of Frizzled 6 is a critical component of B-cell leukemogenesis in a mouse model of chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2008-06-163303 Silverchair:24756 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 E26 leukemia virus converts primitive erythroid cells into cycling multilineage progenitors The American Society of Hematology American Society of Hematology 10.1182/blood-2002-04-1050 Silverchair:88826 Total_Item_Investigations 8 8 0 0 0 0 0 0 0 0 0 0 0 E26 leukemia virus converts primitive erythroid cells into cycling multilineage progenitors The American Society of Hematology American Society of Hematology 10.1182/blood-2002-04-1050 Silverchair:88826 Total_Item_Requests 7 7 0 0 0 0 0 0 0 0 0 0 0 E26 leukemia virus converts primitive erythroid cells into cycling multilineage progenitors The American Society of Hematology American Society of Hematology 10.1182/blood-2002-04-1050 Silverchair:88826 Unique_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 E26 leukemia virus converts primitive erythroid cells into cycling multilineage progenitors The American Society of Hematology American Society of Hematology 10.1182/blood-2002-04-1050 Silverchair:88826 Unique_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020005514 Silverchair:463598 No_License 4 0 0 3 0 0 1 0 0 0 0 0 0 Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020005514 Silverchair:463598 Total_Item_Investigations 15 0 0 12 0 0 3 0 0 0 0 0 0 Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020005514 Silverchair:463598 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020005514 Silverchair:463598 Unique_Item_Investigations 3 0 0 2 0 0 1 0 0 0 0 0 0 Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020005514 Silverchair:463598 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Early Clonal Hematopoiesis Detected in Gata2 heterozygosity By Color-Barcoding of Hematopoietic Stem Cells in Zebrafish The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118236 Silverchair:266149 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Early Clonal Hematopoiesis Detected in Gata2 heterozygosity By Color-Barcoding of Hematopoietic Stem Cells in Zebrafish The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118236 Silverchair:266149 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Early Clonal Hematopoiesis Detected in Gata2 heterozygosity By Color-Barcoding of Hematopoietic Stem Cells in Zebrafish The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118236 Silverchair:266149 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Early Clonal Hematopoiesis Detected in Gata2 heterozygosity By Color-Barcoding of Hematopoietic Stem Cells in Zebrafish The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118236 Silverchair:266149 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survival American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003797 Silverchair:475514 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survival American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003797 Silverchair:475514 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survival American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003797 Silverchair:475514 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survival American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003797 Silverchair:475514 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134538 Silverchair:470028 Total_Item_Investigations 3 0 0 2 0 0 1 0 0 0 0 0 0 Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134538 Silverchair:470028 Total_Item_Requests 3 0 0 2 0 0 1 0 0 0 0 0 0 Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134538 Silverchair:470028 Unique_Item_Investigations 3 0 0 2 0 0 1 0 0 0 0 0 0 Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134538 Silverchair:470028 Unique_Item_Requests 3 0 0 2 0 0 1 0 0 0 0 0 0 Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126208 Silverchair:427927 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126208 Silverchair:427927 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126208 Silverchair:427927 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126208 Silverchair:427927 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 EBF1 and PAX5 control pro-B cell expansion via opposing regulation of the Myc gene. The American Society of Hematology American Society of Hematology 10.1182/blood.2020009564 Silverchair:475285 Total_Item_Investigations 9 0 0 9 0 0 0 0 0 0 0 0 0 EBF1 and PAX5 control pro-B cell expansion via opposing regulation of the Myc gene. The American Society of Hematology American Society of Hematology 10.1182/blood.2020009564 Silverchair:475285 Unique_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 EBF1 As a Novel Regulator of Bone Marrow Mesenchymal Stromal Progenitors The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.96.96 Silverchair:83655 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 EBF1 As a Novel Regulator of Bone Marrow Mesenchymal Stromal Progenitors The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.96.96 Silverchair:83655 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 EBF1 As a Novel Regulator of Bone Marrow Mesenchymal Stromal Progenitors The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.96.96 Silverchair:83655 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 EBF1 As a Novel Regulator of Bone Marrow Mesenchymal Stromal Progenitors The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.96.96 Silverchair:83655 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity The American Society of Hematology American Society of Hematology 10.1182/blood.2020008520 Silverchair:474186 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity The American Society of Hematology American Society of Hematology 10.1182/blood.2020008520 Silverchair:474186 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity The American Society of Hematology American Society of Hematology 10.1182/blood.2020008520 Silverchair:474186 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity The American Society of Hematology American Society of Hematology 10.1182/blood.2020008520 Silverchair:474186 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 EBV-positive diffuse large B-cell lymphoma of the elderly The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-489708 Silverchair:31763 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 EBV-positive diffuse large B-cell lymphoma of the elderly The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-489708 Silverchair:31763 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 EBV-positive diffuse large B-cell lymphoma of the elderly The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-489708 Silverchair:31763 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 EBV-positive diffuse large B-cell lymphoma of the elderly The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-489708 Silverchair:31763 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Eculizumab and aHUS: to stop or not The American Society of Hematology American Society of Hematology 10.1182/blood.2020010234 Silverchair:475859 Total_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 Eculizumab and aHUS: to stop or not The American Society of Hematology American Society of Hematology 10.1182/blood.2020010234 Silverchair:475859 Total_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 Eculizumab and aHUS: to stop or not The American Society of Hematology American Society of Hematology 10.1182/blood.2020010234 Silverchair:475859 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Eculizumab and aHUS: to stop or not The American Society of Hematology American Society of Hematology 10.1182/blood.2020010234 Silverchair:475859 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study The American Society of Hematology American Society of Hematology 10.1182/blood.2020009280 Silverchair:474388 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study The American Society of Hematology American Society of Hematology 10.1182/blood.2020009280 Silverchair:474388 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study The American Society of Hematology American Society of Hematology 10.1182/blood.2020009280 Silverchair:474388 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study The American Society of Hematology American Society of Hematology 10.1182/blood.2020009280 Silverchair:474388 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Eculizumab for Refractory Thrombosis in Antiphospholipid Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140535 Silverchair:473256 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Eculizumab for Refractory Thrombosis in Antiphospholipid Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140535 Silverchair:473256 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Eculizumab for Refractory Thrombosis in Antiphospholipid Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140535 Silverchair:473256 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Eculizumab for Refractory Thrombosis in Antiphospholipid Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140535 Silverchair:473256 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "Editorial: Riddle: What Do Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH) and ""Hypoplastic"" Leukemia Have in Common?" The American Society of Hematology American Society of Hematology 10.1182/blood.V30.2.251.251 Silverchair:38060 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Editorial: Riddle: What Do Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH) and ""Hypoplastic"" Leukemia Have in Common?" The American Society of Hematology American Society of Hematology 10.1182/blood.V30.2.251.251 Silverchair:38060 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Effect of Blood Transfusion On Serum Haptoglobin. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.3138.3138 Silverchair:132891 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Effect of Blood Transfusion On Serum Haptoglobin. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.3138.3138 Silverchair:132891 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Effect of Blood Transfusion On Serum Haptoglobin. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.3138.3138 Silverchair:132891 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Effect of Blood Transfusion On Serum Haptoglobin. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.3138.3138 Silverchair:132891 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines The American Society of Hematology American Society of Hematology 10.1182/blood.2020008758 Silverchair:474376 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines The American Society of Hematology American Society of Hematology 10.1182/blood.2020008758 Silverchair:474376 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines The American Society of Hematology American Society of Hematology 10.1182/blood.2020008758 Silverchair:474376 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines The American Society of Hematology American Society of Hematology 10.1182/blood.2020008758 Silverchair:474376 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Effect of Luspatercept on Biomarkers of Erythropoiesis in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Medalist Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136705 Silverchair:471914 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Effect of Luspatercept on Biomarkers of Erythropoiesis in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Medalist Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136705 Silverchair:471914 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Effect of Luspatercept on Biomarkers of Erythropoiesis in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Medalist Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136705 Silverchair:471914 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Effect of Luspatercept on Biomarkers of Erythropoiesis in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Medalist Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136705 Silverchair:471914 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-798751 Silverchair:36452 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-798751 Silverchair:36452 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-798751 Silverchair:36452 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-798751 Silverchair:36452 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects The American Society of Hematology American Society of Hematology 10.1182/blood-2004-04-1525 Silverchair:19370 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects The American Society of Hematology American Society of Hematology 10.1182/blood-2004-04-1525 Silverchair:19370 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects The American Society of Hematology American Society of Hematology 10.1182/blood-2004-04-1525 Silverchair:19370 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects The American Society of Hematology American Society of Hematology 10.1182/blood-2004-04-1525 Silverchair:19370 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Effective therapy of AML with RUNX1 mutation by co-treatment with inhibitors of protein translation and BCL2 The American Society of Hematology American Society of Hematology 10.1182/blood.2021013156 Silverchair:477139 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Effective therapy of AML with RUNX1 mutation by co-treatment with inhibitors of protein translation and BCL2 The American Society of Hematology American Society of Hematology 10.1182/blood.2021013156 Silverchair:477139 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Effective therapy of AML with RUNX1 mutation by co-treatment with inhibitors of protein translation and BCL2 The American Society of Hematology American Society of Hematology 10.1182/blood.2021013156 Silverchair:477139 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Effective therapy of AML with RUNX1 mutation by co-treatment with inhibitors of protein translation and BCL2 The American Society of Hematology American Society of Hematology 10.1182/blood.2021013156 Silverchair:477139 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Effective Treatment of Cold Agglutinin Disease/Cold Agglutinin Syndrome with Ibrutinib: An International Case Series The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139131 Silverchair:471416 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Effective Treatment of Cold Agglutinin Disease/Cold Agglutinin Syndrome with Ibrutinib: An International Case Series The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139131 Silverchair:471416 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Effective Treatment of Cold Agglutinin Disease/Cold Agglutinin Syndrome with Ibrutinib: An International Case Series The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139131 Silverchair:471416 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Effective Treatment of Cold Agglutinin Disease/Cold Agglutinin Syndrome with Ibrutinib: An International Case Series The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139131 Silverchair:471416 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-12-290403 Silverchair:20428 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-12-290403 Silverchair:20428 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-12-290403 Silverchair:20428 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-12-290403 Silverchair:20428 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Effects of a partly self-administered exercise program before, during, and after allogeneic stem cell transplantation" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-306308 Silverchair:28267 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 "Effects of a partly self-administered exercise program before, during, and after allogeneic stem cell transplantation" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-306308 Silverchair:28267 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 "Effects of a partly self-administered exercise program before, during, and after allogeneic stem cell transplantation" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-306308 Silverchair:28267 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Effects of a partly self-administered exercise program before, during, and after allogeneic stem cell transplantation" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-306308 Silverchair:28267 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Effects of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-11-4282 Silverchair:21562 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Effects of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-11-4282 Silverchair:21562 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Effects of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-11-4282 Silverchair:21562 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Effects of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-11-4282 Silverchair:21562 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2007-09-107953 Silverchair:24316 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2007-09-107953 Silverchair:24316 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2007-09-107953 Silverchair:24316 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2007-09-107953 Silverchair:24316 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Effects of inflammatory cytokines on the release and cleavage of the endothelial cell–derived ultralarge von Willebrand factor multimers under flow The American Society of Hematology American Society of Hematology 10.1182/blood-2004-01-0107 Silverchair:114506 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Effects of inflammatory cytokines on the release and cleavage of the endothelial cell–derived ultralarge von Willebrand factor multimers under flow The American Society of Hematology American Society of Hematology 10.1182/blood-2004-01-0107 Silverchair:114506 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Effects of inflammatory cytokines on the release and cleavage of the endothelial cell–derived ultralarge von Willebrand factor multimers under flow The American Society of Hematology American Society of Hematology 10.1182/blood-2004-01-0107 Silverchair:114506 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Effects of inflammatory cytokines on the release and cleavage of the endothelial cell–derived ultralarge von Willebrand factor multimers under flow The American Society of Hematology American Society of Hematology 10.1182/blood-2004-01-0107 Silverchair:114506 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-05-1669 Silverchair:19383 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-05-1669 Silverchair:19383 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-05-1669 Silverchair:19383 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-05-1669 Silverchair:19383 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety The American Society of Hematology American Society of Hematology 10.1182/blood-2006-01-0054 Silverchair:133549 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety The American Society of Hematology American Society of Hematology 10.1182/blood-2006-01-0054 Silverchair:133549 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety The American Society of Hematology American Society of Hematology 10.1182/blood-2006-01-0054 Silverchair:133549 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety The American Society of Hematology American Society of Hematology 10.1182/blood-2006-01-0054 Silverchair:133549 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials The American Society of Hematology American Society of Hematology 10.1182/blood-2006-03-008953 Silverchair:22642 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials The American Society of Hematology American Society of Hematology 10.1182/blood-2006-03-008953 Silverchair:22642 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials The American Society of Hematology American Society of Hematology 10.1182/blood-2006-03-008953 Silverchair:22642 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials The American Society of Hematology American Society of Hematology 10.1182/blood-2006-03-008953 Silverchair:22642 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Effects of Platelets and Erythrocytes on the Dynamic Size and Mechanical Properties of Blood Clots during Contraction The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4225.4225 Silverchair:91831 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Effects of Platelets and Erythrocytes on the Dynamic Size and Mechanical Properties of Blood Clots during Contraction The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4225.4225 Silverchair:91831 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Effects of Platelets and Erythrocytes on the Dynamic Size and Mechanical Properties of Blood Clots during Contraction The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4225.4225 Silverchair:91831 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Effects of Platelets and Erythrocytes on the Dynamic Size and Mechanical Properties of Blood Clots during Contraction The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4225.4225 Silverchair:91831 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Effects of Prophylactic Platelet (Plt) Dose on Transfusion (Tx) Outcomes (PLADO Trial) The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.285.285 Silverchair:59622 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Effects of Prophylactic Platelet (Plt) Dose on Transfusion (Tx) Outcomes (PLADO Trial) The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.285.285 Silverchair:59622 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Effects of Prophylactic Platelet (Plt) Dose on Transfusion (Tx) Outcomes (PLADO Trial) The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.285.285 Silverchair:59622 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Effects of Prophylactic Platelet (Plt) Dose on Transfusion (Tx) Outcomes (PLADO Trial) The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.285.285 Silverchair:59622 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ Production The American Society of Hematology American Society of Hematology 10.1182/blood.V90.7.2541 Silverchair:238647 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ Production The American Society of Hematology American Society of Hematology 10.1182/blood.V90.7.2541 Silverchair:238647 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ Production The American Society of Hematology American Society of Hematology 10.1182/blood.V90.7.2541 Silverchair:238647 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ Production The American Society of Hematology American Society of Hematology 10.1182/blood.V90.7.2541 Silverchair:238647 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy: The a-TREAT Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138920 Silverchair:470165 Total_Item_Investigations 6 2 4 0 0 0 0 0 0 0 0 0 0 Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy: The a-TREAT Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138920 Silverchair:470165 Total_Item_Requests 6 2 4 0 0 0 0 0 0 0 0 0 0 Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy: The a-TREAT Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138920 Silverchair:470165 Unique_Item_Investigations 3 1 2 0 0 0 0 0 0 0 0 0 0 Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy: The a-TREAT Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138920 Silverchair:470165 Unique_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 Efficacy and Cost Effectiveness of Intravenous Ferric Carboxymaltose Versus Iron Sucrose in Adult Patients with Iron Deficiency Anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134537 Silverchair:471304 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Efficacy and Cost Effectiveness of Intravenous Ferric Carboxymaltose Versus Iron Sucrose in Adult Patients with Iron Deficiency Anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134537 Silverchair:471304 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Efficacy and Cost Effectiveness of Intravenous Ferric Carboxymaltose Versus Iron Sucrose in Adult Patients with Iron Deficiency Anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134537 Silverchair:471304 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Efficacy and Cost Effectiveness of Intravenous Ferric Carboxymaltose Versus Iron Sucrose in Adult Patients with Iron Deficiency Anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134537 Silverchair:471304 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Efficacy and Feasibility of Sorafenib As a Maintenance Agent after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4624.4624 Silverchair:101510 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Efficacy and Feasibility of Sorafenib As a Maintenance Agent after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4624.4624 Silverchair:101510 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Efficacy and Feasibility of Sorafenib As a Maintenance Agent after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4624.4624 Silverchair:101510 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Efficacy and Feasibility of Sorafenib As a Maintenance Agent after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4624.4624 Silverchair:101510 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001466 Silverchair:456149 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001466 Silverchair:456149 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001466 Silverchair:456149 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001466 Silverchair:456149 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Direct Oral Anticoagulants in Extremes Weights The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137150 Silverchair:473266 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Direct Oral Anticoagulants in Extremes Weights The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137150 Silverchair:473266 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Direct Oral Anticoagulants in Extremes Weights The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137150 Silverchair:473266 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Direct Oral Anticoagulants in Extremes Weights The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137150 Silverchair:473266 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Direct Oral Anticoagulants in Obese Patients with Venous Thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2019-121765 Silverchair:428240 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Direct Oral Anticoagulants in Obese Patients with Venous Thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2019-121765 Silverchair:428240 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Direct Oral Anticoagulants in Obese Patients with Venous Thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2019-121765 Silverchair:428240 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Direct Oral Anticoagulants in Obese Patients with Venous Thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2019-121765 Silverchair:428240 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Direct Oral Factor Xa Inhibitors in Patients after Bariatric Surgery The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127645 Silverchair:422960 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Direct Oral Factor Xa Inhibitors in Patients after Bariatric Surgery The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127645 Silverchair:422960 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Direct Oral Factor Xa Inhibitors in Patients after Bariatric Surgery The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127645 Silverchair:422960 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Direct Oral Factor Xa Inhibitors in Patients after Bariatric Surgery The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127645 Silverchair:422960 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Four Factor Prothrombin Complex Concentrates As a Reversal Agent for Oral Xa Inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4668.4668 Silverchair:93449 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Four Factor Prothrombin Complex Concentrates As a Reversal Agent for Oral Xa Inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4668.4668 Silverchair:93449 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Four Factor Prothrombin Complex Concentrates As a Reversal Agent for Oral Xa Inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4668.4668 Silverchair:93449 Unique_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Four Factor Prothrombin Complex Concentrates As a Reversal Agent for Oral Xa Inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4668.4668 Silverchair:93449 Unique_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Human Fibrinogen Concentrate for the Treatment of Patients with Congenital Fibrinogen Deficiency: Combined Results of the FORMA-02 and FORMA-04 Clinical Trials The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141280 Silverchair:470609 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Human Fibrinogen Concentrate for the Treatment of Patients with Congenital Fibrinogen Deficiency: Combined Results of the FORMA-02 and FORMA-04 Clinical Trials The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141280 Silverchair:470609 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Human Fibrinogen Concentrate for the Treatment of Patients with Congenital Fibrinogen Deficiency: Combined Results of the FORMA-02 and FORMA-04 Clinical Trials The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141280 Silverchair:470609 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Human Fibrinogen Concentrate for the Treatment of Patients with Congenital Fibrinogen Deficiency: Combined Results of the FORMA-02 and FORMA-04 Clinical Trials The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141280 Silverchair:470609 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134322 Silverchair:471108 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134322 Silverchair:471108 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134322 Silverchair:471108 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134322 Silverchair:471108 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137232 Silverchair:472802 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137232 Silverchair:472802 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137232 Silverchair:472802 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137232 Silverchair:472802 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Efficacy and safety of once-weekly bortezomib in multiple myeloma patients The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-294983 Silverchair:28318 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Efficacy and safety of once-weekly bortezomib in multiple myeloma patients The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-294983 Silverchair:28318 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Efficacy and safety of once-weekly bortezomib in multiple myeloma patients The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-294983 Silverchair:28318 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Efficacy and safety of once-weekly bortezomib in multiple myeloma patients The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-294983 Silverchair:28318 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic The American Society of Hematology American Society of Hematology 10.1182/blood-2020-133922 Silverchair:470383 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic The American Society of Hematology American Society of Hematology 10.1182/blood-2020-133922 Silverchair:470383 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic The American Society of Hematology American Society of Hematology 10.1182/blood-2020-133922 Silverchair:470383 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic The American Society of Hematology American Society of Hematology 10.1182/blood-2020-133922 Silverchair:470383 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Efficacy and Safety of Romiplostim in Patients with Acquired Aplastic Anemia Ineligible or Refractory to Immunosuppressive Therapy: Interim Analysis of Phase 2/3 Clinical Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112478 Silverchair:262960 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Romiplostim in Patients with Acquired Aplastic Anemia Ineligible or Refractory to Immunosuppressive Therapy: Interim Analysis of Phase 2/3 Clinical Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112478 Silverchair:262960 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Romiplostim in Patients with Acquired Aplastic Anemia Ineligible or Refractory to Immunosuppressive Therapy: Interim Analysis of Phase 2/3 Clinical Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112478 Silverchair:262960 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Romiplostim in Patients with Acquired Aplastic Anemia Ineligible or Refractory to Immunosuppressive Therapy: Interim Analysis of Phase 2/3 Clinical Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112478 Silverchair:262960 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study The American Society of Hematology American Society of Hematology 10.1182/blood-2021-146039 Silverchair:478172 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study The American Society of Hematology American Society of Hematology 10.1182/blood-2021-146039 Silverchair:478172 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study The American Society of Hematology American Society of Hematology 10.1182/blood-2021-146039 Silverchair:478172 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study The American Society of Hematology American Society of Hematology 10.1182/blood-2021-146039 Silverchair:478172 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136855 Silverchair:470443 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136855 Silverchair:470443 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136855 Silverchair:470443 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136855 Silverchair:470443 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138983 Silverchair:470985 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138983 Silverchair:470985 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138983 Silverchair:470985 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138983 Silverchair:470985 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139705 Silverchair:469983 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139705 Silverchair:469983 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139705 Silverchair:469983 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139705 Silverchair:469983 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134611 Silverchair:470006 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134611 Silverchair:470006 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134611 Silverchair:470006 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134611 Silverchair:470006 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134280 Silverchair:471032 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134280 Silverchair:471032 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134280 Silverchair:471032 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134280 Silverchair:471032 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood.2019004753 Silverchair:463592 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 "Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood.2019004753 Silverchair:463592 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 "Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood.2019004753 Silverchair:463592 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 "Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood.2019004753 Silverchair:463592 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Efficacy and Thrombotic Adverse Events of Romiplostim Use in Patients with Thrombocytopenia Related to Underlying Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2324.2324 Silverchair:80279 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy and Thrombotic Adverse Events of Romiplostim Use in Patients with Thrombocytopenia Related to Underlying Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2324.2324 Silverchair:80279 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy and Thrombotic Adverse Events of Romiplostim Use in Patients with Thrombocytopenia Related to Underlying Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2324.2324 Silverchair:80279 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy and Thrombotic Adverse Events of Romiplostim Use in Patients with Thrombocytopenia Related to Underlying Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2324.2324 Silverchair:80279 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy of 5% Albumin and Fresh Frozen Plasma (AFFP) Versus Fresh Frozen Plasma (FFP) only as Replacement fluid in Plasma Exchange for Thrombotic Thrombocytopenic Purpura (TTP) The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.272.272 Silverchair:102193 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Efficacy of 5% Albumin and Fresh Frozen Plasma (AFFP) Versus Fresh Frozen Plasma (FFP) only as Replacement fluid in Plasma Exchange for Thrombotic Thrombocytopenic Purpura (TTP) The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.272.272 Silverchair:102193 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Efficacy of 5% Albumin and Fresh Frozen Plasma (AFFP) Versus Fresh Frozen Plasma (FFP) only as Replacement fluid in Plasma Exchange for Thrombotic Thrombocytopenic Purpura (TTP) The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.272.272 Silverchair:102193 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Efficacy of 5% Albumin and Fresh Frozen Plasma (AFFP) Versus Fresh Frozen Plasma (FFP) only as Replacement fluid in Plasma Exchange for Thrombotic Thrombocytopenic Purpura (TTP) The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.272.272 Silverchair:102193 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Efficacy of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients with Relapsed/Refractory Multiple Myeloma: An Interim Report from an International Electronic Observational Study The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.3027.3027 Silverchair:112129 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Efficacy of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients with Relapsed/Refractory Multiple Myeloma: An Interim Report from an International Electronic Observational Study The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.3027.3027 Silverchair:112129 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Efficacy of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients with Relapsed/Refractory Multiple Myeloma: An Interim Report from an International Electronic Observational Study The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.3027.3027 Silverchair:112129 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Efficacy of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients with Relapsed/Refractory Multiple Myeloma: An Interim Report from an International Electronic Observational Study The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.3027.3027 Silverchair:112129 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139559 Silverchair:472045 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139559 Silverchair:472045 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139559 Silverchair:472045 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139559 Silverchair:472045 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy of Eculizumab in Gemcitabine-Induced Thrombotic Microangiopathy: Experience of the French Thrombotic Microangiopathies Reference Centre The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.136.136 Silverchair:96200 Total_Item_Investigations 4 0 0 0 4 0 0 0 0 0 0 0 0 Efficacy of Eculizumab in Gemcitabine-Induced Thrombotic Microangiopathy: Experience of the French Thrombotic Microangiopathies Reference Centre The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.136.136 Silverchair:96200 Total_Item_Requests 4 0 0 0 4 0 0 0 0 0 0 0 0 Efficacy of Eculizumab in Gemcitabine-Induced Thrombotic Microangiopathy: Experience of the French Thrombotic Microangiopathies Reference Centre The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.136.136 Silverchair:96200 Unique_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Efficacy of Eculizumab in Gemcitabine-Induced Thrombotic Microangiopathy: Experience of the French Thrombotic Microangiopathies Reference Centre The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.136.136 Silverchair:96200 Unique_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 Efficacy of Eltrombopag In Splenectomized Versus Nonsplenectomized Patients with Chronic ITP In the RAISE Study The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2512.2512 Silverchair:131658 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Efficacy of Eltrombopag In Splenectomized Versus Nonsplenectomized Patients with Chronic ITP In the RAISE Study The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2512.2512 Silverchair:131658 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Efficacy of Eltrombopag In Splenectomized Versus Nonsplenectomized Patients with Chronic ITP In the RAISE Study The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2512.2512 Silverchair:131658 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Efficacy of Eltrombopag In Splenectomized Versus Nonsplenectomized Patients with Chronic ITP In the RAISE Study The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2512.2512 Silverchair:131658 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Efficacy of Modified Vrd-Lite for Transplant Ineligible Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143459 Silverchair:473646 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy of Modified Vrd-Lite for Transplant Ineligible Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143459 Silverchair:473646 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy of Modified Vrd-Lite for Transplant Ineligible Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143459 Silverchair:473646 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy of Modified Vrd-Lite for Transplant Ineligible Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143459 Silverchair:473646 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142807 Silverchair:470172 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Efficacy of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142807 Silverchair:470172 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Efficacy of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142807 Silverchair:470172 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Efficacy of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142807 Silverchair:470172 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Efficacy of Same-Day Vs. Next-Day Pegfilgrastim for the Prevention of Chemotherapy-Induced (Febrile) Neutropenia (CIN/FN): A Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4764.4764 Silverchair:93535 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Efficacy of Same-Day Vs. Next-Day Pegfilgrastim for the Prevention of Chemotherapy-Induced (Febrile) Neutropenia (CIN/FN): A Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4764.4764 Silverchair:93535 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Efficacy of Same-Day Vs. Next-Day Pegfilgrastim for the Prevention of Chemotherapy-Induced (Febrile) Neutropenia (CIN/FN): A Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4764.4764 Silverchair:93535 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Efficacy of Same-Day Vs. Next-Day Pegfilgrastim for the Prevention of Chemotherapy-Induced (Febrile) Neutropenia (CIN/FN): A Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4764.4764 Silverchair:93535 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2021011568 Silverchair:475742 Total_Item_Investigations 5 0 0 0 0 0 2 1 1 1 0 0 0 Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2021011568 Silverchair:475742 Total_Item_Requests 5 0 0 0 0 0 2 1 1 1 0 0 0 Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2021011568 Silverchair:475742 Unique_Item_Investigations 4 0 0 0 0 0 1 1 1 1 0 0 0 Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2021011568 Silverchair:475742 Unique_Item_Requests 4 0 0 0 0 0 1 1 1 1 0 0 0 Efficacy of VDT PACE-like Regimens in Treatment of Relapsed/Refractory Multiple Myeloma—a Single Center Experience The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3096.3096 Silverchair:80779 Total_Item_Investigations 3 1 1 0 0 0 0 0 0 1 0 0 0 Efficacy of VDT PACE-like Regimens in Treatment of Relapsed/Refractory Multiple Myeloma—a Single Center Experience The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3096.3096 Silverchair:80779 Total_Item_Requests 3 1 1 0 0 0 0 0 0 1 0 0 0 Efficacy of VDT PACE-like Regimens in Treatment of Relapsed/Refractory Multiple Myeloma—a Single Center Experience The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3096.3096 Silverchair:80779 Unique_Item_Investigations 3 1 1 0 0 0 0 0 0 1 0 0 0 Efficacy of VDT PACE-like Regimens in Treatment of Relapsed/Refractory Multiple Myeloma—a Single Center Experience The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3096.3096 Silverchair:80779 Unique_Item_Requests 3 1 1 0 0 0 0 0 0 1 0 0 0 Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-788786 Silverchair:36573 Total_Item_Investigations 4 0 2 0 0 0 0 0 0 1 1 0 0 Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-788786 Silverchair:36573 Total_Item_Requests 4 0 2 0 0 0 0 0 0 1 1 0 0 Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-788786 Silverchair:36573 Unique_Item_Investigations 3 0 1 0 0 0 0 0 0 1 1 0 0 Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-788786 Silverchair:36573 Unique_Item_Requests 3 0 1 0 0 0 0 0 0 1 1 0 0 Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables The American Society of Hematology American Society of Hematology 10.1182/blood.2018882555 Silverchair:260687 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables The American Society of Hematology American Society of Hematology 10.1182/blood.2018882555 Silverchair:260687 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables The American Society of Hematology American Society of Hematology 10.1182/blood.2018882555 Silverchair:260687 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables The American Society of Hematology American Society of Hematology 10.1182/blood.2018882555 Silverchair:260687 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Efficacy Outcomes of Treatments for Double Relapsed/Refractory Follicular Lymphoma (R/R FL): A Systematic Literature Review The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136228 Silverchair:473469 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy Outcomes of Treatments for Double Relapsed/Refractory Follicular Lymphoma (R/R FL): A Systematic Literature Review The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136228 Silverchair:473469 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy Outcomes of Treatments for Double Relapsed/Refractory Follicular Lymphoma (R/R FL): A Systematic Literature Review The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136228 Silverchair:473469 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Efficacy Outcomes of Treatments for Double Relapsed/Refractory Follicular Lymphoma (R/R FL): A Systematic Literature Review The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136228 Silverchair:473469 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 E-Iron: Rethinking the Way We Deliver Intravenous Iron. Report of a Pilot Telemedicine Initiative The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143356 Silverchair:470107 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 E-Iron: Rethinking the Way We Deliver Intravenous Iron. Report of a Pilot Telemedicine Initiative The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143356 Silverchair:470107 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 E-Iron: Rethinking the Way We Deliver Intravenous Iron. Report of a Pilot Telemedicine Initiative The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143356 Silverchair:470107 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 E-Iron: Rethinking the Way We Deliver Intravenous Iron. Report of a Pilot Telemedicine Initiative The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143356 Silverchair:470107 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 EKLF/KLF1-regulated cell cycle exit is essential for erythroblast enucleation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-03-706671 Silverchair:73122 Total_Item_Investigations 8 0 3 5 0 0 0 0 0 0 0 0 0 EKLF/KLF1-regulated cell cycle exit is essential for erythroblast enucleation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-03-706671 Silverchair:73122 Total_Item_Requests 8 0 3 5 0 0 0 0 0 0 0 0 0 EKLF/KLF1-regulated cell cycle exit is essential for erythroblast enucleation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-03-706671 Silverchair:73122 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 EKLF/KLF1-regulated cell cycle exit is essential for erythroblast enucleation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-03-706671 Silverchair:73122 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Elevated Factor VIII Activity In Patients With Hypercoagulability Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4802.4802 Silverchair:13149 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Elevated Factor VIII Activity In Patients With Hypercoagulability Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4802.4802 Silverchair:13149 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Elevated Factor VIII Activity In Patients With Hypercoagulability Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4802.4802 Silverchair:13149 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Elevated Factor VIII Activity In Patients With Hypercoagulability Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4802.4802 Silverchair:13149 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Elevated MCV in Patients with Hereditary Hemochromatosis. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.3733.3733 Silverchair:127310 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Elevated MCV in Patients with Hereditary Hemochromatosis. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.3733.3733 Silverchair:127310 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Elevated MCV in Patients with Hereditary Hemochromatosis. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.3733.3733 Silverchair:127310 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Elevated MCV in Patients with Hereditary Hemochromatosis. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.3733.3733 Silverchair:127310 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Elevated P21 (CDKN1a) Mediates Apoptosis of Beta-Thalassemic Erythroid Cells in Mice but Its Ablation Doesn't Improve Erythroid Maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143384 Silverchair:470724 Total_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 Elevated P21 (CDKN1a) Mediates Apoptosis of Beta-Thalassemic Erythroid Cells in Mice but Its Ablation Doesn't Improve Erythroid Maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143384 Silverchair:470724 Total_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 Elevated P21 (CDKN1a) Mediates Apoptosis of Beta-Thalassemic Erythroid Cells in Mice but Its Ablation Doesn't Improve Erythroid Maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143384 Silverchair:470724 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Elevated P21 (CDKN1a) Mediates Apoptosis of Beta-Thalassemic Erythroid Cells in Mice but Its Ablation Doesn't Improve Erythroid Maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143384 Silverchair:470724 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Elevated plasma concentration of complement factor C5 is associated with risk of future venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood.2021010822 Silverchair:476493 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 Elevated plasma concentration of complement factor C5 is associated with risk of future venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood.2021010822 Silverchair:476493 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 Elevated plasma concentration of complement factor C5 is associated with risk of future venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood.2021010822 Silverchair:476493 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Elevated plasma concentration of complement factor C5 is associated with risk of future venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood.2021010822 Silverchair:476493 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 "Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-352971 Silverchair:28851 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 "Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-352971 Silverchair:28851 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 "Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-352971 Silverchair:28851 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-352971 Silverchair:28851 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Elevated Serum Ferritin Levels Are Highly Associated with Diabetes Mellitus and Hypothyroidism in Thalassemia Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.5174.5174 Silverchair:87223 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Elevated Serum Ferritin Levels Are Highly Associated with Diabetes Mellitus and Hypothyroidism in Thalassemia Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.5174.5174 Silverchair:87223 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Elevated Serum Ferritin Levels Are Highly Associated with Diabetes Mellitus and Hypothyroidism in Thalassemia Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.5174.5174 Silverchair:87223 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Elevated Serum Ferritin Levels Are Highly Associated with Diabetes Mellitus and Hypothyroidism in Thalassemia Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.5174.5174 Silverchair:87223 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-758409 Silverchair:35964 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-758409 Silverchair:35964 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-758409 Silverchair:35964 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-758409 Silverchair:35964 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 ELIPSIS: developing tools to better understand VOC in SCD The American Society of Hematology American Society of Hematology 10.1182/blood.2020009466 Silverchair:475707 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 ELIPSIS: developing tools to better understand VOC in SCD The American Society of Hematology American Society of Hematology 10.1182/blood.2020009466 Silverchair:475707 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 ELIPSIS: developing tools to better understand VOC in SCD The American Society of Hematology American Society of Hematology 10.1182/blood.2020009466 Silverchair:475707 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 ELIPSIS: developing tools to better understand VOC in SCD The American Society of Hematology American Society of Hematology 10.1182/blood.2020009466 Silverchair:475707 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Eltrombopag Combined with G-CSF and Cyclosporine Could Effect for Severe Acquired Aplastic Anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115779 Silverchair:265850 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Eltrombopag Combined with G-CSF and Cyclosporine Could Effect for Severe Acquired Aplastic Anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115779 Silverchair:265850 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Eltrombopag Combined with G-CSF and Cyclosporine Could Effect for Severe Acquired Aplastic Anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115779 Silverchair:265850 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Eltrombopag Combined with G-CSF and Cyclosporine Could Effect for Severe Acquired Aplastic Anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115779 Silverchair:265850 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study The American Society of Hematology American Society of Hematology 10.1182/blood.2019001617 Silverchair:375012 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study The American Society of Hematology American Society of Hematology 10.1182/blood.2019001617 Silverchair:375012 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study The American Society of Hematology American Society of Hematology 10.1182/blood.2019001617 Silverchair:375012 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study The American Society of Hematology American Society of Hematology 10.1182/blood.2019001617 Silverchair:375012 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001657 Silverchair:454469 Total_Item_Investigations 5 0 5 0 0 0 0 0 0 0 0 0 0 Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001657 Silverchair:454469 Total_Item_Requests 5 0 5 0 0 0 0 0 0 0 0 0 0 Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001657 Silverchair:454469 Unique_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001657 Silverchair:454469 Unique_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-399667 Silverchair:30408 Total_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-399667 Silverchair:30408 Total_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-399667 Silverchair:30408 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-399667 Silverchair:30408 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-884486 Silverchair:273818 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-884486 Silverchair:273818 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-884486 Silverchair:273818 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-884486 Silverchair:273818 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019002289 Silverchair:374991 Total_Item_Investigations 3 0 0 0 0 0 0 0 3 0 0 0 0 Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019002289 Silverchair:374991 Total_Item_Requests 3 0 0 0 0 0 0 0 3 0 0 0 0 Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019002289 Silverchair:374991 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019002289 Silverchair:374991 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Emergence of clonal cytogenetic abnormalities in Ph−cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority The American Society of Hematology American Society of Hematology 10.1182/blood-2002-07-2053 Silverchair:106677 Total_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 Emergence of clonal cytogenetic abnormalities in Ph−cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority The American Society of Hematology American Society of Hematology 10.1182/blood-2002-07-2053 Silverchair:106677 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Emergence of clonal cytogenetic abnormalities in Ph−cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority The American Society of Hematology American Society of Hematology 10.1182/blood-2002-07-2053 Silverchair:106677 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Emergence of clonal cytogenetic abnormalities in Ph−cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority The American Society of Hematology American Society of Hematology 10.1182/blood-2002-07-2053 Silverchair:106677 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Emerging therapies for inv(16) AML The American Society of Hematology American Society of Hematology 10.1182/blood.2020009933 Silverchair:475678 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Emerging therapies for inv(16) AML The American Society of Hematology American Society of Hematology 10.1182/blood.2020009933 Silverchair:475678 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Emerging treatments for classical myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-695965 Silverchair:36312 Total_Item_Investigations 10 0 5 5 0 0 0 0 0 0 0 0 0 Emerging treatments for classical myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-695965 Silverchair:36312 Total_Item_Requests 10 0 5 5 0 0 0 0 0 0 0 0 0 Emerging treatments for classical myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-695965 Silverchair:36312 Unique_Item_Investigations 6 0 3 3 0 0 0 0 0 0 0 0 0 Emerging treatments for classical myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-695965 Silverchair:36312 Unique_Item_Requests 6 0 3 3 0 0 0 0 0 0 0 0 0 Emicizumab for the treatment of acquired hemophilia A The American Society of Hematology American Society of Hematology 10.1182/blood.2020006315 Silverchair:461764 Total_Item_Investigations 16 2 7 7 0 0 0 0 0 0 0 0 0 Emicizumab for the treatment of acquired hemophilia A The American Society of Hematology American Society of Hematology 10.1182/blood.2020006315 Silverchair:461764 Total_Item_Requests 5 2 3 0 0 0 0 0 0 0 0 0 0 Emicizumab for the treatment of acquired hemophilia A The American Society of Hematology American Society of Hematology 10.1182/blood.2020006315 Silverchair:461764 Unique_Item_Investigations 8 2 3 3 0 0 0 0 0 0 0 0 0 Emicizumab for the treatment of acquired hemophilia A The American Society of Hematology American Society of Hematology 10.1182/blood.2020006315 Silverchair:461764 Unique_Item_Requests 4 2 2 0 0 0 0 0 0 0 0 0 0 Emicizumab for the treatment of acquired hemophilia A The American Society of Hematology American Society of Hematology 10.1182/blood.2020006315 Silverchair:461764 No_License 5 0 2 3 0 0 0 0 0 0 0 0 0 Emicizumab for the Treatment of Acquired Hemophilia_A: Lessons Learned from 4 Very Different Cases The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116973 Silverchair:263968 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Emicizumab for the Treatment of Acquired Hemophilia_A: Lessons Learned from 4 Very Different Cases The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116973 Silverchair:263968 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Emicizumab for the Treatment of Acquired Hemophilia_A: Lessons Learned from 4 Very Different Cases The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116973 Silverchair:263968 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Emicizumab for the Treatment of Acquired Hemophilia_A: Lessons Learned from 4 Very Different Cases The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116973 Silverchair:263968 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS)" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.343.343 Silverchair:98009 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS)" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.343.343 Silverchair:98009 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS)" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.343.343 Silverchair:98009 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS)" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.343.343 Silverchair:98009 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-779405 Silverchair:36814 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-779405 Silverchair:36814 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-779405 Silverchair:36814 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-779405 Silverchair:36814 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Encouraging activity for R-CHOP in advanced stage nodular lymphocyte–predominant Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-766121 Silverchair:37078 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Encouraging activity for R-CHOP in advanced stage nodular lymphocyte–predominant Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-766121 Silverchair:37078 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Encouraging activity for R-CHOP in advanced stage nodular lymphocyte–predominant Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-766121 Silverchair:37078 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Encouraging activity for R-CHOP in advanced stage nodular lymphocyte–predominant Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-766121 Silverchair:37078 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Endocytosis of soluble immune complexes leads to their clearance by FcγRIIIB but induces neutrophil extracellular traps via FcγRIIA in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-401133 Silverchair:73051 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Endocytosis of soluble immune complexes leads to their clearance by FcγRIIIB but induces neutrophil extracellular traps via FcγRIIA in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-401133 Silverchair:73051 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Endocytosis of soluble immune complexes leads to their clearance by FcγRIIIB but induces neutrophil extracellular traps via FcγRIIA in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-401133 Silverchair:73051 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Endocytosis of soluble immune complexes leads to their clearance by FcγRIIIB but induces neutrophil extracellular traps via FcγRIIA in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-401133 Silverchair:73051 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR The American Society of Hematology American Society of Hematology 10.1182/blood.2020005185 Silverchair:460603 Total_Item_Investigations 29 0 0 29 0 0 0 0 0 0 0 0 0 Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR The American Society of Hematology American Society of Hematology 10.1182/blood.2020005185 Silverchair:460603 Unique_Item_Investigations 5 0 0 5 0 0 0 0 0 0 0 0 0 Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR The American Society of Hematology American Society of Hematology 10.1182/blood.2020005185 Silverchair:460603 No_License 13 0 0 13 0 0 0 0 0 0 0 0 0 Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after CD19 CAR-T Cell Immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.805.805 Silverchair:83373 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after CD19 CAR-T Cell Immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.805.805 Silverchair:83373 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after CD19 CAR-T Cell Immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.805.805 Silverchair:83373 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after CD19 CAR-T Cell Immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.805.805 Silverchair:83373 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Endothelial cells produce bone morphogenetic protein 6 required for iron homeostasis in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-721571 Silverchair:36190 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Endothelial cells produce bone morphogenetic protein 6 required for iron homeostasis in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-721571 Silverchair:36190 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Endothelial cells produce bone morphogenetic protein 6 required for iron homeostasis in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-721571 Silverchair:36190 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Endothelial cells produce bone morphogenetic protein 6 required for iron homeostasis in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-721571 Silverchair:36190 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Endothelial cells provide an instructive niche for the differentiation and functional polarization of M2-like macrophages The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-422758 Silverchair:30641 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Endothelial cells provide an instructive niche for the differentiation and functional polarization of M2-like macrophages The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-422758 Silverchair:30641 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Endothelial cells provide an instructive niche for the differentiation and functional polarization of M2-like macrophages The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-422758 Silverchair:30641 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Endothelial cells provide an instructive niche for the differentiation and functional polarization of M2-like macrophages The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-422758 Silverchair:30641 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Endothelial RAF1/ERK activation regulates arterial morphogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-474601 Silverchair:105699 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Endothelial RAF1/ERK activation regulates arterial morphogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-474601 Silverchair:105699 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Endothelial RAF1/ERK activation regulates arterial morphogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-474601 Silverchair:105699 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Endothelial RAF1/ERK activation regulates arterial morphogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-474601 Silverchair:105699 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Endothelial reticulon-4B (Nogo-B) regulates ICAM-1–mediated leukocyte transmigration and acute inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-281956 Silverchair:28227 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Endothelial reticulon-4B (Nogo-B) regulates ICAM-1–mediated leukocyte transmigration and acute inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-281956 Silverchair:28227 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Endothelial reticulon-4B (Nogo-B) regulates ICAM-1–mediated leukocyte transmigration and acute inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-281956 Silverchair:28227 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Endothelial reticulon-4B (Nogo-B) regulates ICAM-1–mediated leukocyte transmigration and acute inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-281956 Silverchair:28227 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Endothelial signaling by neutrophil-released oncostatin M enhances P-selectin–dependent inflammation and thrombosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018026294 Silverchair:246596 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Endothelial signaling by neutrophil-released oncostatin M enhances P-selectin–dependent inflammation and thrombosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018026294 Silverchair:246596 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Endothelial signaling by neutrophil-released oncostatin M enhances P-selectin–dependent inflammation and thrombosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018026294 Silverchair:246596 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Endothelial signaling by neutrophil-released oncostatin M enhances P-selectin–dependent inflammation and thrombosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018026294 Silverchair:246596 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Enforced expression of Hlx homeobox gene prompts myeloid cell maturation and altered adherence properties of T cells The American Society of Hematology American Society of Hematology 10.1182/blood.V81.12.3242.3242 Silverchair:170236 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Enforced expression of Hlx homeobox gene prompts myeloid cell maturation and altered adherence properties of T cells The American Society of Hematology American Society of Hematology 10.1182/blood.V81.12.3242.3242 Silverchair:170236 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Enforced expression of Hlx homeobox gene prompts myeloid cell maturation and altered adherence properties of T cells The American Society of Hematology American Society of Hematology 10.1182/blood.V81.12.3242.3242 Silverchair:170236 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Enforced expression of Hlx homeobox gene prompts myeloid cell maturation and altered adherence properties of T cells The American Society of Hematology American Society of Hematology 10.1182/blood.V81.12.3242.3242 Silverchair:170236 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Engage - a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Eliglustat in Adults with Gaucher Disease Type 1: Results after 18 Months" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2732.2732 Silverchair:95739 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Engage - a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Eliglustat in Adults with Gaucher Disease Type 1: Results after 18 Months" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2732.2732 Silverchair:95739 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Engage - a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Eliglustat in Adults with Gaucher Disease Type 1: Results after 18 Months" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2732.2732 Silverchair:95739 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Engage - a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Eliglustat in Adults with Gaucher Disease Type 1: Results after 18 Months" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2732.2732 Silverchair:95739 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Engagement of CD11b and CD11c β2 integrin by antibodies or soluble CD23 induces IL-1β production on primary human monocytes through mitogen-activated protein kinase–dependent pathways The American Society of Hematology American Society of Hematology 10.1182/blood.V95.12.3868 Silverchair:267337 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Engagement of CD11b and CD11c β2 integrin by antibodies or soluble CD23 induces IL-1β production on primary human monocytes through mitogen-activated protein kinase–dependent pathways The American Society of Hematology American Society of Hematology 10.1182/blood.V95.12.3868 Silverchair:267337 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Engagement of CD11b and CD11c β2 integrin by antibodies or soluble CD23 induces IL-1β production on primary human monocytes through mitogen-activated protein kinase–dependent pathways The American Society of Hematology American Society of Hematology 10.1182/blood.V95.12.3868 Silverchair:267337 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Engagement of CD11b and CD11c β2 integrin by antibodies or soluble CD23 induces IL-1β production on primary human monocytes through mitogen-activated protein kinase–dependent pathways The American Society of Hematology American Society of Hematology 10.1182/blood.V95.12.3868 Silverchair:267337 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Engine: Phase III Randomized Study of Enzastaurin/R-CHOP Versus Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Novel Genomic Biomarker DGM1 The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124930 Silverchair:425223 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Engine: Phase III Randomized Study of Enzastaurin/R-CHOP Versus Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Novel Genomic Biomarker DGM1 The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124930 Silverchair:425223 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Engine: Phase III Randomized Study of Enzastaurin/R-CHOP Versus Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Novel Genomic Biomarker DGM1 The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124930 Silverchair:425223 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Engine: Phase III Randomized Study of Enzastaurin/R-CHOP Versus Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Novel Genomic Biomarker DGM1 The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124930 Silverchair:425223 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Engraftment of CLL-Derived T Cells in NSG Mice Is Feasible, Can Support CLL Cell Proliferation, and Eliminates the Need for Third Party Antigen Presenting Cells" The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.975.975 Silverchair:82915 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Engraftment of CLL-Derived T Cells in NSG Mice Is Feasible, Can Support CLL Cell Proliferation, and Eliminates the Need for Third Party Antigen Presenting Cells" The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.975.975 Silverchair:82915 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Engraftment of CLL-Derived T Cells in NSG Mice Is Feasible, Can Support CLL Cell Proliferation, and Eliminates the Need for Third Party Antigen Presenting Cells" The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.975.975 Silverchair:82915 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Engraftment of CLL-Derived T Cells in NSG Mice Is Feasible, Can Support CLL Cell Proliferation, and Eliminates the Need for Third Party Antigen Presenting Cells" The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.975.975 Silverchair:82915 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Enhanced phagocytosis of ring-parasitized mutant erythrocytes: a common mechanism that may explain protection against falciparum malaria in sickle trait and beta-thalassemia trait The American Society of Hematology American Society of Hematology 10.1182/blood-2003-11-3820 Silverchair:18746 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Enhanced phagocytosis of ring-parasitized mutant erythrocytes: a common mechanism that may explain protection against falciparum malaria in sickle trait and beta-thalassemia trait The American Society of Hematology American Society of Hematology 10.1182/blood-2003-11-3820 Silverchair:18746 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Enhanced phagocytosis of ring-parasitized mutant erythrocytes: a common mechanism that may explain protection against falciparum malaria in sickle trait and beta-thalassemia trait The American Society of Hematology American Society of Hematology 10.1182/blood-2003-11-3820 Silverchair:18746 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Enhanced phagocytosis of ring-parasitized mutant erythrocytes: a common mechanism that may explain protection against falciparum malaria in sickle trait and beta-thalassemia trait The American Society of Hematology American Society of Hematology 10.1182/blood-2003-11-3820 Silverchair:18746 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Enhancer-gene rewiring in the pathogenesis of Quebec platelet disorder The American Society of Hematology American Society of Hematology 10.1182/blood.2020005394 Silverchair:461326 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Enhancer-gene rewiring in the pathogenesis of Quebec platelet disorder The American Society of Hematology American Society of Hematology 10.1182/blood.2020005394 Silverchair:461326 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Enhancer-gene rewiring in the pathogenesis of Quebec platelet disorder The American Society of Hematology American Society of Hematology 10.1182/blood.2020005394 Silverchair:461326 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Enhancer-gene rewiring in the pathogenesis of Quebec platelet disorder The American Society of Hematology American Society of Hematology 10.1182/blood.2020005394 Silverchair:461326 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001966 Silverchair:463645 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001966 Silverchair:463645 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001966 Silverchair:463645 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001966 Silverchair:463645 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Enhancing Therapy To Avoid Fetal Blood Sampling (FBS) In Antenatal Management Of Alloimmune Thrombocytopenia (AIT) The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.1072.1072 Silverchair:103503 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 Enhancing Therapy To Avoid Fetal Blood Sampling (FBS) In Antenatal Management Of Alloimmune Thrombocytopenia (AIT) The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.1072.1072 Silverchair:103503 Total_Item_Requests 4 0 4 0 0 0 0 0 0 0 0 0 0 Enhancing Therapy To Avoid Fetal Blood Sampling (FBS) In Antenatal Management Of Alloimmune Thrombocytopenia (AIT) The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.1072.1072 Silverchair:103503 Unique_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Enhancing Therapy To Avoid Fetal Blood Sampling (FBS) In Antenatal Management Of Alloimmune Thrombocytopenia (AIT) The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.1072.1072 Silverchair:103503 Unique_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Eosinophil homing to the bone marrow The American Society of Hematology American Society of Hematology 10.1182/blood.2020007948 Silverchair:474268 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Eosinophil homing to the bone marrow The American Society of Hematology American Society of Hematology 10.1182/blood.2020007948 Silverchair:474268 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Eosinophil homing to the bone marrow The American Society of Hematology American Society of Hematology 10.1182/blood.2020007948 Silverchair:474268 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Eosinophil homing to the bone marrow The American Society of Hematology American Society of Hematology 10.1182/blood.2020007948 Silverchair:474268 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Eosinophilia: a pragmatic approach to diagnosis and treatment The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.92 Silverchair:20764 Total_Item_Investigations 5 0 2 3 0 0 0 0 0 0 0 0 0 Eosinophilia: a pragmatic approach to diagnosis and treatment The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.92 Silverchair:20764 Total_Item_Requests 5 0 2 3 0 0 0 0 0 0 0 0 0 Eosinophilia: a pragmatic approach to diagnosis and treatment The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.92 Silverchair:20764 Unique_Item_Investigations 4 0 1 3 0 0 0 0 0 0 0 0 0 Eosinophilia: a pragmatic approach to diagnosis and treatment The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.92 Silverchair:20764 Unique_Item_Requests 4 0 1 3 0 0 0 0 0 0 0 0 0 EPCR/PAR1 Signaling Navigates Long-Term Repopulating Hematopoietic Stem Cell Bone Marrow Homing to Thrombomodulin-Enriched Blood Vessels The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.33.33 Silverchair:91090 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 EPCR/PAR1 Signaling Navigates Long-Term Repopulating Hematopoietic Stem Cell Bone Marrow Homing to Thrombomodulin-Enriched Blood Vessels The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.33.33 Silverchair:91090 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 EPCR/PAR1 Signaling Navigates Long-Term Repopulating Hematopoietic Stem Cell Bone Marrow Homing to Thrombomodulin-Enriched Blood Vessels The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.33.33 Silverchair:91090 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 EPCR/PAR1 Signaling Navigates Long-Term Repopulating Hematopoietic Stem Cell Bone Marrow Homing to Thrombomodulin-Enriched Blood Vessels The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.33.33 Silverchair:91090 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Ependymal cells in cerebrospinal fluid: a traumatic occurrence The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-610477 Silverchair:33744 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Ependymal cells in cerebrospinal fluid: a traumatic occurrence The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-610477 Silverchair:33744 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Ependymal cells in cerebrospinal fluid: a traumatic occurrence The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-610477 Silverchair:33744 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Ependymal cells in cerebrospinal fluid: a traumatic occurrence The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-610477 Silverchair:33744 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Epidemiology of cancer-associated venous thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-460121 Silverchair:31702 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 3 0 0 0 Epidemiology of cancer-associated venous thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-460121 Silverchair:31702 Total_Item_Requests 2 0 0 0 0 0 0 0 0 2 0 0 0 Epidemiology of cancer-associated venous thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-460121 Silverchair:31702 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Epidemiology of cancer-associated venous thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-460121 Silverchair:31702 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 "Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-01-134858 Silverchair:24036 Total_Item_Investigations 3 0 0 0 3 0 0 0 0 0 0 0 0 "Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-01-134858 Silverchair:24036 Total_Item_Requests 3 0 0 0 3 0 0 0 0 0 0 0 0 "Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-01-134858 Silverchair:24036 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 "Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-01-134858 Silverchair:24036 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Epidermal growth factor receptor–dependent DNA repair promotes murine and human hematopoietic regeneration The American Society of Hematology American Society of Hematology 10.1182/blood.2020005895 Silverchair:454772 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Epidermal growth factor receptor–dependent DNA repair promotes murine and human hematopoietic regeneration The American Society of Hematology American Society of Hematology 10.1182/blood.2020005895 Silverchair:454772 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Epidermal growth factor receptor–dependent DNA repair promotes murine and human hematopoietic regeneration The American Society of Hematology American Society of Hematology 10.1182/blood.2020005895 Silverchair:454772 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Epidermal growth factor receptor–dependent DNA repair promotes murine and human hematopoietic regeneration The American Society of Hematology American Society of Hematology 10.1182/blood.2020005895 Silverchair:454772 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Epigenetic chromatin states uniquely define the developmental plasticity of murine hematopoietic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-235176 Silverchair:26972 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Epigenetic chromatin states uniquely define the developmental plasticity of murine hematopoietic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-235176 Silverchair:26972 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Epigenetic chromatin states uniquely define the developmental plasticity of murine hematopoietic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-235176 Silverchair:26972 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Epigenetic chromatin states uniquely define the developmental plasticity of murine hematopoietic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-235176 Silverchair:26972 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Epigenetic priming: the target? The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-357533 Silverchair:29086 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Epigenetic priming: the target? The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-357533 Silverchair:29086 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Epigenetic priming: the target? The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-357533 Silverchair:29086 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Epigenetic priming: the target? The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-357533 Silverchair:29086 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 eQTLs in platelets and iPSC-megakaryocytes The American Society of Hematology American Society of Hematology 10.1182/blood.2020009461 Silverchair:475221 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 eQTLs in platelets and iPSC-megakaryocytes The American Society of Hematology American Society of Hematology 10.1182/blood.2020009461 Silverchair:475221 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 eQTLs in platelets and iPSC-megakaryocytes The American Society of Hematology American Society of Hematology 10.1182/blood.2020009461 Silverchair:475221 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 eQTLs in platelets and iPSC-megakaryocytes The American Society of Hematology American Society of Hematology 10.1182/blood.2020009461 Silverchair:475221 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 ER71 specifies Flk-1+ hemangiogenic mesoderm by inhibiting cardiac mesoderm and Wnt signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-403766 Silverchair:29583 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 ER71 specifies Flk-1+ hemangiogenic mesoderm by inhibiting cardiac mesoderm and Wnt signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-403766 Silverchair:29583 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 ER71 specifies Flk-1+ hemangiogenic mesoderm by inhibiting cardiac mesoderm and Wnt signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-403766 Silverchair:29583 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 ER71 specifies Flk-1+ hemangiogenic mesoderm by inhibiting cardiac mesoderm and Wnt signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-403766 Silverchair:29583 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-281931 Silverchair:28095 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-281931 Silverchair:28095 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-281931 Silverchair:28095 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-281931 Silverchair:28095 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 ER-associated degradation preserves hematopoietic stem cell quiescence and self-renewal by restricting mTOR activity The American Society of Hematology American Society of Hematology 10.1182/blood.2020007975 Silverchair:474082 Total_Item_Investigations 13 13 0 0 0 0 0 0 0 0 0 0 0 ER-associated degradation preserves hematopoietic stem cell quiescence and self-renewal by restricting mTOR activity The American Society of Hematology American Society of Hematology 10.1182/blood.2020007975 Silverchair:474082 Total_Item_Requests 12 12 0 0 0 0 0 0 0 0 0 0 0 ER-associated degradation preserves hematopoietic stem cell quiescence and self-renewal by restricting mTOR activity The American Society of Hematology American Society of Hematology 10.1182/blood.2020007975 Silverchair:474082 Unique_Item_Investigations 6 6 0 0 0 0 0 0 0 0 0 0 0 ER-associated degradation preserves hematopoietic stem cell quiescence and self-renewal by restricting mTOR activity The American Society of Hematology American Society of Hematology 10.1182/blood.2020007975 Silverchair:474082 Unique_Item_Requests 6 6 0 0 0 0 0 0 0 0 0 0 0 Erdheim-Chester disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019002766 Silverchair:452578 No_License 3 0 3 0 0 0 0 0 0 0 0 0 0 Erdheim-Chester disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019002766 Silverchair:452578 Total_Item_Investigations 5 0 5 0 0 0 0 0 0 0 0 0 0 Erdheim-Chester disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019002766 Silverchair:452578 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003323 Silverchair:474746 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003323 Silverchair:474746 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003323 Silverchair:474746 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003323 Silverchair:474746 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Erythroferrone contributes to recovery from anemia of inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-584607 Silverchair:33214 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Erythroferrone contributes to recovery from anemia of inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-584607 Silverchair:33214 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Erythroferrone contributes to recovery from anemia of inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-584607 Silverchair:33214 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Erythroferrone contributes to recovery from anemia of inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-584607 Silverchair:33214 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality The American Society of Hematology American Society of Hematology 10.1182/blood-2002-01-0124 Silverchair:106136 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality The American Society of Hematology American Society of Hematology 10.1182/blood-2002-01-0124 Silverchair:106136 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality The American Society of Hematology American Society of Hematology 10.1182/blood-2002-01-0124 Silverchair:106136 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality The American Society of Hematology American Society of Hematology 10.1182/blood-2002-01-0124 Silverchair:106136 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Erythrophagocytosis by neutrophils The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-279364 Silverchair:125503 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Erythrophagocytosis by neutrophils The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-279364 Silverchair:125503 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Erythrophagocytosis by neutrophils The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-279364 Silverchair:125503 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Erythrophagocytosis by neutrophils The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-279364 Silverchair:125503 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Erythropoiesis-Stimulating Agent (ESA) Treatment of MDS: Controversies and Perspectives American Society of Hematology American Society of Hematology 10.1182/hem.V4.5.6032 Silverchair:461979 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Erythropoiesis-Stimulating Agent (ESA) Treatment of MDS: Controversies and Perspectives American Society of Hematology American Society of Hematology 10.1182/hem.V4.5.6032 Silverchair:461979 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Erythropoiesis-Stimulating Agent (ESA) Treatment of MDS: Controversies and Perspectives American Society of Hematology American Society of Hematology 10.1182/hem.V4.5.6032 Silverchair:461979 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Erythropoiesis-Stimulating Agent (ESA) Treatment of MDS: Controversies and Perspectives American Society of Hematology American Society of Hematology 10.1182/hem.V4.5.6032 Silverchair:461979 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Erythropoietin in Elderly Patients with Anemia of Unknown Etiology The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3346.3346 Silverchair:91180 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Erythropoietin in Elderly Patients with Anemia of Unknown Etiology The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3346.3346 Silverchair:91180 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Erythropoietin in Elderly Patients with Anemia of Unknown Etiology The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3346.3346 Silverchair:91180 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Erythropoietin in Elderly Patients with Anemia of Unknown Etiology The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3346.3346 Silverchair:91180 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Erythropoietin Supplementation in Patients with Refractory Anemia and Mild Renal Insufficiency - MDS Meets Renal Anemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3771.3771 Silverchair:58109 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Erythropoietin Supplementation in Patients with Refractory Anemia and Mild Renal Insufficiency - MDS Meets Renal Anemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3771.3771 Silverchair:58109 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Erythropoietin Supplementation in Patients with Refractory Anemia and Mild Renal Insufficiency - MDS Meets Renal Anemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3771.3771 Silverchair:58109 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Erythropoietin Supplementation in Patients with Refractory Anemia and Mild Renal Insufficiency - MDS Meets Renal Anemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3771.3771 Silverchair:58109 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Essential roles for Pot1b in HSC self-renewal and survival The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-361527 Silverchair:29140 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Essential roles for Pot1b in HSC self-renewal and survival The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-361527 Silverchair:29140 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Essential roles for Pot1b in HSC self-renewal and survival The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-361527 Silverchair:29140 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Essential roles for Pot1b in HSC self-renewal and survival The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-361527 Silverchair:29140 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Estimating Mortality in Patients with Hematological Malignancy and COVID-19: A Pooled Analysis of 10 Studies The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141749 Silverchair:473942 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Estimating Mortality in Patients with Hematological Malignancy and COVID-19: A Pooled Analysis of 10 Studies The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141749 Silverchair:473942 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Estimating Mortality in Patients with Hematological Malignancy and COVID-19: A Pooled Analysis of 10 Studies The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141749 Silverchair:473942 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Estimating Mortality in Patients with Hematological Malignancy and COVID-19: A Pooled Analysis of 10 Studies The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141749 Silverchair:473942 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Estrogen stimulates von Willebrand factor production by cultured endothelial cells The American Society of Hematology American Society of Hematology 10.1182/blood.V63.3.657.657 Silverchair:163813 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Estrogen stimulates von Willebrand factor production by cultured endothelial cells The American Society of Hematology American Society of Hematology 10.1182/blood.V63.3.657.657 Silverchair:163813 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 ET190L1-ArtemisTM T Cell Therapy Results in Durable Disease Remissions with No Cytokine Release Syndrome or Neurotoxicity in Patients with Relapsed and Refractory B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113163 Silverchair:273023 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 ET190L1-ArtemisTM T Cell Therapy Results in Durable Disease Remissions with No Cytokine Release Syndrome or Neurotoxicity in Patients with Relapsed and Refractory B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113163 Silverchair:273023 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 ET190L1-ArtemisTM T Cell Therapy Results in Durable Disease Remissions with No Cytokine Release Syndrome or Neurotoxicity in Patients with Relapsed and Refractory B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113163 Silverchair:273023 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 ET190L1-ArtemisTM T Cell Therapy Results in Durable Disease Remissions with No Cytokine Release Syndrome or Neurotoxicity in Patients with Relapsed and Refractory B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113163 Silverchair:273023 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Etiology and Management of Splenic Infarction and Splenic Vein Thrombosis: Unusual Causes of Abdominal Pain in Sickle Cell Trait Patient The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4775.4775 Silverchair:85251 Total_Item_Investigations 3 0 1 1 0 0 0 0 1 0 0 0 0 Etiology and Management of Splenic Infarction and Splenic Vein Thrombosis: Unusual Causes of Abdominal Pain in Sickle Cell Trait Patient The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4775.4775 Silverchair:85251 Total_Item_Requests 3 0 1 1 0 0 0 0 1 0 0 0 0 Etiology and Management of Splenic Infarction and Splenic Vein Thrombosis: Unusual Causes of Abdominal Pain in Sickle Cell Trait Patient The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4775.4775 Silverchair:85251 Unique_Item_Investigations 3 0 1 1 0 0 0 0 1 0 0 0 0 Etiology and Management of Splenic Infarction and Splenic Vein Thrombosis: Unusual Causes of Abdominal Pain in Sickle Cell Trait Patient The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4775.4775 Silverchair:85251 Unique_Item_Requests 3 0 1 1 0 0 0 0 1 0 0 0 0 "ETV6-ABL1 CML Like Disorder with Complex Translocation Involving Chromosome 9, 12 and 14" The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4438.4438 Silverchair:86796 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 "ETV6-ABL1 CML Like Disorder with Complex Translocation Involving Chromosome 9, 12 and 14" The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4438.4438 Silverchair:86796 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 "ETV6-ABL1 CML Like Disorder with Complex Translocation Involving Chromosome 9, 12 and 14" The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4438.4438 Silverchair:86796 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 "ETV6-ABL1 CML Like Disorder with Complex Translocation Involving Chromosome 9, 12 and 14" The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4438.4438 Silverchair:86796 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Evaluating Acute Myeloid Leukemia Induction Regimens in Elderly Patients with Unfavorable Risk Cytogenetics That Are Candidates for Intensive Remission Therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141276 Silverchair:473413 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Evaluating Acute Myeloid Leukemia Induction Regimens in Elderly Patients with Unfavorable Risk Cytogenetics That Are Candidates for Intensive Remission Therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141276 Silverchair:473413 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Evaluating Acute Myeloid Leukemia Induction Regimens in Elderly Patients with Unfavorable Risk Cytogenetics That Are Candidates for Intensive Remission Therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141276 Silverchair:473413 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Evaluating Acute Myeloid Leukemia Induction Regimens in Elderly Patients with Unfavorable Risk Cytogenetics That Are Candidates for Intensive Remission Therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141276 Silverchair:473413 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Evaluating Causes of Back Pain in Patients with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4593.4593 Silverchair:93592 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Evaluating Causes of Back Pain in Patients with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4593.4593 Silverchair:93592 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Evaluating Causes of Back Pain in Patients with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4593.4593 Silverchair:93592 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Evaluating Causes of Back Pain in Patients with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4593.4593 Silverchair:93592 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Evaluating Complete Remission with Incomplete Hematologic Recovery (CRh) As a Response Criterion in Myelodysplastic Syndromes (MDS) The American Society of Hematology American Society of Hematology 10.1182/blood-2021-151815 Silverchair:480122 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Evaluating Complete Remission with Incomplete Hematologic Recovery (CRh) As a Response Criterion in Myelodysplastic Syndromes (MDS) The American Society of Hematology American Society of Hematology 10.1182/blood-2021-151815 Silverchair:480122 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Evaluating Complete Remission with Incomplete Hematologic Recovery (CRh) As a Response Criterion in Myelodysplastic Syndromes (MDS) The American Society of Hematology American Society of Hematology 10.1182/blood-2021-151815 Silverchair:480122 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Evaluating Complete Remission with Incomplete Hematologic Recovery (CRh) As a Response Criterion in Myelodysplastic Syndromes (MDS) The American Society of Hematology American Society of Hematology 10.1182/blood-2021-151815 Silverchair:480122 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Evaluating the Economic Burden and Health Care Utilization Following First-Line Therapy for Diffuse Large B-Cell Lymphoma Patients in the US Medicare Population The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3574.3574 Silverchair:97228 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Evaluating the Economic Burden and Health Care Utilization Following First-Line Therapy for Diffuse Large B-Cell Lymphoma Patients in the US Medicare Population The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3574.3574 Silverchair:97228 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Evaluating the Economic Burden and Health Care Utilization Following First-Line Therapy for Diffuse Large B-Cell Lymphoma Patients in the US Medicare Population The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3574.3574 Silverchair:97228 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Evaluating the Economic Burden and Health Care Utilization Following First-Line Therapy for Diffuse Large B-Cell Lymphoma Patients in the US Medicare Population The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3574.3574 Silverchair:97228 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Evaluation and management of stroke The American Society of Hematology American Society of Hematology 10.1182/asheducation-2009.1.293 Silverchair:19835 Total_Item_Investigations 8 0 0 8 0 0 0 0 0 0 0 0 0 Evaluation and management of stroke The American Society of Hematology American Society of Hematology 10.1182/asheducation-2009.1.293 Silverchair:19835 Total_Item_Requests 6 0 0 6 0 0 0 0 0 0 0 0 0 Evaluation and management of stroke The American Society of Hematology American Society of Hematology 10.1182/asheducation-2009.1.293 Silverchair:19835 Unique_Item_Investigations 4 0 0 4 0 0 0 0 0 0 0 0 0 Evaluation and management of stroke The American Society of Hematology American Society of Hematology 10.1182/asheducation-2009.1.293 Silverchair:19835 Unique_Item_Requests 4 0 0 4 0 0 0 0 0 0 0 0 0 Evaluation of a FLT3 Bite® for Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1354.1354 Silverchair:116200 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Evaluation of a FLT3 Bite® for Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1354.1354 Silverchair:116200 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Evaluation of a FLT3 Bite® for Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1354.1354 Silverchair:116200 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Evaluation of a FLT3 Bite® for Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1354.1354 Silverchair:116200 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Evaluation Of Bcma As a Therapeutic Target In Multiple Myeloma Using An Antibody-Drug Conjugate The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4447.4447 Silverchair:14472 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Evaluation Of Bcma As a Therapeutic Target In Multiple Myeloma Using An Antibody-Drug Conjugate The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4447.4447 Silverchair:14472 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Evaluation Of Bcma As a Therapeutic Target In Multiple Myeloma Using An Antibody-Drug Conjugate The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4447.4447 Silverchair:14472 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Evaluation Of Bcma As a Therapeutic Target In Multiple Myeloma Using An Antibody-Drug Conjugate The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4447.4447 Silverchair:14472 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Evaluation Of Factor V Leiden, Prothrombin Mutations and The Homozygous mutation 677T In The MTHFR Gene In Patients With  Venous Thrombosis" The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4798.4798 Silverchair:13107 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Evaluation Of Factor V Leiden, Prothrombin Mutations and The Homozygous mutation 677T In The MTHFR Gene In Patients With  Venous Thrombosis" The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4798.4798 Silverchair:13107 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Evaluation Of Factor V Leiden, Prothrombin Mutations and The Homozygous mutation 677T In The MTHFR Gene In Patients With  Venous Thrombosis" The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4798.4798 Silverchair:13107 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Evaluation Of Factor V Leiden, Prothrombin Mutations and The Homozygous mutation 677T In The MTHFR Gene In Patients With  Venous Thrombosis" The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4798.4798 Silverchair:13107 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Evaluation of ISTH DIC Score to Predict Significant Bleeding and Thrombosis Events in Pediatric Acute Promyelocytic Leukemia; A Report from the Children’s Oncology Group AAML0631 Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3669.3669 Silverchair:97873 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Evaluation of ISTH DIC Score to Predict Significant Bleeding and Thrombosis Events in Pediatric Acute Promyelocytic Leukemia; A Report from the Children’s Oncology Group AAML0631 Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3669.3669 Silverchair:97873 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Evaluation of ISTH DIC Score to Predict Significant Bleeding and Thrombosis Events in Pediatric Acute Promyelocytic Leukemia; A Report from the Children’s Oncology Group AAML0631 Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3669.3669 Silverchair:97873 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Evaluation of ISTH DIC Score to Predict Significant Bleeding and Thrombosis Events in Pediatric Acute Promyelocytic Leukemia; A Report from the Children’s Oncology Group AAML0631 Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3669.3669 Silverchair:97873 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Evaluation of MAPK and PI3K/AKT Signaling Pathways In Adult Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.3240.3240 Silverchair:66025 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Evaluation of MAPK and PI3K/AKT Signaling Pathways In Adult Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.3240.3240 Silverchair:66025 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Evaluation of MAPK and PI3K/AKT Signaling Pathways In Adult Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.3240.3240 Silverchair:66025 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Evaluation of MAPK and PI3K/AKT Signaling Pathways In Adult Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.3240.3240 Silverchair:66025 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Evaluation of the Antithrombin Potential in a Thrombin Generation Assay Performed at the Surface of Endothelial Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4168.4168 Silverchair:91710 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Evaluation of the Antithrombin Potential in a Thrombin Generation Assay Performed at the Surface of Endothelial Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4168.4168 Silverchair:91710 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Evaluation of the Antithrombin Potential in a Thrombin Generation Assay Performed at the Surface of Endothelial Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4168.4168 Silverchair:91710 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Evaluation of the Antithrombin Potential in a Thrombin Generation Assay Performed at the Surface of Endothelial Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4168.4168 Silverchair:91710 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2013-06-508416 Silverchair:31857 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2013-06-508416 Silverchair:31857 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2013-06-508416 Silverchair:31857 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2013-06-508416 Silverchair:31857 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Evidence for Transient Acute Liver Injury in Mouse Models of Sickle Cell Disease during Steady State Health The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1373.1373 Silverchair:87955 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Evidence for Transient Acute Liver Injury in Mouse Models of Sickle Cell Disease during Steady State Health The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1373.1373 Silverchair:87955 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Evidence for Transient Acute Liver Injury in Mouse Models of Sickle Cell Disease during Steady State Health The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1373.1373 Silverchair:87955 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Evidence for Transient Acute Liver Injury in Mouse Models of Sickle Cell Disease during Steady State Health The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1373.1373 Silverchair:87955 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Evidence that the number of hematopoietic stem cells per animal is conserved in mammals The American Society of Hematology American Society of Hematology 10.1182/blood-2002-03-0822 Silverchair:106104 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Evidence that the number of hematopoietic stem cells per animal is conserved in mammals The American Society of Hematology American Society of Hematology 10.1182/blood-2002-03-0822 Silverchair:106104 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Evidence that the number of hematopoietic stem cells per animal is conserved in mammals The American Society of Hematology American Society of Hematology 10.1182/blood-2002-03-0822 Silverchair:106104 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Evidence that the number of hematopoietic stem cells per animal is conserved in mammals The American Society of Hematology American Society of Hematology 10.1182/blood-2002-03-0822 Silverchair:106104 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients? The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000075 Silverchair:422580 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients? The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000075 Silverchair:422580 Total_Item_Requests 4 0 4 0 0 0 0 0 0 0 0 0 0 Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients? The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000075 Silverchair:422580 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients? The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000075 Silverchair:422580 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Evidence-Based Minireview: Laboratory surveillance of immune-mediated thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000164 Silverchair:474301 Total_Item_Investigations 3 0 0 1 0 0 2 0 0 0 0 0 0 Evidence-Based Minireview: Laboratory surveillance of immune-mediated thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000164 Silverchair:474301 Total_Item_Requests 3 0 0 1 0 0 2 0 0 0 0 0 0 Evidence-Based Minireview: Laboratory surveillance of immune-mediated thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000164 Silverchair:474301 Unique_Item_Investigations 2 0 0 1 0 0 1 0 0 0 0 0 0 Evidence-Based Minireview: Laboratory surveillance of immune-mediated thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000164 Silverchair:474301 Unique_Item_Requests 2 0 0 1 0 0 1 0 0 0 0 0 0 Evidence-Based Minireview: Molecular precision and clinical uncertainty: should molecular profiling be routinely used to guide risk stratification in MDS? The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000320 Silverchair:482949 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Evidence-Based Minireview: Molecular precision and clinical uncertainty: should molecular profiling be routinely used to guide risk stratification in MDS? The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000320 Silverchair:482949 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Evidence-Based Minireview: Molecular precision and clinical uncertainty: should molecular profiling be routinely used to guide risk stratification in MDS? The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000320 Silverchair:482949 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Evidence-Based Minireview: Molecular precision and clinical uncertainty: should molecular profiling be routinely used to guide risk stratification in MDS? The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000320 Silverchair:482949 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Evidence-Based Minireview: Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000163 Silverchair:474284 Total_Item_Investigations 7 2 1 1 0 0 0 0 0 3 0 0 0 Evidence-Based Minireview: Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000163 Silverchair:474284 Total_Item_Requests 6 1 1 1 0 0 0 0 0 3 0 0 0 Evidence-Based Minireview: Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000163 Silverchair:474284 Unique_Item_Investigations 4 1 1 1 0 0 0 0 0 1 0 0 0 Evidence-Based Minireview: Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000163 Silverchair:474284 Unique_Item_Requests 4 1 1 1 0 0 0 0 0 1 0 0 0 Evidence-Based Minireview: Should all newly diagnosed MM patients receive CD38 antibody–based treatment? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000161 Silverchair:474346 Total_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 Evidence-Based Minireview: Should all newly diagnosed MM patients receive CD38 antibody–based treatment? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000161 Silverchair:474346 Total_Item_Requests 3 2 0 1 0 0 0 0 0 0 0 0 0 Evidence-Based Minireview: Should all newly diagnosed MM patients receive CD38 antibody–based treatment? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000161 Silverchair:474346 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Evidence-Based Minireview: Should all newly diagnosed MM patients receive CD38 antibody–based treatment? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000161 Silverchair:474346 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Evolution and Proliferation of CD7 CAR-T Cells Compared to CD19 CAR-T Cells Therapies for Acute Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2021-149978 Silverchair:481335 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Evolution and Proliferation of CD7 CAR-T Cells Compared to CD19 CAR-T Cells Therapies for Acute Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2021-149978 Silverchair:481335 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Evolution and Proliferation of CD7 CAR-T Cells Compared to CD19 CAR-T Cells Therapies for Acute Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2021-149978 Silverchair:481335 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Evolution and Proliferation of CD7 CAR-T Cells Compared to CD19 CAR-T Cells Therapies for Acute Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2021-149978 Silverchair:481335 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Evolving Real-World Treatment Patterns in Patients with Newly-Diagnosed Multiple Myeloma (NDMM) in the United States (U.S.) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124301 Silverchair:423680 Total_Item_Investigations 5 5 0 0 0 0 0 0 0 0 0 0 0 Evolving Real-World Treatment Patterns in Patients with Newly-Diagnosed Multiple Myeloma (NDMM) in the United States (U.S.) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124301 Silverchair:423680 Total_Item_Requests 5 5 0 0 0 0 0 0 0 0 0 0 0 Evolving Real-World Treatment Patterns in Patients with Newly-Diagnosed Multiple Myeloma (NDMM) in the United States (U.S.) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124301 Silverchair:423680 Unique_Item_Investigations 5 5 0 0 0 0 0 0 0 0 0 0 0 Evolving Real-World Treatment Patterns in Patients with Newly-Diagnosed Multiple Myeloma (NDMM) in the United States (U.S.) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124301 Silverchair:423680 Unique_Item_Requests 5 5 0 0 0 0 0 0 0 0 0 0 0 Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-738070 Silverchair:35924 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-738070 Silverchair:35924 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-738070 Silverchair:35924 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-738070 Silverchair:35924 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001934 Silverchair:461056 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001934 Silverchair:461056 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001934 Silverchair:461056 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001934 Silverchair:461056 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Existing agents, novel agents, or transplantation for high-risk MDS" The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000125 Silverchair:474306 Total_Item_Investigations 3 0 0 0 0 1 0 1 1 0 0 0 0 "Existing agents, novel agents, or transplantation for high-risk MDS" The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000125 Silverchair:474306 Total_Item_Requests 3 0 0 0 0 1 0 1 1 0 0 0 0 "Existing agents, novel agents, or transplantation for high-risk MDS" The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000125 Silverchair:474306 Unique_Item_Investigations 3 0 0 0 0 1 0 1 1 0 0 0 0 "Existing agents, novel agents, or transplantation for high-risk MDS" The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000125 Silverchair:474306 Unique_Item_Requests 3 0 0 0 0 1 0 1 1 0 0 0 0 "Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-360313 Silverchair:28627 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-360313 Silverchair:28627 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-360313 Silverchair:28627 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-360313 Silverchair:28627 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Exome Sequencing Studies Identify Mutations in STAB2 As a Genetic Risk for Venous Thromboembolic Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.457.457 Silverchair:72104 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Exome Sequencing Studies Identify Mutations in STAB2 As a Genetic Risk for Venous Thromboembolic Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.457.457 Silverchair:72104 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Exome Sequencing Studies Identify Mutations in STAB2 As a Genetic Risk for Venous Thromboembolic Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.457.457 Silverchair:72104 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Exome Sequencing Studies Identify Mutations in STAB2 As a Genetic Risk for Venous Thromboembolic Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.457.457 Silverchair:72104 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Exosomes from red blood cell units bind to monocytes and induce proinflammatory cytokines, boosting T-cell responses in vitro" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-530469 Silverchair:32853 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 "Exosomes from red blood cell units bind to monocytes and induce proinflammatory cytokines, boosting T-cell responses in vitro" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-530469 Silverchair:32853 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 "Exosomes from red blood cell units bind to monocytes and induce proinflammatory cytokines, boosting T-cell responses in vitro" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-530469 Silverchair:32853 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Exosomes from red blood cell units bind to monocytes and induce proinflammatory cytokines, boosting T-cell responses in vitro" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-530469 Silverchair:32853 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef The American Society of Hematology American Society of Hematology 10.1182/blood-2005-04-1513 Silverchair:133411 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef The American Society of Hematology American Society of Hematology 10.1182/blood-2005-04-1513 Silverchair:133411 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef The American Society of Hematology American Society of Hematology 10.1182/blood-2005-04-1513 Silverchair:133411 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef The American Society of Hematology American Society of Hematology 10.1182/blood-2005-04-1513 Silverchair:133411 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123257 Silverchair:423593 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123257 Silverchair:423593 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123257 Silverchair:423593 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123257 Silverchair:423593 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129097 Silverchair:426959 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129097 Silverchair:426959 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129097 Silverchair:426959 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129097 Silverchair:426959 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124210 Silverchair:427172 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124210 Silverchair:427172 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124210 Silverchair:427172 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124210 Silverchair:427172 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Exploring the global landscape of genetic variation in coagulation factor XI deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-780148 Silverchair:37079 Total_Item_Investigations 3 0 0 0 0 0 0 0 3 0 0 0 0 Exploring the global landscape of genetic variation in coagulation factor XI deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-780148 Silverchair:37079 Total_Item_Requests 2 0 0 0 0 0 0 0 2 0 0 0 0 Exploring the global landscape of genetic variation in coagulation factor XI deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-780148 Silverchair:37079 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Exploring the global landscape of genetic variation in coagulation factor XI deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-780148 Silverchair:37079 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018019034 Silverchair:15947 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018019034 Silverchair:15947 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018019034 Silverchair:15947 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018019034 Silverchair:15947 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice The American Society of Hematology American Society of Hematology 10.1182/blood.2020007156 Silverchair:461286 No_License 1 0 0 0 0 1 0 0 0 0 0 0 0 Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice The American Society of Hematology American Society of Hematology 10.1182/blood.2020007156 Silverchair:461286 Total_Item_Investigations 8 0 1 0 0 5 0 2 0 0 0 0 0 Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice The American Society of Hematology American Society of Hematology 10.1182/blood.2020007156 Silverchair:461286 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice The American Society of Hematology American Society of Hematology 10.1182/blood.2020007156 Silverchair:461286 Unique_Item_Investigations 4 0 1 0 0 2 0 1 0 0 0 0 0 Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice The American Society of Hematology American Society of Hematology 10.1182/blood.2020007156 Silverchair:461286 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Expression of CD25 on Acute Myeloid Leukemia (AML) Blasts Is An Independent Risk Factor Associated with Refractory Disease, Which May Be Overcome by Stem Cell Transplantation (SCT)," The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.3560.3560 Silverchair:69449 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Expression of CD25 on Acute Myeloid Leukemia (AML) Blasts Is An Independent Risk Factor Associated with Refractory Disease, Which May Be Overcome by Stem Cell Transplantation (SCT)," The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.3560.3560 Silverchair:69449 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Expression of CD25 on Acute Myeloid Leukemia (AML) Blasts Is An Independent Risk Factor Associated with Refractory Disease, Which May Be Overcome by Stem Cell Transplantation (SCT)," The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.3560.3560 Silverchair:69449 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Expression of CD25 on Acute Myeloid Leukemia (AML) Blasts Is An Independent Risk Factor Associated with Refractory Disease, Which May Be Overcome by Stem Cell Transplantation (SCT)," The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.3560.3560 Silverchair:69449 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Expression of platelet C1 inhibitor The American Society of Hematology American Society of Hematology 10.1182/blood.V82.2.465.465 Silverchair:170398 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Expression of platelet C1 inhibitor The American Society of Hematology American Society of Hematology 10.1182/blood.V82.2.465.465 Silverchair:170398 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Expression of platelet C1 inhibitor The American Society of Hematology American Society of Hematology 10.1182/blood.V82.2.465.465 Silverchair:170398 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Expression of platelet C1 inhibitor The American Society of Hematology American Society of Hematology 10.1182/blood.V82.2.465.465 Silverchair:170398 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Expression of the AID protein in normal and neoplastic B cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-04-1558 Silverchair:18758 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Expression of the AID protein in normal and neoplastic B cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-04-1558 Silverchair:18758 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Expression of the AID protein in normal and neoplastic B cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-04-1558 Silverchair:18758 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Expression of the AID protein in normal and neoplastic B cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-04-1558 Silverchair:18758 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Expression of the CD5 Molecule in Chronic Lymphocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5322.5322 Silverchair:115741 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Expression of the CD5 Molecule in Chronic Lymphocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5322.5322 Silverchair:115741 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Expression of the CD5 Molecule in Chronic Lymphocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5322.5322 Silverchair:115741 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Expression of the CD5 Molecule in Chronic Lymphocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5322.5322 Silverchair:115741 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-06-2416 Silverchair:19615 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-06-2416 Silverchair:19615 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-06-2416 Silverchair:19615 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-06-2416 Silverchair:19615 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004118 Silverchair:475732 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004118 Silverchair:475732 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004118 Silverchair:475732 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004118 Silverchair:475732 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 "Extensive Variability in Platelet Count, Bleeding, and Quality of Life Outcome Measures in Adult and Pediatric Immune Thrombocytopenia: An Appraisal from a Critical Review of the Literature" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138694 Silverchair:470054 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 "Extensive Variability in Platelet Count, Bleeding, and Quality of Life Outcome Measures in Adult and Pediatric Immune Thrombocytopenia: An Appraisal from a Critical Review of the Literature" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138694 Silverchair:470054 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 "Extensive Variability in Platelet Count, Bleeding, and Quality of Life Outcome Measures in Adult and Pediatric Immune Thrombocytopenia: An Appraisal from a Critical Review of the Literature" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138694 Silverchair:470054 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 "Extensive Variability in Platelet Count, Bleeding, and Quality of Life Outcome Measures in Adult and Pediatric Immune Thrombocytopenia: An Appraisal from a Critical Review of the Literature" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138694 Silverchair:470054 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 External Validation of Diffusion Weighted Whole Body MRI (DW-MRI) Response Assessment Category (RAC) Criteria Proposed By the Myeloma Response Assessment and Diagnosis System (MY-RADS) Imaging Recommendations: Prognostic Role of Imaging Response after Transplant in Multiple Myeloma and Comparison with MRD Evaluation By Flow Cytometry The American Society of Hematology American Society of Hematology 10.1182/blood-2020-135969 Silverchair:470035 Total_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 External Validation of Diffusion Weighted Whole Body MRI (DW-MRI) Response Assessment Category (RAC) Criteria Proposed By the Myeloma Response Assessment and Diagnosis System (MY-RADS) Imaging Recommendations: Prognostic Role of Imaging Response after Transplant in Multiple Myeloma and Comparison with MRD Evaluation By Flow Cytometry The American Society of Hematology American Society of Hematology 10.1182/blood-2020-135969 Silverchair:470035 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 External Validation of Diffusion Weighted Whole Body MRI (DW-MRI) Response Assessment Category (RAC) Criteria Proposed By the Myeloma Response Assessment and Diagnosis System (MY-RADS) Imaging Recommendations: Prognostic Role of Imaging Response after Transplant in Multiple Myeloma and Comparison with MRD Evaluation By Flow Cytometry The American Society of Hematology American Society of Hematology 10.1182/blood-2020-135969 Silverchair:470035 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 External Validation of Diffusion Weighted Whole Body MRI (DW-MRI) Response Assessment Category (RAC) Criteria Proposed By the Myeloma Response Assessment and Diagnosis System (MY-RADS) Imaging Recommendations: Prognostic Role of Imaging Response after Transplant in Multiple Myeloma and Comparison with MRD Evaluation By Flow Cytometry The American Society of Hematology American Society of Hematology 10.1182/blood-2020-135969 Silverchair:470035 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 External Validation of the HLH-2004 Diagnostic Criteria and H-Score for Diagnosis of Hemophagocytic Lymphohistiocytosis in Adults The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138589 Silverchair:471459 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 External Validation of the HLH-2004 Diagnostic Criteria and H-Score for Diagnosis of Hemophagocytic Lymphohistiocytosis in Adults The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138589 Silverchair:471459 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 External Validation of the HLH-2004 Diagnostic Criteria and H-Score for Diagnosis of Hemophagocytic Lymphohistiocytosis in Adults The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138589 Silverchair:471459 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 External Validation of the HLH-2004 Diagnostic Criteria and H-Score for Diagnosis of Hemophagocytic Lymphohistiocytosis in Adults The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138589 Silverchair:471459 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Extracavitary primary effusion lymphoma presenting as a thalamic mass in a patient with multicentric Castleman disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019004506 Silverchair:454156 Total_Item_Investigations 2 1 0 0 0 1 0 0 0 0 0 0 0 Extracavitary primary effusion lymphoma presenting as a thalamic mass in a patient with multicentric Castleman disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019004506 Silverchair:454156 Total_Item_Requests 2 1 0 0 0 1 0 0 0 0 0 0 0 Extracavitary primary effusion lymphoma presenting as a thalamic mass in a patient with multicentric Castleman disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019004506 Silverchair:454156 Unique_Item_Investigations 2 1 0 0 0 1 0 0 0 0 0 0 0 Extracavitary primary effusion lymphoma presenting as a thalamic mass in a patient with multicentric Castleman disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019004506 Silverchair:454156 Unique_Item_Requests 2 1 0 0 0 1 0 0 0 0 0 0 0 Extracellular fluid tonicity impacts sickle red blood cell deformability and adhesion The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-780635 Silverchair:36888 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Extracellular fluid tonicity impacts sickle red blood cell deformability and adhesion The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-780635 Silverchair:36888 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Extracellular fluid tonicity impacts sickle red blood cell deformability and adhesion The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-780635 Silverchair:36888 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Extracellular fluid tonicity impacts sickle red blood cell deformability and adhesion The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-780635 Silverchair:36888 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterations The American Society of Hematology American Society of Hematology 10.1182/blood-2017-12-821843 Silverchair:39450 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterations The American Society of Hematology American Society of Hematology 10.1182/blood-2017-12-821843 Silverchair:39450 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterations The American Society of Hematology American Society of Hematology 10.1182/blood-2017-12-821843 Silverchair:39450 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterations The American Society of Hematology American Society of Hematology 10.1182/blood-2017-12-821843 Silverchair:39450 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Extramedullary Disease at Diagnosis of Acute Myeloid Leukemia Does Not Influence Outcome of Patients Undergoing Allogeneic Hematopoietic Cell Transplant in First Complete Remission The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2020.2020 Silverchair:105383 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Extramedullary Disease at Diagnosis of Acute Myeloid Leukemia Does Not Influence Outcome of Patients Undergoing Allogeneic Hematopoietic Cell Transplant in First Complete Remission The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2020.2020 Silverchair:105383 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Extramedullary Disease at Diagnosis of Acute Myeloid Leukemia Does Not Influence Outcome of Patients Undergoing Allogeneic Hematopoietic Cell Transplant in First Complete Remission The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2020.2020 Silverchair:105383 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Extramedullary Disease at Diagnosis of Acute Myeloid Leukemia Does Not Influence Outcome of Patients Undergoing Allogeneic Hematopoietic Cell Transplant in First Complete Remission The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2020.2020 Silverchair:105383 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Extramedullary Disease Is Common In Newly Diagnosed AML But Has No Independent Prognostic Significance, Including CNS Involvement: Analysis Of 3,522 AML Patients Treated On Consecutive ECOG Trials 1980-2008" The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.63.63 Silverchair:94231 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Extramedullary Disease Is Common In Newly Diagnosed AML But Has No Independent Prognostic Significance, Including CNS Involvement: Analysis Of 3,522 AML Patients Treated On Consecutive ECOG Trials 1980-2008" The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.63.63 Silverchair:94231 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Extramedullary Disease Is Common In Newly Diagnosed AML But Has No Independent Prognostic Significance, Including CNS Involvement: Analysis Of 3,522 AML Patients Treated On Consecutive ECOG Trials 1980-2008" The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.63.63 Silverchair:94231 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Extramedullary Disease Is Common In Newly Diagnosed AML But Has No Independent Prognostic Significance, Including CNS Involvement: Analysis Of 3,522 AML Patients Treated On Consecutive ECOG Trials 1980-2008" The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.63.63 Silverchair:94231 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Extramedullary Hematopoiesis in the Absence of Myeloproliferative Neoplasm: Mayo Clinic Case Series of 309 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112587 Silverchair:265773 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Extramedullary Hematopoiesis in the Absence of Myeloproliferative Neoplasm: Mayo Clinic Case Series of 309 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112587 Silverchair:265773 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Extramedullary Hematopoiesis in the Absence of Myeloproliferative Neoplasm: Mayo Clinic Case Series of 309 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112587 Silverchair:265773 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Extramedullary Hematopoiesis in the Absence of Myeloproliferative Neoplasm: Mayo Clinic Case Series of 309 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112587 Silverchair:265773 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Extreme disruption of heterochromatin is required for accelerated hematopoietic aging The American Society of Hematology American Society of Hematology 10.1182/blood.2019002990 Silverchair:454438 No_License 1 0 0 1 0 0 0 0 0 0 0 0 0 Extreme disruption of heterochromatin is required for accelerated hematopoietic aging The American Society of Hematology American Society of Hematology 10.1182/blood.2019002990 Silverchair:454438 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Extreme disruption of heterochromatin is required for accelerated hematopoietic aging The American Society of Hematology American Society of Hematology 10.1182/blood.2019002990 Silverchair:454438 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 EZH! The IRE of DLBCL gets an UPR hand The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-769067 Silverchair:35947 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 EZH! The IRE of DLBCL gets an UPR hand The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-769067 Silverchair:35947 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 EZH! The IRE of DLBCL gets an UPR hand The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-769067 Silverchair:35947 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 EZH! The IRE of DLBCL gets an UPR hand The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-769067 Silverchair:35947 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 EZH2 Gain-of-Function Mutations Generate a Lymphoma-Permissive Immune Niche The American Society of Hematology American Society of Hematology 10.1182/blood-2019-132263 Silverchair:423265 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 EZH2 Gain-of-Function Mutations Generate a Lymphoma-Permissive Immune Niche The American Society of Hematology American Society of Hematology 10.1182/blood-2019-132263 Silverchair:423265 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 EZH2 Gain-of-Function Mutations Generate a Lymphoma-Permissive Immune Niche The American Society of Hematology American Society of Hematology 10.1182/blood-2019-132263 Silverchair:423265 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 EZH2 Gain-of-Function Mutations Generate a Lymphoma-Permissive Immune Niche The American Society of Hematology American Society of Hematology 10.1182/blood-2019-132263 Silverchair:423265 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-634428 Silverchair:73134 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-634428 Silverchair:73134 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-634428 Silverchair:73134 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-634428 Silverchair:73134 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-280149 Silverchair:28064 Total_Item_Investigations 4 0 0 4 0 0 0 0 0 0 0 0 0 EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-280149 Silverchair:28064 Total_Item_Requests 4 0 0 4 0 0 0 0 0 0 0 0 0 EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-280149 Silverchair:28064 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-280149 Silverchair:28064 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Factor V leiden and Prothrombin Gene Mutations: Differences by Gender The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.5135.5135 Silverchair:86831 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Factor V leiden and Prothrombin Gene Mutations: Differences by Gender The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.5135.5135 Silverchair:86831 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Factor V leiden and Prothrombin Gene Mutations: Differences by Gender The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.5135.5135 Silverchair:86831 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Factor V leiden and Prothrombin Gene Mutations: Differences by Gender The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.5135.5135 Silverchair:86831 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-307074 Silverchair:19652 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 2 0 0 0 Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-307074 Silverchair:19652 Total_Item_Requests 2 0 0 0 0 0 0 0 0 2 0 0 0 Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-307074 Silverchair:19652 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-307074 Silverchair:19652 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-483263 Silverchair:31863 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-483263 Silverchair:31863 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-483263 Silverchair:31863 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-483263 Silverchair:31863 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Factor VIII Levels in Blood Group O and Non-O in Patients with Non-Severe Haemophilia a The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123187 Silverchair:426651 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Factor VIII Levels in Blood Group O and Non-O in Patients with Non-Severe Haemophilia a The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123187 Silverchair:426651 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Factor VIII Levels in Blood Group O and Non-O in Patients with Non-Severe Haemophilia a The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123187 Silverchair:426651 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Factor VIII Levels in Blood Group O and Non-O in Patients with Non-Severe Haemophilia a The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123187 Silverchair:426651 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Factor VIII–driven changes in activated factor IX explored by hydrogen-deuterium exchange mass spectrometry The American Society of Hematology American Society of Hematology 10.1182/blood.2020005593 Silverchair:461422 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Factor VIII–driven changes in activated factor IX explored by hydrogen-deuterium exchange mass spectrometry The American Society of Hematology American Society of Hematology 10.1182/blood.2020005593 Silverchair:461422 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Factor VIII–driven changes in activated factor IX explored by hydrogen-deuterium exchange mass spectrometry The American Society of Hematology American Society of Hematology 10.1182/blood.2020005593 Silverchair:461422 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Factor VIII–driven changes in activated factor IX explored by hydrogen-deuterium exchange mass spectrometry The American Society of Hematology American Society of Hematology 10.1182/blood.2020005593 Silverchair:461422 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Factor XII bridges coagulation and fibrinolysis again The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-275263 Silverchair:27189 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Factor XII bridges coagulation and fibrinolysis again The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-275263 Silverchair:27189 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Factor XII bridges coagulation and fibrinolysis again The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-275263 Silverchair:27189 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Factor XII bridges coagulation and fibrinolysis again The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-275263 Silverchair:27189 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Factor XIII cross-links fibrin(ogen) independent of fibrin polymerization in experimental acute liver injury The American Society of Hematology American Society of Hematology 10.1182/blood.2020007415 Silverchair:475231 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Factor XIII cross-links fibrin(ogen) independent of fibrin polymerization in experimental acute liver injury The American Society of Hematology American Society of Hematology 10.1182/blood.2020007415 Silverchair:475231 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates? The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000253 Silverchair:482930 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 0 2 Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates? The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000253 Silverchair:482930 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 0 2 Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates? The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000253 Silverchair:482930 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates? The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000253 Silverchair:482930 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 "Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-08-2724 Silverchair:19933 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-08-2724 Silverchair:19933 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-08-2724 Silverchair:19933 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-08-2724 Silverchair:19933 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Factors Associated with Clinical Outcomes after Venetoclax-Based Combination Therapy in Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139794 Silverchair:470803 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Factors Associated with Clinical Outcomes after Venetoclax-Based Combination Therapy in Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139794 Silverchair:470803 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Factors Associated with Clinical Outcomes after Venetoclax-Based Combination Therapy in Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139794 Silverchair:470803 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Factors Associated with Clinical Outcomes after Venetoclax-Based Combination Therapy in Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139794 Silverchair:470803 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2020006770 Silverchair:463850 Total_Item_Investigations 6 3 1 0 2 0 0 0 0 0 0 0 0 Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2020006770 Silverchair:463850 Total_Item_Requests 4 3 1 0 0 0 0 0 0 0 0 0 0 Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2020006770 Silverchair:463850 Unique_Item_Investigations 4 2 1 0 1 0 0 0 0 0 0 0 0 Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2020006770 Silverchair:463850 Unique_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 Factors that predict thrombosis in relatives of patients with venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2014-03-559757 Silverchair:33060 Total_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 Factors that predict thrombosis in relatives of patients with venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2014-03-559757 Silverchair:33060 Total_Item_Requests 3 2 0 1 0 0 0 0 0 0 0 0 0 Factors that predict thrombosis in relatives of patients with venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2014-03-559757 Silverchair:33060 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Factors that predict thrombosis in relatives of patients with venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2014-03-559757 Silverchair:33060 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) caused by deep intronic mutation and inversion in UNC13D The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-369090 Silverchair:29202 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) caused by deep intronic mutation and inversion in UNC13D The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-369090 Silverchair:29202 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) caused by deep intronic mutation and inversion in UNC13D The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-369090 Silverchair:29202 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) caused by deep intronic mutation and inversion in UNC13D The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-369090 Silverchair:29202 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Familial patterns of hematologic precursors The American Society of Hematology American Society of Hematology 10.1182/blood.2020010035 Silverchair:475718 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Familial patterns of hematologic precursors The American Society of Hematology American Society of Hematology 10.1182/blood.2020010035 Silverchair:475718 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Familial patterns of hematologic precursors The American Society of Hematology American Society of Hematology 10.1182/blood.2020010035 Silverchair:475718 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Familial patterns of hematologic precursors The American Society of Hematology American Society of Hematology 10.1182/blood.2020010035 Silverchair:475718 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Familial predisposition and genetic risk factors for lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-537498 Silverchair:103852 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Familial predisposition and genetic risk factors for lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-537498 Silverchair:103852 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Familial predisposition and genetic risk factors for lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-537498 Silverchair:103852 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Familial predisposition and genetic risk factors for lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-537498 Silverchair:103852 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Familial Pseudohyperkalemia Maps to the Same Locus as Dehydrated Hereditary Stomatocytosis (Hereditary Xerocytosis) The American Society of Hematology American Society of Hematology 10.1182/blood.V93.9.3120 Silverchair:266595 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Familial Pseudohyperkalemia Maps to the Same Locus as Dehydrated Hereditary Stomatocytosis (Hereditary Xerocytosis) The American Society of Hematology American Society of Hematology 10.1182/blood.V93.9.3120 Silverchair:266595 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Familial Pseudohyperkalemia Maps to the Same Locus as Dehydrated Hereditary Stomatocytosis (Hereditary Xerocytosis) The American Society of Hematology American Society of Hematology 10.1182/blood.V93.9.3120 Silverchair:266595 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Familial Pseudohyperkalemia Maps to the Same Locus as Dehydrated Hereditary Stomatocytosis (Hereditary Xerocytosis) The American Society of Hematology American Society of Hematology 10.1182/blood.V93.9.3120 Silverchair:266595 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Familial risk of developing atypical hemolytic-uremic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2020006931 Silverchair:460659 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Familial risk of developing atypical hemolytic-uremic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2020006931 Silverchair:460659 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Familial risk of developing atypical hemolytic-uremic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2020006931 Silverchair:460659 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Familial risk of developing atypical hemolytic-uremic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2020006931 Silverchair:460659 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Fanconi Anemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2011.1.492 Silverchair:96450 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Fanconi Anemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2011.1.492 Silverchair:96450 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Fanconi Anemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2011.1.492 Silverchair:96450 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Fanconi Anemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2011.1.492 Silverchair:96450 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Fanconi anemia, put to sleep" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008462 Silverchair:474939 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "Fanconi anemia, put to sleep" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008462 Silverchair:474939 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "Fanconi anemia, put to sleep" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008462 Silverchair:474939 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Fanconi anemia, put to sleep" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008462 Silverchair:474939 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Fates of human B-cell precursors The American Society of Hematology American Society of Hematology 10.1182/blood.V96.1.9 Silverchair:257862 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Fates of human B-cell precursors The American Society of Hematology American Society of Hematology 10.1182/blood.V96.1.9 Silverchair:257862 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Fates of human B-cell precursors The American Society of Hematology American Society of Hematology 10.1182/blood.V96.1.9 Silverchair:257862 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Fates of human B-cell precursors The American Society of Hematology American Society of Hematology 10.1182/blood.V96.1.9 Silverchair:257862 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Favorable outcomes of hematopoietic stem cell transplantation in children and adolescents with Diamond-Blackfan anemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001210 Silverchair:454551 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Favorable outcomes of hematopoietic stem cell transplantation in children and adolescents with Diamond-Blackfan anemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001210 Silverchair:454551 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Favorable outcomes of hematopoietic stem cell transplantation in children and adolescents with Diamond-Blackfan anemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001210 Silverchair:454551 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Favorable outcomes of hematopoietic stem cell transplantation in children and adolescents with Diamond-Blackfan anemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001210 Silverchair:454551 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Fbxl10 overexpression in murine hematopoietic stem cells induces leukemia involving metabolic activation and upregulation of Nsg2 The American Society of Hematology American Society of Hematology 10.1182/blood-2014-03-562694 Silverchair:34351 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Fbxl10 overexpression in murine hematopoietic stem cells induces leukemia involving metabolic activation and upregulation of Nsg2 The American Society of Hematology American Society of Hematology 10.1182/blood-2014-03-562694 Silverchair:34351 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Fbxl10 overexpression in murine hematopoietic stem cells induces leukemia involving metabolic activation and upregulation of Nsg2 The American Society of Hematology American Society of Hematology 10.1182/blood-2014-03-562694 Silverchair:34351 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Fbxl10 overexpression in murine hematopoietic stem cells induces leukemia involving metabolic activation and upregulation of Nsg2 The American Society of Hematology American Society of Hematology 10.1182/blood-2014-03-562694 Silverchair:34351 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 FBXO11-mediated proteolysis of BAHD1 relieves PRC2-dependent transcriptional repression in erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.2020007809 Silverchair:474112 No_License 1 0 0 1 0 0 0 0 0 0 0 0 0 FBXO11-mediated proteolysis of BAHD1 relieves PRC2-dependent transcriptional repression in erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.2020007809 Silverchair:474112 Total_Item_Investigations 5 2 1 2 0 0 0 0 0 0 0 0 0 FBXO11-mediated proteolysis of BAHD1 relieves PRC2-dependent transcriptional repression in erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.2020007809 Silverchair:474112 Total_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 FBXO11-mediated proteolysis of BAHD1 relieves PRC2-dependent transcriptional repression in erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.2020007809 Silverchair:474112 Unique_Item_Investigations 3 1 1 1 0 0 0 0 0 0 0 0 0 FBXO11-mediated proteolysis of BAHD1 relieves PRC2-dependent transcriptional repression in erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.2020007809 Silverchair:474112 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 FceRI?-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002440 Silverchair:476502 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 FceRI?-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002440 Silverchair:476502 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 FceRI?-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002440 Silverchair:476502 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 FceRI?-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002440 Silverchair:476502 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Fc-independent immune thrombocytopenia via mechanomolecular signaling in platelets The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-784975 Silverchair:39289 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Fc-independent immune thrombocytopenia via mechanomolecular signaling in platelets The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-784975 Silverchair:39289 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Fc-independent immune thrombocytopenia via mechanomolecular signaling in platelets The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-784975 Silverchair:39289 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Fc-independent immune thrombocytopenia via mechanomolecular signaling in platelets The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-784975 Silverchair:39289 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Fcγ-receptor–mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-569244 Silverchair:34055 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Fcγ-receptor–mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-569244 Silverchair:34055 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Fcγ-receptor–mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-569244 Silverchair:34055 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Fcγ-receptor–mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-569244 Silverchair:34055 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 FcγRIIA expression accelerates nephritis and increases platelet activation in systemic lupus erythematosus The American Society of Hematology American Society of Hematology 10.1182/blood.2020004974 Silverchair:461760 No_License 3 0 2 1 0 0 0 0 0 0 0 0 0 FcγRIIA expression accelerates nephritis and increases platelet activation in systemic lupus erythematosus The American Society of Hematology American Society of Hematology 10.1182/blood.2020004974 Silverchair:461760 Total_Item_Investigations 8 2 4 2 0 0 0 0 0 0 0 0 0 FcγRIIA expression accelerates nephritis and increases platelet activation in systemic lupus erythematosus The American Society of Hematology American Society of Hematology 10.1182/blood.2020004974 Silverchair:461760 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 FcγRIIA expression accelerates nephritis and increases platelet activation in systemic lupus erythematosus The American Society of Hematology American Society of Hematology 10.1182/blood.2020004974 Silverchair:461760 Unique_Item_Investigations 4 1 2 1 0 0 0 0 0 0 0 0 0 FcγRIIA expression accelerates nephritis and increases platelet activation in systemic lupus erythematosus The American Society of Hematology American Society of Hematology 10.1182/blood.2020004974 Silverchair:461760 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Feasibility of Outpatient High Dose Cytarabine in Patients with Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129858 Silverchair:427867 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Feasibility of Outpatient High Dose Cytarabine in Patients with Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129858 Silverchair:427867 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Feasibility of Outpatient High Dose Cytarabine in Patients with Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129858 Silverchair:427867 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Feasibility of Outpatient High Dose Cytarabine in Patients with Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129858 Silverchair:427867 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Fedratinib in myelofibrosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000954 Silverchair:454549 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Fedratinib in myelofibrosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000954 Silverchair:454549 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Fedratinib in myelofibrosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000954 Silverchair:454549 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Fedratinib in myelofibrosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000954 Silverchair:454549 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Feedback Regulation of STAT5 Is Critical to Balance MYC and BCL6-Dependent Transcriptional Programs That Regulate Cell Size and Glucose Metabolism The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4069.4069 Silverchair:113851 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Feedback Regulation of STAT5 Is Critical to Balance MYC and BCL6-Dependent Transcriptional Programs That Regulate Cell Size and Glucose Metabolism The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4069.4069 Silverchair:113851 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Feedback Regulation of STAT5 Is Critical to Balance MYC and BCL6-Dependent Transcriptional Programs That Regulate Cell Size and Glucose Metabolism The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4069.4069 Silverchair:113851 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Feedback Regulation of STAT5 Is Critical to Balance MYC and BCL6-Dependent Transcriptional Programs That Regulate Cell Size and Glucose Metabolism The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4069.4069 Silverchair:113851 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Fetal hemoglobin in sickle cell anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-325258 Silverchair:28401 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Fetal hemoglobin in sickle cell anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-325258 Silverchair:28401 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Fetal hemoglobin in sickle cell anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-325258 Silverchair:28401 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Fetal hemoglobin in sickle cell anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-325258 Silverchair:28401 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Fetal hemoglobin in sickle cell anemia: a glass half full? The American Society of Hematology American Society of Hematology 10.1182/blood-2013-09-528067 Silverchair:32281 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Fetal hemoglobin in sickle cell anemia: a glass half full? The American Society of Hematology American Society of Hematology 10.1182/blood-2013-09-528067 Silverchair:32281 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Fetal hemoglobin in sickle cell anemia: a glass half full? The American Society of Hematology American Society of Hematology 10.1182/blood-2013-09-528067 Silverchair:32281 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Fetal hemoglobin in sickle cell anemia: a glass half full? The American Society of Hematology American Society of Hematology 10.1182/blood-2013-09-528067 Silverchair:32281 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Fetal Hemoglobin Rescues Ineffective Erythropoiesis in Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137477 Silverchair:470254 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Fetal Hemoglobin Rescues Ineffective Erythropoiesis in Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137477 Silverchair:470254 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Fetal Hemoglobin Rescues Ineffective Erythropoiesis in Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137477 Silverchair:470254 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Fetal Hemoglobin Rescues Ineffective Erythropoiesis in Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137477 Silverchair:470254 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 FGF-23 from erythroblasts promotes hematopoietic progenitor mobilization The American Society of Hematology American Society of Hematology 10.1182/blood.2020007172 Silverchair:474775 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 FGF-23 from erythroblasts promotes hematopoietic progenitor mobilization The American Society of Hematology American Society of Hematology 10.1182/blood.2020007172 Silverchair:474775 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 FGF-23 from erythroblasts promotes hematopoietic progenitor mobilization The American Society of Hematology American Society of Hematology 10.1182/blood.2020007172 Silverchair:474775 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 FGF-23 from erythroblasts promotes hematopoietic progenitor mobilization The American Society of Hematology American Society of Hematology 10.1182/blood.2020007172 Silverchair:474775 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Filamin A: key actor in platelet biology The American Society of Hematology American Society of Hematology 10.1182/blood.2019000014 Silverchair:374959 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Filamin A: key actor in platelet biology The American Society of Hematology American Society of Hematology 10.1182/blood.2019000014 Silverchair:374959 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Filamin A: key actor in platelet biology The American Society of Hematology American Society of Hematology 10.1182/blood.2019000014 Silverchair:374959 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Filamin A: key actor in platelet biology The American Society of Hematology American Society of Hematology 10.1182/blood.2019000014 Silverchair:374959 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Filgrastim Administered after Early Assessment Bone Marrow Biopsy during 7+3 Induction Therapy for Acute Myeloid Leukemia Reduces Length of Hospital Stay The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131293 Silverchair:423164 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Filgrastim Administered after Early Assessment Bone Marrow Biopsy during 7+3 Induction Therapy for Acute Myeloid Leukemia Reduces Length of Hospital Stay The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131293 Silverchair:423164 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Filgrastim Administered after Early Assessment Bone Marrow Biopsy during 7+3 Induction Therapy for Acute Myeloid Leukemia Reduces Length of Hospital Stay The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131293 Silverchair:423164 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Filgrastim Administered after Early Assessment Bone Marrow Biopsy during 7+3 Induction Therapy for Acute Myeloid Leukemia Reduces Length of Hospital Stay The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131293 Silverchair:423164 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Final Analysis of the Phase I/II Study of CC-486 (Oral Azacitidine) Maintenance Therapy after Allogeneic Stem Cell Transplantation (Allo-SCT) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4512.4512 Silverchair:72418 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Final Analysis of the Phase I/II Study of CC-486 (Oral Azacitidine) Maintenance Therapy after Allogeneic Stem Cell Transplantation (Allo-SCT) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4512.4512 Silverchair:72418 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Final Analysis of the Phase I/II Study of CC-486 (Oral Azacitidine) Maintenance Therapy after Allogeneic Stem Cell Transplantation (Allo-SCT) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4512.4512 Silverchair:72418 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Final Analysis of the Phase I/II Study of CC-486 (Oral Azacitidine) Maintenance Therapy after Allogeneic Stem Cell Transplantation (Allo-SCT) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4512.4512 Silverchair:72418 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134440 Silverchair:469958 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134440 Silverchair:469958 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134440 Silverchair:469958 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134440 Silverchair:469958 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126065 Silverchair:427021 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126065 Silverchair:427021 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126065 Silverchair:427021 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126065 Silverchair:427021 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2780.2780 Silverchair:113659 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2780.2780 Silverchair:113659 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2780.2780 Silverchair:113659 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2780.2780 Silverchair:113659 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020007512 Silverchair:474210 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020007512 Silverchair:474210 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020007512 Silverchair:474210 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020007512 Silverchair:474210 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 "Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003829 Silverchair:476582 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003829 Silverchair:476582 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003829 Silverchair:476582 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003829 Silverchair:476582 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130046 Silverchair:426590 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 "Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130046 Silverchair:426590 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 "Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130046 Silverchair:426590 Unique_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 "Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130046 Silverchair:426590 Unique_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 "Final Results of Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Poor-Risk Cytogenetics" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3897.3897 Silverchair:71820 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Final Results of Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Poor-Risk Cytogenetics" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3897.3897 Silverchair:71820 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Final Results of Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Poor-Risk Cytogenetics" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3897.3897 Silverchair:71820 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Final Results of Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Poor-Risk Cytogenetics" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3897.3897 Silverchair:71820 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Fine-tuning of FOXO3A in cHL as a survival mechanism and a hallmark of abortive plasma cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-795278 Silverchair:36665 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 Fine-tuning of FOXO3A in cHL as a survival mechanism and a hallmark of abortive plasma cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-795278 Silverchair:36665 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Fine-tuning of FOXO3A in cHL as a survival mechanism and a hallmark of abortive plasma cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-795278 Silverchair:36665 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Fine-tuning of FOXO3A in cHL as a survival mechanism and a hallmark of abortive plasma cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-795278 Silverchair:36665 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)" The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.653.653 Silverchair:74746 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)" The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.653.653 Silverchair:74746 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)" The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.653.653 Silverchair:74746 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)" The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.653.653 Silverchair:74746 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "First in Human Phase 1 Single Dose Escalation Studies of the E-Selectin Antagonist GMI-1271 Show a Favorable Safety, Pharmacokinetic, and Biomarker Profile" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.1004.1004 Silverchair:104536 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "First in Human Phase 1 Single Dose Escalation Studies of the E-Selectin Antagonist GMI-1271 Show a Favorable Safety, Pharmacokinetic, and Biomarker Profile" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.1004.1004 Silverchair:104536 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "First in Human Phase 1 Single Dose Escalation Studies of the E-Selectin Antagonist GMI-1271 Show a Favorable Safety, Pharmacokinetic, and Biomarker Profile" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.1004.1004 Silverchair:104536 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "First in Human Phase 1 Single Dose Escalation Studies of the E-Selectin Antagonist GMI-1271 Show a Favorable Safety, Pharmacokinetic, and Biomarker Profile" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.1004.1004 Silverchair:104536 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1148.1148 Silverchair:96162 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1148.1148 Silverchair:96162 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1148.1148 Silverchair:96162 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1148.1148 Silverchair:96162 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124478 Silverchair:424162 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124478 Silverchair:424162 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124478 Silverchair:424162 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124478 Silverchair:424162 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 First Selective KIT D816V Inhibitor for Patients with Systemic Mastocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3217.3217 Silverchair:96812 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 First Selective KIT D816V Inhibitor for Patients with Systemic Mastocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3217.3217 Silverchair:96812 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 First Selective KIT D816V Inhibitor for Patients with Systemic Mastocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3217.3217 Silverchair:96812 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 First Selective KIT D816V Inhibitor for Patients with Systemic Mastocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3217.3217 Silverchair:96812 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: Update on Phase 1 Clinical Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110579 Silverchair:266370 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: Update on Phase 1 Clinical Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110579 Silverchair:266370 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: Update on Phase 1 Clinical Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110579 Silverchair:266370 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: Update on Phase 1 Clinical Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110579 Silverchair:266370 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 First-in-Human Study of the EZH1/2 Dual Inhibitor DS-3201b in Patients with Relapsed or Refractory Non-Hodgkin Lymphomas — Preliminary Results The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4070.4070 Silverchair:72772 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 First-in-Human Study of the EZH1/2 Dual Inhibitor DS-3201b in Patients with Relapsed or Refractory Non-Hodgkin Lymphomas — Preliminary Results The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4070.4070 Silverchair:72772 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 First-in-Human Study of the EZH1/2 Dual Inhibitor DS-3201b in Patients with Relapsed or Refractory Non-Hodgkin Lymphomas — Preliminary Results The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4070.4070 Silverchair:72772 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 First-in-Human Study of the EZH1/2 Dual Inhibitor DS-3201b in Patients with Relapsed or Refractory Non-Hodgkin Lymphomas — Preliminary Results The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4070.4070 Silverchair:72772 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001329 Silverchair:461024 Total_Item_Investigations 3 0 1 2 0 0 0 0 0 0 0 0 0 First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001329 Silverchair:461024 Total_Item_Requests 3 0 1 2 0 0 0 0 0 0 0 0 0 First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001329 Silverchair:461024 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001329 Silverchair:461024 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 First-line Therapy in Highrisk PV: Will JAK2 Inhibitor Treatment Be the Remedy? American Society of Hematology American Society of Hematology Silverchair:475889 Total_Item_Investigations 4 0 0 0 0 4 0 0 0 0 0 0 0 First-line Therapy in Highrisk PV: Will JAK2 Inhibitor Treatment Be the Remedy? American Society of Hematology American Society of Hematology Silverchair:475889 Total_Item_Requests 4 0 0 0 0 4 0 0 0 0 0 0 0 First-line Therapy in Highrisk PV: Will JAK2 Inhibitor Treatment Be the Remedy? American Society of Hematology American Society of Hematology Silverchair:475889 Unique_Item_Investigations 3 0 0 0 0 3 0 0 0 0 0 0 0 First-line Therapy in Highrisk PV: Will JAK2 Inhibitor Treatment Be the Remedy? American Society of Hematology American Society of Hematology Silverchair:475889 Unique_Item_Requests 3 0 0 0 0 3 0 0 0 0 0 0 0 "Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-423046 Silverchair:30757 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-423046 Silverchair:30757 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-423046 Silverchair:30757 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-423046 Silverchair:30757 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-859769 Silverchair:39480 Total_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-859769 Silverchair:39480 Total_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-859769 Silverchair:39480 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-859769 Silverchair:39480 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Five-Year Follow-up of Monoclonal B-Cell Lymphocytosis (MBL) in Individuals with a Normal Blood Count: Expansion of the Abnormal B-Cell Compartment but No Progressive Disease. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.59.59 Silverchair:76977 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Five-Year Follow-up of Monoclonal B-Cell Lymphocytosis (MBL) in Individuals with a Normal Blood Count: Expansion of the Abnormal B-Cell Compartment but No Progressive Disease. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.59.59 Silverchair:76977 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Five-Year Follow-up of Monoclonal B-Cell Lymphocytosis (MBL) in Individuals with a Normal Blood Count: Expansion of the Abnormal B-Cell Compartment but No Progressive Disease. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.59.59 Silverchair:76977 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Five-Year Follow-up of Monoclonal B-Cell Lymphocytosis (MBL) in Individuals with a Normal Blood Count: Expansion of the Abnormal B-Cell Compartment but No Progressive Disease. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.59.59 Silverchair:76977 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-861641 Silverchair:39577 Total_Item_Investigations 6 0 0 6 0 0 0 0 0 0 0 0 0 Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-861641 Silverchair:39577 Total_Item_Requests 6 0 0 6 0 0 0 0 0 0 0 0 0 Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-861641 Silverchair:39577 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-861641 Silverchair:39577 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 "FLAG-IDA Regimen (Fludarabine, Cytarabine, Idarubicin and G-CSF) in the Treatment of Patients with High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes." The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.2866.2866 Silverchair:74612 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "FLAG-IDA Regimen (Fludarabine, Cytarabine, Idarubicin and G-CSF) in the Treatment of Patients with High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes." The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.2866.2866 Silverchair:74612 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "FLAG-IDA Regimen (Fludarabine, Cytarabine, Idarubicin and G-CSF) in the Treatment of Patients with High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes." The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.2866.2866 Silverchair:74612 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "FLAG-IDA Regimen (Fludarabine, Cytarabine, Idarubicin and G-CSF) in the Treatment of Patients with High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes." The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.2866.2866 Silverchair:74612 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Fli1 Is Essential for the Maintenance of Hematopoietic Stem Cell Homeostasis and Function The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3769.3769 Silverchair:71796 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Fli1 Is Essential for the Maintenance of Hematopoietic Stem Cell Homeostasis and Function The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3769.3769 Silverchair:71796 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Fli1 Is Essential for the Maintenance of Hematopoietic Stem Cell Homeostasis and Function The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3769.3769 Silverchair:71796 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Fli1 Is Essential for the Maintenance of Hematopoietic Stem Cell Homeostasis and Function The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3769.3769 Silverchair:71796 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020007732 Silverchair:463757 Total_Item_Investigations 11 0 4 3 1 0 0 0 0 0 3 0 0 Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020007732 Silverchair:463757 Total_Item_Requests 8 0 1 3 1 0 0 0 0 0 3 0 0 Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020007732 Silverchair:463757 Unique_Item_Investigations 6 0 2 1 1 0 0 0 0 0 2 0 0 Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020007732 Silverchair:463757 Unique_Item_Requests 5 0 1 1 1 0 0 0 0 0 2 0 0 Flow cytometric immunophenotyping for hematologic neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2007-11-120535 Silverchair:24550 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Flow cytometric immunophenotyping for hematologic neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2007-11-120535 Silverchair:24550 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Flow cytometric immunophenotyping for hematologic neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2007-11-120535 Silverchair:24550 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Flow cytometric immunophenotyping for hematologic neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2007-11-120535 Silverchair:24550 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 FLT3 as a therapeutic target in AML: still challenging after all these years The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-261867 Silverchair:28007 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 FLT3 as a therapeutic target in AML: still challenging after all these years The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-261867 Silverchair:28007 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 FLT3 as a therapeutic target in AML: still challenging after all these years The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-261867 Silverchair:28007 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 FLT3 as a therapeutic target in AML: still challenging after all these years The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-261867 Silverchair:28007 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019003538 Silverchair:452494 Total_Item_Investigations 3 1 0 0 0 2 0 0 0 0 0 0 0 FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019003538 Silverchair:452494 Total_Item_Requests 3 1 0 0 0 2 0 0 0 0 0 0 0 FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019003538 Silverchair:452494 Unique_Item_Investigations 2 1 0 0 0 1 0 0 0 0 0 0 0 FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019003538 Silverchair:452494 Unique_Item_Requests 2 1 0 0 0 1 0 0 0 0 0 0 0 FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model The American Society of Hematology American Society of Hematology 10.1182/blood.V99.1.310 Silverchair:107286 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model The American Society of Hematology American Society of Hematology 10.1182/blood.V99.1.310 Silverchair:107286 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model The American Society of Hematology American Society of Hematology 10.1182/blood.V99.1.310 Silverchair:107286 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model The American Society of Hematology American Society of Hematology 10.1182/blood.V99.1.310 Silverchair:107286 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 FLT3 Mutations: Biology and Treatment The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.178 Silverchair:19809 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 FLT3 Mutations: Biology and Treatment The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.178 Silverchair:19809 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 FLT3 Mutations: Biology and Treatment The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.178 Silverchair:19809 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 FLT3 Mutations: Biology and Treatment The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.178 Silverchair:19809 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 FLT3-ITD but Not FLT3-TKD Mutations Have Major Prognostic Impact in Normal Karyotype AML. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3486.3486 Silverchair:75357 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 FLT3-ITD but Not FLT3-TKD Mutations Have Major Prognostic Impact in Normal Karyotype AML. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3486.3486 Silverchair:75357 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 FLT3-ITD but Not FLT3-TKD Mutations Have Major Prognostic Impact in Normal Karyotype AML. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3486.3486 Silverchair:75357 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 FLT3-ITD but Not FLT3-TKD Mutations Have Major Prognostic Impact in Normal Karyotype AML. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3486.3486 Silverchair:75357 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2005-06-2395 Silverchair:22138 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2005-06-2395 Silverchair:22138 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2005-06-2395 Silverchair:22138 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2005-06-2395 Silverchair:22138 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Fluorescent labeling of CRISPR/Cas9 RNP for gene knockout in HSPCs and iPSCs reveals an essential role for GADD45b in stress response American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017015511 Silverchair:11152 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Fluorescent labeling of CRISPR/Cas9 RNP for gene knockout in HSPCs and iPSCs reveals an essential role for GADD45b in stress response American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017015511 Silverchair:11152 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Fluorescent labeling of CRISPR/Cas9 RNP for gene knockout in HSPCs and iPSCs reveals an essential role for GADD45b in stress response American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017015511 Silverchair:11152 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Fluorescent labeling of CRISPR/Cas9 RNP for gene knockout in HSPCs and iPSCs reveals an essential role for GADD45b in stress response American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017015511 Silverchair:11152 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "FLVCR is necessary for erythroid maturation, may contribute to platelet maturation, but is dispensable for normal hematopoietic stem cell function" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-10-465104 Silverchair:31791 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "FLVCR is necessary for erythroid maturation, may contribute to platelet maturation, but is dispensable for normal hematopoietic stem cell function" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-10-465104 Silverchair:31791 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "FLVCR is necessary for erythroid maturation, may contribute to platelet maturation, but is dispensable for normal hematopoietic stem cell function" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-10-465104 Silverchair:31791 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "FLVCR is necessary for erythroid maturation, may contribute to platelet maturation, but is dispensable for normal hematopoietic stem cell function" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-10-465104 Silverchair:31791 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002944 Silverchair:474198 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002944 Silverchair:474198 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002944 Silverchair:474198 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002944 Silverchair:474198 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Food Iron Absorption: A Comparison of Vegetable and Animal Foods The American Society of Hematology American Society of Hematology 10.1182/blood.V33.3.430.430 Silverchair:38824 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Food Iron Absorption: A Comparison of Vegetable and Animal Foods The American Society of Hematology American Society of Hematology 10.1182/blood.V33.3.430.430 Silverchair:38824 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Food Iron Absorption: A Comparison of Vegetable and Animal Foods The American Society of Hematology American Society of Hematology 10.1182/blood.V33.3.430.430 Silverchair:38824 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Food Iron Absorption: A Comparison of Vegetable and Animal Foods The American Society of Hematology American Society of Hematology 10.1182/blood.V33.3.430.430 Silverchair:38824 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Forced miR-146a expression causes autoimmune lymphoproliferative syndrome in mice via downregulation of Fas in germinal center B cells The American Society of Hematology American Society of Hematology 10.1182/blood-2012-08-452425 Silverchair:31643 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Forced miR-146a expression causes autoimmune lymphoproliferative syndrome in mice via downregulation of Fas in germinal center B cells The American Society of Hematology American Society of Hematology 10.1182/blood-2012-08-452425 Silverchair:31643 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Forced miR-146a expression causes autoimmune lymphoproliferative syndrome in mice via downregulation of Fas in germinal center B cells The American Society of Hematology American Society of Hematology 10.1182/blood-2012-08-452425 Silverchair:31643 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Forced miR-146a expression causes autoimmune lymphoproliferative syndrome in mice via downregulation of Fas in germinal center B cells The American Society of Hematology American Society of Hematology 10.1182/blood-2012-08-452425 Silverchair:31643 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Fostamatinib for the treatment of chronic immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-852491 Silverchair:273805 Total_Item_Investigations 5 0 0 4 0 0 1 0 0 0 0 0 0 Fostamatinib for the treatment of chronic immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-852491 Silverchair:273805 Total_Item_Requests 5 0 0 4 0 0 1 0 0 0 0 0 0 Fostamatinib for the treatment of chronic immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-852491 Silverchair:273805 Unique_Item_Investigations 3 0 0 2 0 0 1 0 0 0 0 0 0 Fostamatinib for the treatment of chronic immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-852491 Silverchair:273805 Unique_Item_Requests 3 0 0 2 0 0 1 0 0 0 0 0 0 "Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia: Initial Results of the Multicenter, Open-Label Extension Period of the Soar Phase 2 Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110483 Silverchair:264686 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia: Initial Results of the Multicenter, Open-Label Extension Period of the Soar Phase 2 Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110483 Silverchair:264686 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia: Initial Results of the Multicenter, Open-Label Extension Period of the Soar Phase 2 Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110483 Silverchair:264686 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia: Initial Results of the Multicenter, Open-Label Extension Period of the Soar Phase 2 Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110483 Silverchair:264686 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Four-Factor Prothrombin Complex Concentrate (4F-PCC) Is Superior to Three-Factor Prothombin Comlex Concentrates (3F-PCC) for Reversal of Coumarin Anticoagulation The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1472.1472 Silverchair:88582 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Four-Factor Prothrombin Complex Concentrate (4F-PCC) Is Superior to Three-Factor Prothombin Comlex Concentrates (3F-PCC) for Reversal of Coumarin Anticoagulation The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1472.1472 Silverchair:88582 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Four-Factor Prothrombin Complex Concentrate (4F-PCC) Is Superior to Three-Factor Prothombin Comlex Concentrates (3F-PCC) for Reversal of Coumarin Anticoagulation The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1472.1472 Silverchair:88582 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Four-Factor Prothrombin Complex Concentrate (4F-PCC) Is Superior to Three-Factor Prothombin Comlex Concentrates (3F-PCC) for Reversal of Coumarin Anticoagulation The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1472.1472 Silverchair:88582 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-882944 Silverchair:272754 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-882944 Silverchair:272754 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-882944 Silverchair:272754 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-882944 Silverchair:272754 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-399337 Silverchair:105563 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 "Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-399337 Silverchair:105563 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 "Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-399337 Silverchair:105563 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 "Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-399337 Silverchair:105563 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Frequency of Arterial Thromboemobolic Events in Patients with Cancer Associated Venous Thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136101 Silverchair:473182 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Frequency of Arterial Thromboemobolic Events in Patients with Cancer Associated Venous Thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136101 Silverchair:473182 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Frequency of Arterial Thromboemobolic Events in Patients with Cancer Associated Venous Thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136101 Silverchair:473182 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Frequency of Arterial Thromboemobolic Events in Patients with Cancer Associated Venous Thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136101 Silverchair:473182 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Frequency of NUP214-ABL1 Oncogene in Patients with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Analysis of the Activity of Imatinib and Nilotinib in NUP214-ABL1-Expressing T-ALL Cell Lines. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.710.710 Silverchair:129857 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Frequency of NUP214-ABL1 Oncogene in Patients with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Analysis of the Activity of Imatinib and Nilotinib in NUP214-ABL1-Expressing T-ALL Cell Lines. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.710.710 Silverchair:129857 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Frequency of NUP214-ABL1 Oncogene in Patients with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Analysis of the Activity of Imatinib and Nilotinib in NUP214-ABL1-Expressing T-ALL Cell Lines. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.710.710 Silverchair:129857 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Frequency of NUP214-ABL1 Oncogene in Patients with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Analysis of the Activity of Imatinib and Nilotinib in NUP214-ABL1-Expressing T-ALL Cell Lines. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.710.710 Silverchair:129857 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2 The American Society of Hematology American Society of Hematology 10.1182/blood.2021012217 Silverchair:475972 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2 The American Society of Hematology American Society of Hematology 10.1182/blood.2021012217 Silverchair:475972 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003083 Silverchair:469794 Total_Item_Investigations 4 0 0 0 1 0 0 0 0 2 1 0 0 Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003083 Silverchair:469794 Total_Item_Requests 4 0 0 0 1 0 0 0 0 2 1 0 0 Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003083 Silverchair:469794 Unique_Item_Investigations 3 0 0 0 1 0 0 0 0 1 1 0 0 Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003083 Silverchair:469794 Unique_Item_Requests 3 0 0 0 1 0 0 0 0 1 1 0 0 Frequent genetic alterations in immune checkpoint–related genes in intravascular large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020007245 Silverchair:474768 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Frequent genetic alterations in immune checkpoint–related genes in intravascular large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020007245 Silverchair:474768 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Frequent genetic alterations in immune checkpoint–related genes in intravascular large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020007245 Silverchair:474768 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Frequent genetic alterations in immune checkpoint–related genes in intravascular large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020007245 Silverchair:474768 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/hematology.2019001318 Silverchair:422631 Total_Item_Investigations 4 0 0 4 0 0 0 0 0 0 0 0 0 From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/hematology.2019001318 Silverchair:422631 Total_Item_Requests 4 0 0 4 0 0 0 0 0 0 0 0 0 From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/hematology.2019001318 Silverchair:422631 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/hematology.2019001318 Silverchair:422631 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 From the inside: GVHD and glucose metabolism The American Society of Hematology American Society of Hematology 10.1182/blood.2020008541 Silverchair:474793 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 From the inside: GVHD and glucose metabolism The American Society of Hematology American Society of Hematology 10.1182/blood.2020008541 Silverchair:474793 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 From the inside: GVHD and glucose metabolism The American Society of Hematology American Society of Hematology 10.1182/blood.2020008541 Silverchair:474793 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 From the inside: GVHD and glucose metabolism The American Society of Hematology American Society of Hematology 10.1182/blood.2020008541 Silverchair:474793 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-787200 Silverchair:36593 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-787200 Silverchair:36593 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-787200 Silverchair:36593 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-787200 Silverchair:36593 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Frontline Therapy with Bendamustine and Rituximab (BR) in Follicular Lymphoma: Prognosis Among Patients with Progression of Disease By 24 Months (POD24) Is Poor with Majority Having Transformed Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113675 Silverchair:263889 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Frontline Therapy with Bendamustine and Rituximab (BR) in Follicular Lymphoma: Prognosis Among Patients with Progression of Disease By 24 Months (POD24) Is Poor with Majority Having Transformed Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113675 Silverchair:263889 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Frontline Therapy with Bendamustine and Rituximab (BR) in Follicular Lymphoma: Prognosis Among Patients with Progression of Disease By 24 Months (POD24) Is Poor with Majority Having Transformed Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113675 Silverchair:263889 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Frontline Therapy with Bendamustine and Rituximab (BR) in Follicular Lymphoma: Prognosis Among Patients with Progression of Disease By 24 Months (POD24) Is Poor with Majority Having Transformed Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113675 Silverchair:263889 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age = 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126044 Silverchair:424071 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age = 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126044 Silverchair:424071 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age = 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126044 Silverchair:424071 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age = 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126044 Silverchair:424071 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65 years) Patients with Mantle Cell Lymphoma (MCL) - Results from a Phase II Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125800 Silverchair:424078 Total_Item_Investigations 3 1 0 0 0 0 0 0 0 0 0 1 1 Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65 years) Patients with Mantle Cell Lymphoma (MCL) - Results from a Phase II Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125800 Silverchair:424078 Total_Item_Requests 3 1 0 0 0 0 0 0 0 0 0 1 1 Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65 years) Patients with Mantle Cell Lymphoma (MCL) - Results from a Phase II Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125800 Silverchair:424078 Unique_Item_Investigations 3 1 0 0 0 0 0 0 0 0 0 1 1 Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65 years) Patients with Mantle Cell Lymphoma (MCL) - Results from a Phase II Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125800 Silverchair:424078 Unique_Item_Requests 3 1 0 0 0 0 0 0 0 0 0 1 1 "FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003604 Silverchair:475849 Total_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 "FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003604 Silverchair:475849 Total_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 "FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003604 Silverchair:475849 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 "FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003604 Silverchair:475849 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 "Full Doses of Crenolanib, a Type I FLT3 Inhibitor, Can be Safely Administered in AML Patients Post Allogeneic Stem Cell Transplant" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4359.4359 Silverchair:136007 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Full Doses of Crenolanib, a Type I FLT3 Inhibitor, Can be Safely Administered in AML Patients Post Allogeneic Stem Cell Transplant" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4359.4359 Silverchair:136007 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Full Doses of Crenolanib, a Type I FLT3 Inhibitor, Can be Safely Administered in AML Patients Post Allogeneic Stem Cell Transplant" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4359.4359 Silverchair:136007 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Full Doses of Crenolanib, a Type I FLT3 Inhibitor, Can be Safely Administered in AML Patients Post Allogeneic Stem Cell Transplant" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4359.4359 Silverchair:136007 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Full reconstitution of human platelets in humanized mice after macrophage depletion The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-407890 Silverchair:30831 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Full reconstitution of human platelets in humanized mice after macrophage depletion The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-407890 Silverchair:30831 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Full reconstitution of human platelets in humanized mice after macrophage depletion The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-407890 Silverchair:30831 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Full reconstitution of human platelets in humanized mice after macrophage depletion The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-407890 Silverchair:30831 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117729 Silverchair:262624 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117729 Silverchair:262624 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117729 Silverchair:262624 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117729 Silverchair:262624 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Functional analysis of the BMP9 response of ALK1 mutants from HHT2 patients: a diagnostic tool for novel ACVRL1 mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-276881 Silverchair:103897 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Functional analysis of the BMP9 response of ALK1 mutants from HHT2 patients: a diagnostic tool for novel ACVRL1 mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-276881 Silverchair:103897 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Functional analysis of the BMP9 response of ALK1 mutants from HHT2 patients: a diagnostic tool for novel ACVRL1 mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-276881 Silverchair:103897 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Functional analysis of the BMP9 response of ALK1 mutants from HHT2 patients: a diagnostic tool for novel ACVRL1 mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-276881 Silverchair:103897 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Functional architecture of Weibel-Palade bodies The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-267492 Silverchair:20974 Total_Item_Investigations 6 6 0 0 0 0 0 0 0 0 0 0 0 Functional architecture of Weibel-Palade bodies The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-267492 Silverchair:20974 Total_Item_Requests 6 6 0 0 0 0 0 0 0 0 0 0 0 Functional architecture of Weibel-Palade bodies The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-267492 Silverchair:20974 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Functional architecture of Weibel-Palade bodies The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-267492 Silverchair:20974 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003080 Silverchair:475596 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003080 Silverchair:475596 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003080 Silverchair:475596 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003080 Silverchair:475596 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Functional study of the vitamin K cycle in mammalian cells The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-304303 Silverchair:19576 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Functional study of the vitamin K cycle in mammalian cells The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-304303 Silverchair:19576 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Functional study of the vitamin K cycle in mammalian cells The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-304303 Silverchair:19576 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Functional study of the vitamin K cycle in mammalian cells The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-304303 Silverchair:19576 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Functions of BET proteins in erythroid gene expression The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-607309 Silverchair:33801 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Functions of BET proteins in erythroid gene expression The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-607309 Silverchair:33801 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Functions of BET proteins in erythroid gene expression The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-607309 Silverchair:33801 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Functions of BET proteins in erythroid gene expression The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-607309 Silverchair:33801 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Fundamentals of immunology for understanding immunotherapy for lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002537 Silverchair:474233 Total_Item_Investigations 6 0 0 3 3 0 0 0 0 0 0 0 0 Fundamentals of immunology for understanding immunotherapy for lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002537 Silverchair:474233 Total_Item_Requests 6 0 0 3 3 0 0 0 0 0 0 0 0 Fundamentals of immunology for understanding immunotherapy for lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002537 Silverchair:474233 Unique_Item_Investigations 2 0 0 1 1 0 0 0 0 0 0 0 0 Fundamentals of immunology for understanding immunotherapy for lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002537 Silverchair:474233 Unique_Item_Requests 2 0 0 1 1 0 0 0 0 0 0 0 0 Fundamentals of immunology for understanding immunotherapy for lymphoma The American Society of Hematology American Society of Hematology 10.1182/hematology.2020002537 Silverchair:474353 Total_Item_Investigations 3 1 0 0 2 0 0 0 0 0 0 0 0 Fundamentals of immunology for understanding immunotherapy for lymphoma The American Society of Hematology American Society of Hematology 10.1182/hematology.2020002537 Silverchair:474353 Total_Item_Requests 3 1 0 0 2 0 0 0 0 0 0 0 0 Fundamentals of immunology for understanding immunotherapy for lymphoma The American Society of Hematology American Society of Hematology 10.1182/hematology.2020002537 Silverchair:474353 Unique_Item_Investigations 2 1 0 0 1 0 0 0 0 0 0 0 0 Fundamentals of immunology for understanding immunotherapy for lymphoma The American Society of Hematology American Society of Hematology 10.1182/hematology.2020002537 Silverchair:474353 Unique_Item_Requests 2 1 0 0 1 0 0 0 0 0 0 0 0 Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32) The American Society of Hematology American Society of Hematology 10.1182/blood-2004-12-4897 Silverchair:19668 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32) The American Society of Hematology American Society of Hematology 10.1182/blood-2004-12-4897 Silverchair:19668 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32) The American Society of Hematology American Society of Hematology 10.1182/blood-2004-12-4897 Silverchair:19668 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32) The American Society of Hematology American Society of Hematology 10.1182/blood-2004-12-4897 Silverchair:19668 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Future of CAR T cells in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000111 Silverchair:474358 Total_Item_Investigations 11 4 1 5 0 0 0 1 0 0 0 0 0 Future of CAR T cells in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000111 Silverchair:474358 Total_Item_Requests 10 4 1 4 0 0 0 1 0 0 0 0 0 Future of CAR T cells in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000111 Silverchair:474358 Unique_Item_Investigations 7 2 1 3 0 0 0 1 0 0 0 0 0 Future of CAR T cells in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000111 Silverchair:474358 Unique_Item_Requests 7 2 1 3 0 0 0 1 0 0 0 0 0 "GADD45g acts as a novel tumor suppressor, and its activation suggests new combination regimens for the treatment of AML" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008229 Silverchair:475900 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 "GADD45g acts as a novel tumor suppressor, and its activation suggests new combination regimens for the treatment of AML" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008229 Silverchair:475900 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Gardos channelopathy: functional analysis of a novel KCNN4 variant American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003285 Silverchair:474745 Total_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 Gardos channelopathy: functional analysis of a novel KCNN4 variant American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003285 Silverchair:474745 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Gardos channelopathy: functional analysis of a novel KCNN4 variant American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003285 Silverchair:474745 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Gardos channelopathy: functional analysis of a novel KCNN4 variant American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003285 Silverchair:474745 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 "Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-06-228015 Silverchair:27179 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 "Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-06-228015 Silverchair:27179 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 "Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-06-228015 Silverchair:27179 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-06-228015 Silverchair:27179 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Gastrointestinal (GI) Involvement with Non-Hodgkin's Lymphoma (NHL) Impacts Outcome; A Retrospective Single Tertiary Care Center Analysis of Clinico-Pathologic Characteristics Provides an Alternate Insight to Presentation and Outcome The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127152 Silverchair:425260 Total_Item_Investigations 6 6 0 0 0 0 0 0 0 0 0 0 0 Gastrointestinal (GI) Involvement with Non-Hodgkin's Lymphoma (NHL) Impacts Outcome; A Retrospective Single Tertiary Care Center Analysis of Clinico-Pathologic Characteristics Provides an Alternate Insight to Presentation and Outcome The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127152 Silverchair:425260 Total_Item_Requests 6 6 0 0 0 0 0 0 0 0 0 0 0 Gastrointestinal (GI) Involvement with Non-Hodgkin's Lymphoma (NHL) Impacts Outcome; A Retrospective Single Tertiary Care Center Analysis of Clinico-Pathologic Characteristics Provides an Alternate Insight to Presentation and Outcome The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127152 Silverchair:425260 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Gastrointestinal (GI) Involvement with Non-Hodgkin's Lymphoma (NHL) Impacts Outcome; A Retrospective Single Tertiary Care Center Analysis of Clinico-Pathologic Characteristics Provides an Alternate Insight to Presentation and Outcome The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127152 Silverchair:425260 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137669 Silverchair:471701 Total_Item_Investigations 2 0 1 0 0 1 0 0 0 0 0 0 0 "Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137669 Silverchair:471701 Total_Item_Requests 2 0 1 0 0 1 0 0 0 0 0 0 0 "Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137669 Silverchair:471701 Unique_Item_Investigations 2 0 1 0 0 1 0 0 0 0 0 0 0 "Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137669 Silverchair:471701 Unique_Item_Requests 2 0 1 0 0 1 0 0 0 0 0 0 0 GATA factor mutations in hematologic disease The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-687889 Silverchair:36433 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 GATA factor mutations in hematologic disease The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-687889 Silverchair:36433 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 GATA factor mutations in hematologic disease The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-687889 Silverchair:36433 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 GATA factor mutations in hematologic disease The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-687889 Silverchair:36433 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 GATA2 finds its macrophage niche The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-362772 Silverchair:28630 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 GATA2 finds its macrophage niche The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-362772 Silverchair:28630 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 GATA2 finds its macrophage niche The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-362772 Silverchair:28630 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 GATA2 finds its macrophage niche The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-362772 Silverchair:28630 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Gaucher disease and other storage disorders The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.13.3797921 Silverchair:83843 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Gaucher disease and other storage disorders The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.13.3797921 Silverchair:83843 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Gaucher disease and other storage disorders The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.13.3797921 Silverchair:83843 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Gaucher disease and other storage disorders The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.13.3797921 Silverchair:83843 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 GDF11 is not the target of luspatercept The American Society of Hematology American Society of Hematology 10.1182/blood.2019001983 Silverchair:260736 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 GDF11 is not the target of luspatercept The American Society of Hematology American Society of Hematology 10.1182/blood.2019001983 Silverchair:260736 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 GDF11 is not the target of luspatercept The American Society of Hematology American Society of Hematology 10.1182/blood.2019001983 Silverchair:260736 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 GDF11 is not the target of luspatercept The American Society of Hematology American Society of Hematology 10.1182/blood.2019001983 Silverchair:260736 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-246470 Silverchair:26813 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-246470 Silverchair:26813 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-246470 Silverchair:26813 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-246470 Silverchair:26813 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Gender differences in question-asking at the 2019 American Society of Hematology Annual Meeting American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002714 Silverchair:474104 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Gender differences in question-asking at the 2019 American Society of Hematology Annual Meeting American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002714 Silverchair:474104 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Gender differences in question-asking at the 2019 American Society of Hematology Annual Meeting American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002714 Silverchair:474104 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Gender differences in question-asking at the 2019 American Society of Hematology Annual Meeting American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002714 Silverchair:474104 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2005-11-012450 Silverchair:22518 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2005-11-012450 Silverchair:22518 Total_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2005-11-012450 Silverchair:22518 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2005-11-012450 Silverchair:22518 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant–associated ALCL The American Society of Hematology American Society of Hematology 10.1182/blood.2019001904 Silverchair:429193 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant–associated ALCL The American Society of Hematology American Society of Hematology 10.1182/blood.2019001904 Silverchair:429193 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant–associated ALCL The American Society of Hematology American Society of Hematology 10.1182/blood.2019001904 Silverchair:429193 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant–associated ALCL The American Society of Hematology American Society of Hematology 10.1182/blood.2019001904 Silverchair:429193 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-810028 Silverchair:37216 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-810028 Silverchair:37216 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-810028 Silverchair:37216 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-810028 Silverchair:37216 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Gene editing in hemophilia: a “CRISPR” choice? The American Society of Hematology American Society of Hematology 10.1182/blood.2019001180 Silverchair:272762 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Gene editing in hemophilia: a “CRISPR” choice? The American Society of Hematology American Society of Hematology 10.1182/blood.2019001180 Silverchair:272762 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Gene editing in hemophilia: a “CRISPR” choice? The American Society of Hematology American Society of Hematology 10.1182/blood.2019001180 Silverchair:272762 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Gene editing in hemophilia: a “CRISPR” choice? The American Society of Hematology American Society of Hematology 10.1182/blood.2019001180 Silverchair:272762 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Gene Editing of KLF1 to Cure Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142339 Silverchair:470532 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Gene Editing of KLF1 to Cure Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142339 Silverchair:470532 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Gene Editing of KLF1 to Cure Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142339 Silverchair:470532 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Gene Editing of KLF1 to Cure Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142339 Silverchair:470532 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Gene expression and risk of leukemic transformation in myelodysplasia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-783050 Silverchair:36877 Total_Item_Investigations 3 0 0 0 3 0 0 0 0 0 0 0 0 Gene expression and risk of leukemic transformation in myelodysplasia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-783050 Silverchair:36877 Total_Item_Requests 3 0 0 0 3 0 0 0 0 0 0 0 0 Gene expression and risk of leukemic transformation in myelodysplasia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-783050 Silverchair:36877 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Gene expression and risk of leukemic transformation in myelodysplasia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-783050 Silverchair:36877 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Gene expression at a single-molecule level: implications for myelodysplastic syndromes and acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019004261 Silverchair:476230 No_License 1 0 0 0 0 0 0 1 0 0 0 0 0 Gene expression at a single-molecule level: implications for myelodysplastic syndromes and acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019004261 Silverchair:476230 Total_Item_Investigations 3 0 0 0 0 0 0 3 0 0 0 0 0 Gene expression at a single-molecule level: implications for myelodysplastic syndromes and acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019004261 Silverchair:476230 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-218560 Silverchair:26710 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-218560 Silverchair:26710 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-218560 Silverchair:26710 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-218560 Silverchair:26710 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Gene expression patterns in blood leukocytes discriminate patients with acute infections The American Society of Hematology American Society of Hematology 10.1182/blood-2006-02-002477 Silverchair:23236 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Gene expression patterns in blood leukocytes discriminate patients with acute infections The American Society of Hematology American Society of Hematology 10.1182/blood-2006-02-002477 Silverchair:23236 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Gene expression patterns in blood leukocytes discriminate patients with acute infections The American Society of Hematology American Society of Hematology 10.1182/blood-2006-02-002477 Silverchair:23236 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Gene expression patterns in blood leukocytes discriminate patients with acute infections The American Society of Hematology American Society of Hematology 10.1182/blood-2006-02-002477 Silverchair:23236 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003614 Silverchair:475394 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003614 Silverchair:475394 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003614 Silverchair:475394 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003614 Silverchair:475394 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development The American Society of Hematology American Society of Hematology 10.1182/blood-2002-06-1737 Silverchair:88867 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development The American Society of Hematology American Society of Hematology 10.1182/blood-2002-06-1737 Silverchair:88867 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development The American Society of Hematology American Society of Hematology 10.1182/blood-2002-06-1737 Silverchair:88867 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development The American Society of Hematology American Society of Hematology 10.1182/blood-2002-06-1737 Silverchair:88867 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Gene expression–based discovery of atovaquone as a STAT3 inhibitor and anticancer agent The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-660506 Silverchair:35647 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 0 3 0 0 Gene expression–based discovery of atovaquone as a STAT3 inhibitor and anticancer agent The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-660506 Silverchair:35647 Total_Item_Requests 3 0 0 0 0 0 0 0 0 0 3 0 0 Gene expression–based discovery of atovaquone as a STAT3 inhibitor and anticancer agent The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-660506 Silverchair:35647 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Gene expression–based discovery of atovaquone as a STAT3 inhibitor and anticancer agent The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-660506 Silverchair:35647 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Gene therapy for hemophilia The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000007 Silverchair:422595 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Gene therapy for hemophilia The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000007 Silverchair:422595 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Gene therapy for hemophilia The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000007 Silverchair:422595 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Gene therapy for hemophilia The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000007 Silverchair:422595 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Gene Therapy For Hemophilia B Using CB 2679d-GT: A Novel Factor IX Variant With Higher Potency Than Factor IX Padua The American Society of Hematology American Society of Hematology 10.1182/blood.2020006005 Silverchair:475577 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Gene Therapy For Hemophilia B Using CB 2679d-GT: A Novel Factor IX Variant With Higher Potency Than Factor IX Padua The American Society of Hematology American Society of Hematology 10.1182/blood.2020006005 Silverchair:475577 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Gene Therapy For Hemophilia B Using CB 2679d-GT: A Novel Factor IX Variant With Higher Potency Than Factor IX Padua The American Society of Hematology American Society of Hematology 10.1182/blood.2020006005 Silverchair:475577 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Gene Therapy For Hemophilia B Using CB 2679d-GT: A Novel Factor IX Variant With Higher Potency Than Factor IX Padua The American Society of Hematology American Society of Hematology 10.1182/blood.2020006005 Silverchair:475577 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues" The American Society of Hematology American Society of Hematology 10.1182/blood.2019003777 Silverchair:476350 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 3 0 0 0 "Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues" The American Society of Hematology American Society of Hematology 10.1182/blood.2019003777 Silverchair:476350 Unique_Item_Investigations 2 0 0 0 0 0 0 0 0 2 0 0 0 Gene therapy in hemophilia A: a cost-effectiveness analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018021345 Silverchair:16245 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Gene therapy in hemophilia A: a cost-effectiveness analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018021345 Silverchair:16245 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Gene therapy in hemophilia A: a cost-effectiveness analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018021345 Silverchair:16245 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Gene therapy in hemophilia A: a cost-effectiveness analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018021345 Silverchair:16245 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Generation of a Half-Life Extended Anti-CD19 BiTE® Antibody Construct Compatible with Once-Weekly Dosing for Treatment of CD19-Positive Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2815.2815 Silverchair:80433 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Generation of a Half-Life Extended Anti-CD19 BiTE® Antibody Construct Compatible with Once-Weekly Dosing for Treatment of CD19-Positive Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2815.2815 Silverchair:80433 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Generation of a Half-Life Extended Anti-CD19 BiTE® Antibody Construct Compatible with Once-Weekly Dosing for Treatment of CD19-Positive Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2815.2815 Silverchair:80433 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Generation of a Half-Life Extended Anti-CD19 BiTE® Antibody Construct Compatible with Once-Weekly Dosing for Treatment of CD19-Positive Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2815.2815 Silverchair:80433 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Generation of Half-Life Extended Anti-BCMA Bite® Antibody Construct Compatible with Once-Weekly Dosing for Treatment of Multiple Myeloma (MM) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5389.5389 Silverchair:115537 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Generation of Half-Life Extended Anti-BCMA Bite® Antibody Construct Compatible with Once-Weekly Dosing for Treatment of Multiple Myeloma (MM) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5389.5389 Silverchair:115537 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Generation of Half-Life Extended Anti-BCMA Bite® Antibody Construct Compatible with Once-Weekly Dosing for Treatment of Multiple Myeloma (MM) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5389.5389 Silverchair:115537 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Generation of Half-Life Extended Anti-BCMA Bite® Antibody Construct Compatible with Once-Weekly Dosing for Treatment of Multiple Myeloma (MM) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5389.5389 Silverchair:115537 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-754796 Silverchair:35981 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-754796 Silverchair:35981 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-754796 Silverchair:35981 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-754796 Silverchair:35981 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-390252 Silverchair:29978 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-390252 Silverchair:29978 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-390252 Silverchair:29978 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-390252 Silverchair:29978 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001696 Silverchair:461125 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001696 Silverchair:461125 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001696 Silverchair:461125 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001696 Silverchair:461125 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Genetic and Transcript Changesin Cereblon in IMiD-Treated Myeloma Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126828 Silverchair:427533 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Genetic and Transcript Changesin Cereblon in IMiD-Treated Myeloma Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126828 Silverchair:427533 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Genetic and Transcript Changesin Cereblon in IMiD-Treated Myeloma Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126828 Silverchair:427533 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Genetic and Transcript Changesin Cereblon in IMiD-Treated Myeloma Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126828 Silverchair:427533 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-695940 Silverchair:36324 Total_Item_Investigations 7 5 2 0 0 0 0 0 0 0 0 0 0 Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-695940 Silverchair:36324 Total_Item_Requests 6 4 2 0 0 0 0 0 0 0 0 0 0 Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-695940 Silverchair:36324 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-695940 Silverchair:36324 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Genetic inhibition of NFATC2 attenuates asparaginase hypersensitivity in mice American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002478 Silverchair:463754 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Genetic inhibition of NFATC2 attenuates asparaginase hypersensitivity in mice American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002478 Silverchair:463754 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Genetic inhibition of NFATC2 attenuates asparaginase hypersensitivity in mice American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002478 Silverchair:463754 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Genetic inhibition of NFATC2 attenuates asparaginase hypersensitivity in mice American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002478 Silverchair:463754 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001350 Silverchair:461173 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001350 Silverchair:461173 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001350 Silverchair:461173 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001350 Silverchair:461173 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Genetic predisposition to hematologic malignancies: management and surveillance The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-735290 Silverchair:37108 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Genetic predisposition to hematologic malignancies: management and surveillance The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-735290 Silverchair:37108 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Genetic predisposition to hematologic malignancies: management and surveillance The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-735290 Silverchair:37108 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Genetic predisposition to hematologic malignancies: management and surveillance The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-735290 Silverchair:37108 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Genetic predisposition to MDS: diagnosis and management The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000021 Silverchair:422566 Total_Item_Investigations 2 0 0 0 0 0 0 0 2 0 0 0 0 Genetic predisposition to MDS: diagnosis and management The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000021 Silverchair:422566 Total_Item_Requests 2 0 0 0 0 0 0 0 2 0 0 0 0 Genetic predisposition to MDS: diagnosis and management The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000021 Silverchair:422566 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Genetic predisposition to MDS: diagnosis and management The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000021 Silverchair:422566 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Genetic sequence analysis of inherited bleeding diseases The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-505511 Silverchair:32125 Total_Item_Investigations 3 0 1 2 0 0 0 0 0 0 0 0 0 Genetic sequence analysis of inherited bleeding diseases The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-505511 Silverchair:32125 Total_Item_Requests 3 0 1 2 0 0 0 0 0 0 0 0 0 Genetic sequence analysis of inherited bleeding diseases The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-505511 Silverchair:32125 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Genetic sequence analysis of inherited bleeding diseases The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-505511 Silverchair:32125 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-618587 Silverchair:35247 Total_Item_Investigations 7 5 2 0 0 0 0 0 0 0 0 0 0 Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-618587 Silverchair:35247 Total_Item_Requests 6 5 1 0 0 0 0 0 0 0 0 0 0 Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-618587 Silverchair:35247 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-618587 Silverchair:35247 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Genetics of diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-764332 Silverchair:37115 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Genetics of diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-764332 Silverchair:37115 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Genetics of diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-764332 Silverchair:37115 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Genetics of diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-764332 Silverchair:37115 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Genetics of MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-844621 Silverchair:272730 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Genetics of MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-844621 Silverchair:272730 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Genetics of MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-844621 Silverchair:272730 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Genetics of MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-844621 Silverchair:272730 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations The American Society of Hematology American Society of Hematology 10.1182/blood.2020008471 Silverchair:469753 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations The American Society of Hematology American Society of Hematology 10.1182/blood.2020008471 Silverchair:469753 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Genetics of progression from MDS to secondary leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019000942 Silverchair:456027 Total_Item_Investigations 7 0 0 0 2 2 0 3 0 0 0 0 0 Genetics of progression from MDS to secondary leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019000942 Silverchair:456027 Total_Item_Requests 3 0 0 0 0 0 0 3 0 0 0 0 0 Genetics of progression from MDS to secondary leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019000942 Silverchair:456027 Unique_Item_Investigations 4 0 0 0 1 1 0 2 0 0 0 0 0 Genetics of progression from MDS to secondary leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019000942 Silverchair:456027 Unique_Item_Requests 2 0 0 0 0 0 0 2 0 0 0 0 0 Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-440107 Silverchair:30549 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-440107 Silverchair:30549 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-440107 Silverchair:30549 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-440107 Silverchair:30549 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Genome-wide identification of Ikaros targets elucidates its contribution to mouse B-cell lineage specification and pre-B–cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2012-08-450114 Silverchair:31183 Total_Item_Investigations 6 2 3 1 0 0 0 0 0 0 0 0 0 Genome-wide identification of Ikaros targets elucidates its contribution to mouse B-cell lineage specification and pre-B–cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2012-08-450114 Silverchair:31183 Total_Item_Requests 6 2 3 1 0 0 0 0 0 0 0 0 0 Genome-wide identification of Ikaros targets elucidates its contribution to mouse B-cell lineage specification and pre-B–cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2012-08-450114 Silverchair:31183 Unique_Item_Investigations 5 1 3 1 0 0 0 0 0 0 0 0 0 Genome-wide identification of Ikaros targets elucidates its contribution to mouse B-cell lineage specification and pre-B–cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2012-08-450114 Silverchair:31183 Unique_Item_Requests 5 1 3 1 0 0 0 0 0 0 0 0 0 Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-339705 Silverchair:28765 Total_Item_Investigations 6 1 2 3 0 0 0 0 0 0 0 0 0 Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-339705 Silverchair:28765 Total_Item_Requests 6 1 2 3 0 0 0 0 0 0 0 0 0 Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-339705 Silverchair:28765 Unique_Item_Investigations 5 1 2 2 0 0 0 0 0 0 0 0 0 Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-339705 Silverchair:28765 Unique_Item_Requests 5 1 2 2 0 0 0 0 0 0 0 0 0 Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003444 Silverchair:475395 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003444 Silverchair:475395 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003444 Silverchair:475395 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003444 Silverchair:475395 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes" The American Society of Hematology American Society of Hematology 10.1182/blood.2020005289 Silverchair:461130 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 "Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes" The American Society of Hematology American Society of Hematology 10.1182/blood.2020005289 Silverchair:461130 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 "Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes" The American Society of Hematology American Society of Hematology 10.1182/blood.2020005289 Silverchair:461130 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes" The American Society of Hematology American Society of Hematology 10.1182/blood.2020005289 Silverchair:461130 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Genomic and Immunologic Analysis of Cmaf and Hypermutated Multiple Myeloma: Implications for Immunologic Therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131274 Silverchair:423585 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Genomic and Immunologic Analysis of Cmaf and Hypermutated Multiple Myeloma: Implications for Immunologic Therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131274 Silverchair:423585 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Genomic and Immunologic Analysis of Cmaf and Hypermutated Multiple Myeloma: Implications for Immunologic Therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131274 Silverchair:423585 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Genomic and Immunologic Analysis of Cmaf and Hypermutated Multiple Myeloma: Implications for Immunologic Therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131274 Silverchair:423585 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children’s Oncology Group The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-841676 Silverchair:39461 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children’s Oncology Group The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-841676 Silverchair:39461 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children’s Oncology Group The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-841676 Silverchair:39461 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children’s Oncology Group The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-841676 Silverchair:39461 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002469 Silverchair:475050 Total_Item_Investigations 2 0 1 0 0 1 0 0 0 0 0 0 0 Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002469 Silverchair:475050 Total_Item_Requests 2 0 1 0 0 1 0 0 0 0 0 0 0 Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002469 Silverchair:475050 Unique_Item_Investigations 2 0 1 0 0 1 0 0 0 0 0 0 0 Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002469 Silverchair:475050 Unique_Item_Requests 2 0 1 0 0 1 0 0 0 0 0 0 0 Genomic landscape of megakaryopoiesis and platelet function defects The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-607952 Silverchair:34946 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Genomic landscape of megakaryopoiesis and platelet function defects The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-607952 Silverchair:34946 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Genomic landscape of megakaryopoiesis and platelet function defects The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-607952 Silverchair:34946 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Genomic landscape of megakaryopoiesis and platelet function defects The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-607952 Silverchair:34946 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Genomic Landscape of Splicing Factor Mutant Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139470 Silverchair:471724 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Genomic Landscape of Splicing Factor Mutant Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139470 Silverchair:471724 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Genomic Landscape of Splicing Factor Mutant Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139470 Silverchair:471724 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Genomic Landscape of Splicing Factor Mutant Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139470 Silverchair:471724 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Genomic Profiling Identifies Somatic Mutations Predicting Thromboembolic Risk in Patients with Solid Tumors The American Society of Hematology American Society of Hematology 10.1182/blood.2020007488 Silverchair:474387 Total_Item_Investigations 7 0 7 0 0 0 0 0 0 0 0 0 0 Genomic Profiling Identifies Somatic Mutations Predicting Thromboembolic Risk in Patients with Solid Tumors The American Society of Hematology American Society of Hematology 10.1182/blood.2020007488 Silverchair:474387 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Genomic Profiling Identifies Somatic Mutations Predicting Thromboembolic Risk in Patients with Solid Tumors The American Society of Hematology American Society of Hematology 10.1182/blood.2020007488 Silverchair:474387 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Genomic Profiling Identifies Somatic Mutations Predicting Thromboembolic Risk in Patients with Solid Tumors The American Society of Hematology American Society of Hematology 10.1182/blood.2020007488 Silverchair:474387 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Genomic Profiling of a Randomized Trial of Interferon-α versus Hydroxyurea in MPN Reveals Mutation-Specific Responses American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004856 Silverchair:476862 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Genomic Profiling of a Randomized Trial of Interferon-α versus Hydroxyurea in MPN Reveals Mutation-Specific Responses American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004856 Silverchair:476862 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020007236 Silverchair:463609 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020007236 Silverchair:463609 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Genomics of MPN progression The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000129 Silverchair:474342 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Genomics of MPN progression The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000129 Silverchair:474342 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Genomics of MPN progression The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000129 Silverchair:474342 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Genomics of MPN progression The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000129 Silverchair:474342 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000130 Silverchair:474367 Total_Item_Investigations 2 0 0 1 0 0 0 0 1 0 0 0 0 Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000130 Silverchair:474367 Total_Item_Requests 2 0 0 1 0 0 0 0 1 0 0 0 0 Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000130 Silverchair:474367 Unique_Item_Investigations 2 0 0 1 0 0 0 0 1 0 0 0 0 Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000130 Silverchair:474367 Unique_Item_Requests 2 0 0 1 0 0 0 0 1 0 0 0 0 Geographic prevalence variation and phenotype penetrance in porphyria: insights from a Chinese population database American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003150 Silverchair:474780 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Geographic prevalence variation and phenotype penetrance in porphyria: insights from a Chinese population database American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003150 Silverchair:474780 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Geographic prevalence variation and phenotype penetrance in porphyria: insights from a Chinese population database American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003150 Silverchair:474780 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Geographic prevalence variation and phenotype penetrance in porphyria: insights from a Chinese population database American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003150 Silverchair:474780 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera The American Society of Hematology American Society of Hematology 10.1182/blood.2020005792 Silverchair:463332 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera The American Society of Hematology American Society of Hematology 10.1182/blood.2020005792 Silverchair:463332 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera The American Society of Hematology American Society of Hematology 10.1182/blood.2020005792 Silverchair:463332 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera The American Society of Hematology American Society of Hematology 10.1182/blood.2020005792 Silverchair:463332 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Germline IKAROS dimerization haploinsufficiency causes hematologic cytopenias and malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2020007292 Silverchair:463485 No_License 1 0 1 0 0 0 0 0 0 0 0 0 0 Germline IKAROS dimerization haploinsufficiency causes hematologic cytopenias and malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2020007292 Silverchair:463485 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Germline IKAROS dimerization haploinsufficiency causes hematologic cytopenias and malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2020007292 Silverchair:463485 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Germline mutations in the transcription factor IKZF5 cause thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.2019000782 Silverchair:374927 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 0 0 0 3 Germline mutations in the transcription factor IKZF5 cause thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.2019000782 Silverchair:374927 Total_Item_Requests 3 0 0 0 0 0 0 0 0 0 0 0 3 Germline mutations in the transcription factor IKZF5 cause thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.2019000782 Silverchair:374927 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Germline mutations in the transcription factor IKZF5 cause thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.2019000782 Silverchair:374927 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Germline TET2 loss of function causes childhood immunodeficiency and lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020005844 Silverchair:460739 No_License 1 0 1 0 0 0 0 0 0 0 0 0 0 Germline TET2 loss of function causes childhood immunodeficiency and lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020005844 Silverchair:460739 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Germline TET2 loss of function causes childhood immunodeficiency and lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020005844 Silverchair:460739 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Germline variants in DNA repair genes, including BRCA1/2, may cause familial myeloproliferative neoplasms" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004811 Silverchair:476709 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 2 1 0 0 "Germline variants in DNA repair genes, including BRCA1/2, may cause familial myeloproliferative neoplasms" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004811 Silverchair:476709 Total_Item_Requests 3 0 0 0 0 0 0 0 0 2 1 0 0 "Germline variants in DNA repair genes, including BRCA1/2, may cause familial myeloproliferative neoplasms" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004811 Silverchair:476709 Unique_Item_Investigations 2 0 0 0 0 0 0 0 0 1 1 0 0 "Germline variants in DNA repair genes, including BRCA1/2, may cause familial myeloproliferative neoplasms" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004811 Silverchair:476709 Unique_Item_Requests 2 0 0 0 0 0 0 0 0 1 1 0 0 Getting a handle on hereditary CEBPA mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-657908 Silverchair:73102 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Getting a handle on hereditary CEBPA mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-657908 Silverchair:73102 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Getting a handle on hereditary CEBPA mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-657908 Silverchair:73102 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Getting a handle on hereditary CEBPA mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-657908 Silverchair:73102 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Getting Answers Rapidly in the Time of COVID-19: The RAPID COVID COAG Trial American Society of Hematology American Society of Hematology Silverchair:475639 Total_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 Getting Answers Rapidly in the Time of COVID-19: The RAPID COVID COAG Trial American Society of Hematology American Society of Hematology Silverchair:475639 Total_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 Getting Answers Rapidly in the Time of COVID-19: The RAPID COVID COAG Trial American Society of Hematology American Society of Hematology Silverchair:475639 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Getting Answers Rapidly in the Time of COVID-19: The RAPID COVID COAG Trial American Society of Hematology American Society of Hematology Silverchair:475639 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Getting under the skin: a new route for factor VIII? The American Society of Hematology American Society of Hematology 10.1182/blood.2020008909 Silverchair:475253 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Getting under the skin: a new route for factor VIII? The American Society of Hematology American Society of Hematology 10.1182/blood.2020008909 Silverchair:475253 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Getting under the skin: a new route for factor VIII? The American Society of Hematology American Society of Hematology 10.1182/blood.2020008909 Silverchair:475253 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Getting under the skin: a new route for factor VIII? The American Society of Hematology American Society of Hematology 10.1182/blood.2020008909 Silverchair:475253 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000919 Silverchair:441040 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000919 Silverchair:441040 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000919 Silverchair:441040 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000919 Silverchair:441040 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137251 Silverchair:470024 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137251 Silverchair:470024 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137251 Silverchair:470024 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137251 Silverchair:470024 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001991 Silverchair:461267 Total_Item_Investigations 5 5 0 0 0 0 0 0 0 0 0 0 0 Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001991 Silverchair:461267 Total_Item_Requests 5 5 0 0 0 0 0 0 0 0 0 0 0 Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001991 Silverchair:461267 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001991 Silverchair:461267 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 GlcNAc is a mast-cell chromatin-remodeling oncometabolite that promotes systemic mastocytosis aggressiveness The American Society of Hematology American Society of Hematology 10.1182/blood.2020008948 Silverchair:475943 No_License 1 0 0 0 0 0 0 1 0 0 0 0 0 GlcNAc is a mast-cell chromatin-remodeling oncometabolite that promotes systemic mastocytosis aggressiveness The American Society of Hematology American Society of Hematology 10.1182/blood.2020008948 Silverchair:475943 Total_Item_Investigations 3 0 0 0 0 0 0 3 0 0 0 0 0 GlcNAc is a mast-cell chromatin-remodeling oncometabolite that promotes systemic mastocytosis aggressiveness The American Society of Hematology American Society of Hematology 10.1182/blood.2020008948 Silverchair:475943 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Global gene expression analysis of human erythroid progenitors The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-290825 Silverchair:50974 Total_Item_Investigations 4 0 0 4 0 0 0 0 0 0 0 0 0 Global gene expression analysis of human erythroid progenitors The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-290825 Silverchair:50974 Total_Item_Requests 4 0 0 4 0 0 0 0 0 0 0 0 0 Global gene expression analysis of human erythroid progenitors The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-290825 Silverchair:50974 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Global gene expression analysis of human erythroid progenitors The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-290825 Silverchair:50974 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Global transcriptome analysis and enhancer landscape of human primary T follicular helper and T effector lymphocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-582700 Silverchair:33601 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 Global transcriptome analysis and enhancer landscape of human primary T follicular helper and T effector lymphocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-582700 Silverchair:33601 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Global transcriptome analysis and enhancer landscape of human primary T follicular helper and T effector lymphocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-582700 Silverchair:33601 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Global transcriptome analysis and enhancer landscape of human primary T follicular helper and T effector lymphocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-582700 Silverchair:33601 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans The American Society of Hematology American Society of Hematology 10.1182/blood.2020005957 Silverchair:460963 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans The American Society of Hematology American Society of Hematology 10.1182/blood.2020005957 Silverchair:460963 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans The American Society of Hematology American Society of Hematology 10.1182/blood.2020005957 Silverchair:460963 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans The American Society of Hematology American Society of Hematology 10.1182/blood.2020005957 Silverchair:460963 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Glucocorticoids Paradoxically Induce Intrinsic Steroid Resistance through a STAT5-Mediated Survival Mechanism in T-Cell Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119930 Silverchair:266044 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Glucocorticoids Paradoxically Induce Intrinsic Steroid Resistance through a STAT5-Mediated Survival Mechanism in T-Cell Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119930 Silverchair:266044 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Glucocorticoids Paradoxically Induce Intrinsic Steroid Resistance through a STAT5-Mediated Survival Mechanism in T-Cell Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119930 Silverchair:266044 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Glucocorticoids Paradoxically Induce Intrinsic Steroid Resistance through a STAT5-Mediated Survival Mechanism in T-Cell Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119930 Silverchair:266044 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Glucose metabolism impacts the spatiotemporal onset and magnitude of HSC induction in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-471201 Silverchair:31206 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Glucose metabolism impacts the spatiotemporal onset and magnitude of HSC induction in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-471201 Silverchair:31206 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Glucose metabolism impacts the spatiotemporal onset and magnitude of HSC induction in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-471201 Silverchair:31206 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Glucose metabolism impacts the spatiotemporal onset and magnitude of HSC induction in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-471201 Silverchair:31206 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Glycolytic metabolism of pathogenic T cells enables early detection of GVHD by 13C-MRI The American Society of Hematology American Society of Hematology 10.1182/blood.2020005770 Silverchair:461788 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Glycolytic metabolism of pathogenic T cells enables early detection of GVHD by 13C-MRI The American Society of Hematology American Society of Hematology 10.1182/blood.2020005770 Silverchair:461788 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Glycolytic metabolism of pathogenic T cells enables early detection of GVHD by 13C-MRI The American Society of Hematology American Society of Hematology 10.1182/blood.2020005770 Silverchair:461788 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Glycolytic metabolism of pathogenic T cells enables early detection of GVHD by 13C-MRI The American Society of Hematology American Society of Hematology 10.1182/blood.2020005770 Silverchair:461788 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 GM-CSF Blockade during Chimeric Antigen Receptor T Cell Therapy Reduces Cytokine Release Syndrome and Neurotoxicity and May Enhance Their Effector Functions The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111766 Silverchair:266067 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 GM-CSF Blockade during Chimeric Antigen Receptor T Cell Therapy Reduces Cytokine Release Syndrome and Neurotoxicity and May Enhance Their Effector Functions The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111766 Silverchair:266067 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 GM-CSF Blockade during Chimeric Antigen Receptor T Cell Therapy Reduces Cytokine Release Syndrome and Neurotoxicity and May Enhance Their Effector Functions The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111766 Silverchair:266067 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 GM-CSF Blockade during Chimeric Antigen Receptor T Cell Therapy Reduces Cytokine Release Syndrome and Neurotoxicity and May Enhance Their Effector Functions The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111766 Silverchair:266067 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001304 Silverchair:454296 Total_Item_Investigations 3 0 0 2 0 0 1 0 0 0 0 0 0 Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001304 Silverchair:454296 Total_Item_Requests 3 0 0 2 0 0 1 0 0 0 0 0 0 Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001304 Silverchair:454296 Unique_Item_Investigations 2 0 0 1 0 0 1 0 0 0 0 0 0 Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001304 Silverchair:454296 Unique_Item_Requests 2 0 0 1 0 0 1 0 0 0 0 0 0 Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001305 Silverchair:454295 Total_Item_Investigations 5 3 1 1 0 0 0 0 0 0 0 0 0 Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001305 Silverchair:454295 Total_Item_Requests 5 3 1 1 0 0 0 0 0 0 0 0 0 Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001305 Silverchair:454295 Unique_Item_Investigations 4 2 1 1 0 0 0 0 0 0 0 0 0 Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001305 Silverchair:454295 Unique_Item_Requests 4 2 1 1 0 0 0 0 0 0 0 0 0 Grading of Neurotoxicity in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Receiving Tisagenlecleucel Treatment in the JULIET Study The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118595 Silverchair:275436 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Grading of Neurotoxicity in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Receiving Tisagenlecleucel Treatment in the JULIET Study The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118595 Silverchair:275436 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Grading of Neurotoxicity in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Receiving Tisagenlecleucel Treatment in the JULIET Study The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118595 Silverchair:275436 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Grading of Neurotoxicity in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Receiving Tisagenlecleucel Treatment in the JULIET Study The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118595 Silverchair:275436 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated Following Allogeneic Transplantation in Patients with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142696 Silverchair:470010 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated Following Allogeneic Transplantation in Patients with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142696 Silverchair:470010 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated Following Allogeneic Transplantation in Patients with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142696 Silverchair:470010 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated Following Allogeneic Transplantation in Patients with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142696 Silverchair:470010 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Granulocyte colony-stimulating factor reprograms bone marrow stromal cells to actively suppress B lymphopoiesis in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2015-02-629444 Silverchair:33966 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Granulocyte colony-stimulating factor reprograms bone marrow stromal cells to actively suppress B lymphopoiesis in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2015-02-629444 Silverchair:33966 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Granulocyte colony-stimulating factor reprograms bone marrow stromal cells to actively suppress B lymphopoiesis in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2015-02-629444 Silverchair:33966 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Granulocyte colony-stimulating factor reprograms bone marrow stromal cells to actively suppress B lymphopoiesis in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2015-02-629444 Silverchair:33966 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Guideline-based indicators for adult patients with myelodysplastic syndromes American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002314 Silverchair:463455 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Guideline-based indicators for adult patients with myelodysplastic syndromes American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002314 Silverchair:463455 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Guideline-based indicators for adult patients with myelodysplastic syndromes American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002314 Silverchair:463455 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Guideline-based indicators for adult patients with myelodysplastic syndromes American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002314 Silverchair:463455 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Guidelines for determination of the number of prior lines of therapy in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-647636 Silverchair:34467 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Guidelines for determination of the number of prior lines of therapy in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-647636 Silverchair:34467 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Guidelines for determination of the number of prior lines of therapy in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-647636 Silverchair:34467 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Guidelines for determination of the number of prior lines of therapy in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-647636 Silverchair:34467 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Guidelines for quantifying iron overload The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.210 Silverchair:20421 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Guidelines for quantifying iron overload The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.210 Silverchair:20421 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Guidelines for quantifying iron overload The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.210 Silverchair:20421 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Guidelines for quantifying iron overload The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.210 Silverchair:20421 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Hacking the stem cell niche The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-777789 Silverchair:36062 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Hacking the stem cell niche The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-777789 Silverchair:36062 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Hacking the stem cell niche The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-777789 Silverchair:36062 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Hacking the stem cell niche The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-777789 Silverchair:36062 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Hairy cell leukemia in a child?! The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-857938 Silverchair:39373 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Hairy cell leukemia in a child?! The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-857938 Silverchair:39373 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Hairy cell leukemia in a child?! The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-857938 Silverchair:39373 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Hairy cell leukemia in a child?! The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-857938 Silverchair:39373 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001729 Silverchair:454557 Total_Item_Investigations 4 2 0 2 0 0 0 0 0 0 0 0 0 Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001729 Silverchair:454557 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001729 Silverchair:454557 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001729 Silverchair:454557 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000200 Silverchair:261348 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000200 Silverchair:261348 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000200 Silverchair:261348 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000200 Silverchair:261348 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Harnessing lymphoma epigenetics to improve therapies The American Society of Hematology American Society of Hematology 10.1182/hematology.2020006908 Silverchair:474352 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Harnessing lymphoma epigenetics to improve therapies The American Society of Hematology American Society of Hematology 10.1182/hematology.2020006908 Silverchair:474352 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Harnessing lymphoma epigenetics to improve therapies The American Society of Hematology American Society of Hematology 10.1182/hematology.2020006908 Silverchair:474352 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Harnessing lymphoma epigenetics to improve therapies The American Society of Hematology American Society of Hematology 10.1182/hematology.2020006908 Silverchair:474352 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Head-to-Head Comparison of 5-Azacitidine Versus Decitabine for the Treatment of Myelodysplastic Syndrome. The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.2843.2843 Silverchair:102624 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Head-to-Head Comparison of 5-Azacitidine Versus Decitabine for the Treatment of Myelodysplastic Syndrome. The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.2843.2843 Silverchair:102624 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Head-to-Head Comparison of 5-Azacitidine Versus Decitabine for the Treatment of Myelodysplastic Syndrome. The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.2843.2843 Silverchair:102624 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Head-to-Head Comparison of 5-Azacitidine Versus Decitabine for the Treatment of Myelodysplastic Syndrome. The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.2843.2843 Silverchair:102624 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Health Care Costs Associated with Contemporary Chronic Myelogenous Leukemia (CML) Therapy Compared to Other Hematologic Malignancies (HEM) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124106 Silverchair:428427 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Health Care Costs Associated with Contemporary Chronic Myelogenous Leukemia (CML) Therapy Compared to Other Hematologic Malignancies (HEM) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124106 Silverchair:428427 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Health Care Costs Associated with Contemporary Chronic Myelogenous Leukemia (CML) Therapy Compared to Other Hematologic Malignancies (HEM) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124106 Silverchair:428427 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Health Care Costs Associated with Contemporary Chronic Myelogenous Leukemia (CML) Therapy Compared to Other Hematologic Malignancies (HEM) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124106 Silverchair:428427 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Health care resource utilization and cost burden of hemophilia B in the United States American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003424 Silverchair:475681 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Health care resource utilization and cost burden of hemophilia B in the United States American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003424 Silverchair:475681 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Health care resource utilization and cost burden of hemophilia B in the United States American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003424 Silverchair:475681 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Health care resource utilization and cost burden of hemophilia B in the United States American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003424 Silverchair:475681 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Healthcare Costs in Elderly Patients with Acute Myeloid Leukemia (AML) in Routine Clinical Care in the United States (US) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3459.3459 Silverchair:114586 Total_Item_Investigations 3 0 1 2 0 0 0 0 0 0 0 0 0 Healthcare Costs in Elderly Patients with Acute Myeloid Leukemia (AML) in Routine Clinical Care in the United States (US) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3459.3459 Silverchair:114586 Total_Item_Requests 3 0 1 2 0 0 0 0 0 0 0 0 0 Healthcare Costs in Elderly Patients with Acute Myeloid Leukemia (AML) in Routine Clinical Care in the United States (US) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3459.3459 Silverchair:114586 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Healthcare Costs in Elderly Patients with Acute Myeloid Leukemia (AML) in Routine Clinical Care in the United States (US) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3459.3459 Silverchair:114586 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Health-Related Quality of Life and Fatigue in Children and Adults with Pyruvate Kinase Deficiency American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004675 Silverchair:476756 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Health-Related Quality of Life and Fatigue in Children and Adults with Pyruvate Kinase Deficiency American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004675 Silverchair:476756 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Health-Related Quality of Life and Fatigue in Children and Adults with Pyruvate Kinase Deficiency American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004675 Silverchair:476756 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Health-Related Quality of Life and Fatigue in Children and Adults with Pyruvate Kinase Deficiency American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004675 Silverchair:476756 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the Medalist Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136276 Silverchair:471347 Total_Item_Investigations 2 0 1 0 0 1 0 0 0 0 0 0 0 Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the Medalist Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136276 Silverchair:471347 Total_Item_Requests 2 0 1 0 0 1 0 0 0 0 0 0 0 Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the Medalist Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136276 Silverchair:471347 Unique_Item_Investigations 2 0 1 0 0 1 0 0 0 0 0 0 0 Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the Medalist Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136276 Silverchair:471347 Unique_Item_Requests 2 0 1 0 0 1 0 0 0 0 0 0 0 Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells The American Society of Hematology American Society of Hematology 10.1182/blood.V99.9.3326 Silverchair:54147 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells The American Society of Hematology American Society of Hematology 10.1182/blood.V99.9.3326 Silverchair:54147 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells The American Society of Hematology American Society of Hematology 10.1182/blood.V99.9.3326 Silverchair:54147 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells The American Society of Hematology American Society of Hematology 10.1182/blood.V99.9.3326 Silverchair:54147 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Heavy menstrual bleeding: work-up and management The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.236 Silverchair:21050 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Heavy menstrual bleeding: work-up and management The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.236 Silverchair:21050 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Heavy menstrual bleeding: work-up and management The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.236 Silverchair:21050 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Heavy menstrual bleeding: work-up and management The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.236 Silverchair:21050 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Hedgehog regulates distinct vascular patterning events through VEGF-dependent and -independent mechanisms The American Society of Hematology American Society of Hematology 10.1182/blood-2009-12-256644 Silverchair:27510 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Hedgehog regulates distinct vascular patterning events through VEGF-dependent and -independent mechanisms The American Society of Hematology American Society of Hematology 10.1182/blood-2009-12-256644 Silverchair:27510 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Hedgehog regulates distinct vascular patterning events through VEGF-dependent and -independent mechanisms The American Society of Hematology American Society of Hematology 10.1182/blood-2009-12-256644 Silverchair:27510 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Hedgehog regulates distinct vascular patterning events through VEGF-dependent and -independent mechanisms The American Society of Hematology American Society of Hematology 10.1182/blood-2009-12-256644 Silverchair:27510 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123048 Silverchair:425745 Total_Item_Investigations 2 0 1 0 0 1 0 0 0 0 0 0 0 "Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123048 Silverchair:425745 Total_Item_Requests 2 0 1 0 0 1 0 0 0 0 0 0 0 "Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123048 Silverchair:425745 Unique_Item_Investigations 2 0 1 0 0 1 0 0 0 0 0 0 0 "Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123048 Silverchair:425745 Unique_Item_Requests 2 0 1 0 0 1 0 0 0 0 0 0 0 Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127480 Silverchair:424490 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127480 Silverchair:424490 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127480 Silverchair:424490 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127480 Silverchair:424490 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Hematological disorder associated Cxcr4-gain-of-function mutation leads to uncontrolled extrafollicular immune response The American Society of Hematology American Society of Hematology 10.1182/blood.2020007450 Silverchair:475032 Total_Item_Investigations 6 6 0 0 0 0 0 0 0 0 0 0 0 Hematological disorder associated Cxcr4-gain-of-function mutation leads to uncontrolled extrafollicular immune response The American Society of Hematology American Society of Hematology 10.1182/blood.2020007450 Silverchair:475032 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Hematological disorder associated Cxcr4-gain-of-function mutation leads to uncontrolled extrafollicular immune response The American Society of Hematology American Society of Hematology 10.1182/blood.2020007450 Silverchair:475032 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Hematological disorder associated Cxcr4-gain-of-function mutation leads to uncontrolled extrafollicular immune response The American Society of Hematology American Society of Hematology 10.1182/blood.2020007450 Silverchair:475032 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Hematopoiesis in 3 dimensions: human and murine bone marrow architecture visualized by confocal microscopy The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-268466 Silverchair:27728 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Hematopoiesis in 3 dimensions: human and murine bone marrow architecture visualized by confocal microscopy The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-268466 Silverchair:27728 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Hematopoiesis in 3 dimensions: human and murine bone marrow architecture visualized by confocal microscopy The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-268466 Silverchair:27728 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Hematopoiesis in 3 dimensions: human and murine bone marrow architecture visualized by confocal microscopy The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-268466 Silverchair:27728 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Hematopoietic Cell Transplantation with or without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1 The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.864.864 Silverchair:136445 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Hematopoietic Cell Transplantation with or without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1 The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.864.864 Silverchair:136445 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Hematopoietic Cell Transplantation with or without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1 The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.864.864 Silverchair:136445 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Hematopoietic Cell Transplantation with or without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1 The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.864.864 Silverchair:136445 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Hematopoietic findings in a patient with scurvy The American Society of Hematology American Society of Hematology 10.1182/blood.2019002677 Silverchair:429664 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Hematopoietic findings in a patient with scurvy The American Society of Hematology American Society of Hematology 10.1182/blood.2019002677 Silverchair:429664 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Hematopoietic findings in a patient with scurvy The American Society of Hematology American Society of Hematology 10.1182/blood.2019002677 Silverchair:429664 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Hematopoietic findings in a patient with scurvy The American Society of Hematology American Society of Hematology 10.1182/blood.2019002677 Silverchair:429664 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Hematopoietic growth factors American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter04 Silverchair:73721 No_License 1 0 0 0 0 0 0 0 1 0 0 0 0 Hematopoietic growth factors American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter04 Silverchair:73721 Total_Item_Investigations 2 0 0 0 0 0 0 0 2 0 0 0 0 Hematopoietic growth factors American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter04 Silverchair:73721 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Hematopoietic stem cell function in β-thalassemia is impaired and is rescued by targeting the bone marrow niche The American Society of Hematology American Society of Hematology 10.1182/blood.2019002721 Silverchair:454666 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Hematopoietic stem cell function in β-thalassemia is impaired and is rescued by targeting the bone marrow niche The American Society of Hematology American Society of Hematology 10.1182/blood.2019002721 Silverchair:454666 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Hematopoietic stem cell function in β-thalassemia is impaired and is rescued by targeting the bone marrow niche The American Society of Hematology American Society of Hematology 10.1182/blood.2019002721 Silverchair:454666 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Hematopoietic stem cell function in β-thalassemia is impaired and is rescued by targeting the bone marrow niche The American Society of Hematology American Society of Hematology 10.1182/blood.2019002721 Silverchair:454666 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders The American Society of Hematology American Society of Hematology 10.1182/asheducation-2009.1.690 Silverchair:19879 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders The American Society of Hematology American Society of Hematology 10.1182/asheducation-2009.1.690 Silverchair:19879 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders The American Society of Hematology American Society of Hematology 10.1182/asheducation-2009.1.690 Silverchair:19879 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders The American Society of Hematology American Society of Hematology 10.1182/asheducation-2009.1.690 Silverchair:19879 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Hematopoietic stem cells lacking Ott1 display aspects associated with aging and are unable to maintain quiescence during proliferative stress The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-403089 Silverchair:29964 Total_Item_Investigations 12 0 6 6 0 0 0 0 0 0 0 0 0 Hematopoietic stem cells lacking Ott1 display aspects associated with aging and are unable to maintain quiescence during proliferative stress The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-403089 Silverchair:29964 Total_Item_Requests 12 0 6 6 0 0 0 0 0 0 0 0 0 Hematopoietic stem cells lacking Ott1 display aspects associated with aging and are unable to maintain quiescence during proliferative stress The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-403089 Silverchair:29964 Unique_Item_Investigations 4 0 1 3 0 0 0 0 0 0 0 0 0 Hematopoietic stem cells lacking Ott1 display aspects associated with aging and are unable to maintain quiescence during proliferative stress The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-403089 Silverchair:29964 Unique_Item_Requests 4 0 1 3 0 0 0 0 0 0 0 0 0 Hematopoietic stem-cell behavior in nonhuman primates The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-075382 Silverchair:24174 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Hematopoietic stem-cell behavior in nonhuman primates The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-075382 Silverchair:24174 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Hematopoietic stem-cell behavior in nonhuman primates The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-075382 Silverchair:24174 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Hematopoietic stem-cell behavior in nonhuman primates The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-075382 Silverchair:24174 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Heme Excess Impairs the Maturation of Proerythroblasts From Patients with Diamond Blackfan Anemia (DBA) and 5q- Myelodysplastic Syndrome (MDS) The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.514.514 Silverchair:86874 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Heme Excess Impairs the Maturation of Proerythroblasts From Patients with Diamond Blackfan Anemia (DBA) and 5q- Myelodysplastic Syndrome (MDS) The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.514.514 Silverchair:86874 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Heme Excess Impairs the Maturation of Proerythroblasts From Patients with Diamond Blackfan Anemia (DBA) and 5q- Myelodysplastic Syndrome (MDS) The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.514.514 Silverchair:86874 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Heme Excess Impairs the Maturation of Proerythroblasts From Patients with Diamond Blackfan Anemia (DBA) and 5q- Myelodysplastic Syndrome (MDS) The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.514.514 Silverchair:86874 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-529982 Silverchair:32979 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-529982 Silverchair:32979 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-529982 Silverchair:32979 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-529982 Silverchair:32979 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Hemochromatosis mutations in the general population: iron overload progression rate The American Society of Hematology American Society of Hematology 10.1182/blood-2003-10-3564 Silverchair:18043 Total_Item_Investigations 3 0 0 1 0 0 0 0 2 0 0 0 0 Hemochromatosis mutations in the general population: iron overload progression rate The American Society of Hematology American Society of Hematology 10.1182/blood-2003-10-3564 Silverchair:18043 Total_Item_Requests 3 0 0 1 0 0 0 0 2 0 0 0 0 Hemochromatosis mutations in the general population: iron overload progression rate The American Society of Hematology American Society of Hematology 10.1182/blood-2003-10-3564 Silverchair:18043 Unique_Item_Investigations 2 0 0 1 0 0 0 0 1 0 0 0 0 Hemochromatosis mutations in the general population: iron overload progression rate The American Society of Hematology American Society of Hematology 10.1182/blood-2003-10-3564 Silverchair:18043 Unique_Item_Requests 2 0 0 1 0 0 0 0 1 0 0 0 0 Hemoglobin E Syndromes The American Society of Hematology American Society of Hematology 10.1182/asheducation-2007.1.79 Silverchair:19194 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Hemoglobin E Syndromes The American Society of Hematology American Society of Hematology 10.1182/asheducation-2007.1.79 Silverchair:19194 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Hemoglobin E Syndromes The American Society of Hematology American Society of Hematology 10.1182/asheducation-2007.1.79 Silverchair:19194 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Hemoglobin E Syndromes The American Society of Hematology American Society of Hematology 10.1182/asheducation-2007.1.79 Silverchair:19194 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Hemoglobin H disease: not necessarily a benign disorder The American Society of Hematology American Society of Hematology 10.1182/blood-2002-07-1975 Silverchair:88824 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Hemoglobin H disease: not necessarily a benign disorder The American Society of Hematology American Society of Hematology 10.1182/blood-2002-07-1975 Silverchair:88824 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Hemoglobin H disease: not necessarily a benign disorder The American Society of Hematology American Society of Hematology 10.1182/blood-2002-07-1975 Silverchair:88824 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Hemoglobin H disease: not necessarily a benign disorder The American Society of Hematology American Society of Hematology 10.1182/blood-2002-07-1975 Silverchair:88824 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin The American Society of Hematology American Society of Hematology 10.1182/blood-2007-09-111567 Silverchair:24317 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin The American Society of Hematology American Society of Hematology 10.1182/blood-2007-09-111567 Silverchair:24317 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin The American Society of Hematology American Society of Hematology 10.1182/blood-2007-09-111567 Silverchair:24317 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin The American Society of Hematology American Society of Hematology 10.1182/blood-2007-09-111567 Silverchair:24317 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Hemolytic anemias excluding hemoglobinopathies American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter08 Silverchair:74402 No_License 3 0 2 0 0 0 0 0 1 0 0 0 0 Hemolytic anemias excluding hemoglobinopathies American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter08 Silverchair:74402 Total_Item_Investigations 4 0 2 0 0 0 0 1 1 0 0 0 0 Hemolytic anemias excluding hemoglobinopathies American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter08 Silverchair:74402 Unique_Item_Investigations 3 0 1 0 0 0 0 1 1 0 0 0 0 Hemophagocytic lymphohistiocytosis in SARS-CoV-2 infection The American Society of Hematology American Society of Hematology 10.1182/blood.2020006505 Silverchair:460907 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Hemophagocytic lymphohistiocytosis in SARS-CoV-2 infection The American Society of Hematology American Society of Hematology 10.1182/blood.2020006505 Silverchair:460907 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Hemophagocytic lymphohistiocytosis in SARS-CoV-2 infection The American Society of Hematology American Society of Hematology 10.1182/blood.2020006505 Silverchair:460907 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Hemophagocytic lymphohistiocytosis in SARS-CoV-2 infection The American Society of Hematology American Society of Hematology 10.1182/blood.2020006505 Silverchair:460907 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.657 Silverchair:20988 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.657 Silverchair:20988 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.657 Silverchair:20988 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.657 Silverchair:20988 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Hemopoietic Progenitor Cells in Marrow and Spleen of Mice with Hereditary Iron Deficiency Anemia The American Society of Hematology American Society of Hematology 10.1182/blood.V32.6.908.908 Silverchair:38816 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Hemopoietic Progenitor Cells in Marrow and Spleen of Mice with Hereditary Iron Deficiency Anemia The American Society of Hematology American Society of Hematology 10.1182/blood.V32.6.908.908 Silverchair:38816 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Hemostasis stimulates lymphangiogenesis through release and activation of VEGFC The American Society of Hematology American Society of Hematology 10.1182/blood.2019001736 Silverchair:375013 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Hemostasis stimulates lymphangiogenesis through release and activation of VEGFC The American Society of Hematology American Society of Hematology 10.1182/blood.2019001736 Silverchair:375013 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Hemostasis stimulates lymphangiogenesis through release and activation of VEGFC The American Society of Hematology American Society of Hematology 10.1182/blood.2019001736 Silverchair:375013 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Hemostasis stimulates lymphangiogenesis through release and activation of VEGFC The American Society of Hematology American Society of Hematology 10.1182/blood.2019001736 Silverchair:375013 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Hemostatic defects in liver and renal dysfunction The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.168.3798232 Silverchair:83772 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Hemostatic defects in liver and renal dysfunction The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.168.3798232 Silverchair:83772 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Hemostatic defects in liver and renal dysfunction The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.168.3798232 Silverchair:83772 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Hemostatic defects in liver and renal dysfunction The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.168.3798232 Silverchair:83772 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Heparin-induced thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-709873 Silverchair:36268 Total_Item_Investigations 4 0 2 2 0 0 0 0 0 0 0 0 0 Heparin-induced thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-709873 Silverchair:36268 Total_Item_Requests 4 0 2 2 0 0 0 0 0 0 0 0 0 Heparin-induced thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-709873 Silverchair:36268 Unique_Item_Investigations 3 0 2 1 0 0 0 0 0 0 0 0 0 Heparin-induced thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-709873 Silverchair:36268 Unique_Item_Requests 3 0 2 1 0 0 0 0 0 0 0 0 0 Heparin-induced thrombocytopenia: the female factor The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-040816 Silverchair:22491 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Heparin-induced thrombocytopenia: the female factor The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-040816 Silverchair:22491 Total_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 Heparin-induced thrombocytopenia: the female factor The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-040816 Silverchair:22491 Unique_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Heparin-induced thrombocytopenia: the female factor The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-040816 Silverchair:22491 Unique_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 "Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML" The American Society of Hematology American Society of Hematology 10.1182/blood.2018862383 Silverchair:260729 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 "Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML" The American Society of Hematology American Society of Hematology 10.1182/blood.2018862383 Silverchair:260729 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML" The American Society of Hematology American Society of Hematology 10.1182/blood.2018862383 Silverchair:260729 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML" The American Society of Hematology American Society of Hematology 10.1182/blood.2018862383 Silverchair:260729 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019002907 Silverchair:454783 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019002907 Silverchair:454783 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019002907 Silverchair:454783 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019002907 Silverchair:454783 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Hepatitis C virus (HCV) infection, monoclonal immunoglobulin specific for HCV core protein, and plasma-cell malignancy" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-167569 Silverchair:24656 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Hepatitis C virus (HCV) infection, monoclonal immunoglobulin specific for HCV core protein, and plasma-cell malignancy" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-167569 Silverchair:24656 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Hepatitis C virus (HCV) infection, monoclonal immunoglobulin specific for HCV core protein, and plasma-cell malignancy" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-167569 Silverchair:24656 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Hepatitis C virus (HCV) infection, monoclonal immunoglobulin specific for HCV core protein, and plasma-cell malignancy" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-167569 Silverchair:24656 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Hepcidin Mimetic (PTG-300) Reverses Iron Deficiency While Controlling Hematocrit in Polycythemia Vera Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137304 Silverchair:471468 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Hepcidin Mimetic (PTG-300) Reverses Iron Deficiency While Controlling Hematocrit in Polycythemia Vera Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137304 Silverchair:471468 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Hepcidin Mimetic (PTG-300) Reverses Iron Deficiency While Controlling Hematocrit in Polycythemia Vera Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137304 Silverchair:471468 Unique_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Hepcidin Mimetic (PTG-300) Reverses Iron Deficiency While Controlling Hematocrit in Polycythemia Vera Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137304 Silverchair:471468 Unique_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 HERDOO2 Score: How Long to Treat With Anticoagulation? American Society of Hematology American Society of Hematology 10.1182/hem.V14.4.7468 Silverchair:462922 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 HERDOO2 Score: How Long to Treat With Anticoagulation? American Society of Hematology American Society of Hematology 10.1182/hem.V14.4.7468 Silverchair:462922 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 HERDOO2 Score: How Long to Treat With Anticoagulation? American Society of Hematology American Society of Hematology 10.1182/hem.V14.4.7468 Silverchair:462922 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 HERDOO2 Score: How Long to Treat With Anticoagulation? American Society of Hematology American Society of Hematology 10.1182/hem.V14.4.7468 Silverchair:462922 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Hereditary Hemochromatosis in an Adult Due to H63D Mutation: The Value of Estimating Iron Deposition By MRI T2* and Dissociation Between Serum Ferritin Concentration and Hepatic Iron Overload The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4891.4891 Silverchair:93690 Total_Item_Investigations 4 1 3 0 0 0 0 0 0 0 0 0 0 Hereditary Hemochromatosis in an Adult Due to H63D Mutation: The Value of Estimating Iron Deposition By MRI T2* and Dissociation Between Serum Ferritin Concentration and Hepatic Iron Overload The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4891.4891 Silverchair:93690 Total_Item_Requests 4 1 3 0 0 0 0 0 0 0 0 0 0 Hereditary Hemochromatosis in an Adult Due to H63D Mutation: The Value of Estimating Iron Deposition By MRI T2* and Dissociation Between Serum Ferritin Concentration and Hepatic Iron Overload The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4891.4891 Silverchair:93690 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Hereditary Hemochromatosis in an Adult Due to H63D Mutation: The Value of Estimating Iron Deposition By MRI T2* and Dissociation Between Serum Ferritin Concentration and Hepatic Iron Overload The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4891.4891 Silverchair:93690 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 "Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008739 Silverchair:474132 No_License 1 0 0 0 0 0 0 0 0 1 0 0 0 "Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008739 Silverchair:474132 Total_Item_Investigations 4 0 0 0 0 0 0 0 0 4 0 0 0 "Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008739 Silverchair:474132 Unique_Item_Investigations 2 0 0 0 0 0 0 0 0 2 0 0 0 Hereditary risk factors for thrombophilia and probability of venous thromboembolism during pregnancy and the puerperium The American Society of Hematology American Society of Hematology 10.1182/blood-2016-03-703728 Silverchair:35507 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Hereditary risk factors for thrombophilia and probability of venous thromboembolism during pregnancy and the puerperium The American Society of Hematology American Society of Hematology 10.1182/blood-2016-03-703728 Silverchair:35507 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Hereditary risk factors for thrombophilia and probability of venous thromboembolism during pregnancy and the puerperium The American Society of Hematology American Society of Hematology 10.1182/blood-2016-03-703728 Silverchair:35507 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Hereditary risk factors for thrombophilia and probability of venous thromboembolism during pregnancy and the puerperium The American Society of Hematology American Society of Hematology 10.1182/blood-2016-03-703728 Silverchair:35507 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Hereditary Thrombocytosis Caused By a Novel Germ-Line Mutation In The Gelsolin Gene The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.265.265 Silverchair:83249 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Hereditary Thrombocytosis Caused By a Novel Germ-Line Mutation In The Gelsolin Gene The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.265.265 Silverchair:83249 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Hereditary Thrombocytosis Caused By a Novel Germ-Line Mutation In The Gelsolin Gene The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.265.265 Silverchair:83249 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Hereditary Thrombocytosis Caused By a Novel Germ-Line Mutation In The Gelsolin Gene The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.265.265 Silverchair:83249 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Hereditary thrombocytosis not as innocent as thought? Development into acute leukemia and myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-290718 Silverchair:27975 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Hereditary thrombocytosis not as innocent as thought? Development into acute leukemia and myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-290718 Silverchair:27975 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Hereditary thrombocytosis not as innocent as thought? Development into acute leukemia and myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-290718 Silverchair:27975 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Hereditary thrombocytosis not as innocent as thought? Development into acute leukemia and myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-290718 Silverchair:27975 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2020006157 Silverchair:461781 No_License 2 0 1 1 0 0 0 0 0 0 0 0 0 Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2020006157 Silverchair:461781 Total_Item_Investigations 11 5 4 2 0 0 0 0 0 0 0 0 0 Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2020006157 Silverchair:461781 Total_Item_Requests 6 5 1 0 0 0 0 0 0 0 0 0 0 Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2020006157 Silverchair:461781 Unique_Item_Investigations 6 3 2 1 0 0 0 0 0 0 0 0 0 Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2020006157 Silverchair:461781 Unique_Item_Requests 4 3 1 0 0 0 0 0 0 0 0 0 0 Heterozygosity for Roquinsan leads to angioimmunoblastic T-cell lymphoma-like tumors in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-365130 Silverchair:105610 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Heterozygosity for Roquinsan leads to angioimmunoblastic T-cell lymphoma-like tumors in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-365130 Silverchair:105610 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Heterozygosity for Roquinsan leads to angioimmunoblastic T-cell lymphoma-like tumors in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-365130 Silverchair:105610 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Heterozygosity for Roquinsan leads to angioimmunoblastic T-cell lymphoma-like tumors in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-365130 Silverchair:105610 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002013 Silverchair:469743 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002013 Silverchair:469743 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002013 Silverchair:469743 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002013 Silverchair:469743 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Heterozygous telomerase RNA mutations found in dyskeratosis congenita and aplastic anemia reduce telomerase activity via haploinsufficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2004-05-1829 Silverchair:18984 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Heterozygous telomerase RNA mutations found in dyskeratosis congenita and aplastic anemia reduce telomerase activity via haploinsufficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2004-05-1829 Silverchair:18984 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Heterozygous telomerase RNA mutations found in dyskeratosis congenita and aplastic anemia reduce telomerase activity via haploinsufficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2004-05-1829 Silverchair:18984 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Heterozygous telomerase RNA mutations found in dyskeratosis congenita and aplastic anemia reduce telomerase activity via haploinsufficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2004-05-1829 Silverchair:18984 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 HGF receptor up-regulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro The American Society of Hematology American Society of Hematology 10.1182/blood-2002-06-1731 Silverchair:17060 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 HGF receptor up-regulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro The American Society of Hematology American Society of Hematology 10.1182/blood-2002-06-1731 Silverchair:17060 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 HGF receptor up-regulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro The American Society of Hematology American Society of Hematology 10.1182/blood-2002-06-1731 Silverchair:17060 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 HGF receptor up-regulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro The American Society of Hematology American Society of Hematology 10.1182/blood-2002-06-1731 Silverchair:17060 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-12-545087 Silverchair:32650 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 "HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-12-545087 Silverchair:32650 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-12-545087 Silverchair:32650 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-12-545087 Silverchair:32650 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 High BMP2 Expression Is a Poor Prognostic Factor and a Good Candidate to Identify CBFA2T3-GLIS2-like High-Risk Subgroup in Pediatric Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2583.2583 Silverchair:113000 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 High BMP2 Expression Is a Poor Prognostic Factor and a Good Candidate to Identify CBFA2T3-GLIS2-like High-Risk Subgroup in Pediatric Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2583.2583 Silverchair:113000 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 High BMP2 Expression Is a Poor Prognostic Factor and a Good Candidate to Identify CBFA2T3-GLIS2-like High-Risk Subgroup in Pediatric Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2583.2583 Silverchair:113000 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 High BMP2 Expression Is a Poor Prognostic Factor and a Good Candidate to Identify CBFA2T3-GLIS2-like High-Risk Subgroup in Pediatric Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2583.2583 Silverchair:113000 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127575 Silverchair:423646 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127575 Silverchair:423646 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127575 Silverchair:423646 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127575 Silverchair:423646 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 High Dose Cyclophosphamide and Pre-Treatment Disease Burden Dictate Response and Survival in a Multicenter Clinical Trial Using CD19-Specific CAR T Cells for Relapsed/Refractory B-ALL The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1326.1326 Silverchair:116388 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 High Dose Cyclophosphamide and Pre-Treatment Disease Burden Dictate Response and Survival in a Multicenter Clinical Trial Using CD19-Specific CAR T Cells for Relapsed/Refractory B-ALL The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1326.1326 Silverchair:116388 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 High Dose Cyclophosphamide and Pre-Treatment Disease Burden Dictate Response and Survival in a Multicenter Clinical Trial Using CD19-Specific CAR T Cells for Relapsed/Refractory B-ALL The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1326.1326 Silverchair:116388 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 High Dose Cyclophosphamide and Pre-Treatment Disease Burden Dictate Response and Survival in a Multicenter Clinical Trial Using CD19-Specific CAR T Cells for Relapsed/Refractory B-ALL The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1326.1326 Silverchair:116388 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "High Dose Daunorubicin Improves Survival in AML up to Age 60, Across All Cytogenetic Risk Groups Including Patients with Unfavorable Cytogenetic Risk, and FLT3-ITD Mutant AML: Updated Analyses from Eastern Cooperative Oncology Trial E1900" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.373.373 Silverchair:115105 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "High Dose Daunorubicin Improves Survival in AML up to Age 60, Across All Cytogenetic Risk Groups Including Patients with Unfavorable Cytogenetic Risk, and FLT3-ITD Mutant AML: Updated Analyses from Eastern Cooperative Oncology Trial E1900" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.373.373 Silverchair:115105 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 High Expression of Legumain in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia Is Associated with Central Nervous System Involvement The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3990.3990 Silverchair:71935 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 High Expression of Legumain in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia Is Associated with Central Nervous System Involvement The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3990.3990 Silverchair:71935 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 High Expression of Legumain in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia Is Associated with Central Nervous System Involvement The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3990.3990 Silverchair:71935 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 High Expression of Legumain in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia Is Associated with Central Nervous System Involvement The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3990.3990 Silverchair:71935 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 High factor VIII levels in venous thromboembolism show linkage to imprinted loci on chromosomes 5 and 11 The American Society of Hematology American Society of Hematology 10.1182/blood-2004-05-2018 Silverchair:20066 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 High factor VIII levels in venous thromboembolism show linkage to imprinted loci on chromosomes 5 and 11 The American Society of Hematology American Society of Hematology 10.1182/blood-2004-05-2018 Silverchair:20066 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 High factor VIII levels in venous thromboembolism show linkage to imprinted loci on chromosomes 5 and 11 The American Society of Hematology American Society of Hematology 10.1182/blood-2004-05-2018 Silverchair:20066 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 High factor VIII levels in venous thromboembolism show linkage to imprinted loci on chromosomes 5 and 11 The American Society of Hematology American Society of Hematology 10.1182/blood-2004-05-2018 Silverchair:20066 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 High frequency of NPM1 gene mutations in acute myeloid leukemia with prominent nuclear invaginations (“cuplike” nuclei) The American Society of Hematology American Society of Hematology 10.1182/blood-2006-03-014340 Silverchair:132601 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 High frequency of NPM1 gene mutations in acute myeloid leukemia with prominent nuclear invaginations (“cuplike” nuclei) The American Society of Hematology American Society of Hematology 10.1182/blood-2006-03-014340 Silverchair:132601 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 High frequency of NPM1 gene mutations in acute myeloid leukemia with prominent nuclear invaginations (“cuplike” nuclei) The American Society of Hematology American Society of Hematology 10.1182/blood-2006-03-014340 Silverchair:132601 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 High frequency of NPM1 gene mutations in acute myeloid leukemia with prominent nuclear invaginations (“cuplike” nuclei) The American Society of Hematology American Society of Hematology 10.1182/blood-2006-03-014340 Silverchair:132601 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 High frequency of clonal hematopoiesis in Erdheim-Chester disease The American Society of Hematology American Society of Hematology 10.1182/blood.2020005101 Silverchair:469615 Total_Item_Investigations 7 0 0 7 0 0 0 0 0 0 0 0 0 High frequency of clonal hematopoiesis in Erdheim-Chester disease The American Society of Hematology American Society of Hematology 10.1182/blood.2020005101 Silverchair:469615 Unique_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 High frequency of clonal hematopoiesis in Erdheim-Chester disease The American Society of Hematology American Society of Hematology 10.1182/blood.2020005101 Silverchair:469615 No_License 3 0 0 3 0 0 0 0 0 0 0 0 0 High incidence of Kaposi sarcoma–associated herpesvirus–related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease The American Society of Hematology American Society of Hematology 10.1182/blood.V99.7.2331 Silverchair:106755 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 High incidence of Kaposi sarcoma–associated herpesvirus–related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease The American Society of Hematology American Society of Hematology 10.1182/blood.V99.7.2331 Silverchair:106755 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 High incidence of Kaposi sarcoma–associated herpesvirus–related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease The American Society of Hematology American Society of Hematology 10.1182/blood.V99.7.2331 Silverchair:106755 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 High incidence of Kaposi sarcoma–associated herpesvirus–related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease The American Society of Hematology American Society of Hematology 10.1182/blood.V99.7.2331 Silverchair:106755 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 High Incidence of Peripheral Blood Plasmacytosis In Patients with Dengue Virus Infection: a Prospective Study The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2772.2772 Silverchair:112133 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 High Incidence of Peripheral Blood Plasmacytosis In Patients with Dengue Virus Infection: a Prospective Study The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2772.2772 Silverchair:112133 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 High Incidence of Peripheral Blood Plasmacytosis In Patients with Dengue Virus Infection: a Prospective Study The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2772.2772 Silverchair:112133 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 High Incidence of Peripheral Blood Plasmacytosis In Patients with Dengue Virus Infection: a Prospective Study The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2772.2772 Silverchair:112133 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia The American Society of Hematology American Society of Hematology 10.1182/blood-2003-09-3074 Silverchair:18381 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia The American Society of Hematology American Society of Hematology 10.1182/blood-2003-09-3074 Silverchair:18381 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia The American Society of Hematology American Society of Hematology 10.1182/blood-2003-09-3074 Silverchair:18381 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia The American Society of Hematology American Society of Hematology 10.1182/blood-2003-09-3074 Silverchair:18381 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 High Metabolic Heterogeneity on Baseline 18F-FDG PET/CT Predicts Worse Prognosis of Newly Diagnosed Diffuse Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124390 Silverchair:426598 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 High Metabolic Heterogeneity on Baseline 18F-FDG PET/CT Predicts Worse Prognosis of Newly Diagnosed Diffuse Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124390 Silverchair:426598 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 High Metabolic Heterogeneity on Baseline 18F-FDG PET/CT Predicts Worse Prognosis of Newly Diagnosed Diffuse Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124390 Silverchair:426598 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 High Metabolic Heterogeneity on Baseline 18F-FDG PET/CT Predicts Worse Prognosis of Newly Diagnosed Diffuse Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124390 Silverchair:426598 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-421826 Silverchair:138837 Total_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-421826 Silverchair:138837 Total_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-421826 Silverchair:138837 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-421826 Silverchair:138837 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 High Plasma Lysyloxidase Concentration Is Associated with Inferior Outcome and Extramedullary Disease in Patients with Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.935.935 Silverchair:82933 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 High Plasma Lysyloxidase Concentration Is Associated with Inferior Outcome and Extramedullary Disease in Patients with Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.935.935 Silverchair:82933 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 High Plasma Lysyloxidase Concentration Is Associated with Inferior Outcome and Extramedullary Disease in Patients with Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.935.935 Silverchair:82933 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 High Plasma Lysyloxidase Concentration Is Associated with Inferior Outcome and Extramedullary Disease in Patients with Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.935.935 Silverchair:82933 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 High prevalence of somatic MAP2K1 mutations in BRAF V600E–negative Langerhans cell histiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-577361 Silverchair:32977 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 High prevalence of somatic MAP2K1 mutations in BRAF V600E–negative Langerhans cell histiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-577361 Silverchair:32977 Total_Item_Requests 4 0 4 0 0 0 0 0 0 0 0 0 0 High prevalence of somatic MAP2K1 mutations in BRAF V600E–negative Langerhans cell histiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-577361 Silverchair:32977 Unique_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 High prevalence of somatic MAP2K1 mutations in BRAF V600E–negative Langerhans cell histiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-577361 Silverchair:32977 Unique_Item_Requests 4 0 4 0 0 0 0 0 0 0 0 0 0 High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-329441 Silverchair:29292 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-329441 Silverchair:29292 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-329441 Silverchair:29292 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-329441 Silverchair:29292 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 HIGH-2-LOW risk model to predict venous thromboembolism in allogeneic transplant patients after platelet engraftment American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003353 Silverchair:474819 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 1 2 0 0 HIGH-2-LOW risk model to predict venous thromboembolism in allogeneic transplant patients after platelet engraftment American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003353 Silverchair:474819 Total_Item_Requests 3 0 0 0 0 0 0 0 0 1 2 0 0 HIGH-2-LOW risk model to predict venous thromboembolism in allogeneic transplant patients after platelet engraftment American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003353 Silverchair:474819 Unique_Item_Investigations 2 0 0 0 0 0 0 0 0 1 1 0 0 HIGH-2-LOW risk model to predict venous thromboembolism in allogeneic transplant patients after platelet engraftment American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003353 Silverchair:474819 Unique_Item_Requests 2 0 0 0 0 0 0 0 0 1 1 0 0 High-Dose Cyclophosphamide in Highly Refractory Multiple Myeloma Patients As a Bridge to Further Novel Therapies The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5676.5676 Silverchair:95022 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 High-Dose Cyclophosphamide in Highly Refractory Multiple Myeloma Patients As a Bridge to Further Novel Therapies The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5676.5676 Silverchair:95022 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 High-Dose Cyclophosphamide in Highly Refractory Multiple Myeloma Patients As a Bridge to Further Novel Therapies The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5676.5676 Silverchair:95022 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 High-Dose Cyclophosphamide in Highly Refractory Multiple Myeloma Patients As a Bridge to Further Novel Therapies The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5676.5676 Silverchair:95022 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy? The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3989.3989 Silverchair:113925 Total_Item_Investigations 3 0 2 0 0 0 1 0 0 0 0 0 0 High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy? The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3989.3989 Silverchair:113925 Total_Item_Requests 3 0 2 0 0 0 1 0 0 0 0 0 0 High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy? The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3989.3989 Silverchair:113925 Unique_Item_Investigations 3 0 2 0 0 0 1 0 0 0 0 0 0 High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy? The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3989.3989 Silverchair:113925 Unique_Item_Requests 3 0 2 0 0 0 1 0 0 0 0 0 0 High-dose dexamethasone vs prednisone for adult ITP The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-684118 Silverchair:34888 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 High-dose dexamethasone vs prednisone for adult ITP The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-684118 Silverchair:34888 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 High-dose dexamethasone vs prednisone for adult ITP The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-684118 Silverchair:34888 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 High-dose dexamethasone vs prednisone for adult ITP The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-684118 Silverchair:34888 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-659656 Silverchair:34896 Total_Item_Investigations 3 0 0 1 0 1 0 0 0 0 1 0 0 High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-659656 Silverchair:34896 Total_Item_Requests 3 0 0 1 0 1 0 0 0 0 1 0 0 High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-659656 Silverchair:34896 Unique_Item_Investigations 3 0 0 1 0 1 0 0 0 0 1 0 0 High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-659656 Silverchair:34896 Unique_Item_Requests 3 0 0 1 0 1 0 0 0 0 1 0 0 "Higher Incidence of TTP in African Americans and Females: An Analysis of Demographics, Cost and Length of Stay in Teaching and Nonteaching Hospitals for Thrombotic Thrombocytopenic Purpura Between 1999 and 2013" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4735.4735 Silverchair:101342 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 "Higher Incidence of TTP in African Americans and Females: An Analysis of Demographics, Cost and Length of Stay in Teaching and Nonteaching Hospitals for Thrombotic Thrombocytopenic Purpura Between 1999 and 2013" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4735.4735 Silverchair:101342 Total_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 "Higher Incidence of TTP in African Americans and Females: An Analysis of Demographics, Cost and Length of Stay in Teaching and Nonteaching Hospitals for Thrombotic Thrombocytopenic Purpura Between 1999 and 2013" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4735.4735 Silverchair:101342 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 "Higher Incidence of TTP in African Americans and Females: An Analysis of Demographics, Cost and Length of Stay in Teaching and Nonteaching Hospitals for Thrombotic Thrombocytopenic Purpura Between 1999 and 2013" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4735.4735 Silverchair:101342 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology The American Society of Hematology American Society of Hematology 10.1182/blood-2017-12-820605 Silverchair:36718 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology The American Society of Hematology American Society of Hematology 10.1182/blood-2017-12-820605 Silverchair:36718 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology The American Society of Hematology American Society of Hematology 10.1182/blood-2017-12-820605 Silverchair:36718 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology The American Society of Hematology American Society of Hematology 10.1182/blood-2017-12-820605 Silverchair:36718 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-170415 Silverchair:24800 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-170415 Silverchair:24800 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-170415 Silverchair:24800 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-170415 Silverchair:24800 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors The American Society of Hematology American Society of Hematology 10.1182/blood.V96.10.3392 Silverchair:181033 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors The American Society of Hematology American Society of Hematology 10.1182/blood.V96.10.3392 Silverchair:181033 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors The American Society of Hematology American Society of Hematology 10.1182/blood.V96.10.3392 Silverchair:181033 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors The American Society of Hematology American Society of Hematology 10.1182/blood.V96.10.3392 Silverchair:181033 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Highly effective treatment of acquired immunodeficiency syndrome–related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology The American Society of Hematology American Society of Hematology 10.1182/blood-2002-11-3589 Silverchair:17011 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Highly effective treatment of acquired immunodeficiency syndrome–related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology The American Society of Hematology American Society of Hematology 10.1182/blood-2002-11-3589 Silverchair:17011 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Highly effective treatment of acquired immunodeficiency syndrome–related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology The American Society of Hematology American Society of Hematology 10.1182/blood-2002-11-3589 Silverchair:17011 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Highly effective treatment of acquired immunodeficiency syndrome–related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology The American Society of Hematology American Society of Hematology 10.1182/blood-2002-11-3589 Silverchair:17011 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Highly efficient endosomal labeling of progenitor and stem cells with large magnetic particles allows magnetic resonance imaging of single cells The American Society of Hematology American Society of Hematology 10.1182/blood-2002-12-3669 Silverchair:17349 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Highly efficient endosomal labeling of progenitor and stem cells with large magnetic particles allows magnetic resonance imaging of single cells The American Society of Hematology American Society of Hematology 10.1182/blood-2002-12-3669 Silverchair:17349 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Highly efficient endosomal labeling of progenitor and stem cells with large magnetic particles allows magnetic resonance imaging of single cells The American Society of Hematology American Society of Hematology 10.1182/blood-2002-12-3669 Silverchair:17349 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Highly efficient endosomal labeling of progenitor and stem cells with large magnetic particles allows magnetic resonance imaging of single cells The American Society of Hematology American Society of Hematology 10.1182/blood-2002-12-3669 Silverchair:17349 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Highly Efficient Multiplexed Base Editing with Minimized Off-Targets for the Development of Universal CAR-T Cells to Treat Pediatric T-ALL The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130562 Silverchair:425043 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Highly Efficient Multiplexed Base Editing with Minimized Off-Targets for the Development of Universal CAR-T Cells to Treat Pediatric T-ALL The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130562 Silverchair:425043 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Highly Efficient Multiplexed Base Editing with Minimized Off-Targets for the Development of Universal CAR-T Cells to Treat Pediatric T-ALL The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130562 Silverchair:425043 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Highly Efficient Multiplexed Base Editing with Minimized Off-Targets for the Development of Universal CAR-T Cells to Treat Pediatric T-ALL The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130562 Silverchair:425043 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4521.4521 Silverchair:101264 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4521.4521 Silverchair:101264 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4521.4521 Silverchair:101264 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4521.4521 Silverchair:101264 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 High-Resolution Binding Atlas of U2AF1 Mutants Uncovers New Complexity in Splicing Alterations and Kinetics in Myeloid Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142854 Silverchair:470056 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 High-Resolution Binding Atlas of U2AF1 Mutants Uncovers New Complexity in Splicing Alterations and Kinetics in Myeloid Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142854 Silverchair:470056 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 High-Resolution Binding Atlas of U2AF1 Mutants Uncovers New Complexity in Splicing Alterations and Kinetics in Myeloid Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142854 Silverchair:470056 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 High-Resolution Binding Atlas of U2AF1 Mutants Uncovers New Complexity in Splicing Alterations and Kinetics in Myeloid Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142854 Silverchair:470056 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-314427 Silverchair:22454 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-314427 Silverchair:22454 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-314427 Silverchair:22454 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-314427 Silverchair:22454 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-826008 Silverchair:39410 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-826008 Silverchair:39410 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-826008 Silverchair:39410 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-826008 Silverchair:39410 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000770 Silverchair:460606 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000770 Silverchair:460606 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000770 Silverchair:460606 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000770 Silverchair:460606 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125383 Silverchair:427569 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125383 Silverchair:427569 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125383 Silverchair:427569 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125383 Silverchair:427569 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 High-Yield Knowledge: The ASH Hematology Review Series American Society of Hematology American Society of Hematology 10.1182/hem.V18.4.2021415 Silverchair:476195 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 High-Yield Knowledge: The ASH Hematology Review Series American Society of Hematology American Society of Hematology 10.1182/hem.V18.4.2021415 Silverchair:476195 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 High-Yield Knowledge: The ASH Hematology Review Series American Society of Hematology American Society of Hematology 10.1182/hem.V18.4.2021415 Silverchair:476195 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 High-Yield Knowledge: The ASH Hematology Review Series American Society of Hematology American Society of Hematology 10.1182/hem.V18.4.2021415 Silverchair:476195 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000159 Silverchair:474332 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000159 Silverchair:474332 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000159 Silverchair:474332 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000159 Silverchair:474332 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-362434 Silverchair:29689 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-362434 Silverchair:29689 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-362434 Silverchair:29689 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-362434 Silverchair:29689 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-235663 Silverchair:27607 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-235663 Silverchair:27607 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-235663 Silverchair:27607 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-235663 Silverchair:27607 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Histones to the cytosol: exportin 7 is essential for normal terminal erythroid nuclear maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-537761 Silverchair:33032 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Histones to the cytosol: exportin 7 is essential for normal terminal erythroid nuclear maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-537761 Silverchair:33032 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Histones to the cytosol: exportin 7 is essential for normal terminal erythroid nuclear maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-537761 Silverchair:33032 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Histones to the cytosol: exportin 7 is essential for normal terminal erythroid nuclear maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-537761 Silverchair:33032 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Historical review: megakaryopoiesis and thrombopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2007-05-088500 Silverchair:25493 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Historical review: megakaryopoiesis and thrombopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2007-05-088500 Silverchair:25493 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Historical review: megakaryopoiesis and thrombopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2007-05-088500 Silverchair:25493 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Historical review: megakaryopoiesis and thrombopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2007-05-088500 Silverchair:25493 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004458 Silverchair:476385 Total_Item_Investigations 2 0 0 0 0 0 0 1 0 0 0 1 0 HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004458 Silverchair:476385 Total_Item_Requests 2 0 0 0 0 0 0 1 0 0 0 1 0 HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004458 Silverchair:476385 Unique_Item_Investigations 2 0 0 0 0 0 0 1 0 0 0 1 0 HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004458 Silverchair:476385 Unique_Item_Requests 2 0 0 0 0 0 0 1 0 0 0 1 0 HIV-Associated Thrombotic Thrombocytopenic Purpura The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.4677.4677 Silverchair:130621 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 HIV-Associated Thrombotic Thrombocytopenic Purpura The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.4677.4677 Silverchair:130621 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 HIV-Associated Thrombotic Thrombocytopenic Purpura The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.4677.4677 Silverchair:130621 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 HIV-Associated Thrombotic Thrombocytopenic Purpura The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.4677.4677 Silverchair:130621 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 HLA class II–restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia–derived dendritic cells to CD4+ T lymphocytes The American Society of Hematology American Society of Hematology 10.1182/blood.V98.5.1498 Silverchair:106045 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 HLA class II–restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia–derived dendritic cells to CD4+ T lymphocytes The American Society of Hematology American Society of Hematology 10.1182/blood.V98.5.1498 Silverchair:106045 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 HLA class II–restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia–derived dendritic cells to CD4+ T lymphocytes The American Society of Hematology American Society of Hematology 10.1182/blood.V98.5.1498 Silverchair:106045 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 HLA class II–restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia–derived dendritic cells to CD4+ T lymphocytes The American Society of Hematology American Society of Hematology 10.1182/blood.V98.5.1498 Silverchair:106045 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 HLA loci predisposing to immune TTP in Japanese: potential role of the shared ADAMTS13 peptide bound to different HLA-DR The American Society of Hematology American Society of Hematology 10.1182/blood.2020005395 Silverchair:454287 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 HLA loci predisposing to immune TTP in Japanese: potential role of the shared ADAMTS13 peptide bound to different HLA-DR The American Society of Hematology American Society of Hematology 10.1182/blood.2020005395 Silverchair:454287 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 HLA loci predisposing to immune TTP in Japanese: potential role of the shared ADAMTS13 peptide bound to different HLA-DR The American Society of Hematology American Society of Hematology 10.1182/blood.2020005395 Silverchair:454287 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 HLA loci predisposing to immune TTP in Japanese: potential role of the shared ADAMTS13 peptide bound to different HLA-DR The American Society of Hematology American Society of Hematology 10.1182/blood.2020005395 Silverchair:454287 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 HLA-DRB1–factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018019323 Silverchair:16240 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 3 0 0 0 HLA-DRB1–factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018019323 Silverchair:16240 Total_Item_Requests 3 0 0 0 0 0 0 0 0 3 0 0 0 HLA-DRB1–factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018019323 Silverchair:16240 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 HLA-DRB1–factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018019323 Silverchair:16240 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2006-11-057125 Silverchair:22993 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2006-11-057125 Silverchair:22993 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2006-11-057125 Silverchair:22993 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2006-11-057125 Silverchair:22993 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 HLH or sepsis: the truth is in the T cells The American Society of Hematology American Society of Hematology 10.1182/blood.2020010236 Silverchair:475802 Total_Item_Investigations 3 0 0 0 0 3 0 0 0 0 0 0 0 HLH or sepsis: the truth is in the T cells The American Society of Hematology American Society of Hematology 10.1182/blood.2020010236 Silverchair:475802 Total_Item_Requests 3 0 0 0 0 3 0 0 0 0 0 0 0 HLH or sepsis: the truth is in the T cells The American Society of Hematology American Society of Hematology 10.1182/blood.2020010236 Silverchair:475802 Unique_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 HLH or sepsis: the truth is in the T cells The American Society of Hematology American Society of Hematology 10.1182/blood.2020010236 Silverchair:475802 Unique_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 Hodgkin lymphoma American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter22 Silverchair:77608 No_License 3 2 0 0 0 0 0 0 1 0 0 0 0 Hodgkin lymphoma American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter22 Silverchair:77608 Total_Item_Investigations 3 2 0 0 0 0 0 0 1 0 0 0 0 Hodgkin lymphoma American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter22 Silverchair:77608 Unique_Item_Investigations 2 1 0 0 0 0 0 0 1 0 0 0 0 Home Administration of Subcutaneous Rituximab Is Safe and Associated with Significant Cost Saving: A Single Center Experience The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4676.4676 Silverchair:72354 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Home Administration of Subcutaneous Rituximab Is Safe and Associated with Significant Cost Saving: A Single Center Experience The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4676.4676 Silverchair:72354 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Home Administration of Subcutaneous Rituximab Is Safe and Associated with Significant Cost Saving: A Single Center Experience The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4676.4676 Silverchair:72354 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Home Administration of Subcutaneous Rituximab Is Safe and Associated with Significant Cost Saving: A Single Center Experience The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4676.4676 Silverchair:72354 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Homozygous hemoglobin C disease The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-498188 Silverchair:31697 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Homozygous hemoglobin C disease The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-498188 Silverchair:31697 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Homozygous hemoglobin C disease The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-498188 Silverchair:31697 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Homozygous hemoglobin C disease The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-498188 Silverchair:31697 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Hospital Volume Does Not Influence in-Hospital Mortality of Autologous Hematopoietic Cell Transplant Among Multiple Myeloma Patients in the United States The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.392.392 Silverchair:97339 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Hospital Volume Does Not Influence in-Hospital Mortality of Autologous Hematopoietic Cell Transplant Among Multiple Myeloma Patients in the United States The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.392.392 Silverchair:97339 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Hospital Volume Does Not Influence in-Hospital Mortality of Autologous Hematopoietic Cell Transplant Among Multiple Myeloma Patients in the United States The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.392.392 Silverchair:97339 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Hospital Volume Does Not Influence in-Hospital Mortality of Autologous Hematopoietic Cell Transplant Among Multiple Myeloma Patients in the United States The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.392.392 Silverchair:97339 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-330407 Silverchair:29171 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-330407 Silverchair:29171 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-330407 Silverchair:29171 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-330407 Silverchair:29171 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Hotspot U2AF1 Mutations Determine Missplicing Selectivity: Novel Mechanisms Altering Splicing Factors The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129367 Silverchair:423394 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Hotspot U2AF1 Mutations Determine Missplicing Selectivity: Novel Mechanisms Altering Splicing Factors The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129367 Silverchair:423394 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Hotspot U2AF1 Mutations Determine Missplicing Selectivity: Novel Mechanisms Altering Splicing Factors The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129367 Silverchair:423394 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Hotspot U2AF1 Mutations Determine Missplicing Selectivity: Novel Mechanisms Altering Splicing Factors The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129367 Silverchair:423394 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 "HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)" The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.40.40 Silverchair:67779 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)" The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.40.40 Silverchair:67779 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)" The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.40.40 Silverchair:67779 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)" The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.40.40 Silverchair:67779 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How do messenger RNA splicing alterations drive myelodysplasia? The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-692715 Silverchair:36253 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 How do messenger RNA splicing alterations drive myelodysplasia? The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-692715 Silverchair:36253 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 How do messenger RNA splicing alterations drive myelodysplasia? The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-692715 Silverchair:36253 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How do messenger RNA splicing alterations drive myelodysplasia? The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-692715 Silverchair:36253 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How do we diagnose immune thrombocytopenia in 2018? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.561 Silverchair:277614 Total_Item_Investigations 3 0 1 2 0 0 0 0 0 0 0 0 0 How do we diagnose immune thrombocytopenia in 2018? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.561 Silverchair:277614 Total_Item_Requests 3 0 1 2 0 0 0 0 0 0 0 0 0 How do we diagnose immune thrombocytopenia in 2018? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.561 Silverchair:277614 Unique_Item_Investigations 3 0 1 2 0 0 0 0 0 0 0 0 0 How do we diagnose immune thrombocytopenia in 2018? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.561 Silverchair:277614 Unique_Item_Requests 3 0 1 2 0 0 0 0 0 0 0 0 0 How I diagnose and manage individuals at risk for inherited myeloid malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-670240 Silverchair:35655 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 How I diagnose and manage individuals at risk for inherited myeloid malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-670240 Silverchair:35655 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 How I diagnose and manage individuals at risk for inherited myeloid malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-670240 Silverchair:35655 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 How I diagnose and manage individuals at risk for inherited myeloid malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-670240 Silverchair:35655 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 How I diagnose and treat NPM1-mutated AML The American Society of Hematology American Society of Hematology 10.1182/blood.2020008211 Silverchair:474131 Total_Item_Investigations 18 0 9 0 0 0 0 0 0 9 0 0 0 How I diagnose and treat NPM1-mutated AML The American Society of Hematology American Society of Hematology 10.1182/blood.2020008211 Silverchair:474131 Unique_Item_Investigations 7 0 4 0 0 0 0 0 0 3 0 0 0 How I diagnose and treat NPM1-mutated AML The American Society of Hematology American Society of Hematology 10.1182/blood.2020008211 Silverchair:474131 No_License 8 0 5 0 0 0 0 0 0 3 0 0 0 How I evaluate and treat thrombocytopenia in the intensive care unit patient The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-693655 Silverchair:116533 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 How I evaluate and treat thrombocytopenia in the intensive care unit patient The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-693655 Silverchair:116533 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 How I evaluate and treat thrombocytopenia in the intensive care unit patient The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-693655 Silverchair:116533 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 How I evaluate and treat thrombocytopenia in the intensive care unit patient The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-693655 Silverchair:116533 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 How I manage acquired pure red cell aplasia in adults The American Society of Hematology American Society of Hematology 10.1182/blood.2021010898 Silverchair:475415 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 0 0 3 0 How I manage acquired pure red cell aplasia in adults The American Society of Hematology American Society of Hematology 10.1182/blood.2021010898 Silverchair:475415 Total_Item_Requests 3 0 0 0 0 0 0 0 0 0 0 3 0 How I manage acquired pure red cell aplasia in adults The American Society of Hematology American Society of Hematology 10.1182/blood.2021010898 Silverchair:475415 Unique_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 How I manage acquired pure red cell aplasia in adults The American Society of Hematology American Society of Hematology 10.1182/blood.2021010898 Silverchair:475415 Unique_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2019-01-846048 Silverchair:272731 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2019-01-846048 Silverchair:272731 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2019-01-846048 Silverchair:272731 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2019-01-846048 Silverchair:272731 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How I manage CLL with venetoclax-based treatments The American Society of Hematology American Society of Hematology 10.1182/blood.2019002841 Silverchair:452521 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 How I manage CLL with venetoclax-based treatments The American Society of Hematology American Society of Hematology 10.1182/blood.2019002841 Silverchair:452521 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How I manage CLL with venetoclax-based treatments The American Society of Hematology American Society of Hematology 10.1182/blood.2019002841 Silverchair:452521 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 How I manage CLL with venetoclax-based treatments The American Society of Hematology American Society of Hematology 10.1182/blood.2019002841 Silverchair:452521 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How I manage cyclic thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.2020008218 Silverchair:474179 No_License 1 0 1 0 0 0 0 0 0 0 0 0 0 How I manage cyclic thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.2020008218 Silverchair:474179 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 How I manage cyclic thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.2020008218 Silverchair:474179 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How I manage cyclic thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.2020008218 Silverchair:474179 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 How I manage cyclic thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.2020008218 Silverchair:474179 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-846808 Silverchair:260463 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-846808 Silverchair:260463 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-846808 Silverchair:260463 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-846808 Silverchair:260463 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 How I manage ibrutinib-refractory chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-693598 Silverchair:36014 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 How I manage ibrutinib-refractory chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-693598 Silverchair:36014 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 How I manage ibrutinib-refractory chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-693598 Silverchair:36014 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How I manage ibrutinib-refractory chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-693598 Silverchair:36014 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I manage monoclonal gammopathy of undetermined significance The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-807560 Silverchair:37011 Total_Item_Investigations 14 2 3 0 5 3 0 1 0 0 0 0 0 How I manage monoclonal gammopathy of undetermined significance The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-807560 Silverchair:37011 Total_Item_Requests 11 1 2 0 4 3 0 1 0 0 0 0 0 How I manage monoclonal gammopathy of undetermined significance The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-807560 Silverchair:37011 Unique_Item_Investigations 8 1 1 0 3 2 0 1 0 0 0 0 0 How I manage monoclonal gammopathy of undetermined significance The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-807560 Silverchair:37011 Unique_Item_Requests 8 1 1 0 3 2 0 1 0 0 0 0 0 How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019000964 Silverchair:463259 Total_Item_Investigations 3 0 0 0 0 3 0 0 0 0 0 0 0 How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019000964 Silverchair:463259 Total_Item_Requests 3 0 0 0 0 3 0 0 0 0 0 0 0 How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019000964 Silverchair:463259 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019000964 Silverchair:463259 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 How I manage pulmonary nodular lesions and nodular infiltrates in patients with hematologic malignancies or undergoing hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2012-02-378976 Silverchair:30902 Total_Item_Investigations 6 0 6 0 0 0 0 0 0 0 0 0 0 How I manage pulmonary nodular lesions and nodular infiltrates in patients with hematologic malignancies or undergoing hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2012-02-378976 Silverchair:30902 Total_Item_Requests 6 0 6 0 0 0 0 0 0 0 0 0 0 How I manage pulmonary nodular lesions and nodular infiltrates in patients with hematologic malignancies or undergoing hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2012-02-378976 Silverchair:30902 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 How I manage pulmonary nodular lesions and nodular infiltrates in patients with hematologic malignancies or undergoing hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2012-02-378976 Silverchair:30902 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2019004000 Silverchair:461120 No_License 1 0 1 0 0 0 0 0 0 0 0 0 0 How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2019004000 Silverchair:461120 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2019004000 Silverchair:461120 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 How I treat acquired aplastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-693481 Silverchair:35931 Total_Item_Investigations 8 2 5 1 0 0 0 0 0 0 0 0 0 How I treat acquired aplastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-693481 Silverchair:35931 Total_Item_Requests 8 2 5 1 0 0 0 0 0 0 0 0 0 How I treat acquired aplastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-693481 Silverchair:35931 Unique_Item_Investigations 6 2 3 1 0 0 0 0 0 0 0 0 0 How I treat acquired aplastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-693481 Silverchair:35931 Unique_Item_Requests 6 2 3 1 0 0 0 0 0 0 0 0 0 How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver The American Society of Hematology American Society of Hematology 10.1182/blood-2015-10-612747 Silverchair:35043 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver The American Society of Hematology American Society of Hematology 10.1182/blood-2015-10-612747 Silverchair:35043 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver The American Society of Hematology American Society of Hematology 10.1182/blood-2015-10-612747 Silverchair:35043 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver The American Society of Hematology American Society of Hematology 10.1182/blood-2015-10-612747 Silverchair:35043 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat acute myeloid leukemia in the era of new drugs The American Society of Hematology American Society of Hematology 10.1182/blood.2019001239 Silverchair:428884 Total_Item_Investigations 12 8 2 1 0 0 0 1 0 0 0 0 0 How I treat acute myeloid leukemia in the era of new drugs The American Society of Hematology American Society of Hematology 10.1182/blood.2019001239 Silverchair:428884 Total_Item_Requests 10 6 2 1 0 0 0 1 0 0 0 0 0 How I treat acute myeloid leukemia in the era of new drugs The American Society of Hematology American Society of Hematology 10.1182/blood.2019001239 Silverchair:428884 Unique_Item_Investigations 6 3 1 1 0 0 0 1 0 0 0 0 0 How I treat acute myeloid leukemia in the era of new drugs The American Society of Hematology American Society of Hematology 10.1182/blood.2019001239 Silverchair:428884 Unique_Item_Requests 6 3 1 1 0 0 0 1 0 0 0 0 0 How I treat acute myeloid leukemia presenting with preexisting comorbidities The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-635060 Silverchair:35392 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat acute myeloid leukemia presenting with preexisting comorbidities The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-635060 Silverchair:35392 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat acute myeloid leukemia presenting with preexisting comorbidities The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-635060 Silverchair:35392 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat acute myeloid leukemia presenting with preexisting comorbidities The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-635060 Silverchair:35392 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat acute promyelocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-216457 Silverchair:26501 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 How I treat acute promyelocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-216457 Silverchair:26501 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 How I treat acute promyelocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-216457 Silverchair:26501 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 How I treat acute promyelocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-216457 Silverchair:26501 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 How I treat adult T-cell leukemia/lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2019004045 Silverchair:469694 No_License 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat adult T-cell leukemia/lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2019004045 Silverchair:469694 Total_Item_Investigations 3 1 2 0 0 0 0 0 0 0 0 0 0 How I treat adult T-cell leukemia/lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2019004045 Silverchair:469694 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat adult T-cell leukemia/lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2019004045 Silverchair:469694 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 How I treat adult T-cell leukemia/lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2019004045 Silverchair:469694 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.2019002132 Silverchair:430058 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.2019002132 Silverchair:430058 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.2019002132 Silverchair:430058 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.2019002132 Silverchair:430058 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat anemia in heart failure The American Society of Hematology American Society of Hematology 10.1182/blood.2019004004 Silverchair:430052 No_License 2 0 1 1 0 0 0 0 0 0 0 0 0 How I treat anemia in heart failure The American Society of Hematology American Society of Hematology 10.1182/blood.2019004004 Silverchair:430052 Total_Item_Investigations 5 1 2 2 0 0 0 0 0 0 0 0 0 How I treat anemia in heart failure The American Society of Hematology American Society of Hematology 10.1182/blood.2019004004 Silverchair:430052 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat anemia in heart failure The American Society of Hematology American Society of Hematology 10.1182/blood.2019004004 Silverchair:430052 Unique_Item_Investigations 3 1 1 1 0 0 0 0 0 0 0 0 0 How I treat anemia in heart failure The American Society of Hematology American Society of Hematology 10.1182/blood.2019004004 Silverchair:430052 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "How I treat anemia in pregnancy: iron, cobalamin, and folate" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-672246 Silverchair:36329 Total_Item_Investigations 8 3 0 0 5 0 0 0 0 0 0 0 0 "How I treat anemia in pregnancy: iron, cobalamin, and folate" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-672246 Silverchair:36329 Total_Item_Requests 7 2 0 0 5 0 0 0 0 0 0 0 0 "How I treat anemia in pregnancy: iron, cobalamin, and folate" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-672246 Silverchair:36329 Unique_Item_Investigations 4 2 0 0 2 0 0 0 0 0 0 0 0 "How I treat anemia in pregnancy: iron, cobalamin, and folate" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-672246 Silverchair:36329 Unique_Item_Requests 4 2 0 0 2 0 0 0 0 0 0 0 0 How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2020004942 Silverchair:463710 Total_Item_Investigations 8 2 6 0 0 0 0 0 0 0 0 0 0 How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2020004942 Silverchair:463710 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2020004942 Silverchair:463710 Unique_Item_Investigations 5 2 3 0 0 0 0 0 0 0 0 0 0 How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2020004942 Silverchair:463710 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2020004942 Silverchair:463710 No_License 3 0 3 0 0 0 0 0 0 0 0 0 0 How I treat anticoagulated patients undergoing an elective procedure or surgery The American Society of Hematology American Society of Hematology 10.1182/blood-2012-06-415943 Silverchair:30631 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 How I treat anticoagulated patients undergoing an elective procedure or surgery The American Society of Hematology American Society of Hematology 10.1182/blood-2012-06-415943 Silverchair:30631 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 How I treat anticoagulated patients undergoing an elective procedure or surgery The American Society of Hematology American Society of Hematology 10.1182/blood-2012-06-415943 Silverchair:30631 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 How I treat anticoagulated patients undergoing an elective procedure or surgery The American Society of Hematology American Society of Hematology 10.1182/blood-2012-06-415943 Silverchair:30631 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 How I treat atypical chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-693630 Silverchair:36180 Total_Item_Investigations 2 0 0 1 0 0 0 0 0 1 0 0 0 How I treat atypical chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-693630 Silverchair:36180 Total_Item_Requests 2 0 0 1 0 0 0 0 0 1 0 0 0 How I treat atypical chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-693630 Silverchair:36180 Unique_Item_Investigations 2 0 0 1 0 0 0 0 0 1 0 0 0 How I treat atypical chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-693630 Silverchair:36180 Unique_Item_Requests 2 0 0 1 0 0 0 0 0 1 0 0 0 How I treat autoimmune hemolytic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-693689 Silverchair:36045 Total_Item_Investigations 7 0 3 0 0 0 2 2 0 0 0 0 0 How I treat autoimmune hemolytic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-693689 Silverchair:36045 Total_Item_Requests 7 0 3 0 0 0 2 2 0 0 0 0 0 How I treat autoimmune hemolytic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-693689 Silverchair:36045 Unique_Item_Investigations 5 0 3 0 0 0 1 1 0 0 0 0 0 How I treat autoimmune hemolytic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-693689 Silverchair:36045 Unique_Item_Requests 5 0 3 0 0 0 1 1 0 0 0 0 0 How I treat bleeding disorder of unknown cause The American Society of Hematology American Society of Hematology 10.1182/blood.2020010038 Silverchair:476587 Total_Item_Investigations 7 0 0 0 0 0 0 0 0 2 0 4 1 How I treat bleeding disorder of unknown cause The American Society of Hematology American Society of Hematology 10.1182/blood.2020010038 Silverchair:476587 Total_Item_Requests 5 0 0 0 0 0 0 0 0 0 0 4 1 How I treat bleeding disorder of unknown cause The American Society of Hematology American Society of Hematology 10.1182/blood.2020010038 Silverchair:476587 Unique_Item_Investigations 3 0 0 0 0 0 0 0 0 1 0 1 1 How I treat bleeding disorder of unknown cause The American Society of Hematology American Society of Hematology 10.1182/blood.2020010038 Silverchair:476587 Unique_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 1 1 How I treat breast implant–associated anaplastic large cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-785972 Silverchair:39611 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat breast implant–associated anaplastic large cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-785972 Silverchair:39611 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat breast implant–associated anaplastic large cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-785972 Silverchair:39611 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat breast implant–associated anaplastic large cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-785972 Silverchair:39611 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat Burkitt lymphoma in adults The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-538504 Silverchair:33277 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat Burkitt lymphoma in adults The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-538504 Silverchair:33277 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat Burkitt lymphoma in adults The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-538504 Silverchair:33277 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat Burkitt lymphoma in adults The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-538504 Silverchair:33277 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat cancer-associated anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019004017 Silverchair:461032 No_License 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat cancer-associated anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019004017 Silverchair:461032 Total_Item_Investigations 3 1 0 2 0 0 0 0 0 0 0 0 0 How I treat cancer-associated anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019004017 Silverchair:461032 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat cancer-associated anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019004017 Silverchair:461032 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 How I treat cancer-associated anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019004017 Silverchair:461032 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat cancer-associated venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-835595 Silverchair:272766 Total_Item_Investigations 5 3 2 0 0 0 0 0 0 0 0 0 0 How I treat cancer-associated venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-835595 Silverchair:272766 Total_Item_Requests 5 3 2 0 0 0 0 0 0 0 0 0 0 How I treat cancer-associated venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-835595 Silverchair:272766 Unique_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 How I treat cancer-associated venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-835595 Silverchair:272766 Unique_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 How I treat catastrophic thrombotic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2014-09-551978 Silverchair:34367 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 How I treat catastrophic thrombotic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2014-09-551978 Silverchair:34367 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 How I treat catastrophic thrombotic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2014-09-551978 Silverchair:34367 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat catastrophic thrombotic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2014-09-551978 Silverchair:34367 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat central venous access device–related upper extremity deep vein thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-693671 Silverchair:36112 Total_Item_Investigations 7 1 2 0 0 0 2 2 0 0 0 0 0 How I treat central venous access device–related upper extremity deep vein thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-693671 Silverchair:36112 Total_Item_Requests 7 1 2 0 0 0 2 2 0 0 0 0 0 How I treat central venous access device–related upper extremity deep vein thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-693671 Silverchair:36112 Unique_Item_Investigations 5 1 1 0 0 0 1 2 0 0 0 0 0 How I treat central venous access device–related upper extremity deep vein thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-693671 Silverchair:36112 Unique_Item_Requests 5 1 1 0 0 0 1 2 0 0 0 0 0 How I treat chronic lymphocytic leukemia after venetoclax The American Society of Hematology American Society of Hematology 10.1182/blood.2020008502 Silverchair:475780 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 How I treat chronic lymphocytic leukemia after venetoclax The American Society of Hematology American Society of Hematology 10.1182/blood.2020008502 Silverchair:475780 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 How I treat chronic myelomonocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-736421 Silverchair:36728 Total_Item_Investigations 7 3 0 0 0 0 0 3 1 0 0 0 0 How I treat chronic myelomonocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-736421 Silverchair:36728 Total_Item_Requests 7 3 0 0 0 0 0 3 1 0 0 0 0 How I treat chronic myelomonocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-736421 Silverchair:36728 Unique_Item_Investigations 5 2 0 0 0 0 0 2 1 0 0 0 0 How I treat chronic myelomonocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-736421 Silverchair:36728 Unique_Item_Requests 5 2 0 0 0 0 0 2 1 0 0 0 0 How I treat CLL patients with ibrutinib The American Society of Hematology American Society of Hematology 10.1182/blood-2017-08-764712 Silverchair:38474 Total_Item_Investigations 4 2 0 0 0 0 2 0 0 0 0 0 0 How I treat CLL patients with ibrutinib The American Society of Hematology American Society of Hematology 10.1182/blood-2017-08-764712 Silverchair:38474 Total_Item_Requests 4 2 0 0 0 0 2 0 0 0 0 0 0 How I treat CLL patients with ibrutinib The American Society of Hematology American Society of Hematology 10.1182/blood-2017-08-764712 Silverchair:38474 Unique_Item_Investigations 2 1 0 0 0 0 1 0 0 0 0 0 0 How I treat CLL patients with ibrutinib The American Society of Hematology American Society of Hematology 10.1182/blood-2017-08-764712 Silverchair:38474 Unique_Item_Requests 2 1 0 0 0 0 1 0 0 0 0 0 0 How I treat CML blast crisis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-380147 Silverchair:105617 Total_Item_Investigations 3 1 0 2 0 0 0 0 0 0 0 0 0 How I treat CML blast crisis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-380147 Silverchair:105617 Total_Item_Requests 3 1 0 2 0 0 0 0 0 0 0 0 0 How I treat CML blast crisis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-380147 Silverchair:105617 Unique_Item_Investigations 3 1 0 2 0 0 0 0 0 0 0 0 0 How I treat CML blast crisis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-380147 Silverchair:105617 Unique_Item_Requests 3 1 0 2 0 0 0 0 0 0 0 0 0 How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.2019000956 Silverchair:452747 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.2019000956 Silverchair:452747 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.2019000956 Silverchair:452747 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.2019000956 Silverchair:452747 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat CNS lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2013-06-453084 Silverchair:32210 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 How I treat CNS lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2013-06-453084 Silverchair:32210 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 How I treat CNS lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2013-06-453084 Silverchair:32210 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 How I treat CNS lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2013-06-453084 Silverchair:32210 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 How I treat cobalamin (vitamin B12) deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2008-03-040253 Silverchair:24841 Total_Item_Investigations 9 2 4 0 0 1 0 0 0 2 0 0 0 How I treat cobalamin (vitamin B12) deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2008-03-040253 Silverchair:24841 Total_Item_Requests 9 2 4 0 0 1 0 0 0 2 0 0 0 How I treat cobalamin (vitamin B12) deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2008-03-040253 Silverchair:24841 Unique_Item_Investigations 5 1 2 0 0 1 0 0 0 1 0 0 0 How I treat cobalamin (vitamin B12) deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2008-03-040253 Silverchair:24841 Unique_Item_Requests 5 1 2 0 0 1 0 0 0 1 0 0 0 How I treat cold agglutinin disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019003809 Silverchair:475028 Total_Item_Investigations 2 0 0 0 1 0 1 0 0 0 0 0 0 How I treat cold agglutinin disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019003809 Silverchair:475028 Total_Item_Requests 2 0 0 0 1 0 1 0 0 0 0 0 0 How I treat cold agglutinin disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019003809 Silverchair:475028 Unique_Item_Investigations 2 0 0 0 1 0 1 0 0 0 0 0 0 How I treat cold agglutinin disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019003809 Silverchair:475028 Unique_Item_Requests 2 0 0 0 1 0 1 0 0 0 0 0 0 How I treat cryoglobulinemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-719773 Silverchair:36030 Total_Item_Investigations 10 6 3 0 0 0 0 1 0 0 0 0 0 How I treat cryoglobulinemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-719773 Silverchair:36030 Total_Item_Requests 10 6 3 0 0 0 0 1 0 0 0 0 0 How I treat cryoglobulinemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-719773 Silverchair:36030 Unique_Item_Investigations 5 3 1 0 0 0 0 1 0 0 0 0 0 How I treat cryoglobulinemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-719773 Silverchair:36030 Unique_Item_Requests 5 3 1 0 0 0 0 1 0 0 0 0 0 How I treat disseminated intravascular coagulation The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-804096 Silverchair:104418 Total_Item_Investigations 12 7 3 1 0 0 1 0 0 0 0 0 0 How I treat disseminated intravascular coagulation The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-804096 Silverchair:104418 Total_Item_Requests 12 7 3 1 0 0 1 0 0 0 0 0 0 How I treat disseminated intravascular coagulation The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-804096 Silverchair:104418 Unique_Item_Investigations 9 5 2 1 0 0 1 0 0 0 0 0 0 How I treat disseminated intravascular coagulation The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-804096 Silverchair:104418 Unique_Item_Requests 9 5 2 1 0 0 1 0 0 0 0 0 0 How I treat double-hit lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-737320 Silverchair:36799 Total_Item_Investigations 7 0 4 0 0 0 0 3 0 0 0 0 0 How I treat double-hit lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-737320 Silverchair:36799 Total_Item_Requests 7 0 4 0 0 0 0 3 0 0 0 0 0 How I treat double-hit lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-737320 Silverchair:36799 Unique_Item_Investigations 5 0 3 0 0 0 0 2 0 0 0 0 0 How I treat double-hit lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-737320 Silverchair:36799 Unique_Item_Requests 5 0 3 0 0 0 0 2 0 0 0 0 0 How I treat dysfibrinogenemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020010116 Silverchair:475833 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 How I treat dysfibrinogenemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020010116 Silverchair:475833 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 How I treat dysfibrinogenemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020010116 Silverchair:475833 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 How I treat dysfibrinogenemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020010116 Silverchair:475833 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 How I treat early-relapsing follicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-822148 Silverchair:260517 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 How I treat early-relapsing follicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-822148 Silverchair:260517 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 How I treat early-relapsing follicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-822148 Silverchair:260517 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 How I treat early-relapsing follicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-822148 Silverchair:260517 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 How I treat EBV lymphoproliferation The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-143545 Silverchair:26734 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 How I treat EBV lymphoproliferation The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-143545 Silverchair:26734 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 How I treat EBV lymphoproliferation The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-143545 Silverchair:26734 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 How I treat EBV lymphoproliferation The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-143545 Silverchair:26734 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 How I treat elderly patients with myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-163329 Silverchair:27546 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat elderly patients with myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-163329 Silverchair:27546 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat elderly patients with myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-163329 Silverchair:27546 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat elderly patients with myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-163329 Silverchair:27546 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat essential thrombocythemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-643346 Silverchair:35610 Total_Item_Investigations 19 11 4 2 0 0 0 0 2 0 0 0 0 How I treat essential thrombocythemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-643346 Silverchair:35610 Total_Item_Requests 19 11 4 2 0 0 0 0 2 0 0 0 0 How I treat essential thrombocythemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-643346 Silverchair:35610 Unique_Item_Investigations 13 6 3 2 0 0 0 0 2 0 0 0 0 How I treat essential thrombocythemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-643346 Silverchair:35610 Unique_Item_Requests 13 6 3 2 0 0 0 0 2 0 0 0 0 How I treat extramedullary acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-347229 Silverchair:28758 Total_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 How I treat extramedullary acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-347229 Silverchair:28758 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 How I treat extramedullary acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-347229 Silverchair:28758 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 How I treat extramedullary acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-347229 Silverchair:28758 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 How I treat extramedullary myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-635383 Silverchair:35145 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 How I treat extramedullary myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-635383 Silverchair:35145 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 How I treat extramedullary myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-635383 Silverchair:35145 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat extramedullary myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-635383 Silverchair:35145 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat FLT3-mutated AML The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-693648 Silverchair:36161 Total_Item_Investigations 12 2 5 3 2 0 0 0 0 0 0 0 0 How I treat FLT3-mutated AML The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-693648 Silverchair:36161 Total_Item_Requests 8 1 3 3 1 0 0 0 0 0 0 0 0 How I treat FLT3-mutated AML The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-693648 Silverchair:36161 Unique_Item_Investigations 7 1 2 3 1 0 0 0 0 0 0 0 0 How I treat FLT3-mutated AML The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-693648 Silverchair:36161 Unique_Item_Requests 7 1 2 3 1 0 0 0 0 0 0 0 0 How I treat fragile myeloma patients The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-612960 Silverchair:34578 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat fragile myeloma patients The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-612960 Silverchair:34578 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat fragile myeloma patients The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-612960 Silverchair:34578 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat fragile myeloma patients The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-612960 Silverchair:34578 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat heavy menstrual bleeding associated with anticoagulants The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-797423 Silverchair:36855 Total_Item_Investigations 4 0 1 2 0 0 0 0 0 0 0 1 0 How I treat heavy menstrual bleeding associated with anticoagulants The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-797423 Silverchair:36855 Total_Item_Requests 4 0 1 2 0 0 0 0 0 0 0 1 0 How I treat heavy menstrual bleeding associated with anticoagulants The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-797423 Silverchair:36855 Unique_Item_Investigations 3 0 1 1 0 0 0 0 0 0 0 1 0 How I treat heavy menstrual bleeding associated with anticoagulants The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-797423 Silverchair:36855 Unique_Item_Requests 3 0 1 1 0 0 0 0 0 0 0 1 0 How I treat hemochromatosis The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-261875 Silverchair:27584 Total_Item_Investigations 14 2 2 0 1 2 2 0 3 0 2 0 0 How I treat hemochromatosis The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-261875 Silverchair:27584 Total_Item_Requests 14 2 2 0 1 2 2 0 3 0 2 0 0 How I treat hemochromatosis The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-261875 Silverchair:27584 Unique_Item_Investigations 9 1 2 0 1 2 1 0 1 0 1 0 0 How I treat hemochromatosis The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-261875 Silverchair:27584 Unique_Item_Requests 9 1 2 0 1 2 1 0 1 0 1 0 0 How I treat hemophagocytic lymphohistiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-278127 Silverchair:29048 Total_Item_Investigations 5 3 0 1 0 0 1 0 0 0 0 0 0 How I treat hemophagocytic lymphohistiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-278127 Silverchair:29048 Total_Item_Requests 5 3 0 1 0 0 1 0 0 0 0 0 0 How I treat hemophagocytic lymphohistiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-278127 Silverchair:29048 Unique_Item_Investigations 4 2 0 1 0 0 1 0 0 0 0 0 0 How I treat hemophagocytic lymphohistiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-278127 Silverchair:29048 Unique_Item_Requests 4 2 0 1 0 0 1 0 0 0 0 0 0 How I treat hemophagocytic lymphohistiocytosis in the adult patient The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-551622 Silverchair:34267 Total_Item_Investigations 15 9 0 6 0 0 0 0 0 0 0 0 0 How I treat hemophagocytic lymphohistiocytosis in the adult patient The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-551622 Silverchair:34267 Total_Item_Requests 12 8 0 4 0 0 0 0 0 0 0 0 0 How I treat hemophagocytic lymphohistiocytosis in the adult patient The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-551622 Silverchair:34267 Unique_Item_Investigations 8 5 0 3 0 0 0 0 0 0 0 0 0 How I treat hemophagocytic lymphohistiocytosis in the adult patient The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-551622 Silverchair:34267 Unique_Item_Requests 8 5 0 3 0 0 0 0 0 0 0 0 0 How I treat heparin-induced thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-376293 Silverchair:29530 Total_Item_Investigations 4 1 0 0 0 0 2 0 1 0 0 0 0 How I treat heparin-induced thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-376293 Silverchair:29530 Total_Item_Requests 4 1 0 0 0 0 2 0 1 0 0 0 0 How I treat heparin-induced thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-376293 Silverchair:29530 Unique_Item_Investigations 4 1 0 0 0 0 2 0 1 0 0 0 0 How I treat heparin-induced thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-376293 Silverchair:29530 Unique_Item_Requests 4 1 0 0 0 0 2 0 1 0 0 0 0 How I treat high-risk myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-653261 Silverchair:105426 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 How I treat high-risk myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-653261 Silverchair:105426 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 How I treat high-risk myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-653261 Silverchair:105426 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 How I treat high-risk myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-653261 Silverchair:105426 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 How I treat HIV-associated lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-373738 Silverchair:29579 Total_Item_Investigations 3 0 1 1 0 1 0 0 0 0 0 0 0 How I treat HIV-associated lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-373738 Silverchair:29579 Total_Item_Requests 3 0 1 1 0 1 0 0 0 0 0 0 0 How I treat HIV-associated lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-373738 Silverchair:29579 Unique_Item_Investigations 3 0 1 1 0 1 0 0 0 0 0 0 0 How I treat HIV-associated lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-373738 Silverchair:29579 Unique_Item_Requests 3 0 1 1 0 1 0 0 0 0 0 0 0 How I treat hypereosinophilic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-551614 Silverchair:126459 Total_Item_Investigations 4 2 0 2 0 0 0 0 0 0 0 0 0 How I treat hypereosinophilic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-551614 Silverchair:126459 Total_Item_Requests 4 2 0 2 0 0 0 0 0 0 0 0 0 How I treat hypereosinophilic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-551614 Silverchair:126459 Unique_Item_Investigations 3 1 0 2 0 0 0 0 0 0 0 0 0 How I treat hypereosinophilic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-551614 Silverchair:126459 Unique_Item_Requests 3 1 0 2 0 0 0 0 0 0 0 0 0 How I treat hyperleukocytosis in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-551507 Silverchair:34025 Total_Item_Investigations 6 4 2 0 0 0 0 0 0 0 0 0 0 How I treat hyperleukocytosis in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-551507 Silverchair:34025 Total_Item_Requests 6 4 2 0 0 0 0 0 0 0 0 0 0 How I treat hyperleukocytosis in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-551507 Silverchair:34025 Unique_Item_Investigations 4 2 2 0 0 0 0 0 0 0 0 0 0 How I treat hyperleukocytosis in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-551507 Silverchair:34025 Unique_Item_Requests 4 2 2 0 0 0 0 0 0 0 0 0 0 How I treat idiopathic thrombocytopenic purpura (ITP) The American Society of Hematology American Society of Hematology 10.1182/blood-2004-12-4598 Silverchair:21649 Total_Item_Investigations 6 2 0 0 0 0 2 0 2 0 0 0 0 How I treat idiopathic thrombocytopenic purpura (ITP) The American Society of Hematology American Society of Hematology 10.1182/blood-2004-12-4598 Silverchair:21649 Total_Item_Requests 6 2 0 0 0 0 2 0 2 0 0 0 0 How I treat idiopathic thrombocytopenic purpura (ITP) The American Society of Hematology American Society of Hematology 10.1182/blood-2004-12-4598 Silverchair:21649 Unique_Item_Investigations 4 2 0 0 0 0 1 0 1 0 0 0 0 How I treat idiopathic thrombocytopenic purpura (ITP) The American Society of Hematology American Society of Hematology 10.1182/blood-2004-12-4598 Silverchair:21649 Unique_Item_Requests 4 2 0 0 0 0 1 0 1 0 0 0 0 How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-309153 Silverchair:30278 Total_Item_Investigations 9 3 1 0 0 3 0 0 0 2 0 0 0 How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-309153 Silverchair:30278 Total_Item_Requests 8 2 1 0 0 3 0 0 0 2 0 0 0 How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-309153 Silverchair:30278 Unique_Item_Investigations 5 2 1 0 0 1 0 0 0 1 0 0 0 How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-309153 Silverchair:30278 Unique_Item_Requests 5 2 1 0 0 1 0 0 0 1 0 0 0 How I treat incidental pulmonary embolism The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-551879 Silverchair:33710 Total_Item_Investigations 12 3 5 1 2 0 0 0 1 0 0 0 0 How I treat incidental pulmonary embolism The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-551879 Silverchair:33710 Total_Item_Requests 10 2 5 1 1 0 0 0 1 0 0 0 0 How I treat incidental pulmonary embolism The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-551879 Silverchair:33710 Unique_Item_Investigations 6 1 2 1 1 0 0 0 1 0 0 0 0 How I treat incidental pulmonary embolism The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-551879 Silverchair:33710 Unique_Item_Requests 6 1 2 1 1 0 0 0 1 0 0 0 0 How I treat infant leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-785980 Silverchair:261427 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat infant leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-785980 Silverchair:261427 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat infant leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-785980 Silverchair:261427 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat infant leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-785980 Silverchair:261427 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat isolated distal deep vein thrombosis (IDDVT) The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-512616 Silverchair:32726 Total_Item_Investigations 19 0 7 4 0 1 5 1 1 0 0 0 0 How I treat isolated distal deep vein thrombosis (IDDVT) The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-512616 Silverchair:32726 Total_Item_Requests 19 0 7 4 0 1 5 1 1 0 0 0 0 How I treat isolated distal deep vein thrombosis (IDDVT) The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-512616 Silverchair:32726 Unique_Item_Investigations 15 0 4 4 0 1 4 1 1 0 0 0 0 How I treat isolated distal deep vein thrombosis (IDDVT) The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-512616 Silverchair:32726 Unique_Item_Requests 15 0 4 4 0 1 4 1 1 0 0 0 0 How I treat Langerhans cell histiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-569301 Silverchair:34346 Total_Item_Investigations 5 1 4 0 0 0 0 0 0 0 0 0 0 How I treat Langerhans cell histiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-569301 Silverchair:34346 Total_Item_Requests 5 1 4 0 0 0 0 0 0 0 0 0 0 How I treat Langerhans cell histiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-569301 Silverchair:34346 Unique_Item_Investigations 5 1 4 0 0 0 0 0 0 0 0 0 0 How I treat Langerhans cell histiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-569301 Silverchair:34346 Unique_Item_Requests 5 1 4 0 0 0 0 0 0 0 0 0 0 How I treat leukemia during pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-283580 Silverchair:105688 Total_Item_Investigations 21 0 19 0 2 0 0 0 0 0 0 0 0 How I treat leukemia during pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-283580 Silverchair:105688 Total_Item_Requests 21 0 19 0 2 0 0 0 0 0 0 0 0 How I treat leukemia during pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-283580 Silverchair:105688 Unique_Item_Investigations 17 0 15 0 2 0 0 0 0 0 0 0 0 How I treat leukemia during pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-283580 Silverchair:105688 Unique_Item_Requests 17 0 15 0 2 0 0 0 0 0 0 0 0 How I treat LGL leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-296962 Silverchair:19561 Total_Item_Investigations 5 1 0 0 0 3 0 0 0 1 0 0 0 How I treat LGL leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-296962 Silverchair:19561 Total_Item_Requests 5 1 0 0 0 3 0 0 0 1 0 0 0 How I treat LGL leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-296962 Silverchair:19561 Unique_Item_Investigations 4 1 0 0 0 2 0 0 0 1 0 0 0 How I treat LGL leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-296962 Silverchair:19561 Unique_Item_Requests 4 1 0 0 0 2 0 0 0 1 0 0 0 How I treat low von Willebrand factor levels The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-844936 Silverchair:260600 Total_Item_Investigations 4 0 0 3 0 0 0 1 0 0 0 0 0 How I treat low von Willebrand factor levels The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-844936 Silverchair:260600 Total_Item_Requests 4 0 0 3 0 0 0 1 0 0 0 0 0 How I treat low von Willebrand factor levels The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-844936 Silverchair:260600 Unique_Item_Investigations 2 0 0 1 0 0 0 1 0 0 0 0 0 How I treat low von Willebrand factor levels The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-844936 Silverchair:260600 Unique_Item_Requests 2 0 0 1 0 0 0 1 0 0 0 0 0 How I treat lymphoma in pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood.2019000961 Silverchair:463256 Total_Item_Investigations 30 0 24 3 3 0 0 0 0 0 0 0 0 How I treat lymphoma in pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood.2019000961 Silverchair:463256 Total_Item_Requests 29 0 24 2 3 0 0 0 0 0 0 0 0 How I treat lymphoma in pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood.2019000961 Silverchair:463256 Unique_Item_Investigations 15 0 13 1 1 0 0 0 0 0 0 0 0 How I treat lymphoma in pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood.2019000961 Silverchair:463256 Unique_Item_Requests 15 0 13 1 1 0 0 0 0 0 0 0 0 How I treat MDS after hypomethylating agent failure The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-785915 Silverchair:260537 Total_Item_Investigations 4 0 3 1 0 0 0 0 0 0 0 0 0 How I treat MDS after hypomethylating agent failure The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-785915 Silverchair:260537 Total_Item_Requests 4 0 3 1 0 0 0 0 0 0 0 0 0 How I treat MDS after hypomethylating agent failure The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-785915 Silverchair:260537 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 How I treat MDS after hypomethylating agent failure The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-785915 Silverchair:260537 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 How I treat MDS and AML in Fanconi anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-583625 Silverchair:35440 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat MDS and AML in Fanconi anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-583625 Silverchair:35440 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat MDS and AML in Fanconi anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-583625 Silverchair:35440 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat MDS and AML in Fanconi anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-583625 Silverchair:35440 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.2019003566 Silverchair:431276 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.2019003566 Silverchair:431276 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.2019003566 Silverchair:431276 No_License 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat microangiopathic hemolytic anemia in patients with cancer The American Society of Hematology American Society of Hematology 10.1182/blood.2019003810 Silverchair:475029 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 How I treat microangiopathic hemolytic anemia in patients with cancer The American Society of Hematology American Society of Hematology 10.1182/blood.2019003810 Silverchair:475029 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 How I treat microangiopathic hemolytic anemia in patients with cancer The American Society of Hematology American Society of Hematology 10.1182/blood.2019003810 Silverchair:475029 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 How I treat microangiopathic hemolytic anemia in patients with cancer The American Society of Hematology American Society of Hematology 10.1182/blood.2019003810 Silverchair:475029 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 How I treat monoclonal gammopathy of renal significance (MGRS) The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-495929 Silverchair:31961 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 How I treat monoclonal gammopathy of renal significance (MGRS) The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-495929 Silverchair:31961 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 How I treat monoclonal gammopathy of renal significance (MGRS) The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-495929 Silverchair:31961 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 How I treat monoclonal gammopathy of renal significance (MGRS) The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-495929 Silverchair:31961 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 How I treat myelodysplastic syndromes of childhood The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-765214 Silverchair:36617 Total_Item_Investigations 6 0 4 2 0 0 0 0 0 0 0 0 0 How I treat myelodysplastic syndromes of childhood The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-765214 Silverchair:36617 Total_Item_Requests 5 0 3 2 0 0 0 0 0 0 0 0 0 How I treat myelodysplastic syndromes of childhood The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-765214 Silverchair:36617 Unique_Item_Investigations 3 0 2 1 0 0 0 0 0 0 0 0 0 How I treat myelodysplastic syndromes of childhood The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-765214 Silverchair:36617 Unique_Item_Requests 3 0 2 1 0 0 0 0 0 0 0 0 0 How I treat myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-575373 Silverchair:33251 Total_Item_Investigations 2 0 0 1 0 0 0 0 0 0 1 0 0 How I treat myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-575373 Silverchair:33251 Total_Item_Requests 2 0 0 1 0 0 0 0 0 0 1 0 0 How I treat myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-575373 Silverchair:33251 Unique_Item_Investigations 2 0 0 1 0 0 0 0 0 0 1 0 0 How I treat myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-575373 Silverchair:33251 Unique_Item_Requests 2 0 0 1 0 0 0 0 0 0 1 0 0 How I treat myelofibrosis after failure of JAK inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-785923 Silverchair:39382 Total_Item_Investigations 2 0 0 1 0 0 0 0 0 1 0 0 0 How I treat myelofibrosis after failure of JAK inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-785923 Silverchair:39382 Total_Item_Requests 2 0 0 1 0 0 0 0 0 1 0 0 0 How I treat myelofibrosis after failure of JAK inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-785923 Silverchair:39382 Unique_Item_Investigations 2 0 0 1 0 0 0 0 0 1 0 0 0 How I treat myelofibrosis after failure of JAK inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-785923 Silverchair:39382 Unique_Item_Requests 2 0 0 1 0 0 0 0 0 1 0 0 0 How I treat newly diagnosed chronic phase CML The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-378919 Silverchair:30736 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 How I treat newly diagnosed chronic phase CML The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-378919 Silverchair:30736 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 How I treat newly diagnosed chronic phase CML The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-378919 Silverchair:30736 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 How I treat newly diagnosed chronic phase CML The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-378919 Silverchair:30736 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children The American Society of Hematology American Society of Hematology 10.1182/blood.2019001557 Silverchair:428813 Total_Item_Investigations 5 1 3 0 0 0 0 0 0 0 0 1 0 How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children The American Society of Hematology American Society of Hematology 10.1182/blood.2019001557 Silverchair:428813 Total_Item_Requests 4 1 2 0 0 0 0 0 0 0 0 1 0 How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children The American Society of Hematology American Society of Hematology 10.1182/blood.2019001557 Silverchair:428813 Unique_Item_Investigations 3 1 1 0 0 0 0 0 0 0 0 1 0 How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children The American Society of Hematology American Society of Hematology 10.1182/blood.2019001557 Silverchair:428813 Unique_Item_Requests 3 1 1 0 0 0 0 0 0 0 0 1 0 How I treat NK/T-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-453233 Silverchair:125555 Total_Item_Investigations 2 0 0 0 0 1 0 1 0 0 0 0 0 How I treat NK/T-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-453233 Silverchair:125555 Total_Item_Requests 2 0 0 0 0 1 0 1 0 0 0 0 0 How I treat NK/T-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-453233 Silverchair:125555 Unique_Item_Investigations 2 0 0 0 0 1 0 1 0 0 0 0 0 How I treat NK/T-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-453233 Silverchair:125555 Unique_Item_Requests 2 0 0 0 0 1 0 1 0 0 0 0 0 How I treat nodular lymphocyte predominant Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-453241 Silverchair:32352 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 How I treat nodular lymphocyte predominant Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-453241 Silverchair:32352 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 How I treat nodular lymphocyte predominant Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-453241 Silverchair:32352 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 How I treat nodular lymphocyte predominant Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-453241 Silverchair:32352 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 How I treat nodular lymphocyte-predominant Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2019004044 Silverchair:463607 No_License 2 0 0 1 0 0 0 1 0 0 0 0 0 How I treat nodular lymphocyte-predominant Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2019004044 Silverchair:463607 Total_Item_Investigations 8 0 0 2 2 0 0 3 1 0 0 0 0 How I treat nodular lymphocyte-predominant Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2019004044 Silverchair:463607 Unique_Item_Investigations 4 0 0 1 1 0 0 1 1 0 0 0 0 How I treat obese patients with oral anticoagulants The American Society of Hematology American Society of Hematology 10.1182/blood.2019003528 Silverchair:440749 Total_Item_Investigations 11 4 3 2 2 0 0 0 0 0 0 0 0 How I treat obese patients with oral anticoagulants The American Society of Hematology American Society of Hematology 10.1182/blood.2019003528 Silverchair:440749 Total_Item_Requests 6 4 0 0 2 0 0 0 0 0 0 0 0 How I treat obese patients with oral anticoagulants The American Society of Hematology American Society of Hematology 10.1182/blood.2019003528 Silverchair:440749 Unique_Item_Investigations 7 4 1 1 1 0 0 0 0 0 0 0 0 How I treat obese patients with oral anticoagulants The American Society of Hematology American Society of Hematology 10.1182/blood.2019003528 Silverchair:440749 Unique_Item_Requests 5 4 0 0 1 0 0 0 0 0 0 0 0 How I treat obese patients with oral anticoagulants The American Society of Hematology American Society of Hematology 10.1182/blood.2019003528 Silverchair:440749 No_License 2 0 1 1 0 0 0 0 0 0 0 0 0 How I treat paroxysmal nocturnal hemoglobinuria The American Society of Hematology American Society of Hematology 10.1182/blood.2019003812 Silverchair:475031 Total_Item_Investigations 8 2 2 2 0 0 2 0 0 0 0 0 0 How I treat paroxysmal nocturnal hemoglobinuria The American Society of Hematology American Society of Hematology 10.1182/blood.2019003812 Silverchair:475031 Total_Item_Requests 3 1 0 0 0 0 2 0 0 0 0 0 0 How I treat paroxysmal nocturnal hemoglobinuria The American Society of Hematology American Society of Hematology 10.1182/blood.2019003812 Silverchair:475031 Unique_Item_Investigations 4 1 1 1 0 0 1 0 0 0 0 0 0 How I treat paroxysmal nocturnal hemoglobinuria The American Society of Hematology American Society of Hematology 10.1182/blood.2019003812 Silverchair:475031 Unique_Item_Requests 2 1 0 0 0 0 1 0 0 0 0 0 0 How I treat patients with a history of heparin-induced thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-635003 Silverchair:35563 Total_Item_Investigations 2 0 1 0 0 0 0 0 1 0 0 0 0 How I treat patients with a history of heparin-induced thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-635003 Silverchair:35563 Total_Item_Requests 2 0 1 0 0 0 0 0 1 0 0 0 0 How I treat patients with a history of heparin-induced thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-635003 Silverchair:35563 Unique_Item_Investigations 2 0 1 0 0 0 0 0 1 0 0 0 0 How I treat patients with a history of heparin-induced thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-635003 Silverchair:35563 Unique_Item_Requests 2 0 1 0 0 0 0 0 1 0 0 0 0 How I treat patients with aggressive lymphoma at high risk of CNS relapse The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-737460 Silverchair:36993 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat patients with aggressive lymphoma at high risk of CNS relapse The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-737460 Silverchair:36993 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat patients with aggressive lymphoma at high risk of CNS relapse The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-737460 Silverchair:36993 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat patients with aggressive lymphoma at high risk of CNS relapse The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-737460 Silverchair:36993 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat patients with hereditary antithrombin deficiency The American Society of Hematology American Society of Hematology 10.1182/blood.2019002927 Silverchair:422690 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 How I treat patients with hereditary antithrombin deficiency The American Society of Hematology American Society of Hematology 10.1182/blood.2019002927 Silverchair:422690 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 How I treat patients with hereditary antithrombin deficiency The American Society of Hematology American Society of Hematology 10.1182/blood.2019002927 Silverchair:422690 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 How I treat patients with hereditary antithrombin deficiency The American Society of Hematology American Society of Hematology 10.1182/blood.2019002927 Silverchair:422690 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage) The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-453183 Silverchair:31589 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage) The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-453183 Silverchair:31589 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage) The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-453183 Silverchair:31589 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage) The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-453183 Silverchair:31589 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat patients with myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-038935 Silverchair:25661 Total_Item_Investigations 2 1 0 0 0 0 0 0 0 0 1 0 0 How I treat patients with myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-038935 Silverchair:25661 Total_Item_Requests 2 1 0 0 0 0 0 0 0 0 1 0 0 How I treat patients with myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-038935 Silverchair:25661 Unique_Item_Investigations 2 1 0 0 0 0 0 0 0 0 1 0 0 How I treat patients with myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-038935 Silverchair:25661 Unique_Item_Requests 2 1 0 0 0 0 0 0 0 0 1 0 0 How I treat patients with polycythemia vera The American Society of Hematology American Society of Hematology 10.1182/blood-2006-12-038968 Silverchair:22963 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat patients with polycythemia vera The American Society of Hematology American Society of Hematology 10.1182/blood-2006-12-038968 Silverchair:22963 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat patients with polycythemia vera The American Society of Hematology American Society of Hematology 10.1182/blood-2006-12-038968 Silverchair:22963 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat patients with polycythemia vera The American Society of Hematology American Society of Hematology 10.1182/blood-2006-12-038968 Silverchair:22963 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat patients with thrombotic thrombocytopenic purpura: 2010 The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-271445 Silverchair:28083 Total_Item_Investigations 4 1 3 0 0 0 0 0 0 0 0 0 0 How I treat patients with thrombotic thrombocytopenic purpura: 2010 The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-271445 Silverchair:28083 Total_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 How I treat patients with thrombotic thrombocytopenic purpura: 2010 The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-271445 Silverchair:28083 Unique_Item_Investigations 3 1 2 0 0 0 0 0 0 0 0 0 0 How I treat patients with thrombotic thrombocytopenic purpura: 2010 The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-271445 Silverchair:28083 Unique_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 How I treat patients with von Willebrand disease The American Society of Hematology American Society of Hematology 10.1182/blood.V97.7.1915 Silverchair:53343 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 How I treat patients with von Willebrand disease The American Society of Hematology American Society of Hematology 10.1182/blood.V97.7.1915 Silverchair:53343 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 How I treat patients with von Willebrand disease The American Society of Hematology American Society of Hematology 10.1182/blood.V97.7.1915 Silverchair:53343 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat patients with von Willebrand disease The American Society of Hematology American Society of Hematology 10.1182/blood.V97.7.1915 Silverchair:53343 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat pediatric venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-742320 Silverchair:36492 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 How I treat pediatric venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-742320 Silverchair:36492 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 How I treat pediatric venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-742320 Silverchair:36492 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat pediatric venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-742320 Silverchair:36492 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat Philadelphia chromosome–positive acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-242750 Silverchair:27934 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat Philadelphia chromosome–positive acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-242750 Silverchair:27934 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat Philadelphia chromosome–positive acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-242750 Silverchair:27934 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat Philadelphia chromosome–positive acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-242750 Silverchair:27934 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat Philadelphia chromosome–positive acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-832105 Silverchair:39555 Total_Item_Investigations 3 2 0 0 0 0 0 1 0 0 0 0 0 How I treat Philadelphia chromosome–positive acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-832105 Silverchair:39555 Total_Item_Requests 3 2 0 0 0 0 0 1 0 0 0 0 0 How I treat Philadelphia chromosome–positive acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-832105 Silverchair:39555 Unique_Item_Investigations 2 1 0 0 0 0 0 1 0 0 0 0 0 How I treat Philadelphia chromosome–positive acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-832105 Silverchair:39555 Unique_Item_Requests 2 1 0 0 0 0 0 1 0 0 0 0 0 How I treat plasma cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-408682 Silverchair:30567 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat plasma cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-408682 Silverchair:30567 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat plasma cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-408682 Silverchair:30567 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat plasma cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-408682 Silverchair:30567 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat POEMS syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-378992 Silverchair:30317 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat POEMS syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-378992 Silverchair:30317 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat POEMS syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-378992 Silverchair:30317 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat POEMS syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-378992 Silverchair:30317 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat polycythemia vera The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-551929 Silverchair:33372 Total_Item_Investigations 2 0 0 0 0 0 0 2 0 0 0 0 0 How I treat polycythemia vera The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-551929 Silverchair:33372 Total_Item_Requests 2 0 0 0 0 0 0 2 0 0 0 0 0 How I treat polycythemia vera The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-551929 Silverchair:33372 Unique_Item_Investigations 2 0 0 0 0 0 0 2 0 0 0 0 0 How I treat polycythemia vera The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-551929 Silverchair:33372 Unique_Item_Requests 2 0 0 0 0 0 0 2 0 0 0 0 0 How I treat polycythemia vera The American Society of Hematology American Society of Hematology 10.1182/blood.2018834044 Silverchair:260695 Total_Item_Investigations 7 1 3 1 0 1 0 0 1 0 0 0 0 How I treat polycythemia vera The American Society of Hematology American Society of Hematology 10.1182/blood.2018834044 Silverchair:260695 Total_Item_Requests 6 1 2 1 0 1 0 0 1 0 0 0 0 How I treat polycythemia vera The American Society of Hematology American Society of Hematology 10.1182/blood.2018834044 Silverchair:260695 Unique_Item_Investigations 6 1 2 1 0 1 0 0 1 0 0 0 0 How I treat polycythemia vera The American Society of Hematology American Society of Hematology 10.1182/blood.2018834044 Silverchair:260695 Unique_Item_Requests 6 1 2 1 0 1 0 0 1 0 0 0 0 How I treat posttransplant lymphoproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-615872 Silverchair:103859 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 How I treat posttransplant lymphoproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-615872 Silverchair:103859 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 How I treat posttransplant lymphoproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-615872 Silverchair:103859 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 How I treat posttransplant lymphoproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-615872 Silverchair:103859 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 How I treat pregnancy-related venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-306589 Silverchair:29752 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat pregnancy-related venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-306589 Silverchair:29752 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat pregnancy-related venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-306589 Silverchair:29752 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat pregnancy-related venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-306589 Silverchair:29752 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat primary CNS lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-321349 Silverchair:28945 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 How I treat primary CNS lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-321349 Silverchair:28945 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 How I treat primary CNS lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-321349 Silverchair:28945 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 How I treat primary CNS lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-321349 Silverchair:28945 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 How I treat primary cutaneous CD30+ lymphoproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood.2019000785 Silverchair:260744 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 How I treat primary cutaneous CD30+ lymphoproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood.2019000785 Silverchair:260744 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat primary cutaneous CD30+ lymphoproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood.2019000785 Silverchair:260744 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat primary cutaneous CD30+ lymphoproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood.2019000785 Silverchair:260744 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment The American Society of Hematology American Society of Hematology 10.1182/blood.2021010968 Silverchair:475696 No_License 1 0 0 0 0 0 0 0 0 1 0 0 0 How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment The American Society of Hematology American Society of Hematology 10.1182/blood.2021010968 Silverchair:475696 Total_Item_Investigations 12 0 0 0 0 6 0 0 0 4 2 0 0 How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment The American Society of Hematology American Society of Hematology 10.1182/blood.2021010968 Silverchair:475696 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment The American Society of Hematology American Society of Hematology 10.1182/blood.2021010968 Silverchair:475696 Unique_Item_Investigations 4 0 0 0 0 2 0 0 0 1 1 0 0 How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment The American Society of Hematology American Society of Hematology 10.1182/blood.2021010968 Silverchair:475696 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 How I treat prolymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-380139 Silverchair:30480 Total_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 How I treat prolymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-380139 Silverchair:30480 Total_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 How I treat prolymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-380139 Silverchair:30480 Unique_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 How I treat prolymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-380139 Silverchair:30480 Unique_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 How I treat recurrent deep-vein thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-671297 Silverchair:35002 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat recurrent deep-vein thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-671297 Silverchair:35002 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat recurrent deep-vein thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-671297 Silverchair:35002 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat recurrent deep-vein thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-671297 Silverchair:35002 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-742304 Silverchair:107600 Total_Item_Investigations 4 0 3 0 0 0 0 0 1 0 0 0 0 How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-742304 Silverchair:107600 Total_Item_Requests 3 0 2 0 0 0 0 0 1 0 0 0 0 How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-742304 Silverchair:107600 Unique_Item_Investigations 3 0 2 0 0 0 0 0 1 0 0 0 0 How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-742304 Silverchair:107600 Unique_Item_Requests 3 0 2 0 0 0 0 0 1 0 0 0 0 How I treat refractory and early relapsed acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-551911 Silverchair:34547 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 How I treat refractory and early relapsed acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-551911 Silverchair:34547 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 How I treat refractory and early relapsed acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-551911 Silverchair:34547 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat refractory and early relapsed acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-551911 Silverchair:34547 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat refractory chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-785899 Silverchair:260481 Total_Item_Investigations 3 1 2 0 0 0 0 0 0 0 0 0 0 How I treat refractory chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-785899 Silverchair:260481 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 How I treat refractory chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-785899 Silverchair:260481 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 How I treat refractory chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-785899 Silverchair:260481 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 How I treat refractory immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-03-603365 Silverchair:73115 Total_Item_Investigations 11 1 1 3 0 5 1 0 0 0 0 0 0 How I treat refractory immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-03-603365 Silverchair:73115 Total_Item_Requests 11 1 1 3 0 5 1 0 0 0 0 0 0 How I treat refractory immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-03-603365 Silverchair:73115 Unique_Item_Investigations 6 1 1 2 0 1 1 0 0 0 0 0 0 How I treat refractory immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-03-603365 Silverchair:73115 Unique_Item_Requests 6 1 1 2 0 1 1 0 0 0 0 0 0 How I treat refractory thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-551580 Silverchair:34308 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 How I treat refractory thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-551580 Silverchair:34308 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 How I treat refractory thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-551580 Silverchair:34308 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 How I treat refractory thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-551580 Silverchair:34308 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 How I treat relapsed acute lymphoblastic leukemia in the pediatric population The American Society of Hematology American Society of Hematology 10.1182/blood.2019004043 Silverchair:461194 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 How I treat relapsed acute lymphoblastic leukemia in the pediatric population The American Society of Hematology American Society of Hematology 10.1182/blood.2019004043 Silverchair:461194 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 How I treat relapsed acute lymphoblastic leukemia in the pediatric population The American Society of Hematology American Society of Hematology 10.1182/blood.2019004043 Silverchair:461194 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat relapsed acute lymphoblastic leukemia in the pediatric population The American Society of Hematology American Society of Hematology 10.1182/blood.2019004043 Silverchair:461194 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 How I treat relapsed and refractory Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-288373 Silverchair:20808 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 How I treat relapsed and refractory Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-288373 Silverchair:20808 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 How I treat relapsed and refractory Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-288373 Silverchair:20808 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 How I treat relapsed and refractory Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-288373 Silverchair:20808 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 How I treat relapsed or refractory AML The American Society of Hematology American Society of Hematology 10.1182/blood.2019001982 Silverchair:460740 Total_Item_Investigations 11 2 0 4 3 2 0 0 0 0 0 0 0 How I treat relapsed or refractory AML The American Society of Hematology American Society of Hematology 10.1182/blood.2019001982 Silverchair:460740 Total_Item_Requests 6 2 0 4 0 0 0 0 0 0 0 0 0 How I treat relapsed or refractory AML The American Society of Hematology American Society of Hematology 10.1182/blood.2019001982 Silverchair:460740 Unique_Item_Investigations 5 2 0 1 1 1 0 0 0 0 0 0 0 How I treat relapsed or refractory AML The American Society of Hematology American Society of Hematology 10.1182/blood.2019001982 Silverchair:460740 Unique_Item_Requests 3 2 0 1 0 0 0 0 0 0 0 0 0 How I treat relapsed or refractory AML The American Society of Hematology American Society of Hematology 10.1182/blood.2019001982 Silverchair:460740 No_License 1 0 0 0 1 0 0 0 0 0 0 0 0 How I treat renal anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019004330 Silverchair:461033 Total_Item_Investigations 2 0 1 0 0 0 1 0 0 0 0 0 0 How I treat renal anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019004330 Silverchair:461033 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat renal anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019004330 Silverchair:461033 Unique_Item_Investigations 2 0 1 0 0 0 1 0 0 0 0 0 0 How I treat renal anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019004330 Silverchair:461033 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat severe combined immunodeficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-380105 Silverchair:114990 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat severe combined immunodeficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-380105 Silverchair:114990 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat severe combined immunodeficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-380105 Silverchair:114990 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat severe combined immunodeficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-380105 Silverchair:114990 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat smoldering multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-551549 Silverchair:33463 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 How I treat smoldering multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-551549 Silverchair:33463 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat smoldering multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-551549 Silverchair:33463 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat smoldering multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-551549 Silverchair:33463 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat splanchnic vein thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-551515 Silverchair:33588 Total_Item_Investigations 4 2 1 1 0 0 0 0 0 0 0 0 0 How I treat splanchnic vein thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-551515 Silverchair:33588 Total_Item_Requests 4 2 1 1 0 0 0 0 0 0 0 0 0 How I treat splanchnic vein thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-551515 Silverchair:33588 Unique_Item_Investigations 4 2 1 1 0 0 0 0 0 0 0 0 0 How I treat splanchnic vein thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-551515 Silverchair:33588 Unique_Item_Requests 4 2 1 1 0 0 0 0 0 0 0 0 0 How I treat steroid-refractory acute graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019000960 Silverchair:452748 Total_Item_Investigations 10 4 4 2 0 0 0 0 0 0 0 0 0 How I treat steroid-refractory acute graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019000960 Silverchair:452748 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 How I treat steroid-refractory acute graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019000960 Silverchair:452748 Unique_Item_Investigations 6 3 1 2 0 0 0 0 0 0 0 0 0 How I treat steroid-refractory acute graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019000960 Silverchair:452748 Unique_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 How I treat steroid-refractory acute graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019000960 Silverchair:452748 No_License 2 0 2 0 0 0 0 0 0 0 0 0 0 How I treat T-cell acute lymphoblastic leukemia in adults The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-551895 Silverchair:34458 Total_Item_Investigations 6 6 0 0 0 0 0 0 0 0 0 0 0 How I treat T-cell acute lymphoblastic leukemia in adults The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-551895 Silverchair:34458 Total_Item_Requests 6 6 0 0 0 0 0 0 0 0 0 0 0 How I treat T-cell acute lymphoblastic leukemia in adults The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-551895 Silverchair:34458 Unique_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 How I treat T-cell acute lymphoblastic leukemia in adults The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-551895 Silverchair:34458 Unique_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 How I treat the acquired von Willebrand syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2010-11-297580 Silverchair:24352 Total_Item_Investigations 4 2 1 0 1 0 0 0 0 0 0 0 0 How I treat the acquired von Willebrand syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2010-11-297580 Silverchair:24352 Total_Item_Requests 4 2 1 0 1 0 0 0 0 0 0 0 0 How I treat the acquired von Willebrand syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2010-11-297580 Silverchair:24352 Unique_Item_Investigations 3 1 1 0 1 0 0 0 0 0 0 0 0 How I treat the acquired von Willebrand syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2010-11-297580 Silverchair:24352 Unique_Item_Requests 3 1 1 0 1 0 0 0 0 0 0 0 0 How I treat the older adult with sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-818161 Silverchair:39513 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 How I treat the older adult with sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-818161 Silverchair:39513 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 How I treat the older adult with sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-818161 Silverchair:39513 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat the older adult with sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-818161 Silverchair:39513 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat the postthrombotic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-785956 Silverchair:6532 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat the postthrombotic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-785956 Silverchair:6532 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat the postthrombotic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-785956 Silverchair:6532 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat the postthrombotic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-785956 Silverchair:6532 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019002477 Silverchair:440580 No_License 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019002477 Silverchair:440580 Total_Item_Investigations 4 2 2 0 0 0 0 0 0 0 0 0 0 How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019002477 Silverchair:440580 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019002477 Silverchair:440580 Unique_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019002477 Silverchair:440580 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 How I treat thrombocytopenia in pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood-2012-08-448944 Silverchair:31058 Total_Item_Investigations 11 6 0 3 0 0 0 0 0 0 2 0 0 How I treat thrombocytopenia in pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood-2012-08-448944 Silverchair:31058 Total_Item_Requests 11 6 0 3 0 0 0 0 0 0 2 0 0 How I treat thrombocytopenia in pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood-2012-08-448944 Silverchair:31058 Unique_Item_Investigations 8 4 0 3 0 0 0 0 0 0 1 0 0 How I treat thrombocytopenia in pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood-2012-08-448944 Silverchair:31058 Unique_Item_Requests 8 4 0 3 0 0 0 0 0 0 1 0 0 How I treat thrombotic thrombocytopenic purpura in pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood.2019000962 Silverchair:463257 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat thrombotic thrombocytopenic purpura in pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood.2019000962 Silverchair:463257 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat thrombotic thrombocytopenic purpura in pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood.2019000962 Silverchair:463257 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat thrombotic thrombocytopenic purpura in pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood.2019000962 Silverchair:463257 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat transfusional iron overload The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-370098 Silverchair:30692 Total_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 How I treat transfusional iron overload The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-370098 Silverchair:30692 Total_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 How I treat transfusional iron overload The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-370098 Silverchair:30692 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 How I treat transfusional iron overload The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-370098 Silverchair:30692 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 How I treat type 2B von Willebrand disease The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-742692 Silverchair:36611 Total_Item_Investigations 8 0 2 0 4 0 0 0 0 0 2 0 0 How I treat type 2B von Willebrand disease The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-742692 Silverchair:36611 Total_Item_Requests 7 0 1 0 4 0 0 0 0 0 2 0 0 How I treat type 2B von Willebrand disease The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-742692 Silverchair:36611 Unique_Item_Investigations 4 0 1 0 2 0 0 0 0 0 1 0 0 How I treat type 2B von Willebrand disease The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-742692 Silverchair:36611 Unique_Item_Requests 4 0 1 0 2 0 0 0 0 0 1 0 0 How I treat unexplained refractory iron deficiency anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-512624 Silverchair:32289 Total_Item_Investigations 2 0 1 0 0 0 1 0 0 0 0 0 0 How I treat unexplained refractory iron deficiency anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-512624 Silverchair:32289 Total_Item_Requests 2 0 1 0 0 0 1 0 0 0 0 0 0 How I treat unexplained refractory iron deficiency anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-512624 Silverchair:32289 Unique_Item_Investigations 2 0 1 0 0 0 1 0 0 0 0 0 0 How I treat unexplained refractory iron deficiency anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-512624 Silverchair:32289 Unique_Item_Requests 2 0 1 0 0 0 1 0 0 0 0 0 0 How I treat venous thromboembolism in pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood.2019000963 Silverchair:463258 Total_Item_Investigations 6 0 4 0 0 0 0 0 0 0 0 2 0 How I treat venous thromboembolism in pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood.2019000963 Silverchair:463258 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 How I treat venous thromboembolism in pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood.2019000963 Silverchair:463258 Unique_Item_Investigations 4 0 3 0 0 0 0 0 0 0 0 1 0 How I treat venous thromboembolism in pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood.2019000963 Silverchair:463258 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 How I treat venous thromboembolism in pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood.2019000963 Silverchair:463258 No_License 1 0 1 0 0 0 0 0 0 0 0 0 0 How I treat von Willebrand disease The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-153296 Silverchair:26158 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 How I treat von Willebrand disease The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-153296 Silverchair:26158 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 How I treat von Willebrand disease The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-153296 Silverchair:26158 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat von Willebrand disease The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-153296 Silverchair:26158 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How I treat Waldenström macroglobulinemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-553974 Silverchair:34613 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 How I treat Waldenström macroglobulinemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-553974 Silverchair:34613 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 How I treat Waldenström macroglobulinemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-553974 Silverchair:34613 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 How I treat Waldenström macroglobulinemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-553974 Silverchair:34613 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 How I treat Waldenström macroglobulinemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019000725 Silverchair:374984 Total_Item_Investigations 4 0 2 0 0 2 0 0 0 0 0 0 0 How I treat Waldenström macroglobulinemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019000725 Silverchair:374984 Total_Item_Requests 4 0 2 0 0 2 0 0 0 0 0 0 0 How I treat Waldenström macroglobulinemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019000725 Silverchair:374984 Unique_Item_Investigations 4 0 2 0 0 2 0 0 0 0 0 0 0 How I treat Waldenström macroglobulinemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019000725 Silverchair:374984 Unique_Item_Requests 4 0 2 0 0 2 0 0 0 0 0 0 0 How I treat warm autoimmune hemolytic anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019003808 Silverchair:475030 Total_Item_Investigations 4 0 0 0 0 0 0 0 3 1 0 0 0 How I treat warm autoimmune hemolytic anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019003808 Silverchair:475030 Total_Item_Requests 4 0 0 0 0 0 0 0 3 1 0 0 0 How I treat warm autoimmune hemolytic anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019003808 Silverchair:475030 Unique_Item_Investigations 2 0 0 0 0 0 0 0 1 1 0 0 0 How I treat warm autoimmune hemolytic anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019003808 Silverchair:475030 Unique_Item_Requests 2 0 0 0 0 0 0 0 1 1 0 0 0 How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-516237 Silverchair:32643 Total_Item_Investigations 6 1 3 0 0 0 0 1 0 0 0 0 1 How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-516237 Silverchair:32643 Total_Item_Requests 6 1 3 0 0 0 0 1 0 0 0 0 1 How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-516237 Silverchair:32643 Unique_Item_Investigations 4 1 1 0 0 0 0 1 0 0 0 0 1 How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-516237 Silverchair:32643 Unique_Item_Requests 4 1 1 0 0 0 0 1 0 0 0 0 1 How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-551952 Silverchair:34462 Total_Item_Investigations 3 0 1 0 0 0 0 0 0 0 2 0 0 How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-551952 Silverchair:34462 Total_Item_Requests 3 0 1 0 0 0 0 0 0 0 2 0 0 How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-551952 Silverchair:34462 Unique_Item_Investigations 2 0 1 0 0 0 0 0 0 0 1 0 0 How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-551952 Silverchair:34462 Unique_Item_Requests 2 0 1 0 0 0 0 0 0 0 1 0 0 How I use catheter-directed interventional therapy to treat patients with venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-693663 Silverchair:39280 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 How I use catheter-directed interventional therapy to treat patients with venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-693663 Silverchair:39280 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How I use catheter-directed interventional therapy to treat patients with venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-693663 Silverchair:39280 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 How I use catheter-directed interventional therapy to treat patients with venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-693663 Silverchair:39280 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How I use laboratory monitoring of antiplatelet therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-742338 Silverchair:36787 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 How I use laboratory monitoring of antiplatelet therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-742338 Silverchair:36787 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How I use laboratory monitoring of antiplatelet therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-742338 Silverchair:36787 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 How I use laboratory monitoring of antiplatelet therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-742338 Silverchair:36787 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How I vaccinate blood and marrow transplant recipients The American Society of Hematology American Society of Hematology 10.1182/blood-2015-12-550475 Silverchair:35292 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 How I vaccinate blood and marrow transplant recipients The American Society of Hematology American Society of Hematology 10.1182/blood-2015-12-550475 Silverchair:35292 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How I vaccinate blood and marrow transplant recipients The American Society of Hematology American Society of Hematology 10.1182/blood-2015-12-550475 Silverchair:35292 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 How I vaccinate blood and marrow transplant recipients The American Society of Hematology American Society of Hematology 10.1182/blood-2015-12-550475 Silverchair:35292 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018013060 Silverchair:15944 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018013060 Silverchair:15944 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018013060 Silverchair:15944 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018013060 Silverchair:15944 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How much has allogeneic stem cell transplant–related mortality improved since the 1980s? A retrospective analysis from the EBMT American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003418 Silverchair:474704 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 How much has allogeneic stem cell transplant–related mortality improved since the 1980s? A retrospective analysis from the EBMT American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003418 Silverchair:474704 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 How much has allogeneic stem cell transplant–related mortality improved since the 1980s? A retrospective analysis from the EBMT American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003418 Silverchair:474704 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 How much has allogeneic stem cell transplant–related mortality improved since the 1980s? A retrospective analysis from the EBMT American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003418 Silverchair:474704 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 How to approach chronic anemia The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.183.3798257 Silverchair:83845 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 How to approach chronic anemia The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.183.3798257 Silverchair:83845 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 How to approach chronic anemia The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.183.3798257 Silverchair:83845 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 How to approach chronic anemia The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.183.3798257 Silverchair:83845 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "How to approach shared decision making when determining consolidation, maintenance therapy, and transplantation in acute myeloid leukemia" The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000088 Silverchair:474296 Total_Item_Investigations 3 2 0 0 0 0 0 0 0 1 0 0 0 "How to approach shared decision making when determining consolidation, maintenance therapy, and transplantation in acute myeloid leukemia" The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000088 Silverchair:474296 Total_Item_Requests 3 2 0 0 0 0 0 0 0 1 0 0 0 "How to approach shared decision making when determining consolidation, maintenance therapy, and transplantation in acute myeloid leukemia" The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000088 Silverchair:474296 Unique_Item_Investigations 2 1 0 0 0 0 0 0 0 1 0 0 0 "How to approach shared decision making when determining consolidation, maintenance therapy, and transplantation in acute myeloid leukemia" The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000088 Silverchair:474296 Unique_Item_Requests 2 1 0 0 0 0 0 0 0 1 0 0 0 How to approach thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.191.3798260 Silverchair:84114 Total_Item_Investigations 5 3 1 1 0 0 0 0 0 0 0 0 0 How to approach thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.191.3798260 Silverchair:84114 Total_Item_Requests 4 2 1 1 0 0 0 0 0 0 0 0 0 How to approach thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.191.3798260 Silverchair:84114 Unique_Item_Investigations 3 1 1 1 0 0 0 0 0 0 0 0 0 How to approach thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.191.3798260 Silverchair:84114 Unique_Item_Requests 3 1 1 1 0 0 0 0 0 0 0 0 0 How to evaluate and treat the spectrum of TMA syndromes in pregnancy The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000290 Silverchair:483001 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 How to evaluate and treat the spectrum of TMA syndromes in pregnancy The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000290 Silverchair:483001 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 How to evaluate and treat the spectrum of TMA syndromes in pregnancy The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000290 Silverchair:483001 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 How to evaluate and treat the spectrum of TMA syndromes in pregnancy The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000290 Silverchair:483001 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 How to generate large numbers of CD103+ dendritic cells The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-595298 Silverchair:33237 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How to generate large numbers of CD103+ dendritic cells The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-595298 Silverchair:33237 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How to generate large numbers of CD103+ dendritic cells The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-595298 Silverchair:33237 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How to generate large numbers of CD103+ dendritic cells The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-595298 Silverchair:33237 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How to manage CML patients with comorbidities The American Society of Hematology American Society of Hematology 10.1182/blood.2020006911 Silverchair:474218 Total_Item_Investigations 3 0 0 2 0 0 0 0 0 1 0 0 0 How to manage CML patients with comorbidities The American Society of Hematology American Society of Hematology 10.1182/blood.2020006911 Silverchair:474218 Total_Item_Requests 3 0 0 2 0 0 0 0 0 1 0 0 0 How to manage CML patients with comorbidities The American Society of Hematology American Society of Hematology 10.1182/blood.2020006911 Silverchair:474218 Unique_Item_Investigations 2 0 0 1 0 0 0 0 0 1 0 0 0 How to manage CML patients with comorbidities The American Society of Hematology American Society of Hematology 10.1182/blood.2020006911 Silverchair:474218 Unique_Item_Requests 2 0 0 1 0 0 0 0 0 1 0 0 0 How to Prepare an Outstanding Journal Club Presentation American Society of Hematology American Society of Hematology 10.1182/hem.V3.1.1308 Silverchair:461839 Total_Item_Investigations 3 1 2 0 0 0 0 0 0 0 0 0 0 How to Prepare an Outstanding Journal Club Presentation American Society of Hematology American Society of Hematology 10.1182/hem.V3.1.1308 Silverchair:461839 Total_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 How to Prepare an Outstanding Journal Club Presentation American Society of Hematology American Society of Hematology 10.1182/hem.V3.1.1308 Silverchair:461839 Unique_Item_Investigations 3 1 2 0 0 0 0 0 0 0 0 0 0 How to Prepare an Outstanding Journal Club Presentation American Society of Hematology American Society of Hematology 10.1182/hem.V3.1.1308 Silverchair:461839 Unique_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 How To Treat the Patient With Antiphospholipid Antibody Syndrome Who Needs Anticoagulation? American Society of Hematology American Society of Hematology 10.1182/hem.V17.1.10174 Silverchair:463231 Total_Item_Investigations 6 2 4 0 0 0 0 0 0 0 0 0 0 How To Treat the Patient With Antiphospholipid Antibody Syndrome Who Needs Anticoagulation? American Society of Hematology American Society of Hematology 10.1182/hem.V17.1.10174 Silverchair:463231 Total_Item_Requests 5 2 3 0 0 0 0 0 0 0 0 0 0 How To Treat the Patient With Antiphospholipid Antibody Syndrome Who Needs Anticoagulation? American Society of Hematology American Society of Hematology 10.1182/hem.V17.1.10174 Silverchair:463231 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 How To Treat the Patient With Antiphospholipid Antibody Syndrome Who Needs Anticoagulation? American Society of Hematology American Society of Hematology 10.1182/hem.V17.1.10174 Silverchair:463231 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003577 Silverchair:476896 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 0 2 How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003577 Silverchair:476896 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 0 2 How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003577 Silverchair:476896 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003577 Silverchair:476896 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 How we evaluate and treat neutropenia in adults The American Society of Hematology American Society of Hematology 10.1182/blood-2014-02-482612 Silverchair:33512 Total_Item_Investigations 5 0 3 1 0 0 1 0 0 0 0 0 0 How we evaluate and treat neutropenia in adults The American Society of Hematology American Society of Hematology 10.1182/blood-2014-02-482612 Silverchair:33512 Total_Item_Requests 5 0 3 1 0 0 1 0 0 0 0 0 0 How we evaluate and treat neutropenia in adults The American Society of Hematology American Society of Hematology 10.1182/blood-2014-02-482612 Silverchair:33512 Unique_Item_Investigations 3 0 1 1 0 0 1 0 0 0 0 0 0 How we evaluate and treat neutropenia in adults The American Society of Hematology American Society of Hematology 10.1182/blood-2014-02-482612 Silverchair:33512 Unique_Item_Requests 3 0 1 1 0 0 1 0 0 0 0 0 0 How we treat a hemophilia A patient with a factor VIII inhibitor The American Society of Hematology American Society of Hematology 10.1182/blood-2008-06-160432 Silverchair:24374 Total_Item_Investigations 4 0 0 0 1 1 0 0 0 2 0 0 0 How we treat a hemophilia A patient with a factor VIII inhibitor The American Society of Hematology American Society of Hematology 10.1182/blood-2008-06-160432 Silverchair:24374 Total_Item_Requests 4 0 0 0 1 1 0 0 0 2 0 0 0 How we treat a hemophilia A patient with a factor VIII inhibitor The American Society of Hematology American Society of Hematology 10.1182/blood-2008-06-160432 Silverchair:24374 Unique_Item_Investigations 3 0 0 0 1 1 0 0 0 1 0 0 0 How we treat a hemophilia A patient with a factor VIII inhibitor The American Society of Hematology American Society of Hematology 10.1182/blood-2008-06-160432 Silverchair:24374 Unique_Item_Requests 3 0 0 0 1 1 0 0 0 1 0 0 0 How we treat chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-551994 Silverchair:33872 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How we treat chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-551994 Silverchair:33872 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How we treat chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-551994 Silverchair:33872 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How we treat chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-551994 Silverchair:33872 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How we treat higher-risk myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-496935 Silverchair:32594 Total_Item_Investigations 4 1 0 0 1 0 1 1 0 0 0 0 0 How we treat higher-risk myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-496935 Silverchair:32594 Total_Item_Requests 4 1 0 0 1 0 1 1 0 0 0 0 0 How we treat higher-risk myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-496935 Silverchair:32594 Unique_Item_Investigations 4 1 0 0 1 0 1 1 0 0 0 0 0 How we treat higher-risk myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-496935 Silverchair:32594 Unique_Item_Requests 4 1 0 0 1 0 1 1 0 0 0 0 0 How we treat lower-risk myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-453068 Silverchair:31301 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 How we treat lower-risk myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-453068 Silverchair:31301 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How we treat lower-risk myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-453068 Silverchair:31301 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 How we treat lower-risk myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-453068 Silverchair:31301 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 How we treat sickle hepatopathy and liver transplantation in adults The American Society of Hematology American Society of Hematology 10.1182/blood-2013-12-542076 Silverchair:32262 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How we treat sickle hepatopathy and liver transplantation in adults The American Society of Hematology American Society of Hematology 10.1182/blood-2013-12-542076 Silverchair:32262 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 How we treat sickle hepatopathy and liver transplantation in adults The American Society of Hematology American Society of Hematology 10.1182/blood-2013-12-542076 Silverchair:32262 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 How we treat sickle hepatopathy and liver transplantation in adults The American Society of Hematology American Society of Hematology 10.1182/blood-2013-12-542076 Silverchair:32262 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 HSCs revive their niche after transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.2020008923 Silverchair:474271 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 HSCs revive their niche after transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.2020008923 Silverchair:474271 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 HSCs revive their niche after transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.2020008923 Silverchair:474271 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 HSCs revive their niche after transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.2020008923 Silverchair:474271 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization The American Society of Hematology American Society of Hematology 10.1182/blood-2017-12-819706 Silverchair:39389 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization The American Society of Hematology American Society of Hematology 10.1182/blood-2017-12-819706 Silverchair:39389 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization The American Society of Hematology American Society of Hematology 10.1182/blood-2017-12-819706 Silverchair:39389 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization The American Society of Hematology American Society of Hematology 10.1182/blood-2017-12-819706 Silverchair:39389 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-590034 Silverchair:33719 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-590034 Silverchair:33719 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-590034 Silverchair:33719 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-590034 Silverchair:33719 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72(2):567-572." The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-750182 Silverchair:116538 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72(2):567-572." The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-750182 Silverchair:116538 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72(2):567-572." The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-750182 Silverchair:116538 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72(2):567-572." The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-750182 Silverchair:116538 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Huang W, Sun G-L, Li X-S, et al. Acute promyelocytic leukemia: clinical relevance of two major PML-RARα isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood. 1993;82(4):1264-1269." The American Society of Hematology American Society of Hematology 10.1182/blood-2015-08-665737 Silverchair:34676 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Huang W, Sun G-L, Li X-S, et al. Acute promyelocytic leukemia: clinical relevance of two major PML-RARα isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood. 1993;82(4):1264-1269." The American Society of Hematology American Society of Hematology 10.1182/blood-2015-08-665737 Silverchair:34676 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Huang W, Sun G-L, Li X-S, et al. Acute promyelocytic leukemia: clinical relevance of two major PML-RARα isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood. 1993;82(4):1264-1269." The American Society of Hematology American Society of Hematology 10.1182/blood-2015-08-665737 Silverchair:34676 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Huang W, Sun G-L, Li X-S, et al. Acute promyelocytic leukemia: clinical relevance of two major PML-RARα isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood. 1993;82(4):1264-1269." The American Society of Hematology American Society of Hematology 10.1182/blood-2015-08-665737 Silverchair:34676 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Human RPS19, the gene mutated in Diamond-Blackfan anemia, encodes a ribosomal protein required for the maturation of 40S ribosomal subunits" The American Society of Hematology American Society of Hematology 10.1182/blood-2006-07-038232 Silverchair:23926 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Human RPS19, the gene mutated in Diamond-Blackfan anemia, encodes a ribosomal protein required for the maturation of 40S ribosomal subunits" The American Society of Hematology American Society of Hematology 10.1182/blood-2006-07-038232 Silverchair:23926 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Human RPS19, the gene mutated in Diamond-Blackfan anemia, encodes a ribosomal protein required for the maturation of 40S ribosomal subunits" The American Society of Hematology American Society of Hematology 10.1182/blood-2006-07-038232 Silverchair:23926 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Human RPS19, the gene mutated in Diamond-Blackfan anemia, encodes a ribosomal protein required for the maturation of 40S ribosomal subunits" The American Society of Hematology American Society of Hematology 10.1182/blood-2006-07-038232 Silverchair:23926 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Human TET2 bridges cancer and immunity The American Society of Hematology American Society of Hematology 10.1182/blood.2020006881 Silverchair:463418 Total_Item_Investigations 3 1 0 2 0 0 0 0 0 0 0 0 0 Human TET2 bridges cancer and immunity The American Society of Hematology American Society of Hematology 10.1182/blood.2020006881 Silverchair:463418 Total_Item_Requests 3 1 0 2 0 0 0 0 0 0 0 0 0 Human TET2 bridges cancer and immunity The American Society of Hematology American Society of Hematology 10.1182/blood.2020006881 Silverchair:463418 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Human TET2 bridges cancer and immunity The American Society of Hematology American Society of Hematology 10.1182/blood.2020006881 Silverchair:463418 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 "Human CD34+ stem cells express the hiwigene, a human homologue of the Drosophila genepiwi" The American Society of Hematology American Society of Hematology 10.1182/blood.V97.2.426 Silverchair:52879 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Human CD34+ stem cells express the hiwigene, a human homologue of the Drosophila genepiwi" The American Society of Hematology American Society of Hematology 10.1182/blood.V97.2.426 Silverchair:52879 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "Human CD34+ stem cells express the hiwigene, a human homologue of the Drosophila genepiwi" The American Society of Hematology American Society of Hematology 10.1182/blood.V97.2.426 Silverchair:52879 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Human CD34+ stem cells express the hiwigene, a human homologue of the Drosophila genepiwi" The American Society of Hematology American Society of Hematology 10.1182/blood.V97.2.426 Silverchair:52879 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Human CD62L– memory T cells are less responsive to alloantigen stimulation than CD62L+ naive T cells: potential for adoptive immunotherapy and allodepletion The American Society of Hematology American Society of Hematology 10.1182/blood-2003-12-4431 Silverchair:19104 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Human CD62L– memory T cells are less responsive to alloantigen stimulation than CD62L+ naive T cells: potential for adoptive immunotherapy and allodepletion The American Society of Hematology American Society of Hematology 10.1182/blood-2003-12-4431 Silverchair:19104 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Human CD62L– memory T cells are less responsive to alloantigen stimulation than CD62L+ naive T cells: potential for adoptive immunotherapy and allodepletion The American Society of Hematology American Society of Hematology 10.1182/blood-2003-12-4431 Silverchair:19104 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Human CD62L– memory T cells are less responsive to alloantigen stimulation than CD62L+ naive T cells: potential for adoptive immunotherapy and allodepletion The American Society of Hematology American Society of Hematology 10.1182/blood-2003-12-4431 Silverchair:19104 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Human CD68 promoter GFP transgenic mice allow analysis of monocyte to macrophage differentiation in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-568691 Silverchair:33466 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Human CD68 promoter GFP transgenic mice allow analysis of monocyte to macrophage differentiation in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-568691 Silverchair:33466 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Human CD68 promoter GFP transgenic mice allow analysis of monocyte to macrophage differentiation in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-568691 Silverchair:33466 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Human CD68 promoter GFP transgenic mice allow analysis of monocyte to macrophage differentiation in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-568691 Silverchair:33466 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Human induced pluripotent stem cells are capable of B-cell lymphopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-299941 Silverchair:20659 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Human induced pluripotent stem cells are capable of B-cell lymphopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-299941 Silverchair:20659 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Human induced pluripotent stem cells are capable of B-cell lymphopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-299941 Silverchair:20659 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Human induced pluripotent stem cells are capable of B-cell lymphopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-299941 Silverchair:20659 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Human marrow megakaryocyte differentiation: multiparameter correlative analysis identifies von Willebrand factor as a sensitive and distinctive marker for early (2N and 4N) megakaryocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2004-02-0769 Silverchair:19362 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Human marrow megakaryocyte differentiation: multiparameter correlative analysis identifies von Willebrand factor as a sensitive and distinctive marker for early (2N and 4N) megakaryocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2004-02-0769 Silverchair:19362 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Human marrow megakaryocyte differentiation: multiparameter correlative analysis identifies von Willebrand factor as a sensitive and distinctive marker for early (2N and 4N) megakaryocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2004-02-0769 Silverchair:19362 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Human marrow megakaryocyte differentiation: multiparameter correlative analysis identifies von Willebrand factor as a sensitive and distinctive marker for early (2N and 4N) megakaryocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2004-02-0769 Silverchair:19362 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Human megakaryocytes possess intrinsic antiviral immunity through regulated induction of IFITM3 The American Society of Hematology American Society of Hematology 10.1182/blood-2018-09-873984 Silverchair:273820 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Human megakaryocytes possess intrinsic antiviral immunity through regulated induction of IFITM3 The American Society of Hematology American Society of Hematology 10.1182/blood-2018-09-873984 Silverchair:273820 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Human megakaryocytes possess intrinsic antiviral immunity through regulated induction of IFITM3 The American Society of Hematology American Society of Hematology 10.1182/blood-2018-09-873984 Silverchair:273820 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Human megakaryocytes possess intrinsic antiviral immunity through regulated induction of IFITM3 The American Society of Hematology American Society of Hematology 10.1182/blood-2018-09-873984 Silverchair:273820 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2006-05-020800 Silverchair:23560 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2006-05-020800 Silverchair:23560 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2006-05-020800 Silverchair:23560 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2006-05-020800 Silverchair:23560 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Human microRNA-27a* targets Prf1 and GzmB expression to regulate NK-cell cytotoxicity The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-347526 Silverchair:29776 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Human microRNA-27a* targets Prf1 and GzmB expression to regulate NK-cell cytotoxicity The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-347526 Silverchair:29776 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Human microRNA-27a* targets Prf1 and GzmB expression to regulate NK-cell cytotoxicity The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-347526 Silverchair:29776 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Human microRNA-27a* targets Prf1 and GzmB expression to regulate NK-cell cytotoxicity The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-347526 Silverchair:29776 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset The American Society of Hematology American Society of Hematology 10.1182/blood.V97.10.3146 Silverchair:89683 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset The American Society of Hematology American Society of Hematology 10.1182/blood.V97.10.3146 Silverchair:89683 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset The American Society of Hematology American Society of Hematology 10.1182/blood.V97.10.3146 Silverchair:89683 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset The American Society of Hematology American Society of Hematology 10.1182/blood.V97.10.3146 Silverchair:89683 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Human neutrophil heterogeneity exists, but is it meaningful?" The American Society of Hematology American Society of Hematology 10.1182/blood.V63.5.977.977 Silverchair:164167 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "Human neutrophil heterogeneity exists, but is it meaningful?" The American Society of Hematology American Society of Hematology 10.1182/blood.V63.5.977.977 Silverchair:164167 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Human neutrophil heterogeneity exists, but is it meaningful?" The American Society of Hematology American Society of Hematology 10.1182/blood.V63.5.977.977 Silverchair:164167 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Human neutrophil heterogeneity exists, but is it meaningful?" The American Society of Hematology American Society of Hematology 10.1182/blood.V63.5.977.977 Silverchair:164167 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Human NK cells prime inflammatory DC precursors to induce Tc17 differentiation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002084 Silverchair:463457 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Human NK cells prime inflammatory DC precursors to induce Tc17 differentiation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002084 Silverchair:463457 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Human NK cells prime inflammatory DC precursors to induce Tc17 differentiation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002084 Silverchair:463457 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Human NK cells prime inflammatory DC precursors to induce Tc17 differentiation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002084 Silverchair:463457 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Human Plasminogen Activator Inhibitor-1 (PAI-1) Deficiency: Characterization of a Large Kindred With a Null Mutation in the PAI-1 Gene The American Society of Hematology American Society of Hematology 10.1182/blood.V90.1.204 Silverchair:236428 Total_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 Human Plasminogen Activator Inhibitor-1 (PAI-1) Deficiency: Characterization of a Large Kindred With a Null Mutation in the PAI-1 Gene The American Society of Hematology American Society of Hematology 10.1182/blood.V90.1.204 Silverchair:236428 Total_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 Human Plasminogen Activator Inhibitor-1 (PAI-1) Deficiency: Characterization of a Large Kindred With a Null Mutation in the PAI-1 Gene The American Society of Hematology American Society of Hematology 10.1182/blood.V90.1.204 Silverchair:236428 Unique_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 Human Plasminogen Activator Inhibitor-1 (PAI-1) Deficiency: Characterization of a Large Kindred With a Null Mutation in the PAI-1 Gene The American Society of Hematology American Society of Hematology 10.1182/blood.V90.1.204 Silverchair:236428 Unique_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence The American Society of Hematology American Society of Hematology 10.1182/blood-2003-01-0297 Silverchair:17388 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence The American Society of Hematology American Society of Hematology 10.1182/blood-2003-01-0297 Silverchair:17388 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence The American Society of Hematology American Society of Hematology 10.1182/blood-2003-01-0297 Silverchair:17388 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence The American Society of Hematology American Society of Hematology 10.1182/blood-2003-01-0297 Silverchair:17388 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Human t(14;18)positive germinal center B cells: a new step in follicular lymphoma pathogenesis? The American Society of Hematology American Society of Hematology 10.1182/blood-2013-12-545954 Silverchair:32548 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Human t(14;18)positive germinal center B cells: a new step in follicular lymphoma pathogenesis? The American Society of Hematology American Society of Hematology 10.1182/blood-2013-12-545954 Silverchair:32548 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Human t(14;18)positive germinal center B cells: a new step in follicular lymphoma pathogenesis? The American Society of Hematology American Society of Hematology 10.1182/blood-2013-12-545954 Silverchair:32548 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Human t(14;18)positive germinal center B cells: a new step in follicular lymphoma pathogenesis? The American Society of Hematology American Society of Hematology 10.1182/blood-2013-12-545954 Silverchair:32548 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 HUS and atypical HUS The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-709865 Silverchair:36275 Total_Item_Investigations 4 1 2 0 0 0 0 0 0 0 0 0 1 HUS and atypical HUS The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-709865 Silverchair:36275 Total_Item_Requests 4 1 2 0 0 0 0 0 0 0 0 0 1 HUS and atypical HUS The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-709865 Silverchair:36275 Unique_Item_Investigations 3 1 1 0 0 0 0 0 0 0 0 0 1 HUS and atypical HUS The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-709865 Silverchair:36275 Unique_Item_Requests 3 1 1 0 0 0 0 0 0 0 0 0 1 Hydrogen peroxide inhibits IL-12 p40 induction in macrophages by inhibiting c-rel translocation to the nucleus through activation of calmodulin protein The American Society of Hematology American Society of Hematology 10.1182/blood-2005-04-1707 Silverchair:133659 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Hydrogen peroxide inhibits IL-12 p40 induction in macrophages by inhibiting c-rel translocation to the nucleus through activation of calmodulin protein The American Society of Hematology American Society of Hematology 10.1182/blood-2005-04-1707 Silverchair:133659 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Hydrogen peroxide inhibits IL-12 p40 induction in macrophages by inhibiting c-rel translocation to the nucleus through activation of calmodulin protein The American Society of Hematology American Society of Hematology 10.1182/blood-2005-04-1707 Silverchair:133659 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Hydrogen peroxide inhibits IL-12 p40 induction in macrophages by inhibiting c-rel translocation to the nucleus through activation of calmodulin protein The American Society of Hematology American Society of Hematology 10.1182/blood-2005-04-1707 Silverchair:133659 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Hydroxocobalamin V. Prolonged Maintenance of High Vitamin B12 Blood Levels following a Short Course of Hydroxocobalamin Injections The American Society of Hematology American Society of Hematology 10.1182/blood.V27.2.234.234 Silverchair:38199 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Hydroxocobalamin V. Prolonged Maintenance of High Vitamin B12 Blood Levels following a Short Course of Hydroxocobalamin Injections The American Society of Hematology American Society of Hematology 10.1182/blood.V27.2.234.234 Silverchair:38199 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Hydroxyurea in the Early Management of Acute Myeloid Leukemia and Hyperleukocytosis. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4368.4368 Silverchair:84046 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Hydroxyurea in the Early Management of Acute Myeloid Leukemia and Hyperleukocytosis. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4368.4368 Silverchair:84046 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Hydroxyurea in the Early Management of Acute Myeloid Leukemia and Hyperleukocytosis. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4368.4368 Silverchair:84046 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Hydroxyurea in the Early Management of Acute Myeloid Leukemia and Hyperleukocytosis. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4368.4368 Silverchair:84046 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Hydroxyurea Mucocutaneous Toxicity: A Prospective Cohort Study of 110 ET and PV Patients from a Single Institution The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4208.4208 Silverchair:72905 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Hydroxyurea Mucocutaneous Toxicity: A Prospective Cohort Study of 110 ET and PV Patients from a Single Institution The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4208.4208 Silverchair:72905 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Hydroxyurea Mucocutaneous Toxicity: A Prospective Cohort Study of 110 ET and PV Patients from a Single Institution The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4208.4208 Silverchair:72905 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Hydroxyurea Mucocutaneous Toxicity: A Prospective Cohort Study of 110 ET and PV Patients from a Single Institution The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4208.4208 Silverchair:72905 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Hyperbilirubinemia in Myelodysplastic Syndromes American Society of Hematology American Society of Hematology 10.1182/hem.V17.3.10386 Silverchair:461805 Total_Item_Investigations 10 8 2 0 0 0 0 0 0 0 0 0 0 Hyperbilirubinemia in Myelodysplastic Syndromes American Society of Hematology American Society of Hematology 10.1182/hem.V17.3.10386 Silverchair:461805 Total_Item_Requests 10 8 2 0 0 0 0 0 0 0 0 0 0 Hyperbilirubinemia in Myelodysplastic Syndromes American Society of Hematology American Society of Hematology 10.1182/hem.V17.3.10386 Silverchair:461805 Unique_Item_Investigations 8 6 2 0 0 0 0 0 0 0 0 0 0 Hyperbilirubinemia in Myelodysplastic Syndromes American Society of Hematology American Society of Hematology 10.1182/hem.V17.3.10386 Silverchair:461805 Unique_Item_Requests 8 6 2 0 0 0 0 0 0 0 0 0 0 Hypercalcemia in B-Cell Chronic Lymphocytic Leukemia: Report of a Case and Review of the Literature. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.5009.5009 Silverchair:117397 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Hypercalcemia in B-Cell Chronic Lymphocytic Leukemia: Report of a Case and Review of the Literature. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.5009.5009 Silverchair:117397 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Hypercalcemia in B-Cell Chronic Lymphocytic Leukemia: Report of a Case and Review of the Literature. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.5009.5009 Silverchair:117397 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Hypercalcemia in B-Cell Chronic Lymphocytic Leukemia: Report of a Case and Review of the Literature. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.5009.5009 Silverchair:117397 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities? The American Society of Hematology American Society of Hematology 10.1182/blood-2003-07-2274 Silverchair:17772 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities? The American Society of Hematology American Society of Hematology 10.1182/blood-2003-07-2274 Silverchair:17772 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities? The American Society of Hematology American Society of Hematology 10.1182/blood-2003-07-2274 Silverchair:17772 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities? The American Society of Hematology American Society of Hematology 10.1182/blood-2003-07-2274 Silverchair:17772 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Hypereosinophilic syndrome: approach to treatment in the era of precision medicine The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.326 Silverchair:277572 Total_Item_Investigations 4 2 0 2 0 0 0 0 0 0 0 0 0 Hypereosinophilic syndrome: approach to treatment in the era of precision medicine The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.326 Silverchair:277572 Total_Item_Requests 4 2 0 2 0 0 0 0 0 0 0 0 0 Hypereosinophilic syndrome: approach to treatment in the era of precision medicine The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.326 Silverchair:277572 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Hypereosinophilic syndrome: approach to treatment in the era of precision medicine The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.326 Silverchair:277572 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Hypoferritinemia without Anemia the Possible Diagnostic Thought The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119540 Silverchair:262006 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Hypoferritinemia without Anemia the Possible Diagnostic Thought The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119540 Silverchair:262006 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Hypoferritinemia without Anemia the Possible Diagnostic Thought The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119540 Silverchair:262006 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Hypoferritinemia without Anemia the Possible Diagnostic Thought The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119540 Silverchair:262006 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Hypomethylating Agent Maintenance Therapy after Allogeneic Stem Cell Transplant Improves Transplant Outcome in High Risk Acute Myelogenous Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128316 Silverchair:423852 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Hypomethylating Agent Maintenance Therapy after Allogeneic Stem Cell Transplant Improves Transplant Outcome in High Risk Acute Myelogenous Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128316 Silverchair:423852 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Hypomethylating Agent Maintenance Therapy after Allogeneic Stem Cell Transplant Improves Transplant Outcome in High Risk Acute Myelogenous Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128316 Silverchair:423852 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Hypomethylating Agent Maintenance Therapy after Allogeneic Stem Cell Transplant Improves Transplant Outcome in High Risk Acute Myelogenous Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128316 Silverchair:423852 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Hypomethylating Agents in Combination with Venetoclax As a Bridge to Allogeneic Transplant in Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143002 Silverchair:471282 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Hypomethylating Agents in Combination with Venetoclax As a Bridge to Allogeneic Transplant in Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143002 Silverchair:471282 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Hypomethylating Agents in Combination with Venetoclax As a Bridge to Allogeneic Transplant in Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143002 Silverchair:471282 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Hypomethylating Agents in Combination with Venetoclax As a Bridge to Allogeneic Transplant in Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143002 Silverchair:471282 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Hypoplastic MDS Is a Distinct Clinico-Pathological Entity with Somatic Mutations Frequent in Patients with Prior Aplastic Anaemia with Favorable Clinical Outcome The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3269.3269 Silverchair:97882 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Hypoplastic MDS Is a Distinct Clinico-Pathological Entity with Somatic Mutations Frequent in Patients with Prior Aplastic Anaemia with Favorable Clinical Outcome The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3269.3269 Silverchair:97882 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Hypoplastic MDS Is a Distinct Clinico-Pathological Entity with Somatic Mutations Frequent in Patients with Prior Aplastic Anaemia with Favorable Clinical Outcome The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3269.3269 Silverchair:97882 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Hypoplastic MDS Is a Distinct Clinico-Pathological Entity with Somatic Mutations Frequent in Patients with Prior Aplastic Anaemia with Favorable Clinical Outcome The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3269.3269 Silverchair:97882 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Hypoplastic MDS with PNH Clone Treated Successfully with Eculizumab The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.4380.4380 Silverchair:78912 Total_Item_Investigations 2 0 0 1 0 0 1 0 0 0 0 0 0 Hypoplastic MDS with PNH Clone Treated Successfully with Eculizumab The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.4380.4380 Silverchair:78912 Total_Item_Requests 2 0 0 1 0 0 1 0 0 0 0 0 0 Hypoplastic MDS with PNH Clone Treated Successfully with Eculizumab The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.4380.4380 Silverchair:78912 Unique_Item_Investigations 2 0 0 1 0 0 1 0 0 0 0 0 0 Hypoplastic MDS with PNH Clone Treated Successfully with Eculizumab The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.4380.4380 Silverchair:78912 Unique_Item_Requests 2 0 0 1 0 0 1 0 0 0 0 0 0 "Hypoplastic Myelodysplastic Syndrome: Clinical, Histopathological and Molecular Characterization" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.588.588 Silverchair:115640 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Hypoplastic Myelodysplastic Syndrome: Clinical, Histopathological and Molecular Characterization" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.588.588 Silverchair:115640 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Hypoplastic Myelodysplastic Syndrome: Clinical, Histopathological and Molecular Characterization" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.588.588 Silverchair:115640 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Hypoplastic Myelodysplastic Syndrome: Clinical, Histopathological and Molecular Characterization" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.588.588 Silverchair:115640 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Hypoxia-inducible factor-1 and hypoxia response elements mediate the induction of plasminogen activator inhibitor-1 gene expression by insulin in primary rat hepatocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2002-06-1693 Silverchair:88852 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Hypoxia-inducible factor-1 and hypoxia response elements mediate the induction of plasminogen activator inhibitor-1 gene expression by insulin in primary rat hepatocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2002-06-1693 Silverchair:88852 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Hypoxia-inducible factor-1 and hypoxia response elements mediate the induction of plasminogen activator inhibitor-1 gene expression by insulin in primary rat hepatocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2002-06-1693 Silverchair:88852 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Hypoxia-inducible factor-1 and hypoxia response elements mediate the induction of plasminogen activator inhibitor-1 gene expression by insulin in primary rat hepatocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2002-06-1693 Silverchair:88852 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-195941 Silverchair:26118 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-195941 Silverchair:26118 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-195941 Silverchair:26118 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-195941 Silverchair:26118 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 I have a gut feeling… The American Society of Hematology American Society of Hematology 10.1182/blood.2020007186 Silverchair:463735 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 I have a gut feeling… The American Society of Hematology American Society of Hematology 10.1182/blood.2020007186 Silverchair:463735 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 I have a gut feeling… The American Society of Hematology American Society of Hematology 10.1182/blood.2020007186 Silverchair:463735 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 I have a gut feeling… The American Society of Hematology American Society of Hematology 10.1182/blood.2020007186 Silverchair:463735 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001369 Silverchair:469699 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001369 Silverchair:469699 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001369 Silverchair:469699 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001369 Silverchair:469699 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126824 Silverchair:427818 Total_Item_Investigations 2 0 0 0 0 0 1 0 0 0 0 0 1 Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126824 Silverchair:427818 Total_Item_Requests 2 0 0 0 0 0 1 0 0 0 0 0 1 Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126824 Silverchair:427818 Unique_Item_Investigations 2 0 0 0 0 0 1 0 0 0 0 0 1 Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126824 Silverchair:427818 Unique_Item_Requests 2 0 0 0 0 0 1 0 0 0 0 0 1 Ibrutinib for chronic graft-versus-host disease after failure of prior therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-793786 Silverchair:36673 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Ibrutinib for chronic graft-versus-host disease after failure of prior therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-793786 Silverchair:36673 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Ibrutinib for chronic graft-versus-host disease after failure of prior therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-793786 Silverchair:36673 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Ibrutinib for chronic graft-versus-host disease after failure of prior therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-793786 Silverchair:36673 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-879593 Silverchair:272774 Total_Item_Investigations 2 0 0 0 0 0 0 0 2 0 0 0 0 Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-879593 Silverchair:272774 Total_Item_Requests 2 0 0 0 0 0 0 0 2 0 0 0 0 Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-879593 Silverchair:272774 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-879593 Silverchair:272774 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 "Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling" The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-604272 Silverchair:33627 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 "Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling" The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-604272 Silverchair:33627 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling" The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-604272 Silverchair:33627 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling" The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-604272 Silverchair:33627 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-722900 Silverchair:36592 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-722900 Silverchair:36592 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-722900 Silverchair:36592 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-722900 Silverchair:36592 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Ibrutinib Monotherapy in Relapse or Refractory Primary CNS Lymphoma (PCNSL) and Primary Vitreo-Retinal Lymphoma (PVRL). Result of the Interim Analysis of the iLOC Phase II Study from the Lysa and the French LOC Network The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.784.784 Silverchair:99167 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Ibrutinib Monotherapy in Relapse or Refractory Primary CNS Lymphoma (PCNSL) and Primary Vitreo-Retinal Lymphoma (PVRL). Result of the Interim Analysis of the iLOC Phase II Study from the Lysa and the French LOC Network The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.784.784 Silverchair:99167 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Ibrutinib Monotherapy in Relapse or Refractory Primary CNS Lymphoma (PCNSL) and Primary Vitreo-Retinal Lymphoma (PVRL). Result of the Interim Analysis of the iLOC Phase II Study from the Lysa and the French LOC Network The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.784.784 Silverchair:99167 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Ibrutinib Monotherapy in Relapse or Refractory Primary CNS Lymphoma (PCNSL) and Primary Vitreo-Retinal Lymphoma (PVRL). Result of the Interim Analysis of the iLOC Phase II Study from the Lysa and the French LOC Network The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.784.784 Silverchair:99167 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008727 Silverchair:474141 Total_Item_Investigations 11 0 5 6 0 0 0 0 0 0 0 0 0 "Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008727 Silverchair:474141 Total_Item_Requests 8 0 4 4 0 0 0 0 0 0 0 0 0 "Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008727 Silverchair:474141 Unique_Item_Investigations 6 0 2 4 0 0 0 0 0 0 0 0 0 "Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008727 Silverchair:474141 Unique_Item_Requests 5 0 2 3 0 0 0 0 0 0 0 0 0 "Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008727 Silverchair:474141 No_License 1 0 0 1 0 0 0 0 0 0 0 0 0 Ibrutinib-associated tumor lysis syndrome in a patient with chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-591875 Silverchair:33476 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Ibrutinib-associated tumor lysis syndrome in a patient with chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-591875 Silverchair:33476 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Ibrutinib-associated tumor lysis syndrome in a patient with chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-591875 Silverchair:33476 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Ibrutinib-associated tumor lysis syndrome in a patient with chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-591875 Silverchair:33476 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 "ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002395 Silverchair:469710 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 "ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002395 Silverchair:469710 Total_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 "ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002395 Silverchair:469710 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 "ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002395 Silverchair:469710 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 "Identification and characterization of VEGF-A–responsive neutrophils expressing CD49d, VEGFR1, and CXCR4 in mice and humans" The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-631572 Silverchair:34443 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Identification and characterization of VEGF-A–responsive neutrophils expressing CD49d, VEGFR1, and CXCR4 in mice and humans" The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-631572 Silverchair:34443 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Identification and characterization of VEGF-A–responsive neutrophils expressing CD49d, VEGFR1, and CXCR4 in mice and humans" The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-631572 Silverchair:34443 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Identification and characterization of VEGF-A–responsive neutrophils expressing CD49d, VEGFR1, and CXCR4 in mice and humans" The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-631572 Silverchair:34443 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Identification and functional analysis of endothelial tip cell–enriched genes The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-270819 Silverchair:28074 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Identification and functional analysis of endothelial tip cell–enriched genes The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-270819 Silverchair:28074 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Identification and functional analysis of endothelial tip cell–enriched genes The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-270819 Silverchair:28074 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Identification and functional analysis of endothelial tip cell–enriched genes The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-270819 Silverchair:28074 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Identification and transcriptome analysis of erythroblastic island macrophages The American Society of Hematology American Society of Hematology 10.1182/blood.2019000430 Silverchair:273905 Total_Item_Investigations 3 0 0 0 0 3 0 0 0 0 0 0 0 Identification and transcriptome analysis of erythroblastic island macrophages The American Society of Hematology American Society of Hematology 10.1182/blood.2019000430 Silverchair:273905 Total_Item_Requests 3 0 0 0 0 3 0 0 0 0 0 0 0 Identification and transcriptome analysis of erythroblastic island macrophages The American Society of Hematology American Society of Hematology 10.1182/blood.2019000430 Silverchair:273905 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Identification and transcriptome analysis of erythroblastic island macrophages The American Society of Hematology American Society of Hematology 10.1182/blood.2019000430 Silverchair:273905 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-405555 Silverchair:30521 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-405555 Silverchair:30521 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-405555 Silverchair:30521 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-405555 Silverchair:30521 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+T cells The American Society of Hematology American Society of Hematology 10.1182/blood.V96.12.3838 Silverchair:256761 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+T cells The American Society of Hematology American Society of Hematology 10.1182/blood.V96.12.3838 Silverchair:256761 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+T cells The American Society of Hematology American Society of Hematology 10.1182/blood.V96.12.3838 Silverchair:256761 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+T cells The American Society of Hematology American Society of Hematology 10.1182/blood.V96.12.3838 Silverchair:256761 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Identification of a Homeobox-Like Protein Immune Response in Bone Marrow Transplant Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.4856.4856 Silverchair:61999 Total_Item_Investigations 4 0 3 1 0 0 0 0 0 0 0 0 0 Identification of a Homeobox-Like Protein Immune Response in Bone Marrow Transplant Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.4856.4856 Silverchair:61999 Total_Item_Requests 4 0 3 1 0 0 0 0 0 0 0 0 0 Identification of a Homeobox-Like Protein Immune Response in Bone Marrow Transplant Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.4856.4856 Silverchair:61999 Unique_Item_Investigations 3 0 2 1 0 0 0 0 0 0 0 0 0 Identification of a Homeobox-Like Protein Immune Response in Bone Marrow Transplant Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.4856.4856 Silverchair:61999 Unique_Item_Requests 3 0 2 1 0 0 0 0 0 0 0 0 0 Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-838235 Silverchair:39396 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-838235 Silverchair:39396 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-838235 Silverchair:39396 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-838235 Silverchair:39396 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood The American Society of Hematology American Society of Hematology 10.1182/blood-2004-04-1396 Silverchair:19414 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood The American Society of Hematology American Society of Hematology 10.1182/blood-2004-04-1396 Silverchair:19414 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood The American Society of Hematology American Society of Hematology 10.1182/blood-2004-04-1396 Silverchair:19414 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood The American Society of Hematology American Society of Hematology 10.1182/blood-2004-04-1396 Silverchair:19414 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Identification of a Small Subpopulation of Candidate Leukemia Initiating Cells within the Side Population (SP) of Patients with Acute Myeloid Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4120.4120 Silverchair:84136 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Identification of a Small Subpopulation of Candidate Leukemia Initiating Cells within the Side Population (SP) of Patients with Acute Myeloid Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4120.4120 Silverchair:84136 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Identification of a Small Subpopulation of Candidate Leukemia Initiating Cells within the Side Population (SP) of Patients with Acute Myeloid Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4120.4120 Silverchair:84136 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Identification of a Small Subpopulation of Candidate Leukemia Initiating Cells within the Side Population (SP) of Patients with Acute Myeloid Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4120.4120 Silverchair:84136 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-736892 Silverchair:35817 Total_Item_Investigations 7 2 2 3 0 0 0 0 0 0 0 0 0 Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-736892 Silverchair:35817 Total_Item_Requests 7 2 2 3 0 0 0 0 0 0 0 0 0 Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-736892 Silverchair:35817 Unique_Item_Investigations 5 2 1 2 0 0 0 0 0 0 0 0 0 Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-736892 Silverchair:35817 Unique_Item_Requests 5 2 1 2 0 0 0 0 0 0 0 0 0 Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells The American Society of Hematology American Society of Hematology 10.1182/blood-2006-07-034124 Silverchair:23209 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells The American Society of Hematology American Society of Hematology 10.1182/blood-2006-07-034124 Silverchair:23209 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells The American Society of Hematology American Society of Hematology 10.1182/blood-2006-07-034124 Silverchair:23209 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells The American Society of Hematology American Society of Hematology 10.1182/blood-2006-07-034124 Silverchair:23209 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-415380 Silverchair:30225 Total_Item_Investigations 13 0 10 3 0 0 0 0 0 0 0 0 0 Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-415380 Silverchair:30225 Total_Item_Requests 11 0 9 2 0 0 0 0 0 0 0 0 0 Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-415380 Silverchair:30225 Unique_Item_Investigations 5 0 4 1 0 0 0 0 0 0 0 0 0 Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-415380 Silverchair:30225 Unique_Item_Requests 5 0 4 1 0 0 0 0 0 0 0 0 0 Identification of Lin–Sca1+kit+CD34+Flt3– short-term hematopoietic stem cells capable of rapidly reconstituting and rescuing myeloablated transplant recipients The American Society of Hematology American Society of Hematology 10.1182/blood-2004-06-2159 Silverchair:20234 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Identification of Lin–Sca1+kit+CD34+Flt3– short-term hematopoietic stem cells capable of rapidly reconstituting and rescuing myeloablated transplant recipients The American Society of Hematology American Society of Hematology 10.1182/blood-2004-06-2159 Silverchair:20234 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Identification of Lin–Sca1+kit+CD34+Flt3– short-term hematopoietic stem cells capable of rapidly reconstituting and rescuing myeloablated transplant recipients The American Society of Hematology American Society of Hematology 10.1182/blood-2004-06-2159 Silverchair:20234 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Identification of Lin–Sca1+kit+CD34+Flt3– short-term hematopoietic stem cells capable of rapidly reconstituting and rescuing myeloablated transplant recipients The American Society of Hematology American Society of Hematology 10.1182/blood-2004-06-2159 Silverchair:20234 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Identification of megakaryocytes, macrophages, and eosinophils in colonies of human bone marrow containing neurtophilic granulocytes and erythroblasts" The American Society of Hematology American Society of Hematology 10.1182/blood.V53.5.1023.1023 Silverchair:161329 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Identification of megakaryocytes, macrophages, and eosinophils in colonies of human bone marrow containing neurtophilic granulocytes and erythroblasts" The American Society of Hematology American Society of Hematology 10.1182/blood.V53.5.1023.1023 Silverchair:161329 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Identification of myelodysplastic syndrome–specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction The American Society of Hematology American Society of Hematology 10.1182/blood.V98.2.422 Silverchair:107047 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Identification of myelodysplastic syndrome–specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction The American Society of Hematology American Society of Hematology 10.1182/blood.V98.2.422 Silverchair:107047 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Identification of myelodysplastic syndrome–specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction The American Society of Hematology American Society of Hematology 10.1182/blood.V98.2.422 Silverchair:107047 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Identification of myelodysplastic syndrome–specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction The American Society of Hematology American Society of Hematology 10.1182/blood.V98.2.422 Silverchair:107047 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-08-239681 Silverchair:28350 Total_Item_Investigations 4 0 0 4 0 0 0 0 0 0 0 0 0 "Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-08-239681 Silverchair:28350 Total_Item_Requests 4 0 0 4 0 0 0 0 0 0 0 0 0 "Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-08-239681 Silverchair:28350 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 "Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-08-239681 Silverchair:28350 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-840132 Silverchair:39419 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-840132 Silverchair:39419 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-840132 Silverchair:39419 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-840132 Silverchair:39419 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Identification of the Energy Stress Sensor AMPK As Therapeutic Target in Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2771.2771 Silverchair:113561 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Identification of the Energy Stress Sensor AMPK As Therapeutic Target in Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2771.2771 Silverchair:113561 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Identification of the Energy Stress Sensor AMPK As Therapeutic Target in Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2771.2771 Silverchair:113561 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Identification of the Energy Stress Sensor AMPK As Therapeutic Target in Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2771.2771 Silverchair:113561 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Identification of the receptor scavenging hemopexin-heme complexes The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-1185 Silverchair:21696 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Identification of the receptor scavenging hemopexin-heme complexes The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-1185 Silverchair:21696 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Identification of the receptor scavenging hemopexin-heme complexes The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-1185 Silverchair:21696 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Identification of the receptor scavenging hemopexin-heme complexes The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-1185 Silverchair:21696 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment The American Society of Hematology American Society of Hematology 10.1182/blood.2019003599 Silverchair:428874 Total_Item_Investigations 6 6 0 0 0 0 0 0 0 0 0 0 0 Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment The American Society of Hematology American Society of Hematology 10.1182/blood.2019003599 Silverchair:428874 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment The American Society of Hematology American Society of Hematology 10.1182/blood.2019003599 Silverchair:428874 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment The American Society of Hematology American Society of Hematology 10.1182/blood.2019003599 Silverchair:428874 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-276691 Silverchair:27513 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-276691 Silverchair:27513 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-276691 Silverchair:27513 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-276691 Silverchair:27513 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Identifying potential germline variants from sequencing hematopoietic malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2020006910 Silverchair:474217 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Identifying potential germline variants from sequencing hematopoietic malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2020006910 Silverchair:474217 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Identifying potential germline variants from sequencing hematopoietic malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2020006910 Silverchair:474217 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Identifying potential germline variants from sequencing hematopoietic malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2020006910 Silverchair:474217 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Identifying the Genomic Profile of Functional High-Risk Multiple Myeloma Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136553 Silverchair:471061 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Identifying the Genomic Profile of Functional High-Risk Multiple Myeloma Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136553 Silverchair:471061 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Identifying the Genomic Profile of Functional High-Risk Multiple Myeloma Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136553 Silverchair:471061 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Identifying the Genomic Profile of Functional High-Risk Multiple Myeloma Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136553 Silverchair:471061 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000019 Silverchair:422628 Total_Item_Investigations 4 0 0 4 0 0 0 0 0 0 0 0 0 Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000019 Silverchair:422628 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000019 Silverchair:422628 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000019 Silverchair:422628 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 IFITM3 Is a Central Regulator of Lipid Raft Signaling and Essential for CD19 Surface Expression and PI3K Signaling in Human B Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2738.2738 Silverchair:113635 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 IFITM3 Is a Central Regulator of Lipid Raft Signaling and Essential for CD19 Surface Expression and PI3K Signaling in Human B Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2738.2738 Silverchair:113635 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 IFITM3 Is a Central Regulator of Lipid Raft Signaling and Essential for CD19 Surface Expression and PI3K Signaling in Human B Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2738.2738 Silverchair:113635 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 IFITM3 Is a Central Regulator of Lipid Raft Signaling and Essential for CD19 Surface Expression and PI3K Signaling in Human B Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2738.2738 Silverchair:113635 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 IFITM3-Mediated Regulation of Cell Membrane Dynamics Is Essential for Malignant B-Cell Transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117472 Silverchair:263398 Total_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 IFITM3-Mediated Regulation of Cell Membrane Dynamics Is Essential for Malignant B-Cell Transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117472 Silverchair:263398 Total_Item_Requests 3 2 0 1 0 0 0 0 0 0 0 0 0 IFITM3-Mediated Regulation of Cell Membrane Dynamics Is Essential for Malignant B-Cell Transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117472 Silverchair:263398 Unique_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 IFITM3-Mediated Regulation of Cell Membrane Dynamics Is Essential for Malignant B-Cell Transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117472 Silverchair:263398 Unique_Item_Requests 3 2 0 1 0 0 0 0 0 0 0 0 0 IFN-α promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2003-03-0981 Silverchair:17274 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 IFN-α promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2003-03-0981 Silverchair:17274 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 IFN-α promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2003-03-0981 Silverchair:17274 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 IFN-α promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2003-03-0981 Silverchair:17274 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 IFN-γ binds TPO to inhibit hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-03-900977 Silverchair:273812 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 IFN-γ binds TPO to inhibit hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-03-900977 Silverchair:273812 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 IFN-γ binds TPO to inhibit hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-03-900977 Silverchair:273812 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 IFN-γ binds TPO to inhibit hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-03-900977 Silverchair:273812 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 IgA Anticardiolipin Antibodies as a Risk Factor for Arterial and Venous Thrombotic Events. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.4127.4127 Silverchair:122803 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 IgA Anticardiolipin Antibodies as a Risk Factor for Arterial and Venous Thrombotic Events. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.4127.4127 Silverchair:122803 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 IgA Anticardiolipin Antibodies as a Risk Factor for Arterial and Venous Thrombotic Events. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.4127.4127 Silverchair:122803 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 IgA Anticardiolipin Antibodies as a Risk Factor for Arterial and Venous Thrombotic Events. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.4127.4127 Silverchair:122803 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019002655 Silverchair:455304 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019002655 Silverchair:455304 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019002655 Silverchair:455304 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019002655 Silverchair:455304 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2007-09-113050 Silverchair:23355 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2007-09-113050 Silverchair:23355 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2007-09-113050 Silverchair:23355 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2007-09-113050 Silverchair:23355 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2006-02-004747 Silverchair:132619 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 0 3 0 0 IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2006-02-004747 Silverchair:132619 Total_Item_Requests 3 0 0 0 0 0 0 0 0 0 3 0 0 IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2006-02-004747 Silverchair:132619 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2006-02-004747 Silverchair:132619 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 IL6 Signaling Regulates Embryonic Hematopoietic Stem Cell Emergence The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1136.1136 Silverchair:116124 Total_Item_Investigations 5 5 0 0 0 0 0 0 0 0 0 0 0 IL6 Signaling Regulates Embryonic Hematopoietic Stem Cell Emergence The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1136.1136 Silverchair:116124 Total_Item_Requests 5 5 0 0 0 0 0 0 0 0 0 0 0 IL6 Signaling Regulates Embryonic Hematopoietic Stem Cell Emergence The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1136.1136 Silverchair:116124 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 IL6 Signaling Regulates Embryonic Hematopoietic Stem Cell Emergence The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1136.1136 Silverchair:116124 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 IL-7 induces rapid clathrin-mediated internalization and JAK3-dependent degradation of IL-7Rα in T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-246876 Silverchair:27013 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 IL-7 induces rapid clathrin-mediated internalization and JAK3-dependent degradation of IL-7Rα in T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-246876 Silverchair:27013 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 IL-7 induces rapid clathrin-mediated internalization and JAK3-dependent degradation of IL-7Rα in T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-246876 Silverchair:27013 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 IL-7 induces rapid clathrin-mediated internalization and JAK3-dependent degradation of IL-7Rα in T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-246876 Silverchair:27013 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival The American Society of Hematology American Society of Hematology 10.1182/blood-2007-06-096297 Silverchair:133301 Total_Item_Investigations 3 0 0 2 0 0 1 0 0 0 0 0 0 IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival The American Society of Hematology American Society of Hematology 10.1182/blood-2007-06-096297 Silverchair:133301 Total_Item_Requests 2 0 0 1 0 0 1 0 0 0 0 0 0 IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival The American Society of Hematology American Society of Hematology 10.1182/blood-2007-06-096297 Silverchair:133301 Unique_Item_Investigations 2 0 0 1 0 0 1 0 0 0 0 0 0 IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival The American Society of Hematology American Society of Hematology 10.1182/blood-2007-06-096297 Silverchair:133301 Unique_Item_Requests 2 0 0 1 0 0 1 0 0 0 0 0 0 IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-844209 Silverchair:39323 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-844209 Silverchair:39323 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-844209 Silverchair:39323 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-844209 Silverchair:39323 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Imaging in multiple myeloma: How? When? The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-825356 Silverchair:260542 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Imaging in multiple myeloma: How? When? The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-825356 Silverchair:260542 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Imaging in multiple myeloma: How? When? The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-825356 Silverchair:260542 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Imaging in multiple myeloma: How? When? The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-825356 Silverchair:260542 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Imatinib for refractory chronic graft-versus-host disease with fibrotic features The American Society of Hematology American Society of Hematology 10.1182/blood-2009-02-204156 Silverchair:131108 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Imatinib for refractory chronic graft-versus-host disease with fibrotic features The American Society of Hematology American Society of Hematology 10.1182/blood-2009-02-204156 Silverchair:131108 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Imatinib for refractory chronic graft-versus-host disease with fibrotic features The American Society of Hematology American Society of Hematology 10.1182/blood-2009-02-204156 Silverchair:131108 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Imatinib for refractory chronic graft-versus-host disease with fibrotic features The American Society of Hematology American Society of Hematology 10.1182/blood-2009-02-204156 Silverchair:131108 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study The American Society of Hematology American Society of Hematology 10.1182/blood.V99.6.1928 Silverchair:53574 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study The American Society of Hematology American Society of Hematology 10.1182/blood.V99.6.1928 Silverchair:53574 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study The American Society of Hematology American Society of Hematology 10.1182/blood.V99.6.1928 Silverchair:53574 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study The American Society of Hematology American Society of Hematology 10.1182/blood.V99.6.1928 Silverchair:53574 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyPresented in part at the 43rd Annual Meeting of The American Society of Hematology, Orlando, FL, December 11, 2001." The American Society of Hematology American Society of Hematology 10.1182/blood.V99.10.3530 Silverchair:106992 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyPresented in part at the 43rd Annual Meeting of The American Society of Hematology, Orlando, FL, December 11, 2001." The American Society of Hematology American Society of Hematology 10.1182/blood.V99.10.3530 Silverchair:106992 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyPresented in part at the 43rd Annual Meeting of The American Society of Hematology, Orlando, FL, December 11, 2001." The American Society of Hematology American Society of Hematology 10.1182/blood.V99.10.3530 Silverchair:106992 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyPresented in part at the 43rd Annual Meeting of The American Society of Hematology, Orlando, FL, December 11, 2001." The American Society of Hematology American Society of Hematology 10.1182/blood.V99.10.3530 Silverchair:106992 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138810 Silverchair:472721 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138810 Silverchair:472721 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138810 Silverchair:472721 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138810 Silverchair:472721 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 IMiD compounds affect CD34+ cell fate and maturation via CRBN-induced IKZF1 degradation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017010348 Silverchair:15793 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 IMiD compounds affect CD34+ cell fate and maturation via CRBN-induced IKZF1 degradation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017010348 Silverchair:15793 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 IMiD compounds affect CD34+ cell fate and maturation via CRBN-induced IKZF1 degradation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017010348 Silverchair:15793 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 IMiD compounds affect CD34+ cell fate and maturation via CRBN-induced IKZF1 degradation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017010348 Silverchair:15793 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Immature Platelet Fraction: A Useful Marker for Identifying the Cause of Thrombocytopenia and Predicting Platelet Recovery The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113202 Silverchair:262651 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Immature Platelet Fraction: A Useful Marker for Identifying the Cause of Thrombocytopenia and Predicting Platelet Recovery The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113202 Silverchair:262651 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Immature Platelet Fraction: A Useful Marker for Identifying the Cause of Thrombocytopenia and Predicting Platelet Recovery The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113202 Silverchair:262651 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Immature Platelet Fraction: A Useful Marker for Identifying the Cause of Thrombocytopenia and Predicting Platelet Recovery The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113202 Silverchair:262651 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load The American Society of Hematology American Society of Hematology 10.1182/blood-2003-09-3333 Silverchair:18441 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load The American Society of Hematology American Society of Hematology 10.1182/blood-2003-09-3333 Silverchair:18441 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load The American Society of Hematology American Society of Hematology 10.1182/blood-2003-09-3333 Silverchair:18441 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load The American Society of Hematology American Society of Hematology 10.1182/blood-2003-09-3333 Silverchair:18441 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Immune Checkpoint Blockade Enhances Mutated Calreticulin-Induced T Cell Immunity in Myeloproliferative Neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.384.384 Silverchair:71666 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Immune Checkpoint Blockade Enhances Mutated Calreticulin-Induced T Cell Immunity in Myeloproliferative Neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.384.384 Silverchair:71666 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Immune Checkpoint Blockade Enhances Mutated Calreticulin-Induced T Cell Immunity in Myeloproliferative Neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.384.384 Silverchair:71666 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Immune Checkpoint Blockade Enhances Mutated Calreticulin-Induced T Cell Immunity in Myeloproliferative Neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.384.384 Silverchair:71666 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127422 Silverchair:427374 Total_Item_Investigations 2 0 0 1 1 0 0 0 0 0 0 0 0 Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127422 Silverchair:427374 Total_Item_Requests 2 0 0 1 1 0 0 0 0 0 0 0 0 Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127422 Silverchair:427374 Unique_Item_Investigations 2 0 0 1 1 0 0 0 0 0 0 0 0 Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127422 Silverchair:427374 Unique_Item_Requests 2 0 0 1 1 0 0 0 0 0 0 0 0 Immune control of cytomegalovirus reactivation in stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.2020010028 Silverchair:476240 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Immune control of cytomegalovirus reactivation in stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.2020010028 Silverchair:476240 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Immune dysfunctionality of replicative senescent mesenchymal stromal cells is corrected by IFNγ priming American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017006205 Silverchair:15639 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Immune dysfunctionality of replicative senescent mesenchymal stromal cells is corrected by IFNγ priming American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017006205 Silverchair:15639 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Immune dysfunctionality of replicative senescent mesenchymal stromal cells is corrected by IFNγ priming American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017006205 Silverchair:15639 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Immune dysfunctionality of replicative senescent mesenchymal stromal cells is corrected by IFNγ priming American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017006205 Silverchair:15639 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predictive Biomarkers and Clinical Outcomes The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125400 Silverchair:423803 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predictive Biomarkers and Clinical Outcomes The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125400 Silverchair:423803 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predictive Biomarkers and Clinical Outcomes The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125400 Silverchair:423803 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predictive Biomarkers and Clinical Outcomes The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125400 Silverchair:423803 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies The American Society of Hematology American Society of Hematology 10.1182/blood.2019003186 Silverchair:441064 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies The American Society of Hematology American Society of Hematology 10.1182/blood.2019003186 Silverchair:441064 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies The American Society of Hematology American Society of Hematology 10.1182/blood.2019003186 Silverchair:441064 No_License 2 0 2 0 0 0 0 0 0 0 0 0 0 Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002732 Silverchair:474814 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002732 Silverchair:474814 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002732 Silverchair:474814 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002732 Silverchair:474814 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Immune responses to AAV vectors: overcoming barriers to successful gene therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-306647 Silverchair:31570 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Immune responses to AAV vectors: overcoming barriers to successful gene therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-306647 Silverchair:31570 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Immune responses to AAV vectors: overcoming barriers to successful gene therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-306647 Silverchair:31570 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Immune responses to AAV vectors: overcoming barriers to successful gene therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-306647 Silverchair:31570 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Immune Therapies for Myeloma: The CARs Are Here but What's Next? American Society of Hematology American Society of Hematology 10.1182/hem.V18.4.2021413 Silverchair:476193 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Immune Therapies for Myeloma: The CARs Are Here but What's Next? American Society of Hematology American Society of Hematology 10.1182/hem.V18.4.2021413 Silverchair:476193 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Immune Therapies for Myeloma: The CARs Are Here but What's Next? American Society of Hematology American Society of Hematology 10.1182/hem.V18.4.2021413 Silverchair:476193 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Immune Therapies for Myeloma: The CARs Are Here but What's Next? American Society of Hematology American Society of Hematology 10.1182/hem.V18.4.2021413 Silverchair:476193 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Immune Thrombocytopenia Associated with COVID-19 - Case Series The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142611 Silverchair:473195 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Immune Thrombocytopenia Associated with COVID-19 - Case Series The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142611 Silverchair:473195 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Immune Thrombocytopenia Associated with COVID-19 - Case Series The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142611 Silverchair:473195 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Immune Thrombocytopenia Associated with COVID-19 - Case Series The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142611 Silverchair:473195 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Immune Thrombocytopenia with Pulmonary Embolism and Deep-Vein ThrombosisRecommendations for Bone Marrow Aspirate and Biopsy American Society of Hematology American Society of Hematology 10.1182/hem.V8.6.1208 Silverchair:462485 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Immune Thrombocytopenia with Pulmonary Embolism and Deep-Vein ThrombosisRecommendations for Bone Marrow Aspirate and Biopsy American Society of Hematology American Society of Hematology 10.1182/hem.V8.6.1208 Silverchair:462485 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Immune Thrombocytopenia with Pulmonary Embolism and Deep-Vein ThrombosisRecommendations for Bone Marrow Aspirate and Biopsy American Society of Hematology American Society of Hematology 10.1182/hem.V8.6.1208 Silverchair:462485 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Immune Thrombocytopenia with Pulmonary Embolism and Deep-Vein ThrombosisRecommendations for Bone Marrow Aspirate and Biopsy American Society of Hematology American Society of Hematology 10.1182/hem.V8.6.1208 Silverchair:462485 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper The American Society of Hematology American Society of Hematology 10.1182/blood.V96.5.1698 Silverchair:258752 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper The American Society of Hematology American Society of Hematology 10.1182/blood.V96.5.1698 Silverchair:258752 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper The American Society of Hematology American Society of Hematology 10.1182/blood.V96.5.1698 Silverchair:258752 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper The American Society of Hematology American Society of Hematology 10.1182/blood.V96.5.1698 Silverchair:258752 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Immune-Mediated Hematologic Complications of Checkpoint Inhibitors: A Review of the Literature The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113341 Silverchair:263031 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Immune-Mediated Hematologic Complications of Checkpoint Inhibitors: A Review of the Literature The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113341 Silverchair:263031 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Immune-Mediated Hematologic Complications of Checkpoint Inhibitors: A Review of the Literature The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113341 Silverchair:263031 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Immune-Mediated Hematologic Complications of Checkpoint Inhibitors: A Review of the Literature The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113341 Silverchair:263031 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Immunodeficiency and severe susceptibility to bacterial infection associated with a loss-of-function homozygous mutation of MKL1 The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-611012 Silverchair:105442 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Immunodeficiency and severe susceptibility to bacterial infection associated with a loss-of-function homozygous mutation of MKL1 The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-611012 Silverchair:105442 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Immunodeficiency and severe susceptibility to bacterial infection associated with a loss-of-function homozygous mutation of MKL1 The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-611012 Silverchair:105442 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Immunodeficiency and severe susceptibility to bacterial infection associated with a loss-of-function homozygous mutation of MKL1 The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-611012 Silverchair:105442 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal? The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-842559 Silverchair:39601 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal? The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-842559 Silverchair:39601 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal? The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-842559 Silverchair:39601 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal? The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-842559 Silverchair:39601 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Immunodepletion of MDSC By AMV564, a Novel Tetravalent Bispecific CD33/CD3 T Cell Engager Restores Immune Homeostasis in MDS in Vitro" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.51.51 Silverchair:81009 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Immunodepletion of MDSC By AMV564, a Novel Tetravalent Bispecific CD33/CD3 T Cell Engager Restores Immune Homeostasis in MDS in Vitro" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.51.51 Silverchair:81009 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Immunodepletion of MDSC By AMV564, a Novel Tetravalent Bispecific CD33/CD3 T Cell Engager Restores Immune Homeostasis in MDS in Vitro" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.51.51 Silverchair:81009 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Immunodepletion of MDSC By AMV564, a Novel Tetravalent Bispecific CD33/CD3 T Cell Engager Restores Immune Homeostasis in MDS in Vitro" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.51.51 Silverchair:81009 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-108357 Silverchair:103743 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-108357 Silverchair:103743 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-108357 Silverchair:103743 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-108357 Silverchair:103743 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Immunomodulation with Azacytidine and Donor Lymphocyte Infusion Following Sequential Conditioning Allogenic Stem Cell Transplantation Improves Outcome of Unfavorable AML The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131314 Silverchair:424853 Total_Item_Investigations 2 1 0 0 1 0 0 0 0 0 0 0 0 Immunomodulation with Azacytidine and Donor Lymphocyte Infusion Following Sequential Conditioning Allogenic Stem Cell Transplantation Improves Outcome of Unfavorable AML The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131314 Silverchair:424853 Total_Item_Requests 2 1 0 0 1 0 0 0 0 0 0 0 0 Immunomodulation with Azacytidine and Donor Lymphocyte Infusion Following Sequential Conditioning Allogenic Stem Cell Transplantation Improves Outcome of Unfavorable AML The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131314 Silverchair:424853 Unique_Item_Investigations 2 1 0 0 1 0 0 0 0 0 0 0 0 Immunomodulation with Azacytidine and Donor Lymphocyte Infusion Following Sequential Conditioning Allogenic Stem Cell Transplantation Improves Outcome of Unfavorable AML The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131314 Silverchair:424853 Unique_Item_Requests 2 1 0 0 1 0 0 0 0 0 0 0 0 "Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies" The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-741041 Silverchair:107685 Total_Item_Investigations 6 3 3 0 0 0 0 0 0 0 0 0 0 "Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies" The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-741041 Silverchair:107685 Total_Item_Requests 6 3 3 0 0 0 0 0 0 0 0 0 0 "Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies" The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-741041 Silverchair:107685 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 "Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies" The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-741041 Silverchair:107685 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Immunotherapy with Long-Lived Anti-CD123 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human AML Cell Lines and of CD123+ Cells in Monkeys: A Potential Therapy for Acute Myelogenous Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2316.2316 Silverchair:90017 Total_Item_Investigations 5 0 5 0 0 0 0 0 0 0 0 0 0 Immunotherapy with Long-Lived Anti-CD123 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human AML Cell Lines and of CD123+ Cells in Monkeys: A Potential Therapy for Acute Myelogenous Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2316.2316 Silverchair:90017 Total_Item_Requests 5 0 5 0 0 0 0 0 0 0 0 0 0 Immunotherapy with Long-Lived Anti-CD123 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human AML Cell Lines and of CD123+ Cells in Monkeys: A Potential Therapy for Acute Myelogenous Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2316.2316 Silverchair:90017 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Immunotherapy with Long-Lived Anti-CD123 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human AML Cell Lines and of CD123+ Cells in Monkeys: A Potential Therapy for Acute Myelogenous Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2316.2316 Silverchair:90017 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "Impact of FLT3 Mutation Clearance after Front-Line Treatment with Gilteritinib Plus Azacitidine, or Gilteritinib or Azacitidine Alone in Patients with Newly Diagnosed AML: Results from the Phase 2/3 Lacewing Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2021-145362 Silverchair:479613 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 "Impact of FLT3 Mutation Clearance after Front-Line Treatment with Gilteritinib Plus Azacitidine, or Gilteritinib or Azacitidine Alone in Patients with Newly Diagnosed AML: Results from the Phase 2/3 Lacewing Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2021-145362 Silverchair:479613 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 "Impact of FLT3 Mutation Clearance after Front-Line Treatment with Gilteritinib Plus Azacitidine, or Gilteritinib or Azacitidine Alone in Patients with Newly Diagnosed AML: Results from the Phase 2/3 Lacewing Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2021-145362 Silverchair:479613 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 "Impact of FLT3 Mutation Clearance after Front-Line Treatment with Gilteritinib Plus Azacitidine, or Gilteritinib or Azacitidine Alone in Patients with Newly Diagnosed AML: Results from the Phase 2/3 Lacewing Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2021-145362 Silverchair:479613 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC The American Society of Hematology American Society of Hematology 10.1182/blood.2020007193 Silverchair:469791 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC The American Society of Hematology American Society of Hematology 10.1182/blood.2020007193 Silverchair:469791 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC The American Society of Hematology American Society of Hematology 10.1182/blood.2020007193 Silverchair:469791 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC The American Society of Hematology American Society of Hematology 10.1182/blood.2020007193 Silverchair:469791 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131530 Silverchair:426228 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131530 Silverchair:426228 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131530 Silverchair:426228 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131530 Silverchair:426228 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analyses of the AMLSG 16-10 Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.449.449 Silverchair:101354 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analyses of the AMLSG 16-10 Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.449.449 Silverchair:101354 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analyses of the AMLSG 16-10 Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.449.449 Silverchair:101354 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analyses of the AMLSG 16-10 Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.449.449 Silverchair:101354 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-608315 Silverchair:33999 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-608315 Silverchair:33999 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-608315 Silverchair:33999 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-608315 Silverchair:33999 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Impact of anemia on hospitalization and mortality in older adults The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-4308 Silverchair:109753 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Impact of anemia on hospitalization and mortality in older adults The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-4308 Silverchair:109753 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Impact of anemia on hospitalization and mortality in older adults The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-4308 Silverchair:109753 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Impact of anemia on hospitalization and mortality in older adults The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-4308 Silverchair:109753 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study The American Society of Hematology American Society of Hematology 10.1182/blood.2020006941 Silverchair:458074 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study The American Society of Hematology American Society of Hematology 10.1182/blood.2020006941 Silverchair:458074 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study The American Society of Hematology American Society of Hematology 10.1182/blood.2020006941 Silverchair:458074 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study The American Society of Hematology American Society of Hematology 10.1182/blood.2020006941 Silverchair:458074 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Impact of Blood Group Type on Severity of Disease in COVID-19 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139021 Silverchair:469934 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Impact of Blood Group Type on Severity of Disease in COVID-19 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139021 Silverchair:469934 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Impact of Blood Group Type on Severity of Disease in COVID-19 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139021 Silverchair:469934 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Impact of Blood Group Type on Severity of Disease in COVID-19 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139021 Silverchair:469934 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Impact of Body Mass Index (BMI) on Survival Endpoints in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117915 Silverchair:263033 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Impact of Body Mass Index (BMI) on Survival Endpoints in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117915 Silverchair:263033 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Impact of Body Mass Index (BMI) on Survival Endpoints in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117915 Silverchair:263033 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Impact of Body Mass Index (BMI) on Survival Endpoints in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117915 Silverchair:263033 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Impact of Disease Burden in Myelofibrosis Patients: A Sub Analysis from Italian Romei Observational Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125778 Silverchair:425645 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Impact of Disease Burden in Myelofibrosis Patients: A Sub Analysis from Italian Romei Observational Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125778 Silverchair:425645 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Impact of Disease Burden in Myelofibrosis Patients: A Sub Analysis from Italian Romei Observational Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125778 Silverchair:425645 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Impact of Disease Burden in Myelofibrosis Patients: A Sub Analysis from Italian Romei Observational Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125778 Silverchair:425645 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Impact of event-free survival status after stem cell transplantation on subsequent survival of patients with lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003735 Silverchair:475398 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Impact of event-free survival status after stem cell transplantation on subsequent survival of patients with lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003735 Silverchair:475398 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Impact of event-free survival status after stem cell transplantation on subsequent survival of patients with lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003735 Silverchair:475398 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Impact of event-free survival status after stem cell transplantation on subsequent survival of patients with lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003735 Silverchair:475398 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Impact of gender and caregiving responsibilities on academic success in hematology American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000084 Silverchair:452552 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 0 2 Impact of gender and caregiving responsibilities on academic success in hematology American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000084 Silverchair:452552 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 0 2 Impact of gender and caregiving responsibilities on academic success in hematology American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000084 Silverchair:452552 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Impact of gender and caregiving responsibilities on academic success in hematology American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000084 Silverchair:452552 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 "Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD–induced myeloproliferation" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-289207 Silverchair:29313 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD–induced myeloproliferation" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-289207 Silverchair:29313 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD–induced myeloproliferation" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-289207 Silverchair:29313 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD–induced myeloproliferation" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-289207 Silverchair:29313 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) with FLT3 Mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110971 Silverchair:272921 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) with FLT3 Mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110971 Silverchair:272921 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) with FLT3 Mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110971 Silverchair:272921 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) with FLT3 Mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110971 Silverchair:272921 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms (MPN) The American Society of Hematology American Society of Hematology 10.1182/blood.2020010402 Silverchair:475903 Total_Item_Investigations 3 0 0 0 0 0 0 2 0 0 1 0 0 Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms (MPN) The American Society of Hematology American Society of Hematology 10.1182/blood.2020010402 Silverchair:475903 Unique_Item_Investigations 2 0 0 0 0 0 0 1 0 0 1 0 0 Impact of Post-Hematopoietic Cell Transplant (HCT) Survival on Cost-Effectiveness of CPX-351 Versus 7+3 in the Treatment of Therapy-Related AML or AML-MRC in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112252 Silverchair:263012 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 1 1 0 Impact of Post-Hematopoietic Cell Transplant (HCT) Survival on Cost-Effectiveness of CPX-351 Versus 7+3 in the Treatment of Therapy-Related AML or AML-MRC in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112252 Silverchair:263012 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 1 1 0 Impact of Post-Hematopoietic Cell Transplant (HCT) Survival on Cost-Effectiveness of CPX-351 Versus 7+3 in the Treatment of Therapy-Related AML or AML-MRC in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112252 Silverchair:263012 Unique_Item_Investigations 2 0 0 0 0 0 0 0 0 0 1 1 0 Impact of Post-Hematopoietic Cell Transplant (HCT) Survival on Cost-Effectiveness of CPX-351 Versus 7+3 in the Treatment of Therapy-Related AML or AML-MRC in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112252 Silverchair:263012 Unique_Item_Requests 2 0 0 0 0 0 0 0 0 0 1 1 0 Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004665 Silverchair:475898 Total_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004665 Silverchair:475898 Total_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004665 Silverchair:475898 Unique_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004665 Silverchair:475898 Unique_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 Impact of somatic and germline mutations on the outcome of systemic mastocytosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018020628 Silverchair:16172 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Impact of somatic and germline mutations on the outcome of systemic mastocytosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018020628 Silverchair:16172 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Impact of somatic and germline mutations on the outcome of systemic mastocytosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018020628 Silverchair:16172 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Impact of somatic and germline mutations on the outcome of systemic mastocytosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018020628 Silverchair:16172 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-843771 Silverchair:39628 Total_Item_Investigations 6 0 1 2 1 0 0 0 0 0 0 2 0 Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-843771 Silverchair:39628 Total_Item_Requests 6 0 1 2 1 0 0 0 0 0 0 2 0 Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-843771 Silverchair:39628 Unique_Item_Investigations 4 0 1 1 1 0 0 0 0 0 0 1 0 Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-843771 Silverchair:39628 Unique_Item_Requests 4 0 1 1 1 0 0 0 0 0 0 1 0 Impact of TBI-Based Conditioning Regimen on Outcomes of Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant: Systematic Review and Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131126 Silverchair:428657 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Impact of TBI-Based Conditioning Regimen on Outcomes of Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant: Systematic Review and Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131126 Silverchair:428657 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Impact of TBI-Based Conditioning Regimen on Outcomes of Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant: Systematic Review and Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131126 Silverchair:428657 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Impact of TBI-Based Conditioning Regimen on Outcomes of Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant: Systematic Review and Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131126 Silverchair:428657 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Impact of TKIs post–allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive ALL The American Society of Hematology American Society of Hematology 10.1182/blood.2019004685 Silverchair:460671 Total_Item_Investigations 4 0 0 4 0 0 0 0 0 0 0 0 0 Impact of TKIs post–allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive ALL The American Society of Hematology American Society of Hematology 10.1182/blood.2019004685 Silverchair:460671 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Impact of TKIs post–allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive ALL The American Society of Hematology American Society of Hematology 10.1182/blood.2019004685 Silverchair:460671 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Impact of TKIs post–allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive ALL The American Society of Hematology American Society of Hematology 10.1182/blood.2019004685 Silverchair:460671 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Impact of Treatment and Anticoagulation on Thrombosis in COVID-19 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137707 Silverchair:470292 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Impact of Treatment and Anticoagulation on Thrombosis in COVID-19 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137707 Silverchair:470292 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Impact of Treatment and Anticoagulation on Thrombosis in COVID-19 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137707 Silverchair:470292 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Impact of Treatment and Anticoagulation on Thrombosis in COVID-19 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137707 Silverchair:470292 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Impact of treatment delay in acute myeloid leukemia revisited American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003806 Silverchair:475082 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Impact of treatment delay in acute myeloid leukemia revisited American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003806 Silverchair:475082 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Impact of treatment delay in acute myeloid leukemia revisited American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003806 Silverchair:475082 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Impact of treatment delay in acute myeloid leukemia revisited American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003806 Silverchair:475082 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Impaired adhesion of neutrophils expressing Slc44a2/HNA-3b to VWF protects against NETosis under venous shear rates The American Society of Hematology American Society of Hematology 10.1182/blood.2020008345 Silverchair:475196 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Impaired adhesion of neutrophils expressing Slc44a2/HNA-3b to VWF protects against NETosis under venous shear rates The American Society of Hematology American Society of Hematology 10.1182/blood.2020008345 Silverchair:475196 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Impaired Bone Health and Wound Dehiscence in Carriers of Hemophilia a and B The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130846 Silverchair:428289 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 0 0 0 3 Impaired Bone Health and Wound Dehiscence in Carriers of Hemophilia a and B The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130846 Silverchair:428289 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 0 2 Impaired Bone Health and Wound Dehiscence in Carriers of Hemophilia a and B The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130846 Silverchair:428289 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Impaired Bone Health and Wound Dehiscence in Carriers of Hemophilia a and B The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130846 Silverchair:428289 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies The American Society of Hematology American Society of Hematology 10.1182/blood.2021012443 Silverchair:476275 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 2 1 0 0 Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies The American Society of Hematology American Society of Hematology 10.1182/blood.2021012443 Silverchair:476275 Total_Item_Requests 3 0 0 0 0 0 0 0 0 2 1 0 0 Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies The American Society of Hematology American Society of Hematology 10.1182/blood.2021012443 Silverchair:476275 Unique_Item_Investigations 2 0 0 0 0 0 0 0 0 1 1 0 0 Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies The American Society of Hematology American Society of Hematology 10.1182/blood.2021012443 Silverchair:476275 Unique_Item_Requests 2 0 0 0 0 0 0 0 0 1 1 0 0 Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death The American Society of Hematology American Society of Hematology 10.1182/blood.2020007452 Silverchair:474958 Total_Item_Investigations 3 0 2 0 0 0 1 0 0 0 0 0 0 Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death The American Society of Hematology American Society of Hematology 10.1182/blood.2020007452 Silverchair:474958 Unique_Item_Investigations 2 0 1 0 0 0 1 0 0 0 0 0 0 "Impaired survival of peripheral T cells, disrupted NK/NKT cell development, and liver failure in mice lacking Gimap5" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-03-146555 Silverchair:24943 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Impaired survival of peripheral T cells, disrupted NK/NKT cell development, and liver failure in mice lacking Gimap5" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-03-146555 Silverchair:24943 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Impaired survival of peripheral T cells, disrupted NK/NKT cell development, and liver failure in mice lacking Gimap5" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-03-146555 Silverchair:24943 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Impaired survival of peripheral T cells, disrupted NK/NKT cell development, and liver failure in mice lacking Gimap5" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-03-146555 Silverchair:24943 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Implementation of Outpatient High-Dose Cytarabine (HiDAC) for AML: Evaluation of the Impact of Transitioned Outpatient Chemotherapy in an Oncology Care Model Setting The American Society of Hematology American Society of Hematology 10.1182/blood-2019-132121 Silverchair:427873 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Implementation of Outpatient High-Dose Cytarabine (HiDAC) for AML: Evaluation of the Impact of Transitioned Outpatient Chemotherapy in an Oncology Care Model Setting The American Society of Hematology American Society of Hematology 10.1182/blood-2019-132121 Silverchair:427873 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Implementation of Outpatient High-Dose Cytarabine (HiDAC) for AML: Evaluation of the Impact of Transitioned Outpatient Chemotherapy in an Oncology Care Model Setting The American Society of Hematology American Society of Hematology 10.1182/blood-2019-132121 Silverchair:427873 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Implementation of Outpatient High-Dose Cytarabine (HiDAC) for AML: Evaluation of the Impact of Transitioned Outpatient Chemotherapy in an Oncology Care Model Setting The American Society of Hematology American Society of Hematology 10.1182/blood-2019-132121 Silverchair:427873 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-4073 Silverchair:133551 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-4073 Silverchair:133551 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-4073 Silverchair:133551 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-4073 Silverchair:133551 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Improved Overall Survival Among Newly Diagnosed Aggressive Adult T-Cell Leukemia/Lymphoma Patients Treated with Mogamulizumab Plus EPOCH Compared to Mogamulizumab Plus Vcap-AMP-Vecp The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123984 Silverchair:424418 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Improved Overall Survival Among Newly Diagnosed Aggressive Adult T-Cell Leukemia/Lymphoma Patients Treated with Mogamulizumab Plus EPOCH Compared to Mogamulizumab Plus Vcap-AMP-Vecp The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123984 Silverchair:424418 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Improved Overall Survival Among Newly Diagnosed Aggressive Adult T-Cell Leukemia/Lymphoma Patients Treated with Mogamulizumab Plus EPOCH Compared to Mogamulizumab Plus Vcap-AMP-Vecp The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123984 Silverchair:424418 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Improved Overall Survival Among Newly Diagnosed Aggressive Adult T-Cell Leukemia/Lymphoma Patients Treated with Mogamulizumab Plus EPOCH Compared to Mogamulizumab Plus Vcap-AMP-Vecp The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123984 Silverchair:424418 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-547760 Silverchair:32623 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-547760 Silverchair:32623 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Improved transduction of human sheep repopulating cells by retrovirus vectors pseudotyped with feline leukemia virus type C or RD114 envelopes The American Society of Hematology American Society of Hematology 10.1182/blood-2004-11-4491 Silverchair:103174 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Improved transduction of human sheep repopulating cells by retrovirus vectors pseudotyped with feline leukemia virus type C or RD114 envelopes The American Society of Hematology American Society of Hematology 10.1182/blood-2004-11-4491 Silverchair:103174 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Improved transduction of human sheep repopulating cells by retrovirus vectors pseudotyped with feline leukemia virus type C or RD114 envelopes The American Society of Hematology American Society of Hematology 10.1182/blood-2004-11-4491 Silverchair:103174 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Improved transduction of human sheep repopulating cells by retrovirus vectors pseudotyped with feline leukemia virus type C or RD114 envelopes The American Society of Hematology American Society of Hematology 10.1182/blood-2004-11-4491 Silverchair:103174 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-293902 Silverchair:28081 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 "Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-293902 Silverchair:28081 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 "Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-293902 Silverchair:28081 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-293902 Silverchair:28081 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Improving interpretation of genetic testing for hereditary hemorrhagic, thrombotic, and platelet disorders" The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000091 Silverchair:474329 Total_Item_Investigations 6 0 0 2 0 0 2 0 0 0 0 0 2 "Improving interpretation of genetic testing for hereditary hemorrhagic, thrombotic, and platelet disorders" The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000091 Silverchair:474329 Total_Item_Requests 6 0 0 2 0 0 2 0 0 0 0 0 2 "Improving interpretation of genetic testing for hereditary hemorrhagic, thrombotic, and platelet disorders" The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000091 Silverchair:474329 Unique_Item_Investigations 3 0 0 1 0 0 1 0 0 0 0 0 1 "Improving interpretation of genetic testing for hereditary hemorrhagic, thrombotic, and platelet disorders" The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000091 Silverchair:474329 Unique_Item_Requests 3 0 0 1 0 0 1 0 0 0 0 0 1 Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-432203 Silverchair:31410 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-432203 Silverchair:31410 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-432203 Silverchair:31410 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-432203 Silverchair:31410 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Improving specificity in HIT testing The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-289835 Silverchair:27404 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Improving specificity in HIT testing The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-289835 Silverchair:27404 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Improving specificity in HIT testing The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-289835 Silverchair:27404 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Improving specificity in HIT testing The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-289835 Silverchair:27404 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 In vitro activation of coagulation by human neutrophil DNA and histone proteins but not neutrophil extracellular traps The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-722298 Silverchair:36344 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 In vitro activation of coagulation by human neutrophil DNA and histone proteins but not neutrophil extracellular traps The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-722298 Silverchair:36344 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 In vitro activation of coagulation by human neutrophil DNA and histone proteins but not neutrophil extracellular traps The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-722298 Silverchair:36344 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 In vitro activation of coagulation by human neutrophil DNA and histone proteins but not neutrophil extracellular traps The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-722298 Silverchair:36344 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 In Vitro T Cell Differentiation from Human Hematopoietic Stem Cells (HSC) and Lymphoid Progenitors. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.4159.4159 Silverchair:73477 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 In Vitro T Cell Differentiation from Human Hematopoietic Stem Cells (HSC) and Lymphoid Progenitors. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.4159.4159 Silverchair:73477 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 In Vitro T Cell Differentiation from Human Hematopoietic Stem Cells (HSC) and Lymphoid Progenitors. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.4159.4159 Silverchair:73477 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 In Vitro T Cell Differentiation from Human Hematopoietic Stem Cells (HSC) and Lymphoid Progenitors. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.4159.4159 Silverchair:73477 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 In vitro–expanded human CD4+CD25+ T-regulatory cells can markedly inhibit allogeneic dendritic cell–stimulated MLR cultures The American Society of Hematology American Society of Hematology 10.1182/blood-2004-01-0151 Silverchair:18315 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 In vitro–expanded human CD4+CD25+ T-regulatory cells can markedly inhibit allogeneic dendritic cell–stimulated MLR cultures The American Society of Hematology American Society of Hematology 10.1182/blood-2004-01-0151 Silverchair:18315 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 In vitro–expanded human CD4+CD25+ T-regulatory cells can markedly inhibit allogeneic dendritic cell–stimulated MLR cultures The American Society of Hematology American Society of Hematology 10.1182/blood-2004-01-0151 Silverchair:18315 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 In vitro–expanded human CD4+CD25+ T-regulatory cells can markedly inhibit allogeneic dendritic cell–stimulated MLR cultures The American Society of Hematology American Society of Hematology 10.1182/blood-2004-01-0151 Silverchair:18315 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance The American Society of Hematology American Society of Hematology 10.1182/blood-2006-10-049312 Silverchair:125604 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance The American Society of Hematology American Society of Hematology 10.1182/blood-2006-10-049312 Silverchair:125604 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance The American Society of Hematology American Society of Hematology 10.1182/blood-2006-10-049312 Silverchair:125604 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance The American Society of Hematology American Society of Hematology 10.1182/blood-2006-10-049312 Silverchair:125604 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance The American Society of Hematology American Society of Hematology 10.1182/blood-2009-04-214569 Silverchair:26506 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance The American Society of Hematology American Society of Hematology 10.1182/blood-2009-04-214569 Silverchair:26506 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance The American Society of Hematology American Society of Hematology 10.1182/blood-2009-04-214569 Silverchair:26506 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance The American Society of Hematology American Society of Hematology 10.1182/blood-2009-04-214569 Silverchair:26506 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 In vivo fate-tracing studies using the Scl stem cell enhancer: embryonic hematopoietic stem cells significantly contribute to adult hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2004-08-3037 Silverchair:20185 Total_Item_Investigations 8 3 5 0 0 0 0 0 0 0 0 0 0 In vivo fate-tracing studies using the Scl stem cell enhancer: embryonic hematopoietic stem cells significantly contribute to adult hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2004-08-3037 Silverchair:20185 Total_Item_Requests 8 3 5 0 0 0 0 0 0 0 0 0 0 In vivo fate-tracing studies using the Scl stem cell enhancer: embryonic hematopoietic stem cells significantly contribute to adult hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2004-08-3037 Silverchair:20185 Unique_Item_Investigations 4 2 2 0 0 0 0 0 0 0 0 0 0 In vivo fate-tracing studies using the Scl stem cell enhancer: embryonic hematopoietic stem cells significantly contribute to adult hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2004-08-3037 Silverchair:20185 Unique_Item_Requests 4 2 2 0 0 0 0 0 0 0 0 0 0 In vivo peripheral expansion of naive CD4+CD25highFoxP3+ regulatory T cells in patients with multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2005-09-3671 Silverchair:109814 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 In vivo peripheral expansion of naive CD4+CD25highFoxP3+ regulatory T cells in patients with multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2005-09-3671 Silverchair:109814 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 In vivo peripheral expansion of naive CD4+CD25highFoxP3+ regulatory T cells in patients with multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2005-09-3671 Silverchair:109814 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 In vivo peripheral expansion of naive CD4+CD25highFoxP3+ regulatory T cells in patients with multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2005-09-3671 Silverchair:109814 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-415349 Silverchair:30681 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-415349 Silverchair:30681 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-415349 Silverchair:30681 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-415349 Silverchair:30681 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Incidence and Clinical Relevance of TEL/AML1 Fusion Genes in Children With Acute Lymphoblastic Leukemia Enrolled in the German and Italian Multicenter Therapy Trials The American Society of Hematology American Society of Hematology 10.1182/blood.V90.2.571 Silverchair:236598 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Incidence and Clinical Relevance of TEL/AML1 Fusion Genes in Children With Acute Lymphoblastic Leukemia Enrolled in the German and Italian Multicenter Therapy Trials The American Society of Hematology American Society of Hematology 10.1182/blood.V90.2.571 Silverchair:236598 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Incidence and Clinical Relevance of TEL/AML1 Fusion Genes in Children With Acute Lymphoblastic Leukemia Enrolled in the German and Italian Multicenter Therapy Trials The American Society of Hematology American Society of Hematology 10.1182/blood.V90.2.571 Silverchair:236598 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Incidence and Clinical Relevance of TEL/AML1 Fusion Genes in Children With Acute Lymphoblastic Leukemia Enrolled in the German and Italian Multicenter Therapy Trials The American Society of Hematology American Society of Hematology 10.1182/blood.V90.2.571 Silverchair:236598 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis The American Society of Hematology American Society of Hematology 10.1182/blood.2021011849 Silverchair:476634 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis The American Society of Hematology American Society of Hematology 10.1182/blood.2021011849 Silverchair:476634 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis The American Society of Hematology American Society of Hematology 10.1182/blood.2021011849 Silverchair:476634 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis The American Society of Hematology American Society of Hematology 10.1182/blood.2021011849 Silverchair:476634 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Incidence and Prognostic Impact of Crh in Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142551 Silverchair:470575 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Incidence and Prognostic Impact of Crh in Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142551 Silverchair:470575 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Incidence and Prognostic Impact of Crh in Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142551 Silverchair:470575 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Incidence and Prognostic Impact of Crh in Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142551 Silverchair:470575 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with Hydroxyurea The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127568 Silverchair:426189 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with Hydroxyurea The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127568 Silverchair:426189 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with Hydroxyurea The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127568 Silverchair:426189 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with Hydroxyurea The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127568 Silverchair:426189 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Incidence and risk factors of transfusion reactions in postpartum blood transfusions American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000074 Silverchair:260581 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Incidence and risk factors of transfusion reactions in postpartum blood transfusions American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000074 Silverchair:260581 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Incidence and risk factors of transfusion reactions in postpartum blood transfusions American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000074 Silverchair:260581 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Incidence and risk factors of transfusion reactions in postpartum blood transfusions American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000074 Silverchair:260581 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.830.830 Silverchair:83667 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.830.830 Silverchair:83667 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.830.830 Silverchair:83667 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.830.830 Silverchair:83667 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138834 Silverchair:470182 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138834 Silverchair:470182 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138834 Silverchair:470182 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138834 Silverchair:470182 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Incidence of Differentiation Syndrome with Ivosidenib (IVO) and Enasidenib (ENA) for Treatment of Patients with Relapsed or Refractory (R/R) Isocitrate Dehydrogenase (IDH)1- or IDH2-Mutated Acute Myeloid Leukemia (AML): A Systematic Analysis By the U.S. Food and Drug Administration (FDA) The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117426 Silverchair:263959 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Incidence of Differentiation Syndrome with Ivosidenib (IVO) and Enasidenib (ENA) for Treatment of Patients with Relapsed or Refractory (R/R) Isocitrate Dehydrogenase (IDH)1- or IDH2-Mutated Acute Myeloid Leukemia (AML): A Systematic Analysis By the U.S. Food and Drug Administration (FDA) The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117426 Silverchair:263959 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Incidence of Differentiation Syndrome with Ivosidenib (IVO) and Enasidenib (ENA) for Treatment of Patients with Relapsed or Refractory (R/R) Isocitrate Dehydrogenase (IDH)1- or IDH2-Mutated Acute Myeloid Leukemia (AML): A Systematic Analysis By the U.S. Food and Drug Administration (FDA) The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117426 Silverchair:263959 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Incidence of Differentiation Syndrome with Ivosidenib (IVO) and Enasidenib (ENA) for Treatment of Patients with Relapsed or Refractory (R/R) Isocitrate Dehydrogenase (IDH)1- or IDH2-Mutated Acute Myeloid Leukemia (AML): A Systematic Analysis By the U.S. Food and Drug Administration (FDA) The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117426 Silverchair:263959 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Incidence of Germline ATM Variants in a Consecutive Clinical Cohort of CLL Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127180 Silverchair:427514 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Incidence of Germline ATM Variants in a Consecutive Clinical Cohort of CLL Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127180 Silverchair:427514 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Incidence of Germline ATM Variants in a Consecutive Clinical Cohort of CLL Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127180 Silverchair:427514 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Incidence of Germline ATM Variants in a Consecutive Clinical Cohort of CLL Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127180 Silverchair:427514 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003349 Silverchair:474700 Total_Item_Investigations 2 1 0 0 0 0 0 0 0 0 0 0 1 "Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003349 Silverchair:474700 Total_Item_Requests 2 1 0 0 0 0 0 0 0 0 0 0 1 "Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003349 Silverchair:474700 Unique_Item_Investigations 2 1 0 0 0 0 0 0 0 0 0 0 1 "Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003349 Silverchair:474700 Unique_Item_Requests 2 1 0 0 0 0 0 0 0 0 0 0 1 Incidence of Vascular Thromboembolic Events in Patients Receiving Immunotherapy: A Single Institution Experience The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4864.4864 Silverchair:72519 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Incidence of Vascular Thromboembolic Events in Patients Receiving Immunotherapy: A Single Institution Experience The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4864.4864 Silverchair:72519 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Incidence of Vascular Thromboembolic Events in Patients Receiving Immunotherapy: A Single Institution Experience The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4864.4864 Silverchair:72519 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Incidence of Vascular Thromboembolic Events in Patients Receiving Immunotherapy: A Single Institution Experience The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4864.4864 Silverchair:72519 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy" The American Society of Hematology American Society of Hematology 10.1182/blood.2020007878 Silverchair:469619 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 0 2 "Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy" The American Society of Hematology American Society of Hematology 10.1182/blood.2020007878 Silverchair:469619 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 0 2 "Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy" The American Society of Hematology American Society of Hematology 10.1182/blood.2020007878 Silverchair:469619 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 "Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy" The American Society of Hematology American Society of Hematology 10.1182/blood.2020007878 Silverchair:469619 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Incidental pulmonary embolism The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-625780 Silverchair:33723 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Incidental pulmonary embolism The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-625780 Silverchair:33723 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002454 Silverchair:463770 Total_Item_Investigations 3 2 0 0 0 0 0 0 0 1 0 0 0 Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002454 Silverchair:463770 Total_Item_Requests 3 2 0 0 0 0 0 0 0 1 0 0 0 Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002454 Silverchair:463770 Unique_Item_Investigations 3 2 0 0 0 0 0 0 0 1 0 0 0 Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002454 Silverchair:463770 Unique_Item_Requests 3 2 0 0 0 0 0 0 0 1 0 0 0 Incidentally found pulmonary embolism: what's the clinician to do? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.197 Silverchair:20746 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 0 2 Incidentally found pulmonary embolism: what's the clinician to do? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.197 Silverchair:20746 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 0 2 Incidentally found pulmonary embolism: what's the clinician to do? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.197 Silverchair:20746 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Incidentally found pulmonary embolism: what's the clinician to do? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.197 Silverchair:20746 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-732800 Silverchair:36366 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-732800 Silverchair:36366 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-732800 Silverchair:36366 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-732800 Silverchair:36366 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Increased adhesion of erythrocytes to components of the extracellular matrix: isolation and characterization of a red blood cell lipid that binds thrombospondin and laminin The American Society of Hematology American Society of Hematology 10.1182/blood.V87.11.4879.bloodjournal87114879 Silverchair:124842 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 Increased adhesion of erythrocytes to components of the extracellular matrix: isolation and characterization of a red blood cell lipid that binds thrombospondin and laminin The American Society of Hematology American Society of Hematology 10.1182/blood.V87.11.4879.bloodjournal87114879 Silverchair:124842 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Increased adhesion of erythrocytes to components of the extracellular matrix: isolation and characterization of a red blood cell lipid that binds thrombospondin and laminin The American Society of Hematology American Society of Hematology 10.1182/blood.V87.11.4879.bloodjournal87114879 Silverchair:124842 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Increased adhesion of erythrocytes to components of the extracellular matrix: isolation and characterization of a red blood cell lipid that binds thrombospondin and laminin The American Society of Hematology American Society of Hematology 10.1182/blood.V87.11.4879.bloodjournal87114879 Silverchair:124842 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Increased Expression of CD47 Is a Constant Marker in Mouse and Human Myeloid Leukemias. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.3260.3260 Silverchair:121483 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Increased Expression of CD47 Is a Constant Marker in Mouse and Human Myeloid Leukemias. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.3260.3260 Silverchair:121483 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Increased Expression of CD47 Is a Constant Marker in Mouse and Human Myeloid Leukemias. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.3260.3260 Silverchair:121483 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Increased Expression of CD47 Is a Constant Marker in Mouse and Human Myeloid Leukemias. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.3260.3260 Silverchair:121483 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Increased frequency (12%) of circulating chronic lymphocytic leukemia–like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-197368 Silverchair:26064 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Increased frequency (12%) of circulating chronic lymphocytic leukemia–like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-197368 Silverchair:26064 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Increased frequency (12%) of circulating chronic lymphocytic leukemia–like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-197368 Silverchair:26064 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Increased frequency (12%) of circulating chronic lymphocytic leukemia–like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-197368 Silverchair:26064 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Increased incidence of germline PIEZO1 mutations in individuals with idiopathic erythrocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2020008424 Silverchair:474139 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Increased incidence of germline PIEZO1 mutations in individuals with idiopathic erythrocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2020008424 Silverchair:474139 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Increased incidence of germline PIEZO1 mutations in individuals with idiopathic erythrocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2020008424 Silverchair:474139 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Increased incidence of germline PIEZO1 mutations in individuals with idiopathic erythrocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2020008424 Silverchair:474139 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment The American Society of Hematology American Society of Hematology 10.1182/blood.2020005602 Silverchair:463339 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment The American Society of Hematology American Society of Hematology 10.1182/blood.2020005602 Silverchair:463339 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment The American Society of Hematology American Society of Hematology 10.1182/blood.2020005602 Silverchair:463339 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment The American Society of Hematology American Society of Hematology 10.1182/blood.2020005602 Silverchair:463339 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Increased Reactive Oxygen Species and the B-Cell Receptor in Chronic Lymphocytic Leukemia Signaling The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3291.3291 Silverchair:97617 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Increased Reactive Oxygen Species and the B-Cell Receptor in Chronic Lymphocytic Leukemia Signaling The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3291.3291 Silverchair:97617 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Increased Reactive Oxygen Species and the B-Cell Receptor in Chronic Lymphocytic Leukemia Signaling The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3291.3291 Silverchair:97617 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Increased Reactive Oxygen Species and the B-Cell Receptor in Chronic Lymphocytic Leukemia Signaling The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3291.3291 Silverchair:97617 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Increased Risk of Adverse Bone Health Outcomes in People with Bleeding Disorders The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.250.250 Silverchair:98847 Total_Item_Investigations 13 0 0 0 0 0 0 0 1 10 0 0 2 Increased Risk of Adverse Bone Health Outcomes in People with Bleeding Disorders The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.250.250 Silverchair:98847 Total_Item_Requests 13 0 0 0 0 0 0 0 1 10 0 0 2 Increased Risk of Adverse Bone Health Outcomes in People with Bleeding Disorders The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.250.250 Silverchair:98847 Unique_Item_Investigations 12 0 0 0 0 0 0 0 1 9 0 0 2 Increased Risk of Adverse Bone Health Outcomes in People with Bleeding Disorders The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.250.250 Silverchair:98847 Unique_Item_Requests 12 0 0 0 0 0 0 0 1 9 0 0 2 Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V77.7.1423.1423 Silverchair:168566 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V77.7.1423.1423 Silverchair:168566 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V77.7.1423.1423 Silverchair:168566 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V77.7.1423.1423 Silverchair:168566 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-772368 Silverchair:36994 Total_Item_Investigations 5 0 5 0 0 0 0 0 0 0 0 0 0 Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-772368 Silverchair:36994 Total_Item_Requests 5 0 5 0 0 0 0 0 0 0 0 0 0 Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-772368 Silverchair:36994 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-772368 Silverchair:36994 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Indirect Treatment Comparison of CC-486 Versus Azacitidine (AZA) As Maintenance Therapy for Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136752 Silverchair:473067 Total_Item_Investigations 2 0 1 0 0 1 0 0 0 0 0 0 0 Indirect Treatment Comparison of CC-486 Versus Azacitidine (AZA) As Maintenance Therapy for Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136752 Silverchair:473067 Total_Item_Requests 2 0 1 0 0 1 0 0 0 0 0 0 0 Indirect Treatment Comparison of CC-486 Versus Azacitidine (AZA) As Maintenance Therapy for Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136752 Silverchair:473067 Unique_Item_Investigations 2 0 1 0 0 1 0 0 0 0 0 0 0 Indirect Treatment Comparison of CC-486 Versus Azacitidine (AZA) As Maintenance Therapy for Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136752 Silverchair:473067 Unique_Item_Requests 2 0 1 0 0 1 0 0 0 0 0 0 0 Inducing iron deficiency improves erythropoiesis and photosensitivity in congenital erythropoietic porphyria The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-584664 Silverchair:34505 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Inducing iron deficiency improves erythropoiesis and photosensitivity in congenital erythropoietic porphyria The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-584664 Silverchair:34505 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Inducing iron deficiency improves erythropoiesis and photosensitivity in congenital erythropoietic porphyria The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-584664 Silverchair:34505 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Inducing iron deficiency improves erythropoiesis and photosensitivity in congenital erythropoietic porphyria The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-584664 Silverchair:34505 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Induction of the Plasminogen Activator Inhibitor-1 Gene Expression by Mild Hypoxia Via a Hypoxia Response Element Binding the Hypoxia-Inducible Factor-1 in Rat Hepatocytes The American Society of Hematology American Society of Hematology 10.1182/blood.V94.12.4177 Silverchair:247954 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Induction of the Plasminogen Activator Inhibitor-1 Gene Expression by Mild Hypoxia Via a Hypoxia Response Element Binding the Hypoxia-Inducible Factor-1 in Rat Hepatocytes The American Society of Hematology American Society of Hematology 10.1182/blood.V94.12.4177 Silverchair:247954 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Induction of the Plasminogen Activator Inhibitor-1 Gene Expression by Mild Hypoxia Via a Hypoxia Response Element Binding the Hypoxia-Inducible Factor-1 in Rat Hepatocytes The American Society of Hematology American Society of Hematology 10.1182/blood.V94.12.4177 Silverchair:247954 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Induction of the Plasminogen Activator Inhibitor-1 Gene Expression by Mild Hypoxia Via a Hypoxia Response Element Binding the Hypoxia-Inducible Factor-1 in Rat Hepatocytes The American Society of Hematology American Society of Hematology 10.1182/blood.V94.12.4177 Silverchair:247954 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Inferior Vena Cava Filter - Appropriate Use and Retrieval The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5912.5912 Silverchair:94944 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Inferior Vena Cava Filter - Appropriate Use and Retrieval The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5912.5912 Silverchair:94944 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Inferior Vena Cava Filter - Appropriate Use and Retrieval The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5912.5912 Silverchair:94944 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Inferior Vena Cava Filter - Appropriate Use and Retrieval The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5912.5912 Silverchair:94944 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Inferior vena cava filters: a framework for evidence-based use The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000149 Silverchair:474327 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Inferior vena cava filters: a framework for evidence-based use The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000149 Silverchair:474327 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Inferior vena cava filters: a framework for evidence-based use The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000149 Silverchair:474327 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Inferior vena cava filters: a framework for evidence-based use The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000149 Silverchair:474327 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Inferring the dynamic of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.2021010986 Silverchair:476602 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Inferring the dynamic of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.2021010986 Silverchair:476602 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Inflammation Drives Coagulopathies in Sars-Cov-2 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142848 Silverchair:473167 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Inflammation Drives Coagulopathies in Sars-Cov-2 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142848 Silverchair:473167 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Inflammation Drives Coagulopathies in Sars-Cov-2 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142848 Silverchair:473167 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Inflammation Drives Coagulopathies in Sars-Cov-2 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142848 Silverchair:473167 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "Inflammation, von Willebrand factor, and ADAMTS13" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-769000 Silverchair:39218 Total_Item_Investigations 2 0 0 0 0 0 2 0 0 0 0 0 0 "Inflammation, von Willebrand factor, and ADAMTS13" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-769000 Silverchair:39218 Total_Item_Requests 2 0 0 0 0 0 2 0 0 0 0 0 0 "Inflammation, von Willebrand factor, and ADAMTS13" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-769000 Silverchair:39218 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 "Inflammation, von Willebrand factor, and ADAMTS13" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-769000 Silverchair:39218 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells The American Society of Hematology American Society of Hematology 10.1182/blood-2002-05-1300 Silverchair:106723 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells The American Society of Hematology American Society of Hematology 10.1182/blood-2002-05-1300 Silverchair:106723 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells The American Society of Hematology American Society of Hematology 10.1182/blood-2002-05-1300 Silverchair:106723 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells The American Society of Hematology American Society of Hematology 10.1182/blood-2002-05-1300 Silverchair:106723 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Inflammatory signaling regulates hematopoietic stem and progenitor cell emergence in vertebrates The American Society of Hematology American Society of Hematology 10.1182/blood-2014-09-601542 Silverchair:34186 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Inflammatory signaling regulates hematopoietic stem and progenitor cell emergence in vertebrates The American Society of Hematology American Society of Hematology 10.1182/blood-2014-09-601542 Silverchair:34186 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Inflammatory signaling regulates hematopoietic stem and progenitor cell emergence in vertebrates The American Society of Hematology American Society of Hematology 10.1182/blood-2014-09-601542 Silverchair:34186 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Inflammatory signaling regulates hematopoietic stem and progenitor cell emergence in vertebrates The American Society of Hematology American Society of Hematology 10.1182/blood-2014-09-601542 Silverchair:34186 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Influence of FLT3-ITD Mutation and Length on the Treatment Response and Prognosis in Cytogenetically Normal AML Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111063 Silverchair:265848 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Influence of FLT3-ITD Mutation and Length on the Treatment Response and Prognosis in Cytogenetically Normal AML Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111063 Silverchair:265848 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Influence of FLT3-ITD Mutation and Length on the Treatment Response and Prognosis in Cytogenetically Normal AML Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111063 Silverchair:265848 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Influence of FLT3-ITD Mutation and Length on the Treatment Response and Prognosis in Cytogenetically Normal AML Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111063 Silverchair:265848 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Influence of FLT3-ITD Mutation and Length on the Prognosis in Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5089.5089 Silverchair:80889 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Influence of FLT3-ITD Mutation and Length on the Prognosis in Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5089.5089 Silverchair:80889 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Influence of FLT3-ITD Mutation and Length on the Prognosis in Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5089.5089 Silverchair:80889 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Influence of FLT3-ITD Mutation and Length on the Prognosis in Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5089.5089 Silverchair:80889 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial The American Society of Hematology American Society of Hematology 10.1182/blood-2008-06-163279 Silverchair:24454 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial The American Society of Hematology American Society of Hematology 10.1182/blood-2008-06-163279 Silverchair:24454 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial The American Society of Hematology American Society of Hematology 10.1182/blood-2008-06-163279 Silverchair:24454 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial The American Society of Hematology American Society of Hematology 10.1182/blood-2008-06-163279 Silverchair:24454 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Influenza virus H1N1 activates platelets through FcγRIIA signaling and thrombin generation The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-515536 Silverchair:32488 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Influenza virus H1N1 activates platelets through FcγRIIA signaling and thrombin generation The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-515536 Silverchair:32488 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Influenza virus H1N1 activates platelets through FcγRIIA signaling and thrombin generation The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-515536 Silverchair:32488 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Influenza virus H1N1 activates platelets through FcγRIIA signaling and thrombin generation The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-515536 Silverchair:32488 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Inherited Disorders of the Ras-MAPK Pathway The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-109379 Silverchair:266339 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Inherited Disorders of the Ras-MAPK Pathway The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-109379 Silverchair:266339 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Inherited Disorders of the Ras-MAPK Pathway The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-109379 Silverchair:266339 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Inherited Disorders of the Ras-MAPK Pathway The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-109379 Silverchair:266339 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Inherited marrow failure syndromes and myeloid disorders American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter16 Silverchair:76395 No_License 10 7 0 0 0 0 0 0 1 0 1 1 0 Inherited marrow failure syndromes and myeloid disorders American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter16 Silverchair:76395 Total_Item_Investigations 11 7 0 0 0 0 0 0 1 1 1 1 0 Inherited marrow failure syndromes and myeloid disorders American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter16 Silverchair:76395 Unique_Item_Investigations 8 4 0 0 0 0 0 0 1 1 1 1 0 Inherited microcytic anemias The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000158 Silverchair:474326 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Inherited microcytic anemias The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000158 Silverchair:474326 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Inherited microcytic anemias The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000158 Silverchair:474326 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Inherited microcytic anemias The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000158 Silverchair:474326 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Inherited thrombocytopenia: when a low platelet count does not mean ITP The American Society of Hematology American Society of Hematology 10.1182/blood-2003-05-1742 Silverchair:17810 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Inherited thrombocytopenia: when a low platelet count does not mean ITP The American Society of Hematology American Society of Hematology 10.1182/blood-2003-05-1742 Silverchair:17810 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Inherited thrombocytopenia: when a low platelet count does not mean ITP The American Society of Hematology American Society of Hematology 10.1182/blood-2003-05-1742 Silverchair:17810 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Inherited thrombocytopenia: when a low platelet count does not mean ITP The American Society of Hematology American Society of Hematology 10.1182/blood-2003-05-1742 Silverchair:17810 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Inherited thrombophilia: a double-edged sword The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.1 Silverchair:21120 Total_Item_Investigations 5 0 3 0 0 0 0 0 2 0 0 0 0 Inherited thrombophilia: a double-edged sword The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.1 Silverchair:21120 Total_Item_Requests 5 0 3 0 0 0 0 0 2 0 0 0 0 Inherited thrombophilia: a double-edged sword The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.1 Silverchair:21120 Unique_Item_Investigations 2 0 1 0 0 0 0 0 1 0 0 0 0 Inherited thrombophilia: a double-edged sword The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.1 Silverchair:21120 Unique_Item_Requests 2 0 1 0 0 0 0 0 1 0 0 0 0 Inhibiting the Hippo Signaling Pathway Key Molecule YAP Suppresses Mantle Cell Lymphoma Proliferation By Regulating Multiple Pathogenrelated Signaling Pathways The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129860 Silverchair:423293 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Inhibiting the Hippo Signaling Pathway Key Molecule YAP Suppresses Mantle Cell Lymphoma Proliferation By Regulating Multiple Pathogenrelated Signaling Pathways The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129860 Silverchair:423293 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Inhibiting the Hippo Signaling Pathway Key Molecule YAP Suppresses Mantle Cell Lymphoma Proliferation By Regulating Multiple Pathogenrelated Signaling Pathways The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129860 Silverchair:423293 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Inhibiting the Hippo Signaling Pathway Key Molecule YAP Suppresses Mantle Cell Lymphoma Proliferation By Regulating Multiple Pathogenrelated Signaling Pathways The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129860 Silverchair:423293 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Inhibition of Factor XIIa-Mediated Factor XI Activation Reduces Infarct Size in a Mouse Model of Myocardial Ischemia and Reperfusion The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2873.2873 Silverchair:96937 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Inhibition of Factor XIIa-Mediated Factor XI Activation Reduces Infarct Size in a Mouse Model of Myocardial Ischemia and Reperfusion The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2873.2873 Silverchair:96937 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Inhibition of Factor XIIa-Mediated Factor XI Activation Reduces Infarct Size in a Mouse Model of Myocardial Ischemia and Reperfusion The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2873.2873 Silverchair:96937 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Inhibition of Factor XIIa-Mediated Factor XI Activation Reduces Infarct Size in a Mouse Model of Myocardial Ischemia and Reperfusion The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2873.2873 Silverchair:96937 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Inhibition of phagocytosis in HIV-1–infected macrophages relies on Nef-dependent alteration of focal delivery of recycling compartments The American Society of Hematology American Society of Hematology 10.1182/blood-2009-12-259473 Silverchair:133748 Total_Item_Investigations 5 5 0 0 0 0 0 0 0 0 0 0 0 Inhibition of phagocytosis in HIV-1–infected macrophages relies on Nef-dependent alteration of focal delivery of recycling compartments The American Society of Hematology American Society of Hematology 10.1182/blood-2009-12-259473 Silverchair:133748 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 Inhibition of phagocytosis in HIV-1–infected macrophages relies on Nef-dependent alteration of focal delivery of recycling compartments The American Society of Hematology American Society of Hematology 10.1182/blood-2009-12-259473 Silverchair:133748 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Inhibition of phagocytosis in HIV-1–infected macrophages relies on Nef-dependent alteration of focal delivery of recycling compartments The American Society of Hematology American Society of Hematology 10.1182/blood-2009-12-259473 Silverchair:133748 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Inhibition of PI3K or Integrin-Linked Kinase (ILK) Target Primary AML Cells within the Bone Marrow Microenvironment in the In Vitro Co-Culture System. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.1903.1903 Silverchair:127773 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Inhibition of PI3K or Integrin-Linked Kinase (ILK) Target Primary AML Cells within the Bone Marrow Microenvironment in the In Vitro Co-Culture System. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.1903.1903 Silverchair:127773 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Inhibition of PI3K or Integrin-Linked Kinase (ILK) Target Primary AML Cells within the Bone Marrow Microenvironment in the In Vitro Co-Culture System. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.1903.1903 Silverchair:127773 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Inhibition of PI3K or Integrin-Linked Kinase (ILK) Target Primary AML Cells within the Bone Marrow Microenvironment in the In Vitro Co-Culture System. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.1903.1903 Silverchair:127773 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-718171 Silverchair:36300 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-718171 Silverchair:36300 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-718171 Silverchair:36300 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-718171 Silverchair:36300 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Inhibition of WNT signaling in the bone marrow niche prevents the development of MDS in the Apcdel/+ MDS mouse model The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-736454 Silverchair:36063 Total_Item_Investigations 3 2 0 0 1 0 0 0 0 0 0 0 0 Inhibition of WNT signaling in the bone marrow niche prevents the development of MDS in the Apcdel/+ MDS mouse model The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-736454 Silverchair:36063 Total_Item_Requests 2 1 0 0 1 0 0 0 0 0 0 0 0 Inhibition of WNT signaling in the bone marrow niche prevents the development of MDS in the Apcdel/+ MDS mouse model The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-736454 Silverchair:36063 Unique_Item_Investigations 2 1 0 0 1 0 0 0 0 0 0 0 0 Inhibition of WNT signaling in the bone marrow niche prevents the development of MDS in the Apcdel/+ MDS mouse model The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-736454 Silverchair:36063 Unique_Item_Requests 2 1 0 0 1 0 0 0 0 0 0 0 0 Inhibitors and mortality in persons with nonsevere hemophilia A in the United States American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002626 Silverchair:463997 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 2 1 0 0 Inhibitors and mortality in persons with nonsevere hemophilia A in the United States American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002626 Silverchair:463997 Total_Item_Requests 3 0 0 0 0 0 0 0 0 2 1 0 0 Inhibitors and mortality in persons with nonsevere hemophilia A in the United States American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002626 Silverchair:463997 Unique_Item_Investigations 2 0 0 0 0 0 0 0 0 1 1 0 0 Inhibitors and mortality in persons with nonsevere hemophilia A in the United States American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002626 Silverchair:463997 Unique_Item_Requests 2 0 0 0 0 0 0 0 0 1 1 0 0 Inhibitory effect of tumor cell–derived lactic acid on human T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2006-07-035972 Silverchair:23601 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Inhibitory effect of tumor cell–derived lactic acid on human T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2006-07-035972 Silverchair:23601 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Inhibitory effect of tumor cell–derived lactic acid on human T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2006-07-035972 Silverchair:23601 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Inhibitory effect of tumor cell–derived lactic acid on human T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2006-07-035972 Silverchair:23601 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Initial Hodgkin treatment of the frail elderly The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-812966 Silverchair:36588 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Initial Hodgkin treatment of the frail elderly The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-812966 Silverchair:36588 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Initial Hodgkin treatment of the frail elderly The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-812966 Silverchair:36588 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Initial Hodgkin treatment of the frail elderly The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-812966 Silverchair:36588 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "Initial Platelet Recovery Rate During Plasma Exchange Predicts Long-Term Survival in Patients with Thrombotic Thrombocytopenic Purpura," The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.3283.3283 Silverchair:69264 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Initial Platelet Recovery Rate During Plasma Exchange Predicts Long-Term Survival in Patients with Thrombotic Thrombocytopenic Purpura," The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.3283.3283 Silverchair:69264 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Initial Platelet Recovery Rate During Plasma Exchange Predicts Long-Term Survival in Patients with Thrombotic Thrombocytopenic Purpura," The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.3283.3283 Silverchair:69264 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Initial Platelet Recovery Rate During Plasma Exchange Predicts Long-Term Survival in Patients with Thrombotic Thrombocytopenic Purpura," The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.3283.3283 Silverchair:69264 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116953 Silverchair:262309 Total_Item_Investigations 5 0 0 5 0 0 0 0 0 0 0 0 0 "Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116953 Silverchair:262309 Total_Item_Requests 5 0 0 5 0 0 0 0 0 0 0 0 0 "Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116953 Silverchair:262309 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116953 Silverchair:262309 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Initial treatment for patients with CML The American Society of Hematology American Society of Hematology 10.1182/asheducation-2009.1.453 Silverchair:19875 Total_Item_Investigations 2 0 0 0 0 0 2 0 0 0 0 0 0 Initial treatment for patients with CML The American Society of Hematology American Society of Hematology 10.1182/asheducation-2009.1.453 Silverchair:19875 Total_Item_Requests 2 0 0 0 0 0 2 0 0 0 0 0 0 Initial treatment for patients with CML The American Society of Hematology American Society of Hematology 10.1182/asheducation-2009.1.453 Silverchair:19875 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Initial treatment for patients with CML The American Society of Hematology American Society of Hematology 10.1182/asheducation-2009.1.453 Silverchair:19875 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Initial treatment of CLL: integrating biology and functional status The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-585067 Silverchair:34539 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Initial treatment of CLL: integrating biology and functional status The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-585067 Silverchair:34539 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Initial treatment of CLL: integrating biology and functional status The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-585067 Silverchair:34539 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Initial treatment of CLL: integrating biology and functional status The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-585067 Silverchair:34539 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Inotuzumab Ozogamicin in Combination with Bosutinib for Patients with Relapsed or Refractory Ph+ ALL or CML in Lymphoid Blast Phase The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.143.143 Silverchair:79401 Total_Item_Investigations 2 0 0 0 0 0 0 2 0 0 0 0 0 Inotuzumab Ozogamicin in Combination with Bosutinib for Patients with Relapsed or Refractory Ph+ ALL or CML in Lymphoid Blast Phase The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.143.143 Silverchair:79401 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Inotuzumab Ozogamicin in Combination with Bosutinib for Patients with Relapsed or Refractory Ph+ ALL or CML in Lymphoid Blast Phase The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.143.143 Silverchair:79401 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Inotuzumab Ozogamicin in Combination with Bosutinib for Patients with Relapsed or Refractory Ph+ ALL or CML in Lymphoid Blast Phase The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.143.143 Silverchair:79401 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1 The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-632893 Silverchair:34036 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1 The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-632893 Silverchair:34036 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1 The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-632893 Silverchair:34036 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1 The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-632893 Silverchair:34036 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias The American Society of Hematology American Society of Hematology 10.1182/blood.2020010167 Silverchair:475685 Total_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias The American Society of Hematology American Society of Hematology 10.1182/blood.2020010167 Silverchair:475685 Total_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias The American Society of Hematology American Society of Hematology 10.1182/blood.2020010167 Silverchair:475685 Unique_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias The American Society of Hematology American Society of Hematology 10.1182/blood.2020010167 Silverchair:475685 Unique_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity The American Society of Hematology American Society of Hematology 10.1182/blood.2019002121 Silverchair:429647 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity The American Society of Hematology American Society of Hematology 10.1182/blood.2019002121 Silverchair:429647 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity The American Society of Hematology American Society of Hematology 10.1182/blood.2019002121 Silverchair:429647 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity The American Society of Hematology American Society of Hematology 10.1182/blood.2019002121 Silverchair:429647 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Integrated Genetic and Epigenetic Analysis of Childhood Acute Lymphoblastic Leukemia Reveals a Synergistic Role for Structural and Epigenetic Lesions In Determining Disease Phenotype The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.537.537 Silverchair:66829 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Integrated Genetic and Epigenetic Analysis of Childhood Acute Lymphoblastic Leukemia Reveals a Synergistic Role for Structural and Epigenetic Lesions In Determining Disease Phenotype The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.537.537 Silverchair:66829 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Integrated Genetic and Epigenetic Analysis of Childhood Acute Lymphoblastic Leukemia Reveals a Synergistic Role for Structural and Epigenetic Lesions In Determining Disease Phenotype The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.537.537 Silverchair:66829 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Integrated Genetic and Epigenetic Analysis of Childhood Acute Lymphoblastic Leukemia Reveals a Synergistic Role for Structural and Epigenetic Lesions In Determining Disease Phenotype The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.537.537 Silverchair:66829 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity The American Society of Hematology American Society of Hematology 10.1182/blood.2020009655 Silverchair:476136 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity The American Society of Hematology American Society of Hematology 10.1182/blood.2020009655 Silverchair:476136 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity The American Society of Hematology American Society of Hematology 10.1182/blood.2020009655 Silverchair:476136 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity The American Society of Hematology American Society of Hematology 10.1182/blood.2020009655 Silverchair:476136 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003081 Silverchair:474968 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003081 Silverchair:474968 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003081 Silverchair:474968 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003081 Silverchair:474968 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Integrative Analysis of RNA-Interactome and Translatome Reveal Functional Targets of MSI2 in Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1881.1881 Silverchair:100305 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Integrative Analysis of RNA-Interactome and Translatome Reveal Functional Targets of MSI2 in Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1881.1881 Silverchair:100305 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Integrative Analysis of RNA-Interactome and Translatome Reveal Functional Targets of MSI2 in Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1881.1881 Silverchair:100305 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Integrative Analysis of RNA-Interactome and Translatome Reveal Functional Targets of MSI2 in Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1881.1881 Silverchair:100305 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000779 Silverchair:452606 Total_Item_Investigations 10 0 0 0 0 2 0 2 4 0 0 2 0 Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000779 Silverchair:452606 Total_Item_Requests 7 0 0 0 0 1 0 1 3 0 0 2 0 Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000779 Silverchair:452606 Unique_Item_Investigations 5 0 0 0 0 1 0 1 2 0 0 1 0 Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000779 Silverchair:452606 Unique_Item_Requests 5 0 0 0 0 1 0 1 2 0 0 1 0 "Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-05-282780 Silverchair:27951 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-05-282780 Silverchair:27951 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-05-282780 Silverchair:27951 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-05-282780 Silverchair:27951 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-832253 Silverchair:39426 Total_Item_Investigations 3 0 0 0 0 0 3 0 0 0 0 0 0 Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-832253 Silverchair:39426 Total_Item_Requests 3 0 0 0 0 0 3 0 0 0 0 0 0 Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-832253 Silverchair:39426 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-832253 Silverchair:39426 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-406272 Silverchair:31189 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-406272 Silverchair:31189 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-406272 Silverchair:31189 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-406272 Silverchair:31189 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Integrin αIIbβ3 outside-in signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-773614 Silverchair:107662 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Integrin αIIbβ3 outside-in signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-773614 Silverchair:107662 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Integrin αIIbβ3 outside-in signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-773614 Silverchair:107662 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Integrin αIIbβ3 outside-in signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-773614 Silverchair:107662 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019001417 Silverchair:454180 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019001417 Silverchair:454180 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019001417 Silverchair:454180 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019001417 Silverchair:454180 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-276485 Silverchair:107857 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-276485 Silverchair:107857 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-276485 Silverchair:107857 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-276485 Silverchair:107857 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood.V85.11.3058.bloodjournal85113058 Silverchair:123110 Total_Item_Investigations 23 2 21 0 0 0 0 0 0 0 0 0 0 Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood.V85.11.3058.bloodjournal85113058 Silverchair:123110 Total_Item_Requests 10 0 10 0 0 0 0 0 0 0 0 0 0 Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood.V85.11.3058.bloodjournal85113058 Silverchair:123110 Unique_Item_Investigations 20 2 18 0 0 0 0 0 0 0 0 0 0 Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood.V85.11.3058.bloodjournal85113058 Silverchair:123110 Unique_Item_Requests 9 0 9 0 0 0 0 0 0 0 0 0 0 Interactome Analysis of APOBEC3B in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126856 Silverchair:426703 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Interactome Analysis of APOBEC3B in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126856 Silverchair:426703 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Interactome Analysis of APOBEC3B in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126856 Silverchair:426703 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Interactome Analysis of APOBEC3B in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126856 Silverchair:426703 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Interference of hyperleukocytosis in red blood cell count The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-811141 Silverchair:39220 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Interference of hyperleukocytosis in red blood cell count The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-811141 Silverchair:39220 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Interference of hyperleukocytosis in red blood cell count The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-811141 Silverchair:39220 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Interference of hyperleukocytosis in red blood cell count The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-811141 Silverchair:39220 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "Interferon γ Induces Upregulation and Activation of Caspases 1, 3, and 8 to Produce Apoptosis in Human Erythroid Progenitor Cells" The American Society of Hematology American Society of Hematology 10.1182/blood.V93.10.3309.410k04_3309_3316 Silverchair:138069 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Interferon γ Induces Upregulation and Activation of Caspases 1, 3, and 8 to Produce Apoptosis in Human Erythroid Progenitor Cells" The American Society of Hematology American Society of Hematology 10.1182/blood.V93.10.3309.410k04_3309_3316 Silverchair:138069 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Interferon γ Induces Upregulation and Activation of Caspases 1, 3, and 8 to Produce Apoptosis in Human Erythroid Progenitor Cells" The American Society of Hematology American Society of Hematology 10.1182/blood.V93.10.3309.410k04_3309_3316 Silverchair:138069 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Interferon γ Induces Upregulation and Activation of Caspases 1, 3, and 8 to Produce Apoptosis in Human Erythroid Progenitor Cells" The American Society of Hematology American Society of Hematology 10.1182/blood.V93.10.3309.410k04_3309_3316 Silverchair:138069 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141223 Silverchair:470199 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141223 Silverchair:470199 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141223 Silverchair:470199 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141223 Silverchair:470199 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Interferons limit inflammatory responses by induction of tristetraprolin The American Society of Hematology American Society of Hematology 10.1182/blood-2005-07-3058 Silverchair:129284 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Interferons limit inflammatory responses by induction of tristetraprolin The American Society of Hematology American Society of Hematology 10.1182/blood-2005-07-3058 Silverchair:129284 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Interferons limit inflammatory responses by induction of tristetraprolin The American Society of Hematology American Society of Hematology 10.1182/blood-2005-07-3058 Silverchair:129284 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Interferons limit inflammatory responses by induction of tristetraprolin The American Society of Hematology American Society of Hematology 10.1182/blood-2005-07-3058 Silverchair:129284 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Interferon-α promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis The American Society of Hematology American Society of Hematology 10.1182/blood-2007-05-089086 Silverchair:24011 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Interferon-α promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis The American Society of Hematology American Society of Hematology 10.1182/blood-2007-05-089086 Silverchair:24011 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Interferon-α promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis The American Society of Hematology American Society of Hematology 10.1182/blood-2007-05-089086 Silverchair:24011 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Interferon-α promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis The American Society of Hematology American Society of Hematology 10.1182/blood-2007-05-089086 Silverchair:24011 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134300 Silverchair:469978 Total_Item_Investigations 4 2 0 1 0 0 1 0 0 0 0 0 0 Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134300 Silverchair:469978 Total_Item_Requests 4 2 0 1 0 0 1 0 0 0 0 0 0 Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134300 Silverchair:469978 Unique_Item_Investigations 3 1 0 1 0 0 1 0 0 0 0 0 0 Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134300 Silverchair:469978 Unique_Item_Requests 3 1 0 1 0 0 1 0 0 0 0 0 0 Interleukin-1 in the pathogenesis and treatment of inflammatory diseases The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-273417 Silverchair:20517 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Interleukin-1 in the pathogenesis and treatment of inflammatory diseases The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-273417 Silverchair:20517 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Interleukin-1 in the pathogenesis and treatment of inflammatory diseases The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-273417 Silverchair:20517 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Interleukin-1 in the pathogenesis and treatment of inflammatory diseases The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-273417 Silverchair:20517 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Interleukin-12 Therapy of Cutaneous T-Cell Lymphoma Induces Lesion Regression and Cytotoxic T-Cell Responses The American Society of Hematology American Society of Hematology 10.1182/blood.V94.3.902.415k23_902_908 Silverchair:125358 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Interleukin-12 Therapy of Cutaneous T-Cell Lymphoma Induces Lesion Regression and Cytotoxic T-Cell Responses The American Society of Hematology American Society of Hematology 10.1182/blood.V94.3.902.415k23_902_908 Silverchair:125358 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Interleukin-12 Therapy of Cutaneous T-Cell Lymphoma Induces Lesion Regression and Cytotoxic T-Cell Responses The American Society of Hematology American Society of Hematology 10.1182/blood.V94.3.902.415k23_902_908 Silverchair:125358 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Interleukin-12 Therapy of Cutaneous T-Cell Lymphoma Induces Lesion Regression and Cytotoxic T-Cell Responses The American Society of Hematology American Society of Hematology 10.1182/blood.V94.3.902.415k23_902_908 Silverchair:125358 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Interleukin-15 (IL-15) Induces NF-κB Activation and IL-8 Production in Human Neutrophils The American Society of Hematology American Society of Hematology 10.1182/blood.V92.12.4828 Silverchair:245101 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Interleukin-15 (IL-15) Induces NF-κB Activation and IL-8 Production in Human Neutrophils The American Society of Hematology American Society of Hematology 10.1182/blood.V92.12.4828 Silverchair:245101 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Interleukin-15 (IL-15) Induces NF-κB Activation and IL-8 Production in Human Neutrophils The American Society of Hematology American Society of Hematology 10.1182/blood.V92.12.4828 Silverchair:245101 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Interleukin-15 (IL-15) Induces NF-κB Activation and IL-8 Production in Human Neutrophils The American Society of Hematology American Society of Hematology 10.1182/blood.V92.12.4828 Silverchair:245101 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4 The American Society of Hematology American Society of Hematology 10.1182/blood.V95.10.3183 Silverchair:180933 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4 The American Society of Hematology American Society of Hematology 10.1182/blood.V95.10.3183 Silverchair:180933 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4 The American Society of Hematology American Society of Hematology 10.1182/blood.V95.10.3183 Silverchair:180933 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4 The American Society of Hematology American Society of Hematology 10.1182/blood.V95.10.3183 Silverchair:180933 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Interleukin-3 and interferon β cooperate to induce differentiation of monocytes into dendritic cells with potent helper T-cell stimulatory properties The American Society of Hematology American Society of Hematology 10.1182/blood.V99.3.993 Silverchair:53483 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Interleukin-3 and interferon β cooperate to induce differentiation of monocytes into dendritic cells with potent helper T-cell stimulatory properties The American Society of Hematology American Society of Hematology 10.1182/blood.V99.3.993 Silverchair:53483 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Interleukin-3 and interferon β cooperate to induce differentiation of monocytes into dendritic cells with potent helper T-cell stimulatory properties The American Society of Hematology American Society of Hematology 10.1182/blood.V99.3.993 Silverchair:53483 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Interleukin-3 and interferon β cooperate to induce differentiation of monocytes into dendritic cells with potent helper T-cell stimulatory properties The American Society of Hematology American Society of Hematology 10.1182/blood.V99.3.993 Silverchair:53483 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production The American Society of Hematology American Society of Hematology 10.1182/blood-2009-02-203372 Silverchair:107830 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production The American Society of Hematology American Society of Hematology 10.1182/blood-2009-02-203372 Silverchair:107830 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production The American Society of Hematology American Society of Hematology 10.1182/blood-2009-02-203372 Silverchair:107830 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production The American Society of Hematology American Society of Hematology 10.1182/blood-2009-02-203372 Silverchair:107830 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Interleukin-6 induces hepcidin expression through STAT3 The American Society of Hematology American Society of Hematology 10.1182/blood-2006-06-027631 Silverchair:22588 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Interleukin-6 induces hepcidin expression through STAT3 The American Society of Hematology American Society of Hematology 10.1182/blood-2006-06-027631 Silverchair:22588 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Interleukin-6 induces hepcidin expression through STAT3 The American Society of Hematology American Society of Hematology 10.1182/blood-2006-06-027631 Silverchair:22588 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Interleukin-6 induces hepcidin expression through STAT3 The American Society of Hematology American Society of Hematology 10.1182/blood-2006-06-027631 Silverchair:22588 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Interleukin-7 is produced by afferent lymphatic vessels and supports lymphatic drainage The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-478073 Silverchair:31727 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Interleukin-7 is produced by afferent lymphatic vessels and supports lymphatic drainage The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-478073 Silverchair:31727 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Interleukin-7 is produced by afferent lymphatic vessels and supports lymphatic drainage The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-478073 Silverchair:31727 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Interleukin-7 is produced by afferent lymphatic vessels and supports lymphatic drainage The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-478073 Silverchair:31727 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 International consensus report on the investigation and management of primary immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2009-06-225565 Silverchair:26966 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 International consensus report on the investigation and management of primary immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2009-06-225565 Silverchair:26966 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 International consensus report on the investigation and management of primary immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2009-06-225565 Silverchair:26966 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 International consensus report on the investigation and management of primary immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2009-06-225565 Silverchair:26966 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003334 Silverchair:474413 Total_Item_Investigations 4 0 0 0 2 0 0 0 2 0 0 0 0 International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003334 Silverchair:474413 Total_Item_Requests 4 0 0 0 2 0 0 0 2 0 0 0 0 International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003334 Silverchair:474413 Unique_Item_Investigations 2 0 0 0 1 0 0 0 1 0 0 0 0 International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003334 Silverchair:474413 Unique_Item_Requests 2 0 0 0 1 0 0 0 1 0 0 0 0 International Normalized Ratio Relevance to the Observed Coagulation Abnormalities in Warfarin Treated and Those with Disseminated Intravascular Coagulation The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3797.3797 Silverchair:97369 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 International Normalized Ratio Relevance to the Observed Coagulation Abnormalities in Warfarin Treated and Those with Disseminated Intravascular Coagulation The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3797.3797 Silverchair:97369 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 International Normalized Ratio Relevance to the Observed Coagulation Abnormalities in Warfarin Treated and Those with Disseminated Intravascular Coagulation The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3797.3797 Silverchair:97369 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 International Normalized Ratio Relevance to the Observed Coagulation Abnormalities in Warfarin Treated and Those with Disseminated Intravascular Coagulation The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.3797.3797 Silverchair:97369 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI" The American Society of Hematology American Society of Hematology 10.1182/blood.2019002729 Silverchair:452696 Total_Item_Investigations 2 0 0 0 0 0 0 2 0 0 0 0 0 "International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI" The American Society of Hematology American Society of Hematology 10.1182/blood.2019002729 Silverchair:452696 Total_Item_Requests 2 0 0 0 0 0 0 2 0 0 0 0 0 "International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI" The American Society of Hematology American Society of Hematology 10.1182/blood.2019002729 Silverchair:452696 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 "International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI" The American Society of Hematology American Society of Hematology 10.1182/blood.2019002729 Silverchair:452696 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019003453 Silverchair:454292 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019003453 Silverchair:454292 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019003453 Silverchair:454292 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019003453 Silverchair:454292 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-458521 Silverchair:31160 Total_Item_Investigations 2 0 0 0 0 0 2 0 0 0 0 0 0 International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-458521 Silverchair:31160 Total_Item_Requests 2 0 0 0 0 0 2 0 0 0 0 0 0 International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-458521 Silverchair:31160 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-458521 Silverchair:31160 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 "International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-746933 Silverchair:36100 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-746933 Silverchair:36100 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-746933 Silverchair:36100 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-746933 Silverchair:36100 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-862334 Silverchair:39506 Total_Item_Investigations 10 2 0 4 0 0 1 0 0 0 1 0 2 "International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-862334 Silverchair:39506 Total_Item_Requests 10 2 0 4 0 0 1 0 0 0 1 0 2 "International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-862334 Silverchair:39506 Unique_Item_Investigations 8 1 0 4 0 0 1 0 0 0 1 0 1 "International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-862334 Silverchair:39506 Unique_Item_Requests 8 1 0 4 0 0 1 0 0 0 1 0 1 Interrelation between polyploidization and megakaryocyte differentiation: a gene profiling approach The American Society of Hematology American Society of Hematology 10.1182/blood-2006-07-037838 Silverchair:23675 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Interrelation between polyploidization and megakaryocyte differentiation: a gene profiling approach The American Society of Hematology American Society of Hematology 10.1182/blood-2006-07-037838 Silverchair:23675 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Interrelation between polyploidization and megakaryocyte differentiation: a gene profiling approach The American Society of Hematology American Society of Hematology 10.1182/blood-2006-07-037838 Silverchair:23675 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Interrelation between polyploidization and megakaryocyte differentiation: a gene profiling approach The American Society of Hematology American Society of Hematology 10.1182/blood-2006-07-037838 Silverchair:23675 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-360875 Silverchair:30006 Total_Item_Investigations 3 0 0 0 3 0 0 0 0 0 0 0 0 "Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-360875 Silverchair:30006 Total_Item_Requests 3 0 0 0 3 0 0 0 0 0 0 0 0 "Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-360875 Silverchair:30006 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 "Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-360875 Silverchair:30006 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy The American Society of Hematology American Society of Hematology 10.1182/blood.2020009515 Silverchair:475737 Total_Item_Investigations 2 0 0 0 0 0 2 0 0 0 0 0 0 Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy The American Society of Hematology American Society of Hematology 10.1182/blood.2020009515 Silverchair:475737 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 "Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group" The American Society of Hematology American Society of Hematology 10.1182/blood-2005-12-011809 Silverchair:22394 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group" The American Society of Hematology American Society of Hematology 10.1182/blood-2005-12-011809 Silverchair:22394 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group" The American Society of Hematology American Society of Hematology 10.1182/blood-2005-12-011809 Silverchair:22394 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group" The American Society of Hematology American Society of Hematology 10.1182/blood-2005-12-011809 Silverchair:22394 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-737445 Silverchair:39314 Total_Item_Investigations 6 1 0 3 2 0 0 0 0 0 0 0 0 Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-737445 Silverchair:39314 Total_Item_Requests 6 1 0 3 2 0 0 0 0 0 0 0 0 Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-737445 Silverchair:39314 Unique_Item_Investigations 4 1 0 2 1 0 0 0 0 0 0 0 0 Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-737445 Silverchair:39314 Unique_Item_Requests 4 1 0 2 1 0 0 0 0 0 0 0 0 Intravascular lymphoma: from vessels to genes The American Society of Hematology American Society of Hematology 10.1182/blood.2020010457 Silverchair:475495 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Intravascular lymphoma: from vessels to genes The American Society of Hematology American Society of Hematology 10.1182/blood.2020010457 Silverchair:475495 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Intravascular lymphoma: from vessels to genes The American Society of Hematology American Society of Hematology 10.1182/blood.2020010457 Silverchair:475495 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Intravascular lymphoma: from vessels to genes The American Society of Hematology American Society of Hematology 10.1182/blood.2020010457 Silverchair:475495 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-647552 Silverchair:34824 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-647552 Silverchair:34824 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-647552 Silverchair:34824 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-647552 Silverchair:34824 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Intravenous Immunoglobulin (IVIg) Is a Highly Effective Treatment for HIT: Critical Role of the IgG Fc Domain in Inhibiting HIT Antibody-Mediated Platelet Activation The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2600.2600 Silverchair:98554 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Intravenous Immunoglobulin (IVIg) Is a Highly Effective Treatment for HIT: Critical Role of the IgG Fc Domain in Inhibiting HIT Antibody-Mediated Platelet Activation The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2600.2600 Silverchair:98554 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Intravenous Immunoglobulin (IVIg) Is a Highly Effective Treatment for HIT: Critical Role of the IgG Fc Domain in Inhibiting HIT Antibody-Mediated Platelet Activation The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2600.2600 Silverchair:98554 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Intravenous Immunoglobulin (IVIg) Is a Highly Effective Treatment for HIT: Critical Role of the IgG Fc Domain in Inhibiting HIT Antibody-Mediated Platelet Activation The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2600.2600 Silverchair:98554 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion The American Society of Hematology American Society of Hematology 10.1182/blood-2007-04-084061 Silverchair:103739 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion The American Society of Hematology American Society of Hematology 10.1182/blood-2007-04-084061 Silverchair:103739 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion The American Society of Hematology American Society of Hematology 10.1182/blood-2007-04-084061 Silverchair:103739 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion The American Society of Hematology American Society of Hematology 10.1182/blood-2007-04-084061 Silverchair:103739 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Intravenous Iron Infusion Administration Schedule and Hematologic Response; A Single-Center Retrospective Cohort Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143345 Silverchair:470611 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Intravenous Iron Infusion Administration Schedule and Hematologic Response; A Single-Center Retrospective Cohort Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143345 Silverchair:470611 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Intravenous Iron Infusion Administration Schedule and Hematologic Response; A Single-Center Retrospective Cohort Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143345 Silverchair:470611 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Intravenous Iron Infusion Administration Schedule and Hematologic Response; A Single-Center Retrospective Cohort Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143345 Silverchair:470611 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Introduction to a How I Treat series on acquired hemolytic anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020009747 Silverchair:475027 Total_Item_Investigations 9 0 0 0 3 2 2 2 0 0 0 0 0 Introduction to a How I Treat series on acquired hemolytic anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020009747 Silverchair:475027 Total_Item_Requests 9 0 0 0 3 2 2 2 0 0 0 0 0 Introduction to a How I Treat series on acquired hemolytic anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020009747 Silverchair:475027 Unique_Item_Investigations 8 0 0 0 3 1 2 2 0 0 0 0 0 Introduction to a How I Treat series on acquired hemolytic anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020009747 Silverchair:475027 Unique_Item_Requests 8 0 0 0 3 1 2 2 0 0 0 0 0 Introduction to a How I Treat series on anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020007025 Silverchair:461030 Total_Item_Investigations 3 0 2 1 0 0 0 0 0 0 0 0 0 Introduction to a How I Treat series on anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020007025 Silverchair:461030 Total_Item_Requests 3 0 2 1 0 0 0 0 0 0 0 0 0 Introduction to a How I Treat series on anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020007025 Silverchair:461030 Unique_Item_Investigations 3 0 2 1 0 0 0 0 0 0 0 0 0 Introduction to a How I Treat series on anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020007025 Silverchair:461030 Unique_Item_Requests 3 0 2 1 0 0 0 0 0 0 0 0 0 Introduction to a review series on biological insights into lymphoid tumors The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-824052 Silverchair:37111 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Introduction to a review series on biological insights into lymphoid tumors The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-824052 Silverchair:37111 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Introduction to a review series on biological insights into lymphoid tumors The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-824052 Silverchair:37111 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Introduction to a review series on biological insights into lymphoid tumors The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-824052 Silverchair:37111 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Introduction to a review series on iron metabolism and its disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-876466 Silverchair:6610 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Introduction to a review series on iron metabolism and its disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-876466 Silverchair:6610 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Introduction to a review series on iron metabolism and its disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-876466 Silverchair:6610 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Introduction to a review series on iron metabolism and its disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-876466 Silverchair:6610 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Introduction to a review series on molecular mechanisms of hematologic malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2021012680 Silverchair:476233 Total_Item_Investigations 5 0 0 0 0 0 0 2 3 0 0 0 0 Introduction to a review series on molecular mechanisms of hematologic malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2021012680 Silverchair:476233 Total_Item_Requests 4 0 0 0 0 0 0 1 3 0 0 0 0 Introduction to a review series on molecular mechanisms of hematologic malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2021012680 Silverchair:476233 Unique_Item_Investigations 4 0 0 0 0 0 0 1 3 0 0 0 0 Introduction to a review series on molecular mechanisms of hematologic malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2021012680 Silverchair:476233 Unique_Item_Requests 4 0 0 0 0 0 0 1 3 0 0 0 0 Introduction to a review series on myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2018-12-886549 Silverchair:272713 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Introduction to a review series on myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2018-12-886549 Silverchair:272713 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Introduction to a review series on myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2018-12-886549 Silverchair:272713 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Introduction to a review series on myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2018-12-886549 Silverchair:272713 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Introduction to a review series on myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-756619 Silverchair:36308 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Introduction to a review series on myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-756619 Silverchair:36308 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Introduction to a review series on myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-756619 Silverchair:36308 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Introduction to a review series on myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-756619 Silverchair:36308 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2021012674 Silverchair:476470 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2021012674 Silverchair:476470 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2021012674 Silverchair:476470 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2021012674 Silverchair:476470 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Introduction to the review series on leukemic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-753319 Silverchair:36071 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Introduction to the review series on leukemic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-753319 Silverchair:36071 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Introduction to the review series on leukemic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-753319 Silverchair:36071 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Introduction to the review series on leukemic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-753319 Silverchair:36071 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Introduction to the review series on T-cell malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-741389 Silverchair:36571 Total_Item_Investigations 2 1 0 0 0 0 0 0 0 0 0 1 0 Introduction to the review series on T-cell malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-741389 Silverchair:36571 Total_Item_Requests 2 1 0 0 0 0 0 0 0 0 0 1 0 Introduction to the review series on T-cell malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-741389 Silverchair:36571 Unique_Item_Investigations 2 1 0 0 0 0 0 0 0 0 0 1 0 Introduction to the review series on T-cell malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-741389 Silverchair:36571 Unique_Item_Requests 2 1 0 0 0 0 0 0 0 0 0 1 0 Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000930 Silverchair:429582 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000930 Silverchair:429582 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000930 Silverchair:429582 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000930 Silverchair:429582 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Iron Chelation and Ferritin below 500 Mcg/L in Transfusion Dependent Thalassemia: Beyond the Limits of Clinical Trials The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130237 Silverchair:428369 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Iron Chelation and Ferritin below 500 Mcg/L in Transfusion Dependent Thalassemia: Beyond the Limits of Clinical Trials The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130237 Silverchair:428369 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Iron Chelation and Ferritin below 500 Mcg/L in Transfusion Dependent Thalassemia: Beyond the Limits of Clinical Trials The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130237 Silverchair:428369 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Iron Chelation and Ferritin below 500 Mcg/L in Transfusion Dependent Thalassemia: Beyond the Limits of Clinical Trials The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130237 Silverchair:428369 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Iron clad: iron homeostasis and the diagnosis of hereditary iron overload The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.202 Silverchair:20522 Total_Item_Investigations 3 0 1 0 0 2 0 0 0 0 0 0 0 Iron clad: iron homeostasis and the diagnosis of hereditary iron overload The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.202 Silverchair:20522 Total_Item_Requests 2 0 1 0 0 1 0 0 0 0 0 0 0 Iron clad: iron homeostasis and the diagnosis of hereditary iron overload The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.202 Silverchair:20522 Unique_Item_Investigations 2 0 1 0 0 1 0 0 0 0 0 0 0 Iron clad: iron homeostasis and the diagnosis of hereditary iron overload The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.202 Silverchair:20522 Unique_Item_Requests 2 0 1 0 0 1 0 0 0 0 0 0 0 Iron deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2018-05-815944 Silverchair:6613 Total_Item_Investigations 14 12 0 0 0 0 0 0 0 0 2 0 0 Iron deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2018-05-815944 Silverchair:6613 Total_Item_Requests 13 11 0 0 0 0 0 0 0 0 2 0 0 Iron deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2018-05-815944 Silverchair:6613 Unique_Item_Investigations 6 5 0 0 0 0 0 0 0 0 1 0 0 Iron deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2018-05-815944 Silverchair:6613 Unique_Item_Requests 6 5 0 0 0 0 0 0 0 0 1 0 0 Iron Deficiency and Vitamin B12/Folate Levels. A Case-Control Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.3709.3709 Silverchair:122255 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Iron Deficiency and Vitamin B12/Folate Levels. A Case-Control Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.3709.3709 Silverchair:122255 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Iron Deficiency and Vitamin B12/Folate Levels. A Case-Control Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.3709.3709 Silverchair:122255 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Iron Deficiency and Vitamin B12/Folate Levels. A Case-Control Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.3709.3709 Silverchair:122255 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Iron Deficiency As a Common Treatable Cause of Chronic Normocytic Anemia The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4032.4032 Silverchair:115028 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Iron Deficiency As a Common Treatable Cause of Chronic Normocytic Anemia The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4032.4032 Silverchair:115028 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Iron Deficiency As a Common Treatable Cause of Chronic Normocytic Anemia The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4032.4032 Silverchair:115028 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Iron Deficiency As a Common Treatable Cause of Chronic Normocytic Anemia The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4032.4032 Silverchair:115028 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Iron deficiency in gynecology and obstetrics: clinical implications and management The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.152 Silverchair:21084 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 Iron deficiency in gynecology and obstetrics: clinical implications and management The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.152 Silverchair:21084 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 Iron deficiency in gynecology and obstetrics: clinical implications and management The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.152 Silverchair:21084 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Iron deficiency in gynecology and obstetrics: clinical implications and management The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.152 Silverchair:21084 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 "Iron Deficient Anemia May Obscure a Diagnosis of Low VWF, VWD or Mild Hemophilia a in Biological Females with Heavy Menstrual Bleeding" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138697 Silverchair:472410 Total_Item_Investigations 9 7 0 0 0 0 0 0 2 0 0 0 0 "Iron Deficient Anemia May Obscure a Diagnosis of Low VWF, VWD or Mild Hemophilia a in Biological Females with Heavy Menstrual Bleeding" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138697 Silverchair:472410 Total_Item_Requests 9 7 0 0 0 0 0 0 2 0 0 0 0 "Iron Deficient Anemia May Obscure a Diagnosis of Low VWF, VWD or Mild Hemophilia a in Biological Females with Heavy Menstrual Bleeding" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138697 Silverchair:472410 Unique_Item_Investigations 5 4 0 0 0 0 0 0 1 0 0 0 0 "Iron Deficient Anemia May Obscure a Diagnosis of Low VWF, VWD or Mild Hemophilia a in Biological Females with Heavy Menstrual Bleeding" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138697 Silverchair:472410 Unique_Item_Requests 5 4 0 0 0 0 0 0 1 0 0 0 0 Iron Dextran Versus Iron Sucrose for Non-Hemodialysis Adult Outpatients with Iron Deficiency Anemia: Assessment of Safety and Feasibility for A Randomized Controlled Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.2107.2107 Silverchair:68427 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Iron Dextran Versus Iron Sucrose for Non-Hemodialysis Adult Outpatients with Iron Deficiency Anemia: Assessment of Safety and Feasibility for A Randomized Controlled Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.2107.2107 Silverchair:68427 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Iron Dextran Versus Iron Sucrose for Non-Hemodialysis Adult Outpatients with Iron Deficiency Anemia: Assessment of Safety and Feasibility for A Randomized Controlled Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.2107.2107 Silverchair:68427 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Iron Dextran Versus Iron Sucrose for Non-Hemodialysis Adult Outpatients with Iron Deficiency Anemia: Assessment of Safety and Feasibility for A Randomized Controlled Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.2107.2107 Silverchair:68427 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Iron Handling by Macrophages The American Society of Hematology American Society of Hematology 10.1182/blood-2020-133057 Silverchair:474060 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Iron Handling by Macrophages The American Society of Hematology American Society of Hematology 10.1182/blood-2020-133057 Silverchair:474060 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Iron Handling by Macrophages The American Society of Hematology American Society of Hematology 10.1182/blood-2020-133057 Silverchair:474060 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Iron Handling by Macrophages The American Society of Hematology American Society of Hematology 10.1182/blood-2020-133057 Silverchair:474060 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Iron metabolism under conditions of ineffective erythropoiesis in β-thalassemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-815928 Silverchair:6614 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Iron metabolism under conditions of ineffective erythropoiesis in β-thalassemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-815928 Silverchair:6614 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Iron metabolism under conditions of ineffective erythropoiesis in β-thalassemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-815928 Silverchair:6614 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Iron metabolism under conditions of ineffective erythropoiesis in β-thalassemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-815928 Silverchair:6614 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Iron on the move: mobilizing liver iron via NCOA4 The American Society of Hematology American Society of Hematology 10.1182/blood.2020007971 Silverchair:474269 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 Iron on the move: mobilizing liver iron via NCOA4 The American Society of Hematology American Society of Hematology 10.1182/blood.2020007971 Silverchair:474269 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 Iron on the move: mobilizing liver iron via NCOA4 The American Society of Hematology American Society of Hematology 10.1182/blood.2020007971 Silverchair:474269 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Iron on the move: mobilizing liver iron via NCOA4 The American Society of Hematology American Society of Hematology 10.1182/blood.2020007971 Silverchair:474269 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Iron Overload in C282Y Heterozygotes: Identification of New Rare HFE Gene Mutants and a Step Strategy for Diagnosis. The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.1859.1859 Silverchair:57837 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Iron Overload in C282Y Heterozygotes: Identification of New Rare HFE Gene Mutants and a Step Strategy for Diagnosis. The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.1859.1859 Silverchair:57837 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Iron Overload in C282Y Heterozygotes: Identification of New Rare HFE Gene Mutants and a Step Strategy for Diagnosis. The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.1859.1859 Silverchair:57837 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Iron Overload in C282Y Heterozygotes: Identification of New Rare HFE Gene Mutants and a Step Strategy for Diagnosis. The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.1859.1859 Silverchair:57837 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Iron overload in the Asian community The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-199109 Silverchair:26053 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Iron overload in the Asian community The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-199109 Silverchair:26053 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Iron overload in the Asian community The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-199109 Silverchair:26053 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Iron overload in the Asian community The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-199109 Silverchair:26053 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Iron overload in transfusion-dependent patients The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000036 Silverchair:422629 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Iron overload in transfusion-dependent patients The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000036 Silverchair:422629 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Iron overload in transfusion-dependent patients The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000036 Silverchair:422629 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Iron overload in transfusion-dependent patients The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000036 Silverchair:422629 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Iron physiology, iron overload, and the porphyrias" American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter05 Silverchair:73916 No_License 8 1 1 1 0 0 0 0 1 0 3 1 0 "Iron physiology, iron overload, and the porphyrias" American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter05 Silverchair:73916 Total_Item_Investigations 12 1 2 1 1 1 1 0 1 0 3 1 0 "Iron physiology, iron overload, and the porphyrias" American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter05 Silverchair:73916 Unique_Item_Investigations 10 1 1 1 1 1 1 0 1 0 2 1 0 "Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-03-143354 Silverchair:25261 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-03-143354 Silverchair:25261 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-03-143354 Silverchair:25261 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-03-143354 Silverchair:25261 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Iron Therapy Induced Leukopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-135951 Silverchair:473972 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 Iron Therapy Induced Leukopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-135951 Silverchair:473972 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 Iron Therapy Induced Leukopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-135951 Silverchair:473972 Unique_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Iron Therapy Induced Leukopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-135951 Silverchair:473972 Unique_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 "Iron, manganese, and cobalt transport by Nramp1 (Slc11a1) and Nramp2 (Slc11a2) expressed at the plasma membrane" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-02-0425 Silverchair:17516 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "Iron, manganese, and cobalt transport by Nramp1 (Slc11a1) and Nramp2 (Slc11a2) expressed at the plasma membrane" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-02-0425 Silverchair:17516 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Iron, manganese, and cobalt transport by Nramp1 (Slc11a1) and Nramp2 (Slc11a2) expressed at the plasma membrane" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-02-0425 Silverchair:17516 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Iron, manganese, and cobalt transport by Nramp1 (Slc11a1) and Nramp2 (Slc11a2) expressed at the plasma membrane" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-02-0425 Silverchair:17516 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Is allergic disease curable or transferable with allogeneic hematopoietic cell transplantation? The American Society of Hematology American Society of Hematology 10.1182/blood-2008-01-128686 Silverchair:24701 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 Is allergic disease curable or transferable with allogeneic hematopoietic cell transplantation? The American Society of Hematology American Society of Hematology 10.1182/blood-2008-01-128686 Silverchair:24701 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 Is allergic disease curable or transferable with allogeneic hematopoietic cell transplantation? The American Society of Hematology American Society of Hematology 10.1182/blood-2008-01-128686 Silverchair:24701 Unique_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Is allergic disease curable or transferable with allogeneic hematopoietic cell transplantation? The American Society of Hematology American Society of Hematology 10.1182/blood-2008-01-128686 Silverchair:24701 Unique_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Is Dose-adjusted EPOCH-R Enough in Burkitt Lymphoma? American Society of Hematology American Society of Hematology Silverchair:464079 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Is Dose-adjusted EPOCH-R Enough in Burkitt Lymphoma? American Society of Hematology American Society of Hematology Silverchair:464079 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Is Dose-adjusted EPOCH-R Enough in Burkitt Lymphoma? American Society of Hematology American Society of Hematology Silverchair:464079 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Is Dose-adjusted EPOCH-R Enough in Burkitt Lymphoma? American Society of Hematology American Society of Hematology Silverchair:464079 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Is Homozygosity for the MTHFR C677T Mutation a Risk Factor for Miscarriage? — Likely. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.4079.4079 Silverchair:120149 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Is Homozygosity for the MTHFR C677T Mutation a Risk Factor for Miscarriage? — Likely. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.4079.4079 Silverchair:120149 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Is Homozygosity for the MTHFR C677T Mutation a Risk Factor for Miscarriage? — Likely. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.4079.4079 Silverchair:120149 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Is Homozygosity for the MTHFR C677T Mutation a Risk Factor for Miscarriage? — Likely. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.4079.4079 Silverchair:120149 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Is Serum Hepcidin a Useful Diagnostic Test for Iron Deficiency? The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2056.2056 Silverchair:111781 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Is Serum Hepcidin a Useful Diagnostic Test for Iron Deficiency? The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2056.2056 Silverchair:111781 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Is Serum Hepcidin a Useful Diagnostic Test for Iron Deficiency? The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2056.2056 Silverchair:111781 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Is Serum Hepcidin a Useful Diagnostic Test for Iron Deficiency? The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2056.2056 Silverchair:111781 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Is testing for clinical cobalamin deficiency truly unreliable? The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-0971 Silverchair:21881 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Is testing for clinical cobalamin deficiency truly unreliable? The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-0971 Silverchair:21881 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Is testing for clinical cobalamin deficiency truly unreliable? The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-0971 Silverchair:21881 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Is testing for clinical cobalamin deficiency truly unreliable? The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-0971 Silverchair:21881 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Is the Future of the Benign Hematology Consult Electronic? American Society of Hematology American Society of Hematology 10.1182/hem.V16.5.9802 Silverchair:463149 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Is the Future of the Benign Hematology Consult Electronic? American Society of Hematology American Society of Hematology 10.1182/hem.V16.5.9802 Silverchair:463149 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Is the Future of the Benign Hematology Consult Electronic? American Society of Hematology American Society of Hematology 10.1182/hem.V16.5.9802 Silverchair:463149 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Is the Future of the Benign Hematology Consult Electronic? American Society of Hematology American Society of Hematology 10.1182/hem.V16.5.9802 Silverchair:463149 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Is the NIH Expert Report on Sickle Cell Disease a “Clinical Practice Guideline We Can Trust?” American Society of Hematology American Society of Hematology 10.1182/hem.V11.6.3408 Silverchair:462642 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Is the NIH Expert Report on Sickle Cell Disease a “Clinical Practice Guideline We Can Trust?” American Society of Hematology American Society of Hematology 10.1182/hem.V11.6.3408 Silverchair:462642 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Is the NIH Expert Report on Sickle Cell Disease a “Clinical Practice Guideline We Can Trust?” American Society of Hematology American Society of Hematology 10.1182/hem.V11.6.3408 Silverchair:462642 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Is the NIH Expert Report on Sickle Cell Disease a “Clinical Practice Guideline We Can Trust?” American Society of Hematology American Society of Hematology 10.1182/hem.V11.6.3408 Silverchair:462642 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? The American Society of Hematology American Society of Hematology 10.1182/blood.V63.4.921.921 Silverchair:163881 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? The American Society of Hematology American Society of Hematology 10.1182/blood.V63.4.921.921 Silverchair:163881 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? The American Society of Hematology American Society of Hematology 10.1182/blood.V63.4.921.921 Silverchair:163881 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? The American Society of Hematology American Society of Hematology 10.1182/blood.V63.4.921.921 Silverchair:163881 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Is Thrombophilia Testing Useful? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2011.1.150 Silverchair:96434 Total_Item_Investigations 5 0 0 5 0 0 0 0 0 0 0 0 0 Is Thrombophilia Testing Useful? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2011.1.150 Silverchair:96434 Total_Item_Requests 5 0 0 5 0 0 0 0 0 0 0 0 0 Is Thrombophilia Testing Useful? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2011.1.150 Silverchair:96434 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Is Thrombophilia Testing Useful? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2011.1.150 Silverchair:96434 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Isolation and transcriptome analyses of human erythroid progenitors: BFU-E and CFU-E The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-588806 Silverchair:33543 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Isolation and transcriptome analyses of human erythroid progenitors: BFU-E and CFU-E The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-588806 Silverchair:33543 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Isolation and transcriptome analyses of human erythroid progenitors: BFU-E and CFU-E The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-588806 Silverchair:33543 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Isolation and transcriptome analyses of human erythroid progenitors: BFU-E and CFU-E The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-588806 Silverchair:33543 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 It takes a village to grow leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020004990 Silverchair:452683 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 It takes a village to grow leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020004990 Silverchair:452683 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 It takes a village to grow leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020004990 Silverchair:452683 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 It takes a village to grow leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020004990 Silverchair:452683 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 ITP and TTP: interpreting evidence in light of patient values The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-622555 Silverchair:33751 Total_Item_Investigations 2 1 0 0 1 0 0 0 0 0 0 0 0 ITP and TTP: interpreting evidence in light of patient values The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-622555 Silverchair:33751 Total_Item_Requests 2 1 0 0 1 0 0 0 0 0 0 0 0 ITP and TTP: interpreting evidence in light of patient values The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-622555 Silverchair:33751 Unique_Item_Investigations 2 1 0 0 1 0 0 0 0 0 0 0 0 ITP and TTP: interpreting evidence in light of patient values The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-622555 Silverchair:33751 Unique_Item_Requests 2 1 0 0 1 0 0 0 0 0 0 0 0 Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123946 Silverchair:425704 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123946 Silverchair:425704 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123946 Silverchair:425704 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123946 Silverchair:425704 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019002140 Silverchair:429665 Total_Item_Investigations 5 0 0 1 1 0 1 0 0 0 2 0 0 Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019002140 Silverchair:429665 Total_Item_Requests 5 0 0 1 1 0 1 0 0 0 2 0 0 Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019002140 Silverchair:429665 Unique_Item_Investigations 4 0 0 1 1 0 1 0 0 0 1 0 0 Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019002140 Silverchair:429665 Unique_Item_Requests 4 0 0 1 1 0 1 0 0 0 1 0 0 "iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL" The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-806398 Silverchair:37141 Total_Item_Investigations 15 2 6 3 0 0 1 1 0 1 0 1 0 "iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL" The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-806398 Silverchair:37141 Total_Item_Requests 15 2 6 3 0 0 1 1 0 1 0 1 0 "iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL" The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-806398 Silverchair:37141 Unique_Item_Investigations 12 2 3 3 0 0 1 1 0 1 0 1 0 "iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL" The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-806398 Silverchair:37141 Unique_Item_Requests 12 2 3 3 0 0 1 1 0 1 0 1 0 Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-791228 Silverchair:36869 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-791228 Silverchair:36869 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-791228 Silverchair:36869 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-791228 Silverchair:36869 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001756 Silverchair:456032 Total_Item_Investigations 24 14 0 10 0 0 0 0 0 0 0 0 0 "JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001756 Silverchair:456032 Total_Item_Requests 16 9 0 7 0 0 0 0 0 0 0 0 0 "JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001756 Silverchair:456032 Unique_Item_Investigations 6 4 0 2 0 0 0 0 0 0 0 0 0 "JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001756 Silverchair:456032 Unique_Item_Requests 6 4 0 2 0 0 0 0 0 0 0 0 0 JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-395228 Silverchair:29859 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-395228 Silverchair:29859 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-395228 Silverchair:29859 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-395228 Silverchair:29859 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-485573 Silverchair:31719 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-485573 Silverchair:31719 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-485573 Silverchair:31719 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-485573 Silverchair:31719 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 JAK/STAT: a pathway through the maze of PTCL? The American Society of Hematology American Society of Hematology 10.1182/blood.2021014238 Silverchair:483201 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 JAK/STAT: a pathway through the maze of PTCL? The American Society of Hematology American Society of Hematology 10.1182/blood.2021014238 Silverchair:483201 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 JAK/STAT: a pathway through the maze of PTCL? The American Society of Hematology American Society of Hematology 10.1182/blood.2021014238 Silverchair:483201 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 JAK/STAT: a pathway through the maze of PTCL? The American Society of Hematology American Society of Hematology 10.1182/blood.2021014238 Silverchair:483201 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2008-01-134114 Silverchair:25215 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2008-01-134114 Silverchair:25215 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2008-01-134114 Silverchair:25215 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2008-01-134114 Silverchair:25215 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 JAK2V617F Promotes Stem Cell Amplification Driving MPN Clonal Dominance in Mice and Treatment by IFNa Prevents This Effect The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.616.616 Silverchair:82240 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 JAK2V617F Promotes Stem Cell Amplification Driving MPN Clonal Dominance in Mice and Treatment by IFNa Prevents This Effect The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.616.616 Silverchair:82240 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 JAK2V617F Promotes Stem Cell Amplification Driving MPN Clonal Dominance in Mice and Treatment by IFNa Prevents This Effect The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.616.616 Silverchair:82240 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 JAK2V617F Promotes Stem Cell Amplification Driving MPN Clonal Dominance in Mice and Treatment by IFNa Prevents This Effect The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.616.616 Silverchair:82240 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 "Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-06-2104 Silverchair:18402 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-06-2104 Silverchair:18402 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-06-2104 Silverchair:18402 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation" The American Society of Hematology American Society of Hematology 10.1182/blood-2003-06-2104 Silverchair:18402 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137156 Silverchair:472004 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137156 Silverchair:472004 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137156 Silverchair:472004 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137156 Silverchair:472004 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 KDM2B in polycomb repressive complex 1.1 functions as a tumor suppressor in the initiation of T-cell leukemogenesis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018028522 Silverchair:261396 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 KDM2B in polycomb repressive complex 1.1 functions as a tumor suppressor in the initiation of T-cell leukemogenesis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018028522 Silverchair:261396 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 KDM2B in polycomb repressive complex 1.1 functions as a tumor suppressor in the initiation of T-cell leukemogenesis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018028522 Silverchair:261396 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 KDM2B in polycomb repressive complex 1.1 functions as a tumor suppressor in the initiation of T-cell leukemogenesis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018028522 Silverchair:261396 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Key diagnostic markers for autoimmune lymphoproliferative syndrome with molecular genetic diagnosis The American Society of Hematology American Society of Hematology 10.1182/blood.2020005486 Silverchair:461223 Total_Item_Investigations 4 1 0 0 0 0 0 0 3 0 0 0 0 Key diagnostic markers for autoimmune lymphoproliferative syndrome with molecular genetic diagnosis The American Society of Hematology American Society of Hematology 10.1182/blood.2020005486 Silverchair:461223 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Key diagnostic markers for autoimmune lymphoproliferative syndrome with molecular genetic diagnosis The American Society of Hematology American Society of Hematology 10.1182/blood.2020005486 Silverchair:461223 Unique_Item_Investigations 2 1 0 0 0 0 0 0 1 0 0 0 0 Key diagnostic markers for autoimmune lymphoproliferative syndrome with molecular genetic diagnosis The American Society of Hematology American Society of Hematology 10.1182/blood.2020005486 Silverchair:461223 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Key diagnostic markers for autoimmune lymphoproliferative syndrome with molecular genetic diagnosis The American Society of Hematology American Society of Hematology 10.1182/blood.2020005486 Silverchair:461223 No_License 1 0 0 0 0 0 0 0 1 0 0 0 0 Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-072934 Silverchair:24005 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-072934 Silverchair:24005 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-072934 Silverchair:24005 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-072934 Silverchair:24005 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Key role of the p110δ isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110δ function in B cells The American Society of Hematology American Society of Hematology 10.1182/blood-2005-07-3041 Silverchair:131480 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Key role of the p110δ isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110δ function in B cells The American Society of Hematology American Society of Hematology 10.1182/blood-2005-07-3041 Silverchair:131480 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Key role of the p110δ isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110δ function in B cells The American Society of Hematology American Society of Hematology 10.1182/blood-2005-07-3041 Silverchair:131480 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Key role of the p110δ isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110δ function in B cells The American Society of Hematology American Society of Hematology 10.1182/blood-2005-07-3041 Silverchair:131480 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Kikuchi-Fujimoto disease The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-736413 Silverchair:36184 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Kikuchi-Fujimoto disease The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-736413 Silverchair:36184 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Kikuchi-Fujimoto disease The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-736413 Silverchair:36184 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Kikuchi-Fujimoto disease The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-736413 Silverchair:36184 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Kinase inhibitors in CLL: drawing the roadmap The American Society of Hematology American Society of Hematology 10.1182/blood.2020010052 Silverchair:475956 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 2 0 0 0 Kinase inhibitors in CLL: drawing the roadmap The American Society of Hematology American Society of Hematology 10.1182/blood.2020010052 Silverchair:475956 Total_Item_Requests 2 0 0 0 0 0 0 0 0 2 0 0 0 Kinase inhibitors in CLL: drawing the roadmap The American Society of Hematology American Society of Hematology 10.1182/blood.2020010052 Silverchair:475956 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Kinase inhibitors in CLL: drawing the roadmap The American Society of Hematology American Society of Hematology 10.1182/blood.2020010052 Silverchair:475956 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Kindlin ignites a new flame The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-519868 Silverchair:32167 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 Kindlin ignites a new flame The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-519868 Silverchair:32167 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 Kindlin ignites a new flame The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-519868 Silverchair:32167 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Kindlin ignites a new flame The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-519868 Silverchair:32167 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Kindlin-3 recruitment to the plasma membrane precedes high-affinity β2-integrin and neutrophil arrest from rolling The American Society of Hematology American Society of Hematology 10.1182/blood.2019003446 Silverchair:461779 No_License 1 0 0 1 0 0 0 0 0 0 0 0 0 Kindlin-3 recruitment to the plasma membrane precedes high-affinity β2-integrin and neutrophil arrest from rolling The American Society of Hematology American Society of Hematology 10.1182/blood.2019003446 Silverchair:461779 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Kindlin-3 recruitment to the plasma membrane precedes high-affinity β2-integrin and neutrophil arrest from rolling The American Society of Hematology American Society of Hematology 10.1182/blood.2019003446 Silverchair:461779 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Kinetics of Central Nervous System Microglial and Macrophage Engraftment: Analysis Using a Transgenic Bone Marrow Transplantation Model The American Society of Hematology American Society of Hematology 10.1182/blood.V90.3.986 Silverchair:237135 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Kinetics of Central Nervous System Microglial and Macrophage Engraftment: Analysis Using a Transgenic Bone Marrow Transplantation Model The American Society of Hematology American Society of Hematology 10.1182/blood.V90.3.986 Silverchair:237135 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Kinetics of Central Nervous System Microglial and Macrophage Engraftment: Analysis Using a Transgenic Bone Marrow Transplantation Model The American Society of Hematology American Society of Hematology 10.1182/blood.V90.3.986 Silverchair:237135 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Kinetics of Central Nervous System Microglial and Macrophage Engraftment: Analysis Using a Transgenic Bone Marrow Transplantation Model The American Society of Hematology American Society of Hematology 10.1182/blood.V90.3.986 Silverchair:237135 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Kit Deficiency Regulates Stable Human Hematopoietic Stem Cell Engraftment in Mice The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.653.653 Silverchair:102140 Total_Item_Investigations 2 1 0 0 0 1 0 0 0 0 0 0 0 Kit Deficiency Regulates Stable Human Hematopoietic Stem Cell Engraftment in Mice The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.653.653 Silverchair:102140 Total_Item_Requests 2 1 0 0 0 1 0 0 0 0 0 0 0 Kit Deficiency Regulates Stable Human Hematopoietic Stem Cell Engraftment in Mice The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.653.653 Silverchair:102140 Unique_Item_Investigations 2 1 0 0 0 1 0 0 0 0 0 0 0 Kit Deficiency Regulates Stable Human Hematopoietic Stem Cell Engraftment in Mice The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.653.653 Silverchair:102140 Unique_Item_Requests 2 1 0 0 0 1 0 0 0 0 0 0 0 KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium The American Society of Hematology American Society of Hematology 10.1182/blood-2005-08-3465 Silverchair:22024 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium The American Society of Hematology American Society of Hematology 10.1182/blood-2005-08-3465 Silverchair:22024 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium The American Society of Hematology American Society of Hematology 10.1182/blood-2005-08-3465 Silverchair:22024 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium The American Society of Hematology American Society of Hematology 10.1182/blood-2005-08-3465 Silverchair:22024 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Knockdown Of The Piwi - Like Protein 4 (PIWIL4) Delays Leukemic Growth and Is Associated With Gross Changes In The Global Histone Methylation Marks In Human MLL - Rearranged AML The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.597.597 Silverchair:94136 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Knockdown Of The Piwi - Like Protein 4 (PIWIL4) Delays Leukemic Growth and Is Associated With Gross Changes In The Global Histone Methylation Marks In Human MLL - Rearranged AML The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.597.597 Silverchair:94136 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Knockdown Of The Piwi - Like Protein 4 (PIWIL4) Delays Leukemic Growth and Is Associated With Gross Changes In The Global Histone Methylation Marks In Human MLL - Rearranged AML The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.597.597 Silverchair:94136 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Knockdown Of The Piwi - Like Protein 4 (PIWIL4) Delays Leukemic Growth and Is Associated With Gross Changes In The Global Histone Methylation Marks In Human MLL - Rearranged AML The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.597.597 Silverchair:94136 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Knowledge Transfer between Artificial Neural Networks for Different Multicolor Flow Cytometry Protocols Improves Classification Performance for Rare B-Cell Neoplasm Subtypes The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130483 Silverchair:427910 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Knowledge Transfer between Artificial Neural Networks for Different Multicolor Flow Cytometry Protocols Improves Classification Performance for Rare B-Cell Neoplasm Subtypes The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130483 Silverchair:427910 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Knowledge Transfer between Artificial Neural Networks for Different Multicolor Flow Cytometry Protocols Improves Classification Performance for Rare B-Cell Neoplasm Subtypes The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130483 Silverchair:427910 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Knowledge Transfer between Artificial Neural Networks for Different Multicolor Flow Cytometry Protocols Improves Classification Performance for Rare B-Cell Neoplasm Subtypes The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130483 Silverchair:427910 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Krauel K, Pötschke C, Weber C, et al. Platelet factor 4 binds to bacteria, inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood. 2011;117(4):1370–1378." The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-347740 Silverchair:21363 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Krauel K, Pötschke C, Weber C, et al. Platelet factor 4 binds to bacteria, inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood. 2011;117(4):1370–1378." The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-347740 Silverchair:21363 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Krauel K, Pötschke C, Weber C, et al. Platelet factor 4 binds to bacteria, inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood. 2011;117(4):1370–1378." The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-347740 Silverchair:21363 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Krauel K, Pötschke C, Weber C, et al. Platelet factor 4 binds to bacteria, inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood. 2011;117(4):1370–1378." The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-347740 Silverchair:21363 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results The American Society of Hematology American Society of Hematology 10.1182/blood.2020009098 Silverchair:475697 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results The American Society of Hematology American Society of Hematology 10.1182/blood.2020009098 Silverchair:475697 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results The American Society of Hematology American Society of Hematology 10.1182/blood.2020009098 Silverchair:475697 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results The American Society of Hematology American Society of Hematology 10.1182/blood.2020009098 Silverchair:475697 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Laboratory hematology American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter12 Silverchair:75488 No_License 6 4 1 0 0 0 0 0 1 0 0 0 0 Laboratory hematology American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter12 Silverchair:75488 Total_Item_Investigations 6 4 1 0 0 0 0 0 1 0 0 0 0 Laboratory hematology American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter12 Silverchair:75488 Unique_Item_Investigations 4 2 1 0 0 0 0 0 1 0 0 0 0 Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-757930 Silverchair:36360 Total_Item_Investigations 4 0 0 2 0 0 0 0 0 0 2 0 0 Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-757930 Silverchair:36360 Total_Item_Requests 4 0 0 2 0 0 0 0 0 0 2 0 0 Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-757930 Silverchair:36360 Unique_Item_Investigations 2 0 0 1 0 0 0 0 0 0 1 0 0 Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-757930 Silverchair:36360 Unique_Item_Requests 2 0 0 1 0 0 0 0 0 0 1 0 0 Lack of Gdf11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of β-thalassemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019001057 Silverchair:260742 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Lack of Gdf11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of β-thalassemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019001057 Silverchair:260742 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Lack of Gdf11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of β-thalassemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019001057 Silverchair:260742 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Lack of Gdf11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of β-thalassemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019001057 Silverchair:260742 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-588236 Silverchair:33930 Total_Item_Investigations 3 0 2 0 1 0 0 0 0 0 0 0 0 Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-588236 Silverchair:33930 Total_Item_Requests 3 0 2 0 1 0 0 0 0 0 0 0 0 Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-588236 Silverchair:33930 Unique_Item_Investigations 2 0 1 0 1 0 0 0 0 0 0 0 0 Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-588236 Silverchair:33930 Unique_Item_Requests 2 0 1 0 1 0 0 0 0 0 0 0 0 Lack of Fc-ε Receptors on Murine Eosinophils: Implications for the Functional Significance of Elevated IgE and Eosinophils in Parasitic Infections The American Society of Hematology American Society of Hematology 10.1182/blood.V89.10.3826 Silverchair:235952 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Lack of Fc-ε Receptors on Murine Eosinophils: Implications for the Functional Significance of Elevated IgE and Eosinophils in Parasitic Infections The American Society of Hematology American Society of Hematology 10.1182/blood.V89.10.3826 Silverchair:235952 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Lack of Fc-ε Receptors on Murine Eosinophils: Implications for the Functional Significance of Elevated IgE and Eosinophils in Parasitic Infections The American Society of Hematology American Society of Hematology 10.1182/blood.V89.10.3826 Silverchair:235952 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Lack of Fc-ε Receptors on Murine Eosinophils: Implications for the Functional Significance of Elevated IgE and Eosinophils in Parasitic Infections The American Society of Hematology American Society of Hematology 10.1182/blood.V89.10.3826 Silverchair:235952 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Lactate dehydrogenase and hemolysis in sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood-2012-10-462135 Silverchair:31025 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Lactate dehydrogenase and hemolysis in sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood-2012-10-462135 Silverchair:31025 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Lactate dehydrogenase and hemolysis in sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood-2012-10-462135 Silverchair:31025 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Lactate dehydrogenase and hemolysis in sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood-2012-10-462135 Silverchair:31025 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Lactate Dehydrogenase Is a Key Prognostic Factor in Acute Myeloid Leukemia and Lymphoma Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125529 Silverchair:423905 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Lactate Dehydrogenase Is a Key Prognostic Factor in Acute Myeloid Leukemia and Lymphoma Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125529 Silverchair:423905 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Lactate Dehydrogenase Is a Key Prognostic Factor in Acute Myeloid Leukemia and Lymphoma Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125529 Silverchair:423905 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Lactate Dehydrogenase Is a Key Prognostic Factor in Acute Myeloid Leukemia and Lymphoma Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125529 Silverchair:423905 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Langerhans cell histiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019000934 Silverchair:452576 Total_Item_Investigations 6 2 4 0 0 0 0 0 0 0 0 0 0 Langerhans cell histiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019000934 Silverchair:452576 Total_Item_Requests 4 2 2 0 0 0 0 0 0 0 0 0 0 Langerhans cell histiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019000934 Silverchair:452576 Unique_Item_Investigations 4 1 3 0 0 0 0 0 0 0 0 0 0 Langerhans cell histiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019000934 Silverchair:452576 Unique_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 Langerhans cell histiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019000934 Silverchair:452576 No_License 1 0 1 0 0 0 0 0 0 0 0 0 0 Langerhans cells: straight from blood to skin? The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-610667 Silverchair:33909 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Langerhans cells: straight from blood to skin? The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-610667 Silverchair:33909 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Langerhans cells: straight from blood to skin? The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-610667 Silverchair:33909 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Langerhans cells: straight from blood to skin? The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-610667 Silverchair:33909 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Large-scale in vitro expansion of polyclonal human CD4+CD25high regulatory T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-01-0086 Silverchair:18515 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Large-scale in vitro expansion of polyclonal human CD4+CD25high regulatory T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-01-0086 Silverchair:18515 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Large-scale in vitro expansion of polyclonal human CD4+CD25high regulatory T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-01-0086 Silverchair:18515 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Large-scale in vitro expansion of polyclonal human CD4+CD25high regulatory T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-01-0086 Silverchair:18515 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001126 Silverchair:452678 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001126 Silverchair:452678 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001126 Silverchair:452678 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001126 Silverchair:452678 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Lenalidomide and Rituximab Maintenance Therapy after Front-Line Induction Chemoimmunotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124489 Silverchair:425131 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Lenalidomide and Rituximab Maintenance Therapy after Front-Line Induction Chemoimmunotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124489 Silverchair:425131 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Lenalidomide and Rituximab Maintenance Therapy after Front-Line Induction Chemoimmunotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124489 Silverchair:425131 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Lenalidomide and Rituximab Maintenance Therapy after Front-Line Induction Chemoimmunotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124489 Silverchair:425131 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-567792 Silverchair:33771 Total_Item_Investigations 5 0 0 5 0 0 0 0 0 0 0 0 0 Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-567792 Silverchair:33771 Total_Item_Requests 5 0 0 5 0 0 0 0 0 0 0 0 0 Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-567792 Silverchair:33771 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-567792 Silverchair:33771 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-268862 Silverchair:107744 Total_Item_Investigations 4 1 1 0 0 0 0 0 0 0 2 0 0 "Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-268862 Silverchair:107744 Total_Item_Requests 4 1 1 0 0 0 0 0 0 0 2 0 0 "Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-268862 Silverchair:107744 Unique_Item_Investigations 3 1 1 0 0 0 0 0 0 0 1 0 0 "Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-268862 Silverchair:107744 Unique_Item_Requests 3 1 1 0 0 0 0 0 0 0 1 0 0 Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-583302 Silverchair:33429 Total_Item_Investigations 2 0 0 0 0 0 0 0 2 0 0 0 0 Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-583302 Silverchair:33429 Total_Item_Requests 2 0 0 0 0 0 0 0 2 0 0 0 0 Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-583302 Silverchair:33429 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-583302 Silverchair:33429 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates The American Society of Hematology American Society of Hematology 10.1182/blood-2001-11-0042 Silverchair:16409 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates The American Society of Hematology American Society of Hematology 10.1182/blood-2001-11-0042 Silverchair:16409 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates The American Society of Hematology American Society of Hematology 10.1182/blood-2001-11-0042 Silverchair:16409 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates The American Society of Hematology American Society of Hematology 10.1182/blood-2001-11-0042 Silverchair:16409 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117186 Silverchair:275754 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117186 Silverchair:275754 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117186 Silverchair:275754 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117186 Silverchair:275754 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2007-04-083402 Silverchair:23885 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2007-04-083402 Silverchair:23885 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2007-04-083402 Silverchair:23885 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2007-04-083402 Silverchair:23885 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Let's give BACH2 a breath of fresh air The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-790402 Silverchair:36811 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Let's give BACH2 a breath of fresh air The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-790402 Silverchair:36811 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Let's give BACH2 a breath of fresh air The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-790402 Silverchair:36811 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Let's give BACH2 a breath of fresh air The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-790402 Silverchair:36811 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Letters to the Editor The American Society of Hematology American Society of Hematology 10.1182/blood.V4.7.890.890 Silverchair:6908 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Letters to the Editor The American Society of Hematology American Society of Hematology 10.1182/blood.V4.7.890.890 Silverchair:6908 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Leukemia secondary to myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.2019000943 Silverchair:456028 No_License 4 0 4 0 0 0 0 0 0 0 0 0 0 Leukemia secondary to myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.2019000943 Silverchair:456028 Total_Item_Investigations 9 0 8 0 0 0 1 0 0 0 0 0 0 Leukemia secondary to myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.2019000943 Silverchair:456028 Unique_Item_Investigations 3 0 2 0 0 0 1 0 0 0 0 0 0 Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019032300 Silverchair:247286 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019032300 Silverchair:247286 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019032300 Silverchair:247286 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019032300 Silverchair:247286 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Leukocyte Alkaline Phosphatase Score as a Marker of Severity and Progression of Myelodysplastic Syndrome. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4625.4625 Silverchair:117860 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Leukocyte Alkaline Phosphatase Score as a Marker of Severity and Progression of Myelodysplastic Syndrome. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4625.4625 Silverchair:117860 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Leukocyte Alkaline Phosphatase Score as a Marker of Severity and Progression of Myelodysplastic Syndrome. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4625.4625 Silverchair:117860 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Leukocyte Alkaline Phosphatase Score as a Marker of Severity and Progression of Myelodysplastic Syndrome. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4625.4625 Silverchair:117860 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status" The American Society of Hematology American Society of Hematology 10.1182/blood-2006-09-046342 Silverchair:23324 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status" The American Society of Hematology American Society of Hematology 10.1182/blood-2006-09-046342 Silverchair:23324 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status" The American Society of Hematology American Society of Hematology 10.1182/blood-2006-09-046342 Silverchair:23324 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status" The American Society of Hematology American Society of Hematology 10.1182/blood-2006-09-046342 Silverchair:23324 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 LFA-1 activity state on dendritic cells regulates contact duration with T cells and promotes T-cell priming The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-224428 Silverchair:27430 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 LFA-1 activity state on dendritic cells regulates contact duration with T cells and promotes T-cell priming The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-224428 Silverchair:27430 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 LFA-1 activity state on dendritic cells regulates contact duration with T cells and promotes T-cell priming The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-224428 Silverchair:27430 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 LFA-1 activity state on dendritic cells regulates contact duration with T cells and promotes T-cell priming The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-224428 Silverchair:27430 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 LGL leukemia: from pathogenesis to treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-692590 Silverchair:36568 Total_Item_Investigations 8 0 2 0 0 4 0 0 1 0 0 1 0 LGL leukemia: from pathogenesis to treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-692590 Silverchair:36568 Total_Item_Requests 8 0 2 0 0 4 0 0 1 0 0 1 0 LGL leukemia: from pathogenesis to treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-692590 Silverchair:36568 Unique_Item_Investigations 6 0 1 0 0 3 0 0 1 0 0 1 0 LGL leukemia: from pathogenesis to treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-692590 Silverchair:36568 Unique_Item_Requests 6 0 1 0 0 3 0 0 1 0 0 1 0 Lgr5 Enables Positive B-Cell Selection and Tumor-Initiation in B-Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116956 Silverchair:265925 Total_Item_Investigations 5 4 0 1 0 0 0 0 0 0 0 0 0 Lgr5 Enables Positive B-Cell Selection and Tumor-Initiation in B-Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116956 Silverchair:265925 Total_Item_Requests 5 4 0 1 0 0 0 0 0 0 0 0 0 Lgr5 Enables Positive B-Cell Selection and Tumor-Initiation in B-Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116956 Silverchair:265925 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Lgr5 Enables Positive B-Cell Selection and Tumor-Initiation in B-Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116956 Silverchair:265925 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Lgr5 Functions As a Critical Negative Regulator of Wnt/β-Catenin Signaling and Is Essential for B-Lymphopoiesis and Malignant B-Cell Transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127263 Silverchair:427056 Total_Item_Investigations 6 3 1 2 0 0 0 0 0 0 0 0 0 Lgr5 Functions As a Critical Negative Regulator of Wnt/β-Catenin Signaling and Is Essential for B-Lymphopoiesis and Malignant B-Cell Transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127263 Silverchair:427056 Total_Item_Requests 5 2 1 2 0 0 0 0 0 0 0 0 0 Lgr5 Functions As a Critical Negative Regulator of Wnt/β-Catenin Signaling and Is Essential for B-Lymphopoiesis and Malignant B-Cell Transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127263 Silverchair:427056 Unique_Item_Investigations 4 1 1 2 0 0 0 0 0 0 0 0 0 Lgr5 Functions As a Critical Negative Regulator of Wnt/β-Catenin Signaling and Is Essential for B-Lymphopoiesis and Malignant B-Cell Transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127263 Silverchair:427056 Unique_Item_Requests 4 1 1 2 0 0 0 0 0 0 0 0 0 Lgr5 Functions As Negative Regulator of Wnt Signaling in B Cells and Is Critical for Self-Renewal of Normal and Transformed B Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3989.3989 Silverchair:71913 Total_Item_Investigations 5 5 0 0 0 0 0 0 0 0 0 0 0 Lgr5 Functions As Negative Regulator of Wnt Signaling in B Cells and Is Critical for Self-Renewal of Normal and Transformed B Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3989.3989 Silverchair:71913 Total_Item_Requests 5 5 0 0 0 0 0 0 0 0 0 0 0 Lgr5 Functions As Negative Regulator of Wnt Signaling in B Cells and Is Critical for Self-Renewal of Normal and Transformed B Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3989.3989 Silverchair:71913 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Lgr5 Functions As Negative Regulator of Wnt Signaling in B Cells and Is Critical for Self-Renewal of Normal and Transformed B Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3989.3989 Silverchair:71913 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Light Transmission Aggregometry American Society of Hematology American Society of Hematology 10.1182/hem.V11.2.2555 Silverchair:462563 Total_Item_Investigations 3 0 0 0 2 0 0 0 0 1 0 0 0 Light Transmission Aggregometry American Society of Hematology American Society of Hematology 10.1182/hem.V11.2.2555 Silverchair:462563 Total_Item_Requests 3 0 0 0 2 0 0 0 0 1 0 0 0 Light Transmission Aggregometry American Society of Hematology American Society of Hematology 10.1182/hem.V11.2.2555 Silverchair:462563 Unique_Item_Investigations 2 0 0 0 1 0 0 0 0 1 0 0 0 Light Transmission Aggregometry American Society of Hematology American Society of Hematology 10.1182/hem.V11.2.2555 Silverchair:462563 Unique_Item_Requests 2 0 0 0 1 0 0 0 0 1 0 0 0 Lineage and species-specific long noncoding RNAs during erythro-megakaryocytic development The American Society of Hematology American Society of Hematology 10.1182/blood-2013-12-544494 Silverchair:32761 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Lineage and species-specific long noncoding RNAs during erythro-megakaryocytic development The American Society of Hematology American Society of Hematology 10.1182/blood-2013-12-544494 Silverchair:32761 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Lineage and species-specific long noncoding RNAs during erythro-megakaryocytic development The American Society of Hematology American Society of Hematology 10.1182/blood-2013-12-544494 Silverchair:32761 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Lineage and species-specific long noncoding RNAs during erythro-megakaryocytic development The American Society of Hematology American Society of Hematology 10.1182/blood-2013-12-544494 Silverchair:32761 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Lineage-Specific Aberrant mRNA Splicing By U2AF1 Mutation Alters Erythroid and Granulomonocytic Differentiation The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.142.142 Silverchair:104907 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Lineage-Specific Aberrant mRNA Splicing By U2AF1 Mutation Alters Erythroid and Granulomonocytic Differentiation The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.142.142 Silverchair:104907 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Lineage-Specific Aberrant mRNA Splicing By U2AF1 Mutation Alters Erythroid and Granulomonocytic Differentiation The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.142.142 Silverchair:104907 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Lineage-Specific Aberrant mRNA Splicing By U2AF1 Mutation Alters Erythroid and Granulomonocytic Differentiation The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.142.142 Silverchair:104907 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Lipid rafts are required for Kit survival and proliferation signals The American Society of Hematology American Society of Hematology 10.1182/blood-2006-05-020925 Silverchair:24156 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Lipid rafts are required for Kit survival and proliferation signals The American Society of Hematology American Society of Hematology 10.1182/blood-2006-05-020925 Silverchair:24156 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Lipid rafts are required for Kit survival and proliferation signals The American Society of Hematology American Society of Hematology 10.1182/blood-2006-05-020925 Silverchair:24156 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Lipid rafts are required for Kit survival and proliferation signals The American Society of Hematology American Society of Hematology 10.1182/blood-2006-05-020925 Silverchair:24156 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142570 Silverchair:470798 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142570 Silverchair:470798 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142570 Silverchair:470798 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142570 Silverchair:470798 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Liprin β1 is highly expressed in lymphatic vasculature and is important for lymphatic vessel integrity The American Society of Hematology American Society of Hematology 10.1182/blood-2009-03-212274 Silverchair:26793 Total_Item_Investigations 5 0 5 0 0 0 0 0 0 0 0 0 0 Liprin β1 is highly expressed in lymphatic vasculature and is important for lymphatic vessel integrity The American Society of Hematology American Society of Hematology 10.1182/blood-2009-03-212274 Silverchair:26793 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Liprin β1 is highly expressed in lymphatic vasculature and is important for lymphatic vessel integrity The American Society of Hematology American Society of Hematology 10.1182/blood-2009-03-212274 Silverchair:26793 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Liprin β1 is highly expressed in lymphatic vasculature and is important for lymphatic vessel integrity The American Society of Hematology American Society of Hematology 10.1182/blood-2009-03-212274 Silverchair:26793 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Longitudinal assessment of clonal mosaicism in human hematopoiesis via mitochondrial mutation tracking American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001196 Silverchair:429648 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Longitudinal assessment of clonal mosaicism in human hematopoiesis via mitochondrial mutation tracking American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001196 Silverchair:429648 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Longitudinal assessment of clonal mosaicism in human hematopoiesis via mitochondrial mutation tracking American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001196 Silverchair:429648 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Longitudinal assessment of clonal mosaicism in human hematopoiesis via mitochondrial mutation tracking American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001196 Silverchair:429648 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Longitudinal effect of disease-modifying therapy on tricuspid regurgitant velocity in children with sickle cell anemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003197 Silverchair:474818 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Longitudinal effect of disease-modifying therapy on tricuspid regurgitant velocity in children with sickle cell anemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003197 Silverchair:474818 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Longitudinal effect of disease-modifying therapy on tricuspid regurgitant velocity in children with sickle cell anemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003197 Silverchair:474818 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Longitudinal effect of disease-modifying therapy on tricuspid regurgitant velocity in children with sickle cell anemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003197 Silverchair:474818 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Long-Term Carfilzomib for High-Risk Patients with Newly Diagnosed Multiple Myeloma: A Pooled Analysis of Two Phase 1/2 Studies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112075 Silverchair:264481 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Long-Term Carfilzomib for High-Risk Patients with Newly Diagnosed Multiple Myeloma: A Pooled Analysis of Two Phase 1/2 Studies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112075 Silverchair:264481 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Long-Term Carfilzomib for High-Risk Patients with Newly Diagnosed Multiple Myeloma: A Pooled Analysis of Two Phase 1/2 Studies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112075 Silverchair:264481 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Long-Term Carfilzomib for High-Risk Patients with Newly Diagnosed Multiple Myeloma: A Pooled Analysis of Two Phase 1/2 Studies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112075 Silverchair:264481 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-312819 Silverchair:50913 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-312819 Silverchair:50913 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-312819 Silverchair:50913 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-312819 Silverchair:50913 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Long-Term Durability, Safety and Efficacy of Fitusiran Prophylaxis in People with Hemophilia a or B, with or without Inhibitors - Results from the Phase II Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136501 Silverchair:470270 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Long-Term Durability, Safety and Efficacy of Fitusiran Prophylaxis in People with Hemophilia a or B, with or without Inhibitors - Results from the Phase II Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136501 Silverchair:470270 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "Long-Term Durability, Safety and Efficacy of Fitusiran Prophylaxis in People with Hemophilia a or B, with or without Inhibitors - Results from the Phase II Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136501 Silverchair:470270 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Long-Term Durability, Safety and Efficacy of Fitusiran Prophylaxis in People with Hemophilia a or B, with or without Inhibitors - Results from the Phase II Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136501 Silverchair:470270 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.681.681 Silverchair:65021 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.681.681 Silverchair:65021 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.681.681 Silverchair:65021 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.681.681 Silverchair:65021 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.68.68 Silverchair:69834 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.68.68 Silverchair:69834 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.68.68 Silverchair:69834 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.68.68 Silverchair:69834 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134431 Silverchair:472120 Total_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134431 Silverchair:472120 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134431 Silverchair:472120 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134431 Silverchair:472120 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020007994 Silverchair:463764 No_License 1 0 1 0 0 0 0 0 0 0 0 0 0 Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020007994 Silverchair:463764 Total_Item_Investigations 6 0 2 0 0 0 0 4 0 0 0 0 0 Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020007994 Silverchair:463764 Unique_Item_Investigations 3 0 1 0 0 0 0 2 0 0 0 0 0 Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-635326 Silverchair:34612 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-635326 Silverchair:34612 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-635326 Silverchair:34612 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-635326 Silverchair:34612 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Long-Term Follow-up of Patients with Mantle Cell Lymphoma Treated with Venetoclax Monotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117210 Silverchair:263507 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Long-Term Follow-up of Patients with Mantle Cell Lymphoma Treated with Venetoclax Monotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117210 Silverchair:263507 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Long-Term Follow-up of Patients with Mantle Cell Lymphoma Treated with Venetoclax Monotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117210 Silverchair:263507 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Long-Term Follow-up of Patients with Mantle Cell Lymphoma Treated with Venetoclax Monotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117210 Silverchair:263507 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-736686 Silverchair:36003 Total_Item_Investigations 3 0 1 0 2 0 0 0 0 0 0 0 0 "Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-736686 Silverchair:36003 Total_Item_Requests 3 0 1 0 2 0 0 0 0 0 0 0 0 "Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-736686 Silverchair:36003 Unique_Item_Investigations 2 0 1 0 1 0 0 0 0 0 0 0 0 "Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-736686 Silverchair:36003 Unique_Item_Requests 2 0 1 0 1 0 0 0 0 0 0 0 0 Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004427 Silverchair:476727 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 0 0 1 2 Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004427 Silverchair:476727 Total_Item_Requests 3 0 0 0 0 0 0 0 0 0 0 1 2 Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004427 Silverchair:476727 Unique_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 1 1 Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004427 Silverchair:476727 Unique_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 1 1 "Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-276246 Silverchair:27477 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-276246 Silverchair:27477 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-276246 Silverchair:27477 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-276246 Silverchair:27477 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF The American Society of Hematology American Society of Hematology 10.1182/blood-2004-10-3872 Silverchair:21873 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF The American Society of Hematology American Society of Hematology 10.1182/blood-2004-10-3872 Silverchair:21873 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF The American Society of Hematology American Society of Hematology 10.1182/blood-2004-10-3872 Silverchair:21873 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF The American Society of Hematology American Society of Hematology 10.1182/blood-2004-10-3872 Silverchair:21873 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies The American Society of Hematology American Society of Hematology 10.1182/blood.2020009217 Silverchair:474603 Total_Item_Investigations 3 0 0 0 1 0 0 0 0 0 2 0 0 Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies The American Society of Hematology American Society of Hematology 10.1182/blood.2020009217 Silverchair:474603 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies The American Society of Hematology American Society of Hematology 10.1182/blood.2020009217 Silverchair:474603 Unique_Item_Investigations 2 0 0 0 1 0 0 0 0 0 1 0 0 Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies The American Society of Hematology American Society of Hematology 10.1182/blood.2020009217 Silverchair:474603 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Long-term prognostic significance of response in multiple myeloma after stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-332320 Silverchair:28902 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Long-term prognostic significance of response in multiple myeloma after stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-332320 Silverchair:28902 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Long-term prognostic significance of response in multiple myeloma after stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-332320 Silverchair:28902 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Long-term prognostic significance of response in multiple myeloma after stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-332320 Silverchair:28902 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group The American Society of Hematology American Society of Hematology 10.1182/blood-2008-03-147025 Silverchair:24705 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group The American Society of Hematology American Society of Hematology 10.1182/blood-2008-03-147025 Silverchair:24705 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group The American Society of Hematology American Society of Hematology 10.1182/blood-2008-03-147025 Silverchair:24705 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group The American Society of Hematology American Society of Hematology 10.1182/blood-2008-03-147025 Silverchair:24705 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP The American Society of Hematology American Society of Hematology 10.1182/blood.2020005846 Silverchair:463600 No_License 2 0 2 0 0 0 0 0 0 0 0 0 0 Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP The American Society of Hematology American Society of Hematology 10.1182/blood.2020005846 Silverchair:463600 Total_Item_Investigations 8 0 7 0 0 0 0 1 0 0 0 0 0 Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP The American Society of Hematology American Society of Hematology 10.1182/blood.2020005846 Silverchair:463600 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP The American Society of Hematology American Society of Hematology 10.1182/blood.2020005846 Silverchair:463600 Unique_Item_Investigations 5 0 4 0 0 0 0 1 0 0 0 0 0 Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP The American Society of Hematology American Society of Hematology 10.1182/blood.2020005846 Silverchair:463600 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Long-Term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139663 Silverchair:470271 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Long-Term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139663 Silverchair:470271 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Long-Term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139663 Silverchair:470271 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Long-Term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139663 Silverchair:470271 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-4165 Silverchair:22373 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-4165 Silverchair:22373 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-4165 Silverchair:22373 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-4165 Silverchair:22373 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-811729 Silverchair:39293 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-811729 Silverchair:39293 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-811729 Silverchair:39293 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-811729 Silverchair:39293 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Long-term, multilineage hematopoiesis occurs in the combined absence of β-catenin and γ-catenin" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-07-102558 Silverchair:107936 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Long-term, multilineage hematopoiesis occurs in the combined absence of β-catenin and γ-catenin" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-07-102558 Silverchair:107936 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Long-term, multilineage hematopoiesis occurs in the combined absence of β-catenin and γ-catenin" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-07-102558 Silverchair:107936 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Long-term, multilineage hematopoiesis occurs in the combined absence of β-catenin and γ-catenin" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-07-102558 Silverchair:107936 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Loss of Asxl1 leads to myelodysplastic syndrome–like disease in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-500272 Silverchair:32324 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Loss of Asxl1 leads to myelodysplastic syndrome–like disease in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-500272 Silverchair:32324 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Loss of Asxl1 leads to myelodysplastic syndrome–like disease in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-500272 Silverchair:32324 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Loss of Asxl1 leads to myelodysplastic syndrome–like disease in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-500272 Silverchair:32324 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Loss of a 7q gene, CUX1, disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms" The American Society of Hematology American Society of Hematology 10.1182/blood.2020009195 Silverchair:476036 Total_Item_Investigations 4 0 0 0 0 0 0 2 0 2 0 0 0 "Loss of a 7q gene, CUX1, disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms" The American Society of Hematology American Society of Hematology 10.1182/blood.2020009195 Silverchair:476036 Unique_Item_Investigations 2 0 0 0 0 0 0 1 0 1 0 0 0 Loss of CD62L Expression in CD4+FoxP3+ Regulatory T Cells Following Freeze-and-Thaw Prevents Protection Against GVHD in Murine Models The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2427.2427 Silverchair:95134 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Loss of CD62L Expression in CD4+FoxP3+ Regulatory T Cells Following Freeze-and-Thaw Prevents Protection Against GVHD in Murine Models The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2427.2427 Silverchair:95134 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Loss of CD62L Expression in CD4+FoxP3+ Regulatory T Cells Following Freeze-and-Thaw Prevents Protection Against GVHD in Murine Models The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2427.2427 Silverchair:95134 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Loss of CD62L Expression in CD4+FoxP3+ Regulatory T Cells Following Freeze-and-Thaw Prevents Protection Against GVHD in Murine Models The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2427.2427 Silverchair:95134 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Loss of Cxcl12/Sdf-1 in adult mice decreases the quiescent state of hematopoietic stem/progenitor cells and alters the pattern of hematopoietic regeneration after myelosuppression The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-266833 Silverchair:28137 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Loss of Cxcl12/Sdf-1 in adult mice decreases the quiescent state of hematopoietic stem/progenitor cells and alters the pattern of hematopoietic regeneration after myelosuppression The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-266833 Silverchair:28137 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Loss of Cxcl12/Sdf-1 in adult mice decreases the quiescent state of hematopoietic stem/progenitor cells and alters the pattern of hematopoietic regeneration after myelosuppression The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-266833 Silverchair:28137 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Loss of Cxcl12/Sdf-1 in adult mice decreases the quiescent state of hematopoietic stem/progenitor cells and alters the pattern of hematopoietic regeneration after myelosuppression The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-266833 Silverchair:28137 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Loss of Gpr68 Enhances Hematopoietic Stem Cell Function during Aging The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125168 Silverchair:424079 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Loss of Gpr68 Enhances Hematopoietic Stem Cell Function during Aging The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125168 Silverchair:424079 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Loss of Gpr68 Enhances Hematopoietic Stem Cell Function during Aging The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125168 Silverchair:424079 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Loss of Gpr68 Enhances Hematopoietic Stem Cell Function during Aging The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125168 Silverchair:424079 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Loss of METTL3 Mediated m6A RNA Modification Results in Double-Stranded RNA Induced Innate Immune Response and Hematopoietic Failure The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130442 Silverchair:426463 Total_Item_Investigations 2 1 0 0 0 1 0 0 0 0 0 0 0 Loss of METTL3 Mediated m6A RNA Modification Results in Double-Stranded RNA Induced Innate Immune Response and Hematopoietic Failure The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130442 Silverchair:426463 Total_Item_Requests 2 1 0 0 0 1 0 0 0 0 0 0 0 Loss of METTL3 Mediated m6A RNA Modification Results in Double-Stranded RNA Induced Innate Immune Response and Hematopoietic Failure The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130442 Silverchair:426463 Unique_Item_Investigations 2 1 0 0 0 1 0 0 0 0 0 0 0 Loss of METTL3 Mediated m6A RNA Modification Results in Double-Stranded RNA Induced Innate Immune Response and Hematopoietic Failure The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130442 Silverchair:426463 Unique_Item_Requests 2 1 0 0 0 1 0 0 0 0 0 0 0 Loss of pleckstrin defines a novel pathway for PKC-mediated exocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-178913 Silverchair:24936 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Loss of pleckstrin defines a novel pathway for PKC-mediated exocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-178913 Silverchair:24936 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Loss of pleckstrin defines a novel pathway for PKC-mediated exocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-178913 Silverchair:24936 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Loss of pleckstrin defines a novel pathway for PKC-mediated exocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-178913 Silverchair:24936 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-555508 Silverchair:34234 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-555508 Silverchair:34234 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-555508 Silverchair:34234 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-555508 Silverchair:34234 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Loss of the exocyst complex component EXOC3 promotes hemostasis and accelerates arterial thrombosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002515 Silverchair:475049 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Loss of the exocyst complex component EXOC3 promotes hemostasis and accelerates arterial thrombosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002515 Silverchair:475049 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Loss of the exocyst complex component EXOC3 promotes hemostasis and accelerates arterial thrombosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002515 Silverchair:475049 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Loss of the exocyst complex component EXOC3 promotes hemostasis and accelerates arterial thrombosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002515 Silverchair:475049 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Loss of the selective autophagy receptor p62 impairs murine myeloid leukemia progression and mitophagy The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-833475 Silverchair:39568 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Loss of the selective autophagy receptor p62 impairs murine myeloid leukemia progression and mitophagy The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-833475 Silverchair:39568 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Loss of the selective autophagy receptor p62 impairs murine myeloid leukemia progression and mitophagy The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-833475 Silverchair:39568 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Loss of the selective autophagy receptor p62 impairs murine myeloid leukemia progression and mitophagy The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-833475 Silverchair:39568 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-374363 Silverchair:29800 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-374363 Silverchair:29800 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-374363 Silverchair:29800 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-374363 Silverchair:29800 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Loss-of-Function Mutations in Dnmt3a and Tet2 Lead to Accelerated Atherosclerosis and Convergent Macrophage Phenotypes in Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118288 Silverchair:266118 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Loss-of-Function Mutations in Dnmt3a and Tet2 Lead to Accelerated Atherosclerosis and Convergent Macrophage Phenotypes in Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118288 Silverchair:266118 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Loss-of-Function Mutations in Dnmt3a and Tet2 Lead to Accelerated Atherosclerosis and Convergent Macrophage Phenotypes in Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118288 Silverchair:266118 Unique_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Loss-of-Function Mutations in Dnmt3a and Tet2 Lead to Accelerated Atherosclerosis and Convergent Macrophage Phenotypes in Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118288 Silverchair:266118 Unique_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Lost in neutrophil heterogeneity? CD10! The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-761585 Silverchair:36016 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Lost in neutrophil heterogeneity? CD10! The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-761585 Silverchair:36016 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Lost in neutrophil heterogeneity? CD10! The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-761585 Silverchair:36016 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Lost in neutrophil heterogeneity? CD10! The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-761585 Silverchair:36016 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Low 5-year health care burden after umbilical cord blood transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003369 Silverchair:475145 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Low 5-year health care burden after umbilical cord blood transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003369 Silverchair:475145 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Low 5-year health care burden after umbilical cord blood transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003369 Silverchair:475145 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Low 5-year health care burden after umbilical cord blood transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003369 Silverchair:475145 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 "Low blood counts: immune mediated, idiopathic, or myelodysplasia" The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.485.3798522 Silverchair:83865 Total_Item_Investigations 3 1 2 0 0 0 0 0 0 0 0 0 0 "Low blood counts: immune mediated, idiopathic, or myelodysplasia" The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.485.3798522 Silverchair:83865 Total_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 "Low blood counts: immune mediated, idiopathic, or myelodysplasia" The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.485.3798522 Silverchair:83865 Unique_Item_Investigations 3 1 2 0 0 0 0 0 0 0 0 0 0 "Low blood counts: immune mediated, idiopathic, or myelodysplasia" The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.485.3798522 Silverchair:83865 Unique_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 Low Doses of Eltrombopag Are Safe and Effective in the Prophylaxis of the Chemotherapy-Induced Thrombocytopenia (CIT) The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4926.4926 Silverchair:99651 Total_Item_Investigations 2 0 0 0 0 0 0 0 2 0 0 0 0 Low Doses of Eltrombopag Are Safe and Effective in the Prophylaxis of the Chemotherapy-Induced Thrombocytopenia (CIT) The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4926.4926 Silverchair:99651 Total_Item_Requests 2 0 0 0 0 0 0 0 2 0 0 0 0 Low Doses of Eltrombopag Are Safe and Effective in the Prophylaxis of the Chemotherapy-Induced Thrombocytopenia (CIT) The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4926.4926 Silverchair:99651 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Low Doses of Eltrombopag Are Safe and Effective in the Prophylaxis of the Chemotherapy-Induced Thrombocytopenia (CIT) The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4926.4926 Silverchair:99651 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Low Iron Promotes Megakaryocytic Commitment of Megakaryocytic-Erythroid Progenitors in Human and Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115124 Silverchair:277544 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Low Iron Promotes Megakaryocytic Commitment of Megakaryocytic-Erythroid Progenitors in Human and Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115124 Silverchair:277544 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Low Iron Promotes Megakaryocytic Commitment of Megakaryocytic-Erythroid Progenitors in Human and Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115124 Silverchair:277544 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Low Iron Promotes Megakaryocytic Commitment of Megakaryocytic-Erythroid Progenitors in Human and Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115124 Silverchair:277544 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Low iron promotes megakaryocytic commitment of megakaryocytic-erythroid progenitors in humans and mice The American Society of Hematology American Society of Hematology 10.1182/blood.2019002039 Silverchair:374971 Total_Item_Investigations 16 8 0 3 3 0 0 2 0 0 0 0 0 Low iron promotes megakaryocytic commitment of megakaryocytic-erythroid progenitors in humans and mice The American Society of Hematology American Society of Hematology 10.1182/blood.2019002039 Silverchair:374971 Total_Item_Requests 15 7 0 3 3 0 0 2 0 0 0 0 0 Low iron promotes megakaryocytic commitment of megakaryocytic-erythroid progenitors in humans and mice The American Society of Hematology American Society of Hematology 10.1182/blood.2019002039 Silverchair:374971 Unique_Item_Investigations 7 3 0 2 1 0 0 1 0 0 0 0 0 Low iron promotes megakaryocytic commitment of megakaryocytic-erythroid progenitors in humans and mice The American Society of Hematology American Society of Hematology 10.1182/blood.2019002039 Silverchair:374971 Unique_Item_Requests 7 3 0 2 1 0 0 1 0 0 0 0 0 Low-burden TP53 mutations in CLL: Clinical impact and clonal evolution within the context of different treatment options The American Society of Hematology American Society of Hematology 10.1182/blood.2020009530 Silverchair:475902 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 Low-burden TP53 mutations in CLL: Clinical impact and clonal evolution within the context of different treatment options The American Society of Hematology American Society of Hematology 10.1182/blood.2020009530 Silverchair:475902 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Low-burden TP53 mutations in CLL: Clinical impact and clonal evolution within the context of different treatment options The American Society of Hematology American Society of Hematology 10.1182/blood.2020009530 Silverchair:475902 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Low-burden TP53 mutations in CLL: Clinical impact and clonal evolution within the context of different treatment options The American Society of Hematology American Society of Hematology 10.1182/blood.2020009530 Silverchair:475902 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.2020008477 Silverchair:475779 Total_Item_Investigations 2 0 0 0 0 0 0 0 2 0 0 0 0 Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.2020008477 Silverchair:475779 Total_Item_Requests 2 0 0 0 0 0 0 0 2 0 0 0 0 Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.2020008477 Silverchair:475779 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.2020008477 Silverchair:475779 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Low-Dose Lenalidomide Maintenance after Induction Therapy in Older Patients with Primary CNS Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112767 Silverchair:275480 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Low-Dose Lenalidomide Maintenance after Induction Therapy in Older Patients with Primary CNS Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112767 Silverchair:275480 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Low-Dose Lenalidomide Maintenance after Induction Therapy in Older Patients with Primary CNS Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112767 Silverchair:275480 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Low-Dose Lenalidomide Maintenance after Induction Therapy in Older Patients with Primary CNS Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112767 Silverchair:275480 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019030858 Silverchair:246604 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 "Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019030858 Silverchair:246604 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 "Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019030858 Silverchair:246604 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019030858 Silverchair:246604 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Low-dose rituximab in autoimmune hemolytic anemia: 10 years after The American Society of Hematology American Society of Hematology 10.1182/blood-2018-12-885228 Silverchair:260622 Total_Item_Investigations 5 3 1 0 1 0 0 0 0 0 0 0 0 Low-dose rituximab in autoimmune hemolytic anemia: 10 years after The American Society of Hematology American Society of Hematology 10.1182/blood-2018-12-885228 Silverchair:260622 Total_Item_Requests 5 3 1 0 1 0 0 0 0 0 0 0 0 Low-dose rituximab in autoimmune hemolytic anemia: 10 years after The American Society of Hematology American Society of Hematology 10.1182/blood-2018-12-885228 Silverchair:260622 Unique_Item_Investigations 4 2 1 0 1 0 0 0 0 0 0 0 0 Low-dose rituximab in autoimmune hemolytic anemia: 10 years after The American Society of Hematology American Society of Hematology 10.1182/blood-2018-12-885228 Silverchair:260622 Unique_Item_Requests 4 2 1 0 1 0 0 0 0 0 0 0 0 "Low-Dose Tamoxifen (LDTam) As a Breast Cancer (BC) Risk-Reduction Strategy in Lymphoma Survivors Exposed to Chest Radiation Therapy (RT) during Adolescence/Young Adulthood - a Randomized, Placebo-Controlled Double Blinded Phase IIb Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126661 Silverchair:423433 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Low-Dose Tamoxifen (LDTam) As a Breast Cancer (BC) Risk-Reduction Strategy in Lymphoma Survivors Exposed to Chest Radiation Therapy (RT) during Adolescence/Young Adulthood - a Randomized, Placebo-Controlled Double Blinded Phase IIb Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126661 Silverchair:423433 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Low-Dose Tamoxifen (LDTam) As a Breast Cancer (BC) Risk-Reduction Strategy in Lymphoma Survivors Exposed to Chest Radiation Therapy (RT) during Adolescence/Young Adulthood - a Randomized, Placebo-Controlled Double Blinded Phase IIb Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126661 Silverchair:423433 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Low-Dose Tamoxifen (LDTam) As a Breast Cancer (BC) Risk-Reduction Strategy in Lymphoma Survivors Exposed to Chest Radiation Therapy (RT) during Adolescence/Young Adulthood - a Randomized, Placebo-Controlled Double Blinded Phase IIb Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126661 Silverchair:423433 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Low-strength T-cell activation promotes Th17 responses The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-272153 Silverchair:28371 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Low-strength T-cell activation promotes Th17 responses The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-272153 Silverchair:28371 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Low-strength T-cell activation promotes Th17 responses The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-272153 Silverchair:28371 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Low-strength T-cell activation promotes Th17 responses The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-272153 Silverchair:28371 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Lung megakaryocytes display distinct transcriptional and phenotypic properties American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002843 Silverchair:474606 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Lung megakaryocytes display distinct transcriptional and phenotypic properties American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002843 Silverchair:474606 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Lung megakaryocytes display distinct transcriptional and phenotypic properties American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002843 Silverchair:474606 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Lung megakaryocytes display distinct transcriptional and phenotypic properties American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002843 Silverchair:474606 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-876888 Silverchair:260592 Total_Item_Investigations 8 5 0 3 0 0 0 0 0 0 0 0 0 Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-876888 Silverchair:260592 Total_Item_Requests 8 5 0 3 0 0 0 0 0 0 0 0 0 Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-876888 Silverchair:260592 Unique_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-876888 Silverchair:260592 Unique_Item_Requests 3 2 0 1 0 0 0 0 0 0 0 0 0 Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with ß-thalassemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-879247 Silverchair:260489 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with ß-thalassemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-879247 Silverchair:260489 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with ß-thalassemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-879247 Silverchair:260489 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with ß-thalassemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-879247 Silverchair:260489 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123655 Silverchair:423548 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123655 Silverchair:423548 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123655 Silverchair:423548 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123655 Silverchair:423548 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Lymphocytic-Variant Hypereosinophilic Syndromes American Society of Hematology American Society of Hematology 10.1182/hem.V14.6.7884 Silverchair:462952 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Lymphocytic-Variant Hypereosinophilic Syndromes American Society of Hematology American Society of Hematology 10.1182/hem.V14.6.7884 Silverchair:462952 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Lymphocytic-Variant Hypereosinophilic Syndromes American Society of Hematology American Society of Hematology 10.1182/hem.V14.6.7884 Silverchair:462952 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Lymphocytic-Variant Hypereosinophilic Syndromes American Society of Hematology American Society of Hematology 10.1182/hem.V14.6.7884 Silverchair:462952 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma in the Bone Marrow: Paratrabecular Involvement As an Important Distinguishing Feature The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5399.5399 Silverchair:92339 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma in the Bone Marrow: Paratrabecular Involvement As an Important Distinguishing Feature The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5399.5399 Silverchair:92339 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma in the Bone Marrow: Paratrabecular Involvement As an Important Distinguishing Feature The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5399.5399 Silverchair:92339 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma in the Bone Marrow: Paratrabecular Involvement As an Important Distinguishing Feature The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5399.5399 Silverchair:92339 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 "Lymphoplasmacytic Lymphoma with IgA Gammopathy, Case Report and Review of Literature." The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4409.4409 Silverchair:117784 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 "Lymphoplasmacytic Lymphoma with IgA Gammopathy, Case Report and Review of Literature." The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4409.4409 Silverchair:117784 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 "Lymphoplasmacytic Lymphoma with IgA Gammopathy, Case Report and Review of Literature." The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4409.4409 Silverchair:117784 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 "Lymphoplasmacytic Lymphoma with IgA Gammopathy, Case Report and Review of Literature." The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4409.4409 Silverchair:117784 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Lymphovenous hemostasis and the role of platelets in regulating lymphatic flow and lymphatic vessel maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-636415 Silverchair:35765 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Lymphovenous hemostasis and the role of platelets in regulating lymphatic flow and lymphatic vessel maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-636415 Silverchair:35765 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Lymphovenous hemostasis and the role of platelets in regulating lymphatic flow and lymphatic vessel maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-636415 Silverchair:35765 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Lymphovenous hemostasis and the role of platelets in regulating lymphatic flow and lymphatic vessel maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-636415 Silverchair:35765 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Lyn and PKCδ order SHIP1 embargo The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-233627 Silverchair:107822 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Lyn and PKCδ order SHIP1 embargo The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-233627 Silverchair:107822 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Lyn and PKCδ order SHIP1 embargo The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-233627 Silverchair:107822 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Lyn and PKCδ order SHIP1 embargo The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-233627 Silverchair:107822 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Lyn, PKC-δ, SHIP-1 interactions regulate GPVI-mediated platelet-dense granule secretion" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-11-188516 Silverchair:107860 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 "Lyn, PKC-δ, SHIP-1 interactions regulate GPVI-mediated platelet-dense granule secretion" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-11-188516 Silverchair:107860 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 "Lyn, PKC-δ, SHIP-1 interactions regulate GPVI-mediated platelet-dense granule secretion" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-11-188516 Silverchair:107860 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Lyn, PKC-δ, SHIP-1 interactions regulate GPVI-mediated platelet-dense granule secretion" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-11-188516 Silverchair:107860 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Lysine Methyltransferase Kmt5a Restricts Myeloid-Biased Output of Lymphoid-Primed Multipotent Progenitors The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1487.1487 Silverchair:91521 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Lysine Methyltransferase Kmt5a Restricts Myeloid-Biased Output of Lymphoid-Primed Multipotent Progenitors The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1487.1487 Silverchair:91521 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Lysine Methyltransferase Kmt5a Restricts Myeloid-Biased Output of Lymphoid-Primed Multipotent Progenitors The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1487.1487 Silverchair:91521 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Lysine Methyltransferase Kmt5a Restricts Myeloid-Biased Output of Lymphoid-Primed Multipotent Progenitors The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1487.1487 Silverchair:91521 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 m6A Maintains Hematopoietic Stem and Progenitor Cell Identity The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117191 Silverchair:264795 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 m6A Maintains Hematopoietic Stem and Progenitor Cell Identity The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117191 Silverchair:264795 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 m6A Maintains Hematopoietic Stem and Progenitor Cell Identity The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117191 Silverchair:264795 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 m6A Maintains Hematopoietic Stem and Progenitor Cell Identity The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117191 Silverchair:264795 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-880849 Silverchair:261476 Total_Item_Investigations 2 0 0 0 0 0 0 0 2 0 0 0 0 "MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-880849 Silverchair:261476 Total_Item_Requests 2 0 0 0 0 0 0 0 2 0 0 0 0 "MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-880849 Silverchair:261476 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 "MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-880849 Silverchair:261476 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Mac-1 (CD11b/CD18) is essential for Fc receptor–mediated neutrophil cytotoxicity and immunologic synapse formation The American Society of Hematology American Society of Hematology 10.1182/blood.V97.8.2478 Silverchair:53243 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Mac-1 (CD11b/CD18) is essential for Fc receptor–mediated neutrophil cytotoxicity and immunologic synapse formation The American Society of Hematology American Society of Hematology 10.1182/blood.V97.8.2478 Silverchair:53243 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Mac-1 (CD11b/CD18) is essential for Fc receptor–mediated neutrophil cytotoxicity and immunologic synapse formation The American Society of Hematology American Society of Hematology 10.1182/blood.V97.8.2478 Silverchair:53243 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Mac-1 (CD11b/CD18) is essential for Fc receptor–mediated neutrophil cytotoxicity and immunologic synapse formation The American Society of Hematology American Society of Hematology 10.1182/blood.V97.8.2478 Silverchair:53243 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Macrophages prevent human red blood cell reconstitution in immunodeficient mice The American Society of Hematology American Society of Hematology 10.1182/blood-2010-11-321414 Silverchair:29174 Total_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 Macrophages prevent human red blood cell reconstitution in immunodeficient mice The American Society of Hematology American Society of Hematology 10.1182/blood-2010-11-321414 Silverchair:29174 Total_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 Macrophages prevent human red blood cell reconstitution in immunodeficient mice The American Society of Hematology American Society of Hematology 10.1182/blood-2010-11-321414 Silverchair:29174 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Macrophages prevent human red blood cell reconstitution in immunodeficient mice The American Society of Hematology American Society of Hematology 10.1182/blood-2010-11-321414 Silverchair:29174 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Macrophages shine bright The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-590372 Silverchair:33448 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Macrophages shine bright The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-590372 Silverchair:33448 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Macrophages shine bright The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-590372 Silverchair:33448 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Macrophages shine bright The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-590372 Silverchair:33448 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Macrophage-specific metalloelastase (MMP-12) truncates and inactivates ELR+ CXC chemokines and generates CCL2, -7, -8, and -13 antagonists: potential" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-12-129080 Silverchair:114976 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 "Macrophage-specific metalloelastase (MMP-12) truncates and inactivates ELR+ CXC chemokines and generates CCL2, -7, -8, and -13 antagonists: potential" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-12-129080 Silverchair:114976 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 "Macrophage-specific metalloelastase (MMP-12) truncates and inactivates ELR+ CXC chemokines and generates CCL2, -7, -8, and -13 antagonists: potential" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-12-129080 Silverchair:114976 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Macrophage-specific metalloelastase (MMP-12) truncates and inactivates ELR+ CXC chemokines and generates CCL2, -7, -8, and -13 antagonists: potential" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-12-129080 Silverchair:114976 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Magnetic Resonance Imaging in Myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood.V92.8.2995 Silverchair:261377 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Magnetic Resonance Imaging in Myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood.V92.8.2995 Silverchair:261377 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Magnetic Resonance Imaging in Myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood.V92.8.2995 Silverchair:261377 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Magnetic Resonance Imaging in Myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood.V92.8.2995 Silverchair:261377 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Maintenance 5-Azactidine May Improve Outcomes after Allogeneic Stem-Cell Transplantation in High-Risk AML and MDS Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129966 Silverchair:423890 Total_Item_Investigations 7 2 0 0 5 0 0 0 0 0 0 0 0 Maintenance 5-Azactidine May Improve Outcomes after Allogeneic Stem-Cell Transplantation in High-Risk AML and MDS Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129966 Silverchair:423890 Total_Item_Requests 7 2 0 0 5 0 0 0 0 0 0 0 0 Maintenance 5-Azactidine May Improve Outcomes after Allogeneic Stem-Cell Transplantation in High-Risk AML and MDS Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129966 Silverchair:423890 Unique_Item_Investigations 2 1 0 0 1 0 0 0 0 0 0 0 0 Maintenance 5-Azactidine May Improve Outcomes after Allogeneic Stem-Cell Transplantation in High-Risk AML and MDS Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129966 Silverchair:423890 Unique_Item_Requests 2 1 0 0 1 0 0 0 0 0 0 0 0 Maintenance Hypomethylating Therapy Post Allogeneic Stem Cell Transplantation Provides Favorable Progression Free Survival in High Risk Acute Myelogenous Leukemia or Non Responsive Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4468.4468 Silverchair:85201 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Maintenance Hypomethylating Therapy Post Allogeneic Stem Cell Transplantation Provides Favorable Progression Free Survival in High Risk Acute Myelogenous Leukemia or Non Responsive Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4468.4468 Silverchair:85201 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Maintenance Hypomethylating Therapy Post Allogeneic Stem Cell Transplantation Provides Favorable Progression Free Survival in High Risk Acute Myelogenous Leukemia or Non Responsive Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4468.4468 Silverchair:85201 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Maintenance Hypomethylating Therapy Post Allogeneic Stem Cell Transplantation Provides Favorable Progression Free Survival in High Risk Acute Myelogenous Leukemia or Non Responsive Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4468.4468 Silverchair:85201 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Maintenance of mouse hematopoietic stem cells ex vivo by reprogramming cellular metabolism The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-568949 Silverchair:33785 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Maintenance of mouse hematopoietic stem cells ex vivo by reprogramming cellular metabolism The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-568949 Silverchair:33785 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Maintenance of mouse hematopoietic stem cells ex vivo by reprogramming cellular metabolism The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-568949 Silverchair:33785 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Maintenance of mouse hematopoietic stem cells ex vivo by reprogramming cellular metabolism The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-568949 Silverchair:33785 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129404 Silverchair:427248 Total_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129404 Silverchair:427248 Total_Item_Requests 3 2 0 1 0 0 0 0 0 0 0 0 0 Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129404 Silverchair:427248 Unique_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129404 Silverchair:427248 Unique_Item_Requests 3 2 0 1 0 0 0 0 0 0 0 0 0 Maintenance Rituximab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) in the First Line Setting or at Relapse The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125980 Silverchair:425138 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Maintenance Rituximab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) in the First Line Setting or at Relapse The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125980 Silverchair:425138 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Maintenance Rituximab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) in the First Line Setting or at Relapse The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125980 Silverchair:425138 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Maintenance Rituximab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) in the First Line Setting or at Relapse The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125980 Silverchair:425138 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Maintenance Sorafenib Is Superior to Prophylactic DLI in Improving the Prognosis of FLT3-ITD-Positive AML after Allogeneic HSCT The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127594 Silverchair:423162 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Maintenance Sorafenib Is Superior to Prophylactic DLI in Improving the Prognosis of FLT3-ITD-Positive AML after Allogeneic HSCT The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127594 Silverchair:423162 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Maintenance Sorafenib Is Superior to Prophylactic DLI in Improving the Prognosis of FLT3-ITD-Positive AML after Allogeneic HSCT The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127594 Silverchair:423162 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Maintenance Sorafenib Is Superior to Prophylactic DLI in Improving the Prognosis of FLT3-ITD-Positive AML after Allogeneic HSCT The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127594 Silverchair:423162 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Maintenance therapy for AML: are we there yet? The American Society of Hematology American Society of Hematology 10.1182/blood-2019-02-897579 Silverchair:261466 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Maintenance therapy for AML: are we there yet? The American Society of Hematology American Society of Hematology 10.1182/blood-2019-02-897579 Silverchair:261466 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Maintenance therapy for AML: are we there yet? The American Society of Hematology American Society of Hematology 10.1182/blood-2019-02-897579 Silverchair:261466 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Maintenance therapy for AML: are we there yet? The American Society of Hematology American Society of Hematology 10.1182/blood-2019-02-897579 Silverchair:261466 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Maintenance therapy for high-risk acute leukemia after allogeneic hematopoietic cell transplantation: wait a minute American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000389 Silverchair:461315 Total_Item_Investigations 5 2 1 2 0 0 0 0 0 0 0 0 0 Maintenance therapy for high-risk acute leukemia after allogeneic hematopoietic cell transplantation: wait a minute American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000389 Silverchair:461315 Total_Item_Requests 5 2 1 2 0 0 0 0 0 0 0 0 0 Maintenance therapy for high-risk acute leukemia after allogeneic hematopoietic cell transplantation: wait a minute American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000389 Silverchair:461315 Unique_Item_Investigations 4 1 1 2 0 0 0 0 0 0 0 0 0 Maintenance therapy for high-risk acute leukemia after allogeneic hematopoietic cell transplantation: wait a minute American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000389 Silverchair:461315 Unique_Item_Requests 4 1 1 2 0 0 0 0 0 0 0 0 0 Maintenance Therapy with 5-Azacytidine (5-AC) after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS): A Dose and Schedule Finding Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.3668.3668 Silverchair:126894 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Maintenance Therapy with 5-Azacytidine (5-AC) after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS): A Dose and Schedule Finding Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.3668.3668 Silverchair:126894 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Maintenance Therapy with 5-Azacytidine (5-AC) after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS): A Dose and Schedule Finding Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.3668.3668 Silverchair:126894 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Maintenance Therapy with 5-Azacytidine (5-AC) after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS): A Dose and Schedule Finding Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.3668.3668 Silverchair:126894 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients The American Society of Hematology American Society of Hematology 10.1182/blood.V99.9.3163 Silverchair:53585 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients The American Society of Hematology American Society of Hematology 10.1182/blood.V99.9.3163 Silverchair:53585 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients The American Society of Hematology American Society of Hematology 10.1182/blood.V99.9.3163 Silverchair:53585 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients The American Society of Hematology American Society of Hematology 10.1182/blood.V99.9.3163 Silverchair:53585 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Maintenance Therapy With Decitabine After Allogeneic Hematopoietic Stem Cell Transplantation For Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4638.4638 Silverchair:11763 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Maintenance Therapy With Decitabine After Allogeneic Hematopoietic Stem Cell Transplantation For Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4638.4638 Silverchair:11763 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Maintenance Therapy With Decitabine After Allogeneic Hematopoietic Stem Cell Transplantation For Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4638.4638 Silverchair:11763 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Maintenance Therapy With Decitabine After Allogeneic Hematopoietic Stem Cell Transplantation For Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4638.4638 Silverchair:11763 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Maintenance Therapy with Decitabine after Allogeneic Hematopoietic Stem Cell Transplantation to Prevent Relapse of High Risk Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124033 Silverchair:423920 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Maintenance Therapy with Decitabine after Allogeneic Hematopoietic Stem Cell Transplantation to Prevent Relapse of High Risk Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124033 Silverchair:423920 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Maintenance Therapy with Decitabine after Allogeneic Hematopoietic Stem Cell Transplantation to Prevent Relapse of High Risk Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124033 Silverchair:423920 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Maintenance Therapy with Decitabine after Allogeneic Hematopoietic Stem Cell Transplantation to Prevent Relapse of High Risk Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124033 Silverchair:423920 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.1134.1134 Silverchair:59039 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.1134.1134 Silverchair:59039 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.1134.1134 Silverchair:59039 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.1134.1134 Silverchair:59039 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111582 Silverchair:266187 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111582 Silverchair:266187 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111582 Silverchair:266187 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111582 Silverchair:266187 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6 The American Society of Hematology American Society of Hematology 10.1182/blood-2009-06-228684 Silverchair:27040 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6 The American Society of Hematology American Society of Hematology 10.1182/blood-2009-06-228684 Silverchair:27040 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6 The American Society of Hematology American Society of Hematology 10.1182/blood-2009-06-228684 Silverchair:27040 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6 The American Society of Hematology American Society of Hematology 10.1182/blood-2009-06-228684 Silverchair:27040 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Malignant or benign leukocytosis The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.475.3798515 Silverchair:83856 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Malignant or benign leukocytosis The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.475.3798515 Silverchair:83856 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Malignant or benign leukocytosis The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.475.3798515 Silverchair:83856 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Malignant or benign leukocytosis The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.475.3798515 Silverchair:83856 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Malignant progression of donor-engrafted clonal hematopoiesis in sibling recipients after stem cell transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003168 Silverchair:474135 Total_Item_Investigations 3 0 0 0 0 0 0 3 0 0 0 0 0 Malignant progression of donor-engrafted clonal hematopoiesis in sibling recipients after stem cell transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003168 Silverchair:474135 Total_Item_Requests 3 0 0 0 0 0 0 3 0 0 0 0 0 Malignant progression of donor-engrafted clonal hematopoiesis in sibling recipients after stem cell transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003168 Silverchair:474135 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Malignant progression of donor-engrafted clonal hematopoiesis in sibling recipients after stem cell transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003168 Silverchair:474135 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Mammalian target of rapamycin regulates neutrophil extracellular trap formation via induction of hypoxia-inducible factor 1 α The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-405993 Silverchair:30639 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Mammalian target of rapamycin regulates neutrophil extracellular trap formation via induction of hypoxia-inducible factor 1 α The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-405993 Silverchair:30639 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Mammalian target of rapamycin regulates neutrophil extracellular trap formation via induction of hypoxia-inducible factor 1 α The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-405993 Silverchair:30639 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Mammalian target of rapamycin regulates neutrophil extracellular trap formation via induction of hypoxia-inducible factor 1 α The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-405993 Silverchair:30639 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Mammalian VPS45 orchestrates trafficking through the endosomal system The American Society of Hematology American Society of Hematology 10.1182/blood.2020006871 Silverchair:474761 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Mammalian VPS45 orchestrates trafficking through the endosomal system The American Society of Hematology American Society of Hematology 10.1182/blood.2020006871 Silverchair:474761 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Mammalian VPS45 orchestrates trafficking through the endosomal system The American Society of Hematology American Society of Hematology 10.1182/blood.2020006871 Silverchair:474761 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Mammalian VPS45 orchestrates trafficking through the endosomal system The American Society of Hematology American Society of Hematology 10.1182/blood.2020006871 Silverchair:474761 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-595496 Silverchair:33595 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 1 2 0 0 Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-595496 Silverchair:33595 Total_Item_Requests 3 0 0 0 0 0 0 0 0 1 2 0 0 Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-595496 Silverchair:33595 Unique_Item_Investigations 2 0 0 0 0 0 0 0 0 1 1 0 0 Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-595496 Silverchair:33595 Unique_Item_Requests 2 0 0 0 0 0 0 0 0 1 1 0 0 Management of acquired hemophilia A: results from the Spanish registry American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004626 Silverchair:476899 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Management of acquired hemophilia A: results from the Spanish registry American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004626 Silverchair:476899 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Management of acquired hemophilia A: results from the Spanish registry American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004626 Silverchair:476899 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Management of acquired hemophilia A: results from the Spanish registry American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004626 Silverchair:476899 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet The American Society of Hematology American Society of Hematology 10.1182/blood-2019-01-894980 Silverchair:273295 Total_Item_Investigations 14 3 3 2 2 0 0 1 0 0 0 3 0 Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet The American Society of Hematology American Society of Hematology 10.1182/blood-2019-01-894980 Silverchair:273295 Total_Item_Requests 11 2 2 2 1 0 0 1 0 0 0 3 0 Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet The American Society of Hematology American Society of Hematology 10.1182/blood-2019-01-894980 Silverchair:273295 Unique_Item_Investigations 6 1 1 1 1 0 0 1 0 0 0 1 0 Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet The American Society of Hematology American Society of Hematology 10.1182/blood-2019-01-894980 Silverchair:273295 Unique_Item_Requests 6 1 1 1 1 0 0 1 0 0 0 1 0 Management of adults with T-cell lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-07-692608 Silverchair:36590 Total_Item_Investigations 4 0 0 1 0 0 0 0 0 0 0 3 0 Management of adults with T-cell lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-07-692608 Silverchair:36590 Total_Item_Requests 4 0 0 1 0 0 0 0 0 0 0 3 0 Management of adults with T-cell lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-07-692608 Silverchair:36590 Unique_Item_Investigations 2 0 0 1 0 0 0 0 0 0 0 1 0 Management of adults with T-cell lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-07-692608 Silverchair:36590 Unique_Item_Requests 2 0 0 1 0 0 0 0 0 0 0 1 0 Management of AL amyloidosis in 2020 The American Society of Hematology American Society of Hematology 10.1182/blood.2020006913 Silverchair:474251 Total_Item_Investigations 4 3 1 0 0 0 0 0 0 0 0 0 0 Management of AL amyloidosis in 2020 The American Society of Hematology American Society of Hematology 10.1182/blood.2020006913 Silverchair:474251 Total_Item_Requests 4 3 1 0 0 0 0 0 0 0 0 0 0 Management of AL amyloidosis in 2020 The American Society of Hematology American Society of Hematology 10.1182/blood.2020006913 Silverchair:474251 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Management of AL amyloidosis in 2020 The American Society of Hematology American Society of Hematology 10.1182/blood.2020006913 Silverchair:474251 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Management of AL amyloidosis in 2020 The American Society of Hematology American Society of Hematology 10.1182/hematology.2020006913 Silverchair:474364 Total_Item_Investigations 4 2 0 0 2 0 0 0 0 0 0 0 0 Management of AL amyloidosis in 2020 The American Society of Hematology American Society of Hematology 10.1182/hematology.2020006913 Silverchair:474364 Total_Item_Requests 4 2 0 0 2 0 0 0 0 0 0 0 0 Management of AL amyloidosis in 2020 The American Society of Hematology American Society of Hematology 10.1182/hematology.2020006913 Silverchair:474364 Unique_Item_Investigations 3 2 0 0 1 0 0 0 0 0 0 0 0 Management of AL amyloidosis in 2020 The American Society of Hematology American Society of Hematology 10.1182/hematology.2020006913 Silverchair:474364 Unique_Item_Requests 3 2 0 0 1 0 0 0 0 0 0 0 0 Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018030387 Silverchair:260121 Total_Item_Investigations 6 0 3 3 0 0 0 0 0 0 0 0 0 Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018030387 Silverchair:260121 Total_Item_Requests 6 0 3 3 0 0 0 0 0 0 0 0 0 Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018030387 Silverchair:260121 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018030387 Silverchair:260121 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Management of direct factor Xa inhibitor–related major bleeding with prothrombin complex concentrate: a meta-analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018024133 Silverchair:246572 Total_Item_Investigations 6 3 3 0 0 0 0 0 0 0 0 0 0 Management of direct factor Xa inhibitor–related major bleeding with prothrombin complex concentrate: a meta-analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018024133 Silverchair:246572 Total_Item_Requests 4 2 2 0 0 0 0 0 0 0 0 0 0 Management of direct factor Xa inhibitor–related major bleeding with prothrombin complex concentrate: a meta-analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018024133 Silverchair:246572 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Management of direct factor Xa inhibitor–related major bleeding with prothrombin complex concentrate: a meta-analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018024133 Silverchair:246572 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Management of Essential Thrombocythemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2011.1.215 Silverchair:96960 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Management of Essential Thrombocythemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2011.1.215 Silverchair:96960 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Management of Essential Thrombocythemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2011.1.215 Silverchair:96960 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Management of Essential Thrombocythemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2011.1.215 Silverchair:96960 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Management of incidental splanchnic vein thrombosis in cancer patients The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.318 Silverchair:20539 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Management of incidental splanchnic vein thrombosis in cancer patients The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.318 Silverchair:20539 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Management of incidental splanchnic vein thrombosis in cancer patients The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.318 Silverchair:20539 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Management of incidental splanchnic vein thrombosis in cancer patients The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.318 Silverchair:20539 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Management of iron deficiency The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000034 Silverchair:422602 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Management of iron deficiency The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000034 Silverchair:422602 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Management of iron deficiency The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000034 Silverchair:422602 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Management of iron deficiency The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000034 Silverchair:422602 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Management of multiple myeloma in the newly diagnosed patient The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.498 Silverchair:21148 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Management of multiple myeloma in the newly diagnosed patient The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.498 Silverchair:21148 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Management of multiple myeloma in the newly diagnosed patient The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.498 Silverchair:21148 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Management of multiple myeloma in the newly diagnosed patient The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.498 Silverchair:21148 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Management of multiple myeloma in the relapsed/refractory patient The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.508 Silverchair:21173 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Management of multiple myeloma in the relapsed/refractory patient The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.508 Silverchair:21173 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Management of multiple myeloma in the relapsed/refractory patient The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.508 Silverchair:21173 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Management of multiple myeloma in the relapsed/refractory patient The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.508 Silverchair:21173 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-396028 Silverchair:30075 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-396028 Silverchair:30075 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-396028 Silverchair:30075 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-396028 Silverchair:30075 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Management of pyruvate kinase deficiency in children and adults The American Society of Hematology American Society of Hematology 10.1182/blood.2019000945 Silverchair:461550 No_License 1 0 0 0 0 0 0 0 1 0 0 0 0 Management of pyruvate kinase deficiency in children and adults The American Society of Hematology American Society of Hematology 10.1182/blood.2019000945 Silverchair:461550 Total_Item_Investigations 3 0 0 0 0 0 0 0 3 0 0 0 0 Management of pyruvate kinase deficiency in children and adults The American Society of Hematology American Society of Hematology 10.1182/blood.2019000945 Silverchair:461550 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group The American Society of Hematology American Society of Hematology 10.1182/blood.2020005221 Silverchair:463322 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group The American Society of Hematology American Society of Hematology 10.1182/blood.2020005221 Silverchair:463322 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group The American Society of Hematology American Society of Hematology 10.1182/blood.2020005221 Silverchair:463322 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group The American Society of Hematology American Society of Hematology 10.1182/blood.2020005221 Silverchair:463322 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000089 Silverchair:474303 Total_Item_Investigations 2 0 1 0 0 0 0 0 0 1 0 0 0 Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000089 Silverchair:474303 Total_Item_Requests 2 0 1 0 0 0 0 0 0 1 0 0 0 Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000089 Silverchair:474303 Unique_Item_Investigations 2 0 1 0 0 0 0 0 0 1 0 0 0 Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000089 Silverchair:474303 Unique_Item_Requests 2 0 1 0 0 0 0 0 0 1 0 0 0 Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017006130 Silverchair:16006 Total_Item_Investigations 4 0 0 0 0 0 0 0 0 2 2 0 0 Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017006130 Silverchair:16006 Total_Item_Requests 4 0 0 0 0 0 0 0 0 2 2 0 0 Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017006130 Silverchair:16006 Unique_Item_Investigations 2 0 0 0 0 0 0 0 0 1 1 0 0 Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017006130 Silverchair:16006 Unique_Item_Requests 2 0 0 0 0 0 0 0 0 1 1 0 0 Management of VWD The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.536 Silverchair:20250 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Management of VWD The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.536 Silverchair:20250 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Management of VWD The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.536 Silverchair:20250 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Management of VWD The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.536 Silverchair:20250 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Management of Waldenström macroglobulinemia in 2020 The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000121 Silverchair:474337 Total_Item_Investigations 2 1 0 0 0 0 1 0 0 0 0 0 0 Management of Waldenström macroglobulinemia in 2020 The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000121 Silverchair:474337 Total_Item_Requests 2 1 0 0 0 0 1 0 0 0 0 0 0 Management of Waldenström macroglobulinemia in 2020 The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000121 Silverchair:474337 Unique_Item_Investigations 2 1 0 0 0 0 1 0 0 0 0 0 0 Management of Waldenström macroglobulinemia in 2020 The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000121 Silverchair:474337 Unique_Item_Requests 2 1 0 0 0 0 1 0 0 0 0 0 0 "Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-189977 Silverchair:28800 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-189977 Silverchair:28800 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-189977 Silverchair:28800 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-189977 Silverchair:28800 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-639138 Silverchair:34584 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-639138 Silverchair:34584 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-639138 Silverchair:34584 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-639138 Silverchair:34584 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-609073 Silverchair:33826 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-609073 Silverchair:33826 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-609073 Silverchair:33826 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-609073 Silverchair:33826 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Marginal zone B cells mediate a CD4 T-cell–dependent extrafollicular antibody response following RBC transfusion in mice The American Society of Hematology American Society of Hematology 10.1182/blood.2020009376 Silverchair:475783 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Marginal zone B cells mediate a CD4 T-cell–dependent extrafollicular antibody response following RBC transfusion in mice The American Society of Hematology American Society of Hematology 10.1182/blood.2020009376 Silverchair:475783 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Marginal zone B cells mediate a CD4 T-cell–dependent extrafollicular antibody response following RBC transfusion in mice The American Society of Hematology American Society of Hematology 10.1182/blood.2020009376 Silverchair:475783 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Marginal zone B cells mediate a CD4 T-cell–dependent extrafollicular antibody response following RBC transfusion in mice The American Society of Hematology American Society of Hematology 10.1182/blood.2020009376 Silverchair:475783 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Markedly elevated serum IgE levels following allogeneic and syngeneic bone marrow transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V61.6.1190.1190 Silverchair:163487 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Markedly elevated serum IgE levels following allogeneic and syngeneic bone marrow transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V61.6.1190.1190 Silverchair:163487 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Markedly elevated serum IgE levels following allogeneic and syngeneic bone marrow transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V61.6.1190.1190 Silverchair:163487 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Markedly elevated serum IgE levels following allogeneic and syngeneic bone marrow transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V61.6.1190.1190 Silverchair:163487 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Markers of complement activation in plasma during quiescent phases in patients with catastrophic antiphospholipid syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2020010575 Silverchair:475391 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Markers of complement activation in plasma during quiescent phases in patients with catastrophic antiphospholipid syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2020010575 Silverchair:475391 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess Blasts The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124772 Silverchair:425617 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess Blasts The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124772 Silverchair:425617 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess Blasts The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124772 Silverchair:425617 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess Blasts The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124772 Silverchair:425617 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Marrow Transplantation for Chronic Myeloid Leukemia: The Influence of Plasma Busulfan Levels on the Outcome of Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V89.8.3055 Silverchair:139228 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Marrow Transplantation for Chronic Myeloid Leukemia: The Influence of Plasma Busulfan Levels on the Outcome of Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V89.8.3055 Silverchair:139228 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Marrow Transplantation for Chronic Myeloid Leukemia: The Influence of Plasma Busulfan Levels on the Outcome of Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V89.8.3055 Silverchair:139228 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Marrow Transplantation for Chronic Myeloid Leukemia: The Influence of Plasma Busulfan Levels on the Outcome of Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V89.8.3055 Silverchair:139228 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Massive splenomegaly and extramedullary hematopoiesis in chronic idiopathic myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2009-09-237388 Silverchair:27556 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Massive splenomegaly and extramedullary hematopoiesis in chronic idiopathic myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2009-09-237388 Silverchair:27556 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Massive splenomegaly and extramedullary hematopoiesis in chronic idiopathic myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2009-09-237388 Silverchair:27556 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Massive splenomegaly and extramedullary hematopoiesis in chronic idiopathic myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2009-09-237388 Silverchair:27556 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-486217 Silverchair:31645 Total_Item_Investigations 6 5 1 0 0 0 0 0 0 0 0 0 0 Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-486217 Silverchair:31645 Total_Item_Requests 5 4 1 0 0 0 0 0 0 0 0 0 0 Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-486217 Silverchair:31645 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-486217 Silverchair:31645 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Mast cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-442400 Silverchair:138842 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Mast cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-442400 Silverchair:138842 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Mast cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-442400 Silverchair:138842 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Mast cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-442400 Silverchair:138842 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Mast cell leukemia and hemophagocytosis in a patient with myelodysplastic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2018886564 Silverchair:273822 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Mast cell leukemia and hemophagocytosis in a patient with myelodysplastic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2018886564 Silverchair:273822 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Mast cell leukemia and hemophagocytosis in a patient with myelodysplastic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2018886564 Silverchair:273822 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Mast cell leukemia and hemophagocytosis in a patient with myelodysplastic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2018886564 Silverchair:273822 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Mast cells/basophils in the peripheral blood of allergic individuals who are HIV-1 susceptible due to their surface expression of CD4 and the chemokine receptors CCR3, CCR5, and CXCR4" The American Society of Hematology American Society of Hematology 10.1182/blood.V97.11.3484 Silverchair:107420 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Mast cells/basophils in the peripheral blood of allergic individuals who are HIV-1 susceptible due to their surface expression of CD4 and the chemokine receptors CCR3, CCR5, and CXCR4" The American Society of Hematology American Society of Hematology 10.1182/blood.V97.11.3484 Silverchair:107420 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Mast cells/basophils in the peripheral blood of allergic individuals who are HIV-1 susceptible due to their surface expression of CD4 and the chemokine receptors CCR3, CCR5, and CXCR4" The American Society of Hematology American Society of Hematology 10.1182/blood.V97.11.3484 Silverchair:107420 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Mast cells/basophils in the peripheral blood of allergic individuals who are HIV-1 susceptible due to their surface expression of CD4 and the chemokine receptors CCR3, CCR5, and CXCR4" The American Society of Hematology American Society of Hematology 10.1182/blood.V97.11.3484 Silverchair:107420 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Matched and mismatched unrelated donor transplantation: is the outcome the same as for matched sibling donor transplantation? The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.223.3798305 Silverchair:83764 Total_Item_Investigations 4 0 0 4 0 0 0 0 0 0 0 0 0 Matched and mismatched unrelated donor transplantation: is the outcome the same as for matched sibling donor transplantation? The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.223.3798305 Silverchair:83764 Total_Item_Requests 4 0 0 4 0 0 0 0 0 0 0 0 0 Matched and mismatched unrelated donor transplantation: is the outcome the same as for matched sibling donor transplantation? The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.223.3798305 Silverchair:83764 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Matched and mismatched unrelated donor transplantation: is the outcome the same as for matched sibling donor transplantation? The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.223.3798305 Silverchair:83764 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Maternal Hepcidin Suppression Is Essential for Healthy Pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141148 Silverchair:471397 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Maternal Hepcidin Suppression Is Essential for Healthy Pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141148 Silverchair:471397 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Maternal Hepcidin Suppression Is Essential for Healthy Pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141148 Silverchair:471397 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Maternal Hepcidin Suppression Is Essential for Healthy Pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141148 Silverchair:471397 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Mature CD10+ and immature CD10− neutrophils present in G-CSF–treated donors display opposite effects on T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-713206 Silverchair:36020 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Mature CD10+ and immature CD10− neutrophils present in G-CSF–treated donors display opposite effects on T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-713206 Silverchair:36020 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Mature CD10+ and immature CD10− neutrophils present in G-CSF–treated donors display opposite effects on T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-713206 Silverchair:36020 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Mature CD10+ and immature CD10− neutrophils present in G-CSF–treated donors display opposite effects on T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-713206 Silverchair:36020 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Mature Osteoblasts Provide a Protective Niche Against Multiple Myeloma Growth and Survival within the Tumor Microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118377 Silverchair:275709 Total_Item_Investigations 3 1 1 1 0 0 0 0 0 0 0 0 0 Mature Osteoblasts Provide a Protective Niche Against Multiple Myeloma Growth and Survival within the Tumor Microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118377 Silverchair:275709 Total_Item_Requests 3 1 1 1 0 0 0 0 0 0 0 0 0 Mature Osteoblasts Provide a Protective Niche Against Multiple Myeloma Growth and Survival within the Tumor Microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118377 Silverchair:275709 Unique_Item_Investigations 3 1 1 1 0 0 0 0 0 0 0 0 0 Mature Osteoblasts Provide a Protective Niche Against Multiple Myeloma Growth and Survival within the Tumor Microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118377 Silverchair:275709 Unique_Item_Requests 3 1 1 1 0 0 0 0 0 0 0 0 0 Maximal Tolerated Dose of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction in Previously Untreated Adults with Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140646 Silverchair:470613 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Maximal Tolerated Dose of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction in Previously Untreated Adults with Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140646 Silverchair:470613 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Maximal Tolerated Dose of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction in Previously Untreated Adults with Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140646 Silverchair:470613 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Maximal Tolerated Dose of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction in Previously Untreated Adults with Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140646 Silverchair:470613 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 May Tigit (T cell Ig and ITIM domain) Expression be a New Target for Hodgkin Lymphoma? The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130794 Silverchair:425180 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 May Tigit (T cell Ig and ITIM domain) Expression be a New Target for Hodgkin Lymphoma? The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130794 Silverchair:425180 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 May Tigit (T cell Ig and ITIM domain) Expression be a New Target for Hodgkin Lymphoma? The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130794 Silverchair:425180 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 May Tigit (T cell Ig and ITIM domain) Expression be a New Target for Hodgkin Lymphoma? The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130794 Silverchair:425180 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 MDS and AML in Shwachman-Diamond Syndrome: Clinical Features and Outcomes The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1177.1177 Silverchair:116100 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 MDS and AML in Shwachman-Diamond Syndrome: Clinical Features and Outcomes The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1177.1177 Silverchair:116100 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 MDS and AML in Shwachman-Diamond Syndrome: Clinical Features and Outcomes The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1177.1177 Silverchair:116100 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 MDS and AML in Shwachman-Diamond Syndrome: Clinical Features and Outcomes The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1177.1177 Silverchair:116100 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients," The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.3793.3793 Silverchair:69047 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients," The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.3793.3793 Silverchair:69047 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients," The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.3793.3793 Silverchair:69047 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients," The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.3793.3793 Silverchair:69047 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Mean Corpuscular Volume (MCV) and Mean Corpuscular Hemoglobin (MCH) Determinations in Newborns with Beta Thalassemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110991 Silverchair:262095 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Mean Corpuscular Volume (MCV) and Mean Corpuscular Hemoglobin (MCH) Determinations in Newborns with Beta Thalassemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110991 Silverchair:262095 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Mean Corpuscular Volume (MCV) and Mean Corpuscular Hemoglobin (MCH) Determinations in Newborns with Beta Thalassemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110991 Silverchair:262095 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Mean Corpuscular Volume (MCV) and Mean Corpuscular Hemoglobin (MCH) Determinations in Newborns with Beta Thalassemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110991 Silverchair:262095 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Measures to reduce red cell use in patients with sickle cell disease requiring red cell exchange during a blood shortage American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004395 Silverchair:476186 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Measures to reduce red cell use in patients with sickle cell disease requiring red cell exchange during a blood shortage American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004395 Silverchair:476186 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Measures to reduce red cell use in patients with sickle cell disease requiring red cell exchange during a blood shortage American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004395 Silverchair:476186 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Measures to reduce red cell use in patients with sickle cell disease requiring red cell exchange during a blood shortage American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004395 Silverchair:476186 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Measuring Reticulocyte Hemoglobin Content As a Marker for Iron Deficiency and Response to Therapy Represents a Paradigm Shift in Care The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134693 Silverchair:471396 Total_Item_Investigations 6 6 0 0 0 0 0 0 0 0 0 0 0 Measuring Reticulocyte Hemoglobin Content As a Marker for Iron Deficiency and Response to Therapy Represents a Paradigm Shift in Care The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134693 Silverchair:471396 Total_Item_Requests 6 6 0 0 0 0 0 0 0 0 0 0 0 Measuring Reticulocyte Hemoglobin Content As a Marker for Iron Deficiency and Response to Therapy Represents a Paradigm Shift in Care The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134693 Silverchair:471396 Unique_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 Measuring Reticulocyte Hemoglobin Content As a Marker for Iron Deficiency and Response to Therapy Represents a Paradigm Shift in Care The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134693 Silverchair:471396 Unique_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 Measuring the symptom burden associated with the treatment of chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-477687 Silverchair:32040 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Measuring the symptom burden associated with the treatment of chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-477687 Silverchair:32040 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Measuring the symptom burden associated with the treatment of chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-477687 Silverchair:32040 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Measuring the symptom burden associated with the treatment of chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-477687 Silverchair:32040 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Mechanism of Action of Azacytidine in Myelodysplastic Syndromes (MDS) The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4315.4315 Silverchair:113863 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Mechanism of Action of Azacytidine in Myelodysplastic Syndromes (MDS) The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4315.4315 Silverchair:113863 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Mechanism of Action of Azacytidine in Myelodysplastic Syndromes (MDS) The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4315.4315 Silverchair:113863 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Mechanism of Action of Azacytidine in Myelodysplastic Syndromes (MDS) The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4315.4315 Silverchair:113863 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Mechanism of Lenalidomide Activity in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.SCI-51.SCI-51 Silverchair:102050 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Mechanism of Lenalidomide Activity in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.SCI-51.SCI-51 Silverchair:102050 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Mechanism of Lenalidomide Activity in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.SCI-51.SCI-51 Silverchair:102050 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Mechanism of Lenalidomide Activity in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.SCI-51.SCI-51 Silverchair:102050 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor The American Society of Hematology American Society of Hematology 10.1182/blood-2002-11-3423 Silverchair:17094 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor The American Society of Hematology American Society of Hematology 10.1182/blood-2002-11-3423 Silverchair:17094 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor The American Society of Hematology American Society of Hematology 10.1182/blood-2002-11-3423 Silverchair:17094 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor The American Society of Hematology American Society of Hematology 10.1182/blood-2002-11-3423 Silverchair:17094 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-05-155846 Silverchair:24657 Total_Item_Investigations 4 3 1 0 0 0 0 0 0 0 0 0 0 "Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-05-155846 Silverchair:24657 Total_Item_Requests 4 3 1 0 0 0 0 0 0 0 0 0 0 "Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-05-155846 Silverchair:24657 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 "Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-05-155846 Silverchair:24657 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Mechanisms Linking Fibrin(ogen) Structure/Function to Tumor Metastasis The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1063.1063 Silverchair:116234 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Mechanisms Linking Fibrin(ogen) Structure/Function to Tumor Metastasis The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1063.1063 Silverchair:116234 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Mechanisms Linking Fibrin(ogen) Structure/Function to Tumor Metastasis The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1063.1063 Silverchair:116234 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Mechanisms Linking Fibrin(ogen) Structure/Function to Tumor Metastasis The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1063.1063 Silverchair:116234 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Mechanisms of induction of endothelial cell E-selectin expression by smooth muscle cells and its inhibition by shear stress The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-040097 Silverchair:22927 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Mechanisms of induction of endothelial cell E-selectin expression by smooth muscle cells and its inhibition by shear stress The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-040097 Silverchair:22927 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Mechanisms of induction of endothelial cell E-selectin expression by smooth muscle cells and its inhibition by shear stress The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-040097 Silverchair:22927 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Mechanisms of induction of endothelial cell E-selectin expression by smooth muscle cells and its inhibition by shear stress The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-040097 Silverchair:22927 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Mechanisms of PD-L1/PD-1–mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model The American Society of Hematology American Society of Hematology 10.1182/blood-2015-02-626754 Silverchair:34507 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Mechanisms of PD-L1/PD-1–mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model The American Society of Hematology American Society of Hematology 10.1182/blood-2015-02-626754 Silverchair:34507 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Mechanisms of PD-L1/PD-1–mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model The American Society of Hematology American Society of Hematology 10.1182/blood-2015-02-626754 Silverchair:34507 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Mechanisms of PD-L1/PD-1–mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model The American Society of Hematology American Society of Hematology 10.1182/blood-2015-02-626754 Silverchair:34507 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2017-08-804344 Silverchair:36914 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2017-08-804344 Silverchair:36914 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2017-08-804344 Silverchair:36914 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2017-08-804344 Silverchair:36914 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Mechanistic basis and efficacy of targeting the ß-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood.2019002922 Silverchair:452517 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Mechanistic basis and efficacy of targeting the ß-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood.2019002922 Silverchair:452517 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Mechanistic basis and efficacy of targeting the ß-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood.2019002922 Silverchair:452517 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Mechanistic basis and efficacy of targeting the ß-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood.2019002922 Silverchair:452517 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2020007093 Silverchair:461761 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2020007093 Silverchair:461761 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2020007093 Silverchair:461761 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2020007093 Silverchair:461761 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 MECOM-associated syndrome: a heterogeneous inherited bone marrow failure syndrome with amegakaryocytic thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018016501 Silverchair:15812 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 MECOM-associated syndrome: a heterogeneous inherited bone marrow failure syndrome with amegakaryocytic thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018016501 Silverchair:15812 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 MECOM-associated syndrome: a heterogeneous inherited bone marrow failure syndrome with amegakaryocytic thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018016501 Silverchair:15812 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 MECOM-associated syndrome: a heterogeneous inherited bone marrow failure syndrome with amegakaryocytic thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018016501 Silverchair:15812 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Medical marijuana certification for patients with sickle cell disease: a report of a single center experience American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002325 Silverchair:461784 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Medical marijuana certification for patients with sickle cell disease: a report of a single center experience American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002325 Silverchair:461784 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Medical marijuana certification for patients with sickle cell disease: a report of a single center experience American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002325 Silverchair:461784 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Medical marijuana certification for patients with sickle cell disease: a report of a single center experience American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002325 Silverchair:461784 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Megakaryocyte endomitosis is a failure of late cytokinesis related to defects in the contractile ring and Rho/Rock signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2008-03-144956 Silverchair:114948 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Megakaryocyte endomitosis is a failure of late cytokinesis related to defects in the contractile ring and Rho/Rock signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2008-03-144956 Silverchair:114948 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Megakaryocyte endomitosis is a failure of late cytokinesis related to defects in the contractile ring and Rho/Rock signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2008-03-144956 Silverchair:114948 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Megakaryocyte endomitosis is a failure of late cytokinesis related to defects in the contractile ring and Rho/Rock signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2008-03-144956 Silverchair:114948 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-679415 Silverchair:126469 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-679415 Silverchair:126469 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-679415 Silverchair:126469 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-679415 Silverchair:126469 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Membrane grease eases platelet maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-655241 Silverchair:126458 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 Membrane grease eases platelet maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-655241 Silverchair:126458 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 Membrane grease eases platelet maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-655241 Silverchair:126458 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Membrane grease eases platelet maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-655241 Silverchair:126458 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Membrane remodeling during reticulocyte maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2009-08-241182 Silverchair:26864 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Membrane remodeling during reticulocyte maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2009-08-241182 Silverchair:26864 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Membrane remodeling during reticulocyte maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2009-08-241182 Silverchair:26864 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Membrane remodeling during reticulocyte maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2009-08-241182 Silverchair:26864 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Memories that last forever: strategies for optimizing vaccine T-cell memory The American Society of Hematology American Society of Hematology 10.1182/blood-2009-06-227546 Silverchair:27206 Total_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Memories that last forever: strategies for optimizing vaccine T-cell memory The American Society of Hematology American Society of Hematology 10.1182/blood-2009-06-227546 Silverchair:27206 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Memories that last forever: strategies for optimizing vaccine T-cell memory The American Society of Hematology American Society of Hematology 10.1182/blood-2009-06-227546 Silverchair:27206 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Memories that last forever: strategies for optimizing vaccine T-cell memory The American Society of Hematology American Society of Hematology 10.1182/blood-2009-06-227546 Silverchair:27206 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 "MEN1112/OBT357, an Anti Bst1/CD157 Humanized Antibody Inducing Acute Myelogenous Leukemia (AML) Blast Depletion in an Autologous Ex Vivo Assay: A Potential New Targeted Therapy for AML" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.788.788 Silverchair:136437 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "MEN1112/OBT357, an Anti Bst1/CD157 Humanized Antibody Inducing Acute Myelogenous Leukemia (AML) Blast Depletion in an Autologous Ex Vivo Assay: A Potential New Targeted Therapy for AML" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.788.788 Silverchair:136437 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "MEN1112/OBT357, an Anti Bst1/CD157 Humanized Antibody Inducing Acute Myelogenous Leukemia (AML) Blast Depletion in an Autologous Ex Vivo Assay: A Potential New Targeted Therapy for AML" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.788.788 Silverchair:136437 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "MEN1112/OBT357, an Anti Bst1/CD157 Humanized Antibody Inducing Acute Myelogenous Leukemia (AML) Blast Depletion in an Autologous Ex Vivo Assay: A Potential New Targeted Therapy for AML" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.788.788 Silverchair:136437 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Metabolic enzyme pyruvate kinase M2 regulates platelet function and arterial thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood.2020007140 Silverchair:464168 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Metabolic enzyme pyruvate kinase M2 regulates platelet function and arterial thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood.2020007140 Silverchair:464168 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Metabolic enzyme pyruvate kinase M2 regulates platelet function and arterial thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood.2020007140 Silverchair:464168 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Metabolic enzyme pyruvate kinase M2 regulates platelet function and arterial thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood.2020007140 Silverchair:464168 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Metastatic myeloma? The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-417337 Silverchair:30295 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Metastatic myeloma? The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-417337 Silverchair:30295 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Metastatic myeloma? The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-417337 Silverchair:30295 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Metastatic myeloma? The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-417337 Silverchair:30295 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Metastatic prostate cancer mimicking thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-608828 Silverchair:34162 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Metastatic prostate cancer mimicking thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-608828 Silverchair:34162 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Metastatic prostate cancer mimicking thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-608828 Silverchair:34162 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Metastatic prostate cancer mimicking thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-608828 Silverchair:34162 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001768 Silverchair:456152 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 0 2 "Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001768 Silverchair:456152 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 0 2 "Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001768 Silverchair:456152 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 "Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001768 Silverchair:456152 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Mettl3 Mediated m6A Modification Is Essential in Fetal Hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119699 Silverchair:265020 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 Mettl3 Mediated m6A Modification Is Essential in Fetal Hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119699 Silverchair:265020 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Mettl3 Mediated m6A Modification Is Essential in Fetal Hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119699 Silverchair:265020 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Mettl3 Mediated m6A Modification Is Essential in Fetal Hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119699 Silverchair:265020 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Mice expressing a neutrophil elastase mutation derived from patients with severe congenital neutropenia have normal granulopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2002-05-1372 Silverchair:16410 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Mice expressing a neutrophil elastase mutation derived from patients with severe congenital neutropenia have normal granulopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2002-05-1372 Silverchair:16410 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Mice expressing a neutrophil elastase mutation derived from patients with severe congenital neutropenia have normal granulopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2002-05-1372 Silverchair:16410 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Mice expressing a neutrophil elastase mutation derived from patients with severe congenital neutropenia have normal granulopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2002-05-1372 Silverchair:16410 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Mice lacking the CCR9 CC-chemokine receptor show a mild impairment of early T- and B-cell development and a reduction in T-cell receptor γδ+ gut intraepithelial lymphocytes The American Society of Hematology American Society of Hematology 10.1182/blood.V98.9.2626 Silverchair:53497 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Mice lacking the CCR9 CC-chemokine receptor show a mild impairment of early T- and B-cell development and a reduction in T-cell receptor γδ+ gut intraepithelial lymphocytes The American Society of Hematology American Society of Hematology 10.1182/blood.V98.9.2626 Silverchair:53497 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Mice lacking the CCR9 CC-chemokine receptor show a mild impairment of early T- and B-cell development and a reduction in T-cell receptor γδ+ gut intraepithelial lymphocytes The American Society of Hematology American Society of Hematology 10.1182/blood.V98.9.2626 Silverchair:53497 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Mice lacking the CCR9 CC-chemokine receptor show a mild impairment of early T- and B-cell development and a reduction in T-cell receptor γδ+ gut intraepithelial lymphocytes The American Society of Hematology American Society of Hematology 10.1182/blood.V98.9.2626 Silverchair:53497 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Microarray analysis of retinal endothelial tip cells identifies CXCR4 as a mediator of tip cell morphology and branching The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-230284 Silverchair:27224 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Microarray analysis of retinal endothelial tip cells identifies CXCR4 as a mediator of tip cell morphology and branching The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-230284 Silverchair:27224 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Microarray analysis of retinal endothelial tip cells identifies CXCR4 as a mediator of tip cell morphology and branching The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-230284 Silverchair:27224 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Microarray analysis of retinal endothelial tip cells identifies CXCR4 as a mediator of tip cell morphology and branching The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-230284 Silverchair:27224 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018018754 Silverchair:15849 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018018754 Silverchair:15849 Total_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018018754 Silverchair:15849 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018018754 Silverchair:15849 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Microlyse; a thrombolytic agent that targets VWF for clearance of microvascular thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood.2021011776 Silverchair:477915 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 0 0 3 0 Microlyse; a thrombolytic agent that targets VWF for clearance of microvascular thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood.2021011776 Silverchair:477915 Total_Item_Requests 3 0 0 0 0 0 0 0 0 0 0 3 0 Microlyse; a thrombolytic agent that targets VWF for clearance of microvascular thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood.2021011776 Silverchair:477915 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Microlyse; a thrombolytic agent that targets VWF for clearance of microvascular thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood.2021011776 Silverchair:477915 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-869453 Silverchair:260612 Total_Item_Investigations 14 6 5 3 0 0 0 0 0 0 0 0 0 Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-869453 Silverchair:260612 Total_Item_Requests 13 5 5 3 0 0 0 0 0 0 0 0 0 Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-869453 Silverchair:260612 Unique_Item_Investigations 7 3 2 2 0 0 0 0 0 0 0 0 0 Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-869453 Silverchair:260612 Unique_Item_Requests 7 3 2 2 0 0 0 0 0 0 0 0 0 Midostaurin approved for FLT3-mutated AML The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-782292 Silverchair:36251 Total_Item_Investigations 6 0 6 0 0 0 0 0 0 0 0 0 0 Midostaurin approved for FLT3-mutated AML The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-782292 Silverchair:36251 Total_Item_Requests 6 0 6 0 0 0 0 0 0 0 0 0 0 Midostaurin approved for FLT3-mutated AML The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-782292 Silverchair:36251 Unique_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 Midostaurin approved for FLT3-mutated AML The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-782292 Silverchair:36251 Unique_Item_Requests 4 0 4 0 0 0 0 0 0 0 0 0 0 Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002904 Silverchair:464332 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002904 Silverchair:464332 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002904 Silverchair:464332 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002904 Silverchair:464332 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017011080 Silverchair:15859 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017011080 Silverchair:15859 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017011080 Silverchair:15859 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017011080 Silverchair:15859 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Minimal Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.435.435 Silverchair:72570 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Minimal Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.435.435 Silverchair:72570 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Minimal Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.435.435 Silverchair:72570 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Minimal Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.435.435 Silverchair:72570 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-858613 Silverchair:40023 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-858613 Silverchair:40023 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-858613 Silverchair:40023 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-858613 Silverchair:40023 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Minimal residual disease–guided therapy in childhood acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-725804 Silverchair:35887 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Minimal residual disease–guided therapy in childhood acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-725804 Silverchair:35887 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Minimal residual disease–guided therapy in childhood acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-725804 Silverchair:35887 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Minimal residual disease–guided therapy in childhood acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-725804 Silverchair:35887 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-801498 Silverchair:36625 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-801498 Silverchair:36625 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-801498 Silverchair:36625 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-801498 Silverchair:36625 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 MIP-1α and MIP-1β differentially mediate mucosal and systemic adaptive immunity The American Society of Hematology American Society of Hematology 10.1182/blood-2002-07-2305 Silverchair:88825 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 MIP-1α and MIP-1β differentially mediate mucosal and systemic adaptive immunity The American Society of Hematology American Society of Hematology 10.1182/blood-2002-07-2305 Silverchair:88825 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 MIP-1α and MIP-1β differentially mediate mucosal and systemic adaptive immunity The American Society of Hematology American Society of Hematology 10.1182/blood-2002-07-2305 Silverchair:88825 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 MIP-1α and MIP-1β differentially mediate mucosal and systemic adaptive immunity The American Society of Hematology American Society of Hematology 10.1182/blood-2002-07-2305 Silverchair:88825 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018026658 Silverchair:11159 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018026658 Silverchair:11159 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018026658 Silverchair:11159 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018026658 Silverchair:11159 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 MiR-130b and miR-128a are essential lineage-specific co-drivers of t(4;11) MLL-AF4 acute leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020006610 Silverchair:476129 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 MiR-130b and miR-128a are essential lineage-specific co-drivers of t(4;11) MLL-AF4 acute leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020006610 Silverchair:476129 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 MiR-181a Is a Master Regulator of the Nuclear Factor-κB Signaling Pathway in Diffuse Large B Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.417.417 Silverchair:86704 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 MiR-181a Is a Master Regulator of the Nuclear Factor-κB Signaling Pathway in Diffuse Large B Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.417.417 Silverchair:86704 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 MiR-181a Is a Master Regulator of the Nuclear Factor-κB Signaling Pathway in Diffuse Large B Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.417.417 Silverchair:86704 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 MiR-181a Is a Master Regulator of the Nuclear Factor-κB Signaling Pathway in Diffuse Large B Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.417.417 Silverchair:86704 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 miR-181a negatively regulates NF-κB signaling and affects activated B-cell–like diffuse large B-cell lymphoma pathogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-680462 Silverchair:35309 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 miR-181a negatively regulates NF-κB signaling and affects activated B-cell–like diffuse large B-cell lymphoma pathogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-680462 Silverchair:35309 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 miR-181a negatively regulates NF-κB signaling and affects activated B-cell–like diffuse large B-cell lymphoma pathogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-680462 Silverchair:35309 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 miR-181a negatively regulates NF-κB signaling and affects activated B-cell–like diffuse large B-cell lymphoma pathogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-680462 Silverchair:35309 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Mir-181c Modulates T Cell Function By Regulating the Expression of BRK1 The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.132.132 Silverchair:96258 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Mir-181c Modulates T Cell Function By Regulating the Expression of BRK1 The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.132.132 Silverchair:96258 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Mir-181c Modulates T Cell Function By Regulating the Expression of BRK1 The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.132.132 Silverchair:96258 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Mir-181c Modulates T Cell Function By Regulating the Expression of BRK1 The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.132.132 Silverchair:96258 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-329433 Silverchair:29143 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-329433 Silverchair:29143 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-329433 Silverchair:29143 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-329433 Silverchair:29143 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 MISTRG extends PDX modeling to favorable AMLs The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-738757 Silverchair:35565 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 MISTRG extends PDX modeling to favorable AMLs The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-738757 Silverchair:35565 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 MISTRG extends PDX modeling to favorable AMLs The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-738757 Silverchair:35565 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 MISTRG extends PDX modeling to favorable AMLs The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-738757 Silverchair:35565 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Mitochondria Clearance Mechanisms Via Interaction with Macrophages in Erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110049 Silverchair:261760 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Mitochondria Clearance Mechanisms Via Interaction with Macrophages in Erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110049 Silverchair:261760 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Mitochondria Clearance Mechanisms Via Interaction with Macrophages in Erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110049 Silverchair:261760 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Mitochondria Clearance Mechanisms Via Interaction with Macrophages in Erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110049 Silverchair:261760 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Mitochondria in the maintenance of hematopoietic stem cells: new perspectives and opportunities The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-808873 Silverchair:260448 Total_Item_Investigations 5 0 5 0 0 0 0 0 0 0 0 0 0 Mitochondria in the maintenance of hematopoietic stem cells: new perspectives and opportunities The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-808873 Silverchair:260448 Total_Item_Requests 5 0 5 0 0 0 0 0 0 0 0 0 0 Mitochondria in the maintenance of hematopoietic stem cells: new perspectives and opportunities The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-808873 Silverchair:260448 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Mitochondria in the maintenance of hematopoietic stem cells: new perspectives and opportunities The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-808873 Silverchair:260448 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Mitochondrial Complex I Inhibitor Iacs-010759 Reverses the NOTCH1-Driven Metabolic Reprogramming in T-ALL Via Blockade of Oxidative Phosphorylation: Synergy with Chemotherapy and Glutaminase Inhibition The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117310 Silverchair:265241 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Mitochondrial Complex I Inhibitor Iacs-010759 Reverses the NOTCH1-Driven Metabolic Reprogramming in T-ALL Via Blockade of Oxidative Phosphorylation: Synergy with Chemotherapy and Glutaminase Inhibition The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117310 Silverchair:265241 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Mitochondrial Complex I Inhibitor Iacs-010759 Reverses the NOTCH1-Driven Metabolic Reprogramming in T-ALL Via Blockade of Oxidative Phosphorylation: Synergy with Chemotherapy and Glutaminase Inhibition The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117310 Silverchair:265241 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Mitochondrial Complex I Inhibitor Iacs-010759 Reverses the NOTCH1-Driven Metabolic Reprogramming in T-ALL Via Blockade of Oxidative Phosphorylation: Synergy with Chemotherapy and Glutaminase Inhibition The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117310 Silverchair:265241 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Mitochondrial dynamics and reactive oxygen species initiate thrombopoiesis from mature megakaryocytes American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002847 Silverchair:475483 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Mitochondrial dynamics and reactive oxygen species initiate thrombopoiesis from mature megakaryocytes American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002847 Silverchair:475483 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Mitochondrial dynamics and reactive oxygen species initiate thrombopoiesis from mature megakaryocytes American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002847 Silverchair:475483 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Mitochondrial dynamics and reactive oxygen species initiate thrombopoiesis from mature megakaryocytes American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002847 Silverchair:475483 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-532200 Silverchair:32534 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-532200 Silverchair:32534 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-532200 Silverchair:32534 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-532200 Silverchair:32534 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 MKL1 deficiency results in a severe neutrophil motility defect due to impaired actin polymerization The American Society of Hematology American Society of Hematology 10.1182/blood.2019002633 Silverchair:452613 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 MKL1 deficiency results in a severe neutrophil motility defect due to impaired actin polymerization The American Society of Hematology American Society of Hematology 10.1182/blood.2019002633 Silverchair:452613 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 MKL1 deficiency results in a severe neutrophil motility defect due to impaired actin polymerization The American Society of Hematology American Society of Hematology 10.1182/blood.2019002633 Silverchair:452613 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 MKL1 deficiency results in a severe neutrophil motility defect due to impaired actin polymerization The American Society of Hematology American Society of Hematology 10.1182/blood.2019002633 Silverchair:452613 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 MKL2 Functions in the Absence of MKL1 to Promote Megakaryocyte Maturation The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.2336.2336 Silverchair:70383 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 MKL2 Functions in the Absence of MKL1 to Promote Megakaryocyte Maturation The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.2336.2336 Silverchair:70383 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 MKL2 Functions in the Absence of MKL1 to Promote Megakaryocyte Maturation The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.2336.2336 Silverchair:70383 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 MKL2 Functions in the Absence of MKL1 to Promote Megakaryocyte Maturation The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.2336.2336 Silverchair:70383 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-272567 Silverchair:103868 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-272567 Silverchair:103868 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-272567 Silverchair:103868 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-272567 Silverchair:103868 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-521914 Silverchair:32782 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-521914 Silverchair:32782 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-521914 Silverchair:32782 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-521914 Silverchair:32782 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Mobilization as a preparative regimen for hematopoietic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2005-09-3593 Silverchair:133455 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Mobilization as a preparative regimen for hematopoietic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2005-09-3593 Silverchair:133455 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Mobilization as a preparative regimen for hematopoietic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2005-09-3593 Silverchair:133455 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Mobilization as a preparative regimen for hematopoietic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2005-09-3593 Silverchair:133455 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure The American Society of Hematology American Society of Hematology 10.1182/blood-2003-01-0318 Silverchair:17077 Total_Item_Investigations 2 1 0 0 0 0 0 0 0 0 1 0 0 Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure The American Society of Hematology American Society of Hematology 10.1182/blood-2003-01-0318 Silverchair:17077 Total_Item_Requests 2 1 0 0 0 0 0 0 0 0 1 0 0 Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure The American Society of Hematology American Society of Hematology 10.1182/blood-2003-01-0318 Silverchair:17077 Unique_Item_Investigations 2 1 0 0 0 0 0 0 0 0 1 0 0 Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure The American Society of Hematology American Society of Hematology 10.1182/blood-2003-01-0318 Silverchair:17077 Unique_Item_Requests 2 1 0 0 0 0 0 0 0 0 1 0 0 Modeling and targeting of erythroleukemia by hematopoietic genome editing The American Society of Hematology American Society of Hematology 10.1182/blood.2020009103 Silverchair:475001 Total_Item_Investigations 6 0 0 6 0 0 0 0 0 0 0 0 0 Modeling and targeting of erythroleukemia by hematopoietic genome editing The American Society of Hematology American Society of Hematology 10.1182/blood.2020009103 Silverchair:475001 Total_Item_Requests 4 0 0 4 0 0 0 0 0 0 0 0 0 Modeling and targeting of erythroleukemia by hematopoietic genome editing The American Society of Hematology American Society of Hematology 10.1182/blood.2020009103 Silverchair:475001 Unique_Item_Investigations 4 0 0 4 0 0 0 0 0 0 0 0 0 Modeling and targeting of erythroleukemia by hematopoietic genome editing The American Society of Hematology American Society of Hematology 10.1182/blood.2020009103 Silverchair:475001 Unique_Item_Requests 4 0 0 4 0 0 0 0 0 0 0 0 0 Modeling de novo leukemogenesis from human cord blood with MN1 and NUP98HOXD13 The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-564666 Silverchair:33497 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Modeling de novo leukemogenesis from human cord blood with MN1 and NUP98HOXD13 The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-564666 Silverchair:33497 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Modeling de novo leukemogenesis from human cord blood with MN1 and NUP98HOXD13 The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-564666 Silverchair:33497 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Modeling de novo leukemogenesis from human cord blood with MN1 and NUP98HOXD13 The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-564666 Silverchair:33497 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Modified SMILE in the Treatment of Natural Killer T-Cell Lymphoma, Nasal and Nasal Type: A Single Center US Experience" The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.2688.2688 Silverchair:70495 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Modified SMILE in the Treatment of Natural Killer T-Cell Lymphoma, Nasal and Nasal Type: A Single Center US Experience" The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.2688.2688 Silverchair:70495 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Modified SMILE in the Treatment of Natural Killer T-Cell Lymphoma, Nasal and Nasal Type: A Single Center US Experience" The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.2688.2688 Silverchair:70495 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Modified SMILE in the Treatment of Natural Killer T-Cell Lymphoma, Nasal and Nasal Type: A Single Center US Experience" The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.2688.2688 Silverchair:70495 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Modified-EASIX predicts severe cytokine release syndrome and neurotoxicity after Chimeric Antigen Receptor (CAR) T cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003885 Silverchair:476670 Total_Item_Investigations 2 0 0 0 0 0 0 0 2 0 0 0 0 Modified-EASIX predicts severe cytokine release syndrome and neurotoxicity after Chimeric Antigen Receptor (CAR) T cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003885 Silverchair:476670 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Modified-EASIX predicts severe cytokine release syndrome and neurotoxicity after Chimeric Antigen Receptor (CAR) T cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003885 Silverchair:476670 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Modified-EASIX predicts severe cytokine release syndrome and neurotoxicity after Chimeric Antigen Receptor (CAR) T cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003885 Silverchair:476670 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Molecular bases for the association of FHR-1 with atypical hemolytic uremic syndrome and other diseases The American Society of Hematology American Society of Hematology 10.1182/blood.2020010069 Silverchair:475400 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Molecular bases for the association of FHR-1 with atypical hemolytic uremic syndrome and other diseases The American Society of Hematology American Society of Hematology 10.1182/blood.2020010069 Silverchair:475400 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Molecular basis of biomaterial-mediated foreign body reactions The American Society of Hematology American Society of Hematology 10.1182/blood.V98.4.1231 Silverchair:107073 Total_Item_Investigations 5 0 4 1 0 0 0 0 0 0 0 0 0 Molecular basis of biomaterial-mediated foreign body reactions The American Society of Hematology American Society of Hematology 10.1182/blood.V98.4.1231 Silverchair:107073 Total_Item_Requests 5 0 4 1 0 0 0 0 0 0 0 0 0 Molecular basis of biomaterial-mediated foreign body reactions The American Society of Hematology American Society of Hematology 10.1182/blood.V98.4.1231 Silverchair:107073 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Molecular basis of biomaterial-mediated foreign body reactions The American Society of Hematology American Society of Hematology 10.1182/blood.V98.4.1231 Silverchair:107073 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Molecular basis of hematology American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter01 Silverchair:73149 No_License 5 0 2 2 0 0 0 0 1 0 0 0 0 Molecular basis of hematology American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter01 Silverchair:73149 Total_Item_Investigations 9 0 2 2 2 0 1 0 1 1 0 0 0 Molecular basis of hematology American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter01 Silverchair:73149 Unique_Item_Investigations 8 0 2 2 1 0 1 0 1 1 0 0 0 Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia The American Society of Hematology American Society of Hematology 10.1182/blood-2005-08-3526 Silverchair:21985 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia The American Society of Hematology American Society of Hematology 10.1182/blood-2005-08-3526 Silverchair:21985 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia The American Society of Hematology American Society of Hematology 10.1182/blood-2005-08-3526 Silverchair:21985 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia The American Society of Hematology American Society of Hematology 10.1182/blood-2005-08-3526 Silverchair:21985 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.2019004229 Silverchair:461099 Total_Item_Investigations 7 0 3 0 0 0 0 0 2 2 0 0 0 Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.2019004229 Silverchair:461099 Total_Item_Requests 5 0 3 0 0 0 0 0 1 1 0 0 0 Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.2019004229 Silverchair:461099 Unique_Item_Investigations 3 0 1 0 0 0 0 0 1 1 0 0 0 Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.2019004229 Silverchair:461099 Unique_Item_Requests 3 0 1 0 0 0 0 0 1 1 0 0 0 Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-604496 Silverchair:34898 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-604496 Silverchair:34898 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-604496 Silverchair:34898 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-604496 Silverchair:34898 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001503 Silverchair:454778 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001503 Silverchair:454778 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001503 Silverchair:454778 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001503 Silverchair:454778 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Molecular MRD status and outcome after transplantation in NPM1-mutated AML The American Society of Hematology American Society of Hematology 10.1182/blood.2019002959 Silverchair:430249 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Molecular MRD status and outcome after transplantation in NPM1-mutated AML The American Society of Hematology American Society of Hematology 10.1182/blood.2019002959 Silverchair:430249 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Molecular MRD status and outcome after transplantation in NPM1-mutated AML The American Society of Hematology American Society of Hematology 10.1182/blood.2019002959 Silverchair:430249 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Molecular MRD status and outcome after transplantation in NPM1-mutated AML The American Society of Hematology American Society of Hematology 10.1182/blood.2019002959 Silverchair:430249 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Molecular pathogenesis of progression to myeloid leukemia from TET-insufficient status American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001324 Silverchair:452605 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Molecular pathogenesis of progression to myeloid leukemia from TET-insufficient status American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001324 Silverchair:452605 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Molecular pathogenesis of progression to myeloid leukemia from TET-insufficient status American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001324 Silverchair:452605 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Molecular pathogenesis of progression to myeloid leukemia from TET-insufficient status American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001324 Silverchair:452605 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML The American Society of Hematology American Society of Hematology 10.1182/blood.2019003988 Silverchair:430257 No_License 1 0 1 0 0 0 0 0 0 0 0 0 0 Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML The American Society of Hematology American Society of Hematology 10.1182/blood.2019003988 Silverchair:430257 Total_Item_Investigations 4 2 2 0 0 0 0 0 0 0 0 0 0 Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML The American Society of Hematology American Society of Hematology 10.1182/blood.2019003988 Silverchair:430257 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML The American Society of Hematology American Society of Hematology 10.1182/blood.2019003988 Silverchair:430257 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML The American Society of Hematology American Society of Hematology 10.1182/blood.2019003988 Silverchair:430257 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Molecular Profiling in Extramedullary Acute Myeloid Leukemia Reveals Distinct Subgroups Defined By Mutations in KIT and RUNX1 The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2663.2663 Silverchair:80263 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Molecular Profiling in Extramedullary Acute Myeloid Leukemia Reveals Distinct Subgroups Defined By Mutations in KIT and RUNX1 The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2663.2663 Silverchair:80263 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Molecular Profiling in Extramedullary Acute Myeloid Leukemia Reveals Distinct Subgroups Defined By Mutations in KIT and RUNX1 The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2663.2663 Silverchair:80263 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Molecular Profiling in Extramedullary Acute Myeloid Leukemia Reveals Distinct Subgroups Defined By Mutations in KIT and RUNX1 The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2663.2663 Silverchair:80263 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Molecular profiling of CD3−CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways The American Society of Hematology American Society of Hematology 10.1182/blood-2008-08-175091 Silverchair:107826 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Molecular profiling of CD3−CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways The American Society of Hematology American Society of Hematology 10.1182/blood-2008-08-175091 Silverchair:107826 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Molecular profiling of CD3−CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways The American Society of Hematology American Society of Hematology 10.1182/blood-2008-08-175091 Silverchair:107826 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Molecular profiling of CD3−CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways The American Society of Hematology American Society of Hematology 10.1182/blood-2008-08-175091 Silverchair:107826 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115958 Silverchair:266153 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115958 Silverchair:266153 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115958 Silverchair:266153 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115958 Silverchair:266153 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification" The American Society of Hematology American Society of Hematology 10.1182/blood-2015-02-585059 Silverchair:34526 Total_Item_Investigations 12 6 1 4 0 0 0 1 0 0 0 0 0 "Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification" The American Society of Hematology American Society of Hematology 10.1182/blood-2015-02-585059 Silverchair:34526 Total_Item_Requests 12 6 1 4 0 0 0 1 0 0 0 0 0 "Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification" The American Society of Hematology American Society of Hematology 10.1182/blood-2015-02-585059 Silverchair:34526 Unique_Item_Investigations 6 3 1 1 0 0 0 1 0 0 0 0 0 "Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification" The American Society of Hematology American Society of Hematology 10.1182/blood-2015-02-585059 Silverchair:34526 Unique_Item_Requests 6 3 1 1 0 0 0 1 0 0 0 0 0 Monoclonal B-cell lymphocytosis in donors The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-546739 Silverchair:32908 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Monoclonal B-cell lymphocytosis in donors The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-546739 Silverchair:32908 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Monoclonal B-cell lymphocytosis in donors The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-546739 Silverchair:32908 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Monoclonal B-cell lymphocytosis in donors The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-546739 Silverchair:32908 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-523704 Silverchair:32937 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-523704 Silverchair:32937 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-523704 Silverchair:32937 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-523704 Silverchair:32937 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Monoclonal B-cell lymphocytosis: right track or red herring? The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-404681 Silverchair:30005 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Monoclonal B-cell lymphocytosis: right track or red herring? The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-404681 Silverchair:30005 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Monoclonal B-cell lymphocytosis: right track or red herring? The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-404681 Silverchair:30005 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Monoclonal B-cell lymphocytosis: right track or red herring? The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-404681 Silverchair:30005 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Monoclonal gammopathies of clinical significance The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000122 Silverchair:474349 Total_Item_Investigations 3 0 1 0 2 0 0 0 0 0 0 0 0 Monoclonal gammopathies of clinical significance The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000122 Silverchair:474349 Total_Item_Requests 3 0 1 0 2 0 0 0 0 0 0 0 0 Monoclonal gammopathies of clinical significance The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000122 Silverchair:474349 Unique_Item_Investigations 2 0 1 0 1 0 0 0 0 0 0 0 0 Monoclonal gammopathies of clinical significance The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000122 Silverchair:474349 Unique_Item_Requests 2 0 1 0 1 0 0 0 0 0 0 0 0 Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-839480 Silverchair:39337 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-839480 Silverchair:39337 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-839480 Silverchair:39337 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-839480 Silverchair:39337 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Monoclonal gammopathy of undetermined significance The American Society of Hematology American Society of Hematology 10.1182/blood.2019846782 Silverchair:273836 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Monoclonal gammopathy of undetermined significance The American Society of Hematology American Society of Hematology 10.1182/blood.2019846782 Silverchair:273836 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Monoclonal gammopathy of undetermined significance The American Society of Hematology American Society of Hematology 10.1182/blood.2019846782 Silverchair:273836 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Monoclonal gammopathy of undetermined significance The American Society of Hematology American Society of Hematology 10.1182/blood.2019846782 Silverchair:273836 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-270140 Silverchair:21406 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-270140 Silverchair:21406 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-270140 Silverchair:21406 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-270140 Silverchair:21406 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies The American Society of Hematology American Society of Hematology 10.1182/asheducation-2013.1.478 Silverchair:20888 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies The American Society of Hematology American Society of Hematology 10.1182/asheducation-2013.1.478 Silverchair:20888 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies The American Society of Hematology American Society of Hematology 10.1182/asheducation-2013.1.478 Silverchair:20888 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies The American Society of Hematology American Society of Hematology 10.1182/asheducation-2013.1.478 Silverchair:20888 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Monoclonal immunoglobulins promote bone loss in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2020006045 Silverchair:461116 No_License 1 0 0 0 0 0 0 0 0 0 1 0 0 Monoclonal immunoglobulins promote bone loss in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2020006045 Silverchair:461116 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 0 3 0 0 Monoclonal immunoglobulins promote bone loss in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2020006045 Silverchair:461116 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-753210 Silverchair:35816 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-753210 Silverchair:35816 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-753210 Silverchair:35816 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-753210 Silverchair:35816 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Monocytes control natural killer cell differentiation to effector phenotypes The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-312264 Silverchair:20849 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Monocytes control natural killer cell differentiation to effector phenotypes The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-312264 Silverchair:20849 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Monocytes control natural killer cell differentiation to effector phenotypes The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-312264 Silverchair:20849 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Monocytes control natural killer cell differentiation to effector phenotypes The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-312264 Silverchair:20849 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Monocytes express high amounts of Notch and undergo cytokine specific apoptosis following interaction with the Notch ligand, Delta-1" The American Society of Hematology American Society of Hematology 10.1182/blood.V95.9.2847.009k19_2847_2854 Silverchair:125523 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Monocytes express high amounts of Notch and undergo cytokine specific apoptosis following interaction with the Notch ligand, Delta-1" The American Society of Hematology American Society of Hematology 10.1182/blood.V95.9.2847.009k19_2847_2854 Silverchair:125523 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Monocytes express high amounts of Notch and undergo cytokine specific apoptosis following interaction with the Notch ligand, Delta-1" The American Society of Hematology American Society of Hematology 10.1182/blood.V95.9.2847.009k19_2847_2854 Silverchair:125523 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Monocytes express high amounts of Notch and undergo cytokine specific apoptosis following interaction with the Notch ligand, Delta-1" The American Society of Hematology American Society of Hematology 10.1182/blood.V95.9.2847.009k19_2847_2854 Silverchair:125523 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-367508 Silverchair:105513 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-367508 Silverchair:105513 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-367508 Silverchair:105513 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies The American Society of Hematology American Society of Hematology 10.1182/blood-2011-07-367508 Silverchair:105513 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Monosomy 13 Is Associated With the Transition of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V94.8.2583.420a05_2583_2589 Silverchair:116566 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Monosomy 13 Is Associated With the Transition of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V94.8.2583.420a05_2583_2589 Silverchair:116566 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Monosomy 13 Is Associated With the Transition of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V94.8.2583.420a05_2583_2589 Silverchair:116566 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Monosomy 13 Is Associated With the Transition of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V94.8.2583.420a05_2583_2589 Silverchair:116566 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Mott cells: pearls of pathology The American Society of Hematology American Society of Hematology 10.1182/blood.2019004154 Silverchair:452500 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Mott cells: pearls of pathology The American Society of Hematology American Society of Hematology 10.1182/blood.2019004154 Silverchair:452500 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Mott cells: pearls of pathology The American Society of Hematology American Society of Hematology 10.1182/blood.2019004154 Silverchair:452500 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Mott cells: pearls of pathology The American Society of Hematology American Society of Hematology 10.1182/blood.2019004154 Silverchair:452500 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Mouse CD99 participates in T-cell recruitment into inflamed skin The American Society of Hematology American Society of Hematology 10.1182/blood-2004-03-1184 Silverchair:18750 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Mouse CD99 participates in T-cell recruitment into inflamed skin The American Society of Hematology American Society of Hematology 10.1182/blood-2004-03-1184 Silverchair:18750 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Mouse CD99 participates in T-cell recruitment into inflamed skin The American Society of Hematology American Society of Hematology 10.1182/blood-2004-03-1184 Silverchair:18750 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Mouse CD99 participates in T-cell recruitment into inflamed skin The American Society of Hematology American Society of Hematology 10.1182/blood-2004-03-1184 Silverchair:18750 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Mouse model of MYD88L265P-dependent DLBCL The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-710434 Silverchair:35123 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Mouse model of MYD88L265P-dependent DLBCL The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-710434 Silverchair:35123 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Mouse model of MYD88L265P-dependent DLBCL The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-710434 Silverchair:35123 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Mouse model of MYD88L265P-dependent DLBCL The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-710434 Silverchair:35123 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Mouse RUNX1C regulates premegakaryocytic/erythroid output and maintains survival of megakaryocyte progenitors The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-723635 Silverchair:36932 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Mouse RUNX1C regulates premegakaryocytic/erythroid output and maintains survival of megakaryocyte progenitors The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-723635 Silverchair:36932 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Mouse RUNX1C regulates premegakaryocytic/erythroid output and maintains survival of megakaryocyte progenitors The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-723635 Silverchair:36932 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Mouse RUNX1C regulates premegakaryocytic/erythroid output and maintains survival of megakaryocyte progenitors The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-723635 Silverchair:36932 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Moving from parked to neutral(izing) The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-760538 Silverchair:36015 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 3 0 0 0 Moving from parked to neutral(izing) The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-760538 Silverchair:36015 Total_Item_Requests 3 0 0 0 0 0 0 0 0 3 0 0 0 Moving from parked to neutral(izing) The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-760538 Silverchair:36015 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Moving from parked to neutral(izing) The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-760538 Silverchair:36015 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients The American Society of Hematology American Society of Hematology 10.1182/blood-2004-10-3982 Silverchair:21527 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients The American Society of Hematology American Society of Hematology 10.1182/blood-2004-10-3982 Silverchair:21527 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients The American Society of Hematology American Society of Hematology 10.1182/blood-2004-10-3982 Silverchair:21527 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients The American Society of Hematology American Society of Hematology 10.1182/blood-2004-10-3982 Silverchair:21527 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 MRTFA augments megakaryocyte maturation by enhancing the SRF regulatory axis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018019448 Silverchair:16122 Total_Item_Investigations 10 2 4 4 0 0 0 0 0 0 0 0 0 MRTFA augments megakaryocyte maturation by enhancing the SRF regulatory axis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018019448 Silverchair:16122 Total_Item_Requests 10 2 4 4 0 0 0 0 0 0 0 0 0 MRTFA augments megakaryocyte maturation by enhancing the SRF regulatory axis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018019448 Silverchair:16122 Unique_Item_Investigations 3 1 1 1 0 0 0 0 0 0 0 0 0 MRTFA augments megakaryocyte maturation by enhancing the SRF regulatory axis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018019448 Silverchair:16122 Unique_Item_Requests 3 1 1 1 0 0 0 0 0 0 0 0 0 Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136023 Silverchair:470004 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136023 Silverchair:470004 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136023 Silverchair:470004 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136023 Silverchair:470004 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Macroglobulinemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112325 Silverchair:263549 Total_Item_Investigations 6 6 0 0 0 0 0 0 0 0 0 0 0 Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Macroglobulinemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112325 Silverchair:263549 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Macroglobulinemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112325 Silverchair:263549 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Macroglobulinemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112325 Silverchair:263549 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Multidisciplinary Implementation of an Iron Deficiency Anemia in Pregnancy Treatment Protocol The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123902 Silverchair:427868 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Multidisciplinary Implementation of an Iron Deficiency Anemia in Pregnancy Treatment Protocol The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123902 Silverchair:427868 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Multidisciplinary Implementation of an Iron Deficiency Anemia in Pregnancy Treatment Protocol The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123902 Silverchair:427868 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Multidisciplinary Implementation of an Iron Deficiency Anemia in Pregnancy Treatment Protocol The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123902 Silverchair:427868 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Multidrug resistance protein attenuates gemtuzumab ozogamicin–induced cytotoxicity in acute myeloid leukemia cells The American Society of Hematology American Society of Hematology 10.1182/blood-2003-02-0396 Silverchair:17095 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Multidrug resistance protein attenuates gemtuzumab ozogamicin–induced cytotoxicity in acute myeloid leukemia cells The American Society of Hematology American Society of Hematology 10.1182/blood-2003-02-0396 Silverchair:17095 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Multidrug resistance protein attenuates gemtuzumab ozogamicin–induced cytotoxicity in acute myeloid leukemia cells The American Society of Hematology American Society of Hematology 10.1182/blood-2003-02-0396 Silverchair:17095 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Multidrug resistance protein attenuates gemtuzumab ozogamicin–induced cytotoxicity in acute myeloid leukemia cells The American Society of Hematology American Society of Hematology 10.1182/blood-2003-02-0396 Silverchair:17095 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin The American Society of Hematology American Society of Hematology 10.1182/blood.V98.4.988 Silverchair:107123 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 0 3 0 0 Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin The American Society of Hematology American Society of Hematology 10.1182/blood.V98.4.988 Silverchair:107123 Total_Item_Requests 3 0 0 0 0 0 0 0 0 0 3 0 0 Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin The American Society of Hematology American Society of Hematology 10.1182/blood.V98.4.988 Silverchair:107123 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin The American Society of Hematology American Society of Hematology 10.1182/blood.V98.4.988 Silverchair:107123 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Multiparameter Flow Cytometry as a Powerful Tool The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.SCI-29.SCI-29 Silverchair:99061 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Multiparameter Flow Cytometry as a Powerful Tool The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.SCI-29.SCI-29 Silverchair:99061 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Multiparameter Flow Cytometry as a Powerful Tool The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.SCI-29.SCI-29 Silverchair:99061 Unique_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Multiparameter Flow Cytometry as a Powerful Tool The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.SCI-29.SCI-29 Silverchair:99061 Unique_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2020007081 Silverchair:461700 No_License 1 0 1 0 0 0 0 0 0 0 0 0 0 Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2020007081 Silverchair:461700 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2020007081 Silverchair:461700 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Multiple donor-derived leukemias in a recipient of allogeneic hematopoietic cell transplantation for myeloid malignancy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002803 Silverchair:464074 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Multiple donor-derived leukemias in a recipient of allogeneic hematopoietic cell transplantation for myeloid malignancy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002803 Silverchair:464074 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Multiple donor-derived leukemias in a recipient of allogeneic hematopoietic cell transplantation for myeloid malignancy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002803 Silverchair:464074 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Multiple donor-derived leukemias in a recipient of allogeneic hematopoietic cell transplantation for myeloid malignancy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002803 Silverchair:464074 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-496752 Silverchair:31661 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 0 2 Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-496752 Silverchair:31661 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 0 2 Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-496752 Silverchair:31661 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-496752 Silverchair:31661 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 "Multiple Myeloma (MM) in the Very Old: Disease Characteristics, Treatment Patterns and Outcomes in the Real World" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143223 Silverchair:473092 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 "Multiple Myeloma (MM) in the Very Old: Disease Characteristics, Treatment Patterns and Outcomes in the Real World" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143223 Silverchair:473092 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 "Multiple Myeloma (MM) in the Very Old: Disease Characteristics, Treatment Patterns and Outcomes in the Real World" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143223 Silverchair:473092 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 "Multiple Myeloma (MM) in the Very Old: Disease Characteristics, Treatment Patterns and Outcomes in the Real World" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143223 Silverchair:473092 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 MULTIPLE MYELOMA AS A FORM OF LEUKEMIA The American Society of Hematology American Society of Hematology 10.1182/blood.V4.9.1049.1049 Silverchair:6859 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 MULTIPLE MYELOMA AS A FORM OF LEUKEMIA The American Society of Hematology American Society of Hematology 10.1182/blood.V4.9.1049.1049 Silverchair:6859 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Multiple Myeloma Patients with Lenalidomide-Associated Skin Rash Have a Favorable Prognosis The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4532.4532 Silverchair:101393 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Multiple Myeloma Patients with Lenalidomide-Associated Skin Rash Have a Favorable Prognosis The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4532.4532 Silverchair:101393 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Multiple Myeloma Patients with Lenalidomide-Associated Skin Rash Have a Favorable Prognosis The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4532.4532 Silverchair:101393 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Multiple Myeloma Patients with Lenalidomide-Associated Skin Rash Have a Favorable Prognosis The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4532.4532 Silverchair:101393 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Multiple signaling pathways promote B lymphocyte stimulator–dependent B-cell growth and survival The American Society of Hematology American Society of Hematology 10.1182/blood-2007-03-077222 Silverchair:103746 Total_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Multiple signaling pathways promote B lymphocyte stimulator–dependent B-cell growth and survival The American Society of Hematology American Society of Hematology 10.1182/blood-2007-03-077222 Silverchair:103746 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Multiple signaling pathways promote B lymphocyte stimulator–dependent B-cell growth and survival The American Society of Hematology American Society of Hematology 10.1182/blood-2007-03-077222 Silverchair:103746 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Multiple signaling pathways promote B lymphocyte stimulator–dependent B-cell growth and survival The American Society of Hematology American Society of Hematology 10.1182/blood-2007-03-077222 Silverchair:103746 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020008812 Silverchair:475848 Total_Item_Investigations 2 0 0 0 0 0 0 2 0 0 0 0 0 Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020008812 Silverchair:475848 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Multispecies RNA tomography reveals regulators of hematopoietic stem cell birth in the embryonic aorta The American Society of Hematology American Society of Hematology 10.1182/blood.2019004446 Silverchair:457791 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Multispecies RNA tomography reveals regulators of hematopoietic stem cell birth in the embryonic aorta The American Society of Hematology American Society of Hematology 10.1182/blood.2019004446 Silverchair:457791 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Multispecies RNA tomography reveals regulators of hematopoietic stem cell birth in the embryonic aorta The American Society of Hematology American Society of Hematology 10.1182/blood.2019004446 Silverchair:457791 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Multispecies RNA tomography reveals regulators of hematopoietic stem cell birth in the embryonic aorta The American Society of Hematology American Society of Hematology 10.1182/blood.2019004446 Silverchair:457791 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Murine hematopoietic stem cell distribution and proliferation in ablated and nonablated bone marrow transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2002-04-1256 Silverchair:106304 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Murine hematopoietic stem cell distribution and proliferation in ablated and nonablated bone marrow transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2002-04-1256 Silverchair:106304 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Murine hematopoietic stem cell distribution and proliferation in ablated and nonablated bone marrow transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2002-04-1256 Silverchair:106304 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Murine hematopoietic stem cell distribution and proliferation in ablated and nonablated bone marrow transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2002-04-1256 Silverchair:106304 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Mutant calreticulin in myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.2019000622 Silverchair:374997 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Mutant calreticulin in myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.2019000622 Silverchair:374997 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Mutant calreticulin in myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.2019000622 Silverchair:374997 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Mutant calreticulin in myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.2019000622 Silverchair:374997 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-491571 Silverchair:31788 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-491571 Silverchair:31788 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-491571 Silverchair:31788 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-491571 Silverchair:31788 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Mutant U2AF1S34F and U2AF1Q157P Induce Distinct RNA Splicing and Hematopoietic Phenotypes In Vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123892 Silverchair:427015 Total_Item_Investigations 2 0 0 0 1 0 0 1 0 0 0 0 0 Mutant U2AF1S34F and U2AF1Q157P Induce Distinct RNA Splicing and Hematopoietic Phenotypes In Vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123892 Silverchair:427015 Total_Item_Requests 2 0 0 0 1 0 0 1 0 0 0 0 0 Mutant U2AF1S34F and U2AF1Q157P Induce Distinct RNA Splicing and Hematopoietic Phenotypes In Vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123892 Silverchair:427015 Unique_Item_Investigations 2 0 0 0 1 0 0 1 0 0 0 0 0 Mutant U2AF1S34F and U2AF1Q157P Induce Distinct RNA Splicing and Hematopoietic Phenotypes In Vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123892 Silverchair:427015 Unique_Item_Requests 2 0 0 0 1 0 0 1 0 0 0 0 0 Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2005-09-3778 Silverchair:109825 Total_Item_Investigations 2 0 0 0 0 0 0 0 1 1 0 0 0 Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2005-09-3778 Silverchair:109825 Total_Item_Requests 2 0 0 0 0 0 0 0 1 1 0 0 0 Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2005-09-3778 Silverchair:109825 Unique_Item_Investigations 2 0 0 0 0 0 0 0 1 1 0 0 0 Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2005-09-3778 Silverchair:109825 Unique_Item_Requests 2 0 0 0 0 0 0 0 1 1 0 0 0 Mutational analysis of hematologic neoplasms in 164 paired peripheral blood and bone marrow samples by next-generation sequencing American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002306 Silverchair:463747 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 Mutational analysis of hematologic neoplasms in 164 paired peripheral blood and bone marrow samples by next-generation sequencing American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002306 Silverchair:463747 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 Mutational analysis of hematologic neoplasms in 164 paired peripheral blood and bone marrow samples by next-generation sequencing American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002306 Silverchair:463747 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Mutational analysis of hematologic neoplasms in 164 paired peripheral blood and bone marrow samples by next-generation sequencing American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002306 Silverchair:463747 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Mutational Complexity Is Related To Disease Severity In Systemic Mastocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4094.4094 Silverchair:94304 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Mutational Complexity Is Related To Disease Severity In Systemic Mastocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4094.4094 Silverchair:94304 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Mutational Complexity Is Related To Disease Severity In Systemic Mastocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4094.4094 Silverchair:94304 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Mutational Complexity Is Related To Disease Severity In Systemic Mastocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4094.4094 Silverchair:94304 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-400994 Silverchair:29574 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-400994 Silverchair:29574 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-400994 Silverchair:29574 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-400994 Silverchair:29574 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Mutations in AP3D1 associated with immunodeficiency and seizures define a new type of Hermansky-Pudlak syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-671636 Silverchair:35150 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Mutations in AP3D1 associated with immunodeficiency and seizures define a new type of Hermansky-Pudlak syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-671636 Silverchair:35150 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Mutations in AP3D1 associated with immunodeficiency and seizures define a new type of Hermansky-Pudlak syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-671636 Silverchair:35150 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Mutations in AP3D1 associated with immunodeficiency and seizures define a new type of Hermansky-Pudlak syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-671636 Silverchair:35150 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Mutations in complement C3 from aHUS patients The American Society of Hematology American Society of Hematology 10.1182/blood-2015-02-625285 Silverchair:33819 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Mutations in complement C3 from aHUS patients The American Society of Hematology American Society of Hematology 10.1182/blood-2015-02-625285 Silverchair:33819 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Mutations in complement C3 from aHUS patients The American Society of Hematology American Society of Hematology 10.1182/blood-2015-02-625285 Silverchair:33819 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Mutations in complement C3 from aHUS patients The American Society of Hematology American Society of Hematology 10.1182/blood-2015-02-625285 Silverchair:33819 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-518746 Silverchair:32575 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-518746 Silverchair:32575 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-518746 Silverchair:32575 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-518746 Silverchair:32575 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Mutations in the mechanotransduction protein PIEZO1 are associated with hereditary xerocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-422253 Silverchair:30918 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Mutations in the mechanotransduction protein PIEZO1 are associated with hereditary xerocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-422253 Silverchair:30918 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Mutations in the mechanotransduction protein PIEZO1 are associated with hereditary xerocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-422253 Silverchair:30918 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Mutations in the mechanotransduction protein PIEZO1 are associated with hereditary xerocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-422253 Silverchair:30918 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2012-06-435842 Silverchair:31465 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2012-06-435842 Silverchair:31465 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2012-06-435842 Silverchair:31465 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2012-06-435842 Silverchair:31465 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 MYC-induced human acute myeloid leukemia requires a continuing IL-3/GM-CSF costimulus The American Society of Hematology American Society of Hematology 10.1182/blood.2020006374 Silverchair:461224 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 MYC-induced human acute myeloid leukemia requires a continuing IL-3/GM-CSF costimulus The American Society of Hematology American Society of Hematology 10.1182/blood.2020006374 Silverchair:461224 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 MYC-induced human acute myeloid leukemia requires a continuing IL-3/GM-CSF costimulus The American Society of Hematology American Society of Hematology 10.1182/blood.2020006374 Silverchair:461224 Unique_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 MYC-induced human acute myeloid leukemia requires a continuing IL-3/GM-CSF costimulus The American Society of Hematology American Society of Hematology 10.1182/blood.2020006374 Silverchair:461224 Unique_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 MYD88 L265P Elicits Mutation-specific Ubiquitination to Drive NF-κB Activation and Lymphomagenesis The American Society of Hematology American Society of Hematology 10.1182/blood.2020004918 Silverchair:464125 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 MYD88 L265P Elicits Mutation-specific Ubiquitination to Drive NF-κB Activation and Lymphomagenesis The American Society of Hematology American Society of Hematology 10.1182/blood.2020004918 Silverchair:464125 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 MYD88 L265P Elicits Mutation-specific Ubiquitination to Drive NF-κB Activation and Lymphomagenesis The American Society of Hematology American Society of Hematology 10.1182/blood.2020004918 Silverchair:464125 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 MYD88 L265P Elicits Mutation-specific Ubiquitination to Drive NF-κB Activation and Lymphomagenesis The American Society of Hematology American Society of Hematology 10.1182/blood.2020004918 Silverchair:464125 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001648 Silverchair:463326 Total_Item_Investigations 8 0 0 8 0 0 0 0 0 0 0 0 0 Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001648 Silverchair:463326 Total_Item_Requests 8 0 0 8 0 0 0 0 0 0 0 0 0 Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001648 Silverchair:463326 Unique_Item_Investigations 4 0 0 4 0 0 0 0 0 0 0 0 0 Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001648 Silverchair:463326 Unique_Item_Requests 4 0 0 4 0 0 0 0 0 0 0 0 0 Myelodysplastic Syndromes: Will WHO classification and WPSS become tools for hematopoietic stem cell American Society of Hematology American Society of Hematology 10.1182/hem.V5.5.6121 Silverchair:462035 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Myelodysplastic Syndromes: Will WHO classification and WPSS become tools for hematopoietic stem cell American Society of Hematology American Society of Hematology 10.1182/hem.V5.5.6121 Silverchair:462035 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Myelodysplastic Syndromes: Will WHO classification and WPSS become tools for hematopoietic stem cell American Society of Hematology American Society of Hematology 10.1182/hem.V5.5.6121 Silverchair:462035 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Myelodysplastic Syndromes: Will WHO classification and WPSS become tools for hematopoietic stem cell American Society of Hematology American Society of Hematology 10.1182/hem.V5.5.6121 Silverchair:462035 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation The American Society of Hematology American Society of Hematology 10.1182/blood-2006-12-061135 Silverchair:23624 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation The American Society of Hematology American Society of Hematology 10.1182/blood-2006-12-061135 Silverchair:23624 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation The American Society of Hematology American Society of Hematology 10.1182/blood-2006-12-061135 Silverchair:23624 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation The American Society of Hematology American Society of Hematology 10.1182/blood-2006-12-061135 Silverchair:23624 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Myeloid malignancies and the microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-670224 Silverchair:36198 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Myeloid malignancies and the microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-670224 Silverchair:36198 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Myeloid malignancies and the microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-670224 Silverchair:36198 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Myeloid malignancies and the microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-670224 Silverchair:36198 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Myeloid neoplasms with eosinophilia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-695973 Silverchair:36333 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Myeloid neoplasms with eosinophilia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-695973 Silverchair:36333 Total_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 Myeloid neoplasms with eosinophilia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-695973 Silverchair:36333 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Myeloid neoplasms with eosinophilia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-695973 Silverchair:36333 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients The American Society of Hematology American Society of Hematology 10.1182/blood.V99.10.3735 Silverchair:107049 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients The American Society of Hematology American Society of Hematology 10.1182/blood.V99.10.3735 Silverchair:107049 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients The American Society of Hematology American Society of Hematology 10.1182/blood.V99.10.3735 Silverchair:107049 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients The American Society of Hematology American Society of Hematology 10.1182/blood.V99.10.3735 Silverchair:107049 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Myelopoiesis is regulated by osteocytes through Gsα-dependent signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2012-06-437160 Silverchair:31406 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Myelopoiesis is regulated by osteocytes through Gsα-dependent signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2012-06-437160 Silverchair:31406 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Myelopoiesis is regulated by osteocytes through Gsα-dependent signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2012-06-437160 Silverchair:31406 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Myelopoiesis is regulated by osteocytes through Gsα-dependent signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2012-06-437160 Silverchair:31406 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Myeloproliferative neoplasms American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter18 Silverchair:76753 No_License 9 3 2 1 0 0 0 0 1 0 0 2 0 Myeloproliferative neoplasms American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter18 Silverchair:76753 Total_Item_Investigations 15 3 2 1 1 0 0 1 1 4 0 2 0 Myeloproliferative neoplasms American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter18 Silverchair:76753 Unique_Item_Investigations 10 1 1 1 1 0 0 1 1 3 0 1 0 Myeloproliferative neoplasms: from origins to outcomes The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-782037 Silverchair:36749 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Myeloproliferative neoplasms: from origins to outcomes The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-782037 Silverchair:36749 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Myeloproliferative neoplasms: from origins to outcomes The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-782037 Silverchair:36749 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Myeloproliferative neoplasms: from origins to outcomes The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-782037 Silverchair:36749 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 NADPH oxidase controls pulmonary neutrophil infiltration in the response to fungal cell walls by limiting LTB4 The American Society of Hematology American Society of Hematology 10.1182/blood.2019003525 Silverchair:431048 Total_Item_Investigations 3 0 1 1 1 0 0 0 0 0 0 0 0 NADPH oxidase controls pulmonary neutrophil infiltration in the response to fungal cell walls by limiting LTB4 The American Society of Hematology American Society of Hematology 10.1182/blood.2019003525 Silverchair:431048 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 NADPH oxidase controls pulmonary neutrophil infiltration in the response to fungal cell walls by limiting LTB4 The American Society of Hematology American Society of Hematology 10.1182/blood.2019003525 Silverchair:431048 Unique_Item_Investigations 3 0 1 1 1 0 0 0 0 0 0 0 0 NADPH oxidase controls pulmonary neutrophil infiltration in the response to fungal cell walls by limiting LTB4 The American Society of Hematology American Society of Hematology 10.1182/blood.2019003525 Silverchair:431048 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families The American Society of Hematology American Society of Hematology 10.1182/blood.2020006322 Silverchair:474760 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families The American Society of Hematology American Society of Hematology 10.1182/blood.2020006322 Silverchair:474760 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families The American Society of Hematology American Society of Hematology 10.1182/blood.2020006322 Silverchair:474760 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families The American Society of Hematology American Society of Hematology 10.1182/blood.2020006322 Silverchair:474760 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Natural History of Tumor Thrombus: A Single-Centre Retrospective Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124476 Silverchair:422890 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Natural History of Tumor Thrombus: A Single-Centre Retrospective Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124476 Silverchair:422890 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Natural History of Tumor Thrombus: A Single-Centre Retrospective Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124476 Silverchair:422890 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Natural History of Tumor Thrombus: A Single-Centre Retrospective Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124476 Silverchair:422890 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Natural IgM antibodies inhibit microvesicle-driven coagulation and thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood.2020007155 Silverchair:474427 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Natural IgM antibodies inhibit microvesicle-driven coagulation and thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood.2020007155 Silverchair:474427 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Naturally Selected Anti-CD7 CAR-T Cells without Additional Genetic Manipulations As a Potentially Superior Therapy for T-Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2021-149384 Silverchair:480835 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Naturally Selected Anti-CD7 CAR-T Cells without Additional Genetic Manipulations As a Potentially Superior Therapy for T-Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2021-149384 Silverchair:480835 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Naturally Selected Anti-CD7 CAR-T Cells without Additional Genetic Manipulations As a Potentially Superior Therapy for T-Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2021-149384 Silverchair:480835 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Naturally Selected Anti-CD7 CAR-T Cells without Additional Genetic Manipulations As a Potentially Superior Therapy for T-Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2021-149384 Silverchair:480835 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Navigating Future Challenges in Lymphoma: A Map for the Road Ahead American Society of Hematology American Society of Hematology 10.1182/hem.V12.3.4003 Silverchair:462691 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Navigating Future Challenges in Lymphoma: A Map for the Road Ahead American Society of Hematology American Society of Hematology 10.1182/hem.V12.3.4003 Silverchair:462691 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Navigating Future Challenges in Lymphoma: A Map for the Road Ahead American Society of Hematology American Society of Hematology 10.1182/hem.V12.3.4003 Silverchair:462691 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Navigating Future Challenges in Lymphoma: A Map for the Road Ahead American Society of Hematology American Society of Hematology 10.1182/hem.V12.3.4003 Silverchair:462691 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Navigating the narrow bridge to CAR T-cell therapy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002346 Silverchair:461121 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Navigating the narrow bridge to CAR T-cell therapy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002346 Silverchair:461121 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Navigating the narrow bridge to CAR T-cell therapy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002346 Silverchair:461121 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Navigating the narrow bridge to CAR T-cell therapy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002346 Silverchair:461121 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Nearly a Third of Clonal Hematopoiesis-Associated DNMT3A Mutations Reduce Protein Stability and May be Associated with Poorer Prognosis The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115275 Silverchair:262565 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Nearly a Third of Clonal Hematopoiesis-Associated DNMT3A Mutations Reduce Protein Stability and May be Associated with Poorer Prognosis The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115275 Silverchair:262565 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Nearly a Third of Clonal Hematopoiesis-Associated DNMT3A Mutations Reduce Protein Stability and May be Associated with Poorer Prognosis The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115275 Silverchair:262565 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Nearly a Third of Clonal Hematopoiesis-Associated DNMT3A Mutations Reduce Protein Stability and May be Associated with Poorer Prognosis The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115275 Silverchair:262565 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis The American Society of Hematology American Society of Hematology 10.1182/blood.2020006252 Silverchair:469714 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis The American Society of Hematology American Society of Hematology 10.1182/blood.2020006252 Silverchair:469714 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis The American Society of Hematology American Society of Hematology 10.1182/blood.2020006252 Silverchair:469714 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis The American Society of Hematology American Society of Hematology 10.1182/blood.2020006252 Silverchair:469714 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866." American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001380 Silverchair:431017 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866." American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001380 Silverchair:431017 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866." American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001380 Silverchair:431017 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866." American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001380 Silverchair:431017 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129593 Silverchair:427975 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129593 Silverchair:427975 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129593 Silverchair:427975 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129593 Silverchair:427975 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Neuropathic pain in sickle cell disease: measurement and management The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000142 Silverchair:474341 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Neuropathic pain in sickle cell disease: measurement and management The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000142 Silverchair:474341 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Neuropathic pain in sickle cell disease: measurement and management The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000142 Silverchair:474341 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Neuropathic pain in sickle cell disease: measurement and management The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000142 Silverchair:474341 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Neutropenia and G-CSF Use In Patients with Relapsed/Refractory Multiple Myeloma Treated with Lenalidomide Plus Dexamethasone The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.5034.5034 Silverchair:66741 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Neutropenia and G-CSF Use In Patients with Relapsed/Refractory Multiple Myeloma Treated with Lenalidomide Plus Dexamethasone The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.5034.5034 Silverchair:66741 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Neutropenia and G-CSF Use In Patients with Relapsed/Refractory Multiple Myeloma Treated with Lenalidomide Plus Dexamethasone The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.5034.5034 Silverchair:66741 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Neutropenia and G-CSF Use In Patients with Relapsed/Refractory Multiple Myeloma Treated with Lenalidomide Plus Dexamethasone The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.5034.5034 Silverchair:66741 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Neutrophil actin regulation: MKL1 is in control The American Society of Hematology American Society of Hematology 10.1182/blood-2015-08-662528 Silverchair:105424 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Neutrophil actin regulation: MKL1 is in control The American Society of Hematology American Society of Hematology 10.1182/blood-2015-08-662528 Silverchair:105424 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Neutrophil actin regulation: MKL1 is in control The American Society of Hematology American Society of Hematology 10.1182/blood-2015-08-662528 Silverchair:105424 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Neutrophil actin regulation: MKL1 is in control The American Society of Hematology American Society of Hematology 10.1182/blood-2015-08-662528 Silverchair:105424 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial The American Society of Hematology American Society of Hematology 10.1182/blood.2021012589 Silverchair:477945 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial The American Society of Hematology American Society of Hematology 10.1182/blood.2021012589 Silverchair:477945 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial The American Society of Hematology American Society of Hematology 10.1182/blood.2021012589 Silverchair:477945 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial The American Society of Hematology American Society of Hematology 10.1182/blood.2021012589 Silverchair:477945 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2020007008 Silverchair:461219 Total_Item_Investigations 13 0 5 0 2 4 2 0 0 0 0 0 0 Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2020007008 Silverchair:461219 Total_Item_Requests 13 0 5 0 2 4 2 0 0 0 0 0 0 Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2020007008 Silverchair:461219 Unique_Item_Investigations 7 0 2 0 1 2 2 0 0 0 0 0 0 Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2020007008 Silverchair:461219 Unique_Item_Requests 7 0 2 0 1 2 2 0 0 0 0 0 0 Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-416156 Silverchair:30659 Total_Item_Investigations 49 0 0 49 0 0 0 0 0 0 0 0 0 Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-416156 Silverchair:30659 Total_Item_Requests 49 0 0 49 0 0 0 0 0 0 0 0 0 Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-416156 Silverchair:30659 Unique_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-416156 Silverchair:30659 Unique_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Neutrophil heterogeneity: implications for homeostasis and pathogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-688887 Silverchair:35073 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Neutrophil heterogeneity: implications for homeostasis and pathogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-688887 Silverchair:35073 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Neutrophil heterogeneity: implications for homeostasis and pathogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-688887 Silverchair:35073 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Neutrophil heterogeneity: implications for homeostasis and pathogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-688887 Silverchair:35073 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Neutrophil plasticity in the tumor microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-844548 Silverchair:273823 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Neutrophil plasticity in the tumor microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-844548 Silverchair:273823 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Neutrophil plasticity in the tumor microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-844548 Silverchair:273823 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Neutrophil plasticity in the tumor microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-844548 Silverchair:273823 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Neutrophil transendothelial migration: updates and new perspectives The American Society of Hematology American Society of Hematology 10.1182/blood-2018-12-844605 Silverchair:273847 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Neutrophil transendothelial migration: updates and new perspectives The American Society of Hematology American Society of Hematology 10.1182/blood-2018-12-844605 Silverchair:273847 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Neutrophil transendothelial migration: updates and new perspectives The American Society of Hematology American Society of Hematology 10.1182/blood-2018-12-844605 Silverchair:273847 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Neutrophil transendothelial migration: updates and new perspectives The American Society of Hematology American Society of Hematology 10.1182/blood-2018-12-844605 Silverchair:273847 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Neutrophilic leukemoid reaction with extended fibrosis due to ectopic G-CSF production The American Society of Hematology American Society of Hematology 10.1182/blood-2019-01-894006 Silverchair:260453 Total_Item_Investigations 4 0 0 4 0 0 0 0 0 0 0 0 0 Neutrophilic leukemoid reaction with extended fibrosis due to ectopic G-CSF production The American Society of Hematology American Society of Hematology 10.1182/blood-2019-01-894006 Silverchair:260453 Total_Item_Requests 4 0 0 4 0 0 0 0 0 0 0 0 0 Neutrophilic leukemoid reaction with extended fibrosis due to ectopic G-CSF production The American Society of Hematology American Society of Hematology 10.1182/blood-2019-01-894006 Silverchair:260453 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Neutrophilic leukemoid reaction with extended fibrosis due to ectopic G-CSF production The American Society of Hematology American Society of Hematology 10.1182/blood-2019-01-894006 Silverchair:260453 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Neutrophils acquire the capacity for antigen presentation to memory CD4+ T cells in vitro and ex vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-744441 Silverchair:35879 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Neutrophils acquire the capacity for antigen presentation to memory CD4+ T cells in vitro and ex vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-744441 Silverchair:35879 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Neutrophils acquire the capacity for antigen presentation to memory CD4+ T cells in vitro and ex vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-744441 Silverchair:35879 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Neutrophils acquire the capacity for antigen presentation to memory CD4+ T cells in vitro and ex vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-744441 Silverchair:35879 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 New diagnostic tools for delineating iron status The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000035 Silverchair:422621 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 New diagnostic tools for delineating iron status The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000035 Silverchair:422621 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 New diagnostic tools for delineating iron status The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000035 Silverchair:422621 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 New diagnostic tools for delineating iron status The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000035 Silverchair:422621 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 New Germline Syndrome Discovery: Heterozygous CSF3R Mutations May Predispose to Myeloid and Lymphoid Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129492 Silverchair:423111 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 New Germline Syndrome Discovery: Heterozygous CSF3R Mutations May Predispose to Myeloid and Lymphoid Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129492 Silverchair:423111 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 New Germline Syndrome Discovery: Heterozygous CSF3R Mutations May Predispose to Myeloid and Lymphoid Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129492 Silverchair:423111 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 New Germline Syndrome Discovery: Heterozygous CSF3R Mutations May Predispose to Myeloid and Lymphoid Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129492 Silverchair:423111 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 New Hope for Antibody-based Immunotherapy for AML: Will the DART Hit the Bullseye? American Society of Hematology American Society of Hematology Silverchair:475870 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 New Hope for Antibody-based Immunotherapy for AML: Will the DART Hit the Bullseye? American Society of Hematology American Society of Hematology Silverchair:475870 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 New Hope for Antibody-based Immunotherapy for AML: Will the DART Hit the Bullseye? American Society of Hematology American Society of Hematology Silverchair:475870 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 New Hope for Antibody-based Immunotherapy for AML: Will the DART Hit the Bullseye? American Society of Hematology American Society of Hematology Silverchair:475870 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 New mutations and pathogenesis of myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2011-02-292102 Silverchair:29688 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 New mutations and pathogenesis of myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2011-02-292102 Silverchair:29688 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 New mutations and pathogenesis of myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2011-02-292102 Silverchair:29688 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 New mutations and pathogenesis of myeloproliferative neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2011-02-292102 Silverchair:29688 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 New oncogenic subtypes in pediatric B-cell precursor acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-742643 Silverchair:36497 Total_Item_Investigations 6 0 6 0 0 0 0 0 0 0 0 0 0 New oncogenic subtypes in pediatric B-cell precursor acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-742643 Silverchair:36497 Total_Item_Requests 6 0 6 0 0 0 0 0 0 0 0 0 0 New oncogenic subtypes in pediatric B-cell precursor acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-742643 Silverchair:36497 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 New oncogenic subtypes in pediatric B-cell precursor acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-742643 Silverchair:36497 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Newly Diagnosed Pernicious Anemia Can be Treated with a Single Megadose of Cobalamin. Results of a Pilot Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118611 Silverchair:262488 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Newly Diagnosed Pernicious Anemia Can be Treated with a Single Megadose of Cobalamin. Results of a Pilot Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118611 Silverchair:262488 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Newly Diagnosed Pernicious Anemia Can be Treated with a Single Megadose of Cobalamin. Results of a Pilot Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118611 Silverchair:262488 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Newly Diagnosed Pernicious Anemia Can be Treated with a Single Megadose of Cobalamin. Results of a Pilot Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118611 Silverchair:262488 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Next Generation CRISPR Gene-Edited and Off-the-Shelf Virus-Specific T-Cells for the Immunocompromised Patient The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125276 Silverchair:427894 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Next Generation CRISPR Gene-Edited and Off-the-Shelf Virus-Specific T-Cells for the Immunocompromised Patient The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125276 Silverchair:427894 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Next Generation CRISPR Gene-Edited and Off-the-Shelf Virus-Specific T-Cells for the Immunocompromised Patient The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125276 Silverchair:427894 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Next Generation CRISPR Gene-Edited and Off-the-Shelf Virus-Specific T-Cells for the Immunocompromised Patient The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125276 Silverchair:427894 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Next-generation cell therapies: the emerging role of CAR-NK cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002547 Silverchair:474235 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Next-generation cell therapies: the emerging role of CAR-NK cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002547 Silverchair:474235 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Next-generation cell therapies: the emerging role of CAR-NK cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002547 Silverchair:474235 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Next-generation cell therapies: the emerging role of CAR-NK cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002547 Silverchair:474235 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.855.855 Silverchair:83474 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.855.855 Silverchair:83474 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.855.855 Silverchair:83474 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.855.855 Silverchair:83474 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 NFAT control of innate immunity The American Society of Hematology American Society of Hematology 10.1182/blood-2012-02-404475 Silverchair:30770 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 NFAT control of innate immunity The American Society of Hematology American Society of Hematology 10.1182/blood-2012-02-404475 Silverchair:30770 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 NFAT control of innate immunity The American Society of Hematology American Society of Hematology 10.1182/blood-2012-02-404475 Silverchair:30770 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 NFAT control of innate immunity The American Society of Hematology American Society of Hematology 10.1182/blood-2012-02-404475 Silverchair:30770 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 NF-E2 domination over Nrf2 promotes ROS accumulation and megakaryocytic maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-223107 Silverchair:27167 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 NF-E2 domination over Nrf2 promotes ROS accumulation and megakaryocytic maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-223107 Silverchair:27167 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 NF-E2 domination over Nrf2 promotes ROS accumulation and megakaryocytic maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-223107 Silverchair:27167 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 NF-E2 domination over Nrf2 promotes ROS accumulation and megakaryocytic maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-223107 Silverchair:27167 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 N-glycan–mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTP The American Society of Hematology American Society of Hematology 10.1182/blood.2020007972 Silverchair:475192 Total_Item_Investigations 3 0 0 0 0 3 0 0 0 0 0 0 0 N-glycan–mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTP The American Society of Hematology American Society of Hematology 10.1182/blood.2020007972 Silverchair:475192 Unique_Item_Investigations 3 0 0 0 0 3 0 0 0 0 0 0 0 Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3 The American Society of Hematology American Society of Hematology 10.1182/blood-2007-12-129718 Silverchair:24985 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3 The American Society of Hematology American Society of Hematology 10.1182/blood-2007-12-129718 Silverchair:24985 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3 The American Society of Hematology American Society of Hematology 10.1182/blood-2007-12-129718 Silverchair:24985 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3 The American Society of Hematology American Society of Hematology 10.1182/blood-2007-12-129718 Silverchair:24985 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Nitazoxanide Is Effective Therapy For Norovirus Gastroenteritis After Chemotherapy and Hematopoietic Stem Cell Transplantation (HSCT) The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4581.4581 Silverchair:11274 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Nitazoxanide Is Effective Therapy For Norovirus Gastroenteritis After Chemotherapy and Hematopoietic Stem Cell Transplantation (HSCT) The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4581.4581 Silverchair:11274 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Nitazoxanide Is Effective Therapy For Norovirus Gastroenteritis After Chemotherapy and Hematopoietic Stem Cell Transplantation (HSCT) The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4581.4581 Silverchair:11274 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Nitazoxanide Is Effective Therapy For Norovirus Gastroenteritis After Chemotherapy and Hematopoietic Stem Cell Transplantation (HSCT) The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.4581.4581 Silverchair:11274 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-074716 Silverchair:25463 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-074716 Silverchair:25463 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-074716 Silverchair:25463 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-074716 Silverchair:25463 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 NKT cells in p53 deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2009-03-211318 Silverchair:25664 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 NKT cells in p53 deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2009-03-211318 Silverchair:25664 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 NKT cells in p53 deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2009-03-211318 Silverchair:25664 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 NKT cells in p53 deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2009-03-211318 Silverchair:25664 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 NKT-dependent B-cell activation in Gaucher disease The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-617514 Silverchair:34164 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 NKT-dependent B-cell activation in Gaucher disease The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-617514 Silverchair:34164 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 NKT-dependent B-cell activation in Gaucher disease The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-617514 Silverchair:34164 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 NKT-dependent B-cell activation in Gaucher disease The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-617514 Silverchair:34164 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 No evidence of SARS-CoV-2 transfusion transmission despite RNA detection in blood donors showing symptoms after donation The American Society of Hematology American Society of Hematology 10.1182/blood.2020008230 Silverchair:463603 Total_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 No evidence of SARS-CoV-2 transfusion transmission despite RNA detection in blood donors showing symptoms after donation The American Society of Hematology American Society of Hematology 10.1182/blood.2020008230 Silverchair:463603 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 No evidence of SARS-CoV-2 transfusion transmission despite RNA detection in blood donors showing symptoms after donation The American Society of Hematology American Society of Hematology 10.1182/blood.2020008230 Silverchair:463603 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 No evidence of SARS-CoV-2 transfusion transmission despite RNA detection in blood donors showing symptoms after donation The American Society of Hematology American Society of Hematology 10.1182/blood.2020008230 Silverchair:463603 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-471672 Silverchair:31285 Total_Item_Investigations 2 0 0 0 0 0 0 2 0 0 0 0 0 No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-471672 Silverchair:31285 Total_Item_Requests 2 0 0 0 0 0 0 2 0 0 0 0 0 No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-471672 Silverchair:31285 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-471672 Silverchair:31285 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Nomenclature of monocytes and dendritic cells in blood The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-258558 Silverchair:27833 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Nomenclature of monocytes and dendritic cells in blood The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-258558 Silverchair:27833 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Nomenclature of monocytes and dendritic cells in blood The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-258558 Silverchair:27833 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Nomenclature of monocytes and dendritic cells in blood The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-258558 Silverchair:27833 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D'D3 and D4 domains American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002334 Silverchair:461592 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D'D3 and D4 domains American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002334 Silverchair:461592 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D'D3 and D4 domains American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002334 Silverchair:461592 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D'D3 and D4 domains American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002334 Silverchair:461592 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Non-Canonical Wnt Signaling Regulates Hematopooetic Repopulation Through the Ryk Receptor The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.852.852 Silverchair:87463 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Non-Canonical Wnt Signaling Regulates Hematopooetic Repopulation Through the Ryk Receptor The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.852.852 Silverchair:87463 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Non-Canonical Wnt Signaling Regulates Hematopooetic Repopulation Through the Ryk Receptor The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.852.852 Silverchair:87463 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Non-Canonical Wnt Signaling Regulates Hematopooetic Repopulation Through the Ryk Receptor The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.852.852 Silverchair:87463 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Non–chemotherapy drug–induced neutropenia: key points to manage the challenges The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.187 Silverchair:21177 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Non–chemotherapy drug–induced neutropenia: key points to manage the challenges The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.187 Silverchair:21177 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Non–chemotherapy drug–induced neutropenia: key points to manage the challenges The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.187 Silverchair:21177 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Non–chemotherapy drug–induced neutropenia: key points to manage the challenges The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.187 Silverchair:21177 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 None of the above: thrombotic microangiopathy beyond TTP and HUS The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-743104 Silverchair:36256 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 None of the above: thrombotic microangiopathy beyond TTP and HUS The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-743104 Silverchair:36256 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 None of the above: thrombotic microangiopathy beyond TTP and HUS The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-743104 Silverchair:36256 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 None of the above: thrombotic microangiopathy beyond TTP and HUS The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-743104 Silverchair:36256 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Non-Hodgkin lymphomas American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter23 Silverchair:77771 No_License 6 2 0 0 1 0 0 0 1 0 1 1 0 Non-Hodgkin lymphomas American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter23 Silverchair:77771 Total_Item_Investigations 10 2 0 0 3 1 0 1 1 0 1 1 0 Non-Hodgkin lymphomas American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter23 Silverchair:77771 Unique_Item_Investigations 7 1 0 0 1 1 0 1 1 0 1 1 0 Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-017863 Silverchair:23761 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-017863 Silverchair:23761 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-017863 Silverchair:23761 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-017863 Silverchair:23761 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001627 Silverchair:463767 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001627 Silverchair:463767 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001627 Silverchair:463767 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001627 Silverchair:463767 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Non-Transferrin-Mediated Iron Delivery The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.SCI-22.SCI-22 Silverchair:99002 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Non-Transferrin-Mediated Iron Delivery The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.SCI-22.SCI-22 Silverchair:99002 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Non-Transferrin-Mediated Iron Delivery The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.SCI-22.SCI-22 Silverchair:99002 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Non-Transferrin-Mediated Iron Delivery The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.SCI-22.SCI-22 Silverchair:99002 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-681171 Silverchair:34963 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-681171 Silverchair:34963 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-681171 Silverchair:34963 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-681171 Silverchair:34963 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Normal peripheral blood neutrophil numbers accompanying ELANE whole gene deletion mutation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000498 Silverchair:260518 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Normal peripheral blood neutrophil numbers accompanying ELANE whole gene deletion mutation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000498 Silverchair:260518 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Normal peripheral blood neutrophil numbers accompanying ELANE whole gene deletion mutation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000498 Silverchair:260518 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Normal peripheral blood neutrophil numbers accompanying ELANE whole gene deletion mutation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000498 Silverchair:260518 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-824607 Silverchair:39348 Total_Item_Investigations 3 0 0 0 3 0 0 0 0 0 0 0 0 North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-824607 Silverchair:39348 Total_Item_Requests 3 0 0 0 3 0 0 0 0 0 0 0 0 North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-824607 Silverchair:39348 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-824607 Silverchair:39348 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Not a oNe TRacK Solid Tumor Mindset Anymore: NTRK Mutations in Hematologic Malignancies American Society of Hematology American Society of Hematology Silverchair:464085 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Not a oNe TRacK Solid Tumor Mindset Anymore: NTRK Mutations in Hematologic Malignancies American Society of Hematology American Society of Hematology Silverchair:464085 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Not a oNe TRacK Solid Tumor Mindset Anymore: NTRK Mutations in Hematologic Malignancies American Society of Hematology American Society of Hematology Silverchair:464085 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Not a oNe TRacK Solid Tumor Mindset Anymore: NTRK Mutations in Hematologic Malignancies American Society of Hematology American Society of Hematology Silverchair:464085 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Not All TP53 Mutations Are Equal American Society of Hematology American Society of Hematology Silverchair:474710 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Not All TP53 Mutations Are Equal American Society of Hematology American Society of Hematology Silverchair:474710 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Not All TP53 Mutations Are Equal American Society of Hematology American Society of Hematology Silverchair:474710 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Not All TP53 Mutations Are Equal American Society of Hematology American Society of Hematology Silverchair:474710 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Notch1 controls macrophage recruitment and Notch signaling is activated at sites of endothelial cell anastomosis during retinal angiogenesis in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2010-12-327015 Silverchair:28839 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 Notch1 controls macrophage recruitment and Notch signaling is activated at sites of endothelial cell anastomosis during retinal angiogenesis in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2010-12-327015 Silverchair:28839 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Notch1 controls macrophage recruitment and Notch signaling is activated at sites of endothelial cell anastomosis during retinal angiogenesis in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2010-12-327015 Silverchair:28839 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Notch1 controls macrophage recruitment and Notch signaling is activated at sites of endothelial cell anastomosis during retinal angiogenesis in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2010-12-327015 Silverchair:28839 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow–derived mesenchymal stromal cells The American Society of Hematology American Society of Hematology 10.1182/blood-2010-12-326694 Silverchair:28512 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow–derived mesenchymal stromal cells The American Society of Hematology American Society of Hematology 10.1182/blood-2010-12-326694 Silverchair:28512 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow–derived mesenchymal stromal cells The American Society of Hematology American Society of Hematology 10.1182/blood-2010-12-326694 Silverchair:28512 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow–derived mesenchymal stromal cells The American Society of Hematology American Society of Hematology 10.1182/blood-2010-12-326694 Silverchair:28512 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Novel 12-LOX Inhibitor ML355 Attenuates Platelet Reactivity and Impairs Thrombus Growth, Stability and Vessel Occlusion In Vivo" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3442.3442 Silverchair:90820 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Novel 12-LOX Inhibitor ML355 Attenuates Platelet Reactivity and Impairs Thrombus Growth, Stability and Vessel Occlusion In Vivo" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3442.3442 Silverchair:90820 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "Novel 12-LOX Inhibitor ML355 Attenuates Platelet Reactivity and Impairs Thrombus Growth, Stability and Vessel Occlusion In Vivo" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3442.3442 Silverchair:90820 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Novel 12-LOX Inhibitor ML355 Attenuates Platelet Reactivity and Impairs Thrombus Growth, Stability and Vessel Occlusion In Vivo" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3442.3442 Silverchair:90820 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Novel agents and immune invasion in Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000029 Silverchair:422549 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Novel agents and immune invasion in Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000029 Silverchair:422549 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Novel agents and immune invasion in Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000029 Silverchair:422549 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Novel agents and immune invasion in Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000029 Silverchair:422549 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-535088 Silverchair:32697 Total_Item_Investigations 2 0 0 0 0 0 2 0 0 0 0 0 0 Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-535088 Silverchair:32697 Total_Item_Requests 2 0 0 0 0 0 2 0 0 0 0 0 0 Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-535088 Silverchair:32697 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-535088 Silverchair:32697 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Novel Biologic Therapy for Untreated Diseases of Vascular Calcification The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2326.2326 Silverchair:98734 Total_Item_Investigations 4 2 2 0 0 0 0 0 0 0 0 0 0 Novel Biologic Therapy for Untreated Diseases of Vascular Calcification The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2326.2326 Silverchair:98734 Total_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 Novel Biologic Therapy for Untreated Diseases of Vascular Calcification The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2326.2326 Silverchair:98734 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Novel Biologic Therapy for Untreated Diseases of Vascular Calcification The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2326.2326 Silverchair:98734 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Novel drug for WHIM The American Society of Hematology American Society of Hematology 10.1182/blood.2020008848 Silverchair:474732 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Novel drug for WHIM The American Society of Hematology American Society of Hematology 10.1182/blood.2020008848 Silverchair:474732 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Novel drug for WHIM The American Society of Hematology American Society of Hematology 10.1182/blood.2020008848 Silverchair:474732 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Novel drug for WHIM The American Society of Hematology American Society of Hematology 10.1182/blood.2020008848 Silverchair:474732 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2015-10-676098 Silverchair:35147 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2015-10-676098 Silverchair:35147 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2015-10-676098 Silverchair:35147 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2015-10-676098 Silverchair:35147 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Novel insights into the pathogenesis of T-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-764357 Silverchair:37107 Total_Item_Investigations 6 2 0 1 0 0 0 0 0 3 0 0 0 Novel insights into the pathogenesis of T-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-764357 Silverchair:37107 Total_Item_Requests 6 2 0 1 0 0 0 0 0 3 0 0 0 Novel insights into the pathogenesis of T-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-764357 Silverchair:37107 Unique_Item_Investigations 3 1 0 1 0 0 0 0 0 1 0 0 0 Novel insights into the pathogenesis of T-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-764357 Silverchair:37107 Unique_Item_Requests 3 1 0 1 0 0 0 0 0 1 0 0 0 Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2019004776 Silverchair:461431 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2019004776 Silverchair:461431 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2019004776 Silverchair:461431 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2019004776 Silverchair:461431 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Novel mechanisms of PIEZO1 dysfunction in hereditary xerocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-786004 Silverchair:36495 Total_Item_Investigations 4 0 0 2 0 0 0 0 0 0 2 0 0 Novel mechanisms of PIEZO1 dysfunction in hereditary xerocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-786004 Silverchair:36495 Total_Item_Requests 4 0 0 2 0 0 0 0 0 0 2 0 0 Novel mechanisms of PIEZO1 dysfunction in hereditary xerocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-786004 Silverchair:36495 Unique_Item_Investigations 2 0 0 1 0 0 0 0 0 0 1 0 0 Novel mechanisms of PIEZO1 dysfunction in hereditary xerocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-786004 Silverchair:36495 Unique_Item_Requests 2 0 0 1 0 0 0 0 0 0 1 0 0 Novel players: tissue-resident memory B cells The American Society of Hematology American Society of Hematology 10.1182/blood.2020007890 Silverchair:474397 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Novel players: tissue-resident memory B cells The American Society of Hematology American Society of Hematology 10.1182/blood.2020007890 Silverchair:474397 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Novel players: tissue-resident memory B cells The American Society of Hematology American Society of Hematology 10.1182/blood.2020007890 Silverchair:474397 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Novel players: tissue-resident memory B cells The American Society of Hematology American Society of Hematology 10.1182/blood.2020007890 Silverchair:474397 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Novel targets in aggressive lymphoma The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000093 Silverchair:474348 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Novel targets in aggressive lymphoma The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000093 Silverchair:474348 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Novel targets in aggressive lymphoma The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000093 Silverchair:474348 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Novel targets in aggressive lymphoma The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000093 Silverchair:474348 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Novel Thyrointegrin avß3 Antagonist for the Effective Management of Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141628 Silverchair:470832 Total_Item_Investigations 2 0 0 1 1 0 0 0 0 0 0 0 0 Novel Thyrointegrin avß3 Antagonist for the Effective Management of Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141628 Silverchair:470832 Total_Item_Requests 2 0 0 1 1 0 0 0 0 0 0 0 0 Novel Thyrointegrin avß3 Antagonist for the Effective Management of Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141628 Silverchair:470832 Unique_Item_Investigations 2 0 0 1 1 0 0 0 0 0 0 0 0 Novel Thyrointegrin avß3 Antagonist for the Effective Management of Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141628 Silverchair:470832 Unique_Item_Requests 2 0 0 1 1 0 0 0 0 0 0 0 0 Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-788935 Silverchair:36868 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-788935 Silverchair:36868 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-788935 Silverchair:36868 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-788935 Silverchair:36868 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2006-01-028647 Silverchair:103647 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2006-01-028647 Silverchair:103647 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2006-01-028647 Silverchair:103647 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2006-01-028647 Silverchair:103647 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2018883140 Silverchair:260694 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2018883140 Silverchair:260694 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2018883140 Silverchair:260694 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2018883140 Silverchair:260694 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "NR2F6, the Mammalian Homologue of Drosophila Seven Up, Can Initiate Myelodysplasia and Acute Leukemia." The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.400.400 Silverchair:84194 Total_Item_Investigations 3 0 0 0 0 0 0 0 1 2 0 0 0 "NR2F6, the Mammalian Homologue of Drosophila Seven Up, Can Initiate Myelodysplasia and Acute Leukemia." The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.400.400 Silverchair:84194 Total_Item_Requests 3 0 0 0 0 0 0 0 1 2 0 0 0 "NR2F6, the Mammalian Homologue of Drosophila Seven Up, Can Initiate Myelodysplasia and Acute Leukemia." The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.400.400 Silverchair:84194 Unique_Item_Investigations 2 0 0 0 0 0 0 0 1 1 0 0 0 "NR2F6, the Mammalian Homologue of Drosophila Seven Up, Can Initiate Myelodysplasia and Acute Leukemia." The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.400.400 Silverchair:84194 Unique_Item_Requests 2 0 0 0 0 0 0 0 1 1 0 0 0 Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018017574 Silverchair:260134 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018017574 Silverchair:260134 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018017574 Silverchair:260134 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018017574 Silverchair:260134 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 NRP1 acts cell autonomously in endothelium to promote tip cell function during sprouting angiogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-424713 Silverchair:31470 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 NRP1 acts cell autonomously in endothelium to promote tip cell function during sprouting angiogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-424713 Silverchair:31470 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 NRP1 acts cell autonomously in endothelium to promote tip cell function during sprouting angiogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-424713 Silverchair:31470 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 NRP1 acts cell autonomously in endothelium to promote tip cell function during sprouting angiogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-424713 Silverchair:31470 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells The American Society of Hematology American Society of Hematology 10.1182/blood.V98.8.2301 Silverchair:53301 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells The American Society of Hematology American Society of Hematology 10.1182/blood.V98.8.2301 Silverchair:53301 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells The American Society of Hematology American Society of Hematology 10.1182/blood.V98.8.2301 Silverchair:53301 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells The American Society of Hematology American Society of Hematology 10.1182/blood.V98.8.2301 Silverchair:53301 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-732636 Silverchair:36792 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-732636 Silverchair:36792 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-732636 Silverchair:36792 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-732636 Silverchair:36792 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000) The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-481341 Silverchair:32396 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000) The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-481341 Silverchair:32396 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000) The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-481341 Silverchair:32396 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000) The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-481341 Silverchair:32396 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.615.615 Silverchair:95146 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.615.615 Silverchair:95146 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.615.615 Silverchair:95146 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.615.615 Silverchair:95146 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Ocular Complications of Bortezomib Therapy in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5743.5743 Silverchair:100800 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Ocular Complications of Bortezomib Therapy in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5743.5743 Silverchair:100800 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Ocular Complications of Bortezomib Therapy in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5743.5743 Silverchair:100800 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Ocular Complications of Bortezomib Therapy in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5743.5743 Silverchair:100800 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124360 Silverchair:426552 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124360 Silverchair:426552 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124360 Silverchair:426552 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124360 Silverchair:426552 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123920 Silverchair:426117 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123920 Silverchair:426117 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123920 Silverchair:426117 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123920 Silverchair:426117 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 On the origin of platelet factor V The American Society of Hematology American Society of Hematology 10.1182/blood-2003-08-2693 Silverchair:17714 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 On the origin of platelet factor V The American Society of Hematology American Society of Hematology 10.1182/blood-2003-08-2693 Silverchair:17714 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 On the origin of platelet factor V The American Society of Hematology American Society of Hematology 10.1182/blood-2003-08-2693 Silverchair:17714 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 On the origin of platelet factor V The American Society of Hematology American Society of Hematology 10.1182/blood-2003-08-2693 Silverchair:17714 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 On the road to optimized BTK inhibition in CLL The American Society of Hematology American Society of Hematology 10.1182/blood.2021011462 Silverchair:476112 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 On the road to optimized BTK inhibition in CLL The American Society of Hematology American Society of Hematology 10.1182/blood.2021011462 Silverchair:476112 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 On the road to optimized BTK inhibition in CLL The American Society of Hematology American Society of Hematology 10.1182/blood.2021011462 Silverchair:476112 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 On the road to optimized BTK inhibition in CLL The American Society of Hematology American Society of Hematology 10.1182/blood.2021011462 Silverchair:476112 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 "Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137303 Silverchair:472921 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 "Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137303 Silverchair:472921 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 "Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137303 Silverchair:472921 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 "Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137303 Silverchair:472921 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Once-Daily Oral Rivaroxaban Versus Placebo in the Long-Term Prevention of Recurrent Symptomatic Venous Thromboembolism. the Einstein-Extension Study The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.LBA-2.LBA-2 Silverchair:65341 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Once-Daily Oral Rivaroxaban Versus Placebo in the Long-Term Prevention of Recurrent Symptomatic Venous Thromboembolism. the Einstein-Extension Study The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.LBA-2.LBA-2 Silverchair:65341 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Once-Daily Oral Rivaroxaban Versus Placebo in the Long-Term Prevention of Recurrent Symptomatic Venous Thromboembolism. the Einstein-Extension Study The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.LBA-2.LBA-2 Silverchair:65341 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Once-Daily Oral Rivaroxaban Versus Placebo in the Long-Term Prevention of Recurrent Symptomatic Venous Thromboembolism. the Einstein-Extension Study The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.LBA-2.LBA-2 Silverchair:65341 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Oncogenic Properties of the T-ALL Associated EML1-ABL1 and NUP214-ABL1 Fusion Proteins. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.1830.1830 Silverchair:127405 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Oncogenic Properties of the T-ALL Associated EML1-ABL1 and NUP214-ABL1 Fusion Proteins. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.1830.1830 Silverchair:127405 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Oncogenic Properties of the T-ALL Associated EML1-ABL1 and NUP214-ABL1 Fusion Proteins. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.1830.1830 Silverchair:127405 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Oncogenic Properties of the T-ALL Associated EML1-ABL1 and NUP214-ABL1 Fusion Proteins. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.1830.1830 Silverchair:127405 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and Outcomes" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140728 Silverchair:469877 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and Outcomes" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140728 Silverchair:469877 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and Outcomes" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140728 Silverchair:469877 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and Outcomes" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140728 Silverchair:469877 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Oncostatin M Is a Novel Niche Factor That Restrains Hematopoietic Stem Cell Mobilization in Response to G-CSF and CXCR4 Antagonist Plerixafor The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127431 Silverchair:424641 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Oncostatin M Is a Novel Niche Factor That Restrains Hematopoietic Stem Cell Mobilization in Response to G-CSF and CXCR4 Antagonist Plerixafor The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127431 Silverchair:424641 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Oncostatin M Is a Novel Niche Factor That Restrains Hematopoietic Stem Cell Mobilization in Response to G-CSF and CXCR4 Antagonist Plerixafor The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127431 Silverchair:424641 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Oncostatin M Is a Novel Niche Factor That Restrains Hematopoietic Stem Cell Mobilization in Response to G-CSF and CXCR4 Antagonist Plerixafor The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127431 Silverchair:424641 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 "One and Half Million Hematopoietic Stem Cell Transplants (HSCT). Dissemination, Trends and Potential to Improve Activity By Telemedicine from the Worldwide Network for Blood and Marrow Transplantation (WBMT)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125232 Silverchair:427903 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "One and Half Million Hematopoietic Stem Cell Transplants (HSCT). Dissemination, Trends and Potential to Improve Activity By Telemedicine from the Worldwide Network for Blood and Marrow Transplantation (WBMT)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125232 Silverchair:427903 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "One and Half Million Hematopoietic Stem Cell Transplants (HSCT). Dissemination, Trends and Potential to Improve Activity By Telemedicine from the Worldwide Network for Blood and Marrow Transplantation (WBMT)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125232 Silverchair:427903 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "One and Half Million Hematopoietic Stem Cell Transplants (HSCT). Dissemination, Trends and Potential to Improve Activity By Telemedicine from the Worldwide Network for Blood and Marrow Transplantation (WBMT)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125232 Silverchair:427903 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation The American Society of Hematology American Society of Hematology 10.1182/blood-2007-03-077644 Silverchair:23977 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation The American Society of Hematology American Society of Hematology 10.1182/blood-2007-03-077644 Silverchair:23977 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation The American Society of Hematology American Society of Hematology 10.1182/blood-2007-03-077644 Silverchair:23977 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation The American Society of Hematology American Society of Hematology 10.1182/blood-2007-03-077644 Silverchair:23977 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004467 Silverchair:475850 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004467 Silverchair:475850 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004467 Silverchair:475850 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004467 Silverchair:475850 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Optimizing the management of chronic pain in sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000143 Silverchair:474283 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Optimizing the management of chronic pain in sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000143 Silverchair:474283 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Optimizing the management of chronic pain in sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000143 Silverchair:474283 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Optimizing the management of chronic pain in sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000143 Silverchair:474283 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Optimizing treatment of HIV-associated lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-791400 Silverchair:374426 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Optimizing treatment of HIV-associated lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-791400 Silverchair:374426 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Optimizing treatment of HIV-associated lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-791400 Silverchair:374426 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Optimizing treatment of HIV-associated lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-791400 Silverchair:374426 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Oral Azacitidine (AZA) Activity in Patients with Acute Myelogenous Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.1546.1546 Silverchair:139835 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Oral Azacitidine (AZA) Activity in Patients with Acute Myelogenous Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.1546.1546 Silverchair:139835 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Oral Azacitidine (AZA) Activity in Patients with Acute Myelogenous Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.1546.1546 Silverchair:139835 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Oral Azacitidine (AZA) Activity in Patients with Acute Myelogenous Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.1546.1546 Silverchair:139835 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08)" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114438 Silverchair:263885 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08)" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114438 Silverchair:263885 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08)" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114438 Silverchair:263885 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08)" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114438 Silverchair:263885 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study The American Society of Hematology American Society of Hematology 10.1182/blood.2019004143 Silverchair:454379 Total_Item_Investigations 17 13 2 1 0 1 0 0 0 0 0 0 0 Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study The American Society of Hematology American Society of Hematology 10.1182/blood.2019004143 Silverchair:454379 Total_Item_Requests 17 13 2 1 0 1 0 0 0 0 0 0 0 Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study The American Society of Hematology American Society of Hematology 10.1182/blood.2019004143 Silverchair:454379 Unique_Item_Investigations 11 8 1 1 0 1 0 0 0 0 0 0 0 Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study The American Society of Hematology American Society of Hematology 10.1182/blood.2019004143 Silverchair:454379 Unique_Item_Requests 11 8 1 1 0 1 0 0 0 0 0 0 0 Oral Etoposide Is Equivalent to Intravenous Administration within the CHOEP-Regimen - Results of a Comparative Pharmacokinetic Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.4662.4662 Silverchair:126005 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Oral Etoposide Is Equivalent to Intravenous Administration within the CHOEP-Regimen - Results of a Comparative Pharmacokinetic Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.4662.4662 Silverchair:126005 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Oral Etoposide Is Equivalent to Intravenous Administration within the CHOEP-Regimen - Results of a Comparative Pharmacokinetic Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.4662.4662 Silverchair:126005 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Oral Etoposide Is Equivalent to Intravenous Administration within the CHOEP-Regimen - Results of a Comparative Pharmacokinetic Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.4662.4662 Silverchair:126005 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-642223 Silverchair:34441 Total_Item_Investigations 3 0 0 0 1 0 2 0 0 0 0 0 0 Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-642223 Silverchair:34441 Total_Item_Requests 3 0 0 0 1 0 2 0 0 0 0 0 0 Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-642223 Silverchair:34441 Unique_Item_Investigations 2 0 0 0 1 0 1 0 0 0 0 0 0 Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-642223 Silverchair:34441 Unique_Item_Requests 2 0 0 0 1 0 1 0 0 0 0 0 0 "Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008787 Silverchair:475589 Total_Item_Investigations 4 0 0 1 0 3 0 0 0 0 0 0 0 "Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008787 Silverchair:475589 Unique_Item_Investigations 2 0 0 1 0 1 0 0 0 0 0 0 0 "Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008787 Silverchair:475589 No_License 1 0 0 0 0 1 0 0 0 0 0 0 0 "Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients with Heavily Pretreated Immune Thrombocytopenia" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134932 Silverchair:470241 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 "Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients with Heavily Pretreated Immune Thrombocytopenia" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134932 Silverchair:470241 Total_Item_Requests 4 0 4 0 0 0 0 0 0 0 0 0 0 "Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients with Heavily Pretreated Immune Thrombocytopenia" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134932 Silverchair:470241 Unique_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 "Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients with Heavily Pretreated Immune Thrombocytopenia" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134932 Silverchair:470241 Unique_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142499 Silverchair:471065 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142499 Silverchair:471065 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142499 Silverchair:471065 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142499 Silverchair:471065 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2005-09-3786 Silverchair:132073 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2005-09-3786 Silverchair:132073 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2005-09-3786 Silverchair:132073 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2005-09-3786 Silverchair:132073 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-299917 Silverchair:20475 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 "Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-299917 Silverchair:20475 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 "Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-299917 Silverchair:20475 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-299917 Silverchair:20475 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Origins of the human B-cell lineage The American Society of Hematology American Society of Hematology 10.1182/blood.2019002573 Silverchair:374941 Total_Item_Investigations 9 0 3 0 0 0 0 2 3 0 0 0 1 Origins of the human B-cell lineage The American Society of Hematology American Society of Hematology 10.1182/blood.2019002573 Silverchair:374941 Total_Item_Requests 9 0 3 0 0 0 0 2 3 0 0 0 1 Origins of the human B-cell lineage The American Society of Hematology American Society of Hematology 10.1182/blood.2019002573 Silverchair:374941 Unique_Item_Investigations 8 0 3 0 0 0 0 1 3 0 0 0 1 Origins of the human B-cell lineage The American Society of Hematology American Society of Hematology 10.1182/blood.2019002573 Silverchair:374941 Unique_Item_Requests 8 0 3 0 0 0 0 1 3 0 0 0 1 Osteocytes regulate neutrophil development through IL-19: A potent cytokine for neutropenia treatment The American Society of Hematology American Society of Hematology 10.1182/blood.2020007731 Silverchair:475461 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Osteocytes regulate neutrophil development through IL-19: A potent cytokine for neutropenia treatment The American Society of Hematology American Society of Hematology 10.1182/blood.2020007731 Silverchair:475461 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Osteomacs interact with megakaryocytes and osteoblasts to regulate murine hematopoietic stem cell function American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017011304 Silverchair:16268 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Osteomacs interact with megakaryocytes and osteoblasts to regulate murine hematopoietic stem cell function American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017011304 Silverchair:16268 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Osteomacs interact with megakaryocytes and osteoblasts to regulate murine hematopoietic stem cell function American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017011304 Silverchair:16268 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Osteomacs interact with megakaryocytes and osteoblasts to regulate murine hematopoietic stem cell function American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017011304 Silverchair:16268 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Osteonecrosis in sickle cell disease: an update on risk factors, diagnosis, and management" The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000038 Silverchair:422583 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 "Osteonecrosis in sickle cell disease: an update on risk factors, diagnosis, and management" The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000038 Silverchair:422583 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Osteonecrosis in sickle cell disease: an update on risk factors, diagnosis, and management" The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000038 Silverchair:422583 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Osteonecrosis in sickle cell disease: an update on risk factors, diagnosis, and management" The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000038 Silverchair:422583 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Ott1 (Rbm15) regulates thrombopoietin response in hematopoietic stem cells through alternative splicing of c-Mpl The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-593392 Silverchair:34080 Total_Item_Investigations 6 4 0 2 0 0 0 0 0 0 0 0 0 Ott1 (Rbm15) regulates thrombopoietin response in hematopoietic stem cells through alternative splicing of c-Mpl The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-593392 Silverchair:34080 Total_Item_Requests 5 3 0 2 0 0 0 0 0 0 0 0 0 Ott1 (Rbm15) regulates thrombopoietin response in hematopoietic stem cells through alternative splicing of c-Mpl The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-593392 Silverchair:34080 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Ott1 (Rbm15) regulates thrombopoietin response in hematopoietic stem cells through alternative splicing of c-Mpl The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-593392 Silverchair:34080 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 OTT-MAL Activates the Notch Signaling Transcription Factor RBPJ and Cooperates with Mutant MPL to Induce Acute Megakaryoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.508.508 Silverchair:61737 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 OTT-MAL Activates the Notch Signaling Transcription Factor RBPJ and Cooperates with Mutant MPL to Induce Acute Megakaryoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.508.508 Silverchair:61737 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 OTT-MAL Activates the Notch Signaling Transcription Factor RBPJ and Cooperates with Mutant MPL to Induce Acute Megakaryoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.508.508 Silverchair:61737 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 OTT-MAL Activates the Notch Signaling Transcription Factor RBPJ and Cooperates with Mutant MPL to Induce Acute Megakaryoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.508.508 Silverchair:61737 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Outcome of Morbidly Obese Patients with Acute Venous Thromboembolism Managed with Direct Oral Anticoagulants The American Society of Hematology American Society of Hematology 10.1182/blood-2019-132202 Silverchair:424943 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Outcome of Morbidly Obese Patients with Acute Venous Thromboembolism Managed with Direct Oral Anticoagulants The American Society of Hematology American Society of Hematology 10.1182/blood-2019-132202 Silverchair:424943 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Outcome of Morbidly Obese Patients with Acute Venous Thromboembolism Managed with Direct Oral Anticoagulants The American Society of Hematology American Society of Hematology 10.1182/blood-2019-132202 Silverchair:424943 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Outcome of Morbidly Obese Patients with Acute Venous Thromboembolism Managed with Direct Oral Anticoagulants The American Society of Hematology American Society of Hematology 10.1182/blood-2019-132202 Silverchair:424943 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001528 Silverchair:469754 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001528 Silverchair:469754 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001528 Silverchair:469754 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001528 Silverchair:469754 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Outcome of Patients with Double-Expressor Lymphomas (DELs) Treated with R-CHOP or R-EPOCH The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5396.5396 Silverchair:100219 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Outcome of Patients with Double-Expressor Lymphomas (DELs) Treated with R-CHOP or R-EPOCH The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5396.5396 Silverchair:100219 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Outcome of Patients with Double-Expressor Lymphomas (DELs) Treated with R-CHOP or R-EPOCH The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5396.5396 Silverchair:100219 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Outcome of Patients with Double-Expressor Lymphomas (DELs) Treated with R-CHOP or R-EPOCH The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5396.5396 Silverchair:100219 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach The American Society of Hematology American Society of Hematology 10.1182/blood.2019004296 Silverchair:461229 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach The American Society of Hematology American Society of Hematology 10.1182/blood.2019004296 Silverchair:461229 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach The American Society of Hematology American Society of Hematology 10.1182/blood.2019004296 Silverchair:461229 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach The American Society of Hematology American Society of Hematology 10.1182/blood.2019004296 Silverchair:461229 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124164 Silverchair:425142 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 "Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124164 Silverchair:425142 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 "Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124164 Silverchair:425142 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 "Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124164 Silverchair:425142 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Outcome of Ruxolitinib and Sirolimus in Preventing aGVHD Post to HLA Matched Hemotopietic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119109 Silverchair:263273 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Outcome of Ruxolitinib and Sirolimus in Preventing aGVHD Post to HLA Matched Hemotopietic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119109 Silverchair:263273 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Outcome of Ruxolitinib and Sirolimus in Preventing aGVHD Post to HLA Matched Hemotopietic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119109 Silverchair:263273 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Outcome of Ruxolitinib and Sirolimus in Preventing aGVHD Post to HLA Matched Hemotopietic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119109 Silverchair:263273 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Outcome with Intensive Chemotherapy Compared to Hypomethylating Agent- Based Induction in Patients Aged 70 Years or Older with Newly Diagnosed Favorable Risk Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2021-151988 Silverchair:478561 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Outcome with Intensive Chemotherapy Compared to Hypomethylating Agent- Based Induction in Patients Aged 70 Years or Older with Newly Diagnosed Favorable Risk Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2021-151988 Silverchair:478561 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Outcome with Intensive Chemotherapy Compared to Hypomethylating Agent- Based Induction in Patients Aged 70 Years or Older with Newly Diagnosed Favorable Risk Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2021-151988 Silverchair:478561 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Outcome with Intensive Chemotherapy Compared to Hypomethylating Agent- Based Induction in Patients Aged 70 Years or Older with Newly Diagnosed Favorable Risk Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2021-151988 Silverchair:478561 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2003-12-4428 Silverchair:18854 Total_Item_Investigations 3 0 0 0 0 3 0 0 0 0 0 0 0 Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2003-12-4428 Silverchair:18854 Total_Item_Requests 3 0 0 0 0 3 0 0 0 0 0 0 0 Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2003-12-4428 Silverchair:18854 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2003-12-4428 Silverchair:18854 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-393975 Silverchair:30038 Total_Item_Investigations 7 0 0 1 1 3 0 0 0 2 0 0 0 Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-393975 Silverchair:30038 Total_Item_Requests 7 0 0 1 1 3 0 0 0 2 0 0 0 Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-393975 Silverchair:30038 Unique_Item_Investigations 4 0 0 1 1 1 0 0 0 1 0 0 0 Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-393975 Silverchair:30038 Unique_Item_Requests 4 0 0 1 1 1 0 0 0 1 0 0 0 Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127251 Silverchair:426160 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127251 Silverchair:426160 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127251 Silverchair:426160 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127251 Silverchair:426160 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project The American Society of Hematology American Society of Hematology 10.1182/blood.2020010387 Silverchair:475653 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project The American Society of Hematology American Society of Hematology 10.1182/blood.2020010387 Silverchair:475653 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Outcomes associated with apixaban vs warfarin in patients with renal dysfunction American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000972 Silverchair:457796 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Outcomes associated with apixaban vs warfarin in patients with renal dysfunction American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000972 Silverchair:457796 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Outcomes associated with apixaban vs warfarin in patients with renal dysfunction American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000972 Silverchair:457796 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Outcomes associated with apixaban vs warfarin in patients with renal dysfunction American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000972 Silverchair:457796 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Outcomes In Acute Myeloid Leukemia (AML) Patients Diagnosed with Myeloid Sarcoma with and without Bone Marrow Involvement The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2165.2165 Silverchair:111612 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Outcomes In Acute Myeloid Leukemia (AML) Patients Diagnosed with Myeloid Sarcoma with and without Bone Marrow Involvement The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2165.2165 Silverchair:111612 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Outcomes In Acute Myeloid Leukemia (AML) Patients Diagnosed with Myeloid Sarcoma with and without Bone Marrow Involvement The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2165.2165 Silverchair:111612 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Outcomes In Acute Myeloid Leukemia (AML) Patients Diagnosed with Myeloid Sarcoma with and without Bone Marrow Involvement The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2165.2165 Silverchair:111612 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002118 Silverchair:463994 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002118 Silverchair:463994 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002118 Silverchair:463994 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002118 Silverchair:463994 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Outcomes of COVID-19 in patients with CLL: a multicenter international experience The American Society of Hematology American Society of Hematology 10.1182/blood.2020006965 Silverchair:461426 Total_Item_Investigations 8 3 4 0 0 0 0 0 0 0 1 0 0 Outcomes of COVID-19 in patients with CLL: a multicenter international experience The American Society of Hematology American Society of Hematology 10.1182/blood.2020006965 Silverchair:461426 Total_Item_Requests 8 3 4 0 0 0 0 0 0 0 1 0 0 Outcomes of COVID-19 in patients with CLL: a multicenter international experience The American Society of Hematology American Society of Hematology 10.1182/blood.2020006965 Silverchair:461426 Unique_Item_Investigations 8 3 4 0 0 0 0 0 0 0 1 0 0 Outcomes of COVID-19 in patients with CLL: a multicenter international experience The American Society of Hematology American Society of Hematology 10.1182/blood.2020006965 Silverchair:461426 Unique_Item_Requests 8 3 4 0 0 0 0 0 0 0 1 0 0 Outcomes of COVID-19 Infection in Patients with Hematologic Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141063 Silverchair:473860 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Outcomes of COVID-19 Infection in Patients with Hematologic Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141063 Silverchair:473860 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Outcomes of COVID-19 Infection in Patients with Hematologic Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141063 Silverchair:473860 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Outcomes of COVID-19 Infection in Patients with Hematologic Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141063 Silverchair:473860 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Outcomes of HMA and Venetoclax in Relapsed AML Post-Allogenic Hematopoietic Stem Cell Transplant The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141715 Silverchair:473830 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Outcomes of HMA and Venetoclax in Relapsed AML Post-Allogenic Hematopoietic Stem Cell Transplant The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141715 Silverchair:473830 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Outcomes of HMA and Venetoclax in Relapsed AML Post-Allogenic Hematopoietic Stem Cell Transplant The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141715 Silverchair:473830 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Outcomes of HMA and Venetoclax in Relapsed AML Post-Allogenic Hematopoietic Stem Cell Transplant The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141715 Silverchair:473830 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Outcomes of Methotrexate-Associated T-Cell and NK/T-Cell Lymphoproliferative Disorders in Patients with a History of Rheumatological Disorders: A Retrospective Analysis of EBV-Association and Response to MTX Withdrawal The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-120070 Silverchair:265522 Total_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 Outcomes of Methotrexate-Associated T-Cell and NK/T-Cell Lymphoproliferative Disorders in Patients with a History of Rheumatological Disorders: A Retrospective Analysis of EBV-Association and Response to MTX Withdrawal The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-120070 Silverchair:265522 Total_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 Outcomes of Methotrexate-Associated T-Cell and NK/T-Cell Lymphoproliferative Disorders in Patients with a History of Rheumatological Disorders: A Retrospective Analysis of EBV-Association and Response to MTX Withdrawal The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-120070 Silverchair:265522 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Outcomes of Methotrexate-Associated T-Cell and NK/T-Cell Lymphoproliferative Disorders in Patients with a History of Rheumatological Disorders: A Retrospective Analysis of EBV-Association and Response to MTX Withdrawal The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-120070 Silverchair:265522 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Outcomes of Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) Vs. Classical Hodgkin Lymphoma (cHL) at Princess Margaret Cancer Centre The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3863.3863 Silverchair:93130 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Outcomes of Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) Vs. Classical Hodgkin Lymphoma (cHL) at Princess Margaret Cancer Centre The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3863.3863 Silverchair:93130 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Outcomes of Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) Vs. Classical Hodgkin Lymphoma (cHL) at Princess Margaret Cancer Centre The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3863.3863 Silverchair:93130 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Outcomes of Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) Vs. Classical Hodgkin Lymphoma (cHL) at Princess Margaret Cancer Centre The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3863.3863 Silverchair:93130 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001267 Silverchair:454263 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001267 Silverchair:454263 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001267 Silverchair:454263 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001267 Silverchair:454263 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003170 Silverchair:474410 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003170 Silverchair:474410 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003170 Silverchair:474410 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003170 Silverchair:474410 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients The American Society of Hematology American Society of Hematology 10.1182/blood.2020008824 Silverchair:469789 Total_Item_Investigations 4 3 1 0 0 0 0 0 0 0 0 0 0 Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients The American Society of Hematology American Society of Hematology 10.1182/blood.2020008824 Silverchair:469789 Total_Item_Requests 4 3 1 0 0 0 0 0 0 0 0 0 0 Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients The American Society of Hematology American Society of Hematology 10.1182/blood.2020008824 Silverchair:469789 Unique_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients The American Society of Hematology American Society of Hematology 10.1182/blood.2020008824 Silverchair:469789 Unique_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000875 Silverchair:431018 Total_Item_Investigations 4 0 0 1 0 0 0 3 0 0 0 0 0 Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000875 Silverchair:431018 Total_Item_Requests 4 0 0 1 0 0 0 3 0 0 0 0 0 Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000875 Silverchair:431018 Unique_Item_Investigations 2 0 0 1 0 0 0 1 0 0 0 0 0 Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000875 Silverchair:431018 Unique_Item_Requests 2 0 0 1 0 0 0 1 0 0 0 0 0 Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018026401 Silverchair:246576 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018026401 Silverchair:246576 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018026401 Silverchair:246576 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018026401 Silverchair:246576 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Outcomes Of Platelet Transfusion In Heparin Induced Thrombocytopenia Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.2311.2311 Silverchair:13656 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Outcomes Of Platelet Transfusion In Heparin Induced Thrombocytopenia Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.2311.2311 Silverchair:13656 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Outcomes Of Platelet Transfusion In Heparin Induced Thrombocytopenia Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.2311.2311 Silverchair:13656 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Outcomes Of Platelet Transfusion In Heparin Induced Thrombocytopenia Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.2311.2311 Silverchair:13656 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000458 Silverchair:375027 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000458 Silverchair:375027 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000458 Silverchair:375027 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000458 Silverchair:375027 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Outpatient Fractionated ICE Protocol in Relapsed/Refractory Lymphomas: Efficacy and Safety The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111538 Silverchair:265628 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Outpatient Fractionated ICE Protocol in Relapsed/Refractory Lymphomas: Efficacy and Safety The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111538 Silverchair:265628 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Outpatient Fractionated ICE Protocol in Relapsed/Refractory Lymphomas: Efficacy and Safety The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111538 Silverchair:265628 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Outpatient Fractionated ICE Protocol in Relapsed/Refractory Lymphomas: Efficacy and Safety The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111538 Silverchair:265628 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000707 Silverchair:452512 Total_Item_Investigations 9 0 7 0 0 0 0 0 0 0 2 0 0 Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000707 Silverchair:452512 Total_Item_Requests 8 0 6 0 0 0 0 0 0 0 2 0 0 Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000707 Silverchair:452512 Unique_Item_Investigations 2 0 1 0 0 0 0 0 0 0 1 0 0 Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000707 Silverchair:452512 Unique_Item_Requests 2 0 1 0 0 0 0 0 0 0 1 0 0 Outpatient transfusions for myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000103 Silverchair:474356 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Outpatient transfusions for myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000103 Silverchair:474356 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Outpatient transfusions for myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000103 Silverchair:474356 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Outpatient transfusions for myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000103 Silverchair:474356 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Ovarian Vein Thrombus: Is Treatment Necessary? The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1433.1433 Silverchair:91398 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Ovarian Vein Thrombus: Is Treatment Necessary? The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1433.1433 Silverchair:91398 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Ovarian Vein Thrombus: Is Treatment Necessary? The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1433.1433 Silverchair:91398 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Ovarian Vein Thrombus: Is Treatment Necessary? The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1433.1433 Silverchair:91398 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Overall Survival of HIV-Positive Patients with HLH The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116479 Silverchair:262178 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Overall Survival of HIV-Positive Patients with HLH The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116479 Silverchair:262178 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Overall Survival of HIV-Positive Patients with HLH The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116479 Silverchair:262178 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Overall Survival of HIV-Positive Patients with HLH The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116479 Silverchair:262178 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Overcoming resistance to targeted therapies in chronic lymphocytic leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003423 Silverchair:474886 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Overcoming resistance to targeted therapies in chronic lymphocytic leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003423 Silverchair:474886 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Overcoming resistance to targeted therapies in chronic lymphocytic leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003423 Silverchair:474886 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Overcoming resistance to targeted therapies in chronic lymphocytic leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003423 Silverchair:474886 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Overcoming T cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH The American Society of Hematology American Society of Hematology 10.1182/blood.2020005867 Silverchair:469695 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Overcoming T cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH The American Society of Hematology American Society of Hematology 10.1182/blood.2020005867 Silverchair:469695 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-350850 Silverchair:29205 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-350850 Silverchair:29205 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-350850 Silverchair:29205 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-350850 Silverchair:29205 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Overexpression of caveolin-1 in adult T-cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2009-08-240044 Silverchair:27053 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Overexpression of caveolin-1 in adult T-cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2009-08-240044 Silverchair:27053 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Overexpression of caveolin-1 in adult T-cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2009-08-240044 Silverchair:27053 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Overexpression of caveolin-1 in adult T-cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2009-08-240044 Silverchair:27053 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122358 Silverchair:427133 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122358 Silverchair:427133 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122358 Silverchair:427133 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122358 Silverchair:427133 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003475 Silverchair:475793 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003475 Silverchair:475793 Total_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003475 Silverchair:475793 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003475 Silverchair:475793 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 p38 MAPK activation controls the TLR3-mediated up-regulation of cytotoxicity and cytokine production in human NK cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-05-1860 Silverchair:18985 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 p38 MAPK activation controls the TLR3-mediated up-regulation of cytotoxicity and cytokine production in human NK cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-05-1860 Silverchair:18985 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 p38 MAPK activation controls the TLR3-mediated up-regulation of cytotoxicity and cytokine production in human NK cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-05-1860 Silverchair:18985 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 p38 MAPK activation controls the TLR3-mediated up-regulation of cytotoxicity and cytokine production in human NK cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-05-1860 Silverchair:18985 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 p53 activation during ribosome biogenesis regulates normal erythroid differentiation The American Society of Hematology American Society of Hematology 10.1182/blood.2019003439 Silverchair:463338 No_License 1 0 0 1 0 0 0 0 0 0 0 0 0 p53 activation during ribosome biogenesis regulates normal erythroid differentiation The American Society of Hematology American Society of Hematology 10.1182/blood.2019003439 Silverchair:463338 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 p53 activation during ribosome biogenesis regulates normal erythroid differentiation The American Society of Hematology American Society of Hematology 10.1182/blood.2019003439 Silverchair:463338 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis The American Society of Hematology American Society of Hematology 10.1182/blood.V87.10.4302.bloodjournal87104302 Silverchair:124466 Total_Item_Investigations 3 2 0 0 0 0 0 1 0 0 0 0 0 p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis The American Society of Hematology American Society of Hematology 10.1182/blood.V87.10.4302.bloodjournal87104302 Silverchair:124466 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis The American Society of Hematology American Society of Hematology 10.1182/blood.V87.10.4302.bloodjournal87104302 Silverchair:124466 Unique_Item_Investigations 2 1 0 0 0 0 0 1 0 0 0 0 0 p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis The American Society of Hematology American Society of Hematology 10.1182/blood.V87.10.4302.bloodjournal87104302 Silverchair:124466 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Pacritinib, a Dual FLT3/JAK2 Inhibitor, Reduces Irak-1 Signaling in Acute Myeloid Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.570.570 Silverchair:134400 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Pacritinib, a Dual FLT3/JAK2 Inhibitor, Reduces Irak-1 Signaling in Acute Myeloid Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.570.570 Silverchair:134400 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Pacritinib, a Dual FLT3/JAK2 Inhibitor, Reduces Irak-1 Signaling in Acute Myeloid Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.570.570 Silverchair:134400 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Pacritinib, a Dual FLT3/JAK2 Inhibitor, Reduces Irak-1 Signaling in Acute Myeloid Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.570.570 Silverchair:134400 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 PAD4-deficiency does not affect bacteremia in polymicrobial sepsis and ameliorates endotoxemic shock The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-587709 Silverchair:33729 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 PAD4-deficiency does not affect bacteremia in polymicrobial sepsis and ameliorates endotoxemic shock The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-587709 Silverchair:33729 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 PAD4-deficiency does not affect bacteremia in polymicrobial sepsis and ameliorates endotoxemic shock The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-587709 Silverchair:33729 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 PAD4-deficiency does not affect bacteremia in polymicrobial sepsis and ameliorates endotoxemic shock The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-587709 Silverchair:33729 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Pairing megakaryopoiesis methylation with PEAR1 The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-723940 Silverchair:35860 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Pairing megakaryopoiesis methylation with PEAR1 The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-723940 Silverchair:35860 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Pairing megakaryopoiesis methylation with PEAR1 The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-723940 Silverchair:35860 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Pairing megakaryopoiesis methylation with PEAR1 The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-723940 Silverchair:35860 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Palmitoylethanolamide-Mediated Inhibition of Nogo-a Signaling Attenuates Pain in Sickle Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138617 Silverchair:470255 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Palmitoylethanolamide-Mediated Inhibition of Nogo-a Signaling Attenuates Pain in Sickle Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138617 Silverchair:470255 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Palmitoylethanolamide-Mediated Inhibition of Nogo-a Signaling Attenuates Pain in Sickle Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138617 Silverchair:470255 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Palmitoylethanolamide-Mediated Inhibition of Nogo-a Signaling Attenuates Pain in Sickle Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138617 Silverchair:470255 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002074 Silverchair:463761 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002074 Silverchair:463761 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002074 Silverchair:463761 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002074 Silverchair:463761 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Paraneoplastic thrombocytosis: the secrets of tumor self-promotion The American Society of Hematology American Society of Hematology 10.1182/blood-2014-03-562538 Silverchair:32906 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Paraneoplastic thrombocytosis: the secrets of tumor self-promotion The American Society of Hematology American Society of Hematology 10.1182/blood-2014-03-562538 Silverchair:32906 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Paraneoplastic thrombocytosis: the secrets of tumor self-promotion The American Society of Hematology American Society of Hematology 10.1182/blood-2014-03-562538 Silverchair:32906 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Paraneoplastic thrombocytosis: the secrets of tumor self-promotion The American Society of Hematology American Society of Hematology 10.1182/blood-2014-03-562538 Silverchair:32906 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Paraoxonase 2 Enables Initiation of B-ALL By Subverting Metabolic Gatekeeper Functions The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125171 Silverchair:427045 Total_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 Paraoxonase 2 Enables Initiation of B-ALL By Subverting Metabolic Gatekeeper Functions The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125171 Silverchair:427045 Total_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 Paraoxonase 2 Enables Initiation of B-ALL By Subverting Metabolic Gatekeeper Functions The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125171 Silverchair:427045 Unique_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 Paraoxonase 2 Enables Initiation of B-ALL By Subverting Metabolic Gatekeeper Functions The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125171 Silverchair:427045 Unique_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130814 Silverchair:425718 Total_Item_Investigations 3 1 0 1 1 0 0 0 0 0 0 0 0 PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130814 Silverchair:425718 Total_Item_Requests 3 1 0 1 1 0 0 0 0 0 0 0 0 PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130814 Silverchair:425718 Unique_Item_Investigations 3 1 0 1 1 0 0 0 0 0 0 0 0 PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130814 Silverchair:425718 Unique_Item_Requests 3 1 0 1 1 0 0 0 0 0 0 0 0 "Parsaclisib, a potent and highly selective PI3Kd inhibitor, in patients with relapsed or refractory B-cell malignancies" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-867499 Silverchair:260507 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 "Parsaclisib, a potent and highly selective PI3Kd inhibitor, in patients with relapsed or refractory B-cell malignancies" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-867499 Silverchair:260507 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 "Parsaclisib, a potent and highly selective PI3Kd inhibitor, in patients with relapsed or refractory B-cell malignancies" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-867499 Silverchair:260507 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 "Parsaclisib, a potent and highly selective PI3Kd inhibitor, in patients with relapsed or refractory B-cell malignancies" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-867499 Silverchair:260507 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Partial F8 gene duplication (factor VIII Padua) associated with high factor VIII levels and familial thrombophilia The American Society of Hematology American Society of Hematology 10.1182/blood.2020008168 Silverchair:474419 No_License 1 0 0 0 0 0 1 0 0 0 0 0 0 Partial F8 gene duplication (factor VIII Padua) associated with high factor VIII levels and familial thrombophilia The American Society of Hematology American Society of Hematology 10.1182/blood.2020008168 Silverchair:474419 Total_Item_Investigations 4 0 0 0 0 0 2 0 0 0 0 2 0 Partial F8 gene duplication (factor VIII Padua) associated with high factor VIII levels and familial thrombophilia The American Society of Hematology American Society of Hematology 10.1182/blood.2020008168 Silverchair:474419 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 Partial F8 gene duplication (factor VIII Padua) associated with high factor VIII levels and familial thrombophilia The American Society of Hematology American Society of Hematology 10.1182/blood.2020008168 Silverchair:474419 Unique_Item_Investigations 2 0 0 0 0 0 1 0 0 0 0 1 0 Partial F8 gene duplication (factor VIII Padua) associated with high factor VIII levels and familial thrombophilia The American Society of Hematology American Society of Hematology 10.1182/blood.2020008168 Silverchair:474419 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-639203 Silverchair:34590 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-639203 Silverchair:34590 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-639203 Silverchair:34590 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-639203 Silverchair:34590 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 PATCH trial: explanatory analyses The American Society of Hematology American Society of Hematology 10.1182/blood.2019003298 Silverchair:452569 No_License 1 0 1 0 0 0 0 0 0 0 0 0 0 PATCH trial: explanatory analyses The American Society of Hematology American Society of Hematology 10.1182/blood.2019003298 Silverchair:452569 Total_Item_Investigations 4 2 2 0 0 0 0 0 0 0 0 0 0 PATCH trial: explanatory analyses The American Society of Hematology American Society of Hematology 10.1182/blood.2019003298 Silverchair:452569 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 PATCH trial: explanatory analyses The American Society of Hematology American Society of Hematology 10.1182/blood.2019003298 Silverchair:452569 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 PATCH trial: explanatory analyses The American Society of Hematology American Society of Hematology 10.1182/blood.2019003298 Silverchair:452569 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Path to Diagnosis of Paroxysmal Nocturnal Hemoglobinuria: The Results of an Exploratory Study Conducted By the Aplastic Anemia and Myelodysplastic Syndrome International Foundation and the National Organization for Rare Disorders Utilizing an Internet-Based Survey The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3264.3264 Silverchair:91196 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Path to Diagnosis of Paroxysmal Nocturnal Hemoglobinuria: The Results of an Exploratory Study Conducted By the Aplastic Anemia and Myelodysplastic Syndrome International Foundation and the National Organization for Rare Disorders Utilizing an Internet-Based Survey The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3264.3264 Silverchair:91196 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Path to Diagnosis of Paroxysmal Nocturnal Hemoglobinuria: The Results of an Exploratory Study Conducted By the Aplastic Anemia and Myelodysplastic Syndrome International Foundation and the National Organization for Rare Disorders Utilizing an Internet-Based Survey The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3264.3264 Silverchair:91196 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Path to Diagnosis of Paroxysmal Nocturnal Hemoglobinuria: The Results of an Exploratory Study Conducted By the Aplastic Anemia and Myelodysplastic Syndrome International Foundation and the National Organization for Rare Disorders Utilizing an Internet-Based Survey The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3264.3264 Silverchair:91196 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Pathophysiologic Mechanisms in Acquired Aplastic Anemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.72 Silverchair:19811 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Pathophysiologic Mechanisms in Acquired Aplastic Anemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.72 Silverchair:19811 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Pathophysiologic Mechanisms in Acquired Aplastic Anemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.72 Silverchair:19811 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Pathophysiologic Mechanisms in Acquired Aplastic Anemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.72 Silverchair:19811 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-121715 Silverchair:427005 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-121715 Silverchair:427005 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-121715 Silverchair:427005 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-121715 Silverchair:427005 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Patient Preferences for Maintenance Treatment of Acute Myeloid Leukemia: Results of a Discrete Choice Experiment The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136335 Silverchair:473134 Total_Item_Investigations 3 0 1 1 0 1 0 0 0 0 0 0 0 Patient Preferences for Maintenance Treatment of Acute Myeloid Leukemia: Results of a Discrete Choice Experiment The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136335 Silverchair:473134 Total_Item_Requests 3 0 1 1 0 1 0 0 0 0 0 0 0 Patient Preferences for Maintenance Treatment of Acute Myeloid Leukemia: Results of a Discrete Choice Experiment The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136335 Silverchair:473134 Unique_Item_Investigations 3 0 1 1 0 1 0 0 0 0 0 0 0 Patient Preferences for Maintenance Treatment of Acute Myeloid Leukemia: Results of a Discrete Choice Experiment The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136335 Silverchair:473134 Unique_Item_Requests 3 0 1 1 0 1 0 0 0 0 0 0 0 Patient-Reported and Neurocognitive Outcomes in Patients Treated with Axicabtagene Ciloleucel The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111711 Silverchair:261910 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Patient-Reported and Neurocognitive Outcomes in Patients Treated with Axicabtagene Ciloleucel The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111711 Silverchair:261910 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Patient-Reported and Neurocognitive Outcomes in Patients Treated with Axicabtagene Ciloleucel The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111711 Silverchair:261910 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Patient-Reported and Neurocognitive Outcomes in Patients Treated with Axicabtagene Ciloleucel The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111711 Silverchair:261910 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor (CAR)-T Cell Therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122755 Silverchair:424885 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor (CAR)-T Cell Therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122755 Silverchair:424885 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor (CAR)-T Cell Therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122755 Silverchair:424885 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor (CAR)-T Cell Therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122755 Silverchair:424885 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-540021 Silverchair:32308 Total_Item_Investigations 4 0 1 0 0 3 0 0 0 0 0 0 0 Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-540021 Silverchair:32308 Total_Item_Requests 4 0 1 0 0 3 0 0 0 0 0 0 0 Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-540021 Silverchair:32308 Unique_Item_Investigations 2 0 1 0 0 1 0 0 0 0 0 0 0 Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-540021 Silverchair:32308 Unique_Item_Requests 2 0 1 0 0 1 0 0 0 0 0 0 0 "Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412" The American Society of Hematology American Society of Hematology 10.1182/blood-2004-03-0891 Silverchair:19995 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412" The American Society of Hematology American Society of Hematology 10.1182/blood-2004-03-0891 Silverchair:19995 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412" The American Society of Hematology American Society of Hematology 10.1182/blood-2004-03-0891 Silverchair:19995 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412" The American Society of Hematology American Society of Hematology 10.1182/blood-2004-03-0891 Silverchair:19995 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001518 Silverchair:454776 Total_Item_Investigations 2 0 1 0 1 0 0 0 0 0 0 0 0 Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001518 Silverchair:454776 Total_Item_Requests 2 0 1 0 1 0 0 0 0 0 0 0 0 Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001518 Silverchair:454776 Unique_Item_Investigations 2 0 1 0 1 0 0 0 0 0 0 0 0 Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001518 Silverchair:454776 Unique_Item_Requests 2 0 1 0 1 0 0 0 0 0 0 0 0 Patients with Mild Hemophilia a with Discrepant FVIII Assays: Thrombin Generation and Bleeding Phenotype The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2844.2844 Silverchair:96610 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Patients with Mild Hemophilia a with Discrepant FVIII Assays: Thrombin Generation and Bleeding Phenotype The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2844.2844 Silverchair:96610 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Patients with Mild Hemophilia a with Discrepant FVIII Assays: Thrombin Generation and Bleeding Phenotype The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2844.2844 Silverchair:96610 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Patients with Mild Hemophilia a with Discrepant FVIII Assays: Thrombin Generation and Bleeding Phenotype The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2844.2844 Silverchair:96610 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001728 Silverchair:454414 Total_Item_Investigations 6 0 0 0 0 2 2 0 0 0 0 2 0 Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001728 Silverchair:454414 Total_Item_Requests 5 0 0 0 0 1 2 0 0 0 0 2 0 Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001728 Silverchair:454414 Unique_Item_Investigations 4 0 0 0 0 1 2 0 0 0 0 1 0 Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001728 Silverchair:454414 Unique_Item_Requests 4 0 0 0 0 1 2 0 0 0 0 1 0 Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-480970 Silverchair:32268 Total_Item_Investigations 3 0 0 0 3 0 0 0 0 0 0 0 0 Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-480970 Silverchair:32268 Total_Item_Requests 3 0 0 0 3 0 0 0 0 0 0 0 0 Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-480970 Silverchair:32268 Unique_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-480970 Silverchair:32268 Unique_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-756841 Silverchair:35948 Total_Item_Investigations 2 0 0 1 1 0 0 0 0 0 0 0 0 PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-756841 Silverchair:35948 Total_Item_Requests 2 0 0 1 1 0 0 0 0 0 0 0 0 PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-756841 Silverchair:35948 Unique_Item_Investigations 2 0 0 1 1 0 0 0 0 0 0 0 0 PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-756841 Silverchair:35948 Unique_Item_Requests 2 0 0 1 1 0 0 0 0 0 0 0 0 PD-1 inhibition in advanced myeloproliferative neoplasms American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005491 Silverchair:477046 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 PD-1 inhibition in advanced myeloproliferative neoplasms American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005491 Silverchair:477046 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 PD-1H (VISTA) Induces Immune Evasion in Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2658.2658 Silverchair:80203 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 PD-1H (VISTA) Induces Immune Evasion in Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2658.2658 Silverchair:80203 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 PD-1H (VISTA) Induces Immune Evasion in Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2658.2658 Silverchair:80203 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 PD-1H (VISTA) Induces Immune Evasion in Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2658.2658 Silverchair:80203 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-622936 Silverchair:34474 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-622936 Silverchair:34474 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-622936 Silverchair:34474 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-622936 Silverchair:34474 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 PECAM-1: a multifaceted regulator of megakaryocytopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2006-05-022087 Silverchair:132001 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 PECAM-1: a multifaceted regulator of megakaryocytopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2006-05-022087 Silverchair:132001 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 PECAM-1: a multifaceted regulator of megakaryocytopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2006-05-022087 Silverchair:132001 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 PECAM-1: a multifaceted regulator of megakaryocytopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2006-05-022087 Silverchair:132001 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Pediatric chronic myeloid leukemia is a unique disease that requires a different approach The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-648667 Silverchair:35042 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Pediatric chronic myeloid leukemia is a unique disease that requires a different approach The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-648667 Silverchair:35042 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Pediatric chronic myeloid leukemia is a unique disease that requires a different approach The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-648667 Silverchair:35042 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Pediatric chronic myeloid leukemia is a unique disease that requires a different approach The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-648667 Silverchair:35042 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Pegfilgrastim Use and Risk of Bleomycin Induced Pulmonary Toxicity in Hodgkin Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5350.5350 Silverchair:100226 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Pegfilgrastim Use and Risk of Bleomycin Induced Pulmonary Toxicity in Hodgkin Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5350.5350 Silverchair:100226 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Pegfilgrastim Use and Risk of Bleomycin Induced Pulmonary Toxicity in Hodgkin Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5350.5350 Silverchair:100226 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Pegfilgrastim Use and Risk of Bleomycin Induced Pulmonary Toxicity in Hodgkin Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5350.5350 Silverchair:100226 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea The American Society of Hematology American Society of Hematology 10.1182/blood.2019000428 Silverchair:374977 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea The American Society of Hematology American Society of Hematology 10.1182/blood.2019000428 Silverchair:374977 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea The American Society of Hematology American Society of Hematology 10.1182/blood.2019000428 Silverchair:374977 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea The American Society of Hematology American Society of Hematology 10.1182/blood.2019000428 Silverchair:374977 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Pelger-Huet anomaly and pseudo (acquired) Pelger-Huet The American Society of Hematology American Society of Hematology 10.1182/blood.V107.9.3428.3428 Silverchair:133465 Total_Item_Investigations 3 0 0 2 0 0 0 1 0 0 0 0 0 Pelger-Huet anomaly and pseudo (acquired) Pelger-Huet The American Society of Hematology American Society of Hematology 10.1182/blood.V107.9.3428.3428 Silverchair:133465 Total_Item_Requests 3 0 0 2 0 0 0 1 0 0 0 0 0 Pelger-Huet anomaly and pseudo (acquired) Pelger-Huet The American Society of Hematology American Society of Hematology 10.1182/blood.V107.9.3428.3428 Silverchair:133465 Unique_Item_Investigations 3 0 0 2 0 0 0 1 0 0 0 0 0 Pelger-Huet anomaly and pseudo (acquired) Pelger-Huet The American Society of Hematology American Society of Hematology 10.1182/blood.V107.9.3428.3428 Silverchair:133465 Unique_Item_Requests 3 0 0 2 0 0 0 1 0 0 0 0 0 Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020007400 Silverchair:463993 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020007400 Silverchair:463993 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020007400 Silverchair:463993 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020007400 Silverchair:463993 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Pembrolizumab in mycosis fungoides with PD-L1 structural variants American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002371 Silverchair:475083 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Pembrolizumab in mycosis fungoides with PD-L1 structural variants American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002371 Silverchair:475083 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Pembrolizumab in mycosis fungoides with PD-L1 structural variants American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002371 Silverchair:475083 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Pembrolizumab in mycosis fungoides with PD-L1 structural variants American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002371 Silverchair:475083 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC" The American Society of Hematology American Society of Hematology 10.1182/blood-2004-10-4117 Silverchair:21568 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC" The American Society of Hematology American Society of Hematology 10.1182/blood-2004-10-4117 Silverchair:21568 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC" The American Society of Hematology American Society of Hematology 10.1182/blood-2004-10-4117 Silverchair:21568 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC" The American Society of Hematology American Society of Hematology 10.1182/blood-2004-10-4117 Silverchair:21568 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Performance of Khorana Score to Predict One-Year Risk of Venous Thromboembolism in over Two Million Patients with Cancer The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139706 Silverchair:470175 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Performance of Khorana Score to Predict One-Year Risk of Venous Thromboembolism in over Two Million Patients with Cancer The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139706 Silverchair:470175 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Performance of Khorana Score to Predict One-Year Risk of Venous Thromboembolism in over Two Million Patients with Cancer The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139706 Silverchair:470175 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Performance of Khorana Score to Predict One-Year Risk of Venous Thromboembolism in over Two Million Patients with Cancer The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139706 Silverchair:470175 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Pericyte recruitment during vasculogenic tube assembly stimulates endothelial basement membrane matrix formation The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-222364 Silverchair:26627 Total_Item_Investigations 3 1 2 0 0 0 0 0 0 0 0 0 0 Pericyte recruitment during vasculogenic tube assembly stimulates endothelial basement membrane matrix formation The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-222364 Silverchair:26627 Total_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 Pericyte recruitment during vasculogenic tube assembly stimulates endothelial basement membrane matrix formation The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-222364 Silverchair:26627 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Pericyte recruitment during vasculogenic tube assembly stimulates endothelial basement membrane matrix formation The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-222364 Silverchair:26627 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Pericytes promote selective vessel regression to regulate vascular patterning The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-332338 Silverchair:30766 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Pericytes promote selective vessel regression to regulate vascular patterning The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-332338 Silverchair:30766 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Pericytes promote selective vessel regression to regulate vascular patterning The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-332338 Silverchair:30766 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Pericytes promote selective vessel regression to regulate vascular patterning The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-332338 Silverchair:30766 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Perioperative Bridging of Anticoagulation - Does Protocol Adherence Improve Outcomes? The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125325 Silverchair:426924 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Perioperative Bridging of Anticoagulation - Does Protocol Adherence Improve Outcomes? The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125325 Silverchair:426924 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Perioperative Bridging of Anticoagulation - Does Protocol Adherence Improve Outcomes? The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125325 Silverchair:426924 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Perioperative Bridging of Anticoagulation - Does Protocol Adherence Improve Outcomes? The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125325 Silverchair:426924 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Perioperative management of patients with von Willebrand disease The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000065 Silverchair:422564 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Perioperative management of patients with von Willebrand disease The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000065 Silverchair:422564 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Perioperative management of patients with von Willebrand disease The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000065 Silverchair:422564 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Perioperative management of patients with von Willebrand disease The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000065 Silverchair:422564 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Peripheral T-cell lymphoma, NOS, with rapidly progressing leukocytosis mimicking acute lymphoblastic leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood.2020005020 Silverchair:454951 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Peripheral T-cell lymphoma, NOS, with rapidly progressing leukocytosis mimicking acute lymphoblastic leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood.2020005020 Silverchair:454951 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Peripheral T-cell lymphoma, NOS, with rapidly progressing leukocytosis mimicking acute lymphoblastic leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood.2020005020 Silverchair:454951 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Peripheral T-cell lymphoma, NOS, with rapidly progressing leukocytosis mimicking acute lymphoblastic leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood.2020005020 Silverchair:454951 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Peripheral T-cell lymphoma, not otherwise specified" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-692566 Silverchair:36579 Total_Item_Investigations 2 0 1 0 0 0 0 0 0 0 0 1 0 "Peripheral T-cell lymphoma, not otherwise specified" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-692566 Silverchair:36579 Total_Item_Requests 2 0 1 0 0 0 0 0 0 0 0 1 0 "Peripheral T-cell lymphoma, not otherwise specified" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-692566 Silverchair:36579 Unique_Item_Investigations 2 0 1 0 0 0 0 0 0 0 0 1 0 "Peripheral T-cell lymphoma, not otherwise specified" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-692566 Silverchair:36579 Unique_Item_Requests 2 0 1 0 0 0 0 0 0 0 0 1 0 Peripheral T-cell lymphoma: novel backbone The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-817734 Silverchair:38532 Total_Item_Investigations 2 0 0 0 0 0 0 0 2 0 0 0 0 Peripheral T-cell lymphoma: novel backbone The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-817734 Silverchair:38532 Total_Item_Requests 2 0 0 0 0 0 0 0 2 0 0 0 0 Peripheral T-cell lymphoma: novel backbone The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-817734 Silverchair:38532 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Peripheral T-cell lymphoma: novel backbone The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-817734 Silverchair:38532 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Pernicious anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020005344 Silverchair:454724 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Pernicious anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020005344 Silverchair:454724 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Pernicious anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020005344 Silverchair:454724 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Pernicious anemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020005344 Silverchair:454724 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019003347 Silverchair:452581 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019003347 Silverchair:452581 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019003347 Silverchair:452581 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019003347 Silverchair:452581 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Persistent Thrombopoietin Mimetic Induced Myelofibrosis in a Woman with Chronic Refractory Immune Thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4659.4659 Silverchair:93370 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Persistent Thrombopoietin Mimetic Induced Myelofibrosis in a Woman with Chronic Refractory Immune Thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4659.4659 Silverchair:93370 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Persistent Thrombopoietin Mimetic Induced Myelofibrosis in a Woman with Chronic Refractory Immune Thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4659.4659 Silverchair:93370 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Persistent Thrombopoietin Mimetic Induced Myelofibrosis in a Woman with Chronic Refractory Immune Thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4659.4659 Silverchair:93370 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-501072 Silverchair:32442 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-501072 Silverchair:32442 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-501072 Silverchair:32442 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-501072 Silverchair:32442 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 PET response–guided radiotherapy for advanced DLBCL? The American Society of Hematology American Society of Hematology 10.1182/blood.2020008740 Silverchair:475213 Total_Item_Investigations 2 0 0 0 0 0 0 2 0 0 0 0 0 PET response–guided radiotherapy for advanced DLBCL? The American Society of Hematology American Society of Hematology 10.1182/blood.2020008740 Silverchair:475213 Total_Item_Requests 2 0 0 0 0 0 0 2 0 0 0 0 0 PET response–guided radiotherapy for advanced DLBCL? The American Society of Hematology American Society of Hematology 10.1182/blood.2020008740 Silverchair:475213 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 PET response–guided radiotherapy for advanced DLBCL? The American Society of Hematology American Society of Hematology 10.1182/blood.2020008740 Silverchair:475213 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Pharmacodynamic Analysis Of The Inhibitory Potency Of The Tyrosine Kinase Inhibitor Midostaurin In Combination With Intensive Chemotherapy Including Allogeneic Hematopoietic Stem Cell Transplantation Followed By Maintenance Therapy In FLT3-ITD Positive Acute Myeloid Leukemia In The Ongoing AMLSG 16-10 Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.1283.1283 Silverchair:103492 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Pharmacodynamic Analysis Of The Inhibitory Potency Of The Tyrosine Kinase Inhibitor Midostaurin In Combination With Intensive Chemotherapy Including Allogeneic Hematopoietic Stem Cell Transplantation Followed By Maintenance Therapy In FLT3-ITD Positive Acute Myeloid Leukemia In The Ongoing AMLSG 16-10 Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.1283.1283 Silverchair:103492 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Pharmacodynamic Analysis Of The Inhibitory Potency Of The Tyrosine Kinase Inhibitor Midostaurin In Combination With Intensive Chemotherapy Including Allogeneic Hematopoietic Stem Cell Transplantation Followed By Maintenance Therapy In FLT3-ITD Positive Acute Myeloid Leukemia In The Ongoing AMLSG 16-10 Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.1283.1283 Silverchair:103492 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Pharmacodynamic Analysis Of The Inhibitory Potency Of The Tyrosine Kinase Inhibitor Midostaurin In Combination With Intensive Chemotherapy Including Allogeneic Hematopoietic Stem Cell Transplantation Followed By Maintenance Therapy In FLT3-ITD Positive Acute Myeloid Leukemia In The Ongoing AMLSG 16-10 Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.1283.1283 Silverchair:103492 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Pharmacologic Activation of Aldehyde Metabolism to Protect Hematopoietic Stem Cells (HSC) in Murine Models of Fanconi Anemia (FA) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124439 Silverchair:426037 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Pharmacologic Activation of Aldehyde Metabolism to Protect Hematopoietic Stem Cells (HSC) in Murine Models of Fanconi Anemia (FA) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124439 Silverchair:426037 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Pharmacologic Activation of Aldehyde Metabolism to Protect Hematopoietic Stem Cells (HSC) in Murine Models of Fanconi Anemia (FA) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124439 Silverchair:426037 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Pharmacologic Activation of Aldehyde Metabolism to Protect Hematopoietic Stem Cells (HSC) in Murine Models of Fanconi Anemia (FA) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124439 Silverchair:426037 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Pharmacological Inhibition of the RNA m6a Writer METTL3 As a Novel Therapeutic Strategy for Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127962 Silverchair:426325 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Pharmacological Inhibition of the RNA m6a Writer METTL3 As a Novel Therapeutic Strategy for Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127962 Silverchair:426325 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Pharmacological Inhibition of the RNA m6a Writer METTL3 As a Novel Therapeutic Strategy for Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127962 Silverchair:426325 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Pharmacological Inhibition of the RNA m6a Writer METTL3 As a Novel Therapeutic Strategy for Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127962 Silverchair:426325 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL) The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3991.3991 Silverchair:93149 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL) The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3991.3991 Silverchair:93149 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL) The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3991.3991 Silverchair:93149 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL) The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3991.3991 Silverchair:93149 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117085 Silverchair:266322 Total_Item_Investigations 7 0 7 0 0 0 0 0 0 0 0 0 0 "Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117085 Silverchair:266322 Total_Item_Requests 7 0 7 0 0 0 0 0 0 0 0 0 0 "Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117085 Silverchair:266322 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117085 Silverchair:266322 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129042 Silverchair:427055 Total_Item_Investigations 10 0 8 0 0 0 0 0 0 0 2 0 0 "Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129042 Silverchair:427055 Total_Item_Requests 10 0 8 0 0 0 0 0 0 0 2 0 0 "Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129042 Silverchair:427055 Unique_Item_Investigations 3 0 2 0 0 0 0 0 0 0 1 0 0 "Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129042 Silverchair:427055 Unique_Item_Requests 3 0 2 0 0 0 0 0 0 0 1 0 0 "Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111529 Silverchair:272888 Total_Item_Investigations 6 0 6 0 0 0 0 0 0 0 0 0 0 "Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111529 Silverchair:272888 Total_Item_Requests 6 0 6 0 0 0 0 0 0 0 0 0 0 "Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111529 Silverchair:272888 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111529 Silverchair:272888 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-772210 Silverchair:36282 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-772210 Silverchair:36282 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-772210 Silverchair:36282 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-772210 Silverchair:36282 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118198 Silverchair:266207 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118198 Silverchair:266207 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118198 Silverchair:266207 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118198 Silverchair:266207 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood.2019004352 Silverchair:454390 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood.2019004352 Silverchair:454390 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood.2019004352 Silverchair:454390 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood.2019004352 Silverchair:454390 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1 The American Society of Hematology American Society of Hematology 10.1182/blood-2015-12-686378 Silverchair:35152 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1 The American Society of Hematology American Society of Hematology 10.1182/blood-2015-12-686378 Silverchair:35152 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1 The American Society of Hematology American Society of Hematology 10.1182/blood-2015-12-686378 Silverchair:35152 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1 The American Society of Hematology American Society of Hematology 10.1182/blood-2015-12-686378 Silverchair:35152 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136375 Silverchair:469902 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136375 Silverchair:469902 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136375 Silverchair:469902 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136375 Silverchair:469902 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Phase 1/2 Study of Tandutinib (MLN518) Plus Standard Induction Chemotherapy in Newly Diagnosed Acute Myelogenous Leukemia (AML). The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.158.158 Silverchair:127159 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Phase 1/2 Study of Tandutinib (MLN518) Plus Standard Induction Chemotherapy in Newly Diagnosed Acute Myelogenous Leukemia (AML). The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.158.158 Silverchair:127159 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Phase 1/2 Study of Tandutinib (MLN518) Plus Standard Induction Chemotherapy in Newly Diagnosed Acute Myelogenous Leukemia (AML). The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.158.158 Silverchair:127159 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Phase 1/2 Study of Tandutinib (MLN518) Plus Standard Induction Chemotherapy in Newly Diagnosed Acute Myelogenous Leukemia (AML). The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.158.158 Silverchair:127159 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130310 Silverchair:425734 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130310 Silverchair:425734 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130310 Silverchair:425734 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130310 Silverchair:425734 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 "Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125990 Silverchair:423673 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125990 Silverchair:423673 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125990 Silverchair:423673 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125990 Silverchair:423673 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128096 Silverchair:426294 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128096 Silverchair:426294 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128096 Silverchair:426294 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128096 Silverchair:426294 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131055 Silverchair:426579 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131055 Silverchair:426579 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131055 Silverchair:426579 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131055 Silverchair:426579 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134451 Silverchair:470002 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134451 Silverchair:470002 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134451 Silverchair:470002 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134451 Silverchair:470002 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-480228 Silverchair:31475 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-480228 Silverchair:31475 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-480228 Silverchair:31475 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation The American Society of Hematology American Society of Hematology 10.1182/blood-2013-01-480228 Silverchair:31475 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-351502 Silverchair:28709 Total_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-351502 Silverchair:28709 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-351502 Silverchair:28709 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-351502 Silverchair:28709 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 "Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-01-068833 Silverchair:107968 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 "Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-01-068833 Silverchair:107968 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 "Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-01-068833 Silverchair:107968 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-01-068833 Silverchair:107968 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002403 Silverchair:461425 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002403 Silverchair:461425 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002403 Silverchair:461425 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002403 Silverchair:461425 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130691 Silverchair:427674 Total_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130691 Silverchair:427674 Total_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130691 Silverchair:427674 Unique_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130691 Silverchair:427674 Unique_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002119 Silverchair:469734 Total_Item_Investigations 3 0 0 0 0 3 0 0 0 0 0 0 0 Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002119 Silverchair:469734 Total_Item_Requests 3 0 0 0 0 3 0 0 0 0 0 0 0 Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002119 Silverchair:469734 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002119 Silverchair:469734 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-651380 Silverchair:34993 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-651380 Silverchair:34993 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-651380 Silverchair:34993 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-651380 Silverchair:34993 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004146 Silverchair:476753 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004146 Silverchair:476753 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004146 Silverchair:476753 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004146 Silverchair:476753 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493)" The American Society of Hematology American Society of Hematology 10.1182/blood.V100.5.1634.h81702001634_1634_1640 Silverchair:106342 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493)" The American Society of Hematology American Society of Hematology 10.1182/blood.V100.5.1634.h81702001634_1634_1640 Silverchair:106342 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493)" The American Society of Hematology American Society of Hematology 10.1182/blood.V100.5.1634.h81702001634_1634_1640 Silverchair:106342 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493)" The American Society of Hematology American Society of Hematology 10.1182/blood.V100.5.1634.h81702001634_1634_1640 Silverchair:106342 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2021-148352 Silverchair:479948 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2021-148352 Silverchair:479948 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2021-148352 Silverchair:479948 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2021-148352 Silverchair:479948 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy or in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2021-148313 Silverchair:478555 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy or in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2021-148313 Silverchair:478555 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy or in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2021-148313 Silverchair:478555 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy or in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2021-148313 Silverchair:478555 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow The American Society of Hematology American Society of Hematology 10.1182/blood.V96.6.2062 Silverchair:181047 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow The American Society of Hematology American Society of Hematology 10.1182/blood.V96.6.2062 Silverchair:181047 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow The American Society of Hematology American Society of Hematology 10.1182/blood.V96.6.2062 Silverchair:181047 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow The American Society of Hematology American Society of Hematology 10.1182/blood.V96.6.2062 Silverchair:181047 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up The American Society of Hematology American Society of Hematology 10.1182/blood-2008-11-186817 Silverchair:25665 Total_Item_Investigations 2 0 0 0 0 0 2 0 0 0 0 0 0 Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up The American Society of Hematology American Society of Hematology 10.1182/blood-2008-11-186817 Silverchair:25665 Total_Item_Requests 2 0 0 0 0 0 2 0 0 0 0 0 0 Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up The American Society of Hematology American Society of Hematology 10.1182/blood-2008-11-186817 Silverchair:25665 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up The American Society of Hematology American Society of Hematology 10.1182/blood-2008-11-186817 Silverchair:25665 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-529974 Silverchair:32302 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-529974 Silverchair:32302 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-529974 Silverchair:32302 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-529974 Silverchair:32302 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure The American Society of Hematology American Society of Hematology 10.1182/blood-2015-10-676924 Silverchair:34776 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure The American Society of Hematology American Society of Hematology 10.1182/blood-2015-10-676924 Silverchair:34776 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure The American Society of Hematology American Society of Hematology 10.1182/blood-2015-10-676924 Silverchair:34776 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure The American Society of Hematology American Society of Hematology 10.1182/blood-2015-10-676924 Silverchair:34776 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2021-145379 Silverchair:479521 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 "Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2021-145379 Silverchair:479521 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 "Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2021-145379 Silverchair:479521 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 "Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2021-145379 Silverchair:479521 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112944 Silverchair:265930 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112944 Silverchair:265930 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112944 Silverchair:265930 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112944 Silverchair:265930 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with FLT3-ITD AML The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.671.671 Silverchair:101878 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with FLT3-ITD AML The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.671.671 Silverchair:101878 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with FLT3-ITD AML The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.671.671 Silverchair:101878 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with FLT3-ITD AML The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.671.671 Silverchair:101878 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125871 Silverchair:427085 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125871 Silverchair:427085 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125871 Silverchair:427085 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125871 Silverchair:427085 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Phase I/II Study of the Deacetylase Inhibitor Panobinostat As Maintenance Therapy after an Allogeneic Stem Cell Transplantation in Patients with High-Risk MDS or AML: The Panobest-Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4344.4344 Silverchair:135796 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Phase I/II Study of the Deacetylase Inhibitor Panobinostat As Maintenance Therapy after an Allogeneic Stem Cell Transplantation in Patients with High-Risk MDS or AML: The Panobest-Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4344.4344 Silverchair:135796 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Phase I/II Study of the Deacetylase Inhibitor Panobinostat As Maintenance Therapy after an Allogeneic Stem Cell Transplantation in Patients with High-Risk MDS or AML: The Panobest-Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4344.4344 Silverchair:135796 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Phase I/II Study of the Deacetylase Inhibitor Panobinostat As Maintenance Therapy after an Allogeneic Stem Cell Transplantation in Patients with High-Risk MDS or AML: The Panobest-Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4344.4344 Silverchair:135796 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's Transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117526 Silverchair:263483 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's Transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117526 Silverchair:263483 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's Transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117526 Silverchair:263483 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's Transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117526 Silverchair:263483 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Phase I/IIa Study of Genetically Engineered NY-ESO-1 SPEAR T-Cells Administered Following Autologous Stem Cell Transplant in HLA-a*02+ Patients with Advanced Multiple Myeloma: Long Term Follow-up (NCT01352286) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.845.845 Silverchair:83350 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Phase I/IIa Study of Genetically Engineered NY-ESO-1 SPEAR T-Cells Administered Following Autologous Stem Cell Transplant in HLA-a*02+ Patients with Advanced Multiple Myeloma: Long Term Follow-up (NCT01352286) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.845.845 Silverchair:83350 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Phase I/IIa Study of Genetically Engineered NY-ESO-1 SPEAR T-Cells Administered Following Autologous Stem Cell Transplant in HLA-a*02+ Patients with Advanced Multiple Myeloma: Long Term Follow-up (NCT01352286) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.845.845 Silverchair:83350 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Phase I/IIa Study of Genetically Engineered NY-ESO-1 SPEAR T-Cells Administered Following Autologous Stem Cell Transplant in HLA-a*02+ Patients with Advanced Multiple Myeloma: Long Term Follow-up (NCT01352286) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.845.845 Silverchair:83350 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128178 Silverchair:426380 Total_Item_Investigations 3 1 2 0 0 0 0 0 0 0 0 0 0 Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128178 Silverchair:426380 Total_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128178 Silverchair:426380 Unique_Item_Investigations 3 1 2 0 0 0 0 0 0 0 0 0 0 Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128178 Silverchair:426380 Unique_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142074 Silverchair:470098 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142074 Silverchair:470098 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142074 Silverchair:470098 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142074 Silverchair:470098 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142092 Silverchair:469961 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142092 Silverchair:469961 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142092 Silverchair:469961 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142092 Silverchair:469961 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3087.3087 Silverchair:96918 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3087.3087 Silverchair:96918 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3087.3087 Silverchair:96918 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3087.3087 Silverchair:96918 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122530 Silverchair:425724 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122530 Silverchair:425724 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122530 Silverchair:425724 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122530 Silverchair:425724 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system The American Society of Hematology American Society of Hematology 10.1182/blood-2004-09-3496 Silverchair:20201 Total_Item_Investigations 5 5 0 0 0 0 0 0 0 0 0 0 0 Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system The American Society of Hematology American Society of Hematology 10.1182/blood-2004-09-3496 Silverchair:20201 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system The American Society of Hematology American Society of Hematology 10.1182/blood-2004-09-3496 Silverchair:20201 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system The American Society of Hematology American Society of Hematology 10.1182/blood-2004-09-3496 Silverchair:20201 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Phenotypic heterogeneity is an evolutionarily conserved feature of the endothelium The American Society of Hematology American Society of Hematology 10.1182/blood-2006-05-026401 Silverchair:23515 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Phenotypic heterogeneity is an evolutionarily conserved feature of the endothelium The American Society of Hematology American Society of Hematology 10.1182/blood-2006-05-026401 Silverchair:23515 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Phenotypic heterogeneity is an evolutionarily conserved feature of the endothelium The American Society of Hematology American Society of Hematology 10.1182/blood-2006-05-026401 Silverchair:23515 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Phenotypic heterogeneity is an evolutionarily conserved feature of the endothelium The American Society of Hematology American Society of Hematology 10.1182/blood-2006-05-026401 Silverchair:23515 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Philadelphia chromosome–like acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-743252 Silverchair:36686 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 Philadelphia chromosome–like acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-743252 Silverchair:36686 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Philadelphia chromosome–like acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-743252 Silverchair:36686 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Philadelphia chromosome–like acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-743252 Silverchair:36686 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Phlebotomy-Induced Iron Deficiency Increases the Expression of Prothrombotic Genes The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141374 Silverchair:472391 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Phlebotomy-Induced Iron Deficiency Increases the Expression of Prothrombotic Genes The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141374 Silverchair:472391 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Phlebotomy-Induced Iron Deficiency Increases the Expression of Prothrombotic Genes The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141374 Silverchair:472391 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Phlebotomy-Induced Iron Deficiency Increases the Expression of Prothrombotic Genes The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141374 Silverchair:472391 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults The American Society of Hematology American Society of Hematology 10.1182/blood-2016-07-726588 Silverchair:36151 Total_Item_Investigations 2 1 0 0 0 0 0 0 0 1 0 0 0 Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults The American Society of Hematology American Society of Hematology 10.1182/blood-2016-07-726588 Silverchair:36151 Total_Item_Requests 2 1 0 0 0 0 0 0 0 1 0 0 0 Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults The American Society of Hematology American Society of Hematology 10.1182/blood-2016-07-726588 Silverchair:36151 Unique_Item_Investigations 2 1 0 0 0 0 0 0 0 1 0 0 0 Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults The American Society of Hematology American Society of Hematology 10.1182/blood-2016-07-726588 Silverchair:36151 Unique_Item_Requests 2 1 0 0 0 0 0 0 0 1 0 0 0 Phorbol ester stimulates a protein kinase C–mediated agatoxin-TK–sensitive calcium permeability pathway in human red blood cells The American Society of Hematology American Society of Hematology 10.1182/blood.V100.9.3392 Silverchair:16456 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Phorbol ester stimulates a protein kinase C–mediated agatoxin-TK–sensitive calcium permeability pathway in human red blood cells The American Society of Hematology American Society of Hematology 10.1182/blood.V100.9.3392 Silverchair:16456 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Phorbol ester stimulates a protein kinase C–mediated agatoxin-TK–sensitive calcium permeability pathway in human red blood cells The American Society of Hematology American Society of Hematology 10.1182/blood.V100.9.3392 Silverchair:16456 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Phorbol ester stimulates a protein kinase C–mediated agatoxin-TK–sensitive calcium permeability pathway in human red blood cells The American Society of Hematology American Society of Hematology 10.1182/blood.V100.9.3392 Silverchair:16456 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-271171 Silverchair:27524 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-271171 Silverchair:27524 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-271171 Silverchair:27524 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-271171 Silverchair:27524 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Phosphatidylinositol transfer proteins regulate megakaryocyte TGF-β1 secretion and hematopoiesis in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-806257 Silverchair:39311 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Phosphatidylinositol transfer proteins regulate megakaryocyte TGF-β1 secretion and hematopoiesis in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-806257 Silverchair:39311 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Phosphatidylinositol transfer proteins regulate megakaryocyte TGF-β1 secretion and hematopoiesis in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-806257 Silverchair:39311 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Phosphatidylinositol transfer proteins regulate megakaryocyte TGF-β1 secretion and hematopoiesis in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-806257 Silverchair:39311 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Physicians Beware: Direct Oral Anticoagulants Do Interact With Some Commonly Used Drugs American Society of Hematology American Society of Hematology 10.1182/hem.V15.2.8269 Silverchair:463034 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Physicians Beware: Direct Oral Anticoagulants Do Interact With Some Commonly Used Drugs American Society of Hematology American Society of Hematology 10.1182/hem.V15.2.8269 Silverchair:463034 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Physicians Beware: Direct Oral Anticoagulants Do Interact With Some Commonly Used Drugs American Society of Hematology American Society of Hematology 10.1182/hem.V15.2.8269 Silverchair:463034 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Physicians Beware: Direct Oral Anticoagulants Do Interact With Some Commonly Used Drugs American Society of Hematology American Society of Hematology 10.1182/hem.V15.2.8269 Silverchair:463034 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 PI3K p110δ regulates T-cell cytokine production during primary and secondary immune responses in mice and humans The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-232330 Silverchair:27028 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 PI3K p110δ regulates T-cell cytokine production during primary and secondary immune responses in mice and humans The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-232330 Silverchair:27028 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 PI3K p110δ regulates T-cell cytokine production during primary and secondary immune responses in mice and humans The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-232330 Silverchair:27028 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 PI3K p110δ regulates T-cell cytokine production during primary and secondary immune responses in mice and humans The American Society of Hematology American Society of Hematology 10.1182/blood-2009-07-232330 Silverchair:27028 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 PI3K regulates pleckstrin-2 in T-cell cytoskeletal reorganization The American Society of Hematology American Society of Hematology 10.1182/blood-2006-02-001339 Silverchair:23898 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 PI3K regulates pleckstrin-2 in T-cell cytoskeletal reorganization The American Society of Hematology American Society of Hematology 10.1182/blood-2006-02-001339 Silverchair:23898 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 PI3K regulates pleckstrin-2 in T-cell cytoskeletal reorganization The American Society of Hematology American Society of Hematology 10.1182/blood-2006-02-001339 Silverchair:23898 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 PI3K regulates pleckstrin-2 in T-cell cytoskeletal reorganization The American Society of Hematology American Society of Hematology 10.1182/blood-2006-02-001339 Silverchair:23898 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 PI3Kgamma (PI3Kγ) is essential for efficient induction of CXCR3 on activated T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-02-135715 Silverchair:114910 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 PI3Kgamma (PI3Kγ) is essential for efficient induction of CXCR3 on activated T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-02-135715 Silverchair:114910 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 PI3Kgamma (PI3Kγ) is essential for efficient induction of CXCR3 on activated T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-02-135715 Silverchair:114910 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 PI3Kgamma (PI3Kγ) is essential for efficient induction of CXCR3 on activated T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-02-135715 Silverchair:114910 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 PIKfyve Inhibitors for the Treatment of Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4423.4423 Silverchair:72902 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 PIKfyve Inhibitors for the Treatment of Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4423.4423 Silverchair:72902 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 PIKfyve Inhibitors for the Treatment of Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4423.4423 Silverchair:72902 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 PIKfyve Inhibitors for the Treatment of Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4423.4423 Silverchair:72902 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Pilot Study of Radiation-Targeted Donor Lymphocyte Infusion for Cancer Progression after Allogeneic Hematopoietic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.1962.1962 Silverchair:105214 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Pilot Study of Radiation-Targeted Donor Lymphocyte Infusion for Cancer Progression after Allogeneic Hematopoietic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.1962.1962 Silverchair:105214 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Pilot Study of Radiation-Targeted Donor Lymphocyte Infusion for Cancer Progression after Allogeneic Hematopoietic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.1962.1962 Silverchair:105214 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Pilot Study of Radiation-Targeted Donor Lymphocyte Infusion for Cancer Progression after Allogeneic Hematopoietic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.1962.1962 Silverchair:105214 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-551234 Silverchair:33048 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-551234 Silverchair:33048 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-551234 Silverchair:33048 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-551234 Silverchair:33048 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 PKCζ decreases eNOS protein stability via inhibitory phosphorylation of ERK5 The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-269134 Silverchair:27457 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 PKCζ decreases eNOS protein stability via inhibitory phosphorylation of ERK5 The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-269134 Silverchair:27457 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 PKCζ decreases eNOS protein stability via inhibitory phosphorylation of ERK5 The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-269134 Silverchair:27457 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 PKCζ decreases eNOS protein stability via inhibitory phosphorylation of ERK5 The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-269134 Silverchair:27457 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Planning for the future workforce in hematology research The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-617811 Silverchair:33803 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Planning for the future workforce in hematology research The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-617811 Silverchair:33803 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Planning for the future workforce in hematology research The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-617811 Silverchair:33803 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Planning for the future workforce in hematology research The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-617811 Silverchair:33803 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Plasma cell disorders American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter25 Silverchair:78249 No_License 4 2 1 0 0 0 0 0 1 0 0 0 0 Plasma cell disorders American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter25 Silverchair:78249 Total_Item_Investigations 5 2 1 0 0 0 0 1 1 0 0 0 0 Plasma cell disorders American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter25 Silverchair:78249 Unique_Item_Investigations 4 1 1 0 0 0 0 1 1 0 0 0 0 Plasma cell leukemia mimicking acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-02-698084 Silverchair:35112 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Plasma cell leukemia mimicking acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-02-698084 Silverchair:35112 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Plasma cell leukemia mimicking acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-02-698084 Silverchair:35112 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Plasma cell leukemia mimicking acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-02-698084 Silverchair:35112 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Plasma cell–directed therapies in monoclonal gammopathy–associated scleromyxedema The American Society of Hematology American Society of Hematology 10.1182/blood.2019002300 Silverchair:440999 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Plasma cell–directed therapies in monoclonal gammopathy–associated scleromyxedema The American Society of Hematology American Society of Hematology 10.1182/blood.2019002300 Silverchair:440999 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Plasma cell–directed therapies in monoclonal gammopathy–associated scleromyxedema The American Society of Hematology American Society of Hematology 10.1182/blood.2019002300 Silverchair:440999 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Plasma cell–directed therapies in monoclonal gammopathy–associated scleromyxedema The American Society of Hematology American Society of Hematology 10.1182/blood.2019002300 Silverchair:440999 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Plasma fibrinolysis, inflammatory markers, and postthrombotic syndrome: preliminary findings from the Kids-DOTT Biobank" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002974 Silverchair:474876 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Plasma fibrinolysis, inflammatory markers, and postthrombotic syndrome: preliminary findings from the Kids-DOTT Biobank" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002974 Silverchair:474876 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Plasma fibrinolysis, inflammatory markers, and postthrombotic syndrome: preliminary findings from the Kids-DOTT Biobank" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002974 Silverchair:474876 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Plasma fibrinolysis, inflammatory markers, and postthrombotic syndrome: preliminary findings from the Kids-DOTT Biobank" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002974 Silverchair:474876 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Plasma Tissue Factor Pathway Inhibitor (TFPI) Levels in Healthy Subjects and Patients with Hemophilia A and B The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4672.4672 Silverchair:93487 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Plasma Tissue Factor Pathway Inhibitor (TFPI) Levels in Healthy Subjects and Patients with Hemophilia A and B The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4672.4672 Silverchair:93487 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Plasma Tissue Factor Pathway Inhibitor (TFPI) Levels in Healthy Subjects and Patients with Hemophilia A and B The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4672.4672 Silverchair:93487 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Plasma Tissue Factor Pathway Inhibitor (TFPI) Levels in Healthy Subjects and Patients with Hemophilia A and B The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4672.4672 Silverchair:93487 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Plasminogen Activator Inhibitor Type 1 (PAI-1) and Thrombophilia: A 10 Year Retrospective Review of Clinical Data at a Large Children's Hospital The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1069.1069 Silverchair:116289 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Plasminogen Activator Inhibitor Type 1 (PAI-1) and Thrombophilia: A 10 Year Retrospective Review of Clinical Data at a Large Children's Hospital The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1069.1069 Silverchair:116289 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Plasminogen Activator Inhibitor Type 1 (PAI-1) and Thrombophilia: A 10 Year Retrospective Review of Clinical Data at a Large Children's Hospital The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1069.1069 Silverchair:116289 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Plasminogen Activator Inhibitor Type 1 (PAI-1) and Thrombophilia: A 10 Year Retrospective Review of Clinical Data at a Large Children's Hospital The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1069.1069 Silverchair:116289 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-806729 Silverchair:36615 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-806729 Silverchair:36615 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-806729 Silverchair:36615 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-806729 Silverchair:36615 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Plasticity of endothelial cells: rapid dedifferentiation of freshly isolated high endothelial venule endothelial cells outside the lymphoid tissue microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2003-10-3537 Silverchair:17921 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 Plasticity of endothelial cells: rapid dedifferentiation of freshly isolated high endothelial venule endothelial cells outside the lymphoid tissue microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2003-10-3537 Silverchair:17921 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 Plasticity of endothelial cells: rapid dedifferentiation of freshly isolated high endothelial venule endothelial cells outside the lymphoid tissue microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2003-10-3537 Silverchair:17921 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Plasticity of endothelial cells: rapid dedifferentiation of freshly isolated high endothelial venule endothelial cells outside the lymphoid tissue microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2003-10-3537 Silverchair:17921 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Platelet 12-LOX is essential for FcγRIIa-mediated platelet activation The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-575878 Silverchair:33109 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 Platelet 12-LOX is essential for FcγRIIa-mediated platelet activation The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-575878 Silverchair:33109 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Platelet 12-LOX is essential for FcγRIIa-mediated platelet activation The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-575878 Silverchair:33109 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelet 12-LOX is essential for FcγRIIa-mediated platelet activation The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-575878 Silverchair:33109 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelet 12-LOX scores a HIT The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-595652 Silverchair:33073 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Platelet 12-LOX scores a HIT The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-595652 Silverchair:33073 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelet 12-LOX scores a HIT The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-595652 Silverchair:33073 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelet 12-LOX scores a HIT The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-595652 Silverchair:33073 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19 The American Society of Hematology American Society of Hematology 10.1182/blood.2020007252 Silverchair:461421 Total_Item_Investigations 9 4 0 1 0 0 4 0 0 0 0 0 0 Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19 The American Society of Hematology American Society of Hematology 10.1182/blood.2020007252 Silverchair:461421 Total_Item_Requests 9 4 0 1 0 0 4 0 0 0 0 0 0 Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19 The American Society of Hematology American Society of Hematology 10.1182/blood.2020007252 Silverchair:461421 Unique_Item_Investigations 4 2 0 1 0 0 1 0 0 0 0 0 0 Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19 The American Society of Hematology American Society of Hematology 10.1182/blood.2020007252 Silverchair:461421 Unique_Item_Requests 4 2 0 1 0 0 1 0 0 0 0 0 0 Platelet and Fibrinogen Sequestration The American Society of Hematology American Society of Hematology 10.1182/blood.V15.5.596.596 Silverchair:7670 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Platelet and Fibrinogen Sequestration The American Society of Hematology American Society of Hematology 10.1182/blood.V15.5.596.596 Silverchair:7670 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelet Cut-Off For Anticoagulant Therapy In Cancer Patients With Venous Thromboembolism and Thrombocytopenia: An Expert Opinion Based On RAND/UCLA Appropriateness Method (RAM) The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.581.581 Silverchair:94211 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Platelet Cut-Off For Anticoagulant Therapy In Cancer Patients With Venous Thromboembolism and Thrombocytopenia: An Expert Opinion Based On RAND/UCLA Appropriateness Method (RAM) The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.581.581 Silverchair:94211 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Platelet Cut-Off For Anticoagulant Therapy In Cancer Patients With Venous Thromboembolism and Thrombocytopenia: An Expert Opinion Based On RAND/UCLA Appropriateness Method (RAM) The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.581.581 Silverchair:94211 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Platelet Cut-Off For Anticoagulant Therapy In Cancer Patients With Venous Thromboembolism and Thrombocytopenia: An Expert Opinion Based On RAND/UCLA Appropriateness Method (RAM) The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.581.581 Silverchair:94211 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Platelet Delta Granule and Serotonin Concentrations Are Decreased in Patients with Postural Orthostatic Tachycardia Syndrome. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.2419.2419 Silverchair:63743 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelet Delta Granule and Serotonin Concentrations Are Decreased in Patients with Postural Orthostatic Tachycardia Syndrome. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.2419.2419 Silverchair:63743 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelet Delta Granule and Serotonin Concentrations Are Decreased in Patients with Postural Orthostatic Tachycardia Syndrome. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.2419.2419 Silverchair:63743 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelet Delta Granule and Serotonin Concentrations Are Decreased in Patients with Postural Orthostatic Tachycardia Syndrome. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.2419.2419 Silverchair:63743 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelet disorders: the next generation is in The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-703215 Silverchair:35269 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Platelet disorders: the next generation is in The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-703215 Silverchair:35269 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Platelet disorders: the next generation is in The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-703215 Silverchair:35269 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelet disorders: the next generation is in The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-703215 Silverchair:35269 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelet factor 4 binding to lipid A of Gram-negative bacteria exposes PF4/heparin-like epitopes The American Society of Hematology American Society of Hematology 10.1182/blood-2012-06-434985 Silverchair:30767 Total_Item_Investigations 5 0 2 0 0 3 0 0 0 0 0 0 0 Platelet factor 4 binding to lipid A of Gram-negative bacteria exposes PF4/heparin-like epitopes The American Society of Hematology American Society of Hematology 10.1182/blood-2012-06-434985 Silverchair:30767 Total_Item_Requests 5 0 2 0 0 3 0 0 0 0 0 0 0 Platelet factor 4 binding to lipid A of Gram-negative bacteria exposes PF4/heparin-like epitopes The American Society of Hematology American Society of Hematology 10.1182/blood-2012-06-434985 Silverchair:30767 Unique_Item_Investigations 2 0 1 0 0 1 0 0 0 0 0 0 0 Platelet factor 4 binding to lipid A of Gram-negative bacteria exposes PF4/heparin-like epitopes The American Society of Hematology American Society of Hematology 10.1182/blood-2012-06-434985 Silverchair:30767 Unique_Item_Requests 2 0 1 0 0 1 0 0 0 0 0 0 0 "Platelet factor 4 binds to bacteria, inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-301424 Silverchair:28566 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 "Platelet factor 4 binds to bacteria, inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-301424 Silverchair:28566 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 "Platelet factor 4 binds to bacteria, inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-301424 Silverchair:28566 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Platelet factor 4 binds to bacteria, inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-301424 Silverchair:28566 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelet gene expression and function in patients with COVID-19 The American Society of Hematology American Society of Hematology 10.1182/blood.2020007214 Silverchair:461106 Total_Item_Investigations 10 5 0 2 0 2 1 0 0 0 0 0 0 Platelet gene expression and function in patients with COVID-19 The American Society of Hematology American Society of Hematology 10.1182/blood.2020007214 Silverchair:461106 Total_Item_Requests 10 5 0 2 0 2 1 0 0 0 0 0 0 Platelet gene expression and function in patients with COVID-19 The American Society of Hematology American Society of Hematology 10.1182/blood.2020007214 Silverchair:461106 Unique_Item_Investigations 6 2 0 2 0 1 1 0 0 0 0 0 0 Platelet gene expression and function in patients with COVID-19 The American Society of Hematology American Society of Hematology 10.1182/blood.2020007214 Silverchair:461106 Unique_Item_Requests 6 2 0 2 0 1 1 0 0 0 0 0 0 Platelet Levels in Infectious Mononucleosis The American Society of Hematology American Society of Hematology 10.1182/blood.V25.5.817.817 Silverchair:37878 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelet Levels in Infectious Mononucleosis The American Society of Hematology American Society of Hematology 10.1182/blood.V25.5.817.817 Silverchair:37878 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-751099 Silverchair:36795 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-751099 Silverchair:36795 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-751099 Silverchair:36795 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-751099 Silverchair:36795 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-11-321398 Silverchair:21410 Total_Item_Investigations 3 0 1 0 0 0 0 0 0 0 2 0 0 Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-11-321398 Silverchair:21410 Total_Item_Requests 3 0 1 0 0 0 0 0 0 0 2 0 0 Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-11-321398 Silverchair:21410 Unique_Item_Investigations 2 0 1 0 0 0 0 0 0 0 1 0 0 Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-11-321398 Silverchair:21410 Unique_Item_Requests 2 0 1 0 0 0 0 0 0 0 1 0 0 Platelet reactivity to thrombin differs between patients with COVID-19 and those with ARDS unrelated to COVID-19 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003513 Silverchair:475043 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Platelet reactivity to thrombin differs between patients with COVID-19 and those with ARDS unrelated to COVID-19 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003513 Silverchair:475043 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Platelet reactivity to thrombin differs between patients with COVID-19 and those with ARDS unrelated to COVID-19 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003513 Silverchair:475043 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Platelet reactivity to thrombin differs between patients with COVID-19 and those with ARDS unrelated to COVID-19 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003513 Silverchair:475043 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Platelet size in man The American Society of Hematology American Society of Hematology 10.1182/blood.V46.3.321.321 Silverchair:160232 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelet size in man The American Society of Hematology American Society of Hematology 10.1182/blood.V46.3.321.321 Silverchair:160232 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Platelet TGF-β1 contributions to plasma TGF-β1, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-09-377648 Silverchair:29717 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Platelet TGF-β1 contributions to plasma TGF-β1, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-09-377648 Silverchair:29717 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Platelet TGF-β1 contributions to plasma TGF-β1, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-09-377648 Silverchair:29717 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Platelet TGF-β1 contributions to plasma TGF-β1, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-09-377648 Silverchair:29717 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelet TGF-β1 deficiency decreases liver fibrosis in a mouse model of liver injury American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017010868 Silverchair:15789 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Platelet TGF-β1 deficiency decreases liver fibrosis in a mouse model of liver injury American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017010868 Silverchair:15789 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Platelet TGF-β1 deficiency decreases liver fibrosis in a mouse model of liver injury American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017010868 Silverchair:15789 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelet TGF-β1 deficiency decreases liver fibrosis in a mouse model of liver injury American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017010868 Silverchair:15789 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelet transfusion goals in oncology patients The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.462 Silverchair:20656 Total_Item_Investigations 5 0 2 3 0 0 0 0 0 0 0 0 0 Platelet transfusion goals in oncology patients The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.462 Silverchair:20656 Total_Item_Requests 5 0 2 3 0 0 0 0 0 0 0 0 0 Platelet transfusion goals in oncology patients The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.462 Silverchair:20656 Unique_Item_Investigations 3 0 2 1 0 0 0 0 0 0 0 0 0 Platelet transfusion goals in oncology patients The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.462 Silverchair:20656 Unique_Item_Requests 3 0 2 1 0 0 0 0 0 0 0 0 0 Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-587139 Silverchair:34016 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-587139 Silverchair:34016 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-587139 Silverchair:34016 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-587139 Silverchair:34016 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Platelet-derived extracellular vesicles infiltrate and modify the bone marrow during inflammation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001758 Silverchair:461240 Total_Item_Investigations 4 0 2 2 0 0 0 0 0 0 0 0 0 Platelet-derived extracellular vesicles infiltrate and modify the bone marrow during inflammation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001758 Silverchair:461240 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Platelet-derived extracellular vesicles infiltrate and modify the bone marrow during inflammation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001758 Silverchair:461240 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Platelet-derived extracellular vesicles infiltrate and modify the bone marrow during inflammation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001758 Silverchair:461240 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Platelet-derived growth factor receptor-β promotes early endothelial cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-014894 Silverchair:22656 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelet-derived growth factor receptor-β promotes early endothelial cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-014894 Silverchair:22656 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelet-derived growth factor receptor-β promotes early endothelial cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-014894 Silverchair:22656 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelet-derived growth factor receptor-β promotes early endothelial cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-014894 Silverchair:22656 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelets and protease-activated receptor-4 contribute to acetaminophen-induced liver injury in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2014-09-598656 Silverchair:34691 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelets and protease-activated receptor-4 contribute to acetaminophen-induced liver injury in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2014-09-598656 Silverchair:34691 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelets and protease-activated receptor-4 contribute to acetaminophen-induced liver injury in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2014-09-598656 Silverchair:34691 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelets and protease-activated receptor-4 contribute to acetaminophen-induced liver injury in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2014-09-598656 Silverchair:34691 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelets can enhance vascular permeability The American Society of Hematology American Society of Hematology 10.1182/blood-2012-02-413047 Silverchair:30530 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Platelets can enhance vascular permeability The American Society of Hematology American Society of Hematology 10.1182/blood-2012-02-413047 Silverchair:30530 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Platelets can enhance vascular permeability The American Society of Hematology American Society of Hematology 10.1182/blood-2012-02-413047 Silverchair:30530 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Platelets can enhance vascular permeability The American Society of Hematology American Society of Hematology 10.1182/blood-2012-02-413047 Silverchair:30530 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Platelets in liver and renal disease The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.251 Silverchair:20969 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Platelets in liver and renal disease The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.251 Silverchair:20969 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Platelets in liver and renal disease The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.251 Silverchair:20969 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Platelets in liver and renal disease The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.251 Silverchair:20969 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Platelets in tissue repair: control of apoptosis and interactions with regenerative cells The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-468694 Silverchair:31870 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Platelets in tissue repair: control of apoptosis and interactions with regenerative cells The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-468694 Silverchair:31870 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Platelets in tissue repair: control of apoptosis and interactions with regenerative cells The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-468694 Silverchair:31870 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelets in tissue repair: control of apoptosis and interactions with regenerative cells The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-468694 Silverchair:31870 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Platelets lacking PIP5KIγ have normal integrin activation but impaired cytoskeletal-membrane integrity and adhesion The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-445205 Silverchair:31115 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 Platelets lacking PIP5KIγ have normal integrin activation but impaired cytoskeletal-membrane integrity and adhesion The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-445205 Silverchair:31115 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 Platelets lacking PIP5KIγ have normal integrin activation but impaired cytoskeletal-membrane integrity and adhesion The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-445205 Silverchair:31115 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Platelets lacking PIP5KIγ have normal integrin activation but impaired cytoskeletal-membrane integrity and adhesion The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-445205 Silverchair:31115 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-573543 Silverchair:33091 Total_Item_Investigations 4 0 2 2 0 0 0 0 0 0 0 0 0 Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-573543 Silverchair:33091 Total_Item_Requests 3 0 2 1 0 0 0 0 0 0 0 0 0 Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-573543 Silverchair:33091 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-573543 Silverchair:33091 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 PLCG1 mutations in cutaneous T-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-504308 Silverchair:32600 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 PLCG1 mutations in cutaneous T-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-504308 Silverchair:32600 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 PLCG1 mutations in cutaneous T-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-504308 Silverchair:32600 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 PLCG1 mutations in cutaneous T-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-504308 Silverchair:32600 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 PLD1-dependent PKCγ activation downstream to Src is essential for the development of pathologic retinal neovascularization The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-271478 Silverchair:27885 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 PLD1-dependent PKCγ activation downstream to Src is essential for the development of pathologic retinal neovascularization The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-271478 Silverchair:27885 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 PLD1-dependent PKCγ activation downstream to Src is essential for the development of pathologic retinal neovascularization The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-271478 Silverchair:27885 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 PLD1-dependent PKCγ activation downstream to Src is essential for the development of pathologic retinal neovascularization The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-271478 Silverchair:27885 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Please “Eat me”: Can Magrolimab Put Higher-risk MDS Back on the Immunologic Menu? American Society of Hematology American Society of Hematology 10.1182/hem.V18.4.2021410 Silverchair:476180 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Please “Eat me”: Can Magrolimab Put Higher-risk MDS Back on the Immunologic Menu? American Society of Hematology American Society of Hematology 10.1182/hem.V18.4.2021410 Silverchair:476180 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Please “Eat me”: Can Magrolimab Put Higher-risk MDS Back on the Immunologic Menu? American Society of Hematology American Society of Hematology 10.1182/hem.V18.4.2021410 Silverchair:476180 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Please “Eat me”: Can Magrolimab Put Higher-risk MDS Back on the Immunologic Menu? American Society of Hematology American Society of Hematology 10.1182/hem.V18.4.2021410 Silverchair:476180 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-042374 Silverchair:133601 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-042374 Silverchair:133601 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-042374 Silverchair:133601 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-042374 Silverchair:133601 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Pleiotropic platelet defects in mice with disrupted FOG1-NuRD interaction The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-363580 Silverchair:29142 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 Pleiotropic platelet defects in mice with disrupted FOG1-NuRD interaction The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-363580 Silverchair:29142 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 Pleiotropic platelet defects in mice with disrupted FOG1-NuRD interaction The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-363580 Silverchair:29142 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Pleiotropic platelet defects in mice with disrupted FOG1-NuRD interaction The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-363580 Silverchair:29142 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2008-08-174946 Silverchair:25873 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2008-08-174946 Silverchair:25873 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2008-08-174946 Silverchair:25873 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2008-08-174946 Silverchair:25873 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "Pneumolysin induces platelet destruction, not platelet activation, which can be prevented by immunoglobulin preparations in vitro" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002372 Silverchair:474718 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 "Pneumolysin induces platelet destruction, not platelet activation, which can be prevented by immunoglobulin preparations in vitro" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002372 Silverchair:474718 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 "Pneumolysin induces platelet destruction, not platelet activation, which can be prevented by immunoglobulin preparations in vitro" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002372 Silverchair:474718 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "Pneumolysin induces platelet destruction, not platelet activation, which can be prevented by immunoglobulin preparations in vitro" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002372 Silverchair:474718 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Pneumoviruses infect eosinophils and elicit MyD88-dependent release of chemoattractant cytokines and interleukin-6 The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-199497 Silverchair:26375 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Pneumoviruses infect eosinophils and elicit MyD88-dependent release of chemoattractant cytokines and interleukin-6 The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-199497 Silverchair:26375 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Pneumoviruses infect eosinophils and elicit MyD88-dependent release of chemoattractant cytokines and interleukin-6 The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-199497 Silverchair:26375 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Pneumoviruses infect eosinophils and elicit MyD88-dependent release of chemoattractant cytokines and interleukin-6 The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-199497 Silverchair:26375 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118551 Silverchair:272963 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118551 Silverchair:272963 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118551 Silverchair:272963 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118551 Silverchair:272963 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004155 Silverchair:476246 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004155 Silverchair:476246 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004155 Silverchair:476246 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004155 Silverchair:476246 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123449 Silverchair:424303 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123449 Silverchair:424303 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123449 Silverchair:424303 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123449 Silverchair:424303 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136361 Silverchair:470363 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136361 Silverchair:470363 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136361 Silverchair:470363 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136361 Silverchair:470363 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Polatuzumab Vedotin Use before Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Aggressive Lymphoma: A US Single Center Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2021-152313 Silverchair:481079 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Polatuzumab Vedotin Use before Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Aggressive Lymphoma: A US Single Center Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2021-152313 Silverchair:481079 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Polatuzumab Vedotin Use before Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Aggressive Lymphoma: A US Single Center Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2021-152313 Silverchair:481079 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Polatuzumab Vedotin Use before Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Aggressive Lymphoma: A US Single Center Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2021-152313 Silverchair:481079 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-195867 Silverchair:131357 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-195867 Silverchair:131357 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-195867 Silverchair:131357 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-195867 Silverchair:131357 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Poly (ADP-ribose) polymerase-1 (PARP1) as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome. American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004638 Silverchair:476933 Total_Item_Investigations 4 0 0 0 0 0 0 0 0 0 4 0 0 Poly (ADP-ribose) polymerase-1 (PARP1) as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome. American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004638 Silverchair:476933 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Poly(I:C) causes failure of immunoprophylaxis to red blood cells expressing the KEL glycoprotein in mice The American Society of Hematology American Society of Hematology 10.1182/blood.2020005018 Silverchair:454294 Total_Item_Investigations 10 4 4 2 0 0 0 0 0 0 0 0 0 Poly(I:C) causes failure of immunoprophylaxis to red blood cells expressing the KEL glycoprotein in mice The American Society of Hematology American Society of Hematology 10.1182/blood.2020005018 Silverchair:454294 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Poly(I:C) causes failure of immunoprophylaxis to red blood cells expressing the KEL glycoprotein in mice The American Society of Hematology American Society of Hematology 10.1182/blood.2020005018 Silverchair:454294 Unique_Item_Investigations 3 1 1 1 0 0 0 0 0 0 0 0 0 Poly(I:C) causes failure of immunoprophylaxis to red blood cells expressing the KEL glycoprotein in mice The American Society of Hematology American Society of Hematology 10.1182/blood.2020005018 Silverchair:454294 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Poly(I:C) causes failure of immunoprophylaxis to red blood cells expressing the KEL glycoprotein in mice The American Society of Hematology American Society of Hematology 10.1182/blood.2020005018 Silverchair:454294 No_License 4 0 3 1 0 0 0 0 0 0 0 0 0 Polyclonal IgA Gammopathy Associated with Polyclonal Plasmacytosis in Patients Receiving Lenalidomide Maintenance Therapy The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.5130.5130 Silverchair:82114 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Polyclonal IgA Gammopathy Associated with Polyclonal Plasmacytosis in Patients Receiving Lenalidomide Maintenance Therapy The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.5130.5130 Silverchair:82114 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Polyclonal IgA Gammopathy Associated with Polyclonal Plasmacytosis in Patients Receiving Lenalidomide Maintenance Therapy The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.5130.5130 Silverchair:82114 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Polyclonal IgA Gammopathy Associated with Polyclonal Plasmacytosis in Patients Receiving Lenalidomide Maintenance Therapy The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.5130.5130 Silverchair:82114 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02 The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-452375 Silverchair:31073 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02 The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-452375 Silverchair:31073 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02 The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-452375 Silverchair:31073 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02 The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-452375 Silverchair:31073 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Pomalidomide Reduces Bleeding and Alters Expression of Angiogenesis-Related Proteins in Patients with Hereditary Hemorrhagic Telangiectasia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127344 Silverchair:425840 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Pomalidomide Reduces Bleeding and Alters Expression of Angiogenesis-Related Proteins in Patients with Hereditary Hemorrhagic Telangiectasia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127344 Silverchair:425840 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Pomalidomide Reduces Bleeding and Alters Expression of Angiogenesis-Related Proteins in Patients with Hereditary Hemorrhagic Telangiectasia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127344 Silverchair:425840 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Pomalidomide Reduces Bleeding and Alters Expression of Angiogenesis-Related Proteins in Patients with Hereditary Hemorrhagic Telangiectasia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127344 Silverchair:425840 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 "Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-863829 Silverchair:39537 Total_Item_Investigations 4 0 0 1 0 0 0 0 0 3 0 0 0 "Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-863829 Silverchair:39537 Total_Item_Requests 4 0 0 1 0 0 0 0 0 3 0 0 0 "Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-863829 Silverchair:39537 Unique_Item_Investigations 2 0 0 1 0 0 0 0 0 1 0 0 0 "Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-863829 Silverchair:39537 Unique_Item_Requests 2 0 0 1 0 0 0 0 0 1 0 0 0 "Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-488676 Silverchair:31781 Total_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 "Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-488676 Silverchair:31781 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 "Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-488676 Silverchair:31781 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 "Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-488676 Silverchair:31781 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Pomalidomide-Based Homo-Protacs for the Chemical Knockdown of Cereblon The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116376 Silverchair:264349 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Pomalidomide-Based Homo-Protacs for the Chemical Knockdown of Cereblon The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116376 Silverchair:264349 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Pomalidomide-Based Homo-Protacs for the Chemical Knockdown of Cereblon The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116376 Silverchair:264349 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Pomalidomide-Based Homo-Protacs for the Chemical Knockdown of Cereblon The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116376 Silverchair:264349 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 PON2 Exemplifies a Unique Dependency of B Cell Lineage ALL Cells on Detoxifying Lactonases The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.882.882 Silverchair:83283 Total_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 PON2 Exemplifies a Unique Dependency of B Cell Lineage ALL Cells on Detoxifying Lactonases The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.882.882 Silverchair:83283 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 PON2 Exemplifies a Unique Dependency of B Cell Lineage ALL Cells on Detoxifying Lactonases The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.882.882 Silverchair:83283 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 PON2 Exemplifies a Unique Dependency of B Cell Lineage ALL Cells on Detoxifying Lactonases The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.882.882 Silverchair:83283 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Ponatinib coronary microangiopathy: novel bedside diagnostic approach and management with N-acetylcysteine American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002644 Silverchair:463590 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Ponatinib coronary microangiopathy: novel bedside diagnostic approach and management with N-acetylcysteine American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002644 Silverchair:463590 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Ponatinib coronary microangiopathy: novel bedside diagnostic approach and management with N-acetylcysteine American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002644 Silverchair:463590 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Ponatinib coronary microangiopathy: novel bedside diagnostic approach and management with N-acetylcysteine American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002644 Silverchair:463590 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-739086 Silverchair:103899 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-739086 Silverchair:103899 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-739086 Silverchair:103899 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-739086 Silverchair:103899 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Postdischarge thrombosis and hemorrhage in patients with COVID-19 The American Society of Hematology American Society of Hematology 10.1182/blood.2020007938 Silverchair:461763 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Postdischarge thrombosis and hemorrhage in patients with COVID-19 The American Society of Hematology American Society of Hematology 10.1182/blood.2020007938 Silverchair:461763 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Postdischarge thrombosis and hemorrhage in patients with COVID-19 The American Society of Hematology American Society of Hematology 10.1182/blood.2020007938 Silverchair:461763 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Postdischarge thrombosis and hemorrhage in patients with COVID-19 The American Society of Hematology American Society of Hematology 10.1182/blood.2020007938 Silverchair:461763 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124750 Silverchair:426967 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124750 Silverchair:426967 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124750 Silverchair:426967 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124750 Silverchair:426967 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Post-Remission Treatment (Tx) Patterns for Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the Connect® MDS/AML Disease Registry The American Society of Hematology American Society of Hematology 10.1182/blood-2020-135877 Silverchair:472174 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Post-Remission Treatment (Tx) Patterns for Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the Connect® MDS/AML Disease Registry The American Society of Hematology American Society of Hematology 10.1182/blood-2020-135877 Silverchair:472174 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Post-Remission Treatment (Tx) Patterns for Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the Connect® MDS/AML Disease Registry The American Society of Hematology American Society of Hematology 10.1182/blood-2020-135877 Silverchair:472174 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Post-Remission Treatment (Tx) Patterns for Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the Connect® MDS/AML Disease Registry The American Society of Hematology American Society of Hematology 10.1182/blood-2020-135877 Silverchair:472174 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy:results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-069666 Silverchair:23012 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy:results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-069666 Silverchair:23012 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy:results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-069666 Silverchair:23012 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy:results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-069666 Silverchair:23012 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-02-336842 Silverchair:22294 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-02-336842 Silverchair:22294 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-02-336842 Silverchair:22294 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-02-336842 Silverchair:22294 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Post-Translational Mechanisms of NT5C2 Activation As Non-Genetic Drivers of Chemotherapy Resistance in Relapsed Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128615 Silverchair:427170 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Post-Translational Mechanisms of NT5C2 Activation As Non-Genetic Drivers of Chemotherapy Resistance in Relapsed Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128615 Silverchair:427170 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Post-Translational Mechanisms of NT5C2 Activation As Non-Genetic Drivers of Chemotherapy Resistance in Relapsed Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128615 Silverchair:427170 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Post-Translational Mechanisms of NT5C2 Activation As Non-Genetic Drivers of Chemotherapy Resistance in Relapsed Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128615 Silverchair:427170 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Post-Transplant Maintenance With The Deacetylase Inhibitor Panobinostat In Patients With High-Risk AML Or MDS: Results Of The Phase I Part Of The Panobest Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.3315.3315 Silverchair:13465 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Post-Transplant Maintenance With The Deacetylase Inhibitor Panobinostat In Patients With High-Risk AML Or MDS: Results Of The Phase I Part Of The Panobest Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.3315.3315 Silverchair:13465 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Post-Transplant Maintenance With The Deacetylase Inhibitor Panobinostat In Patients With High-Risk AML Or MDS: Results Of The Phase I Part Of The Panobest Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.3315.3315 Silverchair:13465 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Post-Transplant Maintenance With The Deacetylase Inhibitor Panobinostat In Patients With High-Risk AML Or MDS: Results Of The Phase I Part Of The Panobest Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.3315.3315 Silverchair:13465 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-01-065888 Silverchair:23987 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-01-065888 Silverchair:23987 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-01-065888 Silverchair:23987 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-01-065888 Silverchair:23987 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-707653 Silverchair:36096 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-707653 Silverchair:36096 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-707653 Silverchair:36096 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-707653 Silverchair:36096 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Potential Anti-Thrombotic Effect without Accompanying Hemorrhage with Fostamatinib Use in Patients with Immune Thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126558 Silverchair:428636 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Potential Anti-Thrombotic Effect without Accompanying Hemorrhage with Fostamatinib Use in Patients with Immune Thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126558 Silverchair:428636 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Potential Anti-Thrombotic Effect without Accompanying Hemorrhage with Fostamatinib Use in Patients with Immune Thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126558 Silverchair:428636 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Potential Anti-Thrombotic Effect without Accompanying Hemorrhage with Fostamatinib Use in Patients with Immune Thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126558 Silverchair:428636 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Potential Overuse of Primary Thromboprophylaxis in Medical Inpatients at Low Risk of Venous Thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131827 Silverchair:423774 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Potential Overuse of Primary Thromboprophylaxis in Medical Inpatients at Low Risk of Venous Thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131827 Silverchair:423774 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Potential Overuse of Primary Thromboprophylaxis in Medical Inpatients at Low Risk of Venous Thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131827 Silverchair:423774 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Potential Overuse of Primary Thromboprophylaxis in Medical Inpatients at Low Risk of Venous Thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131827 Silverchair:423774 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Pozelimab, a Human Antibody Against Complement Factor C5, Demonstrates Robust Inhibition of Alternative Complement Activity Both in Normal Human Serum and in Phase I Normal Healthy Volunteers" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129865 Silverchair:422885 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Pozelimab, a Human Antibody Against Complement Factor C5, Demonstrates Robust Inhibition of Alternative Complement Activity Both in Normal Human Serum and in Phase I Normal Healthy Volunteers" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129865 Silverchair:422885 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Pozelimab, a Human Antibody Against Complement Factor C5, Demonstrates Robust Inhibition of Alternative Complement Activity Both in Normal Human Serum and in Phase I Normal Healthy Volunteers" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129865 Silverchair:422885 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Pozelimab, a Human Antibody Against Complement Factor C5, Demonstrates Robust Inhibition of Alternative Complement Activity Both in Normal Human Serum and in Phase I Normal Healthy Volunteers" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129865 Silverchair:422885 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 PP2A Is Required for B Cell Survival and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.902.902 Silverchair:136354 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 PP2A Is Required for B Cell Survival and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.902.902 Silverchair:136354 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 PP2A Is Required for B Cell Survival and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.902.902 Silverchair:136354 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 PP2A Is Required for B Cell Survival and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.902.902 Silverchair:136354 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018027409 Silverchair:246760 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018027409 Silverchair:246760 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018027409 Silverchair:246760 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018027409 Silverchair:246760 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136983 Silverchair:471441 Total_Item_Investigations 2 1 0 0 0 1 0 0 0 0 0 0 0 Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136983 Silverchair:471441 Total_Item_Requests 2 1 0 0 0 1 0 0 0 0 0 0 0 Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136983 Silverchair:471441 Unique_Item_Investigations 2 1 0 0 0 1 0 0 0 0 0 0 0 Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136983 Silverchair:471441 Unique_Item_Requests 2 1 0 0 0 1 0 0 0 0 0 0 0 Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia in the United States American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005642 Silverchair:477741 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia in the United States American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005642 Silverchair:477741 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia in the United States American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005642 Silverchair:477741 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia in the United States American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021005642 Silverchair:477741 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Pre-B cell receptor–mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-331181 Silverchair:29042 Total_Item_Investigations 6 0 4 2 0 0 0 0 0 0 0 0 0 Pre-B cell receptor–mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-331181 Silverchair:29042 Total_Item_Requests 6 0 4 2 0 0 0 0 0 0 0 0 0 Pre-B cell receptor–mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-331181 Silverchair:29042 Unique_Item_Investigations 5 0 3 2 0 0 0 0 0 0 0 0 0 Pre-B cell receptor–mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-331181 Silverchair:29042 Unique_Item_Requests 5 0 3 2 0 0 0 0 0 0 0 0 0 Pre-BCR Surrogate Light Chain Components VPREB1 and IGLL1 Function As Pre-BCR-Independent Tumor Suppressors in Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115522 Silverchair:263424 Total_Item_Investigations 5 4 1 0 0 0 0 0 0 0 0 0 0 Pre-BCR Surrogate Light Chain Components VPREB1 and IGLL1 Function As Pre-BCR-Independent Tumor Suppressors in Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115522 Silverchair:263424 Total_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 Pre-BCR Surrogate Light Chain Components VPREB1 and IGLL1 Function As Pre-BCR-Independent Tumor Suppressors in Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115522 Silverchair:263424 Unique_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 Pre-BCR Surrogate Light Chain Components VPREB1 and IGLL1 Function As Pre-BCR-Independent Tumor Suppressors in Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115522 Silverchair:263424 Unique_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003805 Silverchair:475794 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 0 2 Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003805 Silverchair:475794 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 0 2 Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003805 Silverchair:475794 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003805 Silverchair:475794 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 "Preclinical Evaluation of MCLA117, a CLEC12AxCD3 Bispecific Antibody Efficiently Targeting a Novel Leukemic Stem Cell Associated Antigen in AML" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.325.325 Silverchair:91038 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Preclinical Evaluation of MCLA117, a CLEC12AxCD3 Bispecific Antibody Efficiently Targeting a Novel Leukemic Stem Cell Associated Antigen in AML" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.325.325 Silverchair:91038 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "Preclinical Evaluation of MCLA117, a CLEC12AxCD3 Bispecific Antibody Efficiently Targeting a Novel Leukemic Stem Cell Associated Antigen in AML" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.325.325 Silverchair:91038 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Preclinical Evaluation of MCLA117, a CLEC12AxCD3 Bispecific Antibody Efficiently Targeting a Novel Leukemic Stem Cell Associated Antigen in AML" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.325.325 Silverchair:91038 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2013-09-529537 Silverchair:32257 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2013-09-529537 Silverchair:32257 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2013-09-529537 Silverchair:32257 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells The American Society of Hematology American Society of Hematology 10.1182/blood-2013-09-529537 Silverchair:32257 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Precocious clonal hematopoiesis in Down syndrome is accompanied by immune dysregulation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003858 Silverchair:475593 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Precocious clonal hematopoiesis in Down syndrome is accompanied by immune dysregulation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003858 Silverchair:475593 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Precocious clonal hematopoiesis in Down syndrome is accompanied by immune dysregulation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003858 Silverchair:475593 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Precocious clonal hematopoiesis in Down syndrome is accompanied by immune dysregulation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003858 Silverchair:475593 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Predicting Early Mortality in Diffuse Large B-Cell Non-Hodgkin Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5411.5411 Silverchair:99926 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Predicting Early Mortality in Diffuse Large B-Cell Non-Hodgkin Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5411.5411 Silverchair:99926 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Predicting Early Mortality in Diffuse Large B-Cell Non-Hodgkin Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5411.5411 Silverchair:99926 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Predicting Early Mortality in Diffuse Large B-Cell Non-Hodgkin Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5411.5411 Silverchair:99926 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-641225 Silverchair:34587 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-641225 Silverchair:34587 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-641225 Silverchair:34587 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-641225 Silverchair:34587 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Predicting Resistance to the Combination of ATO and ATRA in APL Patients with PML-Rara Fusions, Using a Computational Biology Modeling Approach: Mycare-021-01" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140617 Silverchair:472469 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Predicting Resistance to the Combination of ATO and ATRA in APL Patients with PML-Rara Fusions, Using a Computational Biology Modeling Approach: Mycare-021-01" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140617 Silverchair:472469 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Predicting Resistance to the Combination of ATO and ATRA in APL Patients with PML-Rara Fusions, Using a Computational Biology Modeling Approach: Mycare-021-01" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140617 Silverchair:472469 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Predicting Resistance to the Combination of ATO and ATRA in APL Patients with PML-Rara Fusions, Using a Computational Biology Modeling Approach: Mycare-021-01" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140617 Silverchair:472469 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003001 Silverchair:474123 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003001 Silverchair:474123 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003001 Silverchair:474123 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003001 Silverchair:474123 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019031039 Silverchair:246791 Total_Item_Investigations 6 1 0 0 0 0 3 1 0 0 1 0 0 Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019031039 Silverchair:246791 Total_Item_Requests 6 1 0 0 0 0 3 1 0 0 1 0 0 Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019031039 Silverchair:246791 Unique_Item_Investigations 4 1 0 0 0 0 1 1 0 0 1 0 0 Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019031039 Silverchair:246791 Unique_Item_Requests 4 1 0 0 0 0 1 1 0 0 1 0 0 Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139468 Silverchair:470406 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139468 Silverchair:470406 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139468 Silverchair:470406 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139468 Silverchair:470406 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-550244 Silverchair:32899 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-550244 Silverchair:32899 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-550244 Silverchair:32899 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-550244 Silverchair:32899 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-840090 Silverchair:39510 Total_Item_Investigations 2 0 0 0 1 0 1 0 0 0 0 0 0 Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-840090 Silverchair:39510 Total_Item_Requests 2 0 0 0 1 0 1 0 0 0 0 0 0 Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-840090 Silverchair:39510 Unique_Item_Investigations 2 0 0 0 1 0 1 0 0 0 0 0 0 Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-840090 Silverchair:39510 Unique_Item_Requests 2 0 0 0 1 0 1 0 0 0 0 0 0 Pregnancy outcomes after maternal exposure to rituximab The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-295444 Silverchair:28353 Total_Item_Investigations 4 0 2 2 0 0 0 0 0 0 0 0 0 Pregnancy outcomes after maternal exposure to rituximab The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-295444 Silverchair:28353 Total_Item_Requests 4 0 2 2 0 0 0 0 0 0 0 0 0 Pregnancy outcomes after maternal exposure to rituximab The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-295444 Silverchair:28353 Unique_Item_Investigations 4 0 2 2 0 0 0 0 0 0 0 0 0 Pregnancy outcomes after maternal exposure to rituximab The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-295444 Silverchair:28353 Unique_Item_Requests 4 0 2 2 0 0 0 0 0 0 0 0 0 Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-538900 Silverchair:105739 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 0 2 Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-538900 Silverchair:105739 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 0 2 Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-538900 Silverchair:105739 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-538900 Silverchair:105739 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Preleukemic and leukemic evolution at the stem cell level The American Society of Hematology American Society of Hematology 10.1182/blood.2019004397 Silverchair:474417 No_License 2 0 2 0 0 0 0 0 0 0 0 0 0 Preleukemic and leukemic evolution at the stem cell level The American Society of Hematology American Society of Hematology 10.1182/blood.2019004397 Silverchair:474417 Total_Item_Investigations 6 0 4 2 0 0 0 0 0 0 0 0 0 Preleukemic and leukemic evolution at the stem cell level The American Society of Hematology American Society of Hematology 10.1182/blood.2019004397 Silverchair:474417 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Preleukemic and leukemic evolution at the stem cell level The American Society of Hematology American Society of Hematology 10.1182/blood.2019004397 Silverchair:474417 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Preleukemic and leukemic evolution at the stem cell level The American Society of Hematology American Society of Hematology 10.1182/blood.2019004397 Silverchair:474417 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "PRELI is a mitochondrial regulator of human primary T-helper cell apoptosis, STAT6, and Th2-cell differentiation" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-166553 Silverchair:25625 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "PRELI is a mitochondrial regulator of human primary T-helper cell apoptosis, STAT6, and Th2-cell differentiation" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-166553 Silverchair:25625 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "PRELI is a mitochondrial regulator of human primary T-helper cell apoptosis, STAT6, and Th2-cell differentiation" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-166553 Silverchair:25625 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "PRELI is a mitochondrial regulator of human primary T-helper cell apoptosis, STAT6, and Th2-cell differentiation" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-166553 Silverchair:25625 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Preliminary Lasso Regression Analysis Identifies DNA-Damage Gene Expression Signature Predictive of Clinical Outcomes in Patients Using Gemtuzumab Ozogamicin The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131210 Silverchair:427219 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Preliminary Lasso Regression Analysis Identifies DNA-Damage Gene Expression Signature Predictive of Clinical Outcomes in Patients Using Gemtuzumab Ozogamicin The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131210 Silverchair:427219 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Preliminary Lasso Regression Analysis Identifies DNA-Damage Gene Expression Signature Predictive of Clinical Outcomes in Patients Using Gemtuzumab Ozogamicin The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131210 Silverchair:427219 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Preliminary Lasso Regression Analysis Identifies DNA-Damage Gene Expression Signature Predictive of Clinical Outcomes in Patients Using Gemtuzumab Ozogamicin The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131210 Silverchair:427219 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127977 Silverchair:427048 Total_Item_Investigations 14 1 8 0 2 0 0 0 0 0 3 0 0 "Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127977 Silverchair:427048 Total_Item_Requests 14 1 8 0 2 0 0 0 0 0 3 0 0 "Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127977 Silverchair:427048 Unique_Item_Investigations 6 1 3 0 1 0 0 0 0 0 1 0 0 "Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127977 Silverchair:427048 Unique_Item_Requests 6 1 3 0 1 0 0 0 0 0 1 0 0 "Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141619 Silverchair:472605 Total_Item_Investigations 2 0 0 1 1 0 0 0 0 0 0 0 0 "Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141619 Silverchair:472605 Total_Item_Requests 2 0 0 1 1 0 0 0 0 0 0 0 0 "Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141619 Silverchair:472605 Unique_Item_Investigations 2 0 0 1 1 0 0 0 0 0 0 0 0 "Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141619 Silverchair:472605 Unique_Item_Requests 2 0 0 1 1 0 0 0 0 0 0 0 0 Preliminary Results from a Phase II Study of the Combination of Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115720 Silverchair:262113 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Preliminary Results from a Phase II Study of the Combination of Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115720 Silverchair:262113 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Preliminary Results from a Phase II Study of the Combination of Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115720 Silverchair:262113 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Preliminary Results from a Phase II Study of the Combination of Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115720 Silverchair:262113 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Preliminary Results from an Open-Label, Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia (CMML)" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2963.2963 Silverchair:80654 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Preliminary Results from an Open-Label, Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia (CMML)" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2963.2963 Silverchair:80654 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Preliminary Results from an Open-Label, Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia (CMML)" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2963.2963 Silverchair:80654 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Preliminary Results from an Open-Label, Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia (CMML)" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2963.2963 Silverchair:80654 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Pre-Planned Interim Safety Analysis of the Niveau Trial, a Randomized Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139459 Silverchair:472706 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 "Pre-Planned Interim Safety Analysis of the Niveau Trial, a Randomized Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139459 Silverchair:472706 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 "Pre-Planned Interim Safety Analysis of the Niveau Trial, a Randomized Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139459 Silverchair:472706 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 "Pre-Planned Interim Safety Analysis of the Niveau Trial, a Randomized Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139459 Silverchair:472706 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Presence of JAK2V617F Mutation in Endothelial Cells from Budd-Chiari Syndrome Patients Is Not Correlated with Ph-Negative Myeloproliferative Neoplasm The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4998.4998 Silverchair:93765 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Presence of JAK2V617F Mutation in Endothelial Cells from Budd-Chiari Syndrome Patients Is Not Correlated with Ph-Negative Myeloproliferative Neoplasm The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4998.4998 Silverchair:93765 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Presence of JAK2V617F Mutation in Endothelial Cells from Budd-Chiari Syndrome Patients Is Not Correlated with Ph-Negative Myeloproliferative Neoplasm The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4998.4998 Silverchair:93765 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Presence of JAK2V617F Mutation in Endothelial Cells from Budd-Chiari Syndrome Patients Is Not Correlated with Ph-Negative Myeloproliferative Neoplasm The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4998.4998 Silverchair:93765 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Preservation of T-Cell Stemness with a Novel Expansionless CAR-T Manufacturing Process, Which Reduces Manufacturing Time to Less Than Two Days, Drives Enhanced CAR-T Cell Efficacy" The American Society of Hematology American Society of Hematology 10.1182/blood-2021-146246 Silverchair:481328 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 "Preservation of T-Cell Stemness with a Novel Expansionless CAR-T Manufacturing Process, Which Reduces Manufacturing Time to Less Than Two Days, Drives Enhanced CAR-T Cell Efficacy" The American Society of Hematology American Society of Hematology 10.1182/blood-2021-146246 Silverchair:481328 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 "Preservation of T-Cell Stemness with a Novel Expansionless CAR-T Manufacturing Process, Which Reduces Manufacturing Time to Less Than Two Days, Drives Enhanced CAR-T Cell Efficacy" The American Society of Hematology American Society of Hematology 10.1182/blood-2021-146246 Silverchair:481328 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 "Preservation of T-Cell Stemness with a Novel Expansionless CAR-T Manufacturing Process, Which Reduces Manufacturing Time to Less Than Two Days, Drives Enhanced CAR-T Cell Efficacy" The American Society of Hematology American Society of Hematology 10.1182/blood-2021-146246 Silverchair:481328 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 "Pretorius E, Lipinski B. Iron alters red blood cell morphology. Blood. 2013;121(1):9." The American Society of Hematology American Society of Hematology 10.1182/blood-2014-02-554477 Silverchair:105744 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Pretorius E, Lipinski B. Iron alters red blood cell morphology. Blood. 2013;121(1):9." The American Society of Hematology American Society of Hematology 10.1182/blood-2014-02-554477 Silverchair:105744 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Pretorius E, Lipinski B. Iron alters red blood cell morphology. Blood. 2013;121(1):9." The American Society of Hematology American Society of Hematology 10.1182/blood-2014-02-554477 Silverchair:105744 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Pretorius E, Lipinski B. Iron alters red blood cell morphology. Blood. 2013;121(1):9." The American Society of Hematology American Society of Hematology 10.1182/blood-2014-02-554477 Silverchair:105744 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population The American Society of Hematology American Society of Hematology 10.1182/blood.2019001113 Silverchair:273900 Total_Item_Investigations 5 4 0 1 0 0 0 0 0 0 0 0 0 Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population The American Society of Hematology American Society of Hematology 10.1182/blood.2019001113 Silverchair:273900 Total_Item_Requests 5 4 0 1 0 0 0 0 0 0 0 0 0 Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population The American Society of Hematology American Society of Hematology 10.1182/blood.2019001113 Silverchair:273900 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population The American Society of Hematology American Society of Hematology 10.1182/blood.2019001113 Silverchair:273900 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Prevalence and Predictors of Neurocognitive Impairment in Long-Term Survivors of Childhood Hodgkin Lymphoma: A Report from the Childhood Cancer Survivor Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136339 Silverchair:469847 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Prevalence and Predictors of Neurocognitive Impairment in Long-Term Survivors of Childhood Hodgkin Lymphoma: A Report from the Childhood Cancer Survivor Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136339 Silverchair:469847 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Prevalence and Predictors of Neurocognitive Impairment in Long-Term Survivors of Childhood Hodgkin Lymphoma: A Report from the Childhood Cancer Survivor Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136339 Silverchair:469847 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Prevalence and Predictors of Neurocognitive Impairment in Long-Term Survivors of Childhood Hodgkin Lymphoma: A Report from the Childhood Cancer Survivor Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136339 Silverchair:469847 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Prevalence of JAK2 V617F in Individuals That Meet World Health Organization Erythrocytosis Criteria for Polycythemia Vera The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110619 Silverchair:273005 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Prevalence of JAK2 V617F in Individuals That Meet World Health Organization Erythrocytosis Criteria for Polycythemia Vera The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110619 Silverchair:273005 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Prevalence of JAK2 V617F in Individuals That Meet World Health Organization Erythrocytosis Criteria for Polycythemia Vera The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110619 Silverchair:273005 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Prevalence of JAK2 V617F in Individuals That Meet World Health Organization Erythrocytosis Criteria for Polycythemia Vera The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110619 Silverchair:273005 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Prevalence of Low Limb Venous Thromboembolic Events in Mild and Severe/Critically Ill Patients with COVID-19 Despite Pharmacological Thromboprophylaxis The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142077 Silverchair:473194 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Prevalence of Low Limb Venous Thromboembolic Events in Mild and Severe/Critically Ill Patients with COVID-19 Despite Pharmacological Thromboprophylaxis The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142077 Silverchair:473194 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Prevalence of Low Limb Venous Thromboembolic Events in Mild and Severe/Critically Ill Patients with COVID-19 Despite Pharmacological Thromboprophylaxis The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142077 Silverchair:473194 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Prevalence of Low Limb Venous Thromboembolic Events in Mild and Severe/Critically Ill Patients with COVID-19 Despite Pharmacological Thromboprophylaxis The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142077 Silverchair:473194 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Prevalence of Polycythemia Vera and Essential Thrombocythemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4667.4667 Silverchair:117821 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Prevalence of Polycythemia Vera and Essential Thrombocythemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4667.4667 Silverchair:117821 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Prevalence of Polycythemia Vera and Essential Thrombocythemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4667.4667 Silverchair:117821 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Prevalence of Polycythemia Vera and Essential Thrombocythemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4667.4667 Silverchair:117821 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Prevalence of Thrombophilia in Transient Ischemic Attack and Ischemic Stroke Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-133476 Silverchair:473209 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Prevalence of Thrombophilia in Transient Ischemic Attack and Ischemic Stroke Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-133476 Silverchair:473209 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Prevalence of Thrombophilia in Transient Ischemic Attack and Ischemic Stroke Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-133476 Silverchair:473209 Unique_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Prevalence of Thrombophilia in Transient Ischemic Attack and Ischemic Stroke Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-133476 Silverchair:473209 Unique_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 "Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged =80 years" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004062 Silverchair:475741 Total_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 "Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged =80 years" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004062 Silverchair:475741 Total_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 "Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged =80 years" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004062 Silverchair:475741 Unique_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 "Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged =80 years" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020004062 Silverchair:475741 Unique_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000120 Silverchair:474328 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000120 Silverchair:474328 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000120 Silverchair:474328 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000120 Silverchair:474328 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Preventing infections in children and adults with asplenia The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000117 Silverchair:474295 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Preventing infections in children and adults with asplenia The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000117 Silverchair:474295 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Preventing infections in children and adults with asplenia The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000117 Silverchair:474295 Unique_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Preventing infections in children and adults with asplenia The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000117 Silverchair:474295 Unique_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Prevention of transfusion-transmitted infections The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-833996 Silverchair:275902 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Prevention of transfusion-transmitted infections The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-833996 Silverchair:275902 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Prevention of transfusion-transmitted infections The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-833996 Silverchair:275902 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Prevention of transfusion-transmitted infections The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-833996 Silverchair:275902 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy: Real-World Examination of the Impede Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140175 Silverchair:472412 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy: Real-World Examination of the Impede Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140175 Silverchair:472412 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy: Real-World Examination of the Impede Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140175 Silverchair:472412 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy: Real-World Examination of the Impede Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140175 Silverchair:472412 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-653840 Silverchair:35026 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-653840 Silverchair:35026 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-653840 Silverchair:35026 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-653840 Silverchair:35026 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136834 Silverchair:470462 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136834 Silverchair:470462 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136834 Silverchair:470462 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136834 Silverchair:470462 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-627323 Silverchair:34762 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-627323 Silverchair:34762 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-627323 Silverchair:34762 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-627323 Silverchair:34762 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Primary Central Nervous System Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020008377 Silverchair:477460 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Primary Central Nervous System Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020008377 Silverchair:477460 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Primary Central Nervous System Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020008377 Silverchair:477460 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Primary Central Nervous System Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020008377 Silverchair:477460 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "Primary Cutaneous Anaplastic Large-Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis from 2005-2016" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131991 Silverchair:424321 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Primary Cutaneous Anaplastic Large-Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis from 2005-2016" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131991 Silverchair:424321 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "Primary Cutaneous Anaplastic Large-Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis from 2005-2016" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131991 Silverchair:424321 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Primary Cutaneous Anaplastic Large-Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis from 2005-2016" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131991 Silverchair:424321 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Primary human herpesvirus 8–negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002293 Silverchair:463760 Total_Item_Investigations 5 0 5 0 0 0 0 0 0 0 0 0 0 Primary human herpesvirus 8–negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002293 Silverchair:463760 Total_Item_Requests 5 0 5 0 0 0 0 0 0 0 0 0 0 Primary human herpesvirus 8–negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002293 Silverchair:463760 Unique_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Primary human herpesvirus 8–negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002293 Silverchair:463760 Unique_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Primary testicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-530659 Silverchair:32293 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Primary testicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-530659 Silverchair:32293 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Primary testicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-530659 Silverchair:32293 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Primary testicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2013-10-530659 Silverchair:32293 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003115 Silverchair:469733 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003115 Silverchair:469733 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003115 Silverchair:469733 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003115 Silverchair:469733 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Primum non nocere: allo-HSCT for AML in CR1 The American Society of Hematology American Society of Hematology 10.1182/blood.2020008641 Silverchair:475020 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Primum non nocere: allo-HSCT for AML in CR1 The American Society of Hematology American Society of Hematology 10.1182/blood.2020008641 Silverchair:475020 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Primum non nocere: allo-HSCT for AML in CR1 The American Society of Hematology American Society of Hematology 10.1182/blood.2020008641 Silverchair:475020 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Primum non nocere: allo-HSCT for AML in CR1 The American Society of Hematology American Society of Hematology 10.1182/blood.2020008641 Silverchair:475020 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2003-01-0255 Silverchair:17500 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2003-01-0255 Silverchair:17500 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2003-01-0255 Silverchair:17500 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2003-01-0255 Silverchair:17500 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 PRL2 Phosphatase Is a Key Mediator of Oncogenic Cytokine Signaling in Leukemia Stem Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.724.724 Silverchair:98943 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 PRL2 Phosphatase Is a Key Mediator of Oncogenic Cytokine Signaling in Leukemia Stem Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.724.724 Silverchair:98943 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 PRL2 Phosphatase Is a Key Mediator of Oncogenic Cytokine Signaling in Leukemia Stem Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.724.724 Silverchair:98943 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 PRL2 Phosphatase Is a Key Mediator of Oncogenic Cytokine Signaling in Leukemia Stem Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.724.724 Silverchair:98943 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Profiling the Peripheral Blood Immune Cell Repertoire in Large-B Cell Lymphoma Patients Treated with CD19 CAR-T The American Society of Hematology American Society of Hematology 10.1182/blood-2021-151459 Silverchair:482380 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Profiling the Peripheral Blood Immune Cell Repertoire in Large-B Cell Lymphoma Patients Treated with CD19 CAR-T The American Society of Hematology American Society of Hematology 10.1182/blood-2021-151459 Silverchair:482380 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Profiling the Peripheral Blood Immune Cell Repertoire in Large-B Cell Lymphoma Patients Treated with CD19 CAR-T The American Society of Hematology American Society of Hematology 10.1182/blood-2021-151459 Silverchair:482380 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Profiling the Peripheral Blood Immune Cell Repertoire in Large-B Cell Lymphoma Patients Treated with CD19 CAR-T The American Society of Hematology American Society of Hematology 10.1182/blood-2021-151459 Silverchair:482380 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup The American Society of Hematology American Society of Hematology 10.1182/blood-2002-11-3527 Silverchair:17381 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup The American Society of Hematology American Society of Hematology 10.1182/blood-2002-11-3527 Silverchair:17381 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup The American Society of Hematology American Society of Hematology 10.1182/blood-2002-11-3527 Silverchair:17381 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup The American Society of Hematology American Society of Hematology 10.1182/blood-2002-11-3527 Silverchair:17381 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax The American Society of Hematology American Society of Hematology 10.1182/blood.2019004492 Silverchair:452766 No_License 1 0 0 1 0 0 0 0 0 0 0 0 0 Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax The American Society of Hematology American Society of Hematology 10.1182/blood.2019004492 Silverchair:452766 Total_Item_Investigations 4 0 0 4 0 0 0 0 0 0 0 0 0 Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax The American Society of Hematology American Society of Hematology 10.1182/blood.2019004492 Silverchair:452766 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax The American Society of Hematology American Society of Hematology 10.1182/blood.2019004492 Silverchair:452766 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax The American Society of Hematology American Society of Hematology 10.1182/blood.2019004492 Silverchair:452766 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002838 Silverchair:474719 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002838 Silverchair:474719 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002838 Silverchair:474719 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002838 Silverchair:474719 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003120 Silverchair:474196 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003120 Silverchair:474196 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003120 Silverchair:474196 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003120 Silverchair:474196 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients The American Society of Hematology American Society of Hematology 10.1182/blood.V99.3.840 Silverchair:53495 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients The American Society of Hematology American Society of Hematology 10.1182/blood.V99.3.840 Silverchair:53495 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients The American Society of Hematology American Society of Hematology 10.1182/blood.V99.3.840 Silverchair:53495 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients The American Society of Hematology American Society of Hematology 10.1182/blood.V99.3.840 Silverchair:53495 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-587089 Silverchair:34158 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-587089 Silverchair:34158 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-587089 Silverchair:34158 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-587089 Silverchair:34158 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-289280 Silverchair:28093 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-289280 Silverchair:28093 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-289280 Silverchair:28093 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine The American Society of Hematology American Society of Hematology 10.1182/blood-2010-06-289280 Silverchair:28093 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study The American Society of Hematology American Society of Hematology 10.1182/blood-2005-09-3640 Silverchair:133489 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study The American Society of Hematology American Society of Hematology 10.1182/blood-2005-09-3640 Silverchair:133489 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study The American Society of Hematology American Society of Hematology 10.1182/blood-2005-09-3640 Silverchair:133489 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study The American Society of Hematology American Society of Hematology 10.1182/blood-2005-09-3640 Silverchair:133489 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002811 Silverchair:474429 Total_Item_Investigations 3 1 2 0 0 0 0 0 0 0 0 0 0 Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002811 Silverchair:474429 Total_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002811 Silverchair:474429 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002811 Silverchair:474429 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Prognostic impact of CSF3R mutations in favorable risk childhood acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019004179 Silverchair:452717 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Prognostic impact of CSF3R mutations in favorable risk childhood acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019004179 Silverchair:452717 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Prognostic impact of CSF3R mutations in favorable risk childhood acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019004179 Silverchair:452717 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Prognostic impact of CSF3R mutations in favorable risk childhood acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019004179 Silverchair:452717 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001904 Silverchair:463299 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001904 Silverchair:463299 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001904 Silverchair:463299 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001904 Silverchair:463299 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 "Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-307280 Silverchair:28409 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-307280 Silverchair:28409 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-307280 Silverchair:28409 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-307280 Silverchair:28409 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Prognostic irrelevance of ring sideroblast percentage in World Health Organization–defined myelodysplastic syndromes without excess blasts The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-415356 Silverchair:30309 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Prognostic irrelevance of ring sideroblast percentage in World Health Organization–defined myelodysplastic syndromes without excess blasts The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-415356 Silverchair:30309 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Prognostic irrelevance of ring sideroblast percentage in World Health Organization–defined myelodysplastic syndromes without excess blasts The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-415356 Silverchair:30309 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Prognostic irrelevance of ring sideroblast percentage in World Health Organization–defined myelodysplastic syndromes without excess blasts The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-415356 Silverchair:30309 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients The American Society of Hematology American Society of Hematology 10.1182/blood-2007-05-091215 Silverchair:109934 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients The American Society of Hematology American Society of Hematology 10.1182/blood-2007-05-091215 Silverchair:109934 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients The American Society of Hematology American Society of Hematology 10.1182/blood-2007-05-091215 Silverchair:109934 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients The American Society of Hematology American Society of Hematology 10.1182/blood-2007-05-091215 Silverchair:109934 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm The American Society of Hematology American Society of Hematology 10.1182/blood-2002-05-1440 Silverchair:106081 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm The American Society of Hematology American Society of Hematology 10.1182/blood-2002-05-1440 Silverchair:106081 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm The American Society of Hematology American Society of Hematology 10.1182/blood-2002-05-1440 Silverchair:106081 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm The American Society of Hematology American Society of Hematology 10.1182/blood-2002-05-1440 Silverchair:106081 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Prognostic Significance of Anaplastic Lymphoma Kinase (ALK) Protein Expression in Adults With Anaplastic Large Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V93.11.3913 Silverchair:261221 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Prognostic Significance of Anaplastic Lymphoma Kinase (ALK) Protein Expression in Adults With Anaplastic Large Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V93.11.3913 Silverchair:261221 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Prognostic Significance of Anaplastic Lymphoma Kinase (ALK) Protein Expression in Adults With Anaplastic Large Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V93.11.3913 Silverchair:261221 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Prognostic Significance of Anaplastic Lymphoma Kinase (ALK) Protein Expression in Adults With Anaplastic Large Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V93.11.3913 Silverchair:261221 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Progression in smoldering Waldenström macroglobulinemia: long-term results The American Society of Hematology American Society of Hematology 10.1182/blood-2011-10-384768 Silverchair:29975 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Progression in smoldering Waldenström macroglobulinemia: long-term results The American Society of Hematology American Society of Hematology 10.1182/blood-2011-10-384768 Silverchair:29975 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Progression in smoldering Waldenström macroglobulinemia: long-term results The American Society of Hematology American Society of Hematology 10.1182/blood-2011-10-384768 Silverchair:29975 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Progression in smoldering Waldenström macroglobulinemia: long-term results The American Society of Hematology American Society of Hematology 10.1182/blood-2011-10-384768 Silverchair:29975 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001114 Silverchair:452609 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001114 Silverchair:452609 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001114 Silverchair:452609 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001114 Silverchair:452609 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy The American Society of Hematology American Society of Hematology 10.1182/blood.2019003591 Silverchair:431277 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy The American Society of Hematology American Society of Hematology 10.1182/blood.2019003591 Silverchair:431277 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy The American Society of Hematology American Society of Hematology 10.1182/blood.2019003591 Silverchair:431277 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy The American Society of Hematology American Society of Hematology 10.1182/blood.2019003591 Silverchair:431277 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Prolongation of Progression Free Survival In Mantle Cell Lymphoma After RHCVAD: ASCT Consolidation or Rituximab Maintenance The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.3570.3570 Silverchair:66339 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Prolongation of Progression Free Survival In Mantle Cell Lymphoma After RHCVAD: ASCT Consolidation or Rituximab Maintenance The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.3570.3570 Silverchair:66339 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Prolongation of Progression Free Survival In Mantle Cell Lymphoma After RHCVAD: ASCT Consolidation or Rituximab Maintenance The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.3570.3570 Silverchair:66339 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Prolongation of Progression Free Survival In Mantle Cell Lymphoma After RHCVAD: ASCT Consolidation or Rituximab Maintenance The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.3570.3570 Silverchair:66339 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 "Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Krüppel-like factor (KLF2)" The American Society of Hematology American Society of Hematology 10.1182/blood-2002-01-0046 Silverchair:106384 Total_Item_Investigations 4 0 1 3 0 0 0 0 0 0 0 0 0 "Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Krüppel-like factor (KLF2)" The American Society of Hematology American Society of Hematology 10.1182/blood-2002-01-0046 Silverchair:106384 Total_Item_Requests 4 0 1 3 0 0 0 0 0 0 0 0 0 "Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Krüppel-like factor (KLF2)" The American Society of Hematology American Society of Hematology 10.1182/blood-2002-01-0046 Silverchair:106384 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 "Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Krüppel-like factor (KLF2)" The American Society of Hematology American Society of Hematology 10.1182/blood-2002-01-0046 Silverchair:106384 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Prolonged maintenance of hematopoietic stem cells that escape from Thrombopoietin deprivation The American Society of Hematology American Society of Hematology 10.1182/blood.2020005517 Silverchair:475410 Total_Item_Investigations 12 0 0 12 0 0 0 0 0 0 0 0 0 Prolonged maintenance of hematopoietic stem cells that escape from Thrombopoietin deprivation The American Society of Hematology American Society of Hematology 10.1182/blood.2020005517 Silverchair:475410 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Prolonged shear stress and KLF2 suppress constitutive proinflammatory transcription through inhibition of ATF2 The American Society of Hematology American Society of Hematology 10.1182/blood-2006-07-036020 Silverchair:22875 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Prolonged shear stress and KLF2 suppress constitutive proinflammatory transcription through inhibition of ATF2 The American Society of Hematology American Society of Hematology 10.1182/blood-2006-07-036020 Silverchair:22875 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Prolonged shear stress and KLF2 suppress constitutive proinflammatory transcription through inhibition of ATF2 The American Society of Hematology American Society of Hematology 10.1182/blood-2006-07-036020 Silverchair:22875 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Prolonged shear stress and KLF2 suppress constitutive proinflammatory transcription through inhibition of ATF2 The American Society of Hematology American Society of Hematology 10.1182/blood-2006-07-036020 Silverchair:22875 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-788323 Silverchair:36574 Total_Item_Investigations 3 1 0 0 0 0 0 0 0 2 0 0 0 Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-788323 Silverchair:36574 Total_Item_Requests 2 1 0 0 0 0 0 0 0 1 0 0 0 Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-788323 Silverchair:36574 Unique_Item_Investigations 2 1 0 0 0 0 0 0 0 1 0 0 0 Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-788323 Silverchair:36574 Unique_Item_Requests 2 1 0 0 0 0 0 0 0 1 0 0 0 Promyelocytic extracellular chromatin exacerbates coagulation and fibrinolysis in acute promyelocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-739334 Silverchair:35845 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Promyelocytic extracellular chromatin exacerbates coagulation and fibrinolysis in acute promyelocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-739334 Silverchair:35845 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Promyelocytic extracellular chromatin exacerbates coagulation and fibrinolysis in acute promyelocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-739334 Silverchair:35845 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Promyelocytic extracellular chromatin exacerbates coagulation and fibrinolysis in acute promyelocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-739334 Silverchair:35845 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML The American Society of Hematology American Society of Hematology 10.1182/blood.2020009759 Silverchair:475335 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML The American Society of Hematology American Society of Hematology 10.1182/blood.2020009759 Silverchair:475335 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Properties of mouse and human IgG receptors and their contribution to disease models The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-380121 Silverchair:30328 Total_Item_Investigations 10 3 4 3 0 0 0 0 0 0 0 0 0 Properties of mouse and human IgG receptors and their contribution to disease models The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-380121 Silverchair:30328 Total_Item_Requests 10 3 4 3 0 0 0 0 0 0 0 0 0 Properties of mouse and human IgG receptors and their contribution to disease models The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-380121 Silverchair:30328 Unique_Item_Investigations 7 3 2 2 0 0 0 0 0 0 0 0 0 Properties of mouse and human IgG receptors and their contribution to disease models The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-380121 Silverchair:30328 Unique_Item_Requests 7 3 2 2 0 0 0 0 0 0 0 0 0 Prophylactic Antibiotic Use and Risk of Meningococcal Infections in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Eculizumab Who Received Meningococcal Vaccination: Results from the International PNH Registry The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127005 Silverchair:428731 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Prophylactic Antibiotic Use and Risk of Meningococcal Infections in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Eculizumab Who Received Meningococcal Vaccination: Results from the International PNH Registry The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127005 Silverchair:428731 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Prophylactic Antibiotic Use and Risk of Meningococcal Infections in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Eculizumab Who Received Meningococcal Vaccination: Results from the International PNH Registry The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127005 Silverchair:428731 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Prophylactic Antibiotic Use and Risk of Meningococcal Infections in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Eculizumab Who Received Meningococcal Vaccination: Results from the International PNH Registry The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127005 Silverchair:428731 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Prophylactic or Preemptive Low-Dose Azacitidine (AZA) and Donor Lymphocyte Infusion (DLI) Prevent Disease Relapse Following Allogeneic Transplantation in High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123402 Silverchair:424585 Total_Item_Investigations 4 2 0 0 2 0 0 0 0 0 0 0 0 Prophylactic or Preemptive Low-Dose Azacitidine (AZA) and Donor Lymphocyte Infusion (DLI) Prevent Disease Relapse Following Allogeneic Transplantation in High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123402 Silverchair:424585 Total_Item_Requests 4 2 0 0 2 0 0 0 0 0 0 0 0 Prophylactic or Preemptive Low-Dose Azacitidine (AZA) and Donor Lymphocyte Infusion (DLI) Prevent Disease Relapse Following Allogeneic Transplantation in High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123402 Silverchair:424585 Unique_Item_Investigations 2 1 0 0 1 0 0 0 0 0 0 0 0 Prophylactic or Preemptive Low-Dose Azacitidine (AZA) and Donor Lymphocyte Infusion (DLI) Prevent Disease Relapse Following Allogeneic Transplantation in High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123402 Silverchair:424585 Unique_Item_Requests 2 1 0 0 1 0 0 0 0 0 0 0 0 Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134612 Silverchair:472581 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134612 Silverchair:472581 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134612 Silverchair:472581 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134612 Silverchair:472581 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-649319 Silverchair:34665 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-649319 Silverchair:34665 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-649319 Silverchair:34665 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-649319 Silverchair:34665 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Prophylactic Use of Sorafenib in Patients with FLT3-ITD-Positive Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3943.3943 Silverchair:115493 Total_Item_Investigations 4 0 0 4 0 0 0 0 0 0 0 0 0 Prophylactic Use of Sorafenib in Patients with FLT3-ITD-Positive Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3943.3943 Silverchair:115493 Total_Item_Requests 4 0 0 4 0 0 0 0 0 0 0 0 0 Prophylactic Use of Sorafenib in Patients with FLT3-ITD-Positive Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3943.3943 Silverchair:115493 Unique_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Prophylactic Use of Sorafenib in Patients with FLT3-ITD-Positive Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3943.3943 Silverchair:115493 Unique_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Prophylaxis in hemophilia: how much is enough? The American Society of Hematology American Society of Hematology 10.1182/blood.2020009603 Silverchair:475611 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 2 0 0 0 Prophylaxis in hemophilia: how much is enough? The American Society of Hematology American Society of Hematology 10.1182/blood.2020009603 Silverchair:475611 Total_Item_Requests 2 0 0 0 0 0 0 0 0 2 0 0 0 Prophylaxis in hemophilia: how much is enough? The American Society of Hematology American Society of Hematology 10.1182/blood.2020009603 Silverchair:475611 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Prophylaxis in hemophilia: how much is enough? The American Society of Hematology American Society of Hematology 10.1182/blood.2020009603 Silverchair:475611 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Prophylaxis with Intrathecal Chemotherapy and High Dose Methotrexate in Patients with Diffuse Large B Cell Lymphoma at High Risk for Central Nervous System Relapse: A Single Centre Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119164 Silverchair:265837 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Prophylaxis with Intrathecal Chemotherapy and High Dose Methotrexate in Patients with Diffuse Large B Cell Lymphoma at High Risk for Central Nervous System Relapse: A Single Centre Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119164 Silverchair:265837 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Prophylaxis with Intrathecal Chemotherapy and High Dose Methotrexate in Patients with Diffuse Large B Cell Lymphoma at High Risk for Central Nervous System Relapse: A Single Centre Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119164 Silverchair:265837 Unique_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Prophylaxis with Intrathecal Chemotherapy and High Dose Methotrexate in Patients with Diffuse Large B Cell Lymphoma at High Risk for Central Nervous System Relapse: A Single Centre Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119164 Silverchair:265837 Unique_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-857102 Silverchair:272723 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-857102 Silverchair:272723 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-857102 Silverchair:272723 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-857102 Silverchair:272723 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-825349 Silverchair:260549 Total_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-825349 Silverchair:260549 Total_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-825349 Silverchair:260549 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-825349 Silverchair:260549 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study The American Society of Hematology American Society of Hematology 10.1182/blood.2019002969 Silverchair:430031 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study The American Society of Hematology American Society of Hematology 10.1182/blood.2019002969 Silverchair:430031 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study The American Society of Hematology American Society of Hematology 10.1182/blood.2019002969 Silverchair:430031 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study The American Society of Hematology American Society of Hematology 10.1182/blood.2019002969 Silverchair:430031 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115418 Silverchair:263590 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115418 Silverchair:263590 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115418 Silverchair:263590 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115418 Silverchair:263590 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018023077 Silverchair:16102 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018023077 Silverchair:16102 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018023077 Silverchair:16102 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018023077 Silverchair:16102 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Prospective Evaluation of Azacitidine Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.5476.5476 Silverchair:134406 Total_Item_Investigations 2 1 0 0 1 0 0 0 0 0 0 0 0 Prospective Evaluation of Azacitidine Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.5476.5476 Silverchair:134406 Total_Item_Requests 2 1 0 0 1 0 0 0 0 0 0 0 0 Prospective Evaluation of Azacitidine Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.5476.5476 Silverchair:134406 Unique_Item_Investigations 2 1 0 0 1 0 0 0 0 0 0 0 0 Prospective Evaluation of Azacitidine Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.5476.5476 Silverchair:134406 Unique_Item_Requests 2 1 0 0 1 0 0 0 0 0 0 0 0 Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000709 Silverchair:430037 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000709 Silverchair:430037 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000709 Silverchair:430037 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000709 Silverchair:430037 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-192054 Silverchair:25668 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-192054 Silverchair:25668 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-192054 Silverchair:25668 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-192054 Silverchair:25668 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002160 Silverchair:461755 Total_Item_Investigations 3 2 0 0 0 1 0 0 0 0 0 0 0 Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002160 Silverchair:461755 Total_Item_Requests 3 2 0 0 0 1 0 0 0 0 0 0 0 Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002160 Silverchair:461755 Unique_Item_Investigations 2 1 0 0 0 1 0 0 0 0 0 0 0 Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002160 Silverchair:461755 Unique_Item_Requests 2 1 0 0 0 1 0 0 0 0 0 0 0 Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-099168 Silverchair:25529 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-099168 Silverchair:25529 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-099168 Silverchair:25529 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-099168 Silverchair:25529 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Prospective Phase II Study of Prophylactic Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1162.1162 Silverchair:96310 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Prospective Phase II Study of Prophylactic Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1162.1162 Silverchair:96310 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Prospective Phase II Study of Prophylactic Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1162.1162 Silverchair:96310 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Prospective Phase II Study of Prophylactic Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1162.1162 Silverchair:96310 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Prospective Study of Peri-Transplant Use of Sorafenib As Remission Maintenance for FLT3-ITD Patients Undergoing Allogeneic Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3164.3164 Silverchair:91023 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Prospective Study of Peri-Transplant Use of Sorafenib As Remission Maintenance for FLT3-ITD Patients Undergoing Allogeneic Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3164.3164 Silverchair:91023 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Prospective Study of Peri-Transplant Use of Sorafenib As Remission Maintenance for FLT3-ITD Patients Undergoing Allogeneic Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3164.3164 Silverchair:91023 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Prospective Study of Peri-Transplant Use of Sorafenib As Remission Maintenance for FLT3-ITD Patients Undergoing Allogeneic Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.3164.3164 Silverchair:91023 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Prostaglandin E2 stimulates cAMP signaling and resensitizes human leukemia cells to glucocorticoid-induced cell death The American Society of Hematology American Society of Hematology 10.1182/blood.2020005712 Silverchair:461709 No_License 3 0 3 0 0 0 0 0 0 0 0 0 0 Prostaglandin E2 stimulates cAMP signaling and resensitizes human leukemia cells to glucocorticoid-induced cell death The American Society of Hematology American Society of Hematology 10.1182/blood.2020005712 Silverchair:461709 Total_Item_Investigations 5 0 5 0 0 0 0 0 0 0 0 0 0 Prostaglandin E2 stimulates cAMP signaling and resensitizes human leukemia cells to glucocorticoid-induced cell death The American Society of Hematology American Society of Hematology 10.1182/blood.2020005712 Silverchair:461709 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART The American Society of Hematology American Society of Hematology 10.1182/blood.V98.10.3006 Silverchair:53042 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART The American Society of Hematology American Society of Hematology 10.1182/blood.V98.10.3006 Silverchair:53042 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART The American Society of Hematology American Society of Hematology 10.1182/blood.V98.10.3006 Silverchair:53042 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART The American Society of Hematology American Society of Hematology 10.1182/blood.V98.10.3006 Silverchair:53042 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Protease-activated receptors in hemostasis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-636472 Silverchair:35446 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Protease-activated receptors in hemostasis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-636472 Silverchair:35446 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Protease-activated receptors in hemostasis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-636472 Silverchair:35446 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Protease-activated receptors in hemostasis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-636472 Silverchair:35446 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-κB The American Society of Hematology American Society of Hematology 10.1182/blood-2007-10-121137 Silverchair:24532 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-κB The American Society of Hematology American Society of Hematology 10.1182/blood-2007-10-121137 Silverchair:24532 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-κB The American Society of Hematology American Society of Hematology 10.1182/blood-2007-10-121137 Silverchair:24532 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-κB The American Society of Hematology American Society of Hematology 10.1182/blood-2007-10-121137 Silverchair:24532 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism The American Society of Hematology American Society of Hematology 10.1182/blood.2019004571 Silverchair:475138 No_License 1 0 0 0 0 0 0 0 1 0 0 0 0 Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism The American Society of Hematology American Society of Hematology 10.1182/blood.2019004571 Silverchair:475138 Total_Item_Investigations 3 0 0 0 0 0 1 0 2 0 0 0 0 Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism The American Society of Hematology American Society of Hematology 10.1182/blood.2019004571 Silverchair:475138 Unique_Item_Investigations 2 0 0 0 0 0 1 0 1 0 0 0 0 Protein kinase D-HDAC5 signaling regulates erythropoiesis and contributes to erythropoietin cross-talk with GATA1 The American Society of Hematology American Society of Hematology 10.1182/blood-2011-10-387050 Silverchair:30576 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Protein kinase D-HDAC5 signaling regulates erythropoiesis and contributes to erythropoietin cross-talk with GATA1 The American Society of Hematology American Society of Hematology 10.1182/blood-2011-10-387050 Silverchair:30576 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Protein kinase D-HDAC5 signaling regulates erythropoiesis and contributes to erythropoietin cross-talk with GATA1 The American Society of Hematology American Society of Hematology 10.1182/blood-2011-10-387050 Silverchair:30576 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Protein kinase D-HDAC5 signaling regulates erythropoiesis and contributes to erythropoietin cross-talk with GATA1 The American Society of Hematology American Society of Hematology 10.1182/blood-2011-10-387050 Silverchair:30576 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2008-10-184515 Silverchair:26312 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2008-10-184515 Silverchair:26312 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2008-10-184515 Silverchair:26312 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2008-10-184515 Silverchair:26312 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Proteolytic properties of single-chain factor XII: a mechanism for triggering contact activation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-744110 Silverchair:35944 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 Proteolytic properties of single-chain factor XII: a mechanism for triggering contact activation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-744110 Silverchair:35944 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 Proteolytic properties of single-chain factor XII: a mechanism for triggering contact activation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-744110 Silverchair:35944 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Proteolytic properties of single-chain factor XII: a mechanism for triggering contact activation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-744110 Silverchair:35944 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Prothrombin Complex Concentrates (PCCs) Have Limited Effect on TF-Initiated Thrombin Generation in FXa Inhibitor-Anticoagulated Plasma: In Vitro Comparison between Direct Reversal By Andexanet Alfa and ""Work Around"" By PCCs" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124864 Silverchair:427017 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Prothrombin Complex Concentrates (PCCs) Have Limited Effect on TF-Initiated Thrombin Generation in FXa Inhibitor-Anticoagulated Plasma: In Vitro Comparison between Direct Reversal By Andexanet Alfa and ""Work Around"" By PCCs" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124864 Silverchair:427017 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Prothrombin Complex Concentrates (PCCs) Have Limited Effect on TF-Initiated Thrombin Generation in FXa Inhibitor-Anticoagulated Plasma: In Vitro Comparison between Direct Reversal By Andexanet Alfa and ""Work Around"" By PCCs" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124864 Silverchair:427017 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Prothrombin Complex Concentrates (PCCs) Have Limited Effect on TF-Initiated Thrombin Generation in FXa Inhibitor-Anticoagulated Plasma: In Vitro Comparison between Direct Reversal By Andexanet Alfa and ""Work Around"" By PCCs" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124864 Silverchair:427017 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018018036 Silverchair:16083 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018018036 Silverchair:16083 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018018036 Silverchair:16083 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018018036 Silverchair:16083 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-837633 Silverchair:39368 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-837633 Silverchair:39368 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-837633 Silverchair:39368 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-837633 Silverchair:39368 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-274969 Silverchair:28214 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-274969 Silverchair:28214 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-274969 Silverchair:28214 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-274969 Silverchair:28214 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Pseudothrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-295212 Silverchair:20778 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Pseudothrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-295212 Silverchair:20778 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Pseudothrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-295212 Silverchair:20778 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Pseudothrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-295212 Silverchair:20778 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Psychiatric Disturbance As a Presenting Symptom in Central Nervous Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113690 Silverchair:265787 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Psychiatric Disturbance As a Presenting Symptom in Central Nervous Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113690 Silverchair:265787 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Psychiatric Disturbance As a Presenting Symptom in Central Nervous Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113690 Silverchair:265787 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Psychiatric Disturbance As a Presenting Symptom in Central Nervous Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113690 Silverchair:265787 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Pulmonary Embolism Response Teams: Structuring a Dedicated Provider Response to Improve Outcomes for Patients and Institutions American Society of Hematology American Society of Hematology 10.1182/hem.V16.2.9417 Silverchair:463092 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Pulmonary Embolism Response Teams: Structuring a Dedicated Provider Response to Improve Outcomes for Patients and Institutions American Society of Hematology American Society of Hematology 10.1182/hem.V16.2.9417 Silverchair:463092 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Pulmonary Embolism Response Teams: Structuring a Dedicated Provider Response to Improve Outcomes for Patients and Institutions American Society of Hematology American Society of Hematology 10.1182/hem.V16.2.9417 Silverchair:463092 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Pulmonary Embolism Response Teams: Structuring a Dedicated Provider Response to Improve Outcomes for Patients and Institutions American Society of Hematology American Society of Hematology 10.1182/hem.V16.2.9417 Silverchair:463092 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Pure erythroid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2021011030 Silverchair:475928 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Pure erythroid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2021011030 Silverchair:475928 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Pure erythroid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2021011030 Silverchair:475928 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Pure erythroid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2021011030 Silverchair:475928 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Pure red cell aplasia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-717140 Silverchair:35728 Total_Item_Investigations 8 1 4 1 0 0 0 0 0 2 0 0 0 Pure red cell aplasia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-717140 Silverchair:35728 Total_Item_Requests 8 1 4 1 0 0 0 0 0 2 0 0 0 Pure red cell aplasia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-717140 Silverchair:35728 Unique_Item_Investigations 6 1 2 1 0 0 0 0 0 2 0 0 0 Pure red cell aplasia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-717140 Silverchair:35728 Unique_Item_Requests 6 1 2 1 0 0 0 0 0 2 0 0 0 Pursuing a Chemotherapy-free Regimen in Philadelphia Chromosome-Positive ALL American Society of Hematology American Society of Hematology Silverchair:475278 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Pursuing a Chemotherapy-free Regimen in Philadelphia Chromosome-Positive ALL American Society of Hematology American Society of Hematology Silverchair:475278 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Pursuing a Chemotherapy-free Regimen in Philadelphia Chromosome-Positive ALL American Society of Hematology American Society of Hematology Silverchair:475278 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Pursuing a Chemotherapy-free Regimen in Philadelphia Chromosome-Positive ALL American Society of Hematology American Society of Hematology Silverchair:475278 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125825 Silverchair:427848 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125825 Silverchair:427848 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125825 Silverchair:427848 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125825 Silverchair:427848 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers The American Society of Hematology American Society of Hematology 10.1182/blood.V85.7.1954.bloodjournal8571954 Silverchair:123533 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers The American Society of Hematology American Society of Hematology 10.1182/blood.V85.7.1954.bloodjournal8571954 Silverchair:123533 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers The American Society of Hematology American Society of Hematology 10.1182/blood.V85.7.1954.bloodjournal8571954 Silverchair:123533 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers The American Society of Hematology American Society of Hematology 10.1182/blood.V85.7.1954.bloodjournal8571954 Silverchair:123533 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 R* Magnetic Resonance Imaging (MRI) of the Liver for Patients with Iron Overload. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.2670.2670 Silverchair:57230 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 R* Magnetic Resonance Imaging (MRI) of the Liver for Patients with Iron Overload. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.2670.2670 Silverchair:57230 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 R* Magnetic Resonance Imaging (MRI) of the Liver for Patients with Iron Overload. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.2670.2670 Silverchair:57230 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 R* Magnetic Resonance Imaging (MRI) of the Liver for Patients with Iron Overload. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.2670.2670 Silverchair:57230 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 R2* magnetic resonance imaging of the liver in patients with iron overload The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-191643 Silverchair:116492 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 R2* magnetic resonance imaging of the liver in patients with iron overload The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-191643 Silverchair:116492 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 R2* magnetic resonance imaging of the liver in patients with iron overload The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-191643 Silverchair:116492 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 R2* magnetic resonance imaging of the liver in patients with iron overload The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-191643 Silverchair:116492 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Racial Differences in Nutritional Anemias: Analysis of Folate, Vitamin B12, and Iron Deficiencies" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123791 Silverchair:423789 Total_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 "Racial Differences in Nutritional Anemias: Analysis of Folate, Vitamin B12, and Iron Deficiencies" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123791 Silverchair:423789 Total_Item_Requests 3 2 0 1 0 0 0 0 0 0 0 0 0 "Racial Differences in Nutritional Anemias: Analysis of Folate, Vitamin B12, and Iron Deficiencies" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123791 Silverchair:423789 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 "Racial Differences in Nutritional Anemias: Analysis of Folate, Vitamin B12, and Iron Deficiencies" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123791 Silverchair:423789 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Racial/Ethnic Disparities in Cancer-Associated Thrombosis: A Population-Based Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137268 Silverchair:470179 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Racial/Ethnic Disparities in Cancer-Associated Thrombosis: A Population-Based Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137268 Silverchair:470179 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Racial/Ethnic Disparities in Cancer-Associated Thrombosis: A Population-Based Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137268 Silverchair:470179 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Racial/Ethnic Disparities in Cancer-Associated Thrombosis: A Population-Based Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137268 Silverchair:470179 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131499 Silverchair:427480 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131499 Silverchair:427480 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131499 Silverchair:427480 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131499 Silverchair:427480 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3-ITD-Mutated AML The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113582 Silverchair:266179 Total_Item_Investigations 5 2 1 2 0 0 0 0 0 0 0 0 0 Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3-ITD-Mutated AML The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113582 Silverchair:266179 Total_Item_Requests 5 2 1 2 0 0 0 0 0 0 0 0 0 Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3-ITD-Mutated AML The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113582 Silverchair:266179 Unique_Item_Investigations 5 2 1 2 0 0 0 0 0 0 0 0 0 Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3-ITD-Mutated AML The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113582 Silverchair:266179 Unique_Item_Requests 5 2 1 2 0 0 0 0 0 0 0 0 0 "Radius: A Phase 2, Randomized Trial of Standard of Care (SOC) with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients (pts) with FLT3-Itd-Mutated Acute Myeloid Leukemia (AML)" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2248.2248 Silverchair:100708 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Radius: A Phase 2, Randomized Trial of Standard of Care (SOC) with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients (pts) with FLT3-Itd-Mutated Acute Myeloid Leukemia (AML)" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2248.2248 Silverchair:100708 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Radius: A Phase 2, Randomized Trial of Standard of Care (SOC) with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients (pts) with FLT3-Itd-Mutated Acute Myeloid Leukemia (AML)" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2248.2248 Silverchair:100708 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Radius: A Phase 2, Randomized Trial of Standard of Care (SOC) with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients (pts) with FLT3-Itd-Mutated Acute Myeloid Leukemia (AML)" The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2248.2248 Silverchair:100708 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Raf-1 is not required for megakaryocytopoiesis or TPO-induced ERK phosphorylation The American Society of Hematology American Society of Hematology 10.1182/blood-2003-06-1803 Silverchair:18299 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 3 0 0 0 Raf-1 is not required for megakaryocytopoiesis or TPO-induced ERK phosphorylation The American Society of Hematology American Society of Hematology 10.1182/blood-2003-06-1803 Silverchair:18299 Total_Item_Requests 3 0 0 0 0 0 0 0 0 3 0 0 0 Raf-1 is not required for megakaryocytopoiesis or TPO-induced ERK phosphorylation The American Society of Hematology American Society of Hematology 10.1182/blood-2003-06-1803 Silverchair:18299 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Raf-1 is not required for megakaryocytopoiesis or TPO-induced ERK phosphorylation The American Society of Hematology American Society of Hematology 10.1182/blood-2003-06-1803 Silverchair:18299 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Rallying Macrophages in the Fight Against MDS and AML American Society of Hematology American Society of Hematology Silverchair:475187 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Rallying Macrophages in the Fight Against MDS and AML American Society of Hematology American Society of Hematology Silverchair:475187 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Rallying Macrophages in the Fight Against MDS and AML American Society of Hematology American Society of Hematology Silverchair:475187 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Rallying Macrophages in the Fight Against MDS and AML American Society of Hematology American Society of Hematology Silverchair:475187 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 "Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-682518 Silverchair:35170 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 "Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-682518 Silverchair:35170 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 "Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-682518 Silverchair:35170 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 "Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-682518 Silverchair:35170 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-788497 Silverchair:36551 Total_Item_Investigations 14 10 0 2 0 0 1 1 0 0 0 0 0 Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-788497 Silverchair:36551 Total_Item_Requests 13 9 0 2 0 0 1 1 0 0 0 0 0 Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-788497 Silverchair:36551 Unique_Item_Investigations 7 4 0 1 0 0 1 1 0 0 0 0 0 Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-788497 Silverchair:36551 Unique_Item_Requests 7 4 0 1 0 0 1 1 0 0 0 0 0 Randomized Phase 2 Trial of Pevonedistat Plus Azacitidine Versus Azacitidine in Higher-Risk Myelodysplastic Syndromes/Chronic Myelomonocytic Leukemia or Low-Blast Acute Myeloid Leukemia: Exploratory Analysis of Patient-Reported Outcomes The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136935 Silverchair:471917 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Randomized Phase 2 Trial of Pevonedistat Plus Azacitidine Versus Azacitidine in Higher-Risk Myelodysplastic Syndromes/Chronic Myelomonocytic Leukemia or Low-Blast Acute Myeloid Leukemia: Exploratory Analysis of Patient-Reported Outcomes The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136935 Silverchair:471917 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Randomized Phase 2 Trial of Pevonedistat Plus Azacitidine Versus Azacitidine in Higher-Risk Myelodysplastic Syndromes/Chronic Myelomonocytic Leukemia or Low-Blast Acute Myeloid Leukemia: Exploratory Analysis of Patient-Reported Outcomes The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136935 Silverchair:471917 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Randomized Phase 2 Trial of Pevonedistat Plus Azacitidine Versus Azacitidine in Higher-Risk Myelodysplastic Syndromes/Chronic Myelomonocytic Leukemia or Low-Blast Acute Myeloid Leukemia: Exploratory Analysis of Patient-Reported Outcomes The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136935 Silverchair:471917 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018026625 Silverchair:247274 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018026625 Silverchair:247274 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018026625 Silverchair:247274 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018026625 Silverchair:247274 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-531327 Silverchair:32655 Total_Item_Investigations 3 0 0 0 3 0 0 0 0 0 0 0 0 Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-531327 Silverchair:32655 Total_Item_Requests 3 0 0 0 3 0 0 0 0 0 0 0 0 Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-531327 Silverchair:32655 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study The American Society of Hematology American Society of Hematology 10.1182/blood-2013-11-531327 Silverchair:32655 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 "Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-395749 Silverchair:30004 Total_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 "Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-395749 Silverchair:30004 Total_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 "Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-395749 Silverchair:30004 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 "Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-395749 Silverchair:30004 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 "Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2014-03-560557 Silverchair:73070 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2014-03-560557 Silverchair:73070 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2014-03-560557 Silverchair:73070 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2014-03-560557 Silverchair:73070 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Rantes/Ccl5 influences hematopoietic stem cell subtypes and causes myeloid skewing The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-391730 Silverchair:29612 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Rantes/Ccl5 influences hematopoietic stem cell subtypes and causes myeloid skewing The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-391730 Silverchair:29612 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Rantes/Ccl5 influences hematopoietic stem cell subtypes and causes myeloid skewing The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-391730 Silverchair:29612 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Rantes/Ccl5 influences hematopoietic stem cell subtypes and causes myeloid skewing The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-391730 Silverchair:29612 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-256040 Silverchair:28378 Total_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-256040 Silverchair:28378 Total_Item_Requests 3 2 0 1 0 0 0 0 0 0 0 0 0 Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-256040 Silverchair:28378 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-256040 Silverchair:28378 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade The American Society of Hematology American Society of Hematology 10.1182/blood.2019002038 Silverchair:374970 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade The American Society of Hematology American Society of Hematology 10.1182/blood.2019002038 Silverchair:374970 Total_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade The American Society of Hematology American Society of Hematology 10.1182/blood.2019002038 Silverchair:374970 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade The American Society of Hematology American Society of Hematology 10.1182/blood.2019002038 Silverchair:374970 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Rapid single-molecule digital detection of protein biomarkers for continuous monitoring of systemic immune disorders The American Society of Hematology American Society of Hematology 10.1182/blood.2019004399 Silverchair:474418 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Rapid single-molecule digital detection of protein biomarkers for continuous monitoring of systemic immune disorders The American Society of Hematology American Society of Hematology 10.1182/blood.2019004399 Silverchair:474418 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations" The American Society of Hematology American Society of Hematology 10.1182/blood.2019002894 Silverchair:431275 Total_Item_Investigations 5 0 1 2 0 2 0 0 0 0 0 0 0 "Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations" The American Society of Hematology American Society of Hematology 10.1182/blood.2019002894 Silverchair:431275 Total_Item_Requests 4 0 1 1 0 2 0 0 0 0 0 0 0 "Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations" The American Society of Hematology American Society of Hematology 10.1182/blood.2019002894 Silverchair:431275 Unique_Item_Investigations 3 0 1 1 0 1 0 0 0 0 0 0 0 "Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations" The American Society of Hematology American Society of Hematology 10.1182/blood.2019002894 Silverchair:431275 Unique_Item_Requests 3 0 1 1 0 1 0 0 0 0 0 0 0 Rare bleeding disorders: diagnosis and treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-532820 Silverchair:33968 Total_Item_Investigations 2 0 0 0 1 0 0 0 0 0 1 0 0 Rare bleeding disorders: diagnosis and treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-532820 Silverchair:33968 Total_Item_Requests 2 0 0 0 1 0 0 0 0 0 1 0 0 Rare bleeding disorders: diagnosis and treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-532820 Silverchair:33968 Unique_Item_Investigations 2 0 0 0 1 0 0 0 0 0 1 0 0 Rare bleeding disorders: diagnosis and treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-532820 Silverchair:33968 Unique_Item_Requests 2 0 0 0 1 0 0 0 0 0 1 0 0 Rare Inherited Defects of the Complement System in Purpura Fulminans The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138729 Silverchair:470160 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Rare Inherited Defects of the Complement System in Purpura Fulminans The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138729 Silverchair:470160 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Rare Inherited Defects of the Complement System in Purpura Fulminans The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138729 Silverchair:470160 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Rare Inherited Defects of the Complement System in Purpura Fulminans The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138729 Silverchair:470160 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 RAS Pathway Mutations As Predictive Biomarker for Treatment Adaptation in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4087.4087 Silverchair:114203 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 RAS Pathway Mutations As Predictive Biomarker for Treatment Adaptation in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4087.4087 Silverchair:114203 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 RAS Pathway Mutations As Predictive Biomarker for Treatment Adaptation in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4087.4087 Silverchair:114203 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 RAS Pathway Mutations As Predictive Biomarker for Treatment Adaptation in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.4087.4087 Silverchair:114203 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Ras-Driven B-Cell Transformation Targets Developmental Rewiring of Cytokine to Pre-B Cell Receptor Signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115514 Silverchair:262801 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Ras-Driven B-Cell Transformation Targets Developmental Rewiring of Cytokine to Pre-B Cell Receptor Signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115514 Silverchair:262801 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Ras-Driven B-Cell Transformation Targets Developmental Rewiring of Cytokine to Pre-B Cell Receptor Signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115514 Silverchair:262801 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Ras-Driven B-Cell Transformation Targets Developmental Rewiring of Cytokine to Pre-B Cell Receptor Signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115514 Silverchair:262801 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C The American Society of Hematology American Society of Hematology 10.1182/blood.2020010218 Silverchair:475835 Total_Item_Investigations 5 0 0 0 0 2 0 0 3 0 0 0 0 Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C The American Society of Hematology American Society of Hematology 10.1182/blood.2020010218 Silverchair:475835 Total_Item_Requests 4 0 0 0 0 1 0 0 3 0 0 0 0 Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C The American Society of Hematology American Society of Hematology 10.1182/blood.2020010218 Silverchair:475835 Unique_Item_Investigations 3 0 0 0 0 2 0 0 1 0 0 0 0 Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C The American Society of Hematology American Society of Hematology 10.1182/blood.2020010218 Silverchair:475835 Unique_Item_Requests 2 0 0 0 0 1 0 0 1 0 0 0 0 Rationale for targeting the pre–B-cell receptor signaling pathway in acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-567842 Silverchair:34014 Total_Item_Investigations 16 4 9 3 0 0 0 0 0 0 0 0 0 Rationale for targeting the pre–B-cell receptor signaling pathway in acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-567842 Silverchair:34014 Total_Item_Requests 16 4 9 3 0 0 0 0 0 0 0 0 0 Rationale for targeting the pre–B-cell receptor signaling pathway in acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-567842 Silverchair:34014 Unique_Item_Investigations 8 2 5 1 0 0 0 0 0 0 0 0 0 Rationale for targeting the pre–B-cell receptor signaling pathway in acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-567842 Silverchair:34014 Unique_Item_Requests 8 2 5 1 0 0 0 0 0 0 0 0 0 RBCs as targets of infection The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.404 Silverchair:20464 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 RBCs as targets of infection The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.404 Silverchair:20464 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 RBCs as targets of infection The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.404 Silverchair:20464 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 RBCs as targets of infection The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.404 Silverchair:20464 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 RBCs prevent rapid PIEZO1 inactivation and expose slow deactivation as a mechanism of dehydrated hereditary stomatocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019004174 Silverchair:454440 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 RBCs prevent rapid PIEZO1 inactivation and expose slow deactivation as a mechanism of dehydrated hereditary stomatocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019004174 Silverchair:454440 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 RBCs prevent rapid PIEZO1 inactivation and expose slow deactivation as a mechanism of dehydrated hereditary stomatocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019004174 Silverchair:454440 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 RBCs prevent rapid PIEZO1 inactivation and expose slow deactivation as a mechanism of dehydrated hereditary stomatocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019004174 Silverchair:454440 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 RBM15-Mediated RNA Splicing Fine-Tunes Epigenetic Program through Interaction with SF3B1 The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4110.4110 Silverchair:135992 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 RBM15-Mediated RNA Splicing Fine-Tunes Epigenetic Program through Interaction with SF3B1 The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4110.4110 Silverchair:135992 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 RBM15-Mediated RNA Splicing Fine-Tunes Epigenetic Program through Interaction with SF3B1 The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4110.4110 Silverchair:135992 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 RBM15-Mediated RNA Splicing Fine-Tunes Epigenetic Program through Interaction with SF3B1 The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4110.4110 Silverchair:135992 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-793984 Silverchair:37014 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-793984 Silverchair:37014 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-793984 Silverchair:37014 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-793984 Silverchair:37014 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.408.408 Silverchair:76819 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.408.408 Silverchair:76819 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.408.408 Silverchair:76819 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.408.408 Silverchair:76819 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Real World Outcomes of Sars-Cov-2 Thrombosis Rates across Three University Health Systems in the Chicago Metropolitan Area The American Society of Hematology American Society of Hematology 10.1182/blood-2020-135929 Silverchair:470186 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Real World Outcomes of Sars-Cov-2 Thrombosis Rates across Three University Health Systems in the Chicago Metropolitan Area The American Society of Hematology American Society of Hematology 10.1182/blood-2020-135929 Silverchair:470186 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Real World Outcomes of Sars-Cov-2 Thrombosis Rates across Three University Health Systems in the Chicago Metropolitan Area The American Society of Hematology American Society of Hematology 10.1182/blood-2020-135929 Silverchair:470186 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Real World Outcomes of Sars-Cov-2 Thrombosis Rates across Three University Health Systems in the Chicago Metropolitan Area The American Society of Hematology American Society of Hematology 10.1182/blood-2020-135929 Silverchair:470186 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003159 Silverchair:474817 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003159 Silverchair:474817 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003159 Silverchair:474817 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003159 Silverchair:474817 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Real-World Analysis of Adverse Events Associated with CAR T-Cell Therapy Among Adults Age ≥65 Years The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127372 Silverchair:427967 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Real-World Analysis of Adverse Events Associated with CAR T-Cell Therapy Among Adults Age ≥65 Years The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127372 Silverchair:427967 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Real-World Analysis of Adverse Events Associated with CAR T-Cell Therapy Among Adults Age ≥65 Years The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127372 Silverchair:427967 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Real-World Analysis of Adverse Events Associated with CAR T-Cell Therapy Among Adults Age ≥65 Years The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127372 Silverchair:427967 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Real-World Analysis of Ruxolitinib Treatment Patterns and Outcomes Among Patients with Myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124651 Silverchair:428727 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Real-World Analysis of Ruxolitinib Treatment Patterns and Outcomes Among Patients with Myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124651 Silverchair:428727 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Real-World Analysis of Ruxolitinib Treatment Patterns and Outcomes Among Patients with Myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124651 Silverchair:428727 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Real-World Analysis of Ruxolitinib Treatment Patterns and Outcomes Among Patients with Myelofibrosis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124651 Silverchair:428727 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Real-World Clinical and Economic Burden of Hematopoietic Cell Transplantation Among a Large US Commercially Insured Populationhematopoietic CELL Transplantation Among a Large US Commercially Insured Population The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2368.2368 Silverchair:98736 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Real-World Clinical and Economic Burden of Hematopoietic Cell Transplantation Among a Large US Commercially Insured Populationhematopoietic CELL Transplantation Among a Large US Commercially Insured Population The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2368.2368 Silverchair:98736 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Real-World Clinical and Economic Burden of Hematopoietic Cell Transplantation Among a Large US Commercially Insured Populationhematopoietic CELL Transplantation Among a Large US Commercially Insured Population The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2368.2368 Silverchair:98736 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Real-World Clinical and Economic Burden of Hematopoietic Cell Transplantation Among a Large US Commercially Insured Populationhematopoietic CELL Transplantation Among a Large US Commercially Insured Population The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2368.2368 Silverchair:98736 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-573089 Silverchair:32961 Total_Item_Investigations 2 0 0 0 1 0 0 0 0 0 1 0 0 Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-573089 Silverchair:32961 Total_Item_Requests 2 0 0 0 1 0 0 0 0 0 1 0 0 Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-573089 Silverchair:32961 Unique_Item_Investigations 2 0 0 0 1 0 0 0 0 0 1 0 0 Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-573089 Silverchair:32961 Unique_Item_Requests 2 0 0 0 1 0 0 0 0 0 1 0 0 Real-World Experience with a New Human Fibrinogen Concentrate (Fibryga®) in France for the Treatment of Bleeding Episodes and Surgical Prophylaxis The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141303 Silverchair:472354 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Real-World Experience with a New Human Fibrinogen Concentrate (Fibryga®) in France for the Treatment of Bleeding Episodes and Surgical Prophylaxis The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141303 Silverchair:472354 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Real-World Experience with a New Human Fibrinogen Concentrate (Fibryga®) in France for the Treatment of Bleeding Episodes and Surgical Prophylaxis The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141303 Silverchair:472354 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Real-World Experience with a New Human Fibrinogen Concentrate (Fibryga®) in France for the Treatment of Bleeding Episodes and Surgical Prophylaxis The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141303 Silverchair:472354 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Real-world experience with caplacizumab in the management of acute TTP The American Society of Hematology American Society of Hematology 10.1182/blood.2020007599 Silverchair:474077 Total_Item_Investigations 14 0 6 0 2 2 0 0 0 0 0 0 4 Real-world experience with caplacizumab in the management of acute TTP The American Society of Hematology American Society of Hematology 10.1182/blood.2020007599 Silverchair:474077 Total_Item_Requests 5 0 1 0 0 0 0 0 0 0 0 0 4 Real-world experience with caplacizumab in the management of acute TTP The American Society of Hematology American Society of Hematology 10.1182/blood.2020007599 Silverchair:474077 Unique_Item_Investigations 4 0 1 0 1 1 0 0 0 0 0 0 1 Real-world experience with caplacizumab in the management of acute TTP The American Society of Hematology American Society of Hematology 10.1182/blood.2020007599 Silverchair:474077 Unique_Item_Requests 2 0 1 0 0 0 0 0 0 0 0 0 1 Real-world experience with caplacizumab in the management of acute TTP The American Society of Hematology American Society of Hematology 10.1182/blood.2020007599 Silverchair:474077 No_License 2 0 0 0 1 1 0 0 0 0 0 0 0 Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129431 Silverchair:426260 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129431 Silverchair:426260 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129431 Silverchair:426260 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129431 Silverchair:426260 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Real-World Outcome of Dose-Adjusted EPOCH-R, a Single-Centre Experience" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138848 Silverchair:473540 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Real-World Outcome of Dose-Adjusted EPOCH-R, a Single-Centre Experience" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138848 Silverchair:473540 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "Real-World Outcome of Dose-Adjusted EPOCH-R, a Single-Centre Experience" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138848 Silverchair:473540 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Real-World Outcome of Dose-Adjusted EPOCH-R, a Single-Centre Experience" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138848 Silverchair:473540 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001381 Silverchair:456144 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001381 Silverchair:456144 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001381 Silverchair:456144 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001381 Silverchair:456144 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Real-World Survival Among Patients with Intermediate- to High-Risk Myelofibrosis in the United States: Impact of Ruxolitinib Approval The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140820 Silverchair:472760 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Real-World Survival Among Patients with Intermediate- to High-Risk Myelofibrosis in the United States: Impact of Ruxolitinib Approval The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140820 Silverchair:472760 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Real-World Survival Among Patients with Intermediate- to High-Risk Myelofibrosis in the United States: Impact of Ruxolitinib Approval The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140820 Silverchair:472760 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Real-World Survival Among Patients with Intermediate- to High-Risk Myelofibrosis in the United States: Impact of Ruxolitinib Approval The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140820 Silverchair:472760 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136674 Silverchair:471627 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136674 Silverchair:471627 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136674 Silverchair:471627 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136674 Silverchair:471627 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Rearrangement and Deletion of the PAX5 Gene in Pediatric Acute B-Cell Lineage Lymphoblastic Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.981.981 Silverchair:118387 Total_Item_Investigations 3 0 2 1 0 0 0 0 0 0 0 0 0 Rearrangement and Deletion of the PAX5 Gene in Pediatric Acute B-Cell Lineage Lymphoblastic Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.981.981 Silverchair:118387 Total_Item_Requests 3 0 2 1 0 0 0 0 0 0 0 0 0 Rearrangement and Deletion of the PAX5 Gene in Pediatric Acute B-Cell Lineage Lymphoblastic Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.981.981 Silverchair:118387 Unique_Item_Investigations 3 0 2 1 0 0 0 0 0 0 0 0 0 Rearrangement and Deletion of the PAX5 Gene in Pediatric Acute B-Cell Lineage Lymphoblastic Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.981.981 Silverchair:118387 Unique_Item_Requests 3 0 2 1 0 0 0 0 0 0 0 0 0 Rebalanced hemostasis in liver disease: a misunderstood coagulopathy The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000283 Silverchair:482988 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 0 2 Rebalanced hemostasis in liver disease: a misunderstood coagulopathy The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000283 Silverchair:482988 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 0 2 Rebalanced hemostasis in liver disease: a misunderstood coagulopathy The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000283 Silverchair:482988 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Rebalanced hemostasis in liver disease: a misunderstood coagulopathy The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000283 Silverchair:482988 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Recent Trends in the Incidence and Outcomes of Thrombotic Thrombocytopenic Purpura in the United States: Data from the 2009-2014 National Inpatient Sample The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2086.2086 Silverchair:71290 Total_Item_Investigations 2 0 0 0 1 0 1 0 0 0 0 0 0 Recent Trends in the Incidence and Outcomes of Thrombotic Thrombocytopenic Purpura in the United States: Data from the 2009-2014 National Inpatient Sample The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2086.2086 Silverchair:71290 Total_Item_Requests 2 0 0 0 1 0 1 0 0 0 0 0 0 Recent Trends in the Incidence and Outcomes of Thrombotic Thrombocytopenic Purpura in the United States: Data from the 2009-2014 National Inpatient Sample The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2086.2086 Silverchair:71290 Unique_Item_Investigations 2 0 0 0 1 0 1 0 0 0 0 0 0 Recent Trends in the Incidence and Outcomes of Thrombotic Thrombocytopenic Purpura in the United States: Data from the 2009-2014 National Inpatient Sample The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2086.2086 Silverchair:71290 Unique_Item_Requests 2 0 0 0 1 0 1 0 0 0 0 0 0 Recipient priming to one RBC alloantigen directly enhances subsequent alloimmunization in mice American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017010124 Silverchair:16295 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Recipient priming to one RBC alloantigen directly enhances subsequent alloimmunization in mice American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017010124 Silverchair:16295 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Recipient priming to one RBC alloantigen directly enhances subsequent alloimmunization in mice American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017010124 Silverchair:16295 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Recipient priming to one RBC alloantigen directly enhances subsequent alloimmunization in mice American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017010124 Silverchair:16295 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-788026 Silverchair:36693 Total_Item_Investigations 3 0 0 0 2 1 0 0 0 0 0 0 0 Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-788026 Silverchair:36693 Total_Item_Requests 3 0 0 0 2 1 0 0 0 0 0 0 0 Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-788026 Silverchair:36693 Unique_Item_Investigations 2 0 0 0 1 1 0 0 0 0 0 0 0 Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-788026 Silverchair:36693 Unique_Item_Requests 2 0 0 0 1 1 0 0 0 0 0 0 0 "Recombinant ADAMTS-13: goodbye, allergic reactions!" The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-807164 Silverchair:36709 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 "Recombinant ADAMTS-13: goodbye, allergic reactions!" The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-807164 Silverchair:36709 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 "Recombinant ADAMTS-13: goodbye, allergic reactions!" The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-807164 Silverchair:36709 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 "Recombinant ADAMTS-13: goodbye, allergic reactions!" The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-807164 Silverchair:36709 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Recombinant Porcine Factor VIII Use in Bleed Treatment in Non-Severe Hemophilia a Inhibitor Patients: Dosing Strategies and Efficacy The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119196 Silverchair:262787 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Recombinant Porcine Factor VIII Use in Bleed Treatment in Non-Severe Hemophilia a Inhibitor Patients: Dosing Strategies and Efficacy The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119196 Silverchair:262787 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Recombinant Porcine Factor VIII Use in Bleed Treatment in Non-Severe Hemophilia a Inhibitor Patients: Dosing Strategies and Efficacy The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119196 Silverchair:262787 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Recombinant Porcine Factor VIII Use in Bleed Treatment in Non-Severe Hemophilia a Inhibitor Patients: Dosing Strategies and Efficacy The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119196 Silverchair:262787 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 "Recombinant porcine FVIII for bleed treatment in acquired hemophilia A: findings from a single-center, 18-patient cohort" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002977 Silverchair:474705 Total_Item_Investigations 5 1 0 0 0 0 2 0 2 0 0 0 0 "Recombinant porcine FVIII for bleed treatment in acquired hemophilia A: findings from a single-center, 18-patient cohort" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002977 Silverchair:474705 Total_Item_Requests 4 1 0 0 0 0 2 0 1 0 0 0 0 "Recombinant porcine FVIII for bleed treatment in acquired hemophilia A: findings from a single-center, 18-patient cohort" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002977 Silverchair:474705 Unique_Item_Investigations 3 1 0 0 0 0 1 0 1 0 0 0 0 "Recombinant porcine FVIII for bleed treatment in acquired hemophilia A: findings from a single-center, 18-patient cohort" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002977 Silverchair:474705 Unique_Item_Requests 3 1 0 0 0 0 1 0 1 0 0 0 0 Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice The American Society of Hematology American Society of Hematology 10.1182/blood.2020006468 Silverchair:463608 No_License 5 0 5 0 0 0 0 0 0 0 0 0 0 Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice The American Society of Hematology American Society of Hematology 10.1182/blood.2020006468 Silverchair:463608 Total_Item_Investigations 19 0 19 0 0 0 0 0 0 0 0 0 0 Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice The American Society of Hematology American Society of Hematology 10.1182/blood.2020006468 Silverchair:463608 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice The American Society of Hematology American Society of Hematology 10.1182/blood.2020006468 Silverchair:463608 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice The American Society of Hematology American Society of Hematology 10.1182/blood.2020006468 Silverchair:463608 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Recommendations for the management of hemophagocytic lymphohistiocytosis in adults The American Society of Hematology American Society of Hematology 10.1182/blood.2018894618 Silverchair:273833 Total_Item_Investigations 36 16 1 15 0 1 1 1 1 0 0 0 0 Recommendations for the management of hemophagocytic lymphohistiocytosis in adults The American Society of Hematology American Society of Hematology 10.1182/blood.2018894618 Silverchair:273833 Total_Item_Requests 35 16 1 14 0 1 1 1 1 0 0 0 0 Recommendations for the management of hemophagocytic lymphohistiocytosis in adults The American Society of Hematology American Society of Hematology 10.1182/blood.2018894618 Silverchair:273833 Unique_Item_Investigations 24 11 1 8 0 1 1 1 1 0 0 0 0 Recommendations for the management of hemophagocytic lymphohistiocytosis in adults The American Society of Hematology American Society of Hematology 10.1182/blood.2018894618 Silverchair:273833 Unique_Item_Requests 24 11 1 8 0 1 1 1 1 0 0 0 0 Reconstruction of integrin activation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-292128 Silverchair:125755 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Reconstruction of integrin activation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-292128 Silverchair:125755 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Reconstruction of integrin activation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-292128 Silverchair:125755 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Reconstruction of integrin activation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-292128 Silverchair:125755 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Reconstruction of Sickle Cell Disease with Circulating Sickling Red Blood Cells in Novel Humanized Cytokines and Liver Mistrg Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141603 Silverchair:470548 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Reconstruction of Sickle Cell Disease with Circulating Sickling Red Blood Cells in Novel Humanized Cytokines and Liver Mistrg Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141603 Silverchair:470548 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Reconstruction of Sickle Cell Disease with Circulating Sickling Red Blood Cells in Novel Humanized Cytokines and Liver Mistrg Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141603 Silverchair:470548 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Reconstruction of Sickle Cell Disease with Circulating Sickling Red Blood Cells in Novel Humanized Cytokines and Liver Mistrg Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141603 Silverchair:470548 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia Abrogate an Ubiquitination Site and Dysregulate SETBP1 Protein Levels The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.LBA-2.LBA-2 Silverchair:87729 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia Abrogate an Ubiquitination Site and Dysregulate SETBP1 Protein Levels The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.LBA-2.LBA-2 Silverchair:87729 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia Abrogate an Ubiquitination Site and Dysregulate SETBP1 Protein Levels The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.LBA-2.LBA-2 Silverchair:87729 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia Abrogate an Ubiquitination Site and Dysregulate SETBP1 Protein Levels The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.LBA-2.LBA-2 Silverchair:87729 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use The American Society of Hematology American Society of Hematology 10.1182/blood-2015-08-665927 Silverchair:34975 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use The American Society of Hematology American Society of Hematology 10.1182/blood-2015-08-665927 Silverchair:34975 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use The American Society of Hematology American Society of Hematology 10.1182/blood-2015-08-665927 Silverchair:34975 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use The American Society of Hematology American Society of Hematology 10.1182/blood-2015-08-665927 Silverchair:34975 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 "Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-327361 Silverchair:30463 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 "Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-327361 Silverchair:30463 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 "Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-327361 Silverchair:30463 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 "Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-327361 Silverchair:30463 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Red blood cell glycophorins The American Society of Hematology American Society of Hematology 10.1182/blood.V80.8.1869.1869 Silverchair:169711 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Red blood cell glycophorins The American Society of Hematology American Society of Hematology 10.1182/blood.V80.8.1869.1869 Silverchair:169711 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Red blood cell glycophorins The American Society of Hematology American Society of Hematology 10.1182/blood.V80.8.1869.1869 Silverchair:169711 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Red blood cell glycophorins The American Society of Hematology American Society of Hematology 10.1182/blood.V80.8.1869.1869 Silverchair:169711 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Red blood cell transfusion for hematologic disorders The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.454 Silverchair:20638 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Red blood cell transfusion for hematologic disorders The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.454 Silverchair:20638 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Red blood cell transfusion for hematologic disorders The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.454 Silverchair:20638 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Red blood cell transfusion for hematologic disorders The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.454 Silverchair:20638 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Red blood cells in thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-745349 Silverchair:36469 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Red blood cells in thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-745349 Silverchair:36469 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Red blood cells in thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-745349 Silverchair:36469 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Red blood cells in thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-745349 Silverchair:36469 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Red Cell Enzymes The American Society of Hematology American Society of Hematology 10.1182/asheducation-2005.1.19 Silverchair:19272 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Red Cell Enzymes The American Society of Hematology American Society of Hematology 10.1182/asheducation-2005.1.19 Silverchair:19272 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Red Cell Enzymes The American Society of Hematology American Society of Hematology 10.1182/asheducation-2005.1.19 Silverchair:19272 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Red Cell Enzymes The American Society of Hematology American Society of Hematology 10.1182/asheducation-2005.1.19 Silverchair:19272 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Red Cell Exchange in Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.48 Silverchair:19692 Total_Item_Investigations 3 0 0 2 0 0 0 0 1 0 0 0 0 Red Cell Exchange in Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.48 Silverchair:19692 Total_Item_Requests 3 0 0 2 0 0 0 0 1 0 0 0 0 Red Cell Exchange in Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.48 Silverchair:19692 Unique_Item_Investigations 2 0 0 1 0 0 0 0 1 0 0 0 0 Red Cell Exchange in Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.48 Silverchair:19692 Unique_Item_Requests 2 0 0 1 0 0 0 0 1 0 0 0 0 Red cell membrane disorders: structure meets function The American Society of Hematology American Society of Hematology 10.1182/blood.2019000946 Silverchair:461551 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Red cell membrane disorders: structure meets function The American Society of Hematology American Society of Hematology 10.1182/blood.2019000946 Silverchair:461551 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Red cell membrane disorders: structure meets function The American Society of Hematology American Society of Hematology 10.1182/blood.2019000946 Silverchair:461551 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Red cell membrane disorders: structure meets function The American Society of Hematology American Society of Hematology 10.1182/blood.2019000946 Silverchair:461551 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Red cell membrane: past, present, and future" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-161166 Silverchair:24600 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "Red cell membrane: past, present, and future" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-161166 Silverchair:24600 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "Red cell membrane: past, present, and future" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-161166 Silverchair:24600 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Red cell membrane: past, present, and future" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-161166 Silverchair:24600 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Red cell–bound antibodies and transfusion requirements in hospitalized patients with COVID-19 The American Society of Hematology American Society of Hematology 10.1182/blood.2020006695 Silverchair:461066 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Red cell–bound antibodies and transfusion requirements in hospitalized patients with COVID-19 The American Society of Hematology American Society of Hematology 10.1182/blood.2020006695 Silverchair:461066 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Red cell–bound antibodies and transfusion requirements in hospitalized patients with COVID-19 The American Society of Hematology American Society of Hematology 10.1182/blood.2020006695 Silverchair:461066 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Red cell–bound antibodies and transfusion requirements in hospitalized patients with COVID-19 The American Society of Hematology American Society of Hematology 10.1182/blood.2020006695 Silverchair:461066 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Redefining outcomes in immune TTP: an international working group consensus report The American Society of Hematology American Society of Hematology 10.1182/blood.2020009150 Silverchair:475141 Total_Item_Investigations 12 0 2 0 3 1 0 0 0 0 3 0 3 Redefining outcomes in immune TTP: an international working group consensus report The American Society of Hematology American Society of Hematology 10.1182/blood.2020009150 Silverchair:475141 Total_Item_Requests 11 0 1 0 3 1 0 0 0 0 3 0 3 Redefining outcomes in immune TTP: an international working group consensus report The American Society of Hematology American Society of Hematology 10.1182/blood.2020009150 Silverchair:475141 Unique_Item_Investigations 6 0 1 0 2 1 0 0 0 0 1 0 1 Redefining outcomes in immune TTP: an international working group consensus report The American Society of Hematology American Society of Hematology 10.1182/blood.2020009150 Silverchair:475141 Unique_Item_Requests 6 0 1 0 2 1 0 0 0 0 1 0 1 Redefinition of the human mast cell transcriptome by deep-CAGE sequencing The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-483792 Silverchair:32574 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Redefinition of the human mast cell transcriptome by deep-CAGE sequencing The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-483792 Silverchair:32574 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Redefinition of the human mast cell transcriptome by deep-CAGE sequencing The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-483792 Silverchair:32574 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Redefinition of the human mast cell transcriptome by deep-CAGE sequencing The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-483792 Silverchair:32574 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Redirecting T cells to hematological malignancies with bispecific antibodies The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-741058 Silverchair:107712 Total_Item_Investigations 7 3 4 0 0 0 0 0 0 0 0 0 0 Redirecting T cells to hematological malignancies with bispecific antibodies The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-741058 Silverchair:107712 Total_Item_Requests 7 3 4 0 0 0 0 0 0 0 0 0 0 Redirecting T cells to hematological malignancies with bispecific antibodies The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-741058 Silverchair:107712 Unique_Item_Investigations 3 1 2 0 0 0 0 0 0 0 0 0 0 Redirecting T cells to hematological malignancies with bispecific antibodies The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-741058 Silverchair:107712 Unique_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors The American Society of Hematology American Society of Hematology 10.1182/blood.2019001056 Silverchair:374919 Total_Item_Investigations 4 0 0 0 2 2 0 0 0 0 0 0 0 Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors The American Society of Hematology American Society of Hematology 10.1182/blood.2019001056 Silverchair:374919 Total_Item_Requests 3 0 0 0 2 1 0 0 0 0 0 0 0 Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors The American Society of Hematology American Society of Hematology 10.1182/blood.2019001056 Silverchair:374919 Unique_Item_Investigations 2 0 0 0 1 1 0 0 0 0 0 0 0 Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors The American Society of Hematology American Society of Hematology 10.1182/blood.2019001056 Silverchair:374919 Unique_Item_Requests 2 0 0 0 1 1 0 0 0 0 0 0 0 Reduced bone formation in males and increased bone resorption in females drive bone loss in hemophilia A mice American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018027557 Silverchair:246785 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 2 0 0 0 Reduced bone formation in males and increased bone resorption in females drive bone loss in hemophilia A mice American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018027557 Silverchair:246785 Total_Item_Requests 2 0 0 0 0 0 0 0 0 2 0 0 0 Reduced bone formation in males and increased bone resorption in females drive bone loss in hemophilia A mice American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018027557 Silverchair:246785 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Reduced bone formation in males and increased bone resorption in females drive bone loss in hemophilia A mice American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018027557 Silverchair:246785 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Reduced expression of annexin A2 is associated with impaired cell surface fibrinolysis and venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood.2020008123 Silverchair:475054 Total_Item_Investigations 2 0 0 0 1 1 0 0 0 0 0 0 0 Reduced expression of annexin A2 is associated with impaired cell surface fibrinolysis and venous thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood.2020008123 Silverchair:475054 Unique_Item_Investigations 2 0 0 0 1 1 0 0 0 0 0 0 0 Reduced prevalence of SARS-CoV-2 infection in ABO blood group O American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002657 Silverchair:463793 Total_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 Reduced prevalence of SARS-CoV-2 infection in ABO blood group O American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002657 Silverchair:463793 Total_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 Reduced prevalence of SARS-CoV-2 infection in ABO blood group O American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002657 Silverchair:463793 Unique_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 Reduced prevalence of SARS-CoV-2 infection in ABO blood group O American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002657 Silverchair:463793 Unique_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 "Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138569 Silverchair:470612 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 "Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138569 Silverchair:470612 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 "Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138569 Silverchair:470612 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 "Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138569 Silverchair:470612 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Reduced-intensity therapy for pediatric lymphoblastic leukemia: impact of residual disease early in remission induction The American Society of Hematology American Society of Hematology 10.1182/blood.2020007977 Silverchair:464272 No_License 2 0 0 2 0 0 0 0 0 0 0 0 0 Reduced-intensity therapy for pediatric lymphoblastic leukemia: impact of residual disease early in remission induction The American Society of Hematology American Society of Hematology 10.1182/blood.2020007977 Silverchair:464272 Total_Item_Investigations 5 1 0 4 0 0 0 0 0 0 0 0 0 Reduced-intensity therapy for pediatric lymphoblastic leukemia: impact of residual disease early in remission induction The American Society of Hematology American Society of Hematology 10.1182/blood.2020007977 Silverchair:464272 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Reduced-intensity therapy for pediatric lymphoblastic leukemia: impact of residual disease early in remission induction The American Society of Hematology American Society of Hematology 10.1182/blood.2020007977 Silverchair:464272 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Reduced-intensity therapy for pediatric lymphoblastic leukemia: impact of residual disease early in remission induction The American Society of Hematology American Society of Hematology 10.1182/blood.2020007977 Silverchair:464272 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Reduction of T cell–derived ghrelin enhances proinflammatory cytokine expression: implications for age-associated increases in inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-181255 Silverchair:26301 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Reduction of T cell–derived ghrelin enhances proinflammatory cytokine expression: implications for age-associated increases in inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-181255 Silverchair:26301 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Reduction of T cell–derived ghrelin enhances proinflammatory cytokine expression: implications for age-associated increases in inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-181255 Silverchair:26301 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Reduction of T cell–derived ghrelin enhances proinflammatory cytokine expression: implications for age-associated increases in inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-181255 Silverchair:26301 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-254441 Silverchair:27618 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-254441 Silverchair:27618 Total_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-254441 Silverchair:27618 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-254441 Silverchair:27618 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-718528 Silverchair:35743 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-718528 Silverchair:35743 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-718528 Silverchair:35743 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-718528 Silverchair:35743 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR–T-cell responses against ALL The American Society of Hematology American Society of Hematology 10.1182/blood.2020009309 Silverchair:475486 Total_Item_Investigations 10 0 0 3 7 0 0 0 0 0 0 0 0 Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR–T-cell responses against ALL The American Society of Hematology American Society of Hematology 10.1182/blood.2020009309 Silverchair:475486 Unique_Item_Investigations 2 0 0 1 1 0 0 0 0 0 0 0 0 Regulating billions of blood platelets: glycans and beyond The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-569129 Silverchair:34573 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Regulating billions of blood platelets: glycans and beyond The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-569129 Silverchair:34573 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Regulating billions of blood platelets: glycans and beyond The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-569129 Silverchair:34573 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Regulating billions of blood platelets: glycans and beyond The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-569129 Silverchair:34573 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Regulation of B-cell development by BCAP and CD19 through their binding to phosphoinositide 3-kinase The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-109769 Silverchair:25553 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Regulation of B-cell development by BCAP and CD19 through their binding to phosphoinositide 3-kinase The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-109769 Silverchair:25553 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Regulation of B-cell development by BCAP and CD19 through their binding to phosphoinositide 3-kinase The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-109769 Silverchair:25553 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Regulation of B-cell development by BCAP and CD19 through their binding to phosphoinositide 3-kinase The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-109769 Silverchair:25553 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Regulation of ferritin genes and protein The American Society of Hematology American Society of Hematology 10.1182/blood.V99.10.3505 Silverchair:106937 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Regulation of ferritin genes and protein The American Society of Hematology American Society of Hematology 10.1182/blood.V99.10.3505 Silverchair:106937 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Regulation of ferritin genes and protein The American Society of Hematology American Society of Hematology 10.1182/blood.V99.10.3505 Silverchair:106937 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Regulation of ferritin genes and protein The American Society of Hematology American Society of Hematology 10.1182/blood.V99.10.3505 Silverchair:106937 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Regulation of fibrinolysis by S100A10 in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-353482 Silverchair:28503 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Regulation of fibrinolysis by S100A10 in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-353482 Silverchair:28503 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Regulation of fibrinolysis by S100A10 in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-353482 Silverchair:28503 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Regulation of fibrinolysis by S100A10 in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-353482 Silverchair:28503 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Regulation of gene expression by miR-144/451 during mouse erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.2018854604 Silverchair:273840 Total_Item_Investigations 3 0 0 0 0 3 0 0 0 0 0 0 0 Regulation of gene expression by miR-144/451 during mouse erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.2018854604 Silverchair:273840 Total_Item_Requests 3 0 0 0 0 3 0 0 0 0 0 0 0 Regulation of gene expression by miR-144/451 during mouse erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.2018854604 Silverchair:273840 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Regulation of gene expression by miR-144/451 during mouse erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.2018854604 Silverchair:273840 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Regulation of hemoglobin synthesis and proliferation of differentiating erythroid cells by heme-regulated eIF-2α kinase The American Society of Hematology American Society of Hematology 10.1182/blood.V96.9.3241 Silverchair:181211 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Regulation of hemoglobin synthesis and proliferation of differentiating erythroid cells by heme-regulated eIF-2α kinase The American Society of Hematology American Society of Hematology 10.1182/blood.V96.9.3241 Silverchair:181211 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Regulation of hemoglobin synthesis and proliferation of differentiating erythroid cells by heme-regulated eIF-2α kinase The American Society of Hematology American Society of Hematology 10.1182/blood.V96.9.3241 Silverchair:181211 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Regulation of hemoglobin synthesis and proliferation of differentiating erythroid cells by heme-regulated eIF-2α kinase The American Society of Hematology American Society of Hematology 10.1182/blood.V96.9.3241 Silverchair:181211 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Regulation of platelet plug formation by phosphoinositide metabolism The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-427716 Silverchair:32084 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 Regulation of platelet plug formation by phosphoinositide metabolism The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-427716 Silverchair:32084 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 Regulation of platelet plug formation by phosphoinositide metabolism The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-427716 Silverchair:32084 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Regulation of platelet plug formation by phosphoinositide metabolism The American Society of Hematology American Society of Hematology 10.1182/blood-2013-05-427716 Silverchair:32084 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-05-851667 Silverchair:272784 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-05-851667 Silverchair:272784 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-05-851667 Silverchair:272784 Unique_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-05-851667 Silverchair:272784 Unique_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Regulation of transferrin receptor 2 protein levels by transferrin The American Society of Hematology American Society of Hematology 10.1182/blood-2004-06-2481 Silverchair:19010 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Regulation of transferrin receptor 2 protein levels by transferrin The American Society of Hematology American Society of Hematology 10.1182/blood-2004-06-2481 Silverchair:19010 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Regulation of transferrin receptor 2 protein levels by transferrin The American Society of Hematology American Society of Hematology 10.1182/blood-2004-06-2481 Silverchair:19010 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Regulation of transferrin receptor 2 protein levels by transferrin The American Society of Hematology American Society of Hematology 10.1182/blood-2004-06-2481 Silverchair:19010 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Relapsed Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/asheducation-2010.1.303 Silverchair:96365 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Relapsed Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/asheducation-2010.1.303 Silverchair:96365 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Relapsed Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/asheducation-2010.1.303 Silverchair:96365 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Relapsed Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/asheducation-2010.1.303 Silverchair:96365 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Related haploidentical donors are a better choice than matched unrelated donors: Point American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2016002196 Silverchair:15596 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Related haploidentical donors are a better choice than matched unrelated donors: Point American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2016002196 Silverchair:15596 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Related haploidentical donors are a better choice than matched unrelated donors: Point American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2016002196 Silverchair:15596 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Related haploidentical donors are a better choice than matched unrelated donors: Point American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2016002196 Silverchair:15596 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Relationship between Bone Marrow PD-1 and PD-L1 Expression and the Presence of Osteolytic Bone Disease in Multiple Myeloma Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118200 Silverchair:263915 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Relationship between Bone Marrow PD-1 and PD-L1 Expression and the Presence of Osteolytic Bone Disease in Multiple Myeloma Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118200 Silverchair:263915 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Relationship between Bone Marrow PD-1 and PD-L1 Expression and the Presence of Osteolytic Bone Disease in Multiple Myeloma Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118200 Silverchair:263915 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Relationship between Bone Marrow PD-1 and PD-L1 Expression and the Presence of Osteolytic Bone Disease in Multiple Myeloma Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118200 Silverchair:263915 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Relationship Between Cleaved L-Selectin Levels and the Outcome of Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V92.9.3115 Silverchair:261238 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Relationship Between Cleaved L-Selectin Levels and the Outcome of Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V92.9.3115 Silverchair:261238 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Relationship Between Cleaved L-Selectin Levels and the Outcome of Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V92.9.3115 Silverchair:261238 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Relationship Between Cleaved L-Selectin Levels and the Outcome of Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V92.9.3115 Silverchair:261238 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111326 Silverchair:266381 Total_Item_Investigations 5 0 0 0 0 0 0 0 0 0 5 0 0 Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111326 Silverchair:266381 Total_Item_Requests 5 0 0 0 0 0 0 0 0 0 5 0 0 Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111326 Silverchair:266381 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111326 Silverchair:266381 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Remodel your way to fetal hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.2020008380 Silverchair:474900 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Remodel your way to fetal hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.2020008380 Silverchair:474900 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Remodel your way to fetal hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.2020008380 Silverchair:474900 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Remodel your way to fetal hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.2020008380 Silverchair:474900 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Report of Rare Urachal Carcinoma Presenting with Thrombocytopenia and Microangiopathic Hemolytic Anemia The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5026.5026 Silverchair:94020 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Report of Rare Urachal Carcinoma Presenting with Thrombocytopenia and Microangiopathic Hemolytic Anemia The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5026.5026 Silverchair:94020 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Report of Rare Urachal Carcinoma Presenting with Thrombocytopenia and Microangiopathic Hemolytic Anemia The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5026.5026 Silverchair:94020 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Report of Rare Urachal Carcinoma Presenting with Thrombocytopenia and Microangiopathic Hemolytic Anemia The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5026.5026 Silverchair:94020 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Repression via the GATA box is essential for tissue-specific erythropoietin gene expression The American Society of Hematology American Society of Hematology 10.1182/blood-2007-10-115857 Silverchair:24295 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Repression via the GATA box is essential for tissue-specific erythropoietin gene expression The American Society of Hematology American Society of Hematology 10.1182/blood-2007-10-115857 Silverchair:24295 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Repression via the GATA box is essential for tissue-specific erythropoietin gene expression The American Society of Hematology American Society of Hematology 10.1182/blood-2007-10-115857 Silverchair:24295 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Repression via the GATA box is essential for tissue-specific erythropoietin gene expression The American Society of Hematology American Society of Hematology 10.1182/blood-2007-10-115857 Silverchair:24295 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood.2018884338 Silverchair:260693 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 0 3 0 0 Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood.2018884338 Silverchair:260693 Total_Item_Requests 3 0 0 0 0 0 0 0 0 0 3 0 0 Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood.2018884338 Silverchair:260693 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood.2018884338 Silverchair:260693 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Response of Diamond-Blackfan anemia to metoclopramide: evidence for a role for prolactin in erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.V100.8.2687 Silverchair:106373 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Response of Diamond-Blackfan anemia to metoclopramide: evidence for a role for prolactin in erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.V100.8.2687 Silverchair:106373 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Response of Diamond-Blackfan anemia to metoclopramide: evidence for a role for prolactin in erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.V100.8.2687 Silverchair:106373 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Response of Diamond-Blackfan anemia to metoclopramide: evidence for a role for prolactin in erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.V100.8.2687 Silverchair:106373 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "Response Rate, Event-Free Survival (EFS) and Overall Survival (OS) in Higher-Risk Myelodysplastic Syndromes (HR-MDS): U.S. Food and Drug Administration (FDA) Patient-Level Analyses" The American Society of Hematology American Society of Hematology 10.1182/blood-2021-147558 Silverchair:478660 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 "Response Rate, Event-Free Survival (EFS) and Overall Survival (OS) in Higher-Risk Myelodysplastic Syndromes (HR-MDS): U.S. Food and Drug Administration (FDA) Patient-Level Analyses" The American Society of Hematology American Society of Hematology 10.1182/blood-2021-147558 Silverchair:478660 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 "Response Rate, Event-Free Survival (EFS) and Overall Survival (OS) in Higher-Risk Myelodysplastic Syndromes (HR-MDS): U.S. Food and Drug Administration (FDA) Patient-Level Analyses" The American Society of Hematology American Society of Hematology 10.1182/blood-2021-147558 Silverchair:478660 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 "Response Rate, Event-Free Survival (EFS) and Overall Survival (OS) in Higher-Risk Myelodysplastic Syndromes (HR-MDS): U.S. Food and Drug Administration (FDA) Patient-Level Analyses" The American Society of Hematology American Society of Hematology 10.1182/blood-2021-147558 Silverchair:478660 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Response to B-cell–depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-068999 Silverchair:24006 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Response to B-cell–depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-068999 Silverchair:24006 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Response to B-cell–depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-068999 Silverchair:24006 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Response to B-cell–depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-068999 Silverchair:24006 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Restoring RUNX1 deficiency in RUNX1 familial platelet disorder by inhibiting its degradation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002709 Silverchair:475051 Total_Item_Investigations 3 0 0 2 0 0 0 0 0 0 1 0 0 Restoring RUNX1 deficiency in RUNX1 familial platelet disorder by inhibiting its degradation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002709 Silverchair:475051 Total_Item_Requests 3 0 0 2 0 0 0 0 0 0 1 0 0 Restoring RUNX1 deficiency in RUNX1 familial platelet disorder by inhibiting its degradation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002709 Silverchair:475051 Unique_Item_Investigations 2 0 0 1 0 0 0 0 0 0 1 0 0 Restoring RUNX1 deficiency in RUNX1 familial platelet disorder by inhibiting its degradation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002709 Silverchair:475051 Unique_Item_Requests 2 0 0 1 0 0 0 0 0 0 1 0 0 "Restrospective Review of Incidence, Complications and Management of Tumor Lysis Syndrome in High Risk Patients with Hematologic Malignancies" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2621.2621 Silverchair:95480 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Restrospective Review of Incidence, Complications and Management of Tumor Lysis Syndrome in High Risk Patients with Hematologic Malignancies" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2621.2621 Silverchair:95480 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Restrospective Review of Incidence, Complications and Management of Tumor Lysis Syndrome in High Risk Patients with Hematologic Malignancies" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2621.2621 Silverchair:95480 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Restrospective Review of Incidence, Complications and Management of Tumor Lysis Syndrome in High Risk Patients with Hematologic Malignancies" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2621.2621 Silverchair:95480 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127509 Silverchair:426329 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127509 Silverchair:426329 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127509 Silverchair:426329 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127509 Silverchair:426329 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-155 Silverchair:272957 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-155 Silverchair:272957 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-155 Silverchair:272957 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-155 Silverchair:272957 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-301796 Silverchair:20457 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-301796 Silverchair:20457 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-301796 Silverchair:20457 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-301796 Silverchair:20457 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-121731 Silverchair:426449 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-121731 Silverchair:426449 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-121731 Silverchair:426449 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-121731 Silverchair:426449 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Results from Lummicar-1: A Phase 1 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140727 Silverchair:471115 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Results from Lummicar-1: A Phase 1 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140727 Silverchair:471115 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Results from Lummicar-1: A Phase 1 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140727 Silverchair:471115 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Results from Lummicar-1: A Phase 1 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140727 Silverchair:471115 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML) The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119302 Silverchair:273030 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML) The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119302 Silverchair:273030 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML) The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119302 Silverchair:273030 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML) The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119302 Silverchair:273030 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128020 Silverchair:423997 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128020 Silverchair:423997 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128020 Silverchair:423997 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128020 Silverchair:423997 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123854 Silverchair:426543 Total_Item_Investigations 9 0 1 6 1 0 0 1 0 0 0 0 0 "Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123854 Silverchair:426543 Total_Item_Requests 8 0 1 5 1 0 0 1 0 0 0 0 0 "Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123854 Silverchair:426543 Unique_Item_Investigations 7 0 1 4 1 0 0 1 0 0 0 0 0 "Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123854 Silverchair:426543 Unique_Item_Requests 7 0 1 4 1 0 0 1 0 0 0 0 0 "Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137334 Silverchair:470333 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137334 Silverchair:470333 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137334 Silverchair:470333 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137334 Silverchair:470333 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.389.389 Silverchair:115450 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.389.389 Silverchair:115450 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.389.389 Silverchair:115450 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.389.389 Silverchair:115450 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Results of a Phase III Double-Blind Study of the Addition of Tocilizumab Vs. Placebo to Cyclosporin/Methotrexate Gvhd Prophylaxis after HLA-Matched Allogeneic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126285 Silverchair:426235 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Results of a Phase III Double-Blind Study of the Addition of Tocilizumab Vs. Placebo to Cyclosporin/Methotrexate Gvhd Prophylaxis after HLA-Matched Allogeneic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126285 Silverchair:426235 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Results of a Phase III Double-Blind Study of the Addition of Tocilizumab Vs. Placebo to Cyclosporin/Methotrexate Gvhd Prophylaxis after HLA-Matched Allogeneic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126285 Silverchair:426235 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Results of a Phase III Double-Blind Study of the Addition of Tocilizumab Vs. Placebo to Cyclosporin/Methotrexate Gvhd Prophylaxis after HLA-Matched Allogeneic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126285 Silverchair:426235 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111992 Silverchair:264657 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111992 Silverchair:264657 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111992 Silverchair:264657 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111992 Silverchair:264657 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET) The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111946 Silverchair:263247 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET) The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111946 Silverchair:263247 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET) The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111946 Silverchair:263247 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET) The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111946 Silverchair:263247 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124482 Silverchair:423698 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124482 Silverchair:423698 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124482 Silverchair:423698 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124482 Silverchair:423698 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Reticulocyte and red blood cell deformation triggers specific phosphorylation events American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000545 Silverchair:261383 Total_Item_Investigations 7 0 6 1 0 0 0 0 0 0 0 0 0 Reticulocyte and red blood cell deformation triggers specific phosphorylation events American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000545 Silverchair:261383 Total_Item_Requests 7 0 6 1 0 0 0 0 0 0 0 0 0 Reticulocyte and red blood cell deformation triggers specific phosphorylation events American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000545 Silverchair:261383 Unique_Item_Investigations 4 0 3 1 0 0 0 0 0 0 0 0 0 Reticulocyte and red blood cell deformation triggers specific phosphorylation events American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000545 Silverchair:261383 Unique_Item_Requests 4 0 3 1 0 0 0 0 0 0 0 0 0 Retraction of Matsuyama et al. Discoidin domain receptor 1 contributes to eosinophil survival in an NF-κB–dependent manner in Churg-Strauss syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2007-12-127597 Silverchair:109927 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Retraction of Matsuyama et al. Discoidin domain receptor 1 contributes to eosinophil survival in an NF-κB–dependent manner in Churg-Strauss syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2007-12-127597 Silverchair:109927 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Retraction of Matsuyama et al. Discoidin domain receptor 1 contributes to eosinophil survival in an NF-κB–dependent manner in Churg-Strauss syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2007-12-127597 Silverchair:109927 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Retraction of Matsuyama et al. Discoidin domain receptor 1 contributes to eosinophil survival in an NF-κB–dependent manner in Churg-Strauss syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2007-12-127597 Silverchair:109927 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Reversal of Anticoagulation By Ciraparantag: Time to Onset and Duration of Effect The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140524 Silverchair:469857 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Reversal of Anticoagulation By Ciraparantag: Time to Onset and Duration of Effect The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140524 Silverchair:469857 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Reversal of Anticoagulation By Ciraparantag: Time to Onset and Duration of Effect The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140524 Silverchair:469857 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Reversal of Anticoagulation By Ciraparantag: Time to Onset and Duration of Effect The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140524 Silverchair:469857 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Reversing vitamin K antagonists: making the old new again The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.605 Silverchair:21109 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 Reversing vitamin K antagonists: making the old new again The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.605 Silverchair:21109 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 Reversing vitamin K antagonists: making the old new again The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.605 Silverchair:21109 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Reversing vitamin K antagonists: making the old new again The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.605 Silverchair:21109 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-690636 Silverchair:35156 Total_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-690636 Silverchair:35156 Total_Item_Requests 3 2 0 1 0 0 0 0 0 0 0 0 0 Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-690636 Silverchair:35156 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-690636 Silverchair:35156 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-280347 Silverchair:27573 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-280347 Silverchair:27573 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-280347 Silverchair:27573 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-280347 Silverchair:27573 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Revised International Prognostic Scoring System for Myelodysplastic Syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-420489 Silverchair:30571 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Revised International Prognostic Scoring System for Myelodysplastic Syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-420489 Silverchair:30571 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Revised International Prognostic Scoring System for Myelodysplastic Syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-420489 Silverchair:30571 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Revised International Prognostic Scoring System for Myelodysplastic Syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-420489 Silverchair:30571 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-488098 Silverchair:32095 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 3 0 0 0 Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-488098 Silverchair:32095 Total_Item_Requests 3 0 0 0 0 0 0 0 0 3 0 0 0 Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-488098 Silverchair:32095 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-488098 Silverchair:32095 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) The American Society of Hematology American Society of Hematology 10.1182/blood-2007-03-055749 Silverchair:24087 Total_Item_Investigations 11 6 4 0 0 0 1 0 0 0 0 0 0 Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) The American Society of Hematology American Society of Hematology 10.1182/blood-2007-03-055749 Silverchair:24087 Total_Item_Requests 11 6 4 0 0 0 1 0 0 0 0 0 0 Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) The American Society of Hematology American Society of Hematology 10.1182/blood-2007-03-055749 Silverchair:24087 Unique_Item_Investigations 6 4 1 0 0 0 1 0 0 0 0 0 0 Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) The American Society of Hematology American Society of Hematology 10.1182/blood-2007-03-055749 Silverchair:24087 Unique_Item_Requests 6 4 1 0 0 0 1 0 0 0 0 0 0 RhIg-prophylaxis is not influenced by FCGR2/3 polymorphisms involved in red blood cell clearance The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-716365 Silverchair:36361 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 RhIg-prophylaxis is not influenced by FCGR2/3 polymorphisms involved in red blood cell clearance The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-716365 Silverchair:36361 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 RhIg-prophylaxis is not influenced by FCGR2/3 polymorphisms involved in red blood cell clearance The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-716365 Silverchair:36361 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 RhIg-prophylaxis is not influenced by FCGR2/3 polymorphisms involved in red blood cell clearance The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-716365 Silverchair:36361 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-818617 Silverchair:39421 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-818617 Silverchair:39421 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-818617 Silverchair:39421 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2017-11-818617 Silverchair:39421 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Ribosomes in platelets protect the messenger The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-770180 Silverchair:35942 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Ribosomes in platelets protect the messenger The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-770180 Silverchair:35942 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Ribosomes in platelets protect the messenger The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-770180 Silverchair:35942 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Ribosomes in platelets protect the messenger The American Society of Hematology American Society of Hematology 10.1182/blood-2017-03-770180 Silverchair:35942 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Ribosomopathies: human disorders of ribosome dysfunction The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-178129 Silverchair:27031 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Ribosomopathies: human disorders of ribosome dysfunction The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-178129 Silverchair:27031 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Ribosomopathies: human disorders of ribosome dysfunction The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-178129 Silverchair:27031 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Ribosomopathies: human disorders of ribosome dysfunction The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-178129 Silverchair:27031 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 RIC Allo-SCT with Flu/Bu in Comparison to Flu/Mel for AML Results in Similar Overall Survival: A Report from the ALWP of the EBMT The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.545.545 Silverchair:92329 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 RIC Allo-SCT with Flu/Bu in Comparison to Flu/Mel for AML Results in Similar Overall Survival: A Report from the ALWP of the EBMT The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.545.545 Silverchair:92329 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 RIC Allo-SCT with Flu/Bu in Comparison to Flu/Mel for AML Results in Similar Overall Survival: A Report from the ALWP of the EBMT The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.545.545 Silverchair:92329 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 RIC Allo-SCT with Flu/Bu in Comparison to Flu/Mel for AML Results in Similar Overall Survival: A Report from the ALWP of the EBMT The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.545.545 Silverchair:92329 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Richter transformation in the era of novel agents The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.256 Silverchair:277600 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Richter transformation in the era of novel agents The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.256 Silverchair:277600 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Richter transformation in the era of novel agents The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.256 Silverchair:277600 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Richter transformation in the era of novel agents The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.256 Silverchair:277600 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Ring sideroblasts The American Society of Hematology American Society of Hematology 10.1182/blood.V107.5.1746.1746 Silverchair:133373 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Ring sideroblasts The American Society of Hematology American Society of Hematology 10.1182/blood.V107.5.1746.1746 Silverchair:133373 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Ring sideroblasts The American Society of Hematology American Society of Hematology 10.1182/blood.V107.5.1746.1746 Silverchair:133373 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Ring sideroblasts The American Society of Hematology American Society of Hematology 10.1182/blood.V107.5.1746.1746 Silverchair:133373 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001242 Silverchair:460731 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001242 Silverchair:460731 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001242 Silverchair:460731 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001242 Silverchair:460731 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Risk factors in multiple myeloma: is it time for a revision? The American Society of Hematology American Society of Hematology 10.1182/blood.2019004309 Silverchair:464086 Total_Item_Investigations 11 0 5 3 3 0 0 0 0 0 0 0 0 Risk factors in multiple myeloma: is it time for a revision? The American Society of Hematology American Society of Hematology 10.1182/blood.2019004309 Silverchair:464086 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Risk factors in multiple myeloma: is it time for a revision? The American Society of Hematology American Society of Hematology 10.1182/blood.2019004309 Silverchair:464086 Unique_Item_Investigations 5 0 2 2 1 0 0 0 0 0 0 0 0 Risk factors in multiple myeloma: is it time for a revision? The American Society of Hematology American Society of Hematology 10.1182/blood.2019004309 Silverchair:464086 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Risk factors in multiple myeloma: is it time for a revision? The American Society of Hematology American Society of Hematology 10.1182/blood.2019004309 Silverchair:464086 No_License 3 0 2 1 0 0 0 0 0 0 0 0 0 Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS) The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-355743 Silverchair:29008 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS) The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-355743 Silverchair:29008 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS) The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-355743 Silverchair:29008 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS) The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-355743 Silverchair:29008 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Risk of Cancer in Patients with Clinical Monoclonal B-Cell Lymphocytosis (MBL): A Cohort Study of Newly Diagnosed Patients Compared to Controls. The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.2893.2893 Silverchair:102222 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Risk of Cancer in Patients with Clinical Monoclonal B-Cell Lymphocytosis (MBL): A Cohort Study of Newly Diagnosed Patients Compared to Controls. The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.2893.2893 Silverchair:102222 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Risk of Cancer in Patients with Clinical Monoclonal B-Cell Lymphocytosis (MBL): A Cohort Study of Newly Diagnosed Patients Compared to Controls. The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.2893.2893 Silverchair:102222 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Risk of Cancer in Patients with Clinical Monoclonal B-Cell Lymphocytosis (MBL): A Cohort Study of Newly Diagnosed Patients Compared to Controls. The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.2893.2893 Silverchair:102222 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax- Based Therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137097 Silverchair:473008 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax- Based Therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137097 Silverchair:473008 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax- Based Therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137097 Silverchair:473008 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax- Based Therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137097 Silverchair:473008 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-10-121285 Silverchair:25094 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-10-121285 Silverchair:25094 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-10-121285 Silverchair:25094 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-10-121285 Silverchair:25094 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.3143.3143 Silverchair:12045 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.3143.3143 Silverchair:12045 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.3143.3143 Silverchair:12045 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.3143.3143 Silverchair:12045 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Risk of pulmonary emboli after removal of an upper extremity central catheter associated with a deep vein thrombosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004698 Silverchair:476375 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Risk of pulmonary emboli after removal of an upper extremity central catheter associated with a deep vein thrombosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004698 Silverchair:476375 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Risk of pulmonary emboli after removal of an upper extremity central catheter associated with a deep vein thrombosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004698 Silverchair:476375 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Risk of pulmonary emboli after removal of an upper extremity central catheter associated with a deep vein thrombosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004698 Silverchair:476375 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Risk of Skin Rash in Proteasome Inhibitor Bortezomib: A Systematic Literature Review and Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.5120.5120 Silverchair:82006 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Risk of Skin Rash in Proteasome Inhibitor Bortezomib: A Systematic Literature Review and Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.5120.5120 Silverchair:82006 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Risk of Skin Rash in Proteasome Inhibitor Bortezomib: A Systematic Literature Review and Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.5120.5120 Silverchair:82006 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Risk of Skin Rash in Proteasome Inhibitor Bortezomib: A Systematic Literature Review and Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.5120.5120 Silverchair:82006 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-497545 Silverchair:32412 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-497545 Silverchair:32412 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-497545 Silverchair:32412 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-497545 Silverchair:32412 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood.2020005687 Silverchair:460738 Total_Item_Investigations 7 0 7 0 0 0 0 0 0 0 0 0 0 Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood.2020005687 Silverchair:460738 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood.2020005687 Silverchair:460738 No_License 4 0 4 0 0 0 0 0 0 0 0 0 0 "Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.188.188 Silverchair:71362 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.188.188 Silverchair:71362 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.188.188 Silverchair:71362 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.188.188 Silverchair:71362 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Rituximab (Ritux) Maintenance Infusions in Immune Thrombocytopenia (ITP) to Prolong Remission Following Relapse after Initial Ritux Induction but Responded to a Second Course The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114242 Silverchair:265199 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Rituximab (Ritux) Maintenance Infusions in Immune Thrombocytopenia (ITP) to Prolong Remission Following Relapse after Initial Ritux Induction but Responded to a Second Course The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114242 Silverchair:265199 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Rituximab (Ritux) Maintenance Infusions in Immune Thrombocytopenia (ITP) to Prolong Remission Following Relapse after Initial Ritux Induction but Responded to a Second Course The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114242 Silverchair:265199 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Rituximab (Ritux) Maintenance Infusions in Immune Thrombocytopenia (ITP) to Prolong Remission Following Relapse after Initial Ritux Induction but Responded to a Second Course The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114242 Silverchair:265199 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Rituximab and Reduced Dose CHOP (R-mini-CHOP) for Patients Over 80 Years with Diffuse Large B-Cell Lymphoma (DLBCL) – Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-7B The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.853.853 Silverchair:69912 Total_Item_Investigations 7 1 2 1 1 0 0 1 1 0 0 0 0 Rituximab and Reduced Dose CHOP (R-mini-CHOP) for Patients Over 80 Years with Diffuse Large B-Cell Lymphoma (DLBCL) – Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-7B The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.853.853 Silverchair:69912 Total_Item_Requests 7 1 2 1 1 0 0 1 1 0 0 0 0 Rituximab and Reduced Dose CHOP (R-mini-CHOP) for Patients Over 80 Years with Diffuse Large B-Cell Lymphoma (DLBCL) – Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-7B The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.853.853 Silverchair:69912 Unique_Item_Investigations 7 1 2 1 1 0 0 1 1 0 0 0 0 Rituximab and Reduced Dose CHOP (R-mini-CHOP) for Patients Over 80 Years with Diffuse Large B-Cell Lymphoma (DLBCL) – Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-7B The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.853.853 Silverchair:69912 Unique_Item_Requests 7 1 2 1 1 0 0 1 1 0 0 0 0 Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-372649 Silverchair:29415 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-372649 Silverchair:29415 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-372649 Silverchair:29415 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-372649 Silverchair:29415 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell–mediated antibody-dependent cellular cytotoxicity The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-482570 Silverchair:31468 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell–mediated antibody-dependent cellular cytotoxicity The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-482570 Silverchair:31468 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell–mediated antibody-dependent cellular cytotoxicity The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-482570 Silverchair:31468 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell–mediated antibody-dependent cellular cytotoxicity The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-482570 Silverchair:31468 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study The American Society of Hematology American Society of Hematology 10.1182/blood-2008-01-131029 Silverchair:25366 Total_Item_Investigations 7 0 0 0 0 3 0 0 0 4 0 0 0 Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study The American Society of Hematology American Society of Hematology 10.1182/blood-2008-01-131029 Silverchair:25366 Total_Item_Requests 7 0 0 0 0 3 0 0 0 4 0 0 0 Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study The American Society of Hematology American Society of Hematology 10.1182/blood-2008-01-131029 Silverchair:25366 Unique_Item_Investigations 2 0 0 0 0 1 0 0 0 1 0 0 0 Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study The American Society of Hematology American Society of Hematology 10.1182/blood-2008-01-131029 Silverchair:25366 Unique_Item_Requests 2 0 0 0 0 1 0 0 0 1 0 0 0 Rituximab for steroid-refractory chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2006-01-0233 Silverchair:109865 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Rituximab for steroid-refractory chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2006-01-0233 Silverchair:109865 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Rituximab for steroid-refractory chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2006-01-0233 Silverchair:109865 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Rituximab for steroid-refractory chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2006-01-0233 Silverchair:109865 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Rituximab in CD20 Positive Multiple Myeloma: A Prospective Study from the IFM Group. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.3577.3577 Silverchair:127373 Total_Item_Investigations 2 0 0 0 0 0 0 0 2 0 0 0 0 Rituximab in CD20 Positive Multiple Myeloma: A Prospective Study from the IFM Group. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.3577.3577 Silverchair:127373 Total_Item_Requests 2 0 0 0 0 0 0 0 2 0 0 0 0 Rituximab in CD20 Positive Multiple Myeloma: A Prospective Study from the IFM Group. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.3577.3577 Silverchair:127373 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Rituximab in CD20 Positive Multiple Myeloma: A Prospective Study from the IFM Group. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.3577.3577 Silverchair:127373 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Rituximab in Warfarin Resistance Treatment in Patients with Thrombophilia Due to Primary Antiphospholipid Syndrome: A Pilot Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4001.4001 Silverchair:84215 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Rituximab in Warfarin Resistance Treatment in Patients with Thrombophilia Due to Primary Antiphospholipid Syndrome: A Pilot Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4001.4001 Silverchair:84215 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Rituximab in Warfarin Resistance Treatment in Patients with Thrombophilia Due to Primary Antiphospholipid Syndrome: A Pilot Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4001.4001 Silverchair:84215 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Rituximab in Warfarin Resistance Treatment in Patients with Thrombophilia Due to Primary Antiphospholipid Syndrome: A Pilot Study. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.4001.4001 Silverchair:84215 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Rituximab leads to early elimination of circulating CD20+ T and B lymphocytes in patients with iTTP despite ongoing TPEx American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001148 Silverchair:440992 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Rituximab leads to early elimination of circulating CD20+ T and B lymphocytes in patients with iTTP despite ongoing TPEx American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001148 Silverchair:440992 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Rituximab leads to early elimination of circulating CD20+ T and B lymphocytes in patients with iTTP despite ongoing TPEx American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001148 Silverchair:440992 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Rituximab leads to early elimination of circulating CD20+ T and B lymphocytes in patients with iTTP despite ongoing TPEx American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001148 Silverchair:440992 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial The American Society of Hematology American Society of Hematology 10.1182/blood-2006-05-021113 Silverchair:22772 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial The American Society of Hematology American Society of Hematology 10.1182/blood-2006-05-021113 Silverchair:22772 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial The American Society of Hematology American Society of Hematology 10.1182/blood-2006-05-021113 Silverchair:22772 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial The American Society of Hematology American Society of Hematology 10.1182/blood-2006-05-021113 Silverchair:22772 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Rituximab Maintenance Treatment In Immune Mediated Thrombocytopenia (ITP) Including Evans Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2523.2523 Silverchair:131779 Total_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 Rituximab Maintenance Treatment In Immune Mediated Thrombocytopenia (ITP) Including Evans Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2523.2523 Silverchair:131779 Total_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 Rituximab Maintenance Treatment In Immune Mediated Thrombocytopenia (ITP) Including Evans Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2523.2523 Silverchair:131779 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Rituximab Maintenance Treatment In Immune Mediated Thrombocytopenia (ITP) Including Evans Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2523.2523 Silverchair:131779 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-833608 Silverchair:39401 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-833608 Silverchair:39401 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-833608 Silverchair:39401 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance The American Society of Hematology American Society of Hematology 10.1182/blood-2018-02-833608 Silverchair:39401 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2009-08-231613 Silverchair:26878 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2009-08-231613 Silverchair:26878 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2009-08-231613 Silverchair:26878 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2009-08-231613 Silverchair:26878 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Refractory/Relapsed (R/R) DLBCL. a Real Life Study in Patients Ineligible for Autologous Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124143 Silverchair:424369 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Refractory/Relapsed (R/R) DLBCL. a Real Life Study in Patients Ineligible for Autologous Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124143 Silverchair:424369 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Refractory/Relapsed (R/R) DLBCL. a Real Life Study in Patients Ineligible for Autologous Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124143 Silverchair:424369 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Refractory/Relapsed (R/R) DLBCL. a Real Life Study in Patients Ineligible for Autologous Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124143 Silverchair:424369 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Rituximab prevents long-term relapses in TTP The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-878959 Silverchair:39500 Total_Item_Investigations 2 0 0 0 0 0 2 0 0 0 0 0 0 Rituximab prevents long-term relapses in TTP The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-878959 Silverchair:39500 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Rituximab prevents long-term relapses in TTP The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-878959 Silverchair:39500 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Rituximab prevents long-term relapses in TTP The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-878959 Silverchair:39500 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2016-03-703827 Silverchair:35435 Total_Item_Investigations 5 3 0 0 0 0 0 0 0 0 0 0 2 Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2016-03-703827 Silverchair:35435 Total_Item_Requests 5 3 0 0 0 0 0 0 0 0 0 0 2 Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2016-03-703827 Silverchair:35435 Unique_Item_Investigations 2 1 0 0 0 0 0 0 0 0 0 0 1 Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2016-03-703827 Silverchair:35435 Unique_Item_Requests 2 1 0 0 0 0 0 0 0 0 0 0 1 Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) As First-Line Treatment in Patients with Double-Hit Lymphoma: Preliminary Results in 35 Consecutive Patients from Two Institutions The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4154.4154 Silverchair:72780 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) As First-Line Treatment in Patients with Double-Hit Lymphoma: Preliminary Results in 35 Consecutive Patients from Two Institutions The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4154.4154 Silverchair:72780 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) As First-Line Treatment in Patients with Double-Hit Lymphoma: Preliminary Results in 35 Consecutive Patients from Two Institutions The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4154.4154 Silverchair:72780 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) As First-Line Treatment in Patients with Double-Hit Lymphoma: Preliminary Results in 35 Consecutive Patients from Two Institutions The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4154.4154 Silverchair:72780 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001355 Silverchair:452603 Total_Item_Investigations 17 11 5 1 0 0 0 0 0 0 0 0 0 Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001355 Silverchair:452603 Total_Item_Requests 17 11 5 1 0 0 0 0 0 0 0 0 0 Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001355 Silverchair:452603 Unique_Item_Investigations 13 8 4 1 0 0 0 0 0 0 0 0 0 Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001355 Silverchair:452603 Unique_Item_Requests 13 8 4 1 0 0 0 0 0 0 0 0 0 Rituximab-Mediated ADCC Is Augmented by Concomitant Interference with Inhibitory Self-Recognition by Human NK Cells. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.2456.2456 Silverchair:120993 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Rituximab-Mediated ADCC Is Augmented by Concomitant Interference with Inhibitory Self-Recognition by Human NK Cells. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.2456.2456 Silverchair:120993 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Rituximab-Mediated ADCC Is Augmented by Concomitant Interference with Inhibitory Self-Recognition by Human NK Cells. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.2456.2456 Silverchair:120993 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Rituximab-Mediated ADCC Is Augmented by Concomitant Interference with Inhibitory Self-Recognition by Human NK Cells. The American Society of Hematology American Society of Hematology 10.1182/blood.V106.11.2456.2456 Silverchair:120993 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Rivaroxaban Versus Fondaparinux in the Treatment of Superficial Vein Thrombosis - the Surprise Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.85.85 Silverchair:99009 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Rivaroxaban Versus Fondaparinux in the Treatment of Superficial Vein Thrombosis - the Surprise Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.85.85 Silverchair:99009 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Rivaroxaban Versus Fondaparinux in the Treatment of Superficial Vein Thrombosis - the Surprise Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.85.85 Silverchair:99009 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Rivaroxaban Versus Fondaparinux in the Treatment of Superficial Vein Thrombosis - the Surprise Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.85.85 Silverchair:99009 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-848333 Silverchair:105711 Total_Item_Investigations 12 1 4 2 5 0 0 0 0 0 0 0 0 Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-848333 Silverchair:105711 Total_Item_Requests 12 1 4 2 5 0 0 0 0 0 0 0 0 Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-848333 Silverchair:105711 Unique_Item_Investigations 7 1 3 1 2 0 0 0 0 0 0 0 0 Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-848333 Silverchair:105711 Unique_Item_Requests 7 1 3 1 2 0 0 0 0 0 0 0 0 R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-604561 Silverchair:34222 Total_Item_Investigations 7 2 5 0 0 0 0 0 0 0 0 0 0 R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-604561 Silverchair:34222 Total_Item_Requests 7 2 5 0 0 0 0 0 0 0 0 0 0 R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-604561 Silverchair:34222 Unique_Item_Investigations 7 2 5 0 0 0 0 0 0 0 0 0 0 R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-604561 Silverchair:34222 Unique_Item_Requests 7 2 5 0 0 0 0 0 0 0 0 0 0 RNA Editing Enzyme ADAR1 Accelerates Normal Hematopoiesis Cell Cycle By Regulating microRNA Biogenesis The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.887.887 Silverchair:98944 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 RNA Editing Enzyme ADAR1 Accelerates Normal Hematopoiesis Cell Cycle By Regulating microRNA Biogenesis The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.887.887 Silverchair:98944 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 RNA Editing Enzyme ADAR1 Accelerates Normal Hematopoiesis Cell Cycle By Regulating microRNA Biogenesis The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.887.887 Silverchair:98944 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 RNA Editing Enzyme ADAR1 Accelerates Normal Hematopoiesis Cell Cycle By Regulating microRNA Biogenesis The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.887.887 Silverchair:98944 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "RNA Isoforms, Innate Immunity, and Leukemogenesis: IRAK4 As a Novel Therapeutic Target in MDS/AML" American Society of Hematology American Society of Hematology 10.1182/hem.V16.4.9701 Silverchair:463211 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "RNA Isoforms, Innate Immunity, and Leukemogenesis: IRAK4 As a Novel Therapeutic Target in MDS/AML" American Society of Hematology American Society of Hematology 10.1182/hem.V16.4.9701 Silverchair:463211 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "RNA Isoforms, Innate Immunity, and Leukemogenesis: IRAK4 As a Novel Therapeutic Target in MDS/AML" American Society of Hematology American Society of Hematology 10.1182/hem.V16.4.9701 Silverchair:463211 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "RNA Isoforms, Innate Immunity, and Leukemogenesis: IRAK4 As a Novel Therapeutic Target in MDS/AML" American Society of Hematology American Society of Hematology 10.1182/hem.V16.4.9701 Silverchair:463211 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 RNA modifications in hematopoietic malignancies: a new research frontier The American Society of Hematology American Society of Hematology 10.1182/blood.2019004263 Silverchair:476232 No_License 1 0 0 0 0 0 0 1 0 0 0 0 0 RNA modifications in hematopoietic malignancies: a new research frontier The American Society of Hematology American Society of Hematology 10.1182/blood.2019004263 Silverchair:476232 Total_Item_Investigations 2 0 0 0 0 0 0 2 0 0 0 0 0 RNA modifications in hematopoietic malignancies: a new research frontier The American Society of Hematology American Society of Hematology 10.1182/blood.2019004263 Silverchair:476232 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001641 Silverchair:456024 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001641 Silverchair:456024 Total_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001641 Silverchair:456024 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001641 Silverchair:456024 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Role for MKL1 in megakaryocytic maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-180596 Silverchair:25030 Total_Item_Investigations 9 2 4 3 0 0 0 0 0 0 0 0 0 Role for MKL1 in megakaryocytic maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-180596 Silverchair:25030 Total_Item_Requests 9 2 4 3 0 0 0 0 0 0 0 0 0 Role for MKL1 in megakaryocytic maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-180596 Silverchair:25030 Unique_Item_Investigations 3 1 1 1 0 0 0 0 0 0 0 0 0 Role for MKL1 in megakaryocytic maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-180596 Silverchair:25030 Unique_Item_Requests 3 1 1 1 0 0 0 0 0 0 0 0 0 Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-587964 Silverchair:33963 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-587964 Silverchair:33963 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-587964 Silverchair:33963 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience The American Society of Hematology American Society of Hematology 10.1182/blood-2014-07-587964 Silverchair:33963 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-736975 Silverchair:115002 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-736975 Silverchair:115002 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-736975 Silverchair:115002 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-736975 Silverchair:115002 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Role of Anticoagulation in Patients with Inferior Vena Cava Filter but with No Risk Factor or History of DVT/PE The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.4317.4317 Silverchair:79148 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Role of Anticoagulation in Patients with Inferior Vena Cava Filter but with No Risk Factor or History of DVT/PE The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.4317.4317 Silverchair:79148 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Role of Anticoagulation in Patients with Inferior Vena Cava Filter but with No Risk Factor or History of DVT/PE The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.4317.4317 Silverchair:79148 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Role of Anticoagulation in Patients with Inferior Vena Cava Filter but with No Risk Factor or History of DVT/PE The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.4317.4317 Silverchair:79148 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Role of CD28 in fatal autoimmune disorder in scurfy mice The American Society of Hematology American Society of Hematology 10.1182/blood-2006-10-054585 Silverchair:23148 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Role of CD28 in fatal autoimmune disorder in scurfy mice The American Society of Hematology American Society of Hematology 10.1182/blood-2006-10-054585 Silverchair:23148 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Role of CD28 in fatal autoimmune disorder in scurfy mice The American Society of Hematology American Society of Hematology 10.1182/blood-2006-10-054585 Silverchair:23148 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Role of CD28 in fatal autoimmune disorder in scurfy mice The American Society of Hematology American Society of Hematology 10.1182/blood-2006-10-054585 Silverchair:23148 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Role of c-Myc haploinsufficiency in the maintenance of HSCs in mice The American Society of Hematology American Society of Hematology 10.1182/blood.2019004688 Silverchair:463439 Total_Item_Investigations 5 3 0 2 0 0 0 0 0 0 0 0 0 Role of c-Myc haploinsufficiency in the maintenance of HSCs in mice The American Society of Hematology American Society of Hematology 10.1182/blood.2019004688 Silverchair:463439 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Role of c-Myc haploinsufficiency in the maintenance of HSCs in mice The American Society of Hematology American Society of Hematology 10.1182/blood.2019004688 Silverchair:463439 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Role of c-Myc haploinsufficiency in the maintenance of HSCs in mice The American Society of Hematology American Society of Hematology 10.1182/blood.2019004688 Silverchair:463439 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Role of c-Myc haploinsufficiency in the maintenance of HSCs in mice The American Society of Hematology American Society of Hematology 10.1182/blood.2019004688 Silverchair:463439 No_License 1 0 0 1 0 0 0 0 0 0 0 0 0 Role of ephrinB2 expression in endothelial cells during arteriogenesis: impact on smooth muscle cell migration and monocyte recruitment The American Society of Hematology American Society of Hematology 10.1182/blood-2007-12-128835 Silverchair:24089 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Role of ephrinB2 expression in endothelial cells during arteriogenesis: impact on smooth muscle cell migration and monocyte recruitment The American Society of Hematology American Society of Hematology 10.1182/blood-2007-12-128835 Silverchair:24089 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Role of ephrinB2 expression in endothelial cells during arteriogenesis: impact on smooth muscle cell migration and monocyte recruitment The American Society of Hematology American Society of Hematology 10.1182/blood-2007-12-128835 Silverchair:24089 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Role of ephrinB2 expression in endothelial cells during arteriogenesis: impact on smooth muscle cell migration and monocyte recruitment The American Society of Hematology American Society of Hematology 10.1182/blood-2007-12-128835 Silverchair:24089 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Role of Hypercoagulable Studies in Cryptogenic Stroke: A Retrospective Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136723 Silverchair:473951 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Role of Hypercoagulable Studies in Cryptogenic Stroke: A Retrospective Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136723 Silverchair:473951 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Role of Hypercoagulable Studies in Cryptogenic Stroke: A Retrospective Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136723 Silverchair:473951 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Role of Hypercoagulable Studies in Cryptogenic Stroke: A Retrospective Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136723 Silverchair:473951 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Role of Rhoa G17V in Cell Migration and Transformation in Angioimmunoblastic T-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115005 Silverchair:265370 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Role of Rhoa G17V in Cell Migration and Transformation in Angioimmunoblastic T-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115005 Silverchair:265370 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Role of Rhoa G17V in Cell Migration and Transformation in Angioimmunoblastic T-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115005 Silverchair:265370 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Role of Rhoa G17V in Cell Migration and Transformation in Angioimmunoblastic T-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115005 Silverchair:265370 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Role of Wnt/β-Catenin Signalling in Acute Myeloid Leukemia (AML) Cell Response to Chemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2753.2753 Silverchair:113938 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Role of Wnt/β-Catenin Signalling in Acute Myeloid Leukemia (AML) Cell Response to Chemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2753.2753 Silverchair:113938 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Role of Wnt/β-Catenin Signalling in Acute Myeloid Leukemia (AML) Cell Response to Chemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2753.2753 Silverchair:113938 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Role of Wnt/β-Catenin Signalling in Acute Myeloid Leukemia (AML) Cell Response to Chemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.2753.2753 Silverchair:113938 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Romiplostim: chronic therapy for a chronic disease? The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-191486 Silverchair:24330 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Romiplostim: chronic therapy for a chronic disease? The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-191486 Silverchair:24330 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Romiplostim: chronic therapy for a chronic disease? The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-191486 Silverchair:24330 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Romiplostim: chronic therapy for a chronic disease? The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-191486 Silverchair:24330 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 ROR1 targeting with the antibody drug-conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models The American Society of Hematology American Society of Hematology 10.1182/blood.2020008404 Silverchair:474956 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 ROR1 targeting with the antibody drug-conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models The American Society of Hematology American Society of Hematology 10.1182/blood.2020008404 Silverchair:474956 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Rouleaux formation The American Society of Hematology American Society of Hematology 10.1182/blood.V107.11.4205.4205 Silverchair:21991 Total_Item_Investigations 2 0 0 1 0 0 0 0 1 0 0 0 0 Rouleaux formation The American Society of Hematology American Society of Hematology 10.1182/blood.V107.11.4205.4205 Silverchair:21991 Total_Item_Requests 2 0 0 1 0 0 0 0 1 0 0 0 0 Rouleaux formation The American Society of Hematology American Society of Hematology 10.1182/blood.V107.11.4205.4205 Silverchair:21991 Unique_Item_Investigations 2 0 0 1 0 0 0 0 1 0 0 0 0 Rouleaux formation The American Society of Hematology American Society of Hematology 10.1182/blood.V107.11.4205.4205 Silverchair:21991 Unique_Item_Requests 2 0 0 1 0 0 0 0 1 0 0 0 0 Roundtable: How I treat a newly diagnosed patient with high-risk myeloma The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000015 Silverchair:422568 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Roundtable: How I treat a newly diagnosed patient with high-risk myeloma The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000015 Silverchair:422568 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Roundtable: How I treat a newly diagnosed patient with high-risk myeloma The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000015 Silverchair:422568 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Roundtable: How I treat a newly diagnosed patient with high-risk myeloma The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000015 Silverchair:422568 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2002-09-2708 Silverchair:16926 Total_Item_Investigations 5 5 0 0 0 0 0 0 0 0 0 0 0 RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2002-09-2708 Silverchair:16926 Total_Item_Requests 5 5 0 0 0 0 0 0 0 0 0 0 0 RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2002-09-2708 Silverchair:16926 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2002-09-2708 Silverchair:16926 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 RUNX1 haploinsufficiency causes a marked deficiency of megakaryocyte-biased hematopoietic progenitor cells The American Society of Hematology American Society of Hematology 10.1182/blood.2020006389 Silverchair:475230 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 RUNX1 haploinsufficiency causes a marked deficiency of megakaryocyte-biased hematopoietic progenitor cells The American Society of Hematology American Society of Hematology 10.1182/blood.2020006389 Silverchair:475230 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Runx1 negatively regulates inflammatory cytokine production by neutrophils in response to Toll-like receptor signaling American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000785 Silverchair:452759 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Runx1 negatively regulates inflammatory cytokine production by neutrophils in response to Toll-like receptor signaling American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000785 Silverchair:452759 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Runx1 negatively regulates inflammatory cytokine production by neutrophils in response to Toll-like receptor signaling American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000785 Silverchair:452759 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Runx1 negatively regulates inflammatory cytokine production by neutrophils in response to Toll-like receptor signaling American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000785 Silverchair:452759 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1 The American Society of Hematology American Society of Hematology 10.1182/blood.2018893982 Silverchair:260666 Total_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1 The American Society of Hematology American Society of Hematology 10.1182/blood.2018893982 Silverchair:260666 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1 The American Society of Hematology American Society of Hematology 10.1182/blood.2018893982 Silverchair:260666 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1 The American Society of Hematology American Society of Hematology 10.1182/blood.2018893982 Silverchair:260666 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001158 Silverchair:440608 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001158 Silverchair:440608 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001158 Silverchair:440608 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001158 Silverchair:440608 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-785790 Silverchair:36509 Total_Item_Investigations 6 0 0 4 0 2 0 0 0 0 0 0 0 Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-785790 Silverchair:36509 Total_Item_Requests 6 0 0 4 0 2 0 0 0 0 0 0 0 Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-785790 Silverchair:36509 Unique_Item_Investigations 3 0 0 2 0 1 0 0 0 0 0 0 0 Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-785790 Silverchair:36509 Unique_Item_Requests 3 0 0 2 0 1 0 0 0 0 0 0 0 S100A9 Contributes to T Cell Dysfunction through Its Interaction with RAGE in MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128717 Silverchair:425753 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 S100A9 Contributes to T Cell Dysfunction through Its Interaction with RAGE in MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128717 Silverchair:425753 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 S100A9 Contributes to T Cell Dysfunction through Its Interaction with RAGE in MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128717 Silverchair:425753 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 S100A9 Contributes to T Cell Dysfunction through Its Interaction with RAGE in MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128717 Silverchair:425753 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Safe Tension: What the Latest Data Say About Waiting to Induce in AML American Society of Hematology American Society of Hematology Silverchair:464083 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Safe Tension: What the Latest Data Say About Waiting to Induce in AML American Society of Hematology American Society of Hematology Silverchair:464083 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Safe Tension: What the Latest Data Say About Waiting to Induce in AML American Society of Hematology American Society of Hematology Silverchair:464083 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Safe Tension: What the Latest Data Say About Waiting to Induce in AML American Society of Hematology American Society of Hematology Silverchair:464083 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Safety Analysis of Intra-Patient Dose- Study of Crenolanib Maintenance Therapy in Patients with FLT3 Mutant AML Following Allogeneic Hematopoietic Stem Cell Transplant The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119390 Silverchair:264571 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Safety Analysis of Intra-Patient Dose- Study of Crenolanib Maintenance Therapy in Patients with FLT3 Mutant AML Following Allogeneic Hematopoietic Stem Cell Transplant The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119390 Silverchair:264571 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Safety Analysis of Intra-Patient Dose- Study of Crenolanib Maintenance Therapy in Patients with FLT3 Mutant AML Following Allogeneic Hematopoietic Stem Cell Transplant The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119390 Silverchair:264571 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Safety Analysis of Intra-Patient Dose- Study of Crenolanib Maintenance Therapy in Patients with FLT3 Mutant AML Following Allogeneic Hematopoietic Stem Cell Transplant The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119390 Silverchair:264571 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129559 Silverchair:426078 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129559 Silverchair:426078 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129559 Silverchair:426078 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129559 Silverchair:426078 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110617 Silverchair:275495 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110617 Silverchair:275495 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110617 Silverchair:275495 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110617 Silverchair:275495 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety and Efficacy of Adding Venetoclax to Reduced Intensity Conditioning Chemotherapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk Myeloid Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134947 Silverchair:469965 Total_Item_Investigations 3 0 0 2 1 0 0 0 0 0 0 0 0 Safety and Efficacy of Adding Venetoclax to Reduced Intensity Conditioning Chemotherapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk Myeloid Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134947 Silverchair:469965 Total_Item_Requests 3 0 0 2 1 0 0 0 0 0 0 0 0 Safety and Efficacy of Adding Venetoclax to Reduced Intensity Conditioning Chemotherapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk Myeloid Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134947 Silverchair:469965 Unique_Item_Investigations 2 0 0 1 1 0 0 0 0 0 0 0 0 Safety and Efficacy of Adding Venetoclax to Reduced Intensity Conditioning Chemotherapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk Myeloid Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134947 Silverchair:469965 Unique_Item_Requests 2 0 0 1 1 0 0 0 0 0 0 0 0 Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-738385 Silverchair:35994 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-738385 Silverchair:35994 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-738385 Silverchair:35994 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-738385 Silverchair:35994 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.505.505 Silverchair:80932 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.505.505 Silverchair:80932 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.505.505 Silverchair:80932 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.505.505 Silverchair:80932 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Safety and efficacy of CAR T cells in a patient with lymphoma and a coexisting autoimmune neuropathy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003176 Silverchair:474408 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Safety and efficacy of CAR T cells in a patient with lymphoma and a coexisting autoimmune neuropathy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003176 Silverchair:474408 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Safety and efficacy of CAR T cells in a patient with lymphoma and a coexisting autoimmune neuropathy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003176 Silverchair:474408 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Safety and efficacy of CAR T cells in a patient with lymphoma and a coexisting autoimmune neuropathy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003176 Silverchair:474408 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018019661 Silverchair:15994 Total_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018019661 Silverchair:15994 Total_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018019661 Silverchair:15994 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018019661 Silverchair:15994 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139575 Silverchair:470000 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139575 Silverchair:470000 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139575 Silverchair:470000 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139575 Silverchair:470000 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety and Efficacy of Direct Oral Anticoagulants in Comparison to Low Molecular Weight Heparin in Hematological Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3723.3723 Silverchair:71788 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety and Efficacy of Direct Oral Anticoagulants in Comparison to Low Molecular Weight Heparin in Hematological Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3723.3723 Silverchair:71788 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety and Efficacy of Direct Oral Anticoagulants in Comparison to Low Molecular Weight Heparin in Hematological Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3723.3723 Silverchair:71788 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety and Efficacy of Direct Oral Anticoagulants in Comparison to Low Molecular Weight Heparin in Hematological Malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3723.3723 Silverchair:71788 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety and Efficacy of Direct Oral Anticoagulants in Morbidly Obese Patients: A Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125461 Silverchair:426682 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Safety and Efficacy of Direct Oral Anticoagulants in Morbidly Obese Patients: A Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125461 Silverchair:426682 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Safety and Efficacy of Direct Oral Anticoagulants in Morbidly Obese Patients: A Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125461 Silverchair:426682 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Safety and Efficacy of Direct Oral Anticoagulants in Morbidly Obese Patients: A Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125461 Silverchair:426682 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-425512 Silverchair:31014 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 "Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-425512 Silverchair:31014 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 "Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-425512 Silverchair:31014 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-425512 Silverchair:31014 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2004-10-3821 Silverchair:21532 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2004-10-3821 Silverchair:21532 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2004-10-3821 Silverchair:21532 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2004-10-3821 Silverchair:21532 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-748707 Silverchair:36754 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-748707 Silverchair:36754 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-748707 Silverchair:36754 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-748707 Silverchair:36754 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP The American Society of Hematology American Society of Hematology 10.1182/blood-2008-04-150078 Silverchair:24354 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP The American Society of Hematology American Society of Hematology 10.1182/blood-2008-04-150078 Silverchair:24354 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP The American Society of Hematology American Society of Hematology 10.1182/blood-2008-04-150078 Silverchair:24354 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP The American Society of Hematology American Society of Hematology 10.1182/blood-2008-04-150078 Silverchair:24354 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety and Efficacy of Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplant in Acute Myeloid Leukemia and Myelodysplastic Syndrome - a Systematic Review and Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136671 Silverchair:471292 Total_Item_Investigations 4 2 1 0 0 0 1 0 0 0 0 0 0 Safety and Efficacy of Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplant in Acute Myeloid Leukemia and Myelodysplastic Syndrome - a Systematic Review and Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136671 Silverchair:471292 Total_Item_Requests 4 2 1 0 0 0 1 0 0 0 0 0 0 Safety and Efficacy of Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplant in Acute Myeloid Leukemia and Myelodysplastic Syndrome - a Systematic Review and Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136671 Silverchair:471292 Unique_Item_Investigations 3 1 1 0 0 0 1 0 0 0 0 0 0 Safety and Efficacy of Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplant in Acute Myeloid Leukemia and Myelodysplastic Syndrome - a Systematic Review and Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136671 Silverchair:471292 Unique_Item_Requests 3 1 1 0 0 0 1 0 0 0 0 0 0 "Safety and Efficacy of the Contact Activation Inhibitor AB023 in Patients with End-Stage Renal Disease on Chronic Hemodialysis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139948 Silverchair:469854 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 "Safety and Efficacy of the Contact Activation Inhibitor AB023 in Patients with End-Stage Renal Disease on Chronic Hemodialysis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139948 Silverchair:469854 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 "Safety and Efficacy of the Contact Activation Inhibitor AB023 in Patients with End-Stage Renal Disease on Chronic Hemodialysis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139948 Silverchair:469854 Unique_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 "Safety and Efficacy of the Contact Activation Inhibitor AB023 in Patients with End-Stage Renal Disease on Chronic Hemodialysis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139948 Silverchair:469854 Unique_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Safety and Feasibility of Outpatient Liposomal Daunorubicin and Cytarabine (Vyxeos) Induction and Management in Patients with Secondary AML The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115682 Silverchair:264587 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety and Feasibility of Outpatient Liposomal Daunorubicin and Cytarabine (Vyxeos) Induction and Management in Patients with Secondary AML The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115682 Silverchair:264587 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety and Feasibility of Outpatient Liposomal Daunorubicin and Cytarabine (Vyxeos) Induction and Management in Patients with Secondary AML The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115682 Silverchair:264587 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety and Feasibility of Outpatient Liposomal Daunorubicin and Cytarabine (Vyxeos) Induction and Management in Patients with Secondary AML The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115682 Silverchair:264587 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000201 Silverchair:260113 Total_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000201 Silverchair:260113 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000201 Silverchair:260113 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000201 Silverchair:260113 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Safety of a strategy combining D-dimer testing and whole-leg ultrasonography to rule out deep vein thrombosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002173 Silverchair:467893 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Safety of a strategy combining D-dimer testing and whole-leg ultrasonography to rule out deep vein thrombosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002173 Silverchair:467893 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Safety of a strategy combining D-dimer testing and whole-leg ultrasonography to rule out deep vein thrombosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002173 Silverchair:467893 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Safety of a strategy combining D-dimer testing and whole-leg ultrasonography to rule out deep vein thrombosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002173 Silverchair:467893 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Safety of Autologous Stem Cell Transplantation in Patients with Known HTLV-1 Infection: A Case Series of 4 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110230 Silverchair:263385 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Safety of Autologous Stem Cell Transplantation in Patients with Known HTLV-1 Infection: A Case Series of 4 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110230 Silverchair:263385 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Safety of Autologous Stem Cell Transplantation in Patients with Known HTLV-1 Infection: A Case Series of 4 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110230 Silverchair:263385 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety of Autologous Stem Cell Transplantation in Patients with Known HTLV-1 Infection: A Case Series of 4 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110230 Silverchair:263385 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety of Doacs in Patients of Extreme Weight The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1450.1450 Silverchair:91640 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Safety of Doacs in Patients of Extreme Weight The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1450.1450 Silverchair:91640 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Safety of Doacs in Patients of Extreme Weight The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1450.1450 Silverchair:91640 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Safety of Doacs in Patients of Extreme Weight The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1450.1450 Silverchair:91640 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Safety of Lumbar Punctures in Adult Oncology Patients with Thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.1141.1141 Silverchair:104638 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety of Lumbar Punctures in Adult Oncology Patients with Thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.1141.1141 Silverchair:104638 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety of Lumbar Punctures in Adult Oncology Patients with Thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.1141.1141 Silverchair:104638 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety of Lumbar Punctures in Adult Oncology Patients with Thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.1141.1141 Silverchair:104638 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Safety Profile of Platelet Components Treated with Amotosalen-UVA Pathogen Inactivation Transfused in Routine Use: Multi-Year Active Hemovigilance. The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.2278.2278 Silverchair:85777 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Safety Profile of Platelet Components Treated with Amotosalen-UVA Pathogen Inactivation Transfused in Routine Use: Multi-Year Active Hemovigilance. The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.2278.2278 Silverchair:85777 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Safety Profile of Platelet Components Treated with Amotosalen-UVA Pathogen Inactivation Transfused in Routine Use: Multi-Year Active Hemovigilance. The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.2278.2278 Silverchair:85777 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Safety Profile of Platelet Components Treated with Amotosalen-UVA Pathogen Inactivation Transfused in Routine Use: Multi-Year Active Hemovigilance. The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.2278.2278 Silverchair:85777 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126262 Silverchair:426112 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 "Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126262 Silverchair:426112 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 "Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126262 Silverchair:426112 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 "Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126262 Silverchair:426112 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 "Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139492 Silverchair:470435 Total_Item_Investigations 2 0 1 0 0 0 1 0 0 0 0 0 0 "Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139492 Silverchair:470435 Total_Item_Requests 2 0 1 0 0 0 1 0 0 0 0 0 0 "Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139492 Silverchair:470435 Unique_Item_Investigations 2 0 1 0 0 0 1 0 0 0 0 0 0 "Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139492 Silverchair:470435 Unique_Item_Requests 2 0 1 0 0 0 1 0 0 0 0 0 0 "Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137235 Silverchair:470489 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137235 Silverchair:470489 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137235 Silverchair:470489 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137235 Silverchair:470489 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.V98.13.3846 Silverchair:90255 Total_Item_Investigations 4 0 2 2 0 0 0 0 0 0 0 0 0 Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.V98.13.3846 Silverchair:90255 Total_Item_Requests 4 0 2 2 0 0 0 0 0 0 0 0 0 Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.V98.13.3846 Silverchair:90255 Unique_Item_Investigations 3 0 1 2 0 0 0 0 0 0 0 0 0 Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.V98.13.3846 Silverchair:90255 Unique_Item_Requests 3 0 1 2 0 0 0 0 0 0 0 0 0 SARS-CoV-2 Vaccination and Immune Thrombocytopenia in de novo and pre-existing ITP patients The American Society of Hematology American Society of Hematology 10.1182/blood.2021013411 Silverchair:477081 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 0 3 0 0 SARS-CoV-2 Vaccination and Immune Thrombocytopenia in de novo and pre-existing ITP patients The American Society of Hematology American Society of Hematology 10.1182/blood.2021013411 Silverchair:477081 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 SARS-CoV-2 Vaccination and Immune Thrombocytopenia in de novo and pre-existing ITP patients The American Society of Hematology American Society of Hematology 10.1182/blood.2021013411 Silverchair:477081 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 SARS-CoV-2 Vaccination and Immune Thrombocytopenia in de novo and pre-existing ITP patients The American Society of Hematology American Society of Hematology 10.1182/blood.2021013411 Silverchair:477081 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein The American Society of Hematology American Society of Hematology 10.1182/blood.2020008488 Silverchair:469713 Total_Item_Investigations 5 3 1 1 0 0 0 0 0 0 0 0 0 SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein The American Society of Hematology American Society of Hematology 10.1182/blood.2020008488 Silverchair:469713 Total_Item_Requests 5 3 1 1 0 0 0 0 0 0 0 0 0 SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein The American Society of Hematology American Society of Hematology 10.1182/blood.2020008488 Silverchair:469713 Unique_Item_Investigations 4 2 1 1 0 0 0 0 0 0 0 0 0 SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein The American Society of Hematology American Society of Hematology 10.1182/blood.2020008488 Silverchair:469713 Unique_Item_Requests 4 2 1 1 0 0 0 0 0 0 0 0 0 Screening and Management of Hepatitis B Virus before the First Rituximab Infusion: We Must Do Better! The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2754.2754 Silverchair:95481 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Screening and Management of Hepatitis B Virus before the First Rituximab Infusion: We Must Do Better! The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2754.2754 Silverchair:95481 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Screening and Management of Hepatitis B Virus before the First Rituximab Infusion: We Must Do Better! The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2754.2754 Silverchair:95481 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Screening and Management of Hepatitis B Virus before the First Rituximab Infusion: We Must Do Better! The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2754.2754 Silverchair:95481 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Search for and Extraction of Accessory Spleen in Refractory Immune Cytopenias. Effective or a Waste in Resources? The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140454 Silverchair:469907 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Search for and Extraction of Accessory Spleen in Refractory Immune Cytopenias. Effective or a Waste in Resources? The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140454 Silverchair:469907 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Search for and Extraction of Accessory Spleen in Refractory Immune Cytopenias. Effective or a Waste in Resources? The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140454 Silverchair:469907 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Search for and Extraction of Accessory Spleen in Refractory Immune Cytopenias. Effective or a Waste in Resources? The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140454 Silverchair:469907 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA)" The American Society of Hematology American Society of Hematology 10.1182/blood.2019000937 Silverchair:456025 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA)" The American Society of Hematology American Society of Hematology 10.1182/blood.2019000937 Silverchair:456025 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA)" The American Society of Hematology American Society of Hematology 10.1182/blood.2019000937 Silverchair:456025 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA)" The American Society of Hematology American Society of Hematology 10.1182/blood.2019000937 Silverchair:456025 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria The American Society of Hematology American Society of Hematology 10.1182/blood.2019000940 Silverchair:456026 Total_Item_Investigations 29 5 4 6 3 2 3 1 1 0 4 0 0 Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria The American Society of Hematology American Society of Hematology 10.1182/blood.2019000940 Silverchair:456026 Total_Item_Requests 21 5 4 6 0 0 0 1 1 0 4 0 0 Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria The American Society of Hematology American Society of Hematology 10.1182/blood.2019000940 Silverchair:456026 Unique_Item_Investigations 9 1 1 1 1 1 1 1 1 0 1 0 0 Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria The American Society of Hematology American Society of Hematology 10.1182/blood.2019000940 Silverchair:456026 Unique_Item_Requests 6 1 1 1 0 0 0 1 1 0 1 0 0 Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.V95.9.2770.009k16_2770_2775 Silverchair:125526 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.V95.9.2770.009k16_2770_2775 Silverchair:125526 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.V95.9.2770.009k16_2770_2775 Silverchair:125526 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.V95.9.2770.009k16_2770_2775 Silverchair:125526 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Secreted modular calcium-binding protein 1 binds and activates thrombin to account for platelet hyperreactivity in diabetes The American Society of Hematology American Society of Hematology 10.1182/blood.2020009405 Silverchair:475142 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Secreted modular calcium-binding protein 1 binds and activates thrombin to account for platelet hyperreactivity in diabetes The American Society of Hematology American Society of Hematology 10.1182/blood.2020009405 Silverchair:475142 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Secreted modular calcium-binding protein 1 binds and activates thrombin to account for platelet hyperreactivity in diabetes The American Society of Hematology American Society of Hematology 10.1182/blood.2020009405 Silverchair:475142 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Secreted modular calcium-binding protein 1 binds and activates thrombin to account for platelet hyperreactivity in diabetes The American Society of Hematology American Society of Hematology 10.1182/blood.2020009405 Silverchair:475142 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Selectins and chemokines use shared and distinct signals to activate β2 integrins in neutrophils American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017015602 Silverchair:15822 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Selectins and chemokines use shared and distinct signals to activate β2 integrins in neutrophils American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017015602 Silverchair:15822 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Selectins and chemokines use shared and distinct signals to activate β2 integrins in neutrophils American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017015602 Silverchair:15822 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Selectins and chemokines use shared and distinct signals to activate β2 integrins in neutrophils American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017015602 Silverchair:15822 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 "Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-354563 Silverchair:30254 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-354563 Silverchair:30254 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-354563 Silverchair:30254 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-354563 Silverchair:30254 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Selection of Preparative Regimens for Haploidentical Bone Marrow Transplantation With Post-transplant Cyclophosphamide: Age Is Not Just a Number American Society of Hematology American Society of Hematology Silverchair:464078 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Selection of Preparative Regimens for Haploidentical Bone Marrow Transplantation With Post-transplant Cyclophosphamide: Age Is Not Just a Number American Society of Hematology American Society of Hematology Silverchair:464078 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Selection of Preparative Regimens for Haploidentical Bone Marrow Transplantation With Post-transplant Cyclophosphamide: Age Is Not Just a Number American Society of Hematology American Society of Hematology Silverchair:464078 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Selection of Preparative Regimens for Haploidentical Bone Marrow Transplantation With Post-transplant Cyclophosphamide: Age Is Not Just a Number American Society of Hematology American Society of Hematology Silverchair:464078 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 "Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor" The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-019398 Silverchair:23910 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor" The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-019398 Silverchair:23910 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor" The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-019398 Silverchair:23910 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor" The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-019398 Silverchair:23910 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity The American Society of Hematology American Society of Hematology 10.1182/blood-2009-09-246124 Silverchair:27123 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity The American Society of Hematology American Society of Hematology 10.1182/blood-2009-09-246124 Silverchair:27123 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity The American Society of Hematology American Society of Hematology 10.1182/blood-2009-09-246124 Silverchair:27123 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity The American Society of Hematology American Society of Hematology 10.1182/blood-2009-09-246124 Silverchair:27123 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-750174 Silverchair:36283 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-750174 Silverchair:36283 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-750174 Silverchair:36283 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-750174 Silverchair:36283 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Selective Inhibition of the Leukemia Fusion Protein CBFβ-SMMHC By Small Molecule AI-10-49 in the Treatment of Inv(16) AML The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.390.390 Silverchair:115489 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Selective Inhibition of the Leukemia Fusion Protein CBFβ-SMMHC By Small Molecule AI-10-49 in the Treatment of Inv(16) AML The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.390.390 Silverchair:115489 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Selective Inhibition of the Leukemia Fusion Protein CBFβ-SMMHC By Small Molecule AI-10-49 in the Treatment of Inv(16) AML The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.390.390 Silverchair:115489 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Selective Inhibition of the Leukemia Fusion Protein CBFβ-SMMHC By Small Molecule AI-10-49 in the Treatment of Inv(16) AML The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.390.390 Silverchair:115489 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Selective Inhibitor of Nuclear Export Selinexor (KPT-330) and BCL2 Inhibitor ABT-199 Enhance the Anti-Lymphoma Effect of BTK Inhibitor Ibrutinib in Mantle Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2254.2254 Silverchair:89804 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Selective Inhibitor of Nuclear Export Selinexor (KPT-330) and BCL2 Inhibitor ABT-199 Enhance the Anti-Lymphoma Effect of BTK Inhibitor Ibrutinib in Mantle Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2254.2254 Silverchair:89804 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Selective Inhibitor of Nuclear Export Selinexor (KPT-330) and BCL2 Inhibitor ABT-199 Enhance the Anti-Lymphoma Effect of BTK Inhibitor Ibrutinib in Mantle Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2254.2254 Silverchair:89804 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Selective Inhibitor of Nuclear Export Selinexor (KPT-330) and BCL2 Inhibitor ABT-199 Enhance the Anti-Lymphoma Effect of BTK Inhibitor Ibrutinib in Mantle Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2254.2254 Silverchair:89804 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-176875 Silverchair:103825 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-176875 Silverchair:103825 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-176875 Silverchair:103825 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-176875 Silverchair:103825 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Selective Targeting BET Family Bdii Bromodomain with Abbv-744 and BCL-2 with Venetoclax (ABT-199) Is Synergistic in Primary Acute Myeloid Leukemia Models The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128618 Silverchair:427458 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Selective Targeting BET Family Bdii Bromodomain with Abbv-744 and BCL-2 with Venetoclax (ABT-199) Is Synergistic in Primary Acute Myeloid Leukemia Models The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128618 Silverchair:427458 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Selective Targeting BET Family Bdii Bromodomain with Abbv-744 and BCL-2 with Venetoclax (ABT-199) Is Synergistic in Primary Acute Myeloid Leukemia Models The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128618 Silverchair:427458 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Selective Targeting BET Family Bdii Bromodomain with Abbv-744 and BCL-2 with Venetoclax (ABT-199) Is Synergistic in Primary Acute Myeloid Leukemia Models The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128618 Silverchair:427458 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Self-reported positive impact of mentored clinical research training is associated with academic success in hematology American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004421 Silverchair:476423 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 0 2 Self-reported positive impact of mentored clinical research training is associated with academic success in hematology American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004421 Silverchair:476423 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 0 2 Self-reported positive impact of mentored clinical research training is associated with academic success in hematology American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004421 Silverchair:476423 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Self-reported positive impact of mentored clinical research training is associated with academic success in hematology American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004421 Silverchair:476423 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137025 Silverchair:471107 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137025 Silverchair:471107 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137025 Silverchair:471107 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137025 Silverchair:471107 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Selinexor Maintenance Is Feasible and Tolerable after Allogeneic Stem Cell Transplant (allo-SCT) for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3312.3312 Silverchair:114819 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Selinexor Maintenance Is Feasible and Tolerable after Allogeneic Stem Cell Transplant (allo-SCT) for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3312.3312 Silverchair:114819 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Selinexor Maintenance Is Feasible and Tolerable after Allogeneic Stem Cell Transplant (allo-SCT) for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3312.3312 Silverchair:114819 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Selinexor Maintenance Is Feasible and Tolerable after Allogeneic Stem Cell Transplant (allo-SCT) for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3312.3312 Silverchair:114819 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor The American Society of Hematology American Society of Hematology 10.1182/blood-2002-11-3441 Silverchair:17364 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor The American Society of Hematology American Society of Hematology 10.1182/blood-2002-11-3441 Silverchair:17364 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor The American Society of Hematology American Society of Hematology 10.1182/blood-2002-11-3441 Silverchair:17364 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor The American Society of Hematology American Society of Hematology 10.1182/blood-2002-11-3441 Silverchair:17364 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Sepsis alters the transcriptional and translational landscape of human and murine platelets The American Society of Hematology American Society of Hematology 10.1182/blood.2019000067 Silverchair:374913 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Sepsis alters the transcriptional and translational landscape of human and murine platelets The American Society of Hematology American Society of Hematology 10.1182/blood.2019000067 Silverchair:374913 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Sepsis alters the transcriptional and translational landscape of human and murine platelets The American Society of Hematology American Society of Hematology 10.1182/blood.2019000067 Silverchair:374913 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Sepsis alters the transcriptional and translational landscape of human and murine platelets The American Society of Hematology American Society of Hematology 10.1182/blood.2019000067 Silverchair:374913 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Sequence and structure relationships within von Willebrand factor The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-405134 Silverchair:30440 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Sequence and structure relationships within von Willebrand factor The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-405134 Silverchair:30440 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Sequence and structure relationships within von Willebrand factor The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-405134 Silverchair:30440 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Sequence and structure relationships within von Willebrand factor The American Society of Hematology American Society of Hematology 10.1182/blood-2012-01-405134 Silverchair:30440 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Sequencing multiple myeloma therapies with and after antibody therapies The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000109 Silverchair:474335 Total_Item_Investigations 5 4 0 1 0 0 0 0 0 0 0 0 0 Sequencing multiple myeloma therapies with and after antibody therapies The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000109 Silverchair:474335 Total_Item_Requests 5 4 0 1 0 0 0 0 0 0 0 0 0 Sequencing multiple myeloma therapies with and after antibody therapies The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000109 Silverchair:474335 Unique_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 Sequencing multiple myeloma therapies with and after antibody therapies The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000109 Silverchair:474335 Unique_Item_Requests 3 2 0 1 0 0 0 0 0 0 0 0 0 Sequestration Pattern in ITP Liver/Spleen Scan Correlates with the Presence of Anti-Glycoprotein V Antibodies in ITP Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1046.1046 Silverchair:116055 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Sequestration Pattern in ITP Liver/Spleen Scan Correlates with the Presence of Anti-Glycoprotein V Antibodies in ITP Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1046.1046 Silverchair:116055 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Sequestration Pattern in ITP Liver/Spleen Scan Correlates with the Presence of Anti-Glycoprotein V Antibodies in ITP Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1046.1046 Silverchair:116055 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Sequestration Pattern in ITP Liver/Spleen Scan Correlates with the Presence of Anti-Glycoprotein V Antibodies in ITP Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1046.1046 Silverchair:116055 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Serial Analysis of Gene Expression in Human Monocytes and Macrophages The American Society of Hematology American Society of Hematology 10.1182/blood.V94.3.837.413k02_837_844 Silverchair:125324 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Serial Analysis of Gene Expression in Human Monocytes and Macrophages The American Society of Hematology American Society of Hematology 10.1182/blood.V94.3.837.413k02_837_844 Silverchair:125324 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Serial Analysis of Gene Expression in Human Monocytes and Macrophages The American Society of Hematology American Society of Hematology 10.1182/blood.V94.3.837.413k02_837_844 Silverchair:125324 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Serial Analysis of Gene Expression in Human Monocytes and Macrophages The American Society of Hematology American Society of Hematology 10.1182/blood.V94.3.837.413k02_837_844 Silverchair:125324 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Serious Cardiovascular Events and Clinical Outcomes in Secondary Polycythemia: Efficacy of Conventional Phlebotomy and Proposed Hematocrit Target The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4751.4751 Silverchair:72232 Total_Item_Investigations 5 1 2 0 2 0 0 0 0 0 0 0 0 Serious Cardiovascular Events and Clinical Outcomes in Secondary Polycythemia: Efficacy of Conventional Phlebotomy and Proposed Hematocrit Target The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4751.4751 Silverchair:72232 Total_Item_Requests 5 1 2 0 2 0 0 0 0 0 0 0 0 Serious Cardiovascular Events and Clinical Outcomes in Secondary Polycythemia: Efficacy of Conventional Phlebotomy and Proposed Hematocrit Target The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4751.4751 Silverchair:72232 Unique_Item_Investigations 4 1 1 0 2 0 0 0 0 0 0 0 0 Serious Cardiovascular Events and Clinical Outcomes in Secondary Polycythemia: Efficacy of Conventional Phlebotomy and Proposed Hematocrit Target The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4751.4751 Silverchair:72232 Unique_Item_Requests 4 1 1 0 2 0 0 0 0 0 0 0 0 Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V97.9.2900 Silverchair:130347 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V97.9.2900 Silverchair:130347 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V97.9.2900 Silverchair:130347 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V97.9.2900 Silverchair:130347 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Serum Kappa/Lambda Ratio, An Independent Prognostic Factor at Diagnosis and Serum Free-Light Chains Level, An Early Indicator of Relapse/Progression In Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2954.2954 Silverchair:112313 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Serum Kappa/Lambda Ratio, An Independent Prognostic Factor at Diagnosis and Serum Free-Light Chains Level, An Early Indicator of Relapse/Progression In Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2954.2954 Silverchair:112313 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Serum Kappa/Lambda Ratio, An Independent Prognostic Factor at Diagnosis and Serum Free-Light Chains Level, An Early Indicator of Relapse/Progression In Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2954.2954 Silverchair:112313 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Serum Kappa/Lambda Ratio, An Independent Prognostic Factor at Diagnosis and Serum Free-Light Chains Level, An Early Indicator of Relapse/Progression In Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2954.2954 Silverchair:112313 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Serum response factor is an essential transcription factor in megakaryocytic maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-261743 Silverchair:27456 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Serum response factor is an essential transcription factor in megakaryocytic maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-261743 Silverchair:27456 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Serum response factor is an essential transcription factor in megakaryocytic maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-261743 Silverchair:27456 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Serum response factor is an essential transcription factor in megakaryocytic maturation The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-261743 Silverchair:27456 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 SETD1A protects HSCs from activation-induced functional decline in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-806844 Silverchair:36634 Total_Item_Investigations 9 0 5 4 0 0 0 0 0 0 0 0 0 SETD1A protects HSCs from activation-induced functional decline in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-806844 Silverchair:36634 Total_Item_Requests 9 0 5 4 0 0 0 0 0 0 0 0 0 SETD1A protects HSCs from activation-induced functional decline in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-806844 Silverchair:36634 Unique_Item_Investigations 3 0 1 2 0 0 0 0 0 0 0 0 0 SETD1A protects HSCs from activation-induced functional decline in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-806844 Silverchair:36634 Unique_Item_Requests 3 0 1 2 0 0 0 0 0 0 0 0 0 SETDB1 Mediated H3K9 Methylation Suppresses MLL-Fusion Target Expression and Leukemic Transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122610 Silverchair:426138 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 SETDB1 Mediated H3K9 Methylation Suppresses MLL-Fusion Target Expression and Leukemic Transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122610 Silverchair:426138 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 SETDB1 Mediated H3K9 Methylation Suppresses MLL-Fusion Target Expression and Leukemic Transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122610 Silverchair:426138 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 SETDB1 Mediated H3K9 Methylation Suppresses MLL-Fusion Target Expression and Leukemic Transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122610 Silverchair:426138 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Seven new mutations in the nicotinamide adenine dinucleotide reduced–cytochrome b5 reductase gene leading to methemoglobinemia type I The American Society of Hematology American Society of Hematology 10.1182/blood.V97.4.1106 Silverchair:53131 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Seven new mutations in the nicotinamide adenine dinucleotide reduced–cytochrome b5 reductase gene leading to methemoglobinemia type I The American Society of Hematology American Society of Hematology 10.1182/blood.V97.4.1106 Silverchair:53131 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Seven new mutations in the nicotinamide adenine dinucleotide reduced–cytochrome b5 reductase gene leading to methemoglobinemia type I The American Society of Hematology American Society of Hematology 10.1182/blood.V97.4.1106 Silverchair:53131 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Seven new mutations in the nicotinamide adenine dinucleotide reduced–cytochrome b5 reductase gene leading to methemoglobinemia type I The American Society of Hematology American Society of Hematology 10.1182/blood.V97.4.1106 Silverchair:53131 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Severe chronic primary neutropenia in adults: report on a series of 108 patients The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-634493 Silverchair:34425 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 2 0 0 0 Severe chronic primary neutropenia in adults: report on a series of 108 patients The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-634493 Silverchair:34425 Total_Item_Requests 2 0 0 0 0 0 0 0 0 2 0 0 0 Severe chronic primary neutropenia in adults: report on a series of 108 patients The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-634493 Silverchair:34425 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Severe chronic primary neutropenia in adults: report on a series of 108 patients The American Society of Hematology American Society of Hematology 10.1182/blood-2015-03-634493 Silverchair:34425 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 "Severe Cytokine Release Syndrome Is a Fatal Complication after PBSC, but Not after BM Haploidentical Transplantation with Post-Transplant Cyclophosphamide" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.665.665 Silverchair:83701 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 "Severe Cytokine Release Syndrome Is a Fatal Complication after PBSC, but Not after BM Haploidentical Transplantation with Post-Transplant Cyclophosphamide" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.665.665 Silverchair:83701 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 "Severe Cytokine Release Syndrome Is a Fatal Complication after PBSC, but Not after BM Haploidentical Transplantation with Post-Transplant Cyclophosphamide" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.665.665 Silverchair:83701 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Severe Cytokine Release Syndrome Is a Fatal Complication after PBSC, but Not after BM Haploidentical Transplantation with Post-Transplant Cyclophosphamide" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.665.665 Silverchair:83701 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-178871 Silverchair:25821 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-178871 Silverchair:25821 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-178871 Silverchair:25821 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-178871 Silverchair:25821 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124458 Silverchair:425732 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124458 Silverchair:425732 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124458 Silverchair:425732 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124458 Silverchair:425732 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Shift of the Serum Erythropoietin-vs.-Hemoglobin Curve with Frailty Status in Community-Dwelling Older Adults. Results from the Women’s Health and Aging Studies (WHAS) I and II. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.3141.3141 Silverchair:55259 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Shift of the Serum Erythropoietin-vs.-Hemoglobin Curve with Frailty Status in Community-Dwelling Older Adults. Results from the Women’s Health and Aging Studies (WHAS) I and II. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.3141.3141 Silverchair:55259 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Shift of the Serum Erythropoietin-vs.-Hemoglobin Curve with Frailty Status in Community-Dwelling Older Adults. Results from the Women’s Health and Aging Studies (WHAS) I and II. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.3141.3141 Silverchair:55259 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Shift of the Serum Erythropoietin-vs.-Hemoglobin Curve with Frailty Status in Community-Dwelling Older Adults. Results from the Women’s Health and Aging Studies (WHAS) I and II. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.3141.3141 Silverchair:55259 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine The American Society of Hematology American Society of Hematology 10.1182/blood.V72.4.1333.1333 Silverchair:166433 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine The American Society of Hematology American Society of Hematology 10.1182/blood.V72.4.1333.1333 Silverchair:166433 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Short-term BMP-4 treatment initiates mesoderm induction in human embryonic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-074120 Silverchair:133331 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 Short-term BMP-4 treatment initiates mesoderm induction in human embryonic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-074120 Silverchair:133331 Total_Item_Requests 4 0 4 0 0 0 0 0 0 0 0 0 0 Short-term BMP-4 treatment initiates mesoderm induction in human embryonic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-074120 Silverchair:133331 Unique_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Short-term BMP-4 treatment initiates mesoderm induction in human embryonic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-074120 Silverchair:133331 Unique_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Short-term Gain But Long-term Pain? Clonal Hematopoiesis and the Risk of Therapy-related Myeloid Neoplasms After Treatment for Solid Tumors American Society of Hematology American Society of Hematology Silverchair:475183 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Short-term Gain But Long-term Pain? Clonal Hematopoiesis and the Risk of Therapy-related Myeloid Neoplasms After Treatment for Solid Tumors American Society of Hematology American Society of Hematology Silverchair:475183 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Short-term Gain But Long-term Pain? Clonal Hematopoiesis and the Risk of Therapy-related Myeloid Neoplasms After Treatment for Solid Tumors American Society of Hematology American Society of Hematology Silverchair:475183 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Short-term Gain But Long-term Pain? Clonal Hematopoiesis and the Risk of Therapy-related Myeloid Neoplasms After Treatment for Solid Tumors American Society of Hematology American Society of Hematology Silverchair:475183 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Should I rock the boat? When to stop TKIs in CML The American Society of Hematology American Society of Hematology 10.1182/blood.2020008645 Silverchair:475361 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Should I rock the boat? When to stop TKIs in CML The American Society of Hematology American Society of Hematology 10.1182/blood.2020008645 Silverchair:475361 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Should I rock the boat? When to stop TKIs in CML The American Society of Hematology American Society of Hematology 10.1182/blood.2020008645 Silverchair:475361 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Should I rock the boat? When to stop TKIs in CML The American Society of Hematology American Society of Hematology 10.1182/blood.2020008645 Silverchair:475361 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Should the presence of an antiphospholipid antibody affect the duration of anticoagulant treatment in patients with venous thromboembolism? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2013.1.681 Silverchair:20740 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 1 2 0 0 Should the presence of an antiphospholipid antibody affect the duration of anticoagulant treatment in patients with venous thromboembolism? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2013.1.681 Silverchair:20740 Total_Item_Requests 3 0 0 0 0 0 0 0 0 1 2 0 0 Should the presence of an antiphospholipid antibody affect the duration of anticoagulant treatment in patients with venous thromboembolism? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2013.1.681 Silverchair:20740 Unique_Item_Investigations 2 0 0 0 0 0 0 0 0 1 1 0 0 Should the presence of an antiphospholipid antibody affect the duration of anticoagulant treatment in patients with venous thromboembolism? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2013.1.681 Silverchair:20740 Unique_Item_Requests 2 0 0 0 0 0 0 0 0 1 1 0 0 Should we diagnose and treat distal deep vein thrombosis? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.231 Silverchair:21091 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Should we diagnose and treat distal deep vein thrombosis? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.231 Silverchair:21091 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Should we diagnose and treat distal deep vein thrombosis? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.231 Silverchair:21091 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Should we diagnose and treat distal deep vein thrombosis? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.231 Silverchair:21091 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 SHP-1 As a Negative Regulator of FLT3 Associated Aberrant Signaling and a New Potential Target to FLT3-ITD Mutation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115793 Silverchair:265079 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 SHP-1 As a Negative Regulator of FLT3 Associated Aberrant Signaling and a New Potential Target to FLT3-ITD Mutation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115793 Silverchair:265079 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 SHP-1 As a Negative Regulator of FLT3 Associated Aberrant Signaling and a New Potential Target to FLT3-ITD Mutation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115793 Silverchair:265079 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 SHP-1 As a Negative Regulator of FLT3 Associated Aberrant Signaling and a New Potential Target to FLT3-ITD Mutation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115793 Silverchair:265079 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Shwachman-Diamond Syndrome: An Inherited Preleukemic Bone Marrow Failure Disorder With Aberrant Hematopoietic Progenitors and Faulty Marrow Microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood.V94.9.3048 Silverchair:252468 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Shwachman-Diamond Syndrome: An Inherited Preleukemic Bone Marrow Failure Disorder With Aberrant Hematopoietic Progenitors and Faulty Marrow Microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood.V94.9.3048 Silverchair:252468 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Shwachman-Diamond Syndrome: An Inherited Preleukemic Bone Marrow Failure Disorder With Aberrant Hematopoietic Progenitors and Faulty Marrow Microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood.V94.9.3048 Silverchair:252468 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Shwachman-Diamond Syndrome: An Inherited Preleukemic Bone Marrow Failure Disorder With Aberrant Hematopoietic Progenitors and Faulty Marrow Microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood.V94.9.3048 Silverchair:252468 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-702324 Silverchair:36081 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-702324 Silverchair:36081 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-702324 Silverchair:36081 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-702324 Silverchair:36081 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Sickle cell disease and stroke The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-220921 Silverchair:26508 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Sickle cell disease and stroke The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-220921 Silverchair:26508 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Sickle cell disease and stroke The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-220921 Silverchair:26508 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Sickle cell disease and stroke The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-220921 Silverchair:26508 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Sickle Cell Disease in India The American Society of Hematology American Society of Hematology 10.1182/blood.V13.6.552.552 Silverchair:33417 Total_Item_Investigations 5 5 0 0 0 0 0 0 0 0 0 0 0 Sickle Cell Disease in India The American Society of Hematology American Society of Hematology 10.1182/blood.V13.6.552.552 Silverchair:33417 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Sickle Cell Disease in India The American Society of Hematology American Society of Hematology 10.1182/blood.V13.6.552.552 Silverchair:33417 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Sickle Cell Disease in India The American Society of Hematology American Society of Hematology 10.1182/blood.V13.6.552.552 Silverchair:33417 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-745711 Silverchair:35938 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-745711 Silverchair:35938 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-745711 Silverchair:35938 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-745711 Silverchair:35938 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Sickle cell disease: challenges and progress The American Society of Hematology American Society of Hematology 10.1182/blood-2015-12-674606 Silverchair:35208 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Sickle cell disease: challenges and progress The American Society of Hematology American Society of Hematology 10.1182/blood-2015-12-674606 Silverchair:35208 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Sickle cell disease: challenges and progress The American Society of Hematology American Society of Hematology 10.1182/blood-2015-12-674606 Silverchair:35208 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Sickle cell disease: challenges and progress The American Society of Hematology American Society of Hematology 10.1182/blood-2015-12-674606 Silverchair:35208 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Sickle cell disease: when and how to transfuse The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.625 Silverchair:20963 Total_Item_Investigations 5 1 1 3 0 0 0 0 0 0 0 0 0 Sickle cell disease: when and how to transfuse The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.625 Silverchair:20963 Total_Item_Requests 4 1 1 2 0 0 0 0 0 0 0 0 0 Sickle cell disease: when and how to transfuse The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.625 Silverchair:20963 Unique_Item_Investigations 3 1 1 1 0 0 0 0 0 0 0 0 0 Sickle cell disease: when and how to transfuse The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.625 Silverchair:20963 Unique_Item_Requests 3 1 1 1 0 0 0 0 0 0 0 0 0 Siglec-E is a negative regulator of acute pulmonary neutrophil inflammation and suppresses CD11b β2-integrin–dependent signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2012-08-449983 Silverchair:31064 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Siglec-E is a negative regulator of acute pulmonary neutrophil inflammation and suppresses CD11b β2-integrin–dependent signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2012-08-449983 Silverchair:31064 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Siglec-E is a negative regulator of acute pulmonary neutrophil inflammation and suppresses CD11b β2-integrin–dependent signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2012-08-449983 Silverchair:31064 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Siglec-E is a negative regulator of acute pulmonary neutrophil inflammation and suppresses CD11b β2-integrin–dependent signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2012-08-449983 Silverchair:31064 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130774 Silverchair:423978 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130774 Silverchair:423978 Total_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130774 Silverchair:423978 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130774 Silverchair:423978 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Signaling Through the Interaction of Membrane-Restricted Stem Cell Factor and c-kit Receptor Tyrosine Kinase: Genetic Evidence for a Differential Role in Erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.V91.3.879 Silverchair:261077 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Signaling Through the Interaction of Membrane-Restricted Stem Cell Factor and c-kit Receptor Tyrosine Kinase: Genetic Evidence for a Differential Role in Erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.V91.3.879 Silverchair:261077 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Signaling Through the Interaction of Membrane-Restricted Stem Cell Factor and c-kit Receptor Tyrosine Kinase: Genetic Evidence for a Differential Role in Erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.V91.3.879 Silverchair:261077 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Signaling Through the Interaction of Membrane-Restricted Stem Cell Factor and c-kit Receptor Tyrosine Kinase: Genetic Evidence for a Differential Role in Erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.V91.3.879 Silverchair:261077 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Signatures of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Patients with Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130354 Silverchair:427469 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Signatures of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Patients with Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130354 Silverchair:427469 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Signatures of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Patients with Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130354 Silverchair:427469 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Signatures of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Patients with Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130354 Silverchair:427469 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V78.9.2411.2411 Silverchair:173233 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V78.9.2411.2411 Silverchair:173233 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Significant Impact of the Molecular Profile on the Prognosis of Patients with Myeloproliferative Neoplasms and Splanchnic Vein Thromboses The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123775 Silverchair:427068 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Significant Impact of the Molecular Profile on the Prognosis of Patients with Myeloproliferative Neoplasms and Splanchnic Vein Thromboses The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123775 Silverchair:427068 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Significant Impact of the Molecular Profile on the Prognosis of Patients with Myeloproliferative Neoplasms and Splanchnic Vein Thromboses The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123775 Silverchair:427068 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Significant Impact of the Molecular Profile on the Prognosis of Patients with Myeloproliferative Neoplasms and Splanchnic Vein Thromboses The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123775 Silverchair:427068 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Silencing of c-Fos expression by microRNA-155 is critical for dendritic cell maturation and function The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-308064 Silverchair:20887 Total_Item_Investigations 4 1 0 3 0 0 0 0 0 0 0 0 0 Silencing of c-Fos expression by microRNA-155 is critical for dendritic cell maturation and function The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-308064 Silverchair:20887 Total_Item_Requests 4 1 0 3 0 0 0 0 0 0 0 0 0 Silencing of c-Fos expression by microRNA-155 is critical for dendritic cell maturation and function The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-308064 Silverchair:20887 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Silencing of c-Fos expression by microRNA-155 is critical for dendritic cell maturation and function The American Society of Hematology American Society of Hematology 10.1182/blood-2010-09-308064 Silverchair:20887 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 "Single 225µg/Kg Dose Treatment with Eptacog Beta (Factor VIIa, Recombinant) Results in Rapid Hemostasis in Joint Bleeds for Persons with Hemophilia ? or ? with Inhibitors: A PERSEPT1 Subset Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136443 Silverchair:472335 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 "Single 225µg/Kg Dose Treatment with Eptacog Beta (Factor VIIa, Recombinant) Results in Rapid Hemostasis in Joint Bleeds for Persons with Hemophilia ? or ? with Inhibitors: A PERSEPT1 Subset Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136443 Silverchair:472335 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 "Single 225µg/Kg Dose Treatment with Eptacog Beta (Factor VIIa, Recombinant) Results in Rapid Hemostasis in Joint Bleeds for Persons with Hemophilia ? or ? with Inhibitors: A PERSEPT1 Subset Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136443 Silverchair:472335 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 "Single 225µg/Kg Dose Treatment with Eptacog Beta (Factor VIIa, Recombinant) Results in Rapid Hemostasis in Joint Bleeds for Persons with Hemophilia ? or ? with Inhibitors: A PERSEPT1 Subset Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136443 Silverchair:472335 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Single Cell Resolution Mapping of Hematopoietic Stem and Progenitor Cell States throughout Human Life The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136380 Silverchair:472437 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Single Cell Resolution Mapping of Hematopoietic Stem and Progenitor Cell States throughout Human Life The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136380 Silverchair:472437 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Single Cell Resolution Mapping of Hematopoietic Stem and Progenitor Cell States throughout Human Life The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136380 Silverchair:472437 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Single Cell Resolution Mapping of Hematopoietic Stem and Progenitor Cell States throughout Human Life The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136380 Silverchair:472437 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Single Cell Resolution of Glucocorticoid Effects on Erythroid Progenitor Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112445 Silverchair:266191 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Single Cell Resolution of Glucocorticoid Effects on Erythroid Progenitor Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112445 Silverchair:266191 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Single Cell Resolution of Glucocorticoid Effects on Erythroid Progenitor Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112445 Silverchair:266191 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Single Cell Resolution of Glucocorticoid Effects on Erythroid Progenitor Cells The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112445 Silverchair:266191 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Single cell RNA-seq reveals developmental plasticity with coexisting oncogenic and immune evasion programs in ETP-ALL The American Society of Hematology American Society of Hematology 10.1182/blood.2019004547 Silverchair:474247 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Single cell RNA-seq reveals developmental plasticity with coexisting oncogenic and immune evasion programs in ETP-ALL The American Society of Hematology American Society of Hematology 10.1182/blood.2019004547 Silverchair:474247 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Single Cell Transcriptome in Chronic Myeloid Leukemia (CML): Pseudotime Analysis Reveals a Rare Population with Embryonic Stem Cell Features and Druggable Intricated Transitional Stem Cell States The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110679 Silverchair:266275 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Single Cell Transcriptome in Chronic Myeloid Leukemia (CML): Pseudotime Analysis Reveals a Rare Population with Embryonic Stem Cell Features and Druggable Intricated Transitional Stem Cell States The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110679 Silverchair:266275 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Single Cell Transcriptome in Chronic Myeloid Leukemia (CML): Pseudotime Analysis Reveals a Rare Population with Embryonic Stem Cell Features and Druggable Intricated Transitional Stem Cell States The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110679 Silverchair:266275 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Single Cell Transcriptome in Chronic Myeloid Leukemia (CML): Pseudotime Analysis Reveals a Rare Population with Embryonic Stem Cell Features and Druggable Intricated Transitional Stem Cell States The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-110679 Silverchair:266275 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Single-cell analyses and machine learning define hematopoietic progenitor and HSC-like cells derived from human PSCs The American Society of Hematology American Society of Hematology 10.1182/blood.2020006229 Silverchair:461263 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Single-cell analyses and machine learning define hematopoietic progenitor and HSC-like cells derived from human PSCs The American Society of Hematology American Society of Hematology 10.1182/blood.2020006229 Silverchair:461263 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Single-cell analyses and machine learning define hematopoietic progenitor and HSC-like cells derived from human PSCs The American Society of Hematology American Society of Hematology 10.1182/blood.2020006229 Silverchair:461263 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Single-cell analyses and machine learning define hematopoietic progenitor and HSC-like cells derived from human PSCs The American Society of Hematology American Society of Hematology 10.1182/blood.2020006229 Silverchair:461263 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Single-cell analyses demonstrate that a heme–GATA1 feedback loop regulates red cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-05-850412 Silverchair:273293 Total_Item_Investigations 4 0 0 0 0 0 0 0 0 0 4 0 0 Single-cell analyses demonstrate that a heme–GATA1 feedback loop regulates red cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-05-850412 Silverchair:273293 Total_Item_Requests 4 0 0 0 0 0 0 0 0 0 4 0 0 Single-cell analyses demonstrate that a heme–GATA1 feedback loop regulates red cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-05-850412 Silverchair:273293 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Single-cell analyses demonstrate that a heme–GATA1 feedback loop regulates red cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2018-05-850412 Silverchair:273293 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020009855 Silverchair:475531 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020009855 Silverchair:475531 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Single-Cell Characterization of the HSC-Supportive Bone Marrow Vascular Microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-120339 Silverchair:264101 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Single-Cell Characterization of the HSC-Supportive Bone Marrow Vascular Microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-120339 Silverchair:264101 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Single-Cell Characterization of the HSC-Supportive Bone Marrow Vascular Microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-120339 Silverchair:264101 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Single-Cell Characterization of the HSC-Supportive Bone Marrow Vascular Microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-120339 Silverchair:264101 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123974 Silverchair:426383 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123974 Silverchair:426383 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123974 Silverchair:426383 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2019-123974 Silverchair:426383 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Single-Cell Deconvolution Identifies T-Cell Correlates of Response to PD-1 Blockade Treatment in AML The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122081 Silverchair:427955 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Single-Cell Deconvolution Identifies T-Cell Correlates of Response to PD-1 Blockade Treatment in AML The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122081 Silverchair:427955 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Single-Cell Deconvolution Identifies T-Cell Correlates of Response to PD-1 Blockade Treatment in AML The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122081 Silverchair:427955 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Single-Cell Deconvolution Identifies T-Cell Correlates of Response to PD-1 Blockade Treatment in AML The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122081 Silverchair:427955 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020006996 Silverchair:463329 Total_Item_Investigations 13 0 10 2 0 1 0 0 0 0 0 0 0 Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020006996 Silverchair:463329 Total_Item_Requests 9 0 6 2 0 1 0 0 0 0 0 0 0 Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020006996 Silverchair:463329 Unique_Item_Investigations 9 0 7 1 0 1 0 0 0 0 0 0 0 Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020006996 Silverchair:463329 Unique_Item_Requests 7 0 5 1 0 1 0 0 0 0 0 0 0 Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.2020006868 Silverchair:461285 Total_Item_Investigations 6 5 0 0 0 1 0 0 0 0 0 0 0 Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.2020006868 Silverchair:461285 Total_Item_Requests 6 5 0 0 0 1 0 0 0 0 0 0 0 Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.2020006868 Silverchair:461285 Unique_Item_Investigations 3 2 0 0 0 1 0 0 0 0 0 0 0 Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.2020006868 Silverchair:461285 Unique_Item_Requests 3 2 0 0 0 1 0 0 0 0 0 0 0 Single-Cell Mass Cytometry Identifies Mechanisms of Resistance to Immunotherapy in AML The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128601 Silverchair:427492 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Single-Cell Mass Cytometry Identifies Mechanisms of Resistance to Immunotherapy in AML The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128601 Silverchair:427492 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Single-Cell Mass Cytometry Identifies Mechanisms of Resistance to Immunotherapy in AML The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128601 Silverchair:427492 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Single-Cell Mass Cytometry Identifies Mechanisms of Resistance to Immunotherapy in AML The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128601 Silverchair:427492 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Single-Cell RNA Sequencing Reveals Distinct Hematopoietic Stem Cell Hierarchies in MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128798 Silverchair:427106 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Single-Cell RNA Sequencing Reveals Distinct Hematopoietic Stem Cell Hierarchies in MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128798 Silverchair:427106 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Single-Cell RNA Sequencing Reveals Distinct Hematopoietic Stem Cell Hierarchies in MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128798 Silverchair:427106 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Single-Cell RNA Sequencing Reveals Distinct Hematopoietic Stem Cell Hierarchies in MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128798 Silverchair:427106 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Single-cell RNA-Seq of follicular lymphoma reveals malignant B-cell types and coexpression of T-cell immune checkpoints The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-862292 Silverchair:272746 Total_Item_Investigations 10 0 0 7 3 0 0 0 0 0 0 0 0 Single-cell RNA-Seq of follicular lymphoma reveals malignant B-cell types and coexpression of T-cell immune checkpoints The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-862292 Silverchair:272746 Total_Item_Requests 9 0 0 6 3 0 0 0 0 0 0 0 0 Single-cell RNA-Seq of follicular lymphoma reveals malignant B-cell types and coexpression of T-cell immune checkpoints The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-862292 Silverchair:272746 Unique_Item_Investigations 5 0 0 4 1 0 0 0 0 0 0 0 0 Single-cell RNA-Seq of follicular lymphoma reveals malignant B-cell types and coexpression of T-cell immune checkpoints The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-862292 Silverchair:272746 Unique_Item_Requests 5 0 0 4 1 0 0 0 0 0 0 0 0 Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003934 Silverchair:475773 Total_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003934 Silverchair:475773 Total_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003934 Silverchair:475773 Unique_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003934 Silverchair:475773 Unique_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-657981 Silverchair:34867 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-657981 Silverchair:34867 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-657981 Silverchair:34867 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-657981 Silverchair:34867 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Skeletal-Related Events In Patients With Multiple Myeloma In The Era Of Novel Agents: Low Incidence Of Pathological Fractures After Treatment The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.3090.3090 Silverchair:11606 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Skeletal-Related Events In Patients With Multiple Myeloma In The Era Of Novel Agents: Low Incidence Of Pathological Fractures After Treatment The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.3090.3090 Silverchair:11606 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Skeletal-Related Events In Patients With Multiple Myeloma In The Era Of Novel Agents: Low Incidence Of Pathological Fractures After Treatment The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.3090.3090 Silverchair:11606 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Skeletal-Related Events In Patients With Multiple Myeloma In The Era Of Novel Agents: Low Incidence Of Pathological Fractures After Treatment The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.3090.3090 Silverchair:11606 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Skin Associated Staphylococcus Aureus Contributes to Disease Progression in CTCL The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131917 Silverchair:426400 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Skin Associated Staphylococcus Aureus Contributes to Disease Progression in CTCL The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131917 Silverchair:426400 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Skin Associated Staphylococcus Aureus Contributes to Disease Progression in CTCL The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131917 Silverchair:426400 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Skin Associated Staphylococcus Aureus Contributes to Disease Progression in CTCL The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131917 Silverchair:426400 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Skin Changes in a Patient With Essential Thrombocytosis American Society of Hematology American Society of Hematology Silverchair:475874 Total_Item_Investigations 4 0 0 0 0 3 1 0 0 0 0 0 0 Skin Changes in a Patient With Essential Thrombocytosis American Society of Hematology American Society of Hematology Silverchair:475874 Total_Item_Requests 4 0 0 0 0 3 1 0 0 0 0 0 0 Skin Changes in a Patient With Essential Thrombocytosis American Society of Hematology American Society of Hematology Silverchair:475874 Unique_Item_Investigations 2 0 0 0 0 1 1 0 0 0 0 0 0 Skin Changes in a Patient With Essential Thrombocytosis American Society of Hematology American Society of Hematology Silverchair:475874 Unique_Item_Requests 2 0 0 0 0 1 1 0 0 0 0 0 0 Skin colonization by circulating neoplastic clones in cutaneous T-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2019002516 Silverchair:375109 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Skin colonization by circulating neoplastic clones in cutaneous T-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2019002516 Silverchair:375109 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Skin colonization by circulating neoplastic clones in cutaneous T-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2019002516 Silverchair:375109 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Skin colonization by circulating neoplastic clones in cutaneous T-cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2019002516 Silverchair:375109 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-778423 Silverchair:36597 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-778423 Silverchair:36597 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-778423 Silverchair:36597 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2017-04-778423 Silverchair:36597 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Slowed decay of mRNAs enhances platelet specific translation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-736108 Silverchair:35955 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Slowed decay of mRNAs enhances platelet specific translation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-736108 Silverchair:35955 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Slowed decay of mRNAs enhances platelet specific translation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-736108 Silverchair:35955 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Slowed decay of mRNAs enhances platelet specific translation The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-736108 Silverchair:35955 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Smarca5-mediated epigenetic programming facilitates fetal HSPC development in vertebrates The American Society of Hematology American Society of Hematology 10.1182/blood.2020005219 Silverchair:461708 Total_Item_Investigations 5 4 1 0 0 0 0 0 0 0 0 0 0 Smarca5-mediated epigenetic programming facilitates fetal HSPC development in vertebrates The American Society of Hematology American Society of Hematology 10.1182/blood.2020005219 Silverchair:461708 Total_Item_Requests 4 3 1 0 0 0 0 0 0 0 0 0 0 Smarca5-mediated epigenetic programming facilitates fetal HSPC development in vertebrates The American Society of Hematology American Society of Hematology 10.1182/blood.2020005219 Silverchair:461708 Unique_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 Smarca5-mediated epigenetic programming facilitates fetal HSPC development in vertebrates The American Society of Hematology American Society of Hematology 10.1182/blood.2020005219 Silverchair:461708 Unique_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-431460 Silverchair:30625 Total_Item_Investigations 5 0 3 0 0 1 0 0 0 0 1 0 0 SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-431460 Silverchair:30625 Total_Item_Requests 5 0 3 0 0 1 0 0 0 0 1 0 0 SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-431460 Silverchair:30625 Unique_Item_Investigations 4 0 2 0 0 1 0 0 0 0 1 0 0 SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-431460 Silverchair:30625 Unique_Item_Requests 4 0 2 0 0 1 0 0 0 0 1 0 0 Smoking as a Cause for Mild Chronic Neutrophilia. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.3796.3796 Silverchair:78028 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Smoking as a Cause for Mild Chronic Neutrophilia. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.3796.3796 Silverchair:78028 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Smoking as a Cause for Mild Chronic Neutrophilia. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.3796.3796 Silverchair:78028 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Smoking as a Cause for Mild Chronic Neutrophilia. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.3796.3796 Silverchair:78028 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Societal Costs of Sickle Cell Disease in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119420 Silverchair:262363 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Societal Costs of Sickle Cell Disease in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119420 Silverchair:262363 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Societal Costs of Sickle Cell Disease in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119420 Silverchair:262363 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Societal Costs of Sickle Cell Disease in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119420 Silverchair:262363 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Solid cancers after allogeneic hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2008-05-158782 Silverchair:25677 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Solid cancers after allogeneic hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2008-05-158782 Silverchair:25677 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Solid cancers after allogeneic hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2008-05-158782 Silverchair:25677 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Solid cancers after allogeneic hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2008-05-158782 Silverchair:25677 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Soluble glycoprotein VI is a predictor of major bleeding in patients with suspected heparin-induced thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002861 Silverchair:463721 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 Soluble glycoprotein VI is a predictor of major bleeding in patients with suspected heparin-induced thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002861 Silverchair:463721 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 Soluble glycoprotein VI is a predictor of major bleeding in patients with suspected heparin-induced thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002861 Silverchair:463721 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Soluble glycoprotein VI is a predictor of major bleeding in patients with suspected heparin-induced thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002861 Silverchair:463721 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017012310 Silverchair:16250 Total_Item_Investigations 7 0 0 6 0 0 0 0 1 0 0 0 0 Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017012310 Silverchair:16250 Total_Item_Requests 6 0 0 5 0 0 0 0 1 0 0 0 0 Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017012310 Silverchair:16250 Unique_Item_Investigations 3 0 0 2 0 0 0 0 1 0 0 0 0 Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017012310 Silverchair:16250 Unique_Item_Requests 3 0 0 2 0 0 0 0 1 0 0 0 0 Soluble Interleukin-6 (IL-6) Receptor With IL-6 Stimulates Megakaryopoiesis From Human CD34+ Cells Through Glycoprotein (gp)130 Signaling The American Society of Hematology American Society of Hematology 10.1182/blood.V93.8.2525 Silverchair:247870 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Soluble Interleukin-6 (IL-6) Receptor With IL-6 Stimulates Megakaryopoiesis From Human CD34+ Cells Through Glycoprotein (gp)130 Signaling The American Society of Hematology American Society of Hematology 10.1182/blood.V93.8.2525 Silverchair:247870 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Soluble Interleukin-6 (IL-6) Receptor With IL-6 Stimulates Megakaryopoiesis From Human CD34+ Cells Through Glycoprotein (gp)130 Signaling The American Society of Hematology American Society of Hematology 10.1182/blood.V93.8.2525 Silverchair:247870 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Soluble Interleukin-6 (IL-6) Receptor With IL-6 Stimulates Megakaryopoiesis From Human CD34+ Cells Through Glycoprotein (gp)130 Signaling The American Society of Hematology American Society of Hematology 10.1182/blood.V93.8.2525 Silverchair:247870 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Somatic Bzip Mutations of CEBPA Are Associated with Favorable Outcome Regardless of Presence As Single Vs. Double Mutation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126273 Silverchair:426220 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Somatic Bzip Mutations of CEBPA Are Associated with Favorable Outcome Regardless of Presence As Single Vs. Double Mutation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126273 Silverchair:426220 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Somatic Bzip Mutations of CEBPA Are Associated with Favorable Outcome Regardless of Presence As Single Vs. Double Mutation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126273 Silverchair:426220 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Somatic Bzip Mutations of CEBPA Are Associated with Favorable Outcome Regardless of Presence As Single Vs. Double Mutation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126273 Silverchair:426220 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.907.907 Silverchair:136414 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.907.907 Silverchair:136414 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.907.907 Silverchair:136414 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.907.907 Silverchair:136414 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112614 Silverchair:266168 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112614 Silverchair:266168 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112614 Silverchair:266168 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-112614 Silverchair:266168 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant The American Society of Hematology American Society of Hematology 10.1182/blood-2006-02-004457 Silverchair:22416 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant The American Society of Hematology American Society of Hematology 10.1182/blood-2006-02-004457 Silverchair:22416 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant The American Society of Hematology American Society of Hematology 10.1182/blood-2006-02-004457 Silverchair:22416 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant The American Society of Hematology American Society of Hematology 10.1182/blood-2006-02-004457 Silverchair:22416 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Sorafenib Is Contributing to Salvage Chemotherapy and Is Effective Given Alone for Maintenance in AML FLT3 ITD Patients Relapsing Post Allo Hematopoietic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5265.5265 Silverchair:92554 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Sorafenib Is Contributing to Salvage Chemotherapy and Is Effective Given Alone for Maintenance in AML FLT3 ITD Patients Relapsing Post Allo Hematopoietic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5265.5265 Silverchair:92554 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Sorafenib Is Contributing to Salvage Chemotherapy and Is Effective Given Alone for Maintenance in AML FLT3 ITD Patients Relapsing Post Allo Hematopoietic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5265.5265 Silverchair:92554 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Sorafenib Is Contributing to Salvage Chemotherapy and Is Effective Given Alone for Maintenance in AML FLT3 ITD Patients Relapsing Post Allo Hematopoietic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5265.5265 Silverchair:92554 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-363960 Silverchair:105510 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-363960 Silverchair:105510 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-363960 Silverchair:105510 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-363960 Silverchair:105510 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Sox4 cooperates with CREB in myeloid transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-357418 Silverchair:30125 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Sox4 cooperates with CREB in myeloid transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-357418 Silverchair:30125 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Sox4 cooperates with CREB in myeloid transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-357418 Silverchair:30125 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Sox4 cooperates with CREB in myeloid transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-357418 Silverchair:30125 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-428938 Silverchair:31041 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-428938 Silverchair:31041 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-428938 Silverchair:31041 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-428938 Silverchair:31041 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Sp1/Sp3 transcription factors regulate hallmarks of megakaryocyte maturation and platelet formation and function The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-593343 Silverchair:33715 Total_Item_Investigations 5 2 3 0 0 0 0 0 0 0 0 0 0 Sp1/Sp3 transcription factors regulate hallmarks of megakaryocyte maturation and platelet formation and function The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-593343 Silverchair:33715 Total_Item_Requests 5 2 3 0 0 0 0 0 0 0 0 0 0 Sp1/Sp3 transcription factors regulate hallmarks of megakaryocyte maturation and platelet formation and function The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-593343 Silverchair:33715 Unique_Item_Investigations 3 1 2 0 0 0 0 0 0 0 0 0 0 Sp1/Sp3 transcription factors regulate hallmarks of megakaryocyte maturation and platelet formation and function The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-593343 Silverchair:33715 Unique_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 Spatial Distribution of Invasive Pneumococcal Serotypes in West Africa: A Retrospective Analysis to Inform Immunization in Persons with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119406 Silverchair:264798 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Spatial Distribution of Invasive Pneumococcal Serotypes in West Africa: A Retrospective Analysis to Inform Immunization in Persons with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119406 Silverchair:264798 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Spatial Distribution of Invasive Pneumococcal Serotypes in West Africa: A Retrospective Analysis to Inform Immunization in Persons with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119406 Silverchair:264798 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Spatial Distribution of Invasive Pneumococcal Serotypes in West Africa: A Retrospective Analysis to Inform Immunization in Persons with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119406 Silverchair:264798 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Spatial Signatures Identify Immune Escape via PD-1 as a Defining Feature of T-cell/Histiocyte-rich Large B-cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020006464 Silverchair:463601 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Spatial Signatures Identify Immune Escape via PD-1 as a Defining Feature of T-cell/Histiocyte-rich Large B-cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020006464 Silverchair:463601 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Specific stimulation of T lymphocytes with erythropoietin for adoptive immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.2019001645 Silverchair:422689 No_License 1 0 1 0 0 0 0 0 0 0 0 0 0 Specific stimulation of T lymphocytes with erythropoietin for adoptive immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.2019001645 Silverchair:422689 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Specific stimulation of T lymphocytes with erythropoietin for adoptive immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.2019001645 Silverchair:422689 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-179754 Silverchair:25117 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-179754 Silverchair:25117 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-179754 Silverchair:25117 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-179754 Silverchair:25117 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "S-phase–specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51" The American Society of Hematology American Society of Hematology 10.1182/blood-2002-01-0278 Silverchair:106162 Total_Item_Investigations 5 0 0 5 0 0 0 0 0 0 0 0 0 "S-phase–specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51" The American Society of Hematology American Society of Hematology 10.1182/blood-2002-01-0278 Silverchair:106162 Total_Item_Requests 5 0 0 5 0 0 0 0 0 0 0 0 0 "S-phase–specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51" The American Society of Hematology American Society of Hematology 10.1182/blood-2002-01-0278 Silverchair:106162 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 "S-phase–specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51" The American Society of Hematology American Society of Hematology 10.1182/blood-2002-01-0278 Silverchair:106162 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Spi-B inhibits human plasma cell differentiation by repressing BLIMP1 and XBP-1 expression The American Society of Hematology American Society of Hematology 10.1182/blood-2008-01-136440 Silverchair:25538 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Spi-B inhibits human plasma cell differentiation by repressing BLIMP1 and XBP-1 expression The American Society of Hematology American Society of Hematology 10.1182/blood-2008-01-136440 Silverchair:25538 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Spi-B inhibits human plasma cell differentiation by repressing BLIMP1 and XBP-1 expression The American Society of Hematology American Society of Hematology 10.1182/blood-2008-01-136440 Silverchair:25538 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Spi-B inhibits human plasma cell differentiation by repressing BLIMP1 and XBP-1 expression The American Society of Hematology American Society of Hematology 10.1182/blood-2008-01-136440 Silverchair:25538 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-467068 Silverchair:31496 Total_Item_Investigations 5 0 0 0 0 3 0 0 0 2 0 0 0 Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-467068 Silverchair:31496 Total_Item_Requests 5 0 0 0 0 3 0 0 0 2 0 0 0 Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-467068 Silverchair:31496 Unique_Item_Investigations 2 0 0 0 0 1 0 0 0 1 0 0 0 Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-467068 Silverchair:31496 Unique_Item_Requests 2 0 0 0 0 1 0 0 0 1 0 0 0 "Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications" The American Society of Hematology American Society of Hematology 10.1182/blood-2004-03-1168 Silverchair:19376 Total_Item_Investigations 3 0 0 0 0 1 0 0 0 2 0 0 0 "Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications" The American Society of Hematology American Society of Hematology 10.1182/blood-2004-03-1168 Silverchair:19376 Total_Item_Requests 3 0 0 0 0 1 0 0 0 2 0 0 0 "Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications" The American Society of Hematology American Society of Hematology 10.1182/blood-2004-03-1168 Silverchair:19376 Unique_Item_Investigations 2 0 0 0 0 1 0 0 0 1 0 0 0 "Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications" The American Society of Hematology American Society of Hematology 10.1182/blood-2004-03-1168 Silverchair:19376 Unique_Item_Requests 2 0 0 0 0 1 0 0 0 1 0 0 0 Splenectomy for immune thrombocytopenia: down but not out The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-742353 Silverchair:36453 Total_Item_Investigations 15 0 0 1 1 7 0 0 0 6 0 0 0 Splenectomy for immune thrombocytopenia: down but not out The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-742353 Silverchair:36453 Total_Item_Requests 15 0 0 1 1 7 0 0 0 6 0 0 0 Splenectomy for immune thrombocytopenia: down but not out The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-742353 Silverchair:36453 Unique_Item_Investigations 4 0 0 1 1 1 0 0 0 1 0 0 0 Splenectomy for immune thrombocytopenia: down but not out The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-742353 Silverchair:36453 Unique_Item_Requests 4 0 0 1 1 1 0 0 0 1 0 0 0 Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-751024 Silverchair:36338 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-751024 Silverchair:36338 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-751024 Silverchair:36338 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-751024 Silverchair:36338 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Splenic Infarction in a Patient with Spent-Phase Polycythemia Rubra Vera (PRV) Treated with Lenalidomide. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.4903.4903 Silverchair:129724 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Splenic Infarction in a Patient with Spent-Phase Polycythemia Rubra Vera (PRV) Treated with Lenalidomide. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.4903.4903 Silverchair:129724 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Splenic Infarction in a Patient with Spent-Phase Polycythemia Rubra Vera (PRV) Treated with Lenalidomide. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.4903.4903 Silverchair:129724 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Splenic Infarction in a Patient with Spent-Phase Polycythemia Rubra Vera (PRV) Treated with Lenalidomide. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.4903.4903 Silverchair:129724 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Splenic marginal zone lymphoma: from genetics to management The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-624312 Silverchair:34950 Total_Item_Investigations 4 0 3 1 0 0 0 0 0 0 0 0 0 Splenic marginal zone lymphoma: from genetics to management The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-624312 Silverchair:34950 Total_Item_Requests 3 0 2 1 0 0 0 0 0 0 0 0 0 Splenic marginal zone lymphoma: from genetics to management The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-624312 Silverchair:34950 Unique_Item_Investigations 3 0 2 1 0 0 0 0 0 0 0 0 0 Splenic marginal zone lymphoma: from genetics to management The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-624312 Silverchair:34950 Unique_Item_Requests 3 0 2 1 0 0 0 0 0 0 0 0 0 Splicing factor gene mutations in hematologic malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-692400 Silverchair:35997 Total_Item_Investigations 9 0 0 2 5 0 0 2 0 0 0 0 0 Splicing factor gene mutations in hematologic malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-692400 Silverchair:35997 Total_Item_Requests 8 0 0 1 5 0 0 2 0 0 0 0 0 Splicing factor gene mutations in hematologic malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-692400 Silverchair:35997 Unique_Item_Investigations 5 0 0 1 2 0 0 2 0 0 0 0 0 Splicing factor gene mutations in hematologic malignancies The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-692400 Silverchair:35997 Unique_Item_Requests 5 0 0 1 2 0 0 2 0 0 0 0 0 Splicing factor mutations in hematologic malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2019004260 Silverchair:476234 No_License 1 0 0 0 0 0 0 1 0 0 0 0 0 Splicing factor mutations in hematologic malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2019004260 Silverchair:476234 Total_Item_Investigations 10 0 0 0 0 0 0 3 4 0 1 2 0 Splicing factor mutations in hematologic malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2019004260 Silverchair:476234 Total_Item_Requests 3 0 0 0 0 0 0 0 0 0 1 2 0 Splicing factor mutations in hematologic malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2019004260 Silverchair:476234 Unique_Item_Investigations 5 0 0 0 0 0 0 1 2 0 1 1 0 Splicing factor mutations in hematologic malignancies The American Society of Hematology American Society of Hematology 10.1182/blood.2019004260 Silverchair:476234 Unique_Item_Requests 2 0 0 0 0 0 0 0 0 0 1 1 0 Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-549741 Silverchair:33171 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-549741 Silverchair:33171 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-549741 Silverchair:33171 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder The American Society of Hematology American Society of Hematology 10.1182/blood-2014-01-549741 Silverchair:33171 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Spontaneous Remission of Secondary Acute Lymphoblastic Leukemia Associated with Lenalidomide Therapy for Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129257 Silverchair:425126 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Spontaneous Remission of Secondary Acute Lymphoblastic Leukemia Associated with Lenalidomide Therapy for Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129257 Silverchair:425126 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Spontaneous Remission of Secondary Acute Lymphoblastic Leukemia Associated with Lenalidomide Therapy for Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129257 Silverchair:425126 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Spontaneous Remission of Secondary Acute Lymphoblastic Leukemia Associated with Lenalidomide Therapy for Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129257 Silverchair:425126 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Spontaneous splenic rupture in mantle cell lymphoma with leukemic variant The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-566356 Silverchair:33133 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Spontaneous splenic rupture in mantle cell lymphoma with leukemic variant The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-566356 Silverchair:33133 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Spontaneous splenic rupture in mantle cell lymphoma with leukemic variant The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-566356 Silverchair:33133 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Spontaneous splenic rupture in mantle cell lymphoma with leukemic variant The American Society of Hematology American Society of Hematology 10.1182/blood-2014-04-566356 Silverchair:33133 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Spotlight on pathogenesis of TRALI: HNA-3a (CTL2) antibodies The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-538181 Silverchair:33023 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Spotlight on pathogenesis of TRALI: HNA-3a (CTL2) antibodies The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-538181 Silverchair:33023 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Spotlight on pathogenesis of TRALI: HNA-3a (CTL2) antibodies The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-538181 Silverchair:33023 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Spotlight on pathogenesis of TRALI: HNA-3a (CTL2) antibodies The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-538181 Silverchair:33023 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Src family kinases are important negative regulators of G-CSF-dependent granulopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2006-05-024307 Silverchair:22567 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Src family kinases are important negative regulators of G-CSF-dependent granulopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2006-05-024307 Silverchair:22567 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Src family kinases are important negative regulators of G-CSF-dependent granulopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2006-05-024307 Silverchair:22567 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Src family kinases are important negative regulators of G-CSF-dependent granulopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2006-05-024307 Silverchair:22567 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 SRF is required for neutrophil migration in response to inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2013-06-507582 Silverchair:32666 Total_Item_Investigations 6 3 0 3 0 0 0 0 0 0 0 0 0 SRF is required for neutrophil migration in response to inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2013-06-507582 Silverchair:32666 Total_Item_Requests 4 2 0 2 0 0 0 0 0 0 0 0 0 SRF is required for neutrophil migration in response to inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2013-06-507582 Silverchair:32666 Unique_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 SRF is required for neutrophil migration in response to inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2013-06-507582 Silverchair:32666 Unique_Item_Requests 3 2 0 1 0 0 0 0 0 0 0 0 0 Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system The American Society of Hematology American Society of Hematology 10.1182/blood-2005-05-2133 Silverchair:131440 Total_Item_Investigations 6 6 0 0 0 0 0 0 0 0 0 0 0 Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system The American Society of Hematology American Society of Hematology 10.1182/blood-2005-05-2133 Silverchair:131440 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system The American Society of Hematology American Society of Hematology 10.1182/blood-2005-05-2133 Silverchair:131440 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system The American Society of Hematology American Society of Hematology 10.1182/blood-2005-05-2133 Silverchair:131440 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Stable lines and clones of long-term proliferating normal, genetically unmodified murine common lymphoid progenitors" The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-805259 Silverchair:36733 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Stable lines and clones of long-term proliferating normal, genetically unmodified murine common lymphoid progenitors" The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-805259 Silverchair:36733 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "Stable lines and clones of long-term proliferating normal, genetically unmodified murine common lymphoid progenitors" The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-805259 Silverchair:36733 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Stable lines and clones of long-term proliferating normal, genetically unmodified murine common lymphoid progenitors" The American Society of Hematology American Society of Hematology 10.1182/blood-2017-09-805259 Silverchair:36733 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 STAG2 Loss Gives Rise to Therapeutically Targetable DNA Damage Repair Defects and Altered Replication Fork Dynamics in Acute Myeloid Leukaemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129828 Silverchair:426666 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 STAG2 Loss Gives Rise to Therapeutically Targetable DNA Damage Repair Defects and Altered Replication Fork Dynamics in Acute Myeloid Leukaemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129828 Silverchair:426666 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 STAG2 Loss Gives Rise to Therapeutically Targetable DNA Damage Repair Defects and Altered Replication Fork Dynamics in Acute Myeloid Leukaemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129828 Silverchair:426666 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 STAG2 Loss Gives Rise to Therapeutically Targetable DNA Damage Repair Defects and Altered Replication Fork Dynamics in Acute Myeloid Leukaemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129828 Silverchair:426666 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Stage I DLBCL: extranodal may mean extra radiation The American Society of Hematology American Society of Hematology 10.1182/blood.2020008108 Silverchair:474790 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 Stage I DLBCL: extranodal may mean extra radiation The American Society of Hematology American Society of Hematology 10.1182/blood.2020008108 Silverchair:474790 Total_Item_Requests 4 0 4 0 0 0 0 0 0 0 0 0 0 Stage I DLBCL: extranodal may mean extra radiation The American Society of Hematology American Society of Hematology 10.1182/blood.2020008108 Silverchair:474790 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Stage I DLBCL: extranodal may mean extra radiation The American Society of Hematology American Society of Hematology 10.1182/blood.2020008108 Silverchair:474790 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2021-146120 Silverchair:482579 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2021-146120 Silverchair:482579 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2021-146120 Silverchair:482579 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2021-146120 Silverchair:482579 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000086 Silverchair:474290 Total_Item_Investigations 2 0 0 0 0 0 0 0 1 1 0 0 0 Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000086 Silverchair:474290 Total_Item_Requests 2 0 0 0 0 0 0 0 1 1 0 0 0 Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000086 Silverchair:474290 Unique_Item_Investigations 2 0 0 0 0 0 0 0 1 1 0 0 0 Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000086 Silverchair:474290 Unique_Item_Requests 2 0 0 0 0 0 0 0 1 1 0 0 0 Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-442392 Silverchair:31105 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-442392 Silverchair:31105 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-442392 Silverchair:31105 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-442392 Silverchair:31105 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 "Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-162503 Silverchair:109971 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 "Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-162503 Silverchair:109971 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 "Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-162503 Silverchair:109971 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 "Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-162503 Silverchair:109971 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1 The American Society of Hematology American Society of Hematology 10.1182/blood-2002-09-2972 Silverchair:17786 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1 The American Society of Hematology American Society of Hematology 10.1182/blood-2002-09-2972 Silverchair:17786 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1 The American Society of Hematology American Society of Hematology 10.1182/blood-2002-09-2972 Silverchair:17786 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1 The American Society of Hematology American Society of Hematology 10.1182/blood-2002-09-2972 Silverchair:17786 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 STAT3 controls the neutrophil migratory response to CXCR2 ligands by direct activation of G-CSF–induced CXCR2 expression and via modulation of CXCR2 signal transduction The American Society of Hematology American Society of Hematology 10.1182/blood-2009-08-240317 Silverchair:27038 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 STAT3 controls the neutrophil migratory response to CXCR2 ligands by direct activation of G-CSF–induced CXCR2 expression and via modulation of CXCR2 signal transduction The American Society of Hematology American Society of Hematology 10.1182/blood-2009-08-240317 Silverchair:27038 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 STAT3 controls the neutrophil migratory response to CXCR2 ligands by direct activation of G-CSF–induced CXCR2 expression and via modulation of CXCR2 signal transduction The American Society of Hematology American Society of Hematology 10.1182/blood-2009-08-240317 Silverchair:27038 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 STAT3 controls the neutrophil migratory response to CXCR2 ligands by direct activation of G-CSF–induced CXCR2 expression and via modulation of CXCR2 signal transduction The American Society of Hematology American Society of Hematology 10.1182/blood-2009-08-240317 Silverchair:27038 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 STAT3 is required for IL-21–induced secretion of IgE from human naive B cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-02-142745 Silverchair:25481 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 STAT3 is required for IL-21–induced secretion of IgE from human naive B cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-02-142745 Silverchair:25481 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 STAT3 is required for IL-21–induced secretion of IgE from human naive B cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-02-142745 Silverchair:25481 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 STAT3 is required for IL-21–induced secretion of IgE from human naive B cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-02-142745 Silverchair:25481 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-494930 Silverchair:32174 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-494930 Silverchair:32174 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-494930 Silverchair:32174 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-494930 Silverchair:32174 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Stat5 Feedback Control Switches MYC- and BCL6-Dependent Cell Fates in Normal and Transformed B Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1440.1440 Silverchair:79518 Total_Item_Investigations 5 2 1 2 0 0 0 0 0 0 0 0 0 Stat5 Feedback Control Switches MYC- and BCL6-Dependent Cell Fates in Normal and Transformed B Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1440.1440 Silverchair:79518 Total_Item_Requests 5 2 1 2 0 0 0 0 0 0 0 0 0 Stat5 Feedback Control Switches MYC- and BCL6-Dependent Cell Fates in Normal and Transformed B Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1440.1440 Silverchair:79518 Unique_Item_Investigations 4 1 1 2 0 0 0 0 0 0 0 0 0 Stat5 Feedback Control Switches MYC- and BCL6-Dependent Cell Fates in Normal and Transformed B Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1440.1440 Silverchair:79518 Unique_Item_Requests 4 1 1 2 0 0 0 0 0 0 0 0 0 STAT6 in PMBL: pathogenic or passenger? The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-221770 Silverchair:26145 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 STAT6 in PMBL: pathogenic or passenger? The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-221770 Silverchair:26145 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 STAT6 in PMBL: pathogenic or passenger? The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-221770 Silverchair:26145 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 STAT6 in PMBL: pathogenic or passenger? The American Society of Hematology American Society of Hematology 10.1182/blood-2009-05-221770 Silverchair:26145 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Statewide Intervention to Improve Medical Care Services Utilization Patterns of Adults Living with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124462 Silverchair:426481 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Statewide Intervention to Improve Medical Care Services Utilization Patterns of Adults Living with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124462 Silverchair:426481 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Statewide Intervention to Improve Medical Care Services Utilization Patterns of Adults Living with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124462 Silverchair:426481 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Statewide Intervention to Improve Medical Care Services Utilization Patterns of Adults Living with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124462 Silverchair:426481 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Stem and progenitor cell alterations in myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-696062 Silverchair:36080 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Stem and progenitor cell alterations in myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-696062 Silverchair:36080 Total_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 Stem and progenitor cell alterations in myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-696062 Silverchair:36080 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Stem and progenitor cell alterations in myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-696062 Silverchair:36080 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Stem cell maintenance: aMPLe splicing choices The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-616326 Silverchair:34052 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Stem cell maintenance: aMPLe splicing choices The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-616326 Silverchair:34052 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Stem cell maintenance: aMPLe splicing choices The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-616326 Silverchair:34052 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Stem cell maintenance: aMPLe splicing choices The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-616326 Silverchair:34052 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Stem Cell Transplantation for Diamond-Blackfan Anemia. a Retrospective Study on Behalf of Severe Aplastic Anemia Working Party of the European Blood and Marrow Transplantation Group (EBMT) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124644 Silverchair:427840 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Stem Cell Transplantation for Diamond-Blackfan Anemia. a Retrospective Study on Behalf of Severe Aplastic Anemia Working Party of the European Blood and Marrow Transplantation Group (EBMT) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124644 Silverchair:427840 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Stem Cell Transplantation for Diamond-Blackfan Anemia. a Retrospective Study on Behalf of Severe Aplastic Anemia Working Party of the European Blood and Marrow Transplantation Group (EBMT) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124644 Silverchair:427840 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Stem Cell Transplantation for Diamond-Blackfan Anemia. a Retrospective Study on Behalf of Severe Aplastic Anemia Working Party of the European Blood and Marrow Transplantation Group (EBMT) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124644 Silverchair:427840 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Stem cell–specific epigenetic priming and B cell–specific transcriptional activation at the mouse Cd19 locus The American Society of Hematology American Society of Hematology 10.1182/blood-2008-02-142786 Silverchair:25503 Total_Item_Investigations 4 3 1 0 0 0 0 0 0 0 0 0 0 Stem cell–specific epigenetic priming and B cell–specific transcriptional activation at the mouse Cd19 locus The American Society of Hematology American Society of Hematology 10.1182/blood-2008-02-142786 Silverchair:25503 Total_Item_Requests 4 3 1 0 0 0 0 0 0 0 0 0 0 Stem cell–specific epigenetic priming and B cell–specific transcriptional activation at the mouse Cd19 locus The American Society of Hematology American Society of Hematology 10.1182/blood-2008-02-142786 Silverchair:25503 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Stem cell–specific epigenetic priming and B cell–specific transcriptional activation at the mouse Cd19 locus The American Society of Hematology American Society of Hematology 10.1182/blood-2008-02-142786 Silverchair:25503 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Stemness Signature Defined By Logistic Regression Machine Learning and Artificial Intelligence Predicts Outcomes in Diffuse Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141791 Silverchair:472556 Total_Item_Investigations 3 0 0 0 0 0 0 3 0 0 0 0 0 Stemness Signature Defined By Logistic Regression Machine Learning and Artificial Intelligence Predicts Outcomes in Diffuse Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141791 Silverchair:472556 Total_Item_Requests 3 0 0 0 0 0 0 3 0 0 0 0 0 Stemness Signature Defined By Logistic Regression Machine Learning and Artificial Intelligence Predicts Outcomes in Diffuse Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141791 Silverchair:472556 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Stemness Signature Defined By Logistic Regression Machine Learning and Artificial Intelligence Predicts Outcomes in Diffuse Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141791 Silverchair:472556 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2007-07-099564 Silverchair:25393 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2007-07-099564 Silverchair:25393 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2007-07-099564 Silverchair:25393 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2007-07-099564 Silverchair:25393 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Stimulation of the B-Cell Receptor (BCR) Induces Successive Activation of STAT3 and Nuclear Factor-Kappa-B in CLL Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4125.4125 Silverchair:135700 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Stimulation of the B-Cell Receptor (BCR) Induces Successive Activation of STAT3 and Nuclear Factor-Kappa-B in CLL Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4125.4125 Silverchair:135700 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Stimulation of the B-Cell Receptor (BCR) Induces Successive Activation of STAT3 and Nuclear Factor-Kappa-B in CLL Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4125.4125 Silverchair:135700 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Stimulation of the B-Cell Receptor (BCR) Induces Successive Activation of STAT3 and Nuclear Factor-Kappa-B in CLL Cells The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4125.4125 Silverchair:135700 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2007-01-071043 Silverchair:133595 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2007-01-071043 Silverchair:133595 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2007-01-071043 Silverchair:133595 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood-2007-01-071043 Silverchair:133595 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 STING and transplantation: can targeting this pathway improve outcomes? The American Society of Hematology American Society of Hematology 10.1182/blood.2020008911 Silverchair:475284 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 STING and transplantation: can targeting this pathway improve outcomes? The American Society of Hematology American Society of Hematology 10.1182/blood.2020008911 Silverchair:475284 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 "Strategies before, during, and after hematopoietic cell transplantation to improve T-cell immune reconstitution" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-724005 Silverchair:35689 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Strategies before, during, and after hematopoietic cell transplantation to improve T-cell immune reconstitution" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-724005 Silverchair:35689 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Strategies before, during, and after hematopoietic cell transplantation to improve T-cell immune reconstitution" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-724005 Silverchair:35689 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Strategies before, during, and after hematopoietic cell transplantation to improve T-cell immune reconstitution" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-724005 Silverchair:35689 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Strategies for aggressive T-cell lymphoma: divide and conquer The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000101 Silverchair:474340 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Strategies for aggressive T-cell lymphoma: divide and conquer The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000101 Silverchair:474340 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Strategies for aggressive T-cell lymphoma: divide and conquer The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000101 Silverchair:474340 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Strategies for aggressive T-cell lymphoma: divide and conquer The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000101 Silverchair:474340 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Strategies that delay or prevent the timely availability of affordable generic drugs in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-680058 Silverchair:34989 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Strategies that delay or prevent the timely availability of affordable generic drugs in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-680058 Silverchair:34989 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Strategies that delay or prevent the timely availability of affordable generic drugs in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-680058 Silverchair:34989 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Strategies that delay or prevent the timely availability of affordable generic drugs in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-680058 Silverchair:34989 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-04-212530 Silverchair:26956 Total_Item_Investigations 5 0 0 5 0 0 0 0 0 0 0 0 0 "Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-04-212530 Silverchair:26956 Total_Item_Requests 5 0 0 5 0 0 0 0 0 0 0 0 0 "Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-04-212530 Silverchair:26956 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 "Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-04-212530 Silverchair:26956 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Stroke and myocardial infarction in hereditary thrombotic thrombocytopenic purpura: similarities to sickle cell anemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000959 Silverchair:429235 Total_Item_Investigations 3 0 0 0 3 0 0 0 0 0 0 0 0 Stroke and myocardial infarction in hereditary thrombotic thrombocytopenic purpura: similarities to sickle cell anemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000959 Silverchair:429235 Total_Item_Requests 3 0 0 0 3 0 0 0 0 0 0 0 0 Stroke and myocardial infarction in hereditary thrombotic thrombocytopenic purpura: similarities to sickle cell anemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000959 Silverchair:429235 Unique_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Stroke and myocardial infarction in hereditary thrombotic thrombocytopenic purpura: similarities to sickle cell anemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000959 Silverchair:429235 Unique_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-009506 Silverchair:22326 Total_Item_Investigations 3 0 1 2 0 0 0 0 0 0 0 0 0 Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-009506 Silverchair:22326 Total_Item_Requests 3 0 1 2 0 0 0 0 0 0 0 0 0 Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-009506 Silverchair:22326 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-009506 Silverchair:22326 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Structural and functional characterization of a specific antidote for ticagrelor The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-622928 Silverchair:34362 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Structural and functional characterization of a specific antidote for ticagrelor The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-622928 Silverchair:34362 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Structural and functional characterization of a specific antidote for ticagrelor The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-622928 Silverchair:34362 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Structural and functional characterization of a specific antidote for ticagrelor The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-622928 Silverchair:34362 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Structural and Functional Interactions of KCl Cotransport Proteins KCC1 and KCC3 in Sickle and Normal Erythrocyte Membranes The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.2474.2474 Silverchair:61001 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Structural and Functional Interactions of KCl Cotransport Proteins KCC1 and KCC3 in Sickle and Normal Erythrocyte Membranes The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.2474.2474 Silverchair:61001 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Structural and Functional Interactions of KCl Cotransport Proteins KCC1 and KCC3 in Sickle and Normal Erythrocyte Membranes The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.2474.2474 Silverchair:61001 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Structural and Functional Interactions of KCl Cotransport Proteins KCC1 and KCC3 in Sickle and Normal Erythrocyte Membranes The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.2474.2474 Silverchair:61001 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Structural basis for PECAM-1 homophilic binding The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-660092 Silverchair:35157 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Structural basis for PECAM-1 homophilic binding The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-660092 Silverchair:35157 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Structural basis for PECAM-1 homophilic binding The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-660092 Silverchair:35157 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Structural basis for PECAM-1 homophilic binding The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-660092 Silverchair:35157 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Structure and dynamics of the platelet integrin-binding C4 domain of von Willebrand factor The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-843615 Silverchair:272777 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 Structure and dynamics of the platelet integrin-binding C4 domain of von Willebrand factor The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-843615 Silverchair:272777 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Structure and dynamics of the platelet integrin-binding C4 domain of von Willebrand factor The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-843615 Silverchair:272777 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Structure and dynamics of the platelet integrin-binding C4 domain of von Willebrand factor The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-843615 Silverchair:272777 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Structure and function of the leukocyte adhesion molecules CD11/CD18 The American Society of Hematology American Society of Hematology 10.1182/blood.V75.5.1037.1037 Silverchair:167645 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Structure and function of the leukocyte adhesion molecules CD11/CD18 The American Society of Hematology American Society of Hematology 10.1182/blood.V75.5.1037.1037 Silverchair:167645 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Structure and function of the leukocyte adhesion molecules CD11/CD18 The American Society of Hematology American Society of Hematology 10.1182/blood.V75.5.1037.1037 Silverchair:167645 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Structure and function of the leukocyte adhesion molecules CD11/CD18 The American Society of Hematology American Society of Hematology 10.1182/blood.V75.5.1037.1037 Silverchair:167645 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Structure of the platelet glycoprotein Ib receptor in complex with a novel antithrombotic agent The American Society of Hematology American Society of Hematology 10.1182/blood.2020008028 Silverchair:474138 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Structure of the platelet glycoprotein Ib receptor in complex with a novel antithrombotic agent The American Society of Hematology American Society of Hematology 10.1182/blood.2020008028 Silverchair:474138 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Structure of the platelet glycoprotein Ib receptor in complex with a novel antithrombotic agent The American Society of Hematology American Society of Hematology 10.1182/blood.2020008028 Silverchair:474138 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Structure of the platelet glycoprotein Ib receptor in complex with a novel antithrombotic agent The American Society of Hematology American Society of Hematology 10.1182/blood.2020008028 Silverchair:474138 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Studies of a familial platelet disorder The American Society of Hematology American Society of Hematology 10.1182/blood.V65.3.557.557 Silverchair:164265 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Studies of a familial platelet disorder The American Society of Hematology American Society of Hematology 10.1182/blood.V65.3.557.557 Silverchair:164265 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Studies of c-Mpl function distinguish the replication of hematopoietic stem cells from the expansion of differentiating clones The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-044503 Silverchair:23054 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Studies of c-Mpl function distinguish the replication of hematopoietic stem cells from the expansion of differentiating clones The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-044503 Silverchair:23054 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Studies of c-Mpl function distinguish the replication of hematopoietic stem cells from the expansion of differentiating clones The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-044503 Silverchair:23054 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Studies of c-Mpl function distinguish the replication of hematopoietic stem cells from the expansion of differentiating clones The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-044503 Silverchair:23054 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex The American Society of Hematology American Society of Hematology 10.1182/blood.V59.5.1086.1086 Silverchair:162859 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex The American Society of Hematology American Society of Hematology 10.1182/blood.V59.5.1086.1086 Silverchair:162859 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex The American Society of Hematology American Society of Hematology 10.1182/blood.V59.5.1086.1086 Silverchair:162859 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex The American Society of Hematology American Society of Hematology 10.1182/blood.V59.5.1086.1086 Silverchair:162859 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Study AML-BFM 2004: Improved Survival In Childhood Acute Myeloid Leukemia without Increased Toxicity The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.181.181 Silverchair:65411 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Study AML-BFM 2004: Improved Survival In Childhood Acute Myeloid Leukemia without Increased Toxicity The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.181.181 Silverchair:65411 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Study AML-BFM 2004: Improved Survival In Childhood Acute Myeloid Leukemia without Increased Toxicity The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.181.181 Silverchair:65411 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Study AML-BFM 2004: Improved Survival In Childhood Acute Myeloid Leukemia without Increased Toxicity The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.181.181 Silverchair:65411 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Study of Coagulopathies in Covid 19 Positive Patients & Their Correlation with Outcome of Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138679 Silverchair:473310 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Study of Coagulopathies in Covid 19 Positive Patients & Their Correlation with Outcome of Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138679 Silverchair:473310 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Study of Coagulopathies in Covid 19 Positive Patients & Their Correlation with Outcome of Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138679 Silverchair:473310 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Study of Coagulopathies in Covid 19 Positive Patients & Their Correlation with Outcome of Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138679 Silverchair:473310 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019002499 Silverchair:431280 No_License 2 0 2 0 0 0 0 0 0 0 0 0 0 Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019002499 Silverchair:431280 Total_Item_Investigations 5 0 5 0 0 0 0 0 0 0 0 0 0 Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019002499 Silverchair:431280 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Subcutaneous (SC) Administration Of Bortezomib: A Pilot Survey Of Oncology Nurses The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.5585.5585 Silverchair:15472 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Subcutaneous (SC) Administration Of Bortezomib: A Pilot Survey Of Oncology Nurses The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.5585.5585 Silverchair:15472 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Subcutaneous (SC) Administration Of Bortezomib: A Pilot Survey Of Oncology Nurses The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.5585.5585 Silverchair:15472 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Subcutaneous (SC) Administration Of Bortezomib: A Pilot Survey Of Oncology Nurses The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.5585.5585 Silverchair:15472 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2019000667 Silverchair:260752 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2019000667 Silverchair:260752 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2019000667 Silverchair:260752 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2019000667 Silverchair:260752 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Subcutaneous Immunoglobulin (SCIG) in Responders to Intravenous Therapy with Chronic Immune Thrombocytopenia (ITP) The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5012.5012 Silverchair:93907 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Subcutaneous Immunoglobulin (SCIG) in Responders to Intravenous Therapy with Chronic Immune Thrombocytopenia (ITP) The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5012.5012 Silverchair:93907 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Subcutaneous Immunoglobulin (SCIG) in Responders to Intravenous Therapy with Chronic Immune Thrombocytopenia (ITP) The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5012.5012 Silverchair:93907 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Subcutaneous Immunoglobulin (SCIG) in Responders to Intravenous Therapy with Chronic Immune Thrombocytopenia (ITP) The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.5012.5012 Silverchair:93907 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134193 Silverchair:470011 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134193 Silverchair:470011 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134193 Silverchair:470011 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-134193 Silverchair:470011 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children’s Oncology Group The American Society of Hematology American Society of Hematology 10.1182/blood.2020007225 Silverchair:474601 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children’s Oncology Group The American Society of Hematology American Society of Hematology 10.1182/blood.2020007225 Silverchair:474601 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children’s Oncology Group The American Society of Hematology American Society of Hematology 10.1182/blood.2020007225 Silverchair:474601 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children’s Oncology Group The American Society of Hematology American Society of Hematology 10.1182/blood.2020007225 Silverchair:474601 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Subtle differences in CTL cytotoxicity determine susceptibility to hemophagocytic lymphohistiocytosis in mice and humans with Chediak-Higashi syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-356113 Silverchair:29071 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Subtle differences in CTL cytotoxicity determine susceptibility to hemophagocytic lymphohistiocytosis in mice and humans with Chediak-Higashi syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-356113 Silverchair:29071 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Subtle differences in CTL cytotoxicity determine susceptibility to hemophagocytic lymphohistiocytosis in mice and humans with Chediak-Higashi syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-356113 Silverchair:29071 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Subtle differences in CTL cytotoxicity determine susceptibility to hemophagocytic lymphohistiocytosis in mice and humans with Chediak-Higashi syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-356113 Silverchair:29071 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Successful Treatment of Chimeric Antigen Receptor T Cell Therapy in Refractory or Relapsed Acute Leukemia Patients with TP53 alterations The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128013 Silverchair:424264 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Successful Treatment of Chimeric Antigen Receptor T Cell Therapy in Refractory or Relapsed Acute Leukemia Patients with TP53 alterations The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128013 Silverchair:424264 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Successful Treatment of Chimeric Antigen Receptor T Cell Therapy in Refractory or Relapsed Acute Leukemia Patients with TP53 alterations The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128013 Silverchair:424264 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Successful Treatment of Chimeric Antigen Receptor T Cell Therapy in Refractory or Relapsed Acute Leukemia Patients with TP53 alterations The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128013 Silverchair:424264 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2006-12-062174 Silverchair:24171 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2006-12-062174 Silverchair:24171 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2006-12-062174 Silverchair:24171 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2006-12-062174 Silverchair:24171 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Successful Treatment of Mucosal Bleeding with Tranexamic Acid in Pediatric Patients with Hemostatic Disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129360 Silverchair:428735 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Successful Treatment of Mucosal Bleeding with Tranexamic Acid in Pediatric Patients with Hemostatic Disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129360 Silverchair:428735 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Successful Treatment of Mucosal Bleeding with Tranexamic Acid in Pediatric Patients with Hemostatic Disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129360 Silverchair:428735 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Successful Treatment of Mucosal Bleeding with Tranexamic Acid in Pediatric Patients with Hemostatic Disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129360 Silverchair:428735 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Superenhancing AML with Trib1 The American Society of Hematology American Society of Hematology 10.1182/blood.2020008315 Silverchair:474792 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Superenhancing AML with Trib1 The American Society of Hematology American Society of Hematology 10.1182/blood.2020008315 Silverchair:474792 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Superenhancing AML with Trib1 The American Society of Hematology American Society of Hematology 10.1182/blood.2020008315 Silverchair:474792 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Superenhancing AML with Trib1 The American Society of Hematology American Society of Hematology 10.1182/blood.2020008315 Silverchair:474792 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2005-12-5072 Silverchair:22363 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2005-12-5072 Silverchair:22363 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2005-12-5072 Silverchair:22363 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2005-12-5072 Silverchair:22363 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-766204 Silverchair:36066 Total_Item_Investigations 7 3 4 0 0 0 0 0 0 0 0 0 0 Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-766204 Silverchair:36066 Total_Item_Requests 5 2 3 0 0 0 0 0 0 0 0 0 0 Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-766204 Silverchair:36066 Unique_Item_Investigations 4 2 2 0 0 0 0 0 0 0 0 0 0 Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-766204 Silverchair:36066 Unique_Item_Requests 4 2 2 0 0 0 0 0 0 0 0 0 0 Surface CD107a/LAMP-1 protects natural killer cells from degranulation-associated damage The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-441832 Silverchair:32100 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Surface CD107a/LAMP-1 protects natural killer cells from degranulation-associated damage The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-441832 Silverchair:32100 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Surface CD107a/LAMP-1 protects natural killer cells from degranulation-associated damage The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-441832 Silverchair:32100 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Surface CD107a/LAMP-1 protects natural killer cells from degranulation-associated damage The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-441832 Silverchair:32100 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Survival after Hematopoietic Stem Cell Transplantation in an Older, Fit Cohort of Patients with Advanced Myelodysplastic Syndromes: The MDS-TAO Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115601 Silverchair:266194 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Survival after Hematopoietic Stem Cell Transplantation in an Older, Fit Cohort of Patients with Advanced Myelodysplastic Syndromes: The MDS-TAO Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115601 Silverchair:266194 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Survival after Hematopoietic Stem Cell Transplantation in an Older, Fit Cohort of Patients with Advanced Myelodysplastic Syndromes: The MDS-TAO Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115601 Silverchair:266194 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Survival after Hematopoietic Stem Cell Transplantation in an Older, Fit Cohort of Patients with Advanced Myelodysplastic Syndromes: The MDS-TAO Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115601 Silverchair:266194 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136907 Silverchair:470021 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136907 Silverchair:470021 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136907 Silverchair:470021 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136907 Silverchair:470021 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Survival following allogeneic transplant in patients with myelofibrosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001084 Silverchair:454866 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Survival following allogeneic transplant in patients with myelofibrosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001084 Silverchair:454866 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Survival following allogeneic transplant in patients with myelofibrosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001084 Silverchair:454866 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Survival following allogeneic transplant in patients with myelofibrosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001084 Silverchair:454866 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003968 Silverchair:475081 Total_Item_Investigations 2 0 0 1 0 0 0 0 0 0 0 0 1 Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003968 Silverchair:475081 Total_Item_Requests 2 0 0 1 0 0 0 0 0 0 0 0 1 Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003968 Silverchair:475081 Unique_Item_Investigations 2 0 0 1 0 0 0 0 0 0 0 0 1 Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003968 Silverchair:475081 Unique_Item_Requests 2 0 0 1 0 0 0 0 0 0 0 0 1 Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.183.183 Silverchair:134833 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.183.183 Silverchair:134833 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.183.183 Silverchair:134833 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.183.183 Silverchair:134833 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Swanepoel AC, Pretorius E. Red blood cell and platelet interactions in healthy females during early and late pregnancy, as well as postpartum. Blood. 2013;121(19):3788." The American Society of Hematology American Society of Hematology 10.1182/blood-2014-02-554493 Silverchair:105742 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Swanepoel AC, Pretorius E. Red blood cell and platelet interactions in healthy females during early and late pregnancy, as well as postpartum. Blood. 2013;121(19):3788." The American Society of Hematology American Society of Hematology 10.1182/blood-2014-02-554493 Silverchair:105742 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Swanepoel AC, Pretorius E. Red blood cell and platelet interactions in healthy females during early and late pregnancy, as well as postpartum. Blood. 2013;121(19):3788." The American Society of Hematology American Society of Hematology 10.1182/blood-2014-02-554493 Silverchair:105742 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Swanepoel AC, Pretorius E. Red blood cell and platelet interactions in healthy females during early and late pregnancy, as well as postpartum. Blood. 2013;121(19):3788." The American Society of Hematology American Society of Hematology 10.1182/blood-2014-02-554493 Silverchair:105742 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Symptomatic subsegmental pulmonary embolism: to treat or not to treat? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.237 Silverchair:21111 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Symptomatic subsegmental pulmonary embolism: to treat or not to treat? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.237 Silverchair:21111 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Symptomatic subsegmental pulmonary embolism: to treat or not to treat? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.237 Silverchair:21111 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Symptomatic subsegmental pulmonary embolism: to treat or not to treat? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.237 Silverchair:21111 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-792150 Silverchair:36684 Total_Item_Investigations 10 4 0 6 0 0 0 0 0 0 0 0 0 Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-792150 Silverchair:36684 Total_Item_Requests 6 3 0 3 0 0 0 0 0 0 0 0 0 Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-792150 Silverchair:36684 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients The American Society of Hematology American Society of Hematology 10.1182/blood-2017-06-792150 Silverchair:36684 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 "Syntaxin-11, but not syntaxin-2 or syntaxin-4, is required for platelet secretion" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-430603 Silverchair:30581 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Syntaxin-11, but not syntaxin-2 or syntaxin-4, is required for platelet secretion" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-430603 Silverchair:30581 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Syntaxin-11, but not syntaxin-2 or syntaxin-4, is required for platelet secretion" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-430603 Silverchair:30581 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Syntaxin-11, but not syntaxin-2 or syntaxin-4, is required for platelet secretion" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-430603 Silverchair:30581 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Synthetic lethality: exploiting the addiction of cancer to DNA repair The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-313734 Silverchair:22271 Total_Item_Investigations 4 3 1 0 0 0 0 0 0 0 0 0 0 Synthetic lethality: exploiting the addiction of cancer to DNA repair The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-313734 Silverchair:22271 Total_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 Synthetic lethality: exploiting the addiction of cancer to DNA repair The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-313734 Silverchair:22271 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Synthetic lethality: exploiting the addiction of cancer to DNA repair The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-313734 Silverchair:22271 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Systematic Comparison of the EF-1 Alpha Short (EFS) and Viral Promoters for Gene Modification of Human Primary Cells for Clinical Applications The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3497.3497 Silverchair:97941 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Systematic Comparison of the EF-1 Alpha Short (EFS) and Viral Promoters for Gene Modification of Human Primary Cells for Clinical Applications The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3497.3497 Silverchair:97941 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Systematic Comparison of the EF-1 Alpha Short (EFS) and Viral Promoters for Gene Modification of Human Primary Cells for Clinical Applications The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3497.3497 Silverchair:97941 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Systematic Comparison of the EF-1 Alpha Short (EFS) and Viral Promoters for Gene Modification of Human Primary Cells for Clinical Applications The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3497.3497 Silverchair:97941 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Systems-based hematology: highlighting successes and next steps American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002947 Silverchair:463794 Total_Item_Investigations 6 0 0 0 0 0 0 0 0 2 3 1 0 Systems-based hematology: highlighting successes and next steps American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002947 Silverchair:463794 Total_Item_Requests 6 0 0 0 0 0 0 0 0 2 3 1 0 Systems-based hematology: highlighting successes and next steps American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002947 Silverchair:463794 Unique_Item_Investigations 3 0 0 0 0 0 0 0 0 1 1 1 0 Systems-based hematology: highlighting successes and next steps American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002947 Silverchair:463794 Unique_Item_Requests 3 0 0 0 0 0 0 0 0 1 1 1 0 T Cell Determinants of Response and Resistance to PD-1 Blockade in Richter's Transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125904 Silverchair:426306 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 T Cell Determinants of Response and Resistance to PD-1 Blockade in Richter's Transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125904 Silverchair:426306 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 T Cell Determinants of Response and Resistance to PD-1 Blockade in Richter's Transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125904 Silverchair:426306 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 T Cell Determinants of Response and Resistance to PD-1 Blockade in Richter's Transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125904 Silverchair:426306 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 T follicular helper cell expansion and chronic T cell activation are characteristic immune anomalies in Evans syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2021012924 Silverchair:476650 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 T follicular helper cell expansion and chronic T cell activation are characteristic immune anomalies in Evans syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2021012924 Silverchair:476650 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 T follicular helper cell expansion and chronic T cell activation are characteristic immune anomalies in Evans syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2021012924 Silverchair:476650 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 T follicular helper cell expansion and chronic T cell activation are characteristic immune anomalies in Evans syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2021012924 Silverchair:476650 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002396 Silverchair:463988 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002396 Silverchair:463988 Total_Item_Requests 2 0 0 0 2 0 0 0 0 0 0 0 0 T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002396 Silverchair:463988 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002396 Silverchair:463988 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126094 Silverchair:426159 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126094 Silverchair:426159 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126094 Silverchair:426159 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126094 Silverchair:426159 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Table of contents. Blood. 2019;133(18):iii-iv. The American Society of Hematology American Society of Hematology 10.1182/blood.2019001895 Silverchair:260670 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Table of contents. Blood. 2019;133(18):iii-iv. The American Society of Hematology American Society of Hematology 10.1182/blood.2019001895 Silverchair:260670 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Table of contents. Blood. 2019;133(18):iii-iv. The American Society of Hematology American Society of Hematology 10.1182/blood.2019001895 Silverchair:260670 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Table of contents. Blood. 2019;133(18):iii-iv. The American Society of Hematology American Society of Hematology 10.1182/blood.2019001895 Silverchair:260670 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-09-110874 Silverchair:25390 Total_Item_Investigations 5 5 0 0 0 0 0 0 0 0 0 0 0 "TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-09-110874 Silverchair:25390 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 "TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-09-110874 Silverchair:25390 Unique_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 "TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts" The American Society of Hematology American Society of Hematology 10.1182/blood-2007-09-110874 Silverchair:25390 Unique_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 "TACO and TRALI: biology, risk factors, and prevention strategies" The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.585 Silverchair:277621 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "TACO and TRALI: biology, risk factors, and prevention strategies" The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.585 Silverchair:277621 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "TACO and TRALI: biology, risk factors, and prevention strategies" The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.585 Silverchair:277621 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "TACO and TRALI: biology, risk factors, and prevention strategies" The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.585 Silverchair:277621 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Tacrolimus Is Effective Immunosuppressive Therapy in Aplastic Anemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1183.1183 Silverchair:116168 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Tacrolimus Is Effective Immunosuppressive Therapy in Aplastic Anemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1183.1183 Silverchair:116168 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Tacrolimus Is Effective Immunosuppressive Therapy in Aplastic Anemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1183.1183 Silverchair:116168 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Tacrolimus Is Effective Immunosuppressive Therapy in Aplastic Anemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1183.1183 Silverchair:116168 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Tacrolimus-Induced Refractory Immune Thrombocytopenia In Solid Organ Transplant Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.2317.2317 Silverchair:13703 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Tacrolimus-Induced Refractory Immune Thrombocytopenia In Solid Organ Transplant Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.2317.2317 Silverchair:13703 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Tacrolimus-Induced Refractory Immune Thrombocytopenia In Solid Organ Transplant Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.2317.2317 Silverchair:13703 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Tacrolimus-Induced Refractory Immune Thrombocytopenia In Solid Organ Transplant Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.2317.2317 Silverchair:13703 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 "TAM receptors, Gas6, and protein S: roles in inflammation and hemostasis" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-09-528752 Silverchair:32646 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 "TAM receptors, Gas6, and protein S: roles in inflammation and hemostasis" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-09-528752 Silverchair:32646 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 "TAM receptors, Gas6, and protein S: roles in inflammation and hemostasis" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-09-528752 Silverchair:32646 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 "TAM receptors, Gas6, and protein S: roles in inflammation and hemostasis" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-09-528752 Silverchair:32646 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017010686 Silverchair:16212 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017010686 Silverchair:16212 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017010686 Silverchair:16212 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017010686 Silverchair:16212 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003880 Silverchair:475403 Total_Item_Investigations 3 0 0 1 0 0 0 0 0 0 0 2 0 Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003880 Silverchair:475403 Total_Item_Requests 3 0 0 1 0 0 0 0 0 0 0 2 0 Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003880 Silverchair:475403 Unique_Item_Investigations 2 0 0 1 0 0 0 0 0 0 0 1 0 Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003880 Silverchair:475403 Unique_Item_Requests 2 0 0 1 0 0 0 0 0 0 0 1 0 Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002308 Silverchair:461289 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002308 Silverchair:461289 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002308 Silverchair:461289 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002308 Silverchair:461289 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Targeted inhibition of CD47-SIRPα requires Fc-FcγR interactions to maximize activity in T-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood.2019001744 Silverchair:374929 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Targeted inhibition of CD47-SIRPα requires Fc-FcγR interactions to maximize activity in T-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood.2019001744 Silverchair:374929 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Targeted inhibition of CD47-SIRPα requires Fc-FcγR interactions to maximize activity in T-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood.2019001744 Silverchair:374929 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Targeted inhibition of CD47-SIRPα requires Fc-FcγR interactions to maximize activity in T-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood.2019001744 Silverchair:374929 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001156 Silverchair:454447 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001156 Silverchair:454447 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001156 Silverchair:454447 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001156 Silverchair:454447 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism The American Society of Hematology American Society of Hematology 10.1182/blood-2015-10-678706 Silverchair:34959 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism The American Society of Hematology American Society of Hematology 10.1182/blood-2015-10-678706 Silverchair:34959 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism The American Society of Hematology American Society of Hematology 10.1182/blood-2015-10-678706 Silverchair:34959 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism The American Society of Hematology American Society of Hematology 10.1182/blood-2015-10-678706 Silverchair:34959 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells The American Society of Hematology American Society of Hematology 10.1182/blood.2020007748 Silverchair:463715 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells The American Society of Hematology American Society of Hematology 10.1182/blood.2020007748 Silverchair:463715 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells The American Society of Hematology American Society of Hematology 10.1182/blood.2020007748 Silverchair:463715 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells The American Society of Hematology American Society of Hematology 10.1182/blood.2020007748 Silverchair:463715 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 "Targeting and Depletion of Acute Myeloid Leukemia Blasts By MEN1112, a Novel Humanized Defucosylated Monoclonal Antibodies with Specificity for Bst1/CD157 Antigen" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2235.2235 Silverchair:90052 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Targeting and Depletion of Acute Myeloid Leukemia Blasts By MEN1112, a Novel Humanized Defucosylated Monoclonal Antibodies with Specificity for Bst1/CD157 Antigen" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2235.2235 Silverchair:90052 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Targeting and Depletion of Acute Myeloid Leukemia Blasts By MEN1112, a Novel Humanized Defucosylated Monoclonal Antibodies with Specificity for Bst1/CD157 Antigen" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2235.2235 Silverchair:90052 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Targeting and Depletion of Acute Myeloid Leukemia Blasts By MEN1112, a Novel Humanized Defucosylated Monoclonal Antibodies with Specificity for Bst1/CD157 Antigen" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2235.2235 Silverchair:90052 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-651505 Silverchair:34655 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-651505 Silverchair:34655 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-651505 Silverchair:34655 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-651505 Silverchair:34655 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Targeting CD123 in acute myeloid leukemia using a T-cell–directed dual-affinity retargeting platform The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-575704 Silverchair:34882 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Targeting CD123 in acute myeloid leukemia using a T-cell–directed dual-affinity retargeting platform The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-575704 Silverchair:34882 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Targeting CD123 in acute myeloid leukemia using a T-cell–directed dual-affinity retargeting platform The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-575704 Silverchair:34882 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Targeting CD123 in acute myeloid leukemia using a T-cell–directed dual-affinity retargeting platform The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-575704 Silverchair:34882 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical The American Society of Hematology American Society of Hematology 10.1182/blood-2006-12-062927 Silverchair:103604 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical The American Society of Hematology American Society of Hematology 10.1182/blood-2006-12-062927 Silverchair:103604 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical The American Society of Hematology American Society of Hematology 10.1182/blood-2006-12-062927 Silverchair:103604 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical The American Society of Hematology American Society of Hematology 10.1182/blood-2006-12-062927 Silverchair:103604 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Targeting complement activation in COVID-19 The American Society of Hematology American Society of Hematology 10.1182/blood.2020008925 Silverchair:469726 Total_Item_Investigations 4 0 3 0 0 1 0 0 0 0 0 0 0 Targeting complement activation in COVID-19 The American Society of Hematology American Society of Hematology 10.1182/blood.2020008925 Silverchair:469726 Total_Item_Requests 4 0 3 0 0 1 0 0 0 0 0 0 0 Targeting complement activation in COVID-19 The American Society of Hematology American Society of Hematology 10.1182/blood.2020008925 Silverchair:469726 Unique_Item_Investigations 3 0 2 0 0 1 0 0 0 0 0 0 0 Targeting complement activation in COVID-19 The American Society of Hematology American Society of Hematology 10.1182/blood.2020008925 Silverchair:469726 Unique_Item_Requests 3 0 2 0 0 1 0 0 0 0 0 0 0 Targeting cyclooxygenase by indomethacin decelerates progression of acute lymphoblastic leukemia in a xenograft model American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000473 Silverchair:422643 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Targeting cyclooxygenase by indomethacin decelerates progression of acute lymphoblastic leukemia in a xenograft model American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000473 Silverchair:422643 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Targeting cyclooxygenase by indomethacin decelerates progression of acute lymphoblastic leukemia in a xenograft model American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000473 Silverchair:422643 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Targeting cyclooxygenase by indomethacin decelerates progression of acute lymphoblastic leukemia in a xenograft model American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000473 Silverchair:422643 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Targeting endothelial cells by gene therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-518266 Silverchair:31642 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Targeting endothelial cells by gene therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-518266 Silverchair:31642 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Targeting endothelial cells by gene therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-518266 Silverchair:31642 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Targeting endothelial cells by gene therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2013-08-518266 Silverchair:31642 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Targeting GCK pathway: a novel and selective therapeutic strategy against RAS mutated multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2020006334 Silverchair:464430 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Targeting GCK pathway: a novel and selective therapeutic strategy against RAS mutated multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2020006334 Silverchair:464430 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Targeting IL3 Receptor in Chronic Myeloid Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.2172.2172 Silverchair:111363 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Targeting IL3 Receptor in Chronic Myeloid Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.2172.2172 Silverchair:111363 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Targeting IL3 Receptor in Chronic Myeloid Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.2172.2172 Silverchair:111363 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Targeting IL3 Receptor in Chronic Myeloid Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.2172.2172 Silverchair:111363 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-415448 Silverchair:30640 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-415448 Silverchair:30640 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-415448 Silverchair:30640 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-415448 Silverchair:30640 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Targeting Mcl-1 By Proteasome Inhibitors Enhances the Anti-Tumor Activity of Venetoclax in Mantle Cell Lymphoma Pre-Clinical Models The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1538.1538 Silverchair:79643 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Targeting Mcl-1 By Proteasome Inhibitors Enhances the Anti-Tumor Activity of Venetoclax in Mantle Cell Lymphoma Pre-Clinical Models The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1538.1538 Silverchair:79643 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Targeting Mcl-1 By Proteasome Inhibitors Enhances the Anti-Tumor Activity of Venetoclax in Mantle Cell Lymphoma Pre-Clinical Models The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1538.1538 Silverchair:79643 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Targeting Mcl-1 By Proteasome Inhibitors Enhances the Anti-Tumor Activity of Venetoclax in Mantle Cell Lymphoma Pre-Clinical Models The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1538.1538 Silverchair:79643 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Targeting Myeloid-Cell Specific Integrin α9β1 Inhibits Arterial Thrombosis in Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127006 Silverchair:428182 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Targeting Myeloid-Cell Specific Integrin α9β1 Inhibits Arterial Thrombosis in Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127006 Silverchair:428182 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Targeting Myeloid-Cell Specific Integrin α9β1 Inhibits Arterial Thrombosis in Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127006 Silverchair:428182 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Targeting Myeloid-Cell Specific Integrin α9β1 Inhibits Arterial Thrombosis in Mice The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127006 Silverchair:428182 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood.2020008720 Silverchair:475143 No_License 1 0 1 0 0 0 0 0 0 0 0 0 0 Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood.2020008720 Silverchair:475143 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host disease The American Society of Hematology American Society of Hematology 10.1182/blood.2020008720 Silverchair:475143 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Targeting of CLEC12A In Acute Myeloid Leukemia by Antibody-Drug-Conjugates and Bispecific CLL-1×CD3 BiTE Antibody The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2890.2890 Silverchair:112009 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Targeting of CLEC12A In Acute Myeloid Leukemia by Antibody-Drug-Conjugates and Bispecific CLL-1×CD3 BiTE Antibody The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2890.2890 Silverchair:112009 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Targeting of CLEC12A In Acute Myeloid Leukemia by Antibody-Drug-Conjugates and Bispecific CLL-1×CD3 BiTE Antibody The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2890.2890 Silverchair:112009 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Targeting of CLEC12A In Acute Myeloid Leukemia by Antibody-Drug-Conjugates and Bispecific CLL-1×CD3 BiTE Antibody The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2890.2890 Silverchair:112009 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-653113 Silverchair:35088 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-653113 Silverchair:35088 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-653113 Silverchair:35088 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-653113 Silverchair:35088 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Targeting Pre-B Cell Receptor and BCL6 In TCF3-PBX1 B-Lineage Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.349.349 Silverchair:83792 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Targeting Pre-B Cell Receptor and BCL6 In TCF3-PBX1 B-Lineage Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.349.349 Silverchair:83792 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Targeting Pre-B Cell Receptor and BCL6 In TCF3-PBX1 B-Lineage Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.349.349 Silverchair:83792 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Targeting Pre-B Cell Receptor and BCL6 In TCF3-PBX1 B-Lineage Acute Lymphoblastic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.349.349 Silverchair:83792 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019002457 Silverchair:374459 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019002457 Silverchair:374459 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019002457 Silverchair:374459 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2019002457 Silverchair:374459 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-863233 Silverchair:261415 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-863233 Silverchair:261415 Total_Item_Requests 4 0 4 0 0 0 0 0 0 0 0 0 0 Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-863233 Silverchair:261415 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-863233 Silverchair:261415 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-351239 Silverchair:29458 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-351239 Silverchair:29458 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-351239 Silverchair:29458 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-351239 Silverchair:29458 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "Targeting the AnxA1/Fpr2/ALX pathway regulates neutrophil function, promoting thromboinflammation resolution in sickle cell disease" The American Society of Hematology American Society of Hematology 10.1182/blood.2020009166 Silverchair:475039 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 "Targeting the AnxA1/Fpr2/ALX pathway regulates neutrophil function, promoting thromboinflammation resolution in sickle cell disease" The American Society of Hematology American Society of Hematology 10.1182/blood.2020009166 Silverchair:475039 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 "Targeting the AnxA1/Fpr2/ALX pathway regulates neutrophil function, promoting thromboinflammation resolution in sickle cell disease" The American Society of Hematology American Society of Hematology 10.1182/blood.2020009166 Silverchair:475039 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 "Targeting the AnxA1/Fpr2/ALX pathway regulates neutrophil function, promoting thromboinflammation resolution in sickle cell disease" The American Society of Hematology American Society of Hematology 10.1182/blood.2020009166 Silverchair:475039 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Targeting the interleukin-1 pathway in patients with hematological disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-754994 Silverchair:36319 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Targeting the interleukin-1 pathway in patients with hematological disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-754994 Silverchair:36319 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Targeting the interleukin-1 pathway in patients with hematological disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-754994 Silverchair:36319 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Targeting the interleukin-1 pathway in patients with hematological disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-754994 Silverchair:36319 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 TA-TMA: state of the art for diagnosis and treatment American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000321 Silverchair:430192 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 TA-TMA: state of the art for diagnosis and treatment American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000321 Silverchair:430192 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 TA-TMA: state of the art for diagnosis and treatment American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000321 Silverchair:430192 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 TA-TMA: state of the art for diagnosis and treatment American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000321 Silverchair:430192 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis The American Society of Hematology American Society of Hematology 10.1182/blood.2020009499 Silverchair:474597 No_License 1 0 0 0 0 1 0 0 0 0 0 0 0 T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis The American Society of Hematology American Society of Hematology 10.1182/blood.2020009499 Silverchair:474597 Total_Item_Investigations 4 0 0 0 0 4 0 0 0 0 0 0 0 T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis The American Society of Hematology American Society of Hematology 10.1182/blood.2020009499 Silverchair:474597 Unique_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 T-cell acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.580 Silverchair:21136 Total_Item_Investigations 3 1 2 0 0 0 0 0 0 0 0 0 0 T-cell acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.580 Silverchair:21136 Total_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 T-cell acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.580 Silverchair:21136 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 T-cell acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.580 Silverchair:21136 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 T-Cell Battle Royale: Chimeric Antigen Receptor T-cells for the Treatment of T-lineage Acute Lymphoblastic Leukemia American Society of Hematology American Society of Hematology Silverchair:474749 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 T-Cell Battle Royale: Chimeric Antigen Receptor T-cells for the Treatment of T-lineage Acute Lymphoblastic Leukemia American Society of Hematology American Society of Hematology Silverchair:474749 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 T-Cell Battle Royale: Chimeric Antigen Receptor T-cells for the Treatment of T-lineage Acute Lymphoblastic Leukemia American Society of Hematology American Society of Hematology Silverchair:474749 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 T-Cell Battle Royale: Chimeric Antigen Receptor T-cells for the Treatment of T-lineage Acute Lymphoblastic Leukemia American Society of Hematology American Society of Hematology Silverchair:474749 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities The American Society of Hematology American Society of Hematology 10.1182/blood.V95.12.3996 Silverchair:266838 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities The American Society of Hematology American Society of Hematology 10.1182/blood.V95.12.3996 Silverchair:266838 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities The American Society of Hematology American Society of Hematology 10.1182/blood.V95.12.3996 Silverchair:266838 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities The American Society of Hematology American Society of Hematology 10.1182/blood.V95.12.3996 Silverchair:266838 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 T-cell lines from 2 patients with adenosine deaminase (ADA) deficiency showed the restoration of ADA activity resulted from the reversion of an inherited mutation The American Society of Hematology American Society of Hematology 10.1182/blood.V97.9.2896 Silverchair:130346 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 T-cell lines from 2 patients with adenosine deaminase (ADA) deficiency showed the restoration of ADA activity resulted from the reversion of an inherited mutation The American Society of Hematology American Society of Hematology 10.1182/blood.V97.9.2896 Silverchair:130346 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 T-cell lines from 2 patients with adenosine deaminase (ADA) deficiency showed the restoration of ADA activity resulted from the reversion of an inherited mutation The American Society of Hematology American Society of Hematology 10.1182/blood.V97.9.2896 Silverchair:130346 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 T-cell lines from 2 patients with adenosine deaminase (ADA) deficiency showed the restoration of ADA activity resulted from the reversion of an inherited mutation The American Society of Hematology American Society of Hematology 10.1182/blood.V97.9.2896 Silverchair:130346 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 T-cell Lymphoblastic Leukemia: What Are the Prospects for Novel Immunotherapy? American Society of Hematology American Society of Hematology 10.1182/hem.V17.3.10366 Silverchair:461802 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 T-cell Lymphoblastic Leukemia: What Are the Prospects for Novel Immunotherapy? American Society of Hematology American Society of Hematology 10.1182/hem.V17.3.10366 Silverchair:461802 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 T-cell Lymphoblastic Leukemia: What Are the Prospects for Novel Immunotherapy? American Society of Hematology American Society of Hematology 10.1182/hem.V17.3.10366 Silverchair:461802 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 T-cell Lymphoblastic Leukemia: What Are the Prospects for Novel Immunotherapy? American Society of Hematology American Society of Hematology 10.1182/hem.V17.3.10366 Silverchair:461802 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 T-cell lymphoblastic lymphoma and leukemia: different diseases from a common premalignant progenitor? American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001822 Silverchair:461579 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 T-cell lymphoblastic lymphoma and leukemia: different diseases from a common premalignant progenitor? American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001822 Silverchair:461579 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 T-cell lymphoblastic lymphoma and leukemia: different diseases from a common premalignant progenitor? American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001822 Silverchair:461579 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 T-cell lymphoblastic lymphoma and leukemia: different diseases from a common premalignant progenitor? American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001822 Silverchair:461579 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib) American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017010470 Silverchair:15821 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib) American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017010470 Silverchair:15821 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib) American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017010470 Silverchair:15821 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib) American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017010470 Silverchair:15821 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 TCF1 expression marks self-renewing human CD8+ T cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018016279 Silverchair:16230 Total_Item_Investigations 7 0 7 0 0 0 0 0 0 0 0 0 0 TCF1 expression marks self-renewing human CD8+ T cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018016279 Silverchair:16230 Total_Item_Requests 6 0 6 0 0 0 0 0 0 0 0 0 0 TCF1 expression marks self-renewing human CD8+ T cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018016279 Silverchair:16230 Unique_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 TCF1 expression marks self-renewing human CD8+ T cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018016279 Silverchair:16230 Unique_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Tec regulates platelet activation by GPVI in the absence of Btk The American Society of Hematology American Society of Hematology 10.1182/blood-2003-04-1142 Silverchair:16969 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Tec regulates platelet activation by GPVI in the absence of Btk The American Society of Hematology American Society of Hematology 10.1182/blood-2003-04-1142 Silverchair:16969 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Tec regulates platelet activation by GPVI in the absence of Btk The American Society of Hematology American Society of Hematology 10.1182/blood-2003-04-1142 Silverchair:16969 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Tec regulates platelet activation by GPVI in the absence of Btk The American Society of Hematology American Society of Hematology 10.1182/blood-2003-04-1142 Silverchair:16969 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002393 Silverchair:463776 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002393 Silverchair:463776 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002393 Silverchair:463776 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002393 Silverchair:463776 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001721 Silverchair:464196 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001721 Silverchair:464196 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001721 Silverchair:464196 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001721 Silverchair:464196 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Testing and monitoring direct oral anticoagulants The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-791541 Silverchair:39457 Total_Item_Investigations 5 1 1 3 0 0 0 0 0 0 0 0 0 Testing and monitoring direct oral anticoagulants The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-791541 Silverchair:39457 Total_Item_Requests 5 1 1 3 0 0 0 0 0 0 0 0 0 Testing and monitoring direct oral anticoagulants The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-791541 Silverchair:39457 Unique_Item_Investigations 3 1 1 1 0 0 0 0 0 0 0 0 0 Testing and monitoring direct oral anticoagulants The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-791541 Silverchair:39457 Unique_Item_Requests 3 1 1 1 0 0 0 0 0 0 0 0 0 TET2 Regulates CD8+ T Cell Responses to Acute and Chronic Viral Infection The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2227.2227 Silverchair:105314 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 TET2 Regulates CD8+ T Cell Responses to Acute and Chronic Viral Infection The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2227.2227 Silverchair:105314 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 TET2 Regulates CD8+ T Cell Responses to Acute and Chronic Viral Infection The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2227.2227 Silverchair:105314 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 TET2 Regulates CD8+ T Cell Responses to Acute and Chronic Viral Infection The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.2227.2227 Silverchair:105314 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 TGF-β–induced intracellular PAI-1 is responsible for retaining hematopoietic stem cells in the niche The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-767384 Silverchair:36668 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 TGF-β–induced intracellular PAI-1 is responsible for retaining hematopoietic stem cells in the niche The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-767384 Silverchair:36668 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 TGF-β–induced intracellular PAI-1 is responsible for retaining hematopoietic stem cells in the niche The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-767384 Silverchair:36668 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 TGF-β–induced intracellular PAI-1 is responsible for retaining hematopoietic stem cells in the niche The American Society of Hematology American Society of Hematology 10.1182/blood-2017-02-767384 Silverchair:36668 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Thalassemia, sickle cell disease, and other hemoglobinopathies" American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter07 Silverchair:74237 No_License 10 6 1 0 0 0 0 0 1 0 2 0 0 "Thalassemia, sickle cell disease, and other hemoglobinopathies" American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter07 Silverchair:74237 Total_Item_Investigations 14 6 1 0 0 0 0 0 3 2 2 0 0 "Thalassemia, sickle cell disease, and other hemoglobinopathies" American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter07 Silverchair:74237 Unique_Item_Investigations 7 2 1 0 0 0 0 0 1 2 1 0 0 Thalassemia—Hemoglobin C Disease A New Syndrome Presumably due to the Combination of the Genes for Thalassemia and Hemoglobin C The American Society of Hematology American Society of Hematology 10.1182/blood.V9.11.1047.1047 Silverchair:45785 Total_Item_Investigations 3 1 0 1 0 0 0 0 0 0 0 0 1 Thalassemia—Hemoglobin C Disease A New Syndrome Presumably due to the Combination of the Genes for Thalassemia and Hemoglobin C The American Society of Hematology American Society of Hematology 10.1182/blood.V9.11.1047.1047 Silverchair:45785 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Thalassemia—Hemoglobin C Disease A New Syndrome Presumably due to the Combination of the Genes for Thalassemia and Hemoglobin C The American Society of Hematology American Society of Hematology 10.1182/blood.V9.11.1047.1047 Silverchair:45785 Unique_Item_Investigations 3 1 0 1 0 0 0 0 0 0 0 0 1 Thalassemia—Hemoglobin C Disease A New Syndrome Presumably due to the Combination of the Genes for Thalassemia and Hemoglobin C The American Society of Hematology American Society of Hematology 10.1182/blood.V9.11.1047.1047 Silverchair:45785 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 "Thalidomide Plus Prednisone and Methotrexate for Symptomatic Large Granular Lymphocyte Leukemia: A Prospective, Single-Center, Pilot Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139481 Silverchair:469974 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "Thalidomide Plus Prednisone and Methotrexate for Symptomatic Large Granular Lymphocyte Leukemia: A Prospective, Single-Center, Pilot Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139481 Silverchair:469974 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "Thalidomide Plus Prednisone and Methotrexate for Symptomatic Large Granular Lymphocyte Leukemia: A Prospective, Single-Center, Pilot Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139481 Silverchair:469974 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Thalidomide Plus Prednisone and Methotrexate for Symptomatic Large Granular Lymphocyte Leukemia: A Prospective, Single-Center, Pilot Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139481 Silverchair:469974 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "The MLL fusion partner AF10 binds GAS41, a protein that interacts with the human SWI/SNF complex" The American Society of Hematology American Society of Hematology 10.1182/blood.V99.1.275 Silverchair:107183 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "The MLL fusion partner AF10 binds GAS41, a protein that interacts with the human SWI/SNF complex" The American Society of Hematology American Society of Hematology 10.1182/blood.V99.1.275 Silverchair:107183 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "The MLL fusion partner AF10 binds GAS41, a protein that interacts with the human SWI/SNF complex" The American Society of Hematology American Society of Hematology 10.1182/blood.V99.1.275 Silverchair:107183 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "The MLL fusion partner AF10 binds GAS41, a protein that interacts with the human SWI/SNF complex" The American Society of Hematology American Society of Hematology 10.1182/blood.V99.1.275 Silverchair:107183 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The SF3B1 K700E Mutation Induces R-Loop Accumulation and Associated DNA Damage The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126981 Silverchair:425689 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 The SF3B1 K700E Mutation Induces R-Loop Accumulation and Associated DNA Damage The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126981 Silverchair:425689 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 The SF3B1 K700E Mutation Induces R-Loop Accumulation and Associated DNA Damage The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126981 Silverchair:425689 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 The SF3B1 K700E Mutation Induces R-Loop Accumulation and Associated DNA Damage The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126981 Silverchair:425689 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 The 2016 revision of the World Health Organization classification of lymphoid neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-643569 Silverchair:35286 Total_Item_Investigations 6 0 3 2 0 0 0 0 0 0 0 0 1 The 2016 revision of the World Health Organization classification of lymphoid neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-643569 Silverchair:35286 Total_Item_Requests 6 0 3 2 0 0 0 0 0 0 0 0 1 The 2016 revision of the World Health Organization classification of lymphoid neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-643569 Silverchair:35286 Unique_Item_Investigations 4 0 2 1 0 0 0 0 0 0 0 0 1 The 2016 revision of the World Health Organization classification of lymphoid neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-643569 Silverchair:35286 Unique_Item_Requests 4 0 2 1 0 0 0 0 0 0 0 0 1 The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-03-643544 Silverchair:35255 Total_Item_Investigations 39 7 4 6 3 2 1 3 1 4 6 0 2 The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-03-643544 Silverchair:35255 Total_Item_Requests 39 7 4 6 3 2 1 3 1 4 6 0 2 The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-03-643544 Silverchair:35255 Unique_Item_Investigations 22 4 3 3 1 1 1 2 1 2 3 0 1 The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-03-643544 Silverchair:35255 Unique_Item_Requests 22 4 3 3 1 1 1 2 1 2 3 0 1 The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-881268 Silverchair:260505 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-881268 Silverchair:260505 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-881268 Silverchair:260505 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2018-11-881268 Silverchair:260505 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.582.582 Silverchair:81898 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.582.582 Silverchair:81898 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.582.582 Silverchair:81898 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.582.582 Silverchair:81898 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The Addition of Radiation Therapy to Initial Treatment for Extramedullary Acute Myeloid Leukemia Does Not Offer a Survival Benefit When Added to Chemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.960.960 Silverchair:102168 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The Addition of Radiation Therapy to Initial Treatment for Extramedullary Acute Myeloid Leukemia Does Not Offer a Survival Benefit When Added to Chemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.960.960 Silverchair:102168 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The Addition of Radiation Therapy to Initial Treatment for Extramedullary Acute Myeloid Leukemia Does Not Offer a Survival Benefit When Added to Chemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.960.960 Silverchair:102168 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The Addition of Radiation Therapy to Initial Treatment for Extramedullary Acute Myeloid Leukemia Does Not Offer a Survival Benefit When Added to Chemotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.960.960 Silverchair:102168 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-302984 Silverchair:20799 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-302984 Silverchair:20799 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-302984 Silverchair:20799 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-302984 Silverchair:20799 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The American Society of Hematology Clinical Research Training Institute is associated with high retention in academic hematology The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-724211 Silverchair:35662 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 0 2 The American Society of Hematology Clinical Research Training Institute is associated with high retention in academic hematology The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-724211 Silverchair:35662 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 0 2 The American Society of Hematology Clinical Research Training Institute is associated with high retention in academic hematology The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-724211 Silverchair:35662 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 The American Society of Hematology Clinical Research Training Institute is associated with high retention in academic hematology The American Society of Hematology American Society of Hematology 10.1182/blood-2016-06-724211 Silverchair:35662 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-518423 Silverchair:31937 Total_Item_Investigations 4 0 0 2 0 0 0 0 2 0 0 0 0 The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-518423 Silverchair:31937 Total_Item_Requests 4 0 0 2 0 0 0 0 2 0 0 0 0 The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-518423 Silverchair:31937 Unique_Item_Investigations 2 0 0 1 0 0 0 0 1 0 0 0 0 The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-518423 Silverchair:31937 Unique_Item_Requests 2 0 0 1 0 0 0 0 1 0 0 0 0 The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question The American Society of Hematology American Society of Hematology 10.1182/asheducation-2013.1.9 Silverchair:20876 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question The American Society of Hematology American Society of Hematology 10.1182/asheducation-2013.1.9 Silverchair:20876 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question The American Society of Hematology American Society of Hematology 10.1182/asheducation-2013.1.9 Silverchair:20876 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question The American Society of Hematology American Society of Hematology 10.1182/asheducation-2013.1.9 Silverchair:20876 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The ASH Clinical Research Training Institute: A Personal Success Story American Society of Hematology American Society of Hematology 10.1182/hem.V9.6.1102 Silverchair:462371 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 The ASH Clinical Research Training Institute: A Personal Success Story American Society of Hematology American Society of Hematology 10.1182/hem.V9.6.1102 Silverchair:462371 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 The ASH Clinical Research Training Institute: A Personal Success Story American Society of Hematology American Society of Hematology 10.1182/hem.V9.6.1102 Silverchair:462371 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 The ASH Clinical Research Training Institute: A Personal Success Story American Society of Hematology American Society of Hematology 10.1182/hem.V9.6.1102 Silverchair:462371 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002623 Silverchair:464437 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002623 Silverchair:464437 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002623 Silverchair:464437 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002623 Silverchair:464437 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-193037 Silverchair:107779 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-193037 Silverchair:107779 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-193037 Silverchair:107779 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL The American Society of Hematology American Society of Hematology 10.1182/blood-2008-12-193037 Silverchair:107779 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-163 Silverchair:272861 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-163 Silverchair:272861 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-163 Silverchair:272861 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-163 Silverchair:272861 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The BET Inhibitor GS-626510 Converges with Idelalisib through the Inhibition of Tumor-Macrophage Crosstalk and Cytokine Production in Diffuse Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4108.4108 Silverchair:72690 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The BET Inhibitor GS-626510 Converges with Idelalisib through the Inhibition of Tumor-Macrophage Crosstalk and Cytokine Production in Diffuse Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4108.4108 Silverchair:72690 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The BET Inhibitor GS-626510 Converges with Idelalisib through the Inhibition of Tumor-Macrophage Crosstalk and Cytokine Production in Diffuse Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4108.4108 Silverchair:72690 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The BET Inhibitor GS-626510 Converges with Idelalisib through the Inhibition of Tumor-Macrophage Crosstalk and Cytokine Production in Diffuse Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4108.4108 Silverchair:72690 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The biology and management of systemic anaplastic large cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-567461 Silverchair:34344 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The biology and management of systemic anaplastic large cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-567461 Silverchair:34344 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The biology and management of systemic anaplastic large cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-567461 Silverchair:34344 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The biology and management of systemic anaplastic large cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-567461 Silverchair:34344 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The biology and treatment of plasmablastic lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-567479 Silverchair:33825 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The biology and treatment of plasmablastic lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-567479 Silverchair:33825 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The biology and treatment of plasmablastic lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-567479 Silverchair:33825 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The biology and treatment of plasmablastic lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-567479 Silverchair:33825 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The biology of pediatric acute megakaryoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-567859 Silverchair:34744 Total_Item_Investigations 3 1 1 1 0 0 0 0 0 0 0 0 0 The biology of pediatric acute megakaryoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-567859 Silverchair:34744 Total_Item_Requests 3 1 1 1 0 0 0 0 0 0 0 0 0 The biology of pediatric acute megakaryoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-567859 Silverchair:34744 Unique_Item_Investigations 3 1 1 1 0 0 0 0 0 0 0 0 0 The biology of pediatric acute megakaryoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-05-567859 Silverchair:34744 Unique_Item_Requests 3 1 1 1 0 0 0 0 0 0 0 0 0 The Bone Marrow in Pregnancy and the Puerperium The American Society of Hematology American Society of Hematology 10.1182/blood.V12.3.261.261 Silverchair:27763 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The Bone Marrow in Pregnancy and the Puerperium The American Society of Hematology American Society of Hematology 10.1182/blood.V12.3.261.261 Silverchair:27763 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The case against catheter-directed thrombolysis in patients with proximal deep vein thrombosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018018630 Silverchair:16223 Total_Item_Investigations 5 0 0 0 0 0 0 0 0 2 3 0 0 The case against catheter-directed thrombolysis in patients with proximal deep vein thrombosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018018630 Silverchair:16223 Total_Item_Requests 5 0 0 0 0 0 0 0 0 2 3 0 0 The case against catheter-directed thrombolysis in patients with proximal deep vein thrombosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018018630 Silverchair:16223 Unique_Item_Investigations 2 0 0 0 0 0 0 0 0 1 1 0 0 The case against catheter-directed thrombolysis in patients with proximal deep vein thrombosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018018630 Silverchair:16223 Unique_Item_Requests 2 0 0 0 0 0 0 0 0 1 1 0 0 The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation The American Society of Hematology American Society of Hematology 10.1182/blood-2004-04-1596 Silverchair:19982 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation The American Society of Hematology American Society of Hematology 10.1182/blood-2004-04-1596 Silverchair:19982 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation The American Society of Hematology American Society of Hematology 10.1182/blood-2004-04-1596 Silverchair:19982 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation The American Society of Hematology American Society of Hematology 10.1182/blood-2004-04-1596 Silverchair:19982 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 THE CHAIN REACTION OF THE BLOOD CLOTTING MECHANISM IN RELATION TO THE THEORY OF HEMOSTASIS AND THROMBOSIS The American Society of Hematology American Society of Hematology 10.1182/blood.V4.12.1290.1290 Silverchair:39940 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 THE CHAIN REACTION OF THE BLOOD CLOTTING MECHANISM IN RELATION TO THE THEORY OF HEMOSTASIS AND THROMBOSIS The American Society of Hematology American Society of Hematology 10.1182/blood.V4.12.1290.1290 Silverchair:39940 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The characterization of distinct populations of murine skeletal cells that have different roles in B lymphopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.2020005865 Silverchair:475647 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 The characterization of distinct populations of murine skeletal cells that have different roles in B lymphopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.2020005865 Silverchair:475647 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V95.2.627 Silverchair:138593 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V95.2.627 Silverchair:138593 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V95.2.627 Silverchair:138593 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V95.2.627 Silverchair:138593 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL The American Society of Hematology American Society of Hematology 10.1182/blood.2020009813 Silverchair:475785 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL The American Society of Hematology American Society of Hematology 10.1182/blood.2020009813 Silverchair:475785 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL The American Society of Hematology American Society of Hematology 10.1182/blood.2020009813 Silverchair:475785 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL The American Society of Hematology American Society of Hematology 10.1182/blood.2020009813 Silverchair:475785 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 "The Combination of Duvelisib, a PI3K-δ,γ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115241 Silverchair:266410 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "The Combination of Duvelisib, a PI3K-δ,γ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115241 Silverchair:266410 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "The Combination of Duvelisib, a PI3K-δ,γ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115241 Silverchair:266410 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "The Combination of Duvelisib, a PI3K-δ,γ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115241 Silverchair:266410 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1642.1642 Silverchair:91455 Total_Item_Investigations 5 1 4 0 0 0 0 0 0 0 0 0 0 The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1642.1642 Silverchair:91455 Total_Item_Requests 5 1 4 0 0 0 0 0 0 0 0 0 0 The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1642.1642 Silverchair:91455 Unique_Item_Investigations 3 1 2 0 0 0 0 0 0 0 0 0 0 The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.1642.1642 Silverchair:91455 Unique_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.723.723 Silverchair:83424 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.723.723 Silverchair:83424 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.723.723 Silverchair:83424 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.723.723 Silverchair:83424 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The combination of valproic acid and lithium delays hematopoietic stem/progenitor cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-375386 Silverchair:29621 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The combination of valproic acid and lithium delays hematopoietic stem/progenitor cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-375386 Silverchair:29621 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The combination of valproic acid and lithium delays hematopoietic stem/progenitor cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-375386 Silverchair:29621 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The combination of valproic acid and lithium delays hematopoietic stem/progenitor cell differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-375386 Silverchair:29621 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "The Commands Trial: A Phase 3 Study of the Efficacy and Safety of Luspatercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low-, Low-, or Intermediate-Risk MDS in Erythropoiesis Stimulating Agent-Naive Patients Who Require RBC Transfusions" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140284 Silverchair:471973 Total_Item_Investigations 2 0 1 0 0 0 1 0 0 0 0 0 0 "The Commands Trial: A Phase 3 Study of the Efficacy and Safety of Luspatercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low-, Low-, or Intermediate-Risk MDS in Erythropoiesis Stimulating Agent-Naive Patients Who Require RBC Transfusions" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140284 Silverchair:471973 Total_Item_Requests 2 0 1 0 0 0 1 0 0 0 0 0 0 "The Commands Trial: A Phase 3 Study of the Efficacy and Safety of Luspatercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low-, Low-, or Intermediate-Risk MDS in Erythropoiesis Stimulating Agent-Naive Patients Who Require RBC Transfusions" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140284 Silverchair:471973 Unique_Item_Investigations 2 0 1 0 0 0 1 0 0 0 0 0 0 "The Commands Trial: A Phase 3 Study of the Efficacy and Safety of Luspatercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low-, Low-, or Intermediate-Risk MDS in Erythropoiesis Stimulating Agent-Naive Patients Who Require RBC Transfusions" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140284 Silverchair:471973 Unique_Item_Requests 2 0 1 0 0 0 1 0 0 0 0 0 0 The Comparison of Novel Oral Anticoagulants with Conventional Anticoagulants in the Treatment of Cancer-Associated Thrombosis: A Systemic Review The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140816 Silverchair:473291 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 The Comparison of Novel Oral Anticoagulants with Conventional Anticoagulants in the Treatment of Cancer-Associated Thrombosis: A Systemic Review The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140816 Silverchair:473291 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 The Comparison of Novel Oral Anticoagulants with Conventional Anticoagulants in the Treatment of Cancer-Associated Thrombosis: A Systemic Review The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140816 Silverchair:473291 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 The Comparison of Novel Oral Anticoagulants with Conventional Anticoagulants in the Treatment of Cancer-Associated Thrombosis: A Systemic Review The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140816 Silverchair:473291 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria The American Society of Hematology American Society of Hematology 10.1182/blood.2019003399 Silverchair:440744 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria The American Society of Hematology American Society of Hematology 10.1182/blood.2019003399 Silverchair:440744 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria The American Society of Hematology American Society of Hematology 10.1182/blood.2019003399 Silverchair:440744 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria The American Society of Hematology American Society of Hematology 10.1182/blood.2019003399 Silverchair:440744 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "The control of hematopoietic stem cell maintenance, self-renewal, and differentiation by Mysm1-mediated epigenetic regulation" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-489641 Silverchair:31786 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "The control of hematopoietic stem cell maintenance, self-renewal, and differentiation by Mysm1-mediated epigenetic regulation" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-489641 Silverchair:31786 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "The control of hematopoietic stem cell maintenance, self-renewal, and differentiation by Mysm1-mediated epigenetic regulation" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-489641 Silverchair:31786 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "The control of hematopoietic stem cell maintenance, self-renewal, and differentiation by Mysm1-mediated epigenetic regulation" The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-489641 Silverchair:31786 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective The American Society of Hematology American Society of Hematology 10.1182/blood.2021010864 Silverchair:475836 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 0 0 3 0 The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective The American Society of Hematology American Society of Hematology 10.1182/blood.2021010864 Silverchair:475836 Total_Item_Requests 3 0 0 0 0 0 0 0 0 0 0 3 0 The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective The American Society of Hematology American Society of Hematology 10.1182/blood.2021010864 Silverchair:475836 Unique_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective The American Society of Hematology American Society of Hematology 10.1182/blood.2021010864 Silverchair:475836 Unique_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 The cytoprotective protein C pathway The American Society of Hematology American Society of Hematology 10.1182/blood-2006-09-003004 Silverchair:23674 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The cytoprotective protein C pathway The American Society of Hematology American Society of Hematology 10.1182/blood-2006-09-003004 Silverchair:23674 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The cytoprotective protein C pathway The American Society of Hematology American Society of Hematology 10.1182/blood-2006-09-003004 Silverchair:23674 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The cytoprotective protein C pathway The American Society of Hematology American Society of Hematology 10.1182/blood-2006-09-003004 Silverchair:23674 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The development of imatinib as a therapeutic agent for chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2004-08-3097 Silverchair:20208 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 The development of imatinib as a therapeutic agent for chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2004-08-3097 Silverchair:20208 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 The development of imatinib as a therapeutic agent for chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2004-08-3097 Silverchair:20208 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The development of imatinib as a therapeutic agent for chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2004-08-3097 Silverchair:20208 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002097 Silverchair:461771 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002097 Silverchair:461771 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002097 Silverchair:461771 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002097 Silverchair:461771 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns The American Society of Hematology American Society of Hematology 10.1182/blood.V99.4.1144 Silverchair:110035 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns The American Society of Hematology American Society of Hematology 10.1182/blood.V99.4.1144 Silverchair:110035 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns The American Society of Hematology American Society of Hematology 10.1182/blood.V99.4.1144 Silverchair:110035 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns The American Society of Hematology American Society of Hematology 10.1182/blood.V99.4.1144 Silverchair:110035 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130449 Silverchair:427311 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130449 Silverchair:427311 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130449 Silverchair:427311 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130449 Silverchair:427311 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The Dll4/Notch pathway controls postangiogenic blood vessel remodeling and regression by modulating vasoconstriction and blood flow The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-302067 Silverchair:22305 Total_Item_Investigations 5 5 0 0 0 0 0 0 0 0 0 0 0 The Dll4/Notch pathway controls postangiogenic blood vessel remodeling and regression by modulating vasoconstriction and blood flow The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-302067 Silverchair:22305 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 The Dll4/Notch pathway controls postangiogenic blood vessel remodeling and regression by modulating vasoconstriction and blood flow The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-302067 Silverchair:22305 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The Dll4/Notch pathway controls postangiogenic blood vessel remodeling and regression by modulating vasoconstriction and blood flow The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-302067 Silverchair:22305 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "The Dual PI3K-δ,γ Inhibitor Duvelisib Stimulates Anti-Tumor Immunity and Enhances Efficacy of Immune Checkpoint and Co-Stimulatory Antibodies in a B Cell Lymphoma Model" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1541.1541 Silverchair:79683 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "The Dual PI3K-δ,γ Inhibitor Duvelisib Stimulates Anti-Tumor Immunity and Enhances Efficacy of Immune Checkpoint and Co-Stimulatory Antibodies in a B Cell Lymphoma Model" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1541.1541 Silverchair:79683 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "The Dual PI3K-δ,γ Inhibitor Duvelisib Stimulates Anti-Tumor Immunity and Enhances Efficacy of Immune Checkpoint and Co-Stimulatory Antibodies in a B Cell Lymphoma Model" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1541.1541 Silverchair:79683 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "The Dual PI3K-δ,γ Inhibitor Duvelisib Stimulates Anti-Tumor Immunity and Enhances Efficacy of Immune Checkpoint and Co-Stimulatory Antibodies in a B Cell Lymphoma Model" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1541.1541 Silverchair:79683 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-372904 Silverchair:29633 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-372904 Silverchair:29633 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-372904 Silverchair:29633 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-372904 Silverchair:29633 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141388 Silverchair:472696 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141388 Silverchair:472696 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141388 Silverchair:472696 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141388 Silverchair:472696 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-497123 Silverchair:32711 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-497123 Silverchair:32711 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-497123 Silverchair:32711 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-497123 Silverchair:32711 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 The effect of rituximab on vaccine responses in patients with immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-494096 Silverchair:31886 Total_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 The effect of rituximab on vaccine responses in patients with immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-494096 Silverchair:31886 Total_Item_Requests 3 2 0 1 0 0 0 0 0 0 0 0 0 The effect of rituximab on vaccine responses in patients with immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-494096 Silverchair:31886 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 The effect of rituximab on vaccine responses in patients with immune thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2013-04-494096 Silverchair:31886 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 The Effect of Sorafenib Therapy on the Outcome of Acute Myeloid Leukemia with FLT3-ITD Undergoing Allogeneic Hematopoietic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2045.2045 Silverchair:71323 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The Effect of Sorafenib Therapy on the Outcome of Acute Myeloid Leukemia with FLT3-ITD Undergoing Allogeneic Hematopoietic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2045.2045 Silverchair:71323 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The Effect of Sorafenib Therapy on the Outcome of Acute Myeloid Leukemia with FLT3-ITD Undergoing Allogeneic Hematopoietic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2045.2045 Silverchair:71323 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The Effect of Sorafenib Therapy on the Outcome of Acute Myeloid Leukemia with FLT3-ITD Undergoing Allogeneic Hematopoietic Stem Cell Transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2045.2045 Silverchair:71323 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The Effects of BCR/ABL on DNA Damage and Repair Are Dependent on Apoptosis Competence The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.4216.4216 Silverchair:58614 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The Effects of BCR/ABL on DNA Damage and Repair Are Dependent on Apoptosis Competence The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.4216.4216 Silverchair:58614 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The Effects of BCR/ABL on DNA Damage and Repair Are Dependent on Apoptosis Competence The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.4216.4216 Silverchair:58614 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The Effects of BCR/ABL on DNA Damage and Repair Are Dependent on Apoptosis Competence The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.4216.4216 Silverchair:58614 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-015487 Silverchair:22738 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-015487 Silverchair:22738 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-015487 Silverchair:22738 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases The American Society of Hematology American Society of Hematology 10.1182/blood-2006-04-015487 Silverchair:22738 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001310 Silverchair:452520 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001310 Silverchair:452520 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001310 Silverchair:452520 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019001310 Silverchair:452520 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 The efficiency of murine MLL-ENL–driven leukemia initiation changes with age and peaks during neonatal development American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000554 Silverchair:260610 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 The efficiency of murine MLL-ENL–driven leukemia initiation changes with age and peaks during neonatal development American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000554 Silverchair:260610 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 The efficiency of murine MLL-ENL–driven leukemia initiation changes with age and peaks during neonatal development American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000554 Silverchair:260610 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The efficiency of murine MLL-ENL–driven leukemia initiation changes with age and peaks during neonatal development American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000554 Silverchair:260610 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The Elevation of LIVER Enzymes in Patients with Atrial Fibrillation and COVID-19 Is a Marker of Bad Evolution and Mortality The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142451 Silverchair:473286 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 The Elevation of LIVER Enzymes in Patients with Atrial Fibrillation and COVID-19 Is a Marker of Bad Evolution and Mortality The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142451 Silverchair:473286 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 The Elevation of LIVER Enzymes in Patients with Atrial Fibrillation and COVID-19 Is a Marker of Bad Evolution and Mortality The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142451 Silverchair:473286 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 The Elevation of LIVER Enzymes in Patients with Atrial Fibrillation and COVID-19 Is a Marker of Bad Evolution and Mortality The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142451 Silverchair:473286 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-714493 Silverchair:36192 Total_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-714493 Silverchair:36192 Total_Item_Requests 3 2 0 1 0 0 0 0 0 0 0 0 0 The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-714493 Silverchair:36192 Unique_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-714493 Silverchair:36192 Unique_Item_Requests 3 2 0 1 0 0 0 0 0 0 0 0 0 The EMT transcription factor Zeb2 controls adult murine hematopoietic differentiation by regulating cytokine signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-714659 Silverchair:36208 Total_Item_Investigations 3 1 0 2 0 0 0 0 0 0 0 0 0 The EMT transcription factor Zeb2 controls adult murine hematopoietic differentiation by regulating cytokine signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-714659 Silverchair:36208 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 The EMT transcription factor Zeb2 controls adult murine hematopoietic differentiation by regulating cytokine signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-714659 Silverchair:36208 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 The EMT transcription factor Zeb2 controls adult murine hematopoietic differentiation by regulating cytokine signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2016-05-714659 Silverchair:36208 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 The epidermal growth factor–like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans The American Society of Hematology American Society of Hematology 10.1182/blood-2002-11-3540 Silverchair:17757 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The epidermal growth factor–like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans The American Society of Hematology American Society of Hematology 10.1182/blood-2002-11-3540 Silverchair:17757 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The epidermal growth factor–like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans The American Society of Hematology American Society of Hematology 10.1182/blood-2002-11-3540 Silverchair:17757 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The epidermal growth factor–like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans The American Society of Hematology American Society of Hematology 10.1182/blood-2002-11-3540 Silverchair:17757 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The first specific antiplatelet antidote The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-636274 Silverchair:34340 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The first specific antiplatelet antidote The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-636274 Silverchair:34340 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The first specific antiplatelet antidote The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-636274 Silverchair:34340 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The first specific antiplatelet antidote The American Society of Hematology American Society of Hematology 10.1182/blood-2015-04-636274 Silverchair:34340 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126271 Silverchair:426374 Total_Item_Investigations 3 1 2 0 0 0 0 0 0 0 0 0 0 The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126271 Silverchair:426374 Total_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126271 Silverchair:426374 Unique_Item_Investigations 3 1 2 0 0 0 0 0 0 0 0 0 0 The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126271 Silverchair:426374 Unique_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131255 Silverchair:426939 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131255 Silverchair:426939 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131255 Silverchair:426939 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131255 Silverchair:426939 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The Forgotten Story of Vitamin C Deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142801 Silverchair:473240 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 The Forgotten Story of Vitamin C Deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142801 Silverchair:473240 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 The Forgotten Story of Vitamin C Deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142801 Silverchair:473240 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The Forgotten Story of Vitamin C Deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142801 Silverchair:473240 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The Frequency of Calr and MPL Gene Mutations in Jak2 V617F - Positive Chronic Myeloproliferative Neoplasms in Russia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124767 Silverchair:425359 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The Frequency of Calr and MPL Gene Mutations in Jak2 V617F - Positive Chronic Myeloproliferative Neoplasms in Russia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124767 Silverchair:425359 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The Frequency of Calr and MPL Gene Mutations in Jak2 V617F - Positive Chronic Myeloproliferative Neoplasms in Russia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124767 Silverchair:425359 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The Frequency of Calr and MPL Gene Mutations in Jak2 V617F - Positive Chronic Myeloproliferative Neoplasms in Russia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124767 Silverchair:425359 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018020552 Silverchair:15919 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018020552 Silverchair:15919 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018020552 Silverchair:15919 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018020552 Silverchair:15919 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 The Gamma Gap: A Point-of-Care Test That Correlates with Disease Burden and Treatment Response in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4407.4407 Silverchair:72727 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 The Gamma Gap: A Point-of-Care Test That Correlates with Disease Burden and Treatment Response in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4407.4407 Silverchair:72727 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 The Gamma Gap: A Point-of-Care Test That Correlates with Disease Burden and Treatment Response in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4407.4407 Silverchair:72727 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 The Gamma Gap: A Point-of-Care Test That Correlates with Disease Burden and Treatment Response in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4407.4407 Silverchair:72727 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 The genetic basis of myelodysplasia and its clinical relevance The American Society of Hematology American Society of Hematology 10.1182/blood-2013-09-381665 Silverchair:32026 Total_Item_Investigations 2 0 0 0 0 0 0 2 0 0 0 0 0 The genetic basis of myelodysplasia and its clinical relevance The American Society of Hematology American Society of Hematology 10.1182/blood-2013-09-381665 Silverchair:32026 Total_Item_Requests 2 0 0 0 0 0 0 2 0 0 0 0 0 The genetic basis of myelodysplasia and its clinical relevance The American Society of Hematology American Society of Hematology 10.1182/blood-2013-09-381665 Silverchair:32026 Unique_Item_Investigations 2 0 0 0 0 0 0 2 0 0 0 0 0 The genetic basis of myelodysplasia and its clinical relevance The American Society of Hematology American Society of Hematology 10.1182/blood-2013-09-381665 Silverchair:32026 Unique_Item_Requests 2 0 0 0 0 0 0 2 0 0 0 0 0 The genetics and molecular biology of T-ALL The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-706465 Silverchair:36559 Total_Item_Investigations 8 3 0 0 2 0 0 0 0 0 0 3 0 The genetics and molecular biology of T-ALL The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-706465 Silverchair:36559 Total_Item_Requests 8 3 0 0 2 0 0 0 0 0 0 3 0 The genetics and molecular biology of T-ALL The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-706465 Silverchair:36559 Unique_Item_Investigations 4 2 0 0 1 0 0 0 0 0 0 1 0 The genetics and molecular biology of T-ALL The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-706465 Silverchair:36559 Unique_Item_Requests 4 2 0 0 1 0 0 0 0 0 0 1 0 The growing landscape of FLT3 inhibition in AML The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000058 Silverchair:422599 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 The growing landscape of FLT3 inhibition in AML The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000058 Silverchair:422599 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 The growing landscape of FLT3 inhibition in AML The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000058 Silverchair:422599 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 The growing landscape of FLT3 inhibition in AML The American Society of Hematology American Society of Hematology 10.1182/hematology.2019000058 Silverchair:422599 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells The American Society of Hematology American Society of Hematology 10.1182/blood.V99.8.2929 Silverchair:248020 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells The American Society of Hematology American Society of Hematology 10.1182/blood.V99.8.2929 Silverchair:248020 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells The American Society of Hematology American Society of Hematology 10.1182/blood.V99.8.2929 Silverchair:248020 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells The American Society of Hematology American Society of Hematology 10.1182/blood.V99.8.2929 Silverchair:248020 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 The Hbo1-Brd1/Brpf2 complex is responsible for global acetylation of H3K14 and required for fetal liver erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-331892 Silverchair:29525 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 The Hbo1-Brd1/Brpf2 complex is responsible for global acetylation of H3K14 and required for fetal liver erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-331892 Silverchair:29525 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 The Hbo1-Brd1/Brpf2 complex is responsible for global acetylation of H3K14 and required for fetal liver erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-331892 Silverchair:29525 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The Hbo1-Brd1/Brpf2 complex is responsible for global acetylation of H3K14 and required for fetal liver erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-331892 Silverchair:29525 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The Hematologist and Radiation Casualties The American Society of Hematology American Society of Hematology 10.1182/asheducation-2003.1.473 Silverchair:18671 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The Hematologist and Radiation Casualties The American Society of Hematology American Society of Hematology 10.1182/asheducation-2003.1.473 Silverchair:18671 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The Hematologist and Radiation Casualties The American Society of Hematology American Society of Hematology 10.1182/asheducation-2003.1.473 Silverchair:18671 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The Hematologist and Radiation Casualties The American Society of Hematology American Society of Hematology 10.1182/asheducation-2003.1.473 Silverchair:18671 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "The high-affinity human IgG receptor FcγRI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-442541 Silverchair:138813 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "The high-affinity human IgG receptor FcγRI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-442541 Silverchair:138813 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "The high-affinity human IgG receptor FcγRI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-442541 Silverchair:138813 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "The high-affinity human IgG receptor FcγRI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-442541 Silverchair:138813 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The hypercoagulable state in thalassemia The American Society of Hematology American Society of Hematology 10.1182/blood.V99.1.36 Silverchair:107240 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 The hypercoagulable state in thalassemia The American Society of Hematology American Society of Hematology 10.1182/blood.V99.1.36 Silverchair:107240 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 The hypercoagulable state in thalassemia The American Society of Hematology American Society of Hematology 10.1182/blood.V99.1.36 Silverchair:107240 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 The hypercoagulable state in thalassemia The American Society of Hematology American Society of Hematology 10.1182/blood.V99.1.36 Silverchair:107240 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-517847 Silverchair:32654 Total_Item_Investigations 10 5 5 0 0 0 0 0 0 0 0 0 0 The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-517847 Silverchair:32654 Total_Item_Requests 10 5 5 0 0 0 0 0 0 0 0 0 0 The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-517847 Silverchair:32654 Unique_Item_Investigations 6 3 3 0 0 0 0 0 0 0 0 0 0 The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-517847 Silverchair:32654 Unique_Item_Requests 6 3 3 0 0 0 0 0 0 0 0 0 0 The Immature Reticulocyte Fraction As an Aid in the Diagnosis and Prognosis of Parvovirus B19 Infection in Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117152 Silverchair:264897 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The Immature Reticulocyte Fraction As an Aid in the Diagnosis and Prognosis of Parvovirus B19 Infection in Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117152 Silverchair:264897 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The Immature Reticulocyte Fraction As an Aid in the Diagnosis and Prognosis of Parvovirus B19 Infection in Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117152 Silverchair:264897 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The Immature Reticulocyte Fraction As an Aid in the Diagnosis and Prognosis of Parvovirus B19 Infection in Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117152 Silverchair:264897 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The immune landscape and response to immune checkpoint blockade therapy in lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2019000847 Silverchair:429214 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 The immune landscape and response to immune checkpoint blockade therapy in lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2019000847 Silverchair:429214 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 The immune landscape and response to immune checkpoint blockade therapy in lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2019000847 Silverchair:429214 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 The immune landscape and response to immune checkpoint blockade therapy in lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2019000847 Silverchair:429214 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-741025 Silverchair:107694 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-741025 Silverchair:107694 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-741025 Silverchair:107694 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-741025 Silverchair:107694 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141231 Silverchair:473619 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141231 Silverchair:473619 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141231 Silverchair:473619 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2020-141231 Silverchair:473619 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018021436 Silverchair:16111 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018021436 Silverchair:16111 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018021436 Silverchair:16111 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018021436 Silverchair:16111 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2008-03-143412 Silverchair:114947 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2008-03-143412 Silverchair:114947 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2008-03-143412 Silverchair:114947 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2008-03-143412 Silverchair:114947 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and Hydroxyurea Use in Patients with Polycythemia Vera and Essential Thrombocythemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127563 Silverchair:427907 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and Hydroxyurea Use in Patients with Polycythemia Vera and Essential Thrombocythemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127563 Silverchair:427907 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and Hydroxyurea Use in Patients with Polycythemia Vera and Essential Thrombocythemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127563 Silverchair:427907 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and Hydroxyurea Use in Patients with Polycythemia Vera and Essential Thrombocythemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127563 Silverchair:427907 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The implementation of electronic hematology consults at a VA hospital The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-672113 Silverchair:35041 Total_Item_Investigations 3 1 0 0 0 0 0 0 0 0 0 2 0 The implementation of electronic hematology consults at a VA hospital The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-672113 Silverchair:35041 Total_Item_Requests 3 1 0 0 0 0 0 0 0 0 0 2 0 The implementation of electronic hematology consults at a VA hospital The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-672113 Silverchair:35041 Unique_Item_Investigations 2 1 0 0 0 0 0 0 0 0 0 1 0 The implementation of electronic hematology consults at a VA hospital The American Society of Hematology American Society of Hematology 10.1182/blood-2015-09-672113 Silverchair:35041 Unique_Item_Requests 2 1 0 0 0 0 0 0 0 0 0 1 0 The Incidence of Idiopathic Thrombocytopenic Purpura in Adults Increases With Age The American Society of Hematology American Society of Hematology 10.1182/blood.V94.3.909.415k02_909_913 Silverchair:125328 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 2 0 0 0 The Incidence of Idiopathic Thrombocytopenic Purpura in Adults Increases With Age The American Society of Hematology American Society of Hematology 10.1182/blood.V94.3.909.415k02_909_913 Silverchair:125328 Total_Item_Requests 2 0 0 0 0 0 0 0 0 2 0 0 0 The Incidence of Idiopathic Thrombocytopenic Purpura in Adults Increases With Age The American Society of Hematology American Society of Hematology 10.1182/blood.V94.3.909.415k02_909_913 Silverchair:125328 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 The Incidence of Idiopathic Thrombocytopenic Purpura in Adults Increases With Age The American Society of Hematology American Society of Hematology 10.1182/blood.V94.3.909.415k02_909_913 Silverchair:125328 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 The intriguing role of polymorphonuclear neutrophils in antitumor reactions The American Society of Hematology American Society of Hematology 10.1182/blood.V97.2.339 Silverchair:52823 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The intriguing role of polymorphonuclear neutrophils in antitumor reactions The American Society of Hematology American Society of Hematology 10.1182/blood.V97.2.339 Silverchair:52823 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The intriguing role of polymorphonuclear neutrophils in antitumor reactions The American Society of Hematology American Society of Hematology 10.1182/blood.V97.2.339 Silverchair:52823 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The intriguing role of polymorphonuclear neutrophils in antitumor reactions The American Society of Hematology American Society of Hematology 10.1182/blood.V97.2.339 Silverchair:52823 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The ITP syndrome: pathogenic and clinical diversity The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-129155 Silverchair:26188 Total_Item_Investigations 4 0 2 0 0 0 0 0 0 2 0 0 0 The ITP syndrome: pathogenic and clinical diversity The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-129155 Silverchair:26188 Total_Item_Requests 4 0 2 0 0 0 0 0 0 2 0 0 0 The ITP syndrome: pathogenic and clinical diversity The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-129155 Silverchair:26188 Unique_Item_Investigations 2 0 1 0 0 0 0 0 0 1 0 0 0 The ITP syndrome: pathogenic and clinical diversity The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-129155 Silverchair:26188 Unique_Item_Requests 2 0 1 0 0 0 0 0 0 1 0 0 0 The JAK1/2 Inhibitor Ruxolitinib Downregulates the Immune Checkpoint Protein B7-H3 in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131047 Silverchair:427539 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 The JAK1/2 Inhibitor Ruxolitinib Downregulates the Immune Checkpoint Protein B7-H3 in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131047 Silverchair:427539 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The JAK1/2 Inhibitor Ruxolitinib Downregulates the Immune Checkpoint Protein B7-H3 in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131047 Silverchair:427539 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The JAK1/2 Inhibitor Ruxolitinib Downregulates the Immune Checkpoint Protein B7-H3 in Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131047 Silverchair:427539 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-484642 Silverchair:32416 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-484642 Silverchair:32416 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-484642 Silverchair:32416 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-484642 Silverchair:32416 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018016733 Silverchair:16149 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 0 3 0 0 The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018016733 Silverchair:16149 Total_Item_Requests 3 0 0 0 0 0 0 0 0 0 3 0 0 The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018016733 Silverchair:16149 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018016733 Silverchair:16149 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 The kinetics of clonal dominance in myeloproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-1240 Silverchair:21799 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 The kinetics of clonal dominance in myeloproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-1240 Silverchair:21799 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 The kinetics of clonal dominance in myeloproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-1240 Silverchair:21799 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 The kinetics of clonal dominance in myeloproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-1240 Silverchair:21799 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-689976 Silverchair:34953 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-689976 Silverchair:34953 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-689976 Silverchair:34953 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-689976 Silverchair:34953 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The life span of short-lived plasma cells is partly determined by a block on activation of apoptotic caspases acting in combination with endoplasmic reticulum stress The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-250423 Silverchair:27964 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 The life span of short-lived plasma cells is partly determined by a block on activation of apoptotic caspases acting in combination with endoplasmic reticulum stress The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-250423 Silverchair:27964 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 The life span of short-lived plasma cells is partly determined by a block on activation of apoptotic caspases acting in combination with endoplasmic reticulum stress The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-250423 Silverchair:27964 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 The life span of short-lived plasma cells is partly determined by a block on activation of apoptotic caspases acting in combination with endoplasmic reticulum stress The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-250423 Silverchair:27964 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 The L-MIND Trial of the Anti-CD19 Antibody Tafasitamab Combined With Lenalidomide for Lower Risk Relapsed DLBCL American Society of Hematology American Society of Hematology Silverchair:464067 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The L-MIND Trial of the Anti-CD19 Antibody Tafasitamab Combined With Lenalidomide for Lower Risk Relapsed DLBCL American Society of Hematology American Society of Hematology Silverchair:464067 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The L-MIND Trial of the Anti-CD19 Antibody Tafasitamab Combined With Lenalidomide for Lower Risk Relapsed DLBCL American Society of Hematology American Society of Hematology Silverchair:464067 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The L-MIND Trial of the Anti-CD19 Antibody Tafasitamab Combined With Lenalidomide for Lower Risk Relapsed DLBCL American Society of Hematology American Society of Hematology Silverchair:464067 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The Long and Successful Journey of Prophylactic Platelet Transfusion American Society of Hematology American Society of Hematology Silverchair:475871 Total_Item_Investigations 3 0 0 0 0 2 1 0 0 0 0 0 0 The Long and Successful Journey of Prophylactic Platelet Transfusion American Society of Hematology American Society of Hematology Silverchair:475871 Total_Item_Requests 3 0 0 0 0 2 1 0 0 0 0 0 0 The Long and Successful Journey of Prophylactic Platelet Transfusion American Society of Hematology American Society of Hematology Silverchair:475871 Unique_Item_Investigations 2 0 0 0 0 1 1 0 0 0 0 0 0 The Long and Successful Journey of Prophylactic Platelet Transfusion American Society of Hematology American Society of Hematology Silverchair:475871 Unique_Item_Requests 2 0 0 0 0 1 1 0 0 0 0 0 0 The macrophage scavenger receptor CD163 functions as an innate immune sensor for bacteria The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-167064 Silverchair:25016 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The macrophage scavenger receptor CD163 functions as an innate immune sensor for bacteria The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-167064 Silverchair:25016 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The macrophage scavenger receptor CD163 functions as an innate immune sensor for bacteria The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-167064 Silverchair:25016 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The macrophage scavenger receptor CD163 functions as an innate immune sensor for bacteria The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-167064 Silverchair:25016 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The many faces of common variable immunodeficiency The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.301.3798316 Silverchair:83838 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The many faces of common variable immunodeficiency The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.301.3798316 Silverchair:83838 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The many faces of common variable immunodeficiency The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.301.3798316 Silverchair:83838 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The many faces of common variable immunodeficiency The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.301.3798316 Silverchair:83838 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The many faces of marginal zone lymphoma The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.426.3798535 Silverchair:83864 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The many faces of marginal zone lymphoma The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.426.3798535 Silverchair:83864 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The many faces of marginal zone lymphoma The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.426.3798535 Silverchair:83864 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The many faces of marginal zone lymphoma The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.426.3798535 Silverchair:83864 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The MDM2 Antagonist Nutlin-3 Is Lethal to Mantle Cell Lymphoma with Wild Type p53. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.1382.1382 Silverchair:73713 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The MDM2 Antagonist Nutlin-3 Is Lethal to Mantle Cell Lymphoma with Wild Type p53. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.1382.1382 Silverchair:73713 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The MDM2 Antagonist Nutlin-3 Is Lethal to Mantle Cell Lymphoma with Wild Type p53. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.1382.1382 Silverchair:73713 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The MDM2 Antagonist Nutlin-3 Is Lethal to Mantle Cell Lymphoma with Wild Type p53. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.1382.1382 Silverchair:73713 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction The American Society of Hematology American Society of Hematology 10.1182/blood.V99.3.1038 Silverchair:53510 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction The American Society of Hematology American Society of Hematology 10.1182/blood.V99.3.1038 Silverchair:53510 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction The American Society of Hematology American Society of Hematology 10.1182/blood.V99.3.1038 Silverchair:53510 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction The American Society of Hematology American Society of Hematology 10.1182/blood.V99.3.1038 Silverchair:53510 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The mesenchymal niche in MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-844639 Silverchair:272726 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 The mesenchymal niche in MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-844639 Silverchair:272726 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 The mesenchymal niche in MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-844639 Silverchair:272726 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The mesenchymal niche in MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-844639 Silverchair:272726 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The microenvironment in human myeloid malignancies: emerging concepts and therapeutic implications The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-696070 Silverchair:36115 Total_Item_Investigations 4 2 2 0 0 0 0 0 0 0 0 0 0 The microenvironment in human myeloid malignancies: emerging concepts and therapeutic implications The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-696070 Silverchair:36115 Total_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 The microenvironment in human myeloid malignancies: emerging concepts and therapeutic implications The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-696070 Silverchair:36115 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 The microenvironment in human myeloid malignancies: emerging concepts and therapeutic implications The American Society of Hematology American Society of Hematology 10.1182/blood-2016-11-696070 Silverchair:36115 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-488171 Silverchair:31750 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-488171 Silverchair:31750 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-488171 Silverchair:31750 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies The American Society of Hematology American Society of Hematology 10.1182/blood-2013-03-488171 Silverchair:31750 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The mitochondrial ATP-dependent Lon protease: a novel target in lymphoma death mediated by the synthetic triterpenoid CDDO and its derivatives The American Society of Hematology American Society of Hematology 10.1182/blood-2011-02-340075 Silverchair:29575 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The mitochondrial ATP-dependent Lon protease: a novel target in lymphoma death mediated by the synthetic triterpenoid CDDO and its derivatives The American Society of Hematology American Society of Hematology 10.1182/blood-2011-02-340075 Silverchair:29575 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The mitochondrial ATP-dependent Lon protease: a novel target in lymphoma death mediated by the synthetic triterpenoid CDDO and its derivatives The American Society of Hematology American Society of Hematology 10.1182/blood-2011-02-340075 Silverchair:29575 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The mitochondrial ATP-dependent Lon protease: a novel target in lymphoma death mediated by the synthetic triterpenoid CDDO and its derivatives The American Society of Hematology American Society of Hematology 10.1182/blood-2011-02-340075 Silverchair:29575 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-298349 Silverchair:28736 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-298349 Silverchair:28736 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-298349 Silverchair:28736 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells The American Society of Hematology American Society of Hematology 10.1182/blood-2010-07-298349 Silverchair:28736 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 The molecular genetics of sideroblastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-815951 Silverchair:6612 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 The molecular genetics of sideroblastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-815951 Silverchair:6612 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 The molecular genetics of sideroblastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-815951 Silverchair:6612 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The molecular genetics of sideroblastic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-815951 Silverchair:6612 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The multifunctional role of EKLF/KLF1 during erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-331371 Silverchair:29450 Total_Item_Investigations 7 4 3 0 0 0 0 0 0 0 0 0 0 The multifunctional role of EKLF/KLF1 during erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-331371 Silverchair:29450 Total_Item_Requests 7 4 3 0 0 0 0 0 0 0 0 0 0 The multifunctional role of EKLF/KLF1 during erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-331371 Silverchair:29450 Unique_Item_Investigations 3 2 1 0 0 0 0 0 0 0 0 0 0 The multifunctional role of EKLF/KLF1 during erythropoiesis The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-331371 Silverchair:29450 Unique_Item_Requests 3 2 1 0 0 0 0 0 0 0 0 0 0 The Mutational Landscape of Primary Plasma Cell Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116758 Silverchair:262585 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 The Mutational Landscape of Primary Plasma Cell Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116758 Silverchair:262585 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 The Mutational Landscape of Primary Plasma Cell Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116758 Silverchair:262585 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 The Mutational Landscape of Primary Plasma Cell Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-116758 Silverchair:262585 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 The myth of the second remission of acute leukemia in the adult The American Society of Hematology American Society of Hematology 10.1182/blood-2012-08-234492 Silverchair:31525 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 The myth of the second remission of acute leukemia in the adult The American Society of Hematology American Society of Hematology 10.1182/blood-2012-08-234492 Silverchair:31525 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 The myth of the second remission of acute leukemia in the adult The American Society of Hematology American Society of Hematology 10.1182/blood-2012-08-234492 Silverchair:31525 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The myth of the second remission of acute leukemia in the adult The American Society of Hematology American Society of Hematology 10.1182/blood-2012-08-234492 Silverchair:31525 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-11-4273 Silverchair:21338 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 0 3 0 0 The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-11-4273 Silverchair:21338 Total_Item_Requests 3 0 0 0 0 0 0 0 0 0 3 0 0 The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-11-4273 Silverchair:21338 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells The American Society of Hematology American Society of Hematology 10.1182/blood-2004-11-4273 Silverchair:21338 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 The neurotransmitter receptor Gabbr1 regulates proliferation and function of hematopoietic stem and progenitor cells The American Society of Hematology American Society of Hematology 10.1182/blood.2019004415 Silverchair:463619 No_License 2 0 0 2 0 0 0 0 0 0 0 0 0 The neurotransmitter receptor Gabbr1 regulates proliferation and function of hematopoietic stem and progenitor cells The American Society of Hematology American Society of Hematology 10.1182/blood.2019004415 Silverchair:463619 Total_Item_Investigations 4 0 0 4 0 0 0 0 0 0 0 0 0 The neurotransmitter receptor Gabbr1 regulates proliferation and function of hematopoietic stem and progenitor cells The American Society of Hematology American Society of Hematology 10.1182/blood.2019004415 Silverchair:463619 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The new oral anticoagulants The American Society of Hematology American Society of Hematology 10.1182/blood-2009-09-241851 Silverchair:26664 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 The new oral anticoagulants The American Society of Hematology American Society of Hematology 10.1182/blood-2009-09-241851 Silverchair:26664 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 The new oral anticoagulants The American Society of Hematology American Society of Hematology 10.1182/blood-2009-09-241851 Silverchair:26664 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The new oral anticoagulants The American Society of Hematology American Society of Hematology 10.1182/blood-2009-09-241851 Silverchair:26664 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The next(gen) step in coagulation testing The American Society of Hematology American Society of Hematology 10.1182/blood.2019001414 Silverchair:429195 Total_Item_Investigations 5 0 4 0 0 0 0 0 1 0 0 0 0 The next(gen) step in coagulation testing The American Society of Hematology American Society of Hematology 10.1182/blood.2019001414 Silverchair:429195 Total_Item_Requests 5 0 4 0 0 0 0 0 1 0 0 0 0 The next(gen) step in coagulation testing The American Society of Hematology American Society of Hematology 10.1182/blood.2019001414 Silverchair:429195 Unique_Item_Investigations 4 0 3 0 0 0 0 0 1 0 0 0 0 The next(gen) step in coagulation testing The American Society of Hematology American Society of Hematology 10.1182/blood.2019001414 Silverchair:429195 Unique_Item_Requests 4 0 3 0 0 0 0 0 1 0 0 0 0 The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype The American Society of Hematology American Society of Hematology 10.1182/blood-2016-07-730556 Silverchair:35680 Total_Item_Investigations 10 0 9 0 0 0 0 0 0 0 1 0 0 The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype The American Society of Hematology American Society of Hematology 10.1182/blood-2016-07-730556 Silverchair:35680 Total_Item_Requests 10 0 9 0 0 0 0 0 0 0 1 0 0 The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype The American Society of Hematology American Society of Hematology 10.1182/blood-2016-07-730556 Silverchair:35680 Unique_Item_Investigations 3 0 2 0 0 0 0 0 0 0 1 0 0 The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype The American Society of Hematology American Society of Hematology 10.1182/blood-2016-07-730556 Silverchair:35680 Unique_Item_Requests 3 0 2 0 0 0 0 0 0 0 1 0 0 "The Notch ligand, Delta-1, inhibits the differentiation of monocytes into macrophages but permits their differentiation into dendritic cells" The American Society of Hematology American Society of Hematology 10.1182/blood.V98.5.1402 Silverchair:106093 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "The Notch ligand, Delta-1, inhibits the differentiation of monocytes into macrophages but permits their differentiation into dendritic cells" The American Society of Hematology American Society of Hematology 10.1182/blood.V98.5.1402 Silverchair:106093 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "The Notch ligand, Delta-1, inhibits the differentiation of monocytes into macrophages but permits their differentiation into dendritic cells" The American Society of Hematology American Society of Hematology 10.1182/blood.V98.5.1402 Silverchair:106093 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "The Notch ligand, Delta-1, inhibits the differentiation of monocytes into macrophages but permits their differentiation into dendritic cells" The American Society of Hematology American Society of Hematology 10.1182/blood.V98.5.1402 Silverchair:106093 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-692582 Silverchair:36596 Total_Item_Investigations 2 1 0 0 0 0 0 0 0 0 0 1 0 The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-692582 Silverchair:36596 Total_Item_Requests 2 1 0 0 0 0 0 0 0 0 0 1 0 The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-692582 Silverchair:36596 Unique_Item_Investigations 2 1 0 0 0 0 0 0 0 0 0 1 0 The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2016-09-692582 Silverchair:36596 Unique_Item_Requests 2 1 0 0 0 0 0 0 0 0 0 1 0 The novel AML stem cell–associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2007-03-083048 Silverchair:103631 Total_Item_Investigations 6 0 6 0 0 0 0 0 0 0 0 0 0 The novel AML stem cell–associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2007-03-083048 Silverchair:103631 Total_Item_Requests 6 0 6 0 0 0 0 0 0 0 0 0 0 The novel AML stem cell–associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2007-03-083048 Silverchair:103631 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The novel AML stem cell–associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2007-03-083048 Silverchair:103631 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The novel mechanism of lenalidomide activity The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-567958 Silverchair:34644 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 The novel mechanism of lenalidomide activity The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-567958 Silverchair:34644 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 The novel mechanism of lenalidomide activity The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-567958 Silverchair:34644 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 The novel mechanism of lenalidomide activity The American Society of Hematology American Society of Hematology 10.1182/blood-2015-07-567958 Silverchair:34644 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119944 Silverchair:262522 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119944 Silverchair:262522 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119944 Silverchair:262522 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119944 Silverchair:262522 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 The NSG – Human CLL Xenograft Model Recapitulates the Human Lymph Node Microenvironment in Regards to B-Cell Activation and Tumor Proliferation The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.973.973 Silverchair:82898 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The NSG – Human CLL Xenograft Model Recapitulates the Human Lymph Node Microenvironment in Regards to B-Cell Activation and Tumor Proliferation The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.973.973 Silverchair:82898 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The NSG – Human CLL Xenograft Model Recapitulates the Human Lymph Node Microenvironment in Regards to B-Cell Activation and Tumor Proliferation The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.973.973 Silverchair:82898 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The NSG – Human CLL Xenograft Model Recapitulates the Human Lymph Node Microenvironment in Regards to B-Cell Activation and Tumor Proliferation The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.973.973 Silverchair:82898 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The nuclear receptor corepressor NCoR1 regulates hematopoiesis and leukemogenesis in vivo American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018022756 Silverchair:246782 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 The nuclear receptor corepressor NCoR1 regulates hematopoiesis and leukemogenesis in vivo American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018022756 Silverchair:246782 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 The nuclear receptor corepressor NCoR1 regulates hematopoiesis and leukemogenesis in vivo American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018022756 Silverchair:246782 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The nuclear receptor corepressor NCoR1 regulates hematopoiesis and leukemogenesis in vivo American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018022756 Silverchair:246782 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The Occurrence of Four Globin Abnormalities in One Individual: Hb SC Disease with Hb Chicago and Deletional Alpha Thalassemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3802.3802 Silverchair:58003 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The Occurrence of Four Globin Abnormalities in One Individual: Hb SC Disease with Hb Chicago and Deletional Alpha Thalassemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3802.3802 Silverchair:58003 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The Occurrence of Four Globin Abnormalities in One Individual: Hb SC Disease with Hb Chicago and Deletional Alpha Thalassemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3802.3802 Silverchair:58003 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The Occurrence of Four Globin Abnormalities in One Individual: Hb SC Disease with Hb Chicago and Deletional Alpha Thalassemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3802.3802 Silverchair:58003 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-039024 Silverchair:23377 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-039024 Silverchair:23377 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-039024 Silverchair:23377 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-039024 Silverchair:23377 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The Oral JAK2/IRAK1 Inhibitor Pacritinib Demonstrates Spleen Volume Reduction in Myelofibrosis Patients Independent of JAK2V617F Allele Burden The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127609 Silverchair:427542 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The Oral JAK2/IRAK1 Inhibitor Pacritinib Demonstrates Spleen Volume Reduction in Myelofibrosis Patients Independent of JAK2V617F Allele Burden The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127609 Silverchair:427542 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The Oral JAK2/IRAK1 Inhibitor Pacritinib Demonstrates Spleen Volume Reduction in Myelofibrosis Patients Independent of JAK2V617F Allele Burden The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127609 Silverchair:427542 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The Oral JAK2/IRAK1 Inhibitor Pacritinib Demonstrates Spleen Volume Reduction in Myelofibrosis Patients Independent of JAK2V617F Allele Burden The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127609 Silverchair:427542 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The origins of age-related proinflammatory state The American Society of Hematology American Society of Hematology 10.1182/blood-2004-07-2599 Silverchair:20120 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The origins of age-related proinflammatory state The American Society of Hematology American Society of Hematology 10.1182/blood-2004-07-2599 Silverchair:20120 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The origins of age-related proinflammatory state The American Society of Hematology American Society of Hematology 10.1182/blood-2004-07-2599 Silverchair:20120 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The origins of age-related proinflammatory state The American Society of Hematology American Society of Hematology 10.1182/blood-2004-07-2599 Silverchair:20120 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-265769 Silverchair:107823 Total_Item_Investigations 8 1 1 6 0 0 0 0 0 0 0 0 0 The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-265769 Silverchair:107823 Total_Item_Requests 7 1 1 5 0 0 0 0 0 0 0 0 0 The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-265769 Silverchair:107823 Unique_Item_Investigations 3 1 1 1 0 0 0 0 0 0 0 0 0 The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-265769 Silverchair:107823 Unique_Item_Requests 3 1 1 1 0 0 0 0 0 0 0 0 0 "The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008109 Silverchair:475388 Total_Item_Investigations 6 0 0 4 2 0 0 0 0 0 0 0 0 "The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008109 Silverchair:475388 Unique_Item_Investigations 2 0 0 1 1 0 0 0 0 0 0 0 0 "The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms" The American Society of Hematology American Society of Hematology 10.1182/blood.2020008109 Silverchair:475388 No_License 1 0 0 0 1 0 0 0 0 0 0 0 0 The Pathophysiology of ITP Revisited: Ineffective Thrombopoiesis and the Emerging Role of Thrombopoietin Receptor Agonists in the Management of Chronic Immune Thrombocytopenic Purpura The American Society of Hematology American Society of Hematology 10.1182/asheducation-2008.1.219 Silverchair:95790 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 The Pathophysiology of ITP Revisited: Ineffective Thrombopoiesis and the Emerging Role of Thrombopoietin Receptor Agonists in the Management of Chronic Immune Thrombocytopenic Purpura The American Society of Hematology American Society of Hematology 10.1182/asheducation-2008.1.219 Silverchair:95790 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 The Pathophysiology of ITP Revisited: Ineffective Thrombopoiesis and the Emerging Role of Thrombopoietin Receptor Agonists in the Management of Chronic Immune Thrombocytopenic Purpura The American Society of Hematology American Society of Hematology 10.1182/asheducation-2008.1.219 Silverchair:95790 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 The Pathophysiology of ITP Revisited: Ineffective Thrombopoiesis and the Emerging Role of Thrombopoietin Receptor Agonists in the Management of Chronic Immune Thrombocytopenic Purpura The American Society of Hematology American Society of Hematology 10.1182/asheducation-2008.1.219 Silverchair:95790 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 The penny has dropped for sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-758722 Silverchair:35895 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The penny has dropped for sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-758722 Silverchair:35895 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The penny has dropped for sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-758722 Silverchair:35895 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The penny has dropped for sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood-2016-12-758722 Silverchair:35895 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-352492 Silverchair:29294 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-352492 Silverchair:29294 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-352492 Silverchair:29294 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-05-352492 Silverchair:29294 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The PI3K Delta Inhibitor Idelalisib Interferes With Pre-B Cell Receptor Signaling In Acute Lymphoblastic Leukemia (ALL): A New Therapeutic Concept The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.2632.2632 Silverchair:11976 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The PI3K Delta Inhibitor Idelalisib Interferes With Pre-B Cell Receptor Signaling In Acute Lymphoblastic Leukemia (ALL): A New Therapeutic Concept The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.2632.2632 Silverchair:11976 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The PI3K Delta Inhibitor Idelalisib Interferes With Pre-B Cell Receptor Signaling In Acute Lymphoblastic Leukemia (ALL): A New Therapeutic Concept The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.2632.2632 Silverchair:11976 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The PI3K Delta Inhibitor Idelalisib Interferes With Pre-B Cell Receptor Signaling In Acute Lymphoblastic Leukemia (ALL): A New Therapeutic Concept The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.2632.2632 Silverchair:11976 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-263111 Silverchair:28211 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-263111 Silverchair:28211 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-263111 Silverchair:28211 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-263111 Silverchair:28211 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The Pliancy of Plasma Cell Differentiation Status Conceals a Gradient of Chromosomal Instability in Newly Diagnosed Multiple Myeloma Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1769.1769 Silverchair:79395 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The Pliancy of Plasma Cell Differentiation Status Conceals a Gradient of Chromosomal Instability in Newly Diagnosed Multiple Myeloma Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1769.1769 Silverchair:79395 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The Pliancy of Plasma Cell Differentiation Status Conceals a Gradient of Chromosomal Instability in Newly Diagnosed Multiple Myeloma Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1769.1769 Silverchair:79395 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The Pliancy of Plasma Cell Differentiation Status Conceals a Gradient of Chromosomal Instability in Newly Diagnosed Multiple Myeloma Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1769.1769 Silverchair:79395 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The polyphosphate–factor XII pathway drives coagulation in prostate cancer-associated thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-622811 Silverchair:34406 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 The polyphosphate–factor XII pathway drives coagulation in prostate cancer-associated thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-622811 Silverchair:34406 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 The polyphosphate–factor XII pathway drives coagulation in prostate cancer-associated thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-622811 Silverchair:34406 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The polyphosphate–factor XII pathway drives coagulation in prostate cancer-associated thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-622811 Silverchair:34406 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The porphyrias: advances in diagnosis and treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-423186 Silverchair:30886 Total_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 The porphyrias: advances in diagnosis and treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-423186 Silverchair:30886 Total_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 The porphyrias: advances in diagnosis and treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-423186 Silverchair:30886 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 The porphyrias: advances in diagnosis and treatment The American Society of Hematology American Society of Hematology 10.1182/blood-2012-05-423186 Silverchair:30886 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 The Potential Role of Therapeutic Dose of Low Molecular Weight Heparin (LWMH) to Attenuate Hyper-Inflammatory State in Hospitalized COVID-19 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142109 Silverchair:473262 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 The Potential Role of Therapeutic Dose of Low Molecular Weight Heparin (LWMH) to Attenuate Hyper-Inflammatory State in Hospitalized COVID-19 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142109 Silverchair:473262 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 The Potential Role of Therapeutic Dose of Low Molecular Weight Heparin (LWMH) to Attenuate Hyper-Inflammatory State in Hospitalized COVID-19 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142109 Silverchair:473262 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 The Potential Role of Therapeutic Dose of Low Molecular Weight Heparin (LWMH) to Attenuate Hyper-Inflammatory State in Hospitalized COVID-19 Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142109 Silverchair:473262 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-170282 Silverchair:125016 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-170282 Silverchair:125016 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-170282 Silverchair:125016 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-170282 Silverchair:125016 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-842880 Silverchair:39297 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-842880 Silverchair:39297 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-842880 Silverchair:39297 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-842880 Silverchair:39297 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The Presence of Typical and Atypical BCR-ABL Fusion Genes in Leukocytes of Normal Individuals: Biologic Significance and Implications for the Assessment of Minimal Residual Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V92.9.3362 Silverchair:261309 Total_Item_Investigations 4 0 0 4 0 0 0 0 0 0 0 0 0 The Presence of Typical and Atypical BCR-ABL Fusion Genes in Leukocytes of Normal Individuals: Biologic Significance and Implications for the Assessment of Minimal Residual Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V92.9.3362 Silverchair:261309 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 The Presence of Typical and Atypical BCR-ABL Fusion Genes in Leukocytes of Normal Individuals: Biologic Significance and Implications for the Assessment of Minimal Residual Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V92.9.3362 Silverchair:261309 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The Presence of Typical and Atypical BCR-ABL Fusion Genes in Leukocytes of Normal Individuals: Biologic Significance and Implications for the Assessment of Minimal Residual Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V92.9.3362 Silverchair:261309 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129168 Silverchair:424191 Total_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129168 Silverchair:424191 Total_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129168 Silverchair:424191 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129168 Silverchair:424191 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 The Process of Acquiring Health Education for First Time Parents of an Infant with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4282.4282 Silverchair:86582 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The Process of Acquiring Health Education for First Time Parents of an Infant with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4282.4282 Silverchair:86582 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The Process of Acquiring Health Education for First Time Parents of an Infant with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4282.4282 Silverchair:86582 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The Process of Acquiring Health Education for First Time Parents of an Infant with Sickle Cell Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4282.4282 Silverchair:86582 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG) The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-515825 Silverchair:32334 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG) The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-515825 Silverchair:32334 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG) The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-515825 Silverchair:32334 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG) The American Society of Hematology American Society of Hematology 10.1182/blood-2013-07-515825 Silverchair:32334 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The Prognostic Role of CD68 and FoxP3 Expression in Primary Central Nervous System Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.1457.1457 Silverchair:134934 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The Prognostic Role of CD68 and FoxP3 Expression in Primary Central Nervous System Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.1457.1457 Silverchair:134934 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The Prognostic Role of CD68 and FoxP3 Expression in Primary Central Nervous System Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.1457.1457 Silverchair:134934 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The Prognostic Role of CD68 and FoxP3 Expression in Primary Central Nervous System Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.1457.1457 Silverchair:134934 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The Prognostic Value of CD34 Expression In Acute Myeloid Leukemia. A Mystery Solved The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2725.2725 Silverchair:112093 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 The Prognostic Value of CD34 Expression In Acute Myeloid Leukemia. A Mystery Solved The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2725.2725 Silverchair:112093 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 The Prognostic Value of CD34 Expression In Acute Myeloid Leukemia. A Mystery Solved The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2725.2725 Silverchair:112093 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 The Prognostic Value of CD34 Expression In Acute Myeloid Leukemia. A Mystery Solved The American Society of Hematology American Society of Hematology 10.1182/blood.V116.21.2725.2725 Silverchair:112093 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 The promises and challenges of using gene mutations for patient stratification in follicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-737353 Silverchair:36522 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The promises and challenges of using gene mutations for patient stratification in follicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-737353 Silverchair:36522 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The promises and challenges of using gene mutations for patient stratification in follicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-737353 Silverchair:36522 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The promises and challenges of using gene mutations for patient stratification in follicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2017-07-737353 Silverchair:36522 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002731 Silverchair:474240 Total_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002731 Silverchair:474240 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002731 Silverchair:474240 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002731 Silverchair:474240 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128871 Silverchair:428007 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128871 Silverchair:428007 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128871 Silverchair:428007 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128871 Silverchair:428007 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The Pulmonary Metatranscriptome Prior to Pediatric Hematopoietic Cell Transplantation Identifies Post-HCT Lung Injury The American Society of Hematology American Society of Hematology 10.1182/blood.2020009246 Silverchair:474777 Total_Item_Investigations 30 18 5 7 0 0 0 0 0 0 0 0 0 The Pulmonary Metatranscriptome Prior to Pediatric Hematopoietic Cell Transplantation Identifies Post-HCT Lung Injury The American Society of Hematology American Society of Hematology 10.1182/blood.2020009246 Silverchair:474777 Total_Item_Requests 11 7 1 3 0 0 0 0 0 0 0 0 0 The Pulmonary Metatranscriptome Prior to Pediatric Hematopoietic Cell Transplantation Identifies Post-HCT Lung Injury The American Society of Hematology American Society of Hematology 10.1182/blood.2020009246 Silverchair:474777 Unique_Item_Investigations 5 2 1 2 0 0 0 0 0 0 0 0 0 The Pulmonary Metatranscriptome Prior to Pediatric Hematopoietic Cell Transplantation Identifies Post-HCT Lung Injury The American Society of Hematology American Society of Hematology 10.1182/blood.2020009246 Silverchair:474777 Unique_Item_Requests 5 2 1 2 0 0 0 0 0 0 0 0 0 "The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-132405 Silverchair:428840 Total_Item_Investigations 8 5 3 0 0 0 0 0 0 0 0 0 0 "The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-132405 Silverchair:428840 Total_Item_Requests 8 5 3 0 0 0 0 0 0 0 0 0 0 "The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-132405 Silverchair:428840 Unique_Item_Investigations 8 5 3 0 0 0 0 0 0 0 0 0 0 "The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-132405 Silverchair:428840 Unique_Item_Requests 8 5 3 0 0 0 0 0 0 0 0 0 0 The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-247411 Silverchair:27260 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-247411 Silverchair:27260 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-247411 Silverchair:27260 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-247411 Silverchair:27260 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "The relationship between ABO blood group, von Willebrand factor, and primary hemostasis" The American Society of Hematology American Society of Hematology 10.1182/blood.2020005843 Silverchair:461790 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 "The relationship between ABO blood group, von Willebrand factor, and primary hemostasis" The American Society of Hematology American Society of Hematology 10.1182/blood.2020005843 Silverchair:461790 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 "The relationship between ABO blood group, von Willebrand factor, and primary hemostasis" The American Society of Hematology American Society of Hematology 10.1182/blood.2020005843 Silverchair:461790 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "The relationship between ABO blood group, von Willebrand factor, and primary hemostasis" The American Society of Hematology American Society of Hematology 10.1182/blood.2020005843 Silverchair:461790 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-02-205807 Silverchair:26038 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-02-205807 Silverchair:26038 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-02-205807 Silverchair:26038 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-02-205807 Silverchair:26038 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The relative role of PLCβ and PI3Kγ in platelet activation The American Society of Hematology American Society of Hematology 10.1182/blood-2004-05-2005 Silverchair:103185 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 The relative role of PLCβ and PI3Kγ in platelet activation The American Society of Hematology American Society of Hematology 10.1182/blood-2004-05-2005 Silverchair:103185 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 The relative role of PLCβ and PI3Kγ in platelet activation The American Society of Hematology American Society of Hematology 10.1182/blood-2004-05-2005 Silverchair:103185 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 The relative role of PLCβ and PI3Kγ in platelet activation The American Society of Hematology American Society of Hematology 10.1182/blood-2004-05-2005 Silverchair:103185 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 The replication rate of human hematopoietic stem cells in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-303537 Silverchair:20856 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 The replication rate of human hematopoietic stem cells in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-303537 Silverchair:20856 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 The replication rate of human hematopoietic stem cells in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-303537 Silverchair:20856 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 The replication rate of human hematopoietic stem cells in vivo The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-303537 Silverchair:20856 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-038257 Silverchair:23212 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-038257 Silverchair:23212 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-038257 Silverchair:23212 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-038257 Silverchair:23212 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 The Rh blood group system: a review The American Society of Hematology American Society of Hematology 10.1182/blood.V95.2.375 Silverchair:138582 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The Rh blood group system: a review The American Society of Hematology American Society of Hematology 10.1182/blood.V95.2.375 Silverchair:138582 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The Rh blood group system: a review The American Society of Hematology American Society of Hematology 10.1182/blood.V95.2.375 Silverchair:138582 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The Rh blood group system: a review The American Society of Hematology American Society of Hematology 10.1182/blood.V95.2.375 Silverchair:138582 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The RING study: A Randomized Controlled Trial of GCSF-stimulated Granulocytes in Granulocytopenic Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.SCI-16.SCI-16 Silverchair:101736 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The RING study: A Randomized Controlled Trial of GCSF-stimulated Granulocytes in Granulocytopenic Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.SCI-16.SCI-16 Silverchair:101736 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The RING study: A Randomized Controlled Trial of GCSF-stimulated Granulocytes in Granulocytopenic Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.SCI-16.SCI-16 Silverchair:101736 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The RING study: A Randomized Controlled Trial of GCSF-stimulated Granulocytes in Granulocytopenic Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.SCI-16.SCI-16 Silverchair:101736 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The rise of a new “great teacher” The American Society of Hematology American Society of Hematology 10.1182/blood.2021011754 Silverchair:476388 Total_Item_Investigations 4 0 0 0 0 0 0 1 2 0 0 1 0 The rise of a new “great teacher” The American Society of Hematology American Society of Hematology 10.1182/blood.2021011754 Silverchair:476388 Total_Item_Requests 4 0 0 0 0 0 0 1 2 0 0 1 0 The rise of a new “great teacher” The American Society of Hematology American Society of Hematology 10.1182/blood.2021011754 Silverchair:476388 Unique_Item_Investigations 4 0 0 0 0 0 0 1 2 0 0 1 0 The rise of a new “great teacher” The American Society of Hematology American Society of Hematology 10.1182/blood.2021011754 Silverchair:476388 Unique_Item_Requests 4 0 0 0 0 0 0 1 2 0 0 1 0 The RNA Splicing Factor U2AF1 Controls Hematopoietic Stem Cell Survival and Function The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143163 Silverchair:470702 Total_Item_Investigations 2 0 0 0 1 1 0 0 0 0 0 0 0 The RNA Splicing Factor U2AF1 Controls Hematopoietic Stem Cell Survival and Function The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143163 Silverchair:470702 Total_Item_Requests 2 0 0 0 1 1 0 0 0 0 0 0 0 The RNA Splicing Factor U2AF1 Controls Hematopoietic Stem Cell Survival and Function The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143163 Silverchair:470702 Unique_Item_Investigations 2 0 0 0 1 1 0 0 0 0 0 0 0 The RNA Splicing Factor U2AF1 Controls Hematopoietic Stem Cell Survival and Function The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143163 Silverchair:470702 Unique_Item_Requests 2 0 0 0 1 1 0 0 0 0 0 0 0 The Role of Kdm6a in Malignant Hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1227.1227 Silverchair:116189 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The Role of Kdm6a in Malignant Hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1227.1227 Silverchair:116189 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The Role of Kdm6a in Malignant Hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1227.1227 Silverchair:116189 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The Role of Kdm6a in Malignant Hematopoiesis The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.1227.1227 Silverchair:116189 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "The role of apoptosis, proliferation, and the Bcl-2–related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS" The American Society of Hematology American Society of Hematology 10.1182/blood.V96.12.3932 Silverchair:256679 Total_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 "The role of apoptosis, proliferation, and the Bcl-2–related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS" The American Society of Hematology American Society of Hematology 10.1182/blood.V96.12.3932 Silverchair:256679 Total_Item_Requests 3 2 0 1 0 0 0 0 0 0 0 0 0 "The role of apoptosis, proliferation, and the Bcl-2–related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS" The American Society of Hematology American Society of Hematology 10.1182/blood.V96.12.3932 Silverchair:256679 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 "The role of apoptosis, proliferation, and the Bcl-2–related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS" The American Society of Hematology American Society of Hematology 10.1182/blood.V96.12.3932 Silverchair:256679 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 The role of aurora A and polo-like kinases in high-risk lymphomas American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000232 Silverchair:246690 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The role of aurora A and polo-like kinases in high-risk lymphomas American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000232 Silverchair:246690 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The role of aurora A and polo-like kinases in high-risk lymphomas American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000232 Silverchair:246690 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The role of aurora A and polo-like kinases in high-risk lymphomas American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000232 Silverchair:246690 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The Role of CBFβ in T Cell Development. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.3234.3234 Silverchair:77587 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The Role of CBFβ in T Cell Development. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.3234.3234 Silverchair:77587 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The Role of CBFβ in T Cell Development. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.3234.3234 Silverchair:77587 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The Role of CBFβ in T Cell Development. The American Society of Hematology American Society of Hematology 10.1182/blood.V104.11.3234.3234 Silverchair:77587 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The role of hematologists in a changing United States health care system The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-615047 Silverchair:33743 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 The role of hematologists in a changing United States health care system The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-615047 Silverchair:33743 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 The role of hematologists in a changing United States health care system The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-615047 Silverchair:33743 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 The role of hematologists in a changing United States health care system The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-615047 Silverchair:33743 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 The role of rituximab in adults with warm antibody autoimmune hemolytic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-588392 Silverchair:33992 Total_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 The role of rituximab in adults with warm antibody autoimmune hemolytic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-588392 Silverchair:33992 Total_Item_Requests 3 2 0 1 0 0 0 0 0 0 0 0 0 The role of rituximab in adults with warm antibody autoimmune hemolytic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-588392 Silverchair:33992 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 The role of rituximab in adults with warm antibody autoimmune hemolytic anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-588392 Silverchair:33992 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-559211 Silverchair:33786 Total_Item_Investigations 3 1 0 0 0 0 0 0 0 0 0 0 2 The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-559211 Silverchair:33786 Total_Item_Requests 3 1 0 0 0 0 0 0 0 0 0 0 2 The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-559211 Silverchair:33786 Unique_Item_Investigations 2 1 0 0 0 0 0 0 0 0 0 0 1 The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-559211 Silverchair:33786 Unique_Item_Requests 2 1 0 0 0 0 0 0 0 0 0 0 1 The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-567784 Silverchair:34010 Total_Item_Investigations 5 0 0 0 0 5 0 0 0 0 0 0 0 The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-567784 Silverchair:34010 Total_Item_Requests 5 0 0 0 0 5 0 0 0 0 0 0 0 The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-567784 Silverchair:34010 Unique_Item_Investigations 3 0 0 0 0 3 0 0 0 0 0 0 0 The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century The American Society of Hematology American Society of Hematology 10.1182/blood-2014-10-567784 Silverchair:34010 Unique_Item_Requests 3 0 0 0 0 3 0 0 0 0 0 0 0 The role of the annexin A2 heterotetramer in vascular fibrinolysis The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-334672 Silverchair:29308 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The role of the annexin A2 heterotetramer in vascular fibrinolysis The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-334672 Silverchair:29308 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The role of the annexin A2 heterotetramer in vascular fibrinolysis The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-334672 Silverchair:29308 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The role of the annexin A2 heterotetramer in vascular fibrinolysis The American Society of Hematology American Society of Hematology 10.1182/blood-2011-06-334672 Silverchair:29308 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "The Role of Upfront Autologous Hematopoietic Cell Transplantation in the Treatment of Mantle Cell Lymphoma, a Population Based Study Using the National Cancer Data Base (NCDB)" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2009.2009 Silverchair:71389 Total_Item_Investigations 2 0 0 0 0 0 1 1 0 0 0 0 0 "The Role of Upfront Autologous Hematopoietic Cell Transplantation in the Treatment of Mantle Cell Lymphoma, a Population Based Study Using the National Cancer Data Base (NCDB)" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2009.2009 Silverchair:71389 Total_Item_Requests 2 0 0 0 0 0 1 1 0 0 0 0 0 "The Role of Upfront Autologous Hematopoietic Cell Transplantation in the Treatment of Mantle Cell Lymphoma, a Population Based Study Using the National Cancer Data Base (NCDB)" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2009.2009 Silverchair:71389 Unique_Item_Investigations 2 0 0 0 0 0 1 1 0 0 0 0 0 "The Role of Upfront Autologous Hematopoietic Cell Transplantation in the Treatment of Mantle Cell Lymphoma, a Population Based Study Using the National Cancer Data Base (NCDB)" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2009.2009 Silverchair:71389 Unique_Item_Requests 2 0 0 0 0 0 1 1 0 0 0 0 0 The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003259 Silverchair:475250 Total_Item_Investigations 5 0 0 5 0 0 0 0 0 0 0 0 0 The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003259 Silverchair:475250 Total_Item_Requests 5 0 0 5 0 0 0 0 0 0 0 0 0 The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003259 Silverchair:475250 Unique_Item_Investigations 5 0 0 5 0 0 0 0 0 0 0 0 0 The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003259 Silverchair:475250 Unique_Item_Requests 5 0 0 5 0 0 0 0 0 0 0 0 0 "The Schedule Dependent Combination of Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) and Prednisone (P) Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome Inhibitor, in Patients with Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders." The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.2759.2759 Silverchair:128927 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "The Schedule Dependent Combination of Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) and Prednisone (P) Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome Inhibitor, in Patients with Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders." The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.2759.2759 Silverchair:128927 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "The Schedule Dependent Combination of Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) and Prednisone (P) Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome Inhibitor, in Patients with Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders." The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.2759.2759 Silverchair:128927 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "The Schedule Dependent Combination of Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) and Prednisone (P) Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome Inhibitor, in Patients with Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders." The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.2759.2759 Silverchair:128927 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The sensing of poorly deformable red blood cells by the human spleen can be mimicked in vitro The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-312801 Silverchair:28447 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 The sensing of poorly deformable red blood cells by the human spleen can be mimicked in vitro The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-312801 Silverchair:28447 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 The sensing of poorly deformable red blood cells by the human spleen can be mimicked in vitro The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-312801 Silverchair:28447 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The sensing of poorly deformable red blood cells by the human spleen can be mimicked in vitro The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-312801 Silverchair:28447 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The significance of autoantibodies against β2-glycoprotein I The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-378646 Silverchair:30377 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The significance of autoantibodies against β2-glycoprotein I The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-378646 Silverchair:30377 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The significance of autoantibodies against β2-glycoprotein I The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-378646 Silverchair:30377 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The significance of autoantibodies against β2-glycoprotein I The American Society of Hematology American Society of Hematology 10.1182/blood-2012-03-378646 Silverchair:30377 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "The Significance of Leukocytosis in Malignancies: A Novel Paradigm Between Leukocytosis, G-CSF, Myeloid-Derived Suppressor Cells and Prognosis" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117484 Silverchair:262048 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 "The Significance of Leukocytosis in Malignancies: A Novel Paradigm Between Leukocytosis, G-CSF, Myeloid-Derived Suppressor Cells and Prognosis" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117484 Silverchair:262048 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 "The Significance of Leukocytosis in Malignancies: A Novel Paradigm Between Leukocytosis, G-CSF, Myeloid-Derived Suppressor Cells and Prognosis" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117484 Silverchair:262048 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 "The Significance of Leukocytosis in Malignancies: A Novel Paradigm Between Leukocytosis, G-CSF, Myeloid-Derived Suppressor Cells and Prognosis" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117484 Silverchair:262048 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 The Significance of Unexplained Macrocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.3449.3449 Silverchair:60287 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 The Significance of Unexplained Macrocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.3449.3449 Silverchair:60287 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 The Significance of Unexplained Macrocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.3449.3449 Silverchair:60287 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 The Significance of Unexplained Macrocytosis The American Society of Hematology American Society of Hematology 10.1182/blood.V112.11.3449.3449 Silverchair:60287 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases The American Society of Hematology American Society of Hematology 10.1182/blood-2009-04-215368 Silverchair:124927 Total_Item_Investigations 5 2 0 0 0 0 0 0 3 0 0 0 0 The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases The American Society of Hematology American Society of Hematology 10.1182/blood-2009-04-215368 Silverchair:124927 Total_Item_Requests 5 2 0 0 0 0 0 0 3 0 0 0 0 The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases The American Society of Hematology American Society of Hematology 10.1182/blood-2009-04-215368 Silverchair:124927 Unique_Item_Investigations 4 2 0 0 0 0 0 0 2 0 0 0 0 The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases The American Society of Hematology American Society of Hematology 10.1182/blood-2009-04-215368 Silverchair:124927 Unique_Item_Requests 4 2 0 0 0 0 0 0 2 0 0 0 0 The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance The American Society of Hematology American Society of Hematology 10.1182/blood-2015-12-624304 Silverchair:34947 Total_Item_Investigations 4 0 0 4 0 0 0 0 0 0 0 0 0 The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance The American Society of Hematology American Society of Hematology 10.1182/blood-2015-12-624304 Silverchair:34947 Total_Item_Requests 4 0 0 4 0 0 0 0 0 0 0 0 0 The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance The American Society of Hematology American Society of Hematology 10.1182/blood-2015-12-624304 Silverchair:34947 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance The American Society of Hematology American Society of Hematology 10.1182/blood-2015-12-624304 Silverchair:34947 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The spleen is a major site of megakaryopoiesis following transplantation of murine hematopoietic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2002-02-0490 Silverchair:88290 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 The spleen is a major site of megakaryopoiesis following transplantation of murine hematopoietic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2002-02-0490 Silverchair:88290 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The spleen is a major site of megakaryopoiesis following transplantation of murine hematopoietic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2002-02-0490 Silverchair:88290 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The spleen is a major site of megakaryopoiesis following transplantation of murine hematopoietic stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2002-02-0490 Silverchair:88290 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The STAT3-MYC Axis Promotes Survival of Leukemia Stem Cells by Regulating SLC1A5 and Oxidative Phosphorylation The American Society of Hematology American Society of Hematology 10.1182/blood.2021013201 Silverchair:476917 No_License 1 0 0 0 0 0 0 0 0 1 0 0 0 The STAT3-MYC Axis Promotes Survival of Leukemia Stem Cells by Regulating SLC1A5 and Oxidative Phosphorylation The American Society of Hematology American Society of Hematology 10.1182/blood.2021013201 Silverchair:476917 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 3 0 0 0 The STAT3-MYC Axis Promotes Survival of Leukemia Stem Cells by Regulating SLC1A5 and Oxidative Phosphorylation The American Society of Hematology American Society of Hematology 10.1182/blood.2021013201 Silverchair:476917 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-255232 Silverchair:20411 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-255232 Silverchair:20411 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-255232 Silverchair:20411 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors The American Society of Hematology American Society of Hematology 10.1182/blood-2009-11-255232 Silverchair:20411 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002049 Silverchair:464034 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002049 Silverchair:464034 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002049 Silverchair:464034 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1 American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002049 Silverchair:464034 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The t(1;22) (p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group Study The American Society of Hematology American Society of Hematology 10.1182/blood.V78.3.748.748 Silverchair:173182 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The t(1;22) (p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group Study The American Society of Hematology American Society of Hematology 10.1182/blood.V78.3.748.748 Silverchair:173182 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The t(1;22) (p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group Study The American Society of Hematology American Society of Hematology 10.1182/blood.V78.3.748.748 Silverchair:173182 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The t(1;22) (p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group Study The American Society of Hematology American Society of Hematology 10.1182/blood.V78.3.748.748 Silverchair:173182 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The Tao of myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-578732 Silverchair:33040 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 The Tao of myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-578732 Silverchair:33040 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 The Tao of myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-578732 Silverchair:33040 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 The Tao of myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-578732 Silverchair:33040 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 The target-specific oral anticoagulants: practical considerations The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.510 Silverchair:20440 Total_Item_Investigations 4 0 0 0 0 0 0 0 0 2 2 0 0 The target-specific oral anticoagulants: practical considerations The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.510 Silverchair:20440 Total_Item_Requests 4 0 0 0 0 0 0 0 0 2 2 0 0 The target-specific oral anticoagulants: practical considerations The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.510 Silverchair:20440 Unique_Item_Investigations 2 0 0 0 0 0 0 0 0 1 1 0 0 The target-specific oral anticoagulants: practical considerations The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.510 Silverchair:20440 Unique_Item_Requests 2 0 0 0 0 0 0 0 0 1 1 0 0 The thin line between CML and CMML The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-763565 Silverchair:35940 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 The thin line between CML and CMML The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-763565 Silverchair:35940 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 The thin line between CML and CMML The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-763565 Silverchair:35940 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 The thin line between CML and CMML The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-763565 Silverchair:35940 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 The Tie-2 ligand Angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies The American Society of Hematology American Society of Hematology 10.1182/blood-2003-10-3685 Silverchair:17902 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 The Tie-2 ligand Angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies The American Society of Hematology American Society of Hematology 10.1182/blood-2003-10-3685 Silverchair:17902 Total_Item_Requests 4 0 4 0 0 0 0 0 0 0 0 0 0 The Tie-2 ligand Angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies The American Society of Hematology American Society of Hematology 10.1182/blood-2003-10-3685 Silverchair:17902 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The Tie-2 ligand Angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies The American Society of Hematology American Society of Hematology 10.1182/blood-2003-10-3685 Silverchair:17902 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The transcription factor Gli3 regulates differentiation of fetal CD4–CD8– double-negative thymocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-0998 Silverchair:21543 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The transcription factor Gli3 regulates differentiation of fetal CD4–CD8– double-negative thymocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-0998 Silverchair:21543 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The transcription factor Gli3 regulates differentiation of fetal CD4–CD8– double-negative thymocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-0998 Silverchair:21543 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 The transcription factor Gli3 regulates differentiation of fetal CD4–CD8– double-negative thymocytes The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-0998 Silverchair:21543 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 The transmembrane protein disulfide isomerase TMX1 negatively regulates platelet responses The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-844480 Silverchair:261416 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The transmembrane protein disulfide isomerase TMX1 negatively regulates platelet responses The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-844480 Silverchair:261416 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The transmembrane protein disulfide isomerase TMX1 negatively regulates platelet responses The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-844480 Silverchair:261416 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The transmembrane protein disulfide isomerase TMX1 negatively regulates platelet responses The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-844480 Silverchair:261416 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The Use of Anticoagulation in Patients With Thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/hem.V15.3.8503 Silverchair:463004 Total_Item_Investigations 4 3 1 0 0 0 0 0 0 0 0 0 0 The Use of Anticoagulation in Patients With Thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/hem.V15.3.8503 Silverchair:463004 Total_Item_Requests 4 3 1 0 0 0 0 0 0 0 0 0 0 The Use of Anticoagulation in Patients With Thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/hem.V15.3.8503 Silverchair:463004 Unique_Item_Investigations 4 3 1 0 0 0 0 0 0 0 0 0 0 The Use of Anticoagulation in Patients With Thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/hem.V15.3.8503 Silverchair:463004 Unique_Item_Requests 4 3 1 0 0 0 0 0 0 0 0 0 0 The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018019414 Silverchair:16249 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018019414 Silverchair:16249 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018019414 Silverchair:16249 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018019414 Silverchair:16249 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.2021012479 Silverchair:476244 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 The use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.2021012479 Silverchair:476244 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 The use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.2021012479 Silverchair:476244 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 The use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood.2021012479 Silverchair:476244 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 The use of luspatercept for thalassemia in adults American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002725 Silverchair:474891 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 The use of luspatercept for thalassemia in adults American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002725 Silverchair:474891 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 The use of luspatercept for thalassemia in adults American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002725 Silverchair:474891 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The use of luspatercept for thalassemia in adults American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002725 Silverchair:474891 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The Usefulness of CD71 Expression by Flow Cytometry in the Diagnosis of Acute Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.2533.2533 Silverchair:112812 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The Usefulness of CD71 Expression by Flow Cytometry in the Diagnosis of Acute Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.2533.2533 Silverchair:112812 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The Usefulness of CD71 Expression by Flow Cytometry in the Diagnosis of Acute Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.2533.2533 Silverchair:112812 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The Usefulness of CD71 Expression by Flow Cytometry in the Diagnosis of Acute Leukemia. The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.2533.2533 Silverchair:112812 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2005-05-2087 Silverchair:21812 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2005-05-2087 Silverchair:21812 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2005-05-2087 Silverchair:21812 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2005-05-2087 Silverchair:21812 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2003-07-2315 Silverchair:131402 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2003-07-2315 Silverchair:131402 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2003-07-2315 Silverchair:131402 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2003-07-2315 Silverchair:131402 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 The VIALE-C Trial: Venetoclax and Low-dose Cytarabine in Older Patients With AML American Society of Hematology American Society of Hematology Silverchair:464069 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 The VIALE-C Trial: Venetoclax and Low-dose Cytarabine in Older Patients With AML American Society of Hematology American Society of Hematology Silverchair:464069 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 The VIALE-C Trial: Venetoclax and Low-dose Cytarabine in Older Patients With AML American Society of Hematology American Society of Hematology Silverchair:464069 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 The VIALE-C Trial: Venetoclax and Low-dose Cytarabine in Older Patients With AML American Society of Hematology American Society of Hematology Silverchair:464069 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 The von Willebrand factor Tyr2561 allele is a gain-of-function variant and a risk factor for early myocardial infarction The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-843425 Silverchair:272775 Total_Item_Investigations 5 0 5 0 0 0 0 0 0 0 0 0 0 The von Willebrand factor Tyr2561 allele is a gain-of-function variant and a risk factor for early myocardial infarction The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-843425 Silverchair:272775 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 The von Willebrand factor Tyr2561 allele is a gain-of-function variant and a risk factor for early myocardial infarction The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-843425 Silverchair:272775 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 The von Willebrand factor Tyr2561 allele is a gain-of-function variant and a risk factor for early myocardial infarction The American Society of Hematology American Society of Hematology 10.1182/blood-2018-04-843425 Silverchair:272775 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 The Way Things Work: Thrombin American Society of Hematology American Society of Hematology 10.1182/hem.V8.4.1250 Silverchair:462434 Total_Item_Investigations 3 1 0 2 0 0 0 0 0 0 0 0 0 The Way Things Work: Thrombin American Society of Hematology American Society of Hematology 10.1182/hem.V8.4.1250 Silverchair:462434 Total_Item_Requests 3 1 0 2 0 0 0 0 0 0 0 0 0 The Way Things Work: Thrombin American Society of Hematology American Society of Hematology 10.1182/hem.V8.4.1250 Silverchair:462434 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 The Way Things Work: Thrombin American Society of Hematology American Society of Hematology 10.1182/hem.V8.4.1250 Silverchair:462434 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 The winding road toward the myeloma mouse The American Society of Hematology American Society of Hematology 10.1182/blood.2020007942 Silverchair:474800 Total_Item_Investigations 3 0 0 0 0 2 0 1 0 0 0 0 0 The winding road toward the myeloma mouse The American Society of Hematology American Society of Hematology 10.1182/blood.2020007942 Silverchair:474800 Total_Item_Requests 3 0 0 0 0 2 0 1 0 0 0 0 0 The winding road toward the myeloma mouse The American Society of Hematology American Society of Hematology 10.1182/blood.2020007942 Silverchair:474800 Unique_Item_Investigations 2 0 0 0 0 1 0 1 0 0 0 0 0 The winding road toward the myeloma mouse The American Society of Hematology American Society of Hematology 10.1182/blood.2020007942 Silverchair:474800 Unique_Item_Requests 2 0 0 0 0 1 0 1 0 0 0 0 0 The β-tail domain (βTD) regulates physiologic ligand binding to integrin CD11b/CD18 The American Society of Hematology American Society of Hematology 10.1182/blood-2005-11-056689 Silverchair:23744 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 The β-tail domain (βTD) regulates physiologic ligand binding to integrin CD11b/CD18 The American Society of Hematology American Society of Hematology 10.1182/blood-2005-11-056689 Silverchair:23744 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 The β-tail domain (βTD) regulates physiologic ligand binding to integrin CD11b/CD18 The American Society of Hematology American Society of Hematology 10.1182/blood-2005-11-056689 Silverchair:23744 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 The β-tail domain (βTD) regulates physiologic ligand binding to integrin CD11b/CD18 The American Society of Hematology American Society of Hematology 10.1182/blood-2005-11-056689 Silverchair:23744 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2011-09-379214 Silverchair:30399 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2011-09-379214 Silverchair:30399 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2011-09-379214 Silverchair:30399 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling The American Society of Hematology American Society of Hematology 10.1182/blood-2011-09-379214 Silverchair:30399 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Therapeutic development and current uses of BCL-2 inhibition The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000154 Silverchair:474293 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Therapeutic development and current uses of BCL-2 inhibition The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000154 Silverchair:474293 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Therapeutic development and current uses of BCL-2 inhibition The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000154 Silverchair:474293 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Therapeutic development and current uses of BCL-2 inhibition The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000154 Silverchair:474293 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Therapy for lower-risk MDS The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000127 Silverchair:474325 Total_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Therapy for lower-risk MDS The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000127 Silverchair:474325 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Therapy for lower-risk MDS The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000127 Silverchair:474325 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 Therapy for lower-risk MDS The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000127 Silverchair:474325 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-455774 Silverchair:125577 Total_Item_Investigations 6 4 0 2 0 0 0 0 0 0 0 0 0 Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-455774 Silverchair:125577 Total_Item_Requests 6 4 0 2 0 0 0 0 0 0 0 0 0 Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-455774 Silverchair:125577 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-455774 Silverchair:125577 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-765057 Silverchair:107626 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-765057 Silverchair:107626 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-765057 Silverchair:107626 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial The American Society of Hematology American Society of Hematology 10.1182/blood-2017-01-765057 Silverchair:107626 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Therapy-Related AML (t-AML), a Heterogeneous Disease: Multicenter Analysis on Biological and Clinical Differences between Cases Following Breast Cancer and Lymphoma Treatment" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138866 Silverchair:473361 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 "Therapy-Related AML (t-AML), a Heterogeneous Disease: Multicenter Analysis on Biological and Clinical Differences between Cases Following Breast Cancer and Lymphoma Treatment" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138866 Silverchair:473361 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 "Therapy-Related AML (t-AML), a Heterogeneous Disease: Multicenter Analysis on Biological and Clinical Differences between Cases Following Breast Cancer and Lymphoma Treatment" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138866 Silverchair:473361 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 "Therapy-Related AML (t-AML), a Heterogeneous Disease: Multicenter Analysis on Biological and Clinical Differences between Cases Following Breast Cancer and Lymphoma Treatment" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138866 Silverchair:473361 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: a report from the Children's Oncology Group The American Society of Hematology American Society of Hematology 10.1182/blood-2006-01-023101 Silverchair:117125 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: a report from the Children's Oncology Group The American Society of Hematology American Society of Hematology 10.1182/blood-2006-01-023101 Silverchair:117125 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: a report from the Children's Oncology Group The American Society of Hematology American Society of Hematology 10.1182/blood-2006-01-023101 Silverchair:117125 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: a report from the Children's Oncology Group The American Society of Hematology American Society of Hematology 10.1182/blood-2006-01-023101 Silverchair:117125 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Think of HIT The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.408 Silverchair:19776 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Think of HIT The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.408 Silverchair:19776 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Think of HIT The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.408 Silverchair:19776 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Think of HIT The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.408 Silverchair:19776 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Three decades of transplantation for chronic myeloid leukemia: what have we learned? The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-301341 Silverchair:125492 Total_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 Three decades of transplantation for chronic myeloid leukemia: what have we learned? The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-301341 Silverchair:125492 Total_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 Three decades of transplantation for chronic myeloid leukemia: what have we learned? The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-301341 Silverchair:125492 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Three decades of transplantation for chronic myeloid leukemia: what have we learned? The American Society of Hematology American Society of Hematology 10.1182/blood-2010-08-301341 Silverchair:125492 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Three-Dimensional Telomere Analysis Using Teloview® Technology Identifies Smouldering Myeloma Patients with High Risk of Progression to Full Stage Multiple Myeloma in a Proof of Concept Cohort The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140612 Silverchair:473649 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Three-Dimensional Telomere Analysis Using Teloview® Technology Identifies Smouldering Myeloma Patients with High Risk of Progression to Full Stage Multiple Myeloma in a Proof of Concept Cohort The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140612 Silverchair:473649 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Three-Dimensional Telomere Analysis Using Teloview® Technology Identifies Smouldering Myeloma Patients with High Risk of Progression to Full Stage Multiple Myeloma in a Proof of Concept Cohort The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140612 Silverchair:473649 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Three-Dimensional Telomere Analysis Using Teloview® Technology Identifies Smouldering Myeloma Patients with High Risk of Progression to Full Stage Multiple Myeloma in a Proof of Concept Cohort The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140612 Silverchair:473649 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Thrombocytopenia in pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-781971 Silverchair:36666 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Thrombocytopenia in pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-781971 Silverchair:36666 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Thrombocytopenia in pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-781971 Silverchair:36666 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Thrombocytopenia in pregnancy The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-781971 Silverchair:36666 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Thrombocytopenia in pregnancy The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.144 Silverchair:21061 Total_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Thrombocytopenia in pregnancy The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.144 Silverchair:21061 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Thrombocytopenia in pregnancy The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.144 Silverchair:21061 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Thrombocytopenia in pregnancy The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.144 Silverchair:21061 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Thrombocytopenia in pregnancy: is this immune thrombocytopenia or…? The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.198.3798874 Silverchair:84342 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Thrombocytopenia in pregnancy: is this immune thrombocytopenia or…? The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.198.3798874 Silverchair:84342 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Thrombocytopenia in pregnancy: is this immune thrombocytopenia or…? The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.198.3798874 Silverchair:84342 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Thrombocytopenia in pregnancy: is this immune thrombocytopenia or…? The American Society of Hematology American Society of Hematology 10.1182/asheducation.V2012.1.198.3798874 Silverchair:84342 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Thrombocytosis The American Society of Hematology American Society of Hematology 10.1182/asheducation-2009.1.159 Silverchair:19826 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Thrombocytosis The American Society of Hematology American Society of Hematology 10.1182/asheducation-2009.1.159 Silverchair:19826 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Thrombocytosis The American Society of Hematology American Society of Hematology 10.1182/asheducation-2009.1.159 Silverchair:19826 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Thrombocytosis The American Society of Hematology American Society of Hematology 10.1182/asheducation-2009.1.159 Silverchair:19826 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Thrombocytosis and Thrombosis The American Society of Hematology American Society of Hematology 10.1182/asheducation-2007.1.363 Silverchair:19181 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 2 0 0 0 Thrombocytosis and Thrombosis The American Society of Hematology American Society of Hematology 10.1182/asheducation-2007.1.363 Silverchair:19181 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Thrombocytosis and Thrombosis The American Society of Hematology American Society of Hematology 10.1182/asheducation-2007.1.363 Silverchair:19181 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Thrombocytosis and Thrombosis The American Society of Hematology American Society of Hematology 10.1182/asheducation-2007.1.363 Silverchair:19181 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Thrombocytosis as a Presenting Feature in Myelodysplastic Syndromes (MDS) in Adults - 40 Year Experience from a Single Institution in the USA. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.4831.4831 Silverchair:129392 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Thrombocytosis as a Presenting Feature in Myelodysplastic Syndromes (MDS) in Adults - 40 Year Experience from a Single Institution in the USA. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.4831.4831 Silverchair:129392 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Thrombocytosis as a Presenting Feature in Myelodysplastic Syndromes (MDS) in Adults - 40 Year Experience from a Single Institution in the USA. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.4831.4831 Silverchair:129392 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Thrombocytosis as a Presenting Feature in Myelodysplastic Syndromes (MDS) in Adults - 40 Year Experience from a Single Institution in the USA. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.4831.4831 Silverchair:129392 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Thrombocytosis in Iron Deficiency Anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119352 Silverchair:262007 Total_Item_Investigations 4 3 0 0 1 0 0 0 0 0 0 0 0 Thrombocytosis in Iron Deficiency Anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119352 Silverchair:262007 Total_Item_Requests 4 3 0 0 1 0 0 0 0 0 0 0 0 Thrombocytosis in Iron Deficiency Anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119352 Silverchair:262007 Unique_Item_Investigations 2 1 0 0 1 0 0 0 0 0 0 0 0 Thrombocytosis in Iron Deficiency Anemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119352 Silverchair:262007 Unique_Item_Requests 2 1 0 0 1 0 0 0 0 0 0 0 0 "Thromboembolic Events, Recurrent Gastrointestinal Bleeding and Mortality after Resuming Anticoagulant Following Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2799.2799 Silverchair:96619 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Thromboembolic Events, Recurrent Gastrointestinal Bleeding and Mortality after Resuming Anticoagulant Following Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2799.2799 Silverchair:96619 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Thromboembolic Events, Recurrent Gastrointestinal Bleeding and Mortality after Resuming Anticoagulant Following Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2799.2799 Silverchair:96619 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Thromboembolic Events, Recurrent Gastrointestinal Bleeding and Mortality after Resuming Anticoagulant Following Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.2799.2799 Silverchair:96619 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis" The American Society of Hematology American Society of Hematology 10.1182/blood-2005-09-3578 Silverchair:132046 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis" The American Society of Hematology American Society of Hematology 10.1182/blood-2005-09-3578 Silverchair:132046 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis" The American Society of Hematology American Society of Hematology 10.1182/blood-2005-09-3578 Silverchair:132046 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis" The American Society of Hematology American Society of Hematology 10.1182/blood-2005-09-3578 Silverchair:132046 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Thrombopoietin (TPO)-Receptor Agonists In Myelodysplastic Syndromes (MDS): A Systematic Review and Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.2806.2806 Silverchair:13435 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Thrombopoietin (TPO)-Receptor Agonists In Myelodysplastic Syndromes (MDS): A Systematic Review and Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.2806.2806 Silverchair:13435 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Thrombopoietin (TPO)-Receptor Agonists In Myelodysplastic Syndromes (MDS): A Systematic Review and Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.2806.2806 Silverchair:13435 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Thrombopoietin (TPO)-Receptor Agonists In Myelodysplastic Syndromes (MDS): A Systematic Review and Meta-Analysis The American Society of Hematology American Society of Hematology 10.1182/blood.V122.21.2806.2806 Silverchair:13435 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Thrombopoietin receptor agonists as an emergency treatment for severe newly diagnosed immune thrombocytopenia in children The American Society of Hematology American Society of Hematology 10.1182/blood.2020006807 Silverchair:463991 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Thrombopoietin receptor agonists as an emergency treatment for severe newly diagnosed immune thrombocytopenia in children The American Society of Hematology American Society of Hematology 10.1182/blood.2020006807 Silverchair:463991 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Thrombopoietin receptor agonists as an emergency treatment for severe newly diagnosed immune thrombocytopenia in children The American Society of Hematology American Society of Hematology 10.1182/blood.2020006807 Silverchair:463991 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Thrombopoietin receptor agonists as an emergency treatment for severe newly diagnosed immune thrombocytopenia in children The American Society of Hematology American Society of Hematology 10.1182/blood.2020006807 Silverchair:463991 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Thrombosis and anticoagulation in the setting of renal or liver disease The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.188 Silverchair:21057 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Thrombosis and anticoagulation in the setting of renal or liver disease The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.188 Silverchair:21057 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Thrombosis and anticoagulation in the setting of renal or liver disease The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.188 Silverchair:21057 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Thrombosis and anticoagulation in the setting of renal or liver disease The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.188 Silverchair:21057 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Thrombosis and thrombophilia American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter09 Silverchair:74639 No_License 10 2 3 4 0 0 0 0 1 0 0 0 0 Thrombosis and thrombophilia American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter09 Silverchair:74639 Total_Item_Investigations 33 2 3 5 7 4 1 3 4 4 0 0 0 Thrombosis and thrombophilia American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter09 Silverchair:74639 Unique_Item_Investigations 23 1 2 4 4 2 1 2 3 4 0 0 0 "Thrombosis in AML? Yes, but when to worry?" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-734715 Silverchair:35640 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Thrombosis in AML? Yes, but when to worry?" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-734715 Silverchair:35640 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Thrombosis in AML? Yes, but when to worry?" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-734715 Silverchair:35640 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Thrombosis in AML? Yes, but when to worry?" The American Society of Hematology American Society of Hematology 10.1182/blood-2016-08-734715 Silverchair:35640 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Thrombosis in paroxysmal nocturnal hemoglobinuria The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-311381 Silverchair:125576 Total_Item_Investigations 3 1 0 2 0 0 0 0 0 0 0 0 0 Thrombosis in paroxysmal nocturnal hemoglobinuria The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-311381 Silverchair:125576 Total_Item_Requests 3 1 0 2 0 0 0 0 0 0 0 0 0 Thrombosis in paroxysmal nocturnal hemoglobinuria The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-311381 Silverchair:125576 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Thrombosis in paroxysmal nocturnal hemoglobinuria The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-311381 Silverchair:125576 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-258624 Silverchair:130848 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-258624 Silverchair:130848 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-258624 Silverchair:130848 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-258624 Silverchair:130848 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-345678 Silverchair:29462 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-345678 Silverchair:29462 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-345678 Silverchair:29462 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception The American Society of Hematology American Society of Hematology 10.1182/blood-2011-03-345678 Silverchair:29462 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-709857 Silverchair:36273 Total_Item_Investigations 3 0 0 0 0 0 2 0 0 0 0 0 1 Thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-709857 Silverchair:36273 Total_Item_Requests 3 0 0 0 0 0 2 0 0 0 0 0 1 Thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-709857 Silverchair:36273 Unique_Item_Investigations 3 0 0 0 0 0 2 0 0 0 0 0 1 Thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-709857 Silverchair:36273 Unique_Item_Requests 3 0 0 0 0 0 2 0 0 0 0 0 1 THROMBOTIC THROMBOCYTOPENIC PURPURA HEMORRHAGIC DIATHESIS WITH GENERALIZED PLATELET THROMBOSES The American Society of Hematology American Society of Hematology 10.1182/blood.V2.6.542.542 Silverchair:6688 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 THROMBOTIC THROMBOCYTOPENIC PURPURA HEMORRHAGIC DIATHESIS WITH GENERALIZED PLATELET THROMBOSES The American Society of Hematology American Society of Hematology 10.1182/blood.V2.6.542.542 Silverchair:6688 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 THROMBOTIC THROMBOCYTOPENIC PURPURA HEMORRHAGIC DIATHESIS WITH GENERALIZED PLATELET THROMBOSES The American Society of Hematology American Society of Hematology 10.1182/blood.V2.6.542.542 Silverchair:6688 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 THROMBOTIC THROMBOCYTOPENIC PURPURA HEMORRHAGIC DIATHESIS WITH GENERALIZED PLATELET THROMBOSES The American Society of Hematology American Society of Hematology 10.1182/blood.V2.6.542.542 Silverchair:6688 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus) The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-280479 Silverchair:27480 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus) The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-280479 Silverchair:27480 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus) The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-280479 Silverchair:27480 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus) The American Society of Hematology American Society of Hematology 10.1182/blood-2010-04-280479 Silverchair:27480 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017005124 Silverchair:15615 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 0 2 "Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017005124 Silverchair:15615 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 0 2 "Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017005124 Silverchair:15615 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 "Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017005124 Silverchair:15615 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Ticagrelor: agonising over its mechanisms of action The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-743930 Silverchair:35695 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Ticagrelor: agonising over its mechanisms of action The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-743930 Silverchair:35695 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Ticagrelor: agonising over its mechanisms of action The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-743930 Silverchair:35695 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Ticagrelor: agonising over its mechanisms of action The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-743930 Silverchair:35695 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 TIF-90 tips the balance in rRNA synthesis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-578914 Silverchair:33290 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 TIF-90 tips the balance in rRNA synthesis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-578914 Silverchair:33290 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 TIF-90 tips the balance in rRNA synthesis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-578914 Silverchair:33290 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 TIF-90 tips the balance in rRNA synthesis The American Society of Hematology American Society of Hematology 10.1182/blood-2014-06-578914 Silverchair:33290 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-813576 Silverchair:39170 Total_Item_Investigations 5 0 5 0 0 0 0 0 0 0 0 0 0 Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-813576 Silverchair:39170 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-813576 Silverchair:39170 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2017-10-813576 Silverchair:39170 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 TIGIT checkpoint inhibition for myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-864231 Silverchair:39355 Total_Item_Investigations 3 0 2 1 0 0 0 0 0 0 0 0 0 TIGIT checkpoint inhibition for myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-864231 Silverchair:39355 Total_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 TIGIT checkpoint inhibition for myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-864231 Silverchair:39355 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 TIGIT checkpoint inhibition for myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-864231 Silverchair:39355 Unique_Item_Requests 2 0 1 1 0 0 0 0 0 0 0 0 0 TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-825265 Silverchair:39360 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-825265 Silverchair:39360 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-825265 Silverchair:39360 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-01-825265 Silverchair:39360 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation The American Society of Hematology American Society of Hematology 10.1182/blood-2008-10-185884 Silverchair:25110 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation The American Society of Hematology American Society of Hematology 10.1182/blood-2008-10-185884 Silverchair:25110 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation The American Society of Hematology American Society of Hematology 10.1182/blood-2008-10-185884 Silverchair:25110 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation The American Society of Hematology American Society of Hematology 10.1182/blood-2008-10-185884 Silverchair:25110 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Time-dependent changes in mortality and transformation risk in MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2016-02-700054 Silverchair:35867 Total_Item_Investigations 7 5 0 2 0 0 0 0 0 0 0 0 0 Time-dependent changes in mortality and transformation risk in MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2016-02-700054 Silverchair:35867 Total_Item_Requests 5 3 0 2 0 0 0 0 0 0 0 0 0 Time-dependent changes in mortality and transformation risk in MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2016-02-700054 Silverchair:35867 Unique_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 Time-dependent changes in mortality and transformation risk in MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2016-02-700054 Silverchair:35867 Unique_Item_Requests 3 2 0 1 0 0 0 0 0 0 0 0 0 Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002421 Silverchair:461703 Total_Item_Investigations 2 1 0 0 1 0 0 0 0 0 0 0 0 Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002421 Silverchair:461703 Total_Item_Requests 2 1 0 0 1 0 0 0 0 0 0 0 0 Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002421 Silverchair:461703 Unique_Item_Investigations 2 1 0 0 1 0 0 0 0 0 0 0 0 Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002421 Silverchair:461703 Unique_Item_Requests 2 1 0 0 1 0 0 0 0 0 0 0 0 Timing of Primary Prophylaxis G-CSF Use during Chemotherapy in Elderly Patients with NHL The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.6013.6013 Silverchair:100991 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Timing of Primary Prophylaxis G-CSF Use during Chemotherapy in Elderly Patients with NHL The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.6013.6013 Silverchair:100991 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Timing of Primary Prophylaxis G-CSF Use during Chemotherapy in Elderly Patients with NHL The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.6013.6013 Silverchair:100991 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Timing of Primary Prophylaxis G-CSF Use during Chemotherapy in Elderly Patients with NHL The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.6013.6013 Silverchair:100991 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-272393 Silverchair:28041 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-272393 Silverchair:28041 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-272393 Silverchair:28041 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes The American Society of Hematology American Society of Hematology 10.1182/blood-2010-03-272393 Silverchair:28041 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Tisagenlecleucel and Axicabtagene Ciloleucel Expansion Kinetics and CAR T Cell Attributes in the Infusion Products Are Early Predictors of Clinical Efficacy The American Society of Hematology American Society of Hematology 10.1182/blood-2021-152309 Silverchair:481045 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 2 0 Tisagenlecleucel and Axicabtagene Ciloleucel Expansion Kinetics and CAR T Cell Attributes in the Infusion Products Are Early Predictors of Clinical Efficacy The American Society of Hematology American Society of Hematology 10.1182/blood-2021-152309 Silverchair:481045 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 Tisagenlecleucel and Axicabtagene Ciloleucel Expansion Kinetics and CAR T Cell Attributes in the Infusion Products Are Early Predictors of Clinical Efficacy The American Society of Hematology American Society of Hematology 10.1182/blood-2021-152309 Silverchair:481045 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Tisagenlecleucel and Axicabtagene Ciloleucel Expansion Kinetics and CAR T Cell Attributes in the Infusion Products Are Early Predictors of Clinical Efficacy The American Society of Hematology American Society of Hematology 10.1182/blood-2021-152309 Silverchair:481045 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Tissue factor pathway inhibitor and bleeding tendency: can hormonal state explain the differences? American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004651 Silverchair:476043 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Tissue factor pathway inhibitor and bleeding tendency: can hormonal state explain the differences? American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004651 Silverchair:476043 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Tissue factor pathway inhibitor and bleeding tendency: can hormonal state explain the differences? American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004651 Silverchair:476043 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Tissue factor pathway inhibitor and bleeding tendency: can hormonal state explain the differences? American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2021004651 Silverchair:476043 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019001530 Silverchair:374910 Total_Item_Investigations 2 0 0 0 0 0 0 0 2 0 0 0 0 Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019001530 Silverchair:374910 Total_Item_Requests 2 0 0 0 0 0 0 0 2 0 0 0 0 Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019001530 Silverchair:374910 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis The American Society of Hematology American Society of Hematology 10.1182/blood.2019001530 Silverchair:374910 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction The American Society of Hematology American Society of Hematology 10.1182/blood-2009-12-257832 Silverchair:107751 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction The American Society of Hematology American Society of Hematology 10.1182/blood-2009-12-257832 Silverchair:107751 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction The American Society of Hematology American Society of Hematology 10.1182/blood-2009-12-257832 Silverchair:107751 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction The American Society of Hematology American Society of Hematology 10.1182/blood-2009-12-257832 Silverchair:107751 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 TKI resistance in Ph-like ALL The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-833665 Silverchair:6535 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 TKI resistance in Ph-like ALL The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-833665 Silverchair:6535 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 TKI resistance in Ph-like ALL The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-833665 Silverchair:6535 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 TKI resistance in Ph-like ALL The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-833665 Silverchair:6535 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 TKI vs relapse after HSCT: is the jury still out? The American Society of Hematology American Society of Hematology 10.1182/blood.2020007021 Silverchair:464023 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 TKI vs relapse after HSCT: is the jury still out? The American Society of Hematology American Society of Hematology 10.1182/blood.2020007021 Silverchair:464023 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 TKI vs relapse after HSCT: is the jury still out? The American Society of Hematology American Society of Hematology 10.1182/blood.2020007021 Silverchair:464023 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 TKI vs relapse after HSCT: is the jury still out? The American Society of Hematology American Society of Hematology 10.1182/blood.2020007021 Silverchair:464023 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children’s Oncology Group (COG) Study AALL0434" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1.1 Silverchair:87774 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 "T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children’s Oncology Group (COG) Study AALL0434" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1.1 Silverchair:87774 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 "T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children’s Oncology Group (COG) Study AALL0434" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1.1 Silverchair:87774 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 "T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children’s Oncology Group (COG) Study AALL0434" The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.1.1 Silverchair:87774 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-315507 Silverchair:20898 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-315507 Silverchair:20898 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-315507 Silverchair:20898 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-315507 Silverchair:20898 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 TNF-Alpha Promotes Clonal Expansion of Tet2 Deficient Bone Marrow Progenitors in MDS The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.731.731 Silverchair:99010 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 TNF-Alpha Promotes Clonal Expansion of Tet2 Deficient Bone Marrow Progenitors in MDS The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.731.731 Silverchair:99010 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 TNF-Alpha Promotes Clonal Expansion of Tet2 Deficient Bone Marrow Progenitors in MDS The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.731.731 Silverchair:99010 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 TNF-Alpha Promotes Clonal Expansion of Tet2 Deficient Bone Marrow Progenitors in MDS The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.731.731 Silverchair:99010 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "To treat or not to treat, that is the NLPHL question" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-02-900811 Silverchair:273846 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 2 0 0 0 "To treat or not to treat, that is the NLPHL question" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-02-900811 Silverchair:273846 Total_Item_Requests 2 0 0 0 0 0 0 0 0 2 0 0 0 "To treat or not to treat, that is the NLPHL question" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-02-900811 Silverchair:273846 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 "To treat or not to treat, that is the NLPHL question" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-02-900811 Silverchair:273846 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Toll-like receptor 4 in lymphatic endothelial cells contributes to LPS-induced lymphangiogenesis by chemotactic recruitment of macrophages The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-166934 Silverchair:110024 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Toll-like receptor 4 in lymphatic endothelial cells contributes to LPS-induced lymphangiogenesis by chemotactic recruitment of macrophages The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-166934 Silverchair:110024 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Toll-like receptor 4 in lymphatic endothelial cells contributes to LPS-induced lymphangiogenesis by chemotactic recruitment of macrophages The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-166934 Silverchair:110024 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Toll-like receptor 4 in lymphatic endothelial cells contributes to LPS-induced lymphangiogenesis by chemotactic recruitment of macrophages The American Society of Hematology American Society of Hematology 10.1182/blood-2008-07-166934 Silverchair:110024 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Toll-like receptor 7 (TLR7)–driven accumulation of a novel CD11c+ B-cell population is important for the development of autoimmunity The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-331462 Silverchair:28976 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Toll-like receptor 7 (TLR7)–driven accumulation of a novel CD11c+ B-cell population is important for the development of autoimmunity The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-331462 Silverchair:28976 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Toll-like receptor 7 (TLR7)–driven accumulation of a novel CD11c+ B-cell population is important for the development of autoimmunity The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-331462 Silverchair:28976 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Toll-like receptor 7 (TLR7)–driven accumulation of a novel CD11c+ B-cell population is important for the development of autoimmunity The American Society of Hematology American Society of Hematology 10.1182/blood-2011-01-331462 Silverchair:28976 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Toll-like receptor–induced changes in glycolytic metabolism regulate dendritic cell activation The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-249540 Silverchair:27736 Total_Item_Investigations 4 4 0 0 0 0 0 0 0 0 0 0 0 Toll-like receptor–induced changes in glycolytic metabolism regulate dendritic cell activation The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-249540 Silverchair:27736 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 Toll-like receptor–induced changes in glycolytic metabolism regulate dendritic cell activation The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-249540 Silverchair:27736 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Toll-like receptor–induced changes in glycolytic metabolism regulate dendritic cell activation The American Society of Hematology American Society of Hematology 10.1182/blood-2009-10-249540 Silverchair:27736 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Toll-like receptors stimulate human neutrophil function The American Society of Hematology American Society of Hematology 10.1182/blood-2003-04-1078 Silverchair:17964 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Toll-like receptors stimulate human neutrophil function The American Society of Hematology American Society of Hematology 10.1182/blood-2003-04-1078 Silverchair:17964 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Toll-like receptors stimulate human neutrophil function The American Society of Hematology American Society of Hematology 10.1182/blood-2003-04-1078 Silverchair:17964 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Toll-like receptors stimulate human neutrophil function The American Society of Hematology American Society of Hematology 10.1182/blood-2003-04-1078 Silverchair:17964 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Tolvaptan inhibition of desmopressin effects on coagulation factors in a patient with decreased von Willebrand factor and polycystic kidney disease The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-347328 Silverchair:28507 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Tolvaptan inhibition of desmopressin effects on coagulation factors in a patient with decreased von Willebrand factor and polycystic kidney disease The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-347328 Silverchair:28507 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Tolvaptan inhibition of desmopressin effects on coagulation factors in a patient with decreased von Willebrand factor and polycystic kidney disease The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-347328 Silverchair:28507 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Tolvaptan inhibition of desmopressin effects on coagulation factors in a patient with decreased von Willebrand factor and polycystic kidney disease The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-347328 Silverchair:28507 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.2018874115 Silverchair:272767 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.2018874115 Silverchair:272767 Total_Item_Requests 3 0 3 0 0 0 0 0 0 0 0 0 0 Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.2018874115 Silverchair:272767 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation The American Society of Hematology American Society of Hematology 10.1182/blood.2018874115 Silverchair:272767 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-264333 Silverchair:27909 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-264333 Silverchair:27909 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-264333 Silverchair:27909 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2010-01-264333 Silverchair:27909 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Toward classifying the unclassifiable The American Society of Hematology American Society of Hematology 10.1182/blood.2020007157 Silverchair:464224 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Toward classifying the unclassifiable The American Society of Hematology American Society of Hematology 10.1182/blood.2020007157 Silverchair:464224 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Toward classifying the unclassifiable The American Society of Hematology American Society of Hematology 10.1182/blood.2020007157 Silverchair:464224 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Toward classifying the unclassifiable The American Society of Hematology American Society of Hematology 10.1182/blood.2020007157 Silverchair:464224 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Toward optimal therapy for inhibitors in hemophilia The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-577643 Silverchair:33468 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 2 0 0 0 Toward optimal therapy for inhibitors in hemophilia The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-577643 Silverchair:33468 Total_Item_Requests 2 0 0 0 0 0 0 0 0 2 0 0 0 Toward optimal therapy for inhibitors in hemophilia The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-577643 Silverchair:33468 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Toward optimal therapy for inhibitors in hemophilia The American Society of Hematology American Society of Hematology 10.1182/blood-2014-05-577643 Silverchair:33468 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Toward optimal therapy for inhibitors in hemophilia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.364 Silverchair:20521 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 2 0 0 0 Toward optimal therapy for inhibitors in hemophilia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.364 Silverchair:20521 Total_Item_Requests 2 0 0 0 0 0 0 0 0 2 0 0 0 Toward optimal therapy for inhibitors in hemophilia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.364 Silverchair:20521 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Toward optimal therapy for inhibitors in hemophilia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.364 Silverchair:20521 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Toward the identification of a tolerogenic signature in IDO-competent dendritic cells The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-4077 Silverchair:132092 Total_Item_Investigations 4 2 2 0 0 0 0 0 0 0 0 0 0 Toward the identification of a tolerogenic signature in IDO-competent dendritic cells The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-4077 Silverchair:132092 Total_Item_Requests 4 2 2 0 0 0 0 0 0 0 0 0 0 Toward the identification of a tolerogenic signature in IDO-competent dendritic cells The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-4077 Silverchair:132092 Unique_Item_Investigations 2 1 1 0 0 0 0 0 0 0 0 0 0 Toward the identification of a tolerogenic signature in IDO-competent dendritic cells The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-4077 Silverchair:132092 Unique_Item_Requests 2 1 1 0 0 0 0 0 0 0 0 0 0 Toxicities of chimeric antigen receptor T cells: recognition and management The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-703751 Silverchair:35340 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Toxicities of chimeric antigen receptor T cells: recognition and management The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-703751 Silverchair:35340 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Toxicities of chimeric antigen receptor T cells: recognition and management The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-703751 Silverchair:35340 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Toxicities of chimeric antigen receptor T cells: recognition and management The American Society of Hematology American Society of Hematology 10.1182/blood-2016-04-703751 Silverchair:35340 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Toxicity Profile of Brentuximab Vedotin in Combination with Chemotherapy for Newly Diagnosed Patients with ALK+ ALCL: A Children's Oncology Group Study ANHL12P1 The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118450 Silverchair:272806 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Toxicity Profile of Brentuximab Vedotin in Combination with Chemotherapy for Newly Diagnosed Patients with ALK+ ALCL: A Children's Oncology Group Study ANHL12P1 The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118450 Silverchair:272806 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Toxicity Profile of Brentuximab Vedotin in Combination with Chemotherapy for Newly Diagnosed Patients with ALK+ ALCL: A Children's Oncology Group Study ANHL12P1 The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118450 Silverchair:272806 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Toxicity Profile of Brentuximab Vedotin in Combination with Chemotherapy for Newly Diagnosed Patients with ALK+ ALCL: A Children's Oncology Group Study ANHL12P1 The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-118450 Silverchair:272806 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117772 Silverchair:262925 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117772 Silverchair:262925 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117772 Silverchair:262925 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-117772 Silverchair:262925 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 TPO-mimetics and myelofibrosis? A reticulin question! The American Society of Hematology American Society of Hematology 10.1182/blood-2009-09-239863 Silverchair:26542 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 TPO-mimetics and myelofibrosis? A reticulin question! The American Society of Hematology American Society of Hematology 10.1182/blood-2009-09-239863 Silverchair:26542 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 TPO-mimetics and myelofibrosis? A reticulin question! The American Society of Hematology American Society of Hematology 10.1182/blood-2009-09-239863 Silverchair:26542 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 TPO-mimetics and myelofibrosis? A reticulin question! The American Society of Hematology American Society of Hematology 10.1182/blood-2009-09-239863 Silverchair:26542 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140622 Silverchair:470300 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140622 Silverchair:470300 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140622 Silverchair:470300 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140622 Silverchair:470300 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Transcript profiling of human platelets using microarray and serial analysis of gene expression The American Society of Hematology American Society of Hematology 10.1182/blood-2002-09-2797 Silverchair:106520 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Transcript profiling of human platelets using microarray and serial analysis of gene expression The American Society of Hematology American Society of Hematology 10.1182/blood-2002-09-2797 Silverchair:106520 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Transcript profiling of human platelets using microarray and serial analysis of gene expression The American Society of Hematology American Society of Hematology 10.1182/blood-2002-09-2797 Silverchair:106520 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Transcript profiling of human platelets using microarray and serial analysis of gene expression The American Society of Hematology American Society of Hematology 10.1182/blood-2002-09-2797 Silverchair:106520 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Transcription activation function of C/EBPα is required for induction of granulocytic differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2003-02-0477 Silverchair:17111 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Transcription activation function of C/EBPα is required for induction of granulocytic differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2003-02-0477 Silverchair:17111 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Transcription activation function of C/EBPα is required for induction of granulocytic differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2003-02-0477 Silverchair:17111 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Transcription activation function of C/EBPα is required for induction of granulocytic differentiation The American Society of Hematology American Society of Hematology 10.1182/blood-2003-02-0477 Silverchair:17111 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Transcription Activation of an Antisense Long Noncoding RNA (lnc-Mega1) of RBM15 By RUNX1 Enhances Megakaryocyte Differentiation The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4305.4305 Silverchair:91764 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Transcription Activation of an Antisense Long Noncoding RNA (lnc-Mega1) of RBM15 By RUNX1 Enhances Megakaryocyte Differentiation The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4305.4305 Silverchair:91764 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Transcription Activation of an Antisense Long Noncoding RNA (lnc-Mega1) of RBM15 By RUNX1 Enhances Megakaryocyte Differentiation The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4305.4305 Silverchair:91764 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Transcription Activation of an Antisense Long Noncoding RNA (lnc-Mega1) of RBM15 By RUNX1 Enhances Megakaryocyte Differentiation The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4305.4305 Silverchair:91764 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Transcription factor networks in B-cell differentiation link development to acute lymphoid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-575688 Silverchair:34488 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Transcription factor networks in B-cell differentiation link development to acute lymphoid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-575688 Silverchair:34488 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Transcription factor networks in B-cell differentiation link development to acute lymphoid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-575688 Silverchair:34488 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Transcription factor networks in B-cell differentiation link development to acute lymphoid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2014-12-575688 Silverchair:34488 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Transcription factor networks in erythroid cell and megakaryocyte development The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-285981 Silverchair:28502 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Transcription factor networks in erythroid cell and megakaryocyte development The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-285981 Silverchair:28502 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Transcription factor networks in erythroid cell and megakaryocyte development The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-285981 Silverchair:28502 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Transcription factor networks in erythroid cell and megakaryocyte development The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-285981 Silverchair:28502 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Transcriptional interference among the murine β-like globin genes The American Society of Hematology American Society of Hematology 10.1182/blood-2006-06-029868 Silverchair:23189 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Transcriptional interference among the murine β-like globin genes The American Society of Hematology American Society of Hematology 10.1182/blood-2006-06-029868 Silverchair:23189 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Transcriptional interference among the murine β-like globin genes The American Society of Hematology American Society of Hematology 10.1182/blood-2006-06-029868 Silverchair:23189 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Transcriptional interference among the murine β-like globin genes The American Society of Hematology American Society of Hematology 10.1182/blood-2006-06-029868 Silverchair:23189 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Transcriptional profile of platelets and iPSC-derived megakaryocytes from whole-genome and RNA sequencing The American Society of Hematology American Society of Hematology 10.1182/blood.2020006115 Silverchair:469715 Total_Item_Investigations 6 0 6 0 0 0 0 0 0 0 0 0 0 Transcriptional profile of platelets and iPSC-derived megakaryocytes from whole-genome and RNA sequencing The American Society of Hematology American Society of Hematology 10.1182/blood.2020006115 Silverchair:469715 Unique_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 Transcriptional profile of platelets and iPSC-derived megakaryocytes from whole-genome and RNA sequencing The American Society of Hematology American Society of Hematology 10.1182/blood.2020006115 Silverchair:469715 No_License 2 0 2 0 0 0 0 0 0 0 0 0 0 Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1 The American Society of Hematology American Society of Hematology 10.1182/blood-2004-07-2958 Silverchair:20098 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1 The American Society of Hematology American Society of Hematology 10.1182/blood-2004-07-2958 Silverchair:20098 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1 The American Society of Hematology American Society of Hematology 10.1182/blood-2004-07-2958 Silverchair:20098 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1 The American Society of Hematology American Society of Hematology 10.1182/blood-2004-07-2958 Silverchair:20098 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Transcriptomic analyses of murine resolution-phase macrophages The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-345330 Silverchair:29460 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Transcriptomic analyses of murine resolution-phase macrophages The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-345330 Silverchair:29460 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Transcriptomic analyses of murine resolution-phase macrophages The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-345330 Silverchair:29460 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Transcriptomic analyses of murine resolution-phase macrophages The American Society of Hematology American Society of Hematology 10.1182/blood-2011-04-345330 Silverchair:29460 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Transformed lymphoma: what should I do now? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000115 Silverchair:474282 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Transformed lymphoma: what should I do now? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000115 Silverchair:474282 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Transformed lymphoma: what should I do now? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000115 Silverchair:474282 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Transformed lymphoma: what should I do now? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000115 Silverchair:474282 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Transfusion Associated Circulatory Overload (TACO) Incidence and Risk Factors. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.3157.3157 Silverchair:133069 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Transfusion Associated Circulatory Overload (TACO) Incidence and Risk Factors. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.3157.3157 Silverchair:133069 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Transfusion Associated Circulatory Overload (TACO) Incidence and Risk Factors. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.3157.3157 Silverchair:133069 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Transfusion Associated Circulatory Overload (TACO) Incidence and Risk Factors. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.3157.3157 Silverchair:133069 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Transfusion guidelines: when to transfuse The American Society of Hematology American Society of Hematology 10.1182/asheducation-2013.1.638 Silverchair:20793 Total_Item_Investigations 5 2 2 1 0 0 0 0 0 0 0 0 0 Transfusion guidelines: when to transfuse The American Society of Hematology American Society of Hematology 10.1182/asheducation-2013.1.638 Silverchair:20793 Total_Item_Requests 4 1 2 1 0 0 0 0 0 0 0 0 0 Transfusion guidelines: when to transfuse The American Society of Hematology American Society of Hematology 10.1182/asheducation-2013.1.638 Silverchair:20793 Unique_Item_Investigations 4 1 2 1 0 0 0 0 0 0 0 0 0 Transfusion guidelines: when to transfuse The American Society of Hematology American Society of Hematology 10.1182/asheducation-2013.1.638 Silverchair:20793 Unique_Item_Requests 4 1 2 1 0 0 0 0 0 0 0 0 0 Transfusion medicine American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter13 Silverchair:75701 No_License 4 2 1 0 0 0 0 0 1 0 0 0 0 Transfusion medicine American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter13 Silverchair:75701 Total_Item_Investigations 5 2 2 0 0 0 0 0 1 0 0 0 0 Transfusion medicine American Society of Hematology American Society of Hematology 10.1182/ashsap7.chapter13 Silverchair:75701 Unique_Item_Investigations 4 1 2 0 0 0 0 0 1 0 0 0 0 Transfusion-associated circulatory overload and transfusion-related acute lung injury The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-860809 Silverchair:275907 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Transfusion-associated circulatory overload and transfusion-related acute lung injury The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-860809 Silverchair:275907 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Transfusion-associated circulatory overload and transfusion-related acute lung injury The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-860809 Silverchair:275907 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Transfusion-associated circulatory overload and transfusion-related acute lung injury The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-860809 Silverchair:275907 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Transfusion-Related Acute Lung Injury: An Update The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.497 Silverchair:19849 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Transfusion-Related Acute Lung Injury: An Update The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.497 Silverchair:19849 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Transfusion-Related Acute Lung Injury: An Update The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.497 Silverchair:19849 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Transfusion-Related Acute Lung Injury: An Update The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.497 Silverchair:19849 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention The American Society of Hematology American Society of Hematology 10.1182/blood-2008-10-167643 Silverchair:24952 Total_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention The American Society of Hematology American Society of Hematology 10.1182/blood-2008-10-167643 Silverchair:24952 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention The American Society of Hematology American Society of Hematology 10.1182/blood-2008-10-167643 Silverchair:24952 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention The American Society of Hematology American Society of Hematology 10.1182/blood-2008-10-167643 Silverchair:24952 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Transgenic sickle mice have vascular inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2002-10-3313 Silverchair:19135 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Transgenic sickle mice have vascular inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2002-10-3313 Silverchair:19135 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Transgenic sickle mice have vascular inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2002-10-3313 Silverchair:19135 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Transgenic sickle mice have vascular inflammation The American Society of Hematology American Society of Hematology 10.1182/blood-2002-10-3313 Silverchair:19135 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Transient Inhibition of the JAK1/3-STAT5 Pathway By Ruxolitinib Is Insufficient to Produce Clinical Benefit in Patients with Indolent Adult T-Cell Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3840.3840 Silverchair:71678 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Transient Inhibition of the JAK1/3-STAT5 Pathway By Ruxolitinib Is Insufficient to Produce Clinical Benefit in Patients with Indolent Adult T-Cell Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3840.3840 Silverchair:71678 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Transient Inhibition of the JAK1/3-STAT5 Pathway By Ruxolitinib Is Insufficient to Produce Clinical Benefit in Patients with Indolent Adult T-Cell Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3840.3840 Silverchair:71678 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Transient Inhibition of the JAK1/3-STAT5 Pathway By Ruxolitinib Is Insufficient to Produce Clinical Benefit in Patients with Indolent Adult T-Cell Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3840.3840 Silverchair:71678 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Transition of Intensive Chemotherapy for Acute Lymphoblastic Leukemia (ALL) to the Outpatient Setting: Analysis of Safety and Cost Savings The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.5604.5604 Silverchair:134391 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Transition of Intensive Chemotherapy for Acute Lymphoblastic Leukemia (ALL) to the Outpatient Setting: Analysis of Safety and Cost Savings The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.5604.5604 Silverchair:134391 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Transition of Intensive Chemotherapy for Acute Lymphoblastic Leukemia (ALL) to the Outpatient Setting: Analysis of Safety and Cost Savings The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.5604.5604 Silverchair:134391 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Transition of Intensive Chemotherapy for Acute Lymphoblastic Leukemia (ALL) to the Outpatient Setting: Analysis of Safety and Cost Savings The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.5604.5604 Silverchair:134391 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Very Severe Veno-Occlusive Disease after Unmanipulated Haploidentical HSCT with Post-Transplant Cyclophosphamide The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125828 Silverchair:427954 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Very Severe Veno-Occlusive Disease after Unmanipulated Haploidentical HSCT with Post-Transplant Cyclophosphamide The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125828 Silverchair:427954 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Very Severe Veno-Occlusive Disease after Unmanipulated Haploidentical HSCT with Post-Transplant Cyclophosphamide The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125828 Silverchair:427954 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Very Severe Veno-Occlusive Disease after Unmanipulated Haploidentical HSCT with Post-Transplant Cyclophosphamide The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125828 Silverchair:427954 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Translating exercise benefits in sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019003651 Silverchair:429656 Total_Item_Investigations 5 0 5 0 0 0 0 0 0 0 0 0 0 Translating exercise benefits in sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019003651 Silverchair:429656 Total_Item_Requests 5 0 5 0 0 0 0 0 0 0 0 0 0 Translating exercise benefits in sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019003651 Silverchair:429656 Unique_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 Translating exercise benefits in sickle cell disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019003651 Silverchair:429656 Unique_Item_Requests 4 0 4 0 0 0 0 0 0 0 0 0 0 Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003988 Silverchair:475740 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003988 Silverchair:475740 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003988 Silverchair:475740 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003988 Silverchair:475740 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Transplantation and Myelofibrosis: A Little Medicine and a Little Art American Society of Hematology American Society of Hematology 10.1182/hem.V16.2.9427 Silverchair:463090 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Transplantation and Myelofibrosis: A Little Medicine and a Little Art American Society of Hematology American Society of Hematology 10.1182/hem.V16.2.9427 Silverchair:463090 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Transplantation and Myelofibrosis: A Little Medicine and a Little Art American Society of Hematology American Society of Hematology 10.1182/hem.V16.2.9427 Silverchair:463090 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Transplantation and Myelofibrosis: A Little Medicine and a Little Art American Society of Hematology American Society of Hematology 10.1182/hem.V16.2.9427 Silverchair:463090 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Transplantation tolerance induced by intranasal administration of HY peptides The American Society of Hematology American Society of Hematology 10.1182/blood-2003-11-3763 Silverchair:17643 Total_Item_Investigations 10 5 5 0 0 0 0 0 0 0 0 0 0 Transplantation tolerance induced by intranasal administration of HY peptides The American Society of Hematology American Society of Hematology 10.1182/blood-2003-11-3763 Silverchair:17643 Total_Item_Requests 10 5 5 0 0 0 0 0 0 0 0 0 0 Transplantation tolerance induced by intranasal administration of HY peptides The American Society of Hematology American Society of Hematology 10.1182/blood-2003-11-3763 Silverchair:17643 Unique_Item_Investigations 3 1 2 0 0 0 0 0 0 0 0 0 0 Transplantation tolerance induced by intranasal administration of HY peptides The American Society of Hematology American Society of Hematology 10.1182/blood-2003-11-3763 Silverchair:17643 Unique_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 Transplantation without Hemolysis in a Kell Antigen Positive Patient Undergoing Peripheral Hematopoietic Stem Cell Transplant from a Donor with Anti-Kell Antibodies. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.4137.4137 Silverchair:120327 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Transplantation without Hemolysis in a Kell Antigen Positive Patient Undergoing Peripheral Hematopoietic Stem Cell Transplant from a Donor with Anti-Kell Antibodies. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.4137.4137 Silverchair:120327 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Transplantation without Hemolysis in a Kell Antigen Positive Patient Undergoing Peripheral Hematopoietic Stem Cell Transplant from a Donor with Anti-Kell Antibodies. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.4137.4137 Silverchair:120327 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Transplantation without Hemolysis in a Kell Antigen Positive Patient Undergoing Peripheral Hematopoietic Stem Cell Transplant from a Donor with Anti-Kell Antibodies. The American Society of Hematology American Society of Hematology 10.1182/blood.V108.11.4137.4137 Silverchair:120327 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Treating Relapsed and/or Refractory Multiple Myeloma in the Complex Treatment Landscape American Society of Hematology American Society of Hematology Silverchair:464323 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Treating Relapsed and/or Refractory Multiple Myeloma in the Complex Treatment Landscape American Society of Hematology American Society of Hematology Silverchair:464323 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Treating Relapsed and/or Refractory Multiple Myeloma in the Complex Treatment Landscape American Society of Hematology American Society of Hematology Silverchair:464323 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Treating Relapsed and/or Refractory Multiple Myeloma in the Complex Treatment Landscape American Society of Hematology American Society of Hematology Silverchair:464323 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Treating SVT: more than just a “gut feeling” The American Society of Hematology American Society of Hematology 10.1182/blood.2020008962 Silverchair:475362 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Treating SVT: more than just a “gut feeling” The American Society of Hematology American Society of Hematology 10.1182/blood.2020008962 Silverchair:475362 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Treating SVT: more than just a “gut feeling” The American Society of Hematology American Society of Hematology 10.1182/blood.2020008962 Silverchair:475362 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Treating SVT: more than just a “gut feeling” The American Society of Hematology American Society of Hematology 10.1182/blood.2020008962 Silverchair:475362 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-270785 Silverchair:27966 Total_Item_Investigations 6 2 0 0 0 0 1 0 0 0 3 0 0 Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-270785 Silverchair:27966 Total_Item_Requests 5 1 0 0 0 0 1 0 0 0 3 0 0 Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-270785 Silverchair:27966 Unique_Item_Investigations 3 1 0 0 0 0 1 0 0 0 1 0 0 Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-270785 Silverchair:27966 Unique_Item_Requests 3 1 0 0 0 0 1 0 0 0 1 0 0 Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020008119 Silverchair:475041 Total_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020008119 Silverchair:475041 Total_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020008119 Silverchair:475041 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020008119 Silverchair:475041 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 Treatment Failure in Patients Receiving Direct Oral Anticoagulants: Clinical Management and Outcomes from a Single-Center Review of 59 Consecutive Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111108 Silverchair:265728 Total_Item_Investigations 4 1 3 0 0 0 0 0 0 0 0 0 0 Treatment Failure in Patients Receiving Direct Oral Anticoagulants: Clinical Management and Outcomes from a Single-Center Review of 59 Consecutive Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111108 Silverchair:265728 Total_Item_Requests 4 1 3 0 0 0 0 0 0 0 0 0 0 Treatment Failure in Patients Receiving Direct Oral Anticoagulants: Clinical Management and Outcomes from a Single-Center Review of 59 Consecutive Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111108 Silverchair:265728 Unique_Item_Investigations 3 1 2 0 0 0 0 0 0 0 0 0 0 Treatment Failure in Patients Receiving Direct Oral Anticoagulants: Clinical Management and Outcomes from a Single-Center Review of 59 Consecutive Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-111108 Silverchair:265728 Unique_Item_Requests 3 1 2 0 0 0 0 0 0 0 0 0 0 "Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140831 Silverchair:470079 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140831 Silverchair:470079 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140831 Silverchair:470079 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-140831 Silverchair:470079 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Treatment of Acquired von Willebrand Syndrome in Patients With Monoclonal Gammopathy of Uncertain Significance: Comparison of Three Different Therapeutic Approaches The American Society of Hematology American Society of Hematology 10.1182/blood.V92.8.2707 Silverchair:261363 Total_Item_Investigations 2 0 0 0 2 0 0 0 0 0 0 0 0 Treatment of Acquired von Willebrand Syndrome in Patients With Monoclonal Gammopathy of Uncertain Significance: Comparison of Three Different Therapeutic Approaches The American Society of Hematology American Society of Hematology 10.1182/blood.V92.8.2707 Silverchair:261363 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Treatment of Acquired von Willebrand Syndrome in Patients With Monoclonal Gammopathy of Uncertain Significance: Comparison of Three Different Therapeutic Approaches The American Society of Hematology American Society of Hematology 10.1182/blood.V92.8.2707 Silverchair:261363 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Treatment of Acquired von Willebrand Syndrome in Patients With Monoclonal Gammopathy of Uncertain Significance: Comparison of Three Different Therapeutic Approaches The American Society of Hematology American Society of Hematology 10.1182/blood.V92.8.2707 Silverchair:261363 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Treatment of bleeding complications in patients on anticoagulant therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-820746 Silverchair:272782 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Treatment of bleeding complications in patients on anticoagulant therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-820746 Silverchair:272782 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Treatment of bleeding complications in patients on anticoagulant therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-820746 Silverchair:272782 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Treatment of bleeding complications in patients on anticoagulant therapy The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-820746 Silverchair:272782 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Treatment of Ex Vivo Expanded NK Cells with Daratumumab F(ab')2 Fragments Protects Adoptively Transferred NK Cells from Daratumumab-Mediated Killing and Augments Daratumumab-Induced Antibody Dependent Cellular Toxicity (ADCC) of Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4244.4244 Silverchair:136058 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Treatment of Ex Vivo Expanded NK Cells with Daratumumab F(ab')2 Fragments Protects Adoptively Transferred NK Cells from Daratumumab-Mediated Killing and Augments Daratumumab-Induced Antibody Dependent Cellular Toxicity (ADCC) of Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4244.4244 Silverchair:136058 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Treatment of Ex Vivo Expanded NK Cells with Daratumumab F(ab')2 Fragments Protects Adoptively Transferred NK Cells from Daratumumab-Mediated Killing and Augments Daratumumab-Induced Antibody Dependent Cellular Toxicity (ADCC) of Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4244.4244 Silverchair:136058 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Treatment of Ex Vivo Expanded NK Cells with Daratumumab F(ab')2 Fragments Protects Adoptively Transferred NK Cells from Daratumumab-Mediated Killing and Augments Daratumumab-Induced Antibody Dependent Cellular Toxicity (ADCC) of Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4244.4244 Silverchair:136058 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Treatment of hemophagocytic lymphohistiocytosis in adults The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.190 Silverchair:20732 Total_Item_Investigations 6 0 0 5 0 1 0 0 0 0 0 0 0 Treatment of hemophagocytic lymphohistiocytosis in adults The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.190 Silverchair:20732 Total_Item_Requests 6 0 0 5 0 1 0 0 0 0 0 0 0 Treatment of hemophagocytic lymphohistiocytosis in adults The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.190 Silverchair:20732 Unique_Item_Investigations 4 0 0 3 0 1 0 0 0 0 0 0 0 Treatment of hemophagocytic lymphohistiocytosis in adults The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.190 Silverchair:20732 Unique_Item_Requests 4 0 0 3 0 1 0 0 0 0 0 0 0 Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2002-01-0172 Silverchair:106167 Total_Item_Investigations 2 0 0 0 0 0 0 1 1 0 0 0 0 Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2002-01-0172 Silverchair:106167 Total_Item_Requests 2 0 0 0 0 0 0 1 1 0 0 0 0 Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2002-01-0172 Silverchair:106167 Unique_Item_Investigations 2 0 0 0 0 0 0 1 1 0 0 0 0 Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2002-01-0172 Silverchair:106167 Unique_Item_Requests 2 0 0 0 0 0 0 1 1 0 0 0 0 "Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate" The American Society of Hematology American Society of Hematology 10.1182/blood.2020006048 Silverchair:461242 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 "Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate" The American Society of Hematology American Society of Hematology 10.1182/blood.2020006048 Silverchair:461242 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 "Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate" The American Society of Hematology American Society of Hematology 10.1182/blood.2020006048 Silverchair:461242 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 "Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate" The American Society of Hematology American Society of Hematology 10.1182/blood.2020006048 Silverchair:461242 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Treatment of low-risk myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.462 Silverchair:21133 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Treatment of low-risk myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.462 Silverchair:21133 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Treatment of low-risk myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.462 Silverchair:21133 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Treatment of low-risk myelodysplastic syndromes The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.462 Silverchair:21133 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Treatment of MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-844696 Silverchair:272732 Total_Item_Investigations 5 0 2 2 0 0 0 1 0 0 0 0 0 Treatment of MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-844696 Silverchair:272732 Total_Item_Requests 5 0 2 2 0 0 0 1 0 0 0 0 0 Treatment of MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-844696 Silverchair:272732 Unique_Item_Investigations 5 0 2 2 0 0 0 1 0 0 0 0 0 Treatment of MDS The American Society of Hematology American Society of Hematology 10.1182/blood-2018-10-844696 Silverchair:272732 Unique_Item_Requests 5 0 2 2 0 0 0 1 0 0 0 0 0 Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-631200 Silverchair:35445 Total_Item_Investigations 5 1 1 3 0 0 0 0 0 0 0 0 0 Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-631200 Silverchair:35445 Total_Item_Requests 5 1 1 3 0 0 0 0 0 0 0 0 0 Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-631200 Silverchair:35445 Unique_Item_Investigations 3 1 1 1 0 0 0 0 0 0 0 0 0 Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group The American Society of Hematology American Society of Hematology 10.1182/blood-2016-01-631200 Silverchair:35445 Unique_Item_Requests 3 1 1 1 0 0 0 0 0 0 0 0 0 Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996) The American Society of Hematology American Society of Hematology 10.1182/blood-2009-03-211797 Silverchair:26091 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996) The American Society of Hematology American Society of Hematology 10.1182/blood-2009-03-211797 Silverchair:26091 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996) The American Society of Hematology American Society of Hematology 10.1182/blood-2009-03-211797 Silverchair:26091 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996) The American Society of Hematology American Society of Hematology 10.1182/blood-2009-03-211797 Silverchair:26091 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Treatment of primary CNS lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-622498 Silverchair:34195 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Treatment of primary CNS lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-622498 Silverchair:34195 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Treatment of primary CNS lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-622498 Silverchair:34195 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Treatment of primary CNS lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-622498 Silverchair:34195 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Treatment of rare factor deficiencies other than hemophilia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-820738 Silverchair:272776 Total_Item_Investigations 8 0 0 7 0 0 0 0 0 0 1 0 0 Treatment of rare factor deficiencies other than hemophilia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-820738 Silverchair:272776 Total_Item_Requests 8 0 0 7 0 0 0 0 0 0 1 0 0 Treatment of rare factor deficiencies other than hemophilia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-820738 Silverchair:272776 Unique_Item_Investigations 4 0 0 3 0 0 0 0 0 0 1 0 0 Treatment of rare factor deficiencies other than hemophilia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-06-820738 Silverchair:272776 Unique_Item_Requests 4 0 0 3 0 0 0 0 0 0 1 0 0 Treatment of Severe Acyclovir-Resistant Herpes Simplex Virus Infection with Continuous Infusion of High Dose Acyclovir Following Hematopoietic Cell Transplantation. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.2224.2224 Silverchair:111473 Total_Item_Investigations 2 0 0 0 1 1 0 0 0 0 0 0 0 Treatment of Severe Acyclovir-Resistant Herpes Simplex Virus Infection with Continuous Infusion of High Dose Acyclovir Following Hematopoietic Cell Transplantation. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.2224.2224 Silverchair:111473 Total_Item_Requests 2 0 0 0 1 1 0 0 0 0 0 0 0 Treatment of Severe Acyclovir-Resistant Herpes Simplex Virus Infection with Continuous Infusion of High Dose Acyclovir Following Hematopoietic Cell Transplantation. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.2224.2224 Silverchair:111473 Unique_Item_Investigations 2 0 0 0 1 1 0 0 0 0 0 0 0 Treatment of Severe Acyclovir-Resistant Herpes Simplex Virus Infection with Continuous Infusion of High Dose Acyclovir Following Hematopoietic Cell Transplantation. The American Society of Hematology American Society of Hematology 10.1182/blood.V114.22.2224.2224 Silverchair:111473 Unique_Item_Requests 2 0 0 0 1 1 0 0 0 0 0 0 0 Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin The American Society of Hematology American Society of Hematology 10.1182/blood.2021012070 Silverchair:476280 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin The American Society of Hematology American Society of Hematology 10.1182/blood.2021012070 Silverchair:476280 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin The American Society of Hematology American Society of Hematology 10.1182/blood.2021012070 Silverchair:476280 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin The American Society of Hematology American Society of Hematology 10.1182/blood.2021012070 Silverchair:476280 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Treatment of the 5q– Syndrome The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.192 Silverchair:19700 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Treatment of the 5q– Syndrome The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.192 Silverchair:19700 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Treatment of the 5q– Syndrome The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.192 Silverchair:19700 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Treatment of the 5q– Syndrome The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.192 Silverchair:19700 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.637 Silverchair:20636 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.637 Silverchair:20636 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.637 Silverchair:20636 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.637 Silverchair:20636 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Treatment of unusual thrombotic manifestations The American Society of Hematology American Society of Hematology 10.1182/blood.2019000918 Silverchair:430069 Total_Item_Investigations 3 0 0 0 0 0 0 0 0 0 0 3 0 Treatment of unusual thrombotic manifestations The American Society of Hematology American Society of Hematology 10.1182/blood.2019000918 Silverchair:430069 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 2 0 Treatment of unusual thrombotic manifestations The American Society of Hematology American Society of Hematology 10.1182/blood.2019000918 Silverchair:430069 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Treatment of unusual thrombotic manifestations The American Society of Hematology American Society of Hematology 10.1182/blood.2019000918 Silverchair:430069 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Treatment of Upper Extremity Deep Vein Thrombosis with Apixaban and Rivaroxaban The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125099 Silverchair:427918 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Treatment of Upper Extremity Deep Vein Thrombosis with Apixaban and Rivaroxaban The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125099 Silverchair:427918 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Treatment of Upper Extremity Deep Vein Thrombosis with Apixaban and Rivaroxaban The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125099 Silverchair:427918 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Treatment of Upper Extremity Deep Vein Thrombosis with Apixaban and Rivaroxaban The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125099 Silverchair:427918 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Treatment of venous thromboembolism in pediatric patients The American Society of Hematology American Society of Hematology 10.1182/blood.2019001847 Silverchair:430071 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Treatment of venous thromboembolism in pediatric patients The American Society of Hematology American Society of Hematology 10.1182/blood.2019001847 Silverchair:430071 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Treatment of venous thromboembolism in pediatric patients The American Society of Hematology American Society of Hematology 10.1182/blood.2019001847 Silverchair:430071 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Treatment of venous thromboembolism in pediatric patients The American Society of Hematology American Society of Hematology 10.1182/blood.2019001847 Silverchair:430071 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124878 Silverchair:428198 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124878 Silverchair:428198 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124878 Silverchair:428198 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124878 Silverchair:428198 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124013 Silverchair:423385 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124013 Silverchair:423385 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124013 Silverchair:423385 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting The American Society of Hematology American Society of Hematology 10.1182/blood-2019-124013 Silverchair:423385 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Treatment with CPX-351 Induces Deep Responses and TP53 Mutation Clearance in Patients with t-AML and AML MRC, Including Younger Patients and Those with Pre-Existing MPNs: A Real-World Experience" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142891 Silverchair:472527 Total_Item_Investigations 2 1 0 0 0 0 0 0 1 0 0 0 0 "Treatment with CPX-351 Induces Deep Responses and TP53 Mutation Clearance in Patients with t-AML and AML MRC, Including Younger Patients and Those with Pre-Existing MPNs: A Real-World Experience" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142891 Silverchair:472527 Total_Item_Requests 2 1 0 0 0 0 0 0 1 0 0 0 0 "Treatment with CPX-351 Induces Deep Responses and TP53 Mutation Clearance in Patients with t-AML and AML MRC, Including Younger Patients and Those with Pre-Existing MPNs: A Real-World Experience" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142891 Silverchair:472527 Unique_Item_Investigations 2 1 0 0 0 0 0 0 1 0 0 0 0 "Treatment with CPX-351 Induces Deep Responses and TP53 Mutation Clearance in Patients with t-AML and AML MRC, Including Younger Patients and Those with Pre-Existing MPNs: A Real-World Experience" The American Society of Hematology American Society of Hematology 10.1182/blood-2020-142891 Silverchair:472527 Unique_Item_Requests 2 1 0 0 0 0 0 0 1 0 0 0 0 Treatment with Foscarnet after Allogeneic Hematopoietic-Cell Transplant (AlloHCT) Is Associated with Long-Term Loss of Renal Function The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113189 Silverchair:262075 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Treatment with Foscarnet after Allogeneic Hematopoietic-Cell Transplant (AlloHCT) Is Associated with Long-Term Loss of Renal Function The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113189 Silverchair:262075 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Treatment with Foscarnet after Allogeneic Hematopoietic-Cell Transplant (AlloHCT) Is Associated with Long-Term Loss of Renal Function The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113189 Silverchair:262075 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Treatment with Foscarnet after Allogeneic Hematopoietic-Cell Transplant (AlloHCT) Is Associated with Long-Term Loss of Renal Function The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-113189 Silverchair:262075 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Treatment with Temozolomide and Ibrutinib in Recurrent/Refractory Primary (PCNSL) and Secondary CNS Lymphoma (SCNSL) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138764 Silverchair:470993 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Treatment with Temozolomide and Ibrutinib in Recurrent/Refractory Primary (PCNSL) and Secondary CNS Lymphoma (SCNSL) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138764 Silverchair:470993 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Treatment with Temozolomide and Ibrutinib in Recurrent/Refractory Primary (PCNSL) and Secondary CNS Lymphoma (SCNSL) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138764 Silverchair:470993 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Treatment with Temozolomide and Ibrutinib in Recurrent/Refractory Primary (PCNSL) and Secondary CNS Lymphoma (SCNSL) The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138764 Silverchair:470993 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Treatments targeting MDS genetics: a fool’s errand? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.277 Silverchair:277579 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Treatments targeting MDS genetics: a fool’s errand? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.277 Silverchair:277579 Total_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Treatments targeting MDS genetics: a fool’s errand? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.277 Silverchair:277579 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 1 0 Treatments targeting MDS genetics: a fool’s errand? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.277 Silverchair:277579 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 1 0 Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-311894 Silverchair:20502 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-311894 Silverchair:20502 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-311894 Silverchair:20502 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation The American Society of Hematology American Society of Hematology 10.1182/blood-2010-10-311894 Silverchair:20502 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Trib1 promotes acute myeloid leukemia progression by modulating the transcriptional programs of Hoxa9 The American Society of Hematology American Society of Hematology 10.1182/blood.2019004586 Silverchair:461620 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Trib1 promotes acute myeloid leukemia progression by modulating the transcriptional programs of Hoxa9 The American Society of Hematology American Society of Hematology 10.1182/blood.2019004586 Silverchair:461620 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Trib1 promotes acute myeloid leukemia progression by modulating the transcriptional programs of Hoxa9 The American Society of Hematology American Society of Hematology 10.1182/blood.2019004586 Silverchair:461620 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Trib1 promotes acute myeloid leukemia progression by modulating the transcriptional programs of Hoxa9 The American Society of Hematology American Society of Hematology 10.1182/blood.2019004586 Silverchair:461620 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Trib1 regulates eosinophil lineage commitment and identity by restraining the neutrophil program The American Society of Hematology American Society of Hematology 10.1182/blood.2018872218 Silverchair:273881 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Trib1 regulates eosinophil lineage commitment and identity by restraining the neutrophil program The American Society of Hematology American Society of Hematology 10.1182/blood.2018872218 Silverchair:273881 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Trib1 regulates eosinophil lineage commitment and identity by restraining the neutrophil program The American Society of Hematology American Society of Hematology 10.1182/blood.2018872218 Silverchair:273881 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Trib1 regulates eosinophil lineage commitment and identity by restraining the neutrophil program The American Society of Hematology American Society of Hematology 10.1182/blood.2018872218 Silverchair:273881 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.2020006073 Silverchair:464124 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.2020006073 Silverchair:464124 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.2020006073 Silverchair:464124 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy The American Society of Hematology American Society of Hematology 10.1182/blood.2020006073 Silverchair:464124 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-473744 Silverchair:31921 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-473744 Silverchair:31921 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-473744 Silverchair:31921 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab The American Society of Hematology American Society of Hematology 10.1182/blood-2012-12-473744 Silverchair:31921 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Trousseau's syndrome: multiple definitions and multiple mechanisms The American Society of Hematology American Society of Hematology 10.1182/blood-2006-10-053736 Silverchair:24099 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Trousseau's syndrome: multiple definitions and multiple mechanisms The American Society of Hematology American Society of Hematology 10.1182/blood-2006-10-053736 Silverchair:24099 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Trousseau's syndrome: multiple definitions and multiple mechanisms The American Society of Hematology American Society of Hematology 10.1182/blood-2006-10-053736 Silverchair:24099 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Trousseau's syndrome: multiple definitions and multiple mechanisms The American Society of Hematology American Society of Hematology 10.1182/blood-2006-10-053736 Silverchair:24099 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 TSLPR: a new CAR in the showroom for B-ALL The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-650812 Silverchair:126425 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 TSLPR: a new CAR in the showroom for B-ALL The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-650812 Silverchair:126425 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 TSLPR: a new CAR in the showroom for B-ALL The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-650812 Silverchair:126425 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 TSLPR: a new CAR in the showroom for B-ALL The American Society of Hematology American Society of Hematology 10.1182/blood-2015-06-650812 Silverchair:126425 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 TTP: long-term outcomes following recovery The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.548 Silverchair:277607 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 TTP: long-term outcomes following recovery The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.548 Silverchair:277607 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 TTP: long-term outcomes following recovery The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.548 Silverchair:277607 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 TTP: long-term outcomes following recovery The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.548 Silverchair:277607 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 TTP: the evolution of clinical practice The American Society of Hematology American Society of Hematology 10.1182/blood.2020009654 Silverchair:475176 Total_Item_Investigations 10 0 3 0 0 2 2 0 0 0 3 0 0 TTP: the evolution of clinical practice The American Society of Hematology American Society of Hematology 10.1182/blood.2020009654 Silverchair:475176 Total_Item_Requests 8 0 3 0 0 1 1 0 0 0 3 0 0 TTP: the evolution of clinical practice The American Society of Hematology American Society of Hematology 10.1182/blood.2020009654 Silverchair:475176 Unique_Item_Investigations 4 0 1 0 0 1 1 0 0 0 1 0 0 TTP: the evolution of clinical practice The American Society of Hematology American Society of Hematology 10.1182/blood.2020009654 Silverchair:475176 Unique_Item_Requests 4 0 1 0 0 1 1 0 0 0 1 0 0 "Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002394 Silverchair:464200 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002394 Silverchair:464200 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002394 Silverchair:464200 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002394 Silverchair:464200 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Tumor Targeted Nanoparticles Improve Therapeutic Index of BCL2 and MCL1 dual inhibition The American Society of Hematology American Society of Hematology 10.1182/blood.2020008017 Silverchair:469620 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Tumor Targeted Nanoparticles Improve Therapeutic Index of BCL2 and MCL1 dual inhibition The American Society of Hematology American Society of Hematology 10.1182/blood.2020008017 Silverchair:469620 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Tumoral Maximum Standardized Uptake Value > 10 Measured on 18 f-FDG-PET: A New Valid Marker to Discriminate Richter Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3306.3306 Silverchair:97790 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Tumoral Maximum Standardized Uptake Value > 10 Measured on 18 f-FDG-PET: A New Valid Marker to Discriminate Richter Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3306.3306 Silverchair:97790 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Tumoral Maximum Standardized Uptake Value > 10 Measured on 18 f-FDG-PET: A New Valid Marker to Discriminate Richter Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3306.3306 Silverchair:97790 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Tumoral Maximum Standardized Uptake Value > 10 Measured on 18 f-FDG-PET: A New Valid Marker to Discriminate Richter Syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.3306.3306 Silverchair:97790 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-072587 Silverchair:103222 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-072587 Silverchair:103222 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-072587 Silverchair:103222 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells The American Society of Hematology American Society of Hematology 10.1182/blood-2007-02-072587 Silverchair:103222 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL The American Society of Hematology American Society of Hematology 10.1182/blood.2020006287 Silverchair:463621 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL The American Society of Hematology American Society of Hematology 10.1182/blood.2020006287 Silverchair:463621 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL The American Society of Hematology American Society of Hematology 10.1182/blood.2020006287 Silverchair:463621 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL The American Society of Hematology American Society of Hematology 10.1182/blood.2020006287 Silverchair:463621 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-400044 Silverchair:30054 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-400044 Silverchair:30054 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-400044 Silverchair:30054 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-400044 Silverchair:30054 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 TWIST1 preserves hematopoietic stem cell function via CACNA1B/Ca2+/mitochondria axis The American Society of Hematology American Society of Hematology 10.1182/blood.2020007489 Silverchair:475282 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 TWIST1 preserves hematopoietic stem cell function via CACNA1B/Ca2+/mitochondria axis The American Society of Hematology American Society of Hematology 10.1182/blood.2020007489 Silverchair:475282 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Two Cycles of Consolidation Chemotherapy Are Associated with Similar Clinical Outcomes to Three Cycles in AML Patients with Favorable Risk Cytogenetics The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.464.464 Silverchair:72374 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Two Cycles of Consolidation Chemotherapy Are Associated with Similar Clinical Outcomes to Three Cycles in AML Patients with Favorable Risk Cytogenetics The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.464.464 Silverchair:72374 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Two Cycles of Consolidation Chemotherapy Are Associated with Similar Clinical Outcomes to Three Cycles in AML Patients with Favorable Risk Cytogenetics The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.464.464 Silverchair:72374 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Two Cycles of Consolidation Chemotherapy Are Associated with Similar Clinical Outcomes to Three Cycles in AML Patients with Favorable Risk Cytogenetics The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.464.464 Silverchair:72374 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Two Dose Series of High-Dose Influenza Vaccine Is Associated with Longer Duration of Serologic Immunity in Patients with Plasma Cell Disorders The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.438.438 Silverchair:72882 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Two Dose Series of High-Dose Influenza Vaccine Is Associated with Longer Duration of Serologic Immunity in Patients with Plasma Cell Disorders The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.438.438 Silverchair:72882 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Two Dose Series of High-Dose Influenza Vaccine Is Associated with Longer Duration of Serologic Immunity in Patients with Plasma Cell Disorders The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.438.438 Silverchair:72882 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Two Dose Series of High-Dose Influenza Vaccine Is Associated with Longer Duration of Serologic Immunity in Patients with Plasma Cell Disorders The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.438.438 Silverchair:72882 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Two nonsense mutations in the TMPRSS6 gene in a patient with microcytic anemia and iron deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2008-05-154740 Silverchair:25546 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Two nonsense mutations in the TMPRSS6 gene in a patient with microcytic anemia and iron deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2008-05-154740 Silverchair:25546 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Two nonsense mutations in the TMPRSS6 gene in a patient with microcytic anemia and iron deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2008-05-154740 Silverchair:25546 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Two nonsense mutations in the TMPRSS6 gene in a patient with microcytic anemia and iron deficiency The American Society of Hematology American Society of Hematology 10.1182/blood-2008-05-154740 Silverchair:25546 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Two Signaling Pathways Can Increase Fas Expression in Human Thymocytes The American Society of Hematology American Society of Hematology 10.1182/blood.V92.4.1297 Silverchair:247338 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Two Signaling Pathways Can Increase Fas Expression in Human Thymocytes The American Society of Hematology American Society of Hematology 10.1182/blood.V92.4.1297 Silverchair:247338 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Two Signaling Pathways Can Increase Fas Expression in Human Thymocytes The American Society of Hematology American Society of Hematology 10.1182/blood.V92.4.1297 Silverchair:247338 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Two Signaling Pathways Can Increase Fas Expression in Human Thymocytes The American Society of Hematology American Society of Hematology 10.1182/blood.V92.4.1297 Silverchair:247338 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-121909 Silverchair:426026 Total_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 "Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-121909 Silverchair:426026 Total_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 "Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-121909 Silverchair:426026 Unique_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 "Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-121909 Silverchair:426026 Unique_Item_Requests 2 0 0 0 0 2 0 0 0 0 0 0 0 Type B Lactic Acidosis in Advanced Diffuse Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5420.5420 Silverchair:100037 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Type B Lactic Acidosis in Advanced Diffuse Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5420.5420 Silverchair:100037 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Type B Lactic Acidosis in Advanced Diffuse Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5420.5420 Silverchair:100037 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Type B Lactic Acidosis in Advanced Diffuse Large B-Cell Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.5420.5420 Silverchair:100037 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Type II NKT-TFH Cells Against Gaucher Lipids Regulate B Cell Immunity and Inflammation The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.755.755 Silverchair:101809 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Type II NKT-TFH Cells Against Gaucher Lipids Regulate B Cell Immunity and Inflammation The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.755.755 Silverchair:101809 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Type II NKT-TFH Cells Against Gaucher Lipids Regulate B Cell Immunity and Inflammation The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.755.755 Silverchair:101809 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Type II NKT-TFH Cells Against Gaucher Lipids Regulate B Cell Immunity and Inflammation The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.755.755 Silverchair:101809 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Tyrosine kinase inhibitor–induced platelet dysfunction in patients with chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-180604 Silverchair:26216 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Tyrosine kinase inhibitor–induced platelet dysfunction in patients with chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-180604 Silverchair:26216 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Tyrosine kinase inhibitor–induced platelet dysfunction in patients with chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-180604 Silverchair:26216 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Tyrosine kinase inhibitor–induced platelet dysfunction in patients with chronic myeloid leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2008-09-180604 Silverchair:26216 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Tyrosine phosphorylation of DEP-1/CD148 as a mechanism controlling Src kinase activation, endothelial cell permeability, invasion, and capillary formation" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-398040 Silverchair:30837 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 "Tyrosine phosphorylation of DEP-1/CD148 as a mechanism controlling Src kinase activation, endothelial cell permeability, invasion, and capillary formation" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-398040 Silverchair:30837 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Tyrosine phosphorylation of DEP-1/CD148 as a mechanism controlling Src kinase activation, endothelial cell permeability, invasion, and capillary formation" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-398040 Silverchair:30837 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Tyrosine phosphorylation of DEP-1/CD148 as a mechanism controlling Src kinase activation, endothelial cell permeability, invasion, and capillary formation" The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-398040 Silverchair:30837 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 U2AF1 Driver Mutations in Hematopoietic Disorders Alter but Do Not Abrogate RNA Binding and Enlighten Structural Dependencies of the U2AF-RNA Complex The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130759 Silverchair:426742 Total_Item_Investigations 3 0 2 0 0 0 1 0 0 0 0 0 0 U2AF1 Driver Mutations in Hematopoietic Disorders Alter but Do Not Abrogate RNA Binding and Enlighten Structural Dependencies of the U2AF-RNA Complex The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130759 Silverchair:426742 Total_Item_Requests 3 0 2 0 0 0 1 0 0 0 0 0 0 U2AF1 Driver Mutations in Hematopoietic Disorders Alter but Do Not Abrogate RNA Binding and Enlighten Structural Dependencies of the U2AF-RNA Complex The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130759 Silverchair:426742 Unique_Item_Investigations 3 0 2 0 0 0 1 0 0 0 0 0 0 U2AF1 Driver Mutations in Hematopoietic Disorders Alter but Do Not Abrogate RNA Binding and Enlighten Structural Dependencies of the U2AF-RNA Complex The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130759 Silverchair:426742 Unique_Item_Requests 3 0 2 0 0 0 1 0 0 0 0 0 0 UAF1 DNA Binding Activity Is Critical for RAD51-Mediated Homologous DNA Pairing The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130435 Silverchair:423001 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 UAF1 DNA Binding Activity Is Critical for RAD51-Mediated Homologous DNA Pairing The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130435 Silverchair:423001 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 UAF1 DNA Binding Activity Is Critical for RAD51-Mediated Homologous DNA Pairing The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130435 Silverchair:423001 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 UAF1 DNA Binding Activity Is Critical for RAD51-Mediated Homologous DNA Pairing The American Society of Hematology American Society of Hematology 10.1182/blood-2019-130435 Silverchair:423001 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2004-04-1544 Silverchair:20029 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2004-04-1544 Silverchair:20029 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2004-04-1544 Silverchair:20029 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia The American Society of Hematology American Society of Hematology 10.1182/blood-2004-04-1544 Silverchair:20029 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Under the cover of mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020006581 Silverchair:463731 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Under the cover of mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020006581 Silverchair:463731 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Under the cover of mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020006581 Silverchair:463731 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Under the cover of mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood.2020006581 Silverchair:463731 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Understanding Sleep in Pediatric Patients with Sickle Cell Disease Admitted for Vaso-Occlusive Pain Crisis through Objective Data The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4791.4791 Silverchair:72227 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Understanding Sleep in Pediatric Patients with Sickle Cell Disease Admitted for Vaso-Occlusive Pain Crisis through Objective Data The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4791.4791 Silverchair:72227 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Understanding Sleep in Pediatric Patients with Sickle Cell Disease Admitted for Vaso-Occlusive Pain Crisis through Objective Data The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4791.4791 Silverchair:72227 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Understanding Sleep in Pediatric Patients with Sickle Cell Disease Admitted for Vaso-Occlusive Pain Crisis through Objective Data The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4791.4791 Silverchair:72227 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4254.4254 Silverchair:135720 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4254.4254 Silverchair:135720 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4254.4254 Silverchair:135720 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4254.4254 Silverchair:135720 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Undetectable MRD can change the deal The American Society of Hematology American Society of Hematology 10.1182/blood.2020008090 Silverchair:474794 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Undetectable MRD can change the deal The American Society of Hematology American Society of Hematology 10.1182/blood.2020008090 Silverchair:474794 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Undetectable MRD can change the deal The American Society of Hematology American Society of Hematology 10.1182/blood.2020008090 Silverchair:474794 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Undetectable MRD can change the deal The American Society of Hematology American Society of Hematology 10.1182/blood.2020008090 Silverchair:474794 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2012-02-408914 Silverchair:30352 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2012-02-408914 Silverchair:30352 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2012-02-408914 Silverchair:30352 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura The American Society of Hematology American Society of Hematology 10.1182/blood-2012-02-408914 Silverchair:30352 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Unexpected redundancy of Gpr56 and Gpr97 during hematopoietic cell development and differentiation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003693 Silverchair:475137 Total_Item_Investigations 3 0 2 1 0 0 0 0 0 0 0 0 0 Unexpected redundancy of Gpr56 and Gpr97 during hematopoietic cell development and differentiation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003693 Silverchair:475137 Total_Item_Requests 3 0 2 1 0 0 0 0 0 0 0 0 0 Unexpected redundancy of Gpr56 and Gpr97 during hematopoietic cell development and differentiation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003693 Silverchair:475137 Unique_Item_Investigations 3 0 2 1 0 0 0 0 0 0 0 0 0 Unexpected redundancy of Gpr56 and Gpr97 during hematopoietic cell development and differentiation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003693 Silverchair:475137 Unique_Item_Requests 3 0 2 1 0 0 0 0 0 0 0 0 0 Unexplained arterial thrombosis: approach to diagnosis and treatment The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000235 Silverchair:482964 Total_Item_Investigations 5 0 0 0 0 0 0 0 0 0 0 0 5 Unexplained arterial thrombosis: approach to diagnosis and treatment The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000235 Silverchair:482964 Total_Item_Requests 4 0 0 0 0 0 0 0 0 0 0 0 4 Unexplained arterial thrombosis: approach to diagnosis and treatment The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000235 Silverchair:482964 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 Unexplained arterial thrombosis: approach to diagnosis and treatment The American Society of Hematology American Society of Hematology 10.1182/hematology.2021000235 Silverchair:482964 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V94.6.1848 Silverchair:175735 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V94.6.1848 Silverchair:175735 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V94.6.1848 Silverchair:175735 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.V94.6.1848 Silverchair:175735 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Unmutated IGHV and Double Negative CD38/CD49d Predict Good Prognosis and Long Treatment Free Survival (TFS) in Chronic Lymphocytic Leukaemia; Regardless of Genetic Mutations The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5323.5323 Silverchair:115750 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Unmutated IGHV and Double Negative CD38/CD49d Predict Good Prognosis and Long Treatment Free Survival (TFS) in Chronic Lymphocytic Leukaemia; Regardless of Genetic Mutations The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5323.5323 Silverchair:115750 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Unmutated IGHV and Double Negative CD38/CD49d Predict Good Prognosis and Long Treatment Free Survival (TFS) in Chronic Lymphocytic Leukaemia; Regardless of Genetic Mutations The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5323.5323 Silverchair:115750 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Unmutated IGHV and Double Negative CD38/CD49d Predict Good Prognosis and Long Treatment Free Survival (TFS) in Chronic Lymphocytic Leukaemia; Regardless of Genetic Mutations The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5323.5323 Silverchair:115750 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Unprovoked Versus Provoked Venous Thromboembolism in Pediatric Patients: Comparison of Characteristics and Outcomes The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2384.2384 Silverchair:79969 Total_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Unprovoked Versus Provoked Venous Thromboembolism in Pediatric Patients: Comparison of Characteristics and Outcomes The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2384.2384 Silverchair:79969 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Unprovoked Versus Provoked Venous Thromboembolism in Pediatric Patients: Comparison of Characteristics and Outcomes The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2384.2384 Silverchair:79969 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Unprovoked Versus Provoked Venous Thromboembolism in Pediatric Patients: Comparison of Characteristics and Outcomes The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.2384.2384 Silverchair:79969 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Unraveling a novel transcription factor code determining the human arterial-specific endothelial cell signature The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-483255 Silverchair:31962 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Unraveling a novel transcription factor code determining the human arterial-specific endothelial cell signature The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-483255 Silverchair:31962 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Unraveling a novel transcription factor code determining the human arterial-specific endothelial cell signature The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-483255 Silverchair:31962 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Unraveling a novel transcription factor code determining the human arterial-specific endothelial cell signature The American Society of Hematology American Society of Hematology 10.1182/blood-2013-02-483255 Silverchair:31962 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Unraveling a T-ALL Tapestri The American Society of Hematology American Society of Hematology 10.1182/blood.2020008467 Silverchair:475165 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Unraveling a T-ALL Tapestri The American Society of Hematology American Society of Hematology 10.1182/blood.2020008467 Silverchair:475165 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Unraveling a T-ALL Tapestri The American Society of Hematology American Society of Hematology 10.1182/blood.2020008467 Silverchair:475165 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Unraveling a T-ALL Tapestri The American Society of Hematology American Society of Hematology 10.1182/blood.2020008467 Silverchair:475165 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Unraveling von Willebrand factor deficiency The American Society of Hematology American Society of Hematology 10.1182/blood.2021010942 Silverchair:476091 Total_Item_Investigations 3 0 0 0 0 0 2 1 0 0 0 0 0 Unraveling von Willebrand factor deficiency The American Society of Hematology American Society of Hematology 10.1182/blood.2021010942 Silverchair:476091 Total_Item_Requests 3 0 0 0 0 0 2 1 0 0 0 0 0 Unraveling von Willebrand factor deficiency The American Society of Hematology American Society of Hematology 10.1182/blood.2021010942 Silverchair:476091 Unique_Item_Investigations 2 0 0 0 0 0 1 1 0 0 0 0 0 Unraveling von Willebrand factor deficiency The American Society of Hematology American Society of Hematology 10.1182/blood.2021010942 Silverchair:476091 Unique_Item_Requests 2 0 0 0 0 0 1 1 0 0 0 0 0 Unsupervised Discovery of Early Markers of Erythroid Maturation in Human Donor Marrow The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4304.4304 Silverchair:91757 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Unsupervised Discovery of Early Markers of Erythroid Maturation in Human Donor Marrow The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4304.4304 Silverchair:91757 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Unsupervised Discovery of Early Markers of Erythroid Maturation in Human Donor Marrow The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4304.4304 Silverchair:91757 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Unsupervised Discovery of Early Markers of Erythroid Maturation in Human Donor Marrow The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4304.4304 Silverchair:91757 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Unwinding the von Willebrand factor strings puzzle The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-442285 Silverchair:30945 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Unwinding the von Willebrand factor strings puzzle The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-442285 Silverchair:30945 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Unwinding the von Willebrand factor strings puzzle The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-442285 Silverchair:30945 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Unwinding the von Willebrand factor strings puzzle The American Society of Hematology American Society of Hematology 10.1182/blood-2012-07-442285 Silverchair:30945 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Update from the latest WHO classification of MPNs: a user’s manual The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.534 Silverchair:20983 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Update from the latest WHO classification of MPNs: a user’s manual The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.534 Silverchair:20983 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Update from the latest WHO classification of MPNs: a user’s manual The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.534 Silverchair:20983 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Update from the latest WHO classification of MPNs: a user’s manual The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.534 Silverchair:20983 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.437.437 Silverchair:72787 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.437.437 Silverchair:72787 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.437.437 Silverchair:72787 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.437.437 Silverchair:72787 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Update on clinical gene therapy for hemophilia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-820720 Silverchair:272786 Total_Item_Investigations 2 0 0 0 0 0 2 0 0 0 0 0 0 Update on clinical gene therapy for hemophilia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-820720 Silverchair:272786 Total_Item_Requests 2 0 0 0 0 0 2 0 0 0 0 0 0 Update on clinical gene therapy for hemophilia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-820720 Silverchair:272786 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Update on clinical gene therapy for hemophilia The American Society of Hematology American Society of Hematology 10.1182/blood-2018-07-820720 Silverchair:272786 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Update on mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-791392 Silverchair:39353 Total_Item_Investigations 3 2 0 0 0 0 0 0 0 0 0 1 0 Update on mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-791392 Silverchair:39353 Total_Item_Requests 2 1 0 0 0 0 0 0 0 0 0 1 0 Update on mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-791392 Silverchair:39353 Unique_Item_Investigations 2 1 0 0 0 0 0 0 0 0 0 1 0 Update on mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-03-791392 Silverchair:39353 Unique_Item_Requests 2 1 0 0 0 0 0 0 0 0 0 1 0 Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.208 Silverchair:21101 Total_Item_Investigations 3 0 0 0 0 0 3 0 0 0 0 0 0 Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.208 Silverchair:21101 Total_Item_Requests 3 0 0 0 0 0 3 0 0 0 0 0 0 Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.208 Silverchair:21101 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.208 Silverchair:21101 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 "Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126015 Silverchair:427597 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126015 Silverchair:427597 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126015 Silverchair:427597 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126015 Silverchair:427597 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Updated international consensus report on the investigation and management of primary immune thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000812 Silverchair:428877 Total_Item_Investigations 7 1 3 0 1 0 0 0 0 0 2 0 0 Updated international consensus report on the investigation and management of primary immune thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000812 Silverchair:428877 Total_Item_Requests 7 1 3 0 1 0 0 0 0 0 2 0 0 Updated international consensus report on the investigation and management of primary immune thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000812 Silverchair:428877 Unique_Item_Investigations 6 1 3 0 1 0 0 0 0 0 1 0 0 Updated international consensus report on the investigation and management of primary immune thrombocytopenia American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000812 Silverchair:428877 Unique_Item_Requests 6 1 3 0 1 0 0 0 0 0 1 0 0 "Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128000 Silverchair:423826 Total_Item_Investigations 3 2 0 1 0 0 0 0 0 0 0 0 0 "Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128000 Silverchair:423826 Total_Item_Requests 3 2 0 1 0 0 0 0 0 0 0 0 0 "Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128000 Silverchair:423826 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 "Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-128000 Silverchair:423826 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 "Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125136 Silverchair:426963 Total_Item_Investigations 3 0 0 0 0 0 0 0 1 2 0 0 0 "Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125136 Silverchair:426963 Total_Item_Requests 3 0 0 0 0 0 0 0 1 2 0 0 0 "Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125136 Silverchair:426963 Unique_Item_Investigations 3 0 0 0 0 0 0 0 1 2 0 0 0 "Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-125136 Silverchair:426963 Unique_Item_Requests 3 0 0 0 0 0 0 0 1 2 0 0 0 Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000124 Silverchair:474288 Total_Item_Investigations 8 0 6 0 0 0 0 0 0 0 2 0 0 Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000124 Silverchair:474288 Total_Item_Requests 8 0 6 0 0 0 0 0 0 0 2 0 0 Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000124 Silverchair:474288 Unique_Item_Investigations 3 0 2 0 0 0 0 0 0 0 1 0 0 Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000124 Silverchair:474288 Unique_Item_Requests 3 0 2 0 0 0 0 0 0 0 1 0 0 Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-1000 Silverchair:22142 Total_Item_Investigations 5 5 0 0 0 0 0 0 0 0 0 0 0 Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-1000 Silverchair:22142 Total_Item_Requests 4 4 0 0 0 0 0 0 0 0 0 0 0 Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-1000 Silverchair:22142 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function The American Society of Hematology American Society of Hematology 10.1182/blood-2005-03-1000 Silverchair:22142 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114286 Silverchair:264778 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114286 Silverchair:264778 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114286 Silverchair:264778 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114286 Silverchair:264778 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2016001495 Silverchair:16011 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2016001495 Silverchair:16011 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2016001495 Silverchair:16011 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2016001495 Silverchair:16011 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-4006 Silverchair:133449 Total_Item_Investigations 2 0 0 0 0 0 0 0 2 0 0 0 0 Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-4006 Silverchair:133449 Total_Item_Requests 2 0 0 0 0 0 0 0 2 0 0 0 0 Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-4006 Silverchair:133449 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2005-10-4006 Silverchair:133449 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Use of Arsenic Trioxide (As2O3 ) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V89.9.3354 Silverchair:139279 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Use of Arsenic Trioxide (As2O3 ) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V89.9.3354 Silverchair:139279 Total_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Use of Arsenic Trioxide (As2O3 ) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V89.9.3354 Silverchair:139279 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Use of Arsenic Trioxide (As2O3 ) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V89.9.3354 Silverchair:139279 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Use of CD70 Targeted Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127154 Silverchair:424774 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Use of CD70 Targeted Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127154 Silverchair:424774 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Use of CD70 Targeted Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127154 Silverchair:424774 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Use of CD70 Targeted Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Acute Myeloid Leukemia (AML) The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127154 Silverchair:424774 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Use of Convalescent Plasma Therapy in Severe Coronavirus Disease 2019: The Yale-New Haven Health System Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137352 Silverchair:469845 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Use of Convalescent Plasma Therapy in Severe Coronavirus Disease 2019: The Yale-New Haven Health System Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137352 Silverchair:469845 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Use of Convalescent Plasma Therapy in Severe Coronavirus Disease 2019: The Yale-New Haven Health System Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137352 Silverchair:469845 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Use of Convalescent Plasma Therapy in Severe Coronavirus Disease 2019: The Yale-New Haven Health System Experience The American Society of Hematology American Society of Hematology 10.1182/blood-2020-137352 Silverchair:469845 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Use of Direct Oral Anticoagulants in Inherited Thrombophilia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3724.3724 Silverchair:71800 Total_Item_Investigations 6 3 2 1 0 0 0 0 0 0 0 0 0 Use of Direct Oral Anticoagulants in Inherited Thrombophilia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3724.3724 Silverchair:71800 Total_Item_Requests 6 3 2 1 0 0 0 0 0 0 0 0 0 Use of Direct Oral Anticoagulants in Inherited Thrombophilia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3724.3724 Silverchair:71800 Unique_Item_Investigations 6 3 2 1 0 0 0 0 0 0 0 0 0 Use of Direct Oral Anticoagulants in Inherited Thrombophilia The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.3724.3724 Silverchair:71800 Unique_Item_Requests 6 3 2 1 0 0 0 0 0 0 0 0 0 Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-109488 Silverchair:107957 Total_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-109488 Silverchair:107957 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-109488 Silverchair:107957 Unique_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update The American Society of Hematology American Society of Hematology 10.1182/blood-2007-08-109488 Silverchair:107957 Unique_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Use of FoxP3 Diptheria Toxin Receptor (Foxp3DTR) Donor T Cells to Define the Mechanism Involved in the Inhibition of GvHD by Azacytidine in Vivo The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4113.4113 Silverchair:86619 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Use of FoxP3 Diptheria Toxin Receptor (Foxp3DTR) Donor T Cells to Define the Mechanism Involved in the Inhibition of GvHD by Azacytidine in Vivo The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4113.4113 Silverchair:86619 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Use of FoxP3 Diptheria Toxin Receptor (Foxp3DTR) Donor T Cells to Define the Mechanism Involved in the Inhibition of GvHD by Azacytidine in Vivo The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4113.4113 Silverchair:86619 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Use of FoxP3 Diptheria Toxin Receptor (Foxp3DTR) Donor T Cells to Define the Mechanism Involved in the Inhibition of GvHD by Azacytidine in Vivo The American Society of Hematology American Society of Hematology 10.1182/blood.V120.21.4113.4113 Silverchair:86619 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Essential Thrombocythemia: A Population-Based Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119118 Silverchair:262152 Total_Item_Investigations 7 0 7 0 0 0 0 0 0 0 0 0 0 "Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Essential Thrombocythemia: A Population-Based Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119118 Silverchair:262152 Total_Item_Requests 7 0 7 0 0 0 0 0 0 0 0 0 0 "Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Essential Thrombocythemia: A Population-Based Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119118 Silverchair:262152 Unique_Item_Investigations 5 0 5 0 0 0 0 0 0 0 0 0 0 "Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Essential Thrombocythemia: A Population-Based Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119118 Silverchair:262152 Unique_Item_Requests 5 0 5 0 0 0 0 0 0 0 0 0 0 "Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119272 Silverchair:264836 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119272 Silverchair:264836 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119272 Silverchair:264836 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based Study" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-119272 Silverchair:264836 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study The American Society of Hematology American Society of Hematology 10.1182/blood.2020007594 Silverchair:463333 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study The American Society of Hematology American Society of Hematology 10.1182/blood.2020007594 Silverchair:463333 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study The American Society of Hematology American Society of Hematology 10.1182/blood.2020007594 Silverchair:463333 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study The American Society of Hematology American Society of Hematology 10.1182/blood.2020007594 Silverchair:463333 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Use of Thymoglobulin for Graft Versus Host Disease Prophylaxis Does Not Increase the Incidence of Clostridium Difficile Infection in Recipients of Allogeneic Stem Cell Transplant Recipients The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.5447.5447 Silverchair:134585 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Use of Thymoglobulin for Graft Versus Host Disease Prophylaxis Does Not Increase the Incidence of Clostridium Difficile Infection in Recipients of Allogeneic Stem Cell Transplant Recipients The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.5447.5447 Silverchair:134585 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Use of Thymoglobulin for Graft Versus Host Disease Prophylaxis Does Not Increase the Incidence of Clostridium Difficile Infection in Recipients of Allogeneic Stem Cell Transplant Recipients The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.5447.5447 Silverchair:134585 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Use of Thymoglobulin for Graft Versus Host Disease Prophylaxis Does Not Increase the Incidence of Clostridium Difficile Infection in Recipients of Allogeneic Stem Cell Transplant Recipients The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.5447.5447 Silverchair:134585 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study The American Society of Hematology American Society of Hematology 10.1182/blood-2009-08-237354 Silverchair:27169 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study The American Society of Hematology American Society of Hematology 10.1182/blood-2009-08-237354 Silverchair:27169 Total_Item_Requests 4 0 4 0 0 0 0 0 0 0 0 0 0 Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study The American Society of Hematology American Society of Hematology 10.1182/blood-2009-08-237354 Silverchair:27169 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study The American Society of Hematology American Society of Hematology 10.1182/blood-2009-08-237354 Silverchair:27169 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Using mitochondrial activity to select for potent human hematopoietic stem cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003658 Silverchair:475469 Total_Item_Investigations 6 0 0 6 0 0 0 0 0 0 0 0 0 Using mitochondrial activity to select for potent human hematopoietic stem cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003658 Silverchair:475469 Total_Item_Requests 5 0 0 5 0 0 0 0 0 0 0 0 0 Using mitochondrial activity to select for potent human hematopoietic stem cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003658 Silverchair:475469 Unique_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Using mitochondrial activity to select for potent human hematopoietic stem cells American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003658 Silverchair:475469 Unique_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Utility of Safety Switch to Abrogate CD19.CAR T Cell-Associated Neurotoxicity The American Society of Hematology American Society of Hematology 10.1182/blood.2021010784 Silverchair:475336 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Utility of Safety Switch to Abrogate CD19.CAR T Cell-Associated Neurotoxicity The American Society of Hematology American Society of Hematology 10.1182/blood.2021010784 Silverchair:475336 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Utility of Telomere in Diagnosis of Bone Marrow Failure Syndromes The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4793.4793 Silverchair:93493 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Utility of Telomere in Diagnosis of Bone Marrow Failure Syndromes The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4793.4793 Silverchair:93493 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Utility of Telomere in Diagnosis of Bone Marrow Failure Syndromes The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4793.4793 Silverchair:93493 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Utility of Telomere in Diagnosis of Bone Marrow Failure Syndromes The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.4793.4793 Silverchair:93493 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122054 Silverchair:427036 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122054 Silverchair:427036 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122054 Silverchair:427036 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States The American Society of Hematology American Society of Hematology 10.1182/blood-2019-122054 Silverchair:427036 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 Validating a Novel Framework to Classify Inpatient Hematology Consultation Requests The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143185 Silverchair:473863 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Validating a Novel Framework to Classify Inpatient Hematology Consultation Requests The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143185 Silverchair:473863 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Validating a Novel Framework to Classify Inpatient Hematology Consultation Requests The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143185 Silverchair:473863 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Validating a Novel Framework to Classify Inpatient Hematology Consultation Requests The American Society of Hematology American Society of Hematology 10.1182/blood-2020-143185 Silverchair:473863 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Validation of International Working Group (IWG) Response Criteria in Higher-Risk Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC) The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.909.909 Silverchair:136444 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Validation of International Working Group (IWG) Response Criteria in Higher-Risk Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC) The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.909.909 Silverchair:136444 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Validation of International Working Group (IWG) Response Criteria in Higher-Risk Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC) The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.909.909 Silverchair:136444 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Validation of International Working Group (IWG) Response Criteria in Higher-Risk Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC) The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.909.909 Silverchair:136444 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Valine as a Key Metabolic Regulator of Hematopoietic Stem Cell Maintenance The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.SCI-20.SCI-20 Silverchair:83331 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Valine as a Key Metabolic Regulator of Hematopoietic Stem Cell Maintenance The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.SCI-20.SCI-20 Silverchair:83331 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Valine as a Key Metabolic Regulator of Hematopoietic Stem Cell Maintenance The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.SCI-20.SCI-20 Silverchair:83331 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Valine as a Key Metabolic Regulator of Hematopoietic Stem Cell Maintenance The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.SCI-20.SCI-20 Silverchair:83331 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Valproic Acid Expands the Numbers of HSCs from Cord Blood CD34+ Cells By Linking Epigenetic Modifications to Mitochondrial Remodeling and p53 Upregulation The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.369.369 Silverchair:97088 Total_Item_Investigations 6 0 0 6 0 0 0 0 0 0 0 0 0 Valproic Acid Expands the Numbers of HSCs from Cord Blood CD34+ Cells By Linking Epigenetic Modifications to Mitochondrial Remodeling and p53 Upregulation The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.369.369 Silverchair:97088 Total_Item_Requests 6 0 0 6 0 0 0 0 0 0 0 0 0 Valproic Acid Expands the Numbers of HSCs from Cord Blood CD34+ Cells By Linking Epigenetic Modifications to Mitochondrial Remodeling and p53 Upregulation The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.369.369 Silverchair:97088 Unique_Item_Investigations 3 0 0 3 0 0 0 0 0 0 0 0 0 Valproic Acid Expands the Numbers of HSCs from Cord Blood CD34+ Cells By Linking Epigenetic Modifications to Mitochondrial Remodeling and p53 Upregulation The American Society of Hematology American Society of Hematology 10.1182/blood.V128.22.369.369 Silverchair:97088 Unique_Item_Requests 3 0 0 3 0 0 0 0 0 0 0 0 0 Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14) The American Society of Hematology American Society of Hematology 10.1182/blood-2018-09-876433 Silverchair:39677 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14) The American Society of Hematology American Society of Hematology 10.1182/blood-2018-09-876433 Silverchair:39677 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14) The American Society of Hematology American Society of Hematology 10.1182/blood-2018-09-876433 Silverchair:39677 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14) The American Society of Hematology American Society of Hematology 10.1182/blood-2018-09-876433 Silverchair:39677 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Variable Response to BCL2 Inhibition in MDS Is Enhanced across MDS Subtypes with Synergistic Combination of BCL2+MCL1 Inhibition The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126578 Silverchair:423604 Total_Item_Investigations 3 0 2 0 1 0 0 0 0 0 0 0 0 Variable Response to BCL2 Inhibition in MDS Is Enhanced across MDS Subtypes with Synergistic Combination of BCL2+MCL1 Inhibition The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126578 Silverchair:423604 Total_Item_Requests 3 0 2 0 1 0 0 0 0 0 0 0 0 Variable Response to BCL2 Inhibition in MDS Is Enhanced across MDS Subtypes with Synergistic Combination of BCL2+MCL1 Inhibition The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126578 Silverchair:423604 Unique_Item_Investigations 3 0 2 0 1 0 0 0 0 0 0 0 0 Variable Response to BCL2 Inhibition in MDS Is Enhanced across MDS Subtypes with Synergistic Combination of BCL2+MCL1 Inhibition The American Society of Hematology American Society of Hematology 10.1182/blood-2019-126578 Silverchair:423604 Unique_Item_Requests 3 0 2 0 1 0 0 0 0 0 0 0 0 Vascular complications after splenectomy for hematologic disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2009-04-210112 Silverchair:107813 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Vascular complications after splenectomy for hematologic disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2009-04-210112 Silverchair:107813 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Vascular complications after splenectomy for hematologic disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2009-04-210112 Silverchair:107813 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Vascular complications after splenectomy for hematologic disorders The American Society of Hematology American Society of Hematology 10.1182/blood-2009-04-210112 Silverchair:107813 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In VivoPresented in part at the Keystone Symposium “Cellular and Molecular Biology of Dendritic Cells,” Santa Fe, NM, March 3-9, 1998, and at the annual meeting of the American Association for Cancer Research, March 28-April 1, 1998." The American Society of Hematology American Society of Hematology 10.1182/blood.V92.11.4150 Silverchair:260294 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 "Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In VivoPresented in part at the Keystone Symposium “Cellular and Molecular Biology of Dendritic Cells,” Santa Fe, NM, March 3-9, 1998, and at the annual meeting of the American Association for Cancer Research, March 28-April 1, 1998." The American Society of Hematology American Society of Hematology 10.1182/blood.V92.11.4150 Silverchair:260294 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 "Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In VivoPresented in part at the Keystone Symposium “Cellular and Molecular Biology of Dendritic Cells,” Santa Fe, NM, March 3-9, 1998, and at the annual meeting of the American Association for Cancer Research, March 28-April 1, 1998." The American Society of Hematology American Society of Hematology 10.1182/blood.V92.11.4150 Silverchair:260294 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In VivoPresented in part at the Keystone Symposium “Cellular and Molecular Biology of Dendritic Cells,” Santa Fe, NM, March 3-9, 1998, and at the annual meeting of the American Association for Cancer Research, March 28-April 1, 1998." The American Society of Hematology American Society of Hematology 10.1182/blood.V92.11.4150 Silverchair:260294 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome) The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-375816 Silverchair:30106 Total_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome) The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-375816 Silverchair:30106 Total_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome) The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-375816 Silverchair:30106 Unique_Item_Investigations 2 1 0 1 0 0 0 0 0 0 0 0 0 Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome) The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-375816 Silverchair:30106 Unique_Item_Requests 2 1 0 1 0 0 0 0 0 0 0 0 0 Vasculogenesis in the day 6.5 to 9.5 mouse embryo The American Society of Hematology American Society of Hematology 10.1182/blood.V95.5.1671.005k39_1671_1679 Silverchair:138775 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 Vasculogenesis in the day 6.5 to 9.5 mouse embryo The American Society of Hematology American Society of Hematology 10.1182/blood.V95.5.1671.005k39_1671_1679 Silverchair:138775 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 Vasculogenesis in the day 6.5 to 9.5 mouse embryo The American Society of Hematology American Society of Hematology 10.1182/blood.V95.5.1671.005k39_1671_1679 Silverchair:138775 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Vasculogenesis in the day 6.5 to 9.5 mouse embryo The American Society of Hematology American Society of Hematology 10.1182/blood.V95.5.1671.005k39_1671_1679 Silverchair:138775 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000893 Silverchair:429588 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000893 Silverchair:429588 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000893 Silverchair:429588 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2019000893 Silverchair:429588 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 VEGF-A recruits a proangiogenic MMP-9–delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-421040 Silverchair:30890 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 VEGF-A recruits a proangiogenic MMP-9–delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-421040 Silverchair:30890 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 VEGF-A recruits a proangiogenic MMP-9–delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-421040 Silverchair:30890 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 VEGF-A recruits a proangiogenic MMP-9–delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue The American Society of Hematology American Society of Hematology 10.1182/blood-2012-04-421040 Silverchair:30890 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells The American Society of Hematology American Society of Hematology 10.1182/blood-2002-03-0755 Silverchair:88929 Total_Item_Investigations 4 0 4 0 0 0 0 0 0 0 0 0 0 VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells The American Society of Hematology American Society of Hematology 10.1182/blood-2002-03-0755 Silverchair:88929 Total_Item_Requests 4 0 4 0 0 0 0 0 0 0 0 0 0 VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells The American Society of Hematology American Society of Hematology 10.1182/blood-2002-03-0755 Silverchair:88929 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells The American Society of Hematology American Society of Hematology 10.1182/blood-2002-03-0755 Silverchair:88929 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Venetoclax Alone or in Combination with Chemotherapy: Responses in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia with Heterogeneous Genomic Profiles The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136999 Silverchair:470553 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Venetoclax Alone or in Combination with Chemotherapy: Responses in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia with Heterogeneous Genomic Profiles The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136999 Silverchair:470553 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 Venetoclax Alone or in Combination with Chemotherapy: Responses in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia with Heterogeneous Genomic Profiles The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136999 Silverchair:470553 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 Venetoclax Alone or in Combination with Chemotherapy: Responses in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia with Heterogeneous Genomic Profiles The American Society of Hematology American Society of Hematology 10.1182/blood-2020-136999 Silverchair:470553 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 "Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001482 Silverchair:461122 Total_Item_Investigations 17 4 1 3 5 0 1 2 0 0 1 0 0 "Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001482 Silverchair:461122 Total_Item_Requests 14 4 1 3 3 0 1 1 0 0 1 0 0 "Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001482 Silverchair:461122 Unique_Item_Investigations 11 3 1 2 2 0 1 1 0 0 1 0 0 "Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure" American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020001482 Silverchair:461122 Unique_Item_Requests 11 3 1 2 2 0 1 1 0 0 1 0 0 Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020008608 Silverchair:464169 No_License 1 0 1 0 0 0 0 0 0 0 0 0 0 Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020008608 Silverchair:464169 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia The American Society of Hematology American Society of Hematology 10.1182/blood.2020008608 Silverchair:464169 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114840 Silverchair:263947 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114840 Silverchair:263947 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114840 Silverchair:263947 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-114840 Silverchair:263947 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 "Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-868752 Silverchair:6611 Total_Item_Investigations 14 7 0 5 0 0 0 0 0 0 2 0 0 "Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-868752 Silverchair:6611 Total_Item_Requests 14 7 0 5 0 0 0 0 0 0 2 0 0 "Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-868752 Silverchair:6611 Unique_Item_Investigations 12 7 0 4 0 0 0 0 0 0 1 0 0 "Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia" The American Society of Hematology American Society of Hematology 10.1182/blood-2018-08-868752 Silverchair:6611 Unique_Item_Requests 12 7 0 4 0 0 0 0 0 0 1 0 0 Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131988 Silverchair:423225 Total_Item_Investigations 12 9 2 0 0 0 0 1 0 0 0 0 0 Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131988 Silverchair:423225 Total_Item_Requests 12 9 2 0 0 0 0 1 0 0 0 0 0 Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131988 Silverchair:423225 Unique_Item_Investigations 12 9 2 0 0 0 0 1 0 0 0 0 0 Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2019-131988 Silverchair:423225 Unique_Item_Requests 12 9 2 0 0 0 0 1 0 0 0 0 0 Venetoclax Enhances Anti-Leukemia Activity of CD123-Specific BiTE-Secreting T-Cells in AML The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139625 Silverchair:471567 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Venetoclax Enhances Anti-Leukemia Activity of CD123-Specific BiTE-Secreting T-Cells in AML The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139625 Silverchair:471567 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Venetoclax Enhances Anti-Leukemia Activity of CD123-Specific BiTE-Secreting T-Cells in AML The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139625 Silverchair:471567 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Venetoclax Enhances Anti-Leukemia Activity of CD123-Specific BiTE-Secreting T-Cells in AML The American Society of Hematology American Society of Hematology 10.1182/blood-2020-139625 Silverchair:471567 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127416 Silverchair:424199 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127416 Silverchair:424199 Total_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127416 Silverchair:424199 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127416 Silverchair:424199 Unique_Item_Requests 1 0 0 0 0 0 0 0 1 0 0 0 0 Venetoclax Is Safe and Tolerable As Post-Transplant Maintenance Therapy for AML Patients at High Risk for Relapse The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138832 Silverchair:472106 Total_Item_Investigations 7 4 1 2 0 0 0 0 0 0 0 0 0 Venetoclax Is Safe and Tolerable As Post-Transplant Maintenance Therapy for AML Patients at High Risk for Relapse The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138832 Silverchair:472106 Total_Item_Requests 7 4 1 2 0 0 0 0 0 0 0 0 0 Venetoclax Is Safe and Tolerable As Post-Transplant Maintenance Therapy for AML Patients at High Risk for Relapse The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138832 Silverchair:472106 Unique_Item_Investigations 3 1 1 1 0 0 0 0 0 0 0 0 0 Venetoclax Is Safe and Tolerable As Post-Transplant Maintenance Therapy for AML Patients at High Risk for Relapse The American Society of Hematology American Society of Hematology 10.1182/blood-2020-138832 Silverchair:472106 Unique_Item_Requests 3 1 1 1 0 0 0 0 0 0 0 0 0 Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial The American Society of Hematology American Society of Hematology 10.1182/blood.2020004856 Silverchair:454176 Total_Item_Investigations 4 0 1 0 0 0 0 0 0 3 0 0 0 Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial The American Society of Hematology American Society of Hematology 10.1182/blood.2020004856 Silverchair:454176 Total_Item_Requests 4 0 1 0 0 0 0 0 0 3 0 0 0 Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial The American Society of Hematology American Society of Hematology 10.1182/blood.2020004856 Silverchair:454176 Unique_Item_Investigations 2 0 1 0 0 0 0 0 0 1 0 0 0 Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial The American Society of Hematology American Society of Hematology 10.1182/blood.2020004856 Silverchair:454176 Unique_Item_Requests 2 0 1 0 0 0 0 0 0 1 0 0 0 Venetoclax Resistance in Mantle Cell Lymphoma Is Mediated By BCL-XL and Can be Circumvent By Inhibiting the BH4 Domain of BCL-2 The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127931 Silverchair:427336 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Venetoclax Resistance in Mantle Cell Lymphoma Is Mediated By BCL-XL and Can be Circumvent By Inhibiting the BH4 Domain of BCL-2 The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127931 Silverchair:427336 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Venetoclax Resistance in Mantle Cell Lymphoma Is Mediated By BCL-XL and Can be Circumvent By Inhibiting the BH4 Domain of BCL-2 The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127931 Silverchair:427336 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Venetoclax Resistance in Mantle Cell Lymphoma Is Mediated By BCL-XL and Can be Circumvent By Inhibiting the BH4 Domain of BCL-2 The American Society of Hematology American Society of Hematology 10.1182/blood-2019-127931 Silverchair:427336 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression The American Society of Hematology American Society of Hematology 10.1182/blood.2020007899 Silverchair:475387 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression The American Society of Hematology American Society of Hematology 10.1182/blood.2020007899 Silverchair:475387 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression The American Society of Hematology American Society of Hematology 10.1182/blood.2020007899 Silverchair:475387 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression The American Society of Hematology American Society of Hematology 10.1182/blood.2020007899 Silverchair:475387 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002060 Silverchair:463596 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002060 Silverchair:463596 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002060 Silverchair:463596 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002060 Silverchair:463596 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-08-175745 Silverchair:25565 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-08-175745 Silverchair:25565 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-08-175745 Silverchair:25565 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival" The American Society of Hematology American Society of Hematology 10.1182/blood-2008-08-175745 Silverchair:25565 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1 The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-267740 Silverchair:27360 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1 The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-267740 Silverchair:27360 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1 The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-267740 Silverchair:27360 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1 The American Society of Hematology American Society of Hematology 10.1182/blood-2010-02-267740 Silverchair:27360 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 VEXAS syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2021011455 Silverchair:475940 Total_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 VEXAS syndrome The American Society of Hematology American Society of Hematology 10.1182/blood.2021011455 Silverchair:475940 Unique_Item_Investigations 1 0 0 0 0 0 0 0 1 0 0 0 0 "VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-201731 Silverchair:26430 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-201731 Silverchair:26430 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-201731 Silverchair:26430 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy" The American Society of Hematology American Society of Hematology 10.1182/blood-2009-01-201731 Silverchair:26430 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Vincristine Induced Peripheral Neuropathy: A Randomized Controlled Trial Comparing Bolus Injections with One Hour Infusions during Induction in a Pediatric Population of Acute Lymphoblastic Leukemia and Hodgkin's Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115905 Silverchair:265870 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Vincristine Induced Peripheral Neuropathy: A Randomized Controlled Trial Comparing Bolus Injections with One Hour Infusions during Induction in a Pediatric Population of Acute Lymphoblastic Leukemia and Hodgkin's Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115905 Silverchair:265870 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Vincristine Induced Peripheral Neuropathy: A Randomized Controlled Trial Comparing Bolus Injections with One Hour Infusions during Induction in a Pediatric Population of Acute Lymphoblastic Leukemia and Hodgkin's Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115905 Silverchair:265870 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Vincristine Induced Peripheral Neuropathy: A Randomized Controlled Trial Comparing Bolus Injections with One Hour Infusions during Induction in a Pediatric Population of Acute Lymphoblastic Leukemia and Hodgkin's Lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115905 Silverchair:265870 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Viral Infections in Patients with Hematological Malignancies The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.368 Silverchair:19807 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Viral Infections in Patients with Hematological Malignancies The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.368 Silverchair:19807 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Viral Infections in Patients with Hematological Malignancies The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.368 Silverchair:19807 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Viral Infections in Patients with Hematological Malignancies The American Society of Hematology American Society of Hematology 10.1182/asheducation-2006.1.368 Silverchair:19807 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Viral, immunologic, and clinical features of primary effusion lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-01-893339 Silverchair:260503 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Viral, immunologic, and clinical features of primary effusion lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-01-893339 Silverchair:260503 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "Viral, immunologic, and clinical features of primary effusion lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-01-893339 Silverchair:260503 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "Viral, immunologic, and clinical features of primary effusion lymphoma" The American Society of Hematology American Society of Hematology 10.1182/blood-2019-01-893339 Silverchair:260503 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Visualizing hematopoiesis as a stochastic process American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018023705 Silverchair:16120 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Visualizing hematopoiesis as a stochastic process American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018023705 Silverchair:16120 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Visualizing hematopoiesis as a stochastic process American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018023705 Silverchair:16120 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Visualizing hematopoiesis as a stochastic process American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2018023705 Silverchair:16120 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Vitamin B12 deficiency from the perspective of a practicing hematologist The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-569186 Silverchair:36140 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Vitamin B12 deficiency from the perspective of a practicing hematologist The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-569186 Silverchair:36140 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Vitamin B12 deficiency from the perspective of a practicing hematologist The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-569186 Silverchair:36140 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Vitamin B12 deficiency from the perspective of a practicing hematologist The American Society of Hematology American Society of Hematology 10.1182/blood-2016-10-569186 Silverchair:36140 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Vitamin K supplementation during oral anticoagulation: cautions The American Society of Hematology American Society of Hematology 10.1182/blood-2006-12-061200 Silverchair:23700 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Vitamin K supplementation during oral anticoagulation: cautions The American Society of Hematology American Society of Hematology 10.1182/blood-2006-12-061200 Silverchair:23700 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Vitamin K supplementation during oral anticoagulation: cautions The American Society of Hematology American Society of Hematology 10.1182/blood-2006-12-061200 Silverchair:23700 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Vitamin K supplementation during oral anticoagulation: cautions The American Society of Hematology American Society of Hematology 10.1182/blood-2006-12-061200 Silverchair:23700 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Vitamin K–containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7 The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-040709 Silverchair:23729 Total_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 Vitamin K–containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7 The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-040709 Silverchair:23729 Total_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0 Vitamin K–containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7 The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-040709 Silverchair:23729 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Vitamin K–containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7 The American Society of Hematology American Society of Hematology 10.1182/blood-2006-08-040709 Silverchair:23729 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 von Willebrand Disease in Chronic Immune Thrombocytopenic Purpura Children. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3954.3954 Silverchair:58246 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 von Willebrand Disease in Chronic Immune Thrombocytopenic Purpura Children. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3954.3954 Silverchair:58246 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 von Willebrand Disease in Chronic Immune Thrombocytopenic Purpura Children. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3954.3954 Silverchair:58246 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 von Willebrand Disease in Chronic Immune Thrombocytopenic Purpura Children. The American Society of Hematology American Society of Hematology 10.1182/blood.V110.11.3954.3954 Silverchair:58246 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 von Willebrand disease: what does the future hold? The American Society of Hematology American Society of Hematology 10.1182/blood.2020008501 Silverchair:475456 No_License 1 0 0 0 0 1 0 0 0 0 0 0 0 von Willebrand disease: what does the future hold? The American Society of Hematology American Society of Hematology 10.1182/blood.2020008501 Silverchair:475456 Total_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 von Willebrand disease: what does the future hold? The American Society of Hematology American Society of Hematology 10.1182/blood.2020008501 Silverchair:475456 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 Von Willebrand Factor Collagen Binding Provides a Sensitive Screen for Identification of Type 2A and 2B Von Willebrand Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.379.379 Silverchair:69017 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Von Willebrand Factor Collagen Binding Provides a Sensitive Screen for Identification of Type 2A and 2B Von Willebrand Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.379.379 Silverchair:69017 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Von Willebrand Factor Collagen Binding Provides a Sensitive Screen for Identification of Type 2A and 2B Von Willebrand Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.379.379 Silverchair:69017 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Von Willebrand Factor Collagen Binding Provides a Sensitive Screen for Identification of Type 2A and 2B Von Willebrand Disease The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.379.379 Silverchair:69017 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 VT duets: inflammation/coagulation—wall/flow The American Society of Hematology American Society of Hematology 10.1182/blood.2021010838 Silverchair:475745 Total_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 VT duets: inflammation/coagulation—wall/flow The American Society of Hematology American Society of Hematology 10.1182/blood.2021010838 Silverchair:475745 Total_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 VT duets: inflammation/coagulation—wall/flow The American Society of Hematology American Society of Hematology 10.1182/blood.2021010838 Silverchair:475745 Unique_Item_Investigations 1 0 0 0 1 0 0 0 0 0 0 0 0 VT duets: inflammation/coagulation—wall/flow The American Society of Hematology American Society of Hematology 10.1182/blood.2021010838 Silverchair:475745 Unique_Item_Requests 1 0 0 0 1 0 0 0 0 0 0 0 0 VTE risk and family history: provocative findings The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-592535 Silverchair:33054 Total_Item_Investigations 3 2 0 0 0 0 0 0 0 0 1 0 0 VTE risk and family history: provocative findings The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-592535 Silverchair:33054 Total_Item_Requests 3 2 0 0 0 0 0 0 0 0 1 0 0 VTE risk and family history: provocative findings The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-592535 Silverchair:33054 Unique_Item_Investigations 2 1 0 0 0 0 0 0 0 0 1 0 0 VTE risk and family history: provocative findings The American Society of Hematology American Society of Hematology 10.1182/blood-2014-08-592535 Silverchair:33054 Unique_Item_Requests 2 1 0 0 0 0 0 0 0 0 1 0 0 VWF antigen levels are associated with burden of rare nonsynonymous variants in the VWF gene The American Society of Hematology American Society of Hematology 10.1182/blood.2020009999 Silverchair:475195 Total_Item_Investigations 5 0 5 0 0 0 0 0 0 0 0 0 0 VWF antigen levels are associated with burden of rare nonsynonymous variants in the VWF gene The American Society of Hematology American Society of Hematology 10.1182/blood.2020009999 Silverchair:475195 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 VWF antigen levels are associated with burden of rare nonsynonymous variants in the VWF gene The American Society of Hematology American Society of Hematology 10.1182/blood.2020009999 Silverchair:475195 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 VWF antigen levels are associated with burden of rare nonsynonymous variants in the VWF gene The American Society of Hematology American Society of Hematology 10.1182/blood.2020009999 Silverchair:475195 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 VWF maturation and release are controlled by 2 regulators of Weibel-Palade body biogenesis: exocyst and BLOC-2 The American Society of Hematology American Society of Hematology 10.1182/blood.2020005300 Silverchair:461261 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 0 0 2 VWF maturation and release are controlled by 2 regulators of Weibel-Palade body biogenesis: exocyst and BLOC-2 The American Society of Hematology American Society of Hematology 10.1182/blood.2020005300 Silverchair:461261 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 0 0 2 VWF maturation and release are controlled by 2 regulators of Weibel-Palade body biogenesis: exocyst and BLOC-2 The American Society of Hematology American Society of Hematology 10.1182/blood.2020005300 Silverchair:461261 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 0 0 1 VWF maturation and release are controlled by 2 regulators of Weibel-Palade body biogenesis: exocyst and BLOC-2 The American Society of Hematology American Society of Hematology 10.1182/blood.2020005300 Silverchair:461261 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 0 0 1 Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-335612 Silverchair:29212 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-335612 Silverchair:29212 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-335612 Silverchair:29212 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility The American Society of Hematology American Society of Hematology 10.1182/blood-2011-08-335612 Silverchair:29212 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Warm antibody autoimmune hemolytic anemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.690 Silverchair:21048 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Warm antibody autoimmune hemolytic anemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.690 Silverchair:21048 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Warm antibody autoimmune hemolytic anemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.690 Silverchair:21048 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Warm antibody autoimmune hemolytic anemia The American Society of Hematology American Society of Hematology 10.1182/asheducation-2016.1.690 Silverchair:21048 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "We do still transplant CML, don’t we?" The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.177 Silverchair:277555 Total_Item_Investigations 3 0 0 0 0 3 0 0 0 0 0 0 0 "We do still transplant CML, don’t we?" The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.177 Silverchair:277555 Total_Item_Requests 3 0 0 0 0 3 0 0 0 0 0 0 0 "We do still transplant CML, don’t we?" The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.177 Silverchair:277555 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 "We do still transplant CML, don’t we?" The American Society of Hematology American Society of Hematology 10.1182/asheducation-2018.1.177 Silverchair:277555 Unique_Item_Requests 1 0 0 0 0 1 0 0 0 0 0 0 0 "Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCyd) in Elderly Newly Diagnosed Multiple Myeloma Patients: Results of a Phase 2 Study" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.1828.1828 Silverchair:134812 Total_Item_Investigations 2 0 0 2 0 0 0 0 0 0 0 0 0 "Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCyd) in Elderly Newly Diagnosed Multiple Myeloma Patients: Results of a Phase 2 Study" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.1828.1828 Silverchair:134812 Total_Item_Requests 2 0 0 2 0 0 0 0 0 0 0 0 0 "Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCyd) in Elderly Newly Diagnosed Multiple Myeloma Patients: Results of a Phase 2 Study" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.1828.1828 Silverchair:134812 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCyd) in Elderly Newly Diagnosed Multiple Myeloma Patients: Results of a Phase 2 Study" The American Society of Hematology American Society of Hematology 10.1182/blood.V126.23.1828.1828 Silverchair:134812 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Weekly Dosing of Bortezomib in RVD Achieves Minimal Toxicity with No Reduction in Efficacy in a Diverse Cohort of Multiple Myeloma Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5425.5425 Silverchair:115962 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Weekly Dosing of Bortezomib in RVD Achieves Minimal Toxicity with No Reduction in Efficacy in a Diverse Cohort of Multiple Myeloma Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5425.5425 Silverchair:115962 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Weekly Dosing of Bortezomib in RVD Achieves Minimal Toxicity with No Reduction in Efficacy in a Diverse Cohort of Multiple Myeloma Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5425.5425 Silverchair:115962 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Weekly Dosing of Bortezomib in RVD Achieves Minimal Toxicity with No Reduction in Efficacy in a Diverse Cohort of Multiple Myeloma Patients The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.5425.5425 Silverchair:115962 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.480 Silverchair:21108 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.480 Silverchair:21108 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.480 Silverchair:21108 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2017.1.480 Silverchair:21108 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 What is the effect of rivaroxaban on routine coagulation tests? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.334 Silverchair:20283 Total_Item_Investigations 3 0 1 2 0 0 0 0 0 0 0 0 0 What is the effect of rivaroxaban on routine coagulation tests? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.334 Silverchair:20283 Total_Item_Requests 3 0 1 2 0 0 0 0 0 0 0 0 0 What is the effect of rivaroxaban on routine coagulation tests? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.334 Silverchair:20283 Unique_Item_Investigations 3 0 1 2 0 0 0 0 0 0 0 0 0 What is the effect of rivaroxaban on routine coagulation tests? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.334 Silverchair:20283 Unique_Item_Requests 3 0 1 2 0 0 0 0 0 0 0 0 0 What is the role of hemodialysis for dabigatran-associated major bleeding? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.514 Silverchair:20459 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 2 0 0 0 What is the role of hemodialysis for dabigatran-associated major bleeding? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.514 Silverchair:20459 Total_Item_Requests 2 0 0 0 0 0 0 0 0 2 0 0 0 What is the role of hemodialysis for dabigatran-associated major bleeding? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.514 Silverchair:20459 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 What is the role of hemodialysis for dabigatran-associated major bleeding? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2014.1.514 Silverchair:20459 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 What to tell your patient with clonal hematopoiesis and why: insights from 2 specialized clinics The American Society of Hematology American Society of Hematology 10.1182/blood.2019004291 Silverchair:461666 No_License 1 0 0 0 0 1 0 0 0 0 0 0 0 What to tell your patient with clonal hematopoiesis and why: insights from 2 specialized clinics The American Society of Hematology American Society of Hematology 10.1182/blood.2019004291 Silverchair:461666 Total_Item_Investigations 2 0 0 0 0 2 0 0 0 0 0 0 0 What to tell your patient with clonal hematopoiesis and why: insights from 2 specialized clinics The American Society of Hematology American Society of Hematology 10.1182/blood.2019004291 Silverchair:461666 Unique_Item_Investigations 1 0 0 0 0 1 0 0 0 0 0 0 0 What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.2021010764 Silverchair:475788 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 2 0 0 0 What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms The American Society of Hematology American Society of Hematology 10.1182/blood.2021010764 Silverchair:475788 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 What’s NEXT for CML-NGS mutation screening The American Society of Hematology American Society of Hematology 10.1182/blood.2019004559 Silverchair:452499 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 What’s NEXT for CML-NGS mutation screening The American Society of Hematology American Society of Hematology 10.1182/blood.2019004559 Silverchair:452499 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 What’s NEXT for CML-NGS mutation screening The American Society of Hematology American Society of Hematology 10.1182/blood.2019004559 Silverchair:452499 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 What’s NEXT for CML-NGS mutation screening The American Society of Hematology American Society of Hematology 10.1182/blood.2019004559 Silverchair:452499 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 When and why should patients with hematologic malignancies see a palliative care specialist? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.471 Silverchair:20672 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 When and why should patients with hematologic malignancies see a palliative care specialist? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.471 Silverchair:20672 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 When and why should patients with hematologic malignancies see a palliative care specialist? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.471 Silverchair:20672 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 When and why should patients with hematologic malignancies see a palliative care specialist? The American Society of Hematology American Society of Hematology 10.1182/asheducation-2015.1.471 Silverchair:20672 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-625582 Silverchair:35211 Total_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-625582 Silverchair:35211 Total_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-625582 Silverchair:35211 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 1 0 0 0 When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data The American Society of Hematology American Society of Hematology 10.1182/blood-2015-01-625582 Silverchair:35211 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 1 0 0 0 When can we stop anticoagulation in patients with cancer-associated thrombosis? The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-787929 Silverchair:36741 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 When can we stop anticoagulation in patients with cancer-associated thrombosis? The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-787929 Silverchair:36741 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 When can we stop anticoagulation in patients with cancer-associated thrombosis? The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-787929 Silverchair:36741 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 When can we stop anticoagulation in patients with cancer-associated thrombosis? The American Society of Hematology American Society of Hematology 10.1182/blood-2017-05-787929 Silverchair:36741 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 When I treat a patient with acute pulmonary embolism at home The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000106 Silverchair:474300 Total_Item_Investigations 3 0 0 0 1 0 2 0 0 0 0 0 0 When I treat a patient with acute pulmonary embolism at home The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000106 Silverchair:474300 Total_Item_Requests 3 0 0 0 1 0 2 0 0 0 0 0 0 When I treat a patient with acute pulmonary embolism at home The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000106 Silverchair:474300 Unique_Item_Investigations 2 0 0 0 1 0 1 0 0 0 0 0 0 When I treat a patient with acute pulmonary embolism at home The American Society of Hematology American Society of Hematology 10.1182/hematology.2020000106 Silverchair:474300 Unique_Item_Requests 2 0 0 0 1 0 1 0 0 0 0 0 0 When non-Whiteness becomes a condition The American Society of Hematology American Society of Hematology 10.1182/blood.2020008600 Silverchair:474140 Total_Item_Investigations 8 6 0 0 0 0 0 0 0 0 0 0 2 When non-Whiteness becomes a condition The American Society of Hematology American Society of Hematology 10.1182/blood.2020008600 Silverchair:474140 Total_Item_Requests 7 5 0 0 0 0 0 0 0 0 0 0 2 When non-Whiteness becomes a condition The American Society of Hematology American Society of Hematology 10.1182/blood.2020008600 Silverchair:474140 Unique_Item_Investigations 6 5 0 0 0 0 0 0 0 0 0 0 1 When non-Whiteness becomes a condition The American Society of Hematology American Society of Hematology 10.1182/blood.2020008600 Silverchair:474140 Unique_Item_Requests 6 5 0 0 0 0 0 0 0 0 0 0 1 When to transplant in myelodysplasia? Markov helps The American Society of Hematology American Society of Hematology 10.1182/blood-2004-05-1689 Silverchair:18271 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 When to transplant in myelodysplasia? Markov helps The American Society of Hematology American Society of Hematology 10.1182/blood-2004-05-1689 Silverchair:18271 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 When to transplant in myelodysplasia? Markov helps The American Society of Hematology American Society of Hematology 10.1182/blood-2004-05-1689 Silverchair:18271 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 When to transplant in myelodysplasia? Markov helps The American Society of Hematology American Society of Hematology 10.1182/blood-2004-05-1689 Silverchair:18271 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Which ’roid is all the rage? The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-678854 Silverchair:34876 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Which ’roid is all the rage? The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-678854 Silverchair:34876 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Which ’roid is all the rage? The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-678854 Silverchair:34876 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Which ’roid is all the rage? The American Society of Hematology American Society of Hematology 10.1182/blood-2015-11-678854 Silverchair:34876 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)? American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002268 Silverchair:474115 Total_Item_Investigations 5 0 5 0 0 0 0 0 0 0 0 0 0 Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)? American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002268 Silverchair:474115 Total_Item_Requests 5 0 5 0 0 0 0 0 0 0 0 0 0 Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)? American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002268 Silverchair:474115 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)? American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002268 Silverchair:474115 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020002268 Silverchair:474347 Total_Item_Investigations 4 2 0 0 0 0 0 0 0 0 0 0 2 Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020002268 Silverchair:474347 Total_Item_Requests 4 2 0 0 0 0 0 0 0 0 0 0 2 Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020002268 Silverchair:474347 Unique_Item_Investigations 2 1 0 0 0 0 0 0 0 0 0 0 1 Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)? The American Society of Hematology American Society of Hematology 10.1182/hematology.2020002268 Silverchair:474347 Unique_Item_Requests 2 1 0 0 0 0 0 0 0 0 0 0 1 WHO-EORTC classification for cutaneous lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2004-09-3502 Silverchair:19915 Total_Item_Investigations 3 3 0 0 0 0 0 0 0 0 0 0 0 WHO-EORTC classification for cutaneous lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2004-09-3502 Silverchair:19915 Total_Item_Requests 3 3 0 0 0 0 0 0 0 0 0 0 0 WHO-EORTC classification for cutaneous lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2004-09-3502 Silverchair:19915 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 WHO-EORTC classification for cutaneous lymphomas The American Society of Hematology American Society of Hematology 10.1182/blood-2004-09-3502 Silverchair:19915 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Whole Exome Sequencing and Extended Thrombophilia Testing in Patients with Venous Thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115529 Silverchair:264333 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Whole Exome Sequencing and Extended Thrombophilia Testing in Patients with Venous Thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115529 Silverchair:264333 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Whole Exome Sequencing and Extended Thrombophilia Testing in Patients with Venous Thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115529 Silverchair:264333 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Whole Exome Sequencing and Extended Thrombophilia Testing in Patients with Venous Thromboembolism The American Society of Hematology American Society of Hematology 10.1182/blood-2018-99-115529 Silverchair:264333 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-391474 Silverchair:30249 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-391474 Silverchair:30249 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-391474 Silverchair:30249 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma The American Society of Hematology American Society of Hematology 10.1182/blood-2011-11-391474 Silverchair:30249 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Whole-exome sequencing identifies rare variants in STAB2 associated with venous thromboembolic disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019004161 Silverchair:457788 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Whole-exome sequencing identifies rare variants in STAB2 associated with venous thromboembolic disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019004161 Silverchair:457788 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Whole-exome sequencing identifies rare variants in STAB2 associated with venous thromboembolic disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019004161 Silverchair:457788 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 Whole-exome sequencing identifies rare variants in STAB2 associated with venous thromboembolic disease The American Society of Hematology American Society of Hematology 10.1182/blood.2019004161 Silverchair:457788 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Whole-exome sequencing in evaluation of patients with venous thromboembolism American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017005249 Silverchair:15638 Total_Item_Investigations 19 3 2 5 0 0 0 0 0 3 0 3 3 Whole-exome sequencing in evaluation of patients with venous thromboembolism American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017005249 Silverchair:15638 Total_Item_Requests 18 3 1 5 0 0 0 0 0 3 0 3 3 Whole-exome sequencing in evaluation of patients with venous thromboembolism American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017005249 Silverchair:15638 Unique_Item_Investigations 7 1 1 2 0 0 0 0 0 1 0 1 1 Whole-exome sequencing in evaluation of patients with venous thromboembolism American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2017005249 Silverchair:15638 Unique_Item_Requests 7 1 1 2 0 0 0 0 0 1 0 1 1 Whole-genome sequencing suggests a role of MIF in the pathophysiology of TEMPI syndrome American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003783 Silverchair:476128 Total_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Whole-genome sequencing suggests a role of MIF in the pathophysiology of TEMPI syndrome American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003783 Silverchair:476128 Total_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 Whole-genome sequencing suggests a role of MIF in the pathophysiology of TEMPI syndrome American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003783 Silverchair:476128 Unique_Item_Investigations 1 0 0 0 0 0 1 0 0 0 0 0 0 Whole-genome sequencing suggests a role of MIF in the pathophysiology of TEMPI syndrome American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020003783 Silverchair:476128 Unique_Item_Requests 1 0 0 0 0 0 1 0 0 0 0 0 0 "Wnt5a Induces Interleukin-6 Via a ROR1-Dependent Pathway in Chronic Lymphocytic Leukemia, Leading to Leukemia-Cell Activation of STAT3" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4282.4282 Silverchair:72768 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Wnt5a Induces Interleukin-6 Via a ROR1-Dependent Pathway in Chronic Lymphocytic Leukemia, Leading to Leukemia-Cell Activation of STAT3" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4282.4282 Silverchair:72768 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 "Wnt5a Induces Interleukin-6 Via a ROR1-Dependent Pathway in Chronic Lymphocytic Leukemia, Leading to Leukemia-Cell Activation of STAT3" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4282.4282 Silverchair:72768 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 "Wnt5a Induces Interleukin-6 Via a ROR1-Dependent Pathway in Chronic Lymphocytic Leukemia, Leading to Leukemia-Cell Activation of STAT3" The American Society of Hematology American Society of Hematology 10.1182/blood.V130.Suppl_1.4282.4282 Silverchair:72768 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Xenograft models for normal and malignant stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-570218 Silverchair:34128 Total_Item_Investigations 10 0 10 0 0 0 0 0 0 0 0 0 0 Xenograft models for normal and malignant stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-570218 Silverchair:34128 Total_Item_Requests 5 0 5 0 0 0 0 0 0 0 0 0 0 Xenograft models for normal and malignant stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-570218 Silverchair:34128 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Xenograft models for normal and malignant stem cells The American Society of Hematology American Society of Hematology 10.1182/blood-2014-11-570218 Silverchair:34128 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Yolk sac–derived primitive erythroblasts enucleate during mammalian embryogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2003-12-4162 Silverchair:114392 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Yolk sac–derived primitive erythroblasts enucleate during mammalian embryogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2003-12-4162 Silverchair:114392 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 Yolk sac–derived primitive erythroblasts enucleate during mammalian embryogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2003-12-4162 Silverchair:114392 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 Yolk sac–derived primitive erythroblasts enucleate during mammalian embryogenesis The American Society of Hematology American Society of Hematology 10.1182/blood-2003-12-4162 Silverchair:114392 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Young Adults Presenting with Extramedullary Acute Myeloid Leukemia Have A Unique Sensitivity to High Doses of Anthracyclines: Subset Analysis of ECOG 1900," The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.3619.3619 Silverchair:69629 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Young Adults Presenting with Extramedullary Acute Myeloid Leukemia Have A Unique Sensitivity to High Doses of Anthracyclines: Subset Analysis of ECOG 1900," The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.3619.3619 Silverchair:69629 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "Young Adults Presenting with Extramedullary Acute Myeloid Leukemia Have A Unique Sensitivity to High Doses of Anthracyclines: Subset Analysis of ECOG 1900," The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.3619.3619 Silverchair:69629 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 "Young Adults Presenting with Extramedullary Acute Myeloid Leukemia Have A Unique Sensitivity to High Doses of Anthracyclines: Subset Analysis of ECOG 1900," The American Society of Hematology American Society of Hematology 10.1182/blood.V118.21.3619.3619 Silverchair:69629 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 "ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile" The American Society of Hematology American Society of Hematology 10.1182/blood-2002-10-3306 Silverchair:17029 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile" The American Society of Hematology American Society of Hematology 10.1182/blood-2002-10-3306 Silverchair:17029 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 "ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile" The American Society of Hematology American Society of Hematology 10.1182/blood-2002-10-3306 Silverchair:17029 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 "ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile" The American Society of Hematology American Society of Hematology 10.1182/blood-2002-10-3306 Silverchair:17029 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 Zebrafish screen identifies novel compound with selective toxicity against leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-398818 Silverchair:30296 Total_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Zebrafish screen identifies novel compound with selective toxicity against leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-398818 Silverchair:30296 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 Zebrafish screen identifies novel compound with selective toxicity against leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-398818 Silverchair:30296 Unique_Item_Investigations 2 0 2 0 0 0 0 0 0 0 0 0 0 Zebrafish screen identifies novel compound with selective toxicity against leukemia The American Society of Hematology American Society of Hematology 10.1182/blood-2011-12-398818 Silverchair:30296 Unique_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 ZFP91 Regulates Multiple Myeloma Cell Proliferation through IL-1β Mediated IL-6 Secretion in the Tumor Microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129181 Silverchair:424596 Total_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 ZFP91 Regulates Multiple Myeloma Cell Proliferation through IL-1β Mediated IL-6 Secretion in the Tumor Microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129181 Silverchair:424596 Total_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 ZFP91 Regulates Multiple Myeloma Cell Proliferation through IL-1β Mediated IL-6 Secretion in the Tumor Microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129181 Silverchair:424596 Unique_Item_Investigations 1 0 0 1 0 0 0 0 0 0 0 0 0 ZFP91 Regulates Multiple Myeloma Cell Proliferation through IL-1β Mediated IL-6 Secretion in the Tumor Microenvironment The American Society of Hematology American Society of Hematology 10.1182/blood-2019-129181 Silverchair:424596 Unique_Item_Requests 1 0 0 1 0 0 0 0 0 0 0 0 0 Zinc-dependent multimerization of mutant calreticulin is required for MPL binding and MPN pathogenesis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002402 Silverchair:475655 Total_Item_Investigations 2 0 0 0 0 0 0 0 0 0 2 0 0 Zinc-dependent multimerization of mutant calreticulin is required for MPL binding and MPN pathogenesis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002402 Silverchair:475655 Total_Item_Requests 2 0 0 0 0 0 0 0 0 0 2 0 0 Zinc-dependent multimerization of mutant calreticulin is required for MPL binding and MPN pathogenesis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002402 Silverchair:475655 Unique_Item_Investigations 1 0 0 0 0 0 0 0 0 0 1 0 0 Zinc-dependent multimerization of mutant calreticulin is required for MPL binding and MPN pathogenesis American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2020002402 Silverchair:475655 Unique_Item_Requests 1 0 0 0 0 0 0 0 0 0 1 0 0 Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2016000836 Silverchair:15518 Total_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2016000836 Silverchair:15518 Total_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2016000836 Silverchair:15518 Unique_Item_Investigations 1 0 0 0 0 0 0 1 0 0 0 0 0 Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination American Society of Hematology American Society of Hematology 10.1182/bloodadvances.2016000836 Silverchair:15518 Unique_Item_Requests 1 0 0 0 0 0 0 1 0 0 0 0 0 ZRSR2 Mutations Cause Dysregulated RNA Splicing in MDS The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4609.4609 Silverchair:94026 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 ZRSR2 Mutations Cause Dysregulated RNA Splicing in MDS The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4609.4609 Silverchair:94026 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 ZRSR2 Mutations Cause Dysregulated RNA Splicing in MDS The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4609.4609 Silverchair:94026 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 ZRSR2 Mutations Cause Dysregulated RNA Splicing in MDS The American Society of Hematology American Society of Hematology 10.1182/blood.V124.21.4609.4609 Silverchair:94026 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 β2 integrin–derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-457887 Silverchair:105662 Total_Item_Investigations 3 0 3 0 0 0 0 0 0 0 0 0 0 β2 integrin–derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-457887 Silverchair:105662 Total_Item_Requests 2 0 2 0 0 0 0 0 0 0 0 0 0 β2 integrin–derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-457887 Silverchair:105662 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 β2 integrin–derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis The American Society of Hematology American Society of Hematology 10.1182/blood-2012-09-457887 Silverchair:105662 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 β-Catenin stabilization stalls the transition from double-positive to single-positive stage and predisposes thymocytes to malignant transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2006-11-059071 Silverchair:23090 Total_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 β-Catenin stabilization stalls the transition from double-positive to single-positive stage and predisposes thymocytes to malignant transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2006-11-059071 Silverchair:23090 Total_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 β-Catenin stabilization stalls the transition from double-positive to single-positive stage and predisposes thymocytes to malignant transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2006-11-059071 Silverchair:23090 Unique_Item_Investigations 1 1 0 0 0 0 0 0 0 0 0 0 0 β-Catenin stabilization stalls the transition from double-positive to single-positive stage and predisposes thymocytes to malignant transformation The American Society of Hematology American Society of Hematology 10.1182/blood-2006-11-059071 Silverchair:23090 Unique_Item_Requests 1 1 0 0 0 0 0 0 0 0 0 0 0 β-Catenin–TCF/LEF signaling promotes steady-state and emergency granulopoiesis via G-CSF receptor upregulation The American Society of Hematology American Society of Hematology 10.1182/blood.2019004664 Silverchair:463438 Total_Item_Investigations 4 0 2 2 0 0 0 0 0 0 0 0 0 β-Catenin–TCF/LEF signaling promotes steady-state and emergency granulopoiesis via G-CSF receptor upregulation The American Society of Hematology American Society of Hematology 10.1182/blood.2019004664 Silverchair:463438 Unique_Item_Investigations 2 0 1 1 0 0 0 0 0 0 0 0 0 β-Catenin–TCF/LEF signaling promotes steady-state and emergency granulopoiesis via G-CSF receptor upregulation The American Society of Hematology American Society of Hematology 10.1182/blood.2019004664 Silverchair:463438 No_License 2 0 1 1 0 0 0 0 0 0 0 0 0 γ-Glutamyl carboxylase mutations differentially affect the biological function of vitamin K–dependent proteins The American Society of Hematology American Society of Hematology 10.1182/blood.2020006329 Silverchair:461789 Total_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 γ-Glutamyl carboxylase mutations differentially affect the biological function of vitamin K–dependent proteins The American Society of Hematology American Society of Hematology 10.1182/blood.2020006329 Silverchair:461789 Total_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 γ-Glutamyl carboxylase mutations differentially affect the biological function of vitamin K–dependent proteins The American Society of Hematology American Society of Hematology 10.1182/blood.2020006329 Silverchair:461789 Unique_Item_Investigations 1 0 1 0 0 0 0 0 0 0 0 0 0 γ-Glutamyl carboxylase mutations differentially affect the biological function of vitamin K–dependent proteins The American Society of Hematology American Society of Hematology 10.1182/blood.2020006329 Silverchair:461789 Unique_Item_Requests 1 0 1 0 0 0 0 0 0 0 0 0 0 γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2019000050 Silverchair:374996 Total_Item_Investigations 5 5 0 0 0 0 0 0 0 0 0 0 0 γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2019000050 Silverchair:374996 Total_Item_Requests 5 5 0 0 0 0 0 0 0 0 0 0 0 γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2019000050 Silverchair:374996 Unique_Item_Investigations 2 2 0 0 0 0 0 0 0 0 0 0 0 γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma The American Society of Hematology American Society of Hematology 10.1182/blood.2019000050 Silverchair:374996 Unique_Item_Requests 2 2 0 0 0 0 0 0 0 0 0 0 0